Please wait...
| ID | PMID | YEAR | Sequence | MAP | Name | C-ter MOD | N-ter MOD | Linear/Cyclic | Stereo-Chemistry | Modified | Length | Fuction | Activity | RBCs Source | Origin | Experimental structure | Non-Hemolytic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10660589 | 2000 | ALWMTLLKKVLKAAAKAALNAVLVGANA | S4 | Free | Free | Linear | L | None | 28 | Antimicrobial | LC50 =1.4±0.2μM | Human | Dermaseptin S4 (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWMTLLKKVLKAAAKAALDAVLVGANA | D20-S4 | Free | Free | Linear | L | None | 28 | Antimicrobial | LC50 =1.2±0.1μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWDTLLKKVLKAAAKAALNAVLVGANA | D4-S4 | Free | Free | Linear | L | None | 28 | Antimicrobial | LC50 =2.3±0.3μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWDTLLKKVLKAAAKAALDAVLVGANA | D4D20-S4 | Free | Free | Linear | L | None | 28 | Antimicrobial | LC50 =5±1μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWMTLLKKVLKAAAKAALKAVLVGANA | K20-S4 | Free | Free | Linear | L | None | 28 | Antimicrobial | LC50 =1.2±0.4μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWKTLLKKVLKAAAKAALNAVLVGANA | K4-S4 | Free | Free | Linear | L | None | 28 | Antimicrobial | LC50 =2±0.1μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWKTLLKKVLKAAAKAALKAVLVGANA | K4K20-S4 | Free | Free | Linear | L | None | 28 | Antimicrobial | LC50 =0.5±0.1μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWKTLLKKVLKAAAKAALN | S4-(1-20) | Free | Free | Linear | L | None | 20 | Antimicrobial | LC50 =5±1μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWMTLLKKVLKAAAK | S4-(1-16) | Free | Free | Linear | L | None | 16 | Antimicrobial | LC50 =23±1μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWMTLLKKVLK | S4-(1-12) | Free | Free | Linear | L | None | 12 | Antimicrobial | LC50 =100μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | TLLKKVLKAAAK | S4-(5-16) | Free | Free | Linear | L | None | 12 | Antimicrobial | LC50 >80μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | TLLKKVLKAAAKAALNAVLVGANA | S4-(5-28) | Free | Free | Linear | L | None | 24 | Antimicrobial | LC50 =16.5±0.5μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | KVLKAAAKAALNAVLVGANA | S4-(9-28) | Free | Free | Linear | L | None | 20 | Antimicrobial | LC50 =24±1μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | AAAKAALNAVLVGANA | S4-(13-28) | Free | Free | Linear | L | None | 16 | Antimicrobial | LC50 =40μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWKTLLKKVLKAAAK | K4-S4-(1-16) | Free | Free | Linear | L | None | 16 | Antimicrobial | LC50 =57±3μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWKTLLKKVLKAAAK{ct:Amid} | K4-S4-(1-16)a | Amidation | Free | Linear | L | None | 16 | Antimicrobial | LC50 =10±0.5μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWKTLLKKVLKAAA{ct:Amid} | K4-S4-(1-15)a | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 =20±1μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWKTLLKKVLKA{ct:Amid} | K4-S4-(1-13)a | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LC50 =57±3μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10660589 | 2000 | ALWKTLLKKV{ct:Amid} | K4-S4-(1-10)a | Amidation | Free | Linear | L | None | 10 | Antimicrobial | LC50 >100μM | Human | Dermaseptin S4 analog (skin of tree frogs) | α-helix | NA | ||
| 10978343 | 2000 | G{nnr:W*}L{nnr:R**}{nnr:K**}AA{nnr:K**}SVG{nnr:K**}F{nnr:Y*}{nnr:Y*}{nnr:K**}H{nnr:K*}{nnr:Y*}{nnr:Y*}I{nnr:K*}AAWQIGKHAL{ct:Amid} | Styelin D | Amidation | Free | Linear | L | W* = 6-bromotryptophan, R** = dihydroxyarginine, Y* = 3,4-dihydroxyphenylalanine, K* = 5-hydroxylysine, K** = dihydroxylysine | 32 | Antimicrobial | EC50 =10 μg/ml | Human | Stylein D (blood cells of solitary ascidian Styela clava) | α-helix | NA | ||
| 15149180 | 2004 | {conj:lauric acid}YGAAKKAAKAAKKAAKAA | AKK | Free | Conjugated with lauric acid | Linear | L | None | 18 | Antimicrobial | <15% hemolysis at 500μM | Human | Synthetic peptide | α-helix | NA | ||
| 15149180 | 2004 | {conj:lauric acid}YGAKAKAAKAAKAKAAKA | KAK | Free | Conjugated with lauric acid | Linear | L | None | 18 | Antimicrobial | <15% hemolysis at 500μM | Human | Synthetic peptide | α-helix | NA | ||
| 15149180 | 2004 | {conj:lauric acid}KLFKRHLKWKII{ct:Amid} | SC4 | Amidation | Conjugated with lauric acid | Linear | L | None | 12 | Antimicrobial | <15% hemolysis at 500μM | Human | Synthetic peptide | α-helix | NA | ||
| 18081258 | 2008 | GLPVCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | Katala B1 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | HD50 =11.7μM | Human | Cyclotides (Chinese herb from the Violaceae family Viola yedoensis) | NA | NA | ||
| 18081258 | 2008 | GGTIFDCGETCFLGTCYTPGCSCGNYGFCYGTN{cyc:N-C} | Cycloviolacin Y1 | Free | Free | Cyclic | L | None | 33 | Anti-HIV | Poor hemolytic | Human | Cyclotides (Chinese herb from the Violaceae family Viola yedoensis) | NA | NA | ||
| 18081258 | 2008 | GVPCGESCVFIPCITGVIGCSCSSNVCYLN{cyc:N-C} | Cycloviolacin Y4 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | HD50 =9.3μM | Human | Cyclotides (Chinese herb from the Violaceae family Viola yedoensis) | NA | NA | ||
| 18081258 | 2008 | GIPCAESCVWIPCTVTALVGCSCSDKVCYN{cyc:N-C} | Cycloviolacin Y5 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | HD50 = 8.7μM | Human | Cyclotides (Chinese herb from the Violaceae family Viola yedoensis) | NA | NA | ||
| 18243710 | 2008 | DAACAAHCLWR{ct:Amid} | DHWR | Amidation | Free | Linear | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | NA | NA | ||
| 18243710 | 2008 | DAACAAHCLWR{cyc:N-C}{ct:Amid} | DHWRox | Amidation | Free | Cyclic | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 18243710 | 2008 | DAACAAKCLWR{ct:Amid} | DKWR | Amidation | Free | Linear | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 18243710 | 2008 | DAACAAKCLWR{cyc:N-C}{ct:Amid} | DKWRox | Amidation | Free | Cyclic | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 18243710 | 2008 | KAACAAHCLWR{ct:Amid} | KHWR | Amidation | Free | Linear | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 18243710 | 2008 | KAACAAHCLWR{cyc:N-C}{ct:Amid} | KHWRox | Amidation | Free | Cyclic | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 18243710 | 2008 | KAACAAKCLWR{ct:Amid} | KKWR | Amidation | Free | Linear | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 18243710 | 2008 | KAACAAKCLWR{cyc:N-C}{ct:Amid} | KKWRox | Amidation | Free | Cyclic | L | None | 11 | Antimicrobial | HC50 >200μg/ml | Human | α-helical domain of Tenecin 1,an insect defensin | α-helix | NA | ||
| 11087404 | 2000 | RRWCFRVCYRGFCYRKCR{ct:Amid} | PM1 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 100% hemolysis at 21.3μg/ml | Human | Polyphemusin variants (horseshoe crab Limulus Polyphemus) | NA | NA | ||
| 11087404 | 2000 | RRWCFRVCYRGRFCYRKCR{ct:Amid} | PV5 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 100% hemolysis at 42.6μg/ml | Human | Polyphemusin variants (horseshoe crab Limulus Polyphemus) | NA | NA | ||
| 11087404 | 2000 | RRWCFRVCYKGFCRYKCR{ct:Amid} | PV7 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 100% hemolysis at 85μg/ml | Human | Polyphemusin variants (horseshoe crab Limulus Polyphemus) | NA | NA | ||
| 11087404 | 2000 | FRWCFRVCYKGRCRYKCR{ct:Amid} | PV8 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 100% hemolysis at 85μg/ml | Human | Polyphemusin variants (horseshoe crab Limulus Polyphemus) | NA | NA | ||
| 11467858 | 2001 | RGLRRLGRKIAHGVKKYGPTVLRIIRIA{ct:Amid} | SMAP-29 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 60.8% hemolysis at 100μM | Human | Cathelecidin derivative SMAP-29 (sheep myeloid mRNA) | NA | NA | ||
| 11467858 | 2001 | RGLRRLGRKIAHGVKKYGPTVKRIKRKA{ct:Amid} | [K22,25,27]-SMAP-29 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 0% hemolysis at 100μM (non-hemolytic) | Human | Cathelecidin derivative SMAP-29 derivative (sheep myeloid mRNA) | NA | Non-hemolytic | ||
| 11467858 | 2001 | RGLRRLGRKIAHGVKKYGATVLRIIRIA{ct:Amid} | [A19]-SMAP-29 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 50.40% hemolysis at 100μM | Human | Cathelecidin derivative SMAP-29 derivative (sheep myeloid mRNA) | NA | NA | ||
| 11467858 | 2001 | RGLRRLGRKIAHGVKKY{ct:Amid} | SMAP-29(1–17) | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 100μM (non-hemolytic) | Human | Cathelecidin derivative SMAP-29 derivative (sheep myeloid mRNA) | NA | Non-hemolytic | ||
| 11467858 | 2001 | RKLRRLKRKIAHKVKKY{ct:Amid} | [K2,7,13]-SMAP-29(1–17) | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 100μM (non-hemolytic) | Human | Cathelecidin derivative SMAP-29 derivative (sheep myeloid mRNA) | NA | Non-hemolytic | ||
| 11689009 | 2001 | GLNALKKVFQGIHEAIKLINNHVQ | Pseudin-2 | Free | Free | Linear | L | None | 24 | Antimicrobial | 50% hemolysis at >300μM | Human | Pseudin-2 (extract of the skin of the paradoxical frog Pseudis paradoxa (Pseudidae)) | NA | NA | ||
| 15544856 | 2005 | GVVDILKGAAKDIAGHLASKVMNKL{ct:Amid} | Fallaxin | Amidation | Free | Linear | L | None | 25 | Antimicrobial | HC50 >200μM | Human | Fallaxin (skin secretions of the mountain chicken frog Leptodactylus fallax) | NA | NA | ||
| 16236555 | 2005 | GLLDTLKGAAKNVVGSLASKVMEKL{ct:Amid} | Pentadactylin | Amidation | Free | Linear | L | None | 25 | Antimicrobial | LD50 >400μM | Human | Pentadactylin (skin secetion of south American bullfrog Leptodactylus pentadactylus) | NA | NA | ||
| 16413829 | 2006 | GIMSLFKGVLKTAGKHVAGSLVDQLKCKITGGC | Brevinin-2TSa | Free | Free | Linear | L | None | 33 | Antimicrobial | LD50 =100μM | Human | Brevinin (skin of the Tsushima brown frog Rana tsushimensis) | NA | NA | ||
| 16413829 | 2006 | FLGSIVGALASALPSLISKIRN{ct:Amid} | Brevinin-1TSa | Amidation | Free | Linear | L | None | 22 | Antimicrobial | LD50 =12μM | Human | Brevinin (skin of the Tsushima brown frog Rana tsushimensis) | NA | NA | ||
| 19799950 | 2010 | SQLGDLGSGAGQGGGGGGSIRAAGGAFGKLEAAREEEFFYKKQKEQLERLKNDQIHQAEFHHQQIKEHEEAIQRHKDFLNNLHK | SK84 | Free | Free | Linear | L | None | 84 | Antimicrobial and Anticancer | 0.01% hemolysis at 100μM | Human | SK84 (larvae of Drosophila virilis) | NA | NA | ||
| 20044030 | 2010 | GLMDTVKNAAKNLAGQMLDKLKCKITGSC | Ranatuerin-2ONa | Free | Free | Linear | L | None | 29 | Antimicrobial | LD50 =90μM | Human | Ranatuerin-2ONa (leopard frog Lithobates onca) | NA | NA | ||
| 20044030 | 2010 | FLPVIAGAANFLPKLFCAISKKC | Brevinin-1Ya | Free | Free | Linear | L | None | 23 | Antimicrobial | LD50 =14μM | Human | Brevinin analog (leopard frog Lithobates onca) | NA | NA | ||
| 20044030 | 2010 | FLPIIAGAAAKVVQKIFCAISKKC | Brevinin-1Yb | Free | Free | Linear | L | None | 24 | Antimicrobial | LD50 =10μM | Human | Brevinin analog (leopard frog Lithobates onca) | NA | NA | ||
| 20153801 | 2010 | FLLFPLMCKIQGKC | Japonicin-1Npa | Free | Free | Linear | L | None | 14 | Antimicrobial | 1.92% hemolysis at 80μg/ml | Human | Japonicin-1 (skin of Xizang plateau frog Nanorana parkeri) | NA | NA | ||
| 20153801 | 2010 | FVLPLVMCKILRKC | Japonicin-1Npb | Free | Free | Linear | L | None | 14 | Antimicrobial | 3.40% hemolysis at 80μg/ml | Human | Japonicin-1 (skin of Xizang plateau frog Nanorana parkeri) | NA | NA | ||
| 20153801 | 2010 | GWANTLKNVAGGLCKITGAA | Parkerin | Free | Free | Linear | L | None | 20 | Antimicrobial | 2.36% hemolysis at 80μg/ml | Human | Parkerin (skin of Xizang plateau frog Nanorana parkeri) | NA | NA | ||
| 20969885 | 2011 | GIWSSIKNLASKAWNSDIGQSLRNKAAGAINKFVADKIGVTPSQAAS | Vejovine | Free | Free | Linear | L | None | 47 | Antibacterial | HC50 =100μM | Human | Vejovine (scorpion venom of Vaejovis mexicanus) | NA | NA | ||
| 17158938 | 2007 | KWKSFLKTFKSAKKTVLHTALKAISS{nt:Acet}{ct:Amid} | V13KL | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =250μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 17158938 | 2007 | KWKSFAKTFKSAKKTVLHTAAKAISS{nt:Acet}{ct:Amid} | L6A/L21A | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =1000 μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 17158938 | 2007 | KWKSFAKTFKSAKKTVLHTALKAISS{nt:Acet}{ct:Amid} | L6A | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =1000μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 17158938 | 2007 | KWKSFLKTFKSAKKTVLHTALKLISS{nt:Acet}{ct:Amid} | A23L | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =62.5μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 17158938 | 2007 | KWKSFLKTFKSLKKTVLHTALKAISS{nt:Acet}{ct:Amid} | A12L | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =31.3μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 17158938 | 2007 | KWKSFLKTFKSAKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | A20L | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =31.3μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 17158938 | 2007 | KWKSFLKTFKSLKKTVLHTALKLISS{nt:Acet}{ct:Amid} | A12L/A23L | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =15.6μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 17158938 | 2007 | KWKSFLKTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | A12L/A20L | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =8μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 17158938 | 2007 | KWKSFLKTFKSLKKTVLHTLLKLISS{nt:Acet}{ct:Amid} | A12L/A20L/A23L | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =4μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 1 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 3.1 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}{cyc:N-C}{ct:Amid} | Peptide 2 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 1.6 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:ACPC}-L-{nnr:APC}-K-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:APC}-L-{nnr:ACPC}-L-{nnr:ACPC}-L-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 3 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 100 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 4 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 100 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}{cyc:N-C}{ct:Amid} | Peptide 5 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 1.6 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-F-{nnr:ACPC}-L-{nnr:APC}-L-{nnr:ACPC}-F-{nnr:APC}-F-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:APC}{cyc:N-C}{ct:Amid} | Peptide 6 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 1.6 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-K-{nnr:ACPC}-A-{nnr:APC}-A-{nnr:ACPC}-K-{nnr:ACPC}-A-{nnr:APC}-L-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 7 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at >400 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:APC}-L-{nnr:ACPC}-A-{nnr:APC}-A-{nnr:ACPC}-K-{nnr:ACPC}-L-{nnr:ACPC}-K-{nnr:ACPC}-A-{nnr:APC}{cyc:N-C}{ct:Amid} | Peptide 8 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at 100 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17212422 | 2007 | {nnr:ACPC}-A-{nnr:APC}-K-{nnr:APC}-L-{nnr:ACPC}-K-{nnr:APC}-A-{nnr:ACPC}-A-{nnr:ACPC}-L-{nnr:ACPC}{cyc:N-C}{ct:Amid} | Peptide 9 | Amidation | Free | Cyclic | L | APC = APC, ACPC = ACPC | 15 | Antibacterial | >10% hemolysis at >400 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 17307975 | 2007 | {nnr:alK}-{nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 1 | Free | Free | Linear | Mix | a = amino, l = lauric acid, alK = aminolauryl-lysine | 4 | Antiplasmodial | 24.6± 1.2% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:l}K-{nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 2 | Free | Free | Linear | Mix | l = lauric acid, alK = aminolauryl-lysine | 4 | Antiplasmodial | 26.1±4.5% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | K-{nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 3 | Free | Free | Linear | Mix | l = lauric acid, alK = aminolauryl-lysine | 4 | Antiplasmodial | 2.3±1.5% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:a}{nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 4 | Free | Free | Linear | Mix | a = amino, l = lauric acid | 3 | Antiplasmodial | 3.4±0.8% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:l}K-{nnr:l}K-{nnr:l}K | OAK 5 | Free | Free | Linear | Mix | l = lauric acid, alK = aminolauryl-lysine | 3 | Antiplasmodial | 13.3±4.3% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | K-{nnr:l}K-{nnr:l}K | OAK 6 | Free | Free | Linear | Mix | l = lauric acid, alK = aminolauryl-lysine | 3 | Antiplasmodial | <0.1% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:alK}-{nnr:l}K | OAK 7 | Free | Free | Linear | Mix | a = amino, l = lauric acid, alK = aminolauryl-lysine | 2 | Antiplasmodial | 0.14±0.3% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | {nnr:l}K-{nnr:l}K | OAK 8 | Free | Free | Linear | Mix | l = lauric acid | 2 | Antiplasmodial | 4.9±1.7% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17307975 | 2007 | K-{nnr:l}K | OAK 9 | Free | Free | Linear | Mix | l = lauric acid | 2 | Antiplasmodial | <0.1% hemolysis at 100 μM | Human | Oligoacyllysine analog (Synthetic peptide) | NA | NA | ||
| 17328560 | 2007 | FFHHIFRGIVHVGKTIHRLVTG | Piscidin 1 (Pis-1) | Free | Free | Linear | L | None | 22 | Cytotoxic | HC50 =11μM | Human | Piscidin 1 (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17328560 | 2007 | FFHHIFRAIVHVGKTIHRLVTG | Pis-1 AG | Free | Free | Linear | L | None | 22 | Cytotoxic | HC50 =4μM | Human | Piscidin 1 analogs (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17328560 | 2007 | FFHHIFRGIVHVAKTIHRLVTG | Pis-1 GA | Free | Free | Linear | L | None | 22 | Cytotoxic | HC50 =4μM | Human | Piscidin 1 analogs (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17328560 | 2007 | FFHHIFRAIVHVAKTIHRLVTG | Pis-1 AA | Free | Free | Linear | L | None | 22 | Cytotoxic | HC50 =6μM | Human | Piscidin 1 analogs (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17328560 | 2007 | FFHHIFRPIVHVGKTIHRLVTG | Pis-1 PG | Free | Free | Linear | L | None | 22 | Cytotoxic | HC50 >200μM | Human | Piscidin 1 analogs (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17328560 | 2007 | FFHHIFRGIVHVPKTIHRLVTG | Pis-1 GP | Free | Free | Linear | L | None | 22 | Cytotoxic | HC50 >200μM | Human | Piscidin 1 analogs (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17328560 | 2007 | FFHHIFRPIVHVPKTIHRLVTG | Pis-1 PP | Free | Free | Linear | L | None | 22 | Cytotoxic | HC50 >200μM | Human | Piscidin 1 analogs (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17328560 | 2007 | FFHHIFRAIVHVPKTIHRLVTG | Pis-1 AP | Free | Free | Linear | L | None | 22 | Cytotoxic | HC50 =75μM | Human | Piscidin 1 analogs (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17328560 | 2007 | FFHHIFRPIVHVAKTIHRLVTG | Pis-1 PA | Free | Free | Linear | L | None | 22 | Cytotoxic | HC50 =32μM | Human | Piscidin 1 analogs (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17328560 | 2007 | FFHHIFRA{d}IVHVA{d}KTIHRLVTG | Pis-1 aa | Free | Free | Linear | Mix | None | 22 | Cytotoxic | HC50 =8μM | Human | Piscidin 1 analogs (mast cells of hybrid striped bass (Morone saxatilis x M.chrysops ) | α-helix | NA | ||
| 17389605 | 2007 | KILRGVCKKIMRTFLRRISKDILTGKK{ct:Amid} | NK-2 | Amidation | Free | Linear | L | None | 27 | Antimicrobial and Cytotoxic | ~50% hemolysis at 100μg/ml | Human | Synthetic peptide variants based on the NK-2 lysin | α-helix | NA | ||
| 17389605 | 2007 | KILRGVSKKIMRTFLRRISKDILTGKK{ct:Amid} | NK27 | Amidation | Free | Linear | L | None | 27 | Antimicrobial and Cytotoxic | >20% hemolysis at 100μg/ml | Human | Synthetic peptide variants based on the NK-2 lysin | α-helix | NA | ||
| 17389605 | 2007 | KILRGVSKKIMRTFLRRILTGKK{ct:Amid} | NK23c | Amidation | Free | Linear | L | None | 23 | Antimicrobial and Cytotoxic | ~20% hemolysis at 100μg/ml | Human | Synthetic peptide variants based on the NK-2 lysin | α-helix | NA | ||
| 17389605 | 2007 | KISKKIMRTFLRRILTGKK{ct:Amid} | NK19a | Amidation | Free | Linear | L | None | 19 | Antimicrobial and Cytotoxic | ~9% hemolysis at 100μg/ml | Human | Synthetic peptide variants based on the NK-2 lysin | α-helix | NA | ||
| 17389605 | 2007 | RILRGVSRRIMRRILTGRR{ct:Amid} | NK19b-KR | Amidation | Free | Linear | L | None | 19 | Antimicrobial and Cytotoxic | ~8% hemolysis at 100μg/ml | Human | Synthetic peptide variants based on the NK-2 lysin | α-helix | NA | ||
| 17451843 | 2007 | GILSSFKGVAKGVAKDLAGKLLETLKCKITGC | Ranatuerin-2CSa | Free | Free | Linear | L | None | 32 | Antimicrobial | LD50 =150μM | Human | Ranatuerin-2 analog (skin secretions of Rana cascadae) | NA | NA | ||
| 17451843 | 2007 | FLPILAGLAAKIVPKLFCLATKKC | Brevinin-1CSa | Free | Free | Linear | L | None | 24 | Antimicrobial | LD50 =5μM | Human | Brevinin-1analog (skin secretions of Rana cascadae) | NA | NA | ||
| 17451843 | 2007 | FLPIVGKLLSGLL{ct:Amid} | Temporin-1Csa | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 =75μM | Human | Temporin analog (skin secretions of Rana cascadae) | NA | NA | ||
| 17451843 | 2007 | FLPIIGKLLSGLL{ct:Amid} | Temporin-1CSb | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 =95μM | Human | Temporin analog (skin secretions of Rana cascadae) | NA | NA | ||
| 17451843 | 2007 | FLPLVTGLLSGLL{ct:Amid} | Temporin-1CSc | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 >300μM | Human | Temporin analog (skin secretions of Rana cascadae) | NA | NA | ||
| 17451843 | 2007 | NFLGTLVNLAKKIL{ct:Amid} | Temporin-1CSd | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 =50μM | Human | Temporin analog (skin secretions of Rana cascadae) | NA | NA | ||
| 17462733 | 2007 | RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS | K9CATH | Free | Free | Linear | L | None | 38 | Antimicrobial | 30% hemolysis at 100 μM | Human | K9CATH canine cathelicidin present in neutorphil granule content | α-helix | NA | ||
| 18098173 | 2007 | EWESFLETFESAKETVLHTALEAISS{nt:Acet}{ct:Amid} | -5 Peptide | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC >1000.0μg/ml | Human | Amphipathic α-helical antimicrobial peptide L-V13K analogs | α-helix | NA | ||
| 18098173 | 2007 | KWKEFLKEFKEAKKEVLHEALKAISE{nt:Acet}{ct:Amid} | 1 Peptide | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC >1000.0μg/ml | Human | Amphipathic α-helical antimicrobial peptide L-V13K analogs | α-helix | NA | ||
| 18098173 | 2007 | KWKEFLKTFKEAKKEVLHTALKAISS{nt:Acet}{ct:Amid} | +4E Peptide | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =250.0μg/ml | Human | Amphipathic α-helical antimicrobial peptide L-V13K analogs | α-helix | NA | ||
| 18098173 | 2007 | SWKSFLKTFSSAKSTVLHTALKAISS{nt:Acet}{ct:Amid} | +4S Peptide | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =125.0μg/ml | Human | Amphipathic α-helical antimicrobial peptide L-V13K analogs | α-helix | NA | ||
| 18098173 | 2007 | KWKSFLKTFKSAKKTVLHTALKAISS{nt:Acet}{ct:Amid} | V13K Peptide | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =250.0μg/ml | Human | Amphipathic α-helical antimicrobial peptide L-V13K | α-helix | NA | ||
| 18098173 | 2007 | KWKSFLKTFKSAKKKVLHTALKAISS{nt:Acet}{ct:Amid} | 8 Peptide | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =250.0μg/ml | Human | Amphipathic α-helical antimicrobial peptide L-V13K analogs | α-helix | NA | ||
| 18098173 | 2007 | KWKSFLKTFKSAKKKVLHKALKAISS{nt:Acet}{ct:Amid} | 9 Peptide | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC <7.8μg/ml | Human | Amphipathic α-helical antimicrobial peptide L-V13K analogs | α-helix | NA | ||
| 18098173 | 2007 | KWKSFLKTFKSAKKKVLHKALKAISK{nt:Acet}{ct:Amid} | 10 Peptide | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC <7.8μg/ml | Human | Amphipathic α-helical antimicrobial peptide L-V13K analogs | α-helix | NA | ||
| 18186149 | 2008 | KKKKKKAAFAAWAAFDA{cyc:N-C}{ct:Amid} | 7K-F18-1D17 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC =650μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | K{d}K{d}K{d}K{d}K{d}K{d}A{d}A{d}F{d}A{d}A{d}W{d}A{d}A{d}F{d}A{d}A{d}{cyc:N-C}{ct:Amid} | 6k-f17 | Amidation | Free | Cyclic | D | None | 17 | Antimicrobial | MHC =325μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKAAFALWAAFAA{cyc:N-C}{ct:Amid} | 6K-F17-1L11 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC =81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKAAFALWLAFAA{cyc:N-C}{ct:Amid} | 6K-F17-2L11,13 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKAAFLAWALFAA{cyc:N-C}{ct:Amid} | 6K-F17-2L10,14 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | K{d}K{d}K{d}K{d}K{d}K{d}A{d}A{d}F{d}A{d}A{d}W{d}A{d}A{d}F{d}L{d}L{d}{cyc:N-C}{ct:Amid} | 6k-f17-2l16,17 | Amidation | Free | Cyclic | D | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKALFAAWAAFLA{cyc:N-C}{ct:Amid} | 6K-F17-2L8,16 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKLLFAAWAAFAA{cyc:N-C}{ct:Amid} | 6K-F17-2L7,8 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKALFALWLAFAA{cyc:N-C}{ct:Amid} | 6K-F17-3L8,11,13 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <<81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKAAFALWLAFLA{cyc:N-C}{ct:Amid} | 6K-F17-3L11,13,16 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <<81μM | Human | Synthetic peptide | random coil | NA | ||
| 18186149 | 2008 | KKKKKKALFALWLAFLA{cyc:N-C}{ct:Amid} | 6K-F17-4L8,11,13,16 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | MHC <<81μM | Human | Synthetic peptide | random coil | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCVGR | PC1 | Free | Free | Linear | L | None | 18 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGGLCYCRRRFCVCVGR | PC3 | Free | Free | Linear | L | None | 18 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRGWICFCVGR | PC4 | Free | Free | Linear | L | None | 18 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRPRFCVCVGR | PC5 | Free | Free | Linear | L | None | 18 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLAYCRRRFCVAVGR | PC9 | Free | Free | Linear | L | None | 18 | Antimicrobial | 0-3% hemolysis upto 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | No β-hairpin present | NA | ||
| 18455267 | 2008 | RGGRLCYARRRFAVCVGR | PC10 | Free | Free | Linear | L | None | 18 | Antimicrobial | 0-3% hemolysis upto 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | No β-hairpin present | NA | ||
| 18455267 | 2008 | LCYCRRRFCVCVGR | PC11 | Free | Free | Linear | L | None | 14 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RCYCRRRFCVCVGR | PC12 | Free | Free | Linear | L | None | 14 | Antimicrobial | 12-25% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCV | PC13 | Free | Free | Linear | L | None | 16 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCICV | PC14 | Free | Free | Linear | L | None | 16 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCR | PC15 | Free | Free | Linear | L | None | 16 | Antimicrobial | 3-6% hemolysis at 80μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RCYCRRRFCVCR | PC16 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRRRFCVCV | PC17 | Free | Free | Linear | L | None | 12 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYARRRFAVCV | PC18 | Free | Free | Linear | L | None | 12 | Antimicrobial | 3-6% hemolysis at 80μg/ml | Human | Protegrin analogues from the procrine leukocytes | No β-hairpin present | NA | ||
| 18455267 | 2008 | RCYARRRFAVCR | PC18 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | No β-hairpin present | NA | ||
| 18455267 | 2008 | LAYCRRRFCVAV | PC20 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | No β-hairpin present | NA | ||
| 18455267 | 2008 | RAYCRRRFCVAR | PC21 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | No β-hairpin present | NA | ||
| 18455267 | 2008 | CYCRRRFCVCVGR | PC37 | Free | Free | Linear | L | None | 13 | Antimicrobial | 3-6% hemolysis at 80μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVC | PC45 | Free | Free | Linear | L | None | 15 | Antimicrobial | 3-6% hemolysis at 80μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYTRRRFTVCV | PC64 | Free | Free | Linear | L | None | 12 | Antimicrobial | 3-6% hemolysis at 80μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LTYCRRRFCVTV | PC64a | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYTRPRFTVCV | PC65 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYTFRPRFVCV | PC69 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYTFRGRFVCV | PC70 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | CYCRRRFCVCV | PC71 | Free | Free | Linear | L | None | 11 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRRRFCVC | PC72 | Free | Free | Linear | L | None | 11 | Antimicrobial | 6-12% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | CYCRRRFCVC | PC73 | Free | Free | Linear | L | None | 10 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | CYCFRRFCVC | PC74 | Free | Free | Linear | L | None | 10 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRRRRCVCV | PC77 | Free | Free | Linear | L | None | 12 | Antimicrobial | 3-6% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCFRRRCVCV | PC78 | Free | Free | Linear | L | None | 12 | Antimicrobial | 12-25% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRFRRCVCV | PC79 | Free | Free | Linear | L | None | 12 | Antimicrobial | 3-6% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRRFRCVCV | PC80 | Free | Free | Linear | L | None | 12 | Antimicrobial | 12-25% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | YCYCRRRFCVCVGR | PC91 | Free | Free | Linear | L | None | 14 | Antimicrobial | 25-50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | TCYCRRRFCVCVGR | PC92 | Free | Free | Linear | L | None | 14 | Antimicrobial | 12-25% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | ACYCRRRFCVCVGR | PC93 | Free | Free | Linear | L | None | 14 | Antimicrobial | 25-50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | VCYCRRRFCVCVGR | PC94 | Free | Free | Linear | L | None | 14 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | ICYCRRRFCVCVGR | PC95 | Free | Free | Linear | L | None | 14 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | FCYCRRRFCVCVGR | PC96 | Free | Free | Linear | L | None | 14 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | WCYCRRRFCVCVGR | PC97 | Free | Free | Linear | L | None | 14 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | ECYCRRRFCVCVGR | PC98 | Free | Free | Linear | L | None | 14 | Antimicrobial | 3-6% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCY | PC100 | Free | Free | Linear | L | None | 16 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCT | PC101 | Free | Free | Linear | L | None | 16 | Antimicrobial | 12-25% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCA | PC102 | Free | Free | Linear | L | None | 16 | Antimicrobial | 25-50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCL | PC103 | Free | Free | Linear | L | None | 16 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCI | PC104 | Free | Free | Linear | L | None | 16 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCF | PC105 | Free | Free | Linear | L | None | 16 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCW | PC106 | Free | Free | Linear | L | None | 16 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RGGRLCYCRRRFCVCE | PC107 | Free | Free | Linear | L | None | 16 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RLCYTRGRFTVCV | PC109 | Free | Free | Linear | L | None | 13 | Antimicrobial | 12-25% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYTRGRFTVCVR | PC110 | Free | Free | Linear | L | None | 13 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | RLCYTRGRFTVCVR | PC111 | Free | Free | Linear | L | None | 14 | Antimicrobial | 12-25% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCHHHFCVCV | PC112 | Free | Free | Linear | L | None | 12 | Antimicrobial | 6-12% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYTHHHFTVCV | PC113 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRRRFCYCV | PC146 | Free | Free | Linear | L | None | 12 | Antimicrobial | 6-12% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRRRFCFCV | PC147 | Free | Free | Linear | L | None | 12 | Antimicrobial | >50% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRRRFCTCV | PC148 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRRRFCGCV | PC149 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0-3% hemolysis at 80 μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18455267 | 2008 | LCYCRRRFCWCV | PC150 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25-50% hemolysis at 80μg/ml | Human | Protegrin analogues from the procrine leukocytes | β-hairpin | NA | ||
| 18566844 | 2008 | GRRRRSVQWCA | hLF(1–11) | Free | Free | Linear | L | None | 11 | Antimicrobial | 0% hemolysis at ≥200μM | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 18566844 | 2008 | FQWQRNMRKVR | hLF(21–31) | Free | Free | Linear | L | None | 11 | Antimicrobial | >2-3% at ≥16μM | Human | Synthetic peptide | NA | NA | ||
| 18566844 | 2008 | KVAKQEKKKKKTGRAKRR | UBI 18–35 | Free | Free | Linear | L | None | 18 | Antimicrobial | >2-3% at ≥20μM | Human | Synthetic peptide derived from Ubiquicidin | NA | NA | ||
| 18566844 | 2008 | TGRAKRRMQYNRR | UBI 29–41 | Free | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolysis at ≥200μM | Human | Synthetic peptide derived from Ubiquicidin | NA | Non-hemolytic | ||
| 18566844 | 2008 | LLLFLLKKRKKRKY | dhvar5 | Free | Free | Linear | L | None | 14 | Antimicrobial | >2-3% at ≥16μM | Human | Synthetic peptide | NA | NA | ||
| 18570895 | 2008 | LRQSQFVGSR{ct:Amid} | Urechistachykinins I | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 0% hemolysis at 3-100 μM (non-hemolytic) | Human | Neuropeptide derived from Urechis unicinctus | NA | Non-hemolytic | ||
| 18570895 | 2008 | AAGMGFFGAR{ct:Amid} | Urechistachykinins II | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 0% hemolysis at 3-100 μM (non-hemolytic) | Human | Neuropeptide derived from Urechis unicinctus | NA | Non-hemolytic | ||
| 18752624 | 2008 | MSGIVEAISNAVKSGLDHDWVNMGTSIADVVAKGADFIAGFFS | H1C | Free | Free | Linear | L | None | 43 | Cytotoxic | HD50 =3.32±0.12mM | Human | Synergistic hemolysins (Staphylococcus cohnii) | NA | NA | ||
| 18752624 | 2008 | MDFIIDIIKKIVGLFTGK | H2C | Free | Free | Linear | L | None | 18 | Cytotoxic | HD50 =6.34±3.54mM | Human | Synergistic hemolysins (Staphylococcus cohnii) | NA | NA | ||
| 18752624 | 2008 | MSDFVNAISEAVKAGLSADWVTMGTSIADALAKGADFILGFFN | H3C | Free | Free | Linear | L | None | 43 | Cytotoxic | HD50 =2.07±0.05mM | Human | Synergistic hemolysins (Staphylococcus cohnii) | NA | NA | ||
| 18779649 | 2008 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | L-Pleurocidin | Amidation | Free | Linear | L | None | 25 | Antibacterial | 77% hemolysis at 100 μM | Human | Skin mucous of the winter flounder (Pleuronectes americanus ) | α-helix | NA | ||
| 18779649 | 2008 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | L-Pleurocidin | Amidation | Free | Linear | L | None | 25 | Antibacterial | 29% hemolysis at 50 μM | Human | Skin mucous of the winter flounder (Pleuronectes americanus ) | α-helix | NA | ||
| 18779649 | 2008 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | L-Pleurocidin | Amidation | Free | Linear | L | None | 25 | Antibacterial | 0% hemolysis at 3.13-25 μM | Human | Skin mucous of the winter flounder (Pleuronectes americanus ) | α-helix | NA | ||
| 18779649 | 2008 | G{d}W{d}G{d}S{d}F{d}F{d}K{d}K{d}A{d}A{d}H{d}V{d}G{d}K{d}H{d}V{d}G{d}K{d}A{d}A{d}L{d}T{d}H{d}Y{d}L{d}{ct:Amid} | D-Pleurocidin | Amidation | Free | Linear | D | None | 25 | Antibacterial | 19% hemolysis at 100 μM | Human | Skin mucous of the winter flounder (Pleuronectes americanus ) | α-helix | NA | ||
| 18779649 | 2008 | G{d}W{d}G{d}S{d}F{d}F{d}K{d}K{d}A{d}A{d}H{d}V{d}G{d}K{d}H{d}V{d}G{d}K{d}A{d}A{d}L{d}T{d}H{d}Y{d}L{d}{ct:Amid} | D-Pleurocidin | Amidation | Free | Linear | D | None | 25 | Antibacterial | 0% hemolysis at 3.13-50 μM | Human | Skin mucous of the winter flounder (Pleuronectes americanus ) | α-helix | NA | ||
| 18795096 | 2008 | KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF | Cathelicidin-BF | Free | Free | Linear | L | None | 30 | Antimicrobial | Little hemolysis up to 400 mg/ml (non-hemolytic) | Human | Snake venoms of Bungarus fasciatus | random-coil | Non-hemolytic | ||
| 18827353 | 2008 | FFHHIFRGIVHVGKTIHRLVTG{ct:Amid} | Piscidin 1 (P1) | Amidation | Free | Linear | L | None | 22 | Antifungal | 100% hemolysis at 25μM | Human | Mast cells of hybrid striped bass | α-helix | NA | ||
| 18827353 | 2008 | FFHHIFRGIVHVGKTIHRLVTG{ct:Amid} | Piscidin 1 (P1) | Amidation | Free | Linear | L | None | 22 | Antifungal | 96% hemolysis at 12.5μM | Human | Mast cells of hybrid striped bass | α-helix | NA | ||
| 18827353 | 2008 | FFHHIFRGIVHVGKTIHRLVTG{ct:Amid} | Piscidin 1 (P1) | Amidation | Free | Linear | L | None | 22 | Antifungal | 92% hemolysis at 6.25μM | Human | Mast cells of hybrid striped bass | α-helix | NA | ||
| 18827353 | 2008 | FFHHIFRGIVHVGKTIHRLVTG{ct:Amid} | Piscidin 1 (P1) | Amidation | Free | Linear | L | None | 22 | Antifungal | 45% hemolysis at 3.125μM | Human | Mast cells of hybrid striped bass | α-helix | NA | ||
| 18827353 | 2008 | FFHHIFRGIVHVGKTIHRLVTG{ct:Amid} | Piscidin 1 (P1) | Amidation | Free | Linear | L | None | 22 | Antifungal | 9% hemolysis at 1.56μM | Human | Mast cells of hybrid striped bass | α-helix | NA | ||
| 18827353 | 2008 | FFHHIFRGIVHVGKTIHRLVTG{ct:Amid} | Piscidin 1 (P1) | Amidation | Free | Linear | L | None | 22 | Antifungal | 0% hemolysis at 0.78μM | Human | Mast cells of hybrid striped bass | α-helix | NA | ||
| 18827353 | 2008 | FIHHIFRGIVHAGRSIGRFLTG{ct:Amid} | Piscidin 3 (P3) | Amidation | Free | Linear | L | None | 22 | Antifungal | 25% hemolysis at 25μM | Human | Mast cells of hybrid striped bass | α-helix | NA | ||
| 18827353 | 2008 | FIHHIFRGIVHAGRSIGRFLTG{ct:Amid} | Piscidin 3 (P3) | Amidation | Free | Linear | L | None | 22 | Antifungal | 4% hemolysis at 12.5μM | Human | Mast cells of hybrid striped bass | α-helix | NA | ||
| 18827353 | 2008 | FIHHIFRGIVHAGRSIGRFLTG{ct:Amid} | Piscidin 3 (P3) | Amidation | Free | Linear | L | None | 22 | Antifungal | 0% hemolysis at 0.78 - 6.25μM | Human | Mast cells of hybrid striped bass | α-helix | NA | ||
| 18852279 | 2008 | KWKLFKKIGAVLKVL{nt:Acet}{ct:Amid} | CM15 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 45% hemolysis at 64μM | Human | Lysine-enriched analogs of the cecropin-mellitin hybrid | α-helix | NA | ||
| 18852279 | 2008 | KWKKFKKIGAVLKVL{nt:Acet}{ct:Amid} | K4 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 21% hemolysis at 64μM | Human | Lysine-enriched analogs of the cecropin-mellitin hybrid | α-helix | NA | ||
| 18852279 | 2008 | KWKLFKKIGKVLKVL{nt:Acet}{ct:Amid} | K10 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 67% hemolysis at 64μM | Human | Lysine-enriched analogs of the cecropin-mellitin hybrid | α-helix | NA | ||
| 18852279 | 2008 | KWKLFKKIGAVLKKL{nt:Acet}{ct:Amid} | K14 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 4% hemolysis at 64μM | Human | Lysine-enriched analogs of the cecropin-mellitin hybrid | α-helix | NA | ||
| 18852279 | 2008 | KWKKFKKIGKVLKVL{nt:Acet}{ct:Amid} | K410 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 9% hemolysis at 64μM | Human | Lysine-enriched analogs of the cecropin-mellitin hybrid | α-helix | NA | ||
| 18852279 | 2008 | KWKKFKKIGAVLKKL{nt:Acet}{ct:Amid} | K414 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 3% hemolysis at 64μM | Human | Lysine-enriched analogs of the cecropin-mellitin hybrid | α-helix | NA | ||
| 18852279 | 2008 | KWKLFKKIGKVLKKL{nt:Acet}{ct:Amid} | K1014 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 8% hemolysis at 64μM | Human | Lysine-enriched analogs of the cecropin-mellitin hybrid | α-helix | NA | ||
| 18972522 | 2008 | PICTRNGLPVCGETCFGGTCNTPGCTCTW{cyc:N-C} | K1 (B2) | Free | Free | Cyclic | L | None | 29 | Uteroactive and antimicrobial | 100% hemolysis at >0.5 mg/ml | Human | Kalata (Oldenlandia affinis DC) | β-strands | NA | ||
| 18972522 | 2008 | PVCTRNGLPVCGETCVGGTCNTPGCTCSW{cyc:N-C} | K2 (B1) | Free | Free | Cyclic | L | None | 29 | Uteroactive and antimicrobial | 100% hemolysis at >0.5 mg/ml | Human | Kalata (Oldenlandia affinis DC) | β-strands | NA | ||
| 18972522 | 2008 | PICKRNGLPVCGETCTLGTCYTQGCTCSW{cyc:N-C} | K3 (B7) | Free | Free | Cyclic | L | None | 29 | Uteroactive and antimicrobial | 100% hemolysis at >0.5 mg/ml | Human | Kalata (Oldenlandia affinis DC) | β-strands | NA | ||
| 19104020 | 2009 | KLALKLALKALKAALKLA{ct:Amid} | KLAL | Amidation | Free | Linear | L | None | 18 | Antimicrobial | EC50 =13.1μM | Human | Synthetic peptide | α-helix | NA | ||
| 19104020 | 2009 | KLALKLALKALKAALKLA{nt:Acet}{ct:Amid} | Ac-KLAL | Amidation | Acetylation | Linear | L | None | 18 | Antimicrobial | EC50 =9.1μM | Human | Synthetic peptide | α-helix | NA | ||
| 19104020 | 2009 | GIGKFIHAVKKWGKTFIGEIAKS{ct:Amid} | MK5E | Amidation | Free | Linear | L | None | 23 | Antimicrobial | EC50 =33.4μM | Human | Magainin-derived synthetic peptide | α-helix | NA | ||
| 19104020 | 2009 | GIGKFIHAVKKWGKTFIGEIAKS{nt:Acet}{ct:Amid} | Ac-MK5E | Amidation | Acetylation | Linear | L | None | 23 | Antimicrobial | EC50 >400μM | Human | Magainin-derived synthetic peptide | α-helix | NA | ||
| 19111524 | 2009 | TQTVYEWCGVATQLLAAYILL | Hemolysin E (HlyE) | Free | Free | Linear | L | None | 21 | Cytotoxic | ~90% hemolysis at 0.8μM | Human | Synthetic peptide | Helical | NA | ||
| 19111524 | 2009 | TQTVYEWCGDATQLLAAYILL | Mu1-HlyE | Free | Free | Linear | L | None | 21 | Cytotoxic | ~2% hemolysis at 0.8μM | Human | Synthetic peptide | Helical | NA | ||
| 19111524 | 2009 | TQTVYEWCDDATQLLAAYILL | Mu2-HlyE | Free | Free | Linear | L | None | 21 | Cytotoxic | 0% hemolysis at 0.8μM (non-hemolytic) | Human | Synthetic peptide | Helical | Non-hemolytic | ||
| 20033827 | 2011 | FWGALAKGALKLIPSLFSSFSKKD | Pin2 | Free | Free | Linear | L | None | 24 | Antimicrobial | IC50 =3.3μM | Human | Venom of the African scorpion Pandinus imperator | α-helix | NA | ||
| 20033827 | 2011 | FWGALAKGALKLIVSLFSSFSKKD | Pin2 [P14V] | Free | Free | Linear | L | None | 24 | Antimicrobial | IC50 =6.4μM | Human | Venom of the African scorpion Pandinus imperator | α-helix | NA | ||
| 20033827 | 2011 | FWGALAKGALKLIGVSLFSSFSKKD | Pin2 [P14GV] | Free | Free | Linear | L | None | 25 | Antimicrobial | IC50 =9.3μM | Human | Venom of the African scorpion Pandinus imperator | α-helix | NA | ||
| 20033827 | 2011 | FWGALAKGALKLIVGSLFSSFSKKD | Pin2 [P14VG] | Free | Free | Linear | L | None | 25 | Antimicrobial | IC50 =8.8μM | Human | Venom of the African scorpion Pandinus imperator | α-helix | NA | ||
| 20033827 | 2011 | FWGALAKGALKLIGVGSLFSSFSKKD | Pin2 [P14GVG] | Free | Free | Linear | L | None | 26 | Antimicrobial | IC50 =11.5μM | Human | Venom of the African scorpion Pandinus imperator | α-helix | NA | ||
| 19345214 | 2009 | ELLKAVRLIK | Rev-NIS | Free | Free | Linear | L | None | 10 | Antifungal | 0% hemolysis at 1-100μM (non-hemolytic) | Human | Rev (HIV-1) | helical | Non-hemolytic | ||
| 19399781 | 2009 | {nnr:Aib}-GL-{nnr:Aib}-GGL-{nnr:Aib}-GI-LOL{nt:Acet}{ct:leucinol} | Trichogin GA IV | 1,2-aminoalcohol, Lol (leucinol) | Acetylated by lipol (n-octanoyl) | Linear | L | Aib = α-aminoisobutyric acid | 11 | Antifungal and Antibacterial | 2% hemolysis at 15 μM | Human | Trichogin GA IV (Trichoderma longibrachiatum) | mixed 310/α-helical | NA | ||
| 19399781 | 2009 | {nnr:Aib}-GL-{nnr:Aib}-GGL-{nnr:Aib}-GIL{nt:Acet}{ct:Methoxy(Ome)} | Tric-OMe | Methoxy (Ome) | Acetylated by lipol (n-octanoyl) | Linear | L | Aib = α-aminoisobutyric acid | 11 | Antifungal and Antibacterial | 2% hemolysis at 15 μM | Human | Trichogin GA IV analogue (Trichoderma longibrachiatum) | mixed 310/α-helical | NA | ||
| 19399781 | 2009 | {nnr:Aib}-GGL-{nnr:Aib}-GIL{nt:Acet}{ct:Methoxy(Ome)} | Tric-8 | Methoxy (Ome) | Acetylated by lipol (n-octanoyl) | Linear | L | Aib = α-aminoisobutyric acid | 8 | Antifungal and Antibacterial | 0% hemolysis at 15 μM (non-hemolytic) | Human | Trichogin GA IV analogue (Trichoderma longibrachiatum) | mixed 310/α-helical | Non-hemolytic | ||
| 19399781 | 2009 | {nnr:Aib}-GIL{nt:Acet}{ct:Methoxy(Ome)} | Tric-4 | Methoxy (Ome) | Acetylated by lipol (n-octanoyl) | Linear | L | Aib = α-aminoisobutyric acid | 4 | Antifungal and Antibacterial | 0% hemolysis at 15 μM (non-hemolytic) | Human | Trichogin GA IV analogue (Trichoderma longibrachiatum) | mixed 310/α-helical | Non-hemolytic | ||
| 19445503 | 2009 | RRGWVLDLVLYYGRR | VDVY | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.02 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLDLVLYYGRR | VDVY | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.09 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLDLVLYYGRR | VDVY | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.27 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALVLYYGRR | VAVY | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.01 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALVLYYGRR | VAVY | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.19 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALVLYYGRR | VAVY | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.4 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALVLRYGRR | VAVR | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.01 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALVLRYGRR | VAVR | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.15 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALVLRYGRR | VAVR | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.28 fractions hemolysis in 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALYLRYGRR | VAYR | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.01 fracions Hemoysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALYLRYGRR | VAYR | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.2 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALYLRYGRR | VAYR | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.25 fractions hemolyis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLRLALAY | VRAA | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.01 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLRLALAY | VRAA | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.1 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLRLALAY | VRAA | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.14 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWALRLVLAY | ARVA | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.05 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWALRLVLAY | ARVA | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.12 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWALRLVLAY | ARVA | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.18 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWRLVLALVY | RVAV | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.01 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWRLVLALVY | RVAV | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.18 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWRLVLALVY | RVAV | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.3 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WYLTLTLGYGRR | YTTG | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.02 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WYLTLTLGYGRR | YTTG | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.15 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WYLTLTLGYGRR | YTTG | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.45 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WALRLYLVY | ARYV | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.01 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WALRLYLVY | ARYV | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.07 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WALRLYLVY | ARYV | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.14 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRLGY | VVRG | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.02 fractions hemolysis at 0.5μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRLGY | VVRG | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.1 fractions hemolysis at 5.0μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | WVLVLRLGY | VVRG | Free | Free | Linear | L | None | 9 | Antimicrobial | 0.26 fractions hemolysis at 15μM | Human | Synthetic peptide | β-sheet structure | NA | ||
| 19445503 | 2009 | RRGWVLALVL{d}RYGRR | dVAVR | Free | Free | Linear | Mix | None | 15 | Antimicrobial | 5±6 % hemolysis at 15μM | Human | Synthetic peptide | β-sheet | NA | ||
| 19445503 | 2009 | RRGWVLALYL{d}RYGRR | dVAYR | Free | Free | Linear | Mix | None | 15 | Antimicrobial | 5±3% hemolysis at 15μM | Human | Synthetic peptide | β-sheet | NA | ||
| 19445503 | 2009 | RRGWALRLVL{d}AY | dARVA | Free | Free | Linear | Mix | None | 12 | Antimicrobial | 4% hemolysis at 15μM | Human | Synthetic peptide | β-sheet | NA | ||
| 19445503 | 2009 | WVLVLRL{d}GY | dVVRG | Free | Free | Linear | Mix | None | 9 | Antimicrobial | 12±13 % hemolysis at 15μM | Human | Synthetic peptide | β-sheet | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 4.84% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 4.90% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 4.73% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 5.07% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 5.13%hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLK{ct:Amid} | L2K3W4 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 5.07% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.90% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5.13% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.90% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5.19% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5.01% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKWLKK{ct:Amid} | L2K4W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.90% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5.19% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.96% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.73% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.84% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.96% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKK{ct:Amid} | L3K3W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.78% Hmolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.61% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 6.05% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.73% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.44% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.78% hemolysis at12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLLK{ct:Amid} | L4K2W4 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 4.61% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.01% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.84% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.84% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.01% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.44% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKWLKKL{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.78% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.42% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.99% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.13% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.13% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 4.73% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLK{ct:Amid} | L4K3W4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 5.47% hemolysis at 63μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 7.09% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5.36% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 4.73% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 4.84% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5.19% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KLLKWLLKL{ct:Amid} | L5K3W5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 4.84% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLKKLL{ct:Amid} | L5K5W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 7.26% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLKKLL{ct:Amid} | L5K5W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 5.76% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLKKLL{ct:Amid} | L5K5W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 4.72% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLKKLL{ct:Amid} | L5K5W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 5.07% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLKKLL{ct:Amid} | L5K5W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 4.78% hemolysis at12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLKKLL{ct:Amid} | L5K5W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 5.30% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLLKLL{ct:Amid} | L6K4W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 57.58% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLLKLL{ct:Amid} | L6K4W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 14.92% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLLKLL{ct:Amid} | L6K4W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 7.38% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLLKLL{ct:Amid} | L6K4W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 5.01% hemolysis at25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLLKLL{ct:Amid} | L6K4W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 4.96% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | KKLLKWLLKLL{ct:Amid} | L6K4W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 4.73% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKLLKWLLKLL{ct:Amid} | L7K3W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 64.43% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKLLKWLLKLL{ct:Amid} | L7K3W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 34.29% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKLLKWLLKLL{ct:Amid} | L7K3W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 17.58% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKLLKWLLKLL{ct:Amid} | L7K3W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 14.99% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKLLKWLLKLL{ct:Amid} | L7K3W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 6.51% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKLLKWLLKLL{ct:Amid} | L7K3W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 5.13% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKLLKWLLKLLK{ct:Amid} | L7K5W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 47.72% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKLLKWLLKLLK{ct:Amid} | L7K5W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 20.86% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKLLKWLLKLLK{ct:Amid} | L7K5W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 12.80% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKLLKWLLKLLK{ct:Amid} | L7K5W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10.78% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKLLKWLLKLLK{ct:Amid} | L7K5W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 5.31% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LKKLLKWLLKLLK{ct:Amid} | L7K5W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 5.07% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKLLKWLLKLLK{ct:Amid} | L8K4W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 36.37% hemolysis at 200μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKLLKWLLKLLK{ct:Amid} | L8K4W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10.90% hemolysis at 100μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKLLKWLLKLLK{ct:Amid} | L8K4W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 7.61% hemolysis at 50μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKLLKWLLKLLK{ct:Amid} | L8K4W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 5.24% hemolysis at 25μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKLLKWLLKLLK{ct:Amid} | L8K4W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 5.24% hemolysis at 12.5μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19544481 | 2009 | LLKLLKWLLKLLK{ct:Amid} | L8K4W7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 4.44% hemolysis at 6.3μg/ml | Human | Synthetic peptide | helical | NA | ||
| 19563807 | 2009 | GLFGKLIKKFGRKAISYAVKKARGKH | Ltc2a (native) | Free | Free | Linear | L | None | 26 | Antimicrobial and Cytotoxic | EC50 =6μM | Human | Lachesana tarabaevi Spider venom | α-helix | NA | ||
| 19563807 | 2009 | GLFGKLQKKFGRKAISYAVKKARGKH | Ltc2a_I7Q | Free | Free | Linear | L | None | 26 | Antimicrobial and Cytotoxic | EC50 >36μM | Human | Lachesana tarabaevi Spider venom | α-helix | NA | ||
| 19563807 | 2009 | GLFGKLIKKKGRKAISYAVKKARGKH | Ltc2a_F10K | Free | Free | Linear | L | None | 26 | Antimicrobial and Cytotoxic | EC50 >36μM | Human | Lachesana tarabaevi Spider venom | α-helix | NA | ||
| 19563807 | 2009 | GLFGKLIKKFLRKAISYAVKKARGKH | Ltc2a_G11L | Free | Free | Linear | L | None | 26 | Antimicrobial and Cytotoxic | EC50 =3μM | Human | Lachesana tarabaevi Spider venom | α-helix | NA | ||
| 19563807 | 2009 | GKLIKKFGRKAISYAVKKARGKH | Ltc2a_N-trim | Free | Free | Linear | L | None | 23 | Antimicrobial and Cytotoxic | EC50 >36μM | Human | Lachesana tarabaevi Spider venom | α-helix | NA | ||
| 19563807 | 2009 | GFFGKMKEYFKKFGASFKRRFANLKKRL{ct:Amid} | Ltc5 (native) | Amidation | Free | Linear | L | None | 28 | Antimicrobial and Cytotoxic | EC50 =12μM | Human | Lachesana tarabaevi Spider venom | α-helix | NA | ||
| 19563807 | 2009 | GFFGKRKEYFKKFGASFKRRFANLKKRL{ct:Amid} | Ltc5_M6R | Amidation | Free | Linear | L | None | 28 | Antimicrobial and Cytotoxic | EC50 >36μM | Human | Lachesana tarabaevi Spider venom | α-helix | NA | ||
| 19563807 | 2009 | GKMKEYFKKFGASFKRRFANLKKRL{ct:Amid} | Ltc5_N-trim | Amidation | Free | Linear | L | None | 25 | Antimicrobial and Cytotoxic | EC50 >36μM | Human | Lachesana tarabaevi Spider venom | α-helix | NA | ||
| 19576903 | 2009 | ILPWKWPWWPWRR{ct:Amid} | IL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 100% hemolysis at 64μM | Human | Indolicidin (bovine) | NA | NA | ||
| 19576903 | 2009 | ILPWKWKWWPWRR{ct:Amid} | IL-K7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 41.8% hemolysis at 64μM | Human | Indolicidin analog (bovine) | NA | NA | ||
| 19576903 | 2009 | ILPWKWPFFPWRR{ct:Amid} | IL-F89 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 21.4% hemolysis at 64μM | Human | Indolicidin analog (bovine) | NA | NA | ||
| 19576903 | 2009 | ILPWKWKFFPWRR{ct:Amid} | IL-K7F89 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10% hemolysis at 64μM | Human | Indolicidin analog (bovine) | NA | NA | ||
| 19576903 | 2009 | ILPFKFPFFPFRR{ct:Amid} | IL-F | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3.3% hemolysis at 64μM | Human | Indolicidin analog (bovine) | NA | NA | ||
| 19703772 | 2009 | KLLLKLWLKLLK{nt:Acet}{ct:Amid} | KL1 | Amidation | Acetylation | Linear | L | None | 12 | Antibacterial | 100% hemolysis at >50μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 19703772 | 2009 | K{nnr:Ψ[CH2NH]}LLLKLWLKLLK{nt:Acet}{ct:Amid} | KL2 | Amidation | Acetylation | Linear | L | nnr:Ψ[CH2NH] | 12 | Antibacterial | 100% hemolysis at 150μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 19703772 | 2009 | KLLLKLWL{Ψ[CH2NH]}KLLK{nt:Acet}{ct:Amid} | KL3 | Amidation | Acetylation | Linear | L | nnr:Ψ[CH2NH] | 12 | Antibacterial | Low hemolysis upto 200μg/ml | Human | Synthetic peptide | α-helix | NA | ||
| 19804724 | 2009 | MQFITDLIKKAVDFFKGLFGNK | Warnericin RK | Free | Free | Linear | L | None | 22 | Antimicrobial | 100% hemolysis at 200μM | Human | Warnericin RK (Staphylococcus warneri RK strain) | α-helix | NA | ||
| 19635451 | 2010 | GIGAVLKVLALISWIKRKR{ct:Amid} | Mel-H | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 28% hemolysis at 0.4μM | Human | Melittin analog (venom of European honey bee) | α-helix | NA | ||
| 19635451 | 2010 | GIGAVLKVLALISWIKRKR{ct:Amid} | Mel-H | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 42% hemolysis at 23μM | Human | Melittin analog (venom of European honey bee) | α-helix | NA | ||
| 19635451 | 2010 | GIGAV{d}LKV{d}LAL{d}ISWIK{d}RKR{ct:Amid} | Mel-dH | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial | 5% hemolysis at 0.4μM | Human | Melittin analog (venom of European honey bee) | α-helix | NA | ||
| 19635451 | 2010 | GIGAV{d}LKV{d}LAL{d}ISWIK{d}RKR{ct:Amid} | Mel-dH | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial | 12 % hemolysis at 23μM | Human | Melittin analog (venom of European honey bee) | α-helix | NA | ||
| 20176897 | 2010 | G-{nnr:ΔF}-RK-{nnr:ΔF}-HK-{nnr:ΔF}-WA{nt:Acet}{ct:Amid} | ΔFm | Amidation | Acetylation | Linear | L | ΔF = α,β-didehydrophenylalanine | 10 | Antibacterial | 0% hemolysis upto 1358μg/ml (non-hemolytic) | Human | Synthetic peptide | Helical | Non-hemolytic | ||
| 20176897 | 2010 | G-{nnr:ΔF}-RK-{nnr:ΔF}-KA-{nnr:ΔF}-WH{nt:Acet}{ct:Amid} | ΔFmscr | Amidation | Acetylation | Linear | L | ΔF = α,β-didehydrophenylalanine | 10 | Antibacterial | 0% hemolysis upto 679μg/ml (non-hemolytic) | Human | Synthetic peptide | helical | Non-hemolytic | ||
| 20196123 | 2010 | ILPWKWPWWPWRR{ct:Amid} | Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100% hemolysis at 50μM | Human | Indolicidin (bovine) | Random-coil | NA | ||
| 20196123 | 2010 | ILPLKWPWWPWRR{ct:Amid} | [L4]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 73% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKLPWWPWRR{ct:Amid} | [L6]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 88% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKWPLWPWRR{ct:Amid} | [L8]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 63% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKWPWLPWRR{ct:Amid} | [L9]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 6% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKWPWWPLRR{ct:Amid} | [L11]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 13% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPLKLPLLPLRR{ct:Amid} | [L4,6,8,9,11]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPFKFPFFPFRR{ct:Amid} | [F4,6,8,9,11]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 6% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPYKYPYYPYRR{ct:Amid} | [Y4,6,8,9,11]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 4% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPLKLPWWPWRR{ct:Amid} | [L4,6]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 8% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPKKKPWWPWRR{ct:Amid} | [K4,6]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 8% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKWPLLPWRR{ct:Amid} | [L8,9]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 18% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKWPYLPWRR{ct:Amid} | [Y8,L9]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 60% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKWPKLPWRR{ct:Amid} | [K8,L9]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 0% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | Non-hemolytic | ||
| 20196123 | 2010 | ILPWKWPWLPLRR{ct:Amid} | [L9,11]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 3% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKWPWLPYRR{ct:Amid} | [L9,Y11]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 12% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKWPWLPKRR{ct:Amid} | [L9,K11]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 3% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPKKWPKLPWRR{ct:Amid} | [K4,8,L9]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 7% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKKPKLPWRR{ct:Amid} | [K6,8,L9]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 11% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | ILPWKWPWLPWKK{ct:Amid} | [L9,K12,13]Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 8% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | RRWPWWPWKWPLI{ct:Amid} | Retro-Ind | Amidation | Free | Linear | L | None | 13 | Antibacterial | 36% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | RRWPLLPWKWPLI{ct:Amid} | Retro-[L8,9]Indb | Amidation | Free | Linear | L | None | 13 | Antibacterial | 11% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | RRWPLKPWKKPLI{ct:Amid} | Retro-[K4,8,L9]Indb | Amidation | Free | Linear | L | None | 13 | Antibacterial | 9% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20196123 | 2010 | RRWPLKPKKWPLI{ct:Amid} | Retro-[K6,8,L9]Indb | Amidation | Free | Linear | L | None | 13 | Antibacterial | 7% hemolysis at 50μM | Human | Indolicidin analog (synthetic peptide) | Random-coil | NA | ||
| 20213310 | 2010 | RWKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVKG | Papiliocin | Free | Free | Linear | L | None | 38 | Antimicrobial | 0% hemolysis at 3 - 50μM (non-hemolytic) | Human | Papiliocin (Papilio xuthus) | NA | Non-hemolytic | ||
| 20237682 | 2010 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC = 3.0x10-5 g/ml | Human | Indolicidin (bovine neutrophils) | α Helical and β Sheet | NA | ||
| 20237682 | 2010 | ILPWKWPWWPARR{ct:Amid} | Δ5 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC = 2.8x10-3 g/ml | Human | Indolicidin derivative (bovine neutrophils) | α Helical and β Sheet | NA | ||
| 20237682 | 2010 | ILPWKWPWAPARR{ct:Amid} | Δ45 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC = >2.6 x 10-3 g/ml | Human | Indolicidin derivative (bovine neutrophils) | α Helical and β Sheet | NA | ||
| 20237682 | 2010 | ILPWKWPAAPARR{ct:Amid} | Δ345 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC = >6.7x10-3 g/ml | Human | Indolicidin derivative (bovine neutrophils) | NA | NA | ||
| 20237682 | 2010 | ILPWKAPAAPARR{ct:Amid} | Δ2345 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC = >6.4x10-3 g/ml | Human | Indolicidin derivative (bovine neutrophils) | NA | NA | ||
| 20237682 | 2010 | ILPAKAPAAPARR{ct:Amid} | Δ12345 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC = >6.8x10-3 g/ml | Human | Indolicidin derivative (bovine neutrophils) | NA | NA | ||
| 20308076 | 2010 | FFFLSRIF{ct:Amid} | Temporin-SHf | Amidation | Free | Linear | L | None | 8 | Antimicrobial | LC50 = 200μM | Human | Skin of the frog Pelophylax saharica | α Helical | NA | ||
| 20564013 | 2010 | GTPCGESCVYIPCISGVIGCSCTDKVCYLN{cyc:N-C} | Kalata B5 | Free | Free | Cyclic | L | None | 30 | Pesticidal | HD50 =27.4±1.2μM | Human | Cyclotides (Oldenlandia affinis) | typical bracelet cyclotide fold | NA | ||
| 20665599 | 2010 | KLKKLLKKWLKLLKKLLK{ct:Amid} | K9L8W | Amidation | Free | Linear | L | None | 18 | Antifungal | HC50 =14μM | Human | Synthetic peptide | α-helix | NA | ||
| 20665599 | 2010 | KL{d}KK{d}LL{d}KK{d}WL{d}KL{d}LK{d}KL{d}LK{d}{ct:Amid} | D9-K9L8W | Amidation | Free | Linear | Mix | None | 18 | Antifungal | HC50 <800μM | Human | Synthetic peptide | α-helix | NA | ||
| 20690652 | 2010 | KNLRRIIRKGIHIIKKYF | Novicidin | Free | Free | Linear | L | None | 18 | Antimicrobial | IC50 >50μM | Human | Peptide derived from ovispirin, a cationic peptide which originated from the ovine cathelicidin SMAP-29 | Helical | NA | ||
| 20955730 | 2011 | RIKRFWPVVIRTVVAGYNLYRAIKKK | Pc-CATH1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 3.6% hemolysis at 3.15μM | Human | Cathelicidin (ring necked pheasant Phasianus colchicus) | NA | NA | ||
| 20955730 | 2011 | RIKRFWPVVIRTVVAGYNLYRAIKKK | Pc-CATH1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 6.3% hemolysis at 6.30μM | Human | Cathelicidin (ring necked pheasant Phasianus colchicus) | NA | NA | ||
| 20955730 | 2011 | RIKRFWPVVIRTVVAGYNLYRAIKKK | Pc-CATH1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 9.1% hemolysis at 15.7μM | Human | Cathelicidin (ring necked pheasant Phasianus colchicus) | NA | NA | ||
| 20955730 | 2011 | RIKRFWPVVIRTVVAGYNLYRAIKKK | Pc-CATH1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 13.2% hemolysis at 31.5μM | Human | Cathelicidin (ring necked pheasant Phasianus colchicus) | NA | NA | ||
| 21110126 | 2011 | FLGWLFKWASK{ct:Amid} | GA-W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =25μg/ml | Human | Brevinin-1EMa analog (skin of a species of Korean frog Glandirana emeljanovi) | α-helix | NA | ||
| 21110126 | 2011 | FLGWLFKWAWK{ct:Amid} | GA-W3 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =50μg/ml | Human | Brevinin-1EMa analog (skin of a species of Korean frog Glandirana emeljanovi) | α-helix | NA | ||
| 21110126 | 2011 | FLWWLFKWAWK{ct:Amid} | GA-W4 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =25μg/ml | Human | Brevinin-1EMa analog (skin of a species of Korean frog Glandirana emeljanovi) | α-helix | NA | ||
| 21110126 | 2011 | FLGWLFKWAKK{ct:Amid} | GA-K3 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =50μg/ml | Human | Brevinin-1EMa analog (skin of a species of Korean frog Glandirana emeljanovi) | α-helix | NA | ||
| 21110126 | 2011 | FLKWLFKWAKK{ct:Amid} | GA-K4 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =6.3μg/ml | Human | Brevinin-1EMa analog (skin of a species of Korean frog Glandirana emeljanovi) | α-helix | NA | ||
| 21110126 | 2011 | FLKWLFKWLKK{ct:Amid} | GA-K4L | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =12.5μg/ml | Human | Brevinin-1EMa analog (skin of a species of Korean frog Glandirana emeljanovi) | α-helix | NA | ||
| 21110126 | 2011 | FAKWAFKWAKK{ct:Amid} | GA-K4A | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC ≥200μg/ml | Human | Brevinin-1EMa analog (skin of a species of Korean frog Glandirana emeljanovi) | α-helix | NA | ||
| 21110126 | 2011 | FAKWAFKWLKK{ct:Amid} | GA-K4AL | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC ≥200μg/ml | Human | Brevinin-1EMa analog (skin of a species of Korean frog Glandirana emeljanovi) | α-helix | NA | ||
| 21184776 | 2011 | NGVQPKY | Leucrocin I | Free | Free | Linear | L | None | 7 | Antibacterial | 15.88% hemolysis upto 48.0μg | Human | Leucrocin (serum and plasma of Crocodylus siamensis) | 28.57% Extended strand 71.43% Random coil | NA | ||
| 21184776 | 2011 | NAGSLLSGWG | Leucrocin II | Free | Free | Linear | L | None | 10 | Antibacterial | 91.73% hemolysis at 10μg | Human | Leucrocin (serum and plasma of Crocodylus siamensis) | 44.44% Extended strand 55.56% Random coil | NA | ||
| 21184776 | 2011 | NAGSLLSGWG | Leucrocin II | Free | Free | Linear | L | None | 10 | Antibacterial | 11.63% hemolysis at 6.0μg | Human | Leucrocin (serum and plasma of Crocodylus siamensis) | 45.44% Extended strand 55.56% Random coil | NA | ||
| 14709550 | 2004 | K{d}GGGK{d}WGGK{d}GGK{d}{nt:Palmitoylation}{ct:Amid} | PA-D-G | Amidation | Palmitoylation | Linear | Mix | None | 12 | Antifungal and Antibacterial | >75% hemolysis at 100µM | Human | Synthetic peptide | Random coils | NA | ||
| 14709550 | 2004 | KAA{d}A{d}KWAA{d}KA{d}AK{nt:Palmitoylation}{ct:Amid} | PA-D-A | Amidation | Palmitoylation | Linear | Mix | None | 12 | Antifungal and Antibacterial | <25% hemolysis at 100µM | Human | Synthetic peptide | Random coils | NA | ||
| 14709550 | 2004 | KVV{d}V{d}KWVV{d}KV{d}VK{nt:Palmitoylation}{ct:Amid} | PA-D-V | Amidation | Palmitoylation | Linear | Mix | None | 12 | Antifungal and Antibacterial | 100% hemolysis at 100µM | Human | Synthetic peptide | β-aggregates | NA | ||
| 14709550 | 2004 | KLL{d}L{d}KWLL{d}KL{d}LK{nt:Palmitoylation}{ct:Amid} | PA-D-L | Amidation | Palmitoylation | Linear | Mix | None | 12 | Antifungal and Antibacterial | >75% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKLLKLLKKLLK{ct:Amid} | KLW | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 50% hemolysis at 50µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKLLKLLKKLLK{ct:Amid} | KLW | Amidation | Free | Linear | L | None | 18 | Antimicrobial | >50% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKPLKLLKKLLK{ct:Amid} | KLW-L9P | Amidation | Free | Linear | L | None | 18 | Antimicrobial | <10% hemolysis at 50µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKPLKLLKKLLK{ct:Amid} | KLW-L9P | Amidation | Free | Linear | L | None | 18 | Antimicrobial | ~10% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKP{d}LKLLKKLLK{ct:Amid} | KLW-L9p | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | <5 % hemolysis at 50µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKP{d}LKLLKKLLK{ct:Amid} | KLW-L9p | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | ~5% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKLLPLLKKLLK{ct:Amid} | KLW-K11P | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 50% hemolysis at 50µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKLLPLLKKLLK{ct:Amid} | KLW-K11P | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 50% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKLLP{d}LLKKLLK{ct:Amid} | KLW-K11p | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | <20% hemolysis at 50µM | Human | Synthetic peptide | α-helical | NA | ||
| 14733952 | 2004 | KWKKLLKKLLP{d}LLKKLLK{ct:Amid} | KLW-K11p | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | >30% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVQRIKDFFRNLVPRTES | FALL-39 | Free | Free | Linear | L | None | 39 | Antibiotic | >25% hemolysis at 200g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVQRIKDFFRNLVPRTES | FALL-39 | Free | Free | Linear | L | None | 39 | Antibiotic | >30% hemolysis at 400g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVQRIKDFFRKLVPRTES | FALL-39-lys32 | Free | Free | Linear | L | None | 39 | Antibiotic | 30% hemolysis at 200g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVQRIKDFFRKLVPRTES | FALL-39-lys32 | Free | Free | Linear | L | None | 39 | Antibiotic | 40% hemolysis at 400g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVKRIKDFFRNLVPRTES | FALL-39-lys24 | Free | Free | Linear | L | None | 39 | Antibiotic | >30% hemolysis at 200g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 14769216 | 2004 | FALLGDFFRKSKEKIGKEFKRIVKRIKDFFRNLVPRTES | FALL-39-lys24 | Free | Free | Linear | L | None | 39 | Antibiotic | >35% hemolysis at 400g/l | Human | Cathelicidin (Homo sapiens bone marrow) | α-helical | NA | ||
| 15009528 | 2004 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14KD4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =125 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLL{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14LD4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =5 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLF{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14FD4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =2 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLY{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14YD4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =5 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLN{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14ND4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =62 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTTG | HM1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 46% hemolysis at 100µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTTG | HM1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 30% hemolysis at 50µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTWG | HM3 | Free | Free | Linear | L | None | 20 | Antimicrobial | 86% hemolysis at 100µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTWG | HM3 | Free | Free | Linear | L | None | 20 | Antimicrobial | 69% hemolysis at 50µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AWKVFKRLGIGAVLWVLTWG | HM4 | Free | Free | Linear | L | None | 20 | Antimicrobial | 98% hemolysis at 100µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AWKVFKRLGIGAVLWVLTWG | HM4 | Free | Free | Linear | L | None | 20 | Antimicrobial | 83% hemolysis at 50µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15232222 | 2004 | GIFSKLAGKKIKNLLISGLKNIGKEVGMDVVRTGIDIAGCKIKGEC | Esculentin-1c | Free | Free | Linear | L | None | 46 | Antimicrobial | 0.01% hemolysis at 10µg/ml | Human | Esculentin-1 family (skin of the Rana esculenta) | NA | NA | ||
| 15232222 | 2004 | VIPFVASVAAEMMHHVYCAASKRC | Brevinin-1Ed | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.19% hemolysis at 10µg/ml | Human | Brevinin-1 family (skin of the Rana esculenta) | α-helical | NA | ||
| 15232222 | 2004 | FLPLLAGLAANFLPKIFCKITRKC | Brevinin-1E | Free | Free | Linear | L | None | 24 | Antimicrobial | 25.8% hemolysis at 10µg/ml | Human | Brevinin-1 family (skin of the Rana esculenta) | α-helical | NA | ||
| 15232222 | 2004 | VIPFVASVAAEMMQHVYCAASRKC | Brevinin-1Eb | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.02% hemolysis at 10µg/ml | Human | Brevinin-1 family (skin of the Rana esculenta) | α-helical | NA | ||
| 15232222 | 2004 | GIFSKLAGKKIKNLLISGLKNIGKEVGMDVVRTGIDIAGCKIKGEC | Esculentin-1c | Free | Free | Linear | L | None | 46 | Antimicrobial | 0.06% hemolysis at 100µg/ml | Human | Esculentin-1 family (skin of the Rana esculenta) | α-helical | NA | ||
| 15232222 | 2004 | VIPFVASVAAEMMHHVYCAASKRC | Brevinin-1Ed | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.32% hemolysis at 100µg/ml | Human | Brevinin-1 family (skin of the Rana esculenta) | α-helical | NA | ||
| 15232222 | 2004 | FLPLLAGLAANFLPKIFCKITRKC | Brevinin-1E | Free | Free | Linear | L | None | 24 | Antimicrobial | 189.2% hemolysis at 100µg/ml | Human | Brevinin-1 family (skin of the Rana esculenta) | α-helical | NA | ||
| 15232222 | 2004 | VIPFVASVAAEMMQHVYCAASRKC | Brevinin-1Eb | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.08% hemolysis at 100µg/ml | Human | Brevinin-1 family (skin of the Rana esculenta) | α-helical | NA | ||
| 15325526 | 2005 | GILSSFKGVAKGVAKNLAGKLLDELKCKITGC | Ranatuerin-2AUa | Free | Free | Linear | L | None | 32 | Antimicrobial | HC50 =290µM | Human | Ranatuerin-2 from skin secretions of the Northern red-legged frog Rana aurora aurora | NA | NA | ||
| 15325526 | 2005 | FLPILAGLAAKLVPKVFCSITKKC | Brevinin-1AUa | Free | Free | Linear | L | None | 24 | Antimicrobial | HC50 =5µM | Human | Brevinin-1 from skin secretions of the Northern red-legged frog Rana aurora aurora | NA | NA | ||
| 15325526 | 2005 | FLPILAGLAANILPKVFCSITKKC | Brevinin-1AUb | Free | Free | Linear | L | None | 24 | Antimicrobial | HC50 =7µM | Human | Brevinin-1 from skin secretions of the Northern red-legged frog Rana aurora aurora | NA | NA | ||
| 15325526 | 2005 | FLPIIGQLLSGLL{ct:Amid} | Temporin-1AUa | Amidation | Free | Linear | L | None | 13 | Antimicrobial | HC50 >300µM | Human | Temporin-1 from skin secretions of the Northern red-legged frog Rana aurora aurora | NA | NA | ||
| 15639237 | 2005 | GLGSVFGRLARILGRVIPKV{ct:Amid} | P1 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 20% hemolysis at 10µM | Human | Ant venom toxin pilosulin (Myrmecia pilosula) | α-helical | NA | ||
| 15639237 | 2005 | GLLSKFGRLARKLARVIPKV{ct:Amid} | P2 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 15% hemolysis at 10µM | Human | Ant venom toxin pilosulin (Myrmecia pilosula) | α-helical | NA | ||
| 15639237 | 2005 | GLGSVFGRLARILGRVIPKV{ct:Amid} | P1 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 100% hemolysis at 100µM | Human | Ant venom toxin pilosulin (Myrmecia pilosula) | α-helical | NA | ||
| 15639237 | 2005 | GLLSKFGRLARKLARVIPKV{ct:Amid} | P2 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 40% hemolysis at 100µM | Human | Ant venom toxin pilosulin (Myrmecia pilosula) | α-helical | NA | ||
| 15752569 | 2005 | FLSLIPHAINAVSAIAKHN{ct:Amid} | PS-1 | Amidation | Free | Linear | L | None | 19 | Antibacterial and Antiprotozoan | 1.98% hemolysis at 64µM | Human | Skin secretion of the Brazilian tree-frogs, Phyllomedusa hypochondrialis and Phyllomedusa oreades | α-helical | NA | ||
| 15752569 | 2005 | FLSLIPHAINAVSTLVHHF{ct:Amid} | PS-2 | Amidation | Free | Linear | L | None | 19 | Antibacterial and Antiprotozoan | 2.05% hemolysis at 64µM | Human | Skin secretion of the Brazilian tree-frogs, Phyllomedusa hypochondrialis and Phyllomedusa oreades | α-helical | NA | ||
| 16142907 | 2005 | KWKKLLKKLLKLLKKLLK{ct:Amid} | KLW | Amidation | Free | Linear | L | None | 18 | Antimicrobial | >50% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 16142907 | 2005 | KWKKLLKK{nnr:a}LKLLKKLLK{ct:Amid} | KLW-L9-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 16142907 | 2005 | KWKKLLKKL{nnr:a}KLLKKLLK{ct:Amid} | KLW-L10-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | 20% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16142907 | 2005 | KWKKLLKKLL{nnr:a}LLKKLLK{ct:Amid} | KLW-K11-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | ~50% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16142907 | 2005 | KWKKLL{nnr:a}KLL{nnr:a}LLKKLLK{ct:Amid} | KLW-K7,11-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | ~30% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16142907 | 2005 | KWKKLLKKLLKLLKKLLK{ct:Amid} | KLW | Amidation | Free | Linear | L | None | 18 | Antimicrobial | <50% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 16142907 | 2005 | KWKKLLKK{nnr:a}LKLLKKLLK{ct:Amid} | KLW-L9-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | >5% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 16142907 | 2005 | KWKKLLKKL{nnr:a}KLLKKLLK{ct:Amid} | KLW-L10-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | 10-15% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 16142907 | 2005 | KWKKLLKKLL{nnr:a}LLKKLLK{ct:Amid} | KLW-K11-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | ~50% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 16142907 | 2005 | KWKKLL{nnr:a}KLL{nnr:a}LLKKLLK{ct:Amid} | KLW-K7,11-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | 10-15% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 16226345 | 2006 | DAACAAHCLWR{ct:Amid} | L1 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 100% hemolysis at 50μg/ml | Human | Synthetic peptide | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLCYKQRCVTYCRGR{ct:Amid} | Gomesin | Amidation | Free | Linear | L | Z = pyroglutamic acid | 18 | Antimicrobial | At 100µM less than 10% hemolysis | Human | Gomesin(Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}DRRLSYKQRSVTYORGR{cyc:N-C}{ct:Amid} | cyclo(2-15)[Asp2 Ser6,11, Orn15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~10% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}SRRLDYKQROVTYSRGR{cyc:N-C}{ct:Amid} | cyclo(6-11)[Ser2,15, Asp6, Orn11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~10% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLDYKQROVTYCRGR{cyc:N-C}{ct:Amid} | Bicyclo(2-15, 6-11)[Cys2, 15, Asp6, Orn11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | >30% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLDYKQRBVTYCRGR{cyc:N-C}{ct:Amid} | Bicyclo(2-15, 6-11)[Cys2, 15, Asp6, Dap11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | >30% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}DRRLCYKQRCVTYORGR{cyc:N-C}{ct:Amid} | Bicyclo(2-15, 6-11)[Asp2, Cys6, 11, Orn15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~15% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16235231 | 2006 | {nnr:Z}DRRLCYKQRCVTYBRGR{cyc:N-C}{ct:Amid} | Bicyclo(2-15, 6-11)[Asp2, Cys6, Dap15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~15% hemolysis at 100µM | Human | Analog of Gomesin (Acanthoscurria gomesiana) | α-helical and β-sheet | NA | ||
| 16460023 | 2006 | VSAVAKVAMKKGAALLKKMGVKISPLK | P1 | Free | Free | Linear | L | None | 27 | Hemolytic | 50% hemolysis at >900µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16460023 | 2006 | KQLKKVSAVAKVAMKKGAALLKKMGVK | P2 | Free | Free | Linear | L | None | 27 | Hemolytic | 50% hemolysis at 450µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16460023 | 2006 | VGKVLKQLKKVSAVAKVAMKKGAALLK | P3 | Free | Free | Linear | L | None | 27 | Hemolytic | 50% hemolysis at >900µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16460023 | 2006 | KFGKIVGKVLKQLKKVSAVAKVAMKKG | P4 | Free | Free | Linear | L | None | 27 | Hemolytic | 50% hemolysis at 274µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16460023 | 2006 | GKVLDKFGKIVGKVLKQLKKVSAVAKV | P5 | Free | Free | Linear | L | None | 27 | Hemolytic | 50% hemolysis at 117µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16460023 | 2006 | FKIKPGKVLDKFGKIVGKVLKQLKKVSAVAKV | P6 | Free | Free | Linear | L | None | 32 | Hemolytic | 50% hemolysis at 90µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16460023 | 2006 | FKIKPGKVLDKFGKIVGKVLKQLKKVS | P7 | Free | Free | Linear | L | None | 27 | Hemolytic | 50% hemolysis at 296µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16460028 | 2006 | GASLSFKILKTVLEALGNV | EqTII11-29 | Free | Free | Linear | L | None | 19 | Hemolytic | 10% hemolysis at 25µM | Human | Actinoporin from sea anaemone Actinia equina L | NA | NA | ||
| 16616888 | 2006 | FQWQRNIRKVR{nt:acylation (CH3-(CH2)10-CO-NH-)}{ct:Amid} | C12LF11 | Amidation | acylation (CH3-(CH2)10-CO-NH-) | Linear | L | None | 11 | Antimicrobial | 0.25% hemolysis at 100µg/ml | Human | N-lauryl-derivative of LF11(human lactoferrin) | NA | NA | ||
| 16621155 | 2006 | GLFGKILGVGKKVLCGLSGMC | Nigrocin-2GRb | Free | Free | Linear | L | None | 21 | Antimicrobial | LC50 = 40µM | Human | Nigrocin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 16621155 | 2006 | GLLSGILGAGKHIVCGLSGLC | Nigrocin-2GRa | Free | Free | Linear | L | None | 21 | Antimicrobial | LC50 = 295µM | Human | Nigrocin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 16621155 | 2006 | GLLSGILGAGKNIVCGLSGLC | Nigrocin-2GRc | Free | Free | Linear | L | None | 21 | Antimicrobial | LC50 = 500µM | Human | Nigrocin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 16621155 | 2006 | GLFSKFAGKGIKNLIFKGVKHIGKEVGMDVIRTGIDVAGCKIKGEC | Esculentin-IGRa | Free | Free | Linear | L | None | 46 | Antimicrobial | LC50 = 210µM | Human | Esculentin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 16621155 | 2006 | GLLDTFKNLALALNAAKSAGVLNSLSCKLSKTC | Brevinin-2GRa | Free | Free | Linear | L | None | 33 | Antimicrobial | LC50 =140µM | Human | Brevinin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 16621155 | 2006 | GVLGTVKNLLIGAGKSAAQSVLKTLSCKLSNDC | Brevinin-2GRb | Free | Free | Linear | L | None | 33 | Antimicrobial | LC50 = 180µM | Human | Brevinin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 16621155 | 2006 | GLFTLIKGAAKLIGKTVAKEAGKTGLELMACKITNQC | Brevinin-2GRc | Free | Free | Linear | L | None | 37 | Antimicrobial | LC50 = 100µM | Human | Brevinin isolated from an extract of the skin of the Yunnanfu Kunming frog Rana grahami | NA | NA | ||
| 16730857 | 2006 | KFKLKQ{cyc:N-C} | BPC6L | Free | Free | Cyclic | L | None | 6 | Hemolytic | 11±4.6% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKFKLKQ{cyc:N-C} | BPC8L | Free | Free | Cyclic | L | None | 8 | Antibacterial | 68±7.5% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKLKFKLKQ{cyc:N-C} | BPC10L | Free | Free | Cyclic | L | None | 10 | Antibacterial | 81 ± 5.3% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKF{d}KLKQ{cyc:N-C} | BPC8D | Free | Free | Cyclic | Mix | None | 8 | Hemolytic | 37±5.2% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKLKF{d}KLKQ{cyc:N-C} | BPC10D | Free | Free | Cyclic | Mix | None | 10 | Hemolytic | 42± 6.8% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | KLKLKLKQ{cyc:N-C} | BPC8S1 | Free | Free | Cyclic | L | None | 8 | Hemolytic | 1±0.1% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16730857 | 2006 | LKLKLKLQ{cyc:N-C} | BPC8S3 | Free | Free | Cyclic | L | None | 8 | Hemolytic | 5±0.1% hemolysis at 360µM | Human | Synthetic peptide | NA | NA | ||
| 16762455 | 2006 | LNLKGIFKKVASLLT | Eumenitin | Free | Free | Linear | L | None | 15 | Antimicrobial | 20% hemolysis at 1mM | Human | Eumenitin isolated from the venom of the solitary eumenine wasp Eumenes rubronotatus | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLKLLKKLLKKLKKLLK{ct:Amid} | M25 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | ~80% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLKLPKKLLKKLKKLLK{ct:Amid} | M25P | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 11% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLKLLKKLLKKLK{ct:Amid} | M21 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 65% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLPLLKKLLKKLK{ct:Amid} | M21P | Amidation | Free | Linear | L | None | 21 | Antimicrobial | ~40% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLKLLKKLL{ct:Amid} | M17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | ~63% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKPLKLLKKLL{ct:Amid} | M17P | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0-5% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLKLLKKLLKKLKKLLK{ct:Amid} | M25 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 75% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLKLPKKLLKKLKKLLK{ct:Amid} | M25P | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 11% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLKLLKKLLKKLK{ct:Amid} | M21 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 65% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLPLLKKLLKKLK{ct:Amid} | M21P | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 21% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKLLKLLKKLL{ct:Amid} | M17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | ~63% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 16889633 | 2006 | KWKKLLKKPLKLLKKLL{ct:Amid} | M17P | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 4% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 16940084 | 2006 | QRLFQVKGRR | PBP 10 | Free | Free | Linear | L | None | 10 | Antibacterial | >40% hemolysis at 40 µM | Human | Derived from the polyphosphoinositide binding site of gelsolin | NA | NA | ||
| 16997878 | 2006 | VRRFPWWWPFLRR | Tritrpticin | Free | Free | Linear | L | None | 13 | Antimicrobial | EC50 = 380µg/ml | Human | Tritrpticin from cathelicidin family of antimicrobial peptides | NA | NA | ||
| 16997878 | 2006 | VRRFPWWWPFLRR{ct:Amid} | Tritrp1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | EC50 = 190µg/ml | Human | Tritrpticin Analogs | NA | NA | ||
| 16997878 | 2006 | VKKFPWWWPFLKK{ct:Amid} | Tritrp2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | EC50 >1000µg/ml | Human | Tritrpticin Analogs | NA | NA | ||
| 16997878 | 2006 | VRRFAWWWAFLRR{ct:Amid} | Tritrp3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | EC50 = 60µg/ml | Human | Tritrpticin Analogs | NA | NA | ||
| 16997878 | 2006 | VRRFPYYYPFLRR{ct:Amid} | Tritrp4 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | EC50 >1000µg/ml | Human | Tritrpticin Analogs | NA | NA | ||
| 16997878 | 2006 | VRRYPWWWPYLRR{ct:Amid} | Tritrp5 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | EC50 = 220µg/ml | Human | Tritrpticin Analogs | NA | NA | ||
| 16997878 | 2006 | VRRFPFFFPFLRR{ct:Amid} | Tritrp6 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | EC50 >1000µg/ml | Human | Tritrpticin Analogs | NA | NA | ||
| 16997878 | 2006 | VRRFAWWWPFLRR{ct:Amid} | Tritrp7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | EC50 >1000µg/ml | Human | Tritrpticin Analogs | NA | NA | ||
| 16997878 | 2006 | VRRFPWWWAFLRR{ct:Amid} | Tritrp8 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | EC50 =354µg/ml | Human | Tritrpticin Analogs | NA | NA | ||
| 16997878 | 2006 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antimicrobial | EC50 =310µg/ml | Human | Tritrpticin Analogs | NA | NA | ||
| 17065623 | 2006 | RKKWFW{nt:Acet}{ct:Amid} | PAF26 | Amidation | Acetylation | Linear | L | None | 6 | Antifungal | <0.3% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17065623 | 2006 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antifungal | 115.7 ±2.5% hemolysis at 100µM | Human | Melittin analog | NA | NA | ||
| 17065623 | 2006 | GIGAVLIVLTTGLPALISWIKRKRQQ | Mel.subK7I | Free | Free | Linear | L | None | 26 | Antifungal | 30.2±2.8% hemolysis at 100µM | Human | Melittin analog | NA | NA | ||
| 17176094 | 2006 | RGGRLCYCRRRFCVCVGR{ct:Amid} | PG-1 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | ~100% hemolysis at above 100µg/ml | Human | Protegrins analog (porcine) | NA | NA | ||
| 17176094 | 2006 | RGGRLTYTRP{d}RFTVTVGR{ct:Amid} | TTpTT | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | ~10% hemolysis at above 100µg/ml | Human | Protegrins analog (porcine) | NA | NA | ||
| 17176094 | 2006 | RGGRLVYTR{nnr:p*}RFTVIVGR{ct:Amid} | TTp*TT | Amidation | Free | Linear | Mix | p* = amino-functionalized D-proline | 18 | Antimicrobial | ~20% hemolysis at above 100µg/ml | Human | Protegrins analog (porcine) | NA | NA | ||
| 17176094 | 2006 | RGGRLCYTRP{d}RFTVCVGR{ct:Amid} | CTpTC | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | ~60% hemolysis at above 100µg/ml | Human | Protegrins analog (porcine) | NA | NA | ||
| 17560323 | 2007 | HFLGTLVNLAKKIL{ct:Amid} | Temporin-1DRa | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 65µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | KFLGTLVNLAKKIL{ct:Amid} | Lys-1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | LKLGTLVNLAKKIL{ct:Amid} | Lys-2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFKGTLVNLAKKIL{ct:Amid} | Lys-3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLKTLVNLAKKIL{ct:Amid} | Lys-4 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 42µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLKLVNLAKKIL{ct:Amid} | Lys-5 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 100µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTKVNLAKKIL{ct:Amid} | Lys-6 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLKNLAKKIL{ct:Amid} | Lys-7 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 330µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVKLAKKIL{ct:Amid} | Lys-8 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 38µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVNKAKKIL{ct:Amid} | Lys-9 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVNLKKKIL{ct:Amid} | Lys-10 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVNLAKKKL{ct:Amid} | Lys-13 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVNLAKKIK{ct:Amid} | Lys-14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLK{d}TLVNLAKKIL{ct:Amid} | D-Lys-4 | Amidation | Free | Linear | Mix | None | 14 | Antimicrobial | LD50 = 110µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLK{d}LVNLAKKIL{ct:Amid} | D-Lys-5 | Amidation | Free | Linear | Mix | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLK{d}NLAKKIL{ct:Amid} | D-Lys-7 | Amidation | Free | Linear | Mix | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVKLAKKIL{ct:Amid} | D-Lys-8 | Amidation | Free | Linear | Mix | None | 14 | Antimicrobial | LD50 = 385µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVNLAK{d}KIL{ct:Amid} | D-Lys-11 | Amidation | Free | Linear | Mix | None | 14 | Antimicrobial | LD50 = 210µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVNLAKK{d}IL{ct:Amid} | D-Lys-12 | Amidation | Free | Linear | Mix | None | 14 | Antimicrobial | LD50 = 500µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVNLAKKIL{ct:Amid} | Chg-9 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 12µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVNLAKKIL{ct:Amid} | Chg-13 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 16µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17560323 | 2007 | HFLLTLVNLAKKIL{ct:Amid} | Chg-9, Chg-13 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LD50 = 100µM | Human | Analogs of temporin-1DRa | NA | NA | ||
| 17826814 | 2007 | SELAGTIIDGASLTFEVLDKVLGELGKVSRK | St I 1–31 | Free | Free | Linear | L | None | 31 | Hemolytic | Hemolytic activity expresssed as the initial rate (∆A/∆t, min- 1) i.e. at above 100 µM activity is above 0.002 min-1 | Human | Sticholysin (Stichodactyla helianthus) | NA | NA | ||
| 17826814 | 2007 | ELAGTIIDGASLTFEVLDKVLGELGKVSRK | St I 2–31 | Free | Free | Linear | L | None | 30 | Hemolytic | Hemolytic activity expresssed as the initial rate (∆A/∆t, min- 1) i.e. at above 100 µM activity is less than 0.002 min-1 | Human | Sticholysin (Stichodactyla helianthus) | NA | NA | ||
| 17826814 | 2007 | SLTFEVLDKVLGELGKVSRK | St I 12–31 | Free | Free | Linear | L | None | 20 | Hemolytic | Hemolytic activity expresssed as the initial rate (∆A/∆t, min- 1) i.e. at above 100 µM activity is ~0.004 min-1 | Human | Sticholysin (Stichodactyla helianthus) | NA | NA | ||
| 17826814 | 2007 | ALAGTIIAGASLTFQVLDKVLEELGKVSRK | St II 1–30 | Free | Free | Linear | L | None | 30 | Hemolytic | Hemolytic activity expresssed as the initial rate (∆A/∆t, min- 1) i.e. at above 100 µM activity is above 0.010 min-1 | Human | Sticholysin (Stichodactyla helianthus) | NA | NA | ||
| 17826814 | 2007 | SLTFQVLDKVLEELGKVSRK | St II 11–30 | Free | Free | Linear | L | None | 20 | Hemolytic | Hemolytic activity expresssed as the initial rate (∆A/∆t, min- 1) i.e. at above 100 µM activity is ~0.002 min-1 | Human | Sticholysin (Stichodactyla helianthus) | NA | NA | ||
| 17927208 | 2007 | FHPSLWVLIPQYIQLIRKILKSG | Conolysin-Mt | Free | Free | Linear | L | None | 23 | Hemolytic | 40% hemolysis at 1 µM | Human | Conolysin-Mt (Conus mustelinus) | NA | NA | ||
| 17927208 | 2007 | FHPSLWVLIPQYIQLIRKILKSG | Conolysin-Mt | Free | Free | Linear | L | None | 23 | Hemolytic | 90% hemolysis at 10 µM | Human | Conolysin-Mt (Conus mustelinus) | NA | NA | ||
| 17961502 | 2007 | AKKVFKRLRKLFKKI | HPC2A3 | Free | Free | Linear | L | None | 15 | Antimicrobial | 4.5% hemolysis at 100µM | Human | HP(2-20) analog (Helicobacter pylori) | NA | NA | ||
| 17961502 | 2007 | FKRLKKLFKKIWNWK | HPA3NT3 | Free | Free | Linear | L | None | 15 | Antimicrobial | 11.62% hemolysis at 100µM | Human | HP(2-20) analog (Helicobacter pylori) | NA | NA | ||
| 17961502 | 2007 | FKRLEKLFKKIWNWK | HPA3NT2 | Free | Free | Linear | L | None | 15 | Antimicrobial | 14.92% hemolysis at 100µM | Human | HP(2-20) analog (Helicobacter pylori) | NA | NA | ||
| 17961502 | 2007 | FKRLKKLFSKIWNWK | HPA3NT1 | Free | Free | Linear | L | None | 15 | Antimicrobial | 9.65% hemolysis at 100µM | Human | HP(2-20) analog (Helicobacter pylori) | NA | NA | ||
| 17961502 | 2007 | FKRLEKLFSKIWNWK | HPA3NT0 | Free | Free | Linear | L | None | 15 | Antimicrobial | 4.70% hemolysis at 100µM | Human | HP(2-20) analog (Helicobacter pylori) | NA | NA | ||
| 17961502 | 2007 | WKKVFKRLEKLFSKIWNWK | HPA3A1 | Free | Free | Linear | L | None | 19 | Antimicrobial | 94.69% hemolysis at 100µM | Human | HP(2-20) analog (Helicobacter pylori) | NA | NA | ||
| 17961502 | 2007 | AKKVFKRLEKLFSKIWNWK | HPA3 | Free | Free | Linear | L | None | 19 | Antimicrobial | 23.11% hemolysis at 100µM | Human | HP(2-20) analog (Helicobacter pylori) | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKFL{ct:Amid} | BP76 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 3±1% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKVL{nt:Benzoylation}{ct:Amid} | BP31 | Amidation | Benzoylation | Linear | L | None | 11 | Hemolytic | 34±9.2% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKWL{ct:Amid} | BP52 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 51±4.8% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | FKLFKKILKFL{ct:Amid} | BP66 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 9±2.2% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKFL{nt:Acet}{ct:Amid} | BP77 | Amidation | Acetylation | Linear | L | None | 11 | Hemolytic | 6±0.6% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKFL{nt:Tosylation}{ct:Amid} | BP78 | Amidation | Tosylation | Linear | L | None | 11 | Hemolytic | 40±4.0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | LKLFKKILKFL{ct:Amid} | BP81 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 10±1.3% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKYL{ct:Amid} | BP100 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 3±0.1% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKYL{nt:Tosylation}{ct:Amid} | BP102 | Amidation | Tosylation | Linear | L | None | 11 | Hemolytic | 40±3.5% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKYL{nt:Benzoylation}{ct:Amid} | BP103 | Amidation | Benzoylation | Linear | L | None | 11 | Hemolytic | 42±4.7% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | LKLFKKILKYL{ct:Amid} | BP105 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 14±1.6% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | YKLFKKILKKL{nt:Tosylation}{ct:Amid} | BP121 | Amidation | Tosylation | Linear | L | None | 11 | Hemolytic | 22±1.3% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKKL{nt:Tosylation}{ct:Amid} | BP125 | Amidation | Tosylation | Linear | L | None | 11 | Hemolytic | 2±0.7% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKKL{nt:Benzoylation}{ct:Amid} | BP126 | Amidation | Benzoylation | Linear | L | None | 11 | Hemolytic | 2±0.4% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKFL{ct:Amid} | BP76 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 34±2.1% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKVL{nt:Benzoylation}{ct:Amid} | BP31 | Amidation | Benzoylation | Linear | L | None | 11 | Hemolytic | 71±2.3% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKWL{ct:Amid} | BP52 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 84±6.5% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | FKLFKKILKFL{ct:Amid} | BP66 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 63±5.9% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKFL{nt:Acet}{ct:Amid} | BP77 | Amidation | Acetylation | Linear | L | None | 11 | Hemolytic | 40±3.8% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKFL{nt:Tosylation}{ct:Amid} | BP78 | Amidation | Tosylation | Linear | L | None | 11 | Hemolytic | 85±7.4% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | LKLFKKILKFL{ct:Amid} | BP81 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 65±1.5% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKYL{ct:Amid} | BP100 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 22±2.8% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKYL{nt:Tosylation}{ct:Amid} | BP102 | Amidation | Tosylation | Linear | L | None | 11 | Hemolytic | 79±6.5% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKYL{nt:Benzoylation}{ct:Amid} | BP103 | Amidation | Benzoylation | Linear | L | None | 11 | Hemolytic | 83±13.5% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | LKLFKKILKYL{ct:Amid} | BP105 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 91±6.2% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | YKLFKKILKKL{nt:Tosylation}{ct:Amid} | BP121 | Amidation | Tosylation | Linear | L | None | 11 | Hemolytic | 81±3.7% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKKL{ct:Amid} | BP125 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 8±1.6% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17980935 | 2007 | KKLFKKILKKL{ct:Amid} | BP126 | Amidation | Free | Linear | L | None | 11 | Hemolytic | 14±2.9% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 17981364 | 2007 | SLLSLINKLIT{ct:Amid} | Decoralin-NH2 | Amidation | Free | Linear | L | None | 11 | Hemolytic | EC50 = 80 µM | Human | Decoralin analog (Oreumenes decoratus) | NA | NA | ||
| 18052076 | 2007 | FFGWLIKGAIHAGKAIHGLIHRRRH | Chrysophsin | Free | Free | Linear | L | None | 25 | Antimicrobial | EC50 = 1 µM | Human | Chrysophsin-1 (Chrysophrys major) | NA | NA | ||
| 17688900 | 2007 | FLSLALAALPKFLCLVFKKC | Brevinin-1DYa | Free | Free | Linear | L | None | 20 | Antibacterial | LC50 <5 µM | Human | brevinin family (Rana dybowskii) | NA | NA | ||
| 17688900 | 2007 | FLSLALAALPKLFCLIFKKC | Brevinin-1DYb | Free | Free | Linear | L | None | 20 | Antibacterial | LC50 <5 µM | Human | brevinin family (Rana dybowskii) | NA | NA | ||
| 17688900 | 2007 | FLPLLLAGLPKLLCLFFKKC | Brevinin-1DYc | Free | Free | Linear | L | None | 20 | Antibacterial | LC50 <5 µM | Human | brevinin family (Rana dybowskii) | NA | NA | ||
| 15055772 | 2004 | KWKLFKKIPKFLHLAKKF{ct:Amid} | P18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | Non-hemolytic | Human | cecropin A-magainin 2 hybrid | NA | Non-hemolytic | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLKVLTTG | HP(2-9)-ME(1-12) | Free | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLKVLTWG | HM2 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | Analog of HP(2-9)-ME(1-12) | NA | Non-hemolytic | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLKVLKKG | HM5 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | Analog of HP(2-9)-ME(1-12) | NA | Non-hemolytic | ||
| 15196144 | 2004 | DSHEKRHHGYKRKFHEKHHSHRGY | Histatin-5 | Free | Free | Linear | L | None | 24 | Fungicidal | 0% hemolysis at 100µM (non-hemolytic) | Human | Histatin | NA | Non-hemolytic | ||
| 15196144 | 2004 | FKCRRWQWRMKKLG | LFB(17–30) | Free | Free | Linear | L | None | 14 | Fungicidal | 0% hemolysis at 100µM (non-hemolytic) | Human | Human lactoferrin | NA | Non-hemolytic | ||
| 15196144 | 2004 | KRLFKKLLFSLRKY | Dhvar 4 | Free | Free | Linear | L | None | 14 | Fungicidal | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 15196144 | 2004 | KRLFRRWQWRMKKY | JH8194 | Free | Free | Linear | L | None | 14 | Fungicidal | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 15196144 | 2004 | KRLFRRLLFSMKKY | JH8195 | Free | Free | Linear | L | None | 14 | Fungicidal | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 15196144 | 2004 | FKCKKVVISLRRY | JH8944 | Free | Free | Linear | L | None | 13 | Fungicidal | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 15246874 | 2004 | MKLSCLLLTLTIIFVLTIVHAPNVEAKDLADPESEAVGFADAVGEADPNAGLGS | Pilosulins 3 | Free | Free | Linear | L | None | 54 | Antimicrobial | No hemolysis at 50µM (non-hemolytic) | Human | Pilosulins family (Myrmecia pilosula) | NA | Non-hemolytic | ||
| 15246874 | 2004 | MKLSCLLLTLTIIFVLTIVHAPNVEAKDLADPESEAVGFADAVGEADPGLGS | Pilosulins 4 | Free | Free | Linear | L | None | 52 | Antimicrobial | No hemolysis at 50µM (non-hemolytic) | Human | Pilosulins family (Myrmecia pilosula) | NA | Non-hemolytic | ||
| 15304333 | 2004 | ACGILHDNCVYVPAQNPCCRGLQCRYGKCLVQV | Psalmopeotoxin I (PcFK1) | Free | Free | Linear | L | None | 33 | Antimalarial | 0%hemolysis at 100µM (non-hemolytic) | Human | Venom of the tarantula Psalmopoeus cambridgei | NA | Non-hemolytic | ||
| 15304333 | 2004 | ACGILHDNCVYVPAQNPCCRGLQCRYGKCLVQV | Psalmopeotoxin I (PcFK1) | Free | Free | Linear | L | None | 28 | Antimalarial | No hemolysis at 10µM (non-hemolytic) | Human | Venom of the tarantula Psalmopoeus cambridgei | NA | Non-hemolytic | ||
| 15980334 | 2005 | QAKIRVRLSA | M4 | Free | Free | Linear | L | None | 10 | Antimicrobial | <1% hemolysis at 120μg/ml | Human | Synthetic peptide | NA | NA | ||
| 15980334 | 2005 | KIRVRLSA | M5 | Free | Free | Linear | L | None | 8 | Antimicrobial | <1% hemolysis at 120μg/ml | Human | Synthetic peptide | NA | NA | ||
| 15980334 | 2005 | QKKIRVRLSA | M6 | Free | Free | Linear | L | None | 10 | Antimicrobial | <1% hemolysis at 120μg/ml | Human | Synthetic peptide | NA | NA | ||
| 16142907 | 2005 | KWKKLLKK{nnr:a}LKL{nnr:a}KKLLK{ct:Amid} | KLW-L9,13-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16226345 | 2006 | DAACAAKCLWR{ct:Amid} | L2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 0% hemolysis at 200μg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16226345 | 2006 | KAACAAHCLWR{ct:Amid} | L3 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 0% hemolysis at 200μg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16226345 | 2006 | KAACAAKCLWR{ct:Amid} | L4 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 0% hemolysis at 200μg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16344012 | 2006 | KWKLFKKIGIGKFLHSAKKF{ct:Amid} | CA-MA | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | CA-MA (Hyalaphora cecropia and Xenopus laevis) | NA | Non-hemolytic | ||
| 16344012 | 2006 | KWKKLLKKPLLKKLLKKL{ct:Amid} | P5 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | CA-MA analog | NA | Non-hemolytic | ||
| 16460028 | 2006 | SADVAGAVIDGASLSFKILKTVLEALGNVKRK | EqTII1-32 | Free | Free | Linear | L | None | 32 | Antimicrobial | Non-hemolytic | Human | Actinoporin (Actinia equina L) | NA | Non-hemolytic | ||
| 16460028 | 2006 | GASLSFKILKTVLEALGNVKRK | EqTII11-32 | Free | Free | Linear | L | None | 22 | Antimicrobial | Non-hemolytic | Human | Actinoporin (Actinia equina L) | NA | Non-hemolytic | ||
| 16616888 | 2006 | FQWQRNIRKVR{ct:Amid} | LF11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | Non-hemolytic | Human | N-lauryl-derivative of LF11(human lactoferrin) | NA | Non-hemolytic | ||
| 16730857 | 2006 | KFKQ{cyc:N-C} | BPC4L | Free | Free | Cyclic | L | None | 4 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730857 | 2006 | KF{d}KQ{cyc:N-C} | BPC4D | Free | Free | Cyclic | Mix | None | 4 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730857 | 2006 | KF{d}KLKQ{cyc:N-C} | BPC6D | Free | Free | Cyclic | Mix | None | 6 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16730857 | 2006 | KLKLKLKE{cyc:N-C} | BPC8S2 | Free | Free | Cyclic | L | None | 8 | Antibacterial | 0% hemolysis at 360µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 16963159 | 2006 | GLWSTIKNVGKEAAIAAGKAALGAL{ct:Amid} | DPh-1 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | No hemolysis at 6µM (non-hemolytic) | Human | Dermaseptins (Phyllomedusa hypochondrialis) | NA | Non-hemolytic | ||
| 16963159 | 2006 | FLSLIPHAINAVSAIAKHF{ct:Amid} | PS-7 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | No hemolysis at 6µM (non-hemolytic) | Human | Phylloseptin (Phyllomedusa hypochondrialis) | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{ct:Amid} | MP-1 | Amidation | Free | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:Hydroxy cinnamic acid (pHCA)}{ct:Amid} | MP-2 | Amidation | Hydroxy cinnamic acid (pHCA) | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:Acet}{ct:Amid} | MP-3 | Amidation | Acetylation | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:pHCA= Hydroxy cinnamic acid} | MP-4 | Free | pHCA= Hydroxy cinnamic acid | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:CIN= Cinnamic acid}{ct:Amid} | MP-5 | Amidation | CIN= Cinnamic acid | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}WW{nt:HPPA= 3-(4-hydroxyphenyl) propionic acid}{ct:Amid} | MP-6 | Amidation | HPPA= 3-(4-hydroxyphenyl) propionic acid | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | {nnr:O}{nnr:O}FF{nt:pHCA= Hydroxy cinnamic acid}{ct:Amid} | MP-7 | Amidation | pHCA= Hydroxy cinnamic acid | Linear | L | O = L-Ornithine | 4 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17553680 | 2007 | WW{nt:pHCA= Hydroxy cinnamic acid}{ct:Amid} | MP-8 | Amidation | pHCA= Hydroxy cinnamic acid | Linear | L | O = L-Ornithine | 2 | Antimicrobial | No hemolysis at 1000µg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 17961502 | 2007 | AKKVFKRLEKLFSKIQNDK | HP (2–20) | Free | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | KVFKRLEKLFSKIQNDK | HPN1(4–20) | Free | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | FKRLEKLFSKIQNDK | HPN2(6–20) | Free | Free | Linear | L | None | 16 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | RLEKLFSKIQNDK | HPN3(8–20) | Free | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | AKKVFKRLEKLFSKIQN | HPC1(2–18) | Free | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | AKKVFKRLEKLFSKI | HPC2(2–16) | Free | Free | Linear | L | None | 15 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | AKKVFKRLEKLFS | HPC3(2–14) | Free | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | KVFKRLEKLFSKI | HPN1C2(4–16) | Free | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | KVFKRLEKLFS | HPN1C3(4–14) | Free | Free | Linear | L | None | 11 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | FKRLEKLFSKIQNDK | HPN2C4(6–13) | Free | Free | Linear | L | None | 8 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | AKKVFKRLEKLFSKIQNWK | HPA1 | Free | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | AKKVFKRLEKLFSKIWNDK | HPA2 | Free | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | AKKVFKRLEKSFSKIQNDK | HPA4 | Free | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 17961502 | 2007 | AKKVSKRLEKLFSKIQNDK | HPA5 | Free | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | HP(2-20) analog (Helicobacter pylori) | NA | Non-hemolytic | ||
| 20015460 | 2010 | GVIKSVLKGVAKTVALGML{ct:Amid} | B2RP | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LC50 = 280 µM | Human | Skin secretions of the South-East Asian frog Hylarana erythraea (Ranidae) | NA | NA | ||
| 17888907 | 2008 | KWCFRVCYRGICYRRC | Tachyplesin-I | Free | Free | Linear | L | None | 16 | Antimicrobial | 10% hemolysis 100µM | Human | Synthetic peptide | NA | NA | ||
| 17888907 | 2008 | VFQFLGKIIHHVGNFVHGFSHVF | Clavanin-A | Free | Free | Linear | L | None | 23 | Antimicrobial | 20% hemolysis 100 µM | Human | Synthetic peptide | NA | NA | ||
| 17888907 | 2008 | GIGKFLKKAKKFGKAFVKMKK{ct:Amid} | MSI-94 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 45-50% hemolysis 100 µM | Human | Synthetic peptide | NA | NA | ||
| 17888907 | 2008 | GCASRCKAKCAGRRCKGWASASFRGRCYCKCFRC | Mytilin-A | Free | Free | Linear | L | None | 34 | Antimicrobial | 10% hemolysis 100 µM | Human | Synthetic peptide | NA | NA | ||
| 17888907 | 2008 | QGWEAVAAAVASKIVGLWRNEKTELLGHECKFTVKPYLKRFQVYYKGRMWCPGWTAIRGEASTRSQSGVAGKTAKDFVRKAFQKGLLSQQEANQWLSS | ALF—isoform ALFPm3 | Free | Free | Linear | L | None | 98 | Antimicrobial | 55% hemolysis 100 µM | Human | Pichia pastoris | NA | NA | ||
| 18554256 | 2008 | GFKDLLKGAAKALVKTVLF{ct:Amid} | Ascaphin-8 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LD50 = 55µM | Human | Ascaphin-8 (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKLLLKGAAKALVKTVLF{ct:Amid} | Lys-4 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LD50 = 24µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKDLLKKAAKALVKTVLF{ct:Amid} | Lys-8 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LD50 = 11µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKDLLKGAKKALVKTVLF{ct:Amid} | Lys-10 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LD50 >500µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKDLLKGAAKALKKTVLF{ct:Amid} | Lys-14 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LD50 >500µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKDLLKGAAKALVKTVK{d}F{ct:Amid} | Lys-18 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LD50 >500µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKK{d}LLKGAAKALVKTVLF{ct:Amid} | D-Lys-4 | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial | LD50 = 300µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKDLLKK{d}AAKALVKTVLF{ct:Amid} | D-Lys-8 | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial | LD50 = 150µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKDLLKGAK{d}KALVKTVLF{ct:Amid} | D-Lys-10 | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial | LD50 >500 µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKDLLKGAAKALVKTVLF{ct:Amid} | D-Lys-14 | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial | LD50 >500 µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKDLLKGAAKALVKTVK{d}F{ct:Amid} | D-Lys-18 | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial | LD50 >500 µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GFKDLLKGAAKALVKAVLF{ct:Amid} | Ala-16 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LD50 = 22µM | Human | Ascaphin-8 analog (Ascaphus truei) | NA | NA | ||
| 18554256 | 2008 | GLLGPLLKIAAKVGSNLL{ct:Amid} | XT-7 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 = 140µM | Human | XT-7 (Xenopus tropicalis) | NA | NA | ||
| 18554256 | 2008 | KLLGPLLKIAAKVGSNLL{ct:Amid} | Lys-1 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 = 400µM | Human | XT-7 analog (Xenopus tropicalis) | NA | NA | ||
| 18554256 | 2008 | GLLKPLLKIAAKVGSNLL{ct:Amid} | Lys-4 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 >500µM | Human | XT-7 analog (Xenopus tropicalis) | NA | NA | ||
| 18554256 | 2008 | GLLGKLLKIAAKVGSNLL{ct:Amid} | Lys-5 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 = 15µM | Human | XT-7 analog (Xenopus tropicalis) | NA | NA | ||
| 18554256 | 2008 | GLLGPLLKIAKKVGSNLL{ct:Amid} | Lys-11 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 = 350µM | Human | XT-7 analog (Xenopus tropicalis) | NA | NA | ||
| 18554256 | 2008 | GLLGPLLKIAAKVGKNLL{ct:Amid} | Lys-15 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 = 110µM | Human | XT-7 analog (Xenopus tropicalis) | NA | NA | ||
| 18554256 | 2008 | GLLGPLLKIAAKVGSKLL{ct:Amid} | Lys-16 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 = 80µM | Human | XT-7 analog (Xenopus tropicalis) | NA | NA | ||
| 18554256 | 2008 | GLLGPLLKIAAKVGKKLL{ct:Amid} | Lys-15, Lys-16 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 = 60µM | Human | XT-7 analog (Xenopus tropicalis) | NA | NA | ||
| 18554256 | 2008 | GLLGKLLKIAAKVGKKLL{ct:Amid} | Lys-5, Lys-15, Lys-16 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 = 25µM | Human | XT-7 analog (Xenopus tropicalis) | NA | NA | ||
| 18554256 | 2008 | GLLKKLLKIAAKVGKKLL{ct:Amid} | Lys-4, Lys-5,Lys-15, Lys-16 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LD50 = 25µM | Human | XT-7 analog (Xenopus tropicalis) | NA | NA | ||
| 11242518 | 2001 | AVGIGALFLGFLGAAGSTMGARS{ct:Amid} | FP-1 | Amidation | Free | Linear | L | None | 23 | Hemolytic | 50% hemolysis at 40 µM | Human | Synthetic peptides derived from the gp41 domain | NA | NA | ||
| 11242518 | 2001 | AVGIGALFLGFLGAAGSTMGARS{ct:Amid} | FP-1 | Amidation | Free | Linear | L | None | 23 | Hemolytic | 90% hemolysis at 100 µM | Human | Synthetic peptides derived from the gp41 domain | NA | NA | ||
| 11242518 | 2001 | AAGLAMLFLGILSAAGSTMGARA{ct:Amid} | FP-IVAU | Amidation | Free | Linear | L | None | 23 | Hemolytic | 50-55% hemolysis at 40 µM | Human | Synthetic peptides derived from the gp41 domain | NA | NA | ||
| 11242518 | 2001 | AAGLAMLFLGILSAAGSTMGARA{ct:Amid} | FP-IVAU | Amidation | Free | Linear | L | None | 23 | Hemolytic | 55-60% hemolysis at 80 µM | Human | Synthetic peptides derived from the gp41 domain | NA | NA | ||
| 11242518 | 2001 | NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ{ct:Amid} | DP-107 | Amidation | Free | Linear | L | None | 38 | Hemolytic | 20-30% hemolysis at40 µM | Human | Synthetic peptides derived from the gp41 domain | NA | NA | ||
| 11242518 | 2001 | NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ{ct:Amid} | DP-107 | Amidation | Free | Linear | L | None | 38 | Hemolytic | 20-30% hemolysis at 40 µM | Human | Synthetic peptides derived from the gp41 domain | NA | NA | ||
| 11532323 | 2001 | WEAKLAKALAKALAKHLAKALAKALKACEA | KALA | Free | Free | Linear | L | None | 30 | Cytotoxic | 65-70% hemolysis at 10 µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11532323 | 2001 | WEAKLAKALAKALAKHLAKALAKALKACEA | KALA | Free | Free | Linear | L | None | 30 | Cytotoxic | 80-85% hemolysis at 100 µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11532323 | 2001 | WEAKLAKALAKALAKHLAKALAKALKACEA | PEG-KALA | Free | Free | Linear | L | None | 30 | Hemolytic | 50-60% hemolysis at 10 µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11532323 | 2001 | WEAKLAKALAKALAKHLAKALAKALKACEA | PEG-KALA | Free | Free | Linear | L | None | 30 | Hemolytic | 90-95% hemolysis at 100 µg/ml | Human | Synthetic peptide | NA | NA | ||
| 15003829 | 2004 | GLMSLFKGVLKTAGKHIFKNVGGSLLDQAKCKITGEC | Brevinin-2PRa | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 55µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | GLMSLFRGVLKTAGKHIFKNVGGSLLDQAKCKITGEC | Brevinin-2PRb | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 65µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | GLMSVLKGVLKTAGKHIFKNVGGSLLDQAKCKISGQC | Brevinin-2PRc | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 125µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | GLMSVLKGVLKTAGKHIFKNVGGSLLDQAKCKITGQC | Brevinin-2PRd | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 100µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | GLLSVLKGVLKTAGKHIFKNVGGSLLDQAKCKISGEC | Brevinin-2PRe | Free | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 80µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | GLMDVFKGAAKNLLASALDKIRCKVTKC | Ranatuerin-2PRa | Free | Free | Linear | L | None | 28 | Antimicrobial | HC50 = 150µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | FLSLALAALPKLFCLIFKKC | Brevinin-1PRa | Free | Free | Linear | L | None | 20 | Antimicrobial | HC50 = 7µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | ILPILGNLLNGLL{ct:Amid} | Temporin-1PRa | Amidation | Free | Linear | L | None | 13 | Antimicrobial | HC50 >300µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 15003829 | 2004 | ILPILGNLLNSLL{ct:Amid} | Temporin-1PRb | Amidation | Free | Linear | L | None | 13 | Antimicrobial | HC50 >300µM | Human | Rana pirica (brevinin-2) | NA | NA | ||
| 21871946 | 2012 | FVDLKKIANIINSIF{ct:Amid} | Temporin-1CEa | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 60% hemolysis at 100 µM | Human | Rana chensinensis | NA | NA | ||
| 21871946 | 2012 | FVDLKKIANIINSIF{ct:Amid} | Temporin-1CEa | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 100% hemolysis at 200 µM | Human | Rana chensinensis | NA | NA | ||
| 21924309 | 2011 | LKLKSIVSWAKKVL{ct:Amid} | MP-B | Amidation | Free | Linear | L | None | 14 | Antioxidant | Non-hemolytic | Human | MP-B (Vespa basalis) | NA | Non-hemolytic | ||
| 21924309 | 2011 | LKWKSIVSWAKKVL{ct:Amid} | MP-B-1 | Amidation | Free | Linear | L | None | 14 | Antioxidant | Non-hemolytic | Human | MP-B analog (Vespa basalis) | NA | Non-hemolytic | ||
| 21924309 | 2011 | LKLKNIVSWAKKVL{ct:Amid} | MP-B-2 | Amidation | Free | Linear | L | None | 14 | Antioxidant | Non-hemolytic | Human | MP-B analog (Vespa basalis) | NA | Non-hemolytic | ||
| 21924309 | 2011 | LKLKSIVSYAKKVL{ct:Amid} | MP-B-3 | Amidation | Free | Linear | L | None | 14 | Antioxidant | Non-hemolytic | Human | MP-B analog (Vespa basalis) | NA | Non-hemolytic | ||
| 21928440 | 2011 | CGETCVGGTCNTPGCTCSWPVCTRNGLPV{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 29 | Anticancer and Anti-HIV | IC50 = 26 µM | Human | Kalata (Oldenlandia affinis) | NA | NA | ||
| 21928440 | 2011 | C{d}G{d}E{d}T{d}C{d}V{d}G{d}G{d}T{d}C{d}N{d}T{d}P{d}G{d}C{d}T{d}C{d}S{d}W{d}P{d}V{d}C{d}T{d}R{d}N{d}G{d}L{d}N{d}P{d}V{d}{cyc:N-C} | D-Kalata B1 | Free | Free | Cyclic | D | None | 29 | Anticancer and Anti-HIV | IC50 = 77 µM | Human | Kalata analog (Oldenlandia affinis) | NA | NA | ||
| 22115565 | 2012 | FRFGSFLKKVWKSKLAKKLRSKGKQLLKDYANKVLNGPEEEAAAPAE | BmKbpp | Free | Free | Linear | L | None | 47 | Antimicrobial | 22.5% hemolysis at 30 µM | Human | Chinese scorpion Mesobuthus martensii Karsch | NA | NA | ||
| 22115565 | 2012 | FRFGSFLKKVWKSKLAKKLRSKGKQLLKDYANKVLNGPEEEAAAPAE | BmKbpp | Free | Free | Linear | L | None | 47 | Antimicrobial | 39.9% hemolysis at 50 µM | Human | Chinese scorpion Mesobuthus martensii Karsch | NA | NA | ||
| 22123629 | 2012 | GFGSFLGKALKAGLKLGANLLGGAPQQ | CPF-PG1 | Free | Free | Linear | L | None | 27 | Antimicrobial | LC50 = 145 µM | Human | Skin secretions of the tetraploid frogs Xenopus pygmaeus | NA | NA | ||
| 10631295 | 2000 | KLKLKLKLK{nt:Dansylation}{ct:Amid} | (KL)4K | Amidation | Dansylation | Linear | L | None | 9 | Antimicrobial | >20% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10631295 | 2000 | KLKLKLKLKLK{nt:Dansylation}{ct:Amid} | (KL)5K | Amidation | Dansylation | Linear | L | None | 11 | Antimicrobial | 60% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10631295 | 2000 | KLKLKLKLKLKLKLK{nt:Dansylation}{ct:Amid} | (KL)6K | Amidation | Dansylation | Linear | L | None | 13 | Antimicrobial | ~90% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10631295 | 2000 | KLLKLLLKLLLKLLK{nt:Dansylation}{ct:Amid} | (KL)7K | Amidation | Dansylation | Linear | L | None | 15 | Antimicrobial | ~90% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10667861 | 2000 | INLKALAALAKKIL{ct:Amid} | MP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 68.2% hemolysis at 100µM | Human | Mastoparan B isolated from the venom of the hornet Vespa basalis | NA | NA | ||
| 10667861 | 2000 | INLKALAALAKKIL{ct:Amid} | MP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 37.9% hemolysis at 50µM | Human | Mastoparan B (Vespa basalis) | NA | NA | ||
| 10667861 | 2000 | LKAKSIVSWAKKVL{ct:Amid} | [Ala3] MP-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 13.8% hemolysis at 100µM | Human | Mastoparan B analog (Vespa basalis) | NA | NA | ||
| 10667861 | 2000 | LKAKSIVSWAKKVL{ct:Amid} | [Ala3] MP-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 11.9% hemolysis at 50µM | Human | Mastoparan B analog (Vespa basalis) | NA | NA | ||
| 10667861 | 2000 | LKLASIVSWAKKVL{ct:Amid} | [Ala4]MP-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 93.4% hemolysis at 100µM | Human | Mastoparan B analog (Vespa basalis) | NA | NA | ||
| 10667861 | 2000 | LKLASIVSWAKKVL{ct:Amid} | [Ala4]MP-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 60.1% hemolysis at 50µM | Human | Mastoparan B analog (Vespa basalis) | NA | NA | ||
| 10667861 | 2000 | LKLKSIVSAAKKVL{ct:Amid} | [Ala9]MP-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 6.0% hemolysis at 100µM | Human | Mastoparan B analog (Vespa basalis) | NA | NA | ||
| 10667861 | 2000 | LKLKSIVSAAKKVL{ct:Amid} | [Ala9]MP-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 8.5% hemolysis at 50µM | Human | Mastoparan B analog (Vespa basalis) | NA | NA | ||
| 10667861 | 2000 | LKLKSIVSWAKAVL{ct:Amid} | [Ala12]MP-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 66.2% hemolysis at 100µM | Human | Mastoparan B analog (Vespa basalis) | NA | NA | ||
| 10667861 | 2000 | LKLKSIVSWAKAVL{ct:Amid} | [Ala12]MP-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 59.1% hemolysis at 50µM | Human | Mastoparan B analog (Vespa basalis) | NA | NA | ||
| 10675500 | 2000 | KWKLFKKIGIGKFLHSAKKF{ct:Amid} | CA-MA | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | Cecropin A(Hyalophora cecropia), Magainin 2(Xenopus laevis) | NA | Non-hemolytic | ||
| 10675500 | 2000 | KWKLFKKIKFLHSAKKF{ct:Amid} | CA-MA1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | Cecropin A(Hyalophora cecropia), Magainin 2(Xenopus laevis) | NA | Non-hemolytic | ||
| 10675500 | 2000 | KWKLFKKIPKFLHSAKKF{ct:Amid} | CA-MA2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | Cecropin A(Hyalophora cecropia), Magainin 2(Xenopus laevis) | NA | Non-hemolytic | ||
| 10675500 | 2000 | KWKLFKKIGPGKFLHSAKKF{ct:Amid} | CA-MA3 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 100µM (non-hemolytic) | Human | Cecropin A(Hyalophora cecropia), Magainin 2(Xenopus laevis) | NA | Non-hemolytic | ||
| 10817697 | 2000 | DSHAKRHHGYKRKFHEKHHSHRGY{ct:Amid} | Hsn-5 | Amidation | Free | Linear | L | None | 24 | Antifungal | <10% hemolysis at 200µM | Human | Human salivary histatin-5 (Hsn-5) | NA | NA | ||
| 10817697 | 2000 | DSHAKRHHGYKIKFHENHHSHRGY{ct:Amid} | R12I/K17N | Amidation | Free | Linear | L | None | 24 | Antifungal | <10% hemolysis at 200µM | Human | Histatin-6 variants | NA | NA | ||
| 10817697 | 2000 | DSHAKRHHGYKIKFHEKHHSLRGY{ct:Amid} | R12I/H21L | Amidation | Free | Linear | L | None | 24 | Antifungal | <10% hemolysis at 200µM | Human | Histatin-7 variants | NA | NA | ||
| 10817697 | 2000 | EGRERDHELRHRRHHHQSPK{ct:Amid} | MUC7 D1 | Amidation | Free | Linear | L | None | 20 | Antifungal | <10% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 20237682 | 2010 | ILPWKWPWWPWRR{ct:Amid} | Δ0 (Indolicidin) | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC 3.0*10-3 g ml-1 | Human | Indolicidin(Bovine neutrophils) | NA | NA | ||
| 20237682 | 2010 | ILPWKWPWWPARR{ct:Amid} | Δ5 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC 2.8*10-3 g ml-1 | Human | Indolicidin derivatives(Bovine neutrophils) | NA | NA | ||
| 20237682 | 2010 | ILPWKWPWAPARR{ct:Amid} | Δ45 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC >2.6*10-3 g ml-1 | Human | Indolicidin derivatives(Bovine neutrophils) | NA | NA | ||
| 20237682 | 2010 | ILPWKWPAAPARR{ct:Amid} | Δ345 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC >6.7*10-3 g ml-1 | Human | Indolicidin derivatives(Bovine neutrophils) | NA | NA | ||
| 20237682 | 2010 | ILPWKAPAAPARR{ct:Amid} | Δ2345 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC >6.4*10-3 g ml-1 | Human | Indolicidin derivatives(Bovine neutrophils) | NA | Non-hemolytic | ||
| 20237682 | 2010 | ILPAKAPAAPARR{ct:Amid} | Δ12345 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC >6.8*10-3 g ml-1 | Human | Indolicidin derivatives(Bovine neutrophils) | NA | Non-hemolytic | ||
| 20798581 | 2010 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | Ple | Amidation | Free | Linear | L | None | 25 | Antifungal | 7% hemolysis at 100µM | Human | Pleurocidin (Pleuronectes americanus) | NA | NA | ||
| 20798581 | 2010 | SFFKKAAHVGKHVGKAALTHYL{ct:Amid} | Ple (4-25) | Amidation | Free | Linear | L | None | 22 | Antifungal | 0% hemolysis at 100µM (non-hemolytic) | Human | Pleurocidin analogs (Pleuronectes americanus) | NA | Non-hemolytic | ||
| 20798581 | 2010 | KKAAHVGKHVGKAALTHYL{ct:Amid} | Ple (7-25) | Amidation | Free | Linear | L | None | 19 | Antifungal | 0% hemolysis at 100µM (non-hemolytic) | Human | Pleurocidin analogs (Pleuronectes americanus) | NA | Non-hemolytic | ||
| 20798581 | 2010 | GWGSFFKKAAHVGKHVGKAALT{ct:Amid} | Ple (1-22) | Amidation | Free | Linear | L | None | 22 | Antifungal | 0% hemolysis at 100µM (non-hemolytic) | Human | Pleurocidin analogs (Pleuronectes americanus) | NA | Non-hemolytic | ||
| 20798581 | 2010 | GWGSFFKKAAHVGKHVGKA{ct:Amid} | Ple (1-19) | Amidation | Free | Linear | L | None | 19 | Antifungal | 0% hemolysis at 100µM (non-hemolytic) | Human | Pleurocidin analogs (Pleuronectes americanus) | NA | Non-hemolytic | ||
| 21168911 | 2011 | FFRRFFRR{ct:Amid} | (FFRR)2 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | LLRRLLRR{ct:Amid} | (LLRR)2 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | LLKKLLKK{ct:Amid} | (LLKK)2 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | FFRRFFRRFFRR{ct:Amid} | (FFRR)3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | AARRAARRAARR{ct:Amid} | (AARR)3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | LLRRLLRRLLRR{ct:Amid} | (LLRR)3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | LLKKLLKKLLKK{ct:Amid} | (LLKK)3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | HC50 > 500 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | FFRRFFRRFFRRFFRR{ct:Amid} | (FFRR)4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | HC50 > ~26 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | LLRRLLRRLLRRLLRR{ct:Amid} | (LLRR)4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | HC50 > ~12 | Human | Synthetic peptide | NA | NA | ||
| 21168911 | 2011 | LLKKLLKKLLKKLLKK{ct:Amid} | (LLKK)4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | HC50 > ~24 | Human | Synthetic peptide | NA | NA | ||
| 21184791 | 2011 | GRILSFIKGLAEHL{ct:Amid} | OdVP1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | ILGIITSLLKSL{ct:Amid} | OdVP2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | EC50 = 31 (23–41)µM | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | NA | ||
| 21184791 | 2011 | KDLHTVVSAILQAL{ct:Amid} | OdVP3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | LDPKVVQSLL{ct:Amid} | OdVP4 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | INLKGLIKKVASLLT | EpVP1 | Free | Free | Linear | L | None | 15 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | FDLLGLVKKVASAL{ct:Amid} | EpVP2a | Amidation | Free | Linear | L | None | 14 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | FDLLGLVKSVVSAL{ct:Amid} | EpVP2b | Amidation | Free | Linear | L | None | 14 | Antimicrobial | EC50 = 64 (68–70)µM | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | NA | ||
| 21184791 | 2011 | AINPKSVQSLL{ct:Amid} | EpVP3 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | INPKSVQSLL{ct:Amid} | EpVP3S | Amidation | Free | Linear | L | None | 10 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | LSPAVMASLA{ct:Amid} | EpVP4a | Amidation | Free | Linear | L | None | 10 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | LSPAAMASLA{ct:Amid} | EpVP4b | Amidation | Free | Linear | L | None | 10 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | VHVPPICSHRECRK | EpVP5 | Free | Free | Linear | L | None | 14 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 21184791 | 2011 | FGPVIGLLSGILKSLL | EpVP6 | Free | Free | Linear | L | None | 16 | Antimicrobial | Non-hemolytic | Human | Venom peptides (Orancistrocerus drewseni, Eumenes pomiformis) | NA | Non-hemolytic | ||
| 23430306 | 2013 | LRRLWLRANRL | LRR-1 | Free | Free | Linear | L | None | 11 | Antibacterial | 0% hemolysis at 128µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 23430306 | 2013 | LRRLWLRANRLLRRLWLRANRL | LRR-2 | Free | Free | Linear | L | None | 22 | Antibacterial | ~70% hemolysis at 128µM | Human | Synthetic peptide | NA | NA | ||
| 23594231 | 2013 | RKCNFLCKLKEKLRTVITSHIDKVLRPQG | Cathelicidin-PY | Free | Free | Linear | L | None | 29 | Antimicrobial | 2.5% hemolysis at 12.5µg/ml | Human | Cathelicidin-PY from the skin secretions of the frog Paa yunnanensis | NA | NA | ||
| 23594231 | 2013 | RKCNFLCKLKEKLRTVITSHIDKVLRPQG | Cathelicidin-PY | Free | Free | Linear | L | None | 29 | Antimicrobial | 3.5% hemolysis at 25µg/ml | Human | Cathelicidin-PY from the skin secretions of the frog Paa yunnanensis | NA | NA | ||
| 23594231 | 2013 | RKCNFLCKLKEKLRTVITSHIDKVLRPQG | Cathelicidin-PY | Free | Free | Linear | L | None | 29 | Antimicrobial | 5.5% hemolysis at 50µg/ml | Human | Cathelicidin-PY from the skin secretions of the frog Paa yunnanensis | NA | NA | ||
| 16730966 | 2006 | QPTRRPRPGTGPGRRPRPRPRP | QPT22 | Free | Free | Linear | L | None | 22 | Antimicrobial | ~4% hemolysis at 60µM | Human | Synthetic peptide | NA | NA | ||
| 16730966 | 2006 | KRFKQDGGWSHWSPWSS | KRF17 | Free | Free | Linear | L | None | 17 | Antimicrobial | ~3% hemolysis at 60µM | Human | Synthetic peptide | NA | NA | ||
| 22426384 | 2012 | MFTSKKSMLLLFFLGMISMSLCQDERGADEDDGGEMTEEEKRGAFGDLLKGVAKEAGMKLLNMAQCKLSGKC | Brevinin-2LTa | Free | Free | Linear | L | None | 72 | Antimicrobial | LD50 = 520µM | Human | Brevinin from skin of Hylarana latouchii | NA | NA | ||
| 22426384 | 2012 | MFTLKKSLLFLFFLGTISLSFCEEERGADEDDEVEMTEEEKRSILDKIKNVALGVARGAGTGILKALLCKLDKSC | Brevinin-2LTb | Free | Free | Linear | L | None | 75 | Antimicrobial | LD50 = 480µM | Human | Brevinin from skin of Hylarana latouchii | NA | NA | ||
| 22426384 | 2012 | MFTMKKSLLFLFFLGTISLSFCEEERGADEDDEVEMTEEEKRGVLDTFKDVAIGVAKGAGTGVLKALLCKLDKSC | Brevinin-2LTc | Free | Free | Linear | L | None | 75 | Antimicrobial | LD50 > 480µM | Human | Brevinin from skin of Hylarana latouchii | NA | NA | ||
| 22426384 | 2012 | MFTMKKSMLLIVLLGIISLSLCEQERNADEDEQSEMKRISFKKGKGSWIKNGLIKGIKGLGKEISLDVIRTGIDIAGCKIKGEC | Esculentin-1LTa | Free | Free | Linear | L | None | 84 | Antimicrobial | LD50 > 480µM | Human | Esculentin from skin of Hylarana latouchii | NA | NA | ||
| 22426384 | 2012 | MFTMKKSLLFLFFFLGTISLSLCEQERGADEDDGGEEVKRGIFSLFKAGAKFFGKHLLKQAGKAGAEHLACKATNQC | Esculentin-2LTa | Free | Free | Linear | L | None | 77 | Antimicrobial | LD50 > 600µM | Human | Esculentin from skin of Hylarana latouchii | NA | NA | ||
| 22426384 | 2012 | MFTMKKSLLLLFFLGIVSLSLCEQERGADEDEGEDVEEVKRSLWENFKNAGKQFILNILDKIRCRVAGGCRT | Palustrin-2LTa | Free | Free | Linear | L | None | 72 | Antimicrobial | LD50 = 220µM | Human | Palustrin from skin of Hylarana latouchii | NA | NA | ||
| 22426384 | 2012 | MFTLKKSLLLLFFLGTINLSLCEEERDAEEERRDGDDEMDVEVKKRFLAGLIGGLAKMLGK | Temporin-LTe | Free | Free | Linear | L | None | 61 | Antimicrobial | LD50 = 40µM | Human | Temporin from skin of Hylarana latouchii | NA | NA | ||
| 22464970 | 2012 | KWFRVYRGIYRRR{ct:Amid} | CDT | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolysis at 200µg/ml (non-hemolytic) | Human | Tachyplesin-1(Tachypleus tridentatus) | NA | Non-hemolytic | ||
| 22497805 | 2012 | IKLSPETKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | Hymenochirin-1B | Amidation | Free | Linear | L | None | 29 | Antimicrobial | LC50 = 225µM | Human | Hymenochirins from norepinephrine-stimulated skin secretions Hymenochirus boettgeri | NA | NA | ||
| 22497805 | 2012 | LKIPGFVKDTLKKVAKGIFSAVAGAMTPS | Hymenochirin-2B | Free | Free | Linear | L | None | 29 | Antimicrobial | LC50 > 300µM | Human | Hymenochirins from norepinephrine-stimulated skin secretions Hymenochirus boettgeri | NA | NA | ||
| 22497805 | 2012 | IKIPAVVKDTLKKVAKGVLSAVAGALTQ | Hymenochirin-3B | Free | Free | Linear | L | None | 28 | Antimicrobial | LC50 > 300µM | Human | Hymenochirins from norepinephrine-stimulated skin secretions Hymenochirus boettgeri | NA | NA | ||
| 22497805 | 2012 | IKIPAFVKDTLKKVAKGVISAVAGALTQ | Hymenochirin-4B | Free | Free | Linear | L | None | 28 | Antimicrobial | LC50 = 160µM | Human | Hymenochirins from norepinephrine-stimulated skin secretions Hymenochirus boettgeri | NA | NA | ||
| 22497805 | 2012 | IKIPPIVKDTLKKVAKGVLSTIAGALST | Hymenochirin-5B | Free | Free | Linear | L | None | 28 | Antimicrobial | Non-hemolytic | Human | Hymenochirins from norepinephrine-stimulated skin secretions Hymenochirus boettgeri | NA | Non-hemolytic | ||
| 11168895 | 2000 | GWGSFFKKAAHVGKHVGKAALTHYL | Pleurocidin | Free | Free | Linear | L | None | 25 | Antibacterial | 15% hemolysis at 100µM | Human | Pleurocidin isolated from the skin mucous secretions of the winter flounder(Pleuronectes americanus) | NA | NA | ||
| 11168895 | 2000 | AWASFFKKAAHVGKHVGKAALTHYL | [A1,3]Ple | Free | Free | Linear | L | None | 25 | Antibacterial | 8% hemolysis at 100µM | Human | Pleurocidin analogs (Pleuronectes americanus) | NA | NA | ||
| 11168895 | 2000 | GWGSFFKKAAHVAKHVAKAALTHYL | [A13,17]Ple | Free | Free | Linear | L | None | 25 | Antibacterial | 93% hemolysis at 100µM | Human | Pleurocidin analogs (Pleuronectes americanus) | NA | NA | ||
| 11168895 | 2000 | AWASFFKKAAHVAKHVAKAALTHYL | [A1,3,13,17]Ple | Free | Free | Linear | L | None | 25 | Antibacterial | 90% hemolysis at 100µM | Human | Pleurocidin analogs (Pleuronectes americanus) | NA | NA | ||
| 11168895 | 2000 | GWGSFFKKAAAVGKAVGKAALTAYL | [A11,15,23]Ple | Free | Free | Linear | L | None | 25 | Antibacterial | 45% hemolysis at 100µM | Human | Pleurocidin analogs (Pleuronectes americanus) | NA | NA | ||
| 11557475 | 2001 | GFKLKGMARISCLPNGQWSNFPPKCIRECAMVSS | S1 | Free | Free | Linear | L | None | 34 | Antibacterial | 0% hemolysis at 100 µg/ml (non-hemolytic) | Human | Synthetic peptide (Factor C Sushi Peptides) | NA | Non-hemolytic | ||
| 11557475 | 2001 | GFKLKGKAKISCLPNGQWSNFPPKCIRECAMVSS | S1Δ | Free | Free | Linear | L | None | 34 | Antibacterial | 0% hemolysis at 100 µg/ml (non-hemolytic) | Human | Synthetic peptide (Factor C Sushi Peptides) | NA | Non-hemolytic | ||
| 11557475 | 2001 | HAEHKVKIGVEQKYGQFPQGTEVTYTCSGNYFLM | S3 | Free | Free | Linear | L | None | 34 | Antibacterial | 8% hemolysis at 100 µg/ml | Human | Synthetic peptide (Factor C Sushi Peptides) | NA | NA | ||
| 11557475 | 2001 | HAEHKVKIKVKQKYGQFPQGTEVTYTCSGNYFLM | S3Δ | Free | Free | Linear | L | None | 34 | Antibacterial | 37% hemolysis at 100 µg/ml | Human | Synthetic peptide (Factor C Sushi Peptides) | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Nle}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-GY{ct:Amid} | P19(9|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 19 | Antimicrobial | 30% hemolysis at 10μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Nle}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-GY{ct:Amid} | P19(9|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 19 | Antimicrobial | 70% hemolysis at 100μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-GY{ct:Amid} | P17(9|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 17 | Antimicrobial | 15% hemolysis at 10μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-GY{ct:Amid} | P17(9|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 17 | Antimicrobial | 35% hemolysis at 100μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-GY{ct:Amid} | P15(7|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 15 | Antimicrobial | 5% hemolysis at 10μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-GY{ct:Amid} | P15(7|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 15 | Antimicrobial | 30% hemolysis at 100μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-GY{ct:Amid} | P14(7|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 14 | Antimicrobial | 10% hemolysis at 10μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-GY{ct:Amid} | P14(7|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 14 | Antimicrobial | 30% hemolysis at 100μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-GY{ct:Amid} | P13(7|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 13 | Antimicrobial | 5% hemolysis at 10μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Nle}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-GY{ct:Amid} | P13(7|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 13 | Antimicrobial | 25% hemolysis at 100μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Aib}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-{nnr:Nle}-GY{ct:Amid} | P13(5|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 13 | Antimicrobial | 12% hemolysis at 10μM | Human | Synthetic peptide | NA | NA | ||
| 11683882 | 2001 | G-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-{nnr:Aib}-{nnr:Orn}-{nnr:Orn}-{nnr:Nle}-{nnr:Nle}-{nnr:Orn}-GY{ct:Amid} | P14(6|B) | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid, Nle = norleucine, Orn = ornithine | 14 | Antimicrobial | 70% hemolysis at 100μM | Human | Synthetic peptide | NA | NA | ||
| 11995990 | 2001 | FLPLIGRVLSGIL{ct:Amid} | Temporin A (TA) | Amidation | Free | Linear | L | None | 13 | Antifungal | 0% hemolysis at 14 µM | Human | Temporin A isolated from the skin of Rana temporaria | NA | NA | ||
| 11995990 | 2001 | FLPLIGRVLSGIL{ct:Amid} | Temporin A (TA) | Amidation | Free | Linear | L | None | 13 | Antifungal | 100% hemolysis at 225 µM | Human | Temporin A isolated from the skin of Rana temporaria | NA | NA | ||
| 11995990 | 2001 | KWKLFKKLPLIGRVL{ct:Amid} | CA(1-7)TA(2-9)NH2 (CATA) | Amidation | Free | Linear | L | None | 15 | Antifungal | 0% hemolysis at 14 µM | Human | Cecropin A-temporin A hybrid | NA | NA | ||
| 11995990 | 2001 | KWKLFKKLPLIGRVL{ct:Amid} | CA(1-7)TA(2-9)NH2 (CATA) | Amidation | Free | Linear | L | None | 15 | Antifungal | 100% hemolysis at 225 µM | Human | Cecropin A-temporin A hybrid | NA | NA | ||
| 12005420 | 2001 | KWKFKKIPKFLHLAKKF{ct:Amid} | P18 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12005420 | 2001 | KWKLFKKILKFLHLAKKF{ct:Amid} | [L9]-P18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 88.6% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | KWKLFKKISKFLHLAKKF{ct:Amid} | [S9]-P18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 50.4% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | WKLFKKIPKFLHLAKKF{ct:Amid} | N-1 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 10.1% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | FKLFKKIPKFLHLAKKF{ct:Amid} | N-2 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 0.6% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | KWFKKIPKFLHLAKKF{ct:Amid} | N-3 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 1.8% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | WFKKIPKFLHLAKKF{ct:Amid} | N-4 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 1.5% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | WKKIPKFLHLAKKF{ct:Amid} | N-5 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12005420 | 2001 | KWFKKIPKFLHLLKKF{ct:Amid} | N-3L | Amidation | Free | Linear | L | None | 16 | Antibacterial | 27.3% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | WFKKIPKFLHLLKKF{ct:Amid} | N-4L | Amidation | Free | Linear | L | None | 15 | Antibacterial | 28.8% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | WKKIPKFLHLLKKF{ct:Amid} | N-5L | Amidation | Free | Linear | L | None | 14 | Antibacterial | 9.4% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | KWKLFKKIPFLHLAKKF{ct:Amid} | C-1 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 30.3% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | KWKLFKKIPKFLHLAKK{ct:Amid} | C-2 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 19.8% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | KWKLFKKIPLHLAKKF{ct:Amid} | C-3 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 4.7% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | KWKLFKKIPKFLHLAK{ct:Amid} | C-4 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12005420 | 2001 | KWKLFKKIPHLAKKF{ct:Amid} | C-5 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12005420 | 2001 | KWKLFKKIPKFLHLA{ct:Amid} | C-6 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 6.7% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | KWKLFKKIPLAKKF{ct:Amid} | C-7 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12005420 | 2001 | KWKLFKKIPKFLHL{ct:Amid} | C-8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12005420 | 2001 | KWKLFKKIPLKKF{ct:Amid} | C-9 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 6.2% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12005420 | 2001 | KWKLFKKIPKFLH{ct:Amid} | C-10 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 7.6% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 11932493 | 2002 | KNLRRIIRKIIHIIKKYG | Ovispirin-1 | Free | Free | Linear | L | None | 18 | Antimicrobial | 70.2% hemolysis at 80 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 11932493 | 2002 | KNLRRIIRKIIHIIKKYG | Ovispirin-1 | Free | Free | Linear | L | None | 18 | Antimicrobial | 55.0% hemolysis at 40 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 11932493 | 2002 | KNLRRIIRKGIHIIKKYG | Novispirin G-10 | Free | Free | Linear | L | None | 18 | Antimicrobial | 2.5% hemolysis at 80 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 11932493 | 2002 | KNLRRIIRKGIHIIKKYG | Novispirin G-10 | Free | Free | Linear | L | None | 18 | Antimicrobial | 1.8% hemolysis at 40µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11932493 | 2002 | KNLRRITRKIIHIIKKYG | Novispirin T-7 | Free | Free | Linear | L | None | 18 | Antimicrobial | 10.0% hemolysis at 80 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 11932493 | 2002 | KNLRRITRKIIHIIKKYG | Novispirin T-7 | Free | Free | Linear | L | None | 18 | Antimicrobial | 3.0% hemolysis at 80 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 12110678 | 2002 | LKLLKKLLKKLLKLL{ct:Amid} | Amphipathic-1L | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100% hemolysis at 100μM | Human | Synthetic peptide | NA | NA | ||
| 12110678 | 2002 | KLKLLKLLKLLKLLK{ct:Amid} | Scrambled-4L | Amidation | Free | Linear | L | None | 15 | Antibacterial | 82% hemolysis at 100 µM | Human | Synthetic peptide | NA | NA | ||
| 12110678 | 2002 | KKKLLLLLLLLLKKK{ct:Amid} | Segregated-5L | Amidation | Free | Linear | L | None | 15 | Antibacterial | 66% hemolysis at 100 µM | Human | Synthetic peptide | NA | NA | ||
| 12110678 | 2002 | LKL{d}LKK{d}LL{d}K{d}KLLK{d}LL{ct:Amid} | Amphipathic-1D | Amidation | Free | Linear | Mix | None | 15 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12110678 | 2002 | LLK{d}KLL{d}KL{d}L{d}LKLL{d}KK{ct:Amid} | Amphipathic-2D | Amidation | Free | Linear | Mix | None | 15 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12110678 | 2002 | LLK{d}LLK{d}KL{d}L{d}KKLL{d}KL{ct:Amid} | Amphipathic-3D | Amidation | Free | Linear | Mix | None | 15 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12110678 | 2002 | KLK{d}LLK{d}LL{d}K{d}LLKL{d}LK{ct:Amid} | Scrambled-4D | Amidation | Free | Linear | Mix | None | 15 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12110678 | 2002 | KKK{d}LLL{d}LL{d}L{d}LLLK{d}KK{ct:Amid} | Scrambled-5D | Amidation | Free | Linear | Mix | None | 15 | Antibacterial | 3% hemolysis at 100µM | Human | Synthetic peptide | NA | NA | ||
| 12110678 | 2002 | LLL{d}LLK{d}KK{d}K{d}KKLL{d}LL{ct:Amid} | Scrambled-6D | Amidation | Free | Linear | Mix | None | 15 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12207877 | 2002 | VRRFPWWWPFLRR | Tritrpticin | Free | Free | Linear | L | None | 13 | Antibacterial and Antifungal | >80% hemolysis at 200µg/ml | Human | Tritrpticin | NA | NA | ||
| 12207877 | 2002 | VRRFGWWWGFLRR | TPG | Free | Free | Linear | L | None | 13 | Antibacterial and Antifungal | >60% hemolysis at 200µg/ml | Human | Tritrpticin analogs | NA | NA | ||
| 12207877 | 2002 | VRRFAWWWAFLRR | TPA | Free | Free | Linear | L | None | 13 | Antibacterial and Antifungal | ~ 90% hemolysis at 200µg/ml | Human | Tritrpticin analogs | NA | NA | ||
| 12207877 | 2002 | VRRFPFFFPFLRR | TWF | Free | Free | Linear | L | None | 13 | Antibacterial and Antifungal | 0% hemolysis at 200µg/ml (non-hemolytic) | Human | Tritrpticin analogs | NA | Non-hemolytic | ||
| 12207877 | 2002 | VRRFPAAAPFLRR | TWA | Free | Free | Linear | L | None | 13 | Antibacterial and Antifungal | 0% hemolysis at 200µg/ml (non-hemolytic) | Human | Tritrpticin analogs | NA | Non-hemolytic | ||
| 12207877 | 2002 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antibacterial and Antifungal | ~ 80% hemolysis at 200µg/ml | Human | Indolicidin | NA | NA | ||
| 12297012 | 2002 | GSKKPVPIIYCNRRTGKCQRM | Thanatin | Free | Free | Linear | L | None | 21 | Antibacterial | 0% hemolysis at 20.8µM (non-hemolytic) | Human | Thanatin (Podisus maculiventris) | NA | Non-hemolytic | ||
| 12297012 | 2002 | GSKKPVPIIYCNRRGKCQRM | Th1 | Free | Free | Linear | L | None | 20 | Antibacterial | 0% hemolysis at 20.8µM (non-hemolytic) | Human | Thanatin analogs (Podisus maculiventris) | NA | Non-hemolytic | ||
| 12297012 | 2002 | GSKKPVPIIYCNRRTKCQRM | Th2 | Free | Free | Linear | L | None | 20 | Antibacterial | 0% hemolysis at 20.8µM (non-hemolytic) | Human | Thanatin analogs (Podisus maculiventris) | NA | Non-hemolytic | ||
| 12297012 | 2002 | GSKKPVPIIYCNRRKCQRM | Th3 | Free | Free | Linear | L | None | 19 | Antibacterial | 0% hemolysis at 20.8µM (non-hemolytic) | Human | Thanatin analogs (Podisus maculiventris) | NA | Non-hemolytic | ||
| 12297012 | 2002 | GSKKPVPIIYCNRRATGKCQRM | Th4 | Free | Free | Linear | L | None | 22 | Antibacterial | 0% hemolysis at 20.8µM (non-hemolytic) | Human | Thanatin analogs (Podisus maculiventris) | NA | Non-hemolytic | ||
| 12297012 | 2002 | GSKKPVPIIYCNRRAATGKCQRM | Th5 | Free | Free | Linear | L | None | 23 | Antibacterial | 0% hemolysis at 20.8µM (non-hemolytic) | Human | Thanatin analogs (Podisus maculiventris) | NA | Non-hemolytic | ||
| 12297012 | 2002 | GSKKPVPIIYANRRTGKAQRM | Th6 | Free | Free | Linear | L | None | 21 | Antibacterial | 0% hemolysis at 20.8µM (non-hemolytic) | Human | Thanatin analogs (Podisus maculiventris) | NA | Non-hemolytic | ||
| 12354111 | 2002 | GKVWDWIKSTAKKLWNSEPVKELKNTALNAAKNLVAEKIGAATPS | Opistoporin 1 | Free | Free | Linear | L | None | 45 | Antibacterial and Antifungal | ~30% hemolysis at 100 μM | Human | Opistoporin 1(Isolated from venom of Opistophtalmus carinatus) | NA | NA | ||
| 12354111 | 2002 | FKLGSFLKKAWKSKLAKKLRAKGKEMLKDYAKGLLEGGSEEVPGQ | Parabutoporin | Free | Free | Linear | L | None | 45 | Antibacterial and Antifungal | ~60% hemolysis at 100 μM | Human | Parabutoporin (Isolated from venom of Parabuthus schlechteri) | NA | NA | ||
| 12384369 | 2002 | KKAAAFAAAAAFAAWAAFAAAKKKK{ct:Amid} | F25 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 1% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKAAAFAAAAAFAAWAAFAAAKKKK{ct:Amid} | F25 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAAFAAAAAFAAWAAFAAA{ct:Amid} | F25-6K | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 17% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAAFAAAAAFAAWAAFAAA{ct:Amid} | F25-6K | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 11% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKAAAAFAAFAAWFAAFAAAAKKKK{ct:Amid} | 4F | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 42% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKAAAAFAAFAAWFAAFAAAAKKKK{ct:Amid} | 4F | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 17% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKAFAAAAAFAAWAAFAKKKK{ct:Amid} | F21 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 0% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKAFAAAAAFAAWAAFAKKKK{ct:Amid} | F21 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKAAAFAAWAAFAKKK{ct:Amid} | F17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKAAAFAAWAAFAKKK{ct:Amid} | F17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | RRRAAFAAWAAFAARRR{ct:Amid} | F17-R | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | RRRAAFAAWAAFAARRR{ct:Amid} | F17-R | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAFAAWAAFAA{ct:Amid} | F17-6K | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAFAAWAAFAA{ct:Amid} | F17-6K | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | K{d}K{d}K{d}K{d}K{d}K{d}A{d}A{d}F{d}A{d}A{d}W{d}A{d}A{d}F{d}A{d}A{d}{ct:Amid} | All-D F17-6K | Amidation | Free | Linear | D | None | 17 | Antimicrobial | 0% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | K{d}K{d}K{d}K{d}K{d}K{d}A{d}A{d}F{d}A{d}A{d}W{d}A{d}A{d}F{d}A{d}A{d}{ct:Amid} | All-D F17-6K | Amidation | Free | Linear | D | None | 17 | Antimicrobial | 0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | RRRRRRAAFAAWAAFAA{ct:Amid} | F17-6R | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 26% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | RRRRRRAAFAAWAAFAA{ct:Amid} | F17-6R | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 14% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAAAFWAAAAF{ct:Amid} | KAFW | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAAAFWAAAAF{ct:Amid} | KAFW | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAFAAFAAFAA{ct:Amid} | 3F17-6K | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAFAAFAAFAA{ct:Amid} | 3F17-6K | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAWAAWAAWAA{ct:Amid} | W17-6K | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 200µM | Human | Synthetic peptide | NA | NA | ||
| 12384369 | 2002 | KKKKKKAAWAAWAAWAA{ct:Amid} | W17-6K | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0% hemolysis at 50µM | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRLKYRRFKYRV{cyc:N-C} | Mimetic 1 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 27% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRLQYRRFQYRV{cyc:N-C} | Mimetic 2 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 27% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRLEYRRFEYRV{cyc:N-C} | Mimetic 3 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 14% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRLKKRRWKYRV{cyc:N-C} | Mimetic 4 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 1% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRLKKRRWKYRV{cyc:N-C} | Mimetic 5 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 13% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LCLKKRRWKYCV{cyc:N-C} | Mimetic 6 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 3% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12404639 | 2002 | LRCKKRRWKCRV{cyc:N-C} | Mimetic 7 | Free | Free | Cyclic | L | None | 12 | Antibacterial | 1% hemolysis at 100µg ml-1 | Human | Synthetic peptide | NA | NA | ||
| 12581207 | 2003 | FFGWLIKGAIHAGKAIHGLIHRRRH{ct:Amid} | Chrysophsin-1 | Amidation | Free | Linear | L | None | 25 | Antibacterial | 100% hemolysis at 1μM | Human | Synthetic peptide | NA | NA | ||
| 12581207 | 2003 | FFGWLIRGAIHAGKAIHGLIHRRRH{ct:Amid} | Chrysophsin-2 | Amidation | Free | Linear | L | None | 25 | Antibacterial | 100% hemolysis at 1 μM | Human | Synthetic peptide | NA | NA | ||
| 12581207 | 2003 | FIGLLISAGKAIHDLIRRRH{ct:Amid} | Chrysophsin-3 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 100% hemolysis at 5 μM | Human | Synthetic peptide | NA | NA | ||
| 12569105 | 2003 | FFHLHFH-{nnr:dcΔDOPA}{cyc:N-C} | Plicatamide | Free | Free | Cyclic | L | dcΔDOPA = decarboxy-(E)α,β-dehydro3,4-dihydroxyphenylalanine | 8 | Antibacterial | 100% hemolysis at ~40 μM | Human | Plicatamide (Styela plicata) | NA | NA | ||
| 12681513 | 2003 | KKFPWWWPFKK | SYM11KK | Free | Free | Linear | L | None | 11 | Antimicrobial | 0% hemolysis at 200 μg/ml (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 12681513 | 2003 | VKKFPWWWPFLKK | TRK | Free | Free | Linear | L | None | 13 | Antimicrobial | 1% hemolysis at 200 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 12681513 | 2003 | RRFPWWWPFRR | SYM11 | Free | Free | Linear | L | None | 11 | Antimicrobial | ~60% hemolysis at 200 μg/ml | Human | Synthetic peptide | NA | NA | ||
| 12712499 | 2003 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | Y{d}PY{d}P{cyc:N-C} | GS4 | Free | Free | Cyclic | Mix | None | 4 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | KY{d}PKY{d}P{cyc:N-C} | GS6 | Free | Free | Cyclic | Mix | None | 6 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKY{d}PKLY{d}P{cyc:N-C} | GS8 | Free | Free | Cyclic | Mix | None | 8 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLY{d}PVKLY{d}P{cyc:N-C} | GS10 | Free | Free | Cyclic | Mix | None | 10 | Antibacterial and Antifungal | 100% hemolysis at 51–100 µg/mL | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKY{d}PKVKLY{d}P{cyc:N-C} | GS12 | Free | Free | Cyclic | Mix | None | 12 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at <15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | V{d}KLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14V1 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/m | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VK{d}LKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/m | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKL{d}KVY{d}PLKVKLY{d}P{cyc:N-C} | GS14L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at <15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at >150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKV{d}Y{d}PLKVKLY{d}P{cyc:N-C} | GS14V5 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 100–150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVYPLKVKLY{d}P{cyc:N-C} | GS14Y6 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/m | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}P{d}L{d}KVKLY{d}P{cyc:N-C} | GS14P7 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at <15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PL{d}KVKLY{d}P{cyc:N-C} | GS14L8 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLK{d}VKLY{d}P{cyc:N-C} | GS14K9 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 51–100 µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKV{d}KLY{d}P{cyc:N-C} | GS14V10 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at <15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVK{d}LY{d}P{cyc:N-C} | GS14K11 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 100–150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVKL{d}Y{d}P{cyc:N-C} | GS14L12 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVKLYP{cyc:N-C} | GS14Y13 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at < 15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLKVY{d}PLKVKLY{d}P{d}{cyc:N-C} | GS14P14 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at < 15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 100–150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | LKLK{d}LF{d}PLKLKLF{d}P{cyc:N-C} | GS14K4 Y2/F2, V3/L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at < 15µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | LKLK{d}LY{d}PLKLKLY{d}P{cyc:N-C} | GS14K4 V3/L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLK{d}VF{d}PLKVKLF{d}P{cyc:N-C} | GS14K4 Y2/F2 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 15-50µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at > 150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | AKLK{d}AY{d}PLKAKLY{d}P{cyc:N-C} | GS14K4 V3/A3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at > 150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | VKAK{d}VY{d}PAKVKAY{d}P{cyc:N-C} | GS14K4 L3/A3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at > 150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12712499 | 2003 | AKAK{d}AY{d}PAKAKAY{d}P{cyc:N-C} | GS14K4 V3L3/A6 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at > 150µg/ml | Human | Gramicidin S analogs | NA | NA | ||
| 12963031 | 2003 | HVDKKVADKVLLLKQLRIMRLLTRL | Spinigerin | Free | Free | Linear | L | None | 25 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Spinigerin isolated from the fungus-growing termite Pseudacanthotermes spiniger | NA | Non-hemolytic | ||
| 12963031 | 2003 | KKVADKVLLLKQLRIMRL | Spinigerin (4–21) | Free | Free | Linear | L | None | 18 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Spinigerin truncate isolated from the fungus-growing termite Pseudacanthotermes spiniger | NA | Non-hemolytic | ||
| 14514057 | 2003 | KWKLFKKIGIGKFLHSAKKF{ct:Amid} | CA-MA | Amidation | Free | Linear | L | None | 20 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KWKKLLKKPLLKKLLKKL{ct:Amid} | CA-MA analogue P5 | Amidation | Free | Linear | L | None | 18 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KWKLKPLLKKLLKKL{ct:Amid} | P6 | Amidation | Free | Linear | L | None | 15 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KWKKLLKKPLKLKL{ct:Amid} | P7 | Amidation | Free | Linear | L | None | 14 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KPLLKKLLKKL{ct:Amid} | P8 | Amidation | Free | Linear | L | None | 11 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14514057 | 2003 | KLLKKPLKLKL{ct:Amid} | P9 | Amidation | Free | Linear | L | None | 11 | Antibacterial and Antitumor | 0% hemolysis at 100µM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14531844 | 2003 | FLPILASLAAKFGPKLFCLVTKKC | Brevinin-1BYa | Free | Free | Linear | L | None | 24 | Antibacterial | HC50 = 4µM | Human | Brevinin-1B analog | NA | NA | ||
| 14531844 | 2003 | FLPILASLAAKLGPKLFCLVTKKC | Brevinin-1BYb | Free | Free | Linear | L | None | 24 | Antibacterial | HC50 = 4µM | Human | Brevinin-1B analog | NA | NA | ||
| 14531844 | 2003 | FLPILASLAATLGPKLLCLITKKC | Brevinin-1BYc | Free | Free | Linear | L | None | 24 | Antibacterial | Non-hemolytic | Human | Brevinin-1B analog(Rana boylii) | α-helix | Non-hemolytic | ||
| 14531844 | 2003 | GILSTFKGLAKGVAKDLAGNLLDKFKCKITGC | Ranatuerin-2BYa | Free | Free | Linear | L | None | 32 | Antibacterial | HC50 = 120µM | Human | Ranatuerin-2B analog | NA | NA | ||
| 14531844 | 2003 | GIMDSVKGLAKNLAGKLLDSLKCKITGC | Ranatuerin-2BYb | Free | Free | Linear | L | None | 28 | Antibacterial | HC50 >200µM | Human | Ranatuerin-2B analog | NA | NA | ||
| 14531844 | 2003 | FLPIIAKVLSGLL{ct:Amid} | Temporin-1BYa | Amidation | Free | Linear | L | None | 13 | Antibacterial | Non-hemolytic | Human | Temporin-1B analog(Rana boylii) | NA | Non-hemolytic | ||
| 15019213 | 2003 | AKKVFKRLEKLFSKIQNDK | HP (2–20) | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal | <20% hemolysis at 2.15 to 215µM | Human | N-terminus of Helicobacter pylori ribosomal protein 1, HpRpL1 | NA | NA | ||
| 14642822 | 2003 | GYGCPFNQYQCHSHCSGIRGYKGGYCKGTFKQTCKCY | Ornithodoros defensin A | Free | Free | Linear | L | None | 37 | Antibacterial | EC50 >100 (µg/ml) | Human | Synthetic peptide | NA | NA | ||
| 14642822 | 2003 | LTCDLLSFEAKGFAANHSLCAAHCLAIGRKGGACQNGVCVCRR | Oryctes defensin | Free | Free | Linear | L | None | 43 | Antibacterial | EC50 >100 (µg/ml) | Human | Synthetic peptide | NA | NA | ||
| 14596922 | 2003 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antibacterial | HC10 = 1.78 μg/ml | Human | Melittin | NA | NA | ||
| 14596922 | 2003 | GLPALISWIKRKRQQ{ct:Amid} | Mel(12-26) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 4500 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | LLPALISWIKRKRQQ{ct:Amid} | Mel(12-26,L1) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 192 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GSPALISWIKRKRQQ{ct:Amid} | Mel(12-26,S2) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 1588 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GLLALISWIKRKRQQ{ct:Amid} | Mel(12-26,L3) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 35.2 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GLSALISWIKRKRQQ{ct:Amid} | Mel(12-26,S3) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 44 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GLPLLISWIKRKRQQ{ct:Amid} | Mel(12-26,L4) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 203 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GLPASISWIKRKRQQ{ct:Amid} | Mel(12-26,S5) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 3840 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GLPALSSWIKRKRQQ{ct:Amid} | Mel(12-26,S6) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 650 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GLPALILWIKRKRQQ{ct:Amid} | Mel(12-26,L7) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 15.4 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GLPALISLIKRKRQQ{ct:Amid} | Mel(12-26,L8) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 9350 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GLPALISSIKRKRQQ{ct:Amid} | Mel(12-26,S8) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 13800 μg/ml | Human | Melittin analogs | NA | NA | ||
| 14596922 | 2003 | GLPALISWSKRKRQQ{ct:Amid} | Mel(12-26,S9) | Amidation | Free | Linear | L | None | 15 | Antibacterial | HC10 = 6140 μg/ml | Human | Melittin analogs | NA | NA | ||
| 15752569 | 2005 | FLSLIPHAINAVSAIAKHN{ct:Amid} | PS-1 | Amidation | Free | Linear | L | None | 19 | Antibacterial and Antiprotozoa | 1.98% hemolysis at 64µM | Human | Phylloseptin analogs isolated from the skin secretion of the Brazilian tree-frogs, Phyllomedusa hypochondrialis and Phyllomedusa oreades | NA | NA | ||
| 15752569 | 2005 | FLSLIPHAINAVSTLVHHF{ct:Amid} | PS-2 | Amidation | Free | Linear | L | None | 19 | Antibacterial and Antiprotozoa | 2.05% hemolysis at 64µM | Human | Phylloseptin analogs isolated from the skin secretion of the Brazilian tree-frogs, Phyllomedusa hypochondrialis and Phyllomedusa oreades | NA | NA | ||
| 15581850 | 2004 | SIGSALKKALPVAKKIGKIALPIAKAALPVAAGLVG | CtxA | Free | Free | Linear | L | None | 36 | Antibacterial | Hemolytic at 110 µM | Human | Ceratotoxins are α-helical cationic peptides isolated from the medfly Ceratitis capitata | NA | NA | ||
| 15581850 | 2004 | SLGGVISGAKKVAKVAIPIGKAVLPVVAKLVG | CtxC | Free | Free | Linear | L | None | 32 | Antibacterial | Hemolytic 645µM | Human | Ceratotoxins are α-helical cationic peptides isolated from the medfly Ceratitis capitata | NA | NA | ||
| 15581850 | 2004 | SIGTAVKKAVPIAKKVGKVAIPIAKAVLSVVGQLVG | CtxD | Free | Free | Linear | L | None | 36 | Antibacterial | Hemolytic at 84µM | Human | Ceratotoxins are α-helical cationic peptides isolated from the medfly Ceratitis capitata | NA | NA | ||
| 15581850 | 2004 | SIGSALKKALPVAKKIGKIALPIAKAALP | CtxA1–29 | Free | Free | Linear | L | None | 29 | Antibacterial | Hemolytic at 960µM | Human | Ceratotoxins are α-helical cationic peptides isolated from the medfly Ceratitis capitata | NA | NA | ||
| 15328096 | 2004 | CVKVKVKVGSGVKVKVKVC{cyc:N-C}{nt:Acet}{ct:Amid} | V1 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 880000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CVKVSVKVGSGVKVSVKVC{cyc:N-C}{nt:Acet}{ct:Amid} | V2 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 5,89,000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CVKVRVKVGSGVKVRVKVC{cyc:N-C}{nt:Acet}{ct:Amid} | V3 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 590000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CVKVQVKVGSGVKVQVKVC{cyc:N-C}{nt:Acet}{ct:Amid} | V4 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 3226000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CAKAKAKAGSGAKAKAKAC{cyc:N-C}{nt:Acet}{ct:Amid} | V5 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 1055000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CFKFKFKFGSGFKFKFKFC{cyc:N-C}{nt:Acet}{ct:Amid} | V6 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 35000 nM | Human | Synthetic peptide | NA | NA | ||
| 15328096 | 2004 | CWKWKWKWGSGWKWKWKWC{cyc:N-C}{nt:Acet}{ct:Amid} | V7 | Amidation | Acetylation | Cyclic | L | None | 19 | Antibacterial | EC50 = 45000 nM | Human | Synthetic peptide | NA | NA | ||
| 12081622 | 2002 | ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE | CRAMP | Free | Free | Linear | L | None | 38 | Antibacterial | 0% hemolysis at 50 µM (non-hemolytic) | Human | CRAMP (Mouse femoral marrow cells) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVFKRLEKLFSKIQNDK | HP (2 – 20) | Free | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) (Helicobacter pylori) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVFKRLEKLFSKIQNWK | Anal 1 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVFKRLEKLFSKIWNDK | Anal 2 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVFKRLEKLFSKIWNWK | Anal 3 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVFKRLEKSFSKIQNDK | Anal 4 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 12147359 | 2002 | AKKVSKRLEKLFSKIQNDK | Anal 5 | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal and Anticancer | 0% hemolysis at 100μM (non-hemolytic) | Human | HP (2 – 20) analogs (Helicobacter pylori) | NA | Non-hemolytic | ||
| 15345319 | 2004 | TFRRLKWK{cyc:N-C} | LALF-10 | Free | Free | Cyclic | L | None | 8 | Antimicrobial | ~5% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 15345319 | 2004 | TFRRLKWK{cyc:N-C} | LALF-11 | Free | Free | Cyclic | L | None | 8 | Antimicrobial | ~5% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 15345319 | 2004 | KPTFRRLKWKYK{cyc:N-C} | LALF-14 | Free | Free | Cyclic | L | None | 12 | Antimicrobial | ~5% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 15345319 | 2004 | HYRIKPTFRRLKWKYKGKFW{cyc:N-C} | LALf-22 | Free | Free | Cyclic | L | None | 20 | Antimicrobial | ~20% hemolysis at 100µg/ml | Human | Limulus analogs (Limulus polyphemus) | NA | NA | ||
| 15358153 | 2004 | AKKVFKRLEKLFSKIQNDK{ct:Amid} | HP (2–20) | Amidation | Free | Linear | L | None | 19 | Antibacterial | 0% hemolysis at 140µg/ml (non-hemolytic) | Human | HP (2–20) (Helicobacter pylori) | NA | Non-hemolytic | ||
| 15369808 | 2004 | ILGKIWEGIKSLF{ct:Amid} | IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial and Antifungal | 80% hemolysis at 100µM | Human | IsCT | NA | NA | ||
| 15369808 | 2004 | ILGKIAEGIKSLF{ct:Amid} | [A6]-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial and Antifungal | 0% hemolysis at 100µM (non-hemolytic) | Human | IsCT analogs (Opisthacanthus madagascariensis) | NA | Non-hemolytic | ||
| 15369808 | 2004 | ILGKILEGIKSLF{ct:Amid} | [L6]-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial and Antifungal | ~20% hemolysis at 100µM | Human | IsCT analogs (Opisthacanthus madagascariensis) | NA | NA | ||
| 15369808 | 2004 | ILGKIWKGIKSLF{ct:Amid} | [K7]-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial and Antifungal | ~50% hemolysis at 100µM | Human | IsCT analogs (Opisthacanthus madagascariensis) | NA | NA | ||
| 15369808 | 2004 | ILGKILKGIKKLF{ct:Amid} | [L6, K11]-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial and Antifungal | ~20% hemolysis at 100µM | Human | IsCT analogs (Opisthacanthus madagascariensis) | NA | NA | ||
| 15369808 | 2004 | ILGKIWKIKKLF{ct:Amid} | [K7, P8, K11]-IsCT | Amidation | Free | Linear | L | None | 12 | Antibacterial and Antifungal | 0% hemolysis at 100µM (non-hemolytic) | Human | IsCT analogs (Opisthacanthus madagascariensis) | NA | Non-hemolytic | ||
| 12878508 | 2003 | WLNALLHHGLNCAKGVLA{ct:Amid} | 18Hc | Amidation | Free | Linear | L | None | 18 | Antibacterial | ~20% hemolysis at 100µg/ml | Human | Synthetic Analogs of Halocidin (Tunicate Halocynthia aurantium) | NA | NA | ||
| 12878508 | 2003 | WLNALLKKGLNCAKGVLA{ct:Amid} | 18HcKK | Amidation | Free | Linear | L | None | 18 | Antibacterial | <10% hemolysis at 100µg/ml | Human | Synthetic Analogs of Halocidin (Tunicate Halocynthia aurantium) | NA | NA | ||
| 12878508 | 2003 | KWLNALLHHGLNCAKGVLA{ct:Amid} | K19Hc | Amidation | Free | Linear | L | None | 19 | Antibacterial | ~10% hemolysis at 100µg/ml | Human | Synthetic Analogs of Halocidin (Tunicate Halocynthia aurantium) | NA | NA | ||
| 12878508 | 2003 | KWLNALLKKGLNCAKGVLA{ct:Amid} | K19HcKK | Amidation | Free | Linear | L | None | 19 | Antibacterial | <10% hemolysis at 100µg/ml | Human | Synthetic Analogs of Halocidin (Tunicate Halocynthia aurantium) | NA | NA | ||
| 12878508 | 2003 | KWKLFKKIPKFLHLAKKF{ct:Amid} | P18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | <0% hemolysis at 100µg/ml | Human | P18 (Halocynthia aurantium) | NA | Non-hemolytic | ||
| 11846794 | 2002 | RLYR | RLYR | Free | Free | Linear | L | None | 4 | Antibacterial and Antifungal | EC50 = 5200µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRRLYR | (RLYR)2 | Free | Free | Linear | L | None | 8 | Antibacterial and Antifungal | EC50 = 1950µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRRLYRRLYRRLYR | (RLYR)4 | Free | Free | Linear | L | None | 16 | Antibacterial and Antifungal | EC50 = 338µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRRLYRRLYRRLYRRLYRRLYRRLYRRLYR | (RLYR)8 | Free | Free | Linear | L | None | 32 | Antibacterial and Antifungal | EC50 = 48µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRRLYRK | (RLYR)2-[K] | Free | Free | Linear | L | None | 19 | Antibacterial and Antifungal | EC50 = 3700µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRRLYRRLYRRLYRKKK | (RLYR)4-[K2K] | Free | Free | Linear | L | None | 35 | Antibacterial and Antifungal | EC50 = 1510µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRRLYRRLYRRLYRRLYRRLYRRLYRKKKKK | (RLYR)8-([K2K]2K) | Free | Free | Linear | L | None | 8 | Antibacterial and Antifungal | EC50 = 1514µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRKVYG{cyc:N-C} | RLYRKVYG | Free | Free | Cyclic | L | None | 17 | Antibacterial and Antifungal | EC50 = 3950µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRKVYGRLYRKVYGK{cyc:N-C} | (RLYRKVYG)2-[K] | Free | Free | Cyclic | L | None | 17 | Antibacterial and Antifungal | EC50 = 1420µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGKKK{cyc:N-C} | (RLYRKVYG)4-[K2K] | Free | Free | Cyclic | L | None | 35 | Antibacterial and Antifungal | EC50 = 610µM | Human | Synthetic peptide | NA | NA | ||
| 11846794 | 2002 | RLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGRLYRKVYGKKKKK{cyc:N-C} | (RLYRKVYG)8 (K2K)2K | Free | Free | Cyclic | L | None | 63 | Antibacterial and Antifungal | EC50 = 112µM | Human | Synthetic peptide | NA | NA | ||
| 11606214 | 2001 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antimicrobial | Strong hemolysis | Human | Gramicidin S | NA | NA | ||
| 11606214 | 2001 | VKLY{d}PVKLY{d}P{cyc:N-C} | GS10 | Free | Free | Cyclic | Mix | None | 10 | Antimicrobial | Strong hemolysis | Human | Gramicidin S analogs | NA | NA | ||
| 11606214 | 2001 | VKLKY{d}PKVKLY{d}P{cyc:N-C} | GS12 | Free | Free | Cyclic | Mix | None | 12 | Antimicrobial | Weak hemolysis | Human | Gramicidin S analogs | NA | NA | ||
| 11606214 | 2001 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | Very strong hemolysis | Human | Gramicidin S analogs | NA | NA | ||
| 11606214 | 2001 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | [D-Lys]4GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | Weak hemolysis | Human | Gramicidin S analogs | NA | NA | ||
| 11682479 | 2002 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 1.5µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | LKLK{d}LF{d}PLKLKLF{d}P{cyc:N-C} | Y2/F2, V3/L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 12.5µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | LKLK{d}LY{d}PLKLKLY{d}P{cyc:N-C} | V3/L3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 25µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | VKLK{d}VF{d}PLKVKLF{d}P{cyc:N-C} | Y2/F2 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 40µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at 200µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | AKLK{d}AY{d}PLKAKLY{d}P{cyc:N-C} | V3/A3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at >800µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | VKAK{d}VY{d}PAKVKAY{d}P{cyc:N-C} | L3/A3 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at >800µg/ml | Human | Synthetic peptide | NA | NA | ||
| 11682479 | 2002 | AKAK{d}AY{d}PAKAKAY{d}P{cyc:N-C} | V3L3/A6 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial and Antifungal | 100% hemolysis at >800µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10795591 | 2000 | CYCRIPACIAGERRYGTCIYQGRLWAFCC | HNP-2 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.9% hemolysis at 80µg/ml | Human | Human neutrophils | NA | NA | ||
| 10795591 | 2000 | VVCACRRALCLPLERRAGFCRIRGRIHPLCCRR | NP-2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 1.9% hemolysis at 80µg/ml | Human | Rabbit neutrophils | NA | NA | ||
| 10795591 | 2000 | KWCFRVCYRGICYRRCR{ct:Amid} | TP-1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 66.5% hemolysis at 80µg/ml | Human | Limulus hemocytes | NA | NA | ||
| 10795591 | 2000 | RGGRLCYCRRRFCVCVGR{ct:Amid} | PG-1 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 70.3% hemolysis at 80µg/ml | Human | Porcine neutrophils | NA | NA | ||
| 10795591 | 2000 | R{d}G{d}G{d}R{d}L{d}C{d}Y{d}C{d}R{d}R{d}R{d}F{d}C{d}V{d}C{d}V{d}G{d}R{d}{ct:Amid} | dPG-1 | Amidation | Free | Linear | D | None | 18 | Antimicrobial | 90% hemolysis at 80µg/ml | Human | PG-1 analog | NA | NA | ||
| 10795591 | 2000 | RGGRLCYARRRFAVCVGR{ct:Amid} | PG-1 “bullet” | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 14.7% hemolysis at 80µg/ml | Human | PG-1 analog | NA | NA | ||
| 10795591 | 2000 | RGGRLAYCRRRFCVAVGR{ct:Amid} | PG-1 “kite” | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 0% hemolysis at 80µg/ml | Human | PG-1 analog | NA | NA | ||
| 10795591 | 2000 | RGGRLAYARRRFAVAVGR{ct:Amid} | PG-1 “snake” | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 0.8% hemolysis at 80µg/ml | Human | PG-1 analog | NA | NA | ||
| 10795591 | 2000 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 94.6% hemolysis at 80µg/ml | Human | Bee venom | NA | NA | ||
| 10795591 | 2000 | GIGKFLHSAGKFGKAFVGEIMKS | Magainin 1 | Free | Free | Linear | L | None | 23 | Antimicrobial | 0% hemolysis at 80µg/ml | Human | Frog skin | NA | NA | ||
| 10795591 | 2000 | GIGKFLKKAKKFGKAFVKILKK | MSI-78 | Free | Free | Linear | L | None | 22 | Antimicrobial | 11.4% hemolysis at 80µg/ml | Human | Magainin-1 analog | NA | NA | ||
| 10795591 | 2000 | SWLSKTAKKLENSAKKRISEGIAIAIQGGPR | Cecropin P1 | Free | Free | Linear | L | None | 31 | Antimicrobial | 0.3% hemolysis at 80µg/ml | Human | Porcine intestine | NA | NA | ||
| 10795591 | 2000 | KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK | Cecropin A | Free | Free | Linear | L | None | 37 | Antimicrobial | 0.6% hemolysis at 80µg/ml | Human | Insect hemolymph | NA | NA | ||
| 10795591 | 2000 | VFQFLGKIIHHVGNFVHGFSHVF{ct:Amid} | Clavanin A amide | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 3.7% hemolysis at 80µg/ml | Human | Tunicate hemocytes | NA | NA | ||
| 10795591 | 2000 | VFQFLGKIIHHVGNFVHGFSHVF | Clavanin A acid | Free | Free | Linear | L | None | 23 | Antimicrobial | 0% hemolysis at 80µg/ml | Human | Clavanin A analog | NA | NA | ||
| 10795591 | 2000 | VFQFLGKIIKKVGNFVKGFSKVF | Clavanin AK acid | Free | Free | Linear | L | None | 23 | Antimicrobial | 30.6% hemolysis at 80µg/ml | Human | Clavanin A analog | NA | NA | ||
| 10795591 | 2000 | ILPWKWPWWPWRR | Indolicidin | Free | Free | Linear | L | None | 13 | Antimicrobial | 38.2% hemolysis at 80µg/ml | Human | Bovine neutrophils | NA | NA | ||
| 10795591 | 2000 | FLPVLAGIAAKVVPALFCKITKKC | Brevinin-1 | Free | Free | Linear | L | None | 24 | Antimicrobial | 89% hemolysis at 80µg/ml | Human | Frog skin | NA | NA | ||
| 10795591 | 2000 | FLPVLAGIAAKVVPALFCKITKKC | CAM-brevinin | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.5% hemolysis at 80µg/ml | Human | Brevinin-1analog | NA | NA | ||
| 10795591 | 2000 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 17.1% hemolysis at 80µg/ml | Human | Human neutrophils | NA | NA | ||
| 10799508 | 2000 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 10µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 100µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 1% hemolysis at 10µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 8% hemolysis at 100µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 3% hemolysis at 10µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 37% hemolysis at 100µg/ml | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWKLM | Mast 21 | Free | Free | Linear | L | None | 21 | Antimicrobial | 5.4% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGENWELM | Mast 21(+2) | Free | Free | Linear | L | None | 21 | Antimicrobial | 5.3% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGENWKLM | Mast 21(+4) | Free | Free | Linear | L | None | 21 | Antimicrobial | 7.1% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKKIAGMAKKLLKKNWKLM | Mast 21(+8) | Free | Free | Linear | L | None | 21 | Antimicrobial | 6.3% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNW | Mast 18 | Free | Free | Linear | L | None | 18 | Antimicrobial | 2.7% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNW | Mast 19 | Free | Free | Linear | L | None | 18 | Antimicrobial | 5.1% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWELMEK | Mast 23(+4) | Free | Free | Linear | L | None | 23 | Antimicrobial | 6.3% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWELMKK | Mast 23(+6) | Free | Free | Linear | L | None | 23 | Antimicrobial | 7.2% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWKLMKK | Mast 23(+8) | Free | Free | Linear | L | None | 23 | Antimicrobial | 7.2% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWKLM{ct:Amid} | Mast 21N | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 12.3% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | NWKGIAAMAKKLL | Mastoparan X | Free | Free | Linear | L | None | 13 | Antimicrobial | 24% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 10879468 | 2000 | GIGKFLHSAKKFGKAFVGEIMNS | Magainin 2 | Free | Free | Linear | L | None | 23 | Antimicrobial | 4.5% hemolysis at 10µM | Human | Synthetic peptide | NA | NA | ||
| 11779154 | 2002 | RIIDLLWRVRRPQKPKFVTVWVR | PMAP-23 | Free | Free | Linear | L | None | 23 | Antibacterial | 0% hemolysis at 100µM (non-hemolytic) | Human | Porcine myeloid antibacterial peptide | NA | Non-hemolytic | ||
| 12168695 | 2002 | GIGAVLKVLTTGLP{d}ALISWIKRKRQQ{ct:Amid} | Melittin-1 | Amidation | Free | Linear | Mix | None | 26 | Antibacterial | 50% hemolysis at >200µg/ml | Human | Melittin analogs | NA | NA | ||
| 12168695 | 2002 | GIGAVLKVLTTGLP{d}ALISWIKFKRQQ{ct:Amid} | Melittin-2 | Amidation | Free | Linear | Mix | None | 26 | Antibacterial | 50% hemolysis at >80µg/ml | Human | Melittin analogs | NA | NA | ||
| 12168695 | 2002 | GIGAVLKVLTTGLP{d}ALISWIKXXKRQQ{ct:Amid} | Melittin-1P | Amidation | Free | Linear | Mix | None | 27 | Antibacterial | 50% hemolysis at >18µg/ml | Human | Melittin analogs | NA | NA | ||
| 12168695 | 2002 | GIGAVLKVLTTGLP{d}ALISWIKXKRQQ{nt:Acet}{ct:Amid} | Melittin-A1P | Amidation | Acetylation | Linear | Mix | None | 26 | Antibacterial | 50% hemolysis at >200µg/ml | Human | Melittin analogs | NA | NA | ||
| 12168695 | 2002 | GIGAVLKVLTTGLP{d}ALISWIKRKRQQ{nt:Acet}{ct:Amid} | Melittin-A1 | Amidation | Acetylation | Linear | Mix | None | 26 | Antibacterial | 50% hemolysis at >200µg/ml | Human | Melittin analogs | NA | NA | ||
| 12429503 | 2002 | GIFPKIIGKGIVNGIKSLAKGVGMKVFKAGLNNIGNTGCNNRDEC | Palustrin-3AR | Free | Free | Linear | L | None | 45 | Antibacterial | HC50 = 200µM | Human | Palustrin-3 analog (Rana areolata) | NA | NA | ||
| 12429503 | 2002 | GIFSKINKKKAKTGLFNIIKTVGKEAGMDVIRAGIDTISCKIKGEC | Esculentin-1ARa | Free | Free | Linear | L | None | 46 | Antibacterial | HC50 = 180µM | Human | Esculentin-1 analog (Rana areolata) | NA | NA | ||
| 12429503 | 2002 | GLFPKFNKKKVKTGIFDIIKTVGKEAGMDVLRTGIDVIGCKIKGEC | Esculentin-1ARb | Free | Free | Linear | L | None | 46 | Antibacterial | HC50 = 120µM | Human | Esculentin-1 analog (Rana areolata) | NA | NA | ||
| 12429503 | 2002 | GLMDTVKNAAKNLAGQLLDTIKCKMTGC | Ranatuerin-2ARa | Free | Free | Linear | L | None | 28 | Antibacterial | HC50 = 100µM | Human | Ranatuerin-2 analog (Rana areolata) | NA | NA | ||
| 12429503 | 2002 | GILDTIKNAAKTVAVGLLEKIKCKMTGC | Ranatuerin-2ARb | Free | Free | Linear | L | None | 28 | Antibacterial | HC50 = 150µM | Human | Ranatuerin-2 analog (Rana areolata) | NA | NA | ||
| 12429503 | 2002 | GFISTVKNLATNVAGTVIDTIKCKVTGGC | Palustrin-2AR | Free | Free | Linear | L | None | 29 | Antibacterial | HC50 > 300µM | Human | Palustrin-2 analog (Rana areolata) | NA | NA | ||
| 12429503 | 2002 | FLPIVGRLISGLL{ct:Amid} | Temporin-1AR | Amidation | Free | Linear | L | None | 13 | Antibacterial | HC50 = 210µM | Human | Temporin-1 analog (Rana areolata) | NA | NA | ||
| 10747913 | 2000 | CGETCVGGTCNTPGCTCSWPVCTRNGLPV{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolytic at 50μM | Human | Macrocyclic peptides | NA | NA | ||
| 10785392 | 2000 | GILDTLKQFAKGVGKDLVKGAAQGVLSTVSCKLAKTC | Gaegurin 4 (GGN4) | Free | Free | Linear | L | None | 37 | Antimicrobial | Non-hemolytic | Human | Skin of a Korean frog, Rana rugosa | NA | Non-hemolytic | ||
| 10799508 | 2000 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 10μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 100μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 1% hemolytic at 10μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 8% hemolytic at 100μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 3% hemolytic at 10μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10799508 | 2000 | VKKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K3L4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 37% hemolytic at 100μg/ml | Human | Synthetic peptide | NA | NA | ||
| 15195974 | 2004 | KWKKLLKKLLKLL{ct:Amid} | K6L6W | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 75% hemolytic at 100μM | Human | Synthetic peptide | NA | NA | ||
| 15195974 | 2004 | KWKKLPKKLLKLL{ct:Amid} | K6L5WP | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14965277 | 2004 | GWGSFFKKAAHVGKHVGKAALTHYL | Ple | Free | Free | Linear | L | None | 25 | Antimicrobial | 2.5% hemolytic at 100μM | Human | Pleurocidin | NA | NA | ||
| 14965277 | 2004 | GWGSFFKKAAHVAKHVGKAALTHYL | Ple-AG | Free | Free | Linear | L | None | 25 | Antimicrobial | 16.6% hemolytic at 100μM | Human | Pleurocidin | NA | NA | ||
| 14965277 | 2004 | GWGSFFKKAAHVGKHVAKAALTHYL | Ple-GA | Free | Free | Linear | L | None | 25 | Antimicrobial | 15.4% hemolytic at 100μM | Human | Pleurocidin | NA | NA | ||
| 14965277 | 2004 | GWGSFFKKAAHVAKHVAKAALTHYL | Ple-AA | Free | Free | Linear | L | None | 25 | Antimicrobial | 37.4% hemolytic at 100μM | Human | Pleurocidin | NA | NA | ||
| 12931994 | 2003 | RGGRLCYCRRRFCVCVGR{cyc:N-C}{ct:Amid} | Protegrin-I (2) | Amidation | Free | Cyclic | L | None | 18 | Antimicrobial | 37% hemolytic at 100μg/ml | Human | Protegrin | NA | NA | ||
| 12931994 | 2003 | LRLKKRRWKYRVP{d}{cyc:N-C} | 5 | Free | Free | Cyclic | Mix | None | 13 | Antimicrobial | 1.4% hemolytic at 100μg/ml | Human | Protegrin | NA | NA | ||
| 12071741 | 2002 | GIGKFLHAAKKFAKAFVAEIMNS{ct:Amid} | Ala8,13,18-magainin II | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 100% hemolytic at 100μg/ml | Human | Magainin analog | NA | NA | ||
| 11738090 | 2001 | GFLGPLLKLAAKGVAKVIPHLIPSRQQ | XT-1 | Free | Free | Linear | L | None | 27 | Antimicrobial | HC50 = 90μM | Human | Isolated from norepinephrine-stimulated skin secretions of the diploid clawed frog, Xenopus tropicalis | NA | NA | ||
| 11738090 | 2001 | GVFLDALKKFAKGGMNAVLNPK | XT-4 | Free | Free | Linear | L | None | 22 | Antimicrobial | HC50 > 150μM | Human | Isolated from norepinephrine-stimulated skin secretions of the diploid clawed frog, Xenopus tropicalis | NA | NA | ||
| 11738090 | 2001 | GMATKAGTALGKVAKAVIGAAL{ct:Amid} | XT-5 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | HC50 > 150μM | Human | Isolated from norepinephrine-stimulated skin secretions of the diploid clawed frog, Xenopus tropicalis | NA | NA | ||
| 11738090 | 2001 | GFLGSLLKTGLKVGSNLL{ct:Amid} | XT-6 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | HC50 > 150μM | Human | Isolated from norepinephrine-stimulated skin secretions of the diploid clawed frog, Xenopus tropicalis | NA | NA | ||
| 11738090 | 2001 | GLLGPLLKIAAKVGSNLL{ct:Amid} | XT-7 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | HC50 = 70μM | Human | Isolated from norepinephrine-stimulated skin secretions of the diploid clawed frog, Xenopus tropicalis | NA | NA | ||
| 10973820 | 2000 | ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE | CRAMP | Free | Free | Linear | L | None | 38 | Antimicrobial and Anticancer | 2.2% hemolytic at 100μM | Human | Derived from CRMAP, a member of cathelicidin-derived antimicrobial peptides | NA | NA | ||
| 10973820 | 2000 | GEKLKKIGQKIKNFFQKL | CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0% hemolytic at 100μM (non-hemolytic) | Human | CRMAP | NA | Non-hemolytic | ||
| 10973820 | 2000 | GKKLKKIGQKIKNFFQKL | K2-CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0% hemolytic at 100μM (non-hemolytic) | Human | CRMAP-18 analogs | NA | Non-hemolytic | ||
| 10973820 | 2000 | GEKLKKIGKKIKNFFQKL | K9-CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0% hemolytic at 100μM (non-hemolytic) | Human | CRMAP-18 analogs | NA | Non-hemolytic | ||
| 10973820 | 2000 | GEKLKKIGQKIKKFFQKL | K13-CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0% hemolytic at 100μM (non-hemolytic) | Human | CRMAP-18 analogs | NA | Non-hemolytic | ||
| 10973820 | 2000 | GEKLKKIGQKIKNFFKKL | K16-CRAMP-18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Anticancer | 0.2% hemolytic at 100μM | Human | CRMAP-18 analogs | NA | NA | ||
| 10879468 | 2000 | GIGKFLHSAKKFGKAFVGEIMNS | Magainin 2 | Free | Free | Linear | L | None | 23 | Antimicrobial and Hemolytic | 4.5% hemolytic at 10μM | Human | Magainin-2 (Xenopus laevis) | NA | NA | ||
| 10879468 | 2000 | NWKGIAAMAKKLL | Mastroparan X | Free | Free | Linear | L | None | 13 | Antimicrobial and Hemolytic | 24% hemolytic at 10μM | Human | Wasp Venom | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWKLM | Mast 21 | Free | Free | Linear | L | None | 19 | Antimicrobial and Hemolytic | 5.4% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGENWELM | Mast 21(+2) | Free | Free | Linear | L | None | 21 | Antimicrobial and Hemolytic | 5.3% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGENWKLM | Mast 21(+4) | Free | Free | Linear | L | None | 21 | Antimicrobial and Hemolytic | 7.1% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10879468 | 2000 | KNWKKIAGMAKKLLKKNWKLM | Mast 21(+8) | Free | Free | Linear | L | None | 21 | Antimicrobial and Hemolytic | 6.3% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNW | Mast 18 | Free | Free | Linear | L | None | 18 | Antimicrobial and Hemolytic | 2.7% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNW | Mast 19 | Free | Free | Linear | L | None | 18 | Antimicrobial and Hemolytic | 5.1% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWELMEK | Mast 23(+4) | Free | Free | Linear | L | None | 23 | Antimicrobial and Hemolytic | 6.3% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWELMKK | Mast 23(+6) | Free | Free | Linear | L | None | 23 | Antimicrobial and Hemolytic | 7.2% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWKLMKK | Mast 23(+8) | Free | Free | Linear | L | None | 23 | Antimicrobial and Hemolytic | 7.2% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10879468 | 2000 | KNWKGIAGMAKKLLGKNWKLM{ct:Amid} | Mast 21N | Amidation | Free | Linear | L | None | 21 | Antimicrobial and Hemolytic | 12.3% hemolytic at 10μM | Human | Mastoparan X derived peptides | NA | NA | ||
| 10821683 | 2000 | CKLLLKWLLKLLKC{cyc:N-C} | Cyclic-K4L7W | Free | Free | Cyclic | L | None | 14 | Cytolytic | 50% hemolytic at 50μM | Human | Synthetic peptide | NA | NA | ||
| 10821683 | 2000 | CH3-S-CKLLLKWLLKLLKC-S-CH3 | Linear-K4L7W | Free | Free | Linear | L | None | 14 | Cytolytic | 100% hemolytic at 5μM | Human | Synthetic peptide | NA | NA | ||
| 10821683 | 2000 | C{d}K{d}L{d}L{d}L{d}K{d}W{d}L{d}L{d}K{d}L{d}L{d}K{d}C{d}{cyc:N-C} | cyclic-[D]-L3,4,8,10-K4L7W | Free | Free | Cyclic | D | None | 14 | Cytolytic | 90% hemolytic at 50μM | Human | Synthetic peptide | NA | NA | ||
| 10821683 | 2000 | C{d}K{d}L{d}L{d}L{d}K{d}W{d}L{d}L{d}K{d}L{d}L{d}K{d}C{d}{nt:CH3-S-}{ct:-S-CH3} | linear-[D]-L3,4,8,10-K4L7W | Free | Free | Linear | D | None | 14 | Cytolytic | 5% hemolytic at 50μM | Human | Synthetic peptide | NA | NA | ||
| 10673369 | 1999 | KWCFRVCYRGICYRRCR-{nnr:X} | TP-1 | Free | Free | Linear | L | None | 17 | Antimicrobial | EC25 = 29μM | Human | Tachyplesin-1 | NA | NA | ||
| 10673369 | 1999 | KWCFCVCYRGICYCRCRG | cc TP | Free | Free | Linear | L | None | 18 | Antimicrobial | EC25 =590μM | Human | Tachyplesin-1 | NA | NA | ||
| 10673369 | 1999 | GFCRCLCRRGVCRCLCTK | RTD | Free | Free | Linear | L | None | 18 | Antimicrobial | EC25 =2350μM | Human | Tachyplesin-1 | NA | NA | ||
| 18501981 | 2008 | GVIIDTLKGAAKTVAAELLRKAHCKLTNSC{ct:Amid} | Brevinin-2GUb | Amidation | Free | Linear | L | None | 30 | Cytolytic | LC50 = 700μM | Human | Insulin-releasing peptide (Hylarana guntheri) | NA | NA | ||
| 18325325 | 2008 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | Ple | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 77% hemolysis at 100μM | Human | Pleurocidin (Winter flounder) | NA | NA | ||
| 18325325 | 2008 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | Ple | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 29% hemolysis at 50μM | Human | Pleurocidin (Winter flounder) | NA | NA | ||
| 18325325 | 2008 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | Ple | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 6% hemolysis at 25μM | Human | Pleurocidin (Winter flounder) | NA | NA | ||
| 18325325 | 2008 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | Ple | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 0% hemolytic at 12.5μM | Human | Pleurocidin (Winter flounder) | NA | NA | ||
| 18325325 | 2008 | RWRSFFKKAAHRGKHVGKRARTHYL{ct:Amid} | Anal-R | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Pleurocidin (Winter flounder) | NA | Non-hemolytic | ||
| 18325325 | 2008 | SWSSFFKKAAHSGKHVGKSASTHYL{ct:Amid} | Anal-S | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Pleurocidin (Winter flounder) | NA | Non-hemolytic | ||
| 18068868 | 2007 | GFKDLLKGAAKALVKTVLF{ct:Amid} | Ascaphin-8 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LC50 =55μM | Human | Frog skin | NA | NA | ||
| 18068868 | 2007 | GFKKLLKGAAKALVKTVLF{ct:Amid} | Lys4-Ascaphin-8 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LC50 =24μM | Human | Frog skin | NA | NA | ||
| 18068868 | 2007 | GFKDLLKKAAKALVKTVLF{ct:Amid} | Lys8-Ascaphin-8 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LC50 =11μM | Human | Frog skin | NA | NA | ||
| 10224074 | 1999 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antimicrobial and Hemolytic | 100% hemolytic at 12.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 1.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKV{d}KLY{d}P{cyc:N-C} | GS14V10 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 6.2 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKL{d}KVY{d}PLKVKLY{d}P{cyc:N-C} | GS14L3 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 12.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{d}{cyc:N-C} | GS14P14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 6.2 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}P{d}LKVKLY{d}P{cyc:N-C} | GS14P7 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 12.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14V1 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 40 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKL{d}Y{d}P{cyc:N-C} | GS14L12 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 25 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKV{d}Y{d}PLKVKLY{d}P{cyc:N-C} | GS14V5 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 150 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLYP{cyc:N-C} | GS14Y13 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 12.5 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PL{d}KVKLY{d}P{cyc:N-C} | GS14L8 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 50 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVYPLKVKLY{d}P{cyc:N-C} | GS14Y6 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 25 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VK{d}LKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 50 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLK{d}VKLY{d}P{cyc:N-C} | GS14K9 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 100 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 200 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVK{d}LY{d}P{cyc:N-C} | GS14K11 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at 150 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VK{d}LK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at >200 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 10224074 | 1999 | VK{d}LK{d}VY{d}PLK{d}VK{d}LY{d}P{cyc:N-C} | GS14K2K4K9K11 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial and Hemolytic | 100% hemolytic at >200 μg/ml | Human | Derivative of Gramicidin S | NA | NA | ||
| 23624708 | 2013 | KRGFGCNGPWNEDDLRCHNHCKSIKGYKGGYCAKGGFVCKCY | rNZ2114 | Free | Free | Linear | L | None | 42 | Antimicrobial | >0.1% hemolytic upto 128μg/ml | Human | Variant of plectasin | NA | NA | ||
| 23609760 | 2013 | FVDLKKIANIINSIFGK | Temporin-1CEa | Free | Free | Linear | L | None | 17 | Antimicrobial, Anticancer and moderate Hemolytic | LC50 =95.7μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FVDLKKIANIINSIFKK | LK1 | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =1,467μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FKDLKKIANIINSIFKK | LK2(5) | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =1,186μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FVKLKKIANIINSIFKK | LK2(6) | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =1,993μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FKKLKKIANIINSIFKK | LK3 | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =4,649μM | Human | Defencin | NA | NA | ||
| 23609760 | 2013 | FVKLKKILNIINSIFKK | LK2(6)A(L) | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =86.99μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23609760 | 2013 | FVKLKKILNIILSIFKK | LK2(6)AN(2L) | Free | Free | Linear | L | None | 17 | Anticancer | LC50 =28.34μM | Human | Temporin-1CEa (Rana chensinensis) | NA | NA | ||
| 23570790 | 2013 | WKSDVRRWRSRY | TSG-6 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.3 ±0.9% hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 23570790 | 2013 | WKSYVRRWRSRY | TSG-7 | Free | Free | Linear | L | None | 12 | Antimicrobial | 1.5 ±1.4%hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 23570790 | 2013 | WKSYVRRWRSR | TSG-8 | Free | Free | Linear | L | None | 11 | Antimicrobial | -1.2 ± 2.6%hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 23570790 | 2013 | WWSYVRRWRSR | TSG-8-1 | Free | Free | Linear | L | None | 11 | Antimicrobial | 3.4 ±1.3% hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 23570790 | 2013 | WKSYVRRWRS | TSG-9 | Free | Free | Linear | L | None | 10 | Antimicrobial | -0.4 ± 0.5%hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 23570790 | 2013 | KKSYVRRWRS | TSG-9-1 | Free | Free | Linear | L | None | 10 | Antimicrobial | -0.6 ± 1.6% hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 23570790 | 2013 | WKSYVRRWR | TSG-10 | Free | Free | Linear | L | None | 9 | Antimicrobial | 1.1 ±1.3% hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 23570790 | 2013 | WKSYVRRW | TSG-11 | Free | Free | Linear | L | None | 8 | Antimicrobial | 2.0 ±0.3% hemolytic at 100μM | Human | Derivative of Ixosin-B | NA | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear | L | None | 38 | Antimicrobial | ~2% hemolytic at 200μM | Human | Isolated from the larvae of Bombyx mori | NA | NA | ||
| 23519707 | 2013 | GLFDIIKKIAESF | AU | Free | Free | Linear | L | None | 13 | Antimicrobial | 50% hemolytic at 128μmol/L | Human | Aurein 1.2 | NA | NA | ||
| 23519707 | 2013 | GLFDIIKKIAESF | AU | Free | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolytic at 4 -16μmol/L | Human | Aurein 1.2 | NA | NA | ||
| 23519707 | 2013 | FSEAIKKIIDFLGEGLFDIIKKIAESF | E(AU)2 | Free | Free | Linear | L | None | 27 | Antimicrobial | ~5% hemolytic at 128μmol/L | Human | N-terminal dimer of aurein | NA | NA | ||
| 23519707 | 2013 | FSEAIKKIIDFLGEGLFDIIKKIAESF | E(AU)2 | Free | Free | Linear | L | None | 27 | Antimicrobial | 0% hemolytic at 4 -32μmol/L | Human | N-terminal dimer of aurein | NA | NA | ||
| 23519707 | 2013 | GLFDIIKKIAESFKFSEAIKKIIDFLG | (AU)2K | Free | Free | Linear | L | None | 27 | Antimicrobial | ~30% hemolytic at 32μmol/L | Human | C-terminal dimer of aurein | NA | NA | ||
| 23519707 | 2013 | GLFDIIKKIAESFKFSEAIKKIIDFLG | (AU)2K | Free | Free | Linear | L | None | 27 | Antimicrobial | 10% hemolytic at 4μmol/L | Human | C-terminal dimer of aurein | NA | NA | ||
| 23344198 | 2013 | WLKKLLKKLLK{ct:Amid} | L5K5W 1 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 32 μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 23344198 | 2013 | KWLKKLLKKLL{ct:Amid} | L5K5W 2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 16μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 23344198 | 2013 | LKWLKKLLKKL{ct:Amid} | L5K5W 3 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 64μg/mL | Human | Defencin | NA | NA | ||
| 23344198 | 2013 | LLKWLKKLLKK{ct:Amid} | L5K5W 4 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 128μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 23344198 | 2013 | KLLKWLKKLLK{ct:Amid} | L5K5W 5 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 64μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 23344198 | 2013 | KKLLKWLKKLL{ct:Amid} | L5K5W 6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 32μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 23344198 | 2013 | LKKLLKWLKKL{ct:Amid} | L5K5W 7 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 128μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 23344198 | 2013 | LLKKLLKWLKK{ct:Amid} | L5K5W 8 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 128μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 23344198 | 2013 | KLLKKLLKWLK{ct:Amid} | L5K5W 9 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 64μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 23344198 | 2013 | KKLLKKLLKWL{ct:Amid} | L5K5W 10 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 32μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 23344198 | 2013 | LKKLLKKLLKW{ct:Amid} | L5K5W 11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial and Hemolytic | MHC = 128μg/mL | Human | De novo designed L5K5W model peptide isomers | NA | NA | ||
| 22914980 | 2013 | KWKW{ct:Amid} | (KW)2 | Amidation | Free | Linear | L | None | 4 | Antimicrobial | 0% hemolytic at 200μM | Human | Synthetic KW peptides | NA | Non-hemolytic | ||
| 22914980 | 2013 | KWKWKW{ct:Amid} | (KW)3 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 0% hemolytic at 200μM | Human | Synthetic KW peptides | NA | Non-hemolytic | ||
| 22914980 | 2013 | KWKWKWKW{ct:Amid} | (KW)4 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 8% hemolytic at 200μM | Human | Synthetic KW peptides | NA | NA | ||
| 22914980 | 2013 | KWKWKWKWKW{ct:Amid} | (KW)5 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 71% hemolytic at 200μM | Human | Synthetic KW peptides | NA | NA | ||
| 23093034 | 2013 | SWKSMAKKLKEYMEKLKQRA | La5 | Free | Free | Linear | L | None | 20 | Antimicrobial | 2% hemolytic at 25mM | Human | Analogs of antimicrobial peptides La47 (From venom of Lachesana sp.) | NA | NA | ||
| 23093034 | 2013 | FFGSLLSLGSKLLPSVFKLFQRKKE | Css54 | Free | Free | Linear | L | None | 25 | Antimicrobial | 83% hemolytic at 25mM | Human | Analogs of antimicrobial peptides La47 (From venom of Lachesana sp.) | NA | NA | ||
| 23019445 | 2013 | KWASLWNWFNITNWLWYIK{ct:Amid} | gp41w | Amidation | Free | Linear | L | None | 19 | Antimicrobial | EC50 =550μg/ml | Human | Gp41 derivative (HIV) | NA | NA | ||
| 23019445 | 2013 | KWARLWRWFRITRWLWYIK{ct:Amid} | gp41w-4R | Amidation | Free | Linear | L | None | 19 | Antimicrobial | EC50 = 7-14μg/ml | Human | Gp41 derivative (HIV) | NA | NA | ||
| 23019445 | 2013 | KWAKKWKWFAKAAWKWYKK{ct:Amid} | gp41w-KA | Amidation | Free | Linear | L | None | 19 | Antimicrobial | EC50 = 42μg/ml | Human | Gp41 derivative (HIV) | NA | NA | ||
| 23019445 | 2013 | KFAKKFKWFAKAAFKFFKK{ct:Amid} | gp41w-FKA | Amidation | Free | Linear | L | None | 19 | Antimicrobial | EC50 = 195μg/ml | Human | Gp41 derivative (HIV) | NA | NA | ||
| 22921836 | 2012 | MAFKKLEKVGRNIRDGIIKAGPAVAVIGQATSIARPTGK | Pxcec781 | Free | Free | Linear | L | None | 39 | Antimicrobial | Non-hemolytic | Human | Cecropin 1 derivative (Plutella xylostella) | NA | NA | ||
| 22865764 | 2013 | RGRCYTVCRQLYCLRRCQ | Gomesin (Gm) | Free | Free | Linear | L | None | 18 | Antimicrobial | 40% hemolytic at 100mM | Human | Gomesin (Gm) (Acanthoscurria gomesiana) | NA | NA | ||
| 22865764 | 2013 | RGRCYTVCRQLYCLRRCQ | Cys(Acm)2,15]-Gm | Free | Free | Linear | L | None | 18 | Antimicrobial | 16% hemolytic at 100mM | Human | Gomesin (Gm) (Acanthoscurria gomesiana) | NA | NA | ||
| 22865764 | 2013 | RGRCYTVCRQLYCLRRCQ | [Thr2,6,11,15,D-Pro9]-Gm | Free | Free | Linear | L | None | 18 | Antimicrobial | 17% hemolytic at 100mM | Human | Gomesin (Gm) (Acanthoscurria gomesiana) | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}W{d}L{d}L{d}A{d}L{d}K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}{ct:Amid} | D-LAK120 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 4.06±1.30μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}W{d}L{d}P{d}A{d}L{d}K{d}K{d}L{d}A{d}L{d}L{d}A{d}L{d}K{d}K{d}{ct:Amid} | D-LAK120-P13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 11.66±0.03μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}W{d}L{d}A{d}L{d}A{d}K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK120-A | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 17.42±2.17μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}W{d}L{d}P{d}L{d}A{d}K{d}K{d}L{d}A{d}L{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK120-AP13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 58.61±10.41μMc | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}L{d}A{d}L{d}H{d}A{d}L{d}K{d}K{d}W{d}L{d}H{d}A{d}L{d}K{d}K{d}L{d}A{d}H{d}L{d}A{d}L{d}K{d}K{d}{ct:Amid} | D-LAK120-H | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 20.29±2.42μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}A{d}L{d}A{d}H{d}A{d}L{d}K{d}K{d}W{d}L{d}P{d}A{d}L{d}K{d}K{d}L{d}A{d}H{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK120-HP13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 79.61±2.80μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}A{d}L{d}A{d}K{d}A{d}L{d}K{d}H{d}W{d}L{d}P{d}A{d}L{d}H{d}K{d}L{d}A{d}K{d}A{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK80-HP13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 8.61±0.35μM | Human | Synthetic peptide | NA | NA | ||
| 22869378 | 2013 | K{d}K{d}A{d}L{d}K{d}H{d}A{d}L{d}A{d}K{d}W{d}L{d}P{d}A{d}L{d}K{d}A{d}L{d}A{d}H{d}K{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-LAK160-HP13 | Amidation | Free | Linear | D | None | 25 | Antimicrobial, Antiplasmodial and Anticancer | HC50 = 185.0±18.65μM | Human | Synthetic peptide | NA | NA | ||
| 22858580 | 2013 | MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLR | cgUbiquitin | Free | Free | Linear | L | None | 74 | Antimicrobial | 0% hemolytic at 100μg/ml (non-hemolytic) | Human | Ubiquitin (Crassostrea gigas) | NA | Non-hemolytic | ||
| 22837667 | 2013 | KWKSFLKTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | P | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 5.20 ± 0.02μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLK{d}TFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | K7D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 10.4 ± 0.04μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSLKK{d}TVLHTLLKAISS{nt:Acet}{ct:Amid} | K14D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 5.20 ± 0.02μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSLKKTVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 20.81 ± 0.10 μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLK{d}TFKSLKK{d}TVLHTLLKAISS{nt:Acet}{ct:Amid} | K7D/K14 D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 20.81 ± 0.15μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 20.81 ± 0.06μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLK{d}TFKSLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K7D/K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 81.31 ± 0.17μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K7D/K10D/K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC = 325.20 ± 0.82μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWK{d}SFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K3D/K7D/K10D/K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC >325.20μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | K{d}WK{d}SFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K1D/K3D/K7D/K10D/K14D/K22D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC >325.20μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | L6D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =10.40 ± 0.08μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSL{d}KKTVLHTLLKAISS{nt:Acet}{ct:Amid} | L12D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =20.81 ± 0.03μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSLKKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L20D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =20.81 ± 0.13μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSL{d}KKTVLHTLLKAISS{nt:Acet}{ct:Amid} | L6D/L12D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =20.81 ± 0.10 μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFLKTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L12D/L20D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =81.31 ± 0.43μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L6D/L12D/L20D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =162.61 ± 0.19μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L6D/L12D/L17D/L20D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC =81.31 ± 1.05μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22837667 | 2013 | KWKSFL{d}KTFKSL{d}KKTVLHTL{d}L{d}KAISS{nt:Acet}{ct:Amid} | L6D/L12D/L17D/L20D/L21D | Amidation | Acetylation | Linear | Mix | None | 26 | Anticancer | MHC >325.20μmol/L | Human | Synthetic α-helical cationic anticancer peptides | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 3.13μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 6.25μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 12.5μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.1% hemolytic at 25.0μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.1 hemolytic at 50.0μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND | YFGAP-OH | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.4% hemolytic at 100mg/mL | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 3.13μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 6.25μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 2.3% hemolytic at 12.5μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 2.5% hemolytic at 25μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 2.6% hemolytic at 50μg/ml | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22771964 | 2013 | VKVGINGFGRIGRLVTRAAFHGKKVEVVAIND{ct:Amid} | YFGAP-NH2 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 2.7 % hemolytic at 100mg/mL | Human | Yellowfin tuna GAPDH-related anti-microbial peptide (YFGAP) (Thunnus albacares) | NA | NA | ||
| 22699557 | 2012 | IWRIFRRIFRIF{ct:Amid} | HFU4 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | MHC = 19.6 μM | Human | Synthetic peptide | NA | NA | ||
| 22699557 | 2012 | IWRIFRRIFRIFIRF{ct:Amid} | HFU5 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | MHC = 15 μM | Human | Synthetic peptide | NA | NA | ||
| 22578463 | 2012 | KWLRRVWRWWR{ct:Amid} | MAP-04-03 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 100% hemolytic at 100μM | Human | Peptide amide analogs of Ixosin-B | NA | NA | ||
| 22578463 | 2012 | KRLRRVWRRWR{ct:Amid} | MAP-04-04 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 3% hemolytic at 100μM | Human | Peptide amide analogs of Ixosin-B | NA | NA | ||
| 22792229 | 2012 | FIKRIARLLRKIF | Kn2-7 | Free | Free | Linear | L | None | 13 | Antimicrobial | HC50= 90.27 µg/mL | Human | BmKn2 derivative (From venom of Mesobuthus martensii) | NA | NA | ||
| 22792229 | 2012 | FIGAIARLLSKIF | BmKn2 | Free | Free | Linear | L | None | 13 | Antimicrobial | HC50= 17.13 µg/mL | Human | BmKn2 derivative (From venom of Mesobuthus martensii) | NA | NA | ||
| 23652359 | 2013 | KIGAKIKIGAKIKIGAKI{ct:Amid} | KIGAKI-wt | Amidation | Free | Linear | L | None | 18 | Antimicrobial | ~14% hemolytic at 7.5μM | Human | Membrane-active model peptide KIGAKI [(KIGAKI)3-NH2] | NA | NA | ||
| 23652359 | 2013 | KIGAKIKIGAKIKIGAKI{ct:Amid} | KIGAKI-wt | Amidation | Free | Linear | L | None | 18 | Antimicrobial | ~54% hemolytic at 60μM | Human | Membrane-active model peptide KIGAKI [(KIGAKI)3-NH2] | NA | NA | ||
| 23652359 | 2013 | KIGAK{nnr:L-CF3-Bpg}KIGAKIKIGAKI{ct:Amid} | KIGAKI-6L | Amidation | Free | Linear | L | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~23% hemolytic at 7.5μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAK{nnr:L-CF3-Bpg}-KIGAKIKIGAKI{ct:Amid} | KIGAKI-6L | Amidation | Free | Linear | L | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~50% hemolytic at 60μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAK-{nnr:D-CF3-Bpg}-KIGAKIKIGAKI{ct:Amid} | KIGAKI-6D | Amidation | Free | Linear | Mix | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~7% hemolysis at 7.5μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAK-{nnr:D-CF3-Bpg}-KIGAKIKIGAKI{ct:Amid} | KIGAKI-6D | Amidation | Free | Linear | Mix | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~10% hemolytic at 60μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIK-{nnr:L-CF3-Bpg}-GAKIKIGAKI{ct:Amid} | KIGAKI-8L | Amidation | Free | Linear | L | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~13% hemolytic at 7.5μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIK-{nnr:L-CF3-Bpg}-GAKIKIGAKI{ct:Amid} | KIGAKI-8L | Amidation | Free | Linear | L | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~38% hemolytic at 60μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIK-{nnr:D-CF3-Bpg}-GAKIKIGAKI{ct:Amid} | KIGAKI-8D | Amidation | Free | Linear | Mix | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~5% hemolytic at 7.5μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIK-{nnr:D-CF3-Bpg}-GAKIKIGAKI{ct:Amid} | KIGAKI-8D | Amidation | Free | Linear | Mix | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~8% hemolytic at 60μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIKIGAK-{nnr:L-CF3-Bpg}-KIGAKI{ct:Amid} | KIGAKI-12L | Amidation | Free | Linear | L | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~17% hemolytic at 7.5μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIKIGAK-{nnr:L-CF3-Bpg}-KIGAKI{ct:Amid} | KIGAKI-12L | Amidation | Free | Linear | L | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~38% hemolytic at 60μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKI-12DKIGAKIKIGAK-{nnr:D-CF3-Bpg}-KIGAKI{ct:Amid} | KIGAKI-12D | Amidation | Free | Linear | Mix | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~5% hemolysis at 7.5μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKI-12DKIGAKIKIGAK-{nnr:D-CF3-Bpg}-KIGAKI{ct:Amid} | KIGAKI-12D | Amidation | Free | Linear | Mix | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~7% hemolysis at 60μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIKIGAKIK-{nnr:L-CF3-Bpg}-GAKI{ct:Amid} | KIGAKI-14L | Amidation | Free | Linear | L | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~13% hemolysis at 7.5μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIKIGAKIK-{nnr:L-CF3-Bpg}-GAKI{ct:Amid} | KIGAKI-14L | Amidation | Free | Linear | L | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~34% hemolytic at 60μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIKIGAKIK-{nnr:D-CF3-Bpg}-GAKI{ct:Amid} | KIGAKI-14D | Amidation | Free | Linear | Mix | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~6% hemolysis at 7.5μM | Human | KIGAKI analog | NA | NA | ||
| 23652359 | 2013 | KIGAKIKIGAKIK-{nnr:D-CF3-Bpg}-GAKI{ct:Amid} | KIGAKI-14D | Amidation | Free | Linear | Mix | CF3-Bpg = 3-(trifluoromethyl)-bicyclopent-1.1.1-1-ylglycine | 17 | Antimicrobial | ~7% hemolysis at 60μM | Human | KIGAKI analog | NA | NA | ||
| 22029824 | 2012 | TSRCIFYRRKKCS | Andersonin-C1 | Free | Free | Linear | L | None | 13 | Antimicrobial | 15.2 ± 2.1% hemolytic at 50 μg/mL. | Human | Andersonin (Odorrana andersonii) | NA | NA | ||
| 22083756 | 2012 | CLRIGMRGRELMGGIGKTM | pCM19 | Free | Free | Linear | L | None | 19 | Antibacterial | 0.109% hemolytic at 100 μg/mL | Human | Peptide of hGlyrichin,corresponding to amino acids 42 to 60 (Homo sapien) | NA | NA | ||
| 22083756 | 2012 | CLRIGMRGRELMGGIGKTM | pCM19 | Free | Free | Linear | L | None | 19 | Antibacterial | 0.119% hemolytic at 3000 μg/mL | Human | Peptide of hGlyrichin,corresponding to amino acids 42 to 60 (Homo sapien) | NA | NA | ||
| 22249992 | 2012 | NWCKRGRKQCKTHPH | NWC15l | Free | Free | Linear | L | None | 15 | Antimicrobial | ~2% hemolytic at 60μM and 6μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22249992 | 2012 | NWCKRGRKQCKTHPH{cyc:N-C} | NWC15c | Free | Free | Cyclic | L | None | 15 | Antimicrobial | ~2% hemolytic at 6μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22249992 | 2012 | NWCKRGRKQCKTHPH{cyc:N-C} | NWC15c | Free | Free | Cyclic | L | None | 15 | Antimicrobial | ~3% hemolytic at 60μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22249992 | 2012 | NWCKRGRKQCKTHPHFVIPY{cyc:N-C} | NWC20c | Free | Free | Cyclic | L | None | 20 | Antimicrobial | ~4% hemolytic at 6μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22249992 | 2012 | NWCKRGRKQCKTHPHFVIPY{cyc:N-C} | NWC20c | Free | Free | Cyclic | L | None | 20 | Antimicrobial | ~3% hemolytic at 60μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22249992 | 2012 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | ~9% hemolytic at 60μM | Human | ß-amyloid precursor protein derivative (Homo sapien) | NA | NA | ||
| 22328546 | 2012 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | CPP | >80% hemolytic at 25μM at pH 8 | Human | Melittin (Apis mellifera) | NA | NA | ||
| 22328546 | 2012 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | CPP | <60% hemolytic at 25μM at pH 6 | Human | Melittin (Apis mellifera) | NA | NA | ||
| 22328546 | 2012 | GIGAVLKVLTTGLPALISWI | MT20 | Free | Free | Linear | L | None | 20 | CPP | <80% hemolytic at 25μM at pH 8 | Human | Truncated peptides of melittin | NA | NA | ||
| 22328546 | 2012 | GIGAVLKVLTTGLPALISWI | MT20 | Free | Free | Linear | L | None | 20 | CPP | 40% hemolytic at 25μM at pH 5 | Human | Truncated peptides of melittin | NA | NA | ||
| 22328546 | 2012 | GIGAILKVLATGLPTLISWIKNKRKQ | Florae | Free | Free | Linear | L | None | 26 | CPP | <70% hemolytic at 25μM at pH 6 | Human | Melittin analog | NA | NA | ||
| 22328546 | 2012 | GIGAILKVLATGLPTLISWIKNKRKQ | Florae | Free | Free | Linear | L | None | 26 | CPP | ~80% hemolytic at 25μM at pH 8 | Human | Melittin analog | NA | NA | ||
| 22328546 | 2012 | GIGAILKVLATGLPTLISWI | FL20 | Free | Free | Linear | L | None | 20 | CPP | <60% hemolytic at 25μM at pH 5 | Human | Truncated peptides of florae (Apis florae) | NA | NA | ||
| 22328546 | 2012 | GIGAILKVLATGLPTLISWI | FL20 | Free | Free | Linear | L | None | 20 | CPP | ~80% hemolytic at 25μM at pH 8 | Human | Truncated peptides of florae (Apis florae) | NA | NA | ||
| 22371493 | 2012 | MGIIAGIIKVIKSLIEQFTGK | PSMα1 | Free | Free | Linear | L | None | 21 | Immunosuppressive and antimicrobial | 58% hemolytic at 10 μg/mL | Human | Phenol-soluble modulins derivative (Staphylococcus aureus) | NA | NA | ||
| 22371493 | 2012 | GIIKVIKSLIEQFTGK | dPSMα1 | Free | Free | Linear | L | None | 16 | Immunosuppressive and antimicrobial | Non-hemolytic at 10 μg/mL | Human | Phenol-soluble modulins derivative (Staphylococcus aureus) | NA | Non-hemolytic | ||
| 22371493 | 2012 | MAIVGTIIKIIKAIIDIFAK | PSMα4 | Free | Free | Linear | L | None | 20 | Immunosuppressive and antimicrobial | 19% hemolytic at 10 μg/mL | Human | Phenol-soluble modulins derivative (Staphylococcus aureus) | NA | NA | ||
| 22371493 | 2012 | VGTIIKIIKAIIDIFAK | dPSMα4 | Free | Free | Linear | L | None | 17 | Immunosuppressive and antimicrobial | 52% hemolytic at 10 μg/mL | Human | Phenol-soluble modulins derivative (Staphylococcus aureus) | NA | NA | ||
| 22391524 | 2012 | GWLDVAKKIGKAAFNVAKNFL{ct:Amid} | MON | Amidation | Free | Linear | L | None | 21 | Antimicrobial | HC50 = 37.3± 1.4 μmol/L | Human | Ctx-Ha ceratotoxin-like peptide (Hypsiboas albopunctatus) | NA | NA | ||
| 22391524 | 2012 | GWLDVAKKIGKAAFNVAKNFLFNKAVNFAAKGIKKAVDLWG | DSE | Free | Free | Linear | L | None | 42 | Antimicrobial | HC50 = 0.6± 0.1 μmol/L | Human | Dimeric Ctx-Ha without spacer (Hypsiboas albopunctatus) | NA | NA | ||
| 22391524 | 2012 | GWLDVAKKIGKAAFNVAKNFL-{nnr:spacer}-LFNKAVNFAAKGIKKAVDLWG | DEA | Free | Free | Linear | L | spacer = 8-amino-octanoic acid | 42 | Antimicrobial | HC50 = 0.7± 0.1 μmol/L | Human | Dimeric form of Ctx-Ha with a apolar spacer (Hypsiboas albopunctatus) | NA | NA | ||
| 22391524 | 2012 | GWLDVAKKIGKAAFNVAKNFL-{nnr:spacer}-LFNKAVNFAAKGIKKAVDLWG | DEP | Free | Free | Linear | L | spacer = 8-amino-3,6-dioxaoctanoic acid | 42 | Antimicrobial | HC50 = 0.8± 0.1 μmol/L | Human | Dimeric form of Ctx-Ha with a polar spacer (Hypsiboas albopunctatus) | NA | NA | ||
| 22518150 | 2012 | KWKLFKKIPKFLHLAKKF{ct:Amid} | P18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | MHC = 250 μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLTSKFLHLAKKF{ct:Amid} | CP-P | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC = 250 μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLTSKFLHSAKKF{ct:Amid} | S16 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KFKSFIKKLTSKFLHSAKKF{ct:Amid} | F2 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC = 250 μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFINKLTSKFLHSAKKF{ct:Amid} | N7 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKSTSKFLHSAKKF{ct:Amid} | S9 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKAKTSFLHSAKKF{ct:Amid} | A9 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLLSKFLHSAKKF{ct:Amid} | L10 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC <125 μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLASKFLHSAKKF{ct:Amid} | A10 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC= 250 μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLTDKFLHSAKKF{ct:Amid} | D11 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLTKKFLHSAKKF{ct:Amid} | K11 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLTSKALHSAKKF{ct:Amid} | A13 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLTSKFLHSKKKF{ct:Amid} | K17 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLTSKFLHSADKF{ct:Amid} | D18 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLTSKFLHSANKF{ct:Amid} | N18 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22518150 | 2012 | KWKSFIKKLTSKFLHSAKKN{ct:Amid} | N20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC >500μg/mL | Human | Designed antimicrobial peptide CP-P derivative | NA | NA | ||
| 22699557 | 2012 | IWRIFR{ct:Amid} | HFU2 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | MHC >256μM | Human | Synthetic peptides | NA | NA | ||
| 22699557 | 2012 | IWRIFRRIF{ct:Amid} | HFU3 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | MHC =101.4μM | Human | Synthetic peptides | NA | NA | ||
| 22699557 | 2012 | IWRIFRRIFRIF{ct:Amid} | HFU4 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | MHC =19.6μM | Human | Synthetic peptides | NA | NA | ||
| 22699557 | 2012 | IWRIFRRIFRIFIRF{ct:Amid} | HFU5 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | MHC =15.0μM | Human | Synthetic peptides | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKCKGPLKLVCKC{cyc:N-C} | Lasiocepsin | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKCKGPLKLVCKC{cyc:N-C}{ct:Amid} | Lasiocepsin-NH2 | Amidation | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKCKGPLKLVCKC{cyc:N-C} | Las[C8-C27, C17-C25] | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKCKGPLKLVCKC{cyc:N-C} | Las[C8-C17, C25-C27] | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILCAIAKKKGKAKGPLKLVCKA{cyc:N-C} | Las[C8-C25, Ala17,27] | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILAAIAKKKGKCKGPLKLVAKC{cyc:N-C} | Las[C17-C27, Ala8,25] | Free | Free | Cyclic | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILAAIAKKKGKAKGPLKLVAKA | Las[Ala8,17,25,27] | Free | Free | Linear | L | None | 27 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | LCAIAKKKGKCKGPLKLVCKC{cyc:N-C}{ct:Amid} | Las[des1-6]-NH2 | Amidation | Free | Cyclic | L | None | 21 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | AKKKGKCKGPLKLVAKC{cyc:N-C}{ct:Amid} | Las[des1-10, Ala25]-NH2 | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22038181 | 2012 | GLPRKILAAIAKKK{ct:Amid} | Las[des15-27, Ala8]-NH2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | <1% hemolytic at 200μM | Human | Lasiocepsin analogs (From venom of eusocial bee, Lasioglossum laticeps) | NA | NA | ||
| 22526241 | 2012 | GFLSILKKVLPKVMAHMK{ct:Amid} | MEP | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 >100μM | Human | Melectin (wild bee) | NA | NA | ||
| 22526241 | 2012 | GFLSILKKVLPKVXAHXK{ct:Amid} | MEP-N | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 = 50μM | Human | Melectin analog (wild bee) | NA | NA | ||
| 22526241 | 2012 | GFLSILKKVLPKSXAHSK{ct:Amid} | MEP-Ns-1 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 = 18.1μM | Human | Melectin analog (wild bee) | NA | NA | ||
| 22526241 | 2012 | GFLSSLKKSLPKVXAHXK{ct:Amid} | MEP-Ns-2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 = 14.7μM | Human | Melectin analog (wild bee) | NA | NA | ||
| 22526241 | 2012 | GFLSSLKKSLPKSXAHSK{ct:Amid} | MEP-Ns-3 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 = 13.9μM | Human | Melectin analog (wild bee) | NA | NA | ||
| 22526241 | 2012 | GFRSILKKVSPKVXAHXK{ct:Amid} | MEP-Ns-4 cis | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 = 11μM | Human | Melectin analog (wild bee) | NA | NA | ||
| 22526241 | 2012 | GFRSILKKVSPKVXAHXK{ct:Amid} | MEP-Ns-4 trans | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 = 20μM | Human | Melectin analog (wild bee) | NA | NA | ||
| 22526241 | 2012 | GFLSSLKKSLGKSXAHSK{ct:Amid} | MEP-Ns-5 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 = 29μM | Human | Melectin analog (wild bee) | NA | NA | ||
| 22526241 | 2012 | GFLSSLKKSLAKSXAHSK{ct:Amid} | MEP-Ns-6 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 = 39.5μM | Human | Melectin analog (wild bee) | NA | NA | ||
| 22526241 | 2012 | VNWKKILGKIIKVVK{ct:Amid} | LL-III | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 >200μM | Human | Lasioglossin III (wild bee) | NA | NA | ||
| 22526241 | 2012 | VNWKKSLGKSIKVVK{ct:Amid} | LL-IIIs-1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 = 31.3μM | Human | Lasioglossin III (wild bee) | NA | NA | ||
| 22526241 | 2012 | VNWKKILGKSIKVSK{ct:Amid} | LL-IIIs-2 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 = 69μM | Human | Lasioglossin III (wild bee) | NA | NA | ||
| 22526241 | 2012 | VSWKKSLGKIIKVVK{ct:Amid} | LL-IIIs-3 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 = 30μM | Human | Lasioglossin III (wild bee) | NA | NA | ||
| 22526241 | 2012 | VNSKKISGKSIKVSK{ct:Amid} | LL-IIIs-4 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 >100μM | Human | Lasioglossin III (wild bee) | NA | NA | ||
| 22526241 | 2012 | VNRKKILGKSIKVVK{ct:Amid} | LL-IIIs-5 cis | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 = 100μM | Human | Lasioglossin III (wild bee) | NA | NA | ||
| 22526241 | 2012 | VNRKKILGKSIKVVK{ct:Amid} | LL-IIIs-5 trans | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 >100μM | Human | Lasioglossin III (wild bee) | NA | NA | ||
| 22526241 | 2012 | VNSKKISPKSIKVSK{ct:Amid} | LL-IIIs-6a | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 >100μM | Human | Lasioglossin III (wild bee) | NA | NA | ||
| 22526241 | 2012 | VNSKKISPKSIKVSK{ct:Amid} | LL-IIIs-6b | Amidation | Free | Linear | L | None | 15 | Antimicrobial | LC50 = 82μM | Human | Lasioglossin III (wild bee) | NA | NA | ||
| 22578463 | 2012 | QLKVDLWGTRSGIQPEQHSSGKSDVRRWRSRY{ct:Amid} | Ixosin-B-amide | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Ixosin-B-amide | NA | Non-hemolytic | ||
| 22578463 | 2012 | KSLVRRWRSRW{ct:Amid} | MAP-04-01 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Amide analogs of Ixosin-B | NA | Non-hemolytic | ||
| 22578463 | 2012 | KSLRRVWRSWR{ct:Amid} | MAP-04-02 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Amide analogs of Ixosin-B | NA | Non-hemolytic | ||
| 22578463 | 2012 | KWLRRVWRWWR{ct:Amid} | MAP-04-03 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 100% hemolytic at 100μM | Human | Amide analogs of Ixosin-B | NA | NA | ||
| 22578463 | 2012 | KRLRRVWRRWR{ct:Amid} | MAP-04-04 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 3% hemolytic at 100μM | Human | Amide analogs of Ixosin-B | NA | NA | ||
| 22581068 | 2012 | SAVGRHGRRFGLRKHRKH | Chensinin-1 | Free | Free | Linear | L | None | 18 | Antimicrobial | LD50 >500 μM | Human | Skin of Rana chensinensis | NA | NA | ||
| 19635451 | 2010 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100% hemolytic at 0.4μM & 23μM | Human | Melittin (Honey bee) | NA | NA | ||
| 19635451 | 2010 | GIGAVLKVLALISWIKRKR{ct:Amid} | Mel-H | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 28% hemolytic at 0.4μM | Human | Melittin analog (Honey bee) | NA | NA | ||
| 19635451 | 2010 | GIGAVLKVLALISWIKRKR{ct:Amid} | Mel-H | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 42% hemolytic at 23μM | Human | Melittin analog (Honey bee) | NA | NA | ||
| 19635451 | 2010 | GIGA{d}VLK{d}VLA{d}LISWI{d}KRKR{ct:Amid} | Mel-dH | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial | 5% hemolysis at 0.4μM | Human | Melittin diastereomeric analog (Honey bee) | NA | NA | ||
| 19635451 | 2010 | GIGA{d}VLK{d}VLA{d}LISWI{d}KRKR{ct:Amid} | Mel-dH | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial | 12% hemolytic at 23μM | Human | Melittin diastereomeric analog (Honey bee) | NA | NA | ||
| 20015460 | 2010 | GVIKSVLKGVAKTVALGML{ct:Amid} | B2-RP | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LC50 = 280μM | Human | Brevinin-2-related peptides (Hylarana erythraea) | NA | NA | ||
| 20058937 | 2010 | KKL{d}L{d}KLLL{d}KL{d}LK{ct:Amid} | K5L7 | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 20058937 | 2010 | KKL{d}L{d}KLLL{d}KL{d}LK{nt:Acetylation (CH3(CH2)4CO)}{ct:Amid} | C6-K5L7 | Amidation | Acetylation (CH3(CH2)4CO) | Linear | Mix | None | 12 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 20058937 | 2010 | KKL{d}L{d}KLLL{d}KL{d}LK{nt:Acetylation (CH3(CH2)6CO)}{ct:Amid} | C8-K5L7 | Amidation | Acetylation (CH3(CH2)6CO) | Linear | Mix | None | 12 | Antimicrobial | 19% hemolytic at 100μM | Human | Synthetic peptides | NA | NA | ||
| 20058937 | 2010 | KKL{d}L{d}KKLK{d}KL{d}LK{ct:Amid} | K7L5 | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 20058937 | 2010 | KKL{d}L{d}KKLK{d}KL{d}LK{nt:Acetylation (CH3(CH2)4CO)}{ct:Amid} | C6-K7L5 | Amidation | Acetylation (CH3(CH2)4CO) | Linear | Mix | None | 12 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 20058937 | 2010 | KKL{d}L{d}KKLK{d}KL{d}LK{nt:Acetylation (CH3(CH2)6CO)}{ct:Amid} | C8-K7L5 | Amidation | Acetylation (CH3(CH2)6CO) | Linear | Mix | None | 12 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 20058937 | 2010 | KKK{d}L{d}KKLK{d}KK{d}LK{ct:Amid} | K9L3 | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 20058937 | 2010 | KKK{d}L{d}KKLK{d}KK{d}LK{nt:Acetylation (CH3(CH2)4CO)}{ct:Amid} | C6-K9L3 | Amidation | Acetylation (CH3(CH2)4CO) | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 100μM (non-hemolytic) | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 20058937 | 2010 | KKK{d}L{d}KKLK{d}KK{d}LK{nt:Acetylation (CH3(CH2)6CO)}{ct:Amid} | C8-K9L3 | Amidation | Acetylation (CH3(CH2)6CO) | Linear | Mix | None | 12 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 20798581 | 2010 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | Ple | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 7% hemolytic at 100μM | Human | Pleurocidin (Pleuronectes americanus) | NA | NA | ||
| 20798581 | 2010 | SFFKKAAHVGKHVGKAALTHYL{ct:Amid} | Ple (4-25) | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 0% hemolytoc at 100μM (non-hemolytic) | Human | Pleurocidin (Pleuronectes americanus) | NA | Non-hemolytic | ||
| 20798581 | 2010 | KKAAHVGKHVGKAALTHYL{ct:Amid} | Ple (7-25) | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Pleurocidin (Pleuronectes americanus) | NA | Non-hemolytic | ||
| 20798581 | 2010 | GWGSFFKKAAHVGKHVGKAALT{ct:Amid} | Ple (1-22) | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 0% hemolysis at 100μM (non-hemolytic) | Human | Pleurocidin (Pleuronectes americanus) | NA | Non-hemolytic | ||
| 20798581 | 2010 | GWGSFFKKAAHVGKHVGKA{ct:Amid} | Ple (1-19) | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolytic at 100μM (non-hemolytic) | Human | Pleurocidin (Pleuronectes americanus) | NA | Non-hemolytic | ||
| 20848624 | 2010 | F{d}PV{nnr:O}LF{d}PV{nnr:O}L{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antimicrobial | HC50=17.5±1.07μM | Human | Gramicidin S | NA | NA | ||
| 20848624 | 2010 | F{d}PV{nnr:O}LF{d}P-{nnr:Ada}-G{nnr:O}L{cyc:N-C} | GS2 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50=10.1±1.11μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}PV{nnr:O}LF{d}PV{nnr:O}-{nnr:Ada}-A{cyc:N-C} | GS4 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50 =5.20±1.13μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}PV{nnr:O}-{nnr:Ada}-AF{d}PV{nnr:O}-{nnr:Ada}-A{cyc:N-C} | GS5 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50 =10.3±1.07μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}P-{nnr:Ada}-G{nnr:O}-{nnr:Ada}-AF{d}P-{nnr:Ada}-G{nnr:O}-{nnr:Ada}-A{cyc:N-C} | GS6 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50 =7.55±1.10μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | FP-{nnr:tBuGly}-{nnr:O}-{nnr:tBuAla}-F{d}P-{nnr:tBuGly}-{nnr:O}-{nnr:tBuAla}{cyc:N-C} | GS7 | Free | Free | Cyclic | Mix | O = L-Ornithine, tBuGly = tert-butylglycine, tBuAla = tert-butylalanine | 10 | Antimicrobial | HC50 =9.30±1.07μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}P-{nnr:Chg}-{nnr:O}-{nnr:Cha}-F{d}P-{nnr:Chg}-{nnr:O}-{nnr:Cha}{cyc:N-C} | GS8 | Free | Free | Cyclic | Mix | O = L-Ornithine, Chg = Cyclohexylglycine, Cha = Cyclohexylalanine | 10 | Antimicrobial | HC50 =9.12±1.13μM | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}P{nnr:O}V{nnr:O}{cyc:N-C} | GS9 | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antimicrobial | Non-hemolytic | Human | Gramicidin S analogue | NA | NA | ||
| 20848624 | 2010 | F{d}P{nnr:O}-{nnr:Ada}Gly-{nnr:O}F{d}P{nnr:O}-{nnr:Ada}-Gly-{nnr:O}{cyc:N-C} | GS10 | Free | Free | Cyclic | Mix | O = L-Ornithine, Ada = Adamantylglycine | 10 | Antimicrobial | HC50=107±1.07μM | Human | Gramicidin S analogue | NA | NA | ||
| 20858205 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}K{d}S{d}A{d}K{d}K{d}T{d}V{d}L{d}H{d}T{d}A{d}L{d}K{d}A{d}I{d}S{d}S{d}{nt:Acet}{ct:Amid} | D1 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 = 421.5μg/ml | Human | Synthetic peptides | NA | NA | ||
| 20858205 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}K{d}S{d}A{d}K{d}K{d}T{d}V{d}L{d}H{d}T{d}L{d}L{d}K{d}A{d}I{d}S{d}S{d}{nt:Acet}{ct:Amid} | D2 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 = 83μg/ml | Human | Synthetic peptides | NA | NA | ||
| 20858205 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}K{d}S{d}L{d}K{d}K{d}T{d}V{d}L{d}H{d}T{d}L{d}L{d}K{d}A{d}I{d}S{d}S{d}{nt:Acet}{ct:Amid} | D3 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 = 14μg/ml | Human | Synthetic peptides | NA | NA | ||
| 20858205 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}K{d}S{d}L{d}K{d}K{d}T{d}V{d}L{d}H{d}T{d}L{d}L{d}K{d}L{d}I{d}S{d}S{d}{nt:Acet}{ct:Amid} | D4 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 = 3.5μg/ml | Human | Synthetic peptides | NA | NA | ||
| 20858205 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}K{d}S{d}L{d}K{d}K{d}T{d}K{d}L{d}H{d}T{d}L{d}L{d}K{d}L{d}I{d}S{d}S{d}{nt:Acet}{ct:Amid} | D5 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 = 47μg/ml | Human | Synthetic peptides | NA | NA | ||
| 20858205 | 2011 | LLGDEFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | L-LL37 | Amidation | Free | Linear | L | None | 37 | Antimicrobial | HC50 = 43.5μg/ml | Human | Synthetic peptides | NA | NA | ||
| 20858205 | 2011 | L{d}L{d}G{d}D{d}E{d}F{d}R{d}K{d}S{d}K{d}E{d}K{d}I{d}G{d}K{d}E{d}F{d}K{d}R{d}I{d}V{d}Q{d}R{d}I{d}K{d}D{d}F{d}L{d}R{d}N{d}L{d}V{d}P{d}R{d}T{d}E{d}S{d} | D-LL37 | Free | Free | Linear | D | None | 37 | Antimicrobial | HC50 = 125μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20955730 | 2011 | RIKRFWPVVIRTVVAGYNLYRAIKKK | Pc-CATH1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 13.2% hemolytic at 31.5μM | Human | Novel cathelicidin-derived myeloid antimicrobial peptide from Phasianus colchicus | NA | NA | ||
| 20955730 | 2011 | RIKRFWPVVIRTVVAGYNLYRAIKKK | Pc-CATH1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 9.1% hemolytic at 15.7μM | Human | Novel cathelicidin-derived myeloid antimicrobial peptide from Phasianus colchicus | NA | NA | ||
| 20955730 | 2011 | RIKRFWPVVIRTVVAGYNLYRAIKKK | Pc-CATH1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 6.3% hemolytic at 6.30μM | Human | Novel cathelicidin-derived myeloid antimicrobial peptide from Phasianus colchicus | NA | NA | ||
| 20955730 | 2011 | RIKRFWPVVIRTVVAGYNLYRAIKKK | Pc-CATH1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 3.6% hemolytic at 3.15μM | Human | Novel cathelicidin-derived myeloid antimicrobial peptide from Phasianus colchicus | NA | NA | ||
| 21110126 | 2011 | FLGWLFKWASK{ct:Amid} | GA-W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =25μg/ml | Human | Brevinin-1EMa analog (Glandirana emeljanovi) | NA | NA | ||
| 21110126 | 2011 | FLGWLFKWAWK{ct:Amid} | GA-W3 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =50 μg/ml | Human | Brevinin-1EMa analog (Glandirana emeljanovi) | NA | NA | ||
| 21110126 | 2011 | FLWWLFKWAWK{ct:Amid} | GA-W4 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =25μg/ml | Human | Brevinin-1EMa analog (Glandirana emeljanovi) | NA | NA | ||
| 21110126 | 2011 | FLGWLFKWAKK{ct:Amid} | GA-K3 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =50μg/ml | Human | Brevinin-1EMa analog (Glandirana emeljanovi) | NA | NA | ||
| 21110126 | 2011 | FLKWLFKWAKK{ct:Amid} | GA-K4 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =6.3μg/ml | Human | Brevinin-1EMa analog (Glandirana emeljanovi) | NA | NA | ||
| 21110126 | 2011 | FLKWLFKWLKK{ct:Amid} | GA-K4L | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =12.5μg/ml | Human | Brevinin-1EMa analog (Glandirana emeljanovi) | NA | NA | ||
| 21110126 | 2011 | FAKWAFKWAKK{ct:Amid} | GA-K4A | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC >200μg/ml | Human | Brevinin-1EMa analog (Glandirana emeljanovi) | NA | NA | ||
| 21110126 | 2011 | FAKWAFKWLKK{ct:Amid} | GA-K4AL | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC >200μg/ml | Human | Brevinin-1EMa analog (Glandirana emeljanovi) | NA | NA | ||
| 21219588 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}K{d}S{d}A{d}V{d}K{d}T{d}V{d}L{d}H{d}T{d}A{d}L{d}K{d}A{d}I{d}S{d}S{d}{nt:Acet}{ct:Amid} | D1 (V13) | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 =1.8μM | Human | Synthetic peptides | NA | NA | ||
| 21219588 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}K{d}S{d}A{d}K{d}K{d}T{d}V{d}L{d}H{d}T{d}A{d}L{d}K{d}A{d}I{d}S{d}S{d}{nt:Acet}{ct:Amid} | D1 (K13) | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 = 140.9μM | Human | Synthetic peptides | NA | NA | ||
| 21219588 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}S{d}K{d}A{d}K{d}K{d}K{d}V{d}L{d}K{d}T{d}A{d}L{d}K{d}A{d}I{d}S{d}K{d}{nt:Acet}{ct:Amid} | D11 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 = 254.1μM | Human | Synthetic peptides | NA | NA | ||
| 21219588 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}S{d}K{d}A{d}K{d}K{d}K{d}A{d}L{d}K{d}T{d}L{d}L{d}K{d}A{d}I{d}S{d}K{d}{nt:Acet}{ct:Amid} | D22 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 =81.3μM | Human | Synthetic peptides | NA | NA | ||
| 21219588 | 2011 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}S{d}K{d}A{d}K{d}K{d}K{d}K{d}L{d}K{d}T{d}L{d}L{d}K{d}A{d}I{d}S{d}K{d}{nt:Acet}{ct:Amid} | D14 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 =351.5μM | Human | Synthetic peptides | NA | NA | ||
| 21219588 | 2011 | K{d}L{d}K{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}K{d}A{d}K{d}K{d}K{d}L{d}L{d}K{d}T{d}A{d}L{d}K{d}A{d}L{d}S{d}K{d}{nt:Acet}{ct:Amid} | D15 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 =169.6μM | Human | Synthetic peptides | NA | NA | ||
| 21219588 | 2011 | K{d}L{d}K{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}K{d}A{d}K{d}K{d}K{d}K{d}L{d}K{d}T{d}L{d}L{d}K{d}A{d}L{d}S{d}K{d}{nt:Acet}{ct:Amid} | D16 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | HC50 =1342.0μM | Human | Synthetic peptides | NA | NA | ||
| 21300831 | 2011 | GKKLLKKLKKLLKKG{nt:Acet}{ct:Amid} | Pep-1 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 0.3% hemolytic at 3.4mg/ml | Human | Synthetic peptides | NA | NA | ||
| 21300831 | 2011 | GKKL{d}L{d}KKL{d}KKL{d}L{d}KKG{nt:Acet}{ct:Amid} | MA-d | Amidation | Acetylation | Linear | Mix | None | 15 | Antimicrobial | 1% hemolytic at 3.4mg/ml | Human | Synthetic peptides | NA | NA | ||
| 21300831 | 2011 | GKKLLKKLKKLLKKW{nt:Acet}{ct:Amid} | MAw-1 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 17% hemolytic at 3.4mg/ml | Human | Synthetic peptides | NA | NA | ||
| 21300831 | 2011 | GKKLLKKLKKLWKKW{nt:Acet}{ct:Amid} | Maw-2 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 18% hemolytic at 3.4mg/ml | Human | Synthetic peptides | NA | NA | ||
| 21300831 | 2011 | GKKLLKKWKKLWKKW{nt:Acet}{ct:Amid} | Maw-3 | Amidation | Acetylation | Linear | L | None | 15 | Antimicrobial | 5% hemolytic at 3.4mg/ml | Human | Synthetic peptides | NA | NA | ||
| 21319749 | 2011 | FVQWFSKFLGRIL{ct:Amid} | TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 48% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | LLQWLSKLLGRLL{ct:Amid} | TL-1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 25% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | LLQWLSKLLGRWL{ct:Amid} | TL-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 78% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVQWFSKFLLRIL{ct:Amid} | [Leu10]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 80% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVPWFSKFLGRIL{ct:Amid} | [Pro3]TLb | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FLPWFSKFLGRIL{ct:Amid} | [Leu2, Pro3]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 19% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVPWFSKFLPRIL{ct:Amid} | [Pro3, Pro10]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 4.5% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVPWFSKFLP{d}RIL{ct:Amid} | [Pro3, DPro10]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 0.6% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVQWFSKFLGKIL{ct:Amid} | [Lys11]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 14% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVQWFSKFLG{nnr:O}IL{ct:Amid} | [Orn11]TL | Amidation | Free | Linear | L | O = L-Ornithine | 13 | Antimicrobial | 22% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVQWFSRFLGRIL{ct:Amid} | [Arg7]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 29% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVRWFSKFLGRIL{ct:Amid} | [Arg3]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 52% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVRWFSRFLGRIL{ct:Amid} | [Arg3, Arg7]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 43% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | FVPWFSKFLGOIL{ct:Amid} | [Pro3, Orn11]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 2% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | F{d}V{d}Q{d}W{d}F{d}S{d}K{d}F{d}L{d}GR{d}I{d}L{d}{ct:Amid} | D-TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 46% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21319749 | 2011 | L{d}I{d}R{d}GL{d}F{d}K{d}S{d}F{d}W{d}Q{d}V{d}F{d}{ct:Amid} | RI-TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 15% hemolytic at 6μM | Human | Temporin L Analogues | NA | NA | ||
| 21335383 | 2011 | KKLFKKILKYL{ct:Amid} | BP100 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 54 ±0.1% hemolytic at 250μM | Human | Synthetic peptide | NA | NA | ||
| 21335383 | 2011 | KKLFKKILKY{d}L{ct:Amid} | BP138 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 7 ±0.1% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFKKILKYL{d}{ct:Amid} | BP139 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 23 ±0.9% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFKKILK{d}YL{ct:Amid} | BP140 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 0± 0% hemolytic at 250μM (non-hemolytic) | Human | Synthetic peptide of BP100 | NA | Non-hemolytic | ||
| 21335383 | 2011 | KKLFKKIL{d}KYL{ct:Amid} | BP141 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 4 ±0.3% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFK{d}KILKYL{ct:Amid} | BP142 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 3± 0.6% hemolysis at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLF{d}KKILKYL{ct:Amid} | BP143 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 5± 0.8% hemolysis at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKL{d}FKKILKYL{ct:Amid} | BP144 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 7±0.4% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KK{d}LFKKILKYL{ct:Amid} | BP145 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 51±0.5% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFKK{d}ILKYL{ct:Amid} | BP146 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 53 ±1.1% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | K{d}KLFKKILKYL{ct:Amid} | BP147 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 71±0.4% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFKKI{d}LKYL{ct:Amid} | BP148 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 0±0% hemolytic at 250μM (non-hemolytic) | Human | Synthetic peptide of BP100 | NA | Non-hemolytic | ||
| 21335383 | 2011 | KKL{d}FKKILK{d}YL{ct:Amid} | BP149 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 0±0% hemolytic at 250μM (non-hemolytic) | Human | Synthetic peptide of BP100 | NA | Non-hemolytic | ||
| 21335383 | 2011 | KKLFKKIL{d}K{d}YL{ct:Amid} | BP150 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 1±0.1% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KK{d}L{d}FKK{d}ILK{d}YL{ct:Amid} | BP151 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 1±0.3% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFKKI{d}L{d}K{d}YL{ct:Amid} | BP152 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 5±1.6% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | K{d}K{d}LF{d}KKILKYL{ct:Amid} | BP154 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 41±6.2% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFKKIL{d}K{d}Y{d}L{d}{ct:Amid} | BP155 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 3±0.1% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFKKL{d}L{d}K{d}Y{d}L{d}{ct:Amid} | BP156 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 49±1.2% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFKK{d}I{d}L{d}K{d}Y{d}L{d}{ct:Amid} | BP157 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 3±1.0% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLFK{d}K{d}I{d}L{d}K{d}Y{d}L{d}{ct:Amid} | BP158 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 28±2.1% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KKLF{d}K{d}K{d}I{d}L{d}K{d}Y{d}L{d}{ct:Amid} | BP159 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 58±5.7% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KK{d}L{d}F{d}K{d}K{d}I{d}L{d}K{d}Y{d}L{d}{ct:Amid} | BP160 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 65±1.9% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | KK{d}L{d}F{d}K{d}K{d}I{d}L{d}K{d}Y{d}L{d}{ct:Amid} | BP161 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 66±2.9% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | K{d}K{d}L{d}F{d}KKILKYL{ct:Amid} | BP162 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 17±0.7% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | K{d}K{d}L{d}F{d}K{d}KILKYL{ct:Amid} | BP163 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 8±5.0% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | K{d}K{d}L{d}F{d}K{d}K{d}ILKYL{ct:Amid} | BP164 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 0±0% hemolytic at 250μM (non-hemolytic) | Human | Synthetic peptide of BP100 | NA | Non-hemolytic | ||
| 21335383 | 2011 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}LKYL{ct:Amid} | BP165 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 6 ±0.2% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}KYL{ct:Amid} | BP166 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 1±0.2% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}K{d}YL{ct:Amid} | BP167 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 21±7.4% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}K{d}Y{d}L{ct:Amid} | BP168 | Amidation | Free | Linear | Mix | None | 11 | Antimicrobial | 3±2.7% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21335383 | 2011 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}K{d}Y{d}L{d}{ct:Amid} | BP153 | Amidation | Free | Linear | D | None | 11 | Antimicrobial | 50±2.1% hemolytic at 250μM | Human | Synthetic peptide of BP100 | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLSGIL{ct:Amid} | 1Ta | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 27.5% hemolytic at 40μM | Human | Temporin-1Ta (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLSGIL{ct:Amid} | 1Ta | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.5% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | ALPLIGRVLSGIL{ct:Amid} | Ta A1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 62.5% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | ALPLIGRVLSGIL{ct:Amid} | Ta A1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 2% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FAPLIGRVLSGIL{ct:Amid} | Ta A2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 15% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FAPLIGRVLSGIL{ct:Amid} | Ta A2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLALIGRVLSGIL{ct:Amid} | Ta A3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 100% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLALIGRVLSGIL{ct:Amid} | Ta A3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPAIGRVLSGIL{ct:Amid} | Ta A4 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 11.5% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPAIGRVLSGIL{ct:Amid} | Ta A4 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 2% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLAGRVLSGIL{ct:Amid} | Ta A5 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3.5% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLAGRVLSGIL{ct:Amid} | Ta A5 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIARVLSGIL{ct:Amid} | Ta A6 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 97% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIARVLSGIL{ct:Amid} | Ta A6 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGAVLSGIL{ct:Amid} | Ta A7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 39% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGAVLSGIL{ct:Amid} | Ta A7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 6% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRALSGIL{ct:Amid} | Ta A8 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10.5% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRALSGIL{ct:Amid} | Ta A8 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1.5% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVASGIL{ct:Amid} | Ta A9 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3.5% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVASGIL{ct:Amid} | Ta A9 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLAGIL{ct:Amid} | Ta A10 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 70% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLAGIL{ct:Amid} | Ta A10 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLSAIL{ct:Amid} | Ta A11 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 100% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLSAIL{ct:Amid} | Ta A11 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3.5% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLSGAL{ct:Amid} | Ta A12 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLSGAL{ct:Amid} | Ta A12 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLSGIA{ct:Amid} | Ta A13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3.5% hemolytic at 40μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21337476 | 2011 | FLPLIGRVLSGIA{ct:Amid} | Ta A13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolytic at 1.25μM | Human | Temporin-1Ta analog (Skin of Rana temporaria) | NA | NA | ||
| 21343499 | 2011 | K{d}W{d}K{d}L{d}F{d}K{d}K{d}I{d}P{d}K{d}F{d}L{d}H{d}L{d}A{d}K{d}K{d}F{d}{ct:Amid} | HDP D-P18 | Amidation | Free | Linear | D | None | 18 | Antimcrobial and Hemolytic | ~94% hemolytic at 500μM | Human | Host defense peptides analog (Rana temporaria) | NA | NA | ||
| 21343499 | 2011 | K{d}W{d}K{d}L{d}F{d}K{d}K{d}I{d}P{d}K{d}F{d}L{d}H{d}L{d}A{d}K{d}K{d}F{d}{ct:Amid} | HDP D-P18 | Amidation | Free | Linear | D | None | 18 | Antimcrobial and Hemolytic | ~10% hemolytic at 50μM | Human | Host defense peptides analog (Rana temporaria) | NA | NA | ||
| 21343499 | 2011 | EEEEAAAK{d}W{d}K{d}L{d}F{d}K{d}K{d}I{d}P{d}K{d}F{d}L{d}H{d}L{d}A{d}K{d}K{d}F{d}{nt:Acet}{ct:Amid} | Ac-E4-A3–D-P18 | Amidation | Acetylation | Linear | Mix | None | 24 | Antimcrobial and Hemolytic | ~3.5% hemolytic upto 500μM | Human | Host defense peptides analog (Rana temporaria) | NA | NA | ||
| 21355570 | 2011 | FFRHLFRGAKAIFRGARQGXRAHKVVSRYRNRDVPETDNNQEEP | Piscidin 4 | Free | Free | Linear | L | None | 44 | Antimicrobial | ~1.4% hemolytic at 100μg/ml | Human | Piscidin 4 derived from mast cells of hybrid striped bass | NA | NA | ||
| 21729875 | 2011 | GKGRWLERIGKAGGIIIGGALDHL{ct:Amid} | NRC-01 | Amidation | Free | Linear | L | None | 24 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | WLRRIGKGVKIIGGAALDHL{ct:Amid} | NRC-02 | Amidation | Free | Linear | L | None | 20 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GRRKRKWLRRIGKGVKIIGGAALDHL{ct:Amid} | NRC-03 | Amidation | Free | Linear | L | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWGSFFKKAAHVGKHVGKAALTHYL{ct:Amid} | NRC-04 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | FLGALIKGAIHGGRFIHGMIQNHH{ct:Amid} | NRC-05 | Amidation | Free | Linear | L | None | 24 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWGSIFKHGRHAAKHIGHAAVNHYL{ct:Amid} | NRC-06 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | RWGKWFKKATHVGKHVGKAALTAYL{ct:Amid} | NRC-07 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | RSTEDIIKSISGGGFLNAMNA{ct:Amid} | NRC-08 | Amidation | Free | Linear | L | None | 21 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | FFRLLFHGVHHGGGYLNAA{ct:Amid} | NRC-09 | Amidation | Free | Linear | L | None | 19 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | FFRLLFHGVHHVGKIKPRA{ct:Amid} | NRC-10 | Amidation | Free | Linear | L | None | 19 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKSVFRKAKKVGKTVGGLALDHYL{ct:Amid} | NRC-11 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKKWFNRAKKVGKTVGGLAVDHYL{ct:Amid} | NRC-12 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWRTLLKKAEVKTVGKLALKHYL{ct:Amid} | NRC-13 | Amidation | Free | Linear | L | None | 23 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | AGWGSIFKHIFKAGKFIHGAIQAHND{ct:Amid} | NRC-14 | Amidation | Free | Linear | L | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GFWGKLFKLGLHGIGLLHLHL{ct:Amid} | NRC-15 | Amidation | Free | Linear | L | None | 21 | Anticancer | 50% hemolytic at 64μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKKWLRKGAKHLGQAAIK{ct:Amid} | NRC-16 | Amidation | Free | Linear | L | None | 19 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKKWLRKGAKHLGQAAIKGLAS | NRC-17 | Free | Free | Linear | L | None | 23 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKKWFTKGERLSQRHFA | NRC-18 | Free | Free | Linear | L | None | 18 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | FLGLLFHGVHHVGKWIHGLIHGHH{ct:Amid} | NRC-19 | Amidation | Free | Linear | L | None | 24 | Anticancer | 50% hemolytic at 16μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GFLGILFHGVHHGRKKALHMNSERRS | NRC-20 | Free | Free | Linear | L | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWKDWFRKAKKVGKTVGGLALNHYL{ct:Amid} | NRC-123 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GIRKWFKKAAHVGKEVGKVALNACL | NRC-124 | Free | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GLKKWFKKAVHVGKKVGKVALNAYL{ct:Amid} | NRC-125 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GWRKWIKKATHVGKHIGKAALDAYI{ct:Amid} | NRC-126 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GCKKWFKKAAHVGKNVGKVALNAYL{ct:Amid} | NRC-127 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GIRKWFKKAAHVGKKVGKVALNAYL{ct:Amid} | NRC-128 | Amidation | Free | Linear | L | None | 25 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GR{d}R{d}K{d}R{d}K{d}WLR{d}R{d}IGK{d}GVK{d}IIGGAALDHL{ct:Amid} | NRC-03D | Amidation | Free | Linear | Mix | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GRRKRKWLRRIGKGVKIIGGAALDHL{nt:Biotin}{ct:Amid} | NRC-03B | Amidation | Biotin | Linear | L | None | 26 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Pleurocidin variant derived from gut and skin of pleuronectid flatfish | NA | NA | ||
| 21729875 | 2011 | GIGKFLHSAKKFGKAFVGEIMNS{ct:Amid} | Mag2 | Amidation | Free | Linear | L | None | 23 | Anticancer | 50% hemolytic at >256 μg/ml | Human | Magainin-2 | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWICEVLSDFK | C5A | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC= 3.46μM | Human | C5A derived from the membrane anchor domain of the N-terminal region of NS5A protein | NA | NA | ||
| 21801309 | 2011 | SWLRDLWDWICEVLSDFK | I6L | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC = 13.84μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWLCEVLSDFK | I10L | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC =6.92μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWICELLSDFK | V13L | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC = 3.44μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDLWDWLCEVLSDFK | I6L/I10L | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC = 6.92μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDLWDWICELLSDFK | I6L/V13L | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC = 53.75μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWLCELLSDFK | I10L/V13L | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC = 3.44μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDLWDWLCELLSDFK | I6L/I10L/V13L | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC = 107.50μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWLCEVLSDFK | I10L | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC = 6.92μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWVCEVLSDFK | I10V | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC =13.93μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWACEVLSDFK | I10A | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC = 14.10μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWGCEVLSDFK | I10G | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC = 28.38μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWSCEVLSDFK | I10S | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC =28.00μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWECEVLSDFK | I10E | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC =217.91μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21801309 | 2011 | SWLRDIWDWKCEVLSDFK | I10K | Free | Free | Linear | L | None | 18 | Anti-HCV/HIV | MHC =214.81μM | Human | C5A derivatives (HCV) | NA | NA | ||
| 21820306 | 2011 | {nnr:tle}-K-{nnr:tle}-A-{nnr:tle}-A-{nnr:tle}-A{cyc:N-C} | A | Free | Free | Cyclic | Mix | tle = D-Tert-leucine | 8 | Antimicrobial | HC50 =17μM | Human | Synthetic peptides | NA | NA | ||
| 21820306 | 2011 | {nnr:Tle}-K{d}-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}{cyc:N-C} | B | Free | Free | Cyclic | Mix | Tle = Tert-leucine | 8 | Antimicrobial | HC50 =17μM | Human | Synthetic peptides | NA | NA | ||
| 21820306 | 2011 | {nnr:tle}-K{d}-{nnr:tle}-A-{nnr:tle}-A-{nnr:tle}-A{cyc:N-C} | C | Free | Free | Cyclic | Mix | tle = D-Tert-leucine | 8 | Antimicrobial | HC50 =316μM | Human | Synthetic peptides | NA | NA | ||
| 21820306 | 2011 | {nnr:Tle}-K-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}-{nnr:Tle}-A{d}{cyc:N-C} | D | Free | Free | Cyclic | Mix | Tle = Tert-leucine | 8 | Antimicrobial | HC50 =316μM | Human | Synthetic peptides | NA | NA | ||
| 21955251 | 2011 | GIIKKI{ct:Amid} | G(IIKK)I | Amidation | Free | Linear | L | None | 6 | Antimicrobial and Antitumor | Non-hemolytic up to 250 μM | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 21955251 | 2011 | GIIKKIIKKI{ct:Amid} | G(IIKK)2I | Amidation | Free | Linear | L | None | 10 | Antimicrobial and Antitumor | Non-hemolytic up to 250 μM | Human | Synthetic peptides | NA | Non-hemolytic | ||
| 21955251 | 2011 | GIIKKIIKKIIKKI{ct:Amid} | G(IIKK)3I | Amidation | Free | Linear | L | None | 14 | Antimicrobial and Antitumor | EC50 >250μM | Human | Synthetic peptides | NA | NA | ||
| 21955251 | 2011 | GIIKKIIKKIIKKIIKKI{ct:Amid} | G(IIKK)4I | Amidation | Free | Linear | L | None | 18 | Antimicrobial and Antitumor | EC50 = 41±2μM | Human | Synthetic peptides | NA | NA | ||
| 21956793 | 2011 | LLIILRRRIRKQAHAHSK{ct:Amid} | pVEC | Amidation | Free | Linear | L | None | 18 | Antimicrobial and CPP | >10% hemolytic at 200μM | Human | Vascular endothelial-cadherin protein derivative analog (Murine) | NA | NA | ||
| 21956793 | 2011 | LLIILRRRWRKQARARSK{ct:Amid} | pVEC-a1 | Amidation | Free | Linear | L | None | 18 | Antimicrobial and CPP | >10% hemolytic at 200μM | Human | Vascular endothelial-cadherin protein derivative analog (Murine) | NA | NA | ||
| 21956793 | 2011 | LLIILRRRWRKQAKAKSK{ct:Amid} | pVEC-a2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial and CPP | >10% hemolytic at 200μM | Human | Vascular endothelial-cadherin protein derivative analog (Murine) | NA | NA | ||
| 21956793 | 2011 | LLIILRRRWRRQARARSR{ct:Amid} | pVEC-a3 | Amidation | Free | Linear | L | None | 18 | Antimicrobial and CPP | >10% hemolytic at 94μM | Human | Vascular endothelial-cadherin protein derivative analog (Murine) | NA | NA | ||
| 21956793 | 2011 | LLIILKKKWKKQAKAKSK{ct:Amid} | pVEC-a4 | Amidation | Free | Linear | L | None | 18 | Antimicrobial and CPP | >10% hemolytic at 200μM | Human | Vascular endothelial-cadherin protein derivative analog (Murine) | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 4.2% hemolytic at 0μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 4.1% hemolytic at 12.5μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 3.4% hemolytic at 25μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 3.0% hemolytic at 50μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | GLLCYCRKGHCKRGERVRGTCGIRFLYCCPRR | Crp4-wt | Free | Free | Linear | L | None | 32 | Antimicrobial | 3.1% hemolytic at 100 μ g/mL | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 4.2% hemolytic at 0μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 5.4% hemolytic at 12.5μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 5.8% hemolytic at 25μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 5.9% hemolytic at 50μg/ml | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22040603 | 2011 | CYCRKGHCKRGERVRGTCGIRFLYCCPRRGLL{cyc:N-C} | Crp4-1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 4.9% hemolytic at 100 μ g/mL | Human | Synthetic peptide of Crp4 | NA | NA | ||
| 22189867 | 2012 | FKCRRWQWRWKKLGAKPVPIIYCNRRTGKCQRM | LFT33 | Free | Free | Linear | L | None | 33 | Antimicrobial | Non-hemolytic upto 256 μg/ml | Human | Novel hybrid peptide of LfcinB & thanatin | NA | Non-hemolytic | ||
| 21762675 | 2011 | ELLKAVRLIK | Rev–NIS | Free | Free | Linear | L | None | 10 | Antimicrobial | 0% hemolytic upto 100μM (non-hemolytic) | Human | Rev–NIS (HIV) | NA | Non-hemolytic | ||
| 21762675 | 2011 | RLRKAVRLIK | Anal R | Free | Free | Linear | L | None | 10 | Antimicrobial | 0% hemolytic upto 100μM (non-hemolytic) | Human | Rev–NIS analog (HIV) | α helix | Non-hemolytic | ||
| 21762675 | 2011 | ELSKAVRLIK | Anal S | Free | Free | Linear | L | None | 10 | Antimicrobial | 0% hemolytic upto 100μM (non-hemolytic) | Human | Rev–NIS analog (HIV) | α helix | Non-hemolytic | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | kB1 | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 41.2 ±1.5% hemolytic at 25μM | Human | Kalata B1 (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPKCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | V4K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 2.9±0.5% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGDTCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | E7D | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 3.8±0.4% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGEKCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | T8K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 3.4±0.7% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCKGGTCNTPGCTCSWPVCTRN{cyc:N-C} | V10K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 0±1.7% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | Non-hemolytic | ||
| 21576247 | 2011 | GLPVCGETCVGGTCKTPGCTCSWPVCTRN{cyc:N-C} | N15K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 2.1±0.4% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNKPGCTCSWPVCTRN{cyc:N-C} | T16K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 4.3±0.1% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCKCSWPVCTRN{cyc:N-C} | T20K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 51.3±1.6% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSWPKCTRN{cyc:N-C} | V25K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 1.1±1.0% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSWPVCTRK{cyc:N-C} | N29K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 54.5±0.9% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSKPVCTRN{cyc:N-C} | W23K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 2.4±0.7% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCNCSWPVCTRK{cyc:N-C} | T20N29K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 64.4±2.2% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSWPVCTKN{cyc:N-C} | R28K | Free | Free | Cyclic | L | None | 29 | Hemolytic and Anti-HIV | 12.0±1.8% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21576247 | 2011 | GLPVCGETCVGGTCNTPGCTCSWPVCTRN | acyclic | Free | Free | Linear | L | None | 29 | Hemolytic and Anti-HIV | 2.8±0.3% hemolytic at 25μM | Human | kalata B1 analog (Oldenlandia affinis) | NA | NA | ||
| 21462284 | 2011 | WKWKWK | Normal-(WK)3 | Free | Free | Linear | L | None | 6 | Antimicrobial | 0% hemolytic upto 400μM | Human | Synthetic peptides | NA | NA | ||
| 21462284 | 2011 | WKWKWK | Normal-(WK)3 | Free | Free | Linear | L | None | 6 | Antimicrobial | ~10% hemolytic at 600μM | Human | Synthetic peptides | NA | NA | ||
| 21462284 | 2011 | KWKWKW | Reversed-(KW)3 | Free | Free | Linear | L | None | 6 | Antimicrobial | 0% hemolytic upto 400μM | Human | Synthetic peptides | NA | NA | ||
| 21462284 | 2011 | KWKWKW | Reversed-(KW)3 | Free | Free | Linear | L | None | 6 | Antimicrobial | ~10% hemolytic at 600μM | Human | Synthetic peptides | NA | NA | ||
| 22029824 | 2012 | FIFPKKNIINSLFGR | Andersonin-D1 | Free | Free | Linear | L | None | 15 | Antimicrobial | Non-hemolytic upto 50 μg/mL | Human | Skin secretion of frog Odorrana andersonii | NA | Non-hemolytic | ||
| 22029824 | 2012 | KEKLKLKCKAPKCYNDKLACT | Andersonin-G1 | Free | Free | Linear | L | None | 21 | Antimicrobial | Non-hemolytic upto 50 μg/mL | Human | Skin secretion of frog Odorrana andersonii | NA | Non-hemolytic | ||
| 22029824 | 2012 | ENMFNIKSSVESDSFWG | Andersonin-N1 | Free | Free | Linear | L | None | 17 | Antimicrobial | Non-hemolytic upto 50 μg/mL | Human | Skin secretion of frog Odorrana andersonii | NA | Non-hemolytic | ||
| 22029824 | 2012 | EMLKKKEVKMERKT | Andersonin-Q1 | Free | Free | Linear | L | None | 14 | Antimicrobial | Non-hemolytic upto 50 μg/mL | Human | Skin secretion of frog Odorrana andersonii | NA | Non-hemolytic | ||
| 22029824 | 2012 | ENAEEDIVLMENLFCSYIVGSADSFWT | Andersonin-R1 | Free | Free | Linear | L | None | 27 | Antimicrobial | Non-hemolytic upto 50 μg/mL | Human | Skin secretion of frog Odorrana andersonii | NA | Non-hemolytic | ||
| 22029824 | 2012 | DANVENGEDAEDLTDKFIGLMG | Andersonin-S1 | Free | Free | Linear | L | None | 22 | Antimicrobial | Non-hemolytic upto 50 μg/mL | Human | Skin secretion of frog Odorrana andersonii | NA | Non-hemolytic | ||
| 19038369 | 2009 | ILPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID | Amidation | Free | Cyclic | L | None | 13 | Antimicrobial | 5-10% hemolysis at 25μg/mL | Human | Cytoplasmic granules of bovine neutrophils | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID-I | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 5-10% hemolysis at 25μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-W | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 5-10% hemolysis at 25μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-IW | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 5% hemolysis at 25μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID | Amidation | Free | Cyclic | L | None | 13 | Antimicrobial | 10% hemolysis at 50μg/mL | Human | Cytoplasmic granules of bovine neutrophils | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID-I | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10% hemolysis at 50μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-W | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10% hemolysis at 50μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-IW | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 5% hemolysis at 50μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID | Amidation | Free | Cyclic | L | None | 13 | Antimicrobial | 10% hemolysis at 100μg/mL | Human | Cytoplasmic granules of bovine neutrophils | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID-I | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10-15% hemolysis at 100μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-W | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10-15% hemolysis at 100μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-IW | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 10% hemolysis at 100μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID | Amidation | Free | Cyclic | L | None | 13 | Antimicrobial | 30% hemolysis at 200μg/mL | Human | Cytoplasmic granules of bovine neutrophils | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPWWPWRR{cyc:N-C}{ct:Amid} | ID-I | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 30% hemolysis at 200μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | ILPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-W | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | 30% hemolysis at 200μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19038369 | 2009 | I{nnr:*}LPWKWPW{nnr:*}WPWRR{cyc:N-C}{ct:Amid} | ID-IW | Amidation | Free | Cyclic | L | * = Reduced amide bond ψCH2NH | 13 | Antimicrobial | ~10% hemolysis at 200μg/mL | Human | Indolicidin analog | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVCRTGRSRWRDVCRNFMR | Gr-1L(25-50) | Free | Free | Linear | L | None | 26 | Antimicrobial | 20-30% hemolysis at 50μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVCRTGRSRWRDVCRNFMR{cyc:N-C} | Gr-1C(25-50) | Free | Free | Cyclic | L | None | 26 | Antimicrobial | 20-30% hemolysis at 50μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVARTGRSRWRDVARNFMR | Gr-2 (25-50) | Free | Free | Linear | L | None | 26 | Antimicrobial | 20-30% hemolysis at 50μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SRWRDVARNFMRRYQSRVIQGLVA | Gr-3 (39-62) | Free | Free | Linear | L | None | 24 | Antimicrobial | 90% hemolysis at 50μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVCRTGRSRWRDVCRNFMR | Gr-1L(25-50) | Free | Free | Linear | L | None | 26 | Antimicrobial | 40-50% hemolysis at 100μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVCRTGRSRWRDVCRNFMR{cyc:N-C} | Gr-1C(25-50) | Free | Free | Cyclic | L | None | 26 | Antimicrobial | 40-50% hemolysis at 100μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVARTGRSRWRDVARNFMR | Gr-2 (25-50) | Free | Free | Linear | L | None | 26 | Antimicrobial | 40-50% hemolysis at 100μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SRWRDVARNFMRRYQSRVIQGLVA | Gr-3 (39-62) | Free | Free | Linear | L | None | 24 | Antimicrobial | 100% hemolysis at 100μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVCRTGRSRWRDVCRNFMR | Gr-1L(25-50) | Free | Free | Linear | L | None | 26 | Antimicrobial | 80-85% hemolysis at 200μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVCRTGRSRWRDVCRNFMR{cyc:N-C} | Gr-1C(25-50) | Free | Free | Cyclic | L | None | 26 | Antimicrobial | 70% hemolysis at 200μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SVSNAATRVARTGRSRWRDVARNFMR | Gr-2 (25-50) | Free | Free | Linear | L | None | 26 | Antimicrobial | 90% hemolysis at 200μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 19961432 | 2010 | SRWRDVARNFMRRYQSRVIQGLVA | Gr-3 (39-62) | Free | Free | Linear | L | None | 24 | Antimicrobial | 100% hemolysis at 200μM | Human | Derivative of granulysin (Synthetic peptide) | NA | NA | ||
| 20363271 | 2010 | KLKKLL{d}KKWLKL{d}LKKLLK{d}{ct:Amid} | K9L8W | Amidation | Free | Linear | L | None | 18 | Antimicrobial | HC50 =14μM | Human | Synthetic peptide | α-helical | NA | ||
| 20363271 | 2010 | KLKKLL{d}KKWLKL{d}LKKLLK{d}{ct:Amid} | D3-K9L8W-1 | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | HC50 =150μM | Human | Synthetic peptide | Random coil | NA | ||
| 20363271 | 2010 | KLKKL{d}LKKWL{d}KLLKK{d}LLK{ct:Amid} | D3-K9L8W-2 | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | HC50 =116μM | Human | Synthetic peptide | Random coil | NA | ||
| 20363271 | 2010 | KLKK{d}LLKK{d}WLKL{d}LKKL{d}LK{ct:Amid} | D4-K9L8W | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | HC50 =800μM | Human | Synthetic peptide | Random coil | NA | ||
| 20363271 | 2010 | KL{d}K{d}KLL{d}KKW{d}LKL{d}LKK{d}LLK{d}{ct:Amid} | D6-K9L8W | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | HC50 =800μM | Human | Synthetic peptide | Random coil | NA | ||
| 20363271 | 2010 | KL{d}KK{d}LL{d}KK{d}WL{d}KL{d}LK{d}KL{d}LK{d}{ct:Amid} | D9-K9L8W-1 | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | HC50 =800μM | Human | Synthetic peptide | Random coil | NA | ||
| 20363271 | 2010 | KLKKLLKKWL{d}K{d}L{d}L{d}K{d}K{d}L{d}L{d}K{d}{ct:Amid} | D9-K9L8W-2 | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | HC50 =154μM | Human | Synthetic peptide | Random coil | NA | ||
| 20399752 | 2010 | KRFKKFFKKLKNSVKKRAKKFFKKPKVIGVTFPF | NA-CATH | Free | Free | Linear | L | None | 34 | Antimicrobial | EC50 =0.37μM | Human | Naja atra (cathelicidin) | α-helical | NA | ||
| 20399752 | 2010 | KRFKKFFKKLK{ct:Amid} | ATRA-1 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | EC50 =5.98μM | Human | Naja atra analog | α-helical | NA | ||
| 20399752 | 2010 | KRAKKFFKKPK{ct:Amid} | ATRA-2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | EC50 =107μM | Human | Naja atra analog | α-helical | NA | ||
| 20399752 | 2010 | KRAKKFFKKLK{ct:Amid} | ATRA-1A | Amidation | Free | Linear | L | None | 11 | Antimicrobial | EC50 =7.98μM | Human | Naja atra analog | α-helical | NA | ||
| 20399752 | 2010 | KRFKKFFKKPK{ct:Amid} | ATRA-1P | Amidation | Free | Linear | L | None | 11 | Antimicrobial | EC50 =95.92μM | Human | Naja atra analog | α-helical | NA | ||
| 20399752 | 2010 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | EC50 =0.05μM | Human | cathelicidin | α-helical | NA | ||
| 20457198 | 2010 | DVNDLKNLCAKTHNLLPMCAMFGKK | DK25 | Free | Free | Linear | L | None | 25 | Antimicrobial | no hemolysis upto <400μM | Human | Rana tagoi okiensis | NA | Non-hemolytic | ||
| 20457198 | 2010 | DVNDLKNLCAKTHNLLPMCAMF{ct:Amid} | DF-22-amide | Amidation | Free | Linear | L | None | 22 | Antimicrobial | no hemolysis upto <400μM | Human | Rana tagoi okiensis | NA | Non-hemolytic | ||
| 20466006 | 2010 | YVPPVQKPHPNGPKFPTFP | PP30 | Free | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolysis at 125μM | Human | Pteromalus puparum cDNA clone (synthetic peptide) | Random coil | NA | ||
| 20466006 | 2010 | YVPPVQKPHPNGPKFPTFP | PP30 | Free | Free | Linear | L | None | 19 | Antimicrobial | 3.8% hemolysis at 250μM | Human | Pteromalus puparum cDNA clone (synthetic peptide) | Random coil | NA | ||
| 20472009 | 2010 | GIGAVLKVLSTGLPALISWIKRKRQQ | melittin-S | Free | Free | Linear | L | None | 26 | Antimicrobial | 35% hemolysis at | Human | Melittin isoform | α-helical | NA | ||
| 20493915 | 2010 | RWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | ABP-CM4 | Free | Free | Linear | L | None | 35 | Antimicrobial and Cytotoxic | 0% hemolysis at 200μM | Human | Bombyx mori | α-helical | NA | ||
| 20493915 | 2010 | RWKIFKKIEKVGQNIRDGIVKAGPAVAVVGQAATI | ABP-CM4 | Free | Free | Linear | L | None | 35 | Antimicrobial and Cytotoxic | 5% hemolysis at 400μM | Human | Bombyx mori | α-helical | NA | ||
| 20600431 | 2010 | GSKKPVPIIYCNRRSGKCQRM | S-thanatin | Free | Free | Linear | L | None | 21 | Antimicrobial | low hemolytic activity up to 400μg/ml | Human | Thanatin analog | β-sheet | Non-hemolytic | ||
| 20603168 | 2010 | GLKEIFKAGLGSLVKGIAAHVAS | Alyteserin-1c | Free | Free | Linear | L | None | 23 | Antimicrobial | LC50 =220μM | Human | Alytes obstetricans (Alyteserin-1c) | α-helical | NA | ||
| 20603168 | 2010 | GLKK{d}IFKAGLGSLVKGIAAHVAS | E4K | Free | Free | Linear | L | None | 23 | Antimicrobial | LC50 >400μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20603168 | 2010 | GLKK{d}IFKAGLGSLVKGIAAHVAS | E4k | Free | Free | Linear | Mix | None | 23 | Antimicrobial | LC50 >400μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20603168 | 2010 | GLKKIFKKGLGSLVKGIAAHVAS | E4K,A8K | Free | Free | Linear | L | None | 23 | Antimicrobial | LC50 >400μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20603168 | 2010 | GLKK{d}IFKKGLGSLVKGIAAHVAS | E4k,A8K | Free | Free | Linear | Mix | None | 23 | Antimicrobial | LC50 >400μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20603168 | 2010 | GLKK{d}IFKAGLGSLKKGIAAHVAS | E4K,V14K | Free | Free | Linear | L | None | 23 | Antimicrobial | LC50 >400μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20603168 | 2010 | GLKK{d}IFKAGLGSLKKGIAAHVAS | E4k,V14K | Free | Free | Linear | Mix | None | 23 | Antimicrobial | LC50 >400μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20603168 | 2010 | GLKK{d}IFKAGLGSLVKGIKAHVAS | E4K,A18K | Free | Free | Linear | L | None | 23 | Antimicrobial | LC50 >400μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20603168 | 2010 | GLKK{d}IFKAGLGSLVKGIKAHVAS | E4k,A18K | Free | Free | Linear | Mix | None | 23 | Antimicrobial | LC50 >400μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20603168 | 2010 | GLKEIFKAGLGSLVKGIAAHVAS{nt:palmitate(pal)} | N-Pal,E4K | Free | palmitate(pal) | Linear | L | None | 23 | Antimicrobial | LC50 =10μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20603168 | 2010 | GLKKIFKAGLGSLVKGIK{nnr:*}AHVAS | E4K,Pal-A18K | Free | Free | Linear | L | * = palmitate(PAL) | 23 | Antimicrobial | LC50 =30μM | Human | Alyteserin-1c analog | α-helical | NA | ||
| 20656059 | 2010 | GIGKFLHSAGKFGKAFLGEVMKS | Magainin-B2 | Free | Free | Linear | L | None | 23 | Antimicrobial | 0% hemolysis at 200μM | Human | Xenopus borealis | NA | Non-hemolytic | ||
| 20656059 | 2010 | GMASKAGSIVGKIAKIALGAL{ct:Amid} | PGLa-B2 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 27% hemolysis at 200μM | Human | Xenopus borealis | NA | NA | ||
| 20656059 | 2010 | GLGSLLGKAFKIGLKTVGKMMGGAPREQ | CPF-B1 | Free | Free | Linear | L | None | 28 | Antimicrobial | 18% hemolysis at 200μM | Human | Xenopus borealis | NA | NA | ||
| 20735987 | 2010 | CIAKGNGCQPSGVQGNCCSGHCHKEPGWVAGYCK{ct:Amid} | Psacotheasin | Amidation | Free | Linear | L | None | 34 | Antifungal | 0% hemolysis at 100μM | Human | Psacothea hilaris | NA | Non-hemolytic | ||
| 20736034 | 2011 | WLKKW{ct:Amid} | LK2W2 | Amidation | Free | Linear | L | None | 5 | Antimicrobial | negligible hemolysis at 320μg/ml | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 20736034 | 2011 | WLLKW{ct:Amid} | L2KW2 | Amidation | Free | Linear | L | None | 5 | Antimicrobial | negligible hemolysis at 320μg/ml | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 20736034 | 2011 | KWLKKWL{ct:Amid} | L2K3W2 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | negligible hemolysis at 320μg/ml | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 20736034 | 2011 | KWLLKWL{ct:Amid} | L3K2W2 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 0-5% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | KKWLKKWLK{ct:Amid} | L2K5W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | negligible hemolysis at 320μg/ml | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 20736034 | 2011 | LKWLKKWLK{ct:Amid} | L3K4W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLK{ct:Amid} | L4K3W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10% hemolysis at 40μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLL{ct:Amid} | L5K2W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 60% hemolysis at 40μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKKWLKKWLKK{ct:Amid} | L3K6W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | negligible hemolysis at 320μg/ml | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 20736034 | 2011 | LLKWLKKWLKK{ct:Amid} | L4K5W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 0-5% hemolysis at 40μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LLKWLLKWLKK{ct:Amid} | L5K4W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 40-50% hemolysis at 40μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LLKWLLKWLLK{ct:Amid} | L6K3W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 55-60% hemolysis at 40μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | KWLLKWL{ct:Amid} | L3K2W2 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 10% hemolysis at 320μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLKKWLK{ct:Amid} | L3K4W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0-5% hemolysis at 320μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLK{ct:Amid} | L4K3W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 25% hemolysis at 80μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLK{ct:Amid} | L4K3W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 40-50% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLL{ct:Amid} | L5K2W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 65% hemolysis at 80μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LKWLLKWLL{ct:Amid} | L5K2W2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 70% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LLKWLKKWLKK{ct:Amid} | L4K5W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 5% hemolysis at 80μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LLKWLKKWLKK{ct:Amid} | L4K5W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 10% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LLKWLLKWLKK{ct:Amid} | L5K4W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 50-60% hemolysis at 80μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LLKWLLKWLKK{ct:Amid} | L5K4W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 60-65% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LLKWLLKWLLK{ct:Amid} | L6K3W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 60-70% hemolysis at 80μg/ml | Human | Synthetic peptide | NA | NA | ||
| 20736034 | 2011 | LLKWLLKWLLK{ct:Amid} | L6K3W2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 70-75% hemolysis at 160μg/ml | Human | Synthetic peptide | NA | NA | ||
| 21241661 | 2011 | RWCVYAYVRVRGVLVRYRRCW | Arenicin-1 | Free | Free | Linear | L | None | 21 | Antimicrobial | 0% hemolysis at 12.5μM | Human | Derived from coelomocytes of the marine polychaeta lugworm(Arenicola marina) | β-sheet | NA | ||
| 21241661 | 2011 | RWCVYAYVRVRGVLVRYRRCW | Arenicin-1 | Free | Free | Linear | L | None | 21 | Antimicrobial | 12% hemolysis at 25μM | Human | Derived from coelomocytes of the marine polychaeta lugworm(Arenicola marina) | β-sheet | NA | ||
| 21241661 | 2011 | RWCVYAYVRVRGVLVRYRRCW | Arenicin-1 | Free | Free | Linear | L | None | 21 | Antimicrobial | 35% hemolysis at 50μM | Human | Derived from coelomocytes of the marine polychaeta lugworm(Arenicola marina) | β-sheet | NA | ||
| 21241661 | 2011 | RWCVYAYVRVRGVLVRYRRCW | Arenicin-1 | Free | Free | Linear | L | None | 21 | Antimicrobial | 51% hemolysis at 100μM | Human | Derived from coelomocytes of the marine polychaeta lugworm(Arenicola marina) | β-sheet | NA | ||
| 21241661 | 2011 | CVYAYVRVRGVLVRYRRCW | Arenicin-1(analog-1) | Free | Free | Linear | L | None | 19 | Antimicrobial | 0% hemolysis at 50μM | Human | Arenicin-1 analog | NA | NA | ||
| 21241661 | 2011 | CVYAYVRVRGVLVRYRRCW | Arenicin-1(analog-1) | Free | Free | Linear | L | None | 19 | Antimicrobial | 4% hemolysis at 100μM | Human | Arenicin-1 analog | NA | NA | ||
| 21241661 | 2011 | RWCVYAYVRVAGVLVRYRRCW | Arenicin-1(analog-2) | Free | Free | Linear | L | None | 21 | Antimicrobial | 0% hemolysis at 12.5μM | Human | Arenicin-1 analog | NA | NA | ||
| 21241661 | 2011 | RWCVYAYVRVAGVLVRYRRCW | Arenicin-1(analog-2) | Free | Free | Linear | L | None | 21 | Antimicrobial | 7% hemolysis at 25μM | Human | Arenicin-1 analog | NA | NA | ||
| 21241661 | 2011 | RWCVYAYVRVAGVLVRYRRCW | Arenicin-1(analog-2) | Free | Free | Linear | L | None | 21 | Antimicrobial | 32% hemolysis at 50μM | Human | Arenicin-1 analog | NA | NA | ||
| 21241661 | 2011 | RWCVYAYVRVAGVLVRYRRCW | Arenicin-1(analog-2) | Free | Free | Linear | L | None | 21 | Antimicrobial | 45% hemolysis at 100μM | Human | Arenicin-1 analog | NA | NA | ||
| 21497177 | 2011 | GRFKRFRKKFKKLFKKLSPVIPLLHL{ct:Amid} | BMAP -27 | Amidation | Free | Linear | L | None | 27 | Antimicrobial | 10% hemolysis at 6.2μM | Human | Bovine myeloid antimicrobial peptide 27 (BMAP 27) | α-helical | NA | ||
| 21497177 | 2011 | GRFKRFRKKFKKLFKKLS{ct:Amid} | BMAP -18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 10% hemolysis at >400μM | Human | BMAP-27 analog | α-helical | NA | ||
| 21497177 | 2011 | GRWKRWRKKWKKLWKKLS{ct:Amid} | BMAP- 18-W | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 10% hemolysis at 38μM | Human | BMAP-27 analog | α-helical | NA | ||
| 21497177 | 2011 | GRLKRLRKKLKKLLKKLS{ct:Amid} | BMAP -18-L | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 10% hemolysis at 300μM | Human | BMAP-27 analog | α-helical | NA | ||
| 21497177 | 2011 | GRIKRIRKKIKKLIKKLS{ct:Amid} | BMAP -18-I | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 10% hemolysis at 265μM | Human | BMAP-27 analog | α-helical | NA | ||
| 21497177 | 2011 | GR{d}F{d}KRF{d}RKKF{d}KKLF{d}KKLS{ct:Amid} | BMAP -18-f | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | 10% hemolysis at >400μM | Human | BMAP-27 analog | α-helical | NA | ||
| 21664395 | 2011 | GIGKFLHSAGKFGKAFIGEIMKS | Magainin-M1 | Free | Free | Linear | L | None | 23 | Antibacterial | LC50 =180μM | Human | Derived from skin secretions of Xenopus muelleri | NA | NA | ||
| 21664395 | 2011 | WCPPMIPLCSRF{cyc:N-C}{ct:Amid} | Tigerinin-M1 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial | LC50 >500μM | Human | Derived from skin secretions of Xenopus muelleri | NA | NA | ||
| 21664395 | 2011 | GIGKFLHSAGKFGKAFLGEVMKS | Magainin-MW1 | Free | Free | Linear | L | None | 23 | Antibacterial | LC50 >200μM | Human | Derived from skin secretions of Xenopus muelleri West | NA | NA | ||
| 21664395 | 2011 | GMASKAGSVLGKITKIALGAL{ct:Amid} | PGLa-MW1 | Amidation | Free | Linear | L | None | 21 | Antibacterial | LC50 >200μM | Human | Derived from skin secretions of Xenopus muelleri West | NA | NA | ||
| 21664395 | 2011 | GLGSLLGKAFKFGLKTVGKMMGGAPREQ | CPF-MW1 | Free | Free | Linear | L | None | 28 | Antibacterial | LC50 =70μM | Human | Derived from skin secretions of Xenopus muelleri West | NA | NA | ||
| 21664395 | 2011 | GLGSLLGKAFKFGLKTVGKMMGGAPREE | CPF-MW2 | Free | Free | Linear | L | None | 28 | Antibacterial | LC50 =105μM | Human | Derived from skin secretions of Xenopus muelleri West | NA | NA | ||
| 21682682 | 2011 | LGRVDIHVWDGVYIRGR | KK42-63-3H | Free | Free | Linear | L | None | 17 | Cytotoxic | 5.9% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | LGRVDIHVWDGVYI | PIP56-69 | Free | Free | Linear | L | None | 14 | Cytotoxic | 2.48% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVWDGVVDIHVWDGV | PIP-18 | Free | Free | Linear | L | None | 18 | Cytotoxic | 1.16% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVWDGV | PIP[59-67] | Free | Free | Linear | L | None | 9 | Cytotoxic | 3.2% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | LGRVDIHVWDGVYIRGR | P-NT.II | Free | Free | Linear | L | None | 17 | Cytotoxic | 9.5% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | LGRVDIHVWDA{d}VYIRGR | [D-Ala66]-PNT.II | Free | Free | Linear | Mix | None | 17 | Cytotoxic | 3% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVW{nnr:D*}GV | β-Asp65-PIP[59-67] | Free | Free | Linear | L | D* = β-aspartic acid | 9 | Cytotoxic | 1% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVWA{d}GV | D65A-PIP[59-67] | Free | Free | Linear | Mix | None | 9 | Cytotoxic | 7.5% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVWS{d}GV | D65S-PIP[59-67] | Free | Free | Linear | Mix | None | 9 | Cytotoxic | 1.03% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VDIHVWE{d}GV | D65E-PIP[59-67] | Free | Free | Linear | Mix | None | 9 | Cytotoxic | 9.9% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | VE{d}IHVWE{d}GV | D60,65E-PIP[59-67] | Free | Free | Linear | Mix | None | 9 | Cytotoxic | 2.24% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 21682682 | 2011 | CVDIHVWDGVC{cyc:N-C} | Cyclic C-PIP[59-67]C | Free | Free | Cyclic | L | None | 11 | Cytotoxic | 7.2% hemolysis at 100μM | Human | synthetic peptide | NA | NA | ||
| 22800690 | 2012 | GKLEVLHSTKKFAKGFITGLTGQ | Magainin-SE1 | Free | Free | Linear | L | None | 23 | Antimicrobial | LC50 >160μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22800690 | 2012 | GMATKAGTALGKVAKAVIGAAL{ct:Amid} | PGLa-SE1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | LC50 >160μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22800690 | 2012 | GMATAAGTTLGKLAKFVIGAV{ct:Amid} | PGLa-SE2 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | LC50 >160μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22800690 | 2012 | GLASTIGSLLGKFAKGGAQAFLQPK | XPF-SE2 | Free | Free | Linear | L | None | 25 | Antimicrobial | LC50 >160μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22800690 | 2012 | GFWTTAAEGLKKFAKAGLASILNPK | XPF-SE3 | Free | Free | Linear | L | None | 25 | Antimicrobial | LC50 =105μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22800690 | 2012 | GVWTTILGGLKKFAKGGLEALTNPK | XPF-SE4 | Free | Free | Linear | L | None | 25 | Antimicrobial | LC50 =60μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22800690 | 2012 | GFLGPLLKLGLKGVAKVIPHLIPSRQQ | CPF-SE1 | Free | Free | Linear | L | None | 27 | Antimicrobial | LC50 =50μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22800690 | 2012 | GFLGPLLKLGLKGAAKLLPQLLPSRQQ | CPF-SE2 | Free | Free | Linear | L | None | 27 | Antimicrobial | LC50 =50μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22800690 | 2012 | GFLGSLLKTGLKVGSNLL{ct:Amid} | CPF-SE3 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 =220μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22800690 | 2012 | FLGALLGPLMNLLQ{ct:Amid} | PFQa | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LC50 =105μM | Human | Derived from skin secretions of Silurana epitropicalis (magainin) | NA | NA | ||
| 22943778 | 2012 | FLPFLLSALPKVFCFFSKKC{cyc:N-C} | Brevinin-1ZHa | Free | Free | Cyclic | L | None | 20 | Antimicrobial | HC50 =3μM | Human | Derived from skin of Rana zhenhaiensis | NA | NA | ||
| 22943778 | 2012 | FLPLLLASLPSFLCLVFKKC{cyc:N-C} | Brevinin-1ZHb | Free | Free | Cyclic | L | None | 20 | Antimicrobial | HC50 =5μM | Human | Derived from skin of Rana zhenhaiensis | NA | NA | ||
| 22943778 | 2012 | GIMRVFKGVLKTAGKSVAKNVAGSFLDRLKCKISGGC{cyc:N-C} | Brevinin-2ZHa | Free | Free | Cyclic | L | None | 37 | Antimicrobial | HC50 =52μM | Human | Derived from skin of Rana zhenhaiensis | NA | NA | ||
| 22943778 | 2012 | GLADYWRTAFRANFANLGPGIRCKSARC | Ranatuerin-2ZHa | Free | Free | Linear | L | None | 28 | Antimicrobial | HC50 >64μM | Human | Derived from skin of Rana zhenhaiensis | NA | NA | ||
| 22943778 | 2012 | LALKSGGWLRLFGLKDKKH | Chensinin-1ZHa | Free | Free | Linear | L | None | 19 | Antimicrobial | HC50 >92μM | Human | Derived from skin of Rana zhenhaiensis | NA | NA | ||
| 22960382 | 2012 | KIKIPWGKVKDFLVGGMKAV{ct:Amid} | Bicarinalin | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 50% hemolysis at 0.72mg/ml | Human | Derived from venom of Tetramorium bicarinatum | NA | NA | ||
| 22960382 | 2012 | LFKEILEKIKAKL{ct:Amid} | P-17 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | Inactive | Human | Derived from venom of Tetramorium bicarinatum | NA | Non-hemolytic | ||
| 22965637 | 2013 | ILGKLLSTAAGLLSNL{ct:Amid} | Alyteserin-2a | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =140μM | Human | Derived from skin secretions of Alytes obstetricans (alyteserin-2a) | α-helical | NA | ||
| 22965637 | 2013 | ILKKLLSTAAGLLSNL{ct:Amid} | G3K | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =105μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLKTAAGLLSNL{ct:Amid} | S7K | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =28μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLK{d}TAAGLLSNL{ct:Amid} | S7k | Amidation | Free | Linear | Mix | None | 16 | CPP | LC50 =105μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAAKLLSNL{ct:Amid} | G11K | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =24μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAAK{d}LLSNL{ct:Amid} | G11k | Amidation | Free | Linear | Mix | None | 16 | CPP | LC50 =42μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAAGLLKNL{ct:Amid} | S14K | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =55μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAAGLLSKL{ct:Amid} | N15K | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =50μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAAGLLSK{d}L{ct:Amid} | N15k | Amidation | Free | Linear | Mix | None | 16 | CPP | LC50 =310μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLKTAAKLLSNL{ct:Amid} | S7K,G11K | Amidation | Free | Linear | Mix | None | 16 | CPP | LC50 =38μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLK{d}TAAK{d}LLSNL{ct:Amid} | S7k,G11k | Amidation | Free | Linear | Mix | None | 16 | CPP | LC50 =185μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAAKLLSKL{ct:Amid} | G11K,N15K | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =16μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAAK{d}LLSKL{ct:Amid} | G11k,N15K | Amidation | Free | Linear | Mix | None | 16 | CPP | LC50 =195μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSWAAGLLSNL{ct:Amid} | T8W | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =13μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTWAGLLSNL{ct:Amid} | A9W | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =39μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAWGLLSNL{ct:Amid} | A10W | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =11μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAWK{d}LLSNL{ct:Amid} | A10W,G11k | Amidation | Free | Linear | Mix | None | 16 | CPP | LC50 =21μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAWGLLSKL{ct:Amid} | A10W,N15K | Amidation | Free | Linear | L | None | 16 | CPP | LC50 =6μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22965637 | 2013 | ILGKLLSTAWALLSK{d}L{ct:Amid} | A10W,N15k | Amidation | Free | Linear | Mix | None | 16 | CPP | LC50 =27μM | Human | Alyteserin-2a analog | NA | NA | ||
| 22974815 | 2013 | FVQWFSKFLGRIL{ct:Amid} | TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 100% hemolysis at 48μM | Human | Derived from skin of Rana genus (Temporin L) | α-helical | NA | ||
| 22974815 | 2013 | FVQWFSKFLGRIL{ct:Amid} | TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 94% hemolysis at 24μM | Human | Derived from skin of Rana genus (Temporin L) | α-helical | NA | ||
| 22974815 | 2013 | FVQWFSKFLGRIL{ct:Amid} | TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 92% hemolysis at 12μM | Human | Derived from skin of Rana genus (Temporin L) | α-helical | NA | ||
| 22974815 | 2013 | FVQWFSKFLGRIL{ct:Amid} | TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 48% hemolysis at 6μM | Human | Derived from skin of Rana genus (Temporin L) | α-helical | NA | ||
| 22974815 | 2013 | FVQWFSKFLGRIL{ct:Amid} | TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 13% hemolysis at 3μM | Human | Derived from skin of Rana genus (Temporin L) | α-helical | NA | ||
| 22974815 | 2013 | FVQWFSKFLGRIL{ct:Amid} | TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3% hemolysis at 1.5μM | Human | Derived from skin of Rana genus (Temporin L) | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRIL{ct:Amid} | [Pro3]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 100% hemolysis at 48μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRIL{ct:Amid} | [Pro3]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 92% hemolysis at 24μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRIL{ct:Amid} | [Pro3]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 42% hemolysis at 12μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRIL{ct:Amid} | [Pro3]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10% hemolysis at 6μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRIL{ct:Amid} | [Pro3]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 6% hemolysis at 3μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRIL{ct:Amid} | [Pro3]TL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 4.5% hemolysis at 1.5μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSK{d}FLGRIL{ct:Amid} | [Pro3, DLys7]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 18% hemolysis at 48μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSK{d}FLGRIL{ct:Amid} | [Pro3, DLys7]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 8% hemolysis at 24μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSK{d}FLGRIL{ct:Amid} | [Pro3, DLys7]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 5% hemolysis at 12μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSK{d}FLGRIL{ct:Amid} | [Pro3, DLys7]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 7% hemolysis at 6μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSK{d}FLGRIL{ct:Amid} | [Pro3, DLys7]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 4% hemolysis at 3μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSK{d}FLGRIL{ct:Amid} | [Pro3, DLys7]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 2% hemolysis at 1.5μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKF{d}LGRIL{ct:Amid} | [Pro3, DPhe8]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 94% hemolysis at 48μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKF{d}LGRIL{ct:Amid} | [Pro3, DPhe8]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 19% hemolysis at 24μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKF{d}LGRIL{ct:Amid} | [Pro3, DPhe8]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 19% hemolysis at 12μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKF{d}LGRIL{ct:Amid} | [Pro3, DPhe8]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 17% hemolysis at 6μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKF{d}LGRIL{ct:Amid} | [Pro3, DPhe8]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 5% hemolysis at 3μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKF{d}LGRIL{ct:Amid} | [Pro3, DPhe8]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 4% hemolysis at 1.5μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{ct:Amid} | [Pro3, DLeu9]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 9% hemolysis at 48μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{ct:Amid} | [Pro3, DLeu9]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 8% hemolysis at 24μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{ct:Amid} | [Pro3, DLeu9]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 7% hemolysis at 12μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{ct:Amid} | [Pro3, DLeu9]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 3% hemolysis at 6μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{ct:Amid} | [Pro3, DLeu9]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 2% hemolysis at 3μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{ct:Amid} | [Pro3, DLeu9]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 2% hemolysis at 1.5μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGR{d}IL{ct:Amid} | [Pro3, DArg11]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 22% hemolysis at 48μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGR{d}IL{ct:Amid} | [Pro3, DArg11]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 16% hemolysis at 24μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGR{d}IL{ct:Amid} | [Pro3, DArg11]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 8% hemolysis at 12μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGR{d}IL{ct:Amid} | [Pro3, DArg11]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 6% hemolysis at 6μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGR{d}IL{ct:Amid} | [Pro3, DArg11]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 4% hemolysis at 3μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGR{d}IL{ct:Amid} | [Pro3, DArg11]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 2% hemolysis at 1.5μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRI{d}L{ct:Amid} | [Pro3, DIle12]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 17% hemolysis at 48μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRI{d}L{ct:Amid} | [Pro3, DIle12]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 14% hemolysis at 24μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRI{d}L{ct:Amid} | [Pro3, DIle12]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 10% hemolysis at 12μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRI{d}L{ct:Amid} | [Pro3, DIle12]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 5% hemolysis at 6μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRI{d}L{ct:Amid} | [Pro3, DIle12]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 4% hemolysis at 3μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFLGRI{d}L{ct:Amid} | [Pro3, DIle12]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 2% hemolysis at 1.5μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{d}{ct:Amid} | [Pro3, DLeu13]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 15% hemolysis at 48μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{d}{ct:Amid} | [Pro3, DLeu13]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 17% hemolysis at 24μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{d}{ct:Amid} | [Pro3, DLeu13]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 17% hemolysis at 12μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{d}{ct:Amid} | [Pro3, DLeu13]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 8% hemolysis at 6μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{d}{ct:Amid} | [Pro3, DLeu13]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 6% hemolysis at 3μM | Human | Temporin L analog | α-helical | NA | ||
| 22974815 | 2013 | FVPWFSKFL{d}GRIL{d}{ct:Amid} | [Pro3, DLeu13]TL | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 3% hemolysis at 1.5μM | Human | Temporin L analog | α-helical | NA | ||
| 23022146 | 2013 | YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG | Crotamine | Free | Free | Linear | L | None | 42 | Antifungal | 0% hemolysis at 100μM | Human | Derived from venom of Crotalus durissus terrificus | α-helical | Non-hemolytic | ||
| 23026014 | 2013 | WFRKQLKW | L10 | Free | Free | Linear | L | None | 8 | Antibacterial and Antifungal | No hemolysis upto 800μg/ml | Human | Derived from modified N-terminal domain of bovine lactoferrin | NA | Non-hemolytic | ||
| 23103587 | 2013 | TDTNVIGECFDEWSRCHRQTRWWTKILFQSCENRCKCKVQLMGNCIKVPFKCFLWKQKRFMCECYGPISGTKPWYCGWEL | mytimacin-AF | Free | Free | Linear | L | None | 80 | Antimicrobial | 1.1% hemolysis at 5μg/ml | Human | Derived from mucus of Achatina fulica | NA | NA | ||
| 23103587 | 2013 | TDTNVIGECFDEWSRCHRQTRWWTKILFQSCENRCKCKVQLMGNCIKVPFKCFLWKQKRFMCECYGPISGTKPWYCGWEL | mytimacin-AF | Free | Free | Linear | L | None | 80 | Antimicrobial | 1.3% hemolysis at 10μg/ml | Human | Derived from mucus of Achatina fulica | NA | NA | ||
| 23103587 | 2013 | TDTNVIGECFDEWSRCHRQTRWWTKILFQSCENRCKCKVQLMGNCIKVPFKCFLWKQKRFMCECYGPISGTKPWYCGWEL | mytimacin-AF | Free | Free | Linear | L | None | 80 | Antimicrobial | 1.7% hemolysis at 20μg/ml | Human | Derived from mucus of Achatina fulica | NA | NA | ||
| 23103587 | 2013 | TDTNVIGECFDEWSRCHRQTRWWTKILFQSCENRCKCKVQLMGNCIKVPFKCFLWKQKRFMCECYGPISGTKPWYCGWEL | mytimacin-AF | Free | Free | Linear | L | None | 80 | Antimicrobial | 2.4% hemolysis at 40μg/ml | Human | Derived from mucus of Achatina fulica | NA | NA | ||
| 23103587 | 2013 | TDTNVIGECFDEWSRCHRQTRWWTKILFQSCENRCKCKVQLMGNCIKVPFKCFLWKQKRFMCECYGPISGTKPWYCGWEL | mytimacin-AF | Free | Free | Linear | L | None | 80 | Antimicrobial | 2.3% hemolysis at 80μg/ml | Human | Derived from mucus of Achatina fulica | NA | NA | ||
| 23103587 | 2013 | TDTNVIGECFDEWSRCHRQTRWWTKILFQSCENRCKCKVQLMGNCIKVPFKCFLWKQKRFMCECYGPISGTKPWYCGWEL | mytimacin-AF | Free | Free | Linear | L | None | 80 | Antimicrobial | 3.2% hemolysis at 160μg/ml | Human | Derived from mucus of Achatina fulica | NA | NA | ||
| 23103587 | 2013 | TDTNVIGECFDEWSRCHRQTRWWTKILFQSCENRCKCKVQLMGNCIKVPFKCFLWKQKRFMCECYGPISGTKPWYCGWEL | mytimacin-AF | Free | Free | Linear | L | None | 80 | Antimicrobial | 3.9% hemolysis at 320μg/ml | Human | Derived from mucus of Achatina fulica | NA | NA | ||
| 23137439 | 2013 | VTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN | Coprisin | Free | Free | Linear | L | None | 43 | Antimicrobial | 0% hemolysis at 100μM | Human | Copris tripartitus | α-helical | Non-hemolytic | ||
| 23262358 | 2013 | DLLGTLGNLPLPFI{ct:Amid} | frenatin 2D | Amidation | Free | Linear | L | None | 14 | Immunomodulatory | No hemolysis upto 500μM | Human | Derived from skin secretions of Discoglossus sardus (Alytidae) | NA | Non-hemolytic | ||
| 23270672 | 2013 | RRLMAAKAESRK | CL(14-25) | Free | Free | Linear | L | None | 12 | Antimicrobial | No or little hemolysis upto 800μM | Human | Oryza sativa L. japonica (cyanate lyase) | α-helical | Non-hemolytic | ||
| 23270672 | 2013 | RLMAAKAESRK | CL(15-25) | Free | Free | Linear | L | None | 11 | Antimicrobial | No or little hemolysis upto 800μM | Human | CL-analog | α-helical | Non-hemolytic | ||
| 23270672 | 2013 | LMAAKAESRK | CL(16-25) | Free | Free | Linear | L | None | 10 | Antimicrobial | No or little hemolysis upto 800μM | Human | CL-analog | α-helical | Non-hemolytic | ||
| 23270672 | 2013 | RRLMAAKAESR | CL(14-24) | Free | Free | Linear | L | None | 11 | Antimicrobial | No or little hemolysis upto 800μM | Human | CL-analog | α-helical | Non-hemolytic | ||
| 23270672 | 2013 | RRLMAAKAES | CL(14-23) | Free | Free | Linear | L | None | 10 | Antimicrobial | No or little hemolysis upto 800μM | Human | CL-analog | α-helical | Non-hemolytic | ||
| 23403131 | 2013 | GILKTIKSIASKVANTVQKLKRKAKNAVA | Peptide | Free | Free | Linear | L | None | 29 | Antimicrobial | EC50 =46μM | Human | Derived from venom of hadrurin and vejovine(Synthetic peptide) | α-helical | NA | ||
| 23403131 | 2013 | GILKTIKSIASKVANTVQKLKRKAKNAV | Δ(Α29) | Free | Free | Linear | L | None | 28 | Antimicrobial | EC50 =47μM | Human | Derived from venom of hadrurin and vejovine(Synthetic peptide) | α-helical | NA | ||
| 23403131 | 2013 | GILKTIKSIASKLKRKAK | Δ(K12-Q18;Ν26−Α29) | Free | Free | Linear | L | None | 18 | Antimicrobial | EC50 =80μM | Human | Derived from venom of hadrurin and vejovine(Synthetic peptide) | α-helical | NA | ||
| 23403131 | 2013 | GILNTIKSIASKLKRKAK | K4N Δ(K12-Q18; Ν26−Α29) | Free | Free | Linear | L | None | 18 | Antimicrobial | EC50 =139μM | Human | Derived from venom of hadrurin and vejovine(Synthetic peptide) | α-helical | NA | ||
| 23415044 | 2013 | FLGFLKNLF | WT | Free | Free | Linear | L | None | 9 | Antiviral | HC50 =137.9μg/ml | Human | Synthetic peptide (Ctry2459) | α-helical | NA | ||
| 23415044 | 2013 | FLGFLHHLF | H2 | Free | Free | Linear | L | None | 9 | Antiviral | HC50 =203.3μg/ml | Human | Synthetic peptide (Ctry2459) | α-helical | NA | ||
| 23415044 | 2013 | FLHFLHHLF | H3 | Free | Free | Linear | L | None | 9 | Antiviral | HC50 =416.4μg/ml | Human | Synthetic peptide (Ctry2459) | α-helical | NA | ||
| 23523532 | 2013 | GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | Cu 1a | Amidation | Free | Linear | L | None | 35 | Cytolytic | EC50 =7.8μM | Human | Derived from venom of Cupiennius salei | α-helical | NA | ||
| 23523532 | 2013 | GAGALAKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | A-Cu 1a | Amidation | Free | Linear | L | None | 35 | Cytolytic | EC50 >40μM | Human | Cu 1a analog | α-helical | NA | ||
| 23523532 | 2013 | GKGALKKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | K-Cu 1a | Amidation | Free | Linear | L | None | 35 | Cytolytic | EC50 >40μM | Human | Cu 1a analog | α-helical | NA | ||
| 23523532 | 2013 | GFGTILKALAKIAGKVVKKLATKPGATYMLKENLK{ct:Amid} | Cu 2a | Amidation | Free | Linear | L | None | 35 | Cytolytic | EC50 =2.6μM | Human | Derived from venom of Cupiennius salei | α-helical | NA | ||
| 23624072 | 2013 | GILGKLWEGFKSIV{ct:Amid} | Pantinin-1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0% hemolysis up to 32μM | Human | Derived from venom of Pandinus imperator | α-helical | NA | ||
| 23624072 | 2013 | IFGAIWNGIKSLF{ct:Amid} | Pantinin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolysis up to 8μM | Human | Derived from venom of Pandinus imperator | α-helical | NA | ||
| 23624072 | 2013 | FLSTIWNGIKSLL{ct:Amid} | Pantinin-3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0% hemolysis upto 8μM | Human | Derived from venom of Pandinus imperator | α-helical | NA | ||
| 23624072 | 2013 | GILGKLWEGFKSIV{ct:Amid} | Pantinin-1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 21% hemolysis at 64 μM | Human | Derived from venom of Pandinus imperator | α-helical | NA | ||
| 23624072 | 2013 | IFGAIWNGIKSLF{ct:Amid} | Pantinin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 8% hemolysis at 16μM | Human | Derived from venom of Pandinus imperator | α-helical | NA | ||
| 23624072 | 2013 | FLSTIWNGIKSLL{ct:Amid} | Pantinin-3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 70% hemolysis at 16μM | Human | Derived from venom of Pandinus imperator | α-helical | NA | ||
| 23624072 | 2013 | IFGAIWNGIKSLF{ct:Amid} | Pantinin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 81% hemolysis at 32μM | Human | Derived from venom of Pandinus imperator | α-helical | NA | ||
| 23624072 | 2013 | FLSTIWNGIKSLL{ct:Amid} | Pantinin-3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 100% hemolysis at 32μM | Human | Derived from venom of Pandinus imperator | α-helical | NA | ||
| 23624072 | 2013 | IFGAIWNGIKSLF{ct:Amid} | Pantinin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 100% hemolysis at 64μM | Human | Derived from venom of Pandinus imperator | α-helical | NA | ||
| 23776609 | 2013 | RAGLQFPVGRLLR | BR1 | Free | Free | Linear | L | None | 13 | CPP | Inactive | Human | buforin IIb | NA | Non-hemolytic | ||
| 23776609 | 2013 | RAGLQFPVGRLLRRLLR | BR2 | Free | Free | Linear | L | None | 17 | CPP | Inactive | Human | buforin IIb | NA | Non-hemolytic | ||
| 23776609 | 2013 | RAGLQFPVGRLLRRLLRRLLR | BR3 | Free | Free | Linear | L | None | 21 | CPP | 5% hemolysis at 25μM | Human | buforin IIb | NA | NA | ||
| 23776609 | 2013 | RAGLQFPVGRLLRRLLRRLLR | BR3 | Free | Free | Linear | L | None | 21 | CPP | 34.3% hemolysis at 200μM | Human | buforin IIb | NA | NA | ||
| 23776609 | 2013 | RKKRRQRRR | Tat (49–57) | Free | Free | Linear | L | None | 9 | CPP | Inactive | Human | buforin IIb | NA | Non-hemolytic | ||
| 9675125 | 1998 | MASRAAGLAARLARLALRAL | ESF1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0.1% hemolysis at 50μg/ml | Human | magainin PGLa analog | α-helical | NA | ||
| 9675125 | 1998 | MASRAARLAARLARLALRAL | GR7 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0.4% hemolysis at 50μg/ml | Human | ESF1 analog | β-sheet | NA | ||
| 9675125 | 1998 | MAARAARLAARLARLALRAL | SA3 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0.4% hemolysis at 50μg/ml | Human | ESF1 analog | β-sheet | NA | ||
| 9675125 | 1998 | MASRAAGLAARLARLALRAL | ESF1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0.5% hemolysis at 200μg/ml | Human | magainin PGLa analog | α-helical | NA | ||
| 9675125 | 1998 | MASRAARLAARLARLALRAL | GR7 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0.9% hemolysis at 200μg/ml | Human | ESF1 analog | β-sheet | NA | ||
| 9675125 | 1998 | MAARAARLAARLARLALRAL | SA3 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0.8% hemolysis at 200μg/ml | Human | ESF1 analog | β-sheet | NA | ||
| 8163497 | 1994 | FLPLLAGLAANFLPKIFCKITRKC | Brevinin-1E | Free | Free | Linear | L | None | 24 | Antimicrobial | Lethal concentration = 0.5μM | Human | Derived from skin secretion of Rana esculenta | NA | NA | ||
| 8163497 | 1994 | GLMDTLKNLAKTAGKGALQSLLNKASCKLSGQC | Brevinin-2E | Free | Free | Linear | L | None | 33 | Antimicrobial | Lethal concentration >100μM | Human | Derived from skin secretion of Rana esculenta(Brevinin analog) | NA | NA | ||
| 8163497 | 1994 | GIFSKLGRKKIKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC | Esculentin-1 | Free | Free | Linear | L | None | 46 | Antimicrobial | Lethal concentration >100μM | Human | Derived from skin secretion of Rana esculenta (Esculentin analog) | NA | NA | ||
| 2253768 | 1990 | G{d}I{d}G{d}K{d}F{d}L{d}H{d}S{d}A{d}K{d}K{d}F{d}G{d}K{d}A{d}F{d}V{d}G{d}E{d}I{d}M{d}N{d}S{d} | All-D-Magainin-2 | Free | Free | Linear | D | None | 23 | Antibacterial and Antifungal | 0% hemolysis upto 80μg/ml | Human | Derived from skin of Xenopus laevis | NA | NA | ||
| 2253768 | 1990 | G{d}I{d}G{d}K{d}F{d}L{d}H{d}S{d}A{d}K{d}K{d}F{d}G{d}K{d}A{d}F{d}V{d}G{d}E{d}I{d}M{d}N{d}S{d} | All-D-Magainin-2 | Free | Free | Linear | D | None | 23 | Antibacterial and Antifungal | 1% hemolysis at 100μg/ml | Human | Derived from skin of Xenopus laevis | NA | NA | ||
| 2253768 | 1990 | G{d}I{d}G{d}K{d}F{d}L{d}H{d}S{d}A{d}K{d}K{d}F{d}G{d}K{d}A{d}F{d}V{d}G{d}E{d}I{d}M{d}N{d}S{d} | All-D-Magainin-2 | Free | Free | Linear | D | None | 23 | Antibacterial and Antifungal | 2% hemolysis at 200μg/ml | Human | Derived from skin of Xenopus laevis | NA | NA | ||
| 2253768 | 1990 | GIGKFLHSAKKFGKAFVGEIMNS | All-L-Magainin-2 | Free | Free | Linear | L | None | 23 | Antibacterial and Antifungal | 0% hemolysis at 25μg/ml (non hemolytic) | Human | Derived from skin of Xenopus laevis | NA | Non-hemolytic | ||
| 2253768 | 1990 | GIGKFLHSAKKFGKAFVGEIMNS | All-L-Magainin-2 | Free | Free | Linear | L | None | 23 | Antibacterial and Antifungal | 1% hemolysis at 80μg/ml | Human | Derived from skin of Xenopus laevis | NA | NA | ||
| 2253768 | 1990 | GIGKFLHSAKKFGKAFVGEIMNS | All-L-Magainin-2 | Free | Free | Linear | L | None | 23 | Antibacterial and Antifungal | 2% hemolysis at 200μg/ml | Human | Derived from skin of Xenopus laevis | NA | NA | ||
| 2474443 | 1989 | MAQDIISTIGDLVKWIIDTVNKFPKK{nt:Formylation} | Peptide-A | Free | Formylation | Linear | L | None | 26 | Cytolytic | 82% hemolysis at 25μg | Human | δ-toxin (Staphylococcus aurezis) | NA | NA | ||
| 2474443 | 1989 | MAQDIISTIGDLVKWIIDTVNKFPKK{nt:Formylation} | Peptide-A | Free | Formylation | Linear | L | None | 26 | Cytolytic | 100% hemolysis at 75μg | Human | δ-toxin (Staphylococcus aurezis) | NA | NA | ||
| 2474443 | 1989 | MAQDIISTIGDLVKWIIDTVNKFPKK{nt:Formylation} | Peptide-B | Free | Formylation | Linear | L | None | 26 | Cytolytic | 47% hemolysis at 25μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 2474443 | 1989 | MAQDIISTIGDLVKWIIDTVNKFPKK{nt:Formylation} | Peptide-B | Free | Formylation | Linear | L | None | 26 | Cytolytic | 55% hemolysis at 75μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 2474443 | 1989 | MAQDIISTIGDLVKWIIDTVNKFPKK | Peptide-C | Free | Free | Linear | L | None | 26 | Cytolytic | 60% hemolysis at 75μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 2474443 | 1989 | DLVKWIIDTVNKFTKK | Peptide-D | Free | Free | Linear | L | None | 16 | Cytolytic | 0% hemolysis at 75μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 2474443 | 1989 | DLVKWIIDTVNKFTKK | Peptide-D | Free | Free | Linear | L | None | 16 | Cytolytic | 12% hemolysis at 250μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 2474443 | 1989 | DLVKWIIDTVNKFTKK | Peptide-D | Free | Free | Linear | L | None | 16 | Cytolytic | 18% hemolysis at 500μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 2474443 | 1989 | MAQDIISTIGD{nt:Formylation} | Peptide-E | Free | Formylation | Linear | L | None | 11 | Cytolytic | 0% hemolysis at 1000μg (non hemolytic) | Human | δ-toxin derivative (Synthetic peptide) | NA | Non-hemolytic | ||
| 2474443 | 1989 | MLQDLLSSLGDLLKSWLDTLNKFTKK{nt:Formylation} | Peptide-F | Free | Formylation | Linear | L | None | 26 | Cytolytic | 4% hemolysis at 75μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 2474443 | 1989 | MLQDLLSSLGDLLKSWLDTLNKFTKK | Peptide-G | Free | Free | Linear | L | None | 26 | Cytolytic | 13% hemolysis at 75μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 2474443 | 1989 | MLQDWLSSLGDLLKSLLDTVNKFTKK{nt:Fmoc} | Peptide-H | Free | Fmoc | Linear | L | None | 26 | Cytolytic | 59% hemolysis at 75μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 2474443 | 1989 | MLQDWLSSLGDLLKSLLDTVNKFTKK | Peptide-I | Free | Free | Linear | L | None | 26 | Cytolytic | 40% hemolysis at 75μg | Human | δ-toxin derivative (Synthetic peptide) | NA | NA | ||
| 9022710 | 1996 | FLPLIGRVLSGIL{ct:Amid} | Temporin A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | Lethal concentration >120μM | Human | Temporin analog (Rana esculenta) | NA | NA | ||
| 9022710 | 1996 | LLPIVGNLLKSLL{ct:Amid} | Temporin B | Amidation | Free | Linear | L | None | 13 | Antimicrobial | Lethal concentration >120μM | Human | Temporin analog (Rana esculenta) | NA | NA | ||
| 9022710 | 1996 | FIGSALKVLAGVLPSVISWVKQ{ct:Amid} | MLP | Amidation | Free | Linear | L | None | 22 | Antimicrobial | Lethal concentration =0.5μM | Human | Melittin like peptide | NA | NA | ||
| 9784609 | 1998 | FSKYERQKDKRPYSQRKNQYTGPQFLYPPERIPPQKVIKWNEEGLPIYEIPGEGGHAEPAAA | Lumbricin I | Free | Free | Linear | L | None | 62 | Antimicrobial | 0.02% hemolysis at 5μg/ml | Human | Lumbricin (Lumbricus rubellus) | NA | NA | ||
| 9784609 | 1998 | FSKYERQKDKRPYSQRKNQYTGPQFLYPPERIPPQKVIKWNEEGLPIYEIPGEGGHAEPAAA | Lumbricin I | Free | Free | Linear | L | None | 62 | Antimicrobial | 0.06% hemolysis at 10μg/ml | Human | Lumbricin (Lumbricus rubellus) | NA | NA | ||
| 9784609 | 1998 | FSKYERQKDKRPYSQRKNQYTGPQFLYPPERIPPQKVIKWNEEGLPIYEIPGEGGHAEPAAA | Lumbricin I | Free | Free | Linear | L | None | 62 | Antimicrobial | 0.14% hemolysis at 25μg/ml | Human | Lumbricin I (Lumbricus rubellus) | NA | NA | ||
| 9784609 | 1998 | FSKYERQKDKRPYSQRKNQYTGPQFLYPPERIPPQKVIKWNEEGLPIYEIPGEGGHAEPAAA | Lumbricin I | Free | Free | Linear | L | None | 62 | Antimicrobial | 0.19% hemolysis at 50μg/ml | Human | Lumbricin I (Lumbricus rubellus) | NA | NA | ||
| 9784609 | 1998 | FSKYERQKDKRPYSQRKNQYTGPQFLYPPERIPPQKVIKWNEEGLPIYEIPGEGGHAEPAAA | Lumbricin I | Free | Free | Linear | L | None | 62 | Antimicrobial | 0.23% hemolysis at 100μg/ml | Human | Lumbricin I (Lumbricus rubellus) | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.03% hemolysis at 5μg/ml | Human | Lumbricin I (Lumbricus rubellus) | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.07% hemolysis at 10μg/ml | Human | Lumbricin I (Lumbricus rubellus) | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.13% hemolysis at 25μg/ml | Human | Lumbricin I (Lumbricus rubellus) | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.17% hemolysis at 50μg/ml | Human | Lumbricin I (Lumbricus rubellus) | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.21% hemolysis at 100μg/ml | Human | Lumbricin I (Lumbricus rubellus) | NA | NA | ||
| 10430870 | 1999 | CTCSWPVCTRNGLPVCGETCVGGTCNTPG{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 29 | Antimicrobial | 50% hemolysis at >400μM | Human | Kalata (Oldenlandia affinis) | NA | NA | ||
| 10430870 | 1999 | CSCKNKVCYRNGIPCGESCVWIPCISAALG{cyc:N-C} | Cir A | Free | Free | Cyclic | L | None | 30 | Antimicrobial | 50% hemolysis at >400μM | Human | Circulin A (Chassalia parvifolia) | NA | NA | ||
| 10430870 | 1999 | CSCKNKVCYRNGVIPCGESCVFIPCISTLLG{cyc:N-C} | Cir B | Free | Free | Cyclic | L | None | 30 | Antimicrobial | 50% hemolysis at >400μM | Human | Circulin B (Chassalia parvifolia) | NA | NA | ||
| 10430870 | 1999 | CSCKSKVCYKNSIPCGESCVFIPCTVTALLG{cyc:N-C} | CPT | Free | Free | Cyclic | L | None | 30 | Antimicrobial | 50% hemolysis at >400μM | Human | Cyclopsychotride (Psychotria longipes) | NA | NA | ||
| 10942757 | 2000 | ZCRRLCYKQRCVTYCRGR | Gomesin | Free | Free | Linear | L | None | 18 | Antimicrobial | 16% hemolysis at 1μM | Human | Gomesin (Acanthoscurria gomesiana) | NA | NA | ||
| 10942757 | 2000 | ZCRRLCYKQRCVTYCRGR | Gomesin | Free | Free | Linear | L | None | 18 | Antimicrobial | ~23% hemolysis at 100μM | Human | Gomesin (Acanthoscurria gomesiana) | NA | NA | ||
| 10942757 | 2000 | ZCRRLCYKQRCVTYCRGR{ct:Amid} | Gomesin | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 11% hemolysis at 1μM | Human | Gomesin (Acanthoscurria gomesiana) | NA | NA | ||
| 10942757 | 2000 | ZCRRLCYKQRCVTYCRGR{ct:Amid} | Gomesin | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 20% hemolysis at 100μM | Human | Gomesin (Acanthoscurria gomesiana) | NA | NA | ||
| 11085990 | 2001 | GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK | HBD-3 | Free | Free | Linear | L | None | 45 | Antimicrobial | <0.5% hemolysis upto 500μg/ml | Human | Human beta-defensin-3 was isolated from human lesional psoriatic scales and cloned from keratinocytes | NA | NA | ||
| 11713517 | 2001 | FFHHIFRGIVHVGKTIHRLVTG | Piscidin 1 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0% hemolysis at 10μg/ml | Human | Piscidin (aquacultured fish, hybrid striped bass Morone saxatilis x M. Chrysops) | α-helix | NA | ||
| 11713517 | 2001 | FFHHIFRGIVHVGKTIHRLVTG | Piscidin 1 | Free | Free | Linear | L | None | 22 | Antimicrobial | ~90% hemolysis at 100μg/ml | Human | Piscidin (aquacultured fish, hybrid striped bass Morone saxatilis x M. Chrysops) | α-helix | NA | ||
| 11713517 | 2001 | FFHHIFRGIVHVGKTIHKLVTG | Piscidin 2 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0% hemolysis at 10μg/ml | Human | Piscidin (aquacultured fish, hybrid striped bass Morone saxatilis x M. Chrysops) | α-helix | NA | ||
| 11713517 | 2001 | FFHHIFRGIVHVGKTIHKLVTG | Piscidin 2 | Free | Free | Linear | L | None | 22 | Antimicrobial | ~90% hemolysis at 100μg/ml | Human | Piscidin (aquacultured fish, hybrid striped bass Morone saxatilis x M. Chrysops) | α-helix | NA | ||
| 11713517 | 2001 | FIHHIFRGIVHAGRSIGRFLTG | Piscidin 3 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0% hemolysis at 10μg/ml | Human | Piscidin (aquacultured fish, hybrid striped bass Morone saxatilis x M. Chrysops) | α-helix | NA | ||
| 11713517 | 2001 | FIHHIFRGIVHAGRSIGRFLTG | Piscidin 3 | Free | Free | Linear | L | None | 22 | Antimicrobial | ~5% hemolysis at 100μg/ml | Human | Piscidin (aquacultured fish, hybrid striped bass Morone saxatilis x M. Chrysops) | α-helix | NA | ||
| 11739390 | 2002 | FFHHIFRGIVHVGKTIHKLVTG{ct:Amid} | Wb-moronecidin | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 0% hemolysis upto 1.25μM | Human | White bass (Morone chrysops) | α-helix | NA | ||
| 11739390 | 2002 | FFHHIFRGIVHVGKTIHKLVTG{ct:Amid} | Wb-moronecidin | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 1% hemolysis upto 2.5μM | Human | White bass (Morone chrysops) | α-helix | NA | ||
| 11739390 | 2002 | FFHHIFRGIVHVGKTIHKLVTG{ct:Amid} | Wb-moronecidin | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 19% hemolysis at 5μM | Human | White bass (Morone chrysops) | α-helix | NA | ||
| 11739390 | 2002 | FFHHIFRGIVHVGKTIHKLVTG{ct:Amid} | Wb-moronecidin | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 55% hemolysis at 10μM | Human | White bass (Morone chrysops) | α-helix | NA | ||
| 11739390 | 2002 | FFHHIFRGIVHVGKTIHKLVTG{ct:Amid} | Wb-moronecidin | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 100% hemolysis at 80μM | Human | White bass (Morone chrysops) | α-helix | NA | ||
| 11792701 | 2002 | GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | Cupiennin-1a | Amidation | Free | Linear | L | None | 35 | Antimicrobial | EC50 = 24.4μM | Human | Cupiennin analog (Venom of the Spider Cupiennius salei (Ctenidae)) | NA | NA | ||
| 11792701 | 2002 | GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME | Cupiennin-1a | Free | Free | Linear | L | None | 35 | Antimicrobial | EC50 = 20.5μM | Human | Cupiennin analog (Venom of the Spider Cupiennius salei (Ctenidae)) | NA | NA | ||
| 11792701 | 2002 | GFGSLFKFLAKKVAKTVAKQAAKQGAKYVANKHME | Cupiennin-1d | Free | Free | Linear | L | None | 35 | Antimicrobial | EC50 = 14.5μM | Human | Cupiennin analog (Venom of the Spider Cupiennius salei (Ctenidae)) | NA | NA | ||
| 1605597 | 1992 | GIGKFLHSAKKFGKAFVGEIMNS | Peptide-1 | Free | Free | Linear | L | None | 23 | Antibacterial | 0% hemolysis upto 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | GIGKFLHSAKKFGKAFVGEIMNS | Peptide-1 | Free | Free | Linear | L | None | 23 | Antibacterial | 1% hemolysis upto 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKKKKKKKKKGIGKFLHSAKKFGKAFVGEIMNS | Peptide-3 | Free | Free | Linear | L | None | 33 | Antibacterial | 0% hemolysis upto 200μg/ml (non hemolytic) | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | Non-hemolytic | ||
| 1605597 | 1992 | AAAAAAAAAAGIGKFLHSAKKFGKAFVGEIMNS | Peptide-4 | Free | Free | Linear | L | None | 33 | Antibacterial | 2% hemolysis upto 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | AAAAAAAAAAGIGKFLHSAKKFGKAFVGEIMNS | Peptide-4 | Free | Free | Linear | L | None | 33 | Antibacterial | 9% hemolysis upto 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | RRRRRRRRRRGIGKFLHSAKKFGKAFVGEIMNS | Peptide-5 | Free | Free | Linear | L | None | 33 | Antibacterial | 0% hemolysis at 25μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | RRRRRRRRRRGIGKFLHSAKKFGKAFVGEIMNS | Peptide-5 | Free | Free | Linear | L | None | 33 | Antibacterial | 1% hemolysis at 50μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | RRRRRRRRRRGIGKFLHSAKKFGKAFVGEIMNS | Peptide-5 | Free | Free | Linear | L | None | 33 | Antibacterial | 2% hemolysis at 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | RRRRRRRRRRGIGKFLHSAKKFGKAFVGEIMNS | Peptide-5 | Free | Free | Linear | L | None | 33 | Antibacterial | 4% hemolysis at 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKKKKKKKKKKKKKKKKKKKGIGKFLHSAKKFGKAFVGEIMNS | Peptide-6 | Free | Free | Linear | L | None | 43 | Antibacterial | 1% hemolysis at 25μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKKKKKKKKKKKKKKKKKKKGIGKFLHSAKKFGKAFVGEIMNS | Peptide-6 | Free | Free | Linear | L | None | 43 | Antibacterial | 2% hemolysis at 50μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKKKKKKKKKKKKKKKKKKKGIGKFLHSAKKFGKAFVGEIMNS | Peptide-6 | Free | Free | Linear | L | None | 43 | Antibacterial | 6% hemolysis at 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKKKKKKKKKKKKKKKKKKKGIGKFLHSAKKFGKAFVGEIMNS | Peptide-6 | Free | Free | Linear | L | None | 43 | Antibacterial | 14% hemolysis at 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | GIGKFLHSAKKFGKAFVGEIMNSKKKKKKKKKK | Peptide-7 | Free | Free | Linear | L | None | 33 | Antibacterial | 0% hemolysis upto 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | GIGKFLHSAKKFGKAFVGEIMNSKKKKKKKKKK | Peptide-7 | Free | Free | Linear | L | None | 33 | Antibacterial | 1% hemolysis at 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKFLHSAKKWLKAFVKLKKNW | Peptide-8 | Free | Free | Linear | L | None | 21 | Antibacterial | 3% hemolysis at 25μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKFLHSAKKWLKAFVKLKKNW | Peptide-8 | Free | Free | Linear | L | None | 21 | Antibacterial | 16% hemolysis at 50μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKFLHSAKKWLKAFVKLKKNW | Peptide-8 | Free | Free | Linear | L | None | 21 | Antibacterial | 29% hemolysis at 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKFLHSAKKWLKAFVKLKKNW | Peptide-8 | Free | Free | Linear | L | None | 21 | Antibacterial | 41% hemolysis at 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | GIGKLFLHAAKKFAKAFVAEKMNS | Peptide-9 | Free | Free | Linear | L | None | 24 | Antibacterial | 0% hemolysis upto 200μg/ml (non hemolytic) | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | Non-hemolytic | ||
| 1605597 | 1992 | KKKKKKKKKKGIGKLFLHAAKKFAKAFVAEKMNS | Peptide-10 | Free | Free | Linear | L | None | 34 | Antibacterial | 0% hemolysis at 100μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 1605597 | 1992 | KKKKKKKKKKGIGKLFLHAAKKFAKAFVAEKMNS | Peptide-10 | Free | Free | Linear | L | None | 34 | Antibacterial | 2% hemolysis at 200μg/ml | Human | Magainin-2 analog (Skin secretion of the african frog Xenopus laevis) | NA | NA | ||
| 8823199 | 1996 | KLALKLALKALKAALKLA | KLAL | Free | Free | Linear | L | None | 18 | Antibacterial | EC50 = 10μM | Human | Synthetic peptide | NA | NA | ||
| 8823199 | 1996 | K{d}L{d}ALKLALKALKAALKLA | k1/l2 | Free | Free | Linear | Mix | None | 18 | Antibacterial | EC50 = 7μM | Human | Synthetic peptide | NA | NA | ||
| 8823199 | 1996 | KLA{d}L{d}KLALKALKAALKLA | a3/l4 | Free | Free | Linear | Mix | None | 18 | Antibacterial | EC50 = 33μM | Human | Synthetic peptide | NA | NA | ||
| 8823199 | 1996 | KLALK{d}L{d}ALKALKAALKLA | k5/l6 | Free | Free | Linear | Mix | None | 18 | Antibacterial | EC50 = 160μM | Human | Synthetic peptide | NA | NA | ||
| 8823199 | 1996 | KLALKLA{d}L{d}KALKAALKLA | a7/l8 | Free | Free | Linear | Mix | None | 18 | Antibacterial | EC50 = 180μM | Human | Synthetic peptide | NA | NA | ||
| 8823199 | 1996 | KLALKLALK{d}A{d}LKAALKLA | k9/a10 | Free | Free | Linear | Mix | None | 18 | Antibacterial | EC50 = 56μM | Human | Synthetic peptide | NA | NA | ||
| 8823199 | 1996 | KLALKLALKAL{d}K{d}AALKLA | l11/k12 | Free | Free | Linear | Mix | None | 18 | Antibacterial | EC50 = 540μM | Human | Synthetic peptide | NA | NA | ||
| 8823199 | 1996 | KLALKLALKALKA{d}A{d}LKLA | a13/a14 | Free | Free | Linear | Mix | None | 18 | Antibacterial | EC50 = 260μM | Human | Synthetic peptide | NA | NA | ||
| 8823199 | 1996 | KLALKLALKALKAAL{d}K{d}LA | l15/k16 | Free | Free | Linear | Mix | None | 18 | Antibacterial | EC50 = 210μM | Human | Synthetic peptide | NA | NA | ||
| 8823199 | 1996 | KLALKLALKALKAALKL{d}A{d} | l17/a18 | Free | Free | Linear | Mix | None | 18 | Antibacterial | EC50 = 70μM | Human | Synthetic peptide | NA | NA | ||
| 8855958 | 1996 | KKLKKLKKKWKKLKKKLK | Hel 5-13 | Free | Free | Linear | L | None | 18 | Antimicrobial | 0% hemolysis at 100μM | Human | Synthetic peptide | α-helix | NA | ||
| 8855958 | 1996 | KKLKKLLKKWKKLLKKLK | Hel 7-11 | Free | Free | Linear | L | None | 18 | Antimicrobial | ~5% hemolysis upto 100μM (non hemolytic) | Human | Synthetic peptide | α-helix | Non-hemolytic | ||
| 8855958 | 1996 | KLLKKLLKLWKKLLKKLK | Hel 9-9 | Free | Free | Linear | L | None | 18 | Antimicrobial | ~45% hemolysis at 10μM | Human | Synthetic peptide | α-helix | NA | ||
| 8855958 | 1996 | KLLKKLLKLWKKLLKKLK | Hel 9-9 | Free | Free | Linear | L | None | 18 | Antimicrobial | ~60% hemolysis at 100μM | Human | Synthetic peptide | α-helix | NA | ||
| 8855958 | 1996 | KLLKLLLKLWKKLLKLLK | Hel 11-7 | Free | Free | Linear | L | None | 18 | Antimicrobial | ~45% hemolysis at 1μM | Human | Synthetic peptide | α-helix | NA | ||
| 8855958 | 1996 | KLLKLLLKLWKKLLKLLK | Hel 11-7 | Free | Free | Linear | L | None | 18 | Antimicrobial | 100% hemolysis at 10μM | Human | Synthetic peptide | α-helix | NA | ||
| 8855958 | 1996 | KLLKLLLKLWLKLLKLLL | Hel 13-5 | Free | Free | Linear | L | None | 18 | Antimicrobial | 100% hemolysis at 1μM | Human | Synthetic peptide | α-helix | NA | ||
| 11738089 | 2001 | GLLKRIKTLL{ct:Amid} | Anoplin | Amidation | Free | Linear | L | None | 10 | Antimicrobial and Mast cell degranulating | Low hemolytic activity | Human | Anoplin (venom of the solitary wasp Anoplius samariensis) | α-helix | NA | ||
| 11738090 | 2001 | GFLGPLLKLAAKGVAKVIPHLIPSRQQ | XT-1 | Free | Free | Linear | L | None | 27 | Antimicrobial | HC50 =90μM | Human | XT (skin secretions of the diploid frog Xenopus tropicalis) | NA | NA | ||
| 11738090 | 2001 | GVFLDALKKFAKGGMNAVLNPK | XT-4 | Free | Free | Linear | L | None | 22 | Antimicrobial | HC50 >150μM | Human | XT (skin secretions of the diploid frog Xenopus tropicalis) | NA | NA | ||
| 11738090 | 2001 | GMATKAGTALGKVAKAVIGAAL{ct:Amid} | XT-5 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | HC50 >150μM | Human | XT (skin secretions of the diploid frog Xenopus tropicalis) | NA | NA | ||
| 11738090 | 2001 | GFLGSLLKTGLKVGSNLL{ct:Amid} | XT-6 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | HC50 >150μM | Human | XT (skin secretions of the diploid frog Xenopus tropicalis) | NA | NA | ||
| 11738090 | 2001 | GLLGPLLKIAAKVGSNLL{ct:Amid} | XT-7 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | HC50 =70μM | Human | XT (skin secretions of the diploid frog Xenopus tropicalis) | NA | NA | ||
| 14636071 | 2003 | GALRGCWTKSYPPKPCK{ct:Amid} | Ranacyclin T | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 20% hemolysis at 100μM | Human | Ranacyclin (skin secretion of the frog Rana esculenta) | NA | NA | ||
| 14636071 | 2003 | SAPRGCWTKSYPPKPCK{ct:Amid} | Ranacyclin E | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 55% hemolysis at 100μM | Human | Ranacyclin (skin secretion of the frog Rana esculenta) | NA | NA | ||
| 14636071 | 2003 | LVRGCWTKSYPPKPCFVR{ct:Amid} | pLR | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 85% hemolysis at 100μM | Human | pLR (skin of the Northern Leopard frog Rana pipiens) | NA | NA | ||
| 19539775 | 2009 | FLSLALAALPKLFCLIFKKC | Brevinin-1CDYa | Free | Free | Linear | L | None | 20 | Antimicrobial | HC50 =125μM | Human | Brevinin-1 (skin secretions from the Chinese frog Rana dybowskii) | NA | NA | ||
| 19539775 | 2009 | FFPLALLCKVFKKC | Japonicin-1CDYa | Free | Free | Linear | L | None | 14 | Antimicrobial | HC50 >300μM | Human | Japonicin-1 (skin secretions from the Chinese frog Rana dybowskii) | NA | NA | ||
| 19539775 | 2009 | VLPLVGNLLNDLL{ct:Amid} | Temporin-CDYb | Amidation | Free | Linear | L | None | 13 | Antimicrobial | HC50 =180μM | Human | Temporin (skin secretions from the Chinese frog Rana dybowskii) | NA | NA | ||
| 19539775 | 2009 | IIPLPLGYFAKKT | Dybowskin-1CDYa | Free | Free | Linear | L | None | 13 | Antimicrobial | HC50 >300μM | Human | Dybowskin-1 (skin secretions from the Chinese frog Rana dybowskii) | NA | NA | ||
| 19539775 | 2009 | SAVGRHGRRFGLRKHRKH | Dybowskin-2CDYa | Free | Free | Linear | L | None | 18 | Antimicrobial | HC50 >300μM | Human | Dybowskin-2 (skin secretions from the Chinese frog Rana dybowskii) | NA | NA | ||
| 19109988 | 2010 | GFLSALKKYLPIVLKHV | Osmin | Free | Free | Linear | L | None | 17 | Antibacterial and Antifungal | Weak hemolytic activity i.e. 5.0HU/mg | Human | Osmin (venom from the solitary bee Osmia rufa) | NA | NA | ||
| 19109988 | 2010 | GFLSALKKYLPIVLKHV{ct:Amid} | Osmin | Amidation | Free | Linear | L | None | 17 | Antibacterial and Antifungal | Hemolytic activity i.e. 16.6HU/mg | Human | Osmin (venom from the solitary bee Osmia rufa) | NA | NA | ||
| 9166783 | 1997 | GLGKFLHSAKRFGKAFVGEAMNS{ct:Amid} | L2R11A20-M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC50 >1000μM | Human | Maginin-2 analog ( skin of the African clawed frog Xenopus laevis) | NA | NA | ||
| 9166783 | 1997 | GLGKFLHSAKRFGKAFVGEAMNS{ct:Amid} | L2R11A20-M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | 12% hemolysis at 150μM | Human | Maginin-2 analog ( skin of the African clawed frog Xenopus laevis) | NA | NA | ||
| 9166783 | 1997 | GIGKFLHSAKKFGKAFVGEIMNS{ct:Amid} | M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC50 =430μM | Human | Maginin-2 analog ( skin of the African clawed frog Xenopus laevis) | NA | NA | ||
| 9166783 | 1997 | GIGKFLHSAKKFGKAFVGEIMNS{ct:Amid} | M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | 30% hemolysis at 150μM | Human | Maginin-2 analog ( skin of the African clawed frog Xenopus laevis) | NA | NA | ||
| 9166783 | 1997 | GIGKFIHSAKKFGKLFVGEIMNS{ct:Amid} | I6L15-M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC50 =260μM | Human | Maginin-2 analog ( skin of the African clawed frog Xenopus laevis) | NA | NA | ||
| 9166783 | 1997 | GIGKFIHSAKKFGKLFVGEIMNS{ct:Amid} | I6L15-M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | 40% hemolysis at 150μM | Human | Maginin-2 analog ( skin of the African clawed frog Xenopus laevis) | NA | NA | ||
| 9166783 | 1997 | GIGKFIHAAKKFGKLFIGEIMNS{ct:Amid} | I6A8L15I17-M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC50 =32μM | Human | Maginin-2 analog ( skin of the African clawed frog Xenopus laevis) | NA | NA | ||
| 9166783 | 1997 | GIGKFIHAAKKFGKLFIGEIMNS{ct:Amid} | I6A8L15I17-M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | 98% hemolysis at 150μM | Human | Maginin-2 analog ( skin of the African clawed frog Xenopus laevis) | NA | NA | ||
| 11689009 | 2001 | GLNALKKVFQGIHEAIKLINNHVQ | Pseudin-2 | Free | Free | Linear | L | None | 24 | Antimicrobial | EC50 >300μM | Human | Pseudin (extract of the skin of the paradoxical frog Pseudis paradoxa) | NA | NA | ||
| 9813247 | 1998 | GLGSVFGRLARILGRVIPKVAKKLGPKVAKVLPKVMKEAIPMAVEMAKSQEEQQPQ | Pilosulin 1 | Free | Free | Linear | L | None | 56 | Cytotoxic | 100% hemolysis at 40μM | Human | Pilosulin 1(venom of the jumper ant Myrmecia pilosula) | NA | NA | ||
| 11479030 | 2001 | ILQKAVLDCLKAAGSSLSKAAITAIYNKIT | Dicynthaurin | Free | Free | Linear | L | None | 30 | Antimicrobial | 0% hemolysis at 25μg/ml | Human | Dicynthaurin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 11479030 | 2001 | ILQKAVLDCLKAAGSSLSKAAITAIYNKIT | Dicynthaurin | Free | Free | Linear | L | None | 30 | Antimicrobial | 10% hemolysis at 50μg/ml | Human | Dicynthaurin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 11479030 | 2001 | ILQKAVLDCLKAAGSSLSKAAITAIYNKIT | Dicynthaurin | Free | Free | Linear | L | None | 30 | Antimicrobial | 20% hemolysis at 100μg/ml | Human | Dicynthaurin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 11479030 | 2001 | QKAVLDCLKAAGSSLSKAAITAI | Cynthaurin | Free | Free | Linear | L | None | 23 | Antimicrobial | 0% hemolysis at 100μg/ml (non hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 3299384 | 1987 | GIGKFLHSAKKFGKAFVGEIMNS | Magainin-2 | Free | Free | Linear | L | None | 23 | Antimicrobial | 0% hemolysis at 10μg/ml (non hemolytic) | Human | Magainin-2 (skin of the African clawed frog Xenopus laevis) | NA | Non-hemolytic | ||
| 12005415 | 2001 | FLRFIGSVIHGIGHLVHHIGVAL{ct:Amid} | Clavaspirin | Amidation | Free | Linear | L | None | 23 | Antimicrobial | ~70% hemolysis at 20μg/ml | Human | Clavaspirin pharyngeal tissues of the tunicate,Styela clava | NA | NA | ||
| 12005415 | 2001 | FLRFIGSVIHGIGHLVHHIGVAL{ct:Amid} | Clavaspirin | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 75% hemolysis at 80μg/ml | Human | Clavaspirin pharyngeal tissues of the tunicate,Styela clava | NA | NA | ||
| 12067731 | 2002 | WLNALLHHGLNCAKGVLA | 18 monomer halocidin | Free | Free | Linear | L | None | 18 | Antimicrobial | 0% hemolysis at 25μg/ml | Human | Halocidin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 12067731 | 2002 | WLNALLHHGLNCAKGVLA | 18 monomer halocidin | Free | Free | Linear | L | None | 18 | Antimicrobial | <10% hemolysis at 50μg/ml | Human | Halocidin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 12067731 | 2002 | WLNALLHHGLNCAKGVLA | 18 monomer halocidin | Free | Free | Linear | L | None | 18 | Antimicrobial | ~10% hemolysis at 100μg/ml | Human | Halocidin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 12067731 | 2002 | WLNALLHHGLNCAKGVLAWLNALLHHGLNCAKGVLA | 18 homodimer halocidin | Free | Free | Linear | L | None | 36 | Antimicrobial | ~1-2% hemolysis at 25μg/ml | Human | Halocidin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 12067731 | 2002 | WLNALLHHGLNCAKGVLAWLNALLHHGLNCAKGVLA | 18 homodimer halocidin | Free | Free | Linear | L | None | 36 | Antimicrobial | >10% hemolysis at 100μg/ml | Human | Halocidin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | NA | ||
| 12067731 | 2002 | ALLHHGLNCAKGVLA | 15 monomer halocidin | Free | Free | Linear | L | None | 15 | Antimicrobial | 0% hemolysis at 100μg/ml (non hemolytic) | Human | Halocidin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | Non-hemolytic | ||
| 12067731 | 2002 | ALLHHGLNCAKGVLAALLHHGLNCAKGVLA | 15 homodimer halocidin | Free | Free | Linear | L | None | 30 | Antimicrobial | 0% hemolysis at 100μg/ml (non hemolytic) | Human | Halocidin (hemocytes of the solitary tunicate Halocynthia aurantium) | NA | Non-hemolytic | ||
| 12581207 | 2003 | FFGWLIKGAIHAGKAIHGLIHRRRH{ct:Amid} | Chrysophsin-1 | Amidation | Free | Linear | L | None | 25 | Antibacterial | ~40% hemolysis at 1μM | Human | Chrysophsin (the gills of red sea bream Chrysophrys major) | NA | NA | ||
| 12581207 | 2003 | FFGWLIKGAIHAGKAIHGLIHRRRH{ct:Amid} | Chrysophsin-1 | Amidation | Free | Linear | L | None | 25 | Antibacterial | 100% hemolysis at 100μM | Human | Chrysophsin (the gills of red sea bream Chrysophrys major) | NA | NA | ||
| 12581207 | 2003 | FFGWLIRGAIHAGKAIHGLIHRRRH{ct:Amid} | Chrysophsin-2 | Amidation | Free | Linear | L | None | 25 | Antibacterial | >40% hemolysis at 1μM | Human | Chrysophsin (the gills of red sea bream Chrysophrys major) | NA | NA | ||
| 12581207 | 2003 | FFGWLIRGAIHAGKAIHGLIHRRRH{ct:Amid} | Chrysophsin-2 | Amidation | Free | Linear | L | None | 25 | Antibacterial | 100% hemolysis at 100μM | Human | Chrysophsin (the gills of red sea bream Chrysophrys major) | NA | NA | ||
| 12581207 | 2003 | FIGLLISAGKAIHDLIRRRH{ct:Amid} | Chrysophsin-3 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 0% hemolysis at 1μM | Human | Chrysophsin (the gills of red sea bream Chrysophrys major) | NA | NA | ||
| 12581207 | 2003 | FIGLLISAGKAIHDLIRRRH{ct:Amid} | Chrysophsin-3 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 100% hemolysis at 100μM | Human | Chrysophsin (the gills of red sea bream Chrysophrys major) | NA | NA | ||
| 8223491 | 1993 | IIGPVLGLVGSALGGLLKKI{ct:Amid} | Peptide B | Amidation | Free | Linear | L | None | 20 | Antibacterial | Lethal concentration =17.0μM | Human | Synthetic peptide | NA | NA | ||
| 9395500 | 1997 | {nnr:X}ALWKNMLKGIGKLAGKAALGAVKKLVGAES | DS3 | Free | Free | Linear | L | X = H | 31 | Antimicrobial and Cytolytic | No hemolysis at 34μM (non hemolytic) | Human | Dermaseptins (skin of the tree frogs) | NA | Non-hemolytic | ||
| 9395500 | 1997 | {nnr:X}ALWMTLLKKVLKAAAKAALNAVLVGANA | DS4 | Free | Free | Linear | L | X = H | 29 | Antimicrobial and Cytolytic | Hemolysis observed at >8.5μM | Human | Dermaseptins (skin of the tree frogs) | NA | NA | ||
| 15304333 | 2004 | ACGILHDNCVYVPAQNPCCRGLQCRYGKCLVQV{ct:Amid} | PcFK1 | Amidation | Free | Linear | L | None | 33 | Antiplasmodial | No hemolysis at 10μM (non hemolytic) | Human | Psalmopeotoxins (venom of the Trinidad chevron tarantula Psalmopoeus cambridgei) | NA | Non-hemolytic | ||
| 15304333 | 2004 | RCLPAGKTCVRGPMRVPCCGSCSQNKCT | PcFK2 | Free | Free | Linear | L | None | 28 | Antiplasmodial | No hemolysis at 10μM (non hemolytic) | Human | Psalmopeotoxins (venom of the Trinidad chevron tarantula Psalmopoeus cambridgei) | NA | Non-hemolytic | ||
| 18519720 | 2008 | AGYLLGKINLKALAALAKKIL{ct:Amid} | TP10 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 5% hemolysis at 30μM | Human | Synthetic peptide | NA | NA | ||
| 18984589 | 2009 | KKALL{nnr:O}HALH{nnr:O}LALLA{nnr:O}HLAH{nnr:O}LKKA{ct:Amid} | HALO | Amidation | Free | Linear | L | O = L-Ornithine | 26 | Antimicrobial and Antiplasmodial | HC50 =179.2μM | Human | Synthetic peptide | NA | NA | ||
| 18984589 | 2009 | ALALL{nnr:O}HALH{nnr:O}LALLA{nnr:O}HLAH{nnr:O}LALA{ct:Amid} | HALO-2 | Amidation | Free | Linear | L | O = L-Ornithine | 26 | Antimicrobial and Antiplasmodial | HC50 <5.6μM | Human | Synthetic peptide | NA | NA | ||
| 18984589 | 2009 | FFKKL{nnr:O}HALH{nnr:O}LALLA{nnr:O}HLAH{nnr:O}LKKA{ct:Amid} | HALO-F | Amidation | Free | Linear | L | O = L-Ornithine | 26 | Antimicrobial and Antiplasmodial | HC50 <5.6μM | Human | Synthetic peptide | NA | NA | ||
| 18984589 | 2009 | KKALL{nnr:O}HPLH{nnr:O}LALLA{nnr:O}HLAH{nnr:O}LKKA{ct:Amid} | HALO-P8 | Amidation | Free | Linear | L | O = L-Ornithine | 26 | Antimicrobial and Antiplasmodial | HC50 =89.6μM | Human | Synthetic peptide | NA | NA | ||
| 18984589 | 2009 | A{d}K{d}K{d}L{d}{nnr:d-o}H{d}A{d}L{d}H{d}{nnr:d-o}A{d}L{d}L{d}A{d}L{d}{nnr:d-o}H{d}L{d}A{d}H{d}{nnr:d-o}L{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-HALO-rev | Amidation | Free | Linear | D | o = D-Ornithine | 26 | Antimicrobial and Antiplasmodial | HC50 =716.8μM | Human | Synthetic peptide | NA | NA | ||
| 18984589 | 2009 | A{d}K{d}K{d}L{d}{nnr:d-o}H{d}A{d}L{d}H{d}{nnr:d-o}A{d}L{d}L{d}A{d}L{d}{nnr:d-o}H{d}L{d}P{d}H{d}{nnr:d-o}L{d}K{d}K{d}F{d}F{d}{ct:Amid} | D-HALO-P8Frev | Amidation | Free | Linear | D | o = D-Ornithine | 26 | Antimicrobial and Antiplasmodial | HC50 >65.2μM | Human | Synthetic peptide | NA | NA | ||
| 18332165 | 2008 | KILRGVCKKIMRTFLRRISKDILTGKK{ct:Amid} | NK-2 | Amidation | Free | Linear | L | None | 27 | Antiplasmodial | No hemolysis upto 10μM (non hemolytic) | Human | Synthetic shortened analog of the mammalian defense protein NK-lysin | NA | Non-hemolytic | ||
| 10600529 | 1999 | RHARHD | Hannahpep | Free | Free | Linear | L | None | 6 | Plasma-anticlotting | No hemolysis (non hemolytic) | Human | Indian King Cobra (Ophiophagus hannah) Venom | NA | Non-hemolytic | ||
| 9048567 | 1997 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antibacterial | 100% hemolysis at 50μM | Human | Melittin ( venom of the honey bee Apis mellifera) | NA | NA | ||
| 9048567 | 1997 | GIGAV{d}LKV{d}LTTGLPALI{d}SWIK{d}RKRQQ{ct:Amid} | [D]-V5,8,I17,K21-melittin | Amidation | Free | Linear | Mix | None | 26 | Antibacterial | 0% hemolysis at 50μM | Human | Melittin diastereomers ( venom of the honey bee Apis mellifera) | NA | Non-hemolytic | ||
| 9048567 | 1997 | GIGAV{d}LKV{d}LTTGLPALI{d}SWIK{d}RKRQQ | [D]-V5,8,I17,K21-melittin | Free | Free | Linear | Mix | None | 26 | Antibacterial | ~1-2% hemolysis at 50μM | Human | Melittin diastereomers (Apis mellifera) | NA | NA | ||
| 9335545 | 1997 | GVAKFGKAAAHFGKGWIKEMLNS{ct:Amid} | 80°M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC25=307μM | Human | Synthetic peptide | NA | NA | ||
| 9335545 | 1997 | GIAKFGKAAAHFGKKWVGELMNS{ct:Amid} | 100°M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC25=159μM | Human | Synthetic peptide | NA | NA | ||
| 9335545 | 1997 | GIGKFLHSAKKFGKAWVGEIMNS{ct:Amid} | 120°M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC25=271μM | Human | Synthetic peptide | NA | NA | ||
| 9335545 | 1997 | GIGKFLHTLKTFGKKWVGEIMNS{ct:Amid} | 140°M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC25=15μM | Human | Synthetic peptide | NA | NA | ||
| 9335545 | 1997 | GIGKFLHKVKSFGKSWIGEIMNS{ct:Amid} | 160°M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC25=20μM | Human | Synthetic peptide | NA | NA | ||
| 9335545 | 1997 | GIGKFLHKVGSFIKSWKGEIMNS{ct:Amid} | 180°M2a | Amidation | Free | Linear | L | None | 23 | Antibacterial | EC25=24μM | Human | Synthetic peptide | NA | NA | ||
| 10387056 | 1999 | KWKSFIKKLTSAAKKVVTTAKPLISS | CP26p | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC=8μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10387056 | 1999 | KWKSFLKTFKSAVKTVLHTALKAISS | V681n | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC >128μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10387056 | 1999 | KWKSFLRTLKSPAKTVFHTALKAISS | V25p | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC >128μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10387056 | 1999 | KWKSFLKKLTSAAKKVLTTALKPISS | V26p | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC=64μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10387056 | 1999 | KWKSFLKTLKSPVKTVFYTALKPISS | V1pp | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC >128μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10387056 | 1999 | KWKSFLRTFKSPVRTVFHTALKPISS | V8pp | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC=32μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10387056 | 1999 | KWKSFLKTFKSPVKTVFYTALKPISS | V14pp | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC >128μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10387056 | 1999 | KWKSFLKTFKSPARTVLYTALKPISS | V68pp | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC >128μg/ml | Human | Synthetic peptide | NA | NA | ||
| 10387056 | 1999 | KWKSFLKTFKSPARTVLHTALKPISS | V31pp | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC >128μg/ml | Human | Synthetic peptide | NA | NA | ||
| 22074926 | 2012 | CGESCVFIPCITSLAGCSCKNKVCYYDGGSVP{cyc:N-C} | Parigidin_br1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 41% hemolysis at 40µM | Human | Parigidinbr1 (Palicourea rigida) | NA | NA | ||
| 22074926 | 2012 | CGESCVFIPCITSLAGCSCKNKVCYYDGGSVP{cyc:N-C} | Parigidin_br1 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 28% hemolysis at 20µM | Human | Parigidinbr1 (Palicourea rigida) | NA | NA | ||
| 21956830 | 2011 | FLKPLFNAALKLLP | Temporin-Ra | Free | Free | Linear | L | None | 14 | Antimicrobial | 1.3% hemolysis at 60µg/ml | Human | Derived from skin secretions of Rana ridibunda | NA | NA | ||
| 21956830 | 2011 | FLPVLAGVLSRA | Temporin-Rb | Free | Free | Linear | L | None | 12 | Antimicrobial | 1.1% hemolysis at 60µg/ml | Human | Derived from skin secretions of Rana ridibunda | NA | NA | ||
| 18030427 | 2008 | GWMSEKKVQGILDKKLPEGIIRNAAKAIVHKMAKMQFGCFANVDVKGDCKRHCKAEDKEGICHGTKCKCGVPISYL | HgeScplp1 | Free | Free | Linear | L | None | 76 | Antimicrobial | No hemolysis at 200nM | Human | Caraboctonid (Scorpion) | NA | NA | ||
| 18030427 | 2008 | KSTVGQKLKKKLNQAVDKVKEVLNKSEYMCPVVSSFCKQHCARLGKSGQCDLLECIC | HgebKTx | Free | Free | Linear | L | None | 57 | Antimicrobial | No hemolysis at 200nM | Human | Caraboctonid (Scorpion) | NA | NA | ||
| 17927208 | 2007 | FHPSLWVLIPQYIQLIRKILKSG | Conolysin-Mt | Free | Free | Linear | L | None | 23 | Cytolytic | 40% hemolysis at 1µM | Human | Derived from venom of Conus mustelinus | NA | NA | ||
| 17927208 | 2007 | FHPSLWVLIPQYIQLIRKILKSG | Conolysin-Mt | Free | Free | Linear | L | None | 23 | Cytolytic | ~90% hemolysis at 10µM | Human | Derived from venom of Conus mustelinus | NA | NA | ||
| 17884127 | 2007 | GLLDFVTGVGKDIFAQLIKQI{ct:Amid} | Ocellatin 4 | Amidation | Free | Linear | L | None | 21 | Cytolytic | HC50 =14.3 mM | Human | Derived from skin secretion of Leptodactylus ocellatus | NA | NA | ||
| 17764786 | 2007 | SIITMTKEAKLPQLWKQIACRLYNTC{cyc:N-C} | Pleurain-A1 | Free | Free | Cyclic | L | None | 26 | Antimicrobial | Little hemolysis at 200mg/ml | Human | Derived from skin secretion of Rana pleuraden | NA | NA | ||
| 17764786 | 2007 | SIITMTKEAKLPQSWKQIACRLYNTC{cyc:N-C} | Pleurain-A2 | Free | Free | Cyclic | L | None | 26 | Antimicrobial | Little hemolysis at 200mg/ml | Human | Derived from skin secretion of Rana pleuraden | NA | NA | ||
| 17764786 | 2007 | SIITMTREAKLPQLWKQIACRLYNTC{cyc:N-C} | Pleurain-A3 | Free | Free | Cyclic | L | None | 26 | Antimicrobial | Little hemolysis at 200mg/ml | Human | Derived from skin secretion of Rana pleuraden | NA | NA | ||
| 17764786 | 2007 | SIITTTKEAKLPQLWKQIACRLYNTC{cyc:N-C} | Pleurain-A4 | Free | Free | Cyclic | L | None | 26 | Antimicrobial | Little hemolysis at 200mg/ml | Human | Derived from skin secretion of Rana pleuraden | NA | NA | ||
| 17688900 | 2007 | FLSLALAALPKFLCLVFKKC | Brevinin-1DYa | Free | Free | Linear | L | None | 20 | Antimicrobial | LC50 <5µM | Human | Derived from skin of Rana dybowskii | NA | NA | ||
| 17688900 | 2007 | FLSLALAALPKLFCLIFKKC | Brevinin-1DYb | Free | Free | Linear | L | None | 20 | Antimicrobial | LC50 <5µM | Human | Derived from skin of Rana dybowskii | NA | NA | ||
| 17688900 | 2007 | FLPLLLAGLPKLLCLFFKKC | Brevinin-1DYc | Free | Free | Linear | L | None | 20 | Antimicrobial | LC50 <5µM | Human | Derived from skin of Rana dybowskii | NA | NA | ||
| 17272268 | 2007 | GFMDTAKNVAKNVAVTLLDNLKCKITKAC | Odorranain-F1 | Free | Free | Linear | L | None | 29 | Antimicrobial | 15.4±3.5% hemolysis at 50µg/ml | Human | Odorranain (Odorrana grahami) | NA | NA | ||
| 17272268 | 2007 | GLLSGTSVRGSI | Odorranain-V1 | Free | Free | Linear | L | None | 12 | Antimicrobial | 23.9±4.7% hemolysis at 50µg/ml | Human | Odorranain (Odorrana grahami) | NA | NA | ||
| 17272268 | 2007 | GLFGKSSVWGRKYYVDLAGCAKA | Odorranain-W1 | Free | Free | Linear | L | None | 23 | Antimicrobial | 17.6±2.2% hemolysis at 50µg/ml | Human | Odorranain (Odorrana grahami) | NA | NA | ||
| 17272268 | 2007 | GIFGKILGVGKKVLCGLSGVC | Odorranain-H1 | Free | Free | Linear | L | None | 21 | Antimicrobial | 21.6±7.3% hemolysis at 50µg/ml | Human | Odorranain (Odorrana grahami) | NA | NA | ||
| 17272268 | 2007 | GLLGKILGVEKKVLCGLSGMC | Nigrocin-OG2 | Free | Free | Linear | L | None | 21 | Antimicrobial | 60±7.1% hemolysis at 50µg/ml | Human | Nigrocin (Odorrana grahami) | NA | NA | ||
| 17272268 | 2007 | GLLSGILGAGKHIICGLSGLC | Nigrocin-OG4 | Free | Free | Linear | L | None | 21 | Antimicrobial | 65.5±7.7% hemolysis at 50µg/ml | Human | Nigrocin (Odorrana grahami) | NA | NA | ||
| 17272268 | 2007 | GLLSGILGAGKQKVCGLSGLC | Nigrocin-OG5 | Free | Free | Linear | L | None | 21 | Antimicrobial | 87.2±2.6% hemolysis at 50µg/ml | Human | Nigrocin (Odorrana grahami) | NA | NA | ||
| 17272268 | 2007 | GLLSGVLGVGKKVLCGLSGLC | Nigrocin-OG21 | Free | Free | Linear | L | None | 21 | Antimicrobial | 100% hemolysis at 50µg/ml | Human | Nigrocin (Odorrana grahami) | NA | NA | ||
| 17044815 | 2007 | KDRPKKPGLCPPRPQKPCVKECKNDDSCPGQQKCCNYGCKDECRDPIFVG | Omwaprin | Free | Free | Linear | L | None | 50 | Antimicrobial | 0% hemolysis upto 1 mM | Human | Derived from venom of Oxyuranus microlepidotus | NA | Non-hemolytic | ||
| 8843284 | 1996 | KFFKFFKFF | Synthetic peptide | Free | Free | Linear | L | None | 9 | Antibacterial | Strongly hemolytic at 40µg/ml | Human | Synthetic peptide | NA | NA | ||
| 8810288 | 1996 | F{d}PV{nnr:O}LF{d}PV{nnr:O}L{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = L-Ornithine | 10 | Antibacterial | 100% hemolysis at 39µg/ml | Human | Gramicidin S (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PY{d}P{cyc:N-C} | GS4 | Free | Free | Cyclic | Mix | None | 4 | Antibacterial | 100% hemolysis at >800µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PKY{d}PK{cyc:N-C} | GS6 | Free | Free | Cyclic | Mix | None | 6 | Antibacterial | 100% hemolysis at >1600µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PVKY{d}PKL{cyc:N-C} | GS8 | Free | Free | Cyclic | Mix | None | 8 | Antibacterial | 100% hemolysis at >1600µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PVKLY{d}PVKL{cyc:N-C} | GS10 | Free | Free | Cyclic | Mix | None | 10 | Antibacterial | 100% hemolysis at 67µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PVKLKY{d}PKVKL{cyc:N-C} | GS12 | Free | Free | Cyclic | Mix | None | 12 | Antibacterial | 100% hemolysis at 250µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PVKLKVY{d}PLKVKL{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antibacterial | 100% hemolysis at 6µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | Y{d}PLKVKY{d}PKLKV{cyc:N-C} | GS12LV | Free | Free | Cyclic | Mix | None | 12 | Antibacterial | 100% hemolysis at 92µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | F{d}PVKLKF{d}PKVKL{cyc:N-C} | GS12F | Free | Free | Cyclic | Mix | None | 12 | Antibacterial | 100% hemolysis at 400µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | F{d}PV{nnr:O}L{nnr:O}F{d}P{nnr:O}V{nnr:O}L{cyc:N-C} | GS12FO | Free | Free | Cyclic | Mix | O = L-Ornithine | 12 | Antibacterial | 100% hemolysis at 160µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8810288 | 1996 | F{d}PL{nnr:O}L{nnr:O}F{d}P{nnr:O}L{nnr:O}L{cyc:N-C} | GS12FO/LL | Free | Free | Cyclic | Mix | O = L-Ornithine | 12 | Antibacterial | 100% hemolysis at 170µg/ml | Human | Gramicidin S analog (Bacillus brevis) | NA | NA | ||
| 8620888 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGG | Pardaxin | Free | Free | Linear | L | None | 31 | Antibacterial | >20% hemolysis at 25µM | Human | Pardaxin (Pardachirus marmoratus) | NA | NA | ||
| 8620888 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGG | Pardaxin | Free | Free | Linear | L | None | 31 | Antibacterial | >50% hemolysis at 50µM | Human | Pardaxin (Pardachirus marmoratus) | NA | NA | ||
| 8620888 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGGQE{ct:[NH(CH2)2NH2]2} | Pardaxin- [NH(CH2)2NH2]2 | [NH(CH2)2NH2]2 | Free | Linear | L | None | 33 | Antibacterial | >100% hemolysis at 12µM | Human | Pardaxin analog (Pardachirus marmoratus) | NA | NA | ||
| 8620888 | 1996 | GFFALIPKIISSPLFKTLLSAV | Des-(23-33)-pardaxin | Free | Free | Linear | L | None | 22 | Antibacterial | >100% hemolysis at 10µM | Human | Pardaxin analog (Pardachirus marmoratus) | NA | NA | ||
| 8620888 | 1996 | GFFALIPKIISSPLFKTLLSAV{ct:[NH(CH2)2NH2]2} | Des-(23-33)-pardaxin-[NH(CH2)2NH2]2 | [NH(CH2)2NH2]2 | Free | Linear | L | None | 22 | Antibacterial | <20% hemolysis at 50µM | Human | Pardaxin analog (Pardachirus marmoratus) | NA | NA | ||
| 8620888 | 1996 | KGFFALIPKIISSPLFKTLLSAV{ct:[NH(CH2)2NH2]2} | Lys-des-(23- 33)-pardaxin-[NH(CH2)2NH2]2 | [NH(CH2)2NH2]2 | Free | Linear | L | None | 23 | Antibacterial | No hemolysis (Non hemolytic) | Human | Pardaxin analog (Pardachirus marmoratus) | NA | Non-hemolytic | ||
| 8620888 | 1996 | ISSPLFKTLLSAVGSALSSSGGQE | Des-(I -9)-pardaxin | Free | Free | Linear | L | None | 24 | Antibacterial | No hemolysis (Non hemolytic) | Human | Pardaxin analog (Pardachirus marmoratus) | NA | Non-hemolytic | ||
| 8620888 | 1996 | ISSPLFKTLLSAVGSALSSSGGQE{ct:[NH(CH2)2NH2]2} | Des-(I -9)-pardaxin-[NH(CH2)2NH2]2 | [NH(CH2)2NH2]2 | Free | Linear | L | None | 24 | Antibacterial | No hemolysis (Non hemolytic) | Human | Pardaxin analog (Pardachirus marmoratus) | NA | Non-hemolytic | ||
| 8620888 | 1996 | GFFALIPKIIS | Des-(12-33)-pardaxin | Free | Free | Linear | L | None | 11 | Antibacterial | No hemolysis (Non hemolytic) | Human | Pardaxin analog (Pardachirus marmoratus) | NA | Non-hemolytic | ||
| 8620888 | 1996 | GFFALIPKIIS{ct:[NH(CH2)2NH2]2} | Des-(I 2-33)-pardaxin-[NH(CH2)2NH2]2 | [NH(CH2)2NH2]2 | Free | Linear | L | None | 11 | Antibacterial | No hemolysis (Non hemolytic) | Human | Pardaxin analog (Pardachirus marmoratus) | NA | Non-hemolytic | ||
| 8508915 | 1993 | FLPLLAGLAANFLPKIFCKITRKC | Brevinin-1 E | Free | Free | Linear | L | None | 24 | Antimicrobial | LC50 =5µM | Human | Derived from skin secretion of Rana esculenta | NA | NA | ||
| 8508915 | 1993 | FLPVLAGIAAKVVPALFCKITKKC | Brevinin-2 E | Free | Free | Linear | L | None | 24 | Antimicrobial | LC50 >100µM | Human | Derived from skin secretion of Rana esculenta | NA | NA | ||
| 8508915 | 1993 | GIFSKLGRKKIKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC | Esculentin | Free | Free | Linear | L | None | 46 | Antimicrobial | LC50 >100µM | Human | Derived from skin secretion of Rana esculenta | NA | NA | ||
| 8508915 | 1993 | FLPAIAGILSQLF{ct:Amid} | A1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LC50 ~20µM | Human | Derived from skin secretion of Rana esculenta | NA | NA | ||
| 8045297 | 1994 | KLLLKLLKLLLKLLLKLLK{ct:Dansylation} | L13K6 | Dansylation | Free | Linear | L | None | 19 | Cytotoxic | LD50 ~2.1µM | Human | Synthetic peptide | NA | NA | ||
| 8045297 | 1994 | LLLKLLKLLLKLLLKLLK{ct:Dansylation} | L13K5 | Dansylation | Free | Linear | L | None | 18 | Cytotoxic | LD50 =4.7µM | Human | Synthetic peptide | NA | NA | ||
| 8045297 | 1994 | KLLKLLLKLLLKLLK{ct:Dansylation} | L10K5 | Dansylation | Free | Linear | L | None | 15 | Cytotoxic | LD50 ~0.1µM | Human | Synthetic peptide | NA | NA | ||
| 7989335 | 1994 | ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ | DS s1 | Free | Free | Linear | L | None | 34 | Antimicrobial | 100% hemolysis at >70µM | Human | Dermaseptin analog (Phyllomedusa sauvagii) | NA | NA | ||
| 7989335 | 1994 | ALWKTMLKKLGTMALHAGKAALGAAANTISQGTQ | DS s2 | Free | Free | Linear | L | None | 34 | Antimicrobial | 100% hemolysis at 70µM | Human | Dermaseptin analog (Phyllomedusa sauvagii) | NA | NA | ||
| 7989335 | 1994 | ALWKNMLKGIGKLAGKAALGAVKKLVGAES | DS s3 | Free | Free | Linear | L | None | 30 | Antimicrobial | 100% hemolysis at 80µM | Human | Dermaseptin analog (Phyllomedusa sauvagii) | NA | NA | ||
| 7989335 | 1994 | ALWMTLLKKVLKAAAKAALNAVLVGANA | DS s4 | Free | Free | Linear | L | None | 28 | Antimicrobial | 100% hemolysis at 1µM | Human | Dermaseptin analog (Phyllomedusa sauvagii) | NA | NA | ||
| 7989335 | 1994 | GLWSKIKTAGKSVAKAAAKAAVKAVTNAV | DS s5 | Free | Free | Linear | L | None | 29 | Antimicrobial | 100% hemolysis at >90µM | Human | Dermaseptin analog (Phyllomedusa sauvagii) | NA | NA | ||
| 19540868 | 2009 | KDGYIIEHRGCKYSCFFGTNSWCNTECTLKKGSSGYCAWPACWCYGLPDNVKIFDSNNLKC{cyc:N-C} | Bactridine 1 | Free | Free | Cyclic | L | None | 61 | Antibacterial | 0.2% hemolysis at 90µM | Human | Derived from venom of Tityus discrepans | NA | NA | ||
| 19540868 | 2009 | KDGYIIEHRGCKYSCFFGTNSWCNTECTLKKGSSGYCAWPACWCYGLPDNVKIFDSNNLKC{cyc:N-C} | Bactridine 1 | Free | Free | Cyclic | L | None | 61 | Antibacterial | 1.0% hemolysis at 180µM | Human | Derived from venom of Tityus discrepans | NA | NA | ||
| 19540868 | 2009 | KDGYLVGNDGCKYSCFTRPGTYCANECSRVKGKDGYCYAWMACYCYSMPNWVKTWNRATNRCGR{cyc:N-C} | Bactridine 2 | Free | Free | Cyclic | L | None | 64 | Antibacterial | 7.6% hemolysis at 90µM | Human | Derived from venom of Tityus discrepans | NA | NA | ||
| 19540868 | 2009 | KDGYLVGNDGCKYSCFTRPGTYCANECSRVKGKDGYCYAWMACYCYSMPNWVKTWNRATNRCGR{cyc:N-C} | Bactridine 2 | Free | Free | Cyclic | L | None | 64 | Antibacterial | 21.0% hemolysis at 180µM | Human | Derived from venom of Tityus discrepans | NA | NA | ||
| 7999137 | 1994 | SLFSLIKAGAKFLGKNLLKQGACYAACKASKQC | Gaegurin 1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0.59% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 7999137 | 1994 | GIMSIVKDVAKNAAKEAAKGALSTLSCKLAKTC | Gaegurin 2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0.82% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 7999137 | 1994 | GIMSIVKDVAKTAAKEAAKGALSTLSCKLAKTC | Gaegurin 3 | Free | Free | Linear | L | None | 33 | Antimicrobial | 1.20% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 7999137 | 1994 | GILDTLKQFAKGVGKDLVKGAAQGVLSTVSCKLALTC | Gaegurin 4 | Free | Free | Linear | L | None | 37 | Antimicrobial | 1.67% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 7999137 | 1994 | FLGALFKVASKVLPSVKCAITKKC | Gaegurin 5 | Free | Free | Linear | L | None | 24 | Antimicrobial | 1.01% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 7999137 | 1994 | FLPLLAGLAANFLPTIICKISYKC | Gaegurin 6 | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.86% hemolysis at 100µM | Human | Derived from skin of Rana rugosa | NA | NA | ||
| 8353519 | 1993 | SIGSALKKALPVAKKIGKIALPIAKAALP | Ceratotoxin A | Free | Free | Linear | L | None | 29 | Antibacterial | Area of inhibition ~25mm2 at 5 nmol | Human | Derived from secretion of the female reproductive accessory glands of Ceratitis capitata | NA | NA | ||
| 19056441 | 2009 | IFGAILPLALGALKNLIK{ct:Amid} | Hy-a1 | Amidation | Free | Linear | L | None | 18 | Antibacterial | HC50 =18µM | Human | Derived from skin secretion of Hypsiboas albopunctatus | NA | NA | ||
| 19716842 | 2010 | FLPKMSTKLRVPYRRGTKDYH | Scolopin 1 | Free | Free | Linear | L | None | 21 | Antimicrobial | 25±2% hemolysis at 50µg/ml | Human | Derived from venom of Scolopendra subspinipes mutilans | NA | NA | ||
| 19716842 | 2010 | GILKKFMLHRGTKVYKMRTLSKRSH | Scolopin 2 | Free | Free | Linear | L | None | 25 | Antimicrobial | 32±7% hemolysis at 50µg/ml | Human | Derived from venom of Scolopendra subspinipes mutilans | NA | NA | ||
| 23483218 | 2013 | LNWGAILKHIIK{ct:Amid} | PNG-1 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 =119µM | Human | Derived from venom of Panurgus calcaratus | NA | NA | ||
| 23483218 | 2013 | NLWAGILKHIIK{ct:Amid} | PNG-1/1 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | KNWGAILKHIIK{ct:Amid} | PNG-1/2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LKWGAILKHIIK{ct:Amid} | PNG-1/3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNKGAILKHIIK{ct:Amid} | PNG-1/4 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWKAILKHIIK{ct:Amid} | PNG-1/5 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 ~110µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGKILKHIIK{ct:Amid} | PNG-1/6 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >140µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAKLKHIIK{ct:Amid} | PNG-1/7 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAIKKHIIK{ct:Amid} | PNG-1/8 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAILKKIIK{ct:Amid} | PNG-1/9 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAILKHKIK{ct:Amid} | PNG-1/10 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAILKHIKK{ct:Amid} | PNG-1/11 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | KNWGKILKHIIK{ct:Amid} | PNG-1/12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | KNWKAILKHIIK{ct:Amid} | PNG-1/13 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAVLKHVVK{ct:Amid} | PNG-1/14 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGA-{nnr:Abu}-LKH-{nnr:Abu}-{nnr:Abu}-K{ct:Amid} | PNG-1/15 | Amidation | Free | Linear | L | Abu = 2-aminobutyric acid | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAALKHAAK{ct:Amid} | PNG-1/16 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAFLKHFFK{ct:Amid} | PNG-1/17 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 =81µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAGLKHGGK{ct:Amid} | PNG-1/18 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGALLKHLLK{ct:Amid} | PNG-1/19 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 =63µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGA-{nnr:Nle}-LKH-{nnr:Nle}-{nnr:Nle}-K{ct:Amid} | PNG-1/20 | Amidation | Free | Linear | L | Nle = Norleucine | 12 | Antimicrobial | LC50 =40µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGA-{nnr:Aca}-LKH-{nnr:Aca}-{nnr:Aca}-K{ct:Amid} | PNG-1/21 | Amidation | Free | Linear | L | Aca = 1-aminocyclohexane carboxylic acid | 12 | Antimicrobial | LC50 =43µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LNWGAWLKHWWK{ct:Amid} | PNG-1/22 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 =132µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LDVKKIICVACKIKPNPACKKICPK | PNG-K | Free | Free | Linear | L | None | 25 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LDVKKII-{nnr:Abu}-VA-{nnr:Abu}-KIKPNPA-{nnr:Abu}-KKI-{nnr:Abu}-PK | PNG-K/1 | Free | Free | Linear | L | Abu = 2-aminobutyric acid | 25 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LDVKKIICVACKIRPNPACKKICPK | PNG-R | Free | Free | Linear | L | None | 25 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23483218 | 2013 | LDVKKII-{nnr:Abu}-VA-{nnr:Abu}-KIRPNPA-{nnr:Abu}-KKI-{nnr:Abu}-PK | PNG-R/1 | Free | Free | Linear | L | Abu = 2-aminobutyric acid | 25 | Antimicrobial | LC50 >200µM | Human | Panurgine analog (PNG-I) | NA | NA | ||
| 23562719 | 2013 | KAYSMPRCKGGFRAVMCWL{ct:Amid} | Shuchin 3 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 1.7% hemolysis at 200µg/ml | Human | Derived from skin of Rana shuchinae | NA | NA | ||
| 23562719 | 2013 | KAYSTPRCKGLFRALMCWL{ct:Amid} | Shuchin 4 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 2.5% hemolysis at 200µg/ml | Human | Derived from skin of Rana shuchinae | NA | NA | ||
| 23562719 | 2013 | KAYSTPRCKYLFRAVLCWL{ct:Amid} | Shuchin 5 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 1.5% hemolysis at 200µg/ml | Human | Derived from skin of Rana shuchinae | NA | NA | ||
| 12354111 | 2002 | GKVWDWIKSTAKKLWNSEPVKELKNTALNAAKNLVAEKIGATPS | Opistoporin 1 | Free | Free | Linear | L | None | 44 | Antibacterial and Antifungal | 30% hemolysis at 100µM | Human | Opistoporin (Opistophtalmus carinatus) | NA | NA | ||
| 12354111 | 2002 | FKLGSFLKKAWKSKLAKKLRAKGKEMLKDYAKGLLEGGSEEVPGQ | Parabutoporin | Free | Free | Linear | L | None | 45 | Antibacterial and Antifungal | <10% hemolysis upto 5µM | Human | Parabutoporin (Opistophtalmus carinatus) | NA | NA | ||
| 12354111 | 2002 | FKLGSFLKKAWKSKLAKKLRAKGKEMLKDYAKGLLEGGSEEVPGQ | Parabutoporin | Free | Free | Linear | L | None | 45 | Antibacterial and Antifungal | 50% hemolysis at 38µM | Human | Parabutoporin (Opistophtalmus carinatus) | NA | NA | ||
| 12354111 | 2002 | INLKALAALAKKIL | Mastoparan | Free | Free | Linear | L | None | 14 | Antibacterial and Antifungal | ~10% hemolysis at 100µM | Human | Mastoparan (wasp) | NA | NA | ||
| 15639237 | 2005 | GLGSVFGRLARILGRVIPKV{ct:Amid} | Peptide P1 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 20% hemolysis at 10µM | Human | Pilosulin 1 analog(Myrmecia pilosula) | NA | NA | ||
| 15639237 | 2005 | GLGSVFGRLARILGRVIPKV{ct:Amid} | Peptide P1 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 100% hemolysis at 100µM | Human | Pilosulin 1 analog(Myrmecia pilosula) | NA | NA | ||
| 15639237 | 2005 | GLLSKFGRLARKLARVIPKV{ct:Amid} | Peptide P2 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 15% hemolysis at 10µM | Human | Pilosulin 1 analog(Myrmecia pilosula) | NA | NA | ||
| 15639237 | 2005 | GLLSKFGRLARKLARVIPKV{ct:Amid} | Peptide P2 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 40% hemolysis at 100µM | Human | Pilosulin 1 analog(Myrmecia pilosula) | NA | NA | ||
| 10606532 | 1999 | KWL{d}L{d}LLKL{d}LL{d}LK{ct:Amid} | [D]L3,4,8,10-K3L8Wn | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 31% hemolysis at 50μM | Human | Synthetic peptide | NA | NA | ||
| 10606532 | 1999 | KLL{d}L{d}LWKL{d}LL{d}LK{ct:Amid} | [D]L3,4,8,10-K3L8Wm | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 39.4% hemolysis at 50μM | Human | Synthetic peptide | NA | NA | ||
| 10606532 | 1999 | KLL{d}L{d}LLKL{d}LL{d}WK{ct:Amid} | [D]L3,4,8,10-K3L8Wc | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 44.2% hemolysis at 50μM | Human | Synthetic peptide | NA | NA | ||
| 10606532 | 1999 | KWL{d}L{d}KLKL{d}KL{d}LK{ct:Amid} | [D]L3,4,8,10-K5L6Wn | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM (Non hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KLL{d}L{d}KWKL{d}KL{d}LK{ct:Amid} | [D]L3,4,8,10-K5L6Wm | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM (Non hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KLL{d}L{d}KLKL{d}KL{d}WK{ct:Amid} | [D]L3,4,8,10-K5L6Wc | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM (Non hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KKWL{d}KLKL{d}KL{d}KK{ct:Amid} | [D]L4,8,10-K7L4Wn | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM (Non hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KKL{d}L{d}KWKL{d}KL{d}KK{ct:Amid} | [D]L3,4,8,10-K7L4Wm | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM (Non hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KKL{d}L{d}KLKL{d}KW{d}KK{ct:Amid} | [D]L3,4,8-K7L4Wc | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM (Non hemolytic) | Human | Synthetic peptide | NA | Non-hemolytic | ||
| 14636071 | 2003 | GALRGCWTKSYPPKPCK{cyc:N-C}{ct:Amid} | Ranacyclin T | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | 20% hemolysis at 100μM | Human | Derived from skin secretion of Rana temporaria | NA | NA | ||
| 14636071 | 2003 | SAPRGCWTKSYPPKPCK{cyc:N-C}{ct:Amid} | Ranacyclin E | Amidation | Free | Cyclic | L | None | 17 | Antimicrobial | 55% hemolysis at 100μM | Human | Derived from skin secretion of Rana esculenta | NA | NA | ||
| 14636071 | 2003 | LVRGCWTKSYPPKPCFVR{cyc:N-C} | pLR | Free | Free | Cyclic | L | None | 18 | Antimicrobial | 85% hemolysis at 100μM | Human | Derived from skin of Rana pipiens | NA | NA | ||
| 15996769 | 2005 | FLSSIGKILGNLL{ct:Amid} | Temporin-1Va | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 =120μM | Human | Derived from skin secretion of Rana virgatipes | NA | NA | ||
| 15996769 | 2005 | FLSIIAKVLGSLF{ct:Amid} | Temporin-1Vb | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 =30μM | Human | Derived from skin secretion of Rana virgatipes | NA | NA | ||
| 15996769 | 2005 | FLPLVTMLLGKLF{ct:Amid} | Temporin-1Vc | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 =30μM | Human | Derived from skin secretion of Rana virgatipes | NA | NA | ||
| 19635516 | 2009 | IPPFIKKVLTTVF{ct:Amid} | Temporin-CPa | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 =220μM | Human | Derived from skin secretions of Lithobates capito | NA | NA | ||
| 20656059 | 2010 | GMASKAGSIVGKIKIALGAL | PGLa-B2 | Free | Free | Linear | L | None | 20 | Antimicrobial | 27% hemolysis at 200μM | Human | Peptide glycine–leucine-amide (Xenopus borealis) | NA | NA | ||
| 20656059 | 2010 | GLGSLLGKAFKIGLKTVGKMMGGAPREQ | CPF-B1 | Free | Free | Linear | L | None | 25 | Antimicrobial | 18% hemolysis at 200μM | Human | Caerulein-precursor fragments (Xenopus borealis) | NA | NA | ||
| 9010936 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGEQE | PX | Free | Free | Linear | L | None | 33 | Antimicrobial | 100% hemolysis at 14μg/ml | Human | Derived from the amino terminal region of the toxin pardaxin | NA | NA | ||
| 9010936 | 1996 | GFFALIPKIISSPLFKTL{ct:Amid} | 18P | Amidation | Free | Linear | L | None | 18 | Antimicrobial | No hemolysis (Non hemolytic) | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 9010936 | 1996 | GFFALIAKIISSPLFKTL{ct:Amid} | 18A | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 100% hemolysis at 33μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 9010936 | 1996 | GFFALIAQIISSPLFQTL{ct:Amid} | 18Q | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 100% hemolysis at 56μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 9108731 | 1996 | GFFALIPKIISSPLFKTLLSAVGSALSSSGEQE | PX1–33 | Free | Free | Linear | L | None | 33 | Cytolytic | Conc. Required for hemolysis =1.75nmols | Human | Synthetic Peptide | NA | NA | ||
| 9108731 | 1996 | GFFALIAKIISSPLFKTLLSAVGSALSSSGEQE | PX1–33 (P7A) | Free | Free | Linear | L | None | 33 | Cytolytic | Conc. Required for hemolysis =0.6nmols | Human | Synthetic Peptide | NA | NA | ||
| 9108731 | 1996 | GFFALIPKIISSPLFKTLLSAVGSAL | PX1–26 | Free | Free | Linear | L | None | 26 | Cytolytic | Conc. Required for hemolysis =1.1nmols | Human | Synthetic Peptide | NA | NA | ||
| 9108731 | 1996 | GFFALIPKIISSPLFKTL{ct:Amid} | PX1–18 | Amidation | Free | Linear | L | None | 18 | Cytolytic | No hemolysis (Non hemolysis) | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 9108731 | 1996 | GFFALIAKIISSPLFKTL{ct:Amid} | PX1–18 (P7A) | Amidation | Free | Linear | L | None | 18 | Cytolytic | Conc. Required for hemolysis =7.1nmols | Human | Synthetic Peptide | NA | NA | ||
| 9204560 | 1997 | F{d}R{d}L{d}K{d}F{d}H{d} | 66-10 | Free | Free | Linear | D | None | 6 | Antimicrobial | 0% hemolysis at 312 to 0μg/ml | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 9395500 | 1997 | HALWKNMLKGIGKLAGKAALGAVKKLVGAES | DS3 | Free | Free | Linear | L | None | 31 | Cytotoxic | 50% hemolysis at 50μM | Human | Dermaseptin | NA | NA | ||
| 9395500 | 1997 | HALWMTLLKKVLKAAAKAALNAVLVGANA | DS4 | Free | Free | Linear | L | None | 29 | Cytotoxic | 2.6% hemolysis at 10μM | Human | Analog of Dermaseptin | NA | NA | ||
| 9518597 | 1998 | {nnr:Aib}-P-{nnr:Aib}-A-{nnr:Aib}-AQ-{nnr:Aib}-V-{nnr:Aib}-GL-{nnr:Aib}-PV-{nnr:Aib}-{nnr:Aib}-EQ{nt:Acet}{ct:Phenol} | Alam-P14 | Phenol | Acetylation | Linear | L | Aib = α- methylalanine | 19 | Cytolytic | EC50 =30μM | Human | Alamethicin | NA | NA | ||
| 9639668 | 1998 | GVVKVSRLKGESLRARL | bPaAP | Free | Free | Linear | L | None | 17 | Antimicrobial | 0.42% hemolysis at 200μg/ml | Human | Isolated from the stomach of the bullfrog, Rana catesbeiana | NA | NA | ||
| 9639668 | 1998 | IIKVPLKKFKSMREVMRDHGIKAPVVDPATKY | bPcAP | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.36% hemolysis at 200μg/ml | Human | Isolated from the stomach of the bullfrog, Rana catesbeiana | NA | NA | ||
| 9639668 | 1998 | AVVKVPLKKFKSIRE | mPcAP | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.40% hemolysis at 200μg/ml | Human | Isolated from the stomach of the bullfrog, Rana catesbeiana | NA | NA | ||
| 9639668 | 1998 | AVVKVPLKKFKSIRETMKEKGLLEDF | hPcAP | Free | Free | Linear | L | None | 26 | Antimicrobial | 0.49% hemolysis at 200μg/ml | Human | Isolated from the stomach of the bullfrog, Rana catesbeiana | NA | NA | ||
| 9756752 | 1998 | KKVVFKVKFK{ct:Amid} | KSL | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 0% hemolysis at 500μg/ml | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 9784609 | 1998 | FSKYERQKDKRPYSERKNQYTG | Lumbricin I | Free | Free | Linear | L | None | 22 | Antimicrobial | 0.02% hemolysis at 5μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9784609 | 1998 | FSKYERQKDKRPYSERKNQYTG | Lumbricin I | Free | Free | Linear | L | None | 22 | Antimicrobial | 0.06% hemolysis at 10μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9784609 | 1998 | FSKYERQKDKRPYSERKNQYTG | Lumbricin I | Free | Free | Linear | L | None | 22 | Antimicrobial | 0.14% hemolysis at 25μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9784609 | 1998 | FSKYERQKDKRPYSERKNQYTG | Lumbricin I | Free | Free | Linear | L | None | 22 | Antimicrobial | 0.19% hemolysis at 50μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9784609 | 1998 | FSKYERQKDKRPYSERKNQYTG | Lumbricin I | Free | Free | Linear | L | None | 22 | Antimicrobial | 0.23% hemolysis at 100μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.03% hemolysis at 5μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.07% hemolysis at 10μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.13% hemolysis at 25μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.17% hemolysis at 50μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9784609 | 1998 | RQKDKRPYSERKNQYTGPQFLYPPERIPP | Lumbricin I(6-34) | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.21% hemolysis at 100μg/ml | Human | Lumbricus rubellus | NA | NA | ||
| 9824303 | 1998 | KGRGKQGGKVRAKAKTRSS | Parasin I | Free | Free | Linear | L | None | 19 | Antimicrobial | 0.2% hemolysis at 200μg/ml | Human | Parasilurus asotus | NA | NA | ||
| 9889358 | 1998 | KLLLK{nt:Dansylation}{ct:Amid} | DnsLK5NH2 | Amidation | Dansylation | Linear | L | None | 5 | Cytotoxin | LD50 =90μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9889358 | 1998 | KLLLKLLLK{nt:Dansylation} | DnsLK9 | Free | Dansylation | Linear | L | None | 9 | Cytotoxin | LD50 =4.5 μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9889358 | 1998 | KLLLKLLLK{nt:Dansylation}{ct:Amid} | DnsLK9 | Amidation | Dansylation | Linear | L | None | 9 | Cytotoxin | LD50 =2.5 μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9889358 | 1998 | KLLKLLLKLLKLLLKLLLKLLK{nt:Dansylation} | DnsLK22 | Free | Dansylation | Linear | L | None | 22 | Cytotoxin | LD50 =0.3 μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9889358 | 1998 | KLLKLLLKLLKLLLKLLLKLLK{nt:Dansylation}{ct:Amid} | DnsLK22 | Amidation | Dansylation | Linear | L | None | 22 | Cytotoxin | LD50 =0.1 μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9889358 | 1998 | KLLKLLLKLLLKLLK | LK15 | Free | Free | Linear | L | None | 15 | Cytotoxin | LD50 =0.8 μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9889358 | 1998 | KLLKLLLKLLLKLLK{nt:Dansylation} | DnsLK15 | Free | Dansylation | Linear | L | None | 15 | Cytotoxin | LD50 =0.3 μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9889358 | 1998 | LKLLLLKLLKLKLWK | r-LK15 | Free | Free | Linear | L | None | 15 | Cytotoxin | LD50 =5 μM | Human | Synthetic Peptide | α-Helix | NA | ||
| 9914515 | 1999 | GFFALIPKIISSPLFKTLLSAV{ct:NH(CH2)2NH2} | Par[1-22] | NH(CH2)2NH2 | Free | Linear | L | None | 22 | Antimicrobial | 22% hemolysis at 50μM | Human | Synthetic Peptide | NA | NA | ||
| 9914515 | 1999 | GFFALIP{d}KIISSPLFKTL{d}L{d}SAV{ct:NH(CH2)2NH2} | [D]-P7L18,19-Par[1-22] | NH(CH2)2NH2 | Free | Linear | Mix | None | 22 | Antimicrobial | 1% hemolysis at 50μM | Human | Synthetic Peptide | NA | NA | ||
| 9914515 | 1999 | KGFFALIP{d}KIISSPLFKTL{d}L{d}SAV{ct:NH(CH2)2NH2} | K1[D]-P7L18,19-Par[1-22] | NH(CH2)2NH2 | Free | Linear | Mix | None | 23 | Antimicrobial | 0% hemolysis at 50μM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 10224074 | 1999 | VOLF{d}PVOLF{d}P{cyc:N-C} | GS | Free | Free | Cyclic | Mix | None | 10 | Antimicrobial | 100% hemolysis at 12.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 1.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14V10 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 6.2μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKL{d}KVY{d}PLKVKLY{d}P{cyc:N-C} | GS14L3 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 12.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLY{d}P{d}{cyc:N-C} | GS14P14 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 6.2μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}P{d}LKVKLY{d}P{cyc:N-C} | GS14P7 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 12.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | V{d}KLKVYPLKVKLY{d}P{cyc:N-C} | GS14V1 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 40μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKL{d}Y{d}P{cyc:N-C} | GS14L12 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 25μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKV{d}Y{d}PLKVKLY{d}P{cyc:N-C} | GS14V5 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 150μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVKLYP{cyc:N-C} | GS14Y13 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 12.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PL{d}KVKLY{d}P{cyc:N-C} | GS14L8 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 50μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVYPLKVKLY{d}P{cyc:N-C} | GS14Y6 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 25μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VK{d}LKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 50μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLK{d}VKLY{d}P{cyc:N-C} | GS14K9 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VKLKVY{d}PLKVK{d}LY{d}P{cyc:N-C} | GS14K11 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at 150μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VK{d}LK{d}VY{d}PLKVKLY{d}P{cyc:N-C} | GS14K2K4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at >200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10224074 | 1999 | VK{d}LK{d}VY{d}PLK{d}VK{d}LY{d}P{cyc:N-C} | GS14K2K4K9K11 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | 100% hemolysis at >200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 10421892 | 1999 | WNPFKELERAGQRIRDSIISAAP | Cecropin D1 | Free | Free | Linear | L | None | 23 | Antimicrobial | 0% hemolysis at 100μg/ml | Human | Cecropin D (Agrius convolvuli) | NA | Non-hemolytic | ||
| 10421892 | 1999 | WNPFKELERAGQRVRDAIISAAP | Cecropin D2 | Free | Free | Linear | L | None | 23 | Antimicrobial | 0% hemolysis at 100μg/ml | Human | Cecropin D (Agrius convolvuli) | NA | Non-hemolytic | ||
| 10424354 | 1999 | KWKLFKKIGIGKFLHSAKKF{ct:Amid} | CA(1-8) – MA(1-12) | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 25μM | Human | Cecropia moth | NA | Non-hemolytic | ||
| 10424354 | 1999 | KWKLFKKIGIGKFLHSAKKF{ct:Amid} | CA(1-8) – MA(1-12) | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 100μM | Human | Cecropia moth | NA | Non-hemolytic | ||
| 10424354 | 1999 | KWKLFKKIGIGAVLKVLTTG{ct:Amid} | CA(1-8) - ME(1-12) | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 3.1% hemolysis at 25μM | Human | Cecropia moth | NA | NA | ||
| 10424354 | 1999 | KWKLFKKIGIGAVLKVLTTG{ct:Amid} | CA(1-8) - ME(1-12) | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 15.5% hemolysis at 100μM | Human | Cecropia moth | NA | NA | ||
| 11318033 | 2001 | QL{d}LVDL{d}I{cyc:N-C} | Lichenysin | Free | Free | Cyclic | Mix | None | 7 | Chelating agent | 100% hemolysis at 15μM | Human | Bacillus licheniformis | NA | NA | ||
| 15996769 | 2005 | FLSSIGKILGNLL{ct:Amid} | Temporin-1Va | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 =120μM | Human | R. catesbeiana, R. clamitans, R. grylio and R. Septentrionalis | NA | NA | ||
| 15996769 | 2005 | FLSIIAKVLGSLF{ct:Amid} | Temporin-IVb | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 =30μM | Human | R. catesbeiana, R. clamitans, R. grylio and R. Septentrionalis | NA | NA | ||
| 15996769 | 2005 | FLPLVTMLLGKLF{ct:Amid} | Temporin-1Vc | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LD50 =30μM | Human | R. catesbeiana, R. clamitans, R. grylio and R. Septentrionalis | NA | NA | ||
| 18568863 | 2008 | FKRLEKLFSKIWNWK{ct:Amid} | A3-NT | Amidation | Free | Linear | L | None | 15 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | RWCVYAYVRVRGVLVRYRRCW | Arenicin-1 (AR-1) | Free | Free | Linear | L | None | 21 | Antimicrobial | MHC >1μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | RWSVYAYVRVRGVLVRYRRSW | AR-1-S | Free | Free | Linear | L | None | 21 | Antimicrobial | MHC >1μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | GKPRPYSPRPTSHPRPIRV | Drosocin | Free | Free | Linear | L | None | 19 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | LNLKGIFKKVASLLT | Euminitin | Free | Free | Linear | L | None | 15 | Antimicrobial | MHC <1000μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | RVKRVWPLVIRTVIAGYNLYRAIKKK | Fowlicidin-1 | Free | Free | Linear | L | None | 26 | Antimicrobial | MHC =1->440μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P | GS | Free | Free | Linear | Mix | O = L-Ornithine | 10 | Antimicrobial | MHC =12.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | VKLKVY{d}PLKVKLY{d}P | GS14 | Free | Free | Linear | Mix | None | 14 | Antimicrobial | MHC =1.5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | VKLK{d}VY{d}PLKVKLY{d}P | GS14K4 | Free | Free | Linear | Mix | None | 14 | Antimicrobial | MHC =200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | AKLK{d}AY{d}PLKAKLY{d}P | GS14K4 V3/A3 | Free | Free | Linear | Mix | None | 14 | Antimicrobial | MHC >800μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC =25μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | IL-({nnr:Nlys})-WKW-({nnr:Nlys})-WW-({nnr:Nlys})-WRR{ct:Amid} | Indolicidin Ink | Amidation | Free | Linear | L | Nlys = Nlys | 13 | Antimicrobial | MHC >200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS | K9CATH | Free | Free | Linear | L | None | 38 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | GVVDILKGAAKDLAGHLATKVMNKL | Laticeptin | Free | Free | Linear | L | None | 25 | Antimicrobial | MHC <400μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | LEKGLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL | LEK-45 | Free | Free | Linear | L | None | 45 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | MHC ~100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | KILRGVSKKIMRTFLRRILTGKK | NK23c | Free | Free | Linear | L | None | 23 | Antimicrobial | MHC <10μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | GLLSGILGAGKHIVCGLTGCAKA | Odorranain-NR | Free | Free | Linear | L | None | 23 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | KWKKLLKKPLLKKLLKKL{ct:Amid} | P5 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | KWKKLLKKPLLKK{ct:Amid} | P10 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | KWKKPLLKKLLKKL{ct:Amid} | P11 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | KKTWWKTWWTKWSQPKKKRKV | Pep-1-K | Free | Free | Linear | L | None | 21 | Antimicrobial | MHC >200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | GLGSVFGRLARIGRVIPKV{ct:Amid} | Pilosulin P1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | MHC <10μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | GLLSKFGRLARKLARVIPKV{ct:Amid} | Pilosulin P2 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | MHC <10μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | HNKQEGRDHDKSKGHFHRVVIHHKGGKAH | SgI-29 | Free | Free | Linear | L | None | 29 | Antimicrobial | MHC >200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | SSLLEKGLDGAKKAVGGLGKLGK | SSL-23 | Free | Free | Linear | L | None | 22 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | SSLLEKGLDGAKKAVGGLGKLGKDA | SSL-25 | Free | Free | Linear | L | None | 25 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | SSLLEKGLDGAKKAVGGLGKLGKDAVEDL | SSL-29 | Free | Free | Linear | L | None | 29 | Antimicrobial | MHC >100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | VRRFPWWWPFLRR{ct:Amid} | TP | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC >5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | VRRFPWWWPFLRR{ct:Amid} | TP | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC =50μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | VRRF-({nnr:Nphe})-WWW-({nnr:Nphe})-FLRR{ct:Amid} | TPf | Amidation | Free | Linear | L | Nphe = Nphe | 13 | Antimicrobial | MHC >1μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | VRRF-({nnr:Nlys})-WWW-({nnr:Nlys})-FLRR{ct:Amid} | TPk | Amidation | Free | Linear | L | Nlys = Nlys | 13 | Antimicrobial | MHC >200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | VRRFKWWWKFLRR{ct:Amid} | TPK | Amidation | Free | Linear | L | None | 13 | Antimicrobial | MHC >5μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | VRRF-({nnr:Nleu})-WWW-({nnr:Nleu})-FLRR{ct:Amid} | TPl | Amidation | Free | Linear | L | Nleu = Nleu | 13 | Antimicrobial | MHC >1μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | KKFPWWWPFKK{ct:Amid} | Tritrpticin STP | Amidation | Free | Linear | L | None | 11 | Antimicrobial | MHC =100μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | KKF-({nnr:Nlys})-WWW-({nnr:Nlys})-FKK{ct:Amid} | Tritrpticin STPk | Amidation | Free | Linear | L | Nlys = Nlys | 11 | Antimicrobial | MHC >200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | KWKSFLKTFKSAAKTVLHTALKAISS{nt:Acet}{ct:Amid} | V13AD | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =31.3μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | KWKSFLKTFKSAVKTVLHTALKAISS{nt:Acet}{ct:Amid} | V681 | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | MHC =7.8μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18568863 | 2008 | K{d}W{d}K{d}S{d}F{d}L{d}K{d}T{d}F{d}K{d}S{d}A{d}V{d}K{d}T{d}V{d}L{d}H{d}T{d}A{d}L{d}K{d}A{d}I{d}S{d}S{d}{nt:Acet}{ct:Amid} | DV681 | Amidation | Acetylation | Linear | D | None | 26 | Antimicrobial | MHC =7.8μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18723059 | 2008 | FMPIIGRLMSGSL | VESP-VB1 | Free | Free | Linear | L | None | 13 | Antimicrobial | 3.2% hemolysis up to 200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18723059 | 2008 | INMKASAAVAKKLL | MP-VB1 | Free | Free | Linear | L | None | 14 | Antimicrobial | 2.7% hemolysis at 200μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 18855761 | 2008 | KWKLFKKIPKFLHLAKKF{ct:Amid} | P18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | MHC =50μM | Human | Synthetic Peptide | NA | NA | ||
| 18855761 | 2008 | KKKLFWKIPKFLHLAKKF{ct:Amid} | P18-W6 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | MHC <200μM | Human | Synthetic Peptide | NA | NA | ||
| 18855761 | 2008 | KIKLFKKWPKFLHLAKKF{ct:Amid} | P18-W8 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | MHC =200μM | Human | Synthetic Peptide | NA | NA | ||
| 18855761 | 2008 | KAKLFKKIPKFLHLWKKF{ct:Amid} | P18-W15 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | MHC =200μM | Human | Synthetic Peptide | NA | NA | ||
| 18855761 | 2008 | KWKLFKKI-{nnr:Nala}-KFLHLAKKF{ct:Amid} | P18-Nala9 | Amidation | Free | Linear | L | Nala = Nala | 18 | Antimicrobial | MHC =200μM | Human | Synthetic Peptide | NA | NA | ||
| 18855761 | 2008 | KWKLFKKIP{d}KFLHLAKKF{ct:Amid} | P18-D-Pro | Amidation | Free | Linear | L | None | 18 | Antimicrobial | MHC <200μM | Human | Synthetic Peptide | NA | NA | ||
| 8910461 | 1996 | GRFKRFRKKFKKLFKKLSPVIPLLHLG | BMAP-27 | Free | Free | Linear | L | None | 27 | Antimicrobial | 3% hemolysis at 10μM | Human | Cathelicidins (Zanetti, M., Gennaro, R., and Romeo,D.) | NA | NA | ||
| 8910461 | 1996 | GRFKRFRKKFKKLFKKLSPVIPLLHLG | BMAP-27 | Free | Free | Linear | L | None | 27 | Antimicrobial | 6% hemolysis at 30μM | Human | Cathelicidins (Zanetti, M., Gennaro, R., and Romeo,D.) | NA | NA | ||
| 8910461 | 1996 | GRFKRFRKKFKKLFKKLSPVIPLLHLG | BMAP-27 | Free | Free | Linear | L | None | 27 | Antimicrobial | 22% hemolysis at 100μM | Human | Cathelicidins (Zanetti, M., Gennaro, R., and Romeo,D.) | NA | NA | ||
| 8910461 | 1996 | GGLRSLGRKILRAWKKYGPIIVPIIRIG | BMAP-28 | Free | Free | Linear | L | None | 28 | Antimicrobial | 0% hemolysis at 100μM | Human | Cathelicidins (Zanetti, M., Gennaro, R., and Romeo,D.) | NA | Non-hemolytic | ||
| 16441062 | 2005 | CAESCVWIPCTVTALLGCSCSNNVCYNGIP{cyc:N-C} | Cycloviolacin H4 | Free | Free | Cyclic | L | None | 30 | HIV inhibitory, Antimicrobial, Cytotoxic, Neurotensin antagonistic, Trypsin inhibitory, Insecticide | HD50 =5.5μM | Human | Viola hederaceae | NA | NA | ||
| 16488428 | 2006 | SAISCGETCFKFKCYTPRCSCSYPVCK{cyc:N-C} | Violacin A | Free | Free | Cyclic | L | None | 27 | Uterotonic, Insecticidal, Anti-HIV, Antimicrobial, Anti-neurotensive, Cytotoxic and Hemolytic | 30% hemolysis at 1.5μM | Human | Synthetic Peptide | NA | NA | ||
| 10600388 | 1999 | CAESCVYIPCTVTALLGCSCSNRVCYNGIP{cyc:N-C} | Cycloviolacin O1 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISSAIGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin O2 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCLTSAIGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin O3 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISSAIGCSCKNKVCYRNGIP{cyc:N-C} | Cycloviolacin O4 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISSAVGCSCKNKVCYKNGTP{cyc:N-C} | Cycloviolacin O5 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISAAVGCSCKSKVCYKNGTLP{cyc:N-C} | Cycloviolacin O6 | Free | Free | Cyclic | L | None | 31 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCTITALAGCKCKSKVCYNSIP{cyc:N-C} | Cycloviolacin O7 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CESCVWIPCISSVVGCSCKSKVCYKNGTLP{cyc:N-C} | Cycloviolacin O8 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCLTSAVGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin O9 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVYIPCLTSAVGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin O10 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISAVVGCSCKSKVCYKNGTLP{cyc:N-C} | Cycloviolacin O11 | Free | Free | Cyclic | L | None | 31 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVYIPCLTSAIGCSCKSKVCYRNGIP{cyc:N-C} | Cycloviolacin H1 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVYIPCISGVIGCSCTDKVCYLNGTP{cyc:N-C} | Kalata B5 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVWIPCISAALGCSCKNKVCYRNGIP{cyc:N-C} | Circulin A | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVFIPCISTLLGCSCKNKVCYRNGVIP{cyc:N-C} | Circulin B | Free | Free | Cyclic | L | None | 31 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | CGESCVFIPCVTALLGCSCKSKVCYKNSIP{cyc:N-C} | Cyclopsychotride A | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | VCGETCVGGTCNTPGCSCSRPVCTRNGLP{cyc:N-C} | Violapeptide I | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | ICGETCVGGTCNTPGCSCSWPVCTRNGLP{cyc:N-C} | Cycloviolacin O12 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | VCGETCFGGTCNTPGCSCTWPICTRDGLP{cyc:N-C} | Kalata B2 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | TCGETCFGGTCNTPGCTCDPWPICTDRGLP{cyc:N-C} | Kalata B3 | Free | Free | Cyclic | L | None | 30 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | VCGETCVGGTCNTPGCTCSWPVCTRDGLP{cyc:N-C} | Kalata B4 | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 50% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 10600388 | 1999 | VCGETCEGGTCNTPGCSCSWPVCTRNGLP{cyc:N-C} | Kalata S | Free | Free | Cyclic | L | None | 29 | Anti-HIV | 51% hemolysis at ~20μM | Human | Cyclic cystine knot (Viola hederaceae, Viola odorata and Oldenlandia afrnis) | NA | NA | ||
| 17561225 | 2007 | GLWSKIKEAAKAAGKAALNAVTGLVNQGDQPS | Dermaseptin-L1 | Free | Free | Linear | L | None | 32 | Antimicrobial | LC50 =200μM | Human | Skin secretions of the lemur leaf frog Hylomantis lemur | NA | NA | ||
| 17561225 | 2007 | LLGMIPLAISAISALSKL{ct:Amid} | Phylloseptin-L1 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | LC50 =40μM | Human | Skin secretions of the lemur leaf frog Hylomantis lemur | NA | NA | ||
| 21644248 | 2011 | KSLRPRCWIKIKFRCKSLKF | P1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0.7% hemolysis at 0.0625mg/ml | Human | Piceain 1 (Picea sitchensis) | NA | NA | ||
| 21644248 | 2011 | KSLRPRCWIKIKFRCKSLKF | P1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0.8% hemolysis at 0.125mg/ml | Human | Piceain 1 (Picea sitchensis) | NA | NA | ||
| 21644248 | 2011 | KSLRPRCWIKIKFRCKSLKF | P1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 5.9% hemolysis at 0.25mg/ml | Human | Piceain 1 (Picea sitchensis) | NA | NA | ||
| 21644248 | 2011 | KSLRPRCWIKIKFRCKSLKF | P1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 7.6% hemolysis at 0.5mg/ml | Human | Piceain 1 (Picea sitchensis) | NA | NA | ||
| 21644248 | 2011 | KSLRPRCWIKIKFRCKSLKF | P1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 7.8% hemolysis at 1mg/ml | Human | Piceain 1 (Picea sitchensis) | NA | NA | ||
| 21644248 | 2011 | RPRCWIKIKFRCKSLKF | P2 | Free | Free | Linear | L | None | 17 | Antimicrobial | 0.6% hemolysis at 0.0625mg/ml | Human | Piceain 2 (Picea sitchensis) | NA | NA | ||
| 21644248 | 2011 | RPRCWIKIKFRCKSLKF | P2 | Free | Free | Linear | L | None | 17 | Antimicrobial | 0.8% hemolysis at 0.125mg/ml | Human | Piceain 2 (Picea sitchensis) | NA | NA | ||
| 21644248 | 2011 | RPRCWIKIKFRCKSLKF | P2 | Free | Free | Linear | L | None | 17 | Antimicrobial | 5.2% hemolysis at 0.25mg/ml | Human | Piceain 2 (Picea sitchensis) | NA | NA | ||
| 21644248 | 2011 | RPRCWIKIKFRCKSLKF | P2 | Free | Free | Linear | L | None | 17 | Antimicrobial | 5.3% hemolysis at 0.5mg/ml | Human | Piceain 2 (Picea sitchensis) | NA | NA | ||
| 21644248 | 2011 | RPRCWIKIKFRCKSLKF | P2 | Free | Free | Linear | L | None | 17 | Antimicrobial | 11.3% hemolysis at 1mg/ml | Human | Piceain 2 (Picea sitchensis) | NA | NA | ||
| 16675060 | 2006 | AVDLAKIANKVLSSLF{ct:Amid} | Temporin-1TGb | Amidation | Free | Linear | L | None | 16 | Antimicrobial | LD50 =250μM | Human | Extradermal tissues of Tago’s brown frog Rana tagoi | NA | NA | ||
| 16675060 | 2006 | FLPVILPVIGKLLSGIL{ct:Amid} | Temporin-1TGc | Amidation | Free | Linear | L | None | 17 | Antimicrobial | LD50 =50μM | Human | Extradermal tissues of Tago’s brown frog Rana tagoi | NA | NA | ||
| 12804591 | 2003 | FLPILGKLLSGIL{ct:Amid} | MRP | Amidation | Free | Linear | L | None | 10 | Antimicrobial | LC50 = 8μM | Human | Rana tagoi | NA | NA | ||
| 14531844 | 2003 | FLPILASLAAKFGPKLFCLVTKKC | Brevinin-1BYa | Free | Free | Linear | L | None | 24 | Antimicrobial | HC50 = 4μM | Human | Rana boylii | NA | NA | ||
| 14531844 | 2003 | FLPILASLAAKLGPKLFCLVTKKC | Brevinin-1BYb | Free | Free | Linear | L | None | 24 | Antimicrobial | HC50 = 4μM | Human | Rana boylii | NA | NA | ||
| 14531844 | 2003 | GILSTFKGLAKGVAKDLAGNLLDKFKCKITGC | Ranatuerin-2BYa | Free | Free | Linear | L | None | 32 | Antimicrobial | HC50 = 120μM | Human | Rana boylii | NA | NA | ||
| 14531844 | 2003 | GIMDSVKGLAKNLAGKLLDSLKCKITGC | Ranatuerin-2BYb | Free | Free | Linear | L | None | 28 | Antimicrobial | HC50 >200μM | Human | Rana boylii | NA | NA | ||
| 15885852 | 2005 | GFMKYIGPLIPHAVKAISDLI{ct:Amid} | Kassinatuerin-1 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | LD50 =65μM | Human | Skin of the African frog Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | IPHAVKAISDLI{ct:Amid} | Kassinatuerin-1 (10-21)fragment | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0% hemolysis at 400μM | Human | Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | GFMKYIGPLIPHKVKAISDLI{ct:Amid} | Kassinatuerin-1 (Lys13) | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 32% hemolysis at 400μM | Human | Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | GFMKYIGPLIPHAVKAISKLI{ct:Amid} | Kassinatuerin-1 (Lys19) | Amidation | Free | Linear | L | None | 21 | Antimicrobial | LD50 =45μM | Human | Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | GFMKYIGPLIPHAVKAIKKLI{ct:Amid} | Kassinatuerin-1 (Lys18, Lys19) | Amidation | Free | Linear | L | None | 21 | Antimicrobial | LD50 =25μM | Human | Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | GFMKYIKPLIPHAVKAISKLI{ct:Amid} | Kassinatuerin-1 (Lys7, Lys19) | Amidation | Free | Linear | L | None | 21 | Antimicrobial | LD50 =55μM | Human | Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | GFMKYIKPLIPHAVKAIKKLI{ct:Amid} | Kassinatuerin-1 (Lys7, Lys18, Lys19) | Amidation | Free | Linear | L | None | 21 | Antimicrobial | LD50 =40μM | Human | Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | GFMKYIGPLIPHAVKAISDLI | Kassinatuerin-1 (COOH) | Free | Free | Linear | L | None | 21 | Antimicrobial | 39% hemolysis at 400μM | Human | Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | GFMKYIGPLIPHAVKAISKLI | Kassinatuerin-1 (Lys19)(COOH) | Free | Free | Linear | L | None | 21 | Antimicrobial | LD50 =120μM | Human | Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | GFMKYIKPLIPHAVKAISKLI | Kassinatuerin-1 (Lys7, Lys19)(COOH) | Free | Free | Linear | L | None | 21 | Antimicrobial | LD50 =135μM | Human | Kassina senegalensis | NA | NA | ||
| 15885852 | 2005 | GFMKYIKPLIPHAVKAIKKLI | Kassinatuerin-1 (Lys7, Lys18, Lys19) (COOH) | Free | Free | Linear | L | None | 21 | Antimicrobial | LD50 =200μM | Human | Kassina senegalensis | NA | NA | ||
| 3125066 | 1988 | GIGKFLHSAKKFGKAFVGEIMNS | Maganin 2 | Free | Free | Linear | L | None | 23 | Antiparasitic | 4% hemolysis at 50μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GIGKFLHSAKKFGKAFVGEIMNS | Maganin 2 | Free | Free | Linear | L | None | 23 | Antiparasitic | 3% hemolysis at 100μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GIGKFLHSAKKFGKAFVGEIMNS | Maganin 2 | Free | Free | Linear | L | None | 23 | Antiparasitic | 3% hemolysis at 200μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GIGKFLHSAKKFGKAFVGEIMNS | Maganin 2 | Free | Free | Linear | L | None | 23 | Antiparasitic | 4% hemolysis at 500μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GIGKFLHSAKKFGKAFVGEIMNS | Maganin 2 | Free | Free | Linear | L | None | 23 | Antiparasitic | 6% hemolysis at 1000μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GWASKIGQTLGKIAKVGLKELIQPK | XPF | Free | Free | Linear | L | None | 24 | Antiparasitic | 1% hemolysis at 50μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GWASKIGQTLGKIAKVGLKELIQPK | XPF | Free | Free | Linear | L | None | 24 | Antiparasitic | 1% hemolysis at 100μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GWASKIGQTLGKIAKVGLKELIQPK | XPF | Free | Free | Linear | L | None | 24 | Antiparasitic | 2% hemolysis at 200μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GWASKIGQTLGKIAKVGLKELIQPK | XPF | Free | Free | Linear | L | None | 24 | Antiparasitic | 5% hemolysis at 500μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GWASKIGQTLGKIAKVGLKELIQPK | XPF | Free | Free | Linear | L | None | 24 | Antiparasitic | 6% hemolysis at 1000μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GMASKAGAIAGKIAKVALKAL{ct:Amid} | PGLa | Amidation | Free | Linear | L | None | 21 | Antiparasitic | 4% hemolysis at 50μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GMASKAGAIAGKIAKVALKAL{ct:Amid} | PGLa | Amidation | Free | Linear | L | None | 21 | Antiparasitic | 3% hemolysis at 100μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GMASKAGAIAGKIAKVALKAL{ct:Amid} | PGLa | Amidation | Free | Linear | L | None | 21 | Antiparasitic | 4% hemolysis at 200μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GMASKAGAIAGKIAKVALKAL{ct:Amid} | PGLa | Amidation | Free | Linear | L | None | 21 | Antiparasitic | 5% hemolysis at 500μg/ml | Human | Xenopus laevis | NA | NA | ||
| 3125066 | 1988 | GMASKAGAIAGKIAKVALKAL{ct:Amid} | PGLa | Amidation | Free | Linear | L | None | 21 | Antiparasitic | 7% hemolysis at 1000μg/ml | Human | Xenopus laevis | NA | NA | ||
| 11897590 | 2001 | ALWKTLLKKVLKA{ct:Amid} | P | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 5% hemolysis at 10μM | Human | Synthetic Peptide | NA | NA | ||
| 11937508 | 2002 | ALWKTLLKKVLKA{ct:Amid} | K4-S4(1-13)NH2 | Amidation | Free | Linear | L | None | 13 | Antiparasitic | 3% hemolysis at 10μM | Human | Synthetic Peptide | NA | NA | ||
| 11937508 | 2002 | ALWKTLLKKVLKA{nt:H2N-CH2-CO-P}{ct:Amid} | Glycyl-P | Amidation | H2N-CH2-CO-P | Linear | L | None | 13 | Antiparasitic | 2% hemolysis at 10μM | Human | Synthetic Peptide | NA | NA | ||
| 11937508 | 2002 | ALWKTLLKKVLKA{nt:H2N-(CH2)3-CO-P}{ct:Amid} | Aminobutyryl-P | Amidation | H2N-(CH2)3-CO-P | Linear | L | None | 13 | Antiparasitic | 1% hemolysis at 10μM | Human | Synthetic Peptide | NA | NA | ||
| 11937508 | 2002 | ALWKTLLKKVLKA{nt:H2N-(CH2)6-CO-P}{ct:Amid} | Aminoheptanoyl-P | Amidation | H2N-(CH2)6-CO-P | Linear | L | None | 13 | Antiparasitic | 1% hemolysis at 10μM | Human | Synthetic Peptide | NA | NA | ||
| 11937508 | 2002 | ALWKTLLKKVLKA{nt:H2N-(CH2)11-CO-P}{ct:Amid} | Aminolauroyl-P | Amidation | H2N-(CH2)11-CO-P | Linear | L | None | 13 | Antiparasitic | 4% hemolysis at 10μM | Human | Synthetic Peptide | NA | NA | ||
| 11937508 | 2002 | ALWKTLLKKVLKA{nt:H2N-C((CH2)4-NH2)H-CO-P}{ct:Amid} | Lysyl-P | Amidation | H2N-C((CH2)4-NH2)H-CO-P | Linear | L | None | 13 | Antiparasitic | 5% hemolysis at 10μM | Human | Synthetic Peptide | NA | NA | ||
| 12379643 | 2002 | GLWSTIKQKGKEAAIAAAKAAGQAALGAL{ct:Amid} | DS 01 | Amidation | Free | Linear | L | None | 29 | Antiparasitic | 0.41% hemolysis at 4μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 12379643 | 2002 | GLWSTIKQKGKEAAIAAAKAAGQAALGAL{ct:Amid} | DS 01 | Amidation | Free | Linear | L | None | 29 | Antiparasitic | 0.54% hemolysis at 8μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 12379643 | 2002 | GLWSTIKQKGKEAAIAAAKAAGQAALGAL{ct:Amid} | DS 01 | Amidation | Free | Linear | L | None | 29 | Antiparasitic | 0.81% hemolysis at 16μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 12379643 | 2002 | GLWSTIKQKGKEAAIAAAKAAGQAALGAL{ct:Amid} | DS 01 | Amidation | Free | Linear | L | None | 29 | Antiparasitic | 1.08% hemolysis at 32μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 12379643 | 2002 | GLWSTIKQKGKEAAIAAAKAAGQAALGAL{ct:Amid} | DS 01 | Amidation | Free | Linear | L | None | 29 | Antiparasitic | 1.36% hemolysis at 64μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 12379643 | 2002 | GLWSTIKQKGKEAAIAAAKAAGQAALGAL{ct:Amid} | DS 01 | Amidation | Free | Linear | L | None | 29 | Antiparasitic | 2.17% hemolysis at 128μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 15513914 | 2004 | FLPLIGRVLSGIL{ct:Amid} | Temporin A | Amidation | Free | Linear | L | None | 13 | Antiparasitic | LC50 >120μM | Human | Rana temporaria | NA | NA | ||
| 15513914 | 2004 | LLPIVGNLLKSLL{ct:Amid} | Temporin B | Amidation | Free | Linear | L | None | 13 | Antiparasitic | LC50 >120μM | Human | Rana temporaria | NA | NA | ||
| 18984589 | 2009 | KKALL{nnr:O}HALH{nnr:O}LALLA{nnr:O}HLAH{nnr:O}LKKA{ct:Amid} | HALO | Amidation | Free | Linear | L | O = L-Ornithine | 26 | Antiparasitic | HC50 =179.2μM | Human | Synthetic Peptide | NA | NA | ||
| 18984589 | 2009 | ALALL{nnr:O}HALH{nnr:O}LALLA{nnr:O}HLAH{nnr:O}LALA{ct:Amid} | HALO-2 | Amidation | Free | Linear | L | O = L-Ornithine | 26 | Antiparasitic | HC50 <5.6μM | Human | Synthetic Peptide | NA | NA | ||
| 18984589 | 2009 | FFKKL{nnr:O}HALH{nnr:O}LALLA{nnr:O}HLAH{nnr:O}LKKA{ct:Amid} | HALO-F | Amidation | Free | Linear | L | O = L-Ornithine | 26 | Antiparasitic | HC50 <5.6μM | Human | Synthetic Peptide | NA | NA | ||
| 18984589 | 2009 | KKALL{nnr:O}HPLH{nnr:O}LALLA{nnr:O}HLAH{nnr:O}LKKA{ct:Amid} | HALO-P8 | Amidation | Free | Linear | L | O = L-Ornithine | 26 | Antiparasitic | HC50 =89.6μM | Human | Synthetic Peptide | NA | NA | ||
| 18984589 | 2009 | A{d}K{d}K{d}L{d}{nnr:d-o}H{d}A{d}L{d}H{d}{nnr:d-o}A{d}L{d}L{d}A{d}L{d}{nnr:d-o}H{d}L{d}A{d}H{d}{nnr:d-o}L{d}L{d}A{d}K{d}K{d}{ct:Amid} | D-HALO-rev | Amidation | Free | Linear | D | o = D-Ornithine | 26 | Antiparasitic | HC50 =716.8μM | Human | Synthetic Peptide | NA | NA | ||
| 18984589 | 2009 | A{d}K{d}K{d}L{d}{nnr:d-o}H{d}A{d}L{d}H{d}{nnr:d-o}A{d}L{d}L{d}A{d}L{d}{nnr:d-o}H{d}L{d}P{d}H{d}{nnr:d-o}L{d}K{d}K{d}F{d}F{d}{ct:Amid} | D-HALO-P8F-rev | Amidation | Free | Linear | D | o = D-Ornithine | 26 | Antiparasitic | HC50 >65.2μM | Human | Synthetic Peptide | NA | NA | ||
| 10441158 | 1999 | CGETCVGGTCNTPGCTCSWPVCTRNGLPV{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 29 | Uterotonic | HD50 =50μM | Human | O. affinis | NA | NA | ||
| 10441158 | 1999 | CGESCVFIPCISTLLGCSCKNKVCYRNGVIP{cyc:N-C} | Circulin B | Free | Free | Cyclic | L | None | 30 | Uterotonic | HD50 =30μM | Human | O. affinis | NA | NA | ||
| 10606532 | 1999 | KWL{d}L{d}LLKL{d}LL{d}LK{ct:Amid} | [D]L3,4,8,10-K3 L8W(n) | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 31% hemolysis at 50μM | Human | Synthetic Peptide | NA | NA | ||
| 10606532 | 1999 | KLL{d}L{d}LWKL{d}LL{d}LK{ct:Amid} | [D]L3,4,8,10-K3 L8W(m) | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 39.4% hemolysis at 50μM | Human | Synthetic Peptide | NA | NA | ||
| 10606532 | 1999 | KLL{d}L{d}LLKL{d}LL{d}WK{ct:Amid} | [D]L3,4,8,10-K3 L8W(c) | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 44.2% hemolysis at 50μM | Human | Synthetic Peptide | NA | NA | ||
| 10606532 | 1999 | KWL{d}L{d}KLKL{d}KL{d}LK{ct:Amid} | [D]L3,4,8,10-K5L6W(n) | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KLL{d}L{d}KWKL{d}KL{d}LK{ct:Amid} | [D]L3,4,8,10-K5L6W(m) | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KLL{d}L{d}KLKL{d}KL{d}WK{ct:Amid} | [D]L3,4,8,10-K5L6W(c) | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KKW{d}L{d}KLKL{d}KL{d}KK{ct:Amid} | [D]L4,8,10-K7L4W(n) | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KKL{d}L{d}KWKL{d}KL{d}KK{ct:Amid} | [D]L3,4,8,10-K7L4W(m) | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 10606532 | 1999 | KKL{d}L{d}KLKL{d}KW{d}KK{ct:Amid} | [D]L3,4,8-K7L4W(c) | Amidation | Free | Linear | Mix | None | 12 | Antimicrobial | 0% hemolysis at 50μM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 19635516 | 2009 | IPPFIKKVLTTVF{ct:Amid} | Temporin-CPa | Amidation | Free | Linear | L | None | 12 | Antimicrobial | LC50 =220μM | Human | Lithobates capito | NA | NA | ||
| 19635516 | 2009 | HFLGTLVNLAKKIL{ct:Amid} | Temporin-DRa | Amidation | Free | Linear | L | None | 14 | Antimicrobial | LC50 =65μM | Human | Rana draytonii | NA | NA | ||
| 19635516 | 2009 | FVQWFSKFLGRIL{ct:Amid} | Temporin L | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LC50 =2μM | Human | Rana temporaria | NA | NA | ||
| 16142907 | 2005 | KWKKLLKKL{nnr:a}KLLKKLLK{ct:Amid} | KLW-L10-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | >20% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 16142907 | 2005 | KWKKLLKKLL{nnr:a}LLKKLLK{ct:Amid} | KLW-L11-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | >50% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 16142907 | 2005 | KWKKLLKK{nnr:a}LKLLKKLLK{ct:Amid} | KLW-L9,13-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | 0% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 16142907 | 2005 | KWKKLL{nnr:a}KLL{nnr:a}LLKKLLK{ct:Amid} | KLW-K7,11-a | Amidation | Free | Linear | L | a = Nala (Ala-peptoid) | 18 | Antimicrobial | ~30% hemolysis at 100µM | Human | Synthetic peptide | α-helical | NA | ||
| 20564013 | 2010 | GLPVCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | Kalata B1 | Free | Free | Cyclic | L | None | 30 | Pesticidal | HD50 = 20.0±1.1μM | Human | Cyclotides (Oldenlandia affinis) | NA | NA | ||
| 20564013 | 2010 | GLPVCGETCTLGTVYTQGCTCSWPICKRN{cyc:N-C} | Kalata B7 | Free | Free | Cyclic | L | None | 30 | Pesticidal | HD50 = 55.2±1.3μM | Human | Cyclotides (Oldenlandia affinis) | NA | NA | ||
| 15009528 | 2004 | VKLKVY{d}PLKVKLY{d}P{cyc:N-C} | GS14KL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =2 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14LL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =3 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLVY{d}PLKVKLY{d}P{cyc:N-C} | GS14FL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =3 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLYY{d}YPLKVKLY{d}P{cyc:N-C} | GS14YL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =8 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLNVY{d}PLKVKLY{d}P{cyc:N-C} | GS14NL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =2 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 15009528 | 2004 | VKLNVY{d}PLKVKLY{d}P{cyc:N-C} | GS14GL4 | Free | Free | Cyclic | Mix | None | 14 | Antimicrobial | MHC =3 µg/ml | Human | Gramicidin S analog | NA | NA | ||
| 19111524 | 2009 | X-NH-GVATQLLAAYILLFDEYNEKKASAQKDILIKVL{nt:X=H, NBD, Rhodamine}{ct:Amid} | H-88 | Amidation | X=H, NBD, Rhodamine | Linear | L | None | 21 | Cytotoxic | 50% hemolysis at ~0.72μM | Human | Synthetic peptide | Helical | NA | ||
| 19111524 | 2009 | X-NH-GDATQLLAAYILLFDEYNEKKASAQKDILIKVL{nt:X=H, NBD, Rhodamine}{ct:Amid} | Mu1-H88 | Amidation | X=H, NBD, Rhodamine | Linear | L | None | 21 | Cytotoxic | 0% hemolysis at 0.8μM | Human | Synthetic peptide | Helical | Non-hemolytic | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLKVLTTG | HP(2-9)-ME(1-12) | Free | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis upto 100µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | Non-hemolytic | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTTG | HM1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 13% hemolysis at 25µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTTG | HM1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 1% hemolysis at 12.5µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTTG | HM1 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 6.25µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLKVLTWG | HM2 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis upto 100µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | Non-hemolytic | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTWG | HM3 | Free | Free | Linear | L | None | 20 | Antimicrobial | 44% hemolysis at 25µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTWG | HM3 | Free | Free | Linear | L | None | 20 | Antimicrobial | 31% hemolysis at 12.5µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTWG | HM3 | Free | Free | Linear | L | None | 20 | Antimicrobial | 12% hemolysis at 6.25µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTWG | HM3 | Free | Free | Linear | L | None | 20 | Antimicrobial | 4% hemolysis at 3.12µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLWVLTWG | HM3 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 1.5µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AWKVFKRLGIGAVLWVLTWG | HM4 | Free | Free | Linear | L | None | 20 | Antimicrobial | 44% hemolysis at 25µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AWKVFKRLGIGAVLWVLTWG | HM4 | Free | Free | Linear | L | None | 20 | Antimicrobial | 43% hemolysis at 12.5µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AWKVFKRLGIGAVLWVLTWG | HM4 | Free | Free | Linear | L | None | 20 | Antimicrobial | 30% hemolysis at 6.25µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AWKVFKRLGIGAVLWVLTWG | HM4 | Free | Free | Linear | L | None | 20 | Antimicrobial | 29% hemolysis at 3.1µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AWKVFKRLGIGAVLWVLTWG | HM4 | Free | Free | Linear | L | None | 20 | Antimicrobial | 13% hemolysis at 1.5µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AWKVFKRLGIGAVLWVLTWG | HM4 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis at 0.78µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | NA | ||
| 15127790 | 2004 | AKKVFKRLGIGAVLKVLKKG | HM5 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0% hemolysis upto 100µM | Human | Analog of HP(2-9)-ME(1-12) (synthetic peptide) | α-helical | Non-hemolytic | ||
| 12110678 | 2002 | LKLLKKLLKKLLKLL{ct:Amid} | Amphipathic-1L | Amidation | Free | Linear | L | None | 15 | Antibacterial | 100% hemolytic at 100μM | Human | Synthetic peptide | NA | NA | ||
| 12110678 | 2002 | KLKLLKLLKLLKLLK{ct:Amid} | Scrambled-4L | Amidation | Free | Linear | L | None | 15 | Antibacterial | 82% hemolytic at 100μM | Human | Synthetic peptide | NA | NA | ||
| 12110678 | 2002 | KKKLLLLLLLLLKKK{ct:Amid} | Segregated-5L | Amidation | Free | Linear | L | None | 15 | Antibacterial | 66% hemolytic at 100μM | Human | Synthetic peptide | NA | NA | ||
| 12354111 | 2002 | INLKALAALAKKIL | Mastoparan | Free | Free | Linear | L | None | 14 | Antifungal | 10% hemolytic at 100μM | Human | Isolated from scorpion venom | NA | NA | ||
| 22699557 | 2012 | IWRIFR{ct:Amid} | HFU2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | MHC > 256 μM | Human | Synthetic peptide | NA | NA | ||
| 22699557 | 2012 | IWRIFRRIF{ct:Amid} | HFU3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | MHC = 101.4μM | Human | Synthetic peptide | NA | NA | ||
| 16460023 | 2006 | FKIKASKVLDKFGKIVGKVLKQLKKVSAVAKV | P6_1 | Free | Free | Linear | L | None | 32 | Hemolytic | LD50=12.6µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16460023 | 2006 | FSISASKVLDKFGKIVGKVLKQLKKVSAVAKV | P6_2 | Free | Free | Linear | L | None | 32 | Hemolytic | LD50=28.1µM | Human | Peptides derived from Trialysin protein found in the saliva of Triatoma infestans | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLCYKQRCVTYCRGR{cyc:N-C}{ct:Amid} | Gomesin | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~ 40% hemolysis at 100µM | Human | Gomesin (Acanthoscurria gomesiana) | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}SRRLSYKQRSVTYSRGR{ct:Amid} | [Ser2,6,11,15]-Gm | Amidation | Free | Linear | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}SRRLCYKQRCVTYSRGR{cyc:N-C}{ct:Amid} | [Ser2,15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLSYKQRSVTYCRGR{cyc:N-C}{ct:Amid} | [Ser6,11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}DRRLSYKQRSVTYORGR{cyc:N-C}{ct:Amid} | Cyclo(2–15)[Asp2, Ser6, 11, Orn15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}SRRLOYKQRDVTYSRGR{cyc:N-C}{ct:Amid} | Cyclo(6-11)[Ser2,15, Orn6, Asp11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}CRRLEYKQRKVTYCRGR{cyc:N-C}{ct:Amid} | Bicyclo(2–15, 6–11)[Cys2, 15, Glu6, Lys11]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | <10% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 16235231 | 2006 | {nnr:Z}ERRLCYKQRCVTYKRGR{cyc:N-C}{ct:Amid} | Bicyclo(2–15, 6–11)[Glu2, Cys6, 11, Lys15]-Gm | Amidation | Free | Cyclic | L | Z = pyroglutamic acid | 18 | Antimicrobial | ~ 32% hemolysis at 100µM | Human | Gomesin analogs | NA | NA | ||
| 23483218 | 2013 | LNWGAILKHIIK{ct:Amid} | PNG-1 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at 119 µM | Human | Venom Of Bee Panurgus Calcaratus | α-Helix | NA | ||
| 23483218 | 2013 | NLWAGILKHIIK{ct:Amid} | PNG-1/1 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | NLWAGILKHIIK{ct:Amid} | PNG-1/2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LKWGAILKHIIK{ct:Amid} | PNG-1/3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNKGAILKHIIK{ct:Amid} | PNG-1/4 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWKAILKHIIK{ct:Amid} | PNG-1/5 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at ~110 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGKILKHIIK{ct:Amid} | PNG-1/6 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >140 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAKLKHIIK{ct:Amid} | PNG-1/7 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAIKKHIIK{ct:Amid} | PNG-1/8 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAILKKIIK{ct:Amid} | PNG-1/9 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAILKHKIK{ct:Amid} | PNG-1/10 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAILKHIKK{ct:Amid} | PNG-1/11 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | KNWGKILKHIIK{ct:Amid} | PNG-1/12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | KNWKAILKHIIK{ct:Amid} | PNG-1/13 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAVLKHVVK{ct:Amid} | PNG-1/14 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGA{nnr:Abu}LKH{nnr:Abu}{nnr:Abu}K{ct:Amid} | PNG-1/15 | Amidation | Free | Linear | L | Abu = 2-aminobutyric acid | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAALKHAAK{ct:Amid} | PNG-1/16 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAFLKHFFK{ct:Amid} | PNG-1/17 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at 81 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAGLKHGGK{ct:Amid} | PNG-1/18 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGALLKHLLK{ct:Amid} | PNG-1/19 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at 63 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGA{nnr:Nle}LKH{nnr:Nle}{nnr:Nle}K{ct:Amid} | PNG-1/20 | Amidation | Free | Linear | L | Nle = Norleucine | 12 | Antimicrobial | 50 % Hemolysis at 40 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGA{nnr:Aca}LKH{nnr:Aca}{nnr:Aca}K{ct:Amid} | PNG-1/21 | Amidation | Free | Linear | L | Aca = 1-aminocyclohexane carboxylic acid | 12 | Antimicrobial | 50 % Hemolysis at 43 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LNWGAWLKHWWK{ct:Amid} | PNG-1/22 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at 132 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LDVKKIICVACKIKPNPACKKICPK | PNG-K | Free | Free | Linear | L | None | 25 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LDVKKII{nnr:Abu}VA{nnr:Abu}KIKPNPA{nnr:Abu}KKI{nnr:Abu}PK{ct:Amid} | PNG-K/1 | Free | Free | Linear | L | Abu = 2-aminobutyric acid | 25 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LDVKKIICVACKIRPNPACKKICPK | PNG-R | Free | Free | Linear | L | None | 25 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23483218 | 2013 | LDVKKII{nnr:Abu}VA{nnr:Abu}KIRPNPA{nnr:Abu}KKI{nnr:Abu}PK{ct:Amid} | PNG-R/1 | Free | Free | Linear | L | Abu = 2-aminobutyric acid | 25 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Png-1 Analogs | α-Helix | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 10 µM | Human | Bombyx Mori | α-Helix | Non-hemolytic | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bombyx Mori | α-Helix | Non-hemolytic | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | <5 % Hemolysis at 100 µM | Human | Bombyx Mori | α-Helix | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | <5 % Hemolysis at 200 µM | Human | Bombyx Mori | α-Helix | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | 10 % Hemolysis at 400 µM | Human | Bombyx Mori | α-Helix | NA | ||
| 23500722 | 2013 | RWKIFKKIEKMGRNIRDGIVKAGPAIEVLGSAKAIGK | CecropinXJ | Free | Free | Linear or ring-shaped | L | None | 37 | Antimicrobial | 30 % Hemolysis at 800 µM | Human | Bombyx Mori | α-Helix | NA | ||
| 23719232 | 2013 | GLLKRIKTLL{nt:Amid}{ct:Amid} | Anoplin | Amidation | Amidation | Linear | L | None | 10 | Antimicrobial | 50 % Hemolysis at >500 µg/ml | Human | Anoplius Samariensis | α-Helix | NA | ||
| 23719232 | 2013 | G{nnr:Laa}LIKRKTLL{nt:Amid}{ct:Amid} | Ano-Laa02 | Amidation | Amidation | Linear | L | Laa ((S)-2-aminoundecanoic acid) | 10 | Antimicrobial | 50 % Hemolysis at ~108 µg/ml | Human | Anoplin Analogs | α-Helix | NA | ||
| 23719232 | 2013 | GLLKRK{nnr:Laa}TLL{nt:Amid}{ct:Amid} | Ano-Laa06 | Amidation | Amidation | Linear | L | Laa ((S)-2-aminoundecanoic acid) | 10 | Antimicrobial | 50 % Hemolysis at ~39 µg/ml | Human | Anoplin Analogs | α-Helix | NA | ||
| 23719232 | 2013 | GLLIKRKTL{nnr:Laa}{nt:Amid}{ct:Amid} | Ano-Laa10 | Amidation | Amidation | Linear | L | Laa ((S)-2-aminoundecanoic acid) | 10 | Antimicrobial | 50 % Hemolysis at ~77 µg/ml | Human | Anoplin Analogs | α-Helix | NA | ||
| 23719232 | 2013 | GLLIKRKTLL{ct:Amid} | C9-Anoplin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 50 % Hemolysis at ~5 µg/ml | Human | Anoplin Analogs | α-Helix | NA | ||
| 23935838 | 2013 | AKKVFKRLEKLFSKIQNDK{ct:Amid} | HP (2–20) | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 0 % Hemolysis at ~100 µM | Human | Helicobacter Pylori | α-Helix | Non-hemolytic | ||
| 23935838 | 2013 | AKKVFKRLEKLFSKIQNWK{ct:Amid} | Anal 1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 0 % Hemolysis at ~100 µM | Human | Helicobacter Pylori | α-Helix | Non-hemolytic | ||
| 23935838 | 2013 | AKKVFKRLEKLFSKIWNDK{ct:Amid} | Anal 2 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 0 % Hemolysis at ~100 µM | Human | Helicobacter Pylori | α-Helix | Non-hemolytic | ||
| 23935838 | 2013 | AKKVFKRLEKLFSKIWNWK{ct:Amid} | Anal 3 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 0 % Hemolysis at ~100 µM | Human | Helicobacter Pylori | Random coil/Helical | Non-hemolytic | ||
| 23935838 | 2013 | AKKVFKRLEKSFSKIQNDK{ct:Amid} | Anal 4 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 0 % Hemolysis at ~100 µM | Human | Helicobacter Pylori | α-Helix | Non-hemolytic | ||
| 23935838 | 2013 | AKKVSKRLEKLFSKIQNDK{ct:Amid} | Anal 5 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 0 % Hemolysis at ~100 µM | Human | Helicobacter Pylori | α-Helix | Non-hemolytic | ||
| 23935838 | 2013 | AKKVFKRLPKLFSKIWNWK{ct:Amid} | Anal 3-Pro | Amidation | Free | Linear | L | None | 19 | Antibacterial/ Antifungal | 0 % Hemolysis at ~100 µM | Human | Helicobacter Pylori | Helix-hinge-Helix | Non-hemolytic | ||
| 23689723 | 2013 | RQIKIWFQNRRMKWKK{ct:Amid} | Penetratin | Amidation | Free | Linear | L | None | 16 | Antimicrobial | No Hemolysis at 100 µM | Human | Drosophila Transcription Factor Antennapedia | NA | Non-hemolytic | ||
| 23689723 | 2013 | LLIILRRRIRKQAHAHSL{ct:Amid} | pVEC | Amidation | Free | Linear | L | None | 18 | Antimicrobial | No Hemolysis at 100 µM | Human | Murine Vascular Endothelial Cadherin | NA | Non-hemolytic | ||
| 23689723 | 2013 | FILFILFILGGKHKHKHKHKHK{ct:Amid} | R41 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | No Hemolysis at 100 µM | Human | Designed Peptide | NA | Non-hemolytic | ||
| 23689723 | 2013 | GPPRFPPRFPPRFPPRFPPRFP{ct:Amid} | R8 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | No Hemolysis at 100 µM | Human | Design Based On Sequence Of Pr-39 | NA | Non-hemolytic | ||
| 23689723 | 2013 | AGYLLGKINLKALAALAKKIL{ct:Amid} | TP10 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | <2 % Hemolysis at 100 µM | Human | Deletion Analogue Of Transportan, A Chimeric Peptide | NA | NA | ||
| 23689723 | 2013 | MVTVLFRRLRIRRASGPPRVRV{ct:Amid} | M918 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | No Hemolysis at 100 µM | Human | Tumor Suppressor Protein P14Arf | NA | Non-hemolytic | ||
| 23689723 | 2013 | IAWVKAFIRKLRKGPLG{nt:Acet}{ct:Amid} | YTA-4 | Amidation | Acetylation | Linear | L | None | 17 | Antimicrobial | No Hemolysis at 100 µM | Human | Substrate Of Matrix Metalloprotease 2 | NA | Non-hemolytic | ||
| 23689723 | 2013 | KLALKALKALKAALKLA{ct:Amid} | MAP | Amidation | Free | Linear | L | None | 17 | Antimicrobial | <1 % Hemolysis at 100 µM | Human | Designed Model Amphipathic Peptide | NA | Non-hemolytic | ||
| 23689723 | 2013 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | No Hemolysis at 100 µM | Human | Human Cathelicidin | NA | Non-hemolytic | ||
| 24013774 | 2013 | VKRWKKWWRKWKKWV{ct:Amid} | LZ1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | <4 % Hemolysis at 10 µg/ml | Human | Human Cathelicidin Family | NA | NA | ||
| 24013774 | 2013 | VKRWKKWWRKWKKWV{ct:Amid} | LZ1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | <3 % Hemolysis at 20 µg/ml | Human | Human Cathelicidin Family | NA | NA | ||
| 24013774 | 2013 | VKRWKKWWRKWKKWV{ct:Amid} | LZ1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 40 µg/ml | Human | Human Cathelicidin Family | NA | Non-hemolytic | ||
| 24013774 | 2013 | VKRWKKWWRKWKKWV{ct:Amid} | LZ1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | <2 % Hemolysis at 80 µg/ml | Human | Human Cathelicidin Family | NA | NA | ||
| 24013774 | 2013 | VKRWKKWWRKWKKWV{ct:Amid} | LZ1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 2 % Hemolysis at 160 µg/ml | Human | Human Cathelicidin Family | NA | NA | ||
| 24013774 | 2013 | VKRWKKWWRKWKKWV{ct:Amid} | LZ1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | | Human | Human Cathelicidin Family | NA | NA | | ||
| 24004075 | 2013 | RILTMTKRVKMPQLYKQIVCRLFKTC | pleuraina1-thel | Free | Free | Linear | L | None | 26 | Antimicrobial | 2.5 % Hemolysis at 100 µg/ml | Human | Tree Frog Theloderma Kwangsiensis | NA | NA | ||
| 24004075 | 2013 | RILTMTKRVKMPQLYKQIVCRLFKTC | pleuraina1-thel | Free | Free | Linear | L | None | 26 | Antimicrobial | 3.7 % Hemolysis at 200 µg/ml | Human | Tree Frog Theloderma Kwangsiensis | NA | NA | ||
| 23632907 | 2013 | ILPIRSLIKKLL{ct:Amid} | Temporin-1RNa | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at 105.2 ± 10.2 µM | Human | Black-Spotted Frog,Rana Nigromaculata | α-Helix | NA | ||
| 23632907 | 2013 | FLPLKKLRFGLL{ct:Amid} | Temporin-1RNb | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at 136.3 ± 5.6 µM | Human | Black-Spotted Frog,Rana Nigromaculata | α-Helix | NA | ||
| 23632907 | 2013 | GLFDVVKGVLKGVGKNVAGSLLEQLKCKLSGGC | Brevinin-2RNa | Free | Free | Linear | L | None | 33 | Antimicrobial | 50 % Hemolysis at 65.2 ± 7.6 µM | Human | Black-Spotted Frog,Rana Nigromaculata | α-Helix | NA | ||
| 23893605 | 2013 | KILRGVCKKIMRTFLRRISKDILTGKK{ct:Amid} | NK-2 | Amidation | Free | Linear | L | None | 27 | Antimicrobial | <20 % Hemolysis at 10 µM | Human | Porcine Nk-Lysin-Derived Peptide | α-Helix | NA | ||
| 23893605 | 2013 | KILRGVCKKIMRTFLRRISKDILTGKK{ct:Amid} | NK-2 | Amidation | Free | Linear | L | None | 27 | Antimicrobial | <40 % Hemolysis at 100 µM | Human | Porcine Nk-Lysin-Derived Peptide | α-Helix | NA | ||
| 23893605 | 2013 | KILRGVAKKIMRTFLRRISKDILTGKK{ct:Amid} | C7A | Amidation | Free | Linear | L | None | 27 | Antimicrobial | <40 % Hemolysis at 10 µM | Human | Nk-2-Derived Synthetic | α-Helix | NA | ||
| 23893605 | 2013 | KILRGVAKKIMRTFLRRISKDILTGKK{ct:Amid} | C7A | Amidation | Free | Linear | L | None | 27 | Antimicrobial | <80 % Hemolysis at 100 µM | Human | Nk-2-Derived Synthetic | α-Helix | NA | ||
| 23893605 | 2013 | KILRGVAKKIMRTFLRRISKKILTGKK{ct:Amid} | C7A-D21K | Amidation | Free | Linear | L | None | 27 | Antimicrobial | <30 % Hemolysis at 10 µM | Human | Nk-2-Derived Synthetic | α-Helix | NA | ||
| 23893605 | 2013 | KILRGVAKKIMRTFLRRISKKILTGKK{ct:Amid} | C7A-D21K | Amidation | Free | Linear | L | None | 27 | Antimicrobial | 30 % Hemolysis at 100 µM | Human | Nk-2-Derived Synthetic | α-Helix | NA | ||
| 23893605 | 2013 | KILRGVAKKIMRTFLRRILTGKK{ct:Amid} | C7A-Δ | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 10 % Hemolysis at 10 µM | Human | Nk-2-Derived Synthetic | α-Helix | NA | ||
| 23893605 | 2013 | KILRGVAKKIMRTFLRRILTGKK{ct:Amid} | C7A-Δ | Amidation | Free | Linear | L | None | 23 | Antimicrobial | <50 % Hemolysis at 100 µM | Human | Nk-2-Derived Synthetic | α-Helix | NA | ||
| 23893605 | 2013 | KISKRILTGKK{ct:Amid} | NK11 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 10 µM | Human | Variant Of Nk-2 | α-Helix | Non-hemolytic | ||
| 23893605 | 2013 | KISKRILTGKK{ct:Amid} | NK11 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Variant Of Nk-2 | α-Helix | Non-hemolytic | ||
| 23893605 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 90 % Hemolysis at 10 µM | Human | Bee Venom | α-Helix | NA | ||
| 23893605 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | <100 % Hemolysis at 100 µM | Human | Bee Venom | α-Helix | NA | ||
| 23876294 | 2013 | KW{nnr:ΔF}WK{nnr:ΔF}VK{nnr:ΔF}AK{nt:Acet}{ct:Amid} | IJ2 | Amidation | Acetylation | Linear | L | ΔF=α,β-didehydrophenylalanine | 11 | Antifungal | <40 % Hemolysis at 100 µM | Human | Candida Albicans | α-Helix | NA | ||
| 23876294 | 2013 | KA{nnr:ΔF}WK{nnr:ΔF}VK{nnr:ΔF}AK{nt:Acet}{ct:Amid} | IJ3 | Amidation | Acetylation | Linear | L | ΔF=α,β-didehydrophenylalanine | 11 | Antifungal | <40 % Hemolysis at 100 µM | Human | Candida Albicans | α-Helix | NA | ||
| 23876294 | 2013 | KW{nnr:ΔF}WK{nnr:ΔF}AK{nnr:ΔF}AK{nt:Acet}{ct:Amid} | IJ4 | Amidation | Acetylation | Linear | L | ΔF=α,β-didehydrophenylalanine | 11 | Antifungal | <10 % Hemolysis at 100 µM | Human | Candida Albicans | α-Helix | NA | ||
| 23737519 | 2013 | GRFKRFRKKFKKLFKKLSPVIPLLHLGX | cathelicidin BMAP-27(b27) | Free | Free | Linear | L | None | 28 | Antimicrobial | 50 % Hemolysis at >>250 µM | Human | Bovine Myeloid Antimicrobial Peptide-27 | α-Helix | NA | ||
| 23737519 | 2013 | GEFAQFEQEAQSLEQELSQLEQQLESL | anti-cathelicidin BMAP-27 (anti-b27) | Free | Free | Linear | L | None | 27 | Antimicrobial | 50 % Hemolysis at >>250 µM | Human | Bovine Myeloid Antimicrobial Peptide-28 | α-Helix | NA | ||
| 23737519 | 2013 | KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL | cecropin B (CB) | Free | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at >>250 µM | Human | Cecropia Moth Hyalophora Cecropia | α-Helix | NA | ||
| 23737519 | 2013 | KWKVLKKKIKMLRNRINGLVKAGPALKVKLQALAL | cecropin B template (cBt) | Free | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at >>250 µM | Human | Cecropia Moth Hyalophora Cecropia | α-Helix | NA | ||
| 23737519 | 2013 | EAQNLEKEIAALEQAIQGLEKEIPALAQQIQALEL | anti-cecropin B template (anti-cBt) | Free | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at >>250 µM | Human | Cecropia Moth Hyalophora Cecropia | α-Helix | NA | ||
| 24041697 | 2013 | GIVEQCCTSICSLYQLENYCN | Porcine Insulin | Free | Free | Linear | L | None | 21 | Amyloidogenicity | 57.4 ± 4.6 % Hemolysis at 60 µM | Human | Insulin Derived From Pigs | α-Helix | NA | ||
| 24041697 | 2013 | FVNQHLCGSHLVEALYLVCGERGFFYTPKA | DOI | Free | Free | Linear | L | None | 30 | Amyloidogenicity | 45.9 ± 3.4 % Hemolysis at 60 µM | Human | An Insulin Analog | α-Helix | NA | ||
| 23609760 | 2013 | FVDLKKIANIINSIFGK{ct:Amid} | Temporin-1CEa | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 50 % Hemolysis at 99.08 µM | Human | Chinese Brown Frog Rana Chensinensis | α-Helix | NA | ||
| 23896552 | 2013 | RMKKLGNHKVSCERNTKRCRKAI | LBLP | Free | Free | Linear | L | None | 23 | Antifungal | 0 % Hemolysis at 80 µM | Human | Centipede S. S. Mutilans | α-Helix | Non-hemolytic | ||
| 23896552 | 2013 | RMKKLGNHKVSCERNTKRCRKAI | LBLP | Free | Free | Linear | L | None | 23 | Antifungal | 0 % Hemolysis at 40 µM | Human | Centipede S. S. Mutilans | α-Helix | Non-hemolytic | ||
| 23896552 | 2013 | RMKKLGNHKVSCERNTKRCRKAI | LBLP | Free | Free | Linear | L | None | 23 | Antifungal | 0 % Hemolysis at 20 µM | Human | Centipede S. S. Mutilans | α-Helix | Non-hemolytic | ||
| 23896552 | 2013 | RMKKLGNHKVSCERNTKRCRKAI | LBLP | Free | Free | Linear | L | None | 23 | Antifungal | 0 % Hemolysis at 10 µM | Human | Centipede S. S. Mutilans | α-Helix | Non-hemolytic | ||
| 23896552 | 2013 | RMKKLGNHKVSCERNTKRCRKAI | LBLP | Free | Free | Linear | L | None | 23 | Antifungal | 0 % Hemolysis at 5 µM | Human | Centipede S. S. Mutilans | α-Helix | Non-hemolytic | ||
| 23896552 | 2013 | RMKKLGNHKVSCERNTKRCRKAI | LBLP | Free | Free | Linear | L | None | 23 | Antifungal | 0 % Hemolysis at 2.5 µM | Human | Centipede S. S. Mutilans | α-Helix | Non-hemolytic | ||
| 23896552 | 2013 | RMKKLGNHKVSCERNTKRCRKAI | LBLP | Free | Free | Linear | L | None | 23 | Antifungal | 0 % Hemolysis at 1.3 µM | Human | Centipede S. S. Mutilans | α-Helix | Non-hemolytic | ||
| 23896552 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 99 % Hemolysis at 80 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 23896552 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 99.1 % Hemolysis at 40 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 23896552 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 70.2 % Hemolysis at 20 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 23896552 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 54.3 % Hemolysis at 10 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 23896552 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 23.8 % Hemolysis at 5 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 23896552 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 13.3 % Hemolysis at 2.5 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 23896552 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 1.9 % Hemolysis at 1.3 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}YGRKKRRQRRR{ct:Amid} | Tat | Amidation | Free | Linear | L | * = 5(6)-carboxyfluorescein amidated to the N-terminus | 11 | Antimicrobial | 44/88 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}(KK({nnr:x}(CYGRKKRRQRRRCYGRKKRRQRRR))LAQLAQ){ct:Amid} | Tat-G1L | Amidation | Free | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus,x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 29 | Antimicrobial | 5 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | (C(YGRKKRRQRRRYGRKKRRQRRRYGRKKRRQRRRYGRKKRRQRRR){nnr:x}GGGG)(KGKG)KK{d}K{nnr:*}{nt:Acet}{ct:Amid} | Tat-G2a | Amidation | Acetylation | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus | 59 | Antimicrobial | <0.3b % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}RQIKIWFQNRRMKWKK{ct:Amid} | Antp | Amidation | Free | Linear | L | * = 5(6)-carboxyfluorescein amidated to the N-terminus | 16 | Antimicrobial | 45553 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | (C(RQIKIWFQNRRMKWKKRQIKIWFQNRRMKWKK){nnr:x}GG)KK{d}K{nnr:*}{nt:Acet}{ct:Amid} | Antp-G1a | Amidation | Acetylation | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 39 | Antimicrobial | 1 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}(KK({nnr:x}(CRQIKIWFQNRRMKWKKCRQIKIWFQNRRMKWKK))LAQLAQ){ct:Amid} | Antp-G1L | Amidation | Free | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 42 | Antimicrobial | 1 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | (C(RQIKIWFQNRRMKWKKRQIKIWFQNRRMKWKKRQIKIWFQNRRMKWKKRQIKIWFQNRRMKWKK){nnr:x}GGGG)(KGKG)KK{d}K{nnr:*}{nt:Acet}{ct:Amid} | Antp-G2a | Amidation | Acetylation | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 79 | Antimicrobial | <0.3b % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}LLIILRRRIRKQAHAHSK{ct:Amid} | pVEC | Amidation | Free | Linear | L | * = 5(6)-carboxyfluorescein amidated to the N-terminus | 18 | Antimicrobial | 45292 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | (C(LLIILRRRIRKQAHAHSKLLIILRRRIRKQAHAHSK){nnr:x}PSPS)KPSK{nnr:*}{nt:Acet}{ct:Amid} | pVEC-G1b | Amidation | Acetylation | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 46 | Antimicrobial | <0.5b % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}AGYLLGKINKLKALAALAKKIL{ct:Amid} | TP10K | Amidation | Free | Linear | L | * = 5(6)-carboxyfluorescein amidated to the N-terminus | 22 | Antimicrobial | 45324 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | (C(AGYLLGKINKLKALAALAKKILAGYLLGKINKLKALAALAKKIL){nnr:x}PSPS)KPSK{nnr:*}{nt:Acet}{ct:Amid} | TP10K-G1b | Amidation | Acetylation | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 54 | Antimicrobial | <0.5b % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}VRLPPPVRLPPPVRLPPP{ct:Amid} | SAP | Amidation | Free | Linear | L | * = 5(6)-carboxyfluorescein amidated to the N-terminus | 18 | Antimicrobial | >742/>742c % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | (C([VRLPPPVRLPPPVRLPPPVRLPPPVRLPPPVRLPPP]){nnr:x}GG)KK{d}K{nnr:*}{nt:Acet}{ct:Amid} | SAP-G1a | Amidation | Acetylation | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 43 | Antimicrobial | 41 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}(KK({nnr:x}(CVRLPPPVRLPPPVRLPPPCVRLPPPVRLPPPVRLPPP))LAQLAQ){ct:Amid} | SAP-G1L | Amidation | Free | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 46 | Antimicrobial | 79 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | C([VRLPPPVRLPPPVRLPPPVRLPPPVRLPPPVRLPPPVRLPPPVRLPPPVRLPPPVRLPPPVRLPPPVRLPPP]){nnr:x}GGGG)(KGKG)KkK{nnr:*}{nt:Acet}{ct:Amid} | SAP-G2a | Amidation | Acetylation | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 87 | Antimicrobial | >173c % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}(KKKK({nnr:x}(CVRLPPPVRLPPPVRLPPPCVRLPPPVRLPPPVRLPPPCVRLPPPVRLPPPVRLPPPCVRLPPPVRLPPPVRLPPP))LAQLAQLAQLAQ)4{ct:Amid} | SAP-G2L | Amidation | Free | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 92 | Antimicrobial | 41 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | {nnr:*}PPPLRVPPPLRVPPPLRV{ct:Amid} | SAPr | Amidation | Free | Linear | L | * = 5(6)-carboxyfluorescein amidated to the N-terminus | 18 | Antimicrobial | >742/>742c % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23933745 | 2013 | (C(PPPLRVPPPLRVPPPLRV){nnr:x}PSC(PPPLRVPPPLRVPPPLRV){nnr:x}PSKPSK{nnr:*}{nt:Acet}{ct:Amid} | SAPr-G1b | Amidation | Acetylation | Linear | Mix | * = 5(6)-carboxyfluorescein amidated to the N-terminus, x = the S–CH2–CO– bridge between the cysteine side-chain and the N-terminus of the dendrimer or lysine side-chain | 46 | Antimicrobial | 40 % Hemolysis at 10 µM | Human | Natural Translocating Proteins | α-Helix | NA | ||
| 23624072 | 2013 | MKTQFVILMITVILMOMLVOTEGGILGKLWEGFKSIVGKRGLNDRDQLDDLFDSDLSDADIKLLKEMFK{ct:Amid} | Pantinin-1 | Amidation | Free | Linear | L | None | 69 | Antimicrobial | 0 % Hemolysis at <32 µM | Human | Scorpion Pandinus Imperator | α-Helix | Non-hemolytic | ||
| 23624072 | 2013 | MKTQFVILMITVILMOMLVOTEGGILGKLWEGFKSIVGKRGLNDRDQLDDLFDSDLSDADIKLLKEMFK{ct:Amid} | Pantinin-1 | Amidation | Free | Linear | L | None | 69 | Antimicrobial | 21 % Hemolysis at 64 µM | Human | Scorpion Pandinus Imperator | α-Helix | NA | ||
| 23624072 | 2013 | MKTQFVILMITVILMOMLVOTEGGILGKLWEGFKSIVGKRGLNDRDQLDDLFDSDLSDADIKLLKEMFK{ct:Amid} | Pantinin-2 | Amidation | Free | Linear | L | None | 68 | Antimicrobial | 0 % Hemolysis at <8 µM | Human | Scorpion Pandinus Imperator | α-Helix | Non-hemolytic | ||
| 23624072 | 2013 | MKAQFAILLITLVLFOMFSOSEAIFGAIWKGISSLLGKRGLNNLNDFDELFDGEITKADLDFMREIMK{ct:Amid} | Pantinin-2 | Amidation | Free | Linear | L | None | 68 | Antimicrobial | 8 % Hemolysis at 16 µM | Human | Scorpion Pandinus Imperator | α-Helix | NA | ||
| 23624072 | 2013 | MKAQFAILLITLVLFOMFSOSEAIFGAIWKGISSLLGKRGLNNLNDFDELFDGEITKADLDFMREIMK{ct:Amid} | Pantinin-2 | Amidation | Free | Linear | L | None | 68 | Antimicrobial | 81 % Hemolysis at 32 µM | Human | Scorpion Pandinus Imperator | α-Helix | NA | ||
| 23624072 | 2013 | MKAQFAILLITLVLFOMFSOSEAIFGAIWKGISSLLGKRGLNNLNDFDELFDGEITKADLDFMREIMK{ct:Amid} | Pantinin-2 | Amidation | Free | Linear | L | None | 68 | Antimicrobial | 100 % Hemolysis at 64 µM | Human | Scorpion Pandinus Imperator | α-Helix | NA | ||
| 23624072 | 2013 | MKTQFAILLIALVLFOLLSOSCAFLSTIWNGIKSLLGRRGLNELDNLDELFDGEISQADIDFLKELMS{ct:Amid} | Pantinin-3 | Amidation | Free | Linear | L | None | 68 | Antimicrobial | 0 % Hemolysis at <8 µM | Human | Scorpion Pandinus Imperator | α-Helix | Non-hemolytic | ||
| 23624072 | 2013 | MKTQFAILLIALVLFOLLSOSCAFLSTIWNGIKSLLGRRGLNELDNLDELFDGEISQADIDFLKELMS{ct:Amid} | Pantinin-3 | Amidation | Free | Linear | L | None | 68 | Antimicrobial | 70 % Hemolysis at 16 µM | Human | Scorpion Pandinus Imperator | α-Helix | NA | ||
| 23624072 | 2013 | MKTQFAILLIALVLFOLLSOSCAFLSTIWNGIKSLLGRRGLNELDNLDELFDGEISQADIDFLKELMS{ct:Amid} | Pantinin-3 | Amidation | Free | Linear | L | None | 68 | Antimicrobial | 100 % Hemolysis at 32 µM | Human | Scorpion Pandinus Imperator | α-Helix | NA | ||
| 24012601 | 2013 | INLKAIAALAKKLL | Mastoparan-VT1 | Free | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 100 µg/ml | Human | Venom Gland Of The Wasp Vespa Tropica | NA | Non-hemolytic | ||
| 24012601 | 2013 | NLKAIAALAKKLL | Mastoparan-VT2 | Free | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 100 µg/ml | Human | Venom Gland Of The Wasp Vespa Tropica | NA | Non-hemolytic | ||
| 24012601 | 2013 | INLKAIATLAKKLL | Mastoparan-VT3 | Free | Free | Linear | L | None | 14 | Antimicrobial | 25.04±5.12 % Hemolysis at 100 µg/ml | Human | Venom Gland Of The Wasp Vespa Tropica | NA | Non-hemolytic | ||
| 24012601 | 2013 | FLPIIGKLLSGLL | VCP-VT1 | Free | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 100 µg/ml | Human | Venom Gland Of The Wasp Vespa Tropica | NA | Non-hemolytic | ||
| 24012601 | 2013 | FLPIIGKLLSG | VCP-VT2 | Free | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 100 µg/ml | Human | Venom Gland Of The Wasp Vespa Tropica | NA | Non-hemolytic | ||
| 24105706 | 2013 | KRIVQRIKDFLR{ct:Amid} | KR-12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial and Antiendotoxic | 50 % Hemolysis at >800 µM | Human | Ll-37 | α-Helix | NA | ||
| 24105706 | 2013 | KRIVQRIKDWLR{ct:Amid} | KR-12-a1 | Amidation | Free | Linear | L | None | 12 | Antimicrobial and Antiendotoxic | 50 % Hemolysis at >800 µM | Human | Analog Of Kr-12 | α-Helix | NA | ||
| 24105706 | 2013 | KRIVQRIKKWLR{ct:Amid} | KR-12-a2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial and Antiendotoxic | 50 % Hemolysis at >800 µM | Human | Analog Of Kr-12 | α-Helix | NA | ||
| 24105706 | 2013 | KRIVKRIKKWLR{ct:Amid} | KR-12-a3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial and Antiendotoxic | 50 % Hemolysis at >800 µM | Human | Analog Of Kr-12 | α-Helix | NA | ||
| 24105706 | 2013 | KRIVKLIKKWLR{ct:Amid} | KR-12-a4 | Amidation | Free | Linear | L | None | 12 | Antimicrobial and Antiendotoxic | 50 % Hemolysis at >800 µM | Human | Analog Of Kr-12 | α-Helix | NA | ||
| 24105706 | 2013 | KRIVKLILKWLR{ct:Amid} | KR-12-a5 | Amidation | Free | Linear | L | None | 12 | Antimicrobial and Antiendotoxic | 50 % Hemolysis at 96 µM | Human | Analog Of Kr-12 | α-Helix | NA | ||
| 24105706 | 2013 | LRIVKLILKWLR{ct:Amid} | KR-12-a6 | Amidation | Free | Linear | L | None | 12 | Antimicrobial and Antiendotoxic | 50 % Hemolysis at 22 µM | Human | Analog Of Kr-12 | α-Helix | NA | ||
| 24105706 | 2013 | KRIRKRIKKWLR{ct:Amid} | KR-12-a7 | Amidation | Free | Linear | L | None | 12 | Antimicrobial and Antiendotoxic | 50 % Hemolysis at >800 µM | Human | Analog Of Kr-12 | α-Helix | NA | ||
| 24105706 | 2013 | KRIRKRIKKWKR{ct:Amid} | KR-12-a8 | Amidation | Free | Linear | L | None | 12 | Antimicrobial and Antiendotoxic | 50 % Hemolysis at >800 µM | Human | Analog Of Kr-12 | α-Helix | NA | ||
| 24105706 | 2013 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at 175 µM | Human | Human Leukocytes And Epithelia | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPETKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | Hymenochirin-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 213 ± 18 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | LKIPGFVKDTLKKVAKGIFSAVAGAMTPS | Hymenochirin-2B | Free | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 210 ± 21 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKIPAVVKDTLKKVAKGVLSAVAGALTQ | Hymenochirin-3B | Free | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at >400 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKIPAFVKDTLKKVAKGVISAVAGALTQ | Hymenochirin-4B | Free | Free | Linear | L | None | 28 | Antitumor | 50 % Hemolysis at 158 ± 6 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSKETKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [P5K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 205 ± 15 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPKTKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [E6K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 186 ± 4 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPETKKNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [D9K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 174 ± 12 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSKKTKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [P5K,E6K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 137 ± 11 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSKETKKNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [P5K,D9K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 127 ± 9 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPKTKKNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [E6K,D9K]-1B | Amidation | Free | Linear | L | None | 29 | Antitumor | 50 % Hemolysis at 85 ± 5 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPK{d}TKDNLKKVLKGAIKGAIAVAKMV{ct:Amid} | [E6k]-1B | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 29 | Antitumor | 50 % Hemolysis at 188 ± 8 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPETKK{d}NLKKVLKGAIKGAIAVAKMV{ct:Amid} | [D9k]-1B | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 29 | Antitumor | 50 % Hemolysis at >400 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24185042 | 2013 | IKLSPK{d}TKK{d}NLKKVLKGAIKGAIAVAKMV{ct:Amid} | [E6k,D9k]-1B | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 29 | Antitumor | 50 % Hemolysis at 302 ± 21 µM | Human | Congo Clawed Frog Hymenochirus Boettgeri | α-Helix | NA | ||
| 24307932 | 2013 | ARIVQRIKDFLR{ct:Amid} | KR-12A18 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Mutant Of Kr-12, Human Cathelicidin Ll-37 | Helical | Non-hemolytic | ||
| 24307932 | 2013 | KRIVQRIKDFLR{ct:Amid} | KR-12 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 10.6 % Hemolysis at 100 µM | Human | Human Cathelicidin Ll-37 | Helical | NA | ||
| 24307932 | 2013 | KAIVQRIKDFLR{ct:Amid} | KR-12A19 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Mutant Of Kr-12, Human Cathelicidin Ll-38 | Helical | Non-hemolytic | ||
| 24307932 | 2013 | KRIVQAIKDFLR{ct:Amid} | KR-12A23 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 8.5 % Hemolysis at 100 µM | Human | Mutant Of Kr-12, Human Cathelicidin Ll-39 | Helical | NA | ||
| 24307932 | 2013 | KRIVQRIADFLR{ct:Amid} | KR-12A25 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 9.4 % Hemolysis at 100 µM | Human | Mutant Of Kr-12, Human Cathelicidin Ll-40 | Helical | NA | ||
| 24307932 | 2013 | KRIVQRIKDFLA{ct:Amid} | KR-12A29 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0.2 % Hemolysis at 100 µM | Human | Mutant Of Kr-12, Human Cathelicidin Ll-41 | Helical | Non-hemolytic | ||
| 24307932 | 2013 | AQIVQRIKDFLR{ct:Amid} | KR-12A18Q19 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Mutant Of Kr-12, Human Cathelicidin Ll-42 | Helical | Non-hemolytic | ||
| 24307932 | 2013 | KKIVQKIKDFLK{ct:Amid} | KR-12 K | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 5 % Hemolysis at 100 µM | Human | Mutant Of Kr-12, Human Cathelicidin Ll-43 | Helical | NA | ||
| 24307932 | 2013 | RRIVQRIRDFLR{ct:Amid} | KR-12R | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 58 % Hemolysis at 100 µM | Human | Mutant Of Kr-12, Human Cathelicidin Ll-44 | Helical | NA | ||
| 23523532 | 2013 | GFGALFKFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | Cu 1a | Amidation | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at 7.8 (7.5–8.2) µM | Human | Venom Of The Ctenid Spider Cupiennius Salei | α-Helix | NA | ||
| 23523532 | 2013 | G{nnr:a}GAL{nnr:a}KFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | Cu 2a | Amidation | Free | Linear | L | a = exchanged residues of A-Cu 1a and K-Cu 1a | 35 | Antimicrobial | 50 % Hemolysis at 2.6 (2.4–2.8) µM | Human | Venom Of The Ctenid Spider Cupiennius Salei | α-Helix | NA | ||
| 23523532 | 2013 | G{nnr:k}GAL{nnr:k}KFLAKKVAKTVAKQAAKQGAKYVVNKQME{ct:Amid} | A-Cu 1a | Amidation | Free | Linear | L | k = exchanged residues of A-Cu 1a and K-Cu 1a | 35 | Antimicrobial | 50 % Hemolysis at >40 µM | Human | Venom Of The Ctenid Spider Cupiennius Salei | α-Helix | NA | ||
| 23523532 | 2013 | GFGTILKALAKIAGKVVKKLATKPGATYMLKENLK{ct:Amid} | K-Cu 1a | Amidation | Free | Linear | L | None | 35 | Antimicrobial | 50 % Hemolysis at >40 µM | Human | Venom Of The Ctenid Spider Cupiennius Salei | α-Helix | NA | ||
| 24243598 | 2013 | KWKKLLKKPLLKKLLKKL{ct:Amid} | P5 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 23868208 | 2013 | ALAGTIIAGASLTFQVLDKVLEELGKVSRK{ct:Amid} | StII1–30 | Amidation | Free | Linear | L | None | 30 | Cytolytic | 1.0±0.02 % Hemolysis at 40 µM | Human | Stichodactyla Helianthus | α-Helical | Non-hemolytic | ||
| 23868208 | 2013 | AWAGTIIAGASLTFQVLDKVLEELGKVSRK{ct:Amid} | StII1–30L2W | Amidation | Free | Linear | L | None | 30 | Cytolytic | 1.0±0.02 % Hemolysis at 40 µM | Human | Analogs Of Stii1–30 | α-Helical | Non-hemolytic | ||
| 23868208 | 2013 | ALAGTIIAGASWTFQVLDKVLEELGKVSRK{ct:Amid} | StII1–30L12W | Amidation | Free | Linear | L | None | 30 | Cytolytic | 1.0±0.01 % Hemolysis at 40 µM | Human | Analogs Of Stii1–30 | α-Helical | Non-hemolytic | ||
| 23868208 | 2013 | ALAGTIIAGASLTFQVWDKVLEELGKVSRK{ct:Amid} | StII1–30L17W | Amidation | Free | Linear | L | None | 30 | Cytolytic | 0.9 ±0.8 % Hemolysis at 40 µM | Human | Analogs Of Stii1–30 | α-Helical | Non-hemolytic | ||
| 23868208 | 2013 | ALAGTIIAGASLTFQVLDKVLEEWGKVSRK{ct:Amid} | StII1–30L24W | Amidation | Free | Linear | L | None | 30 | Cytolytic | 1.0±0.02 % Hemolysis at 40 µM | Human | Analogs Of Stii1–30 | α-Helical | Non-hemolytic | ||
| 23925670 | 2013 | FWGALAKGALKLIPSLFSSFSKKD | L-Pin2 | Free | Free | Linear | L | None | 24 | Antimicrobial | 80 % Hemolysis at 10 µM | Human | African Scorpion Pandinus Imperator | α-Helical | NA | ||
| 23925670 | 2013 | F{d}W{d}G{d}A{d}L{d}A{d}K{d}G{d}A{d}L{d}K{d}L{d}I{d}P{d}S{d}L{d}F{d}S{d}S{d}F{d}S{d}K{d}K{d}D{d} | D-Pin2 | Free | Free | Linear | D | lowercase letters correspond to D-amino acids | 24 | Antimicrobial | 50 % Hemolysis at 10 µM | Human | African Scorpion Pandinus Imperator | α-Helical | NA | ||
| 23951222 | 2013 | RKKRLKLLKRLV | SP1 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | RKRAARLLKRLV | SP2 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | RKRFARFAKRAV | SP3 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | KKKAARALKRAL | SP4 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | LLIAAFKKLVKK | SP5 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | ALAHFLKKAIKK | SP6 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | NA | NA | ||
| 23951222 | 2013 | LLIKFLKRFIKH | SP7 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | LLIRAAKKFIKK | SP8 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | LLKALKKLLKKLL | SP9 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at 50 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | LRFLKKILKHLF | SP10 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at 100 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | LRALAKALKHKL | SP11 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | LKALRKALKHLA | SP12 | Free | Free | Linear | L | None | 12 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | KRRLIARILRLAARALVKKR | SP13 | Free | Free | Linear | L | None | 20 | Antimicrobial | 25 % Hemolysis at 100 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | KRKLTLVFGVMAGVIGTKKR | SP14 | Free | Free | Linear | L | None | 20 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | Strand | NA | ||
| 23951222 | 2013 | KRKLIFLAAFLAALALFKKR | SP15 | Free | Free | Linear | L | None | 20 | Antimicrobial | 25 % Hemolysis at <20 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23951222 | 2013 | KRRLAAFRAFRGALKSVLKK | SP16 | Free | Free | Linear | L | None | 20 | Antimicrobial | 25 % Hemolysis at >200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.1 % Hemolysis at 25 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.1 % Hemolysis at 50 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.2 % Hemolysis at 100 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.2 % Hemolysis at 150 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.4 % Hemolysis at 200 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 24009675 | 2013 | NIVNVSLVK | NK9 | Free | Free | Linear | L | None | 9 | Cytotoxicity | <0.5 % Hemolysis at 250 µM | Human | Sars Corona Virus E-Protein | α-Helical | Non-hemolytic | ||
| 23710779 | 2013 | IKKILSKIKKLLK | L-K6 | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >5 µM | Human | Frog Skin Peptide Temporin-1Ceb | α-Helical | NA | ||
| 23710779 | 2013 | WKKILSKIKKLLK | I1W | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >5 µM | Human | L-K6 Analogues | α-Helical | NA | ||
| 23710779 | 2013 | IKKWLSKIKKLLK | I4W | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >5 µM | Human | L-K6 Analogues | α-Helical | NA | ||
| 23710779 | 2013 | IKKIWSKIKKLLK | L5W | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >5 µM | Human | L-K6 Analogues | α-Helical | NA | ||
| 23710779 | 2013 | IKKILSKIKKWLK | L11W | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >5 µM | Human | L-K6 Analogues | α-Helical | NA | ||
| 23710779 | 2013 | IKKILSKIKKLWK | L12W | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >5 µM | Human | L-K6 Analogues | α-Helical | NA | ||
| 23710779 | 2013 | IKKIWSKIKKWLK | L5WL11W | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >500 µM | Human | L-K6 Analogues | α-Helical | NA | ||
| 23710779 | 2013 | IKKIWSKIKKLWK | L5WL12W | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >500 µM | Human | L-K6 Analogues | α-Helical | NA | ||
| 23710779 | 2013 | IKKILSKIKKWWK | L11WL12W | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >500 µM | Human | L-K6 Analogues | α-Helical | NA | ||
| 23710779 | 2013 | IKKIWSKIKKWWK | L5WL11WL12W | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >500 µM | Human | L-K6 Analogues | α-Helical | NA | ||
| 23831136 | 2013 | NGVQPKY | Luecrocin I | Free | Free | Linear | L | None | 7 | Antibacterial | 0 % Hemolysis at 91 μg/mL | Human | White Blood Cells Of Crocodylus Siamensis | α-Helical | Non-hemolytic | ||
| 23831136 | 2013 | NGVQPKYKWWKWWKKWW{ct:Amid} | KT2 | Amidation | Free | Linear | L | None | 17 | Antibacterial | <20 % Hemolysis at 91 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23831136 | 2013 | NGVQPKYRWWRWWRRWW{ct:Amid} | RT2 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 10 % Hemolysis at 91 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23831136 | 2013 | NGVQPKYKWWKWWKKWWW{ct:Amid} | KT3 | Amidation | Free | Linear | L | None | 18 | Antibacterial | <60 % Hemolysis at 91 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23831136 | 2013 | NGVQPKYRWWRWWRRWW | CRT2 | Free | Free | Linear | L | None | 17 | Antibacterial | 20 % Hemolysis at 91 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23831136 | 2013 | NGVQPKYRWWRWWRRWWW | CRT3 | Free | Free | Linear | L | None | 18 | Antibacterial | <30 % Hemolysis at 91 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23831136 | 2013 | NGVQPWYKWWKWWKKWW{ct:Amid} | KWKT2 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 60 % Hemolysis at 91 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23831136 | 2013 | NGVQPKYRWWRWWRRWWWW{ct:Amid} | RT4 | Amidation | Free | Linear | L | None | 19 | Antibacterial | <60 % Hemolysis at 91 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23831136 | 2013 | RWWRWWRRWW{ct:Amid} | RW2 | Amidation | Free | Linear | L | None | 10 | Antibacterial | <70 % Hemolysis at 91 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 23831136 | 2013 | RWWRWWRRWWW{ct:Amid} | RW3 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <90 % Hemolysis at 91 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 24105706 | 2013 | KRIVQRIKDFLR{ct:Amid} | KR-12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >800 µM | Human | Smallest Region Of Ll-37 | α-Helical | NA | ||
| 24147906 | 2013 | A{d}L{d}L{d}L | 0 | Free | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 4 | Antibacterial | 15.6 ± 3.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLLLL | 1 | Free | Free | Linear | L | None | 5 | Antibacterial | 6.9 ± 1.8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLLLD | 2 | Free | Free | Linear | L | None | 5 | Antibacterial | 6.0 ± 0.5 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLLDL | 3 | Free | Free | Linear | L | None | 5 | Antibacterial | 2.7 ± 0.1 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLDLL | 4 | Free | Free | Linear | L | None | 5 | Antibacterial | 2.7 ± 1.4 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDLLL | 5 | Free | Free | Linear | L | None | 5 | Antibacterial | 4.2 ± 0.6 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLLLL | 6 | Free | Free | Linear | L | None | 5 | Antibacterial | 4.2 ± 0.8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLLDD | 7 | Free | Free | Linear | L | None | 5 | Antibacterial | 5.1 ± 2.3 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLDLD | 8 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.3 ± 0.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDLLD | 9 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.4 ± 1.5 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLLLD | 10 | Free | Free | Linear | L | None | 5 | Antibacterial | 2.4 ± 0.8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLDDL | 11 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.7 ± 1.7 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDLDL | 12 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.9 ± 2.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLLDL | 13 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.7 ± 0.3 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDDLL | 14 | Free | Free | Linear | L | None | 5 | Antibacterial | 0.5 ± 0.5 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLDLL | 15 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.6 ± 0.6 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDLLL | 16 | Free | Free | Linear | L | None | 5 | Antibacterial | 4.1 ± 0.9 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LLDDD | 17 | Free | Free | Linear | L | None | 5 | Antibacterial | 6.2 ± 0.4 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDLDD | 18 | Free | Free | Linear | L | None | 5 | Antibacterial | 0–0.9 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLLDD | 19 | Free | Free | Linear | L | None | 5 | Antibacterial | 0.5 ± 0.5 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDDLD | 20 | Free | Free | Linear | L | None | 5 | Antibacterial | 0.8 ± 0.1 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLDLD | 21 | Free | Free | Linear | L | None | 5 | Antibacterial | 0–0.6 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDLLD | 22 | Free | Free | Linear | L | None | 5 | Antibacterial | 8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDDDL | 23 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.3 ± 0.3 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLDDL | 24 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.0 ± 0.7 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDLDL | 25 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.5 ± 1.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDDLL | 26 | Free | Free | Linear | L | None | 5 | Antibacterial | 5.3 ± 0.3 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | LDDDD | 27 | Free | Free | Linear | L | None | 5 | Antibacterial | 1.3 ± 0.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DLDDD | 28 | Free | Free | Linear | L | None | 5 | Antibacterial | 0–1.4 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDLDD | 29 | Free | Free | Linear | L | None | 5 | Antibacterial | 3.1 ± 1.1 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDDLD | 30 | Free | Free | Linear | L | None | 5 | Antibacterial | 0–3.1 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDDDL | 31 | Free | Free | Linear | L | None | 5 | Antibacterial | 8.5 ± 3.8 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24147906 | 2013 | DDDDD | 32 | Free | Free | Linear | L | None | 5 | Antibacterial | 15 ± 2.2 % Hemolysis at 142 µM | Human | Synthetic | α-Helical | NA | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 1.3 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 2.5 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 5 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 10 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 20 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 40 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | LLCIALRKK{ct:Amid} | L-CopA3 | Amidation | Free | Linear | L | None | 9 | Antifungal | 0 % Hemolysis at 80 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 1.3 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 2.5 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 5 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 10 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 20 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 40 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | L{d}L{d}C{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | D-CopA3 | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 9 | Antifungal | 0 % Hemolysis at 80 µM | Human | Truncated Coprisin Analog Peptide | α-Helical | Non-hemolytic | ||
| 24041699 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antifungal | 13.5 % Hemolysis at 1.3 µM | Human | Bee Venom | α-Helical | NA | ||
| 24041699 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antifungal | 38.7 % Hemolysis at 2.5 µM | Human | Bee Venom | α-Helical | NA | ||
| 24041699 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antifungal | 74.9 % Hemolysis at 5 µM | Human | Bee Venom | α-Helical | NA | ||
| 24041699 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antifungal | 100 % Hemolysis at 10 µM | Human | Bee Venom | α-Helical | NA | ||
| 24041699 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antifungal | 100 % Hemolysis at 20 µM | Human | Bee Venom | α-Helical | NA | ||
| 24041699 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antifungal | 100 % Hemolysis at 40 µM | Human | Bee Venom | α-Helical | NA | ||
| 24041699 | 2013 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antifungal | 100 % Hemolysis at 80 µM | Human | Bee Venom | α-Helical | NA | ||
| 24055160 | 2013 | FFPFLLGALGSLLPKIF{ct:Amid} | Temporin-SN1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 82.5 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FITGLIGGLMKAL{ct:Amid} | Temporin-SN2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | FISGLIGGLMKAL{ct:Amid} | Temporin-SN3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | FITGLISGLLMKAL{ct:Amid} | Temporin-SN4 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | AMPWRPATGLLPIKKPTHIKPLCGDD | Spinulosain-A1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | GFLNTAMNTVTNLAGTLMDKAKCKIRGC | Ranatuerin-2SN1 | Free | Free | Linear | L | None | 28 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | FLPAVLKVAAHILPTAICAISRRC | Brevinin-1SN1 | Free | Free | Linear | L | None | 24 | Antimicrobial | 10.5 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FMGTALKIAANVLPAAFCKIFKKC | Brevinin-1SN2 | Free | Free | Linear | L | None | 24 | Antimicrobial | 51.5 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GLRDKIKNVAIDVAKGAGTGVLKALLCOLDKSC | Brevinin-2SN1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 31.8 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GVLDTLKNVAIGVAKGAGTGVLKALLCQLDKSC | Brevinin-2SN2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 50.1 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GAFGNLLKGVAKKAGLKILSIAQCKLSGTC | Brevinin-2SN3 | Free | Free | Linear | L | None | 30 | Antimicrobial | 12.7 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GAFGDLLKGVAKEAGLKLLNMAQCKLSGNO | Brevinin-2SN4 | Free | Free | Linear | L | None | 30 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | GIFSLFKAGAKFFGKNLLKEAGKAGAEHLACKAANQC | Esculentin-2SN1 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | FFPFLLGALGSLLPKIF{ct:Amid} | Temporin-SN1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 100 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FITGLIGGLMKAL{ct:Amid} | Temporin-SN2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | FISGLIGGLMKAL{ct:Amid} | Temporin-SN3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10.5 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FITGLISGLLMKAL{ct:Amid} | Temporin-SN4 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 11.1 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | AMPWRPATGLLPIKKPTHIKPLCGDD | Spinulosain-A1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | GFLNTAMNTVTNLAGTLMDKAKCKIRGC | Ranatuerin-2SN1 | Free | Free | Linear | L | None | 28 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | FLPAVLKVAAHILPTAICAISRRC | Brevinin-1SN1 | Free | Free | Linear | L | None | 24 | Antimicrobial | 30.2 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FMGTALKIAANVLPAAFCKIFKKC | Brevinin-1SN2 | Free | Free | Linear | L | None | 24 | Antimicrobial | 91.4 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GLRDKIKNVAIDVAKGAGTGVLKALLCOLDKSC | Brevinin-2SN1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 54.1 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GVLDTLKNVAIGVAKGAGTGVLKALLCQLDKSC | Brevinin-2SN2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 91.4 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GAFGNLLKGVAKKAGLKILSIAQCKLSGTC | Brevinin-2SN3 | Free | Free | Linear | L | None | 30 | Antimicrobial | 29.8 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GAFGDLLKGVAKEAGLKLLNMAQCKLSGNO | Brevinin-2SN4 | Free | Free | Linear | L | None | 30 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | GIFSLFKAGAKFFGKNLLKEAGKAGAEHLACKAANQC | Esculentin-2SN1 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | FFPFLLGALGSLLPKIF{ct:Amid} | Temporin-SN1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 100 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FITGLIGGLMKAL{ct:Amid} | Temporin-SN2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 11.2 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FISGLIGGLMKAL{ct:Amid} | Temporin-SN3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 53.1 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FITGLISGLLMKAL{ct:Amid} | Temporin-SN4 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 51.6 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | AMPWRPATGLLPIKKPTHIKPLCGDD | Spinulosain-A1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 0 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | Non-hemolytic | ||
| 24055160 | 2013 | GFLNTAMNTVTNLAGTLMDKAKCKIRGC | Ranatuerin-2SN1 | Free | Free | Linear | L | None | 28 | Antimicrobial | 10.3 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FLPAVLKVAAHILPTAICAISRRC | Brevinin-1SN1 | Free | Free | Linear | L | None | 24 | Antimicrobial | 50.2 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | FMGTALKIAANVLPAAFCKIFKKC | Brevinin-1SN2 | Free | Free | Linear | L | None | 24 | Antimicrobial | 100 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GLRDKIKNVAIDVAKGAGTGVLKALLCOLDKSC | Brevinin-2SN1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 90.2 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GVLDTLKNVAIGVAKGAGTGVLKALLCQLDKSC | Brevinin-2SN2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 100 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GAFGNLLKGVAKKAGLKILSIAQCKLSGTC | Brevinin-2SN3 | Free | Free | Linear | L | None | 30 | Antimicrobial | 53.4 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GAFGDLLKGVAKEAGLKLLNMAQCKLSGNO | Brevinin-2SN4 | Free | Free | Linear | L | None | 30 | Antimicrobial | 11.9 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 24055160 | 2013 | GIFSLFKAGAKFFGKNLLKEAGKAGAEHLACKAANQC | Esculentin-2SN1 | Free | Free | Linear | L | None | 37 | Antimicrobial | 9.1 % Hemolysis at 200 µM | Human | Skin Of H. Spinulosa | NA | NA | ||
| 23816372 | 2013 | WRWRWR{ct:Amid} | 1 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 10 % Hemolysis at >256 μg/mL | Human | Synthetic | α-Helical | Non-hemolytic | ||
| 23816372 | 2013 | WRWR{ct:Amid} | 2 | Amidation | Free | Linear | L | None | 4 | Antimicrobial | 10 % Hemolysis at >256 μg/mL | Human | Synthetic | α-Helical | Non-hemolytic | ||
| 23816372 | 2013 | RWR{ct:Amid} | 3 | Amidation | Free | Linear | L | None | 3 | Antimicrobial | 10 % Hemolysis at >256 μg/mL | Human | Synthetic | α-Helical | Non-hemolytic | ||
| 24349477 | 2013 | IWGLIAHGVGHVGRLIHGLIRG | Pc-pis | Free | Free | Linear | L | None | 22 | Antimicrobial | 15.303 % Hemolysis at 24 µM | Human | Pseudosciaena Crocea | α-Helix | NA | ||
| 24349477 | 2013 | IWGLIAHGVGHVGRLIHGLIRGH | Pc-pis-His | Free | Free | Linear | L | None | 23 | Antimicrobial | 0 % Hemolysis at 6 µM | Human | Pc-Pis Analogue | α-Helix | Non-hemolytic | ||
| 24349477 | 2013 | IWGLIAHGVGHVGRLIHGLIRGH | Pc-pis-His | Free | Free | Linear | L | None | 23 | Antimicrobial | 3.573 % Hemolysis at 12 µM | Human | Pc-Pis Analogue | α-Helix | NA | ||
| 24279498 | 2013 | RLARIVVIRVAR{ct:Amid} | WT | Amidation | Free | Linear | L | None | 12 | Antimicrobial | ~40 % Hemolysis at 50 µg/ml | Human | Synthetic | NA | NA | ||
| 24279498 | 2013 | RRWRIVVIRVRR{ct:Amid} | sub3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | ~55 % Hemolysis at 50 µg/ml | Human | Synthetic | NA | NA | ||
| 24279498 | 2013 | RLARIVRIRVRR{ct:Amid} | 7R11R | Amidation | Free | Linear | L | None | 12 | Antimicrobial | ≤10 % Hemolysis at 50 µg/ml | Human | Synthetic | NA | NA | ||
| 24279498 | 2013 | RLRRIWVIRVAR{ct:Amid} | 3R6W | Amidation | Free | Linear | L | None | 12 | Antimicrobial | ≤10 % Hemolysis at 50 µg/ml | Human | Synthetic | NA | NA | ||
| 24279498 | 2013 | RLRRIWVIRVAR{ct:Amid} | 2R6W | Amidation | Free | Linear | L | None | 12 | Antimicrobial | ~20 % Hemolysis at 50 µg/ml | Human | Synthetic | NA | NA | ||
| 24279498 | 2013 | RWARRVVIRVAR{ct:Amid} | 2W5R | Amidation | Free | Linear | L | None | 12 | Antimicrobial | ≤10 % Hemolysis at 50 µg/ml | Human | Synthetic | NA | NA | ||
| 24279498 | 2013 | RWWRIVVIRVAR{ct:Amid} | 2W3W | Amidation | Free | Linear | L | None | 12 | Antimicrobial | ~30 % Hemolysis at 50 µg/ml | Human | Synthetic | NA | NA | ||
| 24279498 | 2013 | RLWRWVVIRVAR{ct:Amid} | 3W5W | Amidation | Free | Linear | L | None | 12 | Antimicrobial | ≤10 % Hemolysis at 50 µg/ml | Human | Synthetic | NA | NA | ||
| 24386139 | 2013 | FAVWGCADYRGYCRAACFAFEYSLGPKGCTEGYVCCVPNTF | CFBD-1 | Free | Free | Linear | L | None | 41 | Antimicrobial | 2.5 % Hemolysis at 400 µg/ml | Human | Salamander Skin Secretions Of C. Fudingensis | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYL | BP134 | Free | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLAGPA | BP199 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLKDEL | BP214 | Free | Free | Linear | L | None | 15 | Antimicrobial | 2 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYL | BP203 | Free | Free | Linear | L | None | 22 | Antimicrobial | 91 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYL | BP202 | Free | Free | Linear | L | None | 26 | Antimicrobial | 83 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKKLFKKILKYL | BP193 | Free | Free | Linear | L | None | 27 | Antimicrobial | 62 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKKLFKKILKYL | BP195 | Free | Free | Linear | L | None | 27 | Antimicrobial | 71 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPA | BP200 | Free | Free | Linear | L | None | 30 | Antimicrobial | 79 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYLKDEL | BP198 | Free | Free | Linear | L | None | 26 | Antimicrobial | 59 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP192 | Free | Free | Linear | L | None | 30 | Antimicrobial | 51 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPALYKLIKKFLKKKDEL | BP213 | Free | Free | Linear | L | None | 30 | Antimicrobial | 90 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP194 | Free | Free | Linear | L | None | 31 | Antimicrobial | 71 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP196 | Free | Free | Linear | L | None | 31 | Antimicrobial | 61 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPAKDWEHLKDWEHLKDWEHLKDEL | BP236 | Free | Free | Linear | L | None | 52 | Antimicrobial | 49 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYLKKLFKKILKYL | BP204 | Free | Free | Linear | L | None | 33 | Antimicrobial | 97 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPAKKLFKKILKYL | BP201 | Free | Free | Linear | L | None | 41 | Antimicrobial | 74 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP216 | Free | Free | Linear | L | None | 45 | Antimicrobial | 89 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KDWEHLKDWEHLKDWEHL | tag54 | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KDWEHLKDWEHLKDWEHLKDEL | tag54-2 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLTTGLPALISW | BP170 | Free | Free | Linear | L | None | 21 | Antimicrobial | 82 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPATTGLPALISW | BP171 | Free | Free | Linear | L | None | 25 | Antimicrobial | 5 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPATTGLPALISW | BP207 | Free | Free | Linear | L | None | 26 | Antimicrobial | 5 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPATTGLPALISW | BP208 | Free | Free | Linear | L | None | 26 | Antimicrobial | 15 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLTTGLPALISWKDEL | BP172 | Free | Free | Linear | L | None | 25 | Antimicrobial | 14 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPATTGLPALISWKDEL | BP173 | Free | Free | Linear | L | None | 29 | Antimicrobial | 8 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLGIGAVLKVLTTGLKDEL | BP189 | Free | Free | Linear | L | None | 28 | Antimicrobial | 41 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLTTGLPALISAGPASILAPLGTTLYKLIKKFLKKKDEL | BP217 | Free | Free | Linear | L | None | 48 | Antimicrobial | 91 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKFLHSAK | BP180 | Free | Free | Linear | L | None | 18 | Antimicrobial | 12 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKFLHSAK | BP181 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKFLHSAK | BP211 | Free | Free | Linear | L | None | 23 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKFLHSAK | BP212 | Free | Free | Linear | L | None | 23 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLKFLHSAKKDEL | BP182 | Free | Free | Linear | L | None | 22 | Antimicrobial | 1 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKFLHSAKKDEL | BP183 | Free | Free | Linear | L | None | 26 | Antimicrobial | 1 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKFLHSAKAGPAKDWEHLKDWEHLKDWEHLKDEL | BP235 | Free | Free | Linear | L | None | 48 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLGIGKFLHSAK | BP176 | Free | Free | Linear | L | None | 21 | Antimicrobial | 3 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAGIGKFLHSAK | BP175 | Free | Free | Linear | L | None | 25 | Antimicrobial | 6 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAGIGKFLHSAK | BP209 | Free | Free | Linear | L | None | 26 | Antimicrobial | 1 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAGIGKFLHSAK | BP210 | Free | Free | Linear | L | None | 26 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLGIGKFLHSAKKDEL | BP179 | Free | Free | Linear | L | None | 25 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAGIGKFLHSAKKDEL | BP178 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLAVAVVGQATQIAKKDEL | BP188 | Free | Free | Linear | L | None | 28 | Antimicrobial | 10 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAVAVVGQATQIAKKDEL | BP215 | Free | Free | Linear | L | None | 31 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | AVAVVGQATQIAKKKLFKKILKYLKDEL | BP190 | Free | Free | Linear | L | None | 28 | Antimicrobial | 11 % Hemolysis at 50 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYL | BP134 | Free | Free | Linear | L | None | 11 | Antimicrobial | 8 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPA | BP199 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLKDEL | BP214 | Free | Free | Linear | L | None | 15 | Antimicrobial | 6 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYL | BP203 | Free | Free | Linear | L | None | 22 | Antimicrobial | 93 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYL | BP202 | Free | Free | Linear | L | None | 26 | Antimicrobial | 93 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKKLFKKILKYL | BP193 | Free | Free | Linear | L | None | 27 | Antimicrobial | 63 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKKLFKKILKYL | BP195 | Free | Free | Linear | L | None | 27 | Antimicrobial | 73 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPA | BP200 | Free | Free | Linear | L | None | 30 | Antimicrobial | 80 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYLKDEL | BP198 | Free | Free | Linear | L | None | 26 | Antimicrobial | 72 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP192 | Free | Free | Linear | L | None | 30 | Antimicrobial | 69 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPALYKLIKKFLKKKDEL | BP213 | Free | Free | Linear | L | None | 30 | Antimicrobial | 92 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP194 | Free | Free | Linear | L | None | 31 | Antimicrobial | 87 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP196 | Free | Free | Linear | L | None | 31 | Antimicrobial | 66 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPAKDWEHLKDWEHLKDWEHLKDEL | BP236 | Free | Free | Linear | L | None | 52 | Antimicrobial | 84 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYLKKLFKKILKYL | BP204 | Free | Free | Linear | L | None | 33 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPAKKLFKKILKYL | BP201 | Free | Free | Linear | L | None | 41 | Antimicrobial | 81 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP216 | Free | Free | Linear | L | None | 45 | Antimicrobial | 98 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KDWEHLKDWEHLKDWEHL | tag54 | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KDWEHLKDWEHLKDWEHLKDEL | tag54-2 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLTTGLPALISW | BP170 | Free | Free | Linear | L | None | 21 | Antimicrobial | 93 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPATTGLPALISW | BP171 | Free | Free | Linear | L | None | 25 | Antimicrobial | 16 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPATTGLPALISW | BP207 | Free | Free | Linear | L | None | 26 | Antimicrobial | 36 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPATTGLPALISW | BP208 | Free | Free | Linear | L | None | 26 | Antimicrobial | 47 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLTTGLPALISWKDEL | BP172 | Free | Free | Linear | L | None | 25 | Antimicrobial | 49 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPATTGLPALISWKDEL | BP173 | Free | Free | Linear | L | None | 29 | Antimicrobial | 16 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLGIGAVLKVLTTGLKDEL | BP189 | Free | Free | Linear | L | None | 28 | Antimicrobial | 60 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLTTGLPALISAGPASILAPLGTTLYKLIKKFLKKKDEL | BP217 | Free | Free | Linear | L | None | 48 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKFLHSAK | BP180 | Free | Free | Linear | L | None | 18 | Antimicrobial | 54 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKFLHSAK | BP181 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKFLHSAK | BP211 | Free | Free | Linear | L | None | 23 | Antimicrobial | 1 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKFLHSAK | BP212 | Free | Free | Linear | L | None | 23 | Antimicrobial | 5 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKFLHSAKKDEL | BP182 | Free | Free | Linear | L | None | 22 | Antimicrobial | 38 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKFLHSAKKDEL | BP183 | Free | Free | Linear | L | None | 26 | Antimicrobial | 4 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKFLHSAKAGPAKDWEHLKDWEHLKDWEHLKDEL | BP235 | Free | Free | Linear | L | None | 48 | Antimicrobial | 0 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLGIGKFLHSAK | BP176 | Free | Free | Linear | L | None | 21 | Antimicrobial | 44 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAGIGKFLHSAK | BP175 | Free | Free | Linear | L | None | 25 | Antimicrobial | 14 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAGIGKFLHSAK | BP209 | Free | Free | Linear | L | None | 26 | Antimicrobial | 13 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAGIGKFLHSAK | BP210 | Free | Free | Linear | L | None | 26 | Antimicrobial | 17 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLGIGKFLHSAKKDEL | BP179 | Free | Free | Linear | L | None | 25 | Antimicrobial | 12 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAGIGKFLHSAKKDEL | BP178 | Free | Free | Linear | L | None | 29 | Antimicrobial | 3 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAVAVVGQATQIAKKDEL | BP188 | Free | Free | Linear | L | None | 28 | Antimicrobial | 24 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAVAVVGQATQIAKKDEL | BP215 | Free | Free | Linear | L | None | 31 | Antimicrobial | 3 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | AVAVVGQATQIAKKKLFKKILKYLKDEL | BP190 | Free | Free | Linear | L | None | 28 | Antimicrobial | 17 % Hemolysis at 150 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYL | BP134 | Free | Free | Linear | L | None | 11 | Antimicrobial | 18 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPA | BP199 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLKDEL | BP214 | Free | Free | Linear | L | None | 15 | Antimicrobial | 9 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYL | BP203 | Free | Free | Linear | L | None | 22 | Antimicrobial | 95 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYL | BP202 | Free | Free | Linear | L | None | 26 | Antimicrobial | 98 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKKLFKKILKYL | BP193 | Free | Free | Linear | L | None | 27 | Antimicrobial | 74 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKKLFKKILKYL | BP195 | Free | Free | Linear | L | None | 27 | Antimicrobial | 71 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPA | BP200 | Free | Free | Linear | L | None | 30 | Antimicrobial | 81 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYLKDEL | BP198 | Free | Free | Linear | L | None | 26 | Antimicrobial | 72 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP192 | Free | Free | Linear | L | None | 30 | Antimicrobial | 69 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPALYKLIKKFLKKKDEL | BP213 | Free | Free | Linear | L | None | 30 | Antimicrobial | 98 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP194 | Free | Free | Linear | L | None | 31 | Antimicrobial | 932 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP196 | Free | Free | Linear | L | None | 31 | Antimicrobial | 74 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPAKDWEHLKDWEHLKDWEHLKDEL | BP236 | Free | Free | Linear | L | None | 52 | Antimicrobial | 92 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKKLFKKILKYLKKLFKKILKYL | BP204 | Free | Free | Linear | L | None | 33 | Antimicrobial | 100 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPAKKLFKKILKYL | BP201 | Free | Free | Linear | L | None | 41 | Antimicrobial | 83 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKKLFKKILKYLAGPAKKLFKKILKYLKDEL | BP216 | Free | Free | Linear | L | None | 45 | Antimicrobial | 100 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KDWEHLKDWEHLKDWEHL | tag54 | Free | Free | Linear | L | None | 18 | Antimicrobial | 1 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KDWEHLKDWEHLKDWEHLKDEL | tag54-2 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLTTGLPALISW | BP170 | Free | Free | Linear | L | None | 21 | Antimicrobial | 98 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPATTGLPALISW | BP171 | Free | Free | Linear | L | None | 25 | Antimicrobial | 34 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPATTGLPALISW | BP207 | Free | Free | Linear | L | None | 26 | Antimicrobial | 58 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPATTGLPALISW | BP208 | Free | Free | Linear | L | None | 26 | Antimicrobial | 68 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLTTGLPALISWKDEL | BP172 | Free | Free | Linear | L | None | 25 | Antimicrobial | 63 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPATTGLPALISWKDEL | BP173 | Free | Free | Linear | L | None | 29 | Antimicrobial | 40 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLGIGAVLKVLTTGLKDEL | BP189 | Free | Free | Linear | L | None | 28 | Antimicrobial | 86 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLTTGLPALISAGPASILAPLGTTLYKLIKKFLKKKDEL | BP217 | Free | Free | Linear | L | None | 48 | Antimicrobial | 100 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKFLHSAK | BP180 | Free | Free | Linear | L | None | 18 | Antimicrobial | 58 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKFLHSAK | BP181 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAKFLHSAK | BP211 | Free | Free | Linear | L | None | 23 | Antimicrobial | 6 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAKFLHSAK | BP212 | Free | Free | Linear | L | None | 23 | Antimicrobial | 12 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLKFLHSAKKDEL | BP182 | Free | Free | Linear | L | None | 22 | Antimicrobial | 59 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKFLHSAKKDEL | BP183 | Free | Free | Linear | L | None | 26 | Antimicrobial | 5 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAKFLHSAKAGPAKDWEHLKDWEHLKDWEHLKDEL | BP235 | Free | Free | Linear | L | None | 48 | Antimicrobial | 0 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | Non-hemolytic | ||
| 24376887 | 2013 | KKLFKKILKYLGIGKFLHSAK | BP176 | Free | Free | Linear | L | None | 21 | Antimicrobial | 59 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAGIGKFLHSAK | BP175 | Free | Free | Linear | L | None | 25 | Antimicrobial | 32 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | GKKLFKKILKYLAGPAGIGKFLHSAK | BP209 | Free | Free | Linear | L | None | 26 | Antimicrobial | 24 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | SKKLFKKILKYLAGPAGIGKFLHSAK | BP210 | Free | Free | Linear | L | None | 26 | Antimicrobial | 30 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLGIGKFLHSAKKDEL | BP179 | Free | Free | Linear | L | None | 25 | Antimicrobial | 35 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAGIGKFLHSAKKDEL | BP178 | Free | Free | Linear | L | None | 29 | Antimicrobial | 25 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAVAVVGQATQIAKKDEL | BP188 | Free | Free | Linear | L | None | 28 | Antimicrobial | 42 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | KKLFKKILKYLAGPAVAVVGQATQIAKKDEL | BP215 | Free | Free | Linear | L | None | 31 | Antimicrobial | 14 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 24376887 | 2013 | AVAVVGQATQIAKKKLFKKILKYLKDEL | BP190 | Free | Free | Linear | L | None | 28 | Antimicrobial | 32 % Hemolysis at 250 µM | Human | Bp100 Analogues | NA | NA | ||
| 23860860 | 2014 | SGKLCCRRKK{ct:Amid} | D0 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 2.2 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 23860860 | 2014 | SGKLYYRRKK{ct:Amid} | D1 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 2 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 23860860 | 2014 | SGKLWWRRKK{ct:Amid} | D2 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 2.5 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 23860860 | 2014 | SGKRWWRRKK{ct:Amid} | D3 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 23860860 | 2014 | RGKRWWRRKK{ct:Amid} | D4 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 55 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 23860860 | 2014 | RWKRWWRRKK{ct:Amid} | D5 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 6.5 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 23860860 | 2014 | RKKRWWRRKK{ct:Amid} | D6 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 6.5 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 24021230 | 2014 | GRFRRLRKKTRKRLKKIGKV{ct:Amid} | PMAP-36 (1–20) | Amidation | Free | Linear | L | None | 20 | Antimicrobial | <5 % Hemolysis at >256 µM | Human | Porcine Cathelicidin | α-Helix | Low hemolytic | ||
| 24021230 | 2014 | RFRRLRKKTRKRLKKI{ct:Amid} | RI16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | <5 % Hemolysis at >256 µM | Human | N-Terminal Of Pmap-36 | α-Helix | Low hemolytic | ||
| 24021230 | 2014 | RFRRLRWWTRKRLKKI{ct:Amid} | PRW3 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | <5 % Hemolysis at >256 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 24021230 | 2014 | RFRRLRWKTRWRLKKI{ct:Amid} | PRW4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | <5 % Hemolysis at >256 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 24021230 | 2014 | RFRRLRKWTRWRLKKI{ct:Amid} | PRW5 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | <5 % Hemolysis at >256 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 24021230 | 2014 | RFRRLRWKTRKRLWKI{ct:Amid} | PRW6 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | <5 % Hemolysis at >256 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 24102775 | 2014 | KKLFKKILKYL{ct:Amid} | BP100 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 22.0± 2.8 % Hemolysis at 150 µM | Human | Endoplasmic Reticulum (Er) | α-Helix | NA | ||
| 24102775 | 2014 | KKLFKKILKYLAGPATTGLPALISWKDEL | BP100.m | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.7 % Hemolysis at 150 µM | Human | Endoplasmic Reticulum (Er) | α-Helix | Non-hemolytic | ||
| 24102775 | 2014 | KKLFKKILKYLAGPAKFLHSAKKDEL | BP100.g | Free | Free | Linear | L | None | 26 | Antimicrobial | 0.2 % Hemolysis at 150 µM | Human | Endoplasmic Reticulum (Er) | α-Helix | Non-hemolytic | ||
| 24102775 | 2014 | KKLFKKILKYLAGPAKFLHSAKAGPAKDWEHLKDWEHLKDWEHLKDEL | BP100.gtag | Free | Free | Linear | L | None | 48 | Antimicrobial | 0 % Hemolysis at 150 µM | Human | Endoplasmic Reticulum (Er) | α-Helix | Non-hemolytic | ||
| 24102775 | 2014 | KKLFKKILKYLAGPAGIGKFLHSAKKDEL | BP100.g2 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0.2 % Hemolysis at 150 µM | Human | Endoplasmic Reticulum (Er) | α-Helix | Non-hemolytic | ||
| 24102775 | 2014 | KKLFKKILKYLAGPAVAVVGQATQIAKKDEL | BP100.C | Free | Free | Linear | L | None | 31 | Antimicrobial | 0.1 % Hemolysis at 150 µM | Human | Endoplasmic Reticulum (Er) | α-Helix | Non-hemolytic | ||
| 24102775 | 2014 | KDWEHLKDWEHLKDWEHLKDEL | Tag54 | Free | Free | Linear | L | None | 22 | Antimicrobial | 0 % Hemolysis at 150 µM | Human | Endoplasmic Reticulum (Er) | α-Helix | Non-hemolytic | ||
| 24176194 | 2014 | AKKVFKRLEKLFSKIWNWK{ct:Amid} | HPA3 | Amidation | Free | Linear | L | None | 19 | Antibacterial | 10 % Hemolysis at 49.2 µM | Human | Helicobacter Pylori | α-Helix | NA | ||
| 24176194 | 2014 | AKKVFKRLPKLFSKIWNWK{ct:Amid} | HPA3P | Amidation | Free | Linear | L | None | 19 | Antibacterial | 10 % Hemolysis at >800 µM | Human | Helicobacter Pylori | α-Helix | NA | ||
| 24176194 | 2014 | AKKVFKRLPKLPSKIWNWK{ct:Amid} | HPA3P2 | Amidation | Free | Linear | L | None | 19 | Antibacterial | 10 % Hemolysis at >800 µM | Human | Helicobacter Pylori | α-Helix | NA | ||
| 24176194 | 2014 | AKKVFKRLEKLFSKIWNWK{ct:Amid} | HPA3 | Amidation | Free | Linear | L | None | 19 | Antibacterial | 50 % Hemolysis at 397.7 µM | Human | Helicobacter Pylori | α-Helix | NA | ||
| 24176194 | 2014 | AKKVFKRLPKLFSKIWNWK{ct:Amid} | HPA3P | Amidation | Free | Linear | L | None | 19 | Antibacterial | 50 % Hemolysis at >800 µM | Human | Helicobacter Pylori | α-Helix | NA | ||
| 24176194 | 2014 | AKKVFKRLPKLPSKIWNWK{ct:Amid} | HPA3P2 | Amidation | Free | Linear | L | None | 19 | Antibacterial | 50 % Hemolysis at >800 µM | Human | Helicobacter Pylori | α-Helix | NA | ||
| 24221355 | 2014 | RGLRRLGRKIAHGVKKYGPTVLRIIRIA{ct:Amid} | SMAP-29 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 50 % Hemolysis at 86 µM | Human | Sheep Myeloid | α-Helix | NA | ||
| 24221355 | 2014 | RGLRRLGRKIAHGVKKYG{ct:Amid} | SMAP-18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at >400 µM | Human | Sheep Myeloid | α-Helix | NA | ||
| 24221355 | 2014 | RGWRRWGRKWAHGWKKYG{ct:Amid} | SMAP-18-W | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at >400 µM | Human | Sheep Myeloid | α-Helix | NA | ||
| 24277042 | 2014 | GLLKRIKTLL{ct:Amid} | Anoplin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 50 % Hemolysis at 1052.3 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | G{nnr:Cha}LKK({nnr:2-Nal})KTLL{ct:Amid} | Cha2 Lys5 2Nal6 | Amidation | Free | Linear | L | Cha = β-cyclohexylalanine, 2-Nal = 3-(2-naphthyl)-L-alanine | 10 | Antimicrobial | 50 % Hemolysis at 15.3 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | GLLKR({nnr:2-Nal})KTLL{ct:Amid} | 2Nal6 Lys8 | Amidation | Free | Linear | L | 2-Nal = 3-(2-naphthyl)-L-alanine | 10 | Antimicrobial | 50 % Hemolysis at 50.1 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | GLLKR({nnr:2-Nal})KL{nnr:Cha}{ct:Amid} | Lys5 2Nal6 Cha10 | Amidation | Free | Linear | L | Cha = β-cyclohexylalanine, 2-Nal = 3-(2-naphthyl)-L-alanine | 10 | Antimicrobial | 50 % Hemolysis at 26.6 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | GLLKRIKKL{nnr:Cha}{ct:Amid} | Lys8 Cha10 | Amidation | Free | Linear | L | Cha = β-cyclohexylalanine | 10 | Antimicrobial | 50 % Hemolysis at 12.4 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | G{nnr:Cha}LKKIKKL{nnr:Cha}{ct:Amid} | Cha2 Lys5 Lys8 Cha10 | Amidation | Free | Linear | L | Cha = β-cyclohexylalanine | 10 | Antimicrobial | 50 % Hemolysis at 0.5 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | GLLKKI{d}KTLL{ct:Amid} | Lys5 D-Ile6 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 10 | Antimicrobial | 50 % Hemolysis at 7209 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | GLLKKI{d}KKLL{ct:Amid} | Lys5 D-Ile6 Lys8 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 10 | Antimicrobial | 50 % Hemolysis at 1962.4 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | G{nnr:Cha}LKR({nnr:D-2-Nal})KKLL{ct:Amid} | Cha2 D-2Nal6 Lys8 | Amidation | Free | Linear | Mix | Cha = β-cyclohexylalanine, D-2-Nal = D-3-(2-naphthyl)-L-alanine | 10 | Antimicrobial | 50 % Hemolysis at 27 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | GLLKRiKTL{nnr:Cha}{ct:Amid} | Cha2 D-Ile6 Cha10 | Amidation | Free | Linear | Mix | Cha = β-cyclohexylalanine | 10 | Antimicrobial | 50 % Hemolysis at 225.6 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | GLLKR({nnr:D-2-Nal})KTL{nnr:Cha}{ct:Amid} | D-2Nal6 Cha10 | Amidation | Free | Linear | Mix | Cha = β-cyclohexylalanine, D-2-Nal = D-3-(2-naphthyl)-L-alanine | 10 | Antimicrobial | 50 % Hemolysis at 74.3 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24277042 | 2014 | GLLKKI({nnr:D-2-Nal})KKL{nnr:Cha}{ct:Amid} | Lys5 D-2Nal6 Lys8 Cha10 | Amidation | Free | Linear | Mix | Cha = β-cyclohexylalanine, D-2-Nal = D-3-(2-naphthyl)-L-alanine | 10 | Antimicrobial | 50 % Hemolysis at 23.6 µM | Human | Venom Of Spider Wasp (Anoplius Samariensis) | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLKTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | P | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | 5.2 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLK{d}TFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | K7D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 10.41 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLKTFKSLKK{d}TVLHTLLKAISS{nt:Acet}{ct:Amid} | K14D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 5.2 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLKTFKSLKKTVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K22D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 20.81 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLK{d}TFKSLKK{d}TVLHTLLKAISS{nt:Acet}{ct:Amid} | K7D/K14D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 20.81 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLK{d}TFKSLKKTVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K14D/K22D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 20.81 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLK{d}TFKSLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K7D/K14D/K22D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 81.31 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K7D/K10D/K14D/K22D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 325.2 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWK{d}SFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K3D/K7D/K10D/K14D/K22D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | >325.2 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | K{d}WK{d}SFLK{d}TFK{d}SLKK{d}TVLHTLLK{d}AISS{nt:Acet}{ct:Amid} | K1D/K3D/K7D/K10D/K14D/K22D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | >325.2 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFL{d}KTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | L6D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 10.41 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLKTFKSL{d}KKTVLHTLLKAISS{nt:Acet}{ct:Amid} | L12D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 20.81 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLKTFKSLKKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L20D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 20.81 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFL{d}KTFKSL{d}KKTVLHTLLKAISS{nt:Acet}{ct:Amid} | L6D/L12D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 20.81 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFLKTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L12D/L20D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 81.31 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFL{d}KTFKSL{d}KKTVLHTL{d}LKAISS{nt:Acet}{ct:Amid} | L6D/L12D/L20D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 162.61 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFL{d}KTFKSL{d}KKTVL{d}HTL{d}LKAISS{nt:Acet}{ct:Amid} | L6D/L12D /L17D/L20D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 81.3 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24805306 | 2014 | KWKSFL{d}KTFKSL{d}KKTVL{d}HTL{d}L{d}KAISS{nt:Acet}{ct:Amid} | L6D/L12D /L17D/L20 D /L21D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | >325.2 % Hemolysis at 650.4 μmol/L | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24321546 | 2014 | LL{nnr:SelenoCys}IALRKK{ct:Amid} | CopSe | Amidation | Free | Linear | L | selenocys = selenocysteine | 9 | Antimicrobial | 1.6 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LL{nnr:MethylCys}IALRKK{ct:Amid} | CopMe | Amidation | Free | Linear | L | methylcys = methylcysteine | 9 | Antimicrobial | 1 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLRIALRKK{ct:Amid} | CopR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLLIALRKK{ct:Amid} | CopL | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 30 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLWIALRKK{ct:Amid} | CopW | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 1.5 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | Non-hemolytic | ||
| 24321546 | 2014 | LLLIVLRKK{ct:Amid} | CopLV | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 13.6 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLCIALRKK{ct:Amid} | CopA3 (Mono) | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 2 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLCIALRKKLLCIALRKK{ct:Amid} | CopA3 (Dimer) | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 20 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLCKALRKI{ct:Amid} | CopIK (Mono) | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 2 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24321546 | 2014 | LLCKALRKILLCKALRKI{ct:Amid} | CopIK (Dimer) | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 2.6 % Hemolysis at 200 µg/ml | Human | Coprisin Analogs, Dung Beetle, Copris Tripartitus | α-Helix | NA | ||
| 24389272 | 2014 | GVWDWLKKTAKNVWNSDIVKQLKGKAINAAKNYVAEKIGATPS{ct:Amid} | Heterin-1 | Amidation | Free | Linear | L | None | 43 | Antimicrobial | 0 % Hemolysis at <2.5 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | Non-hemolytic | ||
| 24389272 | 2014 | GVWDWLKKTAKNVWNSDIVKQLKGKAINAAKNYVAEKIGATPS{ct:Amid} | Heterin-1 | Amidation | Free | Linear | L | None | 43 | Antimicrobial | 20.1 % Hemolysis at 5 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | GVWDWLKKTAKNVWNSDIVKQLKGKAINAAKNYVAEKIGATPS{ct:Amid} | Heterin-1 | Amidation | Free | Linear | L | None | 43 | Antimicrobial | 54.2 % Hemolysis at 10 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | GVWDWLKKTAKNVWNSDIVKQLKGKAINAAKNYVAEKIGATPS{ct:Amid} | Heterin-1 | Amidation | Free | Linear | L | None | 43 | Antimicrobial | 74.9 % Hemolysis at 20 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | GVWDWLKKTAKNVWNSDIVKQLKGKAINAAKNYVAEKIGATPS{ct:Amid} | Heterin-1 | Amidation | Free | Linear | L | None | 43 | Antimicrobial | 88.7 % Hemolysis at 40 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | FWGALAKGALKLIPSLVSSFTKKD{ct:Amid} | Heterin-2 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 2 % Hemolysis at 0.8 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | FWGALAKGALKLIPSLVSSFTKKD{ct:Amid} | Heterin-2 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 10.6 % Hemolysis at 1.6 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | FWGALAKGALKLIPSLVSSFTKKD{ct:Amid} | Heterin-2 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 49.3 % Hemolysis at 3.2 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | FWGALAKGALKLIPSLVSSFTKKD{ct:Amid} | Heterin-2 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 94 % Hemolysis at 6.4 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | FWGALAKGALKLIPSLVSSFT{ct:Amid} | Heterin-2M | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 0.8 µM | Human | Analog Of Heterinscorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | FWGALAKGALKLIPSLVSSFT{ct:Amid} | Heterin-2M | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 1.5 % Hemolysis at 1.6 µM | Human | Analog Of Heterinscorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | FWGALAKGALKLIPSLVSSFT{ct:Amid} | Heterin-2M | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 22.1 % Hemolysis at 3.2 µM | Human | Analog Of Heterinscorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | FWGALAKGALKLIPSLVSSFT{ct:Amid} | Heterin-2M | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 50.1 % Hemolysis at 6.4 µM | Human | Analog Of Heterinscorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | ILGEIWKGIKDIL{ct:Amid} | Spiniferin | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at <48 µM | Human | Scorpion Heterometrus Spinifer | α-Helix | Non-hemolytic | ||
| 24389272 | 2014 | ILGKIWKGIKNIL{ct:Amid} | Spiniferin-M | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at <3 µM | Human | Analog Of Spiniferin, Scorpion Heterometrus Spinifer | α-Helix | Non-hemolytic | ||
| 24389272 | 2014 | ILGKIWKGIKNIL{ct:Amid} | Spiniferin-M | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1.7 % Hemolysis at 6 µM | Human | Analog Of Spiniferin, Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | ILGKIWKGIKNIL{ct:Amid} | Spiniferin-M | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 19.1 % Hemolysis at 12 µM | Human | Analog Of Spiniferin, Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | ILGKIWKGIKNIL{ct:Amid} | Spiniferin-M | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 31.9 % Hemolysis at 24 µM | Human | Analog Of Spiniferin, Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24389272 | 2014 | ILGKIWKGIKNIL{ct:Amid} | Spiniferin-M | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 56.6 % Hemolysis at 48 µM | Human | Analog Of Spiniferin, Scorpion Heterometrus Spinifer | α-Helix | NA | ||
| 24595375 | 2014 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MP1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 26 µM | Human | Brazilian Wasp Polybia Paulista | α-Helix | NA | ||
| 24859674 | 2014 | MGWLKKLGKKIERVGQHTRDATIQTIGVAQQAVNVAATLKGLADG KILHNQNVNSWGPITVTPTTDGGETRFDGQIIVQMENDPVVAKAAANL AGKHAESSVVVQLDSDGNYRVVYGDPSKLDGKLRWQLVGHGRDHSET NNTRLSGYSADELAVKLAKFQQSFNQAENINNKPDHISIVGCSLVSDDKQ KGFMGWLKKLGKKIERVGQHTRDATIQTIGVAQQAVNVAATLKGLADG KILHNQNVNSWGPITVTPT | GWKL-LUCILIN-CPD-His8 | Free | Free | Linear | L | None | 257 | Antibacterial | 0 % Hemolysis at 56.4 µM | Human | Recombinant Protein | Random coils | Non-hemolytic | ||
| 24666608 | 2014 | NEGKAKCGNTAGSKLTFKSADECTKTGQK | oshem 1 | Free | Free | Linear | L | None | 29 | cytotoxic | 51.7 ± 6.5 % Hemolysis at 0.2 mg/L | Human | Jellyfish Olindias Sambaquiensis | Random coils and small α-Helix | NA | ||
| 24666608 | 2014 | NNSKAKCGDLAGWSKLTFKSADECTKTGQKS | oshem 2 | Free | Free | Linear | L | None | 31 | cytotoxic | 32.9 ± 8.7 % Hemolysis at 0.2 mg/L | Human | Jellyfish Olindias Sambaquiensis | Random coils | NA | ||
| 24675879 | 2014 | KKCKFFCKVKKKIKSIGFQIPIVSIPFK | Cathelicidin-RC1 | Free | Free | Linear | L | None | 28 | Antimicrobial | 0.2 % Hemolysis at 100 µg/ml | Human | Bullfrog Rana Catesbeiana | 44.8% Alphα-Helix, 12.2% Betα-Sheet, 14.9% Betα-Turn and 26.3% Random-coil | Low hemolytic | ||
| 24675879 | 2014 | KKCKFFCKVKKKIKSIGFQIPIVSIPFK | Cathelicidin-RC1 | Free | Free | Linear | L | None | 28 | Antimicrobial | 2.6 % Hemolysis at 200 µg/ml | Human | Bullfrog Rana Catesbeiana | 44.8% Alphα-Helix, 12.2% Betα-Sheet, 14.9% Betα-Turn and 26.3% Random-coil | Low hemolytic | ||
| 24127254 | 2014 | KWKSFLKTFKSAKKTVLHTALKA{nnr:I}SS{nt:Acet}{ct:Amid} | V13K | Amidation | Acetylation | Linear | L | I = L-Isoleucine, 2S,3S = 2-amino-3-methyl-valeric acid | 26 | Antimicrobial | 10 % Hemolysis at 250 µg/ml | Human | Model Peptide | α-Helix | NA | ||
| 24127254 | 2014 | KWKSFLKTFKSAKKTVLHTALKA{nnr:alloI}SS{nt:Acet}{ct:Amid} | a-V13K | Amidation | Acetylation | Linear | L | alloI = L-allo-Ile, 2S,3R = 2-amino-3-methyl-valeric acid | 26 | Antimicrobial | 10 % Hemolysis at 500 µg/ml | Human | Model Peptide | α-Helix | Non-hemolytic | ||
| 24168384 | 2014 | GFFLNALKNFAKTAGKRLKSLLNHASCKLSGQC | Cyanophlyctin b | Free | Free | Linear | L | None | 33 | Antibacterial | 0.7 % Hemolysis at 500 µg/ml | Human | Skin Secretions Of Euphlyctis Cyanophlyctis | α-Helix | Non-hemolytic | ||
| 24168384 | 2014 | VIPFVASVAAEMMQHIFCAASRKC | Brevini-Eu | Free | Free | Linear | L | None | 24 | Antibacterial | 1.9 % Hemolysis at 500 µg/ml | Human | Skin Secretions Of Euphlyctis Cyanophlyctis | α-Helix | Non-hemolytic | ||
| 24449502 | 2014 | GRAMVECWMDGHCRLLCKDGEDSIIRCRNRKRCCVPSRYLTIQPVTIHGILGWTTPQMSTTAPKMKTNITNR | DEFB120 | Free | Free | Linear | L | None | 68 | Antimicrobial | <5 % Hemolysis at 10 µg/ml | Human | Human Beta-Defensins | β-Sheet | Non-hemolytic | ||
| 24449502 | 2014 | GRAMVECWMDGHCRLLCKDGEDSIIRCRNRKRCCVPSRYLTIQPVTIHGILGWTTPQMSTTAPKMKTNITNR | DEFB120 | Free | Free | Linear | L | None | 68 | Antimicrobial | <5 % Hemolysis at 50 µg/ml | Human | Human Beta-Defensins | β-Sheet | Non-hemolytic | ||
| 24449502 | 2014 | GRAMVECWMDGHCRLLCKDGEDSIIRCRNRKRCCVPSRYLTIQPVTIHGILGWTTPQMSTTAPKMKTNITNR | DEFB120 | Free | Free | Linear | L | None | 68 | Antimicrobial | <5 % Hemolysis at 100 µg/ml | Human | Human Beta-Defensins | β-Sheet | Non-hemolytic | ||
| 24449502 | 2014 | GRAMVECWMDGHCRLLCKDGEDSIIRCRNRKRCCVPSRYLTIQPVTIHGILGWTTPQMSTTAPKMKTNITNR | DEFB120 | Free | Free | Linear | L | None | 68 | Antimicrobial | <5 % Hemolysis at 150 µg/ml | Human | Human Beta-Defensins | β-Sheet | Non-hemolytic | ||
| 24449502 | 2014 | GRAMVECWMDGHCRLLCKDGEDSIIRCRNRKRCCVPSRYLTIQPVTIHGILGWTTPQMSTTAPKMKTNITNR | DEFB120 | Free | Free | Linear | L | None | 68 | Antimicrobial | <5 % Hemolysis at 250 µg/ml | Human | Human Beta-Defensins | β-Sheet | Non-hemolytic | ||
| 24776889 | 2014 | FLFKLIPKAIKKLISKFK{nt:Amid} | AamAP1-Lysine | Free | Amidation | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 1 µM | Human | Analog Of Aamap1,Scorpion Venom | α-Helix | Non-hemolytic | ||
| 24776889 | 2014 | FLFKLIPKAIKKLISKFK{nt:Amid} | AamAP1-Lysine | Free | Amidation | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Analog Of Aamap1,Scorpion Venom | α-Helix | Non-hemolytic | ||
| 24776889 | 2014 | FLFKLIPKAIKKLISKFK{nt:Amid} | AamAP1-Lysine | Free | Amidation | Linear | L | None | 18 | Antimicrobial | 1.38 % Hemolysis at 10 µM | Human | Analog Of Aamap1,Scorpion Venom | α-Helix | NA | ||
| 24776889 | 2014 | FLFKLIPKAIKKLISKFK{nt:Amid} | AamAP1-Lysine | Free | Amidation | Linear | L | None | 18 | Antimicrobial | 7.25 % Hemolysis at 20 µM | Human | Analog Of Aamap1,Scorpion Venom | α-Helix | NA | ||
| 24776889 | 2014 | FLFKLIPKAIKKLISKFK{nt:Amid} | AamAP1-Lysine | Free | Amidation | Linear | L | None | 18 | Antimicrobial | 16.58 % Hemolysis at 40 µM | Human | Analog Of Aamap1,Scorpion Venom | α-Helix | NA | ||
| 24776889 | 2014 | FLFKLIPKAIKKLISKFK{nt:Amid} | AamAP1-Lysine | Free | Amidation | Linear | L | None | 18 | Antimicrobial | 21.29 % Hemolysis at 60 µM | Human | Analog Of Aamap1,Scorpion Venom | α-Helix | NA | ||
| 24776889 | 2014 | FLFKLIPKAIKKLISKFK{nt:Amid} | AamAP1-Lysine | Free | Amidation | Linear | L | None | 18 | Antimicrobial | 29.32 % Hemolysis at 80 µM | Human | Analog Of Aamap1,Scorpion Venom | α-Helix | NA | ||
| 24776889 | 2014 | FLFKLIPKAIKKLISKFK{nt:Amid} | AamAP1-Lysine | Free | Amidation | Linear | L | None | 18 | Antimicrobial | 38.25 % Hemolysis at 100 µM | Human | Analog Of Aamap1,Scorpion Venom | α-Helix | NA | ||
| 24496141 | 2014 | WKKIWSKIKKLLK{ct:Amid} | I1WL5W | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3.6 % Hemolysis at 500 µM | Human | Tryptophan (Trp) Residues | α-Helix | Non-hemolytic | ||
| 24496141 | 2014 | IKKWWSKIKKLLK{ct:Amid} | I4WL5W | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 14.6 % Hemolysis at 500 µM | Human | Tryptophan (Trp) Residues | α-Helix | Non-hemolytic | ||
| 24688525 | 2014 | GATAIKQVKKLFKKKGG{nt:Amid} | Pln149(6-22) | Free | Amidation | Linear | L | None | 17 | Antimicrobial | <5 % Hemolysis at 1-500 µM | Human | Analog Of Plantaricin149, Lactobacillus Plantarum | α-Helix | Non-hemolytic | ||
| 24688525 | 2014 | GATAIKQVKKLFKKKGG{nt:Acet} | Ac-Pln149(6-22) | Free | Acetylation | Linear | L | None | 17 | Antimicrobial | <5 % Hemolysis at 1-500 µM | Human | Analog Of Plantaricin149, Lactobacillus Plantarum | α-Helix | Non-hemolytic | ||
| 24688525 | 2014 | NO{d}C{d}T{d}Y{d}L{d}GATAIKQVKKLFKKKGG{nt:Amid} | Noctyl-Pln149(6-22) | Free | Amidation | Linear | L | None | 17 | Antimicrobial | <5 % Hemolysis at 1-500 µM | Human | Analog Of Plantaricin149, Lactobacillus Plantarum | α-Helix | Non-hemolytic | ||
| 24688525 | 2014 | {nnr:Fmoc}GATAIKQVKKLFKKKGG{nt:Amid} | Fmoc-Pln149(6-22) | Free | Amidation | Linear | L | fmoc = 9-fluorenylmethoxycarbonyl | 17 | Antimicrobial | 12 % Hemolysis at 250 µM | Human | Analog Of Plantaricin149, Lactobacillus Plantarum | α-Helix | NA | ||
| 24688525 | 2014 | {nnr:Fmoc}GATAIKQVKKLFKKKGG{nt:Amid} | Fmoc-Pln149(6-22) | Free | Amidation | Linear | L | fmoc = 9-fluorenylmethoxycarbonyl | 17 | Antimicrobial | 24 % Hemolysis at 500 µM | Human | Analog Of Plantaricin149, Lactobacillus Plantarum | α-Helix | NA | ||
| 24412102 | 2014 | RVCSAIPLPICH{ct:Amid} | Tigerinin-1R | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 500 µg/ml | Human | Hoplobatrachus Rugulosus (Dicroglossidae) | α-Helix | Non-hemolytic | ||
| 24412102 | 2014 | RICYAMWIPYPC | tigerinin-1V | Free | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 500 µg/ml | Human | Lithobates Vaillanti (Ranidae) | α-Helix | Non-hemolytic | ||
| 24412102 | 2014 | WCPPMIPLCSRF{ct:Amid} | tigerinin-1M | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 500 µg/ml | Human | Xenopus Muelleri (Pipidae) | α-Helix | Non-hemolytic | ||
| 24616110 | 2014 | GFGMALKLLKKVL{ct:Amid} | MAC-1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at 160 µM | Human | Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GF{d}GM{d}A{d}L{d}K{d}L{d}L{d}K{d}K{d}V{d}L{d}{ct:Amid} | MAC-1/1 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at 152 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | LVKKLLKLAMGFG{ct:Amid} | MAC-1/7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | L{d}V{d}K{d}K{d}L{d}L{d}K{d}L{d}A{d}M{d}GF{d}G{ct:Amid} | MAC-1/8 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMALKL{nnr:Aca}KKVL{ct:Amid} | MAC-1/24 | Amidation | Free | Linear | Mix | Aca = 1-aminocyclohexane carboxylic acid | 15 | Antimicrobial | 50 % Hemolysis at 88 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMALK{nnr:Aca}LKKVL{ct:Amid} | MAC-1/25 | Amidation | Free | Linear | Mix | Aca = 1-aminocyclohexane carboxylic acid | 15 | Antimicrobial | 50 % Hemolysis at 88 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMA{nnr:Aca}KLLKKVL{ct:Amid} | MAC-1/26 | Amidation | Free | Linear | Mix | Aca = 1-aminocyclohexane carboxylic acid | 15 | Antimicrobial | 50 % Hemolysis at 93 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | AFGMALKLLKKVL{ct:Amid} | MAC-1/2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at 241 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | LFGMALKLLKKVL{ct:Amid} | MAC-1/3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at 53 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFKMALKLLKKVL{ct:Amid} | MAC-1/9 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at 199 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGKALKLLKKVL{ct:Amid} | MAC-1/31 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >800 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMAL{nnr:O}LL{nnr:O}{nnr:O}VL{ct:Amid} | MAC-1/20 | Amidation | Free | Linear | L | O = Ornithine | 13 | Antimicrobial | 50 % Hemolysis at 262 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMALKLLKKVL{d}{ct:Amid} | MAC-1/14 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >>200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMALKLLKKV{d}L{ct:Amid} | MAC-1/15 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at >>200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMALKLLKK{d}VL{ct:Amid} | MAC-1/11 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at >>200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMALKLLK{d}KVL{ct:Amid} | MAC-1/12 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at >>200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMALKLL{d}KKVL{ct:Amid} | MAC-1/16 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMALKL{d}LKKVL{ct:Amid} | MAC-1/17 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >>200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMALK{d}LLKKVL{ct:Amid} | MAC-1/13 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at >>200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMAL{d}KLLKKVL{ct:Amid} | MAC-1/18 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGMA{d}LKLLKKVL{ct:Amid} | MAC-1/4 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFGM{d}ALKLLKKVL{ct:Amid} | MAC-1/19 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GF{d}GMALKLLKKVL{ct:Amid} | MAC-1/6 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at 177 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GFK{d}MALKLLKKVL{ct:Amid} | MAC-1/10 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at 476 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | GF{d}K{d}MALKLLKKVL{ct:Amid} | MAC-1/27 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at 391 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | A{d}FGMALKLLKKVL{ct:Amid} | MAC-1/28 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at 120 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | A{d}FKMALKLLKKVL{ct:Amid} | MAC-1/29 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at 131 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24616110 | 2014 | A{d}FK{d}MALKLLKKVL{ct:Amid} | MAC-1/30 | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 13 | Antimicrobial | 50 % Hemolysis at 476 µM | Human | Analog Of Mac-1, Venom Of Solitary Bee Macropis Fulvipes | α-Helix | NA | ||
| 24704757 | 2014 | GLVGTLLGHIGKAILG{ct:Amid} | Frenatin 2.1S | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at 167 ± 8 µM | Human | Litoria Infrafrenata | α-Helix | NA | ||
| 24704757 | 2014 | GLVGTLLGHIGKAILS{ct:Amid} | Frenatin 2.2S | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at 169 ± 7 µM | Human | Litoria Infrafrenata | α-Helix | NA | ||
| 24704757 | 2014 | GLVGTLLGHIGKAILG | frenatin 2.3S | Free | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at 404 ± 11 µM | Human | Discoglossus Sardus | coil | Non-hemolytic | ||
| 24723458 | 2014 | SSMKLSFRARAYGFRGPGPQL | Catestatin(SL21) | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 80 μg/ml | Human | Endogenous Neuropeptide | α-Helix | Non-hemolytic | ||
| 24945359 | 2014 | RFRRLRKKTRKRLKKI{ct:Amid} | RI16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 5 % Hemolysis at >256 µM | Human | Truncated From Pamp-36 | α-Helix | Low hemolytic | ||
| 24945359 | 2014 | RFRRLFRIRVRVLKKI{ct:Amid} | R-FV-I16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 5 % Hemolysis at 128 µM | Human | Hybrid Peptide | α-Helix | Low hemolytic | ||
| 24945359 | 2014 | FRIRVRV{ct:Amid} | FV7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide Embedded Anti-Biofilm Sequence | α-Helix | Low hemolytic | ||
| 24945359 | 2014 | RKKTRKR{ct:Amid} | RR7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 25019413 | 2014 | FWGALAKGALKLIPSLFSSFSKKD | Pandinin 2(Pin2) | Free | Free | Linear | L | None | 24 | Antimicrobial | 91 % Hemolysis at 25 µM | Human | Scorpion Venom Pandinus Imperator | α-Helix | NA | ||
| 25019413 | 2014 | FWGALAKGALKLIGSLFSSFSKKD | Pin2 [G] | Free | Free | Linear | L | None | 24 | Antimicrobial | 100 % Hemolysis at 25 µM | Human | Variant Of Pandinin 2,Scorpion Venom Pandinus Imperator | α-Helix | NA | ||
| 25019413 | 2014 | FWGALAKGALKLIGPGSLFSSFSKKD | Pin2 [GPG] | Free | Free | Linear | L | None | 26 | Antimicrobial | 30 % Hemolysis at 25 µM | Human | Variant Of Pandinin 2,Scorpion Venom Pandinus Imperator | α-Helix | NA | ||
| 25019413 | 2014 | FWGLKGLKKFSKKL | Pin2 [14] | Free | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 25 µM | Human | Variant Of Pandinin 2,Scorpion Venom Pandinus Imperator | α-Helix | Non-hemolytic | ||
| 25019413 | 2014 | FWGLKGLKKFSKKL | Pin2 [14] | Free | Free | Linear | L | None | 14 | Antimicrobial | 25 % Hemolysis at 100 µM | Human | Variant Of Pandinin 2,Scorpion Venom Pandinus Imperator | α-Helix | NA | ||
| 25019413 | 2014 | FWGLKGLKGPGKFSKKL | Pin2 [17] | Free | Free | Linear | L | None | 17 | Antimicrobial | 0 % Hemolysis at 25 µM | Human | Variant Of Pandinin 2,Scorpion Venom Pandinus Imperator | α-Helix | Non-hemolytic | ||
| 25019413 | 2014 | FWGLKGLKGPGKFSKKL | Pin2 [17] | Free | Free | Linear | L | None | 17 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Variant Of Pandinin 2,Scorpion Venom Pandinus Imperator | α-Helix | Non-hemolytic | ||
| 25061725 | 2014 | KWKSFLKTFKSAKKTVLHTALKAISS{nt:Acet}{ct:Amid} | P | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | 28.3 % Hemolysis at 1000 μg/ml | Human | Na | α-Helix | NA | ||
| 25061725 | 2014 | KWKSFLKTFKSAKKTKLHTALKAISS{nt:Acet}{ct:Amid} | V16LK | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | 6.2 % Hemolysis at 1000 μg/ml | Human | Analog Of V13K | α-Helix | NA | ||
| 25061725 | 2014 | KWKSFLKTFKSAKKTGLHTALKAISS{nt:Acet}{ct:Amid} | V16LG | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | 8.1 % Hemolysis at 1000 μg/ml | Human | Analog Of V13K | α-Helix | NA | ||
| 25061725 | 2014 | KWKSFLKTFKSAKKTSLHTALKAISS{nt:Acet}{ct:Amid} | V16LS | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | 11.3 % Hemolysis at 1000 μg/ml | Human | Analog Of V13K | α-Helix | NA | ||
| 25061725 | 2014 | KWKSFLKTFKSAKKTELHTALKAISS{nt:Acet}{ct:Amid} | V16LE | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | 3.9 % Hemolysis at 1000 μg/ml | Human | Analog Of V13K | α-Helix | NA | ||
| 25061725 | 2014 | KWKSFLKTFKSAKKTALHTALKAISS{nt:Acet}{ct:Amid} | V16LA | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | 14.3 % Hemolysis at 1000 μg/ml | Human | Analog Of V13K | α-Helix | NA | ||
| 25061725 | 2014 | KWKSFLKTFKSAKKTLLHTALKAISS{nt:Acet}{ct:Amid} | V16LL | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial | 53.9 % Hemolysis at 1000 μg/ml | Human | Analog Of V13K | α-Helix | NA | ||
| 25123187 | 2014 | KWKSFLKTFKSLKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | P(PNW) | Amidation | Acetylation | Linear | L | None | 26 | Anticancer | MHC % Hemolysis at 10.41 ± 0.02 µM | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 25123187 | 2014 | KIKSFLKTFKSWKKTVLHTLLKAISS{nt:Acet}{ct:Amid} | PMW | Amidation | Acetylation | Linear | L | None | 26 | Anticancer | MHC % Hemolysis at 10.41 ± 0.01 µM | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 25123187 | 2014 | KIKSFLKTFKSLKKTVLHTLLKAWSS{nt:Acet}{ct:Amid} | PCW | Amidation | Acetylation | Linear | L | None | 26 | Anticancer | MHC % Hemolysis at 10.41 ± 0.01 µM | Human | Peptide A12L/A20L | α-Helix | NA | ||
| 24953028 | 2014 | W-{nnr:3-ABA}-R{ct:Amid} | 1a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 3 | Antibacterial | 10 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | W-{nnr:3-ABA}-R{ct:Amid} | 1a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 3 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WW-{nnr:3-ABA}-R{ct:Amid} | 2a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WW-{nnr:3-ABA}-R{ct:Amid} | 2a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 50 % Hemolysis at 240 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-R{ct:Amid} | 2b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 10 % Hemolysis at 205 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-R{ct:Amid} | 2b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 50 % Hemolysis at 500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-R{ct:Amid} | 2c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 10 % Hemolysis at 300 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-R{ct:Amid} | 2c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 4 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WW-{nnr:3-ABA}-RR{ct:Amid} | 3a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 150 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WW-{nnr:3-ABA}-RR{ct:Amid} | 3a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-RR{ct:Amid} | 3b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 350 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-RR{ct:Amid} | 3b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-RR{ct:Amid} | 3c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 325 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-RR{ct:Amid} | 3c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-WR{ct:Amid} | 3d | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 220 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WR-{nnr:3-ABA}-WR{ct:Amid} | 3d | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-WR{ct:Amid} | 3e | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 250 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RW-{nnr:3-ABA}-WR{ct:Amid} | 3e | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at 410 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WWR-{nnr:3-ABA}-RR{ct:Amid} | 4a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 200 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WWR-{nnr:3-ABA}-RR{ct:Amid} | 4a | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 380 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RWR-{nnr:3-ABA}-WR{ct:Amid} | 4b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 210 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RWR-{nnr:3-ABA}-WR{ct:Amid} | 4b | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RWW-{nnr:3-ABA}-RR{ct:Amid} | 4c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 255 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RWW-{nnr:3-ABA}-RR{ct:Amid} | 4c | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 420 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRR-{nnr:3-ABA}-WR{ct:Amid} | 4d | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 190 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRR-{nnr:3-ABA}-WR{ct:Amid} | 4d | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 380 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRW-{nnr:3-ABA}-RR{ct:Amid} | 4e | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 140 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRW-{nnr:3-ABA}-RR{ct:Amid} | 4e | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 370 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRW-{nnr:3-ABA}-WR{ct:Amid} | 4f | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRW-{nnr:3-ABA}-WR{ct:Amid} | 4f | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 355 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRW-{nnr:3-ABA}-WR{ct:Amid} | 4g | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 80 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRW-{nnr:3-ABA}-WR{ct:Amid} | 4g | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 310 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OW-{nnr:3-ABA}-WO{ct:Amid} | 3f | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 10 % Hemolysis at 190 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OW-{nnr:3-ABA}-WO{ct:Amid} | 3f | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 5 | Antibacterial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OWW-{nnr:3-ABA}-OO{ct:Amid} | 4h | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 150 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OWW-{nnr:3-ABA}-OO{ct:Amid} | 4h | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 440 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOO-{nnr:3-ABA}-WO{ct:Amid} | 4i | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 170 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOO-{nnr:3-ABA}-WO{ct:Amid} | 4i | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 500 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOW-{nnr:3-ABA}-OO{ct:Amid} | 4j | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 175 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOW-{nnr:3-ABA}-OO{ct:Amid} | 4j | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 450 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOW-{nnr:3-ABA}-WO{ct:Amid} | 4k | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 120 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOW-{nnr:3-ABA}-WO{ct:Amid} | 4k | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 450 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOW-{nnr:3-ABA}-WO{ct:Amid} | 4l | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOW-{nnr:3-ABA}-WO{ct:Amid} | 4l | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 390 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRF-{nnr:3-ABA}-FR{ct:Amid} | 4m | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 130 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRF-{nnr:3-ABA}-FR{ct:Amid} | 4m | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 375 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | FRF-{nnr:3-ABA}-FR{ct:Amid} | 4n | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 125 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | FRF-{nnr:3-ABA}-FR{ct:Amid} | 4n | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 310 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOF-{nnr:3-ABA}-FO{ct:Amid} | 4o | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 210 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOF-{nnr:3-ABA}-FO{ct:Amid} | 4o | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 490 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | FOF-{nnr:3-ABA}-FO{ct:Amid} | 4p | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 10 % Hemolysis at 180 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | FOF-{nnr:3-ABA}-FO{ct:Amid} | 4p | Amidation | Free | Linear | L | 3-ABA = 3-amino benzoic acid | 6 | Antibacterial | 50 % Hemolysis at 400 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRWWR{ct:Amid} | 5a | Amidation | Free | Linear | L | None | 5 | Antibacterial | 10 % Hemolysis at 90 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | RRWWR{ct:Amid} | 5a | Amidation | Free | Linear | L | None | 5 | Antibacterial | 50 % Hemolysis at 240 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRWWR{ct:Amid} | 5b | Amidation | Free | Linear | L | None | 5 | Antibacterial | 10 % Hemolysis at 60 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WRWWR{ct:Amid} | 5b | Amidation | Free | Linear | L | None | 5 | Antibacterial | 50 % Hemolysis at 200 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOWWO{ct:Amid} | 5c | Amidation | Free | Linear | L | None | 5 | Antibacterial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | OOWWO{ct:Amid} | 5c | Amidation | Free | Linear | L | None | 5 | Antibacterial | 50 % Hemolysis at 310 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOWWO{ct:Amid} | 5d | Amidation | Free | Linear | L | None | 5 | Antibacterial | 10 % Hemolysis at 65 μg/ml | Human | Synthetic | NA | NA | ||
| 24953028 | 2014 | WOWWO{ct:Amid} | 5d | Amidation | Free | Linear | L | None | 5 | Antibacterial | 50 % Hemolysis at 220 μg/ml | Human | Synthetic | NA | NA | ||
| 24200946 | 2014 | GFWGKLWEGVKNAI{ct:Amid} | UyCT1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 22.8 ± 1.6 µM | Human | Venom Of Australian Scorpion Urodacus Yaschenkoi | α-Helix | NA | ||
| 24200946 | 2014 | FWGKLWEGVKNAI{ct:Amid} | UyCT2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >100 µM | Human | Analog Of Uyct1, Venom Of Australian Scorpion Urodacus Yaschenkoi | α-Helix | NA | ||
| 24200946 | 2014 | ILSAIWSGIKSLF{ct:Amid} | UyCT3 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at 17.3 ± 0.8 µM | Human | Venom Of Australian Scorpion Urodacus Yaschenkoi | α-Helix | NA | ||
| 24200946 | 2014 | IWSAIWSGIKGLL{ct:Amid} | UyCT5 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at 14.1 ± 0.3 µM | Human | Venom Of Australian Scorpion Urodacus Yaschenkoi | α-Helix | NA | ||
| 24649883 | 2014 | GVVVRVGRVVVRWV{ct:Amid} | VR(+4) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 43 µM | Human | Analog Of Vr(+6) | α-Helix | NA | ||
| 24649883 | 2014 | GVVVRVGRVVVRWVRR{ct:Amid} | VR(+6) | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at 94 µM | Human | Val/Arg-Rich Peptides | α-Helix | NA | ||
| 24649883 | 2014 | GVVVRVGRVVVRWVRRRR{ct:Amid} | VR(+8) | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at 90 µM | Human | Analog Of Vr(+6) | α-Helix | NA | ||
| 24649883 | 2014 | GVVVRVPRVVVRWVRR{ct:Amid} | VR(P) | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at >128 µM | Human | Analog Of Vr(+6) | α-Helix | NA | ||
| 24649883 | 2014 | GVVVRVARVVVRWVRR{ct:Amid} | VR(A) | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at 80 µM | Human | Analog Of Vr(+6) | α-Helix | NA | ||
| 24842084 | 2014 | FLSHIAGFLSNLF{ct:Amid} | Temporin-SHc(Temp-SHc) | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at >80 µM | Human | Skin Of Pelophylax Saharica | α-Helix | NA | ||
| 24842084 | 2014 | FLSHLAGFLSNLF{ct:Amid} | L5 temp-SHc | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at >80 µM | Human | Analogue Of Temp-Shc, Skin Of Pelophylax Saharica | α-Helix | NA | ||
| 24842084 | 2014 | HSLFLAGFLSNLF{ct:Amid} | (4-1)L5temp-SHc | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at 2 µM | Human | Analogue Of Temp-Shc, Skin Of Pelophylax Saharica | α-Helix | NA | ||
| 24952979 | 2014 | IRCRRRFCRI{ct:Amid} | IR1 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide, Porcine Leukocytes | β-Sheet | NA | ||
| 24952979 | 2014 | IRIRCRRRFCRIRI{ct:Amid} | IR2 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 128 µM | Human | Synthetic Peptide, Porcine Leukocytes | β-Sheet | NA | ||
| 24952979 | 2014 | FRCRRRFCRF{ct:Amid} | FR1 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide, Porcine Leukocytes | β-Sheet | NA | ||
| 24952979 | 2014 | FRFRCRRRFCRFRF{ct:Amid} | FR2 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 64 µM | Human | Synthetic Peptide, Porcine Leukocytes | β-Sheet | NA | ||
| 24952979 | 2014 | WRCRRRFCRW{ct:Amid} | WR1 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide, Porcine Leukocytes | β-Sheet | NA | ||
| 24952979 | 2014 | WRWRCRRRFCRWRW{ct:Amid} | WR2 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 64 µM | Human | Synthetic Peptide, Porcine Leukocytes | β-Sheet | NA | ||
| 24952979 | 2014 | PRCRRRFCRP{ct:Amid} | PR1 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide, Porcine Leukocytes | β-Sheet | NA | ||
| 24952979 | 2014 | PRPRCRRRFCRPRP{ct:Amid} | PR2 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide, Porcine Leukocytes | β-Sheet | NA | ||
| 24952979 | 2014 | RGGRLCYCRRRFCVCVGR{ct:Amid} | Protegrin-1(PG-1) | Amidation | Free | Linear | L | None | 18 | Antibacterial | 10 % Hemolysis at 2 µM | Human | Porcine Leukocytes | β-Sheet | NA | ||
| 24955933 | 2014 | FKVQNQHGQVVKIFHH | Astacidin 1 | Free | Free | Linear | L | None | 16 | Antifungal | 0 % Hemolysis at 100 µM | Human | Freshwater Crayfish Pacifastacus Leniusculus | NA | Non-hemolytic | ||
| 24955933 | 2014 | FKVQNQHGQVVKIFHH | Astacidin 1 | Free | Free | Linear | L | None | 16 | Antifungal | 0 % Hemolysis at 50 µM | Human | Freshwater Crayfish Pacifastacus Leniusculus | NA | Non-hemolytic | ||
| 24955933 | 2014 | FKVQNQHGQVVKIFHH | Astacidin 1 | Free | Free | Linear | L | None | 16 | Antifungal | 0 % Hemolysis at 25 µM | Human | Freshwater Crayfish Pacifastacus Leniusculus | NA | Non-hemolytic | ||
| 24955933 | 2014 | FKVQNQHGQVVKIFHH | Astacidin 1 | Free | Free | Linear | L | None | 16 | Antifungal | 0 % Hemolysis at 12.5 µM | Human | Freshwater Crayfish Pacifastacus Leniusculus | NA | Non-hemolytic | ||
| 24955933 | 2014 | FKVQNQHGQVVKIFHH | Astacidin 1 | Free | Free | Linear | L | None | 16 | Antifungal | 0 % Hemolysis at 6.3 µM | Human | Freshwater Crayfish Pacifastacus Leniusculus | NA | Non-hemolytic | ||
| 24955933 | 2014 | FKVQNQHGQVVKIFHH | Astacidin 1 | Free | Free | Linear | L | None | 16 | Antifungal | 0 % Hemolysis at 3.1 µM | Human | Freshwater Crayfish Pacifastacus Leniusculus | NA | Non-hemolytic | ||
| 24955933 | 2014 | FKVQNQHGQVVKIFHH | Astacidin 1 | Free | Free | Linear | L | None | 16 | Antifungal | 0 % Hemolysis at 1.6 µM | Human | Freshwater Crayfish Pacifastacus Leniusculus | NA | Non-hemolytic | ||
| 24955933 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 100 µM | Human | Venom Of The Honey Bee Apis Mellifera | NA | NA | ||
| 24955933 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 50 µM | Human | Venom Of The Honey Bee Apis Mellifera | NA | NA | ||
| 24955933 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 25 µM | Human | Venom Of The Honey Bee Apis Mellifera | NA | NA | ||
| 24955933 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 12.5 µM | Human | Venom Of The Honey Bee Apis Mellifera | NA | NA | ||
| 24955933 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 74.8 % Hemolysis at 6.3 µM | Human | Venom Of The Honey Bee Apis Mellifera | NA | NA | ||
| 24955933 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 42 % Hemolysis at 3.1 µM | Human | Venom Of The Honey Bee Apis Mellifera | NA | NA | ||
| 24955933 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 12.7 % Hemolysis at 1.6 µM | Human | Venom Of The Honey Bee Apis Mellifera | NA | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 0 % Hemolysis at 0.75 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | Non-hemolytic | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 0.84 % Hemolysis at 1.5 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 1.01 % Hemolysis at 3 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 1.18 % Hemolysis at 6 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 1.37 % Hemolysis at 12 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 24981062 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | AvBD103b | Free | Free | Linear | L | None | 38 | Antibacterial | 2.61 % Hemolysis at 48 µM | Human | King Penguin (Aptenodytes Patagonicus) | α-Helix/β-Sheet | NA | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 3 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 6 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 12 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 18 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 0 % Hemolysis at 30 µM | Human | Self/Coassembling Peptide | β-Sheet | Non-hemolytic | ||
| 25055061 | 2014 | FEFQFNFK{nt:Acet}{ct:Amid} | AC8 | Amidation | Acetylation | Linear | L | None | 8 | cytotoxic | 5 % Hemolysis at 60 µM | Human | Self/Coassembling Peptide | β-Sheet | NA | ||
| 25086320 | 2014 | GIKEFAHSLGKFGKAFVGGILNQ | Magainin-W1 | Free | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis | Human | Skin Secretions Of Xenopus Wittei | α-Helix | NA | ||
| 25086320 | 2014 | GVGKFLHSASKFGKALVGELMKS | Magainin-W2 | Free | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at >500 µM | Human | Skin Secretions Of Xenopus Wittei | α-Helix | NA | ||
| 25086320 | 2014 | GISKFLHSASKFGKALVGEIMKS | Magainin-W3 | Free | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at >500 µM | Human | Skin Secretions Of Xenopus Wittei | α-Helix | NA | ||
| 25086320 | 2014 | GMASKAGTIVGKLAKVALNAL{ct:Amid} | PGLa-W1 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 50 % Hemolysis | Human | Skin Secretions Of Xenopus Wittei | α-Helix | NA | ||
| 25086320 | 2014 | GWASKIGQTLGKMAKVGLQELIQPK | XPF-W1 | Free | Free | Linear | L | None | 25 | Antimicrobial | 50 % Hemolysis | Human | Skin Secretions Of Xenopus Wittei | α-Helix | NA | ||
| 25086320 | 2014 | GFGSFLGKALKAGLKLGANLLGGAPQQ | CPF-W1 | Free | Free | Linear | L | None | 27 | Antimicrobial | 50 % Hemolysis | Human | Skin Secretions Of Xenopus Wittei | α-Helix | NA | ||
| 25086320 | 2014 | GFGSFLGKALKAGLKLGANLLGGAPQE | CPF-W3 | Free | Free | Linear | L | None | 27 | Antimicrobial | 50 % Hemolysis | Human | Skin Secretions Of Xenopus Wittei | α-Helix | NA | ||
| 25086320 | 2014 | GIGSLLAKAAKLAAGLV{ct:Amid} | CPF-W6 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 50 % Hemolysis at 190 µM | Human | Skin Secretions Of Xenopus Wittei | α-Helix | NA | ||
| 25086320 | 2014 | GLGTFLGNALKTGLKIGTNLL{ct:Amid} | CPF-W7 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 50 % Hemolysis | Human | Skin Secretions Of Xenopus Wittei | α-Helix | NA | ||
| 25030320 | 2014 | KLAKKLAKLAKLAKAL{ct:Amid} | Modelin-5-CONH2 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 2 % Hemolysis at 300 µM | Human | Synthetic | α-Helical | NA | ||
| 25473836 | 2014 | FFHHIFRGIVHVGKTIHRLVTG | Pis-1 | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | ~100 % Hemolysis at 100 µM | Human | Mast Cells Of Aquacultured Hybrid Striped Bass | α-Helical | NA | ||
| 25473836 | 2014 | AFHHIFRGIVHVGKTIHRLVTG | PisF1A | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 100 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | NA | ||
| 25473836 | 2014 | FAHHIFRGIVHVGKTIHRLVTG | PisF2A | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | >12 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | NA | ||
| 25473836 | 2014 | FFHHIARGIVHVGKTIHRLVTG | PisF6A | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 29 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | NA | ||
| 25473836 | 2014 | KFHHIFRGIVHVGKTIHRLVTG | PisF1K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 50 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | NA | ||
| 25473836 | 2014 | FKHHIFRGIVHVGKTIHRLVTG | PisF2K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 0 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | Non-hemolytic | ||
| 25473836 | 2014 | FFHHIKRGIVHVGKTIHRLVTG | PisF6K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 0 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | Non-hemolytic | ||
| 25473836 | 2014 | FFHHIFRGIKHVGKTIHRLVTG | PisV10K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 0 % Hemolysis at 50 µM | Human | Pis-1 Analog | α-Helical | Non-hemolytic | ||
| 25473836 | 2014 | FFHHIFRGIKHVGKTIHRLVTG | PisV10K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 20 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | NA | ||
| 25473836 | 2014 | KFHHIFRGIKHVGKTIHRLVTG | Pis-F1K/V10K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 0 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | Non-hemolytic | ||
| 25473836 | 2014 | FKHHIFRGIKHVGKTIHRLVTG | Pis-F2K/V10K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 0 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | Non-hemolytic | ||
| 25473836 | 2014 | FFHHIKRGIKHVGKTIHRLVTG | Pis-F6K/V10K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 0 % Hemolysis at 100 µM | Human | Pis-1 Analog | α-Helical | Non-hemolytic | ||
| 25473836 | 2014 | KFHHIFRGIKHVGKTIHRLVTG | Pis-F1K/V10K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | <20 % Hemolysis at 200 µM | Human | Pis-1 Analog | α-Helical | NA | ||
| 25473836 | 2014 | FFHHIKRGIKHVGKTIHRLVTG | Pis-F6K/V10K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 19 % Hemolysis at 400 µM | Human | Pis-1 Analog | α-Helical | NA | ||
| 25473836 | 2014 | FFHHIKRGIKHVGKTIHRLVTG | Pis-F2K/V10K | Free | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 0 % Hemolysis at 400 µM | Human | Pis-1 Analog | α-Helical | Non-hemolytic | ||
| 25123582 | 2014 | GMASLLAKVLPHVVKLIK | codesane(COD) | Free | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at 105 µM | Human | Venom Of Wild Bee Colletes Daviesanus | α-Helix | NA | ||
| 25123582 | 2014 | GMAKLLAKVLPHVVKLIK | COD-1 | Free | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | Analog Of Cod, Venom Of Wild Bee Colletes Daviesanus | α-Helix | NA | ||
| 25123582 | 2014 | GMASKLAKVLPHVVKLIK | COD-2 | Free | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Analog Of Cod, Venom Of Wild Bee Colletes Daviesanus | α-Helix | NA | ||
| 25123582 | 2014 | GMASLLAKVLPKVVKLIK | COD-3 | Free | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Analog Of Cod, Venom Of Wild Bee Colletes Daviesanus | α-Helix | NA | ||
| 25123582 | 2014 | GMASLWAKVLPHVVKLIK | COD-4 | Free | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at 162.5 µM | Human | Analog Of Cod, Venom Of Wild Bee Colletes Daviesanus | α-Helix | NA | ||
| 25123582 | 2014 | GMASLW{d}AKVLPHVVKLIK | COD-5 | Free | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 18 | Antimicrobial | 50 % Hemolysis at >>200 µM | Human | Analog Of Cod, Venom Of Wild Bee Colletes Daviesanus | α-Helix | NA | ||
| 25241629 | 2014 | LKLSPKTKDTLKKVLKGAIKGAIAIASMA{ct:Amid} | Hymenochirin-1Pa | Amidation | Free | Linear | L | None | 29 | Antimicrobial, Antitumor | 50 % Hemolysis at 162 ± 13 µM | Human | Skin Secretions Ofthe Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 25241629 | 2014 | LKLSPKTKKTLKKVLKGAIKGAIAIASMA{ct:Amid} | [D9K]Hymenochirin-1Pa | Amidation | Free | Linear | L | None | 29 | Antimicrobial, Antitumor | 50 % Hemolysis at 192 ± 21 µM | Human | Analog Of Hymenochirin-1Pa, Skin Secretions Ofthe Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 25241629 | 2014 | LKLSPKTKK{d}TLKKVLKGAIKGAIAIASMA{ct:Amid} | [D9k]Hymenochirin-1Pa | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 29 | Antimicrobial, Antitumor | 50 % Hemolysis at >400 µM | Human | Analog Of Hymenochirin-1Pa, Skin Secretions Ofthe Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 25447194 | 2014 | IKIPSFFRNILKKVGKEAVSLIAGALKQS | Pseudhymenochirin-1Pb(Ps-1Pb) | Free | Free | Linear | L | None | 29 | Antimicrobial, Antitumor | 50 % Hemolysis at 28 ± 2 µM | Human | Skin Secretions Of The Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 25447194 | 2014 | GIFPIFAKLLGKVIKVASSLISKGRTE | (Pseudhymenochirin-2Pa)Ps-2Pa | Free | Free | Linear | L | None | 27 | Antimicrobial, Antitumor | 50 % Hemolysis at 6.2 ± 1.0 µM | Human | Skin Secretions Of The Frog Pseudhymenochirus Merlini | α-Helix | NA | ||
| 25200682 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin(MLT) | Free | Free | Linear | L | None | 26 | Antimicrobial, Antiviral | 50 % Hemolysis at 5 µM | Human | Bee Venom | α-Helix | NA | ||
| 25200682 | 2014 | GIGAVLKVLTTGLCALISWIKRKRQQ | MLT-P14C | Free | Free | Linear | L | None | 26 | Antibacterial | 50 % Hemolysis at 2.5 µM | Human | Analog Of Melittin, Bee Venom | α-Helix | NA | ||
| 25200682 | 2014 | GIGAVLKVLTTGLCALISWIKRKRQQGIGAVLKVLTTGLCALISWIKRKRQQ | Dimer-MLT-P14C | Free | Free | Linear | L | None | 52 | Antibacterial | 50 % Hemolysis at 1 µM | Human | Analog Of Melittin, Bee Venom | α-Helix | NA | ||
| 25209888 | 2014 | MDSFQKIEKIGEGTYGVVYKAKDKVSGRLVALKKIRLENESEGVPSTA{ct:Amid} | Scolopendin 1 | Amidation | Free | Linear | L | None | 48 | Antibacterial, Antifungal | 0 % Hemolysis at 80 µM | Human | Centipede Scolopendra Subspinipes Mutilans | NA | Non-hemolytic | ||
| 25209888 | 2014 | MDSFQKIEKIGEGTYGVVYKAKDKVSGRLVALKKIRLENESEGVPSTA{ct:Amid} | Scolopendin 1 | Amidation | Free | Linear | L | None | 48 | Antibacterial, Antifungal | 0 % Hemolysis at 40 µM | Human | Centipede Scolopendra Subspinipes Mutilans | NA | Non-hemolytic | ||
| 25209888 | 2014 | MDSFQKIEKIGEGTYGVVYKAKDKVSGRLVALKKIRLENESEGVPSTA{ct:Amid} | Scolopendin 1 | Amidation | Free | Linear | L | None | 48 | Antibacterial, Antifungal | 0 % Hemolysis at 20 µM | Human | Centipede Scolopendra Subspinipes Mutilans | NA | Non-hemolytic | ||
| 25209888 | 2014 | MDSFQKIEKIGEGTYGVVYKAKDKVSGRLVALKKIRLENESEGVPSTA{ct:Amid} | Scolopendin 1 | Amidation | Free | Linear | L | None | 48 | Antibacterial, Antifungal | 0 % Hemolysis at 10 µM | Human | Centipede Scolopendra Subspinipes Mutilans | NA | Non-hemolytic | ||
| 25209888 | 2014 | MDSFQKIEKIGEGTYGVVYKAKDKVSGRLVALKKIRLENESEGVPSTA{ct:Amid} | Scolopendin 1 | Amidation | Free | Linear | L | None | 48 | Antibacterial, Antifungal | 0 % Hemolysis at 5 µM | Human | Centipede Scolopendra Subspinipes Mutilans | NA | Non-hemolytic | ||
| 25209888 | 2014 | MDSFQKIEKIGEGTYGVVYKAKDKVSGRLVALKKIRLENESEGVPSTA{ct:Amid} | Scolopendin 1 | Amidation | Free | Linear | L | None | 48 | Antibacterial, Antifungal | 0 % Hemolysis at 2.5 µM | Human | Centipede Scolopendra Subspinipes Mutilans | NA | Non-hemolytic | ||
| 25209888 | 2014 | MDSFQKIEKIGEGTYGVVYKAKDKVSGRLVALKKIRLENESEGVPSTA{ct:Amid} | Scolopendin 1 | Amidation | Free | Linear | L | None | 48 | Antibacterial, Antifungal | 0 % Hemolysis at 1.3 µM | Human | Centipede Scolopendra Subspinipes Mutilans | NA | Non-hemolytic | ||
| 25209888 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 100 ± 2.3 % Hemolysis at 80 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 25209888 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 100 ± 3.3 % Hemolysis at 40 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 25209888 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 98.4 ± 2.0 % Hemolysis at 20 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 25209888 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 74.0 ± 7.4 % Hemolysis at 10 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 25209888 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 36.7 ± 9.5 % Hemolysis at 5 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 25209888 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 13.4 ± 7.1 % Hemolysis at 2.5 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 25209888 | 2014 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial | 0 % Hemolysis at 1.3 µM | Human | Venom Of The Honey Bee Apis Mellifera | α-Helix | NA | ||
| 25494332 | 2014 | RFRRLRKKTRKRLKKI{ct:Amid} | RI16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 25494332 | 2014 | RFRRLRKKWRKRLKKI{ct:Amid} | T9W | Amidation | Free | Linear | L | None | 16 | Antimicrobial, Antibiofilm | 50 % Hemolysis at >256 µM | Human | Mutant Peptide | α-Helix | NA | ||
| 25494332 | 2014 | RFRRLRKKIRKRLKKI{ct:Amid} | T9I | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at >256 µM | Human | Mutant Peptide | α-Helix | NA | ||
| 25494332 | 2014 | RFRRLRKKKRKRLKKI{ct:Amid} | T9K | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at >256 µM | Human | Mutant Peptide | α-Helix | NA | ||
| 25494332 | 2014 | RFRRLRKKFRKRLKKI{ct:Amid} | T9F | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at >256 µM | Human | Mutant Peptide | α-Helix | NA | ||
| 24825365 | 2014 | EIAALEQEIAALEYKIAALKGGGKIAALKQKIAALKQEIAALEGGG | SaNet | Free | Free | Linear | L | None | 46 | Antimicrobial | 50 % Hemolysis at >>600 µM | Human | Synthetic Peptide | α-Helical | NA | ||
| 24952727 | 2014 | APKAMKLLKKLLKLQKKGI | SHAP1 | Free | Free | Linear | L | None | 19 | Wound healing, Antibacterial, Antifungal | 0 % Hemolysis at 1 µM | Human | Synthetic Peptide | α-Helical | Non-hemolytic | ||
| 24952727 | 2014 | APKAMKLLKKLLKLQKKGI | SHAP1 | Free | Free | Linear | L | None | 19 | Wound healing, Antibacterial, Antifungal | 0 % Hemolysis at 10 µM | Human | Synthetic Peptide | α-Helical | Non-hemolytic | ||
| 24952727 | 2014 | APKAMKLLKKLLKLQKKGI | SHAP1 | Free | Free | Linear | L | None | 19 | Wound healing, Antibacterial, Antifungal | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide | α-Helical | Non-hemolytic | ||
| 24952727 | 2014 | APKAMKLLKKLLKLQKKGI | SHAP1 | Free | Free | Linear | L | None | 19 | Wound healing, Antibacterial, Antifungal | <5 % Hemolysis at 200 µM | Human | Synthetic Peptide | α-Helical | Non-hemolytic | ||
| 24952727 | 2014 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 1 µM | Human | Synthetic Peptide | α-Helical | NA | ||
| 24952727 | 2014 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | <10 % Hemolysis at 10 µM | Human | Synthetic Peptide | α-Helical | NA | ||
| 24952727 | 2014 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | <20 % Hemolysis at 100 µM | Human | Synthetic Peptide | α-Helical | NA | ||
| 24952727 | 2014 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | <40 % Hemolysis at 200 µM | Human | Synthetic Peptide | α-Helical | NA | ||
| 25016054 | 2014 | ENFFKEIERAGQRIRDAIISAAPAVETLAQAQKIIKGGD | GM1 | Free | Free | Linear | L | None | 39 | Antibacterial, Anti-infective | 0 % Hemolysis at 100 μg/ml | Human | Galleria Mellonella Native | NA | Non-hemolytic | ||
| 25016054 | 2014 | ENFFKEKERKGQRIRDAIISRRPRVETLAQAQKIIKGGD | ΔGm1 | Free | Free | Linear | L | None | 39 | Antibacterial, Anti-infective | 0 % Hemolysis at 100 μg/ml | Human | Galleria Mellonella Native Analogue | NA | Non-hemolytic | ||
| 25016054 | 2014 | GIGAVLVKLTTGLPALISWIKRKRQQ{ct:Amid} | melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 50 μg/ml | Human | Bee Venom | NA | NA | ||
| 25025626 | 2014 | KGD | vasotab TY | Free | Free | Linear | L | None | 3 | Anti-thrombosis, vasodilator activity | 0 % Hemolysis at 5 μg/ml | Human | Horsefly Of Tabanus Yao | NA | Non-hemolytic | ||
| 25025626 | 2014 | KGD | vasotab TY | Free | Free | Linear | L | None | 3 | Anti-thrombosis, vasodilator activity | 0 % Hemolysis at 320 μg/ml | Human | Horsefly Of Tabanus Yao | NA | Non-hemolytic | ||
| 25100358 | 2014 | KRFKKFFKKLKNSVKKRAKKFFKKPRVIGVSIPF | Oh_CRAMP | Free | Free | Linear | L | None | 34 | Antimicrobial | 10 % Hemolysis at 100 µM | Human | Reptilian Cramps From Elapids | α-Helix | NA | ||
| 25100358 | 2014 | KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF | crotalicidin | Free | Free | Linear | L | None | 34 | Antimicrobial | 10 % Hemolysis at 25 µM | Human | Reptilian Cramps From Pit Vipers | α-Helix | NA | ||
| 25100358 | 2014 | KRFKKFFKKLKNSVKKRVKKFFRKPRVIGVTFPF | batroxicidin | Free | Free | Linear | L | None | 34 | Antimicrobial | 10 % Hemolysis at 12.5 µM | Human | Reptilian Cramps From Pit Vipers | α-Helix | NA | ||
| 25100358 | 2014 | KRFKKFFMKLKKSVKKRVMKFFKKPMVIGVTFPF | Pt_ CRAMP1 | Free | Free | Linear | L | None | 34 | Antimicrobial | 10 % Hemolysis at ~6.25 µM | Human | Reptilian Cramps From Elapids | α-Helix | NA | ||
| 25100358 | 2014 | SFGLCRLRRGFCARGRCRFPSIPIGRCSRFVQCCRRVW | Pt_ CRAMP1 | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 50 µM | Human | Reptilian Cramps From Elapids | α-Helix | NA | ||
| 24706599 | 2014 | {nnr:pGlu}CRRLCYKQRCVTYCRGR | Gomesin (Gm) | Amidation | Free | Linear | L | pGlu = pyroglutamic | 18 | Antimicrobial | 10 % Hemolysis at 0.4 µM | Human | Hemolymph Of The Spider Acanthoscurria Gomesiana | β-Hairpin | NA | ||
| 24706599 | 2014 | {nnr:pGlu}CRRLCYKQRCVTYCRGR | Gomesin (Gm) | Amidation | Free | Linear | L | pGlu = pyroglutamic | 18 | Antimicrobial | 40 % Hemolysis at 100 µM | Human | Hemolymph Of The Spider Acanthoscurria Gomesiana | β-Hairpin | NA | ||
| 24706599 | 2014 | WCRRLCYKQRCVTYCRGR{ct:Amid} | [Trp1 ]-Gm | Amidation | Free | Linear | L | None | 18 | Antimicrobial | <35 % Hemolysis at 100 µM | Human | Gomesin Analogs | β-Hairpin | NA | ||
| 24706599 | 2014 | {nnr:pGlu}CRRLCWKQRCVTYCRGR | [Trp7 ]-Gm | Amidation | Free | Linear | L | pGlu = pyroglutamic | 18 | Antimicrobial | 35 % Hemolysis at 100 µM | Human | Gomesin Analogs | β-Hairpin | NA | ||
| 24706599 | 2014 | {nnr:pGlu}CRRLCYKWRCVTYCRGR | [Trp9 ]- Gm | Amidation | Free | Linear | L | pGlu = pyroglutamic | 18 | Antimicrobial | 40 % Hemolysis at 100 µM | Human | Gomesin Analogs | β-Hairpin | NA | ||
| 24466055 | 2014 | GVFRRLRKVTRKVLKKIGKVLKWI{ct:Amid} | GI24-V3 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 50 % Hemolysis at 128 µM | Human | Residue-Substituted Derivative Of Cathelicidin Pmap-36 | α-Helix | NA | ||
| 24466055 | 2014 | GVFRVLRKVTRVVLKVIGKVLKWI{ct:Amid} | GI24-V6 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 50 % Hemolysis at 8 µM | Human | Residue-Substituted Derivative Of Cathelicidin Pmap-36 | α-Helix | NA | ||
| 24466055 | 2014 | GRFRRLRKKTRKRLKKIGKVLKWI{ct:Amid} | GI24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | <30 % Hemolysis at 128 µM | Human | Truncated Derivative Of Cathelicidin Pmap-36 | α-Helix | NA | ||
| 24466055 | 2014 | GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGCG{ct:Amid} | PMAP-36 | Amidation | Free | Linear | L | None | 36 | Antimicrobial | <40 % Hemolysis at 128 µM | Human | Porcine Myeloid Antimicrobial Peptide-36 | α-Helix | NA | ||
| 24466055 | 2014 | GRFRRLRKKTRK{ct:Amid} | GK12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 128 µM | Human | Truncated Derivative Of Cathelicidin Pmap-36 | α-Helix | Non-hemolytic | ||
| 24466055 | 2014 | RLKKIGKVLKWI{ct:Amid} | RI12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 128 µM | Human | Truncated Derivative Of Cathelicidin Pmap-36 | α-Helix | Non-hemolytic | ||
| 24466055 | 2014 | PPIVGSIPLGCG{ct:Amid} | PG12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 128 µM | Human | Truncated Derivative Of Cathelicidin Pmap-36 | α-Helix | Non-hemolytic | ||
| 24466055 | 2014 | GRFRRLRKKTRKRLKKIGKVLKAI{ct:Amid} | GI24-W23A | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 128 µM | Human | Residue-Substituted Derivative Of Cathelicidin Pmap-36 | α-Helix | Non-hemolytic | ||
| 24466055 | 2014 | GRFRRLRKKTRKRLKKIGKVLKKI{ct:Amid} | GI24-W23K | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 128 µM | Human | Residue-Substituted Derivative Of Cathelicidin Pmap-36 | α-Helix | Non-hemolytic | ||
| 24466055 | 2014 | GRFRRLRKKTRKRLKKIGKVLKLI{ct:Amid} | GI24-W23L | Amidation | Free | Linear | L | None | 24 | Antimicrobial | <40 % Hemolysis at 128 µM | Human | Residue-Substituted Derivative Of Cathelicidin Pmap-36 | α-Helix | NA | ||
| 24466055 | 2014 | GIGAVLVKLTTGLPALISWIKRKRQQ{ct:Amid} | melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 128 µM | Human | Bee Venom | α-Helix | NA | ||
| 24670666 | 2014 | F{d}F{d}H{d}H{d}I{d}F{d}R{d}G{d}I{d}V{d}H{d}V{d}G{d}K{d}T{d}I{d}H{d}R{d}L{d}V{d}T{d}G{d}{nt:Amid}{ct:Amid} | D-Piscidin 1 | Amidation | Amidation | Linear | D | lowercase letters correspond to D-amino acids | 22 | Antimicrobial | 50 % Hemolysis at 1.8 µM | Human | Hybrid Striped Bass (Morone Saxatilis Male × Morone Chrysops Female) | α-Helix | NA | ||
| 24670666 | 2014 | F{d}F{d}H{d}H{d}I{d}F{d}R{d}G{d}I{d}V{d}H{d}V{d}K{d}K{d}T{d}I{d}H{d}R{d}L{d}V{d}T{d}G{d}{nt:Amid}{ct:Amid} | D-Piscidin 1 G13K | Amidation | Amidation | Linear | D | lowercase letters correspond to D-amino acids | 22 | Antimicrobial | 50 % Hemolysis at 7 µM | Human | Derivative Of Hybrid Striped Bass (Morone Saxatilis Male × Morone Chrysops Female) | α-Helix | NA | ||
| 24670666 | 2014 | F{d}F{d}H{d}H{d}I{d}F{d}R{d}G{d}I{d}V{d}H{d}K{d}G{d}K{d}T{d}I{d}H{d}R{d}L{d}V{d}T{d}G{d}{nt:Amid}{ct:Amid} | D-Piscidin 1 V12K | Amidation | Amidation | Linear | D | lowercase letters correspond to D-amino acids | 22 | Antimicrobial | 50 % Hemolysis at 35 µM | Human | Derivative Of Hybrid Striped Bass (Morone Saxatilis Male × Morone Chrysops Female) | α-Helix | NA | ||
| 24670666 | 2014 | F{d}F{d}H{d}H{d}I{d}F{d}R{d}G{d}K{d}V{d}H{d}V{d}G{d}K{d}T{d}I{d}H{d}R{d}L{d}V{d}T{d}G{d}{nt:Amid}{ct:Amid} | D-Piscidin 1 I9K | Amidation | Amidation | Linear | D | lowercase letters correspond to D-amino acids | 22 | Antimicrobial | 50 % Hemolysis at 98 µM | Human | Derivative Of Hybrid Striped Bass (Morone Saxatilis Male × Morone Chrysops Female) | α-Helix | NA | ||
| 24670666 | 2014 | A{d}L{d}W{d}M{d}T{d}L{d}L{d}K{d}K{d}V{d}L{d}K{d}A{d}A{d}A{d}A{d}K{d}A{d}L{d}N{d}A{d}V{d}L{d}V{d}G{d}A{d}N{d}A{d}{nt:Amid}{ct:Amid} | D-Dermaseptin S4 | Amidation | Amidation | Linear | D | lowercase letters correspond to D-amino acids | 27 | Antimicrobial | 50 % Hemolysis at 0.6 µM | Human | South American Frogs Of The Phyllomedusa | α-Helix | NA | ||
| 24670666 | 2014 | A{d}L{d}W{d}M{d}T{d}L{d}K{d}K{d}K{d}V{d}L{d}K{d}A{d}A{d}A{d}A{d}K{d}A{d}L{d}N{d}A{d}V{d}L{d}V{d}G{d}A{d}N{d}A{d}{nt:Amid}{ct:Amid} | D-Dermaseptin S4 L7K | Amidation | Amidation | Linear | D | lowercase letters correspond to D-amino acids | 27 | Antimicrobial | 50 % Hemolysis at 8.6 µM | Human | Derivative Of D-Dermaseptin S4 | α-Helix | NA | ||
| 24670666 | 2014 | A{d}L{d}W{d}M{d}T{d}L{d}K{d}K{d}K{d}V{d}L{d}K{d}A{d}K{d}A{d}K{d}A{d}L{d}N{d}A{d}V{d}L{d}V{d}G{d}A{d}N{d}A{d}{nt:Amid}{ct:Amid} | D-Dermaseptin S4 L7K,A14K | Amidation | Amidation | Linear | D | lowercase letters correspond to D-amino acids | 27 | Antimicrobial | 50 % Hemolysis at 241 µM | Human | Derivative Of D-Dermaseptin S4 | α-Helix | NA | ||
| 24946217 | 2014 | KWK{nt:C10}{ct:Amid} | AMP-C10-12 | Amidation | C10 | Linear | L | None | 3 | Antimicrobial | <10 % Hemolysis at 250 µM | Human | Synthetic | NA | Non-hemolytic | ||
| 24946217 | 2014 | RKWWK{nt:C10}{ct:Amid} | AMP-C10-3 | Amidation | C10 | Linear | L | None | 5 | Antimicrobial | <10 % Hemolysis at 125 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | RIKWK{nt:C10}{ct:Amid} | AMP-C10-14 | Amidation | C10 | Linear | L | None | 5 | Antimicrobial | <10 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWK{nt:C14}{ct:Amid} | AMP-C14-12 | Amidation | C14 | Linear | L | None | 3 | Antimicrobial | 11 % Hemolysis at 125 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWK{nt:C14}{ct:Amid} | AMP-C14-12 | Amidation | C14 | Linear | L | None | 3 | Antimicrobial | 19 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWKW{nt:C14}{ct:Amid} | AMP-C14-16 | Amidation | C14 | Linear | L | None | 4 | Antimicrobial | 17 % Hemolysis at 125 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWKW{nt:C14}{ct:Amid} | AMP-C14-16 | Amidation | C14 | Linear | L | None | 4 | Antimicrobial | <60 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | KWWK{nt:C14}{ct:Amid} | AMP-C14-1 | Amidation | C14 | Linear | L | None | 4 | Antimicrobial | 56 % Hemolysis at 125 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | RWWR{nt:C14}{ct:Amid} | AMP-C14-5 | Amidation | C14 | Linear | L | None | 4 | Antimicrobial | 90 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | RIKWK{nt:C14}{ct:Amid} | AMP-C14-14 | Amidation | C14 | Linear | L | None | 5 | Antimicrobial | 20 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 24946217 | 2014 | RIKWWK{nt:C14}{ct:Amid} | AMP-C14-4 | Amidation | C14 | Linear | L | None | 6 | Antimicrobial | 60 % Hemolysis at 250 µM | Human | Synthetic | NA | NA | ||
| 25106507 | 2014 | GGHGGHGGHGGHGGHGGHGHGGGGHG{ct:Amid} | Shep I (3-28)a | Amidation | Free | Linear | L | None | 26 | Antifungal, Anticandida | 0 % Hemolysis at 100 µM (IGP buffer) | Human | Shepherin I Is Roots, Shepherd'S Purse, Capsella Bursa-Pastoris Plant Analogues Peptide | β-Pleated Sheet | Non-hemolytic | ||
| 25106507 | 2014 | GGHGGHGGHGGHGGHGHGGGGHG{ct:Amid} | Shep I (6-28)a | Amidation | Free | Linear | L | None | 23 | Antifungal, Anticandida | 0 % Hemolysis at 100 µM (IGP buffer) | Human | Shepherin I Is Roots, Shepherd'S Purse, Capsella Bursa-Pastoris Plant Analogues Peptide | β-Pleated Sheet | Non-hemolytic | ||
| 25106507 | 2014 | GYGGHGGHGGHGGHGGHGGHGHGGGGHG{ct:Amid} | Shep Ia | Amidation | Free | Linear | L | None | 28 | Antifungal, Anticandida | 18 % Hemolysis at 100 µM (IGP buffer) | Human | Shepherin I Is Roots, Shepherd'S Purse, Capsella Bursa-Pastoris Plant Analogues Peptide | β-Pleated Sheet | NA | ||
| 24101243 | 2014 | VDNANDLLSKVKKDKSD | A1 | Free | Free | Linear | L | None | 17 | Antibacterial | 0 % Hemolysis at 500 μg/ml | Human | Human C8Α Complement System Peptide | α-Helix | Non-hemolytic | ||
| 24101243 | 2014 | TSFLNELNKYNEKKFI | A2 | Free | Free | Linear | L | None | 16 | Antibacterial | 0 % Hemolysis at 500 μg/ml | Human | Human C8Α Complement System Peptide | α-Helix | Non-hemolytic | ||
| 24101243 | 2014 | VIDKAKMESLGITSRDTT | A3 | Free | Free | Linear | L | None | 18 | Antibacterial | 0 % Hemolysis at 500 μg/ml | Human | Human C8Α Complement System Peptide | α-Helix | Non-hemolytic | ||
| 24101243 | 2014 | KKFGGGKTERARKAMAVE | A4 | Free | Free | Linear | L | None | 18 | Antibacterial | 0 % Hemolysis at 500 μg/ml | Human | Human C8Α Complement System Peptide | α-Helix | Non-hemolytic | ||
| 25271126 | 2015 | KVLRDNIQGITKPAIRRLARRG | MrH4 N-terminal peptide(KVL22) | Free | Free | Linear | L | None | 22 | Antimicrobial | 8.4 ± 1.2 % Hemolysis at 5 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | KVLRDNIQGITKPAIRRLARRG | MrH4 N-terminal peptide(KVL22) | Free | Free | Linear | L | None | 22 | Antimicrobial | 12.5 ± 1.5 % Hemolysis at 10 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | KVLRDNIQGITKPAIRRLARRG | MrH4 N-terminal peptide(KVL22) | Free | Free | Linear | L | None | 22 | Antimicrobial | 18.4 ± 2.2 % Hemolysis at 25 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | KVLRDNIQGITKPAIRRLARRG | MrH4 N-terminal peptide(KVL22) | Free | Free | Linear | L | None | 22 | Antimicrobial | 24.7 ± 1.7 % Hemolysis at 50 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | KVLRDNIQGITKPAIRRLARRG | MrH4 N-terminal peptide(KVL22) | Free | Free | Linear | L | None | 22 | Antimicrobial | 33.6 ± 2.9 % Hemolysis at 100 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | KVLRDNIQGITKPAIRRLARRG | MrH4 N-terminal peptide(KVL22) | Free | Free | Linear | L | None | 22 | Antimicrobial | 39.4 ± 2.5 % Hemolysis at 150 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | KVLRDNIQGITKPAIRRLARRG | MrH4 N-terminal peptide(KVL22) | Free | Free | Linear | L | None | 22 | Antimicrobial | 45.1 ± 2.1 % Hemolysis at 200 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | KVLRDNIQGITKPAIRRLARRG | MrH4 N-terminal peptide(KVL22) | Free | Free | Linear | L | None | 22 | Antimicrobial | 48.2 ± 1.6 % Hemolysis at 250 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | VVYALKRQGRTLYGF | MrH4 C-terminal peptide(VVY15) | Free | Free | Linear | L | None | 15 | Antimicrobial | 9.6 ± 0.9 % Hemolysis at 5 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | VVYALKRQGRTLYGF | MrH4 C-terminal peptide(VVY15) | Free | Free | Linear | L | None | 15 | Antimicrobial | 14.3 ± 1.2 % Hemolysis at 10 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | VVYALKRQGRTLYGF | MrH4 C-terminal peptide(VVY15) | Free | Free | Linear | L | None | 15 | Antimicrobial | 20.2 ± 1.8 % Hemolysis at 25 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | VVYALKRQGRTLYGF | MrH4 C-terminal peptide(VVY15) | Free | Free | Linear | L | None | 15 | Antimicrobial | 27.3 ± 2.8 % Hemolysis at 50 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | VVYALKRQGRTLYGF | MrH4 C-terminal peptide(VVY15) | Free | Free | Linear | L | None | 15 | Antimicrobial | 35.6 ± 1.4 % Hemolysis at 100 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | VVYALKRQGRTLYGF | MrH4 C-terminal peptide(VVY15) | Free | Free | Linear | L | None | 15 | Antimicrobial | 43.6 ± 2.8 % Hemolysis at 150 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | VVYALKRQGRTLYGF | MrH4 C-terminal peptide(VVY15) | Free | Free | Linear | L | None | 15 | Antimicrobial | 46.6 ± 3.1 % Hemolysis at 200 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25271126 | 2015 | VVYALKRQGRTLYGF | MrH4 C-terminal peptide(VVY15) | Free | Free | Linear | L | None | 15 | Antimicrobial | 51.4 ± 2.3 % Hemolysis at 250 µM | Human | Freshwater Giant Prawn Macrobrachium Rosenbergii | α-Helix | NA | ||
| 25348533 | 2015 | ACPIFTKIQGTYRGKAKRIGRRIC | hBTD-1 | Free | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 0 µM | Human | Hybrid Peptide Of Human Β-Defensin -1 And Θ-Defensin | α-Helix | Non-hemolytic | ||
| 25348533 | 2015 | ACPIFTKIQGTYRGKAKRIGRRIC | hBTD-1 | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.0012 ± 0.001 % Hemolysis at 5 µM | Human | Hybrid Peptide Of Human Β-Defensin -1 And Θ-Defensin | α-Helix | Non-hemolytic | ||
| 25348533 | 2015 | ACPIFTKIQGTYRGKAKRIGRRIC | hBTD-1 | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.0020 ± 0.001 % Hemolysis at 10 µM | Human | Hybrid Peptide Of Human Β-Defensin -1 And Θ-Defensin | α-Helix | Non-hemolytic | ||
| 25348533 | 2015 | ACPIFTKIQGTYRGKAKRIGRRIC | hBTD-1 | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.0040 ± 0.0040 % Hemolysis at 50 µM | Human | Hybrid Peptide Of Human Β-Defensin -1 And Θ-Defensin | α-Helix | Non-hemolytic | ||
| 25348533 | 2015 | ACPIFTKIQGTYRGKAKRIGRRIC | hBTD-1 | Free | Free | Linear | L | None | 24 | Antimicrobial | 0.0053 ± 0.001 % Hemolysis at 100 µM | Human | Hybrid Peptide Of Human Β-Defensin -1 And Θ-Defensin | α-Helix | Non-hemolytic | ||
| 25421112 | 2015 | LLSNVAGLLKQFAK | XPF2 | Free | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 256 μg/ml | Human | Silurana Tropicalis | α-Helix | NA | ||
| 25421112 | 2015 | LLRRVAGLLKQFAK | XPF4 | Free | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 256 μg/ml | Human | Silurana Tropicalis | α-Helix | Low hemolytic | ||
| 25421112 | 2015 | LLRRVARLLKRFAK | XPF6 | Free | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 128 μg/ml | Human | Silurana Tropicalis | α-Helix | Low hemolytic | ||
| 25433327 | 2015 | GIGKFLHSAGKFGKAFVGEIMKS | Magainin-G1 | Free | Free | Linear | L | None | 23 | Antibacterial | 50 % Hemolysis at >160 µM | Human | Skin Secretions Of X. Gilli From The Cape Peninsula | α-Helix | NA | ||
| 25433327 | 2015 | GMASKAGAIAGKIAKVALKAV{ct:Amid} | PGLa-G2 | Amidation | Free | Linear | L | None | 21 | Antibacterial | 50 % Hemolysis at >160 µM | Human | Skin Secretions Of X. Gilli From The Cape Peninsula | α-Helix | NA | ||
| 25433327 | 2015 | GWASKIGQTLGKMAKVGLQELIQPK | XPF-G1 | Free | Free | Linear | L | None | 25 | Antibacterial | 50 % Hemolysis at >160 µM | Human | Skin Secretions Of X. Gilli From The Cape Peninsula | α-Helix | NA | ||
| 25433327 | 2015 | GFGSFLGKALKAALKIGANALGGAPQQ | CPF-G2 | Free | Free | Linear | L | None | 27 | Antibacterial | 50 % Hemolysis | Human | Skin Secretions Of X. Gilli From The Cape Peninsula | α-Helix | NA | ||
| 25433327 | 2015 | GFGSFLGKALKAALKIGANALGGAPEQ | CPF-G3 | Free | Free | Linear | L | None | 27 | Antibacterial | 50 % Hemolysis at 85 µM | Human | Skin Secretions Of X. Gilli From The Cape Peninsula | α-Helix | NA | ||
| 25433327 | 2015 | GFGSVLGKLFKTAVKIIPSLLPSKQE | CPF-G4 | Free | Free | Linear | L | None | 26 | Antibacterial | 50 % Hemolysis at 35 µM | Human | Skin Secretions Of X. Gilli From The Cape Peninsula | α-Helix | NA | ||
| 25433327 | 2015 | GLASFLGKALKAGLKIGANLLGGAPQQ | CPF-G5 | Free | Free | Linear | L | None | 27 | Antibacterial | 50 % Hemolysis | Human | Skin Secretions Of X. Gilli From The Cape Peninsula | α-Helix | NA | ||
| 25433327 | 2015 | GFGSFLGKALKAALKVGANMLGGAPQQ | CPF-G6 | Free | Free | Linear | L | None | 27 | Antibacterial | 50 % Hemolysis at 60 µM | Human | Skin Secretions Of X. Gilli From The Cape Peninsula | α-Helix | NA | ||
| 26688811 | 2015 | KWKYPKLLKKLLK | KW-13 | Free | Free | Linear | L | None | 13 | Antibacterial | <1 % Hemolysis at 10 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 26688811 | 2015 | KWKYPKLLKKLLK | KW-13 | Free | Free | Linear | L | None | 13 | Antibacterial | <1 % Hemolysis at 40 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 26688811 | 2015 | KWKYPKLLKKLLK | KW-13 | Free | Free | Linear | L | None | 13 | Antibacterial | <1 % Hemolysis at 160 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 26688811 | 2015 | KWKYPKLLKKLLK | KW-13 | Free | Free | Linear | L | None | 13 | Antibacterial | <1 % Hemolysis at 640 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 25617899 | 2015 | WKKIRVRLSA{ct:Amid} | SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 4.1 ± 1.2 % Hemolysis at 64 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | WKKIRVRLSA{ct:Amid} | SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 2.1 ± 0.1 % Hemolysis at 32 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | WKKIRVRLSA{ct:Amid} | SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 2.0 ± 1.6 % Hemolysis at 16 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | WKKIRVRLSA{ct:Amid} | SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 2.0 ± 1.4 % Hemolysis at 8 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | WKKIRVRLSA{ct:Amid} | SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 2.0 ± 1.1 % Hemolysis at 4 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | WKKIRVRLSA{ct:Amid} | SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 0.0 ± 0.0 % Hemolysis at 2 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | WKKIRVRLSA{ct:Amid} | SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | Hemolysis at 1 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | WKKIRVRLSA{ct:Amid} | SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | Hemolysis at 0.5 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | WKKIRVRLSA{ct:Amid} | SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | Hemolysis at 0.25 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | KWKIRVRLSA{ct:Amid} | β-SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 11.1 ± 0.9 % Hemolysis at 64 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | KWKIRVRLSA{ct:Amid} | β-SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 10.9 ± 1.9 % Hemolysis at 32 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | KWKIRVRLSA{ct:Amid} | β-SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 6.4 ± 1.6 % Hemolysis at 16 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | KWKIRVRLSA{ct:Amid} | β-SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 5.9 ± 0.2 % Hemolysis at 8 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | KWKIRVRLSA{ct:Amid} | β-SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 2.4 ± 1.1 % Hemolysis at 4 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | KWKIRVRLSA{ct:Amid} | β-SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 2.1 ± 0.5 % Hemolysis at 2 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | KWKIRVRLSA{ct:Amid} | β-SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 2.0 ± 1.2 % Hemolysis at 1 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | KWKIRVRLSA{ct:Amid} | β-SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | Hemolysis at 0.5 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25617899 | 2015 | KWKIRVRLSA{ct:Amid} | β-SB056-lin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | Hemolysis at 0.25 μg/ml | Human | Sb056 Analogues, Mofification Of Sb056-Lin | β-Sheets | NA | ||
| 25462167 | 2015 | AGLQFPVGRIGRLLRK | Scolopendin 2 | Free | Free | Linear | L | None | 16 | Antimicrobial | 0 ± 0.8 % Hemolysis at 1.6 µM | Human | Centipede Scolopendra Subspinipes | α-Helix | Non-hemolytic | ||
| 25462167 | 2015 | AGLQFPVGRIGRLLRK | Scolopendin 2 | Free | Free | Linear | L | None | 16 | Antimicrobial | 0 ± 0.3 % Hemolysis at 3.1 µM | Human | Centipede Scolopendra Subspinipes | α-Helix | Non-hemolytic | ||
| 25462167 | 2015 | AGLQFPVGRIGRLLRK | Scolopendin 2 | Free | Free | Linear | L | None | 16 | Antimicrobial | 0 ± 0.4 % Hemolysis at 6.3 µM | Human | Centipede Scolopendra Subspinipes | α-Helix | Non-hemolytic | ||
| 25462167 | 2015 | AGLQFPVGRIGRLLRK | Scolopendin 2 | Free | Free | Linear | L | None | 16 | Antimicrobial | 0 ± 0.4 % Hemolysis at 12.5 µM | Human | Centipede Scolopendra Subspinipes | α-Helix | Non-hemolytic | ||
| 25462167 | 2015 | AGLQFPVGRIGRLLRK | Scolopendin 2 | Free | Free | Linear | L | None | 16 | Antimicrobial | 0 ± 0.5 % Hemolysis at 25 µM | Human | Centipede Scolopendra Subspinipes | α-Helix | Non-hemolytic | ||
| 25462167 | 2015 | AGLQFPVGRIGRLLRK | Scolopendin 2 | Free | Free | Linear | L | None | 16 | Antimicrobial | 0 ± 0.3 % Hemolysis at 50 µM | Human | Centipede Scolopendra Subspinipes | α-Helix | Non-hemolytic | ||
| 25462167 | 2015 | AGLQFPVGRIGRLLRK | Scolopendin 2 | Free | Free | Linear | L | None | 16 | Antimicrobial | 0 ± 0.2 % Hemolysis at 100 µM | Human | Centipede Scolopendra Subspinipes | α-Helix | Non-hemolytic | ||
| 25557880 | 2015 | RWCVYAYVRVRGVLVRYRRCW | Arenicin-1 | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 4.1 µM | Human | Coelomocytes Of Marine Polychaeta Lugworm Arenicola Marina | β-Hairpin | NA | ||
| 25557880 | 2015 | RGCVYAYVRVRGVLVRYRRCW | W2G | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 5.5 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RSCVYAYVRVRGVLVRYRRCW | W2S | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 5.5 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RRCVYAYVRVRGVLVRYRRCW | W2R | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 9.4 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCGYAYVRVRGVLVRYRRCW | V4G | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 36.2 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCSYAYVRVRGVLVRYRRCW | V4S | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 23.1 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCRYAYVRVRGVLVRYRRCW | V4R | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 48.5 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYGYVRVRGVLVRYRRCW | A6G | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 17 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYSYVRVRGVLVRYRRCW | A6S | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 13.9 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYRYVRVRGVLVRYRRCW | A6R | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 71 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYGRVRGVLVRYRRCW | V8G | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 6.7 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYSRVRGVLVRYRRCW | V8S | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 26.8 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYRRVRGVLVRYRRCW | V8R | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 125 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRGRGVLVRYRRCW | V10G | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 4.9 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRSRGVLVRYRRCW | V10S | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 4.3 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRRRGVLVRYRRCW | V10R | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 9.5 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGGLVRYRRCW | V13G | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 5.9 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGSLVRYRRCW | V13S | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 9.7 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGRLVRYRRCW | V13R | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 13.7 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGVGVRYRRCW | L14G | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 4.4 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGVSVRYRRCW | L14S | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 3.1 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGVRVRYRRCW | L14R | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 3.1 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGVLGRYRRCW | V15G | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 12.8 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGVLSRYRRCW | V15S | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 24.8 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGVLRRYRRCW | V15R | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 28.3 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGVLVRYRRCG | W21G | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 8.4 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGVLVRYRRCS | W21S | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 9.2 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25557880 | 2015 | RWCVYAYVRVRGVLVRYRRCR | W21R | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 10.8 µM | Human | Arenicin Analog | β-Hairpin | NA | ||
| 25575476 | 2015 | AWNTYDYMKREHSLVKPYQG | MrMBL-N20 | Free | Free | Linear | L | None | 20 | Antibacterial | 5.3 ± 0.8 % Hemolysis at 5 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | AWNTYDYMKREHSLVKPYQG | MrMBL-N20 | Free | Free | Linear | L | None | 20 | Antibacterial | 8.9 ± 1.2 % Hemolysis at 10 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | AWNTYDYMKREHSLVKPYQG | MrMBL-N20 | Free | Free | Linear | L | None | 20 | Antibacterial | 14.5 ± 2.1 % Hemolysis at 25 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | AWNTYDYMKREHSLVKPYQG | MrMBL-N20 | Free | Free | Linear | L | None | 20 | Antibacterial | 19.7 ± 2.5 % Hemolysis at 50 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | AWNTYDYMKREHSLVKPYQG | MrMBL-N20 | Free | Free | Linear | L | None | 20 | Antibacterial | 24.7 ± 1.9 % Hemolysis at 100 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | AWNTYDYMKREHSLVKPYQG | MrMBL-N20 | Free | Free | Linear | L | None | 20 | Antibacterial | 28.5 ± 1.5 % Hemolysis at 150 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | AWNTYDYMKREHSLVKPYQG | MrMBL-N20 | Free | Free | Linear | L | None | 20 | Antibacterial | 33.6 ± 2.4 % Hemolysis at 200 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | AWNTYDYMKREHSLVKPYQG | MrMBL-N20 | Free | Free | Linear | L | None | 20 | Antibacterial | 37.4 ± 2.0 % Hemolysis at 250 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | GGLFYVKHKEQQRKRF | MrMBL-C16 | Free | Free | Linear | L | None | 16 | Antibacterial | 7.9 ± 1.4 % Hemolysis at 5 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | GGLFYVKHKEQQRKRF | MrMBL-C16 | Free | Free | Linear | L | None | 16 | Antibacterial | 11.5 ± 1.3 % Hemolysis at 10 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | GGLFYVKHKEQQRKRF | MrMBL-C16 | Free | Free | Linear | L | None | 16 | Antibacterial | 18.7 ± 2.5 % Hemolysis at 25 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | GGLFYVKHKEQQRKRF | MrMBL-C16 | Free | Free | Linear | L | None | 16 | Antibacterial | 25.4 ± 2.2 % Hemolysis at 50 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | GGLFYVKHKEQQRKRF | MrMBL-C16 | Free | Free | Linear | L | None | 16 | Antibacterial | 31.4 ± 3.5 % Hemolysis at 100 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | GGLFYVKHKEQQRKRF | MrMBL-C16 | Free | Free | Linear | L | None | 16 | Antibacterial | 36.8 ± 1.7 % Hemolysis at 150 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | GGLFYVKHKEQQRKRF | MrMBL-C16 | Free | Free | Linear | L | None | 16 | Antibacterial | 41.5 ± 2.5 % Hemolysis at 200 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25575476 | 2015 | GGLFYVKHKEQQRKRF | MrMBL-C16 | Free | Free | Linear | L | None | 16 | Antibacterial | 46.5 ± 2.2 % Hemolysis at 250 µM | Human | Freshwater Prawn Macrobrachium Rosenbergii | α-Helix/Random coil | NA | ||
| 25869360 | 2015 | LRLKSIVSYAKKVL | Mastoparan-S | Free | Free | Linear | L | None | 14 | Antibaterial, Antifungal | 0.2 % Hemolysis at 10 μg/ml | Human | Insect Sphodromantis Viridis | NA | NA | ||
| 25869360 | 2015 | LRLKSIVSYAKKVL | Mastoparan-S | Free | Free | Linear | L | None | 14 | Antibaterial, Antifungal | 0.25 % Hemolysis at 20 μg/ml | Human | Insect Sphodromantis Viridis | NA | NA | ||
| 25869360 | 2015 | LRLKSIVSYAKKVL | Mastoparan-S | Free | Free | Linear | L | None | 14 | Antibaterial, Antifungal | 0.46 % Hemolysis at 40 μg/ml | Human | Insect Sphodromantis Viridis | NA | NA | ||
| 25869360 | 2015 | LRLKSIVSYAKKVL | Mastoparan-S | Free | Free | Linear | L | None | 14 | Antibaterial, Antifungal | 1.2 % Hemolysis at 60 μg/ml | Human | Insect Sphodromantis Viridis | NA | NA | ||
| 25869360 | 2015 | LRLKSIVSYAKKVL | Mastoparan-S | Free | Free | Linear | L | None | 14 | Antibaterial, Antifungal | 2.3 % Hemolysis at 80 μg/ml | Human | Insect Sphodromantis Viridis | NA | NA | ||
| 25869360 | 2015 | LRLKSIVSYAKKVL | Mastoparan-S | Free | Free | Linear | L | None | 14 | Antibaterial, Antifungal | 2.9 % Hemolysis at 100 μg/ml | Human | Insect Sphodromantis Viridis | NA | NA | ||
| 25869360 | 2015 | LRLKSIVSYAKKVL | Mastoparan-S | Free | Free | Linear | L | None | 14 | Antibaterial, Antifungal | 3 % Hemolysis at 20 µM | Human | Insect Sphodromantis Viridis | NA | NA | ||
| 25869360 | 2015 | LKLKSIVSWAKKVL | Mastoparan-В | Free | Free | Linear | L | None | 14 | Antibaterial, Antifungal | 71 % Hemolysis at 20 µM | Human | Insect Sphodromantis Viridis | NA | NA | ||
| 25311453 | 2015 | YSKSLPLSVLNP | Synthesized AN5-1 | Free | Free | Linear | L | None | 12 | Antibacterial | 10 % Hemolysis at 256 μg/ml | Human | Fermentation Broth Of Paenibacillus Alvei | NA | Low hemolytic | ||
| 25311453 | 2015 | YSKSLPLSVLNP | Biosynthesized AN5-1 | Free | Free | Linear | L | None | 12 | Antibacterial | 10 % Hemolysis at 256 μg/ml | Human | Fermentation Broth Of Paenibacillus Alvei | NA | Low hemolytic | ||
| 25680229 | 2015 | GIGKFLKKAKKFGKAFVKILKK{ct:Amid} | MSI-78 | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 53 % Hemolysis at 512 μg/ml | Human | Skin Of The African Clawed Frog | α-Helix | NA | ||
| 25680229 | 2015 | GIGKFLKKAKKFGKAFVKILKK{ct:Amid} | MSI-78 | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 25 % Hemolysis at 256 μg/ml | Human | Skin Of The African Clawed Frog | α-Helix | NA | ||
| 25680229 | 2015 | GIGKFLKKAKKFGKAFVKILKK{ct:Amid} | MSI-78 | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Antibacterial | 13 % Hemolysis at 128 μg/ml | Human | Skin Of The African Clawed Frog | α-Helix | NA | ||
| 25680229 | 2015 | GIGKFLKKAKKF{ct:Amid} | CEM1 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antibacterial | 0 % Hemolysis at 0-512 μg/ml | Human | Pexiganan, Synthetic Peptide | α-Helix | Non-hemolytic | ||
| 25680229 | 2015 | IGKFLKKAKKFG{ct:Amid} | CEM2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antibacterial | 0 % Hemolysis at 0-512 μg/ml | Human | Pexiganan, Synthetic Peptide | α-Helix | Non-hemolytic | ||
| 25735802 | 2015 | RFRRLRWKTRWRLKKI{ct:Amid} | PRW4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial, Antibacterial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 25735802 | 2015 | RFRRLRCKTRCRLKKI{ct:Amid} | K4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial, Antibacterial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 25735802 | 2015 | RFRRLRDKTRDRLKKI{ct:Amid} | K4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial, Antibacterial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 25735802 | 2015 | RFRRLRIKTRIRLKKI{ct:Amid} | K4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial, Antibacterial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 25735802 | 2015 | RFRRLRPKTRPRLKKI{ct:Amid} | K4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial, Antibacterial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 25735802 | 2015 | RFRRLRW{d}KTRW{d}RLKKI{ct:Amid} | PRW4-d | Amidation | Free | Linear | Mix | w = Wd (D-Trp-substituted) | 16 | Antimicrobial, Antibacterial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 25735802 | 2015 | RFRRLRWRTRWRLRRI{ct:Amid} | PRW4-R | Amidation | Free | Linear | L | None | 16 | Antimicrobial, Antibacterial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 25735802 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 16 | Antimicrobial, Antibacterial | 5 % Hemolysis at 0.25 µM | Human | Control,Bee Venom | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKVVNVLKNLF{ct:Amid} | KU1 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at 8.07 ± 1.60 mg/L | Human | Synthetic, Mixed Backbone Of Kabt-Amp And Uperin 3.6 | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKWLNVLKNLF{ct:Amid} | KU2 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at 7.33 ± 0.73 mg/L | Human | Synthetic, Mixed Backbone Of Kabt-Amp And Uperin 3.7 | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKWLKVLKNLF{ct:Amid} | KU3 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at 5.65 ± 0.85 mg/L | Human | Synthetic, Mixed Backbone Of Kabt-Amp And Uperin 3.8 | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKWLKKLKNLF{ct:Amid} | KU4 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at 49.38 ± 5.14 mg/L | Human | Synthetic, Mixed Backbone Of Kabt-Amp And Uperin 3.9 | α-Helix | NA | ||
| 25965506 | 2015 | GVIKAAKKVVNVLKNLF{ct:Amid} | Upn-lys4 | Amidation | Free | Linear | L | None | 17 | Antifungal | 10 % Hemolysis at >256 mg/L | Human | Uperin 3.6 Analogs, Mixed Backbone Of Kabt-Amp And Uperin 3.6 | α-Helix | NA | ||
| 25965506 | 2015 | GVIKAAKKVVKVLKNLF{ct:Amid} | Upn-lys5 | Amidation | Free | Linear | L | None | 17 | Antifungal | 10 % Hemolysis at >256 mg/L | Human | Uperin 3.6 Analogs, Mixed Backbone Of Kabt-Amp And Uperin 3.7 | α-Helix | NA | ||
| 25965506 | 2015 | GVIKAAKKVVKVLKKLF{ct:Amid} | Upn-lys6 | Amidation | Free | Linear | L | None | 17 | Antifungal | 10 % Hemolysis at >256 mg/L | Human | Uperin 3.6 Analogs, Mixed Backbone Of Kabt-Amp And Uperin 3.8 | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKWLKKLLKKLWKKG{ct:Amid} | KABT-AMP | Amidation | Free | Linear | L | None | 22 | Antifungal | 10 % Hemolysis at 4.67 ± 2.09 mg/L | Human | Mixed Backbone Of Kabt-Amp And Uperin 3.6 | α-Helix | NA | ||
| 25965506 | 2015 | GVIDAAKKVVNVLKNLF{ct:Amid} | Uperin 3.6 | Amidation | Free | Linear | L | None | 17 | Antifungal | 10 % Hemolysis at >256 mg/L | Human | Australian Toadlet, Uperoleia Mjobergii | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKVVNVLKNLF{ct:Amid} | KU1 | Amidation | Free | Linear | L | None | 18 | Antifungal | 50 % Hemolysis at 58.19 ± 2.04 mg/L | Human | Mixed Backbone Of Kabt-Amp And Uperin 3.6 | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKWLNVLKNLF{ct:Amid} | KU2 | Amidation | Free | Linear | L | None | 18 | Antifungal | 50 % Hemolysis at 57.71 ± 9.80 mg/L | Human | Mixed Backbone Of Kabt-Amp And Uperin 3.6 | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKWLKVLKNLF{ct:Amid} | KU3 | Amidation | Free | Linear | L | None | 18 | Antifungal | 50 % Hemolysis at 55.20 ± 11.90 mg/L | Human | Mixed Backbone Of Kabt-Amp And Uperin 3.6 | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKWLKKLKNLF{ct:Amid} | KU4 | Amidation | Free | Linear | L | None | 18 | Antifungal | 50 % Hemolysis at >256 mg/L | Human | Mixed Backbone Of Kabt-Amp And Uperin 3.6 | α-Helix | NA | ||
| 25965506 | 2015 | GVIKAAKKVVNVLKNLF{ct:Amid} | Upn-lys4 | Amidation | Free | Linear | L | None | 17 | Antifungal | 50 % Hemolysis at >256 mg/L | Human | Uperin 3.6 Analogs, Mixed Backbone Of Kabt-Amp And Uperin 3.6 | α-Helix | NA | ||
| 25965506 | 2015 | GVIKAAKKVVKVLKNLF{ct:Amid} | Upn-lys5 | Amidation | Free | Linear | L | None | 17 | Antifungal | 50 % Hemolysis at >256 mg/L | Human | Uperin 3.6 Analogs, Mixed Backbone Of Kabt-Amp And Uperin 3.7 | α-Helix | NA | ||
| 25965506 | 2015 | GVIKAAKKVVKVLKKLF{ct:Amid} | Upn-lys6 | Amidation | Free | Linear | L | None | 17 | Antifungal | 50 % Hemolysis at >256 mg/L | Human | Uperin 3.6 Analogs, Mixed Backbone Of Kabt-Amp And Uperin 3.8 | α-Helix | NA | ||
| 25965506 | 2015 | GIWKKWIKKWLKKLLKKLWKKG{ct:Amid} | KABT-AMP | Amidation | Free | Linear | L | None | 22 | Antifungal | 50 % Hemolysis at 81.23 ± 8.92 mg/L | Human | Mixed Backbone Of Kabt-Amp And Uperin 3.6 | α-Helix | NA | ||
| 25965506 | 2015 | GVIDAAKKVVNVLKNLF{ct:Amid} | Uperin 3.6 | Amidation | Free | Linear | L | None | 17 | Antifungal | 50 % Hemolysis at >256 mg/L | Human | Australian Toadlet,Uperoleia Mjobergii | α-Helix | NA | ||
| 25997127 | 2015 | LIAGLAANFLPQILCKIARKC{ct:Amid} | linear B1CTcu5 | Amidation | Free | Linear | L | None | 21 | Antibacterial | 37 % Hemolysis at 25 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | LIAGLAANFLPQILCKIARKC{cyc:N-C}{ct:Amid} | Cyclic B1CTcu5 | Amidation | Free | Cyclic | L | None | 21 | Antibacterial | 40 % Hemolysis at 25 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | IAGLAANFLPQILCKIARKC{ct:Amid} | B1CTcu5-L | Amidation | Free | Linear | L | None | 20 | Antibacterial | 30.5 % Hemolysis at 50 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | AGLAANFLPQILCKIARKC{ct:Amid} | B1CTcu5-LI | Amidation | Free | Linear | L | None | 19 | Antibacterial | 26 % Hemolysis at 50 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | GLAANFLPQILCKIARKC{ct:Amid} | B1CTcu5-LIA | Amidation | Free | Linear | L | None | 18 | Antibacterial | 26.5 % Hemolysis at 100 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | LAANFLPQILCKIARKC{ct:Amid} | B1CTcu5-LIAG | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 30 % Hemolysis at 12.5 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | KIAGLAANFLPQILCKIARKC{ct:Amid} | B1CTcu5K | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antibiofilm | 15 % Hemolysis at 25 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | WIAGLAANFLPQILCKIARKC{ct:Amid} | B1CTcu5W | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antibiofilm | 39.11 % Hemolysis at 100 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | RIAGLAANFLPQILCKIARKC{ct:Amid} | B1CTcu5R | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antibiofilm | 19.4 % Hemolysis at 25 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | HIAGLAANFLPQILCKIARKC{ct:Amid} | B1CTcu5H | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antibiofilm | 30.4 % Hemolysis at 50 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | LGGGLAANFLPQILCKIARKC{ct:Amid} | B1CTcu5LGG | Amidation | Free | Linear | L | None | 21 | Antibacterial | 23.4 % Hemolysis | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | LIAGLAANFLPQILCKIARK{ct:Amid} | B1CTcu5-C | Amidation | Free | Linear | L | None | 20 | Antibacterial | 13 % Hemolysis at 25 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | LIAGLAANFLPQILC(AC{d}M{d})KIARKC{ct:Amid} | B1CTcu5C (Acm) | Amidation | Free | Linear | L | None | 21 | Antibacterial | 25 % Hemolysis at 12.5 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25997127 | 2015 | LIAGLAANFLPQILC{ct:Amid} | B1CTcu5-Rana | Amidation | Free | Linear | L | None | 15 | Antibacterial | NA | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | Non-hemolytic | ||
| 25997127 | 2015 | LIAGLAANFL{ct:Amid} | B1CTcu5L1-L10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | NA | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | Non-hemolytic | ||
| 25997127 | 2015 | PQILCKIARKC{ct:Amid} | B1CTcu5P11-C21 | Amidation | Free | Linear | L | None | 11 | Antibacterial | NA | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | Non-hemolytic | ||
| 25997127 | 2015 | LIAGLAANFLPQILCKIARKC{ct:Amid} | DB1CTcu5 | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antibiofilm | 40.22 % Hemolysis at 25 μg/ml | Human | Smmd-B1Ctcu5 Analogs, Skin Secretion Of Frog Clinotarsus Curtipes | α-Helix | NA | ||
| 25749154 | 2015 | FFGHLYRGITSVVKHVHGLLSG | Cnd | Free | Free | Linear | L | None | 22 | Antimicrobial | ~0.8 % Hemolysis at 50 μg/ml | Human | Gills Of The Chionodraco Hamatus | α-Helix | NA | ||
| 25807936 | 2015 | {nnr:6#}IK{ct:Amid} | P1 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 2 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}CK{ct:Amid} | P2 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{d}{nnr:6#}K{d}{ct:Amid} | P3 | Amidation | Free | Linear | D | 6# = BDZ,benzodiazepine scaffold | 2 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}VH{ct:Amid} | P4 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}K{ct:Amid} | P5 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 2 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}KC{ct:Amid} | P6 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}FK{ct:Amid} | P7 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{d}{nnr:6#}F{d}K{d}{ct:Amid} | P8 | Amidation | Free | Linear | D | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | K{nnr:6#}LK{ct:Amid} | P9 | Amidation | Free | Linear | L | 6# = BDZ,benzodiazepine scaffold | 3 | Antibacterial | 50 % Hemolysis at >1000 μg/ml | Human | Bdz Peptidomimetic Compounds | α-Helix | NA | ||
| 25807936 | 2015 | GIGKFLKKAKKFGKAFVKILKK{ct:Amid} | MSI-78 | Amidation | Free | Linear | L | None | 22 | Antibacterial | 50 % Hemolysis at 120 μg/ml | Human | Magainin Analogue | α-Helix | Non-hemolytic | ||
| 26046345 | 2015 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antibacterial | 56.98 % Hemolysis at 250 μg/ml | Human | Neutrophil Blood Cells Of Cows | α-Helix | NA | ||
| 26046345 | 2015 | LLPWKWPWWKWRR{ct:Amid} | IN1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 3.6 % Hemolysis at 250 μg/ml | Human | Indolicidin Analog | α-Helix | Low hemolytic | ||
| 26046345 | 2015 | RRPWRWPWWPWRR{ct:Amid} | IN2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 15.39 % Hemolysis at 250 μg/ml | Human | Indolicidin Analog | α-Helix | NA | ||
| 26046345 | 2015 | RRPWRWPRWPWRR{ct:Amid} | IN3 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 2.39 % Hemolysis at 250 μg/ml | Human | Indolicidin Analog | α-Helix | Low hemolytic | ||
| 26046345 | 2015 | FLGGLIKIVPAMICAVTKKC{ct:OH} | Ranalexin | OH | Free | Linear | L | None | 20 | Antibacterial | <15 % Hemolysis at 250 μg/ml | Human | Bullfrog (Rana Catesbeiana) Skin | α-Helix | NA | ||
| 26046345 | 2015 | FLGGLIKWWPWRR{ct:Amid} | RN7-IN6 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antipneumococcal | 0 % Hemolysis at 15.62 μg/ml | Human | Indolicidin Ranalexin Hybrid Peptide | α-Helix | Non-hemolytic | ||
| 26046345 | 2015 | FLGGLIKPWWPWRR{ct:Amid} | RN7-IN7 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <10 % Hemolysis at 250 μg/ml | Human | Indolicidin Ranalexin Hybrid Peptide | α-Helix | Non-hemolytic | ||
| 26046345 | 2015 | FLGGLIKWPWWPWRR{ct:Amid} | RN7-IN8 | Amidation | Free | Linear | L | None | 15 | Antibacterial, Antipneumococcal | 0 % Hemolysis at 15.62 μg/ml | Human | Indolicidin Ranalexin Hybrid Peptide | α-Helix | Non-hemolytic | ||
| 26046345 | 2015 | FLGGLIKKWPWWPWRR{ct:Amid} | RN7-IN9 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antipneumococcal | 0 % Hemolysis at 15.62 μg/ml | Human | Indolicidin Ranalexin Hybrid Peptide | α-Helix | Non-hemolytic | ||
| 26046345 | 2015 | FLGGLIKWKWPWWPWRR{ct:Amid} | RN7-IN10 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antipneumococcal | 5.9 % Hemolysis at 15.62 μg/ml | Human | Indolicidin Ranalexin Hybrid Peptide | α-Helix | NA | ||
| 25966444 | 2015 | Q(L)R{nt:C18-aliphatic chain}{ct:Amid} | LP1 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 3 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | QLR{nt:C18-aliphatic chain}{ct:Amid} | LP2 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 3 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | CGCQ(L)R{nt:C18-aliphatic chain}{ct:Amid} | LP3 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 6 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | CGCQLR{nt:C18-aliphatic chain}{ct:Amid} | LP4 | Amidation | C18-aliphatic chain | Linear | L | C18 = aliphatic chain | 6 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Host Defence Peptides | α-Helix | NA | ||
| 25966444 | 2015 | {nnr:βA}{nnr:βA}KIAKLKAKIQKLKQKIAKLK{nt:C12-aliphatic chain}{ct:Amid} | LH | Amidation | C12-aliphatic domain,βA- 2 spacer | Linear | L | C12 = aliphatic domain, βA = 2 spacer | 22 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Host Defence Peptides | α-Helix | NA | ||
| 25826179 | 2015 | FKKLKKLFSKLWNWK{nt:Acet}{ct:Amid} | HPRP-A1 | Amidation | Acetylation | Linear | L | None | 15 | Antibacterial | MHC % Hemolysis at 32 µM | Human | N-Terminus Of Ribosomal Protein L1 Of Helicobacter Pylori | α-Helix | NA | ||
| 25826179 | 2015 | FKKLKKLFSKLKNWW{nt:Acet}{ct:Amid} | HPRP-A2 | Amidation | Acetylation | Linear | L | None | 15 | Antibacterial | MHC % Hemolysis at 16 µM | Human | Analog Of Hprp-A1 | α-Helix | NA | ||
| 25826179 | 2015 | KFLKLKWLKSWKNFK{nt:Acet}{ct:Amid} | HPRP-A3 | Amidation | Acetylation | Linear | L | None | 15 | Antibacterial | MHC % Hemolysis at 250 µM | Human | Analog Of Hprp-A1 | α-Helix | NA | ||
| 25826179 | 2015 | FKLKLKFSNKLKWKW{nt:Acet}{ct:Amid} | HPRP-B | Amidation | Acetylation | Linear | L | None | 15 | Antibacterial | MHC % Hemolysis at 64 µM | Human | Analog Of Hprp-A1 | β-Sheets | NA | ||
| 25826179 | 2015 | LFKKNKLWFKSKKWL{nt:Acet}{ct:Amid} | HPRP-C | Amidation | Acetylation | Linear | L | None | 15 | Antibacterial | MHC % Hemolysis at 500 µM | Human | Analog Of Hprp-A1 | Random coil | NA | ||
| 25869678 | 2015 | MQFITDLIKKAVDFFKGLFGNK | WRK | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 2.78 µM | Human | Staphylococcus Warneri | α-Helix | NA | ||
| 25869678 | 2015 | MQFITDLIGKAVDFFKGLFGNK | WRK_K9G | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at >20 µM | Human | Staphylococcus Warneri | α-Helix | NA | ||
| 25869678 | 2015 | MQFITDLIKKAVDFFKGLFDNK | WRK_G20D | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 9.09 µM | Human | Staphylococcus Warneri | α-Helix | NA | ||
| 25869678 | 2015 | MQFITDLIGKAVDFFKGLFDNK | WRK_K9G-G20D | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at >20 µM | Human | Staphylococcus Warneri | α-Helix | NA | ||
| 25869678 | 2015 | MQFITDLIKKAVDVFKGLFGNK | WRK_F14V | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 12.5 µM | Human | Staphylococcus Warneri | α-Helix | NA | ||
| 25869678 | 2015 | MQFITDLIKKAVDFIKGLFGNK | WRK_F15I | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 2.63 µM | Human | Staphylococcus Warneri | α-Helix | NA | ||
| 25869678 | 2015 | MQFITDLIKKAVDVIKGLFGNK | WRK_F14V-F15I | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 8.33 µM | Human | Staphylococcus Warneri | α-Helix | NA | ||
| 25869678 | 2015 | MQFITDLIKKAVDFFKGLVGNK | WRK_F19V | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 11.1 µM | Human | Staphylococcus Warneri | α-Helix | NA | ||
| 25869678 | 2015 | MQTFQDILGKVIEVIKAIVDAK | rPSM | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 20 µM | Human | Staphylococcus Warneri | α-Helix | NA | ||
| 25869678 | 2015 | MADVIAKIVEIVKGLIDQFTQK | PSM | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 7.14 µM | Human | Staphylococcus Epidermidis | α-Helix | NA | ||
| 25869678 | 2015 | MAGVIAKIVEIVKGLIDQFTQK | PSM_D3G | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 3.7 µM | Human | Staphylococcus Epidermidis | α-Helix | NA | ||
| 25869678 | 2015 | MADVIAKIVEIVKKLIDQFTQK | PSM_G14K | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 9.88 µM | Human | Staphylococcus Epidermidis | α-Helix | NA | ||
| 25869678 | 2015 | MAGVIAKIVEIVKKLIDQFTQK | PSM_D3G-G14K | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 3.125 µM | Human | Staphylococcus Epidermidis | α-Helix | NA | ||
| 25869678 | 2015 | MADVIAKFVEIVKGLIDQFTQK | PSM_I8F | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at >20 µM | Human | Staphylococcus Epidermidis | α-Helix | NA | ||
| 25869678 | 2015 | MADVIAKIFEIVKGLIDQFTQK | PSM_V9F | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 4.76 µM | Human | Staphylococcus Epidermidis | α-Helix | NA | ||
| 25869678 | 2015 | MADVIAKFFEIVKGLIDQFTQK | PSM_I8F-V9F | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at >20 µM | Human | Staphylococcus Epidermidis | α-Helix | NA | ||
| 25869678 | 2015 | MADFIAKIVEIVKGLIDQFTQK | PSM_V4F | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 10 µM | Human | Staphylococcus Epidermidis | α-Helix | NA | ||
| 25869678 | 2015 | MNGFILGKFFDVAKKILDTIFQK | rWRK | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 4 µM | Human | Staphylococcus Epidermidis | α-Helix | NA | ||
| 25941221 | 2015 | RIWVIWRR{ct:Amid} | Bac8c | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 10 % Hemolysis at 128 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 25941221 | 2015 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10 % Hemolysis at 64 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 25941221 | 2015 | RWKRWWRWI{ct:Amid} | GN-2 peptide | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 25941221 | 2015 | RWKKWWRWL{ct:Amid} | GN-4 peptide | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 25941221 | 2015 | RKRWWWWFR{ct:Amid} | GN-6 peptide | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | α-Helix | NA | ||
| 26126210 | 2015 | LKGCWTKSIPPKPCF | ORB-1 | Free | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at >500 μg/ml | Human | Synthetic Peptide | β-Hairpin | Low hemolytic | ||
| 26126210 | 2015 | LKGCWTKSIPPKPCF{ct:Amid} | ORB-N | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at >500 μg/ml | Human | Orb-1 Analog | β-Hairpin | NA | ||
| 26156126 | 2015 | RWKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK{ct:Amid} | Papiliocin | Amidation | Free | Linear | L | None | 37 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RAKIFKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK{ct:Amid} | Papiliocin-2A | Amidation | Free | Linear | L | None | 37 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RWKIAKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK{ct:Amid} | Papiliocin-5A | Amidation | Free | Linear | L | None | 37 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RAKIAKKIEKVGRNVRDGIIKAGPAVAVVGQAATVVK{ct:Amid} | Papiliocin-2A5A | Amidation | Free | Linear | L | None | 37 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RWKIFKKIEKVGRNVRDGIIKA{ct:Amid} | PapN | Amidation | Free | Linear | L | None | 22 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RAKIFKKIEKVGRNVRDGIIKA{ct:Amid} | PapN-2A | Amidation | Free | Linear | L | None | 22 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RWKIAKKIEKVGRNVRDGIIKA{ct:Amid} | PapN-5A | Amidation | Free | Linear | L | None | 22 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RAKIAKKIEKVGRNVRDGIIKA{ct:Amid} | PapN-2A5A | Amidation | Free | Linear | L | None | 22 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | RFKIWKKIEKVGRNVRDGIIKA{ct:Amid} | PapN-2F5W | Amidation | Free | Linear | L | None | 22 | Antimicrobial and Antiinflammatory Activities | 0 % Hemolysis at 100 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | Non-hemolytic | ||
| 26156126 | 2015 | AVAVVGQAATVVK{ct:Amid} | PapC | Amidation | Free | Linear | L | None | 13 | Antimicrobial and Antiinflammatory Activities | 49 % Hemolysis at 6.25 µM | Human | Swallowtail Butterfly Papilio Xuthus | α-Helix | NA | ||
| 26194630 | 2015 | LIQRGRFGRFLGRIRRFRPRINFDIRARGSIRLG | Cl-CATH2 | Free | Free | Linear | L | None | 34 | Antimicrobial | 12.84 % Hemolysis at 200 μg/ml | Human | Columba Livia | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKDAGKQLVAHAMGKIAEKV{ct:Amid} | ocellatin-PT1 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 1.98 ± 0.08 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKDAGKQLVAHATGKIAEKV{ct:Amid} | ocellatin-PT2 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 0 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | Non-hemolytic | ||
| 26107622 | 2015 | GVIDIIKGAGKDLIAHAIGKLAEKV{ct:Amid} | ocellatin-PT3 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 0.69 ± 0.04 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKGAGKQLIAHAMGKIAEKV{ct:Amid} | ocellatin-PT4 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 4.29 ± 0.23 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKDAGRQLVAHAMGKIAEKV{ct:Amid} | ocellatin-PT5 | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 4.05 ± 0.19 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKGAGKQLIAHAMEKIAEKVGLNKDGN | ocellatin-PT6 | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.69 ± 0.04 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKGAGKQLIAHAMGKIAEKVGLNKDGN | ocellatin-PT7 | Free | Free | Linear | L | None | 32 | Antimicrobial | 13.72 ± 1.29 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 26107622 | 2015 | GVFDIIKGAGKQLIARAMGKIAEKVGLNKDGN | ocellatin-PT8 | Free | Free | Linear | L | None | 32 | Antimicrobial | 8.09 ± 0.52 % Hemolysis at 800 μg/ml | Human | Leptodactylus Pustulatus | α-Helix | NA | ||
| 26096124 | 2015 | GLLKRIKTLL{ct:Amid} | Anoplin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 50 % Hemolysis at 512 μg/ml | Human | Venom Of The Solitary Wasp | α-Helix | NA | ||
| 25620367 | 2015 | GFGCNGPWNEDDLRCHNHCKSIKGYKGGYCAKGGFVCKCY | NZ2114 | Free | Free | Linear | L | None | 40 | Antibacterial | <0.05 % Hemolysis at 128 μg/ml | Human | Variant Of Nz2114 | α-Helix | Low hemolytic | ||
| 25620367 | 2015 | GFGCNGPWQEDDVKCHNHCKSIKGYKGGYCAKGGFVCKCY | MP1102 | Free | Free | Linear | L | None | 40 | Antibacterial | <0.05 % Hemolysis at 128 μg/ml | Human | Pseudoplectania Nigrella | α-Helix | Low hemolytic | ||
| 26238108 | 2015 | KWKSFLKTFKSAKKTVLHTLLKAISS | A20L | Free | Free | Linear | L | None | 26 | Antibacterial | MHC % Hemolysis at 213.33 μg/ml | Human | Derivative Of V13K | α-Helix | NA | ||
| 26204061 | 2015 | GIIKKIIKKIIKKI{ct:Amid} | FITC | Amidation | Free | Linear | L | None | 14 | Antibacterial and Anticancer | 50 % Hemolysis at 256 µM | Human | Synthetic Amphiphiles | α-Helix | Low hemolytic | ||
| 26204061 | 2015 | IIKKIIKKIIKKI{ct:Amid} | 1 | Amidation | Free | Linear | L | None | 13 | Antibacterial and Anticancer | 50 % Hemolysis at 256 µM | Human | Synthetic Amphiphiles | α-Helix | Low hemolytic | ||
| 26204061 | 2015 | GIIKKIIKKIIKK{ct:Amid} | 2 | Amidation | Free | Linear | L | None | 13 | Antibacterial and Anticancer | 50 % Hemolysis at 500 µM | Human | Synthetic Amphiphiles | α-Helix | Low hemolytic | ||
| 26204061 | 2015 | IIKKIIKKIIKK{ct:Amid} | Rhodamine | Amidation | Free | Linear | L | None | 12 | Antibacterial and Anticancer | 50 % Hemolysis at >1000 µM | Human | Synthetic Amphiphiles | α-Helix | Low hemolytic | ||
| 26041027 | 2015 | RPHGAGEGIDRVPAGPSPSEVGLAIPSGK{ct:Amid} | Pep-7 | Amidation | Free | Linear | L | None | 29 | Antibacterial | 0.1 ± 0.1 % Hemolysis at 1.7 µM | Human | Porphyromonas Gingivalis | NA | NA | ||
| 26041027 | 2015 | RPHGAGEGIDRVPAGPSPSEVGLAIPSGK{ct:Amid} | Pep-7 | Amidation | Free | Linear | L | None | 29 | Antibacterial | 0.1 ± 0.1 % Hemolysis at 3.4 µM | Human | Porphyromonas Gingivalis | NA | NA | ||
| 26041027 | 2015 | RPHGAGEGIDRVPAGPSPSEVGLAIPSGK{ct:Amid} | Pep-7 | Amidation | Free | Linear | L | None | 29 | Antibacterial | 0.3 ± 0.1 % Hemolysis at 6.8 µM | Human | Porphyromonas Gingivalis | NA | NA | ||
| 26134716 | 2015 | SELAGTIIDGASLTFEVLDKVLGELGKVSRK{ct:Amid} | StI1-31 | Amidation | Free | Linear | L | None | 31 | Hemolytic | 50 % Hemolysis at 7.25 ± 0.01 nM | Human | Stichodactyla Helianthus | α-Helix | NA | ||
| 26134716 | 2015 | ALAGTIIAGASLTFQVLDKVLEELGKVSRK{ct:Amid} | StII1-30 | Amidation | Free | Linear | L | None | 30 | Hemolytic | 50 % Hemolysis at 0.22 ± 0.002 nM | Human | Stichodactyla Helianthus | α-Helix | NA | ||
| 26134716 | 2015 | SADVAGAVIDGASLSFDILKTVLEALGNVKRK{ct:Amid} | EqtII1-32 | Amidation | Free | Linear | L | None | 32 | Hemolytic | 50 % Hemolysis at 0.91 ± 0.01 nM | Human | Actinia Equina | α-Helix | NA | ||
| 26134716 | 2015 | SADVAGAVIDGAGLGFDVLKTVLEALGNVKRK{ct:Amid} | FraC1-32 | Amidation | Free | Linear | L | None | 32 | Hemolytic | 50 % Hemolysis at 0.96 ± 0.06 nM | Human | Actinia Fragacea | α-Helix | NA | ||
| 26149664 | 2015 | RWK({nnr:N3}){nt:H}{ct:Amid} | 3 a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWK({nnr:N3}){nt:H}{ct:Amid} | 3 b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWK({nnr:N3}){nt:H}{ct:Amid} | 3 c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRK({nnr:N3}){nt:H}{ct:Amid} | 4 a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRK({nnr:N3}){nt:H}{ct:Amid} | 4b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRK({nnr:N3}){nt:H}{ct:Amid} | 4c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 3 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRK({nnr:N3}){nt:H}{ct:Amid} | 5a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRK({nnr:N3}){nt:H}{ct:Amid} | 5b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRK({nnr:N3}){nt:H}{ct:Amid} | 5c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRWK({nnr:N3}){nt:H}{ct:Amid} | 6a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRWK({nnr:N3}){nt:H}{ct:Amid} | 6b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | WRWK({nnr:N3}){nt:H}{ct:Amid} | 6c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 4 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRWRWK({nnr:N3}){nt:H}{ct:Amid} | 7a | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 7 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRWRWK({nnr:N3}){nt:H}{ct:Amid} | 7b | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 7 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26149664 | 2015 | RWRWRWK({nnr:N3}){nt:H}{ct:Amid} | 7c | Amidation | H | Linear | L | N3 = 1,2,3-triazol-4-methoxy | 7 | Antibacterial | <1 % Hemolysis at <100 µM | Human | Arg-Trp-Based Peptides | α-Helix | Non-hemolytic | ||
| 26160494 | 2015 | KKYRYHLKPFSKK{nt:NH3+}{ct:Carboxyl (COO-)} | p-(Ser11)-BthTX-I(COO-) | Carboxyl (COO-) | NH3+ | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at >128 µmol/L | Human | Analogues Bothropstoxin-I (Bthtx-I) | α-Helix | NA | ||
| 26160494 | 2015 | KKYRYHLKPFSKK{nt:NH3+}{ct:Amid} | [p-(Ser11)-BthTX-I(CONH2)] | Amidation | NH3+ | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at >128 µmol/L | Human | Analogues Bothropstoxin-I (Bthtx-I) | α-Helix | NA | ||
| 26160494 | 2015 | KKYRYHLKPFCKK{nt:NH3+}{ct:Carboxyl (COO-)} | p-BthTX-I | Carboxyl (COO-) | NH3+ | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at >128 µmol/L | Human | Bothropstoxin-I (Bthtx-I) | α-Helix | NA | ||
| 26160494 | 2015 | KKYRYHLKPFCKKKKYRYHLKPFCKK{nt:NH3+}{ct:Carboxyl (COO-)} | (p-BthTX-I)2 | Carboxyl (COO-) | NH3+ | Linear | L | None | 26 | Antibacterial | 50 % Hemolysis at >128 µmol/L | Human | Analogues Bothropstoxin-I (Bthtx-I) | α-Helix | NA | ||
| 26235946 | 2015 | KAAKAAKKAAKAAWK{nt:Acet}{ct:Amid} | Ac-UM-14W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | <1 % Hemolysis at 25 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKA{nnr:X}KKAAKAAWK{nt:Acet}{ct:Amid} | Ac-SS-14W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | <1 % Hemolysis at 25 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKA{nnr:X}KK{nnr:X}AKA{nnr:X}WK{nt:Acet}{ct:Amid} | Ac-DS-14W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 38.8 % Hemolysis at 25 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKA{nnr:X}KK{nnr:X}AKW{nnr:X}AK{nt:Acet}{ct:Amid} | Ac-DS-12W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 42.5 % Hemolysis at 25 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKW{nnr:X}KK{nnr:X}AKA{nnr:X}AK{nt:Acet}{ct:Amid} | Ac-DS-3W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 42.5 % Hemolysis at 25 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}WKA{nnr:X}KK{nnr:X}AKA{nnr:X}AK{nt:Acet}{ct:Amid} | Ac-DS-5W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 38.5 % Hemolysis at 25 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKW{nnr:X}KK{nnr:X}AKA{nnr:X}AK{nt:Succinylated}{ct:Amid} | Su-DS-5W | Amidation | Succinylated | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 32.6 % Hemolysis at 25 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKW{nnr:X}KK{nnr:X}AKA{nnr:X}AK{nt:H}{ct:Amid} | H-DS-5W | Amidation | H | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 25.5 % Hemolysis at 25 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | KAAKAAKKAAKAAWK{nt:Acet}{ct:Amid} | Ac-UM-14W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | <1 % Hemolysis at 12.5 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKA{nnr:X}KKAAKAAWK{nt:Acet}{ct:Amid} | Ac-SS-14W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | <1 % Hemolysis at 12.5 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKA{nnr:X}KK{nnr:X}AKA{nnr:X}WK{nt:Acet}{ct:Amid} | Ac-DS-14W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 22.1 % Hemolysis at 12.5 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKA{nnr:X}KK{nnr:X}AKW{nnr:X}AK{nt:Acet}{ct:Amid} | Ac-DS-12W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 25.3 % Hemolysis at 12.5 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKW{nnr:X}KK{nnr:X}AKA{nnr:X}AK{nt:Acet}{ct:Amid} | Ac-DS-3W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 28.9 % Hemolysis at 12.5 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}WKA{nnr:X}KK{nnr:X}AKA{nnr:X}AK{nt:Acet}{ct:Amid} | Ac-DS-5W | Amidation | Acetylation | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 22 % Hemolysis at 12.5 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKW{nnr:X}KK{nnr:X}AKA{nnr:X}AK{nt:Succinylated}{ct:Amid} | Su-DS-5W | Amidation | Succinylated | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 19.5 % Hemolysis at 12.5 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26235946 | 2015 | K{nnr:X}AKW{nnr:X}KK{nnr:X}AKA{nnr:X}AK{nt:H}{ct:Amid} | H-DS-5W | Amidation | H | Linear | L | X = residues cross-linked by an oct-4-enyl staple | 15 | Antibacterial | 13.5 % Hemolysis at 12.5 µM | Human | Doubly-Stapled Alanine/Lysine-Based Peptides | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 1 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 215 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LRWLRWG{cyc:N-C} | 2 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 3 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LK{nnr:2-Nal}G{cyc:N-C} | 4 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LK{nnr:2-Nal}G{cyc:N-C} | 5 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKWLKWG{cyc:N-C} | 6 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKFLKFG{cyc:N-C} | 7 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu}){cyc:N-C} | 8 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 230 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:6-Ahx}{cyc:N-C} | 9 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 6-Ahx = 6-aminohexanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 115 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 10 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 22 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:10-Adc}{cyc:N-C} | 11 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 10-Adc = 10-aminodecanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 15 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab}){cyc:N-C} | 12 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 265 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:εK}){cyc:N-C} | 13 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, εK = coupling of 2-Nal6 has occurred on lysine’s ε-amino functionality | 4 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab}{nnr:Dab}){cyc:N-C} | 14 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at >450 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu})({nnr:Dab}){cyc:N-C} | 15 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 420 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab})({nnr:Abu}){cyc:N-C} | 16 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 50 % Hemolysis at 255 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Bip})LR({nnr:Bip})G{cyc:N-C} | 17 | Free | Free | Cyclic | Mix | Bip = 4,4’-biphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 16 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Dip})LR({nnr:Dip})G{cyc:N-C} | 18 | Free | Free | Cyclic | Mix | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 145 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | {nnr:2-Aoc}R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 19 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 20 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 33 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | ({nnr:Cha})R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 21 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 28 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Cha})R{nnr:2-Nal}G{cyc:N-C} | 22 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 60 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Nle})R{nnr:2-Nal}G{cyc:N-C} | 23 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Nle = norleucine | 4 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | PR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 24 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}PR{nnr:2-Nal}G{cyc:N-C} | 25 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LRYG{cyc:N-C} | 26 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 6 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 27 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}TR{nnr:2-Nal}G{cyc:N-C} | 28 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | QR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 29 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:D-2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 30 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}(D-2-Aoc)R{nnr:2-Nal}G{cyc:N-C} | 31 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR(2NalNal)LR{nnr:D-2-Nal}G{cyc:N-C} | 32 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 5 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}IR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 33 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}{nnr:Dab}{nnr:Dab}{cyc:N-C} | 34 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 3 | Antimicrobial | 50 % Hemolysis at 55 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 1 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 27 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LRWLRWG{cyc:N-C} | 2 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 3 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 14 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR(NalNaI)LK{nnr:2-Nal}G{cyc:N-C} | 4 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 19 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LK{nnr:2-Nal}LK{nnr:2-Nal}G{cyc:N-C} | 5 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 13 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKWLKWG{cyc:N-C} | 6 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LKFLKFG{cyc:N-C} | 7 | Free | Free | Cyclic | L | None | 7 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu}){cyc:N-C} | 8 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 22 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:6-Ahx}{cyc:N-C} | 9 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 6-Ahx = 6-aminohexanoic acid | 4 | Antimicrobial | 75 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 10 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:10-Adc}{cyc:N-C} | 11 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 10-Adc = 10-aminodecanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab}){cyc:N-C} | 12 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:εK}){cyc:N-C} | 13 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, εK = coupling of 2-Nal6 has occurred on lysine’s ε-amino functionality | 4 | Antimicrobial | 51 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}{nnr:Dab}{nnr:Dab}{cyc:N-C} | 14 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Abu})({nnr:Dab}){cyc:N-C} | 15 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:2-Nal}({nnr:Dab})({nnr:Abu}){cyc:N-C} | 16 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Dab = 2,4-diaminobutyric acid, Abu = 4-aminobutyric acid | 4 | Antimicrobial | 12 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Bip})LR({nnr:Bip})G{cyc:N-C} | 17 | Free | Free | Cyclic | Mix | Bip = 4,4’-biphenyl-L-alanine | 5 | Antimicrobial | 96 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR({nnr:Dip})LR({nnr:Dip})G{cyc:N-C} | 18 | Free | Free | Cyclic | Mix | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 54 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | {nnr:2-Aoc}R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 19 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 20 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | ({nnr:Cha})R{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 21 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 99 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Cha})R{nnr:2-Nal}G{cyc:N-C} | 22 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Cha = 3-cyclohexyl-L-alanine | 4 | Antimicrobial | 96 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}({nnr:Nle})R{nnr:2-Nal}G{cyc:N-C} | 23 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, Nle = norleucine | 4 | Antimicrobial | 35 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | PR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 24 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}PR{nnr:2-Nal}G{cyc:N-C} | 25 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LRYG{cyc:N-C} | 26 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 6 | Antimicrobial | 19 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 27 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}TR{nnr:2-Nal}G{cyc:N-C} | 28 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | QR{nnr:2-Nal}LR{nnr:2-Nal}G{cyc:N-C} | 29 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:D-2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}G{cyc:N-C} | 30 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 92 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}(D-2-Aoc)R{nnr:2-Nal}G{cyc:N-C} | 31 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 2-Aoc = 2-aminooctanoic acid | 4 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}LR{nnr:D-2-Nal}G{cyc:N-C} | 32 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | TR{nnr:2-Nal}IR{nnr:2-Nal}{nnr:8-Aoc}{cyc:N-C} | 33 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine, 8-Aoc = 8-aminooctanoic acid | 4 | Antimicrobial | 10 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26318064 | 2015 | LR{nnr:2-Nal}{nnr:2-Aoc}R{nnr:2-Nal}{nnr:Dab}{nnr:Dab}{cyc:N-C} | 34 | Free | Free | Cyclic | Mix | 2-Nal = 3-(2-naphthyl)-L-alanine | 3 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26311041 | 2015 | FVQWFSKFLGRIL{ct:Amid} | TL | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 15.4 µM | Human | Amphibian Skin Temporins | α-Helix | NA | ||
| 26311041 | 2015 | FVQWWSKWLGRIL{ct:Amid} | TL-1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 21.4 µM | Human | Analog Of Tl | α-Helix | NA | ||
| 26311041 | 2015 | FVRWWSKWLRRIL{ct:Amid} | TL-2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 8.5 µM | Human | Analog Of Tl | α-Helix | NA | ||
| 26311041 | 2015 | FVRWWSRWLRRIL{ct:Amid} | TL-3 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 8 µM | Human | Analog Of Tl | α-Helix | NA | ||
| 26311041 | 2015 | FVKWWSKWLKKIL{ct:Amid} | TL-4 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 15.9 µM | Human | Analog Of Tl | α-Helix | NA | ||
| 26316200 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:Amid}{ct:Amid} | Melittin | Amidation | Amidation | Linear | L | None | 26 | Antimicrobial | 0 % Hemolysis at 0.0625 μg/ml | Human | Apis Mellifera Meda | α-Helix | NA | ||
| 26316200 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:Amid}{ct:Amid} | Melittin | Amidation | Amidation | Linear | L | None | 26 | Antimicrobial | 0 % Hemolysis at 0.125 μg/ml | Human | Apis Mellifera Meda | α-Helix | NA | ||
| 26316200 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:Amid}{ct:Amid} | Melittin | Amidation | Amidation | Linear | L | None | 26 | Antimicrobial | 0 % Hemolysis at 0.25 μg/ml | Human | Apis Mellifera Meda | α-Helix | NA | ||
| 26316200 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:Amid}{ct:Amid} | Melittin | Amidation | Amidation | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at 0.5 μg/ml | Human | Apis Mellifera Meda | α-Helix | NA | ||
| 26316200 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:Amid}{ct:Amid} | Melittin | Amidation | Amidation | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 1 μg/ml | Human | Apis Mellifera Meda | α-Helix | NA | ||
| 26316200 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:Amid}{ct:Amid} | Melittin | Amidation | Amidation | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 2 μg/ml | Human | Apis Mellifera Meda | α-Helix | NA | ||
| 26316200 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:Amid}{ct:Amid} | Melittin | Amidation | Amidation | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 4 μg/ml | Human | Apis Mellifera Meda | α-Helix | NA | ||
| 26316200 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:Amid}{ct:Amid} | Melittin | Amidation | Amidation | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 8 μg/ml | Human | Apis Mellifera Meda | α-Helix | NA | ||
| 26291880 | 2015 | ILPWKWPWWPWRR{ct:Amid} | IL | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 100 % Hemolysis | Human | Cpp | α-Helix | NA | ||
| 26291880 | 2015 | ILPWKWKWWPWRR{ct:Amid} | IL-K7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 42 % Hemolysis | Human | Indolicidin Modification | α-Helix | NA | ||
| 26291880 | 2015 | ILPWKWPFFPWRR{ct:Amid} | IL-F89 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 22 % Hemolysis | Human | Indolicidin Modification | α-Helix | NA | ||
| 26291880 | 2015 | ILPWRWRFFPWRR{ct:Amid} | IL-R57F89 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 13 % Hemolysis | Human | Indolicidin Modification | α-Helix | NA | ||
| 26291880 | 2015 | ILPWKWKFFPWRR{ct:Amid} | IL-K7F89 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 10 % Hemolysis | Human | Indolicidin Modification | α-Helix | NA | ||
| 26291880 | 2015 | RRWKFFPWRR{ct:Amid} | SAP10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 1 % Hemolysis | Human | Synthetic | α-Helix | NA | ||
| 26291880 | 2015 | RRRRRRRRR{ct:Amid} | R9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | NA | Human | Cpp | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}F{nnr:O}RPVYIPRPRPPHPRL{nt:gu}{ct:OH} | Api723 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.66 ± 0.84 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}{nnr:O}FRPVYIPRPRPPHPRL{nt:gu}{ct:OH} | Api724 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.08 ± 0.60 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}{nnr:O}WRPVYIPRPRPPHPRL{nt:gu}{ct:OH} | Api732 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.99 ± 0.60 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}W{nnr:O}RPVYIPRPRPPHPRL{nt:gu}{ct:OH} | Api733 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.51 ± 0.36 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}F{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu}{ct:OH} | Api753 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.28 ± 0.19 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}{nnr:O}FRPVY{nnr:O}PRPRPPHPRL{nt:gu}{ct:OH} | Api754 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.32 ± 0.38 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}I{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu}{ct:OH} | Api755 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | -0.35 ± 0.89 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}{nnr:O}IRPVY{nnr:O}PRPRPPHPRL{nt:gu}{ct:OH} | Api756 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | -0.12 ± 0.30 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}Y{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu}{ct:OH} | Api757 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.31 ± 0.50 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}{nnr:O}YRPVY{nnr:O}PRPRPPHPRL{nt:gu}{ct:OH} | Api758 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.08 ± 0.17 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}{nnr:O}WRPVY{nnr:O}PRPRPPHPRL{nt:gu}{ct:OH} | Api759 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.55 ± 0.16 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26408816 | 2015 | {nnr:O}W{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu}{ct:OH} | Api760 | OH | gu | Linear | L | gu = N,N,N0,N-tetramethylguanidino, O = L-Ornithine | 18 | Antimicrobial | 0.54 ± 0.46 % Hemolysis at 0.6 g/L | Human | Api137 Analogs | α-Helix | Non-hemolytic | ||
| 26091834 | 2015 | SSRRPCRGRSCGPRLRGGYTLIGRPVKNQNRPKYMWV | BG-CATH37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 400 μg/ml | Human | Toad Bufo Bufo Gargarizans | Random-coil | NA | ||
| 26091834 | 2015 | PCRGRSCGPRLRGGYTLIGRPVKNQNRPKYMWV | BG-CATH(5- 37) | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 400 μg/ml | Human | Toad Bufo Bufo Gargarizans | Random-coil | NA | ||
| 26088720 | 2015 | WKPGKW{ct:Amid} | WK1 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 5 % Hemolysis at 512 µM | Human | Tryptophan Zipper | β-Hairpin | NA | ||
| 26088720 | 2015 | (WKWK)PG(KWKW){ct:Amid} | WK2 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 5 % Hemolysis at 512 µM | Human | Tryptophan Zipper | β-Hairpin | NA | ||
| 26088720 | 2015 | (WKWKWK)PG(KWKWKW){ct:Amid} | WK3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 5 % Hemolysis at 512 µM | Human | Tryptophan Zipper | β-Hairpin | NA | ||
| 26088720 | 2015 | (WKWKWKWK)PG(KWKWKWKW){ct:Amid} | WK4 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 5 % Hemolysis at 8 µM | Human | Tryptophan Zipper | β-Hairpin | NA | ||
| 26088720 | 2015 | (WKWKWKWKWK)PG(KWKWKWKWKW){ct:Amid} | WK5 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 5 % Hemolysis at 4 µM | Human | Tryptophan Zipper | β-Hairpin | NA | ||
| 26342880 | 2015 | SPSEKAGLQPVGRIGIGRMLKK | Scolopendin | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Centipede Scolopendra 21 Subspinipes Mutilans | NA | Non-hemolytic | ||
| 26342880 | 2015 | SPSEKAGLQPVGRIGIGRMLKK | Scolopendin | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Centipede Scolopendra 21 Subspinipes Mutilans | NA | Non-hemolytic | ||
| 26342880 | 2015 | SPSEKAGLQPVGRIGIGRMLKK | Scolopendin | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 25 µM | Human | Centipede Scolopendra 21 Subspinipes Mutilans | NA | Non-hemolytic | ||
| 26342880 | 2015 | SPSEKAGLQPVGRIGIGRMLKK | Scolopendin | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Centipede Scolopendra 21 Subspinipes Mutilans | NA | Non-hemolytic | ||
| 26342880 | 2015 | SPSEKAGLQPVGRIGIGRMLKK | Scolopendin | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Centipede Scolopendra 21 Subspinipes Mutilans | NA | Non-hemolytic | ||
| 26342880 | 2015 | SPSEKAGLQPVGRIGIGRMLKK | Scolopendin | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Centipede Scolopendra 21 Subspinipes Mutilans | NA | Non-hemolytic | ||
| 26342880 | 2015 | SPSEKAGLQPVGRIGIGRMLKK | Scolopendin | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Centipede Scolopendra 21 Subspinipes Mutilans | NA | Non-hemolytic | ||
| 26342880 | 2015 | TRSSRAGLQFPVGRVHRLLRK | Buforin 2 | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Bufo Bufo Gargarizans | Random coil | Non-hemolytic | ||
| 26342880 | 2015 | TRSSRAGLQFPVGRVHRLLRK | Buforin 2 | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Bufo Bufo Gargarizans | Random coil | Non-hemolytic | ||
| 26342880 | 2015 | TRSSRAGLQFPVGRVHRLLRK | Buforin 2 | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 25 µM | Human | Bufo Bufo Gargarizans | Random coil | Non-hemolytic | ||
| 26342880 | 2015 | TRSSRAGLQFPVGRVHRLLRK | Buforin 2 | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Bufo Bufo Gargarizans | Random coil | Non-hemolytic | ||
| 26342880 | 2015 | TRSSRAGLQFPVGRVHRLLRK | Buforin 2 | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Bufo Bufo Gargarizans | Random coil | Non-hemolytic | ||
| 26342880 | 2015 | TRSSRAGLQFPVGRVHRLLRK | Buforin 2 | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Bufo Bufo Gargarizans | Random coil | Non-hemolytic | ||
| 26342880 | 2015 | TRSSRAGLQFPVGRVHRLLRK | Buforin 2 | Free | Free | Linear | L | None | 21 | Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Bufo Bufo Gargarizans | Random coil | Non-hemolytic | ||
| 26342880 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 ± 0.8 % Hemolysis at 100 µM | Human | Bee Vemon | α-Helix | NA | ||
| 26342880 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 ± 1.8 % Hemolysis at 50 µM | Human | Bee Vemon | α-Helix | NA | ||
| 26342880 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 98.1 ± 2.1 % Hemolysis at 25 µM | Human | Bee Vemon | α-Helix | NA | ||
| 26342880 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 87.4 ± 3.3 % Hemolysis at 12.5 µM | Human | Bee Vemon | α-Helix | NA | ||
| 26342880 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 52.6 ± 3.2 % Hemolysis at 6.3 µM | Human | Bee Vemon | α-Helix | NA | ||
| 26342880 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 22.5 ± 2.7 % Hemolysis at 3.1 µM | Human | Bee Vemon | α-Helix | NA | ||
| 26342880 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 8.6 ± 1.4 % Hemolysis at 1.6 µM | Human | Bee Vemon | α-Helix | NA | ||
| 26352292 | 2015 | LPFFLLSLIPSAISAIKKI{ct:Amid} | VpAmp1.0 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 50 % Hemolysis at 9.2 ± 0.3 µM | Human | Scorpion Vaejovispunctatus | α-Helix | NA | ||
| 26352292 | 2015 | FFLLSLIPSAISAIKKI{ct:Amid} | VpAmp1.1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 50 % Hemolysis at 33.7 ± 2.4 µM | Human | Scorpion Vaejovispunctatus | α-Helix | NA | ||
| 26352292 | 2015 | FWGFLGKLAMKAVPSLIGGNKSSSK | VpAmp2.0 | Free | Free | Linear | L | None | 25 | Antimicrobial | 50 % Hemolysis at 167 ± 22.5 µM | Human | Scorpion Vaejovispunctatus | α-Helix | NA | ||
| 26352292 | 2015 | FWGFLGKLAMKAVPSLIGGNKK | VpAmp2.1 | Free | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 103.5 ± 1.7 µM | Human | Scorpion Vaejovispunctatus | α-Helix | NA | ||
| 26530005 | 2015 | GKLWLKG{ct:Amid} | GG1 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | GKLWLKGGKLWLKG{ct:Amid} | GG2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | GKLWLKGGKLWLKGGKLWLKG{ct:Amid} | GG3 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | GKLWLKGGKLWLKGGKLWLKGGKLWLKG{ct:Amid} | GG4 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 5 % Hemolysis at 16 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | GKLWGLKGKLWGLKGKLWGLK{ct:Amid} | GG3s1 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | GLWKGKLGLWKGKLGLWKGKL{ct:Amid} | GG3s2 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | AKLWLKA{ct:Amid} | AA1 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | AKLWLKAAKLWLKA{ct:Amid} | AA2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 5 % Hemolysis at 128 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | AKLWLKAAKLWLKAAKLWLKA{ct:Amid} | AA3 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 5 % Hemolysis at 8 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | AKLWLKAAKLWLKAAKLWLKAAKLWLKA{ct:Amid} | AA4 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 5 % Hemolysis at 1 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | AKLWALKAKLWALKAKLWALK{ct:Amid} | AA3s1 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 5 % Hemolysis at 16 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26530005 | 2015 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 5 % Hemolysis at 0.25 µM | Human | Centrosymmetric | α-Helix | NA | ||
| 26489599 | 2015 | ILRWPWWPWRRK{ct:Amid} | Omiganan | Amidation | Free | Linear | L | None | 12 | Antibacterial | 23 ± 1 % Hemolysis at 100 µM | Human | Derivative Of Indolicidin From Bovine Neutrophils | NA | NA | ||
| 26489599 | 2015 | BRBR{ct:Amid} | 23 | Amidation | Free | Linear | L | None | 4 | Antibacterial | <1 % Hemolysis at 100 µM | Human | Tetrapeptide | NA | Low hemolytic | ||
| 26608073 | 2015 | KRFWQLVPLAIKIYRAWKRR | dCATH | Free | Free | Linear | L | None | 20 | Antimicrobial | 50 % Hemolysis at 20 µM | Human | Cathelicidin Ortholog From Ducks | α-Helix | NA | ||
| 26608073 | 2015 | KRFWQLVPLAIKIYRAWKRR | dCATH | Free | Free | Linear | L | None | 20 | Antimicrobial | 50 % Hemolysis at 32 µM | Human | Cathelicidin Ortholog From Ducks | α-Helix | NA | ||
| 26668630 | 2015 | EVMKCIVEVISDTLSKPSPMPVSQECFETLRGDERILSILRHQNLL | CGA-N46 | Free | Free | Linear | L | None | 46 | Antifungal | <1 % Hemolysis at 0.05 mM | Human | Human Chromogranin A | α-Helix | NA | ||
| 26668630 | 2015 | EVMKCIVEVISDTLSKPSPMPVSQECFETLRGDERILSILRHQNLL | CGA-N46 | Free | Free | Linear | L | None | 46 | Antifungal | 1 % Hemolysis at 0.1 mM | Human | Human Chromogranin A | α-Helix | NA | ||
| 26668630 | 2015 | EVMKCIVEVISDTLSKPSPMPVSQECFETLRGDERILSILRHQNLL | CGA-N46 | Free | Free | Linear | L | None | 46 | Antifungal | <2 % Hemolysis at 0.2 mM | Human | Human Chromogranin A | α-Helix | NA | ||
| 26668630 | 2015 | EVMKCIVEVISDTLSKPSPMPVSQECFETLRGDERILSILRHQNLL | CGA-N46 | Free | Free | Linear | L | None | 46 | Antifungal | 2 % Hemolysis at 0.4 mM | Human | Human Chromogranin A | α-Helix | NA | ||
| 26668630 | 2015 | EVMKCIVEVISDTLSKPSPMPVSQECFETLRGDERILSILRHQNLL | CGA-N46 | Free | Free | Linear | L | None | 46 | Antifungal | 4 % Hemolysis at 0.8 mM | Human | Human Chromogranin A | α-Helix | NA | ||
| 26668630 | 2015 | EVMKCIVEVISDTLSKPSPMPVSQECFETLRGDERILSILRHQNLL | CGA-N46 | Free | Free | Linear | L | None | 46 | Antifungal | 6 % Hemolysis at 1.6 mM | Human | Human Chromogranin A | α-Helix | NA | ||
| 26496638 | 2015 | YLEALEAESITTGV | PT14-4a | Free | Free | Linear | L | None | 14 | Antifungal | 0 % Hemolysis at 0-450 mg/L | Human | Bacteria Bacillus Amyloliquefaciens | α-Helix | Non-hemolytic | ||
| 26680226 | 2015 | NLCASLRARHTIPQCRKFGRR{ct:Amid} | mBjAMP1 | Amidation | Free | Linear | L | None | 21 | Antibacterial | little Hemolysis at 100 μg/ml | Human | Vaguely Eel Amphioxus Branchiostoma Japonicum | α-Helical | Low hemolytic | ||
| 26680226 | 2015 | NLCASLRARHTIPQCRKFGRR{ct:Amid} | mBjAMP1 | Amidation | Free | Linear | L | None | 21 | Antibacterial | little Hemolysis at 50 μg/ml | Human | Vaguely Eel Amphioxus Branchiostoma Japonicum | α-Helical | Low hemolytic | ||
| 26680226 | 2015 | NLCASLRARHTIPQCRKFGRR{ct:Amid} | mBjAMP1 | Amidation | Free | Linear | L | None | 21 | Antibacterial | little Hemolysis at 25 μg/ml | Human | Vaguely Eel Amphioxus Branchiostoma Japonicum | α-Helical | Low hemolytic | ||
| 26680226 | 2015 | NLCASLRARHTIPQCRKFGRR{ct:Amid} | mBjAMP1 | Amidation | Free | Linear | L | None | 21 | Antibacterial | little Hemolysis at 12.5 μg/ml | Human | Vaguely Eel Amphioxus Branchiostoma Japonicum | α-Helical | Low hemolytic | ||
| 26295533 | 2015 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 21 % Hemolysis at 0.25 mg/ml | Human | Bovine Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | ~10 % Hemolysis at 0.1 mg/ml | Human | Bovine Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 5 % Hemolysis at 0.05 mg/ml | Human | Bovine Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 6 % Hemolysis at 0.025 mg/ml | Human | Bovine Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVVIRVAR{cyc:N-C}{ct:Amid} | Bac2A | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.25 mg/ml | Human | Bovine Host Defense Peptide Variant | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVVIRVAR{cyc:N-C}{ct:Amid} | Bac2A | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.1 mg/ml | Human | Bovine Host Defense Peptide Variant | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVVIRVAR{cyc:N-C}{ct:Amid} | Bac2A | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.05 mg/ml | Human | Bovine Host Defense Peptide Variant | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVVIRVAR{cyc:N-C}{ct:Amid} | Bac2A | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bovine Host Defense Peptide Variant | α-Helical | NA | ||
| 26295533 | 2015 | RLRRIVVIRVAR{cyc:N-C}{ct:Amid} | R3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.25 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLRRIVVIRVAR{cyc:N-C}{ct:Amid} | R3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.1 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLRRIVVIRVAR{cyc:N-C}{ct:Amid} | R3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.05 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLRRIVVIRVAR{cyc:N-C}{ct:Amid} | R3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVPIRVAR{cyc:N-C}{ct:Amid} | P7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.25 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVPIRVAR{cyc:N-C}{ct:Amid} | P7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.1 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVPIRVAR{cyc:N-C}{ct:Amid} | P7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.05 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RLARIVPIRVAR{cyc:N-C}{ct:Amid} | P7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | VRWRIRVAVIRA{cyc:N-C}{ct:Amid} | W3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 10 % Hemolysis at 0.25 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | VRWRIRVAVIRA{cyc:N-C}{ct:Amid} | W3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 5 % Hemolysis at 0.1 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | VRWRIRVAVIRA{cyc:N-C}{ct:Amid} | W3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | >5 % Hemolysis at 0.05 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | VRWRIRVAVIRA{cyc:N-C}{ct:Amid} | W3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RRWRIVVIRVRR{cyc:N-C}{ct:Amid} | Sub3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <10 % Hemolysis at 0.25 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RRWRIVVIRVRR{cyc:N-C}{ct:Amid} | Sub3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 10 % Hemolysis at 0.1 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RRWRIVVIRVRR{cyc:N-C}{ct:Amid} | Sub3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 5 % Hemolysis at 0.05 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | RRWRIVVIRVRR{cyc:N-C}{ct:Amid} | Sub3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Bac2A Derivative | α-Helical | NA | ||
| 26295533 | 2015 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | <5 % Hemolysis at 0.25 mg/ml | Human | Human Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | <5 % Hemolysis at 0.1 mg/ml | Human | Human Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | <5 % Hemolysis at 0.05 mg/ml | Human | Human Cathelicidin | α-Helical | NA | ||
| 26295533 | 2015 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | <5 % Hemolysis at 0.025 mg/ml | Human | Human Cathelicidin | α-Helical | NA | ||
| 26100634 | 2015 | GLFGVLAKVAAHVVPAIAEHF{ct:Amid} | Maculatin 1.1 | Amidation | Free | Linear | L | None | 21 | Anticancer, Antibacterial Gram- | 50 % Hemolysis at 29.5 ± 1.0 µM | Human | Australian Tree Frog Litoria Genimaculata | α-Helical | NA | ||
| 26100634 | 2015 | GIGAVLKVTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Anticancer, Antibacterial Gram- | 50 % Hemolysis at 1.2± 0.1 µM | Human | Bee Venom | α-Helical | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA | PA | Free | Free | Linear | L | None | 15 | Hemolytic | 50 % Hemolysis at 0.77 mM | Human | Peptide Inhibitors Of Complement C1 (Pic1) | NA | NA | ||
| 26196285 | 2015 | RALILEPICCQERAA | PA-I1R | Free | Free | Linear | L | None | 15 | Hemolytic | 91.93 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IRLILEPICCQERAA | PA-A2R | Free | Free | Linear | L | None | 15 | Hemolytic | 87.28 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IARILEPICCQERAA | PA-L3R | Free | Free | Linear | L | None | 15 | Hemolytic | 80.45 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALRLEPICCQERAA | PA-I4R | Free | Free | Linear | L | None | 15 | Hemolytic | 43.71 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALIREPICCQERAA | PA-L5R | Free | Free | Linear | L | None | 15 | Hemolytic | 93.4 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILRPICCQERAA | PA-E6R | Free | Free | Linear | L | None | 15 | Hemolytic | 87.59 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILERICCQERAA | PA-P7R | Free | Free | Linear | L | None | 15 | Hemolytic | 89.85 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPRCCQERAA | PA-I8R | Free | Free | Linear | L | None | 15 | Hemolytic | 62.32 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPIRCQERAA | PA-C9R | Free | Free | Linear | L | None | 15 | Hemolytic | 89.54 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICRQERAA | PA-C10R | Free | Free | Linear | L | None | 15 | Hemolytic | 89.8 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICCRERAA | PA-Q11R | Free | Free | Linear | L | None | 15 | Hemolytic | 90.87 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQRRAA | PA-E12R | Free | Free | Linear | L | None | 15 | Hemolytic | 95.83 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERRA | PA-A14R | Free | Free | Linear | L | None | 15 | Hemolytic | 88.65 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAR | PA-A15R | Free | Free | Linear | L | None | 15 | Hemolytic | 44.24 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | EALILEPICCQERAA | PA-I1E | Free | Free | Linear | L | None | 15 | Hemolytic | 89.27 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IELILEPICCQERAA | PA-A2E | Free | Free | Linear | L | None | 15 | Hemolytic | 92.24 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IAEILEPICCQERAA | PA-L3E | Free | Free | Linear | L | None | 15 | Hemolytic | 100.27 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALELEPICCQERAA | PA-I4E | Free | Free | Linear | L | None | 15 | Hemolytic | 92.07 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALIEEPICCQERAA | PA-L5E | Free | Free | Linear | L | None | 15 | Hemolytic | 94.33 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEEICCQERAA | PA-P7E | Free | Free | Linear | L | None | 15 | Hemolytic | 96.1 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPECCQERAA | PA-I8E | Free | Free | Linear | L | None | 15 | Hemolytic | 95.74 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPIECQERAA | PA-C9E | Free | Free | Linear | L | None | 15 | Hemolytic | 91.62 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICEQERAA | PA-C10E | Free | Free | Linear | L | None | 15 | Hemolytic | 95.21 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICCEERAA | PA-Q11E | Free | Free | Linear | L | None | 15 | Hemolytic | 65.6 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQEEAA | PA-R13E | Free | Free | Linear | L | None | 15 | Hemolytic | 101.99 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQEREA | PA-A14E | Free | Free | Linear | L | None | 15 | Hemolytic | 98.09 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAE | PA-A15E | Free | Free | Linear | L | None | 15 | Hemolytic | 93.13 % Hemolysis at 0.77 mM | Human | Pa Derivatives | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA{ct:dPEG24} | PA-dPEG24 | dPEG24 | Free | Linear | L | None | 15 | Inhibits complement activation in vivo | 2.99 % Hemolysis at 0.77 mM | Human | Pegylated Pa Peptides | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA{ct:dPEG20} | PA-dPEG20 | dPEG20 | Free | Linear | L | None | 15 | Hemolytic | 11.41 % Hemolysis at 0.77 mM | Human | Pegylated Pa Peptides | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA{ct:dPEG16} | PA-dPEG16 | dPEG16 | Free | Linear | L | None | 15 | Hemolytic | 12.04 % Hemolysis at 0.77 mM | Human | Pegylated Pa Peptides | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA{ct:dPEG12} | PA-dPEG12 | dPEG12 | Free | Linear | L | None | 15 | Hemolytic | 11.41 % Hemolysis at 0.77 mM | Human | Pegylated Pa Peptides | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA{ct:dPEG08} | PA-dPEG08 | dPEG08 | Free | Linear | L | None | 15 | Hemolytic | 34.66 % Hemolysis at 0.77 mM | Human | Pegylated Pa Peptides | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA{ct:dPEG06} | PA-dPEG06 | dPEG06 | Free | Linear | L | None | 15 | Hemolytic | 44.82 % Hemolysis at 0.77 mM | Human | Pegylated Pa Peptides | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA{ct:dPEG04} | PA-dPEG04 | dPEG04 | Free | Linear | L | None | 15 | Hemolytic | 12.36 % Hemolysis at 0.77 mM | Human | Pegylated Pa Peptides | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA{ct:dPEG03} | PA-dPEG03 | dPEG03 | Free | Linear | L | None | 15 | Hemolytic | 12.57 % Hemolysis at 0.77 mM | Human | Pegylated Pa Peptides | NA | NA | ||
| 26196285 | 2015 | IALILEPICCQERAA{ct:dPEG02} | PA-dPEG02 | dPEG02 | Free | Linear | L | None | 15 | Hemolytic | 11.62 % Hemolysis at 0.77 mM | Human | Pegylated Pa Peptides | NA | NA | ||
| 25982541 | 2015 | FIGAAARLASKIF{ct:Amid} | BmKn2A1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 0 % Hemolysis at 0-100 μg/mL | Human | Analogs Of The Scorpion Venom Bmkn Peptides | α-Helical | Non-hemolytic | ||
| 25982541 | 2015 | FIGAVARLVSKIF{ct:Amid} | BmKn2V1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <100 % Hemolysis at 100 μg/mL | Human | Analogs Of The Scorpion Venom Bmkn Peptides | α-Helical | NA | ||
| 25982541 | 2015 | FIGALARLLSKIF{ct:Amid} | BmKn2L1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <100 % Hemolysis at 100 μg/mL | Human | Analogs Of The Scorpion Venom Bmkn Peptides | α-Helical | NA | ||
| 25982541 | 2015 | FIGAIAKLLKKIF{ct:Amid} | BmKn2K7 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <100 % Hemolysis at 100 μg/mL | Human | Analogs Of The Scorpion Venom Bmkn Peptides | α-Helical | NA | ||
| 25982541 | 2015 | FIGAVKGLLSKIF{ct:Amid} | BmKn1-6Lys | Amidation | Free | Linear | L | None | 13 | Antibacterial | <60 % Hemolysis at 100 μg/mL | Human | Analogs Of The Scorpion Venom Bmkn Peptides | α-Helical | NA | ||
| 25982541 | 2015 | FKGALAGLLSKKF{ct:Amid} | BmKn1L2K2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 0 % Hemolysis at 0-100 μg/mL | Human | Analogs Of The Scorpion Venom Bmkn Peptides | α-Helical | Non-hemolytic | ||
| 25934283 | 2015 | KLDLKLDLKLDL | KLD | Free | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 50 μg/mL | Human | Self-Assembling | β-Sheet | Non-hemolytic | ||
| 25934283 | 2015 | KLDLKLDLKLDL | KLD | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.5 % Hemolysis at 100 μg/mL | Human | Self-Assembling | β-Sheet | Non-hemolytic | ||
| 25934283 | 2015 | KLDLKLDLKLDL | KLD | Free | Free | Linear | L | None | 12 | Antimicrobial | <1 % Hemolysis at 200 μg/mL | Human | Self-Assembling | β-Sheet | Non-hemolytic | ||
| 25934283 | 2015 | RKLDLKLDLKLDL | KLD-R | Free | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 50 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | Non-hemolytic | ||
| 25934283 | 2015 | RKLDLKLDLKLDL | KLD-R | Free | Free | Linear | L | None | 13 | Antimicrobial | 0.5 % Hemolysis at 100 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | Non-hemolytic | ||
| 25934283 | 2015 | RKLDLKLDLKLDL | KLD-R | Free | Free | Linear | L | None | 13 | Antimicrobial | 1.5 % Hemolysis at 200 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | NA | ||
| 25934283 | 2015 | RRKLDLKLDLKLDL | KLD-2R | Free | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 50 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | Non-hemolytic | ||
| 25934283 | 2015 | RRKLDLKLDLKLDL | KLD-2R | Free | Free | Linear | L | None | 14 | Antimicrobial | 1 % Hemolysis at 100 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | NA | ||
| 25934283 | 2015 | RRKLDLKLDLKLDL | KLD-2R | Free | Free | Linear | L | None | 14 | Antimicrobial | <2.5 % Hemolysis at 200 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | NA | ||
| 25934283 | 2015 | RRRKLDLKLDLKLDL | KLD-3R | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.5 % Hemolysis at 50 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | Non-hemolytic | ||
| 25934283 | 2015 | RRRKLDLKLDLKLDL | KLD-3R | Free | Free | Linear | L | None | 15 | Antimicrobial | <1.5 % Hemolysis at 100 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | NA | ||
| 25934283 | 2015 | RRRKLDLKLDLKLDL | KLD-3R | Free | Free | Linear | L | None | 15 | Antimicrobial | 2.5 % Hemolysis at 200 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | NA | ||
| 25934283 | 2015 | RRRRKLDLKLDLKLDL | KLD-4R | Free | Free | Linear | L | None | 16 | Antimicrobial | 1.5 % Hemolysis at 50 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | NA | ||
| 25934283 | 2015 | RRRRKLDLKLDLKLDL | KLD-4R | Free | Free | Linear | L | None | 16 | Antimicrobial | <3 % Hemolysis at 100 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | NA | ||
| 25934283 | 2015 | RRRRKLDLKLDLKLDL | KLD-4R | Free | Free | Linear | L | None | 16 | Antimicrobial | 5 % Hemolysis at 200 μg/mL | Human | Kld-12 Designed Variant | β-Sheet | NA | ||
| 25891396 | 2015 | AGYLLGKINLKALAALAKKIL{ct:Amid} | TP10 | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antibiofilm | 80 % Hemolysis at 512 μg/mL | Human | Deletion Analogue Of The Cpp Transportan | α-Helical-50% TFE solution | NA | ||
| 25891396 | 2015 | AGYLLGKINLKPLAALAKKIL{ct:Amid} | TP10-2 | Amidation | Free | Linear | L | None | 21 | Antibacterial | 0 % Hemolysis at 512 μg/mL | Human | Transportan 10 Analogues | α-Helical | Non-hemolytic | ||
| 25891396 | 2015 | AAYLLAKINLKALAALAKKIL{ct:Amid} | TP10-3 | Amidation | Free | Linear | L | None | 21 | Antibacterial | 39.57 % Hemolysis at 512 μg/mL | Human | Transportan 10 Analogues | α-Helical | NA | ||
| 25891396 | 2015 | AGYLLGKINLKKLAKL({nnr:Aib})KKIL{ct:Amid} | TP10-5 | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid | 21 | Antibacterial, Antibiofilm | 80 % Hemolysis at 512 μg/mL | Human | Transportan 10 Analogues | α-Helical | NA | ||
| 25891396 | 2015 | AGYLLGKINLKPLAKL({nnr:Aib})KKIL{ct:Amid} | TP10-7 | Amidation | Free | Linear | L | Aib = α-aminoisobutyric acid | 21 | Antibacterial, Antibiofilm | 59.45 % Hemolysis at 512 μg/mL | Human | Transportan 10 Analogues | α-Helical | NA | ||
| 25891396 | 2015 | AGYLLPKINLKPLAKLPKKIL{ct:Amid} | TP10-8 | Amidation | Free | Linear | L | None | 21 | Antibacterial | 0 % Hemolysis at 512 μg/mL | Human | Transportan 10 Analogues | α-Helical | Non-hemolytic | ||
| 25839356 | 2015 | FIHHIIGWISHGVRAIHRAIH{ct:Amid} | Gad-1 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram- | 50 % Hemolysis at 43 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FIHHIIGWISHGVRAIHRAIH{ct:Amid} | Gad-1 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 100 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FIHHIIGWISHGVRAIHRAIH{ct:Amid} | Gad-1 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 200 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FIHHIIGWISHGVRAIHRAIH{ct:Amid} | Gad-1 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 400 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FLHHIVGLIHHGLSLFGDR{ct:Amid} | Gad-2 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 50 % Hemolysis at 56 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FLHHIVGLIHHGLSLFGDR{ct:Amid} | Gad-2 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | <90 % Hemolysis at 100 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FLHHIVGLIHHGLSLFGDR{ct:Amid} | Gad-2 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 200 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25839356 | 2015 | FLHHIVGLIHHGLSLFGDR{ct:Amid} | Gad-2 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Anticancer | 100 % Hemolysis at 400 µM | Human | Atlantic Cod (Gadus Morhua) | α-Helical | NA | ||
| 25451872 | 2015 | FIGAVAGLLSKIF{ct:Amid} | BmKn1OR | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100 % Hemolysis at 50 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAVAGLLSKIF{ct:Amid} | BmKn1OR | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100 % Hemolysis at 100 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAIARLLSKIF{ct:Amid} | BmKn2OR | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100 % Hemolysis at 50 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAIARLLSKIF{ct:Amid} | BmKn2OR | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100 % Hemolysis at 100 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAAAGLASKIF{ct:Amid} | BmKn1A1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <10 % Hemolysis at 50 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAAAGLASKIF{ct:Amid} | BmKn1A1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <10 % Hemolysis at 100 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAVAGLVSKIF{ct:Amid} | BmKn1V1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <10 % Hemolysis at 50 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAVAGLVSKIF{ct:Amid} | BmKn1V1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <20 % Hemolysis at 100 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGALAGLLSKIF{ct:Amid} | BmKn1L1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100 % Hemolysis at 50 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGALAGLLSKIF{ct:Amid} | BmKn1L1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100 % Hemolysis at 100 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAVAKLLKKIF{ct:Amid} | BmKn1K7 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <100 % Hemolysis at 50 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAVAKLLKKIF{ct:Amid} | BmKn1K7 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <100 % Hemolysis at 100 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | NA | ||
| 25451872 | 2015 | FIGAVAELLEKIF{ct:Amid} | BmKn1E7 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 0 % Hemolysis at 50 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | Non-hemolytic | ||
| 25451872 | 2015 | FIGAVAELLEKIF{ct:Amid} | BmKn1E7 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 0 % Hemolysis at 100 μg/mL | Human | Analogs Of Peptides From Buthus Martensii Scorpion Venom | α-Helical | Non-hemolytic | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAFVGEIMNS{ct:Amid} | MAG2-WT | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 7±4 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAFVGEIMNS{ct:Amid} | MAG2-WT | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 35±6 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGK{nnr:X}LHSAKKFGKAFVGEIMNS{ct:Amid} | MAG2-F5A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 19±2 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGK{nnr:X}LHSAKKFGKAFVGEIMNS{ct:Amid} | MAG2-F5A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 98±4 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKF{nnr:X}HSAKKFGKAFVGEIMNS{ct:Amid} | MAG2-L6A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 7±6 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKF{nnr:X}HSAKKFGKAFVGEIMNS{ct:Amid} | MAG2-L6A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 25±4 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKK{nnr:X}GKAFVGEIMNS{ct:Amid} | MAG2-F12A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 10±9 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKK{nnr:X}GKAFVGEIMNS{ct:Amid} | MAG2-F12A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 49±12 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKF{nnr:X}KAFVGEIMNS{ct:Amid} | MAG2-G13A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 36±10 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKF{nnr:X}KAFVGEIMNS{ct:Amid} | MAG2-G13A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 100±0 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKA{nnr:X}VGEIMNS{ct:Amid} | MAG2-F16A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 12±3 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKA{nnr:X}VGEIMNS{ct:Amid} | MAG2-F16A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 55±14 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAF{nnr:X}GEIMNS{ct:Amid} | MAG2-V17A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 2±4 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | Non-hemolytic | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAF{nnr:X}GEIMNS{ct:Amid} | MAG2-V17A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 30±7 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAFV{nnr:X}EIMNS{ct:Amid} | MAG2-G18A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 29±5 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAFV{nnr:X}EIMNS{ct:Amid} | MAG2-G18A | Amidation | Free | Linear | L | X = Ala (“alanine scan”) | 23 | Antimicrobial | 88±2 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKF{nnr:CF-3Bpg}HSAKKFGKAFVGEIMNS{ct:Amid} | MAG2-L6B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 17±11 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKF{nnr:CF-3Bpg}HSAKKFGKAFVGEIMNS{ct:Amid} | MAG2-L6B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 35±8 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKF{nnr:CF-3Bpg}KAFVGEIMNS{ct:Amid} | MAG2-G13B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 77±15 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKF{nnr:CF-3Bpg}KAFVGEIMNS{ct:Amid} | MAG2-G13B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 100±0 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGK{nnr:CF-3Bpg}FVGEIMNS{ct:Amid} | MAG2-A15B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 14±3 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGK{nnr:CF-3Bpg}FVGEIMNS{ct:Amid} | MAG2-A15B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 72±13 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKA{nnr:CF-3Bpg}VGEIMNS{ct:Amid} | MAG2-F16B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 27±4 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKA{nnr:CF-3Bpg}VGEIMNS{ct:Amid} | MAG2-F16B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 84±20 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAF{nnr:CF-3Bpg}GEIMNS{ct:Amid} | MAG2-V17B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 20±5 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAF{nnr:CF-3Bpg}GEIMNS{ct:Amid} | MAG2-V17B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 95±9 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAFV{nnr:CF-3Bpg}EIMNS{ct:Amid} | MAG2-G18B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 12±6 % Hemolysis at 8 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25898805 | 2015 | GIGKFLHSAKKFGKAFV{nnr:CF-3Bpg}EIMNS{ct:Amid} | MAG2-G18B | Amidation | Free | Linear | L | CF-3-Bpg = 3-(trifluoromethyl)-Lbicyclopent-1.1.1-1-ylglycine | 23 | Antimicrobial | 24±10 % Hemolysis at 128 μg/mL | Human | Mag2 Analogs | α-Helical | NA | ||
| 25640709 | 2015 | ILGPVLGLVSDTLDDVLGIL{ct:Amid} | MH5N | Amidation | Free | Linear | L | None | 20 | Antibacterial | 20 % Hemolysis at 90 µM | Human | Synthetic Homologue Of Maximin H5 | α-Helical | NA | ||
| 25640709 | 2015 | ILGPVLGLVSDTLDDVLGIL{ct:Amid} | MH5N | Amidation | Free | Linear | L | None | 20 | Antibacterial | <12 % Hemolysis at <25 µM | Human | Synthetic Homologue Of Maximin H6 | α-Helical | NA | ||
| 25640709 | 2015 | ILGPVLGLVSDTLDDVLGIL{ct:Amid} | MH5N | Amidation | Free | Linear | L | None | 20 | Antibacterial | 15 % Hemolysis at >450 µM | Human | Synthetic Homologue Of Maximin H7 | α-Helical | NA | ||
| 25640709 | 2015 | ILGPVLGLVSDTLDDVLGIL{ct:Amid} | MH5C | Amidation | Free | Linear | L | None | 20 | Antibacterial | 12 % Hemolysis at 180 µM | Human | Isoform Of Mh5N | α-Helical | NA | ||
| 25640709 | 2015 | ILGPVLGLVSDTLDDVLGIL{ct:Amid} | MH5C | Amidation | Free | Linear | L | None | 20 | Antibacterial | <12 % Hemolysis at <25 µM | Human | Isoform Of Mh5N | α-Helical | NA | ||
| 25640709 | 2015 | ILGPVLGLVSDTLDDVLGIL{ct:Amid} | MH5C | Amidation | Free | Linear | L | None | 20 | Antibacterial | 25 % Hemolysis at >450 µM | Human | Isoform Of Mh5N | α-Helical | NA | ||
| 26144972 | 2015 | VARGWKRKCPLFGKGG | VG16KRKP | Free | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 0.12 % Hemolysis at 25 µM | Human | Analogue Of Vg16 | Loop-type | Non-hemolytic | ||
| 26144972 | 2015 | VARGWKRKCPLFGKGG | VG16KRKP | Free | Free | Linear | L | None | 16 | Antibacterial, Antifungal | <0.12 % Hemolysis at 50 µM | Human | Analogue Of Vg16 | Loop-type | Non-hemolytic | ||
| 26144972 | 2015 | VARGWKRKCPLFGKGG | VG16KRKP | Free | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 0.1 % Hemolysis at 100 µM | Human | Analogue Of Vg16 | Loop-type | Non-hemolytic | ||
| 26144972 | 2015 | VARGWKRKCPLFGKGG | VG16KRKP | Free | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 0.09 % Hemolysis at 150 µM | Human | Analogue Of Vg16 | Loop-type | Non-hemolytic | ||
| 26144972 | 2015 | VARGWKRKCPLFGKGG | VG16KRKP | Free | Free | Linear | L | None | 16 | Antibacterial, Antifungal | <0.12 % Hemolysis at 200 µM | Human | Analogue Of Vg16 | Loop-type | Non-hemolytic | ||
| 26144972 | 2015 | VARGWKRKCPLFGKGG | VG16KRKP | Free | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 0.1 % Hemolysis at 250 µM | Human | Analogue Of Vg16 | Loop-type | Non-hemolytic | ||
| 25530580 | 2015 | GLLTRIKTLL{ct:Amid} | 4T | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLL{nnr:Hser}RIKTLL{ct:Amid} | 4Hser | Amidation | Free | Linear | L | HSer = homoserine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLLSRIKTLL{ct:Amid} | 4S | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLLKRIKTLL{ct:Amid} | Anoplin | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Solitary Spider Wasp, Anoplius Samariensis | α-Helical | NA | ||
| 25530580 | 2015 | GLL{nnr:O}RIKTLL{ct:Amid} | 4Orn | Amidation | Free | Linear | L | O = L-Ornithine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLLKRIKSLL{ct:Amid} | 8S | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLL{nnr:Dab}RIKTLL{ct:Amid} | 4Dab | Amidation | Free | Linear | L | Dab = 2,4-diaminobutanoic acid | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLL{nnr:Dap}RIKTLL{ct:Amid} | 4Dap | Amidation | Free | Linear | L | Dap = 2,3-diaminopropanoic acid | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLLKKIKKLL{ct:Amid} | 5K8K | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLLKRIKKLL{ct:Amid} | 8K | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLL{nnr:Dab}RIK{nnr:Dab}LL{ct:Amid} | 4,8Dab | Amidation | Free | Linear | L | Dab = 2,4-diaminobutanoic acid | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G({nnr:O-Me-Ser})({nnr:O-Me-Ser})KRIKT({nnr:O-Me-Ser})({nnr:O-Me-Ser}){ct:Amid} | 2,3,9,10(O-Me-Ser) | Amidation | Free | Linear | L | O-Me-Ser = O-methyl-serine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G({nnr:O-Me-Ser})LKRIKTL({nnr:O-Me-Ser}){ct:Amid} | 2,10(O-Me-Ser) | Amidation | Free | Linear | L | O-Me-Ser = O-methyl-serine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GVVKRIKTVV{ct:Amid} | 2,3,9,10V | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GMMKRIKTMM{ct:Amid} | 2,3,9,10M | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G({nnr:O-Me-Ser})LKRIKTLL{ct:Amid} | 2(O-Me-Ser) | Amidation | Free | Linear | L | O-Me-Ser = O-methyl-serine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GNV{d}A{d}NV{d}A{d}KRIKTNV{d}A{d}NV{d}A{d}{ct:Amid} | 2,3,9,10Nva | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GVLKRIKTLV{ct:Amid} | 2,10V | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLMKRIKTML{ct:Amid} | 3,9M | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GMLKRIKTLM{ct:Amid} | 2,10M | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at 500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Nva}LKRIKTL{nnr:Nva}{ct:Amid} | 2,10Nva | Amidation | Free | Linear | L | Nva = Norvaline | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GMLKRIKTLL{ct:Amid} | 2M | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at 400 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Nle}LKRIKTL{nnr:Nle}{ct:Amid} | 2,10Nle | Amidation | Free | Linear | L | Nle = Norleucine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Nle}{nnr:Nle}KRIKT{nnr:Nle}{nnr:Nle}{ct:Amid} | 2,3,9,10Nle | Amidation | Free | Linear | L | Nle = Norleucine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Epa}LKRIKTL{nnr:Epa}{ct:Amid} | 2,10Epa | Amidation | Free | Linear | L | Epa = 2-amino,3-ethylpentanoic acid | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Hle}LKRIKTL{nnr:Hle}{ct:Amid} | 2,10Hle | Amidation | Free | Linear | L | Hle = homoleucine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Cha}LKRIKTLL{ct:Amid} | 2Cha | Amidation | Free | Linear | L | Cha = 3- cyclohexylalanine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLLKRIKTL{nnr:Cha}{ct:Amid} | 10Cha | Amidation | Free | Linear | L | Cha = 3- cyclohexylalanine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:βNal}KRIKTLL{ct:Amid} | 2(βNal) | Amidation | Free | Linear | L | βNal = 3(2-naphtyl)alanine | 10 | Antibacterial | 50 % Hemolysis at >500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Hle}{nnr:Hle}KRIKT{nnr:Hle}{nnr:Hle}{ct:Amid} | 2,3,9,10Hle | Amidation | Free | Linear | L | Hle = homoleucine | 10 | Antibacterial | 50 % Hemolysis at 380 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Aoc}LKRIKTL{nnr:Aoc}{ct:Amid} | 2,10Aoc | Amidation | Free | Linear | L | Aoc = 2-aminooctanoic acid | 10 | Antibacterial | 50 % Hemolysis at 500 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Cha}LKRIKT{nnr:Cha}L{ct:Amid} | 2,9Cha | Amidation | Free | Linear | L | Cha = 3- cyclohexylalanine | 10 | Antibacterial | 50 % Hemolysis at 350 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Cha}LKRIKTL{nnr:Cha}{ct:Amid} | 2,10Cha | Amidation | Free | Linear | L | Cha = 3- cyclohexylalanine | 10 | Antibacterial | 50 % Hemolysis at 300 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Aoc}{nnr:Aoc}KRIKT{nnr:Aoc}{nnr:Aoc}{ct:Amid} | 2,3,9,10Aoc | Amidation | Free | Linear | L | Aoc = 2-aminooctanoic acid | 10 | Antibacterial | 50 % Hemolysis at 125 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GALKR{nnr:βNal}KTLA{ct:Amid} | 2,10A6(βNal) | Amidation | Free | Linear | L | βNal = 3(2-naphtyl)alanine | 10 | Antibacterial | 50 % Hemolysis at 71 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Nva}{nnr:Nva}KR{nnr:βNal}KT{nnr:Nva}{nnr:Nva}{ct:Amid} | 2,3,9,10Nva6(βNal) | Amidation | Free | Linear | L | Nva = Norvaline, βNal = 3(2-naphtyl)alanine | 10 | Antibacterial | 50 % Hemolysis at 120 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | G{nnr:Nva}LKR{nnr:βNal}KTL{nnr:Nva}{ct:Amid} | 2,10Nva6(βNal) | Amidation | Free | Linear | L | Nva = Norvaline, βNal = 3(2-naphtyl)alanine | 10 | Antibacterial | 50 % Hemolysis at 100 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GL{nnr:Nva}KR{nnr:βNal}KT{nnr:Nva}L{ct:Amid} | 3,9Nva6(βNal) | Amidation | Free | Linear | L | Nva = Norvaline, βNal = 3(2-naphtyl)alanine | 10 | Antibacterial | 50 % Hemolysis at 20 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLLKKIKWLL{ct:Amid} | 5K8W | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at 130 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLLKKIKWLL{ct:Amid} | 5W | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at 20 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25530580 | 2015 | GLLKFIKWLL{ct:Amid} | 5F8W | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at 2 µM | Human | Anoplin Analogues | α-Helical | NA | ||
| 25728268 | 2015 | MLIFVHIIAPVISGCAIAFFSYWLSRRNTK{ct:Amid} | PepA1 | Amidation | Free | Linear | L | None | 30 | Antibacterial | 50 % Hemolysis at 70 µM | Human | Bacteria S. Aureus | α-Helical | NA | ||
| 25728268 | 2015 | MLIFVHIIAPVISGC{ct:Amid} | Pep N-ter | Amidation | Free | Linear | L | None | 15 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa1 | NA | NA | ||
| 25728268 | 2015 | AIAFFSYWLSRRNTK{ct:Amid} | Pep C-ter | Amidation | Free | Linear | L | None | 15 | Antibacterial | 50 % Hemolysis at 420 µM | Human | Derived From Pepa2 | NA | NA | ||
| 25728268 | 2015 | FFSYWLSRRNTK{ct:Amid} | Pep1 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa3 | NA | NA | ||
| 25728268 | 2015 | FFSYWLSRRTK{ct:Amid} | Pep2 | Amidation | Free | Linear | L | None | 11 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa4 | NA | NA | ||
| 25728268 | 2015 | FFSWLSRRTK{ct:Amid} | Pep3 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa5 | NA | NA | ||
| 25728268 | 2015 | FFWLSRRTK{ct:Amid} | Pep4 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa6 | NA | NA | ||
| 25728268 | 2015 | FFWLSRTK{ct:Amid} | Pep5 | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa7 | NA | NA | ||
| 25728268 | 2015 | FFWLSRRTK{cyc:N-C} | Pep6 | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 5 µM | Human | Derived From Pepa8 | NA | NA | ||
| 25728268 | 2015 | FFWSRRTK{cyc:N-C} | Pep7 | Free | Free | Cyclic | L | None | 8 | Antibacterial | 50 % Hemolysis at 14 µM | Human | Derived From Pepa9 | NA | NA | ||
| 25728268 | 2015 | FFWRRTK{cyc:N-C} | Pep8 | Free | Free | Cyclic | L | None | 7 | Antibacterial | 50 % Hemolysis at 160 µM | Human | Derived From Pepa10 | NA | NA | ||
| 25728268 | 2015 | FFWLRR{nnr:aza-β3Hyt}K{ct:Amid} | Pep9 | Amidation | Free | Linear | L | aza-β3Hyt = aza-b3 -homohydroxythreonine | 8 | Antibacterial | 50 % Hemolysis at 300-900 µM | Human | Derived From Pepa11 | NA | NA | ||
| 25728268 | 2015 | FFWLRR{nnr:aza-β3Hyt}K{cyc:N-C} | Pep10 | Free | Free | Cyclic | L | aza-b3 = homohydroxythreonine | 8 | Antibacterial | 50 % Hemolysis at 150 µM | Human | Derived From Pepa12 | NA | NA | ||
| 25728268 | 2015 | FFWRR{nnr:aza-β3Hyt}K{cyc:N-C} | Pep11 | Free | Free | Cyclic | L | aza-b3 = homohydroxythreonine | 7 | Antibacterial | 50 % Hemolysis at 840 µM | Human | Derived From Pepa13 | NA | NA | ||
| 25261129 | 2015 | GFGCNGPWSEKDMHCHNHCKSIKGYKGGYCAKGGFICKCY | rMP1106 | Free | Free | Linear | L | None | 43 | Antimicrobial | 1.16 % Hemolysis at 512 μg/mL | Human | Plectasin-Derived | α-Helix/β-Sheets | NA | ||
| 25773522 | 2015 | ILGKIWEGIKSLF{ct:Amid} | IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial | ~86 % Hemolysis at 90 µM | Human | Scorpion, Opisthacanthus Madagascariensis | α-Helical | NA | ||
| 25773522 | 2015 | ILGKIWKGIKSLF{ct:Amid} | E7K-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial | 48 % Hemolysis at 90 µM | Human | Isct Designed Analogs | α-Helical | NA | ||
| 25773522 | 2015 | ILGKIWEGKKSLF{ct:Amid} | I9K-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial | 0.4 % Hemolysis at 90 µM | Human | Isct Designed Analogs | α-Helical | Non-hemolytic | ||
| 25773522 | 2015 | ILGKIWKGKKSLF{ct:Amid} | E7K,I9K-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial | 0.14 % Hemolysis at 90 µM | Human | Isct Designed Analogs | α-Helical | Non-hemolytic | ||
| 25773522 | 2015 | ILGKIWEGIKSLF{ct:Amid} | IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 43.59 µM | Human | Scorpion, Opisthacanthus Madagascariensis | α-Helical | NA | ||
| 25773522 | 2015 | ILGKIWKGIKSLF{ct:Amid} | E7K-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 92.17 µM | Human | Isct Designed Analogs | α-Helical | NA | ||
| 25773522 | 2015 | ILGKIWEGKKSLF{ct:Amid} | I9K-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 500 µM | Human | Isct Designed Analogs | α-Helical | Non-hemolytic | ||
| 25773522 | 2015 | ILGKIWKGKKSLF{ct:Amid} | E7K,I9K-IsCT | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 500 µM | Human | Isct Designed Analogs | α-Helical | Non-hemolytic | ||
| 25583073 | 2015 | VDIHVWDGVVDIHVWDGV | PIP-18[59–76] | Free | Free | Linear | L | None | 18 | Antibacterial, Wound healing activity | <20 % Hemolysis at 100 μg/mL | Human | Python Reticulatus Serum Protein | α-Helical | Low hemolytic | ||
| 25583073 | 2015 | LGRVDIHVWDGVYIRGR | [D-Ala66]-PNT.II | Free | Free | Linear | L | None | 17 | Antibacterial | <30 % Hemolysis at 100 μg/mL | Human | Python Reticulatus Serum Protein | α-Helical | NA | ||
| 25583073 | 2015 | CVDIHVWDGVC{cyc:N-C} | Cyclic C-PIP[57-67]C | Free | Free | Cyclic | L | None | 11 | Antibacterial | 30 % Hemolysis at 100 μg/mL | Human | Python Reticulatus Serum Protein | β or Helical | NA | ||
| 25583073 | 2015 | VEIHVWEGV | D60,65E-PIP[59-67] | Free | Free | Linear | L | None | 9 | Antibacterial | <30 % Hemolysis at 100 μg/mL | Human | Python Reticulatus Serum Protein | α-Helical | NA | ||
| 25583073 | 2015 | VDIHVWDGV | β-Asp65-PIP[59-67] | Free | Free | Linear | L | None | 9 | Antibacterial, Wound healing activity | <20 % Hemolysis at 100 μg/mL | Human | Python Reticulatus Serum Protein | α-Helical | Low hemolytic | ||
| 25425644 | 2015 | {nnr:T1}-VAGVVGLALIVAGVVVLNVAS-{nnr:T2} | TM4 | Free | Free | Linear | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH2 | 28 | Antimicrobial | 10 % Hemolysis at 12.5 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-GLALIVAGV-{nnr:T2} | TM4(90–98) | Free | Free | Linear | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH3 | 9 | Antimicrobial | 10 % Hemolysis at >200 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VGLALIVAGVV-{nnr:T2} | TM4(89–99) | Free | Free | Linear | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH4 | 11 | Antimicrobial | 10 % Hemolysis at >200 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGLALIVAGVVV-{nnr:T2} | TM4(88–100) | Free | Free | Linear | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH5 | 13 | Antimicrobial | 10 % Hemolysis at >200 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGLALINAGVVV-{nnr:T2} | TM4(88–100)-N95 | Free | Free | Linear | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH6 | 13 | Antimicrobial | 10 % Hemolysis at >200 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVLVGIAGVALVV- {nnr:T2} | TM4(88–100)scr | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH7 | 13 | Antimicrobial | Not specified | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGL{nnr:X}LIV{nnr:X}GVVV-{nnr:T2} | S-TM4(88–100) | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH8 | 13 | Antimicrobial | 10 % Hemolysis at 12.5 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGL{nnr:X}LIG{nnr:X}GVVV-{nnr:T2} | S-TM4(88–100)-G95 | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH9 | 13 | Antimicrobial | 10 % Hemolysis at 25 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGL{nnr:X}LIN{nnr:X}GVVV-{nnr:T2} | S-TM4(88–100)-N95 | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH10 | 13 | Antimicrobial | 10 % Hemolysis at >200 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-V{nnr:X'}GLALIN{nnr:X}GVVV-{nnr:T2} | S1-TM4(88–100)-N95 | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH11 | 13 | Antimicrobial | 10 % Hemolysis at 100 µM | Human | Synthetic | α-Helical | NA | ||
| 25425644 | 2015 | {nnr:T1}-VVGL{nnr:X'}LINAGV{nnr:X}V-{nnr:T2} | S2-TM4(88–100)-N95 | Free | Free | Stapled | L | T1 = CH3CO-Ala-Sar3-(N-methyl-Gly), T2 = -Lys3-NH12 | 13 | Antimicrobial | 10 % Hemolysis at 100 µM | Human | Synthetic | α-Helical | NA | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | <0.25 % Hemolysis at 1 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.25 % Hemolysis at 5 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | <0.25 % Hemolysis at 10 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | 0.3 % Hemolysis at 25 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | <0.35 % Hemolysis at 50 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | VARGWKRKCPLFGKGGVARGWKRKCPLFGKGG | VG16KRKP Dimer | Free | Free | Linear | L | None | 32 | Antimicrobial | <0.45 % Hemolysis at 100 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | {nnr:C4}-VARGWKRKCPLFGKGG | C4VG16KRKP | Free | Free | Linear | L | C4 = 4-carbon long acylated analog | 18 | Antimicrobial | <0.25 % Hemolysis at 1 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | {nnr:C4}-VARGWKRKCPLFGKGG | C4VG16KRKP | Free | Free | Linear | L | C4 = 4-carbon long acylated analog | 18 | Antimicrobial | <0.35 % Hemolysis at 5 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | {nnr:C4}-VARGWKRKCPLFGKGG | C4VG16KRKP | Free | Free | Linear | L | C4 = 4-carbon long acylated analog | 18 | Antimicrobial | <0.35 % Hemolysis at 10 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | {nnr:C4}-VARGWKRKCPLFGKGG | C4VG16KRKP | Free | Free | Linear | L | C4 = 4-carbon long acylated analog | 18 | Antimicrobial | <0.35 % Hemolysis at 25 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | {nnr:C4}-VARGWKRKCPLFGKGG | C4VG16KRKP | Free | Free | Linear | L | C4 = 4-carbon long acylated analog | 18 | Antimicrobial | <0.35 % Hemolysis at 50 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26407061 | 2016 | {nnr:C4}-VARGWKRKCPLFGKGG | C4VG16KRKP | Free | Free | Linear | L | C4 = 4-carbon long acylated analog | 18 | Antimicrobial | <0.45 % Hemolysis at 100 µM | Human | N-Terminal Lipidated Analogue | Turn/Loop | Non-hemolytic | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 1.69 % Hemolysis at 0.11 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 1.78 % Hemolysis at 0.22 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 1.8 % Hemolysis at 0.44 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 1.94 % Hemolysis at 0.88 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 2.06 % Hemolysis at 1.75 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 2.1 % Hemolysis at 3.5 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 2.15 % Hemolysis at 7 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 2.37 % Hemolysis at 14.01 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 2.77 % Hemolysis at 28.01 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26549174 | 2016 | FLGMLLHGVGHAIHGLI | Of-Pis1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 3.22 % Hemolysis at 56.02 µM | Human | Rock Bream (Oplegnathus Fasciatus) | α-Helical | NA | ||
| 26574005 | 2016 | KKLFKKILKYL{ct:Amid} | BP100 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 33 % Hemolysis at 150 µM | Human | Cecropin-Α-Melittin 29 Hybrid | NA | NA | ||
| 26574005 | 2016 | RRLFRRILRWL{ct:Amid} | RW-BP100 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKLF{d}KKILKYL{ct:Amid} | BP143 | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKLFKK{d}I{d}L{d}K{d}Y{d}L{d}{ct:Amid} | BP157 | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | 8 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | RKLFKRILKYL{ct:Amid} | BP201 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 45 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KRLFRKILKYL{ct:Amid} | BP202 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 44 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKLFKKILRYL{ct:Amid} | BP203 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 31 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KRLFRKILRYL{ct:Amid} | BP204 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 69 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKLFRRILKYL{ct:Amid} | BP205 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 63 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | RRLFKKILKYL{ct:Amid} | BP206 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 68 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKLFKKI{d}LKYL{ct:Amid} | BP207 | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | Not determined | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKL{nnr:X}KKILKYL{ct:Amid} | BP208 | Amidation | Free | Linear | L | X = F (NPhe) | 18 | Antimicrobial | Not determined | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKLFK{nnr:B}{nnr:Z}{nnr:Z}{nnr:B}{nnr:X}{nnr:Z}{ct:Amid} | BP209 | Amidation | Free | Linear | L | X = F (NPhe), Z = L (NLeu), B= K(NLys) | 18 | Antimicrobial | Not determined | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | RRL({nnr:2Nal})RRILRYL{ct:Amid} | BP210 | Amidation | Free | Linear | L | 2Nal = 2-Nal | 18 | Antimicrobial | 100 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKLF{d}KKILRYL{ct:Amid} | BP211 | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | 43 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKL({nnr:D2-nal})KKILKYL{ct:Amid} | BP212 | Amidation | Free | Linear | Mix | D2-nal = D-2-nal | 18 | Antimicrobial | 85 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | KKLFKK{d}I{d}L{d}R{d}Y{d}L{d}{ct:Amid} | BP213 | Amidation | Free | Linear | Mix | None | 18 | Antimicrobial | <8 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26574005 | 2016 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}L{d}{ct:Amid} | BP214 | Amidation | Free | Linear | D | None | 18 | Antimicrobial | 42 % Hemolysis at 150 µM | Human | Bp Analogue | NA | NA | ||
| 26680221 | 2016 | ILGTILGLLKSL{ct:Amid} | Polybia-CP | Amidation | Free | Linear | L | None | 12 | Antifungal | <20% % Hemolysis at 30 µM | Human | Polybia Paulista | α-Helix | NA | ||
| 26680221 | 2016 | ILGTILGLLKSL{ct:Amid} | Polybia-CP | Amidation | Free | Linear | L | None | 12 | Antifungal | <10 % Hemolysis at <20 µM | Human | Polybia Paulista | α-Helix | NA | ||
| 26680221 | 2016 | ILGTILGLLKSL{ct:Amid} | Polybia-CP | Amidation | Free | Linear | L | None | 12 | Antifungal | 30 % Hemolysis at <30 µM | Human | Polybia Paulista | α-Helix | NA | ||
| 26680221 | 2016 | ILGTILGLLKSL{ct:Amid} | Polybia-CP | Amidation | Free | Linear | L | None | 12 | Antifungal | 60 % Hemolysis at 70 µM | Human | Polybia Paulista | α-Helix | NA | ||
| 26680221 | 2016 | ILGTILGLLKSL{ct:Amid} | Polybia-CP | Amidation | Free | Linear | L | None | 12 | Antifungal | 60 % Hemolysis at 130 µM | Human | Polybia Paulista | α-Helix | NA | ||
| 27774141 | 2016 | WKKKQLQLQLQLQLQLKK{nt:acetic acid}{ct:Amid} | W362 | Amidation | acetic acid | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 5 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | KKKWQLQLQLQLQLQLKK{nt:acetic acid}{ct:Amid} | 3W62 | Amidation | acetic acid | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 5 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | WKKKQLQLQLQLQLQLKK{nt:PEG750}{ct:Amid} | P-W362 | Amidation | PEG750 | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 5 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | KKKWQLQLQLQLQLQLKK{nt:PEG750}{ct:Amid} | P-3W62 | Amidation | PEG750 | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 5 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | WKKKQLQLQLQLQLQLKK{nt:acetic acid}{ct:Amid} | W362 | Amidation | acetic acid | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 10 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | KKKWQLQLQLQLQLQLKK{nt:acetic acid}{ct:Amid} | 3W62 | Amidation | acetic acid | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 10 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | WKKKQLQLQLQLQLQLKK{nt:PEG750}{ct:Amid} | P-W362 | Amidation | PEG750 | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 10 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | KKKWQLQLQLQLQLQLKK{nt:PEG750}{ct:Amid} | P-3W62 | Amidation | PEG750 | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 10 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | WKKKQLQLQLQLQLQLKK{nt:acetic acid}{ct:Amid} | W362 | Amidation | acetic acid | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 20 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | KKKWQLQLQLQLQLQLKK{nt:acetic acid}{ct:Amid} | 3W62 | Amidation | acetic acid | Linear | L | None | 18 | Antimicrobial | <10 % Hemolysis at 20 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | WKKKQLQLQLQLQLQLKK{nt:PEG750}{ct:Amid} | P-W362 | Amidation | PEG750 | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 20 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | KKKWQLQLQLQLQLQLKK{nt:PEG750}{ct:Amid} | P-3W62 | Amidation | PEG750 | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 20 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | WKKKQLQLQLQLQLQLKK{nt:acetic acid}{ct:Amid} | W362 | Amidation | acetic acid | Linear | L | None | 18 | Antimicrobial | 20 % Hemolysis at 40 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | KKKWQLQLQLQLQLQLKK{nt:acetic acid}{ct:Amid} | 3W62 | Amidation | acetic acid | Linear | L | None | 18 | Antimicrobial | 10 % Hemolysis at 40 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | WKKKQLQLQLQLQLQLKK{nt:PEG750}{ct:Amid} | P-W362 | Amidation | PEG750 | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 40 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 27774141 | 2016 | KKKWQLQLQLQLQLQLKK{nt:PEG750}{ct:Amid} | P-3W62 | Amidation | PEG750 | Linear | L | None | 18 | Antimicrobial | <5 % Hemolysis at 40 µM | Human | Self-Assembling Antimicrobial Nanofiber (Saan) | β-Sheets | NA | ||
| 26456194 | 2016 | SPAIWGCDSFLGYCRLACFAHEA | defensin-TK | Free | Free | Linear | L | None | 23 | Antibacterial, Antifungal | 1.5 % Hemolysis at 50 μg/ml | Human | Frog Theloderma Kwangsiensis | α-Helix/β-Sheet | NA | ||
| 26456194 | 2016 | SPAIWGCDSFLGYCRLACFAHEA | defensin-TK | Free | Free | Linear | L | None | 23 | Antibacterial, Antifungal | 2.7 % Hemolysis at 100 μg/ml | Human | Frog Theloderma Kwangsiensis | α-Helix/β-Sheet | NA | ||
| 26456194 | 2016 | SPAIWGCDSFLGYCRLACFAHEA | defensin-TK | Free | Free | Linear | L | None | 23 | Antibacterial, Antifungal | 6.2 % Hemolysis at 200 μg/ml | Human | Frog Theloderma Kwangsiensis | α-Helix/β-Sheet | NA | ||
| 26385363 | 2016 | AAKAAAKAAAKAA{ct:Amid} | KL0A10 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 5 % Hemolysis at >256 µM | Human | Mirror-Like Peptides | α-Helix | NA | ||
| 26385363 | 2016 | LLKAAAKAAAKLL{ct:Amid} | KL4A6 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 5 % Hemolysis at >256 µM | Human | Mirror-Like Peptides | α-Helix | NA | ||
| 26385363 | 2016 | AAKLLLKLLLKAA{ct:Amid} | KL6A4 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 5 % Hemolysis at 8 µM | Human | Mirror-Like Peptides | α-Helix | NA | ||
| 26385363 | 2016 | LLKLLLKLLLKLL{ct:Amid} | KL10A0 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 5 % Hemolysis at 2 µM | Human | Mirror-Like Peptides | α-Helix | NA | ||
| 26656137 | 2016 | KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF | cathelicidin-BF | Free | Free | Linear | L | None | 30 | Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Bungarus Fasciatus | α-Helix | NA | ||
| 26656137 | 2016 | RIKRFWPVVIRTVVAGYNLYRAIKKK | Pc-CATH1 | Free | Free | Linear | L | None | 26 | Antifungal | 50 % Hemolysis at >100 μg/ml | Human | Phasianus Colchicus | α-Helix | NA | ||
| 26656137 | 2016 | LVQRGRFGRFLKKVRRFIPKVIIAAQIGSRFG | Cc-CATH2 | Free | Free | Linear | L | None | 32 | Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Coturnix Coturnix | α-Helix | NA | ||
| 26656137 | 2016 | RVRRFWPLVPVAINTVAAGINLYKAIRRK | Cc-CATH3 | Free | Free | Linear | L | None | 29 | Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Coturnix Coturnix | α-Helix | NA | ||
| 26656137 | 2016 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antifungal | 50 % Hemolysis at 75 μg/ml | Human | Homo Sapiens | α-Helix | NA | ||
| 26814379 | 2016 | RWCVYARVRGVRYRRCW | ALP1 | Free | Free | Linear | L | None | 18 | Antimicrobial | 10 % Hemolysis at 68 µM | Human | Arenicin-Like Peptides | β-Hairpin | NA | ||
| 26814379 | 2016 | RWCVYACVRGVCYRRCW | ALP2 | Free | Free | Linear | L | None | 18 | Antimicrobial | 10 % Hemolysis at 10 µM | Human | Arenicin-Like Peptides | β-Hairpin | NA | ||
| 26814379 | 2016 | RWCVRARVRGVRYRRCW | ALP3 | Free | Free | Linear | L | None | 18 | Antimicrobial | 10 % Hemolysis at 88 µM | Human | Arenicin-Like Peptides | β-Hairpin | NA | ||
| 26814379 | 2016 | RWCVYARRRGVRYRRCW | ALP4 | Free | Free | Linear | L | None | 18 | Antimicrobial | 10 % Hemolysis at 73 µM | Human | Arenicin-Like Peptides | β-Hairpin | NA | ||
| 26814379 | 2016 | RWCVYARVRGRRYRRCW | ALP5 | Free | Free | Linear | L | None | 18 | Antimicrobial | 10 % Hemolysis at 50 µM | Human | Arenicin-Like Peptides | β-Hairpin | NA | ||
| 26814379 | 2016 | RWCVYARVRGVRYRRCR | ALP6 | Free | Free | Linear | L | None | 18 | Antimicrobial | 10 % Hemolysis at 110 µM | Human | Arenicin-Like Peptides | β-Hairpin | NA | ||
| 26814379 | 2016 | RWCVYAAYVRVRGVLVRYRRCW | Arenicin-1 | Free | Free | Linear | L | None | 21 | Antimicrobial | 10 % Hemolysis at 5 µM | Human | Arenicola Marina | β-Hairpin | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 0.78 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | 3 % Hemolysis at 1.56 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 3.13 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 6.25 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 12.5 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 25 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 5 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | <3 % Hemolysis at 100 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 26873587 | 2016 | GFGCPFNQGACHRHCRSIGRRGGYCAGLFKQTCTCYSR | IP | Free | Free | Linear | L | None | 38 | Antimicrobial | 3 % Hemolysis at 200 μg/ml | Human | Ixodes Persulcatus | one α Helix and two β Sheets | NA | ||
| 27014065 | 2016 | SKKPVPIIYCNRRSGKCQRM | TS | Free | Free | Linear | L | None | 20 | Antimicrobial | <15 % Hemolysis at 1 mmol/L | Human | Tumor-Specific Cell-Surface | β-Sheet | NA | ||
| 27014065 | 2016 | CIRTPKISKPIKFELSG | P1c | Free | Free | Linear | L | None | 17 | Antimicrobial | <15 % Hemolysis at 1 mmol/L | Human | Human Connective Tissue | Random coil | NA | ||
| 27014065 | 2016 | GSKKPVPIIYCNRRSGKCQRMGSIRTPKISKPIKFELSG | PTS | Free | Free | Linear | L | None | 39 | Antimicrobial | <15 % Hemolysis at 1 mmol/L | Human | Hybrid Peptide | Random coil | NA | ||
| 26881456 | 2016 | KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF{ct:Amid} | cathelicidin-BF | Amidation | Free | Linear | L | None | 30 | Antimicrobial | 10 % Hemolysis at >320 μg/ml | Human | Bungarus Fasciatus | α-Helix | NA | ||
| 26881456 | 2016 | VKRFKKFFRKLKKSV{ct:Amid} | cathelicidin-BF15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at >320 μg/ml | Human | Bungarus Fasciatus | α-Helix | NA | ||
| 26881456 | 2016 | VKRFKKFFRKFKKSV{ct:Amid} | FS-15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at >320 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKRWKKWWRKLKKSV{ct:Amid} | WS-15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at >320 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKRWKKFWRKWKKWW{ct:Amid} | ZY8 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 51.7 ± 5.3 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKRWKKWRWKWKKWV{ct:Amid} | ZY13 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at >320 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKWRWKKWRWKWKWKV{ct:Amid} | ZY15 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 178.3 ± 11.5 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKWRWKWKWRWKWKWKV{ct:Amid} | ZY16 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 62.8 ± 5.8 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF{ct:Amid} | cathelicidin-BF | Amidation | Free | Linear | L | None | 30 | Antimicrobial | 50 % Hemolysis at >320 μg/ml | Human | Bungarus Fasciatus | α-Helix | NA | ||
| 26881456 | 2016 | VKRFKKFFRKLKKSV{ct:Amid} | cathelicidin-BF15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at >320 μg/ml | Human | Bungarus Fasciatus | α-Helix | NA | ||
| 26881456 | 2016 | VKRFKKFFRKFKKSV{ct:Amid} | FS-15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at >320 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKRWKKWWRKLKKSV{ct:Amid} | WS-15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at >320 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKRWKKFWRKWKKWW{ct:Amid} | ZY8 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at >320 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKRWKKWRWKWKKWV{ct:Amid} | ZY13 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at >320 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKWRWKKWRWKWKWKV{ct:Amid} | ZY15 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at >320 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26881456 | 2016 | VKWRWKWKWRWKWKWKV{ct:Amid} | ZY16 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 50 % Hemolysis at >320 μg/ml | Human | Designed Peptides | α-Helix | NA | ||
| 26918268 | 2016 | {nnr:Fmoc}-K{d}({nnr:iPr})({nnr:Boc}){ct:OH} | gA3K(iPr) | OH | Free | Linear | Mix | K{d} = D-lysine, fmoc = 9-fluorenylmethoxycarbonyl, iPr = Isopropyl group, Boc = ε-amino group of the lysine side chain | 15 | Antibacterial | 0 % Hemolysis at 10 µM | Human | Bacillus Brevis | β-Helix | Non-hemolytic | ||
| 26918268 | 2016 | {nnr:Fmoc}-K{d}({nnr:Cy})({nnr:Boc}){ct:OH} | gA3K(Cy) | OH | Free | Linear | Mix | fmoc = 9-fluorenylmethoxycarbonyl, Cy = Cyclohexyl group, Boc=ε-amino group of the lysine side chain, K{d} = D-Lys | 15 | Antibacterial | 55 % Hemolysis at 20 µM | Human | Bacillus Brevis | β-Helix | NA | ||
| 26918268 | 2016 | {nnr:Fmoc}-K{d}({nnr:CyMe})({nnr:Boc}){ct:OH} | gA3K(CyMe) | OH | Free | Linear | Mix | fmoc = 9-fluorenylmethoxycarbonyl, CyMe = Cyclohexylmethyl group, Boc=ε-amino group of the lysine side chain, K{d} = D-Lys | 15 | Antibacterial | <90 % Hemolysis at 10 µM | Human | Bacillus Brevis | β-Helix | NA | ||
| 26918268 | 2016 | {nnr:Fmoc}-K{d}({nnr:Bn})({nnr:Boc}){ct:OH} | gA3K(Bn) | OH | Free | Linear | Mix | fmoc = 9-fluorenylmethoxycarbonyl, Bn = Benzyl group, Boc=ε-amino group of the lysine side chain, K{d} = D-Lys | 15 | Antibacterial | <90 % Hemolysis at 10 µM | Human | Bacillus Brevis | β-Helix | NA | ||
| 26918268 | 2016 | {nnr:Fmoc}-K{d}({nnr:2pyr})({nnr:Boc}){ct:OH} | gA3K(2pyr) | OH | Free | Linear | Mix | fmoc = 9-fluorenylmethoxycarbonyl, 2pyr = 2-Pyridyl group, Boc = ε-amino group of the lysine side chain, K{d} = D-Lys | 15 | Antibacterial | 0 % Hemolysis at 10 µM | Human | Bacillus Brevis | β-Helix | Non-hemolytic | ||
| 26918268 | 2016 | {nnr:Fmoc}-K{d}({nnr:3pyr})({nnr:Boc}){ct:OH} | gA3K(3pyr) | OH | Free | Linear | Mix | fmoc = 9-fluorenylmethoxycarbonyl, 3pyr = 3-Pyridyl group, Boc = ε-amino group of the lysine side chain, K{d} = D-Lys | 15 | Antibacterial | 0 % Hemolysis at 10 µM | Human | Bacillus Brevis | β-Helix | Non-hemolytic | ||
| 26918268 | 2016 | {nnr:Fmoc}-K{d}({nnr:4pyr})({nnr:Boc}){ct:OH} | gA3K(4pyr) | OH | Free | Linear | Mix | fmoc = 9-fluorenylmethoxycarbonyl, 4pyr = 4-Pyridyl group, Boc=ε-amino group of the lysine side chain, K{d} = D-Lys | 15 | Antibacterial | 0 % Hemolysis at 10 µM | Human | Bacillus Brevis | β-Helix | Non-hemolytic | ||
| 26918268 | 2016 | {nnr:Fmoc}-K{d}({nnr:4AMBn})({nnr:Boc}){ct:OH} | gA3K(4AMBn) | OH | Free | Linear | Mix | fmoc = 9-fluorenylmethoxycarbonyl, 4AMBn = 4-Aminomethylbenzyl group, Boc=ε-amino group of the lysine side chain, K{d} = D-Lys | 15 | Antibacterial | <25 % Hemolysis at 75 µM | Human | Bacillus Brevis | β-Helix | NA | ||
| 27114317 | 2016 | FLKGCWTKWYSLKPKCPF{ct:Amid} | Megin 1 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 2.3 % Hemolysis at 25 µM | Human | Skin Venoms Of Spadefoot Toad Megophrys Minor | NA | NA | ||
| 27114317 | 2016 | FLKGCWTKWYSLKPKCPF{ct:Amid} | Megin 1 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 5.6 % Hemolysis at 50 µM | Human | Skin Venoms Of Spadefoot Toad Megophrys Minor | NA | NA | ||
| 27114317 | 2016 | FLKGCWTKWYSLKPKCPF{ct:Amid} | Megin 1 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 18.7 % Hemolysis at 100 µM | Human | Skin Venoms Of Spadefoot Toad Megophrys Minor | NA | NA | ||
| 27114317 | 2016 | FLKGCWTKWYSLKPKCPF{ct:Amid} | Megin 1 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 29.5 % Hemolysis at 200 µM | Human | Skin Venoms Of Spadefoot Toad Megophrys Minor | NA | NA | ||
| 27114317 | 2016 | FFVLKFLLKWAGKVGLEHLACKFKNWC | Megin 2 | Free | Free | Linear | L | None | 27 | Antibacterial, Antifungal | 3.9 % Hemolysis at 25 µM | Human | Skin Venoms Of Spadefoot Toad Megophrys Minor | NA | NA | ||
| 27114317 | 2016 | FFVLKFLLKWAGKVGLEHLACKFKNWC | Megin 2 | Free | Free | Linear | L | None | 27 | Antibacterial, Antifungal | 13.7 % Hemolysis at 50 µM | Human | Skin Venoms Of Spadefoot Toad Megophrys Minor | NA | NA | ||
| 27114317 | 2016 | FFVLKFLLKWAGKVGLEHLACKFKNWC | Megin 2 | Free | Free | Linear | L | None | 27 | Antibacterial, Antifungal | 27.7 % Hemolysis at 100 µM | Human | Skin Venoms Of Spadefoot Toad Megophrys Minor | NA | NA | ||
| 27114317 | 2016 | FFVLKFLLKWAGKVGLEHLACKFKNWC | Megin 2 | Free | Free | Linear | L | None | 27 | Antibacterial, Antifungal | 45.3 % Hemolysis at 200 µM | Human | Skin Venoms Of Spadefoot Toad Megophrys Minor | NA | NA | ||
| 26998557 | 2016 | GIMSSLMKKLAAHIAK{ct:Amid} | HYL | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Hylaeus Signatus | α-Helix | NA | ||
| 26998557 | 2016 | GIMSSLMKKLKAHIAK{ct:Amid} | HYL-1 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIMSSLMKKLAKHIAK{ct:Amid} | HYL-2 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIMSSLMKKLAAHIKK{ct:Amid} | HYL-3 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIMSSLMKKLKKHIAK{ct:Amid} | HYL-4 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIMISLMKKLAAHIAK{ct:Amid} | HYL-5 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 320 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIMSSLMKKLAAIIAK{ct:Amid} | HYL-6 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 93 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIMSSLMKKLAKIIAK{ct:Amid} | HYL-7 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIMSSLMKKLKKIIAK{ct:Amid} | HYL-8 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | G{d}I{d}M{d}S{d}S{d}L{d}M{d}K{d}K{d}L{d}K{d}K{d}I{d}I{d}A{d}K{d}{ct:Amid} | HYL-9 | Amidation | Free | Linear | D | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIMSSLMKKLAKIIKK{ct:Amid} | HYL-10 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIMSSLMKKLKKIIKK{ct:Amid} | HYL-11 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 284 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GILSSLLKKLKKIIAK{ct:Amid} | HYL-12 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 333 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | G{d}I{d}L{d}S{d}S{d}L{d}L{d}K{d}K{d}L{d}K{d}K{d}I{d}I{d}A{d}K{d}{ct:Amid} | HYL-13 | Amidation | Free | Linear | D | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 373 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GI{nnr:X}SSL{nnr:X}KKLKKIIAK{ct:Amid} | HYL-14 | Amidation | Free | Linear | L | X = norleucine | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GILKSLLKKLKKIIAK{ct:Amid} | HYL-15 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GILSKLLKKLKKIIAK{ct:Amid} | HYL-16 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 364 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | KILSSLLKKLKKIIAK{ct:Amid} | HYL-17 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 165 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GIWSSLLKKLKKIIAK{ct:Amid} | HYL-18 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GILSSWLKKLKKIIAK{ct:Amid} | HYL-19 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 197 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GILSSLWKKLKKIIAK{ct:Amid} | HYL-20 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 191 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | G{d}I{d}L{d}S{d}S{d}L{d}W{d}K{d}K{d}L{d}K{d}K{d}I{d}I{d}A{d}K{d}{ct:Amid} | HYL-21 | Amidation | Free | Linear | D | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GKLSSLWKKLKKIIAK{ct:Amid} | HYL-22 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GILSSLLKKWKKIIAK{ct:Amid} | HYL-23 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 115 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GILSSLLKKLKKWIAK{ct:Amid} | HYL-24 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 57 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GILSSLWKKLKKWIAK{ct:Amid} | HYL-25 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 26998557 | 2016 | GILSSLWKKPKKIIAK{ct:Amid} | HYL-26 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at >400 µM | Human | Analog Of Hyl | α-Helix | NA | ||
| 27128941 | 2016 | VWLSALKFIGKHLAKHQLSKL{ct:Amid} | Lycosin-II | Amidation | Free | Linear | L | None | 21 | Antibacterial | <10 % Hemolysis at 6.25 µM | Human | Chinese Wolf Spider Lycosa Singoriensis | α-Helix | NA | ||
| 27128941 | 2016 | VWLSALKFIGKHLAKHQLSKL{ct:Amid} | Lycosin-II | Amidation | Free | Linear | L | None | 21 | Antibacterial | <10 % Hemolysis at 12.5 µM | Human | Chinese Wolf Spider Lycosa Singoriensis | α-Helix | NA | ||
| 27128941 | 2016 | VWLSALKFIGKHLAKHQLSKL{ct:Amid} | Lycosin-II | Amidation | Free | Linear | L | None | 21 | Antibacterial | <10 % Hemolysis at 25 µM | Human | Chinese Wolf Spider Lycosa Singoriensis | α-Helix | NA | ||
| 27128941 | 2016 | VWLSALKFIGKHLAKHQLSKL{ct:Amid} | Lycosin-II | Amidation | Free | Linear | L | None | 21 | Antibacterial | 20 % Hemolysis at 50 µM | Human | Chinese Wolf Spider Lycosa Singoriensis | α-Helix | NA | ||
| 27128941 | 2016 | VWLSALKFIGKHLAKHQLSKL{ct:Amid} | Lycosin-II | Amidation | Free | Linear | L | None | 21 | Antibacterial | <20 % Hemolysis at 100 µM | Human | Chinese Wolf Spider Lycosa Singoriensis | α-Helix | NA | ||
| 26795535 | 2016 | RGLRRLGRKIAHGVKKYGPTVLRIIRIA{ct:Amid} | SMAP-29 | Amidation | Free | Linear | L | None | 28 | Antimicrobial, Anti-MRSA | 10 % Hemolysis at 6 µM | Human | Sheep Myeloid Cells | α-Helix | NA | ||
| 26795535 | 2016 | R{d}G{d}L{d}R{d}R{d}L{d}G{d}R{d}K{d}I{d}A{d}H{d}G{d}V{d}K{d}K{d}Y{d}G{d}P{d}T{d}V{d}L{d}R{d}I{d}I{d}R{d}I{d}A{d}{ct:Amid} | SMAP-29-E1 | Amidation | Free | Linear | D | i = D-Isoleucine | 28 | Antimicrobial, Anti-MRSA | 10 % Hemolysis at 5.5 µM | Human | Smap-29 D-Enantiomeric Peptides | α-Helix | NA | ||
| 26795535 | 2016 | R{d}G{d}L{d}R{d}R{d}L{d}G{d}R{d}K{d}I{d}A{d}H{d}G{d}V{d}K{d}K{d}Y{d}G{d}P{d}T{d}V{d}L{d}R{d}{nnr:i}{nnr:i}R{d}{nnr:i}A{d}{ct:Amid} | SMAP-29-E2 | Amidation | Free | Linear | D | i = d-allo-isoleucine | 28 | Antimicrobial, Anti-MRSA | 10 % Hemolysis at 16 µM | Human | Smap-29 D-Enantiomeric Peptides | α-Helix | NA | ||
| 26795535 | 2016 | RGLRRLGRKIAHGVKKYGP{d}T{d}V{d}L{d}R{d}I{d}I{d}R{d}I{d}A{d}{ct:Amid} | SMAP-29-D1 | Amidation | Free | Linear | Mix | i = D-Isoleucine | 28 | Antimicrobial, Anti-MRSA, Anti-inflammatory | 10 % Hemolysis at 110 µM | Human | Smap-29 Diastereomeric Peptides | α-Helix | NA | ||
| 26795535 | 2016 | RGLRRLGRKIAHGVKKYGP{d}T{d}V{d}L{d}R{d}{nnr:i}{nnr:i}R{d}{nnr:i}A{d}{ct:Amid} | SMAP-29-D2 | Amidation | Free | Linear | Mix | i = d-allo-isoleucine | 28 | Antimicrobial, Anti-MRSA, Anti-inflammatory | 10 % Hemolysis at 217.5 µM | Human | Smap-29 Diastereomeric Peptides | α-Helix | NA | ||
| 26795535 | 2016 | RGLRRLGRKIAHGVKKYG{ct:Amid} | SMAP-18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Anti-MRSA | 10 % Hemolysis at <512 µM | Human | Derived From Smap-29 | α-Helix | NA | ||
| 26795535 | 2016 | R{d}G{d}L{d}R{d}R{d}L{d}G{d}R{d}K{d}I{d}A{d}H{d}G{d}V{d}K{d}K{d}Y{d}G{d}{ct:Amid} | SMAP-18-E1 | Amidation | Free | Linear | D | i = D-Isoleucine | 18 | Antimicrobial, Anti-MRSA | 10 % Hemolysis at <512 µM | Human | Smap-18 D-Enantiomeric Peptides | α-Helix | NA | ||
| 26795535 | 2016 | R{d}G{d}L{d}R{d}R{d}L{d}G{d}R{d}K{d}{nnr:i}A{d}H{d}G{d}V{d}K{d}K{d}Y{d}G{d}{ct:Amid} | SMAP-18-E2 | Amidation | Free | Linear | D | i = d-allo-isoleucine | 18 | Antimicrobial, Anti-MRSA | 10 % Hemolysis at <512 µM | Human | Smap-18 D-Enantiomeric Peptides | α-Helix | NA | ||
| 26837216 | 2016 | RRRQKRIVVRRRLIR | P3 | Free | Free | Linear | L | None | 15 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Cell-Penetrating Peptides | α-Helix | Non-hemolytic | ||
| 26837216 | 2016 | RRWRRWNRFNRRRCR | P8 | Free | Free | Linear | L | None | 15 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Cell-Penetrating Peptides | α-Helix | Non-hemolytic | ||
| 26896660 | 2016 | RIVQRIKKWLLKWKKLGY{ct:Amid} | peptide 5 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 8 ± 2 % Hemolysis at 55 µM | Human | Cationic Amps | α-Helix | NA | ||
| 26896660 | 2016 | RIVQRILKWLKKWYKLGK{ct:Amid} | peptide 8 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 85 ± 12 % Hemolysis at 55 µM | Human | Cationic Amps | α-Helix | NA | ||
| 26896660 | 2016 | RIVQRIAKWAKKWYKAGK{ct:Amid} | peptide 8.1 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 5 ± 1 % Hemolysis at 55 µM | Human | Cationic Amps | α-Helix | NA | ||
| 26902768 | 2016 | KRFWPLVPVAINTVAAGINLYKAIRRK{ct:Amid} | Fow-3 | Amidation | Free | Linear | L | None | 27 | Antibacterial | 88.1 % Hemolysis at 256 µM | Human | Chicken Cathelicidin | Random coil- sodium phosphate buffer/α-Helical structure-SDS and TFE buffer | Non-hemolytic | ||
| 26902768 | 2016 | KRFWPLVPVAINTVA{ct:Amid} | Fow-3(1-15) | Amidation | Free | Linear | L | None | 15 | Antibacterial | <5 % Hemolysis at 256 µM | Human | Truncated Peptides Of Fowlicidin-3 | α-Helix | NA | ||
| 26902768 | 2016 | KRFWPLVPVAINTVAA{ct:Amid} | Fow-3(1-19) | Amidation | Free | Linear | L | None | 19 | Antibacterial | 38.9 % Hemolysis at 256 µM | Human | Truncated Peptides Of Fowlicidin-3 | α-Helix | NA | ||
| 26902768 | 2016 | LYKAIRRK{ct:Amid} | Fow-3(20-27) | Amidation | Free | Linear | L | None | 8 | Antibacterial | <5 % Hemolysis at 256 µM | Human | Truncated Peptides Of Fowlicidin-3 | α-Helix | NA | ||
| 26902768 | 2016 | KRFWPLVPVAINTVAL{ct:Amid} | Fow-3(1-15-20-27) | Amidation | Free | Linear | L | None | 23 | Antibacterial | <5 % Hemolysis at 256 µM | Human | Truncated Peptides Of Fowlicidin-3 | Random coil- sodium phosphate buffer/α-Helical structure-SDS and TFE buffer | Non-hemolytic | ||
| 27033467 | 2016 | AATKPKKAGAEAAPKKPAKKQTKKKPAKKAGGKKKPKRAGAKKAKK{ct:Amid} | hdMolluscidin | Amidation | Free | Linear | L | None | 46 | Antibacterial | 0 % Hemolysis at 100 μg/ml | Human | Marine Snail Haliotis Discus | α-Helix | Non-hemolytic | ||
| 27243004 | 2016 | {nnr:O}W{nnr:O}W{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu} | Api793 | Free | gu | Linear | L | gu = N,N,N′N′-tetramethylguanidino, O = L-Ornithine | 20 | Antibacterial Gram- | 1.3 ± 0.4 % Hemolysis at 0.1 g/L | Human | Apidaecin Analog Api137 | NA | Non-hemolytic | ||
| 27243004 | 2016 | {nnr:O}W{nnr:O}W{nnr:O}W{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu} | Api794 | Free | gu | Linear | L | gu = N,N,N′N′-tetramethylguanidino, O = L-Ornithine | 22 | Antibacterial Gram- | 1.7 ± 0.2 % Hemolysis at 0.1 g/L | Human | Apidaecin Analog Api137 | NA | Non-hemolytic | ||
| 27243004 | 2016 | {nnr:O}I{nnr:O}I{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu} | Api795 | Free | gu | Linear | L | gu = N,N,N′N′-tetramethylguanidino, O = L-Ornithine | 20 | Antibacterial Gram- | −0.8 ± 0.4 % Hemolysis at 0.1 g/L | Human | Apidaecin Analog Api137 | NA | Non-hemolytic | ||
| 27243004 | 2016 | {nnr:O}I{nnr:O}I{nnr:O}I{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu} | Api796 | Free | gu | Linear | L | gu = N,N,N′N′-tetramethylguanidino, O = L-Ornithine | 22 | Antibacterial Gram- | −0.8 ± 0.2 % Hemolysis at 0.1 g/L | Human | Apidaecin Analog Api137 | NA | Non-hemolytic | ||
| 27243004 | 2016 | {nnr:O}W{nnr:O}W{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu} | Api793 | Free | gu | Linear | L | gu = N,N,N′N′-tetramethylguanidino, O = L-Ornithine | 20 | Antibacterial Gram- | 1.6 ± 0.5 % Hemolysis at 0.6 g/L | Human | Apidaecin Analog Api137 | NA | Non-hemolytic | ||
| 27243004 | 2016 | {nnr:O}W{nnr:O}W{nnr:O}W{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu} | Api794 | Free | gu | Linear | L | gu = N,N,N′N′-tetramethylguanidino, O = L-Ornithine | 22 | Antibacterial Gram- | 1.9 ± 0.3 % Hemolysis at 0.6 g/L | Human | Apidaecin Analog Api137 | NA | Non-hemolytic | ||
| 27243004 | 2016 | {nnr:O}I{nnr:O}I{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu} | Api795 | Free | gu | Linear | L | gu = N,N,N′N′-tetramethylguanidino, O = L-Ornithine | 20 | Antibacterial Gram- | 0.0 ± 0.7 % Hemolysis at 0.6 g/L | Human | Apidaecin Analog Api137 | NA | Non-hemolytic | ||
| 27243004 | 2016 | {nnr:O}I{nnr:O}I{nnr:O}I{nnr:O}RPVY{nnr:O}PRPRPPHPRL{nt:gu} | Api796 | Free | gu | Linear | L | gu = N,N,N′N′-tetramethylguanidino, O = L-Ornithine | 22 | Antibacterial Gram- | −0.1 ± 0.8 % Hemolysis at 0.6 g/L | Human | Apidaecin Analog Api137 | NA | Non-hemolytic | ||
| 26920749 | 2016 | IDGLKAIWKKVADLLKNT{ct:Amid} | L1A | Amidation | Free | Linear | L | None | 18 | Antibacterial | 4 % Hemolysis at 148 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 26920749 | 2016 | IDGLKAIWKKVADLLKNT{nt:Acet}{ct:Amid} | Ac-L1A | Amidation | acetylation | Linear | L | None | 18 | Antibacterial | 5 % Hemolysis at 145 µM | Human | Synthetic Peptide | α-Helix | Non-hemolytic | ||
| 26920749 | 2016 | IDGLKAIVKKVADLLKNT{nt:Abz = ortho-aminobenzoic acid}{ct:Amid} | Abz-L1A-W8V | Amidation | Abz = ortho-aminobenzoic acid | Linear | L | None | 18 | Antibacterial | 46 % Hemolysis at 140 µM | Human | Synthetic Peptide | α-Helix | Non-hemolytic | ||
| 26975251 | 2016 | KKLFKKILKYL{ct:Amid} | BP100-PP | Amidation | Free | Linear | L | None | 11 | Antibacterial | 7 % Hemolysis at 1.25 µM | Human | Parent Peptide | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKYL{ct:Amid} | BP100-PP | Amidation | Free | Linear | L | None | 11 | Antibacterial | 9 % Hemolysis at 2.5 µM | Human | Parent Peptide | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKYL{ct:Amid} | BP100-PP | Amidation | Free | Linear | L | None | 11 | Antibacterial | 13 % Hemolysis at 5 µM | Human | Parent Peptide | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKYL{ct:Amid} | BP100-PP | Amidation | Free | Linear | L | None | 11 | Antibacterial | 18 % Hemolysis at 10 µM | Human | Parent Peptide | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKYL{ct:Amid} | BP100-PP | Amidation | Free | Linear | L | None | 11 | Antibacterial | 36 % Hemolysis at 20 µM | Human | Parent Peptide | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKYL{ct:Amid} | BP100-PP | Amidation | Free | Linear | L | None | 11 | Antibacterial | 59 % Hemolysis at 40 µM | Human | Parent Peptide | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKYL{ct:Amid} | BP100-PP | Amidation | Free | Linear | L | None | 11 | Antibacterial | 80 % Hemolysis at 80 µM | Human | Parent Peptide | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKYL{ct:Amid} | BP100-PP | Amidation | Free | Linear | L | None | 11 | Antibacterial | 92 % Hemolysis at 160 µM | Human | Parent Peptide | α-Helix | NA | ||
| 26975251 | 2016 | {nnr:X}KLFKKILKYL{ct:Amid} | BP100K1A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | {nnr:X}KLFKKILKYL{ct:Amid} | BP100K1A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 9 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | {nnr:X}KLFKKILKYL{ct:Amid} | BP100K1A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 8 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | {nnr:X}KLFKKILKYL{ct:Amid} | BP100K1A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 13 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | {nnr:X}KLFKKILKYL{ct:Amid} | BP100K1A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 26 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | {nnr:X}KLFKKILKYL{ct:Amid} | BP100K1A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 43 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | {nnr:X}KLFKKILKYL{ct:Amid} | BP100K1A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 65 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | {nnr:X}KLFKKILKYL{ct:Amid} | BP100K1A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 87 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | K{nnr:X}LFKKILKYL{ct:Amid} | BP100K2A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | K{nnr:X}LFKKILKYL{ct:Amid} | BP100K2A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 8 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | K{nnr:X}LFKKILKYL{ct:Amid} | BP100K2A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 11 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | K{nnr:X}LFKKILKYL{ct:Amid} | BP100K2A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 9 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | K{nnr:X}LFKKILKYL{ct:Amid} | BP100K2A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 15 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | K{nnr:X}LFKKILKYL{ct:Amid} | BP100K2A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 20 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | K{nnr:X}LFKKILKYL{ct:Amid} | BP100K2A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 31 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | K{nnr:X}LFKKILKYL{ct:Amid} | BP100K2A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 48 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KK{nnr:X}FKKILKYL{ct:Amid} | BP100L3A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 8 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KK{nnr:X}FKKILKYL{ct:Amid} | BP100L3A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 4 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KK{nnr:X}FKKILKYL{ct:Amid} | BP100L3A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KK{nnr:X}FKKILKYL{ct:Amid} | BP100L3A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KK{nnr:X}FKKILKYL{ct:Amid} | BP100L3A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 8 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KK{nnr:X}FKKILKYL{ct:Amid} | BP100L3A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KK{nnr:X}FKKILKYL{ct:Amid} | BP100L3A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KK{nnr:X}FKKILKYL{ct:Amid} | BP100L3A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 12 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKL{nnr:X}KKILKYL{ct:Amid} | BP100F4A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 4 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKL{nnr:X}KKILKYL{ct:Amid} | BP100F4A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 3 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKL{nnr:X}KKILKYL{ct:Amid} | BP100F4A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKL{nnr:X}KKILKYL{ct:Amid} | BP100F4A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 10 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKL{nnr:X}KKILKYL{ct:Amid} | BP100F4A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 10 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKL{nnr:X}KKILKYL{ct:Amid} | BP100F4A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 8 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKL{nnr:X}KKILKYL{ct:Amid} | BP100F4A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 4 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKL{nnr:X}KKILKYL{ct:Amid} | BP100F4A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 5 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLF{nnr:X}KILKYL{ct:Amid} | BP100K5A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 4 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLF{nnr:X}KILKYL{ct:Amid} | BP100K5A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 6 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLF{nnr:X}KILKYL{ct:Amid} | BP100K5A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLF{nnr:X}KILKYL{ct:Amid} | BP100K5A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 6 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLF{nnr:X}KILKYL{ct:Amid} | BP100K5A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 18 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLF{nnr:X}KILKYL{ct:Amid} | BP100K5A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 40 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLF{nnr:X}KILKYL{ct:Amid} | BP100K5A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 69 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLF{nnr:X}KILKYL{ct:Amid} | BP100K5A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 93 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFK{nnr:X}ILKYL{ct:Amid} | BP100K6A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 4 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFK{nnr:X}ILKYL{ct:Amid} | BP100K6A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 5 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFK{nnr:X}ILKYL{ct:Amid} | BP100K6A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFK{nnr:X}ILKYL{ct:Amid} | BP100K6A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 8 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFK{nnr:X}ILKYL{ct:Amid} | BP100K6A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 14 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFK{nnr:X}ILKYL{ct:Amid} | BP100K6A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 36 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFK{nnr:X}ILKYL{ct:Amid} | BP100K6A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 64 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFK{nnr:X}ILKYL{ct:Amid} | BP100K6A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 91 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKK{nnr:X}LKYL{ct:Amid} | BP100I7A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 1 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKK{nnr:X}LKYL{ct:Amid} | BP100I7A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 3 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKK{nnr:X}LKYL{ct:Amid} | BP100I7A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 3 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKK{nnr:X}LKYL{ct:Amid} | BP100I7A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 5 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKK{nnr:X}LKYL{ct:Amid} | BP100I7A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 6 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKK{nnr:X}LKYL{ct:Amid} | BP100I7A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKK{nnr:X}LKYL{ct:Amid} | BP100I7A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 6 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKK{nnr:X}LKYL{ct:Amid} | BP100I7A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKI{nnr:X}KYL{ct:Amid} | BP100L8A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 3 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKI{nnr:X}KYL{ct:Amid} | BP100L8A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 9 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKI{nnr:X}KYL{ct:Amid} | BP100L8A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 8 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKI{nnr:X}KYL{ct:Amid} | BP100L8A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 11 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKI{nnr:X}KYL{ct:Amid} | BP100L8A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 11 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKI{nnr:X}KYL{ct:Amid} | BP100L8A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 10 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKI{nnr:X}KYL{ct:Amid} | BP100L8A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 11 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKI{nnr:X}KYL{ct:Amid} | BP100L8A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 16 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKIL{nnr:X}YL{ct:Amid} | BP100K9A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 12 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKIL{nnr:X}YL{ct:Amid} | BP100K9A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKIL{nnr:X}YL{ct:Amid} | BP100K9A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 6 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKIL{nnr:X}YL{ct:Amid} | BP100K9A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 11 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKIL{nnr:X}YL{ct:Amid} | BP100K9A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 13 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKIL{nnr:X}YL{ct:Amid} | BP100K9A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 22 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKIL{nnr:X}YL{ct:Amid} | BP100K9A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 38 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKIL{nnr:X}YL{ct:Amid} | BP100K9A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 57 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILK{nnr:X}L{ct:Amid} | BP100Y10A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 4 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILK{nnr:X}L{ct:Amid} | BP100Y10A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 4 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILK{nnr:X}L{ct:Amid} | BP100Y10A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 5 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILK{nnr:X}L{ct:Amid} | BP100Y10A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 6 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILK{nnr:X}L{ct:Amid} | BP100Y10A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 12 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILK{nnr:X}L{ct:Amid} | BP100Y10A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 13 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILK{nnr:X}L{ct:Amid} | BP100Y10A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 23 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILK{nnr:X}L{ct:Amid} | BP100Y10A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 37 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKY{nnr:X}{ct:Amid} | BP100L11A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 1 % Hemolysis at 1.25 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKY{nnr:X}{ct:Amid} | BP100L11A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 4 % Hemolysis at 2.5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKY{nnr:X}{ct:Amid} | BP100L11A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 6 % Hemolysis at 5 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKY{nnr:X}{ct:Amid} | BP100L11A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 7 % Hemolysis at 10 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKY{nnr:X}{ct:Amid} | BP100L11A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 5 % Hemolysis at 20 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKY{nnr:X}{ct:Amid} | BP100L11A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 5 % Hemolysis at 40 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKY{nnr:X}{ct:Amid} | BP100L11A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 4 % Hemolysis at 80 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 26975251 | 2016 | KKLFKKILKY{nnr:X}{ct:Amid} | BP100L11A | Amidation | Free | Linear | L | X = Ala-d3(3,3,3-2H3-Ala) | 11 | Antibacterial | 6 % Hemolysis at 160 µM | Human | Bp100 Analogues | α-Helix | NA | ||
| 27046192 | 2016 | RWWRWWRRWWR | WR12 | Free | Free | Linear | L | None | 12 | Antibacterial | <10 % Hemolysis at 20 µM | Human | Cationic Antibiotic Peptides (Ecaps) | α-Helix | NA | ||
| 27046192 | 2016 | KWWKWWKKWWK | WK12 | Free | Free | Linear | L | None | 12 | Antibacterial | <10 % Hemolysis at 20 µM | Human | Cationic Antibiotic Peptides (Ecaps) | α-Helix | NA | ||
| 27129462 | 2016 | RGSALTHLP | RP9 | Free | Free | Linear | L | None | 9 | Antibacterial, Anticancer | 3.3 ± 0.5 % Hemolysis at 61.2 µM | Human | Crocodile Leukocyte Extract | α-Helix | NA | ||
| 27129462 | 2016 | RGSALTHLP | RP9 | Free | Free | Linear | L | None | 9 | Antibacterial, Anticancer | 5.7 ± 0.2 % Hemolysis at 122.4 µM | Human | Crocodile Leukocyte Extract | α-Helix | NA | ||
| 27251456 | 2016 | GRFRRLRKKTRKRLKKIGKVLKWIPPIVGSIPLGCG{ct:Amid} | PMAP-36 | Amidation | Free | Linear | L | None | 36 | Antibacterial, Antifungal | 5 % Hemolysis at 4 µM | Human | Cathelicidin-Related | α-Helix(50% TFE and 30 mM SDS) | NA | ||
| 27251456 | 2016 | RRLRKKTRKRLKKIGKVLKWI{ct:Amid} | RI21 | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antifungal | 5 % Hemolysis at 32 µM | Human | Pmap-36 Analogues | α-Helix(50% TFE and 30 mM SDS) | NA | ||
| 27251456 | 2016 | RKKTRKRLKKIGKVLKWI{ct:Amid} | RI18 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 5 % Hemolysis at 128 µM | Human | Pmap-36 Analogues | α-Helix(50% TFE and 30 mM SDS) | NA | ||
| 27251456 | 2016 | TRKRLKKIGKVLKWI{ct:Amid} | TI15 | Amidation | Free | Linear | L | None | 15 | Antibacterial, Antifungal | 5 % Hemolysis at >128 µM | Human | Pmap-36 Analogues | α-Helix(50% TFE and 30 mM SDS) | NA | ||
| 27251456 | 2016 | RLKKIGKVLKWI{ct:Amid} | RI12 | Amidation | Free | Linear | L | None | 12 | Antibacterial, Antifungal | 5 % Hemolysis at >128 µM | Human | Pmap-36 Analogues | α-Helix(50% TFE and 30 mM SDS) | NA | ||
| 27271216 | 2016 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antibacterial | 10 % Hemolysis at 0.78 µM | Human | Bee Venom | α-Helix | NA | ||
| 27271216 | 2016 | RIGVLLARLPKLFSLFKLMGKKV{ct:Amid} | RV-23 | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 6.25 µM | Human | Rana Draytonii | α-Helix | NA | ||
| 27271216 | 2016 | AIGSILGALAKGLPTLISWIKNR{ct:Amid} | AR-23 | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 3.12 µM | Human | Rana Tagoi | α-Helix | NA | ||
| 27271216 | 2016 | RIGSILGALAKGLPTLISWIKNR{ct:Amid} | A(A1R) | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 3.12 µM | Human | Ar-23 Analogues | α-Helix | NA | ||
| 27271216 | 2016 | AIGSILGRLAKGLPTLISWIKNR{ct:Amid} | A(A8R) | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 3.12 µM | Human | Ar-23 Analogues | α-Helix | NA | ||
| 27271216 | 2016 | AIGSILGALAKGLPTLKSWIKNR{ct:Amid} | A(I17K) | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 50 µM | Human | Ar-23 Analogues | α-Helix | NA | ||
| 27271216 | 2016 | AIGSILGALAKGLPTLRSWIKNR{ct:Amid} | A(I17R) | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 25 µM | Human | Ar-23 Analogues | α-Helix | NA | ||
| 27271216 | 2016 | RIGSILGRLAKGLPTLISWIKNR{ct:Amid} | A(A1R, A8R) | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 6.25 µM | Human | Ar-23 Analogues | α-Helix | NA | ||
| 27271216 | 2016 | RIGSILGALAKGLPTLKSWIKNR{ct:Amid} | A(A1R, I17K) | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 100 µM | Human | Ar-23 Analogues | α-Helix | NA | ||
| 27271216 | 2016 | AIGSILGRLAKGLPTLKSWIKNR{ct:Amid} | A(A8R, I17K) | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 100 µM | Human | Ar-23 Analogues | α-Helix | NA | ||
| 27271216 | 2016 | RIGSILGRLAKGLPTLKSWIKNR{ct:Amid} | A(A1R, A8R, I17K) | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 200 µM | Human | Ar-23 Analogues | α-Helix | NA | ||
| 27271216 | 2016 | RIGSILGRLAKGLPTLRSWIKNR{ct:Amid} | A(A1R, A8R, I17R) | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 100 µM | Human | Ar-23 Analogues | α-Helix | NA | ||
| 27331141 | 2016 | GFCWYVCVYRNGVRVCYRRCN | arenicin-3 | Free | Free | Linear | L | None | 21 | Antibacterial, Antifungal | 4.4 ± 1.1 % Hemolysis at 300 μg/ml | Human | Coelomocytes Of Marine Polychaeta Lugworm Arenicola Marina | β-Hairpin | NA | ||
| 27331141 | 2016 | KWCFRVCYRGICYRRCR{ct:Amid} | tachyplesin-1 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antifungal | 27.8 ± 3.9 % Hemolysis at 300 μg/ml | Human | Hemocyte Debris Of Tachypleus Tridentatus | β-Hairpin | NA | ||
| 27331141 | 2016 | RRWCFRVCYRGFCYRKCR{ct:Amid} | polyphemusin-1 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 29.6 ± 2.4 % Hemolysis at 300 μg/ml | Human | Hemocyte Debris Of Limulus Polyphemus | β-Hairpin | NA | ||
| 27331141 | 2016 | ZCRRLCYKQRCVTYCRGR{nt:Z= N- terminal pyroglutamic acid}{ct:Amid} | gomesin | Amidation | Z= N- terminal pyroglutamic acid | Linear | L | None | 18 | Antibacterial, Antifungal | 4.4 ± 0.1 % Hemolysis at 300 μg/ml | Human | Hemocytes Of The Spider Acanthoscurria Gomesiana | β-Hairpin | NA | ||
| 27331141 | 2016 | RGGRLCYCRRRFCVCVGR{ct:Amid} | protegrin-1 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 64.8 ± 3.5 % Hemolysis at 300 μg/ml | Human | Porcine Neutrophils | β-Hairpin | NA | ||
| 27331141 | 2016 | GSKKPVPIIYCNRRTGKCQRM{ct:Amid} | thanatin | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antifungal | 1.3 ± 0.4 % Hemolysis at 300 μg/ml | Human | Spined Soldier Bug, Podisus Maculiventris | β-Hairpin | NA | ||
| 26883426 | 2016 | QLLGGKVSFFQSVCLLGYCIFPINIEAIVIAFFGSYLPFVVKLIPVFICFAWSAYSSVGFMASLVPPHKKKLAVYPVFLFYLFLSWFSLIV{ct:carboxylic acid} | cPcAMP1 | carboxylic acid | Free | Linear | L | None | 91 | Antimicrobial | Little hemolysis % at 12.5 µg/mL | Human | Ciliata Paramecium Caudatum | α-Helix | NA | ||
| 26883426 | 2016 | QLLGGKVSFFQSVCLLGYCIFPINIEAIVIAFFGSYLPFVVKLIPVFICFAWSAYSSVGFMASLVPPHKKKLAVYPVFLFYLFLSWFSLIV{ct:carboxylic acid} | cPcAMP1 | carboxylic acid | Free | Linear | L | None | 91 | Antimicrobial | Little hemolysis % at 25 µg/mL | Human | Ciliata Paramecium Caudatum | α-Helix | NA | ||
| 26883426 | 2016 | QLLGGKVSFFQSVCLLGYCIFPINIEAIVIAFFGSYLPFVVKLIPVFICFAWSAYSSVGFMASLVPPHKKKLAVYPVFLFYLFLSWFSLIV{ct:carboxylic acid} | cPcAMP1 | carboxylic acid | Free | Linear | L | None | 91 | Antimicrobial | Little hemolysis % at 50 µg/mL | Human | Ciliata Paramecium Caudatum | α-Helix | NA | ||
| 26883426 | 2016 | QLLGGKVSFFQSVCLLGYCIFPINIEAIVIAFFGSYLPFVVKLIPVFICFAWSAYSSVGFMASLVPPHKKKLAVYPVFLFYLFLSWFSLIV{ct:carboxylic acid} | cPcAMP1 | carboxylic acid | Free | Linear | L | None | 91 | Antimicrobial | Little hemolysis % at 100 µg/mL | Human | Ciliata Paramecium Caudatum | α-Helix | NA | ||
| 26883426 | 2016 | PPHKKKLAVYPVFLFYLFLSWFSLIV{ct:Amid} | cPcAMP1/26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | Little hemolysis % at 12.5 µg/mL | Human | Ciliata Paramecium Caudatum | α-Helix | NA | ||
| 26883426 | 2016 | PPHKKKLAVYPVFLFYLFLSWFSLIV{ct:Amid} | cPcAMP1/26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | Little hemolysis % at 25 µg/mL | Human | Ciliata Paramecium Caudatum | α-Helix | NA | ||
| 26883426 | 2016 | PPHKKKLAVYPVFLFYLFLSWFSLIV{ct:Amid} | cPcAMP1/26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | Little hemolysis % at 50 µg/mL | Human | Ciliata Paramecium Caudatum | α-Helix | NA | ||
| 26883426 | 2016 | PPHKKKLAVYPVFLFYLFLSWFSLIV{ct:Amid} | cPcAMP1/26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | Little hemolysis % at 100 µg/mL | Human | Ciliata Paramecium Caudatum | α-Helix | NA | ||
| 27351824 | 2016 | LLPIVGNLLKSLL{ct:Amid} | TB | Amidation | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 0 % Hemolysis at 20-160 µg/mL | Human | Frog Rana Temporaria Skin | α-Helix | NA | ||
| 27351824 | 2016 | LLPIVGNLLKSLL{ct:Amid} | TB | Amidation | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 45 % Hemolysis at 320 µg/mL | Human | Frog Rana Temporaria Skin | α-Helix | NA | ||
| 27165480 | 2016 | PMPVSQECFETLRGHERILSILRHQNLLKELQDLALQGAKERAHQQ{nt:Amid}{ct:carboxylic acid} | CGA-N46 | carboxylic acid | Amidation | Linear | L | None | 46 | Antifungal | 5 % Hemolysis at 0.74 mmol/L | Human | Human Chromogranin A | α-Helix | NA | ||
| 27165480 | 2016 | ERILSILRHQNLLKE{nt:Amid}{ct:carboxylic acid} | CGA-N15 | carboxylic acid | Amidation | Linear | L | None | 15 | Antifungal | 5 % Hemolysis at 0.031 mmol/L | Human | Derivative Of Cga-N46 | α-Helix | NA | ||
| 27165480 | 2016 | LQDLALQGAKERAHQQ{nt:Amid}{ct:carboxylic acid} | CGA-N16 | carboxylic acid | Amidation | Linear | L | None | 16 | Antifungal | 5 % Hemolysis at 0.056 mmol/L | Human | Derivative Of Cga-N46 | α-Helix | NA | ||
| 27165480 | 2016 | ALQGAKERAHQQ{nt:Amid}{ct:carboxylic acid} | CGA-N12 | carboxylic acid | Amidation | Linear | L | None | 12 | Antifungal | 5 % Hemolysis at 0.39 mmol/L | Human | Derivative Of Cga-N46 | α-Helix | NA | ||
| 27165480 | 2016 | GAKERAHQ{nt:Amid}{ct:carboxylic acid} | CGA-N8 | carboxylic acid | Amidation | Linear | L | None | 8 | Antifungal | 5 % Hemolysis at 0.27 mmol/L | Human | Derivative Of Cga-N46 | α-Helix | NA | ||
| 27598770 | 2016 | MQFITDLIKKAVDFFKGLFGNK | WRK | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 2.78 µM | Human | Staphylococci | α-Helix | NA | ||
| 27598770 | 2016 | MQFITDLIKKAVDFFKGLFDNK | WarnG20D | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 12.36 µM | Human | Warnericin Rk Derivative | α-Helix | NA | ||
| 27598770 | 2016 | MQFITDLIKKAVDVFKGLFGNK | WarnF14V | Free | Free | Linear | L | None | 22 | Anti-Legionella | 10 % Hemolysis at 12.5 µM | Human | Warnericin Rk Derivative | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLLKKLLKLAG | LK | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 5 µM | Human | Cell Penetrating Peptides (Cpps) | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLGKKLLKLAG | L8G | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 40 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLSKKLLKLAG | L8S | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 80 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLPKKLLKLAG | L8P | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 1280 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLNKKLLKLAG | L8N | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 640 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLQKKLLKLAG | L7Q | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 640 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLDKKLLKLAG | L8D | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at >1280 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLEKKLLKLAG | L8E | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at >1280 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLKKKLLKLAG | L8K | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 640 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLRKKLLKLAG | L8R | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 640 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27442521 | 2016 | LKKLLKLHKKLLKLAG | L8H | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 160 µM | Human | Lk Mutant Peptide | α-Helix | NA | ||
| 27423268 | 2016 | INLKALAALAKKIL{ct:Amid} | [I5 , R8 ] mastoparan | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at >200 µM | Human | Mp Derived | α-Helix | NA | ||
| 27423268 | 2016 | INLKILARLAKKIL{ct:Amid} | mastoparan L | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 40 % Hemolysis at 10 µM | Human | Wasp Venom | α-Helix | NA | ||
| 27862650 | 2016 | GLLKRIKTLL{ct:Amid} | 1 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | <50 % Hemolysis at 500 µg/mL | Human | Anoplin(Wasp, Anoplius Samariensis) | α-Helix | NA | ||
| 27862650 | 2016 | GLLKRIKTLL{nt:C8-octanoic}{ct:Amid} | 2 | Amidation | C8-octanoic | Linear | L | C8 = Octanoic Acid | 10 | Antimicrobial | <50 % Hemolysis at 500 µg/mL | Human | Analogs Of Anoplin | α-Helix | NA | ||
| 27862650 | 2016 | GLLKRIKTLL{nt:C10- decanoic}{ct:Amid} | 3 | Amidation | C10- decanoic | Linear | L | C10 = decanoic | 10 | Antimicrobial | <50 % Hemolysis at 500 µg/mL | Human | Analogs Of Anoplin | α-Helix | NA | ||
| 27862650 | 2016 | GLLKFIKKLL{ct:Amid} | 4 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | <50 % Hemolysis at 500 µg/mL | Human | Analogs Of Anoplin | α-Helix | NA | ||
| 27862650 | 2016 | KLLKFIKKLL{ct:Amid} | 5 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | <50 % Hemolysis at 500 µg/mL | Human | Analogs Of Anoplin | α-Helix | NA | ||
| 27862650 | 2016 | RLLKFIKKLL{ct:Amid} | 6 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | <50 % Hemolysis at 500 µg/mL | Human | Analogs Of Anoplin | α-Helix | NA | ||
| 27862650 | 2016 | GLLKFIKKLL{nt:C8-octanoic}{ct:Amid} | 7 | Amidation | C8-octanoic | Linear | L | C8 = Octanoic Acid | 10 | Antimicrobial | <50 % Hemolysis at 500 µg/mL | Human | Analogs Of Anoplin | α-Helix | NA | ||
| 27862650 | 2016 | GLLKFIKKLL{nt:C10- decanoic}{ct:Amid} | 8 | Amidation | C10- decanoic | Linear | L | C10 = decanoic | 10 | Antimicrobial | <50 % Hemolysis at 500 µg/mL | Human | Analogs Of Anoplin | α-Helix | NA | ||
| 27862650 | 2016 | GLLKFIKKLL{nt:C12-dodecanoic}{ct:Amid} | 9 | Amidation | C12-dodecanoic | Linear | L | C12 = dodecanoic | 10 | Antimicrobial | <50 % Hemolysis at 500 µg/mL | Human | Analogs Of Anoplin | α-Helix | NA | ||
| 27439393 | 2016 | WMQKVIDRFGG | T-1 | Free | Free | Linear | L | None | 11 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | C-Terminal Sequences Of Porcine Thrombin | α-Helix | NA | ||
| 27439393 | 2016 | KKWMQKVIDRFGG | T-2 | Free | Free | Linear | L | None | 13 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | C-Terminal Sequences Of Porcine Thrombin | α-Helix | NA | ||
| 27439393 | 2016 | RLKKWMQKVIDRFGG | T-3 | Free | Free | Linear | L | None | 15 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | C-Terminal Sequences Of Porcine Thrombin | α-Helix | NA | ||
| 27439393 | 2016 | VFRLKKWMQKVIDRFGG | T-4 | Free | Free | Linear | L | None | 17 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | C-Terminal Sequences Of Porcine Thrombin | α-Helix | NA | ||
| 27439393 | 2016 | THVFRLKKWMQKVIDRFGG | T-5 | Free | Free | Linear | L | None | 19 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | C-Terminal Sequences Of Porcine Thrombin | α-Helix | NA | ||
| 27439393 | 2016 | FYTHVFRLKKWMQKVIDRFGG | T-6 | Free | Free | Linear | L | None | 21 | Antimicrobial | 5 % Hemolysis at >128 µM | Human | C-Terminal Sequences Of Porcine Thrombin | α-Helix | NA | ||
| 27439393 | 2016 | YGFYTHVFRLKKWMQKVIDRFGG | T-7 | Free | Free | Linear | L | None | 23 | Antimicrobial | 5 % Hemolysis at 34.5 µM | Human | C-Terminal Sequences Of Porcine Thrombin | α-Helix | NA | ||
| 27439393 | 2016 | GKYGFYTHVFRLKKWMQKVIDRFGG | T-8 | Free | Free | Linear | L | None | 25 | Antimicrobial | 5 % Hemolysis at 39.4 µM | Human | C-Terminal Sequences Of Porcine Thrombin | α-Helix | NA | ||
| 27809507 | 2016 | PSPCGESCVFIPCISALIGCSCKNKVCYR | parigidin-br3 | Free | Free | Linear | L | None | 29 | cytotoxic, Anticancer | ~13-20 % Hemolysis at 21-42 µM | Human | Plant Palicourea Rigida | α-Helix/β-Sheet | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 1 µM in 1hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 1 µM in 2hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 5 µM in 1hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 5 µM in 2hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 10 µM in 1hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 10 µM in 2hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 20 µM in 1hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 20 µM in 2hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 40 µM in 1hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 40 µM in 2hr | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 4.96 % Hemolysis at 60 µM | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 6.58 % Hemolysis at 60 µM | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 22.31 % Hemolysis at 80 µM | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 22.88 % Hemolysis at 80 µM | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 37.77 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | NA | ||
| 28096686 | 2016 | FLFSLIPSAIGGLISAFK | Pepcon | Free | Free | Linear | L | None | 18 | Antimicrobial | 39.27 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | NA | ||
| 27917162 | 2016 | FFGTLFKLGSKLIPGVMKLFSKKKER | ToAP2 | Free | Free | Linear | L | None | 26 | Antifungal | >50 % Hemolysis at 25 µM | Human | Scorpion Tityus Obscurus | α-Helix | NA | ||
| 27917162 | 2016 | ILSAIWSGIKSLF{ct:Amid} | NDBP-5.7 | Amidation | Free | Linear | L | None | 13 | Antifungal | >50 % Hemolysis at 50 µM | Human | Scorpion Tityus Obscurus | α-Helix | NA | ||
| 26952110 | 2016 | GILGKLWEGVKSIF{ct:Amid} | Hp1404 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <20 % Hemolysis at 100 μg/mL | Human | Scorpion Heterometrus Petersii | α-Helical | NA | ||
| 26952110 | 2016 | GILGKLWKGVKSIF{ct:Amid} | K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <20 % Hemolysis at 100 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 26952110 | 2016 | LILGKLWKGVKSIF{ct:Amid} | L1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 0 % Hemolysis at 100 μg/mL | Human | Hp1404 Derivative | α-Helical | Non-hemolytic | ||
| 26952110 | 2016 | SILGKLWKGVKSIF{ct:Amid} | S1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 0 % Hemolysis at 100 μg/mL | Human | Hp1404 Derivative | α-Helical | Non-hemolytic | ||
| 26952110 | 2016 | FILGKLWKGVKSIF{ct:Amid} | F1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <5 % Hemolysis at 100 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 26952110 | 2016 | KILGKLWKGVKSIF{ct:Amid} | K1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 0 % Hemolysis at 100 μg/mL | Human | Hp1404 Derivative | α-Helical | Non-hemolytic | ||
| 26952110 | 2016 | GILGKLWEGVKSIF{ct:Amid} | Hp1404 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <50 % Hemolysis at 200 μg/mL | Human | Scorpion Heterometrus Petersii | α-Helical | NA | ||
| 26952110 | 2016 | GILGKLWKGVKSIF{ct:Amid} | K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <50 % Hemolysis at 200 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 26952110 | 2016 | LILGKLWKGVKSIF{ct:Amid} | L1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 0 % Hemolysis at 200 μg/mL | Human | Hp1404 Derivative | α-Helical | Non-hemolytic | ||
| 26952110 | 2016 | SILGKLWKGVKSIF{ct:Amid} | S1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <20 % Hemolysis at 200 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 26952110 | 2016 | #ERROR! | F1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <40 % Hemolysis at 200 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 26952110 | 2016 | KILGKLWKGVKSIF{ct:Amid} | K1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 0 % Hemolysis at 200 μg/mL | Human | Hp1404 Derivative | α-Helical | Non-hemolytic | ||
| 26952110 | 2016 | GILGKLWEGVKSIF{ct:Amid} | Hp1404 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <100 % Hemolysis at 400 μg/mL | Human | Scorpion Heterometrus Petersii | α-Helical | NA | ||
| 26952110 | 2016 | GILGKLWKGVKSIF{ct:Amid} | K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <80 % Hemolysis at 400 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 26952110 | 2016 | LILGKLWKGVKSIF{ct:Amid} | L1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <20 % Hemolysis at 400 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 26952110 | 2016 | SILGKLWKGVKSIF{ct:Amid} | S1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 50 % Hemolysis at 400 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 26952110 | 2016 | FILGKLWKGVKSIF{ct:Amid} | F1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <80 % Hemolysis at 400 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 26952110 | 2016 | KILGKLWKGVKSIF{ct:Amid} | K1K8 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 11.5 % Hemolysis at 400 μg/mL | Human | Hp1404 Derivative | α-Helical | NA | ||
| 27104500 | 2016 | INWKKIKSIIKAAMN{ct:Amid} | mastoparan V1 (MP-V1) | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Venom Of Social Wasp Vespula Vulgaris | α-Helical | Non-hemolytic | ||
| 27104500 | 2016 | INWKKIKSIIKAAMN{ct:Amid} | mastoparan V1 (MP-V1) | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 6.6 % Hemolysis at 50 µM | Human | Venom Of Social Wasp Vespula Vulgaris | α-Helical | NA | ||
| 27104500 | 2016 | INWKKIKSIIKAAMN{ct:Amid} | mastoparan V1 (MP-V1) | Amidation | Free | Linear | L | None | 15 | Antimicrobial | ~20 % Hemolysis at 100 µM | Human | Venom Of Social Wasp Vespula Vulgaris | α-Helical | NA | ||
| 27104500 | 2016 | INLKALAALAKKIL{ct:Amid} | mastoparan L (MP-L) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Vespula Lewisii | α-Helical | Non-hemolytic | ||
| 27104500 | 2016 | INLKALAALAKKIL{ct:Amid} | mastoparan L (MP-L) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Vespula Lewisii | α-Helical | Non-hemolytic | ||
| 27104500 | 2016 | INWKGIAAMAKKLL{ct:Amid} | mastoparan X(V) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Vespa Simillina Xanthoptera | α-Helical | Non-hemolytic | ||
| 27104500 | 2016 | INWKGIAAMAKKLL{ct:Amid} | mastoparan X(V) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Vespa Simillina Xanthoptera | α-Helical | Non-hemolytic | ||
| 27104500 | 2016 | INWKGIAAMAKKLL{ct:Amid} | mastoparan X(V) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | <5 % Hemolysis at 100 µM | Human | Vespa Simillina Xanthoptera | α-Helical | NA | ||
| 27104500 | 2016 | LKLKSIVSWAKKVL{ct:Amid} | mastoparan B (MP-B) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Vespa Basalis | α-Helical | Non-hemolytic | ||
| 27104500 | 2016 | LKLKSIVSWAKKVL{ct:Amid} | mastoparan B (MP-B) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Vespa Basalis | α-Helical | Non-hemolytic | ||
| 27104500 | 2016 | LKLKSIVSWAKKVL{ct:Amid} | mastoparan B (MP-B) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Vespa Basalis | α-Helical | Non-hemolytic | ||
| 26450121 | 2016 | GIHDILKYGKPS | Myxinidin | Free | Free | Linear | L | None | 12 | Anti‑biofilm | 0 % Hemolysis at 50-400 µM | Human | Epidermal Mucus Of The Hagfish | α-Helical | Non-hemolytic | ||
| 26450121 | 2016 | GIHHILKYGKPS | Myxinidin 1 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | 0 % Hemolysis at 50-400 µM | Human | Epidermal Mucus Of The Hagfish | α-Helical | Non-hemolytic | ||
| 26450121 | 2016 | KIKWILKYWKWS | Myxinidin 2 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | 10 % Hemolysis at 50 µM | Human | Myxinidin Analogs | α-Helical | NA | ||
| 26450121 | 2016 | KIKWILKYWKWS | Myxinidin 2 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | <20 % Hemolysis at 100 µM | Human | Myxinidin Analogs | α-Helical | NA | ||
| 26450121 | 2016 | KIKWILKYWKWS | Myxinidin 2 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | 30 % Hemolysis at 200 µM | Human | Myxinidin Analogs | α-Helical | NA | ||
| 26450121 | 2016 | KIKWILKYWKWS | Myxinidin 2 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | 50 % Hemolysis at 400 µM | Human | Myxinidin Analogs | α-Helical | NA | ||
| 26450121 | 2016 | RIRWILRYWRWS | Myxinidin 3 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | 12 % Hemolysis at 25 µM | Human | Myxinidin Analogs | α-Helical | NA | ||
| 26450121 | 2016 | RIRWILRYWRWS | Myxinidin 4 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | 30 % Hemolysis at 50 µM | Human | Myxinidin Analogs | α-Helical | NA | ||
| 26450121 | 2016 | RIRWILRYWRWS | Myxinidin 5 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | <50 % Hemolysis at 100 µM | Human | Myxinidin Analogs | α-Helical | NA | ||
| 26450121 | 2016 | RIRWILRYWRWS | Myxinidin 6 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | 60 % Hemolysis at 200 µM | Human | Myxinidin Analogs | α-Helical | NA | ||
| 26450121 | 2016 | RIRWILRYWRWS | Myxinidin 7 | Free | Free | Linear | L | None | 12 | Anti‑biofilm | ~60 % Hemolysis at 400 µM | Human | Myxinidin Analogs | α-Helical | NA | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 10 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 30 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 150 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 225 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 26860588 | 2016 | PFWRIRIRR{ct:Amid} | PFR | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 300 µM | Human | Derivatives Of Lactoferrin | α-Helical | Non-hemolytic | ||
| 27067326 | 2016 | FFHHIFRGIVHVGKTIHRLVTG{ct:Amid} | Piscidin-1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 15 µM | Human | Fish | α-Helical | NA | ||
| 27067326 | 2016 | FFHHAFRGIVHVGKTIHRLVTG{ct:Amid} | I5Apiscidin-1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 500 µM | Human | Piscidin-1 Designed Analog | α-Helical | NA | ||
| 27067326 | 2016 | FFHHIFRGAVHVGKTIHRLVTG{ct:Amid} | I9Apiscidin-1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | Piscidin-1 Designed Analog | α-Helical | NA | ||
| 27067326 | 2016 | FFHHIFRGIVHVGKTAHRLVTG{ct:Amid} | I16Apiscidin-1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 500 µM | Human | Piscidin-1 Designed Analog | α-Helical | NA | ||
| 27067326 | 2016 | FFHHVFRGIVHVGKTIHRLVTG{ct:Amid} | I5Vpiscidin-1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 40 µM | Human | Piscidin-1 Designed Analog | α-Helical | NA | ||
| 27067326 | 2016 | FFHHIFRGVVHVGKTIHRLVTG{ct:Amid} | I9Vpiscidin-1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 35 µM | Human | Piscidin-1 Designed Analog | α-Helical | NA | ||
| 27067326 | 2016 | FFHHIFRGIVHVGKTVHRLVTG{ct:Amid} | I16Vpiscidin-1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 40 µM | Human | Piscidin-1 Designed Analog | α-Helical | NA | ||
| 27067326 | 2016 | FFHHFARGIVHVGKTIHRLVTG{ct:Amid} | I5F,F6Apiscidin-1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | Piscidin-1 Designed Analog | α-Helical | NA | ||
| 27067326 | 2016 | FFHHIFRGIVHIGKTIHRLVTG{ct:Amid} | V12Ipiscidin-1 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 7 µM | Human | Piscidin-1 Designed Analog | α-Helical | NA | ||
| 27936728 | 2016 | CKRWWKWIRW{ct:Amid} | CysHHC10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 50 % Hemolysis at >1000 μg/ml | Human | Synthetic | NA | NA | ||
| 27698732 | 2016 | LVQRGRFGRFLRKIRRFRPKVTITIQGSARF | fowlicidin-2 | Free | Free | Linear | L | None | 31 | Antimicrobial | 50 % Hemolysis at 128-256 μg/ml | Human | Pichia Pastoris X-33 | α-Helical | NA | ||
| 27900727 | 2016 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MPI | Amidation | Free | Linear | L | None | 15 | Antimicrobial | <0.7 % Hemolysis at 256 µM | Human | Social Wasp Polybia Paulista | α-Helical | Non-hemolytic | ||
| 27900727 | 2016 | IDWKKL{d}L{d}DAAKQIL{d}{ct:Amid} | D-lys-MPI | Amidation | Free | Linear | Mix | l = D-Lys lowercase letters correspond to D-amino acids | 15 | Antimicrobial | 0 % Hemolysis at 256 µM | Human | Polybia-Mpi Analogues | α-Helical | Non-hemolytic | ||
| 27900727 | 2016 | I{d}D{d}W{d}K{d}K{d}L{d}L{d}D{d}A{d}A{d}K{d}Q{d}I{d}L{d}{ct:Amid} | D-MPI | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 15 | Antimicrobial | 0.4 % Hemolysis at 256 µM | Human | Polybia-Mpi Analogues | α-Helical | Non-hemolytic | ||
| 26549611 | 2017 | KWCFRVCYRGICYRRCR | THI | Free | Free | Linear | L | None | 17 | Antimicrobial | 2 % Hemolysis at 12 µM | Human | Horseshoe Crab Tachypleus Tridentatus | β-Hairpin | NA | ||
| 26549611 | 2017 | KWCFRSCYRGICYRRCR | V6S | Free | Free | Linear | L | None | 17 | Antimicrobial | 2 % Hemolysis at 280 µM | Human | Thi Analog | β-Hairpin | NA | ||
| 26549611 | 2017 | KWCFRRCYRGICYRRCR | V6R | Free | Free | Linear | L | None | 17 | Antimicrobial | 2 % Hemolysis at 200 µM | Human | Thi Analog | β-Hairpin | NA | ||
| 26549611 | 2017 | KWCFRVCSRGICYRRCR | Y8S | Free | Free | Linear | L | None | 17 | Antimicrobial | 2 % Hemolysis at 310 µM | Human | Thi Analog | β-Hairpin | NA | ||
| 26549611 | 2017 | KWCFRVCRRGICYRRCR | Y8R | Free | Free | Linear | L | None | 17 | Antimicrobial | 2 % Hemolysis at 195 µM | Human | Thi Analog | β-Hairpin | NA | ||
| 26549611 | 2017 | KWCFRVCYRGSCYRRCR | I11S | Free | Free | Linear | L | None | 17 | Antimicrobial | 2 % Hemolysis at 190 µM | Human | Thi Analog | β-Hairpin | NA | ||
| 26549611 | 2017 | KWCFRVCYRGRCYRRCR | I11R | Free | Free | Linear | L | None | 17 | Antimicrobial | 2 % Hemolysis at 180 µM | Human | Thi Analog | β-Hairpin | NA | ||
| 27487034 | 2017 | RRGRRGP{nnr:O}GP{nnr:O}GP{nnr:O}GP{nnr:O}GP{nnr:O}GPCCY{ct:Amid} | RR4 | Amidation | Free | Linear | L | O = 4-hydroxy-L-proline | 25 | Antimicrobial | 0 % Hemolysis at 0.3-30 µM | Human | R3 Derivatives | Triple-Helical | Non-hemolytic | ||
| 27487034 | 2017 | RRGRRGP{nnr:O}GP{nnr:O}GP{nnr:O}GPCCY{ct:Amid} | RR4SS | Amidation | Free | Linear | L | O = 4-hydroxy-L-proline | 19 | Antimicrobial | 0 % Hemolysis at 0.3-30 µM | Human | R3 Derivatives | Triple-Helical | Non-hemolytic | ||
| 27487329 | 2017 | GLPVCGETCVGGTCNTPGCTCSWPVCTRN{cyc:N-C} | kB1 | Free | Free | Cyclic | L | None | 29 | cytotoxic | <60 % Hemolysis at 50 µM | Human | Möbius Family | Loop | NA | ||
| 27487329 | 2017 | GLPVCGETCVGGTCPGACTCSWPVCTRN{cyc:N-C} | kL3 | Free | Free | Cyclic | L | None | 28 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GLPVCGETCVGGTCNTPGCICSWPVCTRN{cyc:N-C} | kL4 | Free | Free | Cyclic | L | None | 29 | cytotoxic | <60 % Hemolysis at 50 µM | Human | Chimeric Cyclotides | Loop | NA | ||
| 27487329 | 2017 | GLPVCGETCVGGTCNTPGCTCRGNGYCTRN{cyc:N-C} | kL5 | Free | Free | Cyclic | L | None | 30 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCGETCRRDSDCPGACICRGNGYCGSGSD{cyc:N-C} | ML1 | Free | Free | Cyclic | L | None | 31 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCVGGTCPGACICRGNGYCGSGSD{cyc:N-C} | ML2 | Free | Free | Cyclic | L | None | 33 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCRRDSDCNTPGCICRGNGYCGSGSD{cyc:N-C} | ML3 | Free | Free | Cyclic | L | None | 35 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCRRDSDCPGACTCRGNGYCGSGSD{cyc:N-C} | ML4 | Free | Free | Cyclic | L | None | 34 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Chimeric Cyclotides | Loop | Non-hemolytic | ||
| 27487329 | 2017 | GGVCPKILKKCRRDSDCPGACICRGNGYCGSGSD{cyc:N-C} | MCoTI-II | Free | Free | Cyclic | L | None | 34 | cytotoxic | 0 % Hemolysis at 10-50 µM | Human | Momordica Cochinchinensis | Loop | Non-hemolytic | ||
| 28025839 | 2017 | IKQVKKLFKK{ct:Amid} | A2 | Amidation | Free | Linear | L | None | 10 | Antifungal | 3.8 % Hemolysis at 6.25 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{ct:Amid} | A2 | Amidation | Free | Linear | L | None | 10 | Antifungal | 4.4 % Hemolysis at 12.5 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{ct:Amid} | A2 | Amidation | Free | Linear | L | None | 10 | Antifungal | 5 % Hemolysis at 25 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{ct:Amid} | A2 | Amidation | Free | Linear | L | None | 10 | Antifungal | 6.9 % Hemolysis at 50 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{ct:Amid} | A2 | Amidation | Free | Linear | L | None | 10 | Antifungal | 8.7 % Hemolysis at 100 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{ct:Amid} | A2 | Amidation | Free | Linear | L | None | 10 | Antifungal | 12.2 % Hemolysis at 200 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{ct:Amid} | A2 | Amidation | Free | Linear | L | None | 10 | Antifungal | 20.9 % Hemolysis at 400 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Octanoicacid}{ct:Amid} | C8:0-A2 | Amidation | Octanoicacid | Linear | L | None | 10 | Antifungal | 6.3 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Octanoicacid}{ct:Amid} | C8:0-A2 | Amidation | Octanoicacid | Linear | L | None | 10 | Antifungal | 9.2 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Octanoicacid}{ct:Amid} | C8:0-A2 | Amidation | Octanoicacid | Linear | L | None | 10 | Antifungal | 10.8 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Octanoicacid}{ct:Amid} | C8:0-A2 | Amidation | Octanoicacid | Linear | L | None | 10 | Antifungal | 11.5 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Octanoicacid}{ct:Amid} | C8:0-A2 | Amidation | Octanoicacid | Linear | L | None | 10 | Antifungal | 23.6 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Octanoicacid}{ct:Amid} | C8:0-A2 | Amidation | Octanoicacid | Linear | L | None | 10 | Antifungal | 61.8 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Octanoicacid}{ct:Amid} | C8:0-A2 | Amidation | Octanoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:nDecanoicacid}{ct:Amid} | C10:0-A2 | Amidation | nDecanoicacid | Linear | L | None | 10 | Antifungal | 9.2 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:nDecanoicacid}{ct:Amid} | C10:0-A2 | Amidation | nDecanoicacid | Linear | L | None | 10 | Antifungal | 9 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:nDecanoicacid}{ct:Amid} | C10:0-A2 | Amidation | nDecanoicacid | Linear | L | None | 10 | Antifungal | 12.25 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:nDecanoicacid}{ct:Amid} | C10:0-A2 | Amidation | nDecanoicacid | Linear | L | None | 10 | Antifungal | 19.7 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:nDecanoicacid}{ct:Amid} | C10:0-A2 | Amidation | nDecanoicacid | Linear | L | None | 10 | Antifungal | 28.2 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:nDecanoicacid}{ct:Amid} | C10:0-A2 | Amidation | nDecanoicacid | Linear | L | None | 10 | Antifungal | 52.8 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:nDecanoicacid}{ct:Amid} | C10:0-A2 | Amidation | nDecanoicacid | Linear | L | None | 10 | Antifungal | 66.6 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:4Methoxydecanoicacid}{ct:Amid} | 4-OMe-C10:0-A2 | Amidation | 4Methoxydecanoicacid | Linear | L | None | 10 | Antifungal | 14.1 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:4Methoxydecanoicacid}{ct:Amid} | 4-OMe-C10:0-A2 | Amidation | 4Methoxydecanoicacid | Linear | L | None | 10 | Antifungal | 28.4 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:4Methoxydecanoicacid}{ct:Amid} | 4-OMe-C10:0-A2 | Amidation | 4Methoxydecanoicacid | Linear | L | None | 10 | Antifungal | 47.5 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:4Methoxydecanoicacid}{ct:Amid} | 4-OMe-C10:0-A2 | Amidation | 4Methoxydecanoicacid | Linear | L | None | 10 | Antifungal | 68.9 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:4Methoxydecanoicacid}{ct:Amid} | 4-OMe-C10:0-A2 | Amidation | 4Methoxydecanoicacid | Linear | L | None | 10 | Antifungal | 84.7 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:4Methoxydecanoicacid}{ct:Amid} | 4-OMe-C10:0-A2 | Amidation | 4Methoxydecanoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:4Methoxydecanoicacid}{ct:Amid} | 4-OMe-C10:0-A2 | Amidation | 4Methoxydecanoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Undec10enoicacid}{ct:Amid} | C11:1-A2 | Amidation | Undec10enoicacid | Linear | L | None | 10 | Antifungal | 28.1 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Undec10enoicacid}{ct:Amid} | C11:1-A2 | Amidation | Undec10enoicacid | Linear | L | None | 10 | Antifungal | 40.7 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Undec10enoicacid}{ct:Amid} | C11:1-A2 | Amidation | Undec10enoicacid | Linear | L | None | 10 | Antifungal | 61.1 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Undec10enoicacid}{ct:Amid} | C11:1-A2 | Amidation | Undec10enoicacid | Linear | L | None | 10 | Antifungal | 82.7 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Undec10enoicacid}{ct:Amid} | C11:1-A2 | Amidation | Undec10enoicacid | Linear | L | None | 10 | Antifungal | 96.3 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Undec10enoicacid}{ct:Amid} | C11:1-A2 | Amidation | Undec10enoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Undec10enoicacid}{ct:Amid} | C11:1-A2 | Amidation | Undec10enoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Dodecanoicacid}{ct:Amid} | C12:0-A2 | Amidation | Dodecanoicacid | Linear | L | None | 10 | Antifungal | 42.1 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Dodecanoicacid}{ct:Amid} | C12:0-A2 | Amidation | Dodecanoicacid | Linear | L | None | 10 | Antifungal | 74.4 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Dodecanoicacid}{ct:Amid} | C12:0-A2 | Amidation | Dodecanoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Dodecanoicacid}{ct:Amid} | C12:0-A2 | Amidation | Dodecanoicacid | Linear | L | None | 10 | Antifungal | 96.7 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Dodecanoicacid}{ct:Amid} | C12:0-A2 | Amidation | Dodecanoicacid | Linear | L | None | 10 | Antifungal | 97.9 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Dodecanoicacid}{ct:Amid} | C12:0-A2 | Amidation | Dodecanoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Dodecanoicacid}{ct:Amid} | C12:0-A2 | Amidation | Dodecanoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Tetradecanoicacid}{ct:Amid} | C14:0-A2 | Amidation | Tetradecanoicacid | Linear | L | None | 10 | Antifungal | 6.2 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Tetradecanoicacid}{ct:Amid} | C14:0-A2 | Amidation | Tetradecanoicacid | Linear | L | None | 10 | Antifungal | 7 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Tetradecanoicacid}{ct:Amid} | C14:0-A2 | Amidation | Tetradecanoicacid | Linear | L | None | 10 | Antifungal | 8.2 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Tetradecanoicacid}{ct:Amid} | C14:0-A2 | Amidation | Tetradecanoicacid | Linear | L | None | 10 | Antifungal | 12.3 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Tetradecanoicacid}{ct:Amid} | C14:0-A2 | Amidation | Tetradecanoicacid | Linear | L | None | 10 | Antifungal | 16.4 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Tetradecanoicacid}{ct:Amid} | C14:0-A2 | Amidation | Tetradecanoicacid | Linear | L | None | 10 | Antifungal | 24.7 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Tetradecanoicacid}{ct:Amid} | C14:0-A2 | Amidation | Tetradecanoicacid | Linear | L | None | 10 | Antifungal | 40.9 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Hexadecanoicacid}{ct:Amid} | C16:0-A2 | Amidation | Hexadecanoicacid | Linear | L | None | 10 | Antifungal | 9.1 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Hexadecanoicacid}{ct:Amid} | C16:0-A2 | Amidation | Hexadecanoicacid | Linear | L | None | 10 | Antifungal | 9.8 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Hexadecanoicacid}{ct:Amid} | C16:0-A2 | Amidation | Hexadecanoicacid | Linear | L | None | 10 | Antifungal | 8.4 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Hexadecanoicacid}{ct:Amid} | C16:0-A2 | Amidation | Hexadecanoicacid | Linear | L | None | 10 | Antifungal | 10.5 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Hexadecanoicacid}{ct:Amid} | C16:0-A2 | Amidation | Hexadecanoicacid | Linear | L | None | 10 | Antifungal | 17.5 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Hexadecanoicacid}{ct:Amid} | C16:0-A2 | Amidation | Hexadecanoicacid | Linear | L | None | 10 | Antifungal | 35.7 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Hexadecanoicacid}{ct:Amid} | C16:0-A2 | Amidation | Hexadecanoicacid | Linear | L | None | 10 | Antifungal | 63.2 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:17Methyloctadec13(Z)Enoicacid}{ct:Amid} | 17-Me-C18:1- A2 | Amidation | 17Methyloctadec13(Z)Enoicacid | Linear | L | None | 10 | Antifungal | 82.7 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:17Methyloctadec13(Z)Enoicacid}{ct:Amid} | 17-Me-C18:1- A2 | Amidation | 17Methyloctadec13(Z)Enoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:17Methyloctadec13(Z)Enoicacid}{ct:Amid} | 17-Me-C18:1- A2 | Amidation | 17Methyloctadec13(Z)Enoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:17Methyloctadec13(Z)Enoicacid}{ct:Amid} | 17-Me-C18:1- A2 | Amidation | 17Methyloctadec13(Z)Enoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:17Methyloctadec13(Z)Enoicacid}{ct:Amid} | 17-Me-C18:1- A2 | Amidation | 17Methyloctadec13(Z)Enoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:17Methyloctadec13(Z)Enoicacid}{ct:Amid} | 17-Me-C18:1- A2 | Amidation | 17Methyloctadec13(Z)Enoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:17Methyloctadec13(Z)Enoicacid}{ct:Amid} | 17-Me-C18:1- A2 | Amidation | 17Methyloctadec13(Z)Enoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Heptadec6ynoicacid}{ct:Amid} | C17:1- A2 | Amidation | Heptadec6ynoicacid | Linear | L | None | 10 | Antifungal | 81 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Heptadec6ynoicacid}{ct:Amid} | C17:1- A2 | Amidation | Heptadec6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Heptadec6ynoicacid}{ct:Amid} | C17:1- A2 | Amidation | Heptadec6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Heptadec6ynoicacid}{ct:Amid} | C17:1- A2 | Amidation | Heptadec6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Heptadec6ynoicacid}{ct:Amid} | C17:1- A2 | Amidation | Heptadec6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Heptadec6ynoicacid}{ct:Amid} | C17:1- A2 | Amidation | Heptadec6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Heptadec6ynoicacid}{ct:Amid} | C17:1- A2 | Amidation | Heptadec6ynoicacid | Linear | L | None | 10 | Antifungal | 96 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Icos6ynoicacid}{ct:Amid} | C20:1- A2 | Amidation | Icos6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 6.25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Icos6ynoicacid}{ct:Amid} | C20:1- A2 | Amidation | Icos6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 12.5 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Icos6ynoicacid}{ct:Amid} | C20:1- A2 | Amidation | Icos6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 25 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Icos6ynoicacid}{ct:Amid} | C20:1- A2 | Amidation | Icos6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 50 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Icos6ynoicacid}{ct:Amid} | C20:1- A2 | Amidation | Icos6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 100 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Icos6ynoicacid}{ct:Amid} | C20:1- A2 | Amidation | Icos6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 200 µM | Human | A2 Analogs | α-Helix | NA | ||
| 28025839 | 2017 | IKQVKKLFKK{nt:Icos6ynoicacid}{ct:Amid} | C20:1- A2 | Amidation | Icos6ynoicacid | Linear | L | None | 10 | Antifungal | 100 % Hemolysis at 400 µM | Human | A2 Analogs | α-Helix | NA | ||
| 27450123 | 2017 | GLLSALRKMIPHILSHIKK{ct:Amid} | ANTP(antapin) | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 50 % Hemolysis at 97.8 µM | Human | Wild Bee Anthophora Plumipes | α-Helix | NA | ||
| 27935673 | 2017 | RIIDLLWRVRRPQKPKFVTVWVR{nt:Dansyl}{ct:Amid} | DNS-PMAP23 | Amidation | Dansyl | Linear | L | Dansyl(DNS) = 5-(dimetylamino)napthalene-1-sulphonyl | 23 | Antimicrobial | 50 % Hemolysis at 29 µM | Human | Analogue Of The Cathelicidin Hdp Pmap-23 | NA | NA | ||
| 27912176 | 2017 | FLGALWNVAKSVF{ct:Amid} | VmCT1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <12 % Hemolysis at 6.25 µmol/L | Human | Vaejovis Mexicanus Smithi | α-Helix | Non-hemolytic | ||
| 27912176 | 2017 | FLKALWNVAKSVF{ct:Amid} | [K]3 -VmCT1-NH2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <12 % Hemolysis at 1.6 µmol/L | Human | Vmct1 Analogs | α-Helix | Non-hemolytic | ||
| 27912176 | 2017 | FLGALWKVAKSVF{ct:Amid} | [K]7 -VmCT1-NH2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <12 % Hemolysis at 1.6 µmol/L | Human | Vmct1 Analogs | α-Helix | Non-hemolytic | ||
| 27912176 | 2017 | FLGALWNVAKKVF{ct:Amid} | [K]11-VmCT1-NH2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <12 % Hemolysis at 1.6 µmol/L | Human | Vmct1 Analogs | α-Helix | Non-hemolytic | ||
| 27912176 | 2017 | FLGELWNVAKSVF{ct:Amid} | [E]4 -VmCT1-NH2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <12 % Hemolysis at 25 µmol/L | Human | Vmct1 Analogs | α-Helix | Non-hemolytic | ||
| 27912176 | 2017 | FLGALWEVAKSVF{ct:Amid} | [E]7 -VmCT1-NH2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <12 % Hemolysis at 1.6 µmol/L | Human | Vmct1 Analogs | α-Helix | Non-hemolytic | ||
| 27912176 | 2017 | FLGALWNVWKSVF{ct:Amid} | [W]9 -VmCT1-NH2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <12 % Hemolysis at 1.6 µmol/L | Human | Vmct1 Analogs | α-Helix | Non-hemolytic | ||
| 27912176 | 2017 | FLGELWNVWKSVF{ct:Amid} | [E]4 [W]9 -VmCT1-NH2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <12 % Hemolysis at 1.6 µmol/L | Human | Vmct1 Analogs | α-Helix | Non-hemolytic | ||
| 28012857 | 2017 | FALALKALKKALKKLKKALKKAL | Hecate | Free | Free | Linear | L | None | 23 | Antimicrobial | <60 % Hemolysis at 25 µM | Human | Synthetic, Derivate Of Melittin | α-Helix | NA | ||
| 28012857 | 2017 | FALALKALKKALKKLKKALKKAL | Hecate | Free | Free | Linear | L | None | 23 | Antimicrobial | <40 % Hemolysis at 15 µM | Human | Synthetic, Derivate Of Melittin | α-Helix | NA | ||
| 28012857 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 80 % Hemolysis at 5 µM | Human | Apis Mellifera | α-Helix | NA | ||
| 28012857 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 25 µM | Human | Apis Mellifera | α-Helix | NA | ||
| 28012857 | 2017 | ILGPVLGLVSDTLDDVLGIL | Maximin H5 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 0-25 µM | Human | Bombina Maxima Smap2 9 Rglrrlgrkiahgvkkygptvlriiri Ag 29 3256.0 0 12.3 1 +9 Derivative Of Ovispi | α-Helix | Non-hemolytic | ||
| 28012857 | 2017 | RGLRRLGRKIAHGVKKYGPTVLRIIRIAG | SMAP29 | Free | Free | Linear | L | None | 29 | Antimicrobial | 40 % Hemolysis at 20 µM | Human | Derivative Of Ovispirin, Ovis Aries | α-Helix | NA | ||
| 28012857 | 2017 | RGLRRLGRKIAHGVKKYGPTVLRIIRIAG | SMAP29 | Free | Free | Linear | L | None | 29 | Antimicrobial | 50 % Hemolysis at 25 µM | Human | Derivative Of Ovispirin, Ovis Aries | α-Helix | NA | ||
| 28012857 | 2017 | KWKLWKKIEKWGQGIGAVLKWLTTWL | CAM-W | Free | Free | Linear | L | None | 26 | Antimicrobial | 10 % Hemolysis at 1 µM | Human | Synthetic, Cecropin A / Melittin Hybrid | α-Helix | NA | ||
| 28012857 | 2017 | KWKLWKKIEKWGQGIGAVLKWLTTWL | CAM-W | Free | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 10 µM | Human | Synthetic, Cecropin A / Melittin Hybrid | α-Helix | NA | ||
| 28012857 | 2017 | KWKLWKKIEKWGQGIGAVLKWLTTWL | CAM-W | Free | Free | Linear | L | None | 26 | Antimicrobial | <80 % Hemolysis at 5 µM | Human | Synthetic, Cecropin A / Melittin Hybrid | α-Helix | NA | ||
| 28012857 | 2017 | WEAALAEALAEALAEHLAEALAEALEALAA | GALA | Free | Free | Linear | L | None | 30 | Antimicrobial | 0 % Hemolysis at 0-25 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 28012857 | 2017 | WEAKLAKALAKALAKHLAKALAKALKACEA | KALA | Free | Free | Linear | L | None | 30 | Antimicrobial | 60 % Hemolysis at 25 µM | Human | Synthetic | α-Helix | NA | ||
| 28108242 | 2017 | INWLKLGKMVIDAL{ct:Amid} | Polybia-MPII | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 48.47 µM | Human | Pseudopolybia Vespiceps Testacea | α-Helix | NA | ||
| 28165293 | 2017 | FKCRRWQWRMKKLGAPSITCVRRAF{cyc:N-C} | LFcinB | Free | Free | Cyclic | L | None | 25 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Lf (Blf) | β-Hairpin | NA | ||
| 28165293 | 2017 | FK{nnr:*}RRWQWRMKKLGAPSIT{nnr:*}VRRAF | LFcinB-CLICK | Free | Free | Linear | L | * = triazole linkage | 23 | Anticancer | <2 % Hemolysis at 10 µM | Human | Lf-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | RRWQWR{nt:Acet}{ct:Amid} | LFcinB1 | Amidation | Acetylation | Linear | L | None | 6 | Anticancer | <2 % Hemolysis at 10 µM | Human | Lf-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCA | hLF11 | Free | Free | Linear | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWSA | hLF11C10S | Free | Free | Linear | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCA{cyc:N-C} | Cyclo-hLF11 | Free | Free | Cyclic | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCA{cyc:N-C} | Cyclo-hLF11C10S | Free | Free | Cyclic | L | None | 11 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCAGRRRRSVQWCA | Dimer hLF11 | Free | Free | Linear | L | None | 22 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWCT | bLF10 | Free | Free | Linear | L | None | 10 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWST | bLF10C9S | Free | Free | Linear | L | None | 10 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWCT{cyc:N-C} | Cyclo-bLF10 | Free | Free | Cyclic | L | None | 10 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWCTAPRKNVRWCT | Dimer bLF10 | Free | Free | Linear | L | None | 20 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | APRKNVRWCTISQPEW | bLF16 | Free | Free | Linear | L | None | 16 | Anticancer | <2 % Hemolysis at 10 µM | Human | Bovine Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCAPRRWQWR{ct:Amid} | hLF11-P-LFcinB1 | Amidation | Free | Linear | L | None | 18 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GRRRRSVQWCAGGRRWQWR{ct:Amid} | hLF11-GG-LFcinB1 | Amidation | Free | Linear | L | None | 19 | Anticancer | <2 % Hemolysis at 10 µM | Human | Human-Derived | β-Hairpin | NA | ||
| 28165293 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Anticancer | 90 % Hemolysis at 10 µM | Human | Bee Venom | Helical | NA | ||
| 28178190 | 2017 | FRIRVRV{ct:Amid} | FV7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 5 % Hemolysis at 4 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28178190 | 2017 | FRIRVRV{ct:Amid} | FV7 | Amidation | Free | Linear | L | None | 7 | Antimicrobial | 15 % Hemolysis at 128 µM | Human | Synthetic Peptide | α-Helix | NA | ||
| 28178190 | 2017 | FRIRVRVFKRIVQRIKDFLR{ct:Amid} | FV-LL | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 128 µM | Human | Hybrid | α-Helix | Non-hemolytic | ||
| 28178190 | 2017 | FRRIRVRVFKRIVQRIKDF{ct:Amid} | FV-MA | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 50 % Hemolysis at 128 µM | Human | Hybrid | α-Helix | NA | ||
| 28178190 | 2017 | FRIRVRVAKKFGKAFVG{ct:Amid} | FV-CE | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 128 µM | Human | Hybrid | α-Helix | Non-hemolytic | ||
| 28275372 | 2017 | IFSAIAGLLSNLL{ct:Amid} | NDBP-5.5 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 6.25-400 µM | Human | Hadrurus Gertschi | α-Helix | Non-hemolytic | ||
| 28275372 | 2017 | IFSAIAGLLSNLL{ct:Amid} | NDBP-5.5 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10 % Hemolysis at 611.8 µM | Human | Hadrurus Gertschi | α-Helix | NA | ||
| 28275372 | 2017 | IFSAIAGLLSNLL{ct:Amid} | NDBP-5.5 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 39 % Hemolysis at 1600 µM | Human | Hadrurus Gertschi | α-Helix | NA | ||
| 28230084 | 2017 | MLKKFRGMF{ct:Amid} | MreB1–9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | Non-hemolytic | ||
| 28230084 | 2017 | MLKKFRGMF{nt:Acet}{ct:Amid} | Ac-MreB1–9 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | Non-hemolytic | ||
| 28230084 | 2017 | WMLKKFRGMF{ct:Amid} | W-MreB1–9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | NA | ||
| 28230084 | 2017 | WMLKKFRGMF{nt:Acet}{ct:Amid} | Ac-W-MreB1–9 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 4.15±0.96 % Hemolysis at 50 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | NA | ||
| 28230084 | 2017 | MLKKFRGMF{ct:Amid} | MreB1–9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | Non-hemolytic | ||
| 28230084 | 2017 | MLKKFRGMF{nt:Acet}{ct:Amid} | Ac-MreB1–9 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | Non-hemolytic | ||
| 28230084 | 2017 | WMLKKFRGMF{ct:Amid} | W-MreB1–9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 1.62±0.08 % Hemolysis at 100 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | NA | ||
| 28230084 | 2017 | WMLKKFRGMF{nt:Acet}{ct:Amid} | Ac-W-MreB1–9 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 11.88±2.44 % Hemolysis at 100 µM | Human | Membrane-Binding Region Of E. Coli Mreb | α-Helix | NA | ||
| 27591703 | 2017 | KKWRWWLKALAKK{ct:Amid} | pEM-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <5 % Hemolysis at 64 μg/ml | Human | Snake Bothrops Asper | α-Helix | Non-hemolytic | ||
| 27591703 | 2017 | LKLKSIVSWAKKVL{ct:Amid} | MP-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | <5 % Hemolysis at 64 μg/ml | Human | Hornet Vespa Basalis | α-Helix | Non-hemolytic | ||
| 27591703 | 2017 | INLKAIAALAKKLL{ct:Amid} | MP-VT1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | <5 % Hemolysis at 64 μg/ml | Human | Venom Of Vespa Tropica | α-Helix | Non-hemolytic | ||
| 27591703 | 2017 | KKWRWWLKALAKKLL{ct:Amid} | PV | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 8 μg/ml | Human | Hybrid | α-Helix | NA | ||
| 27591703 | 2017 | KKWRWWLKALAKKLL{ct:Amid} | PV | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at 16 μg/ml | Human | Hybrid | α-Helix | NA | ||
| 27591703 | 2017 | KKWRWWLKALAKKLL{ct:Amid} | PV | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 85 % Hemolysis at 32 μg/ml | Human | Hybrid | α-Helix | NA | ||
| 27591703 | 2017 | KKWRWWLKALAKKLL{ct:Amid} | PV | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 90 % Hemolysis at 64 μg/ml | Human | Hybrid | α-Helix | NA | ||
| 27591703 | 2017 | LKLKAIAALAKKKW{ct:Amid} | BVP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | <5 % Hemolysis at 64 μg/ml | Human | Hybrid | α-Helix | Non-hemolytic | ||
| 27591703 | 2017 | KKWRKLLKWLAKK{ct:Amid} | PVP | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <5 % Hemolysis at 64 μg/ml | Human | Hybrid | α-Helix | Non-hemolytic | ||
| 27591703 | 2017 | KKWRKLLKKLKKLL{ct:Amid} | PV3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | <5 % Hemolysis at 64 μg/ml | Human | Hybrid | α-Helix | Non-hemolytic | ||
| 27876749 | 2017 | KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF{ct:Amid} | Ctn | Amidation | Free | Linear | L | None | 34 | Antifungal | 70 % Hemolysis at 12.5 µM | Human | South American Rattlesnake Crotalus Durissus Terrificus | α-Helix | NA | ||
| 27876749 | 2017 | KRFKKFFKKVKKSVKKRLKKIFKKPMVIGVTIPF{ct:Amid} | Ctn | Amidation | Free | Linear | L | None | 34 | Antifungal | 80 % Hemolysis at 100 µM | Human | South American Rattlesnake Crotalus Durissus Terrificus | α-Helix | NA | ||
| 27876749 | 2017 | KRFKKFFKKVKKSV{ct:Amid} | Ctn[1–14] | Amidation | Free | Linear | L | None | 14 | Antifungal | 20 % Hemolysis at 50 µM | Human | Fragment Of Ctn | α-Helix | NA | ||
| 27876749 | 2017 | KRFKKFFKKVKKSV{ct:Amid} | Ctn[1–14] | Amidation | Free | Linear | L | None | 14 | Antifungal | 40 % Hemolysis at 100 µM | Human | Fragment Of Ctn | α-Helix | NA | ||
| 27876749 | 2017 | KKRLKKIFKKPMVIGVTIPF{ct:Amid} | Ctn[15–34] | Amidation | Free | Linear | L | None | 20 | Antifungal | <5 % Hemolysis at 100 µM | Human | Fragment Of Ctn | Unstrcutured | NA | ||
| 27999446 | 2017 | ENFFKEIERAGQRIRDAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | WT | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 50 % Hemolysis at >115 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 27999446 | 2017 | ENFFKRIRRAGKRIRDAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | ΔM1 | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 50 % Hemolysis at 1752.3 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 27999446 | 2017 | ENFFKRIRRAGKRIRDAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | ΔM1 | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 2.3 % Hemolysis at 115 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 27999446 | 2017 | RNFFKRIRRAGKRIRKAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | ΔM2 | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 50 % Hemolysis at 735.4 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 27999446 | 2017 | RNFFKRIRRAGKRIRKAIISAAPAVETLAQAQKIIKGGD{nt:Amid}{ct:Acet} | ΔM2 | Acetylation | Amidation | Linear | L | None | 39 | Antimicrobial | 6.88 % Hemolysis at 115 µM | Human | Cecropin D-Like From Galleria Mellonella | α-Helix | NA | ||
| 28248495 | 2017 | RQIKIWFQNRRW | MAAPC01 | Free | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at 516.5 µM | Human | Homeobox Domain Of The Antp Protein | α-Helix | NA | ||
| 28248495 | 2017 | GWIRNQFRKIWQR | MAAPC02 | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >1000 µM | Human | Homeobox Domain Of The Antp Protein | α-Helix | NA | ||
| 28248495 | 2017 | GWRRNQFWIKIQR | MAAPC03 | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >1000 µM | Human | Homeobox Domain Of The Antp Protein | α-Helix | NA | ||
| 28248495 | 2017 | GWRNQIRKGWQR | MAAPC04 | Free | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at >2000 µM | Human | Homeobox Domain Of The Antp Protein | α-Helix | NA | ||
| 28248495 | 2017 | RQIKIWFQNRRW | MAAPC05 | Free | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at 676.7 µM | Human | Homeobox Domain Of The Antp Protein | α-Helix | NA | ||
| 28453851 | 2017 | R{d}L{d}W{d}V{d}L{d}W{d}R{d}R{d} | D-Bac8c2,5Leu | Free | Free | Linear | D | None | 8 | Antimicrobial | 50 % Hemolysis at 414 μg/ml | Human | Synthetic | NA | NA | ||
| 28453851 | 2017 | F{d}A{d}K{d}L{d}L{d}A{d}K{d}L{d}A{d}K{d}K{d}L{d}L{d} | D-HB43 | Free | Free | Linear | D | None | 13 | Antimicrobial | 50 % Hemolysis at 77 μg/ml | Human | Synthetic | NA | NA | ||
| 28453851 | 2017 | F{d}L{d}G{d}G{d}L{d}I{d}K{d}I{d}V{d}P{d}A{d}M{d}I{d}C{d}A{d}V{d}T{d}K{d}K{d}C{d} | D-Ranalexin | Free | Free | Linear | D | None | 20 | Antimicrobial | 50 % Hemolysis at 195 μg/ml | Human | Synthetic | NA | NA | ||
| 28453851 | 2017 | RRWCFRVCYRGFCYRKCR | L-Polyphemusin | Free | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at 1885 μg/ml | Human | Synthetic | NA | NA | ||
| 28453851 | 2017 | W{d}G{d}L{d}R{d}R{d}L{d}L{d}K{d}Y{d}G{d}K{d}R{d}S{d} | D-WMR3,6Leu | Free | Free | Linear | D | None | 13 | Antimicrobial | 50 % Hemolysis at >4000 μg/ml | Human | Synthetic | NA | NA | ||
| 28453851 | 2017 | K{d}W{d}K{d}L{d}F{d}K{d}K{d}L{d}P{d}K{d}F{d}L{d}H{d}L{d}A{d}K{d}K{d}F{d} | DP188Leu | Free | Free | Linear | D | None | 13 | Antimicrobial | 50 % Hemolysis at 873 μg/ml | Human | Synthetic | NA | NA | ||
| 28453851 | 2017 | I{d}L{d}R{d}W{d}P{d}W{d}W{d}P{d}W{d}R{d}R{d}K{d} | D-Omiganan | Free | Free | Linear | D | None | 12 | Antimicrobial | 50 % Hemolysis at 1775.5 μg/ml | Human | Synthetic | NA | NA | ||
| 28282123 | 2017 | KKAGKIAKKAGKIA{ct:Amid} | KIA(7)14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 3 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKKAGKIAK{ct:Amid} | KIA(7)15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 5 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKKAGKIAKIA{ct:Amid} | KIA(7)17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 5 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGK{ct:Amid} | KIA19 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 12 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGKIA{ct:Amid} | KIA21 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 9 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGKIAK{ct:Amid} | KIA(7)22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 16 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGKIAKIA{ct:Amid} | KIA(7)24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 18 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGAIAKIAGK{ct:Amid} | KIA(7)26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 39 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGAIAKIAGKIA{ct:Amid} | KIA(7)28 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 90 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAKKIAKIAKKIA{ct:Amid} | KIKA14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 2 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAKKIAK{ct:Amid} | KIKA15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 8 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAKKIAKIA{ct:Amid} | KIKA17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 9 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGKIAK{ct:Amid} | KISA22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 7 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGKIAKIA{ct:Amid} | KISA24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 24 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGSIAKIAGK{ct:Amid} | KISA26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 18 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGSIAKIAGKIA{ct:Amid} | KISA28 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 53 % Hemolysis at 8 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KKAGKIAKKAGKIA{ct:Amid} | KIA(7)14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 3 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKKAGKIAK{ct:Amid} | KIA(7)15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 6 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKKAGKIAKIA{ct:Amid} | KIA(7)17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 5 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGK{ct:Amid} | KIA19 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 5 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGKIA{ct:Amid} | KIA21 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 17 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGKIAK{ct:Amid} | KIA(7)22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 24 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGKIAKIA{ct:Amid} | KIA(7)24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 62 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGAIAKIAGK{ct:Amid} | KIA(7)26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 72 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGAIAKIAGKIA{ct:Amid} | KIA(7)28 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 100 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAKKIAKIAKKIA{ct:Amid} | KIKA14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 3 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAKKIAK{ct:Amid} | KIKA15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 4 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAKKIAKIA{ct:Amid} | KIKA17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 6 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGKIAK{ct:Amid} | KISA22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 12 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGKIAKIA{ct:Amid} | KISA24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 44 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGSIAKIAGK{ct:Amid} | KISA26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 29 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGSIAKIAGKIA{ct:Amid} | KISA28 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 82 % Hemolysis at 32 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KKAGKIAKKAGKIA{ct:Amid} | KIA(7)14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 4 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKKAGKIAK{ct:Amid} | KIA(7)15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 5 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKKAGKIAKIA{ct:Amid} | KIA(7)17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 4 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGK{ct:Amid} | KIA19 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 7 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGKIA{ct:Amid} | KIA21 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 43 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGKIAK{ct:Amid} | KIA(7)22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 44 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGKIAKIA{ct:Amid} | KIA(7)24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 98 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGAIAKIAGK{ct:Amid} | KIA(7)26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 98 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGAIAKIAGKIA{ct:Amid} | KIA(7)28 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 100 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAKKIAKIAKKIA{ct:Amid} | KIKA14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 4 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAKKIAK{ct:Amid} | KIKA15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 4 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAKKIAKIA{ct:Amid} | KIKA17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 9 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGKIAK{ct:Amid} | KISA22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 19 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGKIAKIA{ct:Amid} | KISA24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 89 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGSIAKIAGK{ct:Amid} | KISA26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 63 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGSIAKIAGKIA{ct:Amid} | KISA28 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 98 % Hemolysis at 128 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KKAGKIAKKAGKIA{ct:Amid} | KIA(7)14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 6 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKKAGKIAK{ct:Amid} | KIA(7)15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 5 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKKAGKIAKIA{ct:Amid} | KIA(7)17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 5 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGK{ct:Amid} | KIA19 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 10 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGKIA{ct:Amid} | KIA21 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 83 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGKIAK{ct:Amid} | KIA(7)22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 76 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGKIAKIA{ct:Amid} | KIA(7)24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 100 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGAIAKIAGK{ct:Amid} | KIA(7)26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAAIAGKIAKIAGAIAKIAGKIA{ct:Amid} | KIA(7)28 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 100 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAKKIAKIAKKIA{ct:Amid} | KIKA14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 5 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAKKIAK{ct:Amid} | KIKA15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 6 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAKKIAKIA{ct:Amid} | KIKA17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 14 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGKIAK{ct:Amid} | KISA22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 39 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIAKIAGKIAKIAGKIAKIA{ct:Amid} | KISA24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 100 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGSIAKIAGK{ct:Amid} | KISA26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28282123 | 2017 | KIAGKIASIAGKIAKIAGSIAKIAGKIA{ct:Amid} | KISA28 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 99 % Hemolysis at 512 μg/ml | Human | Msi-103 Analogues | α-Helix | NA | ||
| 28322271 | 2017 | GGLRSLGRKILRAWKKYGPIIVPIIRI{ct:Amid} | BMAP-28 | Amidation | Free | Linear | L | None | 27 | Antimicrobial, Antiprotozoal | 38 % Hemolysis at 10 µM | Human | Synthetic | α-Helix | NA | ||
| 28322271 | 2017 | GGLRSLGRKILRAWKKYGPIIVPIIRI{ct:Amid} | BMAP-28 | Amidation | Free | Linear | L | None | 27 | Antimicrobial, Antiprotozoal | 81.7 % Hemolysis at 30 µM | Human | Synthetic | α-Helix | NA | ||
| 28322271 | 2017 | GGLRSLGRKILRAWKKYG{ct:Amid} | BMAP-28(1-18) | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Antiprotozoal | 3.4 % Hemolysis at 10 µM | Human | Bmap-28 Derivatives | α-Helix | NA | ||
| 28322271 | 2017 | GGLRSLGRKILRAWKKYG{ct:Amid} | BMAP-28(1-18) | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Antiprotozoal | 9.6 % Hemolysis at 30 µM | Human | Bmap-28 Derivatives | α-Helix | NA | ||
| 28322271 | 2017 | GGFRSFGRKIFRAWKKYG{ct:Amid} | Syn1 | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Antiprotozoal | 1.9 % Hemolysis at 10 µM | Human | Bmap-28 Derivatives | α-Helix | NA | ||
| 28322271 | 2017 | GGFRSFGRKIFRAWKKYG{ct:Amid} | Syn1 | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Antiprotozoal | 7.2 % Hemolysis at 30 µM | Human | Bmap-28 Derivatives | α-Helix | NA | ||
| 28322271 | 2017 | GGLRSLGRKAARAWKKYG{ct:Amid} | Syn2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Antiprotozoal | 0.8 % Hemolysis at 10 µM | Human | Bmap-28 Derivatives | α-Helix | NA | ||
| 28322271 | 2017 | GGLRSLGRKAARAWKKYG{ct:Amid} | Syn2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Antiprotozoal | 1.9 % Hemolysis at 30 µM | Human | Bmap-28 Derivatives | α-Helix | NA | ||
| 28322271 | 2017 | GRKILRAWKKYG{ct:Amid} | Syn3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antiprotozoal | 0.5 % Hemolysis at 10 µM | Human | Bmap-28 Derivatives | α-Helix | NA | ||
| 28322271 | 2017 | GRKILRAWKKYG{ct:Amid} | Syn3 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antiprotozoal | 1.2 % Hemolysis at 30 µM | Human | Bmap-28 Derivatives | α-Helix | NA | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 8 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 15.6 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 31.2 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 62.5 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 125 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 250 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | 0 % Hemolysis at 500 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28533236 | 2017 | {nnr:Dap}L{d}WK{d}N{d}R{d}{cyc:N-C} | CLP-4 | Free | Free | Cyclic | Mix | Dap = 2,3-diaminopropionic acid, l = D-leucine, k = D-lysine, n = D-asparagine, r = D-arginine | 5 | Antibacterial, Antibiofilm | <10 % Hemolysis at 1000 μg/ml | Human | Fusaricidin | NA | Non-hemolytic | ||
| 28230992 | 2017 | LRRLRRRWRRRLRRL{ct:Amid} | 1 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at >256 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28230992 | 2017 | ARRARRRWRRRARRA{ct:Amid} | 2 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at >256 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28230992 | 2017 | FRRFRRRWRRRFRRF{ct:Amid} | 3 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at >256 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28230992 | 2017 | WRRWRRRWRRRWRRW{ct:Amid} | 4 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at >256 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28230992 | 2017 | LRRLRRRWLRRLRRR{ct:Amid} | 5 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at >256 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28230992 | 2017 | LRRLRRRLRRLRRRWRRRLRRLRRRLRRL{ct:Amid} | 6 | Amidation | Free | Branched | L | None | 29 | Antibacterial | 10 % Hemolysis at 64 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28230992 | 2017 | LRRLRRRLRRLRRRLRRLRRRWRRRLRRLRRRLRRLRRRLRRL{ct:Amid} | 7 | Amidation | Free | Branched | L | None | 43 | Antibacterial | 10 % Hemolysis at 64 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28230992 | 2017 | LRRLRRRWWRRRLRRL{ct:Amid} | 8 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 10 % Hemolysis at 256 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28230992 | 2017 | LRRLRRRWWWRRRLRR{ct:Amid} | 9 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 10 % Hemolysis at >256 mg/L | Human | Synthetic | α-Helix | NA | ||
| 28408902 | 2017 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 4.47 (±0.35) % Hemolysis at 175 μg/ml | Human | Human Cathelicidin | α-Helix | NA | ||
| 28408902 | 2017 | KEFKRIVQRIKDFLRNLV | KE-18 | Free | Free | Linear | L | None | 18 | Antimicrobial | 1.17 (±0.18) % Hemolysis at 175 μg/ml | Human | Truncated Mimetics | α-Helix | NA | ||
| 28408902 | 2017 | KRIVQRIKDFLR | KR-12 | Free | Free | Linear | L | None | 12 | Antimicrobial | 0.45 (±0.10) % Hemolysis at 175 μg/ml | Human | Truncated Mimetics | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 100 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 0 % Hemolysis at 150 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | <5 % Hemolysis at 200 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 250 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | <10 % Hemolysis at 300 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | VGVGGGFGR{ct:Amid} | Crinicepsin-1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 18 % Hemolysis at 500 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | RERSKGSKYLYVG{ct:Amid} | Crinicepsin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <5 % Hemolysis at 100 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | RERSKGSKYLYVG{ct:Amid} | Crinicepsin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <5 % Hemolysis at 150 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | RERSKGSKYLYVG{ct:Amid} | Crinicepsin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <5 % Hemolysis at 200 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | RERSKGSKYLYVG{ct:Amid} | Crinicepsin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 10 % Hemolysis at 250 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | RERSKGSKYLYVG{ct:Amid} | Crinicepsin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <15 % Hemolysis at 300 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28346717 | 2017 | RERSKGSKYLYVG{ct:Amid} | Crinicepsin-2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 14.5 % Hemolysis at 500 μg/ml | Human | Ant Trichomyrmex Criniceps(Mayr) | α-Helix | NA | ||
| 28429216 | 2017 | KWCFRVCYGICYRRCR{nt:Acet}{ct:Amid} | tachyplesin I | Amidation | Acetylation | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at 90 µM | Human | Horseshoe Crab Tachypleus Tridentatus | β-Hairpin | NA | ||
| 28429216 | 2017 | KWCFRVCYGICYRRCR{nt:Acet}{ct:Amid} | tachyplesin I | Amidation | Acetylation | Linear | L | None | 16 | Antimicrobial | 25 % Hemolysis at 50 µM | Human | Horseshoe Crab Tachypleus Tridentatus | β-Hairpin | NA | ||
| 28443279 | 2017 | LLPIVGNLLKSLL{ct:Amid} | TB | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 96 µM | Human | Frog Skin-Derived | α-Helix | Non-hemolytic | ||
| 28443279 | 2017 | FLPIVGLLKSLLK{ct:Amid} | TB_L1FK | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <10 % Hemolysis at 48 µM | Human | Tb Analogs | α-Helix | Non-hemolytic | ||
| 28443279 | 2017 | FLPIVGLLKSLLK{ct:Amid} | TB_L1FK | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 40 % Hemolysis at 96 µM | Human | Tb Analogs | α-Helix | NA | ||
| 28443279 | 2017 | KKLLPIVANLLKSLL{ct:Amid} | TB_KKG6A | Amidation | Free | Linear | L | None | 15 | Antimicrobial | <10 % Hemolysis at 24 µM | Human | Tb Analogs | α-Helix | Non-hemolytic | ||
| 28443279 | 2017 | KKLLPIVANLLKSLL{ct:Amid} | TB_KKG6A | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 48 µM | Human | Tb Analogs | α-Helix | NA | ||
| 28443279 | 2017 | KKLLPIVANLLKSLL{ct:Amid} | TB_KKG6A | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 55 % Hemolysis at 96 µM | Human | Tb Analogs | α-Helix | NA | ||
| 28073163 | 2017 | {nnr:Val}WWVAARAARR{ct:Amid} | LP1 | Amidation | Free | Linear | L | Val = valerylamide, X = (S)-2-(4-pentenyl)-alanine | 10 | Antimicrobial | 50 % Hemolysis at 1810 µM | Human | Synthetic | β-Strand | NA | ||
| 28073163 | 2017 | {nnr:Val}WWV{nnr:X}ARA{nnr:X}RR{ct:Amid} | Val-HSLP | Amidation | Free | Linear | L | Val = valerylamide, X = (S)-2-(4-pentenyl)-alanine, * = Hydrocarbon-stapled using Grubbs 1st Generation Catalyst | 10 | Antimicrobial | 50 % Hemolysis at 14.5 µM | Human | Hslp Analogs | β-Strand | NA | ||
| 28073163 | 2017 | {nnr:Val}WWV{nnr:X}ARA{nnr:X}RR{ct:Amid} | Val-nHSLP | Amidation | Free | Linear | L | Val = valerylamide, X = (S)-2-(4-pentenyl)-alanine | 10 | Antimicrobial | 50 % Hemolysis at 13.4 µM | Human | Hslp Analogs | β-Strand | NA | ||
| 28073163 | 2017 | {nnr:Cap}WWV{nnr:X}AFA{nnr:X}RRR{ct:Amid} | Cap-HSLP | Amidation | Free | Linear | L | Cap = caproylamide, X = (S)-2-(4-pentenyl)-alanine, *= Hydrocarbon-stapled | 11 | Antimicrobial | 50 % Hemolysis at 4.49 µM | Human | Hslp Analogs | β-Strand | NA | ||
| 28073163 | 2017 | {nnr:Cap}WWV{nnr:X}AFA{nnr:X}RRR{ct:Amid} | Cap-nHSLP | Amidation | Free | Linear | L | Cap = caproylamide, X = (S)-2-(4-pentenyl)-alanine | 11 | Antimicrobial | 50 % Hemolysis at 3.59 µM | Human | Hslp Analogs | β-Strand | NA | ||
| 28236791 | 2017 | GLLWKWGWKWKEFLRIVGY{ct:Amid} | Peptido 6 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 51.36 % Hemolysis at 128 μg/ml | Human | Synthetic | α-Helix | NA | ||
| 28236791 | 2017 | GLLRKWGKKWKEFLRRVWK{ct:Amid} | Peptido 6.2 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 34.46 % Hemolysis at 128 μg/ml | Human | Synthetic | α-Helix | NA | ||
| 28370835 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 93 at pH-7.4 % Hemolysis at 2.5 µM | Human | Apis Mellifera Honeybees | α-Helix | NA | ||
| 28370835 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 4 at pH-5 % Hemolysis at 2.5 µM | Human | Apis Mellifera Honeybees | α-Helix | NA | ||
| 28370835 | 2017 | GIGAVLEVLTTGLPALISWIEEEEQQ{ct:Amid} | aMel | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 74 at pH-5 % Hemolysis at 10 µM | Human | Mel Analogs | α-Helix | NA | ||
| 28370835 | 2017 | GIGAVLEVLTTGLPALISWIEEEEQQ{ct:Amid} | aMel | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 15 at pH-7.4 % Hemolysis at 10 µM | Human | Mel Analogs | α-Helix | NA | ||
| 28370835 | 2017 | RIGVLLARLPKLFSLFKLMGKKV{ct:Amid} | RV-23 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 4 at pH-7.4 % Hemolysis at 2.5 µM | Human | Mel Analogs | α-Helix | NA | ||
| 28370835 | 2017 | RIGVLLAELPELFSLFELMGEEV{ct:Amid} | aRV | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 0 at pH-7.4 % Hemolysis at 160 µM | Human | Mel Analogs | α-Helix | Non-hemolytic | ||
| 28347740 | 2017 | RWKIFKKIERVGQNVRDGIIKAGPAIQVLGTAKALGK | ABP-dHC-Cecropin A | Free | Free | Linear | L | None | 37 | Antibacterial | 0 % Hemolysis at 1-800 µM | Human | Drury (Hyphantria Cunea) (Dhc) | α-Helix | Non-hemolytic | ||
| 28347740 | 2017 | RWKIFKKIERVGQNVRDGIIKAGKAIQVLGTAKALGK | ABP-dHC-Cecropin A-K(24) | Free | Free | Linear | L | None | 37 | Antibacterial | 0 % Hemolysis at 1-800 µM | Human | Abp-Dhc-Cecropin A Analog | α-Helix | Non-hemolytic | ||
| 28258530 | 2017 | MMRVMRRKTKVIWEKKDFIGLYSID | Catesbeianin-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | 8 % Hemolysis at 100 μg/ml | Human | Lithobates Catesbeianus | α-Helix | NA | ||
| 28258530 | 2017 | MMRVMRRKTKVIWEKKDFIGLYSID | Catesbeianin-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | 30 % Hemolysis at 200 μg/ml | Human | Lithobates Catesbeianus | α-Helix | NA | ||
| 28258530 | 2017 | MMRVMRRKTKVIWEKKDFIGLYSID | Catesbeianin-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | 50 % Hemolysis at 300 μg/ml | Human | Lithobates Catesbeianus | α-Helix | NA | ||
| 28258530 | 2017 | MMRVMRRKTKVIWEKKDFIGLYSID | Catesbeianin-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | <100 % Hemolysis at 400 μg/ml | Human | Lithobates Catesbeianus | α-Helix | NA | ||
| 28258530 | 2017 | MMRVMRRKTKVIWEKKDFIGLYSID | Catesbeianin-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | <100 % Hemolysis at 500 μg/ml | Human | Lithobates Catesbeianus | α-Helix | NA | ||
| 28314993 | 2017 | YGRKKRRQRRR{ct:Amid} | Tat(47–57) | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 50 % Hemolysis at >300 µM | Human | Sequence Of Hiv Transactivator Protein | α-Helix | NA | ||
| 28314993 | 2017 | RQIKIWFQNRRMKWKK{ct:Amid} | Penetratin | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at >300 µM | Human | Third Helix Of The Homeodomain Of Drosophila Antennapedia Protein | α-Helix | NA | ||
| 28314993 | 2017 | AGYLLGKINLKALAALAKKIL{ct:Amid} | Transportan | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 50 % Hemolysis at 38.0 ± 3.79 µM | Human | Hybrid Peptide | α-Helix | NA | ||
| 28314993 | 2017 | GIGKFLHSAKKFGKAFVGEIMNS{ct:Amid} | Magainin | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at >300 µM | Human | Amphibians | α-Helix | NA | ||
| 28314993 | 2017 | RAGLQFPVGRVHRLLRK{ct:Amid} | Buforin II (5-21) | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 50 % Hemolysis at >300 µM | Human | Amphibians | α-Helix | NA | ||
| 28314993 | 2017 | VCRTGRSRWRDVCRNFMRRYQSR{ct:Amid} | GranF2 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at >300 µM | Human | Synthetic Derivative | Helix-Loop-Helix | NA | ||
| 28314993 | 2017 | KRLFKKLLFSLRKY{ct:Amid} | Dhvar4 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at >300 µM | Human | Synthetic Derivatives | α-Helix | NA | ||
| 28314993 | 2017 | YKQCHKKGGKKGSG{ct:Amid} | Crot(1–9,38–42) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at >300 µM | Human | Venom Of Rattlesnake | α-Helix | NA | ||
| 28314993 | 2017 | KWKLFKKIGAVLKVL{ct:Amid} | CM15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at 18.9 ± 1.71 µM | Human | Hybrid | α-Helix | NA | ||
| 28314993 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at 0.339 ± 0.0854 µM | Human | Bee Venom | α-Helix | NA | ||
| 28314993 | 2017 | TKPKGTKPKGTKPKGTKPKG{ct:Amid} | OT20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 50 % Hemolysis at >300 µM | Human | Synthetic | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | ALA | Amidation | Free | Linear | L | * = cross-linked residues, X = Ala | 7 | Antimicrobial | <1 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | LEU | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | <1 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | VAL | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | 2.5 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | ILE | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | 3 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | NLE | Amidation | Free | Linear | L | * = cross-linked residues, X = Nle | 7 | Antimicrobial | 7.9 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | PHE | Amidation | Free | Linear | L | * = cross-linked residues, X = Phe | 7 | Antimicrobial | 4.4 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | TRP | Amidation | Free | Linear | L | * = cross-linked residues, X = Trp | 7 | Antimicrobial | 5.9 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | GLU | Amidation | Free | Linear | L | * = cross-linked residues, X = Glu | 7 | Antimicrobial | <1 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | LYS | Amidation | Free | Linear | L | * = cross-linked residues, X = Lys | 7 | Antimicrobial | <1 % Hemolysis at 50 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | ALA | Amidation | Free | Linear | L | * = cross-linked residues, X = Ala | 7 | Antimicrobial | <1 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | LEU | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | <1 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | VAL | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | 1.3 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | ILE | Amidation | Free | Linear | L | * = cross-linked residues, X = Leu | 7 | Antimicrobial | 1.5 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | NLE | Amidation | Free | Linear | L | * = cross-linked residues, X = Nle | 7 | Antimicrobial | 3.3 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | PHE | Amidation | Free | Linear | L | * = cross-linked residues, X = Phe | 7 | Antimicrobial | 1.9 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | TRP | Amidation | Free | Linear | L | * = cross-linked residues, X = Trp | 7 | Antimicrobial | 3.2 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | GLU | Amidation | Free | Linear | L | * = cross-linked residues, X = Glu | 7 | Antimicrobial | <1 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28547390 | 2017 | K{nnr:*}WK{nnr:X}{nnr:*}K{ct:Amid} | LYS | Amidation | Free | Linear | L | * = cross-linked residues, X = Lys | 7 | Antimicrobial | <1 % Hemolysis at 25 µM | Human | Stapled Heptapeptide Helices | α-Helix | NA | ||
| 28611397 | 2017 | FFGWLIKGAIHAGKAIHGLIHRRRH | Chrysophsin-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | 100 % Hemolysis at 10-50 µM | Human | Chrysophrys Major | α-Helix | NA | ||
| 28611397 | 2017 | FFGWLIKPAIHAGKAIHGLIHRRRH | G8P-Chr-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | 20 % Hemolysis at 50 µM | Human | Chrysophsin-1 Analogs | α-Helix | Low hemolytic | ||
| 28611397 | 2017 | FFGWLIKGAIHAPKAIHGLIHRRRH | G13P-Chr-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | <20 % Hemolysis at 50 µM | Human | Chrysophsin-1 Analogs | α-Helix | Low hemolytic | ||
| 28611397 | 2017 | FFGWLIKGAIHAGKAIHPLIHRRRH | G18P-Chr-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | <10 % Hemolysis at 50 µM | Human | Chrysophsin-1 Analogs | α-Helix | Low hemolytic | ||
| 28611397 | 2017 | FFGWLIKGAIHAPKAIHPLIHRRRH | G13,18P-Chr-1 | Free | Free | Linear | L | None | 25 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Chrysophsin-1 Analogs | α-Helix | Non-hemolytic | ||
| 28657596 | 2017 | ILGKIWEGIKSLF{ct:Amid} | IsCT1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | ~100 % Hemolysis at 50 μg/ml | Human | Scorpion Opithancatus Madagascariensis | α-Helix | NA | ||
| 28657596 | 2017 | ILGKIWEGIKSLF{ct:Amid} | IsCT1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | ~100 % Hemolysis at 100 μg/ml | Human | Scorpion Opithancatus Madagascariensis | α-Helix | NA | ||
| 28657596 | 2017 | IFGAIWNGIKSLF{ct:Amid} | IsCT2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | ~100 % Hemolysis at 50 μg/ml | Human | Scorpion Opithancatus Madagascariensis | α-Helix | NA | ||
| 28657596 | 2017 | IFGAIWNGIKSLF{ct:Amid} | IsCT2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | ~100 % Hemolysis at 100 μg/ml | Human | Scorpion Opithancatus Madagascariensis | α-Helix | NA | ||
| 28657596 | 2017 | ILGKAWEGAKSLF{ct:Amid} | IsCT1A1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 10 % Hemolysis at 100 μg/ml | Human | Analogs Of Scorpion Venom Isct Peptides | α-Helix | NA | ||
| 28657596 | 2017 | ILGKVWEGVKSLF{ct:Amid} | IsCT1V1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <10 % Hemolysis at 100 μg/ml | Human | Analogs Of Scorpion Venom Isct Peptides | α-Helix | NA | ||
| 28657596 | 2017 | ILGKLWEGLKSLF{ct:Amid} | IsCT1L1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 80 % Hemolysis at 50 μg/ml | Human | Analogs Of Scorpion Venom Isct Peptides | α-Helix | NA | ||
| 28657596 | 2017 | ILGKLWEGLKSLF{ct:Amid} | IsCT1L1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <100 % Hemolysis at 100 μg/ml | Human | Analogs Of Scorpion Venom Isct Peptides | α-Helix | NA | ||
| 28657596 | 2017 | ILGKIWKGIKSLF{ct:Amid} | IsCT1K7 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 50 μg/ml | Human | Analogs Of Scorpion Venom Isct Peptides | α-Helix | NA | ||
| 28657596 | 2017 | ILGKIWKGIKSLF{ct:Amid} | IsCT1K7 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <70 % Hemolysis at 100 μg/ml | Human | Analogs Of Scorpion Venom Isct Peptides | α-Helix | NA | ||
| 28657596 | 2017 | ILGKIWEGIESLF{ct:Amid} | IsCT1E7 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 0 % Hemolysis at 100 μg/ml | Human | Analogs Of Scorpion Venom Isct Peptides | α-Helix | Non-hemolytic | ||
| 28657596 | 2017 | ILGAAWNGAKSLF{ct:Amid} | IsCT2A1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 0 % Hemolysis at 100 μg/ml | Human | Analogs Of Scorpion Venom Isct Peptides | α-Helix | Non-hemolytic | ||
| 28657596 | 2017 | ILGAVWNGVKSLF{ct:Amid} | IsCT2V1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 20 % Hemolysis at 100 μg/ml | Human | Analogs Of Scorpion Venom Isct Peptides | α-Helix | NA | ||
| 28661457 | 2017 | DLRDSWKVIGSDKK | AI-Hemocidin 2 | Free | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at >500 μg/ml | Human | Arca Inflata | α-Helix | NA | ||
| 28661457 | 2017 | DLRDSWKVIGSDKK | AI-Hemocidin 2 | Free | Free | Linear | L | None | 14 | Antibacterial | 10.27 ± 0.42 % Hemolysis at 500 μg/ml | Human | Arca Inflata | α-Helix | NA | ||
| 28004513 | 2017 | GVSRCLSRRGVSRCLSRR | 2Ser_L | Free | Free | Linear | L | None | 12 | Antitumour | 0.0 ± 0.4 % Hemolysis at 5 μg/ml | Human | Synthesized Θ-Defensin Analogues | NA | Non-hemolytic | ||
| 28004513 | 2017 | GVSRCLSRRGVSRCLSRR | 2Ser_L | Free | Free | Linear | L | None | 12 | Antitumour | 0.0 ± 0.5 % Hemolysis at 10 μg/ml | Human | Synthesized Θ-Defensin Analogues | NA | Non-hemolytic | ||
| 28004513 | 2017 | GVSRCLSRRGVSRCLSRR | 2Ser_L | Free | Free | Linear | L | None | 12 | Antitumour | 0.0 ± 0.1 % Hemolysis at 25 μg/ml | Human | Synthesized Θ-Defensin Analogues | NA | Non-hemolytic | ||
| 28372989 | 2017 | RRWWRHWRR{ct:Amid} | P1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at > 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRWHRWWRR{ct:Amid} | P2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at > 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRHWRWWRR{ct:Amid} | P3 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at > 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRWHRHWRR{ct:Amid} | P4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at > 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRWWRWWRR{ct:Amid} | P5 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 33.33 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | HRWWRWWRR{ct:Amid} | P6 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | RRWWHWWRR{ct:Amid} | P7 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28372989 | 2017 | HRWWRWWRH{ct:Amid} | P8 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 86.67 µM | Human | Synthetic | α-Helix | NA | ||
| 28461043 | 2017 | AIGHCLGATL | Andricin 01 | Free | Free | Linear | L | None | 10 | Antimicrobial | 0 % Hemolysis at 25 μg/ml | Human | Andrias Davidianus, The Chinese Giant Salamander | NA | NA | ||
| 28461043 | 2017 | AIGHCLGATL | Andricin 01 | Free | Free | Linear | L | None | 10 | Antimicrobial | 0 % Hemolysis at 50 μg/ml | Human | Andrias Davidianus, The Chinese Giant Salamander | NA | NA | ||
| 28461043 | 2017 | AIGHCLGATL | Andricin 01 | Free | Free | Linear | L | None | 10 | Antimicrobial | 4.3 ± 0.16 % Hemolysis at 100 μg/ml | Human | Andrias Davidianus, The Chinese Giant Salamander | NA | NA | ||
| 28461043 | 2017 | AIGHCLGATL | Andricin 01 | Free | Free | Linear | L | None | 10 | Antimicrobial | 16.3 ± 2.16 % Hemolysis at 200 μg/ml | Human | Andrias Davidianus, The Chinese Giant Salamander | NA | NA | ||
| 28675109 | 2017 | FKRIVQRIKDFLRNLV{ct:Amid} | FK-16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at ~35 µM | Human | Ll-37 Peptide | α-Helix | NA | ||
| 28731688 | 2017 | WWWLRRIW{ct:Amid} | WT | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 35 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | RWWLRRIW{ct:Amid} | W1R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WRWLRRIW{ct:Amid} | W2R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 100 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WWRLRRIW{ct:Amid} | W3R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WWWRRRIW{ct:Amid} | L4R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WWWLRRRW{ct:Amid} | I7R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 150 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28731688 | 2017 | WWWLRRIR{ct:Amid} | W8R | Amidation | Free | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 µM | Human | Motif Of A Short Trp-Rich | α-Helix | NA | ||
| 28733329 | 2017 | YPCKLNLKLGKVPFH{ct:Amid} | Periplanetasin-2 | Amidation | Free | Linear | L | None | 15 | Antifungal | 0 % Hemolysis at 80 µM | Human | American Cockroach Periplaneta Americana | NA | Non-hemolytic | ||
| 28733329 | 2017 | YPCKLNLKLGKVPFH{ct:Amid} | Periplanetasin-2 | Amidation | Free | Linear | L | None | 15 | Antifungal | 0 % Hemolysis at 40 µM | Human | American Cockroach Periplaneta Americana | NA | Non-hemolytic | ||
| 28733329 | 2017 | YPCKLNLKLGKVPFH{ct:Amid} | Periplanetasin-2 | Amidation | Free | Linear | L | None | 15 | Antifungal | 0 % Hemolysis at 20 µM | Human | American Cockroach Periplaneta Americana | NA | Non-hemolytic | ||
| 28733329 | 2017 | YPCKLNLKLGKVPFH{ct:Amid} | Periplanetasin-2 | Amidation | Free | Linear | L | None | 15 | Antifungal | 0 % Hemolysis at 10 µM | Human | American Cockroach Periplaneta Americana | NA | Non-hemolytic | ||
| 28733329 | 2017 | YPCKLNLKLGKVPFH{ct:Amid} | Periplanetasin-2 | Amidation | Free | Linear | L | None | 15 | Antifungal | 0 % Hemolysis at 5 µM | Human | American Cockroach Periplaneta Americana | NA | Non-hemolytic | ||
| 28733329 | 2017 | YPCKLNLKLGKVPFH{ct:Amid} | Periplanetasin-2 | Amidation | Free | Linear | L | None | 15 | Antifungal | 0 % Hemolysis at 2.5 µM | Human | American Cockroach Periplaneta Americana | NA | Non-hemolytic | ||
| 28733329 | 2017 | YPCKLNLKLGKVPFH{ct:Amid} | Periplanetasin-2 | Amidation | Free | Linear | L | None | 15 | Antifungal | 0 % Hemolysis at 1.3 µM | Human | American Cockroach Periplaneta Americana | NA | Non-hemolytic | ||
| 28733329 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 99 % Hemolysis at 80 µM | Human | Bee Venom | NA | NA | ||
| 28733329 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 91.1 % Hemolysis at 40 µM | Human | Bee Venom | NA | NA | ||
| 28733329 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 70.2 % Hemolysis at 20 µM | Human | Bee Venom | NA | NA | ||
| 28733329 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 54.3 % Hemolysis at 10 µM | Human | Bee Venom | NA | NA | ||
| 28733329 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 23.8 % Hemolysis at 5 µM | Human | Bee Venom | NA | NA | ||
| 28733329 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 13.3 % Hemolysis at 2.5 µM | Human | Bee Venom | NA | NA | ||
| 28733329 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 1.9 % Hemolysis at 1.3 µM | Human | Bee Venom | NA | NA | ||
| 28608418 | 2017 | LVGKLLKGAVGDVCGLLPIC | OA-A1 | Free | Free | Linear | L | None | 20 | Anti-diabetic | 1.82% ± 0.14 % Hemolysis at 1 nM | Human | Skin Secretions Of Odorrana Andersonii | NA | NA | ||
| 28608418 | 2017 | LVGKLLKGAVGDVCGLLPIC | OA-A1 | Free | Free | Linear | L | None | 20 | Anti-diabetic | 2.82% ± 0.17 % Hemolysis at 10 nM | Human | Skin Secretions Of Odorrana Andersonii | NA | NA | ||
| 28608418 | 2017 | LVGKLLKGAVGDVCGLLPIC | OA-A1 | Free | Free | Linear | L | None | 20 | Anti-diabetic | 1.03% ± 0.86 % Hemolysis at 100 nM | Human | Skin Secretions Of Odorrana Andersonii | NA | NA | ||
| 28608418 | 2017 | LVGKLLKGAVGDVCGLLPIC | OA-A1 | Free | Free | Linear | L | None | 20 | Anti-diabetic | 2.72% ± 0.54 % Hemolysis at 1 µM | Human | Skin Secretions Of Odorrana Andersonii | NA | NA | ||
| 28608418 | 2017 | LVGKLLKGAVGDVCGLLPIC | OA-A1 | Free | Free | Linear | L | None | 20 | Anti-diabetic | 2.58% ± 0.11 % Hemolysis at 10 µM | Human | Skin Secretions Of Odorrana Andersonii | NA | NA | ||
| 28608418 | 2017 | LVGKLLKGAVGDVCGLLPIC | OA-A1 | Free | Free | Linear | L | None | 20 | Anti-diabetic | 1.26% ± 0.39 % Hemolysis at 100 µM | Human | Skin Secretions Of Odorrana Andersonii | NA | NA | ||
| 28883642 | 2017 | LCLRNWDQGHRP | L12P | Free | Free | Linear | L | None | 12 | Fungicidal | 0.32 % Hemolysis at 50 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LCLRNWDQGHRP | L12P | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 50 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LCLRNWDQGHRP | L12P | Free | Free | Linear | L | None | 12 | Fungicidal | 0.16 % Hemolysis at 100 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LCLRNWDQGHRP | L12P | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 100 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LCLRNWDQGHRP | L12P | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 250 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LCLRNWDQGHRP | L12P | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 250 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LCLRNWDQGHRP | L12P | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 500 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LCLRNWDQGHRP | L12P | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 500 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | WTFGQGTKVEIK | W12K | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 50 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | WTFGQGTKVEIK | W12K | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 50 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | WTFGQGTKVEIK | W12K | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 100 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | WTFGQGTKVEIK | W12K | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 100 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | WTFGQGTKVEIK | W12K | Free | Free | Linear | L | None | 12 | Fungicidal | 0.21 % Hemolysis at 250 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | WTFGQGTKVEIK | W12K | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 250 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | WTFGQGTKVEIK | W12K | Free | Free | Linear | L | None | 12 | Fungicidal | 0.16 % Hemolysis at 500 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | WTFGQGTKVEIK | W12K | Free | Free | Linear | L | None | 12 | Fungicidal | 0 % Hemolysis at 500 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | GYCSGGSCYS | G10S | Free | Free | Linear | L | None | 10 | Fungicidal | 0 % Hemolysis at 50 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | GYCSGGSCYS | G10S | Free | Free | Linear | L | None | 10 | Fungicidal | 0.59 % Hemolysis at 50 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | GYCSGGSCYS | G10S | Free | Free | Linear | L | None | 10 | Fungicidal | 0 % Hemolysis at 100 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | GYCSGGSCYS | G10S | Free | Free | Linear | L | None | 10 | Fungicidal | 0 % Hemolysis at 100 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | GYCSGGSCYS | G10S | Free | Free | Linear | L | None | 10 | Fungicidal | 0.11 % Hemolysis at 250 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | GYCSGGSCYS | G10S | Free | Free | Linear | L | None | 10 | Fungicidal | 0.51 % Hemolysis at 250 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | GYCSGGSCYS | G10S | Free | Free | Linear | L | None | 10 | Fungicidal | 0.53 % Hemolysis at 500 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | GYCSGGSCYS | G10S | Free | Free | Linear | L | None | 10 | Fungicidal | 0.98 % Hemolysis at 500 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LLVLRSLGPWHPGHCLLR | L18R | Free | Free | Linear | L | None | 18 | Fungicidal | 0 % Hemolysis at 50 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LLVLRSLGPWHPGHCLLR | L18R | Free | Free | Linear | L | None | 18 | Fungicidal | 4.4 % Hemolysis at 50 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LLVLRSLGPWHPGHCLLR | L18R | Free | Free | Linear | L | None | 18 | Fungicidal | 0 % Hemolysis at 100 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LLVLRSLGPWHPGHCLLR | L18R | Free | Free | Linear | L | None | 18 | Fungicidal | 5.8 % Hemolysis at 100 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LLVLRSLGPWHPGHCLLR | L18R | Free | Free | Linear | L | None | 18 | Fungicidal | 0 % Hemolysis at 250 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LLVLRSLGPWHPGHCLLR | L18R | Free | Free | Linear | L | None | 18 | Fungicidal | 7.54 % Hemolysis at 250 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LLVLRSLGPWHPGHCLLR | L18R | Free | Free | Linear | L | None | 18 | Fungicidal | 0.2 % Hemolysis at 500 µM in 30min | Human | Synthetic | NA | Non-hemolytic | ||
| 28883642 | 2017 | LLVLRSLGPWHPGHCLLR | L18R | Free | Free | Linear | L | None | 18 | Fungicidal | 9.66 % Hemolysis at 500 µM in 120min | Human | Synthetic | NA | Non-hemolytic | ||
| 28894233 | 2017 | IFGAILPLALGALKNLIK | RGD-Hylin a1 | Free | Free | Linear | L | None | 18 | Antibacterial | 30 % Hemolysis at 12.5 μg/ml | Human | Skin Of South American Tree Frogs | NA | NA | ||
| 28894233 | 2017 | IFGAILPLALGALKNLIK | RGD-Hylin a1 | Free | Free | Linear | L | None | 18 | Antibacterial | 76 % Hemolysis at 25 μg/ml | Human | Skin Of South American Tree Frogs | NA | NA | ||
| 28894233 | 2017 | IFGAILPLALGALKNLIK | RGD-Hylin a1 | Free | Free | Linear | L | None | 18 | Antibacterial | 82 % Hemolysis at 37 μg/ml | Human | Skin Of South American Tree Frogs | NA | NA | ||
| 28894233 | 2017 | IFGAILPLALGALKNLIK | RGD-Hylin a1 | Free | Free | Linear | L | None | 18 | Antibacterial | 99 % Hemolysis at 50 μg/ml | Human | Skin Of South American Tree Frogs | NA | NA | ||
| 28653651 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:Amid}{ct:Amid} | melittin | Amidation | Amidation | Linear | L | None | 26 | Antimicrobial | 10 % Hemolysis at 25 µM | Human | Bee Venom | α-Helix | NA | ||
| 28834399 | 2017 | YA{d}F{nnr:Cyn} | 1 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 0.8±0.1 % Hemolysis at 0 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}F{nnr:Cyn} | 1 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 2.2±0.0 % Hemolysis at 100 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}F{nnr:Cyn} | 1 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 2.4±0.1 % Hemolysis at 250 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}W{cyn} | 2 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 1.1±0.0 % Hemolysis at 0 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}W{cyn} | 2 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 1.7±0.0 % Hemolysis at 100 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YA{d}W{cyn} | 2 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, a = D-Ala | 3 | Antitumour | 2.4±0.0 % Hemolysis at 250 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}F{nnr:Cyn} | 3 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 1.2±0.1 % Hemolysis at 0 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}F{nnr:Cyn} | 3 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 1.8±0.1 % Hemolysis at 100 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}F{nnr:Cyn} | 3 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 1.8±0.1 % Hemolysis at 250 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}W{nnr:Cyn} | 4 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 0.8±0.1 % Hemolysis at 0 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}W{nnr:Cyn} | 4 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 1.0±0.1 % Hemolysis at 100 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28834399 | 2017 | YT{d}W{nnr:Cyn} | 4 | Free | Free | Linear | Mix | Cyn = trans-1-cinnamilpiperazine, t = D-Thr | 3 | Antitumour | 0.9±0.0 % Hemolysis at 250 µM | Human | Synthetic Peptidomimetics | NA | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}GRIL{ct:Amid} | 1 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 21(±4) % Hemolysis at 50 µM | Human | Amphibian Temporins | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}GRIL{ct:Amid} | 1 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 7(±3) % Hemolysis at 25 µM | Human | Amphibian Temporins | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}GRIL{ct:Amid} | 1 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 6(±3) % Hemolysis at 12.5 µM | Human | Amphibian Temporins | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}GRIL{ct:Amid} | 1 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 3(±2) % Hemolysis at 6.25 µM | Human | Amphibian Temporins | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}GRIL{ct:Amid} | 1 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 1(±1) % Hemolysis at 3.125 µM | Human | Amphibian Temporins | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}K{d}RIL{ct:Amid} | 9 | Amidation | Free | Linear | Mix | l = D-Leucine, k = D-Lys | 13 | Antibacterial | 7(±4) % Hemolysis at 50 µM | Human | Tl Analogue | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}K{d}RIL{ct:Amid} | 9 | Amidation | Free | Linear | Mix | l = D-Leucine, k = D-Lys | 13 | Antibacterial | 5(±3) % Hemolysis at 25 µM | Human | Tl Analogue | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}K{d}RIL{ct:Amid} | 9 | Amidation | Free | Linear | Mix | l = D-Leucine, k = D-Lys | 13 | Antibacterial | 5(±2) % Hemolysis at 12.5 µM | Human | Tl Analogue | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}K{d}RIL{ct:Amid} | 9 | Amidation | Free | Linear | Mix | l = D-Leucine, k = D-Lys | 13 | Antibacterial | 1(±2) % Hemolysis at 6.25 µM | Human | Tl Analogue | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}K{d}RIL{ct:Amid} | 9 | Amidation | Free | Linear | Mix | l = D-Leucine, k = D-Lys | 13 | Antibacterial | 0(±1) % Hemolysis at 3.125 µM | Human | Tl Analogue | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}WRIL{ct:Amid} | 10 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 37(±1) % Hemolysis at 50 µM | Human | Tl Analogue | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}WRIL{ct:Amid} | 10 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 20(±3) % Hemolysis at 25 µM | Human | Tl Analogue | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}WRIL{ct:Amid} | 10 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 7(±1) % Hemolysis at 12.5 µM | Human | Tl Analogue | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}WRIL{ct:Amid} | 10 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 4(±2) % Hemolysis at 6.25 µM | Human | Tl Analogue | α-Helix | NA | ||
| 28863356 | 2017 | FVPWFSKFL{d}WRIL{ct:Amid} | 10 | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial | 2(±1) % Hemolysis at 3.125 µM | Human | Tl Analogue | α-Helix | NA | ||
| 27820977 | 2017 | YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRC | RVG9RC | Free | Free | Linear | L | None | 42 | Cytotoxic | No Hemolysis activity at 7 pH | Human | Fusion Peptide | NA | Non-hemolytic | ||
| 27820977 | 2017 | YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRC | RVG9RC | Free | Free | Linear | L | None | 42 | Cytotoxic | 36 % Hemolysis at 5.5 pH | Human | Fusion Peptide | NA | NA | ||
| 27820977 | 2017 | YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRLLC | RVG9R2LC | Free | Free | Linear | L | None | 44 | Cytotoxic | 50 % Hemolysis at 5.5 pH | Human | Fusion Peptide | NA | NA | ||
| 27820977 | 2017 | YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRLLLC | RVG9R3LC | Free | Free | Linear | L | None | 45 | Cytotoxic | 52 % Hemolysis at 6 pH | Human | Fusion Peptide | NA | NA | ||
| 27820977 | 2017 | YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRLLLC | RVG9R3LC | Free | Free | Linear | L | None | 45 | Cytotoxic | 61 % Hemolysis at 5.5 pH | Human | Fusion Peptide | NA | NA | ||
| 27820977 | 2017 | YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRLLLLC | RVG9R4LC | Free | Free | Linear | L | None | 46 | Cytotoxic | 72 % Hemolysis at 6 pH | Human | Fusion Peptide | NA | NA | ||
| 27820977 | 2017 | YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRLLLLC | RVG9R4LC | Free | Free | Linear | L | None | 46 | Cytotoxic | 80 % Hemolysis at 5.5 pH | Human | Fusion Peptide | NA | NA | ||
| 27820977 | 2017 | YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRLLLLLC | RVG9R5LC | Free | Free | Linear | L | None | 47 | Cytotoxic | 85 % Hemolysis at 6 pH | Human | Fusion Peptide | NA | NA | ||
| 27820977 | 2017 | YTIWMPENPRPGTPCDIFTNSRGKRASNGGGGRRRRRRRRRLLLLLC | RVG9R5LC | Free | Free | Linear | L | None | 47 | Cytotoxic | 91 % Hemolysis at 5.5 pH | Human | Fusion Peptide | NA | NA | ||
| 27937055 | 2017 | GHHNGR | oleylpeptide | Free | Free | Linear | L | None | 6 | Anticancer | 1.3 ± 0.04 % Hemolysis at 2 mM | Human | Resin | β-Turns and Bent | Non-hemolytic | ||
| 29185466 | 2017 | GFGMALKLLKKVL{ct:Amid} | Macropin | Amidation | Free | Linear | L | None | 13 | Anti-bioflm, Antibacterial | 5 % Hemolysis at 25 µM | Human | Macropis Fulvipes Venom | α-Helical | NA | ||
| 29185466 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 93 % Hemolysis at 25 µM | Human | Bee Venom | α-Helical | NA | ||
| 29163899 | 2017 | C{d}WK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH1 | Amidation | Free | Cyclic | Mix | None | 6 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH2 | Amidation | Free | Cyclic | Mix | None | 7 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C{d}WW{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH3 | Amidation | Free | Cyclic | Mix | None | 8 | Antimicrobial | MHC at 500 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WW{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH4 | Amidation | Free | Cyclic | Mix | None | 9 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WW{d}KK{d}KK{d}KC{cyc:N-C}{ct:Amid} | RH5 | Amidation | Free | Cyclic | Mix | None | 10 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WW{d}WK{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH6 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 31 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C{d}WW{d}WW{d}KK{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH7 | Amidation | Free | Cyclic | Mix | None | 12 | Antimicrobial | MHC at 31 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWwWkKkKkC{cyc:N-C}{ct:Amid} | RH6m | Amidation | Free | Cyclic | Mix | Cyclized with α,α′-dichloro-meta-xylene | 11 | Antimicrobial | MHC at 31 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWwWkKkKkC{cyc:N-C}{ct:Amid} | RH6o | Amidation | Free | Cyclic | Mix | Cyclized with α,α′-dichloro-ortho-xylene. | 11 | Antimicrobial | MHC at 31 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWwWkKkKkC{cyc:N-C}{ct:Amid} | RH6ss | Amidation | Free | Cyclic | Mix | Cyclized with disulfide bridge | 11 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CF{d}FF{d}FK{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH8 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 500 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CL{d}LL{d}LK{d}KK{d}KK{d}C{cyc:N-C}{ct:Amid} | RH9 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at >2000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CK{d}KK{d}WW{d}WW{d}KK{d}C{cyc:N-C}{ct:Amid} | RH10 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 250 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WK{d}KK{d}KK{d}WW{d}C{cyc:N-C}{ct:Amid} | RH11 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C{d}WW{d}KK{d}KK{d}KW{d}WC{d}{cyc:N-C}{ct:Amid} | dRH11 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWkKkKkWwC{cyc:N-C}{ct:Amid} | RH11m | Amidation | Free | Cyclic | Mix | Cyclized with α,α′-dichloro-meta-xylene | 11 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwWkKkKkWwC{cyc:N-C}{ct:Amid} | RH11o | Amidation | Free | Cyclic | Mix | Cyclized with α,α′-dichloro-ortho-xylene. | 11 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CK{d}WK{d}WK{d}WK{d}WK{d}C{cyc:N-C}{ct:Amid} | RH12 | Amidation | Free | Cyclic | Mix | None | 10 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CWW{d}KK{d}KK{d}KW{d}WW{d}C{cyc:N-C}{ct:Amid} | RH13 | Amidation | Free | Cyclic | Mix | None | 12 | Antimicrobial | MHC at 125 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C{d}W{d}WK{d}KK{d}KK{d}WW{d}WC{d}{cyc:N-C}{ct:Amid} | dRH13 | Amidation | Free | Cyclic | Mix | None | 12 | Antimicrobial | Minimum Hemolytic Concentration | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}WK{d}KK{d}KW{d}WW{d}C{cyc:N-C}{ct:Amid} | RH14 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 8 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CW{d}KK{d}KK{d}KK{d}WW{d}C{cyc:N-C}{ct:Amid} | RH15 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 250 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CL{d}LK{d}KK{d}KK{d}LL{d}C{cyc:N-C}{ct:Amid} | RH16 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at >2000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CWWKKKKKWWC{cyc:N-C}{ct:Amid} | RH17 | Amidation | Free | Cyclic | Mix | None | 11 | Antimicrobial | MHC at 250 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | C({nnr:Me})wWkKkKkW({nnr:Me})wC{cyc:N-C}{ct:Amid} | RH18 | Amidation | Free | Cyclic | Mix | Me = N-methylation of the peptide bond. | 11 | Antimicrobial | MHC at 8 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | Cw({nnr:Me})WkKkKkW({nnr:Me})wC{cyc:N-C}{ct:Amid} | RH19 | Amidation | Free | Cyclic | Mix | Me = N-methylation of the peptide bond. | 11 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 29163899 | 2017 | CwW({nnr:Me})kKkK({nnr:Me})kWwC{cyc:N-C}{ct:Amid} | RH20 | Amidation | Free | Cyclic | Mix | Me = N-methylation of the peptide bond. | 11 | Antimicrobial | MHC at 1000 µg/mL | Human | Camp | β-Sheet | NA | ||
| 28904355 | 2017 | NPEKALEPLIAIQIAIKGMLNGWFTGVGFRRKR | LysAB2 P0 | Free | Free | Linear | L | None | 33 | Antibacterial | 63.2 % Hemolysis at 64 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab2 | α-Helix | NA | ||
| 28904355 | 2017 | NPEKALEPLIAIQIAIKGMLNGWFTGVGFRRKR | LysAB2 P0 | Free | Free | Linear | L | None | 33 | Antibacterial | 100 % Hemolysis at 128 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab3 | α-Helix | NA | ||
| 28904355 | 2017 | EKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P1 | Free | Free | Linear | L | None | 31 | Antibacterial | 50 % Hemolysis at 32 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab4 | α-Helix | NA | ||
| 28904355 | 2017 | EKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P1 | Free | Free | Linear | L | None | 31 | Antibacterial | 60 % Hemolysis at 64 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab5 | α-Helix | NA | ||
| 28904355 | 2017 | EKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P1 | Free | Free | Linear | L | None | 31 | Antibacterial | 80 % Hemolysis at 128 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab6 | α-Helix | NA | ||
| 28904355 | 2017 | EKALEKLIAIQKAIKGMLAGWFTGVGARRKR | LysAB2 P2 | Free | Free | Linear | L | None | 31 | Antibacterial | 90 % Hemolysis at 128 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab7 | α-Helix | NA | ||
| 28904355 | 2017 | NPEKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P3 | Free | Free | Linear | L | None | 33 | Antibacterial | 1.97 % Hemolysis at 4 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab8 | α-Helix | NA | ||
| 28904355 | 2017 | NPEKALEKLIAIQKAIKGMLNGWFTGVGFRRKR | LysAB2 P3 | Free | Free | Linear | L | None | 33 | Antibacterial | <10 % Hemolysis at 256 µM | Human | Acinetobacter Baumannii Phage Endolysin Lysab9 | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Hc-CATH | Free | Free | Linear | L | None | 30 | Antimicrobial | 0 % Hemolysis at 12.5 µg/mL | Human | Sea Snake, Hydrophis Cyanocinctus | α-Helix | Non-hemolytic | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Hc-CATH | Free | Free | Linear | L | None | 30 | Antimicrobial | 0 % Hemolysis at 25 µg/mL | Human | Sea Snake, Hydrophis Cyanocinctus | α-Helix | Non-hemolytic | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Hc-CATH | Free | Free | Linear | L | None | 30 | Antimicrobial | 0 % Hemolysis at 50 µg/mL | Human | Sea Snake, Hydrophis Cyanocinctus | α-Helix | Non-hemolytic | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Hc-CATH | Free | Free | Linear | L | None | 30 | Antimicrobial | 0 % Hemolysis at 100 µg/mL | Human | Sea Snake, Hydrophis Cyanocinctus | α-Helix | Non-hemolytic | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Hc-CATH | Free | Free | Linear | L | None | 30 | Antimicrobial | 5.25 % Hemolysis at 200 µg/mL | Human | Sea Snake, Hydrophis Cyanocinctus | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRK{ct:Amid} | Hc1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 1.09 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRK{ct:Amid} | Hc1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 2.9 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRK{ct:Amid} | Hc1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 3.26 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRK{ct:Amid} | Hc1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 4.35 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFRK{ct:Amid} | Hc1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 8.33 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFR{ct:Amid} | Hc2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 1.45 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFR{ct:Amid} | Hc2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 0.36 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFR{ct:Amid} | Hc2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 1.09 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFR{ct:Amid} | Hc2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 2.9 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFR{ct:Amid} | Hc2 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 3.98 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKF{ct:Amid} | Hc3 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 2.17 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKF{ct:Amid} | Hc3 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 4.35 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKF{ct:Amid} | Hc3 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 5.43 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKF{ct:Amid} | Hc3 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 5.8 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKF{ct:Amid} | Hc3 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 6.88 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKK{ct:Amid} | Hc4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 2.9 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKK{ct:Amid} | Hc4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 1.81 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKK{ct:Amid} | Hc4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 1.09 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKK{ct:Amid} | Hc4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 2.54 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKK{ct:Amid} | Hc4 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 4.71 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVK{ct:Amid} | Hc5 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 3.62 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVK{ct:Amid} | Hc5 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 1.09 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVK{ct:Amid} | Hc5 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 2.9 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVK{ct:Amid} | Hc5 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 5.43 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVK{ct:Amid} | Hc5 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 5.07 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAV{ct:Amid} | Hc6 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 1.45 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAV{ct:Amid} | Hc6 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 2.9 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAV{ct:Amid} | Hc6 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 1.81 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAV{ct:Amid} | Hc6 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0.72 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAV{ct:Amid} | Hc6 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 3.62 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRA{ct:Amid} | Hc7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 2.17 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRA{ct:Amid} | Hc7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1.45 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRA{ct:Amid} | Hc7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.72 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRA{ct:Amid} | Hc7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3.26 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRA{ct:Amid} | Hc7 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 5.07 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKFRK{ct:Amid} | Hc8 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 2.17 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKFRK{ct:Amid} | Hc8 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 3.62 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKFRK{ct:Amid} | Hc8 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 0.36 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKFRK{ct:Amid} | Hc8 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 2.17 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKFRK{ct:Amid} | Hc8 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 1.45 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKFRK{ct:Amid} | Hc9 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 3.99 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKFRK{ct:Amid} | Hc9 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 2.9 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKFRK{ct:Amid} | Hc9 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 2.54 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKFRK{ct:Amid} | Hc9 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 2.54 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKFRK{ct:Amid} | Hc9 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 4.17 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KRLLKSVRRAVKKFRK{ct:Amid} | Hc10 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 2.17 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KRLLKSVRRAVKKFRK{ct:Amid} | Hc10 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 2.9 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KRLLKSVRRAVKKFRK{ct:Amid} | Hc10 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 3.99 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KRLLKSVRRAVKKFRK{ct:Amid} | Hc10 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 1.81 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KRLLKSVRRAVKKFRK{ct:Amid} | Hc10 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 2.17 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | RLLKSVRRAVKKFRK{ct:Amid} | Hc11 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 4.71 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | RLLKSVRRAVKKFRK{ct:Amid} | Hc11 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 3.26 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | RLLKSVRRAVKKFRK{ct:Amid} | Hc11 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 2.9 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | RLLKSVRRAVKKFRK{ct:Amid} | Hc11 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 4.71 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | RLLKSVRRAVKKFRK{ct:Amid} | Hc11 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 5.8 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LLKSVRRAVKKFRK{ct:Amid} | Hc12 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 2.17 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LLKSVRRAVKKFRK{ct:Amid} | Hc12 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 1.45 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LLKSVRRAVKKFRK{ct:Amid} | Hc12 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0.11 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LLKSVRRAVKKFRK{ct:Amid} | Hc12 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 4.35 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LLKSVRRAVKKFRK{ct:Amid} | Hc12 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 3.99 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LKSVRRAVKKFRK{ct:Amid} | Hc13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1.45 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LKSVRRAVKKFRK{ct:Amid} | Hc13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1.81 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LKSVRRAVKKFRK{ct:Amid} | Hc13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.36 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LKSVRRAVKKFRK{ct:Amid} | Hc13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1.45 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | LKSVRRAVKKFRK{ct:Amid} | Hc13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 4.16 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKF{ct:Amid} | Hc14 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 3.98 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKF{ct:Amid} | Hc14 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 2.54 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKF{ct:Amid} | Hc14 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 1.98 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKF{ct:Amid} | Hc14 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 1.36 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FFKRLLKSVRRAVKKF{ct:Amid} | Hc14 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 3.26 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKF{ct:Amid} | Hc15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 3.62 % Hemolysis at 12.5 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKF{ct:Amid} | Hc15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 4.35 % Hemolysis at 25 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKF{ct:Amid} | Hc15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 5.07 % Hemolysis at 50 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKF{ct:Amid} | Hc15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 8.7 % Hemolysis at 100 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | FKRLLKSVRRAVKKF{ct:Amid} | Hc15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 9.06 % Hemolysis at 200 µg/mL | Human | Hc-Cath Truncated Derivatives | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFCWTKSIPPKPC | H3TI | Free | Free | Linear | L | None | 28 | Antimicrobial | 1.8 % Hemolysis at 12.5 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFCWTKSIPPKPC | H3TI | Free | Free | Linear | L | None | 28 | Antimicrobial | 1.55 % Hemolysis at 25 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFCWTKSIPPKPC | H3TI | Free | Free | Linear | L | None | 28 | Antimicrobial | 2.28 % Hemolysis at 50 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFCWTKSIPPKPC | H3TI | Free | Free | Linear | L | None | 28 | Antimicrobial | 3.5 % Hemolysis at 100 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRLLKSVRRAVKKFCWTKSIPPKPC | H3TI | Free | Free | Linear | L | None | 28 | Antimicrobial | 7.39 % Hemolysis at 200 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRFFKSFRRAFKKFCWTKSIPPKPC | H3TIF | Free | Free | Linear | L | None | 28 | Antimicrobial | 1.6 % Hemolysis at 12.5 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRFFKSFRRAFKKFCWTKSIPPKPC | H3TIF | Free | Free | Linear | L | None | 28 | Antimicrobial | 1.23 % Hemolysis at 25 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRFFKSFRRAFKKFCWTKSIPPKPC | H3TIF | Free | Free | Linear | L | None | 28 | Antimicrobial | 1.96 % Hemolysis at 50 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRFFKSFRRAFKKFCWTKSIPPKPC | H3TIF | Free | Free | Linear | L | None | 28 | Antimicrobial | 2.35 % Hemolysis at 100 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | KFFKRFFKSFRRAFKKFCWTKSIPPKPC | H3TIF | Free | Free | Linear | L | None | 28 | Antimicrobial | 5.53 % Hemolysis at 200 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRLLKSVRRAVKKF{ct:Amid} | TIH3 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 1.94 % Hemolysis at 12.5 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRLLKSVRRAVKKF{ct:Amid} | TIH3 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 0.94 % Hemolysis at 25 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRLLKSVRRAVKKF{ct:Amid} | TIH3 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 1.76 % Hemolysis at 50 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRLLKSVRRAVKKF{ct:Amid} | TIH3 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 3.17 % Hemolysis at 100 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRLLKSVRRAVKKF{ct:Amid} | TIH3 | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 3.08 % Hemolysis at 200 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRFFKSFRRAFKKF{ct:Amid} | TIH3F | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 4.91 % Hemolysis at 12.5 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRFFKSFRRAFKKF{ct:Amid} | TIH3F | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 2.62 % Hemolysis at 25 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRFFKSFRRAFKKF{ct:Amid} | TIH3F | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 5.44 % Hemolysis at 50 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRFFKSFRRAFKKF{ct:Amid} | TIH3F | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 6.41 % Hemolysis at 100 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28572668 | 2017 | CWTKSIPPKPCKFFKRFFKSFRRAFKKF{ct:Amid} | TIH3F | Amidation | Free | Linear | L | None | 28 | Antimicrobial | 10 % Hemolysis at 200 µg/mL | Human | Hybrid Peptide | α-Helix | NA | ||
| 28203232 | 2017 | K{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 1 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 2 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 16 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 3 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 32 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 4 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 16 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 5 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 6 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 64 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C16 = Heksadecanoic fatty acid chain}{ct:Amid} | 7 | Amidation | X = C16 = Heksadecanoic fatty acid chain | Linear | L | C16 = Heksadecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 64 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | K{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 8 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 9 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 128 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 10 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 11 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 12 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 13 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 128 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C14 = Tetradecanoic fatty acid chain}{ct:Amid} | 14 | Amidation | X = C14 = Tetradecanoic fatty acid chain | Linear | L | C14 = Tetradecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | K{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 15 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at 1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 16 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 17 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 18 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 19 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 20 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at 1000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C12 = Dodecanoic fatty acid chain}{ct:Amid} | 21 | Amidation | X = C12 = Dodecanoic fatty acid chain | Linear | L | C12 = Dodecanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | K{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 22 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 23 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at 4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 24 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 25 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 26 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 27 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C10 = Decanoic fatty acid chain}{ct:Amid} | 28 | Amidation | X = C10 = Decanoic fatty acid chain | Linear | L | C10 = Decanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | K{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 29 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 1 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KK{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 30 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKK{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 31 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KKKK{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 32 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KG{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 33 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 2 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGK{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 34 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 3 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28203232 | 2017 | KGKG{nt:X = C8 = Octanoic fatty acid chain}{ct:Amid} | 35 | Amidation | X = C8 = Octanoic fatty acid chain | Linear | L | C8 = Octanoic fatty acid chain | 4 | Antimicrobial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Cationic Lipopeptides | NA | NA | ||
| 28402481 | 2017 | FFPMLADLVSKIFGK{ct:Amid} | Temporin-DY1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 14.5 % Hemolysis at 200 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FFPMLADLVSKIFGK{ct:Amid} | Temporin-DY1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 11.2 % Hemolysis at 100 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FFPMLADLVSKIFGK{ct:Amid} | Temporin-DY1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 7.8 % Hemolysis at 50 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FFPMLADLVSKIFGK{ct:Amid} | Temporin-DY1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPMLADLVSKIFGK{ct:Amid} | Temporin-DY1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPMLADLVSKIFGK{ct:Amid} | Temporin-DY1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPMLADLVSKIFGK{ct:Amid} | Temporin-DY1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPMLADLVSKIFGK{ct:Amid} | Temporin-DY1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLPLLAGLAANFLPTIICKIARKC{ct:Amid} | Brevinin-1DY1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 100 % Hemolysis at 200 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAANFLPTIICKIARKC{ct:Amid} | Brevinin-1DY1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 91.5 % Hemolysis at 100 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAANFLPTIICKIARKC{ct:Amid} | Brevinin-1DY1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 89.3 % Hemolysis at 50 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAANFLPTIICKIARKC{ct:Amid} | Brevinin-1DY1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 86.9 % Hemolysis at 25 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAANFLPTIICKIARKC{ct:Amid} | Brevinin-1DY1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 85.2 % Hemolysis at 12.5 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAANFLPTIICKIARKC{ct:Amid} | Brevinin-1DY1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 84.9 % Hemolysis at 6.3 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAANFLPTIICKIARKC{ct:Amid} | Brevinin-1DY1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 10.8 % Hemolysis at 3.1 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAANFLPTIICKIARKC{ct:Amid} | Brevinin-1DY1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 10.3 % Hemolysis at 1.6 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | GIMDTIKNAAKDVVQSLLNKASCKLAKTC{ct:Amid} | Palustrin-2DY1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 19.5 % Hemolysis at 200 µM | Human | Amolops Daiyunensis | NA | NA | ||
| 28402481 | 2017 | GIMDTIKNAAKDVVQSLLNKASCKLAKTC{ct:Amid} | Palustrin-2DY1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GIMDTIKNAAKDVVQSLLNKASCKLAKTC{ct:Amid} | Palustrin-2DY1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GIMDTIKNAAKDVVQSLLNKASCKLAKTC{ct:Amid} | Palustrin-2DY1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GIMDTIKNAAKDVVQSLLNKASCKLAKTC{ct:Amid} | Palustrin-2DY1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GIMDTIKNAAKDVVQSLLNKASCKLAKTC{ct:Amid} | Palustrin-2DY1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GIMDTIKNAAKDVVQSLLNKASCKLAKTC{ct:Amid} | Palustrin-2DY1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GIMDTIKNAAKDVVQSLLNKASCKLAKTC{ct:Amid} | Palustrin-2DY1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CGYKYGCMVKVDR{ct:Amid} | Daiyunin-1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 200 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CGYKYGCMVKVDR{ct:Amid} | Daiyunin-1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CGYKYGCMVKVDR{ct:Amid} | Daiyunin-1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CGYKYGCMVKVDR{ct:Amid} | Daiyunin-1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CGYKYGCMVKVDR{ct:Amid} | Daiyunin-1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CGYKYGCMVKVDR{ct:Amid} | Daiyunin-1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CGYKYGCMVKVDR{ct:Amid} | Daiyunin-1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CGYKYGCMVKVDR{ct:Amid} | Daiyunin-1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFGTKGIFSKVEPIFCKISHSC{ct:Amid} | Daiyunin-2 | Amidation | Free | Linear | L | None | 22 | Antioxidant, Antimicrobial | 0 % Hemolysis at 200 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFGTKGIFSKVEPIFCKISHSC{ct:Amid} | Daiyunin-2 | Amidation | Free | Linear | L | None | 22 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFGTKGIFSKVEPIFCKISHSC{ct:Amid} | Daiyunin-2 | Amidation | Free | Linear | L | None | 22 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFGTKGIFSKVEPIFCKISHSC{ct:Amid} | Daiyunin-2 | Amidation | Free | Linear | L | None | 22 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFGTKGIFSKVEPIFCKISHSC{ct:Amid} | Daiyunin-2 | Amidation | Free | Linear | L | None | 22 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFGTKGIFSKVEPIFCKISHSC{ct:Amid} | Daiyunin-2 | Amidation | Free | Linear | L | None | 22 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFGTKGIFSKVEPIFCKISHSC{ct:Amid} | Daiyunin-2 | Amidation | Free | Linear | L | None | 22 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFGTKGIFSKVEPIFCKISHSC{ct:Amid} | Daiyunin-2 | Amidation | Free | Linear | L | None | 22 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | IVRPPIRCKAAFC{ct:Amid} | Daiyunin-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 200 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | IVRPPIRCKAAFC{ct:Amid} | Daiyunin-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | IVRPPIRCKAAFC{ct:Amid} | Daiyunin-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | IVRPPIRCKAAFC{ct:Amid} | Daiyunin-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | IVRPPIRCKAAFC{ct:Amid} | Daiyunin-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | IVRPPIRCKAAFC{ct:Amid} | Daiyunin-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | IVRPPIRCKAAFC{ct:Amid} | Daiyunin-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | IVRPPIRCKAAFC{ct:Amid} | Daiyunin-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Amolops Daiyunensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLPLLAGLAAKWFGK{ct:Amid} | Temporin-HB1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 78.1 % Hemolysis at 200 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAAKWFGK{ct:Amid} | Temporin-HB1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 48.8 % Hemolysis at 100 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAAKWFGK{ct:Amid} | Temporin-HB1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 20.2 % Hemolysis at 50 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAAKWFGK{ct:Amid} | Temporin-HB1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 7.3 % Hemolysis at 25 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPLLAGLAAKWFGK{ct:Amid} | Temporin-HB1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLPLLAGLAAKWFGK{ct:Amid} | Temporin-HB1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLPLLAGLAAKWFGK{ct:Amid} | Temporin-HB1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLPLLAGLAAKWFGK{ct:Amid} | Temporin-HB1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLPFLAGLFGKIFGK{ct:Amid} | Temporin-HB2 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 78 % Hemolysis at 200 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPFLAGLFGKIFGK{ct:Amid} | Temporin-HB2 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 77.8 % Hemolysis at 100 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPFLAGLFGKIFGK{ct:Amid} | Temporin-HB2 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 77.4 % Hemolysis at 50 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPFLAGLFGKIFGK{ct:Amid} | Temporin-HB2 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 64.8 % Hemolysis at 25 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPFLAGLFGKIFGK{ct:Amid} | Temporin-HB2 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 33.3 % Hemolysis at 12.5 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPFLAGLFGKIFGK{ct:Amid} | Temporin-HB2 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 7.9 % Hemolysis at 6.3 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPFLAGLFGKIFGK{ct:Amid} | Temporin-HB2 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLPFLAGLFGKIFGK{ct:Amid} | Temporin-HB2 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLPAIIGMAAKVLPAFLCKITKKC{ct:Amid} | Brevinin-1HB1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 61.8 % Hemolysis at 200 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPAIIGMAAKVLPAFLCKITKKC{ct:Amid} | Brevinin-1HB1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 61.3 % Hemolysis at 100 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPAIIGMAAKVLPAFLCKITKKC{ct:Amid} | Brevinin-1HB1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 60.6 % Hemolysis at 50 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPAIIGMAAKVLPAFLCKITKKC{ct:Amid} | Brevinin-1HB1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 46 % Hemolysis at 25 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPAIIGMAAKVLPAFLCKITKKC{ct:Amid} | Brevinin-1HB1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 38.1 % Hemolysis at 12.5 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPAIIGMAAKVLPAFLCKITKKC{ct:Amid} | Brevinin-1HB1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 10.2 % Hemolysis at 6.3 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | FLPAIIGMAAKVLPAFLCKITKKC{ct:Amid} | Brevinin-1HB1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLPAIIGMAAKVLPAFLCKITKKC{ct:Amid} | Brevinin-1HB1 | Amidation | Free | Linear | L | None | 24 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GILMDTFKGAAKNVAGFLLDKLKCKITGGC{ct:Amid} | Pelophylaxin-HB1 | Amidation | Free | Linear | L | None | 30 | Antioxidant, Antimicrobial | 40.9 % Hemolysis at 200 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GILMDTFKGAAKNVAGFLLDKLKCKITGGC{ct:Amid} | Pelophylaxin-HB1 | Amidation | Free | Linear | L | None | 30 | Antioxidant, Antimicrobial | 23.1 % Hemolysis at 100 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GILMDTFKGAAKNVAGFLLDKLKCKITGGC{ct:Amid} | Pelophylaxin-HB1 | Amidation | Free | Linear | L | None | 30 | Antioxidant, Antimicrobial | 11.7 % Hemolysis at 50 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GILMDTFKGAAKNVAGFLLDKLKCKITGGC{ct:Amid} | Pelophylaxin-HB1 | Amidation | Free | Linear | L | None | 30 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GILMDTFKGAAKNVAGFLLDKLKCKITGGC{ct:Amid} | Pelophylaxin-HB1 | Amidation | Free | Linear | L | None | 30 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GILMDTFKGAAKNVAGFLLDKLKCKITGGC{ct:Amid} | Pelophylaxin-HB1 | Amidation | Free | Linear | L | None | 30 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GILMDTFKGAAKNVAGFLLDKLKCKITGGC{ct:Amid} | Pelophylaxin-HB1 | Amidation | Free | Linear | L | None | 30 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GILMDTFKGAAKNVAGFLLDKLKCKITGGC{ct:Amid} | Pelophylaxin-HB1 | Amidation | Free | Linear | L | None | 30 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GAPKGCWTKSYPPQPCFGKK{ct:Amid} | Ranacyclin-HB1 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 8.5 % Hemolysis at 200 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GAPKGCWTKSYPPQPCFGKK{ct:Amid} | Ranacyclin-HB1 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 6.8 % Hemolysis at 100 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GAPKGCWTKSYPPQPCFGKK{ct:Amid} | Ranacyclin-HB1 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GAPKGCWTKSYPPQPCFGKK{ct:Amid} | Ranacyclin-HB1 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GAPKGCWTKSYPPQPCFGKK{ct:Amid} | Ranacyclin-HB1 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GAPKGCWTKSYPPQPCFGKK{ct:Amid} | Ranacyclin-HB1 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GAPKGCWTKSYPPQPCFGKK{ct:Amid} | Ranacyclin-HB1 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GAPKGCWTKSYPPQPCFGKK{ct:Amid} | Ranacyclin-HB1 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | GLWTTIKEGLKKFSLGVLDKIRCKIAGGC{ct:Amid} | Palustrin-2HB1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 100 % Hemolysis at 200 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GLWTTIKEGLKKFSLGVLDKIRCKIAGGC{ct:Amid} | Palustrin-2HB1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 68.4 % Hemolysis at 100 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GLWTTIKEGLKKFSLGVLDKIRCKIAGGC{ct:Amid} | Palustrin-2HB1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 45.4 % Hemolysis at 50 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GLWTTIKEGLKKFSLGVLDKIRCKIAGGC{ct:Amid} | Palustrin-2HB1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 35.2 % Hemolysis at 25 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GLWTTIKEGLKKFSLGVLDKIRCKIAGGC{ct:Amid} | Palustrin-2HB1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 22.8 % Hemolysis at 12.5 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GLWTTIKEGLKKFSLGVLDKIRCKIAGGC{ct:Amid} | Palustrin-2HB1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 13 % Hemolysis at 6.3 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GLWTTIKEGLKKFSLGVLDKIRCKIAGGC{ct:Amid} | Palustrin-2HB1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 8.4 % Hemolysis at 3.1 µM | Human | Pelophylax Hubeiensis | NA | NA | ||
| 28402481 | 2017 | GLWTTIKEGLKKFSLGVLDKIRCKIAGGC{ct:Amid} | Palustrin-2HB1 | Amidation | Free | Linear | L | None | 29 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Pelophylax Hubeiensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLTGLIGGLMKALGK{ct:Amid} | Temporin-MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 99.8 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | FLTGLIGGLMKALGK{ct:Amid} | Temporin-MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 95.3 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | FLTGLIGGLMKALGK{ct:Amid} | Temporin-MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 59 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | FLTGLIGGLMKALGK{ct:Amid} | Temporin-MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 13 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | FLTGLIGGLMKALGK{ct:Amid} | Temporin-MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLTGLIGGLMKALGK{ct:Amid} | Temporin-MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLTGLIGGLMKALGK{ct:Amid} | Temporin-MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FLTGLIGGLMKALGK{ct:Amid} | Temporin-MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPLVLGALGSILPKVFGK{ct:Amid} | Temporin-MS4 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 92.4 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | FFPLVLGALGSILPKVFGK{ct:Amid} | Temporin-MS4 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 84.8 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPLVLGALGSILPKVFGK{ct:Amid} | Temporin-MS4 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 39.9 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPLVLGALGSILPKVFGK{ct:Amid} | Temporin-MS4 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 15.9 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | FFPLVLGALGSILPKVFGK{ct:Amid} | Temporin-MS4 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPLVLGALGSILPKVFGK{ct:Amid} | Temporin-MS4 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPLVLGALGSILPKVFGK{ct:Amid} | Temporin-MS4 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFPLVLGALGSILPKVFGK{ct:Amid} | Temporin-MS4 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | QYRPGSFGPLNQK{ct:Amid} | Maosonensis-1MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | QYRPGSFGPLNQK{ct:Amid} | Maosonensis-1MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | QYRPGSFGPLNQK{ct:Amid} | Maosonensis-1MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | QYRPGSFGPLNQK{ct:Amid} | Maosonensis-1MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | QYRPGSFGPLNQK{ct:Amid} | Maosonensis-1MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | QYRPGSFGPLNQK{ct:Amid} | Maosonensis-1MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | QYRPGSFGPLNQK{ct:Amid} | Maosonensis-1MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | QYRPGSFGPLNQK{ct:Amid} | Maosonensis-1MS1 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DYSIRTRLHQESSRNDF{ct:Amid} | Odorranaopin-MS1 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DYSIRTRLHQESSRNDF{ct:Amid} | Odorranaopin-MS1 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DYSIRTRLHQESSRNDF{ct:Amid} | Odorranaopin-MS1 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DYSIRTRLHQESSRNDF{ct:Amid} | Odorranaopin-MS1 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DYSIRTRLHQESSRNDF{ct:Amid} | Odorranaopin-MS1 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DYSIRTRLHQESSRNDF{ct:Amid} | Odorranaopin-MS1 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DYSIRTRLHQESSRNDF{ct:Amid} | Odorranaopin-MS1 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DYSIRTRLHQESSRNDF{ct:Amid} | Odorranaopin-MS1 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DNVYSRPPQRFGQNVIS{ct:Amid} | Odorranaopin-MS2 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DNVYSRPPQRFGQNVIS{ct:Amid} | Odorranaopin-MS2 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DNVYSRPPQRFGQNVIS{ct:Amid} | Odorranaopin-MS2 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DNVYSRPPQRFGQNVIS{ct:Amid} | Odorranaopin-MS2 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DNVYSRPPQRFGQNVIS{ct:Amid} | Odorranaopin-MS2 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DNVYSRPPQRFGQNVIS{ct:Amid} | Odorranaopin-MS2 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DNVYSRPPQRFGQNVIS{ct:Amid} | Odorranaopin-MS2 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | DNVYSRPPQRFGQNVIS{ct:Amid} | Odorranaopin-MS2 | Amidation | Free | Linear | L | None | 17 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 58.5 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 28.1 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 8.4 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 4.3 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SFLDKFKDVAIGVAKGAVTGVLKALLCKLDNSC{ct:Amid} | Brevinin-2MS1 | Amidation | Free | Linear | L | None | 33 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CVVSSGWKWNYKIRCKLTGMC{ct:Amid} | Nigroain-B-MS1 | Amidation | Free | Linear | L | None | 21 | Antioxidant, Antimicrobial | 8.6 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | CVVSSGWKWNYKIRCKLTGMC{ct:Amid} | Nigroain-B-MS1 | Amidation | Free | Linear | L | None | 21 | Antioxidant, Antimicrobial | 5.7 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | CVVSSGWKWNYKIRCKLTGMC{ct:Amid} | Nigroain-B-MS1 | Amidation | Free | Linear | L | None | 21 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CVVSSGWKWNYKIRCKLTGMC{ct:Amid} | Nigroain-B-MS1 | Amidation | Free | Linear | L | None | 21 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CVVSSGWKWNYKIRCKLTGMC{ct:Amid} | Nigroain-B-MS1 | Amidation | Free | Linear | L | None | 21 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CVVSSGWKWNYKIRCKLTGMC{ct:Amid} | Nigroain-B-MS1 | Amidation | Free | Linear | L | None | 21 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CVVSSGWKWNYKIRCKLTGMC{ct:Amid} | Nigroain-B-MS1 | Amidation | Free | Linear | L | None | 21 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CVVSSGWKWNYKIRCKLTGMC{ct:Amid} | Nigroain-B-MS1 | Amidation | Free | Linear | L | None | 21 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FKTWKNRPILSSCSGIIKG{ct:Amid} | Nigroain-C-MS1 | Amidation | Free | Linear | L | None | 19 | Antioxidant, Antimicrobial | 5 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | FKTWKNRPILSSCSGIIKG{ct:Amid} | Nigroain-C-MS1 | Amidation | Free | Linear | L | None | 19 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FKTWKNRPILSSCSGIIKG{ct:Amid} | Nigroain-C-MS1 | Amidation | Free | Linear | L | None | 19 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FKTWKNRPILSSCSGIIKG{ct:Amid} | Nigroain-C-MS1 | Amidation | Free | Linear | L | None | 19 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FKTWKNRPILSSCSGIIKG{ct:Amid} | Nigroain-C-MS1 | Amidation | Free | Linear | L | None | 19 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FKTWKNRPILSSCSGIIKG{ct:Amid} | Nigroain-C-MS1 | Amidation | Free | Linear | L | None | 19 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FKTWKNRPILSSCSGIIKG{ct:Amid} | Nigroain-C-MS1 | Amidation | Free | Linear | L | None | 19 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FKTWKNRPILSSCSGIIKG{ct:Amid} | Nigroain-C-MS1 | Amidation | Free | Linear | L | None | 19 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CQWQFISPSRAGCIGP{ct:Amid} | Nigroain-D-SN1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 16.6 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | CQWQFISPSRAGCIGP{ct:Amid} | Nigroain-D-SN1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 16.1 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | CQWQFISPSRAGCIGP{ct:Amid} | Nigroain-D-SN1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CQWQFISPSRAGCIGP{ct:Amid} | Nigroain-D-SN1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CQWQFISPSRAGCIGP{ct:Amid} | Nigroain-D-SN1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CQWQFISPSRAGCIGP{ct:Amid} | Nigroain-D-SN1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CQWQFISPSRAGCIGP{ct:Amid} | Nigroain-D-SN1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | CQWQFISPSRAGCIGP{ct:Amid} | Nigroain-D-SN1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 85.3 % Hemolysis at 200 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 67.1 % Hemolysis at 100 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 40.1 % Hemolysis at 50 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 23 % Hemolysis at 25 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 11.9 % Hemolysis at 12.5 µM | Human | Hylarana Maosuoensis | NA | NA | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | SLWETIKNAGKGFILNILDKIRCKVAGGCKT{ct:Amid} | Nigroain-K-SN1 | Amidation | Free | Linear | L | None | 31 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Hylarana Maosuoensis | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLPIPGVRCKILRTC{ct:Amid} | Pleskein-1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 200 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLPIPGVRCKILRTC{ct:Amid} | Pleskein-1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLPIPGVRCKILRTC{ct:Amid} | Pleskein-1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLPIPGVRCKILRTC{ct:Amid} | Pleskein-1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLPIPGVRCKILRTC{ct:Amid} | Pleskein-1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLPIPGVRCKILRTC{ct:Amid} | Pleskein-1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLPIPGVRCKILRTC{ct:Amid} | Pleskein-1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLPIPGVRCKILRTC{ct:Amid} | Pleskein-1 | Amidation | Free | Linear | L | None | 16 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLLPIPNDVKCKLGICKS{ct:Amid} | Pleskein-2 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 200 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLLPIPNDVKCKLGICKS{ct:Amid} | Pleskein-2 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLLPIPNDVKCKLGICKS{ct:Amid} | Pleskein-2 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLLPIPNDVKCKLGICKS{ct:Amid} | Pleskein-2 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLLPIPNDVKCKLGICKS{ct:Amid} | Pleskein-2 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLLPIPNDVKCKLGICKS{ct:Amid} | Pleskein-2 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLLPIPNDVKCKLGICKS{ct:Amid} | Pleskein-2 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | FFLLPIPNDVKCKLGICKS{ct:Amid} | Pleskein-2 | Amidation | Free | Linear | L | None | 20 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | ILPSKLCRLLGNC{ct:Amid} | Pleskein-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 200 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | ILPSKLCRLLGNC{ct:Amid} | Pleskein-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 100 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | ILPSKLCRLLGNC{ct:Amid} | Pleskein-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 50 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | ILPSKLCRLLGNC{ct:Amid} | Pleskein-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 25 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | ILPSKLCRLLGNC{ct:Amid} | Pleskein-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 12.5 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | ILPSKLCRLLGNC{ct:Amid} | Pleskein-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 6.3 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | ILPSKLCRLLGNC{ct:Amid} | Pleskein-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 3.1 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28402481 | 2017 | ILPSKLCRLLGNC{ct:Amid} | Pleskein-3 | Amidation | Free | Linear | L | None | 13 | Antioxidant, Antimicrobial | 0 % Hemolysis at 1.6 µM | Human | Nanorana Pleskei | NA | Non-hemolytic | ||
| 28833783 | 2017 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MPI | Amidation | Free | Linear | L | None | 14 | Antimicrobial | <10 % Hemolysis at 50 µM | Human | Venom Of The Social Wasp Polybia Paulista | NA | NA | ||
| 28833783 | 2017 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MPI | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 30 % Hemolysis at 150 µM | Human | Venom Of The Social Wasp Polybia Paulista | NA | NA | ||
| 28833783 | 2017 | IDWKKLLKAAK{nnr:Pra}IL{cyc:N-C}{nt:Acet}{ct:Amid} | C-MPI-1 | Amidation | Acetylation | Cyclic | Mix | Pra = L-propargylglycine | 16 | Antimicrobial | 30 % Hemolysis at 50 µM | Human | Mpi Analogs | α-Helical | NA | ||
| 28833783 | 2017 | IDWKKLLKAAK{nnr:Pra}IL{cyc:N-C}{nt:Acet}{ct:Amid} | C-MPI-1 | Amidation | Acetylation | Cyclic | Mix | Pra = L-propargylglycine | 16 | Antimicrobial | 35 % Hemolysis at 150 µM | Human | Mpi Analogs | α-Helical | NA | ||
| 28981608 | 2017 | ILGTILGLLKSL{ct:Amid} | Polybia-CP | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0.1 % Hemolysis at <20 µM | Human | Social Wasp Polybia Paulista | α-Helical | NA | ||
| 28981608 | 2017 | ILGTILGLLK{d}SL{ct:Amid} | D-lys-CP | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 12 | Antimicrobial | 0 % Hemolysis at <20 µM | Human | D-Lysine Substituted Derivative | α-Helical | Non-hemolytic | ||
| 28981608 | 2017 | I{d}L{d}G{d}T{d}I{d}L{d}G{d}L{d}L{d}K{d}S{d}L{d}{ct:Amid} | D-CP | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 12 | Antimicrobial | <0.2 % Hemolysis at <20 µM | Human | D-Counterpart Of Polybia-Cp | Left-hand α-Helical | NA | ||
| 28981608 | 2017 | ILGTILGLLKSL{ct:Amid} | Polybia-CP | Amidation | Free | Linear | L | None | 12 | Antimicrobial | <0.4 % Hemolysis at >30 µM | Human | Social Wasp Polybia Paulista | α-Helical | NA | ||
| 28981608 | 2017 | ILGTILGLLK{d}SL{ct:Amid} | D-lys-CP | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 12 | Antimicrobial | 0 % Hemolysis at >30 µM | Human | D-Lysine Substituted Derivative | α-Helical | Non-hemolytic | ||
| 28981608 | 2017 | I{d}L{d}G{d}T{d}I{d}L{d}G{d}L{d}L{d}K{d}S{d}L{d}{ct:Amid} | D-CP | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 12 | Antimicrobial | <0.4 % Hemolysis at >30 µM | Human | D-Counterpart Of Polybia-Cp | Left-hand α-Helical | NA | ||
| 28981608 | 2017 | ILGTILGLLKSL{ct:Amid} | Polybia-CP | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0.6 % Hemolysis at <70 µM | Human | Social Wasp Polybia Paulista | α-Helical | NA | ||
| 28981608 | 2017 | ILGTILGLLK{d}SL{ct:Amid} | D-lys-CP | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 12 | Antimicrobial | 0 % Hemolysis at <70 µM | Human | D-Lysine Substituted Derivative | α-Helical | Non-hemolytic | ||
| 28981608 | 2017 | I{d}L{d}G{d}T{d}I{d}L{d}G{d}L{d}L{d}K{d}S{d}L{d}{ct:Amid} | D-CP | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 12 | Antimicrobial | <0.5 % Hemolysis at <70 µM | Human | D-Counterpart Of Polybia-Cp | Left-hand α-Helical | NA | ||
| 28981608 | 2017 | ILGTILGLLKSL{ct:Amid} | Polybia-CP | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0.6 % Hemolysis at 130 µM | Human | Social Wasp Polybia Paulista | α-Helical | NA | ||
| 28981608 | 2017 | ILGTILGLLK{d}SL{ct:Amid} | D-lys-CP | Amidation | Free | Linear | Mix | lowercase letters correspond to D-amino acids | 12 | Antimicrobial | 0.2 % Hemolysis at 130 µM | Human | D-Lysine Substituted Derivative | α-Helical | NA | ||
| 28981608 | 2017 | I{d}L{d}G{d}T{d}I{d}L{d}G{d}L{d}L{d}K{d}S{d}L{d}{ct:Amid} | D-CP | Amidation | Free | Linear | D | lowercase letters correspond to D-amino acids | 12 | Antimicrobial | 0.5 % Hemolysis at 130 µM | Human | D-Counterpart Of Polybia-Cp | Left-hand α-Helical | NA | ||
| 28856417 | 2017 | KIQGTCYRGKAKCCK | HBD-1 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 1 μg/ml in 1hr | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 28856417 | 2017 | KIQGTCYRGKAKCCK | HBD-1 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 5 μg/ml in 1hr | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 28856417 | 2017 | KIQGTCYRGKAKCCK | HBD-1 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 50 μg/ml in 1hr | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 28856417 | 2017 | KIQGTCYRGKAKCCK | HBD-1 | Free | Free | Linear | L | None | 15 | Antimicrobial | <5 % Hemolysis at 100 μg/ml in 1hr | Human | Synthetic Peptide | NA | NA | ||
| 28856417 | 2017 | ACPIFTKIQGTCYRG | Pep-B | Free | Free | Linear | L | None | 15 | Antimicrobial | <5 % Hemolysis at 1 μg/ml in 1hr | Human | Hbd-1 Motif | NA | NA | ||
| 28856417 | 2017 | ACPIFTKIQGTCYRG | Pep-B | Free | Free | Linear | L | None | 15 | Antimicrobial | <5 % Hemolysis at 5 μg/ml in 1hr | Human | Hbd-1 Motif | NA | NA | ||
| 28856417 | 2017 | ACPIFTKIQGTCYRG | Pep-B | Free | Free | Linear | L | None | 15 | Antimicrobial | <5 % Hemolysis at 50 μg/ml in 1hr | Human | Hbd-1 Motif | NA | NA | ||
| 28856417 | 2017 | ACPIFTKIQGTCYRG | Pep-B | Free | Free | Linear | L | None | 15 | Antimicrobial | <5 % Hemolysis at 100 μg/ml in 1hr | Human | Hbd-1 Motif | NA | NA | ||
| 28856417 | 2017 | KIQGTCYRGKAKCCK | HBD-1 | Free | Free | Linear | L | None | 15 | Antimicrobial | <5 % Hemolysis at 1 μg/ml in 24hr | Human | Synthetic Peptide | NA | NA | ||
| 28856417 | 2017 | KIQGTCYRGKAKCCK | HBD-1 | Free | Free | Linear | L | None | 15 | Antimicrobial | <10 % Hemolysis at 5 μg/ml in 24hr | Human | Synthetic Peptide | NA | NA | ||
| 28856417 | 2017 | KIQGTCYRGKAKCCK | HBD-1 | Free | Free | Linear | L | None | 15 | Antimicrobial | <15 % Hemolysis at 50 μg/ml in 24hr | Human | Synthetic Peptide | NA | NA | ||
| 28856417 | 2017 | KIQGTCYRGKAKCCK | HBD-1 | Free | Free | Linear | L | None | 15 | Antimicrobial | 21.62 % Hemolysis at 100 μg/ml in 24hr | Human | Synthetic Peptide | NA | NA | ||
| 28856417 | 2017 | ACPIFTKIQGTCYRG | Pep-B | Free | Free | Linear | L | None | 15 | Antimicrobial | 5 % Hemolysis at 1 μg/ml in 24hr | Human | Hbd-1 Motif | NA | NA | ||
| 28856417 | 2017 | ACPIFTKIQGTCYRG | Pep-B | Free | Free | Linear | L | None | 15 | Antimicrobial | <10 % Hemolysis at 5 μg/ml in 24hr | Human | Hbd-1 Motif | NA | NA | ||
| 28856417 | 2017 | ACPIFTKIQGTCYRG | Pep-B | Free | Free | Linear | L | None | 15 | Antimicrobial | <10 % Hemolysis at 50 μg/ml in 24hr | Human | Hbd-1 Motif | NA | NA | ||
| 28856417 | 2017 | ACPIFTKIQGTCYRG | Pep-B | Free | Free | Linear | L | None | 15 | Antimicrobial | 9 % Hemolysis at 100 μg/ml in 24hr | Human | Hbd-1 Motif | NA | NA | ||
| 28756544 | 2017 | GLFDIIKKIAESF{ct:Amid} | aurein 1.2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 1-512 μg/ml | Human | Australian Bell Frogs, Ranoidea Aurea | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | FSEAIKKIIDFLG{ct:Amid} | r-aurein 1.2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 1-64 μg/ml | Human | Analog Of Aurein 1.2 | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | FSEAIKKIIDFLG{ct:Amid} | r-aurein 1.2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | <10 % Hemolysis at 512 μg/ml | Human | Analog Of Aurein 1.2 | α-Helical | NA | ||
| 28756544 | 2017 | KWKLFKKIGAVLKVL{ct:Amid} | CAMEL | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 45299 μg/ml | Human | Hybrid Peptide | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | KWKLFKKIGAVLKVL{ct:Amid} | CAMEL | Amidation | Free | Linear | L | None | 15 | Antimicrobial | <10 % Hemolysis at 64 μg/ml | Human | Hybrid Peptide | α-Helical | NA | ||
| 28756544 | 2017 | KWKLFKKIGAVLKVL{ct:Amid} | CAMEL | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at 512 μg/ml | Human | Hybrid Peptide | α-Helical | NA | ||
| 28756544 | 2017 | LVKLVAGIKKFLKWK{ct:Amid} | r-CAMEL | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 1-64 μg/ml | Human | Analog Of Camel | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | LVKLVAGIKKFLKWK{ct:Amid} | r-CAMEL | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 512 μg/ml | Human | Analog Of Camel | α-Helical | NA | ||
| 28756544 | 2017 | GLFDVIKKVASVIGGL{ct:Amid} | citropin 1.1 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 1-64 μg/ml | Human | Green Tree Frog, Ranoidea Citropa | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | GLFDVIKKVASVIGGL{ct:Amid} | citropin 1.1 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | <20 % Hemolysis at 512 μg/ml | Human | Green Tree Frog, Ranoidea Citropa | α-Helical | NA | ||
| 28756544 | 2017 | LGGIVSAVKKIVDFLG{ct:Amid} | r-citropin 1.1 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 1-512 μg/ml | Human | Analog Of Citropin 1.1 | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | ILRWPWWPWRRK{ct:Amid} | omiganan | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 1-64 μg/ml | Human | Analog Of Indolicidin, Cytoplasmic Granules Of Bovine Neutrophils | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | ILRWPWWPWRRK{ct:Amid} | omiganan | Amidation | Free | Linear | L | None | 12 | Antimicrobial | <10 % Hemolysis at 512 μg/ml | Human | Analog Of Indolicidin, Cytoplasmic Granules Of Bovine Neutrophils | α-Helical | NA | ||
| 28756544 | 2017 | KRRWPWWPWRLI{ct:Amid} | r-omiganan | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 1-64 μg/ml | Human | Analog Of Omiganan | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | KRRWPWWPWRLI{ct:Amid} | r-omiganan | Amidation | Free | Linear | L | None | 12 | Antimicrobial | <20 % Hemolysis at 512 μg/ml | Human | Analog Of Omiganan | α-Helical | NA | ||
| 28756544 | 2017 | GIGKFLKKAKKFGKAFVKILKK{ct:Amid} | pexiganan | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 0 % Hemolysis at 1 μg/ml | Human | African Clawed Frog, Xenopus Laevis | distorted α-Helix | Non-hemolytic | ||
| 28756544 | 2017 | GIGKFLKKAKKFGKAFVKILKK{ct:Amid} | pexiganan | Amidation | Free | Linear | L | None | 22 | Antimicrobial | <20 % Hemolysis at 512 μg/ml | Human | African Clawed Frog, Xenopus Laevis | distorted α-Helix | NA | ||
| 28756544 | 2017 | KKLIKVFAKGFKKAKKLFKGIG{ct:Amid} | r-pexiganan | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 0 % Hemolysis at 1-512 μg/ml | Human | Analog Of Pexiganan | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | FLPLIGRVLSGIL{ct:Amid} | temporin A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 1-64 μg/ml | Human | European Red Frog, Rana Temporaria | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | FLPLIGRVLSGIL{ct:Amid} | temporin A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 70 % Hemolysis at 512 μg/ml | Human | European Red Frog, Rana Temporaria | α-Helical | NA | ||
| 28756544 | 2017 | LIGSLVRGILPLF{ct:Amid} | r-temporin A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 1-64 μg/ml | Human | Analog Of Temporin A | α-Helical | Non-hemolytic | ||
| 28756544 | 2017 | LIGSLVRGILPLF{ct:Amid} | r-temporin A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | <10 % Hemolysis at 512 μg/ml | Human | Analog Of Temporin A | α-Helical | NA | ||
| 28969703 | 2017 | FNARRCHRHCRSIRRRAGYCAGRLRLLTCTCVR | HlDFS1 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | Non-hemolytic | ||
| 28969703 | 2017 | FNARRCHRHCRSIRRRAGYCAGRLRLLTCTCVR | HlDFS1 | Free | Free | Linear | L | None | 33 | Antimicrobial | <50 % Hemolysis at 10 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | NA | ||
| 28969703 | 2017 | FNARRCHRHCRSIRRRAGYCAGRLRLLTCTCVR | HlDFS1 | Free | Free | Linear | L | None | 33 | Antimicrobial | <50 % Hemolysis at 20 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | NA | ||
| 28969703 | 2017 | FNARRCHRHCRSIRRRAGYCAGRLRLLTCTCVR | HlDFS1 | Free | Free | Linear | L | None | 33 | Antimicrobial | <100 % Hemolysis at 50 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | NA | ||
| 28969703 | 2017 | LNQGACHRHCRSIRRRGGYCSGIIKQTCTCYRN | HlDFS2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | Non-hemolytic | ||
| 28969703 | 2017 | LNQGACHRHCRSIRRRGGYCSGIIKQTCTCYRN | HlDFS2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 10 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | Non-hemolytic | ||
| 28969703 | 2017 | LNQGACHRHCRSIRRRGGYCSGIIKQTCTCYRN | HlDFS2 | Free | Free | Linear | L | None | 33 | Antimicrobial | 0 % Hemolysis at 20 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | Non-hemolytic | ||
| 28969703 | 2017 | LNQGACHRHCRSIRRRGGYCSGIIKQTCTCYRN | HlDFS2 | Free | Free | Linear | L | None | 33 | Antimicrobial | <50 % Hemolysis at 50 µM | Human | Hard Tick Haemaphysalis Longicornis | NA | NA | ||
| 28921993 | 2017 | QQRKRKIWSILAPLGTTLVKLVAGIG{ct:Amid} | DRIM(1) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 60 % Hemolysis at 5 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSILAPLGTTLVKLVAGIG{ct:Amid} | DRIM(1) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | <100 % Hemolysis at 10 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSILAPLGTTLVKLVAGIG{ct:Amid} | DRIM(1) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 15 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSILAPLGTTLVKLVAGIG{ct:Amid} | DRIM(1) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | <100 % Hemolysis at 20 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSILAPLGTTLVKLVAGIG{ct:Amid} | DRIM(1) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | <100 % Hemolysis at 25 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSILAPLGTTLVKLVAGIG{ct:Amid} | DRIM(1) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 30 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSILAPLGTTLVKLVAGIG{ct:Amid} | DRIM(1) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 40 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | PLILLRLLRGQF{ct:Amid} | WWSP(2) | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 5-40 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | AAVLLPVLLAAP{ct:Amid} | KFGF(3) | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 5-40 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | KLALKALKALKAALKLA{ct:Amid} | MAP-1(4) | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0 % Hemolysis at 5-40 μg/mL | Human | Cell-Penetrating Peptides (Cpps) | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSKLAPDGTTLVKLVAGIG{ct:Amid} | sDRIM(5) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | <20 % Hemolysis at 5 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSKLAPDGTTLVKLVAGIG{ct:Amid} | sDRIM(5) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | <30 % Hemolysis at 10 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSKLAPDGTTLVKLVAGIG{ct:Amid} | sDRIM(5) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 30 % Hemolysis at 15 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSKLAPDGTTLVKLVAGIG{ct:Amid} | sDRIM(5) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 40 % Hemolysis at 20 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSKLAPDGTTLVKLVAGIG{ct:Amid} | sDRIM(5) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | <50 % Hemolysis at 25 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSKLAPDGTTLVKLVAGIG{ct:Amid} | sDRIM(5) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | <40 % Hemolysis at 30 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28921993 | 2017 | QQRKRKIWSKLAPDGTTLVKLVAGIG{ct:Amid} | sDRIM(5) | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at 40 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28921993 | 2017 | PLIKLRLDRGQF{ct:Amid} | sWWSP(6) | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 5-40 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28921993 | 2017 | AAKLLPDLLAAP{ct:Amid} | sKFGF(7) | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 0 % Hemolysis at 5-40 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28921993 | 2017 | KLALKALKKLKADLKLA{ct:Amid} | sMAP-1(8) | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0 % Hemolysis at 5-40 μg/mL | Human | Cpps Stapled Analogues | α-Helical | NA | ||
| 28483966 | 2017 | GGLKKLGKKLEGAGKRVFNAAEKALPVVAGAKALRK | cecropin A2 | Free | Free | Linear | L | None | 36 | Antimicrobial | 0 % Hemolysis at 60 μg/mL | Human | Aedes Aegypti Cecropin A | α-Helical | Non-hemolytic | ||
| 31554187 | 2019 | INLLKIAKGIIKSL{ct:Amid} | EMP-AF | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 50 µM | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31554187 | 2019 | FDVMGIIKKIASAL{ct:Amid} | EMP-EF | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 181 µM | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31554187 | 2019 | FDIMGLIKKVAGAL{ct:Amid} | EMP-ER | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 200 µM | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31554187 | 2019 | LKLMGIVKKVLGAL{ct:Amid} | EMP-EM1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31554187 | 2019 | LKLLGIVKKVLGAI{ct:Amid} | EMP-EM2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31554187 | 2019 | LNLKGIFKKVKSLLT | Eumenitin | Free | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31554187 | 2019 | LNLKGLFKKVASLLT | Eumenitin-F | Free | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at 353 µM | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31554187 | 2019 | LNLKGLIKKVASLLN | Eumenitin-R | Free | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at 530 µM | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31554187 | 2019 | SLLSLIRKLIT{ct:Amid} | Decoralin | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 50 % Hemolysis | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31554187 | 2019 | GLLKRIKTLL{ct:Amid} | Anoplin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 50 % Hemolysis | Human | Solitary Wasp Venoms | α-Helical | NA | ||
| 31311351 | 2019 | KRWWKWIRW{ct:Amid} | HHC-10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 5 % Hemolysis at 130 µM | Human | Synthetic | α-Helical | NA | ||
| 37809653 | 2023 | AILFLSLGAIKKG | BRGP-001 | Free | Free | Linear | L | None | 13 | Antimicrobial | 17.48 % Hemolysis at 1.127 mM | Human | Synthetic | α-Helical | NA | ||
| 37809653 | 2023 | FLIKSLAGAKGIL | BRGP-002 | Free | Free | Linear | L | None | 13 | Antimicrobial | 2.87 % Hemolysis at 1.879 mM | Human | Synthetic | α-Helical | NA | ||
| 37809653 | 2023 | KGGAIKSLFLILA | BRGP-003 | Free | Free | Linear | L | None | 13 | Antimicrobial | 8.8 % Hemolysis at 1.127 mM | Human | Synthetic | α-Helical | NA | ||
| 37809653 | 2023 | KGIKGALSILFAL | BRGP-004 | Free | Free | Linear | L | None | 13 | Antimicrobial | 27.9 % Hemolysis at 1.503 mM | Human | Synthetic | α-Helical | NA | ||
| 37809653 | 2023 | GIKGALKSILFAL | BRGP-005 | Free | Free | Linear | L | None | 13 | Antimicrobial | 13.81 % Hemolysis at 0.188 mM | Human | Synthetic | α-Helical | NA | ||
| 37809653 | 2023 | FALSILGALGIKK | BRGP-006 | Free | Free | Linear | L | None | 13 | Antimicrobial | 16.34 % Hemolysis at 1.503 mM | Human | Synthetic | α-Helical | NA | ||
| 37809653 | 2023 | PQQYPEMNTRRNW | BRGP-007 | Free | Free | Linear | L | None | 13 | Antimicrobial | 7.58 % Hemolysis at 1.454 mM | Human | Synthetic | not Helix | NA | ||
| 37764334 | 2023 | ALWKSILKNAGKAALNEINQIVQ{ct:Amid} | SS1 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at 256 µM | Human | American Tarsier Leaf Frog, Phyllomedusa Tarsius | α-Helical | NA | ||
| 37764334 | 2023 | ALWKSILKNAGKALNEINQIVQ{ct:Amid} | L14 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 256 µM | Human | Ss1 Analogues | α-Helical | NA | ||
| 37764334 | 2023 | ALWKSILKNAGKAVLNEINQIVQ{ct:Amid} | 14V | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at 256 µM | Human | Ss1 Analogues | α-Helical | NA | ||
| 37764334 | 2023 | ALWKSILKNAGKAGLNEINQIVQ{ct:Amid} | 14G | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at 256 µM | Human | Ss1 Analogues | α-Helical | NA | ||
| 37764334 | 2023 | ALWKSILKNVGKVLNEINQIVQ{ct:Amid} | L2V | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 256 µM | Human | Ss1 Analogues | α-Helical | NA | ||
| 37764334 | 2023 | ALWKKILKNAGKAVLNEINQIVQ{ct:Amid} | 14V5K | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at 256 µM | Human | Ss1 Analogues | α-Helical | NA | ||
| 37764334 | 2023 | ALWKSILKNAGKAVLNEINQIV{ct:Amid} | 14VL23 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 256 µM | Human | Ss1 Analogues | α-Helical | NA | ||
| 37746048 | 2023 | DASTKKLSECLRRIGDELDS | BHP | Free | Free | Linear | L | None | 20 | Antitumor | 0 % Hemolysis at 3-200 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 37888622 | 2023 | INLLKIAKGIIKSL{ct:Amid} | EMP-AF | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Anterhynchium Flavormarginatum Micado | α-Helical | NA | ||
| 37888622 | 2023 | INLLKIAKGIIKSL{ct:Amid} | EMP-AF | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 110.6 ± 9.8 µM | Human | Anterhynchium Flavormarginatum Micado | α-Helical | NA | ||
| 37888622 | 2023 | FDVMGIIKKIASAL{ct:Amid} | EMP-EF | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Eumenes Fraterculus | α-Helical | NA | ||
| 37888622 | 2023 | FDVMGIIKKIASAL{ct:Amid} | EMP-EF | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 125.2 ± 20.6 µM | Human | Eumenes Fraterculus | α-Helical | NA | ||
| 37888622 | 2023 | FDIMGLIKKVAGAL{ct:Amid} | EMP-ER | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 25 % Hemolysis at 320 μg/mL | Human | Eumenes Rubrofemoratus | α-Helical | NA | ||
| 37888622 | 2023 | LNLKGLIKKVASLLN | Eumenitin-R | Free | Free | Linear | L | None | 15 | Antimicrobial | 5 % Hemolysis at 320 μg/mL | Human | Eumenes Rubronotatus | α-Helical | NA | ||
| 37888622 | 2023 | LNLKGLFKKVASLLT | Eumenitin-F | Free | Free | Linear | L | None | 15 | Antimicrobial | 67 % Hemolysis at 320 μg/mL | Human | Eumenes Rubronotatus | α-Helical | NA | ||
| 37888622 | 2023 | LNLKGIFKKVASLLT | Eumenitin | Free | Free | Linear | L | None | 15 | Antimicrobial | 6 % Hemolysis at 320 μg/mL | Human | Eumenes Rubronotatus | α-Helical | NA | ||
| 37888622 | 2023 | LNLKGLFKKVASLLT | Eumenitin-F | Free | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at 157.1 ± 2.6 µM | Human | Eumenes Rubronotatus | α-Helical | NA | ||
| 37888622 | 2023 | INLKGLIKKVASLLT | EpVP1 | Free | Free | Linear | L | None | 15 | Antimicrobial | 9 % Hemolysis at 320 μg/mL | Human | Eumenes Pomiformis | α-Helical | NA | ||
| 37888622 | 2023 | FDLLGLVKKVASAL{ct:Amid} | EpVP2a | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 79 % Hemolysis at 320 μg/mL | Human | Eumenes Pomiformis | α-Helical | NA | ||
| 37888622 | 2023 | FDLLGLVKSVVSAL{ct:Amid} | EpVP2b | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Eumenes Pomiformis | α-Helical | NA | ||
| 37888622 | 2023 | FDLLGLVKKVASAL{ct:Amid} | EpVP2a | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 151.9 ± 6.3 µM | Human | Eumenes Pomiformis | α-Helical | NA | ||
| 37888622 | 2023 | FDLLGLVKSVVSAL{ct:Amid} | EpVP2b | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 34.1 ± 3.5 µM | Human | Eumenes Pomiformis | α-Helical | NA | ||
| 37888622 | 2023 | LKLMGIVKKVLGAL{ct:Amid} | EMP-EM1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 21 % Hemolysis at 320 μg/mL | Human | Eumenes Micado | α-Helical | NA | ||
| 37888622 | 2023 | LKLLGIVKKVLGAI{ct:Amid} | EMP-EM2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 8 % Hemolysis at 320 μg/mL | Human | Eumenes Micado | α-Helical | NA | ||
| 37888622 | 2023 | GRILSFIKGLAEHL{ct:Amid} | EMP-OD | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 2 % Hemolysis at 320 μg/mL | Human | Orancistrocerus Drewseni | α-Helical | NA | ||
| 37888622 | 2023 | KDLHTVVSAILQAL{ct:Amid} | OdVP3a | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 24 % Hemolysis at 320 μg/mL | Human | Orancistrocerus Drewseni | α-Helical | NA | ||
| 37888622 | 2023 | INLKALAALAKKIL{ct:Amid} | Mastoparan (L) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Vespula Lewisii | α-Helical | NA | ||
| 37888622 | 2023 | INLKALAALAKKIL{ct:Amid} | Mastoparan (L) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 82.9 ± 3.8 µM | Human | Vespula Lewisii | α-Helical | NA | ||
| 37888622 | 2023 | INWKKIKSIIKAAMN{ct:Amid} | Mastoparan-V1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 9 % Hemolysis at 320 μg/mL | Human | Vespula Vulgaris | α-Helical | NA | ||
| 37888622 | 2023 | INWKKIKSLIKAAMS{ct:Amid} | Mastoparan-V2 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 15 % Hemolysis at 320 μg/mL | Human | Vespula Vulgaris | α-Helical | NA | ||
| 37888622 | 2023 | INMKASAAVAKKLL{ct:Amid} | MP-VB1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 320 μg/mL | Human | Vespa Bicolor | α-Helical | Non-hemolytic | ||
| 37888622 | 2023 | INMKAVAAVAKKPL{ct:Amid} | MP-VB2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 320 μg/mL | Human | Vespa Bicolor | α-Helical | Non-hemolytic | ||
| 37888622 | 2023 | INWKGIAAMAKKLL{ct:Amid} | Mastoparan-X(V) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 29 % Hemolysis at 320 μg/mL | Human | Vespa. Xanthoptera | α-Helical | NA | ||
| 37888622 | 2023 | INWKGIAAMAKKLL{ct:Amid} | Mastoparan-X(V) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 349.4 ± 4.9 µM | Human | Vespa. Xanthoptera | α-Helical | NA | ||
| 37888622 | 2023 | IKWKAILDAVKKVL{ct:Amid} | Mastoparan-A | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 7 % Hemolysis at 320 μg/mL | Human | Vespa Analis | α-Helical | NA | ||
| 37888622 | 2023 | LKLKSIVSWAKKVL{ct:Amid} | Mastoparan-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 22 % Hemolysis at 320 μg/mL | Human | Vespa Basalis | α-Helical | NA | ||
| 37888622 | 2023 | INLKALLAVAKKIL{ct:Amid} | Mastoparan-C | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Vespa Crabro | α-Helical | NA | ||
| 37888622 | 2023 | INLKALLAVAKKIL{ct:Amid} | Mastoparan-C | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 30.2 ± 1.3 µM | Human | Vespa Crabro | α-Helical | NA | ||
| 37888622 | 2023 | INLKALAALVKKVL{ct:Amid} | Mastoparan-II | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 78 % Hemolysis at 320 μg/mL | Human | Vespa Orientalis | α-Helical | NA | ||
| 37888622 | 2023 | INLKAIAALVKKVL{ct:Amid} | HR1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 56 % Hemolysis at 320 μg/mL | Human | Vespa Orientalis | α-Helical | NA | ||
| 37888622 | 2023 | INLKALAALVKKVL{ct:Amid} | Mastoparan-II | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 134.6 ± 1.2 µM | Human | Vespa Orientalis | α-Helical | NA | ||
| 37888622 | 2023 | INLKAIAALVKKVL{ct:Amid} | HR1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 197.7 ± 8.9 µM | Human | Vespa Orientalis | α-Helical | NA | ||
| 37888622 | 2023 | INWKKIFQKVKNLV{ct:Amid} | PDD-A | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 30 % Hemolysis at 320 μg/mL | Human | Polistes Dorsalis | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKILGAL{ct:Amid} | PDD-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Polistes Dorsalis | α-Helical | NA | ||
| 37888622 | 2023 | INWKKIFQKVKNLV{ct:Amid} | PDD-A | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 353.5 ± 44.8 µM | Human | Polistes Dorsalis | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKILGAL{ct:Amid} | PDD-B | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 48.5 ± 3.4 µM | Human | Polistes Dorsalis | α-Helical | NA | ||
| 37888622 | 2023 | INWKKIAEIGKQVLSAL{ct:Amid} | Dominulin A | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 4 % Hemolysis at 320 μg/mL | Human | Polistes Dominulus | α-Helical | NA | ||
| 37888622 | 2023 | INWKKIAEIGKQVLSAL{ct:Amid} | Dominulin A | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0 % Hemolysis at 320 μg/mL | Human | Polistes Dominulus | α-Helical | Non-hemolytic | ||
| 37888622 | 2023 | INWLKLGKKILGAI{ct:Amid} | Pm-R1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Polistes Rothneyi Iwatai | α-Helical | NA | ||
| 37888622 | 2023 | LNFKALAALAKKIL{ct:Amid} | Pm-R2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 66 % Hemolysis at 320 μg/mL | Human | Polistes Rothneyi Iwatai | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKQILGAL{ct:Amid} | Pm-R3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Polistes Rothneyi Iwatai | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKILGAI{ct:Amid} | Pm-R1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 72.0 ± 8.5 µM | Human | Polistes Rothneyi Iwatai | α-Helical | NA | ||
| 37888622 | 2023 | LNFKALAALAKKIL{ct:Amid} | Pm-R2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 165.9 ± 8.0 µM | Human | Polistes Rothneyi Iwatai | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKQILGAL{ct:Amid} | Pm-R3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 32.3 ± 1.7 µM | Human | Polistes Rothneyi Iwatai | α-Helical | NA | ||
| 37888622 | 2023 | INLKAIAAFAKKLL{ct:Amid} | Mastoparan-T(D) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 15 % Hemolysis at 320 μg/mL | Human | Vespa Tropica | α-Helical | NA | ||
| 37888622 | 2023 | INLKVFAALVKKFL{ct:Amid} | Mastoparan-T1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Vespa Tropica | α-Helical | NA | ||
| 37888622 | 2023 | INLKVFAALVKKLL{ct:Amid} | Mastoparan-T2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Vespa Tropica | α-Helical | NA | ||
| 37888622 | 2023 | INLRGFAALVKKFL{ct:Amid} | Mastoparan-T3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Vespa Tropica | α-Helical | NA | ||
| 37888622 | 2023 | INLFGFAALVKKFL{ct:Amid} | Mastoparan-T4 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Vespa Tropica | α-Helical | NA | ||
| 37888622 | 2023 | INLKVFAALVKKFL{ct:Amid} | Mastoparan-T1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 30.8 ± 1.6 µM | Human | Vespa Tropica | α-Helical | NA | ||
| 37888622 | 2023 | INLKVFAALVKKLL{ct:Amid} | Mastoparan-T2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 11.8 ± 3.1 µM | Human | Vespa Tropica | α-Helical | NA | ||
| 37888622 | 2023 | INLRGFAALVKKFL{ct:Amid} | Mastoparan-T3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 112.1 ± 8.0 µM | Human | Vespa Tropica | α-Helical | NA | ||
| 37888622 | 2023 | INLFGFAALVKKFL{ct:Amid} | Mastoparan-T4 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 28.5 ± 2.3 µM | Human | Vespa Tropica | α-Helical | NA | ||
| 37888622 | 2023 | INWKGIAAMKKLL{ct:Amid} | Mastoparan-like peptide 12b | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 320 μg/mL | Human | Vespa Magnifica | α-Helical | Non-hemolytic | ||
| 37888622 | 2023 | INLKAIAALAKKLL{ct:Amid} | Mastoparan-M | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 18 % Hemolysis at 320 μg/mL | Human | Vespa Mandarinia | α-Helical | NA | ||
| 37888622 | 2023 | INLKAIAALAKKLF{ct:Amid} | Mastoparan AF | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 47 % Hemolysis at 320 μg/mL | Human | Vespa Affinis | α-Helical | NA | ||
| 37888622 | 2023 | INLKAIAALAKKLF{ct:Amid} | Mastoparan AF | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 227.0 ± 3.1 µM | Human | Vespa Affinis | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAIIDAL{ct:Amid} | Agelaia-MPI | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Agelaia Pallipes Pallipes | α-Helical | NA | ||
| 37888622 | 2023 | INWKAILQRIKKML{ct:Amid} | Agelaia-MPII | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Agelaia Pallipes Pallipes | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAIIDAL{ct:Amid} | Agelaia-MPI | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 3.7 ± 0.14 µM | Human | Agelaia Pallipes Pallipes | α-Helical | NA | ||
| 37888622 | 2023 | INWKAILQRIKKML{ct:Amid} | Agelaia-MPII | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 44.8 ± 10.4 µM | Human | Agelaia Pallipes Pallipes | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKMMSAL{ct:Amid} | MP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 87 % Hemolysis at 320 μg/mL | Human | Mischocyttarus Phthisicus | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKMMSAL{ct:Amid} | MP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 123.6 ± 15.3 µM | Human | Mischocyttarus Phthisicus | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKVSAIL{ct:Amid} | Protopolybia-MP I | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 5 % Hemolysis at 320 μg/mL | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWKAIIEAAKQAL{ct:Amid} | ProtopolybiaMPII | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 13 % Hemolysis at 320 μg/mL | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAVIDAL{ct:Amid} | ProtopolybiaMPIII | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 96 % Hemolysis at 320 μg/mL | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAVIDAL{ct:Amid} | ProtopolybiaMPIII | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 61.9 ± 8.3 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWKALLDAAKKVL{ct:Amid} | ProtonectarinaMP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Protonectarina Sylveirae | α-Helical | NA | ||
| 37888622 | 2023 | INWKALLDAAKKVL{ct:Amid} | ProtonectarinaMP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 85.2 ± 5.9 µM | Human | Protonectarina Sylveirae | α-Helical | NA | ||
| 37888622 | 2023 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MP I | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 56 % Hemolysis at 320 μg/mL | Human | Polybia Paulista | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKMVIDAL{ct:Amid} | Polybia-MP II | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 91 % Hemolysis at 320 μg/mL | Human | Polybia Paulista | α-Helical | NA | ||
| 37888622 | 2023 | IDWLKLGKMVMDVL{ct:Amid} | Polybia-MP III | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 79 % Hemolysis at 320 μg/mL | Human | Polybia Paulista | α-Helical | NA | ||
| 37888622 | 2023 | IDWLKLRVISVIDL{ct:Amid} | Polybia-MP IV | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 320 μg/mL | Human | Polybia Paulista | α-Helical | Non-hemolytic | ||
| 37888622 | 2023 | INWHDIAIKNIDAL{ct:Amid} | Polybia-MP V | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at 320 μg/mL | Human | Polybia Paulista | α-Helical | Non-hemolytic | ||
| 37888622 | 2023 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MP I | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 176.6 ± 7.0 µM | Human | Polybia Paulista | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKMVIDAL{ct:Amid} | Polybia-MP II | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 23.3 ± 1.4 µM | Human | Polybia Paulista | α-Helical | NA | ||
| 37888622 | 2023 | IDWLKLGKMVMDVL{ct:Amid} | Polybia-MP III | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 38.5 ± 5.9 µM | Human | Polybia Paulista | α-Helical | NA | ||
| 37888622 | 2023 | INWKKMAATALKMI{ct:Amid} | Parapolybia-MP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 32 % Hemolysis at 320 μg/mL | Human | Parapolybia Indica | α-Helical | NA | ||
| 37888622 | 2023 | INWKKMAATALKMI{ct:Amid} | Parapolybia-MP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 306.4 ± 162.6 µM | Human | Parapolybia Indica | α-Helical | NA | ||
| 37888622 | 2023 | INWAKLGKLALQAL{ct:Amid} | Ropalidia-MP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Ropalidia | α-Helical | NA | ||
| 37888622 | 2023 | INWAKLGKLALQAL{ct:Amid} | Ropalidia-MP | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 42.5 ± 1.7 µM | Human | Ropalidia | α-Helical | NA | ||
| 37888622 | 2023 | VDWKKIGQHILSVL{ct:Amid} | Mastoparan-J | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Polistes Jadwigae | α-Helical | NA | ||
| 37888622 | 2023 | VDWKKIGQHILSVL{ct:Amid} | Mastoparan-J | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 69.5 ± 3.2 µM | Human | Polistes Jadwigae | α-Helical | NA | ||
| 37888622 | 2023 | INWKKIASIGKEVLKAL{ct:Amid} | PMM2 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 100 % Hemolysis at 320 μg/mL | Human | Polistes Major Major | α-Helical | NA | ||
| 37888622 | 2023 | INWKKIASIGKEVLKAL{ct:Amid} | PMM2 | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 50 % Hemolysis at 42.6 ± 2.5 µM | Human | Polistes Major Major | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKVIDAL{ct:Amid} | Protopolybia-MPIII-1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 176.4 ± 1.0 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAVSDAL{ct:Amid} | Protopolybia-MPIII-2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 673.3 ± 189.0 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAVIAAL{ct:Amid} | Protopolybia-MPIII-3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 16.8 ± 1.0 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAVIDIL{ct:Amid} | Protopolybia-MPIII-4 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 11.3 ± 6.2 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKVIAAL{ct:Amid} | Protopolybia-MPIII-6 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 110.0 ± 2.5 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKVIDIL{ct:Amid} | Protopolybia-MPIII-7 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 37.8 ± 3.7 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAVSAAL{ct:Amid} | Protopolybia-MPIII-8 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 307.8 ± 6.2 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAVSDIL{ct:Amid} | Protopolybia-MPIII-9 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 167.3 ± 2.7 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAVIAIL{ct:Amid} | Protopolybia-MPIII-10 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 11.3 ± 1.2 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKAVSAIL{ct:Amid} | Protopolybia-MPIII-11 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 140.6 ± 2.4 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37888622 | 2023 | INWLKLGKKVIAIL{ct:Amid} | Protopolybia-MPIII-12 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 43.9 ± 3.6 µM | Human | Protopolybia Exigua | α-Helical | NA | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P2 | Free | Free | Linear | L | None | 12 | Antibiofilm | 0.84 ± 1.42 % Hemolysis at 1 μg/mL | Human | Brevibacillus Strain | α-Helix | Non-hemolytic | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P3 | Free | Free | Linear | L | None | 12 | Antibiofilm | 0 % Hemolysis at 2 μg/mL | Human | Brevibacillus Strain | α-Helix | Non-hemolytic | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P4 | Free | Free | Linear | L | None | 12 | Antibiofilm | 0 % Hemolysis at 4 μg/mL | Human | Brevibacillus Strain | α-Helix | Non-hemolytic | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P5 | Free | Free | Linear | L | None | 12 | Antibiofilm | 0 % Hemolysis at 8 μg/mL | Human | Brevibacillus Strain | α-Helix | Non-hemolytic | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P6 | Free | Free | Linear | L | None | 12 | Antibiofilm | <10 % Hemolysis at 16 μg/mL | Human | Brevibacillus Strain | α-Helix | Non-hemolytic | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P7 | Free | Free | Linear | L | None | 12 | Antibiofilm | 10 % Hemolysis at 32 μg/mL | Human | Brevibacillus Strain | α-Helix | NA | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P8 | Free | Free | Linear | L | None | 12 | Antibiofilm | 9.92 ± 1.04 % Hemolysis at 64 μg/mL | Human | Brevibacillus Strain | α-Helix | NA | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P9 | Free | Free | Linear | L | None | 12 | Antibiofilm | 16.62 ± 0.85 % Hemolysis at 128 μg/mL | Human | Brevibacillus Strain | α-Helix | NA | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P10 | Free | Free | Linear | L | None | 12 | Antibiofilm | <40 % Hemolysis at 256 μg/mL | Human | Brevibacillus Strain | α-Helix | NA | ||
| 37810790 | 2023 | MFLVVKVLKYVV | P11 | Free | Free | Linear | L | None | 12 | Antibiofilm | 72.03 ± 5.61 % Hemolysis at 512 μg/mL | Human | Brevibacillus Strain | α-Helix | NA | ||
| 37867694 | 2023 | RWQWRWQWR | [Pal] | Free | Free | Linear | L | None | 9 | Anticancer | 13.2 % Hemolysis at 200 μg/mL | Human | Bovine Lactoferricin | α-Helical | NA | ||
| 37867694 | 2023 | {nnr:Ahx}RWQWRWQWR | Ahx-[Pal] | Free | Free | Linear | L | Ahx = amino hexanoic acid | 9 | Anticancer | 7.7 % Hemolysis at 200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 37867694 | 2023 | RWQWRWQW{nnr:O} | 9[Orn] [Pal] | Free | Free | Linear | L | O = L-Ornithine | 8 | Anticancer | 6.6 % Hemolysis at 200 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 38062792 | 2023 | VDKPPYLPRPRPPRRIYNR | Onc | Free | Free | Linear | L | None | 19 | Antimicrobial | MHC at >1000 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 38062792 | 2023 | KKLLKLLKLLL | ln65 | Free | Free | Linear | L | None | 11 | Antimicrobial | MHC at 125 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | K{d}K{d}LLK{d}LLK{d}LLL | ln69 | Free | Free | Linear | Mix | k = D-lysine | 11 | Antimicrobial | MHC at 1000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | {nnr:NLys}KLLKLLKLL{nnr:NLeu} | EB1 | Free | Free | Linear | L | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at 1000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | {nnr:Nlys}KLLKLLK{d}LL{nnr:Nleu} | EB2 | Free | Free | Linear | Mix | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at >2000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | KKLLKLLK{nnr:Nleu}{nnr:Nleu}{nnr:Nleu} | EB3 | Free | Free | Linear | L | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at >2000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | KKLLK{nnr:Nleu}{nnr:Nleu}{nnr:Nlys}{nnr:Nleu}{nnr:Nleu}{nnr:Nleu} | EB4 | Free | Free | Linear | Mix | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at >2000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | {nnr:Nlys}{nnr:Nlys}{nnr:Nleu}{nnr:Nleu}{nnr:Nlys}LLKLLL | EB5 | Free | Free | Linear | Mix | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at 1000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | {nnr:Nlys}{nnr:Nlys}LL{nnr:Nlys}LLKLLL | EB6 | Free | Free | Linear | Mix | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at 250 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | {nnr:Nlys}{nnr:Nlys}LL{nnr:Nlys}LL{nnr:Nlys}LLL | EB7 | Free | Free | Linear | Mix | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at >2000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | KK{nnr:Nleu}{nnr:Nleu}K{nnr:Nleu}{nnr:Nleu}K{nnr:Nleu}{nnr:Nleu}{nnr:Nleu} | EB8 | Free | Free | Linear | L | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at >2000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | K{nnr:Nlys}L{nnr:Nleu}K{nnr:Nleu}L{nnr:Nlys}L{nnr:Nleu}L | EB9 | Free | Free | Linear | Mix | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at >2000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | {nnr:Nlys}K{nnr:Nleu}L{nnr:Nlys}L{nnr:Nleu}K{nnr:Nleu}L{nnr:Nleu} | EB10 | Free | Free | Linear | Mix | NLys = (lysine-like residue), NLeu = (leucine-like residue) | 11 | Antimicrobial | MHC at >2000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 38062792 | 2023 | K{d}K{d}L{d}L{d}K{d}L{d}L{d}K{d}L{d}L{d}L{d} | EB11 | Free | Free | Linear | D | None | 11 | Antimicrobial | MHC at >2000 μg/mL | Human | Peptide−Peptoid Hybrids | α-Helical | NA | ||
| 37797458 | 2023 | VDKPPYLPRPRPPRRIYNR{ct:Amid} | oncocin(1a) | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 6.5 % Hemolysis at 800 μg/mL | Human | Resin Bound | NA | NA | ||
| 37797458 | 2023 | ({nnr:gVal})DKPPYLPRPRPPRRIYNR{ct:Amid} | 1b | Amidation | Free | Linear | L | gVal = N-terminal-guanidine valine | 18 | Antimicrobial | 0.7 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | (Me4{nnr:gVal})DKPPYLPRPRPPRRIYNR{ct:Amid} | 1c | Amidation | Free | Linear | L | gVal = N-terminal-guanidine valine | 18 | Antimicrobial | 0.2 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKPPYLP({nnr:Har})PRPPRRIYNR{ct:Amid} | 2a | Amidation | Free | Linear | L | Har = homoarginine | 20 | Antimicrobial | No Hemolysis determined at 800 μg/mL | Human | Analogues Of Oncocin | NA | Non-hemolytic | ||
| 37797458 | 2023 | VDKPPYLPRP({nnr:Har})PPRRIYNR{ct:Amid} | 2b | Amidation | Free | Linear | L | Har = homoarginine | 20 | Antimicrobial | No Hemolysis determined at 800 μg/mL | Human | Analogues Of Oncocin | NA | Non-hemolytic | ||
| 37797458 | 2023 | VDKPPYLPRPRPP({nnr:Har})RIYNR{ct:Amid} | 2c | Amidation | Free | Linear | L | Har = homoarginine | 20 | Antimicrobial | No Hemolysis determined at 800 μg/mL | Human | Analogues Of Oncocin | NA | Non-hemolytic | ||
| 37797458 | 2023 | VDKPPYLPRPRPPR({nnr:Har})IYNR{ct:Amid} | 2d | Amidation | Free | Linear | L | Har = homoarginine | 20 | Antimicrobial | 0.2 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKPPYLPRPRPPRRIYN({nnr:Har}){ct:Amid} | 2e | Amidation | Free | Linear | L | Har = homoarginine | 20 | Antimicrobial | 1.4 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKPPYLPRPRPPR({nnr:Har})IYN({nnr:Har}){ct:Amid} | 3 | Amidation | Free | Linear | L | Har = homoarginine | 18 | Antimicrobial | 1.4 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKPPYLP({nnr:Har})P({nnr:Har})PP({nnr:Har})({nnr:Har})IYN({nnr:Har}){ct:Amid} | 4 | Amidation | Free | Linear | L | Har = homoarginine | 15 | Antimicrobial | 1.3 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | ({nnr:gVal})DKPPYLP({nnr:Har})P({nnr:Har})PP({nnr:Har})({nnr:Har})IYN({nnr:Har}){ct:Amid} | 5 | Amidation | Free | Linear | L | Har = homoarginine, gVal = N-terminal-guanidine valine | 14 | Antimicrobial | 0.5 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDK({nnr:Hyp})PYLPRPRPPRRIYNR{ct:Amid} | 6a | Amidation | Free | Linear | L | Hyp = trans-4-Hydroxy-l-proline | 19 | Antimicrobial | 1.4 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKP({nnr:Hyp})YLPRPRPPRRIYNR{ct:Amid} | 6b | Amidation | Free | Linear | L | Hyp = trans-4-Hydroxy-l-proline | 19 | Antimicrobial | 1.5 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKPPYL({nnr:Hyp})RPRPPRRIYNR{ct:Amid} | 6c | Amidation | Free | Linear | L | Hyp = trans-4-Hydroxy-l-proline | 19 | Antimicrobial | No Hemolysis determined at 800 μg/mL | Human | Analogues Of Oncocin | NA | Non-hemolytic | ||
| 37797458 | 2023 | VDKPPYLPR({nnr:Hyp})RPPRRIYNR{ct:Amid} | 6d | Amidation | Free | Linear | L | Hyp = trans-4-Hydroxy-l-proline | 19 | Antimicrobial | No Hemolysis determined at 800 μg/mL | Human | Analogues Of Oncocin | NA | Non-hemolytic | ||
| 37797458 | 2023 | VDKPPYLPRPR({nnr:Hyp})PRRIYNR{ct:Amid} | 6e | Amidation | Free | Linear | L | Hyp = trans-4-Hydroxy-l-proline | 19 | Antimicrobial | 1.4 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKPPYLPRPRP({nnr:Hyp})RRIYNR{ct:Amid} | 6f | Amidation | Free | Linear | L | Hyp = trans-4-Hydroxy-l-proline | 19 | Antimicrobial | No Hemolysis determined at 800 μg/mL | Human | Analogues Of Oncocin | NA | Non-hemolytic | ||
| 37797458 | 2023 | VDK({nnr:Dfp})PYLPRPRPPRRIYNR{ct:Amid} | 7a | Amidation | Free | Linear | L | Dfp = 4,4-Difluoro-l-proline | 19 | Antimicrobial | 1 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKP({nnr:Dfp})YLPRPRPPRRIYNR{ct:Amid} | 7b | Amidation | Free | Linear | L | Dfp = 4,4-Difluoro-l-proline | 19 | Antimicrobial | 1.5 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKPPYL({nnr:Dfp})PRPRPPRRIYNR{ct:Amid} | 7c | Amidation | Free | Linear | L | Dfp = 4,4-Difluoro-l-proline | 19 | Antimicrobial | No Hemolysis determined at 800 μg/mL | Human | Analogues Of Oncocin | NA | Non-hemolytic | ||
| 37797458 | 2023 | VDKPPYLPR({nnr:Dfp})PRPPRRIYNR{ct:Amid} | 7d | Amidation | Free | Linear | L | Dfp = 4,4-Difluoro-l-proline | 19 | Antimicrobial | No Hemolysis determined at 800 μg/mL | Human | Analogues Of Oncocin | NA | Non-hemolytic | ||
| 37797458 | 2023 | VDKPPYLPRPR({nnr:Dfp})PRRIYNR{ct:Amid} | 7e | Amidation | Free | Linear | L | Dfp = 4,4-Difluoro-l-proline | 19 | Antimicrobial | 1 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKPPYLPRPRP({nnr:Dfp})RRIYNR{ct:Amid} | 7f | Amidation | Free | Linear | L | Dfp = 4,4-Difluoro-l-proline | 19 | Antimicrobial | Hemolysis determined at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDKPPYLPRPRPPRR{d}IYNR{d}{ct:Amid} | Oncocin112(8) | Amidation | Free | Linear | Mix | None | 21 | Antimicrobial | 3.3 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDK({nnr:Hyp})({nnr:Hyp})YLPRPR({nnr:Hyp})PRR{d}IYNR{d}{ct:Amid} | 9 | Amidation | Free | Linear | Mix | Hyp = trans-4-Hydroxy-l-proline | 17 | Antimicrobial | 1.2 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37797458 | 2023 | VDK({nnr:Dfp})({nnr:Dfp})YLPRPR({nnr:Dfp})PRR{d}IYNR{d}{ct:Amid} | 10 | Amidation | Free | Linear | Mix | Dfp = 4,4-Difluoro-l-proline | 17 | Antimicrobial | 0.2 % Hemolysis at 800 μg/mL | Human | Analogues Of Oncocin | NA | NA | ||
| 37770629 | 2023 | K{nt:myristic — C14}{ct:Amid} | 1M | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 1 | Antimicrobial | 50 % Hemolysis at 477.61 ± 28.02 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KK{nt:myristic — C14}{ct:Amid} | 2M | Amidation | myristic — C14 | Linear | L | C14 = myristic | 2 | Antimicrobial | 50 % Hemolysis at 345.21 ± 12.80 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKK{nt:myristic — C14}{ct:Amid} | 3M | Amidation | myristic — C14 | Linear | L | C14 = myristic | 3 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKKK{nt:myristic — C14}{ct:Amid} | 4M | Amidation | myristic — C14 | Linear | L | C14 = myristic | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | K{nt:palmitic — C16}{ct:Amid} | 1P | Amidation | palmitic — C16 | Linear | L | C16 = palmitic | 1 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KK{nt:palmitic — C16}{ct:Amid} | 2P | Amidation | palmitic — C16 | Linear | L | C16 = palmitic | 2 | Antimicrobial | 50 % Hemolysis at 55.21 ± 1.69 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKK{nt:palmitic — C16}{ct:Amid} | 3P | Amidation | palmitic — C16 | Linear | L | C16 = palmitic | 3 | Antimicrobial | 50 % Hemolysis at 135.46 ± 8.69 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKKK{nt:palmitic — C16}{ct:Amid} | 4P | Amidation | palmitic — C16 | Linear | L | C16 = palmitic | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | K{nt:stearic — C18}{ct:Amid} | 1S | Amidation | stearic — C18 | Linear | L | C18 = stearic | 1 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KK{nt:stearic — C18}{ct:Amid} | 2S | Amidation | stearic — C18 | Linear | L | C18 = stearic | 2 | Antimicrobial | 50 % Hemolysis at 21.88 ± 0.68 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKK{nt:stearic — C18}{ct:Amid} | 3S | Amidation | stearic — C18 | Linear | L | C18 = stearic | 3 | Antimicrobial | 50 % Hemolysis at 32.11 ± 1.54 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | KKKK{nt:stearic — C18}{ct:Amid} | 4S | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 4 | Antimicrobial | 50 % Hemolysis at 48.44 ± 4.12 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C14}K({nnr:Me3}){nt:myristic — C14}{ct:Amid} | 1Mq | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 1 | Antimicrobial | 50 % Hemolysis at 88.25 ± 1.57 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C14}K({nnr:Me3})K({nnr:Me3}){nt:myristic — C14}{ct:Amid} | 2Mq | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 2 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C14}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:myristic — C14}{ct:Amid} | 3Mq | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 3 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C14}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:myristic — C14}{ct:Amid} | 4Mq | Amidation | myristic — C14 | Linear | L | C14 = myristic, Me3 = trimethyl | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C16}K({nnr:Me3}){nt:palmitic — C16}{ct:Amid} | 1Pq | Amidation | palmitic — C16 | Linear | L | C16 = palmitic, Me3 = trimethyl | 1 | Antimicrobial | 50 % Hemolysis at 32.21 ± 1.97 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C16}K({nnr:Me3})K({nnr:Me3}){nt:palmitic — C16}{ct:Amid} | 2Pq | Amidation | palmitic — C16 | Linear | L | C16 = palmitic, Me3 = trimethyl | 2 | Antimicrobial | 50 % Hemolysis at 133.32 ± 6.27 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C16}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:palmitic — C16}{ct:Amid} | 3Pq | Amidation | palmitic — C16 | Linear | L | C16 = palmitic, Me3 = trimethyl | 3 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C16}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:palmitic — C16}{ct:Amid} | 4Pq | Amidation | palmitic — C16 | Linear | L | C16 = palmitic, Me3 = trimethyl | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C18}K({nnr:Me3}){nt:stearic — C18}{ct:Amid} | 1Sq | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 1 | Antimicrobial | 50 % Hemolysis at 16.13 ± 9.88 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C18}K({nnr:Me3})K({nnr:Me3}){nt:stearic — C18}{ct:Amid} | 2Sq | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 2 | Antimicrobial | 50 % Hemolysis at 22.42 ± 0.98 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C18}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:stearic — C18}{ct:Amid} | 3Sq | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 3 | Antimicrobial | 50 % Hemolysis at 385.50 ± 71.51 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 37770629 | 2023 | {nnr:C18}K({nnr:Me3})K({nnr:Me3})K({nnr:Me3})K({nnr:Me3}){nt:stearic — C18}{ct:Amid} | 4Sq | Amidation | stearic — C18 | Linear | L | C18 = stearic, Me3 = trimethyl | 4 | Antimicrobial | 50 % Hemolysis at >512 μg/mL | Human | Ultrashort Cationic Lipopeptides (Uscls) | NA | NA | ||
| 38435443 | 2023 | RFGRFLRKILRFLKK | mCHTL131-140 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.355731 ± 0.0395 % Hemolysis at 1 mg/ml | Human | Chicken Cathelicidin-2 | α-Helical | Non-hemolytic | ||
| 38435443 | 2023 | RFGRFLRKILRFLKK | mCHTL131-141 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.250329 ± 0.0456 % Hemolysis at 0.5 mg/ml | Human | Chicken Cathelicidin-3 | α-Helical | Non-hemolytic | ||
| 38435443 | 2023 | RFGRFLRKILRFLKK | mCHTL131-142 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.27668 ± 0.0395 % Hemolysis at 0.25 mg/ml | Human | Chicken Cathelicidin-4 | α-Helical | Non-hemolytic | ||
| 38435443 | 2023 | RFGRFLRKILRFLKK | mCHTL131-143 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.184453 ± 0.114 % Hemolysis at 0.125 mg/ml | Human | Chicken Cathelicidin-5 | α-Helical | Non-hemolytic | ||
| 38435443 | 2023 | RFGRFLRKILRFLKK | mCHTL131-144 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.184453 ± 0.0604 % Hemolysis at 0.0625 mg/ml | Human | Chicken Cathelicidin-6 | α-Helical | Non-hemolytic | ||
| 38435443 | 2023 | RFGRFLRKILRFLKK | mCHTL131-145 | Free | Free | Linear | L | None | 15 | Antimicrobial | 0.184453 ± 0.0913 % Hemolysis at 0.03125 mg/ml | Human | Chicken Cathelicidin-7 | α-Helical | Non-hemolytic | ||
| 38097636 | 2023 | KWKLFKKIGAVLKVL{ct:Amid} | C(1–7)M(2–9) | Amidation | Free | Linear | L | None | 15 | Antibioflm | 50 % Hemolysis at 88.89±4.62 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 38097636 | 2023 | KWKLFKKIGKVLKVL{ct:Amid} | CM-10K | Amidation | Free | Linear | L | None | 15 | Antibioflm | 50 % Hemolysis at 85.78±9.01 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 38097636 | 2023 | KWKLFKKIGKVLKKL{ct:Amid} | CM-10K14K | Amidation | Free | Linear | L | None | 15 | Antibioflm | 50 % Hemolysis at 561.90±88.19 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 38097636 | 2023 | VWKLFKKIGKVLKKL{ct:Amid} | CM-1V10K14K | Amidation | Free | Linear | L | None | 15 | Antibioflm | 50 % Hemolysis at 118.90±8.19 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 38097636 | 2023 | VWKLFKKIGAVLKKL{ct:Amid} | CM-1V14K | Amidation | Free | Linear | L | None | 15 | Antibioflm | 50 % Hemolysis at 131.70±9.23 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 38097636 | 2023 | KWKLFKKIGAVLKVLA{ct:Amid} | CM-A | Amidation | Free | Linear | L | None | 16 | Antibioflm | 50 % Hemolysis at 42.58±1.98 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 38247578 | 2023 | KGGDLGLFEPTL | EYHp6 | Free | Free | Linear | L | None | 12 | Anti-Salmonella | 0 % Hemolysis at 4 mM | Human | Egg Yolk Hydrolysate | NA | Non-hemolytic | ||
| 38247578 | 2023 | KGGDLGLFEPTL | EYHp6 | Free | Free | Linear | L | None | 12 | Anti-Salmonella | <20 % Hemolysis at 8 mM | Human | Egg Yolk Hydrolysate | NA | NA | ||
| 38247598 | 2023 | KFRNWFSQHFKKFKQKLKNTFA | GATR-3 | Free | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 5000 μg/mL | Human | Short Apo6 Peptide | α-Helical | NA | ||
| 38663759 | 2024 | RRRW-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 1a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 50 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 1b | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 75 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Dip}-{nnr:Dip}-W{cyc:N-C} | 1c | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 65 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRW-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 2a | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 60 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Nal}-W-{nnr:Nal}{cyc:N-C} | 2b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 55 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRR-{nnr:Nal}-{nnr:Nal}-W{cyc:N-C} | 2c | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 45 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 3a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 85 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 3b | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 230 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-{nnr:Dip}-W{cyc:N-C} | 3c | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 4a | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 150 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-W-{nnr:Nal}{cyc:N-C} | 4b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 175 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-{nnr:Nal}-W{cyc:N-C} | 4c | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 105 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Dip}-W{cyc:N-C} | 5a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antimicrobial | 50 % Hemolysis at 220 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRRW-{nnr:Nal}-W{cyc:N-C} | 5b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antimicrobial | 50 % Hemolysis at 200 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-L-{nnr:Dip}{cyc:N-C} | 6a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 155 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-L-{nnr:Nal}{cyc:N-C} | 6b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 5 | Antimicrobial | 50 % Hemolysis at 170 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | {nnr:Agp}-{nnr:Agp}-{nnr:Agp}-{nnr:Agp}-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 7a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine, Agp = (S)−2-amino-3-guanidinopropionic acid | 1 | Antimicrobial | 50 % Hemolysis at 240 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | {nnr:Agb}-{nnr:Agb}-{nnr:Agb}-{nnr:Agb}-{nnr:Dip}-W-{nnr:Dip}{cyc:N-C} | 7b | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine, Agb = (S)−2-amino-4-guanidinobutyric acid | 1 | Antimicrobial | 50 % Hemolysis at 190 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | {nnr:hArg}R{nnr:hArg}R{nnr:Dip}W{nnr:Dip}{cyc:N-C} | 7c | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine, hArg = homo-arginine (S)−2-amino-6-guanidino-hexanoic acid | 7 | Antimicrobial | 50 % Hemolysis at 160 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 8a | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 70 μg/mL | Human | Synthetic | NA | NA | ||
| 38663759 | 2024 | RRRR-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 8b | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 4 | Antimicrobial | 50 % Hemolysis at 80 μg/mL | Human | Synthetic | NA | NA | ||
| 38802469 | 2024 | AFCGGRCRGFRRRLFCTKAC | AMP | Free | Free | Linear | L | None | 20 | Antibacterial and Antibioflm | <1 % Hemolysis at 1.5625-100 μg/mL | Human | Synthetic | expanded conformation | Non-hemolytic | ||
| 38287360 | 2024 | RWCVYAYVRVRGVLVRYRRCW | Ar-1 | Free | Free | Linear | L | None | 21 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | RWCVYAYVRVRGVLVRYRRCW | Ar-1 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 20.2±1.8 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | RW-{nnr:Abu}-VYAYVRVRGVLVRYRR-{nnr:Abu}-W | Ar-1-Abu | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | RW-{nnr:Abu}-VYAYVRVRGVLVRYRR-{nnr:Abu}-W | Ar-1-Abu | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 10 % Hemolysis at >100 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | RWCVYAYVRIRGVLVRYRRCW | Ar-2 | Free | Free | Linear | L | None | 21 | Antibacterial | 50 % Hemolysis at 29.2±2.4 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | RWCVYAYVRIRGVLVRYRRCW | Ar-2 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 4.9±0.7 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | RW-{nnr:Abu}-VYAYVRIRGVLVRYRR-{nnr:Abu}-W | Ar-2-Abu | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | RW-{nnr:Abu}-VYAYVRIRGVLVRYRR-{nnr:Abu}-W | Ar-2-Abu | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 10 % Hemolysis at 15.4±1.0 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | GFCWYVCVYRNGVRVCYRRCN | Ar-3 | Free | Free | Linear | L | None | 21 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | GFCWYVCVYRNGVRVCYRRCN | Ar-3 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 30.3±2.5 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | GF-{nnr:Abu}-WYV-{nnr:Abu}-VYRNGVRV-{nnr:Abu}-YRR-{nnr:Abu}-N | Ar-3-Abu | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | GF-{nnr:Abu}-WYV-{nnr:Abu}-VYRNGVRV-{nnr:Abu}-YRR-{nnr:Abu}-N | Ar-3-Abu | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 10 % Hemolysis at 39.3±3.2 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | GFCWYV-{nnr:Abu}-VYRNGVRV-{nnr:Abu}-YRRCN | Ar-3(3–20) | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | GFCWYV-{nnr:Abu}-VYRNGVRV-{nnr:Abu}-YRRCN | Ar-3(3–20) | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 10 % Hemolysis at >100 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | GF-{nnr:Abu}-WYVCVYRNGVRVCYRR-{nnr:Abu}-N | Ar-3(7–16) | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38287360 | 2024 | GF-{nnr:Abu}-WYVCVYRNGVRVCYRR-{nnr:Abu}-N | Ar-3(7–16) | Free | Free | Linear | L | Abu = alpha-amino-n-butyric acid | 21 | Antibacterial | 10 % Hemolysis at 41.1±4.3 µM | Human | Arenicin Derivatives | anti-parallel β-Sheets | NA | ||
| 38467553 | 2024 | {nnr:GA}-YYLK{ct:Amid} | AB-10 | Amidation | Free | Linear | L | GA = gallic acid | 6 | Antioxidant (Antiradical) | 0 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-YYLK{ct:Amid} | AB-10 | Amidation | Free | Linear | L | GA = gallic acid | 6 | Antioxidant (Antiradical) | 0 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-YYLK{ct:Amid} | AB-10 | Amidation | Free | Linear | L | GA = gallic acid | 6 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | ({nnr:GA}-KKIRRLK){ct:Amid} | AB-11 | Amidation | Free | Linear | L | GA = gallic acid | 9 | Antioxidant (Antiradical) | <10 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | ({nnr:GA}-KKIRRLK){ct:Amid} | AB-11 | Amidation | Free | Linear | L | GA = gallic acid | 9 | Antioxidant (Antiradical) | <10 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | ({nnr:GA}-KKIRRLK){ct:Amid} | AB-11 | Amidation | Free | Linear | L | GA = gallic acid | 9 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-KKIRARLKYAC{ct:Amid} | AB-12 | Amidation | Free | Linear | L | GA = gallic acid | 13 | Antioxidant (Antiradical) | 0 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-KKIRARLKYAC{ct:Amid} | AB-12 | Amidation | Free | Linear | L | GA = gallic acid | 13 | Antioxidant (Antiradical) | 0 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-KKIRARLKYAC{ct:Amid} | AB-12 | Amidation | Free | Linear | L | GA = gallic acid | 13 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | RRRRRRRRKKKKKKKACAC{ct:Amid} | AB-13 | Amidation | Free | Linear | L | None | 19 | Antioxidant (Antiradical) | 0 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | RRRRRRRRKKKKKKKACAC{ct:Amid} | AB-13 | Amidation | Free | Linear | L | None | 19 | Antioxidant (Antiradical) | 0 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | RRRRRRRRKKKKKKKACAC{ct:Amid} | AB-13 | Amidation | Free | Linear | L | None | 19 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | (WKKIRVRLSWKKIRVRLS)KAC{ct:Amid} | AB-14 | Amidation | Free | Linear | L | None | 21 | Antioxidant (Antiradical) | <20 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | (WKKIRVRLSWKKIRVRLS)KAC{ct:Amid} | AB-14 | Amidation | Free | Linear | L | None | 21 | Antioxidant (Antiradical) | 10 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | (WKKIRVRLSWKKIRVRLS)KAC{ct:Amid} | AB-14 | Amidation | Free | Linear | L | None | 21 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | ({nnr:GA}KKIRARLK{nnr:GA}KKIRARLK)KYAC{ct:Amid} | AB-15 | Amidation | Free | Linear | L | GA = gallic acid | 24 | Antioxidant (Antiradical) | <20 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | ({nnr:GA}KKIRARLK{nnr:GA}KKIRARLK)KYAC{ct:Amid} | AB-15 | Amidation | Free | Linear | L | GA = gallic acid | 24 | Antioxidant (Antiradical) | <10 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | ({nnr:GA}KKIRARLK{nnr:GA}KKIRARLK)KYAC{ct:Amid} | AB-15 | Amidation | Free | Linear | L | GA = gallic acid | 24 | Antioxidant (Antiradical) | <10 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | NA | ||
| 38467553 | 2024 | (KKLRLKTAFKKKLRLKTAFK)KAC{ct:Amid} | ST-10 | Amidation | Free | Linear | L | None | 23 | Antioxidant (Antiradical) | 0 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | (KKLRLKTAFKKKLRLKTAFK)KAC{ct:Amid} | ST-10 | Amidation | Free | Linear | L | None | 23 | Antioxidant (Antiradical) | 0 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | (KKLRLKTAFKKKLRLKTAFK)KAC{ct:Amid} | ST-10 | Amidation | Free | Linear | L | None | 23 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-KK{ct:Amid} | AST-1 | Amidation | Free | Linear | L | GA = gallic acid | 4 | Antioxidant (Antiradical) | 0 % Hemolysis at 1000 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-KK{ct:Amid} | AST-1 | Amidation | Free | Linear | L | GA = gallic acid | 4 | Antioxidant (Antiradical) | 0 % Hemolysis at 500 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38467553 | 2024 | {nnr:GA}-KK{ct:Amid} | AST-1 | Amidation | Free | Linear | L | GA = gallic acid | 4 | Antioxidant (Antiradical) | 0 % Hemolysis at 100 μg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 38328670 | 2024 | MAKRRKKAKKKAKKAKKRRRRR | MR-22 | Free | Free | Linear | L | None | 21 | Antibacterial | 0 % Hemolysis at 2-256 μg/mL | Human | Synthetic | Helix/coil | Non-hemolytic | ||
| 38535822 | 2024 | FLWGLIPGAISAVTSLIKK{ct:Amid} | Ctriporin | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 90.6 ± 11.8 % Hemolysis at 256 μg/mL | Human | Scorpion Chaerilus Tricostatus | α-Helical | NA | ||
| 38535822 | 2024 | FLWKLIPGAISAVTSLIKK{ct:Amid} | CM1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 75.6 ± 10.1 % Hemolysis at 256 μg/mL | Human | Ctriporin Analogs | α-Helical | NA | ||
| 38535822 | 2024 | FLWKLIPKAISAVTSLIKK{ct:Amid} | CM2 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 74.3 ± 9.2 % Hemolysis at 256 μg/mL | Human | Ctriporin Analogs | α-Helical | NA | ||
| 38535822 | 2024 | FLWKLIPKAIKAVTSLIKK{ct:Amid} | CM3 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 89.1 ± 12.1 % Hemolysis at 256 μg/mL | Human | Ctriporin Analogs | α-Helical | NA | ||
| 38535822 | 2024 | FLWKLIPKAIKKVTSLIKK{ct:Amid} | CM4 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 14.0 ± 4.7 % Hemolysis at 256 μg/mL | Human | Ctriporin Analogs | α-Helical | NA | ||
| 38535822 | 2024 | FLWKLIPKAIKKVKSLIKK{ct:Amid} | CM5 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 9.8 ± 0.6 % Hemolysis at 256 μg/mL | Human | Ctriporin Analogs | α-Helical | NA | ||
| 38535822 | 2024 | FLWKLIPKAIKKVKKLIKK{ct:Amid} | CM6 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 8.1 ± 1.9 % Hemolysis at 256 μg/mL | Human | Ctriporin Analogs | α-Helical | NA | ||
| 38535822 | 2024 | FLWKLIKKAIKKVKKLIKK{ct:Amid} | CM7 | Amidation | Free | Linear | L | None | 19 | Antimicrobial | 57.5 ± 9.8 % Hemolysis at 256 μg/mL | Human | Ctriporin Analogs | α-Helical | NA | ||
| 38791374 | 2024 | KRCRFRIYRWGFPRRRF | blap-6 | Free | Free | Linear | L | None | 17 | Antifungal | 0 % Hemolysis at 1.3 µM | Human | Chinese Medicinal Beetle Blaps Rhynchopetera | β-Sheet and Random coli | Non-hemolytic | ||
| 38791374 | 2024 | KRCRFRIYRWGFPRRRF | blap-6 | Free | Free | Linear | L | None | 17 | Antifungal | 0 % Hemolysis at 2.6 µM | Human | Chinese Medicinal Beetle Blaps Rhynchopetera | β-Sheet and Random coli | Non-hemolytic | ||
| 38791374 | 2024 | KRCRFRIYRWGFPRRRF | blap-6 | Free | Free | Linear | L | None | 17 | Antifungal | 0 % Hemolysis at 5.2 µM | Human | Chinese Medicinal Beetle Blaps Rhynchopetera | β-Sheet and Random coli | Non-hemolytic | ||
| 38791374 | 2024 | KRCRFRIYRWGFPRRRF | blap-6 | Free | Free | Linear | L | None | 17 | Antifungal | <5 % Hemolysis at 10.4 µM | Human | Chinese Medicinal Beetle Blaps Rhynchopetera | β-Sheet and Random coli | NA | ||
| 38791374 | 2024 | KRCRFRIYRWGFPRRRF | blap-6 | Free | Free | Linear | L | None | 17 | Antifungal | <5 % Hemolysis at 20.8 µM | Human | Chinese Medicinal Beetle Blaps Rhynchopetera | β-Sheet and Random coli | NA | ||
| 38791374 | 2024 | KRCRFRIYRWGFPRRRF | blap-6 | Free | Free | Linear | L | None | 17 | Antifungal | <10 % Hemolysis at 41.7 µM | Human | Chinese Medicinal Beetle Blaps Rhynchopetera | β-Sheet and Random coli | NA | ||
| 38791374 | 2024 | KRCRFRIYRWGFPRRRF | blap-6 | Free | Free | Linear | L | None | 17 | Antifungal | <20 % Hemolysis at 83.3 µM | Human | Chinese Medicinal Beetle Blaps Rhynchopetera | β-Sheet and Random coli | NA | ||
| 38791374 | 2024 | KRCRFRIYRWGFPRRRF | blap-6 | Free | Free | Linear | L | None | 17 | Antifungal | 90 % Hemolysis at 166.6 µM | Human | Chinese Medicinal Beetle Blaps Rhynchopetera | β-Sheet and Random coli | NA | ||
| 38755634 | 2024 | FLVKLIL{ct:Amid} | BiF | Amidation | Free | Linear | L | None | 7 | Antimicrobial, Antibiofilm | 10 % Hemolysis at 15.63 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 38755634 | 2024 | FLVKLILKILRR{ct:Amid} | BiF2 | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antibiofilm | 10 % Hemolysis at 1.95 μg/mL | Human | Derivative Of Bif | α-Helical | NA | ||
| 38755634 | 2024 | FLVKLIKKILRR{ct:Amid} | BiF2_7K | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antibiofilm | 10 % Hemolysis at 15.63 μg/mL | Human | Derivative Of Bif | α-Helical | NA | ||
| 38755634 | 2024 | FLVKKIKKILRR{ct:Amid} | BiF2_5K7K | Amidation | Free | Linear | L | None | 12 | Antimicrobial, Antibiofilm | 10 % Hemolysis at >250 μg/mL | Human | Lysine-Substituted Hybrid Peptide | α-Helical | NA | ||
| 38755634 | 2024 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 10 % Hemolysis at <0.98 μg/mL | Human | Bee Venom | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 0.19 µM | Human | Synthetic | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 0.39 µM | Human | Synthetic | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 0.78 µM | Human | Synthetic | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 1.56 µM | Human | Synthetic | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 3.12 µM | Human | Synthetic | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 6.25 µM | Human | Synthetic | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 12.5 µM | Human | Synthetic | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 25 µM | Human | Synthetic | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 50 µM | Human | Synthetic | α-Helical | NA | ||
| 38657271 | 2024 | P{d}KSRLHKWAND{nnr:Aic}EDRTYQ{nt:Acet}{ct:Amid} | SR16 | Amidation | Acetylation | Linear | Mix | p = D-Proline, Aic = α-aminoisobutyric acid | 18 | Antiviral | <5 % Hemolysis at 100 µM | Human | Synthetic | α-Helical | NA | ||
| 38585074 | 2024 | KGIRGYKGGYKGAFKQTKYWWWWW | Os−C(W5) | Free | Free | Linear | L | None | 24 | Antifungal | <10 % Hemolysis at 0.78 µM | Human | Modified Form Of Os−C | Disordered | NA | ||
| 38585074 | 2024 | KGIRGYKGGYKGAFKQTKYWWWWW | Os−C(W5) | Free | Free | Linear | L | None | 24 | Antifungal | <10 % Hemolysis at 1.56 µM | Human | Modified Form Of Os−C | Disordered | NA | ||
| 38585074 | 2024 | KGIRGYKGGYKGAFKQTKYWWWWW | Os−C(W5) | Free | Free | Linear | L | None | 24 | Antifungal | <10 % Hemolysis at 3.12 µM | Human | Modified Form Of Os−C | Disordered | NA | ||
| 38585074 | 2024 | KGIRGYKGGYKGAFKQTKYWWWWW | Os−C(W5) | Free | Free | Linear | L | None | 24 | Antifungal | <10 % Hemolysis at 6.25 µM | Human | Modified Form Of Os−C | Disordered | NA | ||
| 38585074 | 2024 | KGIRGYKGGYKGAFKQTKYWWWWW | Os−C(W5) | Free | Free | Linear | L | None | 24 | Antifungal | <10 % Hemolysis at 12.5 µM | Human | Modified Form Of Os−C | Disordered | NA | ||
| 38585074 | 2024 | KGIRGYKGGYKGAFKQTKYWWWWW | Os−C(W5) | Free | Free | Linear | L | None | 24 | Antifungal | <10 % Hemolysis at 25 µM | Human | Modified Form Of Os−C | Disordered | NA | ||
| 38585074 | 2024 | KGIRGYKGGYKGAFKQTKYWWWWW | Os−C(W5) | Free | Free | Linear | L | None | 24 | Antifungal | <10 % Hemolysis at 50 µM | Human | Modified Form Of Os−C | Disordered | NA | ||
| 38585074 | 2024 | KGIRGYKGGYKGAFKQTKYWWWWW | Os−C(W5) | Free | Free | Linear | L | None | 24 | Antifungal | <10 % Hemolysis at 100 µM | Human | Modified Form Of Os−C | Disordered | NA | ||
| 38655253 | 2024 | TLKQKLLSVCDKVGFLKSMCKGLMKKH | NK1 | Free | Free | Linear | L | None | 27 | Antimicrobial | <30 % Hemolysis at 10 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSYCGKLPLVKSTCEDLVKKH | NK2 | Free | Free | Linear | L | None | 27 | Antimicrobial | <20 % Hemolysis at 10 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSVCDKMGLLKSLCKGMVKKH | NK3 | Free | Free | Linear | L | None | 27 | Antimicrobial | 10 % Hemolysis at 10 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | TLKQKLLSVCDKVGFLKSMCKGLMKKH | NK1 | Free | Free | Linear | L | None | 27 | Antimicrobial | <50 % Hemolysis at 20 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSYCGKLPLVKSTCEDLVKKH | NK2 | Free | Free | Linear | L | None | 27 | Antimicrobial | <20 % Hemolysis at 20 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSVCDKMGLLKSLCKGMVKKH | NK3 | Free | Free | Linear | L | None | 27 | Antimicrobial | <20 % Hemolysis at 20 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | TLKQKLLSVCDKVGFLKSMCKGLMKKH | NK1 | Free | Free | Linear | L | None | 27 | Antimicrobial | <60 % Hemolysis at 30 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSYCGKLPLVKSTCEDLVKKH | NK2 | Free | Free | Linear | L | None | 27 | Antimicrobial | <20 % Hemolysis at 30 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSVCDKMGLLKSLCKGMVKKH | NK3 | Free | Free | Linear | L | None | 27 | Antimicrobial | 10 % Hemolysis at 30 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | TLKQKLLSVCDKVGFLKSMCKGLMKKH | NK1 | Free | Free | Linear | L | None | 27 | Antimicrobial | <80 % Hemolysis at 40 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSYCGKLPLVKSTCEDLVKKH | NK2 | Free | Free | Linear | L | None | 27 | Antimicrobial | 10 % Hemolysis at 40 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSVCDKMGLLKSLCKGMVKKH | NK3 | Free | Free | Linear | L | None | 27 | Antimicrobial | <30 % Hemolysis at 40 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | TLKQKLLSVCDKVGFLKSMCKGLMKKH | NK1 | Free | Free | Linear | L | None | 27 | Antimicrobial | <80 % Hemolysis at 50 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSYCGKLPLVKSTCEDLVKKH | NK2 | Free | Free | Linear | L | None | 27 | Antimicrobial | 10 % Hemolysis at 50 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSVCDKMGLLKSLCKGMVKKH | NK3 | Free | Free | Linear | L | None | 27 | Antimicrobial | <30 % Hemolysis at 50 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | TLKQKLLSVCDKVGFLKSMCKGLMKKH | NK1 | Free | Free | Linear | L | None | 27 | Antimicrobial | 100 % Hemolysis at 100 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSYCGKLPLVKSTCEDLVKKH | NK2 | Free | Free | Linear | L | None | 27 | Antimicrobial | <30 % Hemolysis at 100 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38655253 | 2024 | EIKQKLLSVCDKMGLLKSLCKGMVKKH | NK3 | Free | Free | Linear | L | None | 27 | Antimicrobial | 10 % Hemolysis at 100 µM | Human | Pig Small Intestine, Nk-Lysin-Derived | Helical-bundle | NA | ||
| 38399250 | 2024 | FVVWGCADYRGSCRTACFAYEYSLGAKGCADGYICCVPNTFRLM | CFBD-1 | Free | Free | Linear | L | None | 44 | Antiviral | >100 % Hemolysis at 100 µM | Human | Salamandra Salamandra | NA | NA | ||
| 36988897 | 2024 | GIGAVLKVLTTGLPALISWIKRKRQQCONH2{ct:Amid} | MLT | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 100 % Hemolysis at 16 μg/mL | Human | Bee Venom Apis Mellifera | α-Helical | NA | ||
| 36988897 | 2024 | GLPLLISWIKRKRQQ{ct:Amid} | M1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 40 % Hemolysis at 16 μg/mL | Human | Analog Of Mlt | α-Helical | NA | ||
| 36988897 | 2024 | GLPLLRSWIKRKRQQ{ct:Amid} | M2 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 14.25 % Hemolysis at 16 μg/mL | Human | Analog Of Mlt | α-Helical | NA | ||
| 38043914 | 2024 | FVKWFKKFLTRIL | TRIL | Free | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 16 µM | Human | Analogue Of Temporin-L | NA | Non-hemolytic | ||
| 38043914 | 2024 | FVKWFKKFLTRIL | TRIL | Free | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 32 µM | Human | Analogue Of Temporin-L | NA | Non-hemolytic | ||
| 38043914 | 2024 | FVKWFKKFLTRIL | TRIL | Free | Free | Linear | L | None | 13 | Antimicrobial | <50 % Hemolysis at 64 µM | Human | Analogue Of Temporin-L | NA | NA | ||
| 38043914 | 2024 | FVKWFKKFLTRIL | TRIL | Free | Free | Linear | L | None | 13 | Antimicrobial | <100 % Hemolysis at 128 µM | Human | Analogue Of Temporin-L | NA | NA | ||
| 38043914 | 2024 | FVKWFKKFLTRIL | TRIL | Free | Free | Linear | L | None | 13 | Antimicrobial | <100 % Hemolysis at 256 µM | Human | Analogue Of Temporin-L | NA | NA | ||
| 38043914 | 2024 | FVKWFKKFLTRIL | TRIL | Free | Free | Linear | L | None | 13 | Antimicrobial | 100 % Hemolysis at 512 µM | Human | Analogue Of Temporin-L | NA | NA | ||
| 37992185 | 2024 | YGKAAAAK‐{nnr:Aic}‐AAAKAAAAK | peptideA | Free | Free | Linear | L | Aic = 2−aminoindane‐2‐carboxylicacid | 18 | Antibacterial | 0 % Hemolysis at | Human | Synthetic | NA | Non-hemolytic | | ||
| 37946110 | 2024 | WFKIIKK | AurH1 | Free | Free | Linear | L | None | 7 | Antifungal | <5 % Hemolysis at 1000 μg/mL | Human | Aurein1.2 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK{nt:Acet} | Ac-AurH1 | Free | Acetylation | Linear | L | None | 7 | Antifungal | <5 % Hemolysis at 1000 μg/mL | Human | Form Of Aurh1 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK{ct:Amid} | AurH1-NH2 | Amidation | Free | Linear | L | None | 7 | Antifungal | <5 % Hemolysis at 1000 μg/mL | Human | Form Of Aurh1 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK | AurH1 | Free | Free | Linear | L | None | 7 | Antifungal | 50 % Hemolysis at 13484 μg/mL | Human | Aurein1.2 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK{nt:Acet} | Ac-AurH1 | Free | Acetylation | Linear | L | None | 7 | Antifungal | 50 % Hemolysis at 10127 μg/mL | Human | Form Of Aurh1 | NA | NA | ||
| 37946110 | 2024 | WFKIIKK{ct:Amid} | AurH1-NH2 | Amidation | Free | Linear | L | None | 7 | Antifungal | 50 % Hemolysis at 14246 μg/mL | Human | Form Of Aurh1 | NA | NA | ||
| 37880286 | 2024 | GIGAVLKVLTTGLPALISWIKRKRQQ | Mel | Free | Free | Linear | L | None | 26 | Anticancer | <40 % Hemolysis at 256 μg/mL | Human | Bee Venom | α-Helical | NA | ||
| 37880286 | 2024 | CGIGAVLKVLTTGLPALISWIKRKRQQ | C-Mel | Free | Free | Linear | L | None | 27 | Anticancer | 30 % Hemolysis at 256 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 37880286 | 2024 | GIGAVLKVLTTGLPALISWIKRKRQQC | Mel-C | Free | Free | Linear | L | None | 27 | Anticancer | <40 % Hemolysis at 256 μg/mL | Human | Synthetic | α-Helical | NA | ||
| 37907616 | 2024 | LIQRGRFGRFLGKIRHFRPRVKFNVHLRGSVGLG{ct:Amid} | Corvus CATH-2 | Amidation | Free | Linear | L | None | 38 | Antimicrobial | 22 % Hemolysis at 62.89 µM | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | FLWRISKFLGKKL{ct:Amid} | HRZN-13 | Amidation | Free | Linear | L | None | 13 | Antibacterial/ Antibiofilm | 0.7 % Hemolysis at 100 μg/mL | Human | Sythesized | α-Helical | Non-hemolytic | ||
| 37760693 | 2024 | FLWRISKFLGRKL{ct:Amid} | HRZN-14 | Amidation | Free | Linear | L | None | 13 | Antibacterial/ Antibiofilm | 5.6 % Hemolysis at 100 μg/mL | Human | Sythesized | α-Helical | Non-hemolytic | ||
| 37760693 | 2024 | FLPWISKFLGKIL{ct:Amid} | HRZN-15 | Amidation | Free | Linear | L | None | 13 | Antibacterial/ Antibiofilm | 100 % Hemolysis at 100 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | FLPWISKFLGKIL{ct:Amid} | HRZN-15 | Amidation | Free | Linear | L | None | 13 | Antibacterial/ Antibiofilm | 8.6 % Hemolysis at 10 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | FLKKIWKLLGKLL{ct:Amid} | HRZN-16 | Amidation | Free | Linear | L | None | 13 | Antibacterial/ Antibiofilm | 100 % Hemolysis at 100 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | FLKKIWKLLGKLL{ct:Amid} | HRZN-16 | Amidation | Free | Linear | L | None | 13 | Antibacterial/ Antibiofilm | 67 % Hemolysis at 10 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | KLWKLLKKLGRLL{ct:Amid} | HRZN-17 | Amidation | Free | Linear | L | None | 13 | Antibacterial/ Antibiofilm | 18 % Hemolysis at 10 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | KLWKLLKKLGRLL{ct:Amid} | HRZN-17 | Amidation | Free | Linear | L | None | 13 | Antibacterial/ Antibiofilm | 74 % Hemolysis at 100 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 39 | Antibacterial/ Antibiofilm | 5.4 % Hemolysis at 10 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 37760693 | 2024 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 39 | Antibacterial/ Antibiofilm | 22 % Hemolysis at 100 μg/mL | Human | Sythesized | α-Helical | NA | ||
| 29075946 | 2017 | IDWKKLLDAAKQIL{ct:Amid} | MP1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | <1 % Hemolysis at 12.5 µM | Human | Venom Of The Social Wasp Polybia Paulista | α-Helix | NA | ||
| 29075946 | 2017 | IDWKK{nnr:*}LDA{nnr:*}KQIL{ct:Amid} | MP1S | Amidation | Free | Linear | L | * = indicate cross-linked residues connected by oct-4-enyl hydrocarbon staple | 12 | Antimicrobial | 6.7 % Hemolysis at 12.5 µM | Human | Stapled Helices Of Polybia-Mp1 | Helical | NA | ||
| 29075946 | 2017 | IDWKK{nnr:*}LNA{nnr:*}KQIL{ct:Amid} | MP1S-D8N | Amidation | Free | Linear | L | * = indicate cross-linked residues connected by oct-4-enyl hydrocarbon staple | 12 | Antimicrobial | 16.3 % Hemolysis at 12.5 µM | Human | Stapled Helices Of Polybia-Mp1 | Helical | NA | ||
| 29075946 | 2017 | IDWKK{nnr:*}LDA{nnr:*}KKIL{ct:Amid} | MP1S-Q12K | Amidation | Free | Linear | L | * = indicate cross-linked residues connected by oct-4-enyl hydrocarbon staple | 12 | Antimicrobial | 9.6 % Hemolysis at 12.5 µM | Human | Stapled Helices Of Polybia-Mp1 | Helical | NA | ||
| 29075946 | 2017 | IDWKKLLDAAKQIL{ct:Amid} | MP1 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 3.2 % Hemolysis at 25 µM | Human | Venom Of The Social Wasp Polybia Paulista | α-Helix | NA | ||
| 29075946 | 2017 | IDWKK{nnr:*}LDA{nnr:*}KQIL{ct:Amid} | MP1S | Amidation | Free | Linear | L | * = indicate cross-linked residues connected by oct-4-enyl hydrocarbon staple | 12 | Antimicrobial | 12.3 % Hemolysis at 25 µM | Human | Stapled Helices Of Polybia-Mp1 | Helical | NA | ||
| 29075946 | 2017 | IDWKK{nnr:*}LNA{nnr:*}KQIL{ct:Amid} | MP1S-D8N | Amidation | Free | Linear | L | * = indicate cross-linked residues connected by oct-4-enyl hydrocarbon staple | 12 | Antimicrobial | 37.8 % Hemolysis at 25 µM | Human | Stapled Helices Of Polybia-Mp1 | Helical | NA | ||
| 29075946 | 2017 | IDWKK{nnr:*}LDA{nnr:*}KKIL{ct:Amid} | MP1S-Q12K | Amidation | Free | Linear | L | * = indicate cross-linked residues connected by oct-4-enyl hydrocarbon staple | 12 | Antimicrobial | 13.9 % Hemolysis at 25 µM | Human | Stapled Helices Of Polybia-Mp1 | Helical | NA | ||
| 29077406 | 2017 | F{d}PV{nnr:O}L-F{d}PV{nnr:O}L{cyc:N-C} | GS | Free | Free | Cyclic | Mix | O = Ornithine, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 12 μg/mL | Human | Aneurinibacillus Migulanus | C2-symmetric antiparallel β-Sheet | NA | ||
| 29077406 | 2017 | F{d}({nnr:Dyp})V{nnr:O}LF{d}PV{nnr:O}L{cyc:N-C} | GS mimetic 15 | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 85 μg/mL | Human | Gs Derivative Synthesized | β-Turn | NA | ||
| 29077406 | 2017 | {nnr:D-Hot═Tap}-V-{nnr:O}-L-F{d}-P-V-{nnr:O}-L{cyc:N-C} | dimethylketal modified GS analogue | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, D-Hot═Tap = D-Hot═Tap, f = D-Phenylalanine | 9 | Antimicrobial | 90 % Hemolysis at >200 μg/mL | Human | Dihydroxylated Dipeptide D-Hot═Tap (D-Hydroxythreonine═Thiaproline With The “═” Representing The Two Covalent Ring Connections) | twisted β-Sheet structure | NA | ||
| 29077406 | 2017 | {nnr:D-Hot[(7S,8S)-{nnr:O}-(2(S)-decyliden)]═Tap}-V-{nnr:O}-L-F{d}-P-V-{nnr:O}-L{cyc:N-C} | GS mimetic 17 | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, D-Hot═Tap = D-Hot═Tap, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 38 μg/mL | Human | Gs Analogue Modified With A C8- Alkyl Chain | twisted β-Sheet structure | NA | ||
| 29077406 | 2017 | {nnr:D-Hot[(7S,8S)-{nnr:O}-(2(S)-pentadecyliden)]═Tap}-V-{nnr:O}-L- F{d}-P-V-{nnr:O}-L{cyc:N-C} | GS mimetic 18 | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, D-Hot═Tap = D-Hot═Tap, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 6 μg/mL | Human | Gs Analogue 18 Modified With A C13-Alkyl Chain | twisted β-Sheet structure | NA | ||
| 29077406 | 2017 | {nnr:D-Hot[(7S,8S)-{nnr:O}-(2(S)-8-pentadecyliden)]═Tap}-V-{nnr:O}L-F{d}-P-V-{nnr:O}-L{cyc:N-C} | GS mimetic 19 | Free | Free | Cyclic | Mix | O = Ornithine, Dyp = cis-dihydroxyproline, D-Hot═Tap = D-Hot═Tap, f = D-Phenylalanine | 10 | Antimicrobial | 90 % Hemolysis at 5 μg/mL | Human | Gs Analogue Modified With Two C7-Alkyl Chains | twisted β-Sheet structure | NA | ||
| 29196622 | 2017 | GIGKFLKKAKKFGKAFVKILKK{ct:Amid} | pexiganan | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 10 % Hemolysis at 73 μM | Human | Synthetic Peptide Xenopus Laevis Frog | α-Helical | NA | ||
| 29196622 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 10 % Hemolysis at 1 μM | Human | Bee Venom-Derived | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Anticancer, Antimicrobial | 10 % Hemolysis at 14 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-P-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1-Pro6 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Antimicrobial | 10 % Hemolysis at 83 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-P-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1-Pro9 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Antimicrobial | 10 % Hemolysis at 165 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1 11mer | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 11 | Antimicrobial | 10 % Hemolysis at 103 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1 17mer | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 17 | Antimicrobial | 10 % Hemolysis at 3 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nssb}-{nnr:Nssb}-{nnr:NLys}-{nnr:Nssb}-{nnr:Nssb}-{nnr:NLys}-{nnr:Nssb}-{nnr:Nssb}-{nnr:NLys}-{nnr:Nssb}-{nnr:Nssb}{nt:H}{ct:Amid} | peptoid 2 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nssb = N-(S)-(sec-butyl)glycine | 12 | Antimicrobial | 10 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | RVKRVWPLVIRTVIAGYNLYRAIKKK | fowlicidin-1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 10 % Hemolysis at 7 μM | Human | Cathelicidin-1 | α-Helical | NA | ||
| 29196622 | 2017 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial Agents and Chemotherapy | 10 % Hemolysis at >100 μM | Human | Human Neutrophils | α-Helical peptide | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Npm}-{nnr:Npm}-{nnr:NLys}-{nnr:Npm}-{nnr:Npm}-{nnr:NLys}-{nnr:Npm}-{nnr:Npm}-{nnr:NLys}-{nnr:Npm}-{nnr:Npm}{nt:H}{ct:Amid} | peptoid 1 achiral | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Npm = N-(phenylmethyl)glycine | 12 | Antimicrobial | 10 % Hemolysis at 180 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:NLys}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:NLys}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1-NLys5,11 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Antimicrobial | 10 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nsna}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nsna}{nt:H}{ct:Amid} | peptoid 1-Nsna6,12 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine, Nsna = (S)-N-(1-naphthylethyl) glycine | 12 | Antimicrobial | 10 % Hemolysis at 7 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:Ntridec}-({nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}){nt:H}{ct:Amid} | peptoid 1-C134mer | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine, Ntridec = N-(tridecyl)glycine | 4 | Antimicrobial | 10 % Hemolysis at 65 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | GIGKFLKKAKKFGKAFVKILKK{ct:Amid} | pexiganan | Amidation | Free | Linear | L | None | 22 | Antimicrobial peptides | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide Xenopus Laevis Frog | α-Helical | NA | ||
| 29196622 | 2017 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial peptide | 50 % Hemolysis at 6 μM | Human | Bee Venom-Derived | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Anticancer, Antimicrobial | 50 % Hemolysis at 62 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-P-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1-Pro6 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Antimicrobial | 50 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-P-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1-Pro9 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Antimicrobial | 50 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1 11mer | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 11 | Antimicrobial | 50 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1 17mer | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 17 | Antimicrobial | 50 % Hemolysis at 15 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nssb}-{nnr:Nssb}-{nnr:NLys}-{nnr:Nssb}-{nnr:Nssb}-{nnr:NLys}-{nnr:Nssb}-{nnr:Nssb}-{nnr:NLys}-{nnr:Nssb}-{nnr:Nssb}{nt:H}{ct:Amid} | peptoid 2 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nssb = N-(S)-(sec-butyl)glycine | 12 | Antimicrobial | 50 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | RVKRVWPLVIRTVIAGYNLYRAIKKK | fowlicidin-1 | Free | Free | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at >20 μM | Human | Cathelicidin-1 | α-Helical | NA | ||
| 29196622 | 2017 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial Agents and Chemotherapy | 50 % Hemolysis at >100 μM | Human | Human Neutrophils | α-Helical peptide | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Npm}-{nnr:Npm}-{nnr:NLys}-{nnr:Npm}-{nnr:Npm}-{nnr:NLys}-{nnr:Npm}-{nnr:Npm}-{nnr:NLys}-{nnr:Npm}-{nnr:Npm}{nt:H}{ct:Amid} | peptoid 1 achiral | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Npm = N-(phenylmethyl)glycine | 12 | Antimicrobial | 50 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:NLys}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:NLys}-{nnr:Nspe}{nt:H}{ct:Amid} | peptoid 1-NLys5,11 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine | 12 | Antimicrobial | 50 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nsna}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}-{nnr:Nspe}-{nnr:Nsna}{nt:H}{ct:Amid} | peptoid 1-Nsna6,12 | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine, Nsna = (S)-N-(1-naphthylethyl) glycine | 12 | Antimicrobial | 50 % Hemolysis at 27 μM | Human | Synthetic | NA | NA | ||
| 29196622 | 2017 | {nnr:Ntridec}-({nnr:NLys}-{nnr:Nspe}-{nnr:Nspe}-{nnr:NLys}){nt:H}{ct:Amid} | peptoid 1-C134mer | Amidation | H | Linear | L | Nlys = N-(4-aminobutyl)glycine, Nspe = N-(S)-(1-phenylethyl)glycine, Ntridec = N-(tridecyl)glycine | 4 | Antimicrobial | 50 % Hemolysis at >200 μM | Human | Synthetic | NA | NA | ||
| 28960954 | 2017 | KWCFRVCYRGICYRRCR | TP1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.25 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | β-Hairpin | Low hemolytic | ||
| 28960954 | 2017 | AWCFRVCYRGICYRRCR | TP1[K1A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 2.1 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KACFRVCYRGICYRRCR | TP1[W2A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 8 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWAFRVCYRGICYRRSR | TP1[C3A,C16S] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 8 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCARVCYRGICYRRCR | TP1[F4A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 40 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | β-Hairpin | NA | ||
| 28960954 | 2017 | KWCFAVCYRGICYRRCR | TP1[R5A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 2 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRACYRGICYRRCR | TP1[V6A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 1.2 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVAYRGISYRRCR | TP1[C7A,C12S] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 1 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVCARGICYRRCR | TP1[Y8A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 8 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVCYAGICYRRCR | TP1[R9A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 2 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVCYRAICYRRCR | TP1[G10A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.5 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVCYRGACYRRCR | TP1[I11A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 32 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | β-Hairpin | NA | ||
| 28960954 | 2017 | KWCFRVSYRGIAYRRCR | TP1[C7S,C12A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.6 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVCYRGICARRCR | TP1[Y13A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 1 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVCYRGICYARCR | TP1[R14A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.5 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVCYRGICYRACR | TP1[R15A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.45 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWSFRVCYRGICYRRAR | TP1[C3S,C16A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 3 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVCYRGICYRRCA | TP1[R17A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.45 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWAFRVCYRGICYRRAR | TP1[C3A,C16A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 40 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | β-Sheet | NA | ||
| 28960954 | 2017 | KWCFRVAYRGIAYRRCR | TP1[C7A,C12A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 8 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWAFRVAYRGIAYRRAR | TP1[C3A,C7A,C12A,C16A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.24 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | Low hemolytic | ||
| 28960954 | 2017 | KWCFRRCYAGICYRRCR | TP1[V6R,R9A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 11 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | RWCFRVCYRGICYRRCR | TP1[K1R] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 1 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCGRVCYRGICYRRCR | TP1[F4G] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.47 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCSRVCYRGICYRRCR | TP1[F4S] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.23 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | Low hemolytic | ||
| 28960954 | 2017 | KWCFRVCGRGICYRRCR | TP1[Y8G] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.4 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWCFRVCYRGGCYRRCR | TP1[I11G] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.2 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | Low hemolytic | ||
| 28960954 | 2017 | KWCARVCARGACYRRCR | TP1[F4A,Y8A,I11A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.9 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | KWC-FVCYRGICYRRCG | TP1[-R5,R17G] | Free | Free | Linear | L | None | 16 | Antimicrobial | 10 % Hemolysis at 0.3 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | AWCARVCYRGICYRRCR | TP1[K1A,F4A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 32 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | AWCFRVCARGICYRRCR | TP1[K1A,Y8A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.4 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | NA | ||
| 28960954 | 2017 | AWCFRVCYRGACYRRCR | TP1[K1A,I11A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.2 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | Low hemolytic | ||
| 28960954 | 2017 | KWCFRVCYAGICYRRCA | TP1[R9A,R17A] | Free | Free | Linear | L | None | 17 | Antimicrobial | 10 % Hemolysis at 0.2 μg/ml | Human | Horseshoe Crab Tachypleus Tridentatus | Random Coil (RC) | Low hemolytic | ||
| 29188836 | 2017 | F{d}PVRLF{d}PVRL{cyc:N-C} | GS-2 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 10.03±0.49 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | A{d}PVRLF{d}PVRL{cyc:N-C} | MGR-1 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 67.18±2.94 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}AVRLF{d}PVRL{cyc:N-C} | MGR-2 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 55.03±1.77 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PARLF{d}PVRL{cyc:N-C} | MGR-3 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 30.56±1.80 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PVALF{d}PVRL{cyc:N-C} | MGR-4 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 14.41±0.51 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PVRAF{d}PVRL{cyc:N-C} | MGR-5 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 36.33±1.98 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | A{d}PVRLA{d}PVRL{cyc:N-C} | DGR-1 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 137.40±6.20 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}AVRLF{d}AVRL{cyc:N-C} | DGR-2 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 199.90±9.80 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PARLF{d}PARL{cyc:N-C} | DGR-3 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at 88.95±7.51 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PVALF{d}PVAL{cyc:N-C} | DGR-4 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at >200 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29188836 | 2017 | F{d}PVRAF{d}PVRA{cyc:N-C} | DGR-5 | Free | Free | Cyclic | Mix | None | 10 | Antibiotic | 50 % Hemolysis at >200 (mean±SD, μM) | Human | Bacillus Brevis (Gramicidin S (Gs)) | NA | Low hemolytic | ||
| 29091404 | 2017 | GLFDIIKKIAESF{ct:Amid} | 1 | Amidation | Free | Linear | L | None | 13 | Antifungal | 10 % Hemolysis at 7.6 ± 0.9 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | GLFKIIKKIAKSF{ct:Amid} | 2 | Amidation | Free | Linear | L | None | 13 | Antifungal | 10 % Hemolysis at 2.9 ± 0.1 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}F{nnr:βK}I{nnr:βI}K{nnr:βK}I{nnr:βA}K{nnr:βS}F{ct:Amid} | 3a | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.5 ± 0.1 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}F{nnr:βK}I{nnr:βI}K{nnr:βK}I{nnr:βL}K{nnr:βS}F{ct:Amid} | 3b | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 3.2 ± 0.3 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}F{nnr:βK}I{nnr:βI}K{nnr:βK}I{nnr:βL}K{nnr:βL}F{ct:Amid} | 3c | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 19.2 ± 2.6 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}F{nnr:βK}I{nnr:X}K{nnr:βK}I{nnr:βA}K{nnr:X}F{ct:Amid} | 3Ca | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 4.3 ± 0.2 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}F{nnr:βK}I{nnr:X}K{nnr:βK}I{nnr:βL}K{nnr:X}F{ct:Amid} | 3Cb | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 21.6 ± 6.8 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | GL{nnr:βF}KI{nnr:βI}KK{nnr:βI}AK{nnr:βS}F{ct:Amid} | 4a | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 7.1 ± 1.0 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | GL{nnr:βF}KI{nnr:βI}KK{nnr:βI}LK{nnr:βS}F{ct:Amid} | 4b | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 6.8 ± 0.8 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | GL{nnr:βF}KI{nnr:βI}KK{nnr:βI}LK{nnr:βL}F{ct:Amid} | 4c | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 32.6 ± 2.3 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | GL{nnr:X}KI{nnr:βI}KK{nnr:X}AK{nnr:βS}F{ct:Amid} | 4Ca | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.6 ± 0.1 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | GL{nnr:X}KI{nnr:βI}KK{nnr:X}LK{nnr:βS}F{ct:Amid} | 4Cb | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.3 ± 0.1 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | GL{nnr:X}KI{nnr:βI}KK{nnr:X}LK{nnr:βL}F{ct:Amid} | 4Cc | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 24.5 ± 2.0 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}FKI{nnr:βI}KKI{nnr:βA}KSF{ct:Amid} | 5a | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.6 ± 0.3 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}FKI{nnr:βI}KKI{nnr:βL}KSF{ct:Amid} | 5b | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 5.5 ± 1.6 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}FKI{nnr:βI}KKI{nnr:βL}KLF{ct:Amid} | 5c | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 41.9 ± 5.2 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}FKI{nnr:βI}KKI{nnr:X}KSF{ct:Amid} | 5Ca | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.6 ± 0.2 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}FKI{nnr:βI}KKI{nnr:X}KLF{ct:Amid} | 5Cb | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 19.8 ± 2.5 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}F{nnr:βK}II{nnr:βK}K{nnr:βI}A{nnr:βK}SF{ct:Amid} | 6a | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 4.3 ± 0.4 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}F{nnr:βK}II{nnr:βK}K{nnr:βI}L{nnr:βK}SF{ct:Amid} | 6b | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 3.4 ± 0.1 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}F{nnr:βK}II{nnr:βK}K{nnr:βI}L{nnr:βK}LF{ct:Amid} | 6c | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 3.4 ± 0.2 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}F{nnr:βK}II{nnr:βK}K{nnr:X}A{nnr:βK}SF{ct:Amid} | 6Ca | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 4.9 ± 0.4 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}F{nnr:βK}II{nnr:βK}K{nnr:X}L{nnr:βK}SF{ct:Amid} | 6Cb | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.7 ± 0.2 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}F{nnr:βK}II{nnr:βK}K{nnr:X}L{nnr:βK}LF{ct:Amid} | 6Cc | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.3 ± 0.1 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}FKI{nnr:βI}KK{nnr:βI}AKS{nnr:βF}{ct:Amid} | 7a | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.6 ± 0.3 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}FKI{nnr:βI}KK{nnr:βI}LKS{nnr:βF}{ct:Amid} | 7b | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 8.7 ± 0.3 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}FKI{nnr:βI}KK{nnr:βI}LKL{nnr:βF}{ct:Amid} | 7c | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 40.1 ± 3.0 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}FKI{nnr:βI}KK{nnr:X}AKS{nnr:βF}{ct:Amid} | 7Ca | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.4 ± 0.3 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}FKI{nnr:βI}KK{nnr:X}LKS{nnr:βF}{ct:Amid} | 7Cb | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 5.2 ± 0.7 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}FKI{nnr:βI}KK{nnr:X}LKL{nnr:βF}{ct:Amid} | 7Cc | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 28.4 ± 5.0 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}FKI{nnr:βI}KK{nnr:X}AES{nnr:βF}{ct:Amid} | 8 | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 3.1 ± 0.4 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}FDI{nnr:βI}KK{nnr:X}AKS{nnr:βF}{ct:Amid} | 9 | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.3 ± 0.1 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:X}FKI{nnr:βI}KK{nnr:βI}AKS{nnr:βF}{ct:Amid} | 10 | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 4.8 ± 0.2 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29091404 | 2017 | G{nnr:βL}FKI{nnr:βI}KK{nnr:X}AKS{nnr:βF}{ct:Amid} | 11 | Amidation | Free | Linear | L | replacing key α-amino acids with β-amino acids | 13 | Antifungal | 10 % Hemolysis at 2.9 ± 0.2 μg/ml | Human | Α/Β-Peptide Aurein Analogues (Australian Bell Frogs) | H-bonded helices | NA | ||
| 29280948 | 2017 | KWKSFLKTFKSAKKTVLHTALKAISS{nt:Acet}{ct:Amid} | V13K | Amidation | Acetylation | Linear | L | None | 26 | Antimicrobial, Anticancer | <20 % Hemolysis at 250 μM | Human | Magainin (African Clawed Frog) | α-Helical | Low hemolytic | ||
| 29280948 | 2017 | KWKSFLKTFKSAKK{d}TVLHTALKAISS{nt:Acet}{ct:Amid} | K14D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | <20 % Hemolysis at 125 μM | Human | V13K Analogs | NA | Low hemolytic | ||
| 29280948 | 2017 | KWKSFLKTFKS{d}AKK{d}TVLHTALKAISS{nt:Acet}{ct:Amid} | S11D/K14D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | <20 % Hemolysis at 125 μM | Human | V13K Analogs | NA | Low hemolytic | ||
| 29280948 | 2017 | KWKSFLKTFKSAKK{d}T{d}VLHTALKAISS{nt:Acet}{ct:Amid} | K14D/T15D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | <20 % Hemolysis at 250 μM | Human | V13K Analogs | NA | Low hemolytic | ||
| 29280948 | 2017 | KWKSFLKTFKS{d}AKK{d}T{d}VLHTALKAISS{nt:Acet}{ct:Amid} | S11D/K14D/T15D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | <20 % Hemolysis at 250 μM | Human | V13K Analogs | NA | Low hemolytic | ||
| 29280948 | 2017 | KWKSFLKTFKSA{d}KKTVLHTALKAISS{nt:Acet}{ct:Amid} | A12D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | <20 % Hemolysis at 125 μM | Human | V13K Analogs | NA | Low hemolytic | ||
| 29280948 | 2017 | KWKSFLKTFKSA{d}KKTVLHTALKAISS{nt:Acet}{ct:Amid} | F9D/A12D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | <20 % Hemolysis at 250 μM | Human | V13K Analogs | NA | Low hemolytic | ||
| 29280948 | 2017 | KWKSFLKTFKSA{d}KKTVLHTALKAISS{nt:Acet}{ct:Amid} | A12D/V16D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 0 % Hemolysis at >500 μM | Human | V13K Analogs | NA | Non-hemolytic | ||
| 29280948 | 2017 | KWKSFLKTF{d}KSA{d}KKTV{d}LHTALKAISS{nt:Acet}{ct:Amid} | F9D/A12D/V16D | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acids | 26 | Antimicrobial | 0 % Hemolysis at >500 μM | Human | V13K Analogs | NA | Non-hemolytic | ||
| 28636781 | 2018 | GIGGALLSAGKSALKGLAKGLAEHFAN{ct:Amid} | BLP-7 | Amidation | Free | Linear | L | None | 27 | Antimicrobial and Haemolytic | 0 % Hemolysis at 128 mg/ml | Human | African Clawed Frog (Xenopus Laevis) | α-Helical | NA | ||
| 28636781 | 2018 | GIGGALLSAGKSALKGLAKGLAEHFAN{ct:Amid} | BLP-7 | Amidation | Free | Linear | L | None | 27 | Antimicrobial and Haemolytic | >80 % Hemolysis at 256 mg/ml | Human | African Clawed Frog (Xenopus Laevis) | α-Helical | NA | ||
| 28636781 | 2018 | IIGPV LGLIG KALGG LL{ct:Amid} | Bombinin H-BO | Amidation | Free | Linear | L | None | 17 | Antimicrobial and Haemolytic | 38 % Hemolysis at 128 mg/ml | Human | African Clawed Frog (Xenopus Laevis) | α-Helical | NA | ||
| 28636781 | 2018 | IIGPV LGLIG KALGG LL{ct:Amid} | Bombinin H-BO | Amidation | Free | Linear | L | None | 17 | Antimicrobial and Haemolytic | 85 % Hemolysis at 256 mg/ml | Human | African Clawed Frog (Xenopus Laevis) | α-Helical | NA | ||
| 28636788 | 2018 | A{d}L{d}K{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}K{d}A{d}K{d}A{d}A{d}K{d}L{d}K{d}T{d}L{d}L{d}K{d}A{d}L{d}S{d}K{d}{nt:Acet}{ct:Amid} | D33 | Amidation | Acetylation | Linear | D | Positions 13 and 16 are Lys residues is Non-polar{nnr} | 26 | Antimicrobial peptides | 30 % Hemolysis at 89 μM | Human | Synthesized | α-Helical | NA | ||
| 28636788 | 2018 | A{d}L{d}K{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}A{d}A{d}K{d}K{d}K{d}K{d}L{d}A{d}T{d}L{d}L{d}K{d}A{d}L{d}S{d}K{d}{nt:Acet}{ct:Amid} | D34 | Amidation | Acetylation | Linear | D | Positions 13 and 16 are Lys residues is Non-polar{nnr} | 26 | Antimicrobial peptides | 30 % Hemolysis at 126 μM | Human | Synthesized | α-Helical | NA | ||
| 28636788 | 2018 | A{d}L{d}K{d}S{d}L{d}L{d}A{d}T{d}L{d}S{d}K{d}A{d}K{d}K{d}K{d}K{d}L{d}K{d}T{d}L{d}L{d}A{d}A{d}L{d}S{d}K{d}{nt:Acet}{ct:Amid} | D35 | Amidation | Acetylation | Linear | D | Positions 13 and 16 are Lys residues is Non-polar{nnr} | 26 | Antimicrobial peptides | 30 % Hemolysis at 30 μM | Human | Synthesized | α-Helical | NA | ||
| 28636788 | 2018 | A{d}L{d}A{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}K{d}A{d}K{d}K{d}K{d}K{d}L{d}K{d}T{d}L{d}L{d}K{d}A{d}L{d}S{d}A{d}{nt:Acet}{ct:Amid} | D36 | Amidation | Acetylation | Linear | D | Positions 13 and 16 are Lys residues is Non-polar{nnr} | 26 | Antimicrobial peptides | 30 % Hemolysis at 61 μM | Human | Synthesized | α-Helical | NA | ||
| 28636788 | 2018 | A{d}L{d}K{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}K{d}A{d}A{d}A{d}A{d}A{d}L{d}K{d}T{d}L{d}L{d}K{d}A{d}L{d}S{d}K{d}{nt:Acet}{ct:Amid} | D37 | Amidation | Acetylation | Linear | D | Positions 13 and 16 are Ala residues is Non-polar{nnr} | 26 | Antimicrobial peptides | 30 % Hemolysis at 2.6 μM | Human | Synthesized | α-Helical | NA | ||
| 28636788 | 2018 | A{d}L{d}K{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}A{d}A{d}A{d}K{d}K{d}A{d}L{d}A{d}T{d}L{d}L{d}K{d}A{d}L{d}S{d}K{d}{nt:Acet}{ct:Amid} | D38 | Amidation | Acetylation | Linear | D | Positions 13 and 16 are Ala residues is Non-polar{nnr} | 26 | Antimicrobial peptides | 30 % Hemolysis at 2.8 μM | Human | Synthesized | α-Helical | NA | ||
| 28636788 | 2018 | A{d}L{d}K{d}S{d}L{d}L{d}A{d}T{d}L{d}S{d}K{d}A{d}A{d}K{d}K{d}A{d}L{d}K{d}T{d}L{d}L{d}A{d}A{d}L{d}S{d}K{d}{nt:Acet}{ct:Amid} | D39 | Amidation | Acetylation | Linear | D | Positions 13 and 16 are Ala residues is Non-polar{nnr} | 26 | Antimicrobial peptides | 30 % Hemolysis at 2.8 μM | Human | Synthesized | α-Helical | NA | ||
| 28636788 | 2018 | A{d}L{d}A{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}K{d}A{d}A{d}K{d}K{d}A{d}L{d}K{d}T{d}L{d}L{d}K{d}A{d}L{d}S{d}A{d}{nt:Acet}{ct:Amid} | D40 | Amidation | Acetylation | Linear | D | Positions 13 and 16 are Ala residues is Non-polar{nnr} | 26 | Antimicrobial peptides | 30 % Hemolysis at 2.8 μM | Human | Synthesized | α-Helical | NA | ||
| 28650592 | 2018 | LVGKLLKGAVGDVCGLLPIC{ct:disulfide bridge} | OM-LV20 | disulfide bridge | Free | Linear | L | None | 20 | Wound healing activity | 0 % Hemolysis at 1 mM | Human | Frog(Odorrana Margaretae) | NA | Non-hemolytic | ||
| 28815904 | 2018 | RWCVYAYVRVRGVLVRYRRCW | Arenicin-1 | Free | Free | Linear | L | None | 21 | Antimicrobial peptides | 50 % Hemolysis at 21 μM | Human | Polychaeta Arenicola Marina | β-Hairpin | NA | ||
| 28815904 | 2018 | KWCFRVCYRGICYRRCR{ct:Amid} | Tachyplesin I | Amidation | Free | Linear | L | None | 17 | Antimicrobial peptides | ~20 % Hemolysis at 50 μM | Human | Horseshoe Crab Tachypleus Tridentatus | β-Hairpin | NA | ||
| 28815904 | 2018 | {nnr:Z}CRRLCYKQRCVTYCRGR{nt:Z- pyroglutamic acid}{ct:Amid} | Gomesin | Amidation | Z- pyroglutamic acid | Linear | L | Z = pyroglutamic acid | 18 | Antimicrobial peptides | 8 % Hemolysis at 100 μM | Human | Spider Acanthoscurria Gomesiana | β-Hairpin | NA | ||
| 28837852 | 2018 | VKLKKRNVNLKTILGVG | MrChit3 - MrVG | Free | Free | Linear | L | None | 17 | Antimicrobial | ≤5 % Hemolysis at 20 μM | Human | Prawn (Macrobrachium Rosenbergii) Chitinase-3 | NA | Low hemolytic | ||
| 28837852 | 2018 | VKLKKRNVNLKTILGVG | MrChit3 - MrVG | Free | Free | Linear | L | None | 17 | Antimicrobial | ≤5 % Hemolysis at 40 μM | Human | Prawn (Macrobrachium Rosenbergii) Chitinase-3 | NA | Low hemolytic | ||
| 28837852 | 2018 | VKLKKRNVNLKTILGVG | MrChit3 - MrVG | Free | Free | Linear | L | None | 17 | Antimicrobial | ≤5 % Hemolysis at 80 μM | Human | Prawn (Macrobrachium Rosenbergii) Chitinase-3 | NA | Low hemolytic | ||
| 28837852 | 2018 | VKLKKRNVNLKTILGVG | MrChit3 - MrVG | Free | Free | Linear | L | None | 17 | Antimicrobial | ≤5 % Hemolysis at 160 μM | Human | Prawn (Macrobrachium Rosenbergii) Chitinase-3 | NA | Low hemolytic | ||
| 28887200 | 2018 | FLFTVA-{nnr:Dhb}{ct:Acet} | ASP-1 | Acetylation | Free | Linear | L | Dhb = dehydrobutyrine | 7 | Antibacterial, Anti-MRSA, Antibiofilm | ~6 % Hemolysis at 128 μg/ml | Human | Bacillus Subtilis Urid 12.1 | β-Sheet | Low hemolytic | ||
| 28887200 | 2018 | FLFTVA-{nnr:Dhb}{ct:Acet} | ASP-1 | Acetylation | Free | Linear | L | Dhb = dehydrobutyrine | 7 | Antimicrobial, Anti-MRSA | 31.5 % Hemolysis at 256 μg/ml | Human | Bacillus Subtilis Urid 12.1 | β-Sheet | Low hemolytic | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF3 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17 | 8 | Antifungal | 10 % Hemolysis at 8 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF3 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17 | 8 | Antifungal | 50 % Hemolysis at 16.4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF4 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17 | 8 | Antifungal | ∼5.6 % Hemolysis at 8 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF4 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17 | 8 | Antifungal | 50 % Hemolysis at 17.7 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant} | AF5 | Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 8 | Antifungal | 50 % Hemolysis at 8 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF3, AF4 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17, X = Xaa is a β-amino fatty acid variant for AF4-iso-C17 | 16 | Antifungal, Antifungal | 3.87±3.7 % Hemolysis at 4,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF3, AF5 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17, X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 16 | Antifungal, Antifungal | 3.43±3.1 % Hemolysis at 4,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF3, AF5 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF3-anteiso-C17, X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 16 | Antifungal, Antifungal | 4.11±5.9 % Hemolysis at 2,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF4, AF5 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17, X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 16 | Antifungal, Antifungal | 3.12±3.4 % Hemolysis at 4,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29038271 | 2018 | NPYNQTS{nnr:X}NPYNQTS{nnr:X}{cyc:N-C}{ct:Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant} | AF4, AF5 | Xaa - β-amino fatty acid variant, Xaa - β-amino fatty acid variant | Free | Cyclic | L | X = Xaa is a β-amino fatty acid variant for AF4-iso-C17, X = Xaa is a β-amino fatty acid variant for AF5-iso-C18 | 16 | Antifungal, Antifungal | 2.96±4.1 % Hemolysis at 2,4 μg/ml | Human | Bacillus Subtilis Rlid 12.1 | NA | NA | ||
| 29108968 | 2018 | FIHHIIGGLFHVGKSIHDLIR | pteroicidin-α-COOH or α-Pte | Free | Free | Linear | L | None | 21 | Antimicrobial | 60 % Hemolysis at 200 μM | Human | Lionfish (Pterois Volitans),Piscidin-1 | NA | NA | ||
| 29108968 | 2018 | FIHHIIGGLFHVGKSIHDLIR{ct:Amid} | Pteroicidin-α-CONH2 or α-Pte-CONH2 | Amidation | Free | Linear | L | None | 21 | Antimicrobial | 90 % Hemolysis at 50 μM | Human | Lionfish (Pterois Volitans),Piscidin-1 | α-Helix | NA | ||
| 29130500 | 2018 | GLTRLFSVIK | andricin B | Free | Free | Linear | L | None | 10 | Antimicrobial peptides | 1 % Hemolysis at 8 μg/ml | Human | Andrias Davidianus (Chinese Giant Salamander) | Random coil | Low hemolytic | ||
| 29130500 | 2018 | GLTRLFSVIK | andricin B | Free | Free | Linear | L | None | 10 | Antimicrobial peptides | 1 % Hemolysis at 16 μg/ml | Human | Andrias Davidianus (Chinese Giant Salamander) | Random coil | Low hemolytic | ||
| 29130500 | 2018 | GLTRLFSVIK | andricin B | Free | Free | Linear | L | None | 10 | Antimicrobial peptides | 1 % Hemolysis at 32 μg/ml | Human | Andrias Davidianus (Chinese Giant Salamander) | Random coil | Low hemolytic | ||
| 29130500 | 2018 | GLTRLFSVIK | andricin B | Free | Free | Linear | L | None | 10 | Antimicrobial peptides | 1 % Hemolysis at 64 μg/ml | Human | Andrias Davidianus (Chinese Giant Salamander) | Random coil | Low hemolytic | ||
| 29130500 | 2018 | GLTRLFSVIK | andricin B | Free | Free | Linear | L | None | 10 | Antimicrobial peptides | 1 % Hemolysis at 128 μg/ml | Human | Andrias Davidianus (Chinese Giant Salamander) | Random coil | Low hemolytic | ||
| 29130500 | 2018 | GLTRLFSVIK | andricin B | Free | Free | Linear | L | None | 10 | Antimicrobial peptides | 2.4 % Hemolysis at 256 μg/ml | Human | Andrias Davidianus (Chinese Giant Salamander) | Random coil | Low hemolytic | ||
| 29130500 | 2018 | GLTRLFSVIK | andricin B | Free | Free | Linear | L | None | 10 | Antimicrobial peptides | <20 % Hemolysis at 512 μg/ml | Human | Andrias Davidianus (Chinese Giant Salamander) | Random coil | NA | ||
| 32624860 | 2018 | KIIIPPLFH | barleycin | Free | Free | Linear | L | None | 9 | Antibacterial | 0 % Hemolysis at 64 μg/mL | Human | Highland Barley Or Tibetan Barley | α-Helix | Non-hemolytic | ||
| 32624860 | 2018 | KIIIPPLFH | barleycin | Free | Free | Linear | L | None | 9 | Antibacterial | 0 % Hemolysis at 128 μg/mL | Human | Highland Barley Or Tibetan Barley | α-Helix | Non-hemolytic | ||
| 32624860 | 2018 | KIIIPPLFH | barleycin | Free | Free | Linear | L | None | 9 | Antibacterial | 3.2 ± 1.7 % Hemolysis at 256 μg/mL | Human | Highland Barley Or Tibetan Barley | α-Helix | NA | ||
| 32624860 | 2018 | KIIIPPLFH | barleycin | Free | Free | Linear | L | None | 9 | Antibacterial | 19.5 ± 3.5 % Hemolysis at 512 μg/mL | Human | Highland Barley Or Tibetan Barley | α-Helix | NA | ||
| 29343843 | 2018 | IGRDPTWSHLAASCLKCIFDDLPKTHN | Cathelicidin-OA1 | Free | Free | Linear | L | None | 27 | Antioxidant activity | 5.4 ± 0.14 % Hemolysis at 1 nM | Human | Frog (Odorrana Andersonii) | NA | NA | ||
| 29343843 | 2018 | IGRDPTWSHLAASCLKCIFDDLPKTHN | Cathelicidin-OA1 | Free | Free | Linear | L | None | 27 | Antioxidant activity | 4.5 ± 0.61 % Hemolysis at 10 nM | Human | Frog (Odorrana Andersonii) | NA | NA | ||
| 29343843 | 2018 | IGRDPTWSHLAASCLKCIFDDLPKTHN | Cathelicidin-OA1 | Free | Free | Linear | L | None | 27 | Antioxidant activity | 5.4 ± 0.81 % Hemolysis at 100 nM | Human | Frog (Odorrana Andersonii) | NA | NA | ||
| 29343843 | 2018 | IGRDPTWSHLAASCLKCIFDDLPKTHN | Cathelicidin-OA1 | Free | Free | Linear | L | None | 27 | Antioxidant activity | 6.9 ± 0.57 % Hemolysis at 1 μM | Human | Frog (Odorrana Andersonii) | NA | NA | ||
| 29343843 | 2018 | IGRDPTWSHLAASCLKCIFDDLPKTHN | Cathelicidin-OA1 | Free | Free | Linear | L | None | 27 | Antioxidant activity | 5.0 ± 0.86 % Hemolysis at 10 μM | Human | Frog (Odorrana Andersonii) | NA | NA | ||
| 29343843 | 2018 | IGRDPTWSHLAASCLKCIFDDLPKTHN | Cathelicidin-OA1 | Free | Free | Linear | L | None | 27 | Antioxidant activity | 7.7 ± 0.11 % Hemolysis at 100 μM | Human | Frog (Odorrana Andersonii) | NA | NA | ||
| 29359791 | 2018 | ALAGTIIAGASLTFQVLDKVLEELGKVSRK{ct:Amid} | StII1-30 | Amidation | Free | Linear | L | None | 30 | Candidacidal | 50 % Hemolysis at 42.5 μM | Human | Derived From Sticholysin Ii (Sea Anemone Stichodactyla Helianthus) | amphiphilic α-Helix | NA | ||
| 29359791 | 2018 | VLDKVLEELGKVSRKIAVGI{ct:Amid} | StII16-35 | Amidation | Free | Linear | L | None | 20 | Candidacidal | 50 % Hemolysis at 128 μM | Human | Derived From Sticholysin Ii (Sea Anemone Stichodactyla Helianthus) | amphiphilic α-Helix | NA | ||
| 29360748 | 2018 | RVCSAIPLPICH{cyc:3-11}{ct:Amid} | tigerinin-1R | Amidation | Free | Cyclic | L | C–C in parentheses means that the two Cys residues in the sequences form intermolecular disulfide bond | 12 | Non-toxic insulin-releasing peptide | <2 % Hemolysis at 250 μM | Human | Frog (Hoplobatrachus Ugulosus) | Random coils (48), and type I reverse βTurns (12) in 50 aqueous TFE | Non-hemolytic | ||
| 29360748 | 2018 | RVCSLLPLPLCH{cyc:3-11}{ct:Amid} | tigerinin-1R-L4 | Amidation | Free | Cyclic | L | C–C in parentheses means that the two Cys residues in the sequences form intermolecular disulfide bond | 12 | Non-toxic insulin-releasing peptide | <3 % Hemolysis at 250 μM | Human | Tigerinin-1R Analogs | Random coil | Low hemolytic | ||
| 29360748 | 2018 | CSAIPLPIC{cyc:1-9}{ct:Amid} | tigerinin-cyclic | Amidation | Free | Cyclic | L | C–C in parentheses means that the two Cys residues in the sequences form intermolecular disulfide bond | 9 | Non-toxic insulin-releasing peptide | <2 % Hemolysis at 250 μM | Human | Tigerinin-1R Analogs | Random coil | Non-hemolytic | ||
| 29360748 | 2018 | RVASAIPLPIAH{nt:Acet}{ct:Amid} | tigerinin-linear | Amidation | Acetylation | Linear | L | Ac = N-acetyl; C-Terminal = amide | 12 | Non-toxic insulin-releasing peptide | <2 % Hemolysis at 250 μM | Human | Tigerinin-1R Analogs | Random coil | Low hemolytic | ||
| 29360748 | 2018 | RVKSAIPLPICH{nt:Acet}{ct:Amid} | [C3K]tigerinin-1R | Amidation | Acetylation | Linear | L | Ac = N-acetyl; C-Terminal = amide | 12 | Non-toxic insulin-releasing peptide | <2 % Hemolysis at 250 μM | Human | Tigerinin-1R Analogs | Random coil | Low hemolytic | ||
| 29360748 | 2018 | RVCSAIPLPIKH{nt:Acet}{ct:Amid} | [C11K]tigerinin-1R | Amidation | Acetylation | Linear | L | Ac = N-acetyl; C-Terminal = amide | 12 | Non-toxic insulin-releasing peptide | <2 % Hemolysis at 250 μM | Human | Tigerinin-1R Analogs | Random coil | Low hemolytic | ||
| 29098406 | 2018 | GIGSAILSAGKSIIKGLAKGLAEHF{ct:Amid} | Bombinin-BO1 | Amidation | Free | Linear | L | None | 25 | broad-spectrum Antimicrobial | 2.89 % Hemolysis at 26.3 μM | Human | Oriental Fre-Bellied Toad, Bombina Orientalis, | Alphα-Helical amphipathic | NA | ||
| 29098406 | 2018 | GIGSAILSAGKSIIKGLAKGLAEHF{ct:Amid} | Bombinin-BO1 | Amidation | Free | Linear | L | None | 25 | broad-spectrum Antimicrobial | 38.05 % Hemolysis at 52.5 μM | Human | Oriental Fre-Bellied Toad, Bombina Orientalis, | Alphα-Helical amphipathic | NA | ||
| 29098406 | 2018 | IIGPVLGLVGKALGGLL{ct:Amid} | Bombinin H-BO1 | Amidation | Free | Linear | L | None | 17 | broad-spectrum Antimicrobial | 42.03 % Hemolysis at 40.4 μM | Human | Oriental Fre-Bellied Toad, Bombina Orientalis, | Alphα-Helical amphipathic | NA | ||
| 29098406 | 2018 | IIGPVLGLVGKALGGLL{ct:Amid} | Bombinin H-BO1 | Amidation | Free | Linear | L | None | 17 | broad-spectrum Antimicrobial | 100 % Hemolysis at 161.1 μM | Human | Oriental Fre-Bellied Toad, Bombina Orientalis, | Alphα-Helical amphipathic | NA | ||
| 29310083 | 2018 | KWLKKWLKWLKK{ct:Amid} | A-12 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 56 % Hemolysis at 250 μg/ml | Human | Analogues Of Α/Β Diastereomeric Peptide | α-Helical | NA | ||
| 29310083 | 2018 | KW{nnr:L}KKW{nnr:L}KW{nnr:L}KK{ct:Amid} | βA-12 | Amidation | Free | Linear | L | L = β-amino acid | 12 | Antibacterial | 0 % Hemolysis at 250 μg/ml | Human | Analogues Of Α/Β Diastereomeric Peptide | α-Helical | Non-hemolytic | ||
| 29310083 | 2018 | K{d}W{d}LK{d}K{d}W{d}LK{d}W{d}LK{d}K{d}{ct:Amid} | DA-12 | Amidation | Free | Linear | Mix | None | 12 | Antibacterial | 0 % Hemolysis at 250 μg/ml | Human | Analogues Of Α/Β Diastereomeric Peptide | α-Helical | Non-hemolytic | ||
| 29310083 | 2018 | K{d}W{d}{nnr:L}K{d}K{d}W{d}{nnr:L}K{d}W{d}{nnr:L}K{d}K{d}{ct:Amid} | UNA-12 | Amidation | Free | Linear | Mix | L = β-amino acid | 12 | Antibacterial | 0 % Hemolysis at 250 μg/ml | Human | Analogues Of Α/Β Diastereomeric Peptide | α-Helical | Non-hemolytic | ||
| 29310083 | 2018 | ILPWKWPWWPWRR{ct:Amid} | IL | Amidation | Free | Linear | L | None | 13 | Antibacterial | 70 % Hemolysis at 250 μg/ml | Human | Control Host Defense Peptide | NA | NA | ||
| 29392557 | 2018 | KRFKKFFRKLKKSVKKRAKEFFKKPRVIGVSIPF | Cath-BF | Free | Free | Linear | L | None | 32 | Antimicrobial | 20 % Hemolysis at 500 μg/ml | Human | Snakes Naja Atra, Bugarus Fasciatus | NA | NA | ||
| 29392557 | 2018 | KRFKKFFRKLKKSVKKRKKEFKKKPRVIKVSIPF | Cath-A | Free | Free | Linear | L | None | 32 | Antimicrobial | 20 % Hemolysis at 500 μg/ml | Human | Snakes Naja Atra, Bugarus Fasciatus | α-Helix | NA | ||
| 29392557 | 2018 | KRFKKFFRKLKKSVKKRKKEFKKKPRVIGVSIPF | Cath-B | Free | Free | Linear | L | None | 32 | Antimicrobial | 5 % Hemolysis at 500 μg/ml | Human | Snakes Naja Atra, Bugarus Fasciatus | α-Helix | Low hemolytic | ||
| 29277569 | 2018 | VYPFMWGGAYCFCKAKLV{ct:Amid} | VT18-KKLV | Amidation | Free | Linear | L | None | 18 | Antibacterial | 3 % Hemolysis at 100 µg/ml | Human | Chikungunya Virus Fusion Domain Vt18-Derived Peptides | Double Strand β-Sheet | Low hemolytic | ||
| 29277569 | 2018 | VYPFCWGGAYAFCKAKLV{ct:Amid} | VT18-CAKKLV | Amidation | Free | Linear | L | None | 18 | Antibacterial | 3.8 % Hemolysis at 100 µg/ml | Human | Chikungunya Virus Fusion Domain Vt18-Derived Peptides | Double Strand β-Sheet | Low hemolytic | ||
| 29277569 | 2018 | VYPFCWGGAYAFCKAKLV{cyc:N-C}{ct:Amid} | cVT18-CAKKLV | Amidation | Free | Cyclic | L | None | 18 | Antibacterial | 1.8 % Hemolysis at 100 µg/ml | Human | Vt18-Cakklv Cyclized Between Cys88 And Cys96 | Double Strand β-Sheet | Low hemolytic | ||
| 29551999 | 2018 | RRWQWR | Monomer LfcinB (20–25) | Free | Free | Linear | L | None | 6 | Antibacterial | 7.1 % Hemolysis at 25 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RWQWRWQWR | Palindromic (PLS) | Free | Free | Linear | L | None | 9 | Antibacterial | 24.8 % Hemolysis at 100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | FKCRRWQWRMKKLGA | Reference Peptide (LfcinB (17–31)) | Free | Free | Linear | L | None | 15 | Antibacterial | 6.6 % Hemolysis at 25 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RRWQWRRRWQWRK{nnr:Ahx} | Dimeric (LfcinB (20–25)2) | Free | Free | Branched | L | Ahx = hydrophobic spacer that prevents steric hindrance | 15 | Antibacterial | 5.6 % Hemolysis at 100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RRWQWRRRWQWRRRWQWRRRWQWRKK{nnr:Ahx}{nnr:Ahx}CC | Tetrameric (LfcinB (20–25)4) | Free | Free | Branched | L | Ahx = hydrophobic spacer that prevents steric hindrance | 30 | Antibacterial | 49.1 % Hemolysis at 100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RRWQWR | Monomer LfcinB (20–25) | Free | Free | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RWQWRWQWR | Palindromic (PLS) | Free | Free | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | FKCRRWQWRMKKLGA | Reference Peptide (LfcinB (17–31)) | Free | Free | Linear | L | None | 15 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RRWQWRRRWQWRK{nnr:Ahx} | Dimeric (LfcinB (20–25)2) | Free | Free | Branched | L | Ahx = hydrophobic spacer that prevents steric hindrance | 15 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29551999 | 2018 | RRWQWRRRWQWRRRWQWRRRWQWRKK{nnr:Ahx}{nnr:Ahx}CC | Tetrameric (LfcinB (20–25)4) | Free | Free | Branched | L | Ahx = hydrophobic spacer that prevents steric hindrance | 30 | Antibacterial | 50 % Hemolysis at >100 µM | Human | Bovine Lfcinb -Lactoferricin B (Lfcinb)-Based Synthetic Peptides | NA | NA | ||
| 29275987 | 2018 | KKKKKK-AAFAAWAAFAA{nt:6 Lys}{ct:Amid} | 6K-F17 | Amidation | 6 Lys | Linear | L | None | 17 | Antimicrobial Peptide | 10 % Hemolysis at 320 µM | Human | Cationic Antimicrobial Peptide | Random coil | NA | ||
| 29275987 | 2018 | KKKKKK-AAF{nnr:X}AWA{nnr:X}FAA{nt:6 Lys}{ct:Amid} | S-6K-F17 | Amidation | 6 Lys | Stapled | L | X = Ala residues replaced by 2-(40 -pentenyl)alanine residues are underlined | 17 | Antibacterial | 2 % Hemolysis at 4 µM | Human | 6K-F17 Hydrocarbon Staple | Random coil | NA | ||
| 29275987 | 2018 | KKKKKK-AGF{nnr:X}AWA{nnr:X}FGA{nt:6 Lys}{ct:Amid} | S-6K-F17-2G | Amidation | 6 Lys | Stapled | L | X = Ala residues replaced by 2-(40 -pentenyl)alanine residues are underlined | 17 | Antibacterial | MHC at 15[5.8] µM | Human | 6K-F17 Hydrocarbon Staple | NA | NA | ||
| 29275987 | 2018 | KKKKKK-AGF{nnr:X}AWG{nnr:X}FGA{nt:6 Lys}{ct:Amid} | S-6K-F17-3G | Amidation | 6 Lys | Stapled | L | X = Ala residues replaced by 2-(40 -pentenyl)alanine residues are underlined | 17 | Antibacterial | MHC at 128[43.8] µM | Human | 6K-F17 Hydrocarbon Staple | Random coil | NA | ||
| 29275987 | 2018 | KKKKKK-NGF{nnr:X}AWG{nnr:X}FGA{nt:6 Lys}{ct:Amid} | S-6K-F17-3GN | Amidation | 6 Lys | Stapled | L | X = Ala residues replaced by 2-(40 -pentenyl)alanine residues are underlined | 17 | Antibacterial | MHC at 587[130.6] µM | Human | 6K-F17 Hydrocarbon Staple | Helical | NA | ||
| 29515090 | 2018 | KFFKKLKNSVKKRAKKFFKKPRVIGVSIPF | OH-CATH30 | Free | Free | Linear | L | None | 30 | Antimicrobial | ~10 % Hemolysis at 125 µg/mL | Human | Cathelicidin-Derived Peptide From The King Cobra | NA | NA | ||
| 29515090 | 2018 | K{d}F{d}F{d}K{d}K{d}L{d}K{d}N{d}S{d}V{d}K{d}K{d}R{d}A{d}K{d}K{d}F{d}F{d}K{d}K{d}P{d}R{d}V{d}I{d}G{d}V{d}S{d}I{d}P{d}F{d} | analog D-OH-CATH30 | Free | Free | Linear | D | None | 30 | Antimicrobial | ~10 % Hemolysis at 125 µg/mL | Human | Cathelicidin-Derived Peptide From The King Cobra | NA | NA | ||
| 29515090 | 2018 | KFFKKLKNSVKKRAKKFFKKPRVIGVSIPF | OH-CATH30 | Free | Free | Linear | L | None | 30 | Antimicrobial | 70 % Hemolysis at 250 µg/mL | Human | Analog D-Oh-Cath30 | NA | NA | ||
| 29515090 | 2018 | K{d}F{d}F{d}K{d}K{d}L{d}K{d}N{d}S{d}V{d}K{d}K{d}R{d}A{d}K{d}K{d}F{d}F{d}K{d}K{d}P{d}R{d}V{d}I{d}G{d}V{d}S{d}I{d}P{d}F{d} | analog D-OH-CATH30 | Free | Free | Linear | D | None | 30 | Antimicrobial | 80 % Hemolysis at 250 µg/mL | Human | Analog D-Oh-Cath30 | NA | NA | ||
| 29264738 | 2018 | K{nt:C16}{ct:Amid} | 1 | Amidation | C16 | Linear | L | C16 | 1 | Antibacterial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C16}{ct:Amid} | 2 | Amidation | C16 | Linear | L | C16 | 2 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KKK{nt:C16}{ct:Amid} | 3 | Amidation | C16 | Linear | L | C16 | 3 | Antibacterial | 10 % Hemolysis at 32 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KKKK{nt:C16}{ct:Amid} | 4 | Amidation | C16 | Linear | L | C16 | 4 | Antibacterial | 10 % Hemolysis at 16 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KG{nt:C16}{ct:Amid} | 5 | Amidation | C16 | Linear | L | C16 | 2 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KGK{nt:C16}{ct:Amid} | 6 | Amidation | C16 | Linear | L | C16 | 3 | Antibacterial | 10 % Hemolysis at 64 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KGKG{nt:C16}{ct:Amid} | 7 | Amidation | C16 | Linear | L | C16 | 4 | Antibacterial | 10 % Hemolysis at 64 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | K{nt:C14}{ct:Amid} | 8 | Amidation | C14 | Linear | L | C14 | 1 | Antibacterial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C14}{ct:Amid} | 9 | Amidation | C14 | Linear | L | C14 | 2 | Antibacterial | 10 % Hemolysis at 128 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KKK{nt:C14}{ct:Amid} | 10 | Amidation | C14 | Linear | L | C14 | 3 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KKKK{nt:C14}{ct:Amid} | 11 | Amidation | C14 | Linear | L | C14 | 4 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KG{nt:C14}{ct:Amid} | 12 | Amidation | C14 | Linear | L | C14 | 2 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGK{nt:C14}{ct:Amid} | 13 | Amidation | C14 | Linear | L | C14 | 3 | Antibacterial | 10 % Hemolysis at 128 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | KGKG{nt:C14}{ct:Amid} | 14 | Amidation | C14 | Linear | L | C14 | 4 | Antibacterial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | K{nt:C12}{ct:Amid} | 15 | Amidation | C12 | Linear | L | C12 | 1 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C12}{ct:Amid} | 16 | Amidation | C12 | Linear | L | C12 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKK{nt:C12}{ct:Amid} | 17 | Amidation | C12 | Linear | L | C12 | 3 | Antibacterial | 10 % Hemolysis at 512 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKKK{nt:C12}{ct:Amid} | 18 | Amidation | C12 | Linear | L | C12 | 4 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KG{nt:C12}{ct:Amid} | 19 | Amidation | C12 | Linear | L | C12 | 2 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGK{nt:C12}{ct:Amid} | 20 | Amidation | C12 | Linear | L | C12 | 3 | Antibacterial | 10 % Hemolysis at >1000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGKG{nt:C12}{ct:Amid} | 21 | Amidation | C12 | Linear | L | C12 | 4 | Antibacterial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Lipopeptides | NA | NA | ||
| 29264738 | 2018 | K{nt:C10}{ct:Amid} | 22 | Amidation | C10 | Linear | L | C10 | 1 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C10}{ct:Amid} | 23 | Amidation | C10 | Linear | L | C10 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKK{nt:C10}{ct:Amid} | 24 | Amidation | C10 | Linear | L | C10 | 3 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKKK{nt:C10}{ct:Amid} | 25 | Amidation | C10 | Linear | L | C10 | 4 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KG{nt:C10}{ct:Amid} | 26 | Amidation | C10 | Linear | L | C10 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGK{nt:C10}{ct:Amid} | 27 | Amidation | C10 | Linear | L | C10 | 3 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGKG{nt:C10}{ct:Amid} | 28 | Amidation | C10 | Linear | L | C10 | 4 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | K{nt:C8}{ct:Amid} | 29 | Amidation | C8 | Linear | L | C8 | 1 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KK{nt:C8}{ct:Amid} | 30 | Amidation | C8 | Linear | L | C8 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKK{nt:C8}{ct:Amid} | 31 | Amidation | C8 | Linear | L | C8 | 3 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KKKK{nt:C8}{ct:Amid} | 32 | Amidation | C8 | Linear | L | C8 | 4 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KG{nt:C8}{ct:Amid} | 33 | Amidation | C8 | Linear | L | C8 | 2 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGK{nt:C8}{ct:Amid} | 34 | Amidation | C8 | Linear | L | C8 | 3 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29264738 | 2018 | KGKG{nt:C8}{ct:Amid} | 35 | Amidation | C8 | Linear | L | C8 | 4 | Antibacterial | 10 % Hemolysis at >4000 µg/mL | Human | Synthetic Lipopeptides | NA | Low hemolytic | ||
| 29282543 | 2018 | GKEFKRIVWLSKTAKKL{ct:Amid} | LC | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 0.14 % Hemolysis at 128 μM | Human | Lc From Ll37 And Cp-1 | at aq :unordered conformation, at membrane : α-Helix | Low hemolytic | ||
| 29282543 | 2018 | GKEFKRIVKWPWWPWRR{ct:Amid} | LI | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 2.42 % Hemolysis at 128 μM | Human | Ll37 Hybrids With Indolicidin And Np-1, | at aq :unordered conformation, at membrane :β-Turn and β-Hairpin structures | Low hemolytic | ||
| 29282543 | 2018 | GKEFKRIVGRIYRLCCR{ct:Amid} | LN | Amidation | Free | Linear | L | None | 17 | Antimicrobial | 2.08 % Hemolysis at 128 μM | Human | Ll37 Hybrids With Indolicidin And Np-1, | at aq :unordered conformation, at membrane : α-Helix | Low hemolytic | ||
| 29282543 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL37 | Amidation | Free | Linear | L | None | 37 | Antimicrobial | 8.6 % Hemolysis at 128 μM | Human | Homo Sapiens | NA | Low hemolytic | ||
| 29282543 | 2018 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 46.22 % Hemolysis at 128 μM | Human | Bos Taurus | NA | Low hemolytic | ||
| 29282543 | 2018 | SWLSKTAKKLENSAKKRISEGIAIAQGGPR{ct:Amid} | CP-1 | Amidation | Free | Linear | L | None | 30 | Antimicrobial | 0.35 % Hemolysis at 128 μM | Human | Pig (Ascaris Suum) | NA | Low hemolytic | ||
| 29282543 | 2018 | VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR{ct:Amid} | NP-1 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | 0.72 % Hemolysis at 128 μM | Human | Rat (Rattus Norvegicus) | NA | Low hemolytic | ||
| 29282543 | 2018 | GKEFKRIVWLSKTAKKL{ct:Amid} | LC | Amidation | Free | Linear | L | None | 17 | Antimicrobial | ≥5 % Hemolysis at >128 μM | Human | Lc From Ll37 And Cp-1 | at aq :unordered conformation, at membrane : α-Helix | Low hemolytic | ||
| 29282543 | 2018 | GKEFKRIVKWPWWPWRR{ct:Amid} | LI | Amidation | Free | Linear | L | None | 17 | Antimicrobial | ≥5 % Hemolysis at >128 μM | Human | Ll37 Hybrids With Indolicidin And Np-1, | at aq :unordered conformation, at membrane :β-Turn and β-Hairpin structures | Low hemolytic | ||
| 29282543 | 2018 | GKEFKRIVGRIYRLCCR{ct:Amid} | LN | Amidation | Free | Linear | L | None | 17 | Antimicrobial | ≥5 % Hemolysis at >128 μM | Human | Ll37 Hybrids With Indolicidin And Np-1, | at aq :unordered conformation, at membrane : α-Helix | Low hemolytic | ||
| 29282543 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL37 | Amidation | Free | Linear | L | None | 37 | Antimicrobial | ≥5 % Hemolysis at 64 μM | Human | Homo Sapiens | NA | Low hemolytic | ||
| 29282543 | 2018 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin | Amidation | Free | Linear | L | None | 13 | Antimicrobial | ≥5 % Hemolysis at 32 μM | Human | Bos Taurus | NA | Low hemolytic | ||
| 29282543 | 2018 | SWLSKTAKKLENSAKKRISEGIAIAQGGPR{ct:Amid} | CP-1 | Amidation | Free | Linear | L | None | 30 | Antimicrobial | ≥5 % Hemolysis at >128 μM | Human | Pig (Ascaris Suum) | NA | Low hemolytic | ||
| 29282543 | 2018 | VTCYCRRTRCGFRERLSGACGYRGRIYRLCCR{ct:Amid} | NP-1 | Amidation | Free | Linear | L | None | 32 | Antimicrobial | ≥5 % Hemolysis at >128 μM | Human | Rat (Rattus Norvegicus) | NA | Low hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Cbz}{ct:NHCH2CH2OH} | 1 | NHCH2CH2OH | Cbz | Linear | L | Cbz = carboxybenzyl, AzPro = azaproline | 16 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Hexadecameric Analogous Peptides | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Acet}{ct:NHCH2CH2OH} | 2 | NHCH2CH2OH | Acetylation | Linear | L | AzPro = azaproline, Ac = N-acetyl | 16 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Hexadecameric Analogous Peptides | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Formyl}{ct:NHCH2CH2OH} | 3 | NHCH2CH2OH | Formyl | Linear | L | AzPro = azaproline, Formyl = Formyl | 16 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Hexadecameric Analogous Peptides | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Formyl}{ct:NHCH2CH2OH} | 5 | NHCH2CH2OH | Formyl | Linear | L | AzPro = azaproline, Formyl = Formyl | 14 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Formyl}{ct:NHCH2CH2OH} | 6 | NHCH2CH2OH | Formyl | Linear | L | AzPro = azaproline, Formyl = Formyl | 12 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Formyl}{ct:NHCH2CH2OH} | 7 | NHCH2CH2OH | Formyl | Linear | L | AzPro = azaproline, Formyl = Formyl | 10 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Cbz}{ct:OtBu} | 8 | OtBu | Cbz | Linear | L | AzPro = azaproline, OtBu = ortho-tert-butyl, Cbz = carboxybenzyl | 16 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Hexadecameric Analogous Peptides | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}{nt:Boc}{ct:Cbz} | 10 | Cbz | Boc | Linear | L | AzPro = azaproline, Boc = tert-butyloxycarbonyl, Cbz = carboxybenzyl | 16 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Hexadecameric Analogous Peptides | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Cbz}{ct:OtBu} | 11 | OtBu | Cbz | Linear | L | AzPro = azaproline, OtBu = ortho-tert-butyl, Cbz = carboxybenzyl | 32 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Hexadecameric Analogous Peptides | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Cbz}{ct:OH} | 14 | OH | Cbz | Linear | L | AzPro = azaproline, Cbz = carboxybenzyl, OH = Hydroxyl | 16 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:HCl.H}{ct:OtBu} | 15 | OtBu | HCl.H | Linear | L | AzPro = azaproline, HCl = hydrochloric acid, OtBu = ortho-tert-butyl | 16 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Cbz}{ct:OtBu} | 18 | OtBu | Cbz | Linear | L | AzPro = azaproline, OtBu = ortho-tert-butyl, Cbz = carboxybenzyl | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:Cbz}{ct:OH} | 19 | OH | Cbz | Linear | L | AzPro = azaproline, Cbz = carboxybenzyl, OH = Hydroxyl | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | {nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P{nt:H}{ct:OtBu} | 20 | OtBu | H | Linear | L | AzPro = azaproline, OtBu = ortho-tert-butyl, H = Hydrogen | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}{nt:Boc}{ct:Cbz} | 21 | Cbz | Boc | Linear | L | AzPro = azaproline, Cbz = carboxybenzyl, Boc = tert-butyloxycarbonyl | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}{nt:Boc}{ct:H} | 22 | H | Boc | Linear | L | AzPro = azaproline, Boc = tert-butyloxycarbonyl, H = Hydrogen | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}-P-{nnr:AzPro}{nt:HCl.H}{ct:Cbz} | 23 | Cbz | HCl.H | Linear | L | AzPro = azaproline, Cbz = carboxybenzyl, HCl = hydrochloric acid | 8 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Gas Shorter Peptide Analogs | β 6.3-Helical | Non-hemolytic | ||
| 29501941 | 2018 | VGAL{d}AV{d}VV{d}WL{d}WL{d}WL{d}W{nt:Formyl}{ct:NHCH2CH2OH}{nt:Formyl}{ct:NHCH2CH2OH} | 24(Gramicidin A) | NHCH2CH2OH | Formyl | Linear | Mix | N-Terminal = Formyl | 15 | Antibacterial | 50 % Hemolysis at 5 µM | Human | Gramicidin A Amp | β 6.3-Helical | NA | ||
| 29553266 | 2018 | KIAKGALKALKIAKVALKAL{ct:Amid} | kiadin-2 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 50 % Hemolysis at 30 ± 3 µM | Human | Modification Of Kiadin-1 Natural Amp (Pgla-H) | α-Helical | NA | ||
| 29553266 | 2018 | KIAKGALKALKIAKGALKAL{ct:Amid} | kiadin-3 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 50 % Hemolysis at 100± 5 µM | Human | Modification Of Kiadin-1 Natural Amp (Pgla-H) | α-Helical | NA | ||
| 29553266 | 2018 | KIGKALGKALKALGKALGKA{ct:Amid} | kiadin-4 | Amidation | Free | Linear | L | None | 20 | Antimicrobial and cytotoxic activity | 50 % Hemolysis at 15± 2 µM | Human | Ab Initio Designed | α-Helical | NA | ||
| 29553266 | 2018 | KIAGKAGKIAKIAGKAGKIA{ct:Amid} | kiadin-5 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 50 % Hemolysis at 0 µM | Human | Ab Initio Designed | α-Helical | Non-hemolytic | ||
| 29553266 | 2018 | KIALKALKALKALGKALKAL{ct:Amid} | kiadin-6 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 50 % Hemolysis at 10 ± 1 µM | Human | Ab Initio Designed | α-Helical | NA | ||
| 29670004 | 2018 | FFSLIPSLVGGLISAFK{ct:Amid} | Stigmurin | Amidation | Free | Linear | L | None | 17 | Antimicrobial,Antiproliferative, Antiparasitic | 3 % Hemolysis at 75 µM | Human | Scorpion Tityus Stigmurus Venom Gland | Random | Low hemolytic | ||
| 29670004 | 2018 | FFSLIPKLVKGLISAFK{ct:Amid} | StigA6 | Amidation | Free | Linear | L | None | 17 | Antiparasitic, Antimicrobial, Anticancer | 30 % Hemolysis at 75 µM | Human | Analogs To Stigmurin | Random coil | NA | ||
| 29670004 | 2018 | FFKLIPKLVKGLISAFK{ct:Amid} | StigA16 | Amidation | Free | Linear | L | None | 17 | Antiparasitic, Antimicrobial, Anticancer | 30 % Hemolysis at 75 µM | Human | Analogs To Stigmurin | Random coil | NA | ||
| 29549839 | 2018 | SKVWRHWRRFWHRAHRKL | Chensinin-1b | Free | Free | Linear | L | None | 14 | Antimicrobial | 0 % Hemolysis at >500 µM | Human | Chinese Brown Frog Rana Cheninensis | NA | Non-hemolytic | ||
| 29549839 | 2018 | {conj:CH3(CH2)6CO}SKVWRHWRRFWHRAHRKL | OA-C1b | Free | CH3(CH2)6CO | Linear | L | octanoic acid (OA),conjugation of aliphatic acid was designed lipo-chensinin-1b | 14 | Antimicrobial | 0 % Hemolysis at >500 µM | Human | Designed Lipo-Chensinin-1B | Random coil at aq, α-Helical at TFE solution | Non-hemolytic | ||
| 29549839 | 2018 | {conj:CH3(CH2)10CO}SKVWRHWRRFWHRAHRKL | LA-C1b | Free | CH3(CH2)10CO | Linear | L | lauric acid (LA) conjugation of aliphatic acid was designed lipo-chensinin-1b | 14 | Antimicrobial | 0 % Hemolysis at >500 µM | Human | Designed Lipo-Chensinin-1B | Random coil at aq | Non-hemolytic | ||
| 29549839 | 2018 | {conj:CH3(CH2)14CO}SKVWRHWRRFWHRAHRKL | PA-C1b | Free | CH3(CH2)14CO | Linear | L | palmitic acid (PA) conjugation of aliphatic acid was designed lipo-chensinin-1b | 14 | Anticancer and Anti-inflammation | 0 % Hemolysis at >500 µM | Human | Designed Lipo-Chensinin-1B | Random coil at aq, β-Strand at TFE solution | Non-hemolytic | ||
| 29266746 | 2018 | WLSKTAKKL{ct:Amid} | WL1 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | >5 % Hemolysis at >128 µM | Human | Tandem Repeat Cecropin P1 | unordered conformations | Non-hemolytic | ||
| 29266746 | 2018 | WLSKTAKKLWLSKTAKKL{ct:Amid} | WL2 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | >5 % Hemolysis at >128 µM | Human | Tandem Repeat Cecropin P1 | Random coil at aq, α-Helical at 50% TFE solution | Non-hemolytic | ||
| 29266746 | 2018 | WLSKTAKKLWLSKTAKKLWLSKTAKKL{ct:Amid} | WL3 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | >5 % Hemolysis at >128 µM | Human | Tandem Repeat Cecropin P1 | Random coil at aq, α-Helical at 50% TFE solution | Non-hemolytic | ||
| 29266746 | 2018 | SWLSKTAKKLENSAKKRISEGIAIAQGGPR{ct:Amid} | CP-1 | Amidation | Free | Linear | L | None | 30 | Antimicrobial | >5 % Hemolysis at >128 µM | Human | Pig Nematode Porcine Small Intestine | Helical | Non-hemolytic | ||
| 29307075 | 2018 | KWKLFKKIGAVLKVL ({nnr:AcO−}){ct:Amid} | CAMEL acetate | Amidation | Free | Linear | L | AcO− = Counter-ion acetate | 15 | Antimicrobial | 80 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | NA | ||
| 29307075 | 2018 | GLFDVIKKVASVIGGL ({nnr:AcO−}){ct:Amid} | Citropin 1.1 acetate | Amidation | Free | Linear | L | AcO− = Counter-ion acetate | 16 | Antimicrobial | 10 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | NA | ||
| 29307075 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES ({nnr:AcO−}) | LL-37 acetate | Free | Free | Linear | L | AcO− = Counter-ion acetate | 37 | Antimicrobial | ~4 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 29307075 | 2018 | GIGKFLKKAKKFGKAFVKILKK ({nnr:AcO−}){ct:Amid} | Pexiganan acetate | Amidation | Free | Linear | L | AcO− = Counter-ion acetate | 22 | Antimicrobial | 30.75 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | NA | ||
| 29307075 | 2018 | FLPLIGRVLSGIL ({nnr:AcO−}){ct:Amid} | Temporin A acetate | Amidation | Free | Linear | L | AcO− = Counter-ion acetate | 13 | Antimicrobial | ~4 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 29307075 | 2018 | KWKLFKKIGAVLKVL ({nnr:TFA−}){ct:Amid} | CAMEL trifluoroacetate | Amidation | Free | Linear | L | TFA− = Counter-ion trifluoroacetate | 15 | Antimicrobial | 50 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | NA | ||
| 29307075 | 2018 | GLFDVIKKVASVIGGL ({nnr:TFA−}){ct:Amid} | Citropin 1.1 trifluoroacetate | Amidation | Free | Linear | L | TFA− = Counter-ion trifluoroacetate | 16 | Antimicrobial | 12 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | NA | ||
| 29307075 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES ({nnr:TFA−}) | LL-37 trifluoroacetate | Free | Free | Linear | L | TFA− = Counter-ion trifluoroacetate | 37 | Antimicrobial | ~4 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 29307075 | 2018 | GIGKFLKKAKKFGKAFVKILKK ({nnr:TFA−}){ct:Amid} | Pexiganan trifluoroacetate | Amidation | Free | Linear | L | TFA− = Counter-ion trifluoroacetate | 22 | Antimicrobial | 8.51 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | NA | ||
| 29307075 | 2018 | FLPLIGRVLSGIL ({nnr:TFA−}){ct:Amid} | Temporin A trifluoroacetate | Amidation | Free | Linear | L | TFA− = Counter-ion trifluoroacetate | 13 | Antimicrobial | 2.5 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 29307075 | 2018 | KWKLFKKIGAVLKVL ({nnr:Cl−}){ct:Amid} | CAMEL chloride | Amidation | Free | Linear | L | Cl− = Counter-ion chloride | 15 | Antistaphylococcal | 65 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | NA | ||
| 29307075 | 2018 | GLFDVIKKVASVIGGL ({nnr:Cl−}){ct:Amid} | Citropin 1.1 chloride | Amidation | Free | Linear | L | Cl− = Counter-ion chloride | 16 | Antimicrobial | 6 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | NA | ||
| 29307075 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES ({nnr:Cl−}) | LL-37 chloride | Free | Free | Linear | L | Cl− = Counter-ion chloride | 37 | Antimicrobial | ~4 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 29307075 | 2018 | GIGKFLKKAKKFGKAFVKILKK ({nnr:Cl−}){ct:Amid} | Pexiganan chloride | Amidation | Free | Linear | L | Cl− = Counter-ion chloride | 22 | Antimicrobial | 9 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | NA | ||
| 29307075 | 2018 | FLPLIGRVLSGIL({nnr:Cl−}){ct:Amid} | Temporin A chloride | Amidation | Free | Linear | L | Cl− = Counter-ion chloride | 13 | Antimicrobial | 1 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 29688003 | 2018 | GIGKFLHSAKKFGKAFVGEIMNSC | Magainin 2 | Free | Free | Linear | L | None | 24 | Antibacterial | 7 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 29648811 | 2018 | RLRLLLRLR{ct:Amid} | 1 - L4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical at membrane-mimetic environments | Low hemolytic | ||
| 29648811 | 2018 | LLRRLRRLL{ct:Amid} | 2 - L4pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RFRFFFRFR{ct:Amid} | 3 - F4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | FFRRFRRFF{ct:Amid} | 4 - F4pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RIRIIIRIR{ct:Amid} | 5 - I4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | IIRRIRRII{ct:Amid} | 6 - I4pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RWRWWWRWR{ct:Amid} | 7 - W4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | WWRRWRRWW{ct:Amid} | 8 - W4pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 9 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RRLRLLLRLRR{ct:Amid} | 9 - L6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RLLRRLRRLLR{ct:Amid} | 10 - L6pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 11 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RRFRFFFRFRR{ct:Amid} | 11 - F6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RFFRRFRRFFR{ct:Amid} | 12 - F6pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 11 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RRIRIIIRIRR{ct:Amid} | 13 - I6 | Amidation | Free | Linear | L | None | 11 | Antifungal, Antibacterial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RIIRRIRRIIR{ct:Amid} | 14 - I6pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 11 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RRWRWWWRWRR{ct:Amid} | 15 - W6 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RWWRRWRRWWR{ct:Amid} | 16 - W6pf | Amidation | Free | Linear | L | pf = perfect amphipathicity peptides | 11 | Antimicrobial | 10 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29648811 | 2018 | RRIRIIIRIRR{nt:Fluorescein isothiocyanate (FITC)-labeled peptide}{ct:Amid} | 17 - FITC-I6 | Amidation | Fluorescein isothiocyanate (FITC)-labeled peptide | Linear | L | FITC = Fluorescein isothiocyanate-labeled peptide | 11 | Antimicrobial | 9.26 % Hemolysis at >128 µM | Human | Synthetic Peptide - Developed Based On The Imperfectly Amphipathic Palindromic Structure Rn(Xrxxxrx)Rn (N = 1, 2; X Represents L, I, F, Or W) | α-Helical | Low hemolytic | ||
| 29783753 | 2018 | LRLKKYKVPQL{ct:Amid} | Cp1 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 16 µM | Human | Synthesized From Bovine Αs1-Casein | unordered conformation at different environment | Non-hemolytic | ||
| 29783753 | 2018 | LRLKKYKVPQL{ct:Amid} | Cp1 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 5 % Hemolysis at 32 µM | Human | Synthesized From Bovine Αs1-Casein | unordered conformation at different environment | Low hemolytic | ||
| 29783753 | 2018 | LRLKKYKVPQL{ct:Amid} | Cp1 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 23.54 % Hemolysis at 512 µM | Human | Synthesized From Bovine Αs1-Casein | unordered conformation at different environment | NA | ||
| 29783753 | 2018 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 5 % Hemolysis at 1 µM | Human | Bee Venom | unordered conformation at 10 mM sodium phosphate, α-Helix at TFE and SDS | NA | ||
| 29783753 | 2018 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 46.8 % Hemolysis at 2 µM | Human | Bee Venom | unordered conformation at 10 mM sodium phosphate, α-Helix at TFE and SDS | NA | ||
| 29738954 | 2018 | FGRKKRRQRRR{nt:Acet}{ct:Amid} | ctrlTat peptide | Amidation | Acetylation | Linear | L | None | 11 | Antibacterial | 12 % Hemolysis at 1 µM | Human | Human Immunodeficiency Virus 1 (Hiv-1) Tat Protein | at water Random coil structure, at TFE α-Helical | NA | ||
| 29738954 | 2018 | FG{nnr:r}KKR{nnr:r}Q{nnr:r}R{nnr:r}-{nnr:βA}{nt:Acet}{ct:Amid} | γTatM4 | Amidation | Acetylation | Linear | Mix | r = (2S,4S)-4-amino-N-(3-guanidinopropyl)-proline, βA = βAla(β-Alanine){nnr:Bala} – β-Alanine | 11 | Antibacterial and Anti-TB | 10 % Hemolysis at 1 µM | Human | Tat Peptide Analogues | NA | NA | ||
| 29738954 | 2018 | FGRKKRRQRRR{nt:Acet}{ct:Amid} | ctrlTat peptide | Amidation | Acetylation | Linear | L | None | 11 | Antibacterial | 14 % Hemolysis at 40 µM | Human | Human Immunodeficiency Virus 1 (Hiv-1) Tat Protein | at water Random coil structure, at TFE α-Helical | NA | ||
| 29738954 | 2018 | FG{nnr:r}KKR{nnr:r}Q{nnr:r}R{nnr:r}-{nnr:βA}{nt:Acet}{ct:Amid} | γTatM4 | Amidation | Acetylation | Linear | Mix | r = (2S,4S)-4-amino-N-(3-guanidinopropyl)-proline, βA = βAla(β-Alanine){nnr:Bala} – β-Alanine | 11 | Antibacterial and Anti-TB | 12 % Hemolysis at 40 µM | Human | Tat Peptide Analogues | NA | NA | ||
| 28659061 | 2018 | NLLNDALGTVNGLLGRS | Dc1 | Free | Free | Linear | L | None | 17 | Antimicrobial | 50 % Hemolysis at >256 µM | Human | Frog Skin Secretion Of D. Columbianus | water = unordered structures , TFE = α-Helix | Non-hemolytic | ||
| 28659061 | 2018 | NLLNKALGTVNGLLGRS | Dc1.1 | Free | Free | Linear | L | None | 17 | Antibacterial | 50 % Hemolysis at >256 µM | Human | Dc1 Analogue | water = unordered structures , TFE = α-Helix | Non-hemolytic | ||
| 28659061 | 2018 | NLLKSALKTVNKLLAAS{ct:Amid} | Dc1.2 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 50 % Hemolysis at >256 µM | Human | Dc1 Analogue | water = unordered structures , TFE = α-Helix | Non-hemolytic | ||
| 29614317 | 2018 | GLLKRIKTLL{ct:Amid} | Anoplin | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 0 % Hemolysis | Human | Solitary Wasp | water = Random coil, TFE/H2O(30%) = α-Helix | Non-hemolytic | ||
| 29614317 | 2018 | GLLKRIKTLL{nt:palmitoyl group (C16)}{ct:Amid} | Pal-anoplin | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 10 | Antifungal | 0 % Hemolysis | Human | Truncated Analogues Of Pal-Anoplin | water = Helical, TFE/H2O(30%) = Helical | NA | ||
| 29614317 | 2018 | GLLKRIKTL{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-9 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 9 | Antifungal | 50 % Hemolysis at 18.92 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Helical, TFE/H2O(30%) = Helical | NA | ||
| 29614317 | 2018 | GLLKRIKT{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-8 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 8 | Antimicrobial | 50 % Hemolysis at 33.74 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Random coil, TFE/H2O(30%) = Helical | NA | ||
| 29614317 | 2018 | GLLKRIK{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-7 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 7 | Antimicrobial | 50 % Hemolysis at 37.7 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Random coil, TFE/H2O(30%) = Helical | NA | ||
| 29614317 | 2018 | GLLKRI{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-6 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 6 | Antifungal | 50 % Hemolysis at 7.51 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Helical, TFE/H2O(30%) = Helical | NA | ||
| 29614317 | 2018 | GLLKR{nt:palmitoyl group (C16)}{ct:Amid} | Pal-ano-5 | Amidation | palmitoyl group (C16) | Linear | L | C16 = palmitoyl group | 5 | Antimicrobial | 50 % Hemolysis at 66.12 μg/mL | Human | Truncated Analogues Of Pal-Anoplin | water = Random coil, TFE/H2O(30%) = Random coil | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{cyc:N-C} | C1 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Npm = N-(1-phenylmethyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 250 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Ndmb}{nnr:Nap}{nnr:Ndmb}{nnr:Nap}{nnr:Ndmb}{cyc:N-C} | C2 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Ndmb = N-(3,5-dimethylbenzyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 125 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Nsne}{nnr:Nap}{nnr:Nsne}{nnr:Nap}{nnr:Nsne}{cyc:N-C} | C3 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Nsne = (S)-N-(1-naphthylethyl)glycine | 6 | Antibacterial | 10 % Hemolysis | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Ndp}{nnr:Nap}{nnr:Ndp}{nnr:Nap}{nnr:Ndp}{cyc:N-C} | C4 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Ndp = N-(2,2-diphenylethyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 31.3 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Nbtfmb}{nnr:Nap}{nnr:Nbtfmb}{nnr:Nap}{nnr:Nbtfmb}{cyc:N-C} | C5 | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Nbtfmb = N-(3,5-bis-trifluoromethylbenzyl)glycine | 6 | Antibacterial | 10 % Hemolysis at 31.3 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | {nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{nnr:Nap}{nnr:Npm}{cyc:N-C} | C1dec | Free | Free | Cyclic | Mix | Nap = N-(3-aminopropyl)glycine, Npm = N-(1-phenylmethyl)glycine | 10 | Antibacterial | 10 % Hemolysis at 250 μg/mL | Human | Synthetic Peptoids Mimic Antimicrobial Peptides | NA | NA | ||
| 29621496 | 2018 | V{nnr:O}LF{d}PV{nnr:O}LF{d}P{cyc:N-C} | CGS (gramicidin S) | Free | Free | Cyclic | Mix | O = L-Ornithine, f = D-phenylalanine | 10 | Antibacterial | 10 % Hemolysis at >15.6 μg/mL | Human | Gram-Positive Bacterium Brevibacillus Brevis | NA | NA | ||
| 29626660 | 2018 | INLKAIAALAKKLL{ct:Amid} | Mastoparan-1 (MP-I) | Amidation | Free | Linear | L | None | 14 | Antimicrobial against MRSA | 18.7 % Hemolysis at 128 mg/L | Human | Hornet Venom | Helical | NA | ||
| 29626660 | 2018 | INLKAIAALAKKLL{ct:Amid} | Mastoparan-1 (MP-I) | Amidation | Free | Linear | L | None | 14 | Antimicrobial against MRSA | 0 % Hemolysis at 0.5 mg/L | Human | Hornet Venom | Helical | Non-hemolytic | ||
| 29626660 | 2018 | INLKAIAALAKKLL{ct:Amid} | Mastoparan-1 (MP-I) | Amidation | Free | Linear | L | None | 14 | Antimicrobial against MRSA | 0 % Hemolysis at 64 mg/L | Human | Hornet Venom | Helical | Non-hemolytic | ||
| 29870123 | 2018 | KWCFRVCYRGICYRRCR{ct:Amid} | Tachyplesin I | Amidation | Free | Linear | L | First Disulfide Bond = CysII─CysIII, Second Disulfide Bond = CysI─CysIV | 17 | Antimicrobial | 9.6 % Hemolysis at 8 μg/mL | Human | Horseshoe Crabs(Limulus Lymphocyte Granulosa Cells) | antiparallel β‐Strand connected by a β‐Turn and stabilized by 2 disulfide bonds | NA | ||
| 29870123 | 2018 | KWCFRVCYRGICYRRCR{ct:Amid} | 3C7C | Amidation | Free | Linear | L | First Disulfide Bond = CysI─CysIII, Second Disulfide Bond = CysII─CysIV | 17 | Antimicrobial | 14.3 % Hemolysis at 8 μg/mL | Human | Tachyplesin I Isomers | Random coil | NA | ||
| 29870123 | 2018 | KWCFRVCYRGICYRRCR{ct:Amid} | 3C12C | Amidation | Free | Linear | L | First Disulfide Bond = CysI─CysII, Second Disulfide Bond = CysIII─CysIV | 17 | Antimicrobial | 4.8 % Hemolysis at 8 μg/mL | Human | Tachyplesin I Isomers | Random coil | NA | ||
| 29870123 | 2018 | KWCFRVCYRGICYRRCR{ct:Amid} | Tachyplesin I | Amidation | Free | Linear | L | First Disulfide Bond = CysII─CysIII, Second Disulfide Bond = CysI─CysIV | 17 | Antimicrobial | 72.8 % Hemolysis at 512 μg/mL | Human | Horseshoe Crabs(Limulus Lymphocyte Granulosa Cells) | antiparallel β‐Strand connected by a β‐Turn and stabilized by 2 disulfide bonds | NA | ||
| 29870123 | 2018 | KWCFRVCYRGICYRRCR{ct:Amid} | 3C7C | Amidation | Free | Linear | L | First Disulfide Bond = CysI─CysIII, Second Disulfide Bond = CysII─CysIV | 17 | Antimicrobial | 20.5 % Hemolysis at 64 μg/mL | Human | Tachyplesin I Isomers | Random coil | NA | ||
| 29870123 | 2018 | KWCFRVCYRGICYRRCR{ct:Amid} | 3C12C | Amidation | Free | Linear | L | First Disulfide Bond = CysI─CysII, Second Disulfide Bond = CysIII─CysIV | 17 | Antimicrobial | 14.9 % Hemolysis at 64 μg/mL | Human | Tachyplesin I Isomers | Random coil | NA | ||
| 29910626 | 2018 | KFKKLFKKLSPVIGKEFKRIVERIKRFLR | H4 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | N-Terminal Fragment Obtained From Residues 9–26 Of Bmap-27 And A C-Terminal Fragment From Residues 1–16 Of Op-145 | α-Helix | Non-hemolytic | ||
| 29910626 | 2018 | KFKKLFKKLSPVIGKEFKRIVERIKRFLR | H4 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0 % Hemolysis at 10 µM | Human | N-Terminal Fragment Obtained From Residues 9–26 Of Bmap-27 And A C-Terminal Fragment From Residues 1–16 Of Op-145 | α-Helix | Non-hemolytic | ||
| 29910626 | 2018 | KFKKLFKKLSPVIGKEFKRIVERIKRFLR | H4 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0 % Hemolysis at 25 µM | Human | N-Terminal Fragment Obtained From Residues 9–26 Of Bmap-27 And A C-Terminal Fragment From Residues 1–16 Of Op-145 | α-Helix | Non-hemolytic | ||
| 29910626 | 2018 | KFKKLFKKLSPVIGKEFKRIVERIKRFLR | H4 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0 % Hemolysis at 40 µM | Human | N-Terminal Fragment Obtained From Residues 9–26 Of Bmap-27 And A C-Terminal Fragment From Residues 1–16 Of Op-145 | α-Helix | Non-hemolytic | ||
| 29910626 | 2018 | KFKKLFKKLSPVIGKEFKRIVERIKRFLR | H4 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0 % Hemolysis at 55 µM | Human | N-Terminal Fragment Obtained From Residues 9–26 Of Bmap-27 And A C-Terminal Fragment From Residues 1–16 Of Op-145 | α-Helix | Non-hemolytic | ||
| 29910626 | 2018 | KFKKLFKKLSPVIGKEFKRIVERIKRFLR | H4 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0 % Hemolysis at 70 µM | Human | N-Terminal Fragment Obtained From Residues 9–26 Of Bmap-27 And A C-Terminal Fragment From Residues 1–16 Of Op-145 | α-Helix | Non-hemolytic | ||
| 29910626 | 2018 | KFKKLFKKLSPVIGKEFKRIVERIKRFLR | H4 | Free | Free | Linear | L | None | 29 | Antimicrobial | 0 % Hemolysis at 85 µM | Human | N-Terminal Fragment Obtained From Residues 9–26 Of Bmap-27 And A C-Terminal Fragment From Residues 1–16 Of Op-145 | α-Helix | Non-hemolytic | ||
| 29910626 | 2018 | KFKKLFKKLSPVIGKEFKRIVERIKRFLR | H4 | Free | Free | Linear | L | None | 29 | Antimicrobial | 2.1 % Hemolysis at 100 µM | Human | N-Terminal Fragment Obtained From Residues 9–26 Of Bmap-27 And A C-Terminal Fragment From Residues 1–16 Of Op-145 | α-Helix | NA | ||
| 29984236 | 2018 | RRWQWR | Motif | Free | Free | Linear | L | None | 6 | Antibacterial | 7.1 % Hemolysis at 25 μM | Human | Bovine Lactoferricin | branched conformation | NA | ||
| 29984236 | 2018 | RWQWR WQWR | Palindromic | Free | Free | Linear | L | None | 9 | Antibacterial | 24.8 % Hemolysis at 100 μM | Human | Synthesised From Motif | NA | NA | ||
| 29984236 | 2018 | FKC R RWQWRM KKLGA | LfcinB reference | Free | Free | Linear | L | None | 15 | Antibacterial | 7.9 % Hemolysis at 12.5 μM | Human | Bovine Lactoferricin B | NA | NA | ||
| 29984236 | 2018 | RRWQWRRRWQWR-K-{nnr:Ahx} | Dimeric | Free | Free | Linear | L | Ahx = Aminohexanoic acid | 13 | Antibacterial | <5 % Hemolysis at 100 μM | Human | Synthesised And Modified From Motif | NA | Low hemolytic | ||
| 29984236 | 2018 | RRWQWRRRWQWRK-{nnr:Ahx}-CRRWQWRRRWQWRK-{nnr:Ahx}-C | Tetrameric | Free | Free | Linear | L | Ahx = Aminohexanoic acid | 28 | Antibacterial | 49.1 % Hemolysis at 100 μM | Human | Synthesised And Modified From Motif | NA | NA | ||
| 29752337 | 2018 | GLLSGHYGRVVSTQSGHYGRG | OA-GL21 | Free | Free | Linear | L | None | 21 | Wound-healing | 0 % Hemolysis at 50 μM | Human | Frog Skin Secretions Of Odorrana Andersonii | aqueous = Helical conformation, membrane-mimetic environments = Helical conformation | Non-hemolytic | ||
| 29966346 | 2018 | GLFDVIKKVASVIGGL | citropin 1.1 | Free | Free | Linear | L | None | 16 | Antimicrobial | 9 % Hemolysis at 128 µg/mL | Human | Frog Litoria Citropa | water = Random coil, TFE or SDS = Alphα-Helical structure | NA | ||
| 29966346 | 2018 | GLFDVIKKVASVIGGL | citropin 1.1 | Free | Free | Linear | L | None | 16 | Antimicrobial | 74 % Hemolysis at 512 µg/mL | Human | Frog Litoria Citropa | water = Random coil, TFE or SDS = Alphα-Helical structure | NA | ||
| 29799150 | 2018 | AAGK{d}W{d}K{d}L{d}F{d}K{d}K{d}L{d}P{d}K{d}F{d}L{d}H{d}L{d}A{d}K{d}K{d}F{d}{ct:Amid} | AAG‐P18 | Amidation | Free | Linear | Mix | None | 18 | Antibacterial | 75 % Hemolysis at 250 μM | Human | Cecropin/Magainin Hybrid | NA | NA | ||
| 29799150 | 2018 | EEEEAAAGK{d}W{d}K{d}L{d}F{d}K{d}K{d}L{d}P{d}K{d}F{d}L{d}H{d}L{d}A{d}K{d}K{d}F{d}{nt:Acet}{ct:Amid} | Pro‐P18 | Amidation | Acetylation | Linear | Mix | None | 26 | ND | 0 % Hemolysis at 10 μM | Human | Cecropin/Magainin Hybrid | NA | Non-hemolytic | ||
| 29799150 | 2018 | AAGW{d}G{d}L{d}R{d}R{d}L{d}L{d}K{d}Y{d}G{d}K{d}R{d}S{d}{ct:Amid} | AAG‐WMR | Amidation | Free | Linear | Mix | None | 13 | Antibacterial | 5 % Hemolysis at 10 μM | Human | Myxinidin Analogue From Hagfish | NA | NA | ||
| 29799150 | 2018 | EEEEAAAGW{d}G{d}L{d}R{d}R{d}L{d}L{d}K{d}Y{d}G{d}K{d}R{d}S{d}{nt:Acet}{ct:Amid} | Pro‐WMR | Amidation | Acetylation | Linear | Mix | None | 21 | ND | 0 % Hemolysis at 10 μM | Human | Myxinidin Analogue From Hagfish | NA | Non-hemolytic | ||
| 30004427 | 2018 | FLFSLIRKAIGGLISAFK | A3 | Free | Free | Linear | L | None | 18 | Antimicrobial and Antibiofilm activities | 0 % Hemolysis at 1 μM | Human | North African Scorpion Androctonus Amoeruxi, | α-Helix | Non-hemolytic | ||
| 30004427 | 2018 | FLFSLIRKAIGGLISAFK | A3 | Free | Free | Linear | L | None | 18 | Antimicrobial and Antibiofilm activities | 0 % Hemolysis at 5 μM | Human | North African Scorpion Androctonus Amoeruxi, | α-Helix | Non-hemolytic | ||
| 30004427 | 2018 | FLFSLIRKAIGGLISAFK | A3 | Free | Free | Linear | L | None | 18 | Antimicrobial and Antibiofilm activities | 5.1 % Hemolysis at 10 μM | Human | North African Scorpion Androctonus Amoeruxi, | α-Helix | NA | ||
| 30004427 | 2018 | FLFSLIRKAIGGLISAFK | A3 | Free | Free | Linear | L | None | 18 | Antimicrobial and Antibiofilm activities | 16.8 % Hemolysis at 20 μM | Human | North African Scorpion Androctonus Amoeruxi, | α-Helix | NA | ||
| 30004427 | 2018 | FLFSLIRKAIGGLISAFK | A3 | Free | Free | Linear | L | None | 18 | Antimicrobial and Antibiofilm activities | 36.1 % Hemolysis at 40 μM | Human | North African Scorpion Androctonus Amoeruxi, | α-Helix | NA | ||
| 30004427 | 2018 | FLFSLIRKAIGGLISAFK | A3 | Free | Free | Linear | L | None | 18 | Antimicrobial and Antibiofilm activities | 47.9 % Hemolysis at 60 μM | Human | North African Scorpion Androctonus Amoeruxi, | α-Helix | NA | ||
| 30004427 | 2018 | FLFSLIRKAIGGLISAFK | A3 | Free | Free | Linear | L | None | 18 | Antimicrobial and Antibiofilm activities | 49.4 % Hemolysis at 80 μM | Human | North African Scorpion Androctonus Amoeruxi, | α-Helix | NA | ||
| 29197569 | 2018 | KWKLFKKYGRKKRRQRRR | CA-TAT | Free | Free | Linear | L | None | 18 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Attaching Cecropin A (1-7)+ Tat(47-57) | NA | Low hemolytic | ||
| 29197569 | 2018 | YGRKKRRQRRR | TAT(47-57) | Free | Free | Linear | L | None | 11 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Human Immunodeficiency Virus Type 1 (Hiv–1) Transactivation Of Transcription (Tat) Protein | NA | Low hemolytic | ||
| 29197569 | 2018 | KWKLFKK | cecropin A(1-7) | Free | Free | Linear | L | None | 7 | Antibacterial | 5 % Hemolysis at >64 μM | Human | Hemolymph Of Giant Silk | NA | NA | ||
| 28072492 | 2018 | FFPGIIKVASAILPTAICAITKRC | Brevinin1 HYba1 B1/1 COOH | Free | Free | Linear | L | None | 24 | Antimicrobial, Antibacterial | >40 % Hemolysis at 100 μM | Human | Frog Crude Skin Secretion Of Hydrophylax Bahuvistara | membrane-mimetic environment like trifluoroethanol (TFE) in water 30% (v/v = Alphα-Helical conformation | NA | ||
| 28072492 | 2018 | FFPGIIKVASAILPTAICAITKRC{ct:Amid} | Brevinin1 HYba1 B1/1 CONH2 | Amidation | Free | Linear | L | None | 24 | Antimicrobial, Antibacterial | >80 % Hemolysis at 100 μM | Human | Frog Crude Skin Secretion Of Hydrophylax Bahuvistara | membrane-mimetic environment like trifluoroethanol (TFE) in water 30% (v/v = Alphα-Helical conformation | NA | ||
| 28072492 | 2018 | FFPGIIKVAGAILPTAICAITKRC | Brevinin1 HYba2 B1/2 COOH | Free | Free | Linear | L | None | 24 | Antimicrobial, Antibacterial | >50 % Hemolysis at 100 μM | Human | Frog Crude Skin Secretion Of Hydrophylax Bahuvistara | membrane-mimetic environment like trifluoroethanol (TFE) in water 30% (v/v = Alphα-Helical conformation | NA | ||
| 28072492 | 2018 | FFPGIIKVAGAILPTAICAITKRC{ct:Amid} | Brevinin1 HYba2 B1/2 CONH2 | Amidation | Free | Linear | L | None | 24 | Antimicrobial, Antibacterial | >90 % Hemolysis at 100 μM | Human | Frog Crude Skin Secretion Of Hydrophylax Bahuvistara | membrane-mimetic environment like trifluoroethanol (TFE) in water 30% (v/v = Alphα-Helical conformation | NA | ||
| 29750913 | 2018 | KKLFKKILKYL{ct:Amid} | BP100 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 50 % Hemolysis at >64 μM | Human | Combination Of Melittin And Cecropin A | membrane = α-Helical | NA | ||
| 29750913 | 2018 | KKLFKKILKYLA-hexadecyl-1-amine{ct:n-hexadecyl acyl chain} | BP100-Ala-NH-C16H33 | n-hexadecyl acyl chain | Free | Linear | L + chain | additional alanine and an n-hexadecyl acyl chain at the C-terminus | 12 | Antimicrobial | 50 % Hemolysis at 6.3 μM | Human | Synthesized Analog Of Bp100 | membrane = α-Helical | NA | ||
| 29750913 | 2018 | C{d}ILC-KKLFKKILKYL{cyc:1‑4} | Cyclo (1‑4)‑cILC-BP100 | Free | Free | Cyclic | Mix | disulfide bond between D-Cys1 and Cys4 at N-Terminal | 11 | Antimicrobial | 50 % Hemolysis at 8.7 μM | Human | Synthesized Analog Of Bp100 | membrane =Partly α-Helical and partly β-Turn | NA | ||
| 29842923 | 2018 | FLPIVGRLISGIL | Temporin-CPb | Free | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at >100 μM | Human | Gopher Frog Lithobates Capito | NA | NA | ||
| 29842923 | 2018 | SILPTIVSFLSKVF | Temporin-1Ga | Free | Free | Linear | L | None | 14 | Antibacterial, Antifungal, Anticancer | 50 % Hemolysis at 12.5 μM | Human | Frog Rana Grylio | NA | NA | ||
| 29842923 | 2018 | FLPFLKSILGKIL | Temporin-1OLa | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Anticancer | 50 % Hemolysis at 50 μM | Human | Frog Rana Okaloosae | α-Helical | NA | ||
| 29842923 | 2018 | FLSAITSILGKFF | Temporin-1SPa | Free | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 37.5 μM | Human | Frog Rana Septentrionalis | NA | NA | ||
| 29842923 | 2018 | FLPLLASLFSRLF | Temporin-1Oc | Free | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at <12.5 μM | Human | Frog Rana Ornativentris | NA | NA | ||
| 29842923 | 2018 | IPPFIKKVLTTVF | Temporin-CPa | Free | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at >100 μM | Human | Gopher Frog Lithobates Capito | NA | NA | ||
| 30011202 | 2018 | VVKCSFRPGSPAPRCK | odorranain-A-OT | Free | Free | Linear | L | None | 16 | Antioxidant | 5 % Hemolysis at 150 μM | Human | Frog Odorranain | NA | NA | ||
| 30011202 | 2018 | FVPAILCSILKTC | odorranain-G-OT | Free | Free | Linear | L | None | 13 | Antioxidant | 4 % Hemolysis at 150 μM | Human | Frog Odorranain | NA | NA | ||
| 30011202 | 2018 | FFRTSCRSVC | MFL | Free | Free | Linear | L | None | 10 | Antioxidant | 7 % Hemolysis at 150 μM | Human | Derived From Margaratain-B1, Andersnin-C1, And Pleurain-R1 | NA | NA | ||
| 30011202 | 2018 | FRTSCSAC | M1 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 2 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Mfl | NA | NA | ||
| 30011202 | 2018 | FRTCRSVC | M2 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 3 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Mfl | NA | Non-hemolytic | ||
| 30011202 | 2018 | FFRSCRVC | M3 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 2 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Mfl | NA | Non-hemolytic | ||
| 30011202 | 2018 | TSRCIFYRRCVCS | AFL | Free | Free | Linear | L | None | 10 | Antioxidant | 21 % Hemolysis at 150 μM | Human | Derived From Margaratain-B1, Andersnin-C1, And Pleurain-R1 | NA | NA | ||
| 30011202 | 2018 | TRAFRCVS | A1 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 1 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Afl | NA | Non-hemolytic | ||
| 30011202 | 2018 | TRCFRVCS | A2 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 1 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Afl | NA | Non-hemolytic | ||
| 30011202 | 2018 | TSRCFRVC | A3 | Free | Free | Linear | L | None | 8 | Antioxidant and tyrosinase inhibition | 1 % Hemolysis at 150 μM | Human | Designed As Shortened Variants Of Afl | NA | Non-hemolytic | ||
| 30011202 | 2018 | CVRFRTNTARTVCIAP | PFL | Free | Free | Linear | L | None | 16 | Antioxidant | 5 % Hemolysis at 150 μM | Human | Derived From Margaratain-B1, Andersnin-C1, And Pleurain-R1 | NA | NA | ||
| 30105347 | 2018 | ADLPFE{d}F | PapR7-dE | Free | Free | Linear | Mix | e = D-glutamic acid | 7 | NA | 50 % Hemolysis at 1 μM | Human | Synthetic Peptide | NA | NA | ||
| 30161192 | 2018 | SLTFEVLDKVLGELGKVSRK | StI12-31 | Free | Free | Linear | L | None | 20 | NA | 0 % Hemolysis at 64 μM | Human | Derived From Sea Anemone Actinoporins Sticholysin I | α-Helical | Non-hemolytic | ||
| 30161192 | 2018 | SLTFQVLDKVLEELGKVSRK | StII11-30 | Free | Free | Linear | L | None | 20 | NA | 0 % Hemolysis at 64 μM | Human | Derived From Sea Anemone Actinoporins Sticholysin Ii | α-Helical | Non-hemolytic | ||
| 30161192 | 2018 | {nnr:TOAC}-SLTFQVLDKVLEELGKVSRK{nt:TOAC} | N-TOAC-StII11-30 | Free | TOAC | Linear | L | TOAC = 2,2,6,6-tetramethyl-N-oxyl-4-amino-4-carboxylic acid | 20 | NA | 0 % Hemolysis at 64 μM | Human | Derived From Sea Anemone Actinoporins Sticholysin Ii | α-Helical | Non-hemolytic | ||
| 29890152 | 2018 | MNFNKFFVLFALIMVAVVGQSEAGWLKKLGKKIERVGQHTRDATIQTIGVAQQAVNVAATLKG | Lucilin | Free | Free | Linear | L | None | 63 | Antibacterial | 0 % Hemolysis at 250 μg/ml | Human | Australian Sheep Blowfly (Lucilia Cuprina) | α-Helix | Non-hemolytic | ||
| 30192822 | 2018 | IFGAILPLALGALKNLIK | Hylin-a1 | Free | Free | Linear | L | None | 18 | Antimicrobial | 1 % Hemolysis at 25 mM | Human | Hypsiboas Albopunctatus | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | KIFGAIWPLALGALKNLIK | K0-W6-Hy-a1 | Free | Free | Linear | L | None | 19 | Antibacterial | 1 % Hemolysis at 25 mM | Human | Analogue Of Hylin-A1 | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | VRRFPWWWPFLRR | Tritrpticin | Free | Free | Linear | L | None | 13 | Antimicrobial | 14 % Hemolysis at 25 mM | Human | Porcine Cathelicidin | amphipathic α-Helix | NA | ||
| 30192822 | 2018 | KLLKFVTKVGKAIFKALIKAI{d} | Ocellatin4-analogue | Free | Free | Linear | Mix | None | 21 | Antimicrobial | 88 % Hemolysis at 25 mM | Human | Leptodatylus Ocellatus Analogue Of Ocellatin 4 | amphipathic α-Helix | NA | ||
| 30192822 | 2018 | IETFLKQLRSAANKIVGL | Citrus-amp1 | Free | Free | Linear | L | None | 18 | Antibacterial | 1 % Hemolysis at 25 mM | Human | Citrus Sinensis | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | LESLASSAVRTANKARAKL | Citrus-amp2 | Free | Free | Linear | L | None | 19 | NA | 0 % Hemolysis at 25 mM | Human | Citrus Aurantium | amphipathic α-Helix | Non-hemolytic | ||
| 30192822 | 2018 | IFGAILPLALGALKNLIK | Hylin-a1 | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 50 mM | Human | Hypsiboas Albopunctatus | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | KIFGAIWPLALGALKNLIK | K0-W6-Hy-a1 | Free | Free | Linear | L | None | 19 | Antibacterial | 0 % Hemolysis at 50 mM | Human | Analogue Of Hylin-A1 | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | VRRFPWWWPFLRR | Tritrpticin | Free | Free | Linear | L | None | 13 | Antimicrobial | 53 % Hemolysis at 50 mM | Human | Porcine Cathelicidin | amphipathic α-Helix | NA | ||
| 30192822 | 2018 | KLLKFVTKVGKAIFKALIKAI{d} | Ocellatin4-analogue | Free | Free | Linear | Mix | None | 21 | Antimicrobial | 100 % Hemolysis at 50 mM | Human | Leptodatylus Ocellatus Analogue Of Ocellatin 4 | amphipathic α-Helix | NA | ||
| 30192822 | 2018 | IETFLKQLRSAANKIVGL | Citrus-amp1 | Free | Free | Linear | L | None | 18 | Antibacterial | 3 % Hemolysis at 50 mM | Human | Citrus Sinensis | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | LESLASSAVRTANKARAKL | Citrus-amp2 | Free | Free | Linear | L | None | 19 | NA | 0 % Hemolysis at 50 mM | Human | Citrus Aurantium | amphipathic α-Helix | Non-hemolytic | ||
| 30192822 | 2018 | IFGAILPLALGALKNLIK | Hylin-a1 | Free | Free | Linear | L | None | 18 | Antimicrobial | 0 % Hemolysis at 75 mM | Human | Hypsiboas Albopunctatus | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | KIFGAIWPLALGALKNLIK | K0-W6-Hy-a1 | Free | Free | Linear | L | None | 19 | Antibacterial | 0 % Hemolysis at 75 mM | Human | Analogue Of Hylin-A1 | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | VRRFPWWWPFLRR | Tritrpticin | Free | Free | Linear | L | None | 13 | Antimicrobial | 83 % Hemolysis at 75 mM | Human | Porcine Cathelicidin | amphipathic α-Helix | NA | ||
| 30192822 | 2018 | KLLKFVTKVGKAIFKALIKAI{d} | Ocellatin4-analogue | Free | Free | Linear | Mix | None | 21 | Antimicrobial | 100 % Hemolysis at 75 mM | Human | Leptodatylus Ocellatus Analogue Of Ocellatin 4 | amphipathic α-Helix | NA | ||
| 30192822 | 2018 | IETFLKQLRSAANKIVGL | Citrus-amp1 | Free | Free | Linear | L | None | 18 | Antibacterial | 10 % Hemolysis at 75 mM | Human | Citrus Sinensis | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | LESLASSAVRTANKARAKL | Citrus-amp2 | Free | Free | Linear | L | None | 19 | NA | 0 % Hemolysis at 75 mM | Human | Citrus Aurantium | amphipathic α-Helix | Non-hemolytic | ||
| 30192822 | 2018 | IFGAILPLALGALKNLIK | Hylin-a1 | Free | Free | Linear | L | None | 18 | Antimicrobial | 1 % Hemolysis at 100 mM | Human | Hypsiboas Albopunctatus | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | KIFGAIWPLALGALKNLIK | K0-W6-Hy-a1 | Free | Free | Linear | L | None | 19 | Antibacterial | 0 % Hemolysis at 100 mM | Human | Analogue Of Hylin-A1 | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | VRRFPWWWPFLRR | Tritrpticin | Free | Free | Linear | L | None | 13 | Antimicrobial | 99 % Hemolysis at 100 mM | Human | Porcine Cathelicidin | amphipathic α-Helix | NA | ||
| 30192822 | 2018 | KLLKFVTKVGKAIFKALIKAI{d} | Ocellatin4-analogue | Free | Free | Linear | Mix | None | 21 | Antimicrobial | 100 % Hemolysis at 100 mM | Human | Leptodatylus Ocellatus Analogue Of Ocellatin 4 | amphipathic α-Helix | NA | ||
| 30192822 | 2018 | IETFLKQLRSAANKIVGL | Citrus-amp1 | Free | Free | Linear | L | None | 18 | Antibacterial | 28 % Hemolysis at 100 mM | Human | Citrus Sinensis | amphipathic α-Helix | Low hemolytic | ||
| 30192822 | 2018 | LESLASSAVRTANKARAKL | Citrus-amp2 | Free | Free | Linear | L | None | 19 | NA | 1 % Hemolysis at 100 mM | Human | Citrus Aurantium | amphipathic α-Helix | Non-hemolytic | ||
| 29859288 | 2018 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 2.9±0.7 % Hemolysis at 500 μg/ml | Human | Human Cathelicidin-Derived Peptide | α-Helical | Low hemolytic | ||
| 29859288 | 2018 | DSHAKRHHGYKRKFHEKHHSHRGY | histatin Hst-5 | Free | Free | Linear | L | None | 24 | Antifungal | 1.6±0.6 % Hemolysis at 500 μg/ml | Human | Human Saliva Histatin | α-Helical | Low hemolytic | ||
| 29859288 | 2018 | LGDFFRKSKEKIGKEFKRIVQRIKDFLRNLAKRHHGYKRKFH | L31-P113 | Free | Free | Linear | L | None | 42 | Antibacterial, Antifungal | 12.0±0.7 % Hemolysis at 500 μg/ml | Human | Hybrid Peptide Of Ll-37 And Hst-5 | α-Helical | NA | ||
| 29859288 | 2018 | ALGDFFRKSKEKIGKEFKRIVQRIKDFLRNLAKRHHGYKRKFHLEY | AL32-P113 a | Free | Free | Linear | L | None | 46 | Antibacterial, Antifungal | 10.4±2.2 % Hemolysis at 500 μg/ml | Human | Recombinant Hybrid Peptide Of Ll-37 And Hst-5 | α-Helical | NA | ||
| 30070835 | 2018 | LKWLKKL{nt:Amid}{ct:Amid} | P4 | Amidation | Amidation | Linear | L | None | 7 | Antimicrobial, Antifungal | < 10 % Hemolysis at 200 μM | Human | Salt Tolerant De Novo Designed Leucine-Lysine Based Peptides | water = Random coil | Low hemolytic | ||
| 30070835 | 2018 | LRWLRRL{nt:Amid}{ct:Amid} | P5 | Amidation | Amidation | Linear | L | None | 7 | Antimicrobial, Antifungal | < 10 % Hemolysis at 200 μM | Human | Salt Tolerant De Novo Designed Leucine-Lysine Based Peptides | water = Random coil | Low hemolytic | ||
| 30070835 | 2018 | LKWLKKL{nt:Amid}{ct:Amid} | P4 | Amidation | Amidation | Linear | L | None | 7 | Antimicrobial, Antifungal | >2 % Hemolysis at 1 μM | Human | Salt Tolerant De Novo Designed Leucine-Lysine Based Peptides | water = Random coil | Non-hemolytic | ||
| 30070835 | 2018 | LRWLRRL{nt:Amid}{ct:Amid} | P5 | Amidation | Amidation | Linear | L | None | 7 | Antimicrobial, Antifungal | >2 % Hemolysis at 1 μM | Human | Salt Tolerant De Novo Designed Leucine-Lysine Based Peptides | water = Random coil | Non-hemolytic | ||
| 30095906 | 2018 | GFAWNVCVYRNGVRVCHRRAN | 2 | Free | Free | Linear | L | None | 21 | Antibacterial | 2.06 % Hemolysis at 100 μM | Human | Cathepsin-Cleavable Linker | NA | Non-hemolytic | ||
| 30216370 | 2018 | ILKPGGGTSGGLLGGLLGKVTSVIPGLNNI | α4 | Free | Free | Linear | L | None | 30 | Antibiofilm | 0 % Hemolysis at 100 μM | Human | Human Splunc1 (Short Palate Lung And Nasal Epithelial Clone 1) | Helical amphipathic structure | Non-hemolytic | ||
| 30216370 | 2018 | ILKKWWGTSGGLLGGLLGKVTSVIKGLNNI | α4M1 | Free | Free | Linear | L | None | 30 | Antibiofilm | 0 % Hemolysis at 100 μM | Human | Human Splunc1 (Short Palate Lung And Nasal Epithelial Clone 1) | Helical amphipathic structure | Non-hemolytic | ||
| 30216370 | 2018 | RRWVRRVRRVWRRVVRVVRRWVRR | WLBU2 | Free | Free | Linear | L | None | 24 | Antibacterial | 20 % Hemolysis at 100 μM | Human | Human Splunc1 (Short Palate Lung And Nasal Epithelial Clone 1) | Helical amphipathic structure | NA | ||
| 30262770 | 2018 | KWRRWQWRRWK{ct:Amid} | KW-WK | Amidation | Free | Linear | L | None | 11 | Antibacterial | 5 % Hemolysis at >256 μM | Human | Derived From Lfcinb18–28 | 10 mM PBS = unordered conformations, 50% TFE = α-Helix (negative bands at 208 nm, 222 nm), 30 mM SDS = α-Helix | Non-hemolytic | ||
| 30262770 | 2018 | FPRRWQWRRPF{ct:Amid} | FP-PF | Amidation | Free | Linear | L | None | 11 | Antibacterial | 5 % Hemolysis at >256 μM | Human | Derived From Lfcinb18–28 | 10 mM PBS = unordered conformations, 50% TFE = Disordered structure, 30 mM SDS = Disordered structure | Non-hemolytic | ||
| 30262770 | 2018 | FWRRWQWRRRWF{ct:Amid} | FW-WF | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at 8 μM | Human | Derived From Lfcinb18–28 | 10 mM PBS = unordered conformations, 50% TFE = α-Helix (negative bands at 208 nm, 222 nm), 30 mM SDS = α-Helix | NA | ||
| 30262770 | 2018 | FWRRWQWRRRWF{ct:Amid} | FW-WF | Amidation | Free | Linear | L | None | 12 | Antibacterial | 52.91 % Hemolysis at 128 μM | Human | Derived From Lfcinb18–28 | 10 mM PBS = unordered conformations, 50% TFE = α-Helix (negative bands at 208 nm, 222 nm), 30 mM SDS = α-Helix | NA | ||
| 30262770 | 2018 | KKRRWQWRRKK{ct:Amid} | KK-KK | Amidation | Free | Linear | L | None | 11 | Antibacterial | 5 % Hemolysis at >256 μM | Human | Derived From Lfcinb18–28 | 10 mM PBS = unordered conformations, 50% TFE = α-Helix (negative bands at 208 nm, 222 nm), 30 mM SDS = Disordered structure | Non-hemolytic | ||
| 30262770 | 2018 | KCRRWQWRMKK{ct:Amid} | LFcinB18–28 | Amidation | Free | Linear | L | None | 11 | Antibacterial | 5 % Hemolysis at >256 μM | Human | Truncated Peptide Of Lfcinb | 10 mM PBS = unordered conformations, 50% TFE = β-Sheet (positive peak 195-198 nm, negative peak 217-218 nm), 30 mM SDS = Disordered structure | Non-hemolytic | ||
| 29626331 | 2018 | AILRKATRRLVKLIV{ct:Amid} | P3-B | Amidation | Free | Linear | L | None | 15 | Antibacterial | 4.4 % Hemolysis at 50 μM | Human | Synthetic Amps | α-Helix | Low hemolytic | ||
| 29626331 | 2018 | AIWRKATRRLVKLIV{ct:Amid} | P3-C | Amidation | Free | Linear | L | None | 15 | Antibacterial | 68.7 % Hemolysis at 50 μM | Human | Synthetic Amps | α-Helix Loop | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}KK{cyc:N-C} | 5a | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at >500 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}GK{cyc:N-C} | 5b | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at >500 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}AK{cyc:N-C} | 5c | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at >500 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:cf}FK{cyc:N-C} | 5d | Free | Free | Cyclic | Mix | β = lipophilic β2,2‐amino acid, cf = 4-CF3 (β-phenylalanine derivative has a trifluoromethyl CF3 ) | 4 | Antibacterial | 50 % Hemolysis at 88 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}KK{cyc:N-C} | 6a | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 216 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}GK{cyc:N-C} | 6b | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 100 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}AK{cyc:N-C} | 6c | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 67 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30112781 | 2018 | K{nnr:β}{nnr:dicf}FK{cyc:N-C} | 6d | Free | Free | Cyclic | Mix | β = β^(2,2), dicf = 3,5diCF3(β-phenylalanine derivative has trifluoromethyl CF3 groups) | 4 | Antibacterial | 50 % Hemolysis at 84 μg/mL | Human | Synthetic Cyclic Amps | NA | NA | ||
| 30215282 | 2018 | GIRCPKSWKCKAFKQRVLKRLLAMLRQHAF | Oxt 4a | Free | Free | Linear | L | None | 30 | Antibacterial | 50 % Hemolysis at 7 μM | Human | Lynx Spider Peptide | aqueous = Disordered, SDS= α-Helical | NA | ||
| 30215282 | 2018 | KAFKQRVLKRKKAMKRQKAF | P1 | Free | Free | Linear | L | None | 20 | Antibacterial | 0 % Hemolysis at 100 μM | Human | Mutation Oxki4A(11-30)4K | aqueous = Random coil, SDS= α-Helical | Non-hemolytic | ||
| 30215282 | 2018 | GIRAPKSWKAKAFKQRVLKR | P2 | Free | Free | Linear | L | None | 20 | Antibacterial | 0 % Hemolysis at 100 μM | Human | Mutation Oxt 4A(1-20)(C→A) | aqueous = Random coil, SDS= α-Helical | Non-hemolytic | ||
| 30215282 | 2018 | KSWKAKAFKQRVLKRLLAML | P3 | Free | Free | Linear | L | None | 20 | Antibacterial | 40 % Hemolysis at 100 μM | Human | Mutation Oxt 4A(6-25) (C→A) | aqueous = Random coil, SDS= α-Helical | NA | ||
| 30215282 | 2018 | FAHQRLMALLRKLVRQKFAK | P4 | Free | Free | Linear | L | None | 20 | Antibacterial | 40 % Hemolysis at 100 μM | Human | Mutation Oxt 4A(10-30)Inversion | aqueous = Random coil, SDS= α-Helical | NA | ||
| 30215282 | 2018 | SMWSGMWRKRLKAMLRQHAF | P5 | Free | Free | Linear | L | None | 20 | Antibacterial | >5 % Hemolysis at 100 μM | Human | Mutation Ltc1(1-8)Oxt 4A(19-30)(L22→K) | aqueous = Random coil, SDS= α-Helical | Low hemolytic | ||
| 30279591 | 2018 | GFKLKGMARISCLPNGQWSNFPPKCIRECAMVSS | Sushi 1 Wild Type | Free | Free | Linear | L | None | 34 | Antibacterial | 100 % Hemolysis at 50 μM | Human | Horseshoe Crabs | aqueous = Random coil + Extended Strand, PBS = Random coil | NA | ||
| 30279591 | 2018 | GFGLGGLARILCLGNRQWSNFFKKLNRKCAMVKK | SRP-1 | Free | Free | Linear | L | None | 34 | Antibacterial | 0 % Hemolysis at 50 μM | Human | Designed From Horseshoe Crab Peptide | aqueous = α-Helix | Non-hemolytic | ||
| 30279591 | 2018 | GFALAGLARILCLWFREFSGFFRRLNRRFAMRRR | SRP-2 | Free | Free | Linear | L | None | 34 | Antibacterial | 0 % Hemolysis at 50 μM | Human | Designed From Horseshoe Crab Peptide | aqueous = α-Helix, 50% TFE = α-Helix | Non-hemolytic | ||
| 30279591 | 2018 | GAALAGLAKILCLWAKEFTGAFKKLNKKFAMKKK | SRP-3 | Free | Free | Linear | L | None | 34 | Antibacterial | 100 % Hemolysis at 50 μM | Human | Designed From Horseshoe Crab Peptide | aqueous = α-Helix | NA | ||
| 30283025 | 2018 | KKKKKKAAFAAWAAFAA{ct:Amid} | 6K-F17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm | 0 % Hemolysis at >500 μg/ml | Human | Synthetic Amps | NA | Non-hemolytic | ||
| 30364142 | 2018 | FKLFKKILKVL{nt:Acet}{ct:Amid} | BP21 | Amidation | Acetylation | Linear | L | None | 11 | Antifungal | 4.3 % Hemolysis at 8 µmol L−1 | Human | Giant Silk Moth Hyalophora Cecropia Cecropins | NA | Low hemolytic | ||
| 30240951 | 2018 | GLFAVIKKVASVIKGL{ct:Amid} | A4K14-citropin 1.1 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | >20 % Hemolysis at 10 µM | Human | Australian Freetail Lizards | α-Helix | NA | ||
| 30240951 | 2018 | GKWLSLLKHILK{ct:Amid} | Halictine-2/11 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | >35 % Hemolysis at 10 µM | Human | Derived From Bee Venom | α-Helix | NA | ||
| 30240951 | 2018 | VNWKKILGKIIKVVK{ct:Amid} | Lasioglossin-III | Amidation | Free | Linear | L | None | 15 | Antimicrobial, Anticancer | >35 % Hemolysis at 10 µM | Human | Derived From Bee Venom | α-Helix | NA | ||
| 30240951 | 2018 | GLFAVIKKVASVIKGL{ct:Amid} | A4K14-citropin 1.1 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 100 % Hemolysis at 100 µM | Human | Australian Freetail Lizards | α-Helix | NA | ||
| 30240951 | 2018 | GKWLSLLKHILK{ct:Amid} | Halictine-2/11 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 100 % Hemolysis at 100 µM | Human | Derived From Bee Venom | α-Helix | NA | ||
| 30240951 | 2018 | VNWKKILGKIIKVVK{ct:Amid} | Lasioglossin-III | Amidation | Free | Linear | L | None | 15 | Antimicrobial, Anticancer | 100 % Hemolysis at 100 µM | Human | Derived From Bee Venom | α-Helix | NA | ||
| 30360541 | 2018 | GFWSSVWDGAKNVGTAIIKNAKVCVYAVCVSHK | Nicomicin-1 | Free | Free | Linear | L | None | 33 | Antibacterial | 50 % Hemolysis at 64 µM | Human | Polychaeta Tubeworm Nicomache Minor | aqueous = Disordered, Membrane-Mimicking Environment = α-Helix | NA | ||
| 30360541 | 2018 | GFWSSVWDGAKNVGTAI | Nico(1-17) | Free | Free | Linear | L | None | 17 | Antibacterial | 1 % Hemolysis at 128 µM | Human | Fragment Of Nicomicin-1 | aqueous = α-Helix, Membrane-Mimicking Environment = α-Helix | Non-hemolytic | ||
| 30360541 | 2018 | IKNAKVCVYAVCVSHK | Nico(18-33) | Free | Free | Linear | L | None | 16 | Antibacterial | 50 % Hemolysis at 128 µM | Human | Fragment Of Nicomicin-1 | aqueous = Random coil, Membrane-Mimicking Environment = Disordered | NA | ||
| 30325956 | 2018 | GVWGIAKIAGKVLGNILPHVFSSNQS{nt:H3N = amine}{ct:Carboxyl (COO-)} | DMS-DA6-OH | Carboxyl (COO-) | H3N = amine | Linear | L | None | 26 | Antibacterial | 0.9 ± 1.5 % Hemolysis at 10 µM | Human | Frog Pachymedusa Dacnicolor | phosphate buffer = Random coil, POPG = α-Helix | Non-hemolytic | ||
| 30325956 | 2018 | GVWGIAKIAGKVLGNILPHVFSSNQS{nt:H3N = amine}{ct:Amid} | DMS-DA6-NH2 | Amidation | H3N = amine | Linear | L | None | 26 | Antibacterial | 1.2 ± 1.8 % Hemolysis at 10 µM | Human | Frog Pachymedusa Dacnicolor | phosphate buffer = Random coil, POPG = α-Helix | Non-hemolytic | ||
| 30325956 | 2018 | GVWGIAKIAGKVLGNILPHVFSSNQS{nt:H3N = amine}{ct:Carboxyl (COO-)} | DMS-DA6-OH | Carboxyl (COO-) | H3N = amine | Linear | L | None | 26 | Antibacterial | 7.4 ± 5.5 % Hemolysis at 50 µM | Human | Frog Pachymedusa Dacnicolor | phosphate buffer = Random coil, POPG = α-Helix | NA | ||
| 30325956 | 2018 | GVWGIAKIAGKVLGNILPHVFSSNQS{nt:H3N = amine}{ct:Amid} | DMS-DA6-NH2 | Amidation | H3N = amine | Linear | L | None | 26 | Antibacterial | 3.7 ± 3.3 % Hemolysis at 50 µM | Human | Frog Pachymedusa Dacnicolor | phosphate buffer = Random coil, POPG = α-Helix | Low hemolytic | ||
| 30365554 | 2018 | FLRSLLRGAKAIYRGARAGWRG | dicentracin-like | Free | Free | Linear | L | None | 22 | Antibacterial | 50 % Hemolysis at 2.34 μg/ml | Human | Fish Barramundi (Lates Calcarifer) | α-Helix | NA | ||
| 30365554 | 2018 | FLRSLLRGAKAIYRGARAGWRG | dicentracin-like | Free | Free | Linear | L | None | 22 | Antibacterial | <100 % Hemolysis at 75 μg/ml | Human | Fish Barramundi (Lates Calcarifer) | α-Helix | NA | ||
| 30365554 | 2018 | FFHHIFRGIVHVGKTIHRLVTG | moronecidin | Free | Free | Linear | L | None | 22 | Antibacterial | 50 % Hemolysis at 57 μg/ml | Human | Fish Striped Bass (Morone Saxatilis) | α-Helix | NA | ||
| 30121851 | 2018 | FIFHIIRFFNFRVFRI | FI16 | Free | Free | Linear | L | None | 16 | Antimicrobial | 2 % Hemolysis at 5 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | KIFDAEILLNGKRKGLG | KG17 | Free | Free | Linear | L | None | 17 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | FIKIFHHIFKGNPKFSIIK | FK19 | Free | Free | Linear | L | None | 19 | Antibacterial | 0 % Hemolysis at 5 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | Non-hemolytic | ||
| 30121851 | 2018 | KIRFTRTVSRLLKAALAST | KT19 | Free | Free | Linear | L | None | 19 | Antibacterial | 0 % Hemolysis at 5 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | Non-hemolytic | ||
| 30121851 | 2018 | AKAFKKAFEKLAAVVPFGGT | AT20 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 5 µM | Human | Fish (Sepia Ofcinalis) | ɑ-Helix | Non-hemolytic | ||
| 30121851 | 2018 | GKSNKPALTLIQARILKHKT | GT20 | Free | Free | Linear | L | None | 20 | Antimicrobial | 1 % Hemolysis at 5 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | VILTRFRFLNRIVEPLLKKA | VA20 | Free | Free | Linear | L | None | 20 | Antibacterial | 0 % Hemolysis at 5 µM | Human | Fish (Sepia Ofcinalis) | ɑ-Helix | Non-hemolytic | ||
| 30121851 | 2018 | GSTSFHLIYNKWFAVKRRRKR | GR21 | Free | Free | Linear | L | None | 21 | Antibacterial | 0 % Hemolysis at 5 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | Non-hemolytic | ||
| 30121851 | 2018 | FFHHIFDPQIKSGLLVSMYD | FD20 | Free | Free | Linear | L | None | 20 | Antibacterial | 0 % Hemolysis at 5 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | FIFHIIRFFNFRVFRI | FI16 | Free | Free | Linear | L | None | 16 | Antimicrobial | 5.39 % Hemolysis at 50 µM | Human | Fish (Sepia Ofcinalis) | NA | NA | ||
| 30121851 | 2018 | KIFDAEILLNGKRKGLG | KG17 | Free | Free | Linear | L | None | 17 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | FIKIFHHIFKGNPKFSIIK | FK19 | Free | Free | Linear | L | None | 19 | Antibacterial | 44.03 % Hemolysis at 50 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | NA | ||
| 30121851 | 2018 | KIRFTRTVSRLLKAALAST | KT19 | Free | Free | Linear | L | None | 19 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | Non-hemolytic | ||
| 30121851 | 2018 | AKAFKKAFEKLAAVVPFGGT | AT20 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Fish (Sepia Ofcinalis) | ɑ-Helix | Non-hemolytic | ||
| 30121851 | 2018 | GKSNKPALTLIQARILKHKT | GT20 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 50 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | VILTRFRFLNRIVEPLLKKA | VA20 | Free | Free | Linear | L | None | 20 | Antibacterial | 10.79 % Hemolysis at 50 µM | Human | Fish (Sepia Ofcinalis) | ɑ-Helix | NA | ||
| 30121851 | 2018 | GSTSFHLIYNKWFAVKRRRKR | GR21 | Free | Free | Linear | L | None | 21 | Antibacterial | 3.76 % Hemolysis at 50 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | NA | ||
| 30121851 | 2018 | FFHHIFDPQIKSGLLVSMYD | FD20 | Free | Free | Linear | L | None | 20 | Antibacterial | 0 % Hemolysis at 50 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | FIFHIIRFFNFRVFRI | FI16 | Free | Free | Linear | L | None | 16 | Antimicrobial | 9.53 % Hemolysis at 100 µM | Human | Fish (Sepia Ofcinalis) | NA | NA | ||
| 30121851 | 2018 | KIFDAEILLNGKRKGLG | KG17 | Free | Free | Linear | L | None | 17 | Antimicrobial | 1.25 % Hemolysis at 100 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | FIKIFHHIFKGNPKFSIIK | FK19 | Free | Free | Linear | L | None | 19 | Antibacterial | 63.35 % Hemolysis at 100 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | NA | ||
| 30121851 | 2018 | KIRFTRTVSRLLKAALAST | KT19 | Free | Free | Linear | L | None | 19 | Antibacterial | 7.78 % Hemolysis at 100 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | NA | ||
| 30121851 | 2018 | AKAFKKAFEKLAAVVPFGGT | AT20 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Fish (Sepia Ofcinalis) | ɑ-Helix | Non-hemolytic | ||
| 30121851 | 2018 | GKSNKPALTLIQARILKHKT | GT20 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 100 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | VILTRFRFLNRIVEPLLKKA | VA20 | Free | Free | Linear | L | None | 20 | Antibacterial | 25.34 % Hemolysis at 100 µM | Human | Fish (Sepia Ofcinalis) | ɑ-Helix | NA | ||
| 30121851 | 2018 | GSTSFHLIYNKWFAVKRRRKR | GR21 | Free | Free | Linear | L | None | 21 | Antibacterial | 7.15 % Hemolysis at 100 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | NA | ||
| 30121851 | 2018 | FFHHIFDPQIKSGLLVSMYD | FD20 | Free | Free | Linear | L | None | 20 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | FIFHIIRFFNFRVFRI | FI16 | Free | Free | Linear | L | None | 16 | Antimicrobial | 10.79 % Hemolysis at 200 µM | Human | Fish (Sepia Ofcinalis) | NA | NA | ||
| 30121851 | 2018 | KIFDAEILLNGKRKGLG | KG17 | Free | Free | Linear | L | None | 17 | Antimicrobial | 1.13 % Hemolysis at 200 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | FIKIFHHIFKGNPKFSIIK | FK19 | Free | Free | Linear | L | None | 19 | Antibacterial | 66.49 % Hemolysis at 200 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | NA | ||
| 30121851 | 2018 | KIRFTRTVSRLLKAALAST | KT19 | Free | Free | Linear | L | None | 19 | Antibacterial | 21.58 % Hemolysis at 200 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | NA | ||
| 30121851 | 2018 | AKAFKKAFEKLAAVVPFGGT | AT20 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 200 µM | Human | Fish (Sepia Ofcinalis) | ɑ-Helix | Non-hemolytic | ||
| 30121851 | 2018 | GKSNKPALTLIQARILKHKT | GT20 | Free | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 200 µM | Human | Fish (Sepia Ofcinalis) | NA | Non-hemolytic | ||
| 30121851 | 2018 | VILTRFRFLNRIVEPLLKKA | VA20 | Free | Free | Linear | L | None | 20 | Antibacterial | 42 % Hemolysis at 200 µM | Human | Fish (Sepia Ofcinalis) | ɑ-Helix | NA | ||
| 30121851 | 2018 | GSTSFHLIYNKWFAVKRRRKR | GR21 | Free | Free | Linear | L | None | 21 | Antibacterial | 8.5 % Hemolysis at 200 µM | Human | Fish (Sepia Ofcinalis) | 70%TFE = α-Helix | NA | ||
| 30121851 | 2018 | FFHHIFDPQIKSGLLVSMYD | FD20 | Free | Free | Linear | L | None | 20 | Antibacterial | 9.2 % Hemolysis at 200 µM | Human | Fish (Sepia Ofcinalis) | NA | NA | ||
| 30135470 | 2018 | {nnr:R}-{nnr:dab}V{nnr:dab}FL{nnr:dab}VLS{cyc:N-C} | PGP-E | Free | Free | Cyclic | Mix | Dab = Diaminobutyric acid, R = CH2CH2CH3(propyl group) | 9 | Antimicrobial | <50 % Hemolysis at 200 µM | Human | Bacteria Paenibacillus Elgii Bc34-6 | NA | NA | ||
| 30325566 | 2018 | TELLVDLL{nt:Amid}{ct:Amid} | SP1 | Amidation | Amidation | Linear | L | None | 8 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | SELLVDLL{nt:Amid}{ct:Amid} | SP2 | Amidation | Amidation | Linear | L | None | 8 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | EELLVDLL{nt:Amid}{ct:Amid} | SP3 | Amidation | Amidation | Linear | L | None | 8 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | TCELLVDLLC{nt:Amid}{ct:Amid} | SP4 | Amidation | Amidation | Linear | L | None | 8 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | DDDELLVDLL{nt:CH3-(CH2)16-(CO)-NH = fatty acid chain}{ct:Amid} | LP5 | Amidation | CH3-(CH2)16-(CO)-NH = fatty acid chain | Linear | L | CH3-(CH2)16-(CO)-NH = N-Terminal fatty acid chain | 10 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Lipopeptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | HHHELLVDLL{nt:CH3-(CH2)16-(CO)-NH = fatty acid chain}{ct:Amid} | LP6 | Amidation | CH3-(CH2)16-(CO)-NH = fatty acid chain | Linear | L | CH3-(CH2)16-(CO)-NH = N-Terminal fatty acid chain | 10 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Lipopeptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | RRRELLVDLL{nt:CH3-(CH2)16-(CO)-NH = fatty acid chain}{ct:Amid} | LP7 | Amidation | CH3-(CH2)16-(CO)-NH = fatty acid chain | Linear | L | CH3-(CH2)16-(CO)-NH = N-Terminal fatty acid chain | 10 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Lipopeptide | NA | Non-hemolytic | ||
| 30325566 | 2018 | YYYELLVDLL{nt:CH3-(CH2)16-(CO)-NH = fatty acid chain}{ct:Amid} | LP8 | Amidation | CH3-(CH2)16-(CO)-NH = fatty acid chain | Linear | L | CH3-(CH2)16-(CO)-NH = N-Terminal fatty acid chain | 10 | Antibacterial | high % Hemolysis at 100 µM | Human | Synthetic Lipopeptide | NA | NA | ||
| 30325566 | 2018 | ELL{d}VDL{d}L{cyc:N-C}{nt:Amid} | surfactin | Free | Amidation | Cyclic | Mix | l = D-Leucine | 7 | Antimicrobial | high % Hemolysis at 100 µM | Human | Bacteria Bacillus Subtilis | NA | NA | ||
| 30361948 | 2018 | K{nnr:*}WK{nnr:Nle}{nnr:*}K{ct:Amid} | KKK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 3 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WK{nnr:Nle}{nnr:*}K{ct:Amid} | RKK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 4.3 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | K{nnr:*}WR{nnr:Nle}{nnr:*}K{ct:Amid} | KRK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 2 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | K{nnr:*}WK{nnr:Nle}{nnr:*}R{ct:Amid} | KKR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 5.4 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | R{nnr:*}WR{nnr:Nle}{nnr:*}K{ct:Amid} | RRK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | <1 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Non-hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WK{nnr:Nle}{nnr:*}R{ct:Amid} | RKR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 17 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | K{nnr:*}WR{nnr:Nle}{nnr:*}R{ct:Amid} | KRR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 5.6 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | R{nnr:*}WR{nnr:Nle}{nnr:*}R{ct:Amid} | RRR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 3.2 % Hemolysis at 50 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | K{nnr:*}WK{nnr:Nle}{nnr:*}K{ct:Amid} | KKK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 1.5 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WK{nnr:Nle}{nnr:*}K{ct:Amid} | RKK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 1.5 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | K{nnr:*}WR{nnr:Nle}{nnr:*}K{ct:Amid} | KRK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | < 1 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Non-hemolytic | ||
| 30361948 | 2018 | K{nnr:*}WK{nnr:Nle}{nnr:*}R{ct:Amid} | KKR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 1.4 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WR{nnr:Nle}{nnr:*}K{ct:Amid} | RRK | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | < 1 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Non-hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WK{nnr:Nle}{nnr:*}R{ct:Amid} | RKR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 8.2 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | NA | ||
| 30361948 | 2018 | K{nnr:*}WR{nnr:Nle}{nnr:*}R{ct:Amid} | KRR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | 1.8 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Low hemolytic | ||
| 30361948 | 2018 | R{nnr:*}WR{nnr:Nle}{nnr:*}R{ct:Amid} | RRR | Amidation | Free | Linear | Mix | Nle = Norleucine, oct4-enyl = hydrocarbon staple, * = shows the staple site | 7 | Antibacterial | < 1 % Hemolysis at 25 µM | Human | Synthetic Stapled Heptapeptides | ɑ-Helix | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 6.3 % Hemolysis at 32 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 36.1 % Hemolysis at 64 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 82.8 % Hemolysis at 128 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 96.4 % Hemolysis at 256 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-4R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 100 % Hemolysis at 512 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 3.6 % Hemolysis at 128 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 18.6 % Hemolysis at 256 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C14 - myristic acid}{ct:Amid} | C14-4R | Amidation | C14 - myristic acid | Linear | L | C14 = myristic acid | 4 | Antifungal, Antibacterial | 63.7 % Hemolysis at 512 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 128 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 256 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | RRRR{nt:C12 - lauric acid}{ct:Amid} | C12-4R | Amidation | C12 - lauric acid | Linear | L | C12 = lauric acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 512 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 0 % Hemolysis at 14 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | Non-hemolytic | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 12.6 % Hemolysis at 30 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 57.6 % Hemolysis at 60 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 91 % Hemolysis at 128 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 97.1 % Hemolysis at 256 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30409520 | 2018 | PRRR{nt:C16 - palmitic acid}{ct:Amid} | C16-P3R | Amidation | C16 - palmitic acid | Linear | L | C16 = palmitic acid | 4 | Antifungal, Antibacterial | 100 % Hemolysis at 512 μg/mL | Human | Synthetic Arginine-Rich Lipopeptides | NA | NA | ||
| 30423858 | 2018 | DEMKLDGFNMHLE{ct:Amid} | P1-Ll-1577 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 12 % Hemolysis at 320 µM | Human | Frog Leptodactylus Latrans | Random coil | NA | ||
| 30423858 | 2018 | AAGKGLVSNLLEK{ct:Amid} | P2-Ll-1298 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 100 % Hemolysis at 320 µM | Human | Frog Leptodactylus Latrans | TFE = ɑ-Helix | NA | ||
| 30423858 | 2018 | GLLDFLKAAGKGLVSNLLEK{ct:Amid} | P3-Ll-2085 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 100 % Hemolysis at 40 µM | Human | Frog Leptodactylus Latrans | TFE = ɑ-Helix | NA | ||
| 30462698 | 2018 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK | PACAP38 | Free | Free | Linear | L | None | 38 | Antibacterial | 0 % Hemolysis at 45 μg/mL | Human | Human | α-Helix | Non-hemolytic | ||
| 30462698 | 2018 | SYSRYRKQMAVKKYLAAVLGKRYKQRVKNK | PACAP(9–38) | Free | Free | Linear | L | None | 30 | Antibacterial | 0 % Hemolysis at 45 μg/mL | Human | Human | α-Helix | Non-hemolytic | ||
| 30387611 | 2018 | GLPICGETCVFGKCNTPGCSCRRPICYKN{cyc:N-C} | Rivi1 | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≫10 µM | Human | Plant Rinorea Virgata | Loop | NA | ||
| 30387611 | 2018 | GSYLCGETCVQGKCYTPGCTCSWPICKKN{cyc:N-C} | Rivi2 | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≫10 µM | Human | Plant Rinorea Virgata | Loop | NA | ||
| 30387611 | 2018 | GLPICGETCLLGKCYTPGCSCRRPVCYKN{cyc:N-C} | Rivi3 | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≫10 µM | Human | Plant Rinorea Virgata | Loop | NA | ||
| 30538681 | 2018 | IHKFWRCRRRFCRWFKHI{ct:Amid} | PQ | Amidation | Free | Linear | L | None | 18 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Designs Amps | 10 mM PBS = unordered, 30 mM SDS and 50% TFE = α-Helix | Low hemolytic | ||
| 30538681 | 2018 | IHKFWRPGRWFKHI{ct:Amid} | PP | Amidation | Free | Linear | L | None | 14 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Designs Amps | 10 mM PBS = unordered, 30 mM SDS and 50% TFE = α-Helix | Low hemolytic | ||
| 30538681 | 2018 | IHKFWRGGRWFKHI{ct:Amid} | GG | Amidation | Free | Linear | L | None | 14 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Designs Amps | 10 mM PBS = unordered, 30 mM SDS and 50% TFE = α-Helix | Low hemolytic | ||
| 30538681 | 2018 | IHKFWRRWFKHI{ct:Amid} | Qa | Amidation | Free | Linear | L | None | 12 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Designs Amps | α-Helix | Low hemolytic | ||
| 30538681 | 2018 | IHFKWRRWKFHI{ct:Amid} | Qna | Amidation | Free | Linear | L | None | 12 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Designs Amps | unordered | Low hemolytic | ||
| 30538681 | 2018 | RGGRLCYCRRRFCVCVGR{ct:Amid} | PG-1 | Amidation | Free | Linear | L | None | 18 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Designs Amps | β-Hairpin | Low hemolytic | ||
| 30555984 | 2018 | YYHFWHRGVTKR | YR12 | Free | Free | Linear | L | None | 12 | Antibacterial | ~5 % Hemolysis at 100 µM | Human | Human Prodomain Of Human Furin | NA | Low hemolytic | ||
| 30555984 | 2018 | YYHFWHRGVTKRSLSPHRPR | YR20 | Free | Free | Linear | L | None | 20 | Antibacterial | ~5 % Hemolysis at 100 µM | Human | Human Prodomain Of Human Furin | NA | Low hemolytic | ||
| 30555984 | 2018 | YYHFWHRGVTKRSLSPHRPRHSR | YR23 | Free | Free | Linear | L | None | 23 | Antibacterial | ~5 % Hemolysis at 100 µM | Human | Human Prodomain Of Human Furin | NA | Low hemolytic | ||
| 30555984 | 2018 | YYHFWHRGVTKRSLSPHRPRHSRLQR | YR26 | Free | Free | Linear | L | None | 26 | Antibacterial | ~8 % Hemolysis at 100 µM | Human | Human Prodomain Of Human Furin | SDS micelle = Helix-Turn-Helix | NA | ||
| 30555984 | 2018 | RKHGFLNLQGIFGDYYHFWHRGV | RV23 | Free | Free | Linear | L | None | 23 | Antibacterial | 48 % Hemolysis at 100 µM | Human | Human Prodomain Of Human Furin | NA | NA | ||
| 30039186 | 2018 | FFRNLWKGAKAAFRAGHAAWRA | Moronecidin-like | Free | Free | Linear | L | None | 22 | Antimicrobial, Anti-bioflim | 50 % Hemolysis at 87.5 μg/mL | Human | Fish Seahorse Hippocampus Comes | α-Helix | NA | ||
| 30039186 | 2018 | FFHHIFRGIVHVGKTIHRLVTG | Moronecidin | Free | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at 2.34 μg/mL | Human | Fish Hybrid Striped Bass | α-Helix | Low hemolytic | ||
| 30208331 | 2018 | MKKKIISAILMSTVILSAAAPLSGVYALDISSTCDADLIWKLLVKAQEKFGRGKPSKRVKKMRRQWQACKSSHHHHHH{ct:His-tag} | cLFchimera | His-tag | Free | Linear | L | None | 78 | Antimicrobial | 2.5 % Hemolysis at 250 μg/mL | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 30570384 | 2018 | RKYVRFLHRWVKYFRAYL | Adevonin | Free | Free | Linear | L | None | 18 | Antibacterial | 0 % Hemolysis at 87.5 µM | Human | Plant Adenanthera Pavonina Designed From Apti | SDS = α-Helix | Non-hemolytic | ||
| 30570384 | 2018 | RKYVRFLHRWVKYFRAYL | Adevonin | Free | Free | Linear | L | None | 18 | Antibacterial | >70 % Hemolysis at 175 µM | Human | Plant Adenanthera Pavonina Designed From Apti | SDS = α-Helix | NA | ||
| 30563217 | 2018 | VGTDFSGNDDISDVQK | Lg-AMP1 | Free | Free | Linear | L | None | 16 | Antibacterial | 0.1 % Hemolysis at 68.5 µM | Human | Spider Venom (Loxosceles Gaucho) | α-Helix | Non-hemolytic | ||
| 30563217 | 2018 | VGTDFSGNDDISDVQK | Lg-AMP1 | Free | Free | Linear | L | None | 16 | Antibacterial | 0.15 % Hemolysis at 137 µM | Human | Spider Venom (Loxosceles Gaucho) | α-Helix | Non-hemolytic | ||
| 35559296 | 2018 | WFGHLYRGITKVVKHVHGLLKG | KS-Cnd | Free | Free | Linear | L | None | 22 | Antibacterial | 10 % Hemolysis at 8 µM | Human | Fish Derived From Chionodracine(Chionodraco Hamatus) | aqueous = Random coil, POPC = α-Helix | NA | ||
| 35559296 | 2018 | WFGKLYRGITSVVKKVKGLLSG | KH-Cnd | Free | Free | Linear | L | None | 22 | Antibacterial | 10 % Hemolysis at 9 µM | Human | Fish Derived From Chionodracine(Chionodraco Hamatus) | aqueous = Random coil, POPC = α-Helix | NA | ||
| 35559296 | 2018 | WFGKLYRGITKVVKKVKGLLKG | KHS_Cnd | Free | Free | Linear | L | None | 22 | Antibacterial | 10 % Hemolysis at 13 µM | Human | Fish Derived From Chionodracine(Chionodraco Hamatus) | aqueous = Random coil, POPC = α-Helix | NA | ||
| 30622471 | 2018 | GRFKRFRKKLKRLWHKVGPFVGPILHY | ChMAP-28 | Free | Free | Linear | L | None | 27 | Anticancer | <10 % Hemolysis at 10 µM | Human | Capra Hircus Goat Leukocytes | α-Helix | NA | ||
| 30622471 | 2018 | GRFKRFRKKLKRLWHKVGPFVGPILHY | ChMAP-28 | Free | Free | Linear | L | None | 27 | Anticancer | 50 % Hemolysis at ~100 µM | Human | Capra Hircus Goat Leukocytes | α-Helix | NA | ||
| 29959905 | 2019 | KRFIKWYNAWNEKRRVY{ct:Amid} | CXCL14-C17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm, Anti-inflammatory | <10 % Hemolysis at 1024 µM | Human | Human Chemokine Cxcl14 | α-Helix | NA | ||
| 29959905 | 2019 | KRFIKWYKAWNKKRRVY{ct:Amid} | CXCL14-C17-a1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm, Anti-inflammatory | <10 % Hemolysis at 1024 µM | Human | Analog Of Cxcl14-C17 With Substitutions | α-Helix | NA | ||
| 29959905 | 2019 | KRFIKWYKAWNKKWRKY{ct:Amid} | CXCL14-C17-a2 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm, Anti-inflammatory | 10 % Hemolysis at 480 µM | Human | Analog Of Cxcl14-C17 With Substitutions | α-Helix | NA | ||
| 29959905 | 2019 | KRFKKWYKAWRKKWRKY{ct:Amid} | CXCL14-C17-a3 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm, Anti-inflammatory | 10 % Hemolysis at 700 µM | Human | Analog Of Cxcl14-C17 With Substitutions | α-Helix | NA | ||
| 29959905 | 2019 | KRFIKWYNAWNEKRRVY{ct:Amid} | CXCL14-C17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm, Anti-inflammatory | <5 % Hemolysis at 256 µM | Human | Human Chemokine Cxcl14 | α-Helix | Non-hemolytic | ||
| 29959905 | 2019 | KRFIKWYKAWNKKRRVY{ct:Amid} | CXCL14-C17-a1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm, Anti-inflammatory | <5 % Hemolysis at 256 µM | Human | Analog Of Cxcl14-C17 With Substitutions | α-Helix | Non-hemolytic | ||
| 29959905 | 2019 | KRFIKWYKAWNKKWRKY{ct:Amid} | CXCL14-C17-a2 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm, Anti-inflammatory | <5 % Hemolysis at 256 µM | Human | Analog Of Cxcl14-C17 With Substitutions | α-Helix | Non-hemolytic | ||
| 29959905 | 2019 | KRFKKWYKAWRKKWRKY{ct:Amid} | CXCL14-C17-a3 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm, Anti-inflammatory | <5 % Hemolysis at 256 µM | Human | Analog Of Cxcl14-C17 With Substitutions | α-Helix | Non-hemolytic | ||
| 30120878 | 2019 | TSVRQRWRWRQRVRTS{ct:Amid} | P38 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 50 μg/ml | Human | Derived From Human Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 30120878 | 2019 | KRSKRKRRIHQRVRIS{ct:Amid} | P22 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 50 μg/ml | Human | Derived From Human Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 30120878 | 2019 | TLSKEKERIVQRVRTS{ct:Amid} | P7 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 50 μg/ml | Human | Derived From Human Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 30176540 | 2019 | AKRHHGYKRKFH{nt:Acet}{ct:Amid} | P-113 | Amidation | Acetylation | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μg/ml | Human | Human Fragment Of The Saliva Protein Histatin 5 | NA | Non-hemolytic | ||
| 30176540 | 2019 | AKRFFGYKRKFF{nt:Acet}{ct:Amid} | Phe-P-113 | Amidation | Acetylation | Linear | L | None | 12 | Antimicrobial, Anti-inflammatory | 0 % Hemolysis at 25 μg/ml | Human | Analoge Of P-113 | NA | Non-hemolytic | ||
| 30176540 | 2019 | AKR{nnr:nal}{nnr:nal}GYKRKF{nnr:nal}{nt:Acet}{ct:Amid} | Nal-P-113 | Amidation | Acetylation | Linear | L | Nal = β-naphthylalanine | 12 | Antimicrobial, Anti-inflammatory | 0 % Hemolysis at 25 μg/ml | Human | Analoge Of P-113 | NA | Non-hemolytic | ||
| 30176540 | 2019 | AKR{nnr:bip}{nnr:bip}GYKRKF{nnr:bip}{nt:Acet}{ct:Amid} | Bip-P-113 | Amidation | Acetylation | Linear | L | Bip = β-(4,4’-biphenyl)alanine | 12 | Antimicrobial, Anti-inflammatory | 4 % Hemolysis at 25 μg/ml | Human | Analoge Of P-113 | NA | NA | ||
| 30176540 | 2019 | AKR{nnr:dip}{nnr:dip}GYKRKF{nnr:dip}{nt:Acet}{ct:Amid} | Dip-P-113 | Amidation | Acetylation | Linear | L | Dip = β-diphenylalanine | 12 | Antimicrobial, Anti-inflammatory,salt resistance, serum proteolytic stability, peptide-induced permeabilization | 0 % Hemolysis at 25 μg/ml | Human | Analoge Of P-113 | NA | Non-hemolytic | ||
| 30393205 | 2019 | LLWIALRKK{ct:Amid} | CopW | Amidation | Free | Linear | L | None | 9 | Antibacterial | 0.08 ± 0.04 % Hemolysis at 100 µM | Human | Derived From Coprisin Dung Beetle Copris Tripartitus | NA | Non-hemolytic | ||
| 30393205 | 2019 | LLWIALRKK{conj:C10:0}{ct:Amid} | CopW3 | Amidation | Free | Linear | L | C10 = decanoic acid | 9 | Antibacterial | 11.84 ± 0.46 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{ct:Amid} | dCopW | Amidation | Free | Linear | D | None | 9 | Antibacterial | 2.32 ± 0.78 % Hemolysis at 100 µM | Human | Synthetic Copw With D-Amino | NA | Non-hemolytic | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C6:0}{ct:Amid} | dCopW1 | Amidation | Free | Linear | D | C6 = hexanoic acid | 9 | Antibacterial | 0.39 ± 0.66 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | Non-hemolytic | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C8:0}{ct:Amid} | dCopW2 | Amidation | Free | Linear | D | C8 = Octanoic Acid | 9 | Antibacterial | 0.68 ± 0.47 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | Non-hemolytic | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C10:0}{ct:Amid} | dCopW3 | Amidation | Free | Linear | D | C10 = decanoic acid | 9 | Antibacterial | 3.66 ± 0.39 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | Non-hemolytic | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C12:0}{ct:Amid} | dCopW4 | Amidation | Free | Linear | D | C12 = Dodecanoic Acid | 9 | Antibacterial | 7.10 ± 0.32 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C14:0}{ct:Amid} | dCopW5 | Amidation | Free | Linear | D | C14 = Tetradecanoic Acid | 9 | Antibacterial | 8.36 ± 0.26 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 30393205 | 2019 | L{d}L{d}W{d}I{d}A{d}L{d}R{d}K{d}K{d}{conj:C16:0}{ct:Amid} | dCopW6 | Amidation | Free | Linear | D | C16 = hexadecanoic acid | 9 | Antibacterial | 11.67 ± 0.55 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 30393205 | 2019 | K{d}{conj:C10:0}K{d}R{d}L{d}A{d}I{d}W{d}L{d}L{d}{ct:Amid} | Retro-dCopW3 | Amidation | Free | Linear | D | C10 = decanoic acid | 9 | Antibacterial | 20.88 ± 1.15 % Hemolysis at 100 µM | Human | Synthetic Copw With Fatty Acid-Conjugated | NA | NA | ||
| 34377965 | 2019 | K{d}L{d}LS{d}L{d}L{d}LT{d}L{d}S{d}LA{d}K{d}A{d}A{d}K{d}L{d}LT{d}L{d}L{d}LA{d}L{d}S{d}L{nt:Acet}{ct:Amid} | D84 (Lys1-6 Lys-1) | Amidation | Acetylation | Linear | Mix | None | 26 | Antibacterial | 50 % Hemolysis at 54.3 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 34377965 | 2019 | K{d}L{d}{nnr:Dab}S{d}L{d}L{d}{nnr:Dab}T{d}L{d}S{d}{nnr:Dab}A{d}K{d}A{d}A{d}K{d}L{d}{nnr:Dab}T{d}L{d}L{d}{nnr:Dab}A{d}L{d}S{d}{nnr:Dab}{nt:Acet}{ct:Amid} | D86 (Lys1-6 Dab-1) | Amidation | Acetylation | Linear | Mix | L-Dab = (2,4-diaminobutyric acid) | 26 | Antibacterial | 50 % Hemolysis at >742 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 34377965 | 2019 | K{d}L{d}{nnr:Dap}S{d}L{d}L{d}{nnr:Dap}T{d}L{d}S{d}{nnr:Dap}A{d}K{d}A{d}A{d}K{d}L{d}{nnr:Dap}T{d}L{d}L{d}{nnr:Dap}A{d}L{d}S{d}{nnr:Dap}{nt:Acet}{ct:Amid} | D105 (Lys1-6 Dap-1) | Amidation | Acetylation | Linear | Mix | L-Dap = (2,3-diaminopropionic acid) | 26 | Antibacterial | 50 % Hemolysis at >1148 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 34377965 | 2019 | K{d}L{d}LS{d}L{d}L{d}LT{d}L{d}S{d}LA{d}K{d}A{d}A{d}K{d}L{d}LT{d}L{d}L{d}LA{d}L{d}S{d}S{nt:Acet}{ct:Amid} | D101 (Lys1Ser26-5 Lys-1) | Amidation | Acetylation | Linear | Mix | None | 26 | Antibacterial | 50 % Hemolysis at 103.9 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 34377965 | 2019 | K{d}L{d}{nnr:Dab}S{d}L{d}L{d}{nnr:Dab}T{d}L{d}S{d}{nnr:Dab}A{d}K{d}A{d}A{d}K{d}L{d}{nnr:Dab}T{d}L{d}L{d}{nnr:Dab}A{d}L{d}S{d}S{nt:Acet}{ct:Amid} | D102 (Lys1Ser26-5 Dab-1) | Amidation | Acetylation | Linear | Mix | L-Dab = (2,4-diaminobutyric acid) | 26 | Antibacterial | 50 % Hemolysis at >708 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 34377965 | 2019 | K{d}L{d}LS{d}L{d}L{d}LT{d}L{d}S{d}A{d}A{d}K{d}LLK{d}L{d}A{d}T{d}L{d}L{d}LA{d}L{d}S{d}L{nt:Acet}{ct:Amid} | D88 (Lys1-6 Lys-2) | Amidation | Acetylation | Linear | Mix | None | 26 | Antibacterial | 50 % Hemolysis at 80.6 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 34377965 | 2019 | AKR{nnr:bip}{nnr:bip}GYKRKF{nnr:bip}{nt:Acet}{ct:Amid} | D89 (Lys1-6 Dab-2) | Amidation | Acetylation | Linear | Mix | L-Dab = (2,4-diaminobutyric acid) | 26 | Antibacterial | 50 % Hemolysis at >1112 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 34377965 | 2019 | K{d}L{d}{nnr:Dap}S{d}L{d}L{d}{nnr:Dap}T{d}L{d}S{d}A{d}A{d}K{d}{nnr:Dap}{nnr:Dap}K{d}L{d}A{d}T{d}L{d}L{d}{nnr:Dap}A{d}L{d}S{d}{nnr:Dap}{nt:Acet}{ct:Amid} | D106 (Lys1-6 Dap-2) | Amidation | Acetylation | Linear | Mix | L-Dap = (2,3-diaminopropionic acid) | 26 | Antibacterial | 50 % Hemolysis at 340.2 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 34377965 | 2019 | K{d}L{d}LS{d}L{d}L{d}LT{d}L{d}S{d}A{d}A{d}K{d}LLK{d}L{d}A{d}T{d}L{d}L{d}LA{d}L{d}S{d}S{nt:Acet}{ct:Amid} | D103 (Lys1Ser26-5 Lys-2) | Amidation | Acetylation | Linear | Mix | None | 26 | Antibacterial | 50 % Hemolysis at 134.9 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 34377965 | 2019 | K{d}L{d}{nnr:Dab}S{d}L{d}L{d}{nnr:Dab}T{d}L{d}S{d}A{d}A{d}K{d}{nnr:Dab}{nnr:Dab}K{d}L{d}A{d}T{d}L{d}L{d}{nnr:Dab}A{d}L{d}S{d}S{nt:Acet}{ct:Amid} | D104 (Lys1Ser26-5 Dab-2) | Amidation | Acetylation | Linear | Mix | L-Dab = (2,4-diaminobutyric acid) | 26 | Antibacterial | 50 % Hemolysis at >1490 µM | Human | Synthetic Cationic Antimicrobial Peptides | aqueous = α-Helix, 50%TFE = α-Helix | NA | ||
| 30658410 | 2019 | GILDWGKKVMDWIKDKM{ct:Amid} | PLP1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 50 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | GWGSIFKTVGKMIAKAAVKAAPEAISAMASQNE | PLP2 | Free | Free | Linear | L | None | 33 | Antimicrobial, histamine-releasing activity | 10.4 % Hemolysis at 50 µM | Human | Ant Odontomachus Monticola | α-Helix | NA | ||
| 30658410 | 2019 | KIKWGKIFKKGGKLIGKTALEAAANAAASEAISAMASQNE | PLP3 | Free | Free | Linear | L | None | 40 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 50 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | GVKELFGKAWGLVKKHLPKACGLLGYVKQ | PLP4 | Free | Free | Linear | L | None | 29 | Antimicrobial, histamine-releasing activity | 10.5 % Hemolysis at 50 µM | Human | Ant Odontomachus Monticola | α-Helix | NA | ||
| 30658410 | 2019 | IWGALLGTLIPAITSAIQ{ct:Amid} | PLP5 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 94.8 % Hemolysis at 50 µM | Human | Ant Odontomachus Monticola | α-Helix | NA | ||
| 30658410 | 2019 | IKGKKIMKNMGKAMKIAGKVAKAMAPIVVPLIVSAA{ct:Amid} | PLP6 | Amidation | Free | Linear | L | None | 36 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 50 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | GILDWGKKVMDWIKDKM{ct:Amid} | PLP1 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 10 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | GWGSIFKTVGKMIAKAAVKAAPEAISAMASQNE | PLP2 | Free | Free | Linear | L | None | 33 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 10 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | KIKWGKIFKKGGKLIGKTALEAAANAAASEAISAMASQNE | PLP3 | Free | Free | Linear | L | None | 40 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 10 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | GVKELFGKAWGLVKKHLPKACGLLGYVKQ | PLP4 | Free | Free | Linear | L | None | 29 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 10 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30658410 | 2019 | IWGALLGTLIPAITSAIQ{ct:Amid} | PLP5 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 6.9 % Hemolysis at 10 µM | Human | Ant Odontomachus Monticola | α-Helix | NA | ||
| 30658410 | 2019 | IKGKKIMKNMGKAMKIAGKVAKAMAPIVVPLIVSAA{ct:Amid} | PLP6 | Amidation | Free | Linear | L | None | 36 | Antimicrobial, histamine-releasing activity | 0 % Hemolysis at 10 µM | Human | Ant Odontomachus Monticola | α-Helix | Non-hemolytic | ||
| 30709056 | 2019 | FFSLIPSLVGGLISAFK | Stigmurin | Free | Free | Linear | L | None | 17 | Antimicrobial | 5.8 % Hemolysis at 150 µM | Human | Scorpion Tityus Stigmurus Venom | Water and PBS = Random coil, SDS 20mM = α-Helix, 40% TFE = α-Helix | Low hemolytic | ||
| 30709056 | 2019 | FFSLIPSLVKKLIKAFK | StigA25 | Free | Free | Linear | L | None | 17 | Antimicrobial, Antiparasitic | 18.5 % Hemolysis at 9.4 µM | Human | Analogs Of Stigmurin | Water and PBS = Random coil, SDS 20mM = α-Helix, 60% TFE = α-Helix | NA | ||
| 30709056 | 2019 | FFKLIPKLVKKLIKAFK | StigA31 | Free | Free | Linear | L | None | 17 | Antimicrobial, Antiparasitic | 11.2 % Hemolysis at 9.4 µM | Human | Analogs Of Stigmurin | Water and PBS = Random coil, SDS 20mM = α-Helix, 30% TFE = α-Helix | NA | ||
| 30389515 | 2019 | CPAIQRCC | Mo-CBP3-PepI | Free | Free | Linear | L | None | 8 | Antibacterial, Anticandidal | 0 % Hemolysis at 70 µM | Human | Plant Moringa Oleifera Seeds | 75% α-Helix and 25% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | NIQPPCRCC | Mo-CBP3-PepII | Free | Free | Linear | L | None | 9 | Antibacterial, Anticandidal | 0 % Hemolysis at 70 µM | Human | Plant Moringa Oleifera Seeds | 60% α-Helix and 40% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | AIQRCC | Mo-CBP3-PepIII | Free | Free | Linear | L | None | 6 | Antibacterial, Anticandidal | 0 % Hemolysis at 70 µM | Human | Plant Moringa Oleifera Seeds | 75% α-Helix and 25% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | CPAIQRCC | Mo-CBP3-PepI | Free | Free | Linear | L | None | 8 | Antibacterial, Anticandidal | 0 % Hemolysis at 280 µM | Human | Plant Moringa Oleifera Seeds | 75% α-Helix and 25% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | NIQPPCRCC | Mo-CBP3-PepII | Free | Free | Linear | L | None | 9 | Antibacterial, Anticandidal | 0 % Hemolysis at 280 µM | Human | Plant Moringa Oleifera Seeds | 60% α-Helix and 40% β-Turns | Non-hemolytic | ||
| 30389515 | 2019 | AIQRCC | Mo-CBP3-PepIII | Free | Free | Linear | L | None | 6 | Antibacterial, Anticandidal | 0 % Hemolysis at 280 µM | Human | Plant Moringa Oleifera Seeds | 75% α-Helix and 25% β-Turns | Non-hemolytic | ||
| 30384016 | 2019 | SISLL | BRCA1(782–786) | Free | Free | Linear | L | None | 5 | Antibacterial | 5 % Hemolysis at >250 μg/ml | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30384016 | 2019 | YGRKKRRQRRR | TAT(47–57) | Free | Free | Linear | L | None | 11 | Antibacterial | 5 % Hemolysis at >62.5 μg/ml | Human | Synthetic Peptide | NA | NA | ||
| 30384016 | 2019 | YGRKKRRQRRRSISLL | TAT–SISLL | Free | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >250 μg/ml | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30384016 | 2019 | SISLLYGRKKRRQRRR | SISLL–TAT | Free | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >250 μg/ml | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30702120 | 2019 | RRWVRRVRRWVRRVVRVVRRWVRR | WLBU2 | Free | Free | Linear | L | None | 24 | Antibacterial | 14 ± 1 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | NA | ||
| 30702120 | 2019 | RRWV{d}RRV{d}RRWV{d}RRV{d}V{d}RV{d}V{d}RRWV{d}RR | D8 | Free | Free | Linear | Mix | None | 24 | Antibacterial | 0 ± 1 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30789942 | 2019 | RIWR{nt:Lau}{ct:Amid} | Lp-I | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 4 | Antibacterial, Antifungal | ≤10 % Hemolysis at 25 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RRIWRR{nt:Lau}{ct:Amid} | Lp-IRR | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 6 | Antibacterial, Antifungal | ≤10 % Hemolysis at 25 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RIWR{nt:Lau}{ct:Amid} | Lp-I | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 4 | Antibacterial, Antifungal | ≤60 % Hemolysis at 50 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RRIWRR{nt:Lau}{ct:Amid} | Lp-IRR | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 6 | Antibacterial, Antifungal | ≤10 % Hemolysis at 50 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RIWR{nt:Lau}{ct:Amid} | Lp-I | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 4 | Antibacterial, Antifungal | 100 % Hemolysis at 100 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30789942 | 2019 | RRIWRR{nt:Lau}{ct:Amid} | Lp-IRR | Amidation | Lau | Linear | L | l = Lau(lauric acid (C12)) | 6 | Antibacterial, Antifungal | ≤60 % Hemolysis at 100 μg/mL | Human | Synthetic Argrich Ultra-Short Cationic Lipopeptides | NA | NA | ||
| 30811391 | 2019 | KLKNFAKGVAQSLLNKASCKLSGQC | Brevinin 2R | Free | Free | Linear | L | None | 25 | Antibacterial, Anti-leishmanial | 0 % Hemolysis at 500 μg/mL | Human | Frog Skin (Rana Brevipoda) | NA | Non-hemolytic | ||
| 30811391 | 2019 | KLKNFAKGVAQSLLNKASCKLSGQC{nt:lauric acid} | L- Brevinin 2R | Free | lauric acid | Linear | L | l = Lau(lauric acid) | 25 | Antibacterial, Anti-leishmanial | 50 % Hemolysis at 250 μg/mL | Human | Modified Brevinin 2R | NA | NA | ||
| 30811391 | 2019 | LPKPPKPVSKMRMATPLLMQALPM | CLIP | Free | Free | Linear | L | None | 24 | Antibacterial, Anti-leishmanial | 0 % Hemolysis at 500 μg/mL | Human | Derived From The Mhc Class Ii Associated Invariant Chain | NA | Non-hemolytic | ||
| 30811391 | 2019 | LPKPPKPVSKMRMATPLLMQALPM{nt:lauric acid} | L-CLIP | Free | lauric acid | Linear | L | l = Lau(lauric acid) | 24 | Antibacterial, Anti-leishmanial | 30 % Hemolysis at 500 μg/mL | Human | Modified Clip | NA | NA | ||
| 30414293 | 2019 | RNCTWLFSTKLKLPA | RN15 | Free | Free | Linear | L | None | 15 | Antibacterial | <10 % Hemolysis at 200 μg/mL | Human | Siamese Crocodile Crocodylus Siamensis | α-Helix | Low hemolytic | ||
| 30449002 | 2019 | IWLTALKFLGKNLGKLAKQQLAKL{ct:Amid} | LyeTxI-b | Amidation | Free | Linear | L | None | 24 | Anticancer, Antitumor | ~35 % Hemolysis at 100 µM | Human | Spider Venom Lycosa Erythrognatha | α-Helix | Low hemolytic | ||
| 30476118 | 2019 | FTKIIHKLKKFIRYRKVLRWSRMWWVLLVREIVGDN{ct:Amid} | EXP2-HD | Amidation | Free | Linear | L | None | 36 | NA | 50 % Hemolysis at 10.71 µM | Human | Synthetic Peptide | NA | NA | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 0 % Hemolysis at 75 µM | Human | Catfish Clarias Gariepinus | α-Helix | Non-hemolytic | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | <3 % Hemolysis at 150 µM | Human | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30481557 | 2019 | HSDGIFTDSYSRYRKQMAVKKYLAAVLGRRYRQRFRNK{ct:Amid} | PACAP | Amidation | Free | Linear | L | None | 38 | Anticancer, Antimicrobial | 6 % Hemolysis at 300 µM | Human | Catfish Clarias Gariepinus | α-Helix | NA | ||
| 30842436 | 2019 | K-K-{nnr:(NBu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N4-MeBn)Gly}-{nnr:(N1-Nal)Gly} | B1 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (N4-MeBn)Gly = N-(4-methylbenzyl)glycine | 7 | Antimicrobial | 32 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-{nnr:(NBu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly} | 2 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-{nnr:(NBu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly} | 3 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(NBu)Gly}-K-K-K | 4 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | 24 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly}-K-{nnr:(NBu)Gly}-K-K | 5 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 96 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 55 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 8 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 34 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 9 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 39 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-K-L-K-K | 10 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(2-Nal)Ala}-F -{nnr:(2-Nal)Ala}-K-L-K-K | 11 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 12 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala}-L-K-K-K | 13 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 15 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 14 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 58 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 15 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 88 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 16 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 60 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L{d}-K-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 17 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 40 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala}-K-L{d}-K-K | 18 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala}-L{d}-K-K-K | 19 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala}-K-L{d}-K-K | 20 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | {nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala}-L{d}-K-K-K | 21 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 22 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 14 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antimicrobial | 59 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 24 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 60 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-Y{d}-{nnr:(1-Nal)ala} | 25 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 53 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:nle}-(1-Nal)ala-F{d}-(1-Nal)ala | 26 | Free | Free | Linear | Mix | nle = D-Norleucine, (1-Nal)Ala = 1-Naphthylalanine | 7 | Antimicrobial | 56 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 27 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 54 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-(2-Nal)ala-Y{d}-(2-Nal)ala | 28 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 64 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:NLys}-{nnr:NLys}-{nnr:NLys}-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 29 | Free | Free | Linear | L | (2-Nal)Ala = D-2-Naphthylalanine, NLys | 7 | Antibacterial | 46 % Hemolysis at 150 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-{nnr:(NBu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N4-MeBn)Gly}-{nnr:(N1-Nal)Gly} | B1 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (N4-MeBn)Gly = N-(4-methylbenzyl)glycine | 7 | Antimicrobial | 10 % Hemolysis at 64 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(N1-Nal)Gly}-{nnr:(NPhe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(NBu)Gly}-K-K-K | 4 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (NPhe)Gly = N-Phenylalanine glycine | 7 | Antibacterial | 10 % Hemolysis at 54 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 5 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 8 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 8 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 56 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 9 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 46 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | {nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala}-L-K-K-K | 13 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 110 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 14 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 28 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 15 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 8 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 16 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 18 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L{d}-K-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 17 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 8 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 22 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 117 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antimicrobial | 10 % Hemolysis at 14 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 24 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 10 % Hemolysis at 3 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-Y{d}-{nnr:(1-Nal)ala} | 25 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 38 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 27 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 10 % Hemolysis at 3 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | Low hemolytic | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-Y{d}-{nnr:(2-Nal)ala} | 28 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 10 % Hemolysis at 6 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | NLys-NLys-NLys-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 29 | Free | Free | Linear | L | (2-Nal)Ala = D-2-Naphthylalanine, NLys | 7 | Antibacterial | 10 % Hemolysis at 9 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-{nnr:(NBu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N4-MeBn)Gly}-{nnr:(N1-Nal)Gly} | B1 | Free | Free | Linear | L | (NBu)Gly = N-(4-aminobutyl)glycine, (N1-Nal)Gly = N-(1-naphthyl)glycine, (N4-MeBn)Gly = N-(4-methylbenzyl)glycine | 7 | Antimicrobial | 50 % Hemolysis at 230 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 58 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 140 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-L-K-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 14 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 128 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 15 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 40 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-F{d}-{nnr:(2-Nal)ala} | 16 | Free | Free | Linear | Mix | (2-Nal)ala = D-2-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 118 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine | 7 | Antimicrobial | 50 % Hemolysis at 104 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 24 | Free | Free | Linear | L | (1-Nal)Ala = 1-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 50 % Hemolysis at 41 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(1-Nal)ala}-Y{d}-{nnr:(1-Nal)ala} | 25 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 138 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:nle}-{nnr:(1-Nal)ala}-F{d}-{nnr:(1-Nal)ala} | 26 | Free | Free | Linear | Mix | nle = D-Norleucine, (1-Nal)Ala = 1-Naphthylalanine | 7 | Antimicrobial | 50 % Hemolysis at 63 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 27 | Free | Free | Linear | L | (2-Nal)Ala = 2-Naphthylalanine, Nle= norleucine | 7 | Antibacterial | 50 % Hemolysis at 56 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30842436 | 2019 | K-K-K-L{d}-{nnr:(2-Nal)ala}-Y{d}-{nnr:(2-Nal)ala} | 28 | Free | Free | Linear | Mix | (1-Nal)ala = D-1-Naphthylalanine | 7 | Antibacterial | 50 % Hemolysis at 50 µM | Human | Synthetic Peptide-Peptoid Hybrid | Random coil | NA | ||
| 30872680 | 2019 | FLPKLFAKITKKNMAHIR | Andersonin-Y1 (AY1) | Free | Free | Linear | L | None | 18 | Antibacterial | 5 % Hemolysis at 100 µM | Human | Frog Odorrana Andersonii | membrane bound structure = Helical Hairpin (Helix-Loop-Helix) structure, Aqueous = unstructured | Low hemolytic | ||
| 30521892 | 2019 | RYAKMKRRRRRVARRHRRR | PEP-NKSM | Free | Free | Linear | L | None | 19 | biofilm Anti-adherent activity, Antibiofilm | 12 % Hemolysis at 256 µM | Human | Derived From Human Virus Proteomes | α-Helix | Low hemolytic | ||
| 30842341 | 2019 | GLLSGINAEWPC | OA-GL12 | Free | Free | Linear | L | None | 12 | Wound-healing peptide, Antioxidant | 8.9 ± 0.43 % Hemolysis at 0.1 nM | Human | Frog Odorrana Andersonii | NA | NA | ||
| 30842341 | 2019 | GLLSGINAEWPC | OA-GL12 | Free | Free | Linear | L | None | 12 | Wound-healing peptide, Antioxidant | 9.8 ± 0.45 % Hemolysis at 1 nM | Human | Frog Odorrana Andersonii | NA | NA | ||
| 30842341 | 2019 | GLLSGINAEWPC | OA-GL12 | Free | Free | Linear | L | None | 12 | Wound-healing peptide, Antioxidant | 9.9 ± 0.75 % Hemolysis at 10 nM | Human | Frog Odorrana Andersonii | NA | NA | ||
| 30648626 | 2019 | QSHLSLCRWCCNCCHNKGCGFCCKF | Bthepc | Free | Free | Linear | L | None | 25 | Antimicrobial | 50 % Hemolysis at 34.71 µM | Human | Hepcidin Gene Brown Trout (Salmo Trutta) | NA | NA | ||
| 30648626 | 2019 | QSHLSLCRWCCNCCHNKGCGFCCKF | Bthepc | Free | Free | Linear | L | None | 25 | Antimicrobial | 28.2 % Hemolysis at 2.17 µM | Human | Hepcidin Gene Brown Trout (Salmo Trutta) | NA | NA | ||
| 30967458 | 2019 | ILKPGGGTSGGLLGGLLGKVTSVIPGLNNI | α4 | Free | Free | Linear | L | None | 30 | Antibacterial, Antiiofilm | 0 % Hemolysis at 64 µM | Human | Derived From The Human Respiratory Host Defense Protein Splunc1 | α-Helix | Non-hemolytic | ||
| 30967458 | 2019 | LKKWW K TS K GLLGGLLGKVTSVIK | α4-short | Free | Free | Linear | L | None | 24 | Antibacterial, Antiiofilm | 0 % Hemolysis at 64 µM | Human | Modified Α4 | NA | Non-hemolytic | ||
| 30848594 | 2019 | K{d}L{d}R{d}S{d}L{d}L{d}R{d}T{d}L{d}S{d}R{d}A{d}K{d}A{d}A{d}K{d}L{d}R{d}T{d}L{d}L{d}R{d}A{d}L{d}S{d}R{d}{nt:Acet}{ct:Amid} | D87(Lys'-6 Arg-1) | Amidation | Acetylation | Linear | D | substituted with positive charged Arg | 26 | Antimicrobial | 50 % Hemolysis at 12 μg/mL | Human | Synthetic Peptide | α-Helix | NA | ||
| 30848594 | 2019 | K{d}L{d}K{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}K{d}A{d}K{d}A{d}A{d}K{d}L{d}K{d}T{d}L{d}L{d}K{d}A{d}L{d}S{d}K{d}{nt:Acet}{ct:Amid} | D84(Lys¹-6 Lys-1) | Amidation | Acetylation | Linear | D | substituted with positive charged Lys | 26 | Antimicrobial | 50 % Hemolysis at 155.5 μg/mL | Human | Synthetic Peptide | α-Helix | NA | ||
| 30848594 | 2019 | K{d}L{d}{nnr:o}S{d}L{d}L{d}{nnr:o}T{d}L{d}S{d}{nnr:o}A{d}K{d}A{d}A{d}K{d}L{d}{nnr:o}T{d}L{d}L{d}{nnr:o}A{d}L{d}S{d}{nnr:o} | D85(Lys'-6 Orn-1) | Amidation | Acetylation | Linear | D | o = D-Ornithine | 26 | Antimicrobial | 50 % Hemolysis at 406.5 μg/mL | Human | Synthetic Peptide | α-Helix | NA | ||
| 30848594 | 2019 | K{d}L{d}{nnr:Dab}S{d}L{d}L{d}{nnr:Dab}T{d}L{d}S{d}{nnr:Dab}A{d}K{d}A{d}A{d}K{d}L{d}{nnr:Dab}T{d}L{d}L{d}{nnr:Dab}A{d}L{d}S{d}{nnr:Dab} | D86(Lys¹-6 Dab-1) | Amidation | Acetylation | Linear | Mix | Dab = diaminobutyric acid | 26 | Antimicrobial | 50 % Hemolysis at >2000 μg/mL | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 30848594 | 2019 | K{d}L{d}{nnr:Dap}S{d}L{d}L{d}{nnr:Dap}T{d}L{d}S{d}{nnr:Dap}aK{d}A{d}A{d}K{d}L{d}{nnr:Dap}T{d}L{d}L{d}{nnr:Dap}A{d}L{d}S{d}{nnr:Dap} | D105(Lys¹-6 Dap-1) | Amidation | Acetylation | Linear | Mix | Dap = diaminopropionic acid | 26 | Antimicrobial | 50 % Hemolysis at >3000 μg/mL | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 30848594 | 2019 | K{d}L{d}K{d}S{d}L{d}L{d}K{d}T{d}L{d}S{d}K{d}A{d}K{d}A{d}A{d}K{d}L{d}K{d}T{d}L{d}L{d}K{d}A{d}L{d}S{d}S{d}{nt:Acet}{ct:Amid} | D101(Lys' Ser26-5 Lys-1) | Amidation | Acetylation | Linear | D | substituted with positive charged Lys | 26 | Antimicrobial | 50 % Hemolysis at 279 μg/mL | Human | Synthetic Peptide | α-Helix | NA | ||
| 30848594 | 2019 | K{d}L{d}{nnr:Dab}S{d}L{d}L{d}{nnr:Dab}T{d}L{d}S{d}{nnr:Dab}A{d}K{d}A{d}A{d}K{d}L{d}{nnr:Dab}T{d}L{d}L{d}{nnr:Dab}A{d}L{d}S{d}S{d} | D102(Lys Ser26-5 Dab-1) | Amidation | Acetylation | Linear | Mix | Dab = diaminobutyric acid | 26 | Antimicrobial | 50 % Hemolysis at >2000 μg/mL | Human | Synthetic Peptide | α-Helix | Low hemolytic | ||
| 30848594 | 2019 | K{d}L{d}{nnr:o}S{d}L{d}L{d}{nnr:o}T{d}L{d}S{d}{nnr:o}A{d}A{d}A{d}A{d}A{d}L{d}{nnr:o}T{d}L{d}L{d}{nnr:o}A{d}L{d}S{d}{nnr:o} | D85(K13A/K16A) -(Lys'-6 Orn-1) | Amidation | Acetylation | Linear | D | o = D-Ornithine | 26 | Antimicrobial | 50 % Hemolysis at 2.3 μg/mL | Human | Synthetic Peptide | α-Helix | NA | ||
| 30848594 | 2019 | K{d}L{d}{nnr:Dab}S{d}L{d}L{d}{nnr:Dab}T{d}L{d}S{d}{nnr:Dab}A{d}A{d}A{d}A{d}A{d}L{d}{nnr:Dab}T{d}L{d}L{d}{nnr:Dab}A{d}L{d}S{d}{nnr:Dab} | D86(K13A/K16A) -(Lys¹-6 Dab-1) | Amidation | Acetylation | Linear | Mix | Dab = diaminobutyric acid | 26 | Antimicrobial | 50 % Hemolysis at 20 μg/mL | Human | Synthetic Peptide | α-Helix | NA | ||
| 30848594 | 2019 | K{d}L{d}{nnr:Dap}S{d}L{d}L{d}{nnr:Dap}T{d}L{d}S{d}{nnr:Dap}A{d}A{d}A{d}A{d}A{d}L{d}{nnr:Dap}T{d}L{d}L{d}{nnr:Dap}A{d}L{d}S{d}{nnr:Dap} | D105(K13A/K16A) -(Lys'-6 Dap-1) | Amidation | Acetylation | Linear | Mix | Dap = diaminopropionic acid | 26 | Antimicrobial | 50 % Hemolysis at 7.2 μg/mL | Human | Synthetic Peptide | α-Helix | NA | ||
| 31118709 | 2019 | KFKKLFKKLSPVFKRIVQRIKDFLR{nt:Amid} | B1 | Free | Amidation | Linear | L | None | 25 | Antibiofilm, Antibacterial | 37 % Hemolysis at 150 µM | Human | Hybrid Peptide From Ll-37 And Bmap-27 | α-Helix = 88% and Random coils = 12% | NA | ||
| 30753486 | 2019 | VNWKKILGKIIKVVK{ct:Amid} | LL-III | Amidation | Free | Linear | L | None | 15 | Antibiofilm, Antifungal | 50 % Hemolysis at 157 µM | Human | Lasioglossum Laticeps Bee Venoms | 30% TFE = α-Helix | NA | ||
| 30753486 | 2019 | VNWKKILGK{d}IIKVVK{ct:Amid} | LL-III/43 | Amidation | Free | Linear | Mix | None | 15 | Antibiofilm, Antifungal | 50 % Hemolysis at 400 µM | Human | Derived From Ll-Iii But With D-Leu | 30% TFE = α-Helix | NA | ||
| 30753486 | 2019 | GKWMSLLKHILK{ct:Amid} | HAL-2 | Amidation | Free | Linear | L | None | 12 | Antibiofilm, Antifungal | 50 % Hemolysis at 78 µM | Human | Halictus Sexcinctus Bee Venom | 30% TFE = α-Helix | NA | ||
| 30753486 | 2019 | GKWMKLLKKILK{ct:Amid} | peptide I | Amidation | Free | Linear | L | None | 12 | Antibiofilm, Antifungal | 50 % Hemolysis at 339 µM | Human | Analogs Of Hal-2 | 30% TFE = α-Helix | NA | ||
| 30753486 | 2019 | GKWMKLL{d}KKILK{ct:Amid} | peptide VIII | Amidation | Free | Linear | Mix | None | 12 | Antibiofilm, Antifungal | 50 % Hemolysis at 400 µM | Human | Modified Hal-2 | 30% TFE = α-Helix | NA | ||
| 30773822 | 2019 | LSVKAFTGLQLRGVCGLEVKARG | MCh-AMP1 | Free | Free | Linear | L | None | 23 | Antifungal | 10.6 % Hemolysis at 105.58 µM | Human | Matricaria Chamomilla | NA | NA | ||
| 30773822 | 2019 | LSVKAFTGLQLRGVCGLEVKARG | MCh-AMP1 | Free | Free | Linear | L | None | 23 | Antifungal | 3.65 % Hemolysis at 13.32 µM | Human | Matricaria Chamomilla | NA | Low hemolytic | ||
| 30794440 | 2019 | RQCKAESNTFTGICIAKPPCRQACIREKFTDGHCSKVLRRCLCTKRC | NoD173 | Free | Free | Linear | L | None | 47 | Antitumor, Antiproliferative, Antimicrobial | ~12 % Hemolysis at 100 µM | Human | Plant Nicotiana Occidentalis Defensin 173 (Nod173) | single α-Helix braced by 3 disulfide bonds to a Triple-Stranded antiparallel b-Sheet | Low hemolytic | ||
| 31016971 | 2019 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | cathelicidin LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 5 % Hemolysis at 10 µM | Human | Homo Sapiens (Human) Cathelicidin Amp | α-Helix | Low hemolytic | ||
| 31016971 | 2019 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNL | Fragment LL-32 | Free | Free | Linear | L | None | 32 | Antimicrobial | 40 % Hemolysis at 10 µM | Human | Fragment Of Cathelicidin Ll-37 | α-Helix | NA | ||
| 31016971 | 2019 | LLGDFFRKSKEKIGKEFKRI | Fragment LL-20 | Free | Free | Linear | L | None | 20 | Antibacterial | 0 % Hemolysis at 10 µM | Human | Fragment Of Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 30127331 | 2019 | FLPFFAACAITRKC{ct:Amid} | Amurin-9KY | Amidation | Free | Linear | L | C8-C14 = heptapeptide ring | 14 | Antibacterial | 2 % Hemolysis at 100 μg/mL | Human | Frog Rana Kunyuensis China | water = Random coil, 50% TFE-water = α-Helix | Non-hemolytic | ||
| 30127331 | 2019 | FLPFFAACAITRKC{ct:Amid} | Amurin-9KY1 | Amidation | Free | Linear | L | None | 14 | Antibacterial, Antifungal | 15.4 % Hemolysis at 100 μg/mL | Human | Derived From Amurin-9Ky | NA | NA | ||
| 30127331 | 2019 | FLPFFAACAITRKC{ct:heptapeptide ring C8-C14} | Amurin-9KY2 | heptapeptide ring C8-C14 | Free | Linear | L | None | 14 | NA | 17.9 % Hemolysis at 100 μg/mL | Human | Derived From Amurin-9Ky | NA | NA | ||
| 30127331 | 2019 | FLPFFAACAITRKC | Amurin-9KY3 | Free | Free | Linear | L | None | 14 | NA | 20.8 % Hemolysis at 100 μg/mL | Human | Derived From Amurin-9Ky | NA | NA | ||
| 30919848 | 2019 | GKKLGLWLGLKKG{ct:Amid} | F1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = α-Helix | Non-hemolytic | ||
| 30919848 | 2019 | KKLLGWGLLKK{ct:Amid} | F2 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = unordered conformations | Non-hemolytic | ||
| 30919848 | 2019 | KKLGWGLKK{ct:Amid} | F3 | Amidation | Free | Linear | L | None | 9 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = unordered conformations | Non-hemolytic | ||
| 30919848 | 2019 | KKLGLWLGLKK{ct:Amid} | F4 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = α-Helix | Non-hemolytic | ||
| 30919848 | 2019 | GKKLLWLLKKG{ct:Amid} | F5 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = α-Helix | Non-hemolytic | ||
| 30919848 | 2019 | LKGKLWLKGKL{ct:Amid} | F6 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = α-Helix | Non-hemolytic | ||
| 30919848 | 2019 | KLLGKWKGLLK{ct:Amid} | F7 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30919848 | 2019 | KKLLKGLLKGW{ct:Amid} | F8 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 30919848 | 2019 | KKIGIWIGIKK{ct:Amid} | F9 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = α-Helix | Non-hemolytic | ||
| 30919848 | 2019 | RRLGLWLGLRR{ct:Amid} | F10 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = α-Helix | Non-hemolytic | ||
| 30919848 | 2019 | KKLTLWLTLKK{ct:Amid} | F11 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | 30 mM SDS and 50% TFE = α-Helix | Non-hemolytic | ||
| 30919848 | 2019 | KKLGLCLGLKK{ct:Amid} | F12 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 31159194 | 2019 | CGIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 27 | Antimicrobial | 50 % Hemolysis at 0.8 ± 0.2 (n at25) µM (pH 5.5) | Human | Cell-Penetrating Peptide | NA | NA | ||
| 31159194 | 2019 | CYGRKKRRQRR | Tat | Free | Free | Linear | L | None | 11 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Cell Penetrating Cargo Delivery Peptides | NA | NA | ||
| 31159194 | 2019 | CRQIKIWFQNRRMKWKK | Penetratin | Free | Free | Linear | L | None | 17 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Cell Penetrating Cargo Delivery Peptides | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAGFIENGWEGMIDGWYG | HA2 | Free | Free | Linear | L | None | 24 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Parent Influenza Hemagglutinin Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG | INF7 | Free | Free | Linear | L | None | 24 | Antimicrobial | 50 % Hemolysis at 16 µM (pH 5.5) | Human | Ha2 Analog | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAGFIENGWEGMIDGWYGYGRKKRRQRR | HA2-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 2.3 ± 0.5 (n at 10) µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | INF7-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 1.4 ± 0.4 (n at 10) µM (pH 5.5) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | pH 5.5 = α-Helix | NA | ||
| 31159194 | 2019 | CGLFHAIAHFIHGGWHGLIHGWYGYGRKKRRQRR | H5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 5.9 µM (pH 5.5) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFKAIAKFIKGGWKGLIKGWYGYGRKKRRQRR | K5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 1.9 µM (pH 5.5) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | E5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAGFIENGWEGMIDGWYGRQIKIWFQNRRMKWKKGG | HA2-Penetratin | Free | Free | Linear | L | None | 42 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Chimeric Fusion Peptides Of Ha2 And Inf7 With Penetratin | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGRQIKIWFQNRRMKWKKGG | INF7-Penetratin | Free | Free | Linear | L | None | 42 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Chimeric Fusion Peptides Of Ha2 And Inf7 With Penetratin | NA | NA | ||
| 31159194 | 2019 | CRLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.8 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12c | Free | Free | Linear | L | None | 36 | NA | 50 % Hemolysis at 1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C({nnr:Nle})LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12d | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 0.8 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CVLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.72 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12f | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at 0.38 ± 0.17 (n at 5) µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CSLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.66 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.35 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGKFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGEFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGNFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLNEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLGEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLKEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLEEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14e | Free | Free | Linear | L | None | 34 | NA | ~65 % Hemolysis at 1.3 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLLEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.93 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.4 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFAAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.26 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFNAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.12 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFLAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFKAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.71 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFENIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFELIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.23 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.26 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEKIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAKEGFIENGWEGMIDGWYGYGRKKRRQRR | 17a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAEEGFIENGWEGMIDGWYGYGRKKRRQRR | 17b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.74 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEALEGFIENGWEGMIDGWYGYGRKKRRQRR | 17c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.8 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIWGFIENGWEGMIDGWYGYGRKKRRQRR | 18a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.9 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIKGFIENGWEGMIDGWYGYGRKKRRQRR | 18b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIHGFIENGWEGMIDGWYGYGRKKRRQRR | 18c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.7 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIRGFIENGWEGMIDGWYGYGRKKRRQRR | 18d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIDGFIENGWEGMIDGWYGYGRKKRRQRR | 18e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.7 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIGGFIENGWEGMIDGWYGYGRKKRRQRR | 18f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIENFIENGWEGMIDGWYGYGRKKRRQRR | 19a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.7 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEKFIENGWEGMIDGWYGYGRKKRRQRR | 19b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.32 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEEFIENGWEGMIDGWYGYGRKKRRQRR | 19c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.41 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 19d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.88 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.24 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 20c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.88 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.24 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFGENGWEGMIDGWYGYGRKKRRQRR | 21a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFAENGWEGMIDGWYGYGRKKRRQRR | 21b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.59 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFLENGWEGMIDGWYGYGRKKRRQRR | 21c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.59 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFWENGWEGMIDGWYGYGRKKRRQRR | 21d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.35 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFKENGWEGMIDGWYGYGRKKRRQRR | 21e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFNENGWEGMIDGWYGYGRKKRRQRR | 21f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFILNGWEGMIDGWYGYGRKKRRQRR | 22a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.06 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIWNGWEGMIDGWYGYGRKKRRQRR | 22b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.44 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIKNGWEGMIDGWYGYGRKKRRQRR | 22c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.27 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIGNGWEGMIDGWYGYGRKKRRQRR | 22d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.16 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEGGWEGMIDGWYGYGRKKRRQRR | 23c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.11 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIELGWEGMIDGWYGYGRKKRRQRR | 23d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.34 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEWGWEGMIDGWYGYGRKKRRQRR | 23e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.54 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEKGWEGMIDGWYGYGRKKRRQRR | 23f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENEWEGMIDGWYGYGRKKRRQRR | 24a | Free | Free | Linear | L | None | 34 | NA | ~45 % Hemolysis at 2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENKWEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENNWEGMIDGWYGYGRKKRRQRR | 24c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.39 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENHWEGMIDGWYGYGRKKRRQRR | 24d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.06 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENPWEGMIDGWYGYGRKKRRQRR | 24e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.71 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENAWEGMIDGWYGYGRKKRRQRR | 24f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.88 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENWWEGMIDGWYGYGRKKRRQRR | 24g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGEEGMIDGWYGYGRKKRRQRR | 25a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.55 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGKEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLEGMIDGWYGYGRKKRRQRR | 25c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.66 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWDGMIDGWYGYGRKKRRQRR | 26a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.55 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWRGMIDGWYGYGRKKRRQRR | 26b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.19 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDGWYGYGRKKRRQRR | 26c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.34 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWHGMIDGWYGYGRKKRRQRR | 26d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.54 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWNGMIDGWYGYGRKKRRQRR | 26e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.47 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWLGMIDGWYGYGRKKRRQRR | 26f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.84 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWAGMIDGWYGYGRKKRRQRR | 26g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.3 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWGGMIDGWYGYGRKKRRQRR | 26h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.1 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEAMIDGWYGYGRKKRRQRR | 27a | Free | Free | Linear | L | None | 34 | NA | ~65 % Hemolysis at 0.12 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWENMIDGWYGYGRKKRRQRR | 27b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.42 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEKMIDGWYGYGRKKRRQRR | 27c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.01 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEEMIDGWYGYGRKKRRQRR | 27d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.76 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:M sulfoxide})IDGWYGYGRKKRRQRR | 28a | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG{nnr:M sulfone}IDGWYGYGRKKRRQRR | 28b | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGNIDGWYGYGRKKRRQRR | 28c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGQIDGWYGYGRKKRRQRR | 28d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGTIDGWYGYGRKKRRQRR | 28e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGSIDGWYGYGRKKRRQRR | 28f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 28g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.71 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:Nle})IDGWYGYGRKKRRQRR | 28h | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 0.53 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGYIDGWYGYGRKKRRQRR | 28i | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.56 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGFIDGWYGYGRKKRRQRR | 28j | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.52 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGIDGWYGYGRKKRRQRR | 28k | Free | Free | Linear | L | delete | 33 | NA | 50 % Hemolysis at 50 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMLDGWYGYGRKKRRQRR | 29a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 10.2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMADGWYGYGRKKRRQRR | 29b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMGDGWYGYGRKKRRQRR | 29c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.53 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMNDGWYGYGRKKRRQRR | 29d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMKDGWYGYGRKKRRQRR | 29e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.17 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMEDGWYGYGRKKRRQRR | 29f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIEGWYGYGRKKRRQRR | 30a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.4 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIAGWYGYGRKKRRQRR | 30b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIWGWYGYGRKKRRQRR | 30c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMILGWYGYGRKKRRQRR | 30d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDAWYGYGRKKRRQRR | 31a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.4 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDLWYGYGRKKRRQRR | 31b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.32 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDIWYGYGRKKRRQRR | 31c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.68 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDWWYGYGRKKRRQRR | 31d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.55 ± 0.25 (n at 8) µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDNWYGYGRKKRRQRR | 31e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.07 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDKWYGYGRKKRRQRR | 31f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.86 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDEWYGYGRKKRRQRR | 31g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGYGRKKRRQRR | 32a | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGGGYGRKKRRQRR | 32b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGLYGYGRKKRRQRR | 33a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.24 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGAYGYGRKKRRQRR | 33b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.07 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGYGYGRKKRRQRR | 33c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGNYGYGRKKRRQRR | 33d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.5 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGKYGYGRKKRRQRR | 33e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.6 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGEYGYGRKKRRQRR | 33f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.26 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWAGYGRKKRRQRR | 34a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWHGYGRKKRRQRR | 34b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 5.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWNGYGRKKRRQRR | 34c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.13 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWEGYGRKKRRQRR | 34d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.94 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYAYGRKKRRQRR | 35a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYWYGRKKRRQRR | 35b | Free | Free | Linear | L | None | 34 | NA | ~70 % Hemolysis at 0.17 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYEYGRKKRRQRR | 35c | Free | Free | Linear | L | None | 34 | NA | ~60% % Hemolysis at 1.04 µM (pH 5.5) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGCYGRKKRRQRR | 36a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.09 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 36b | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 0.7 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 3})YGRKKRRQRR | 36c | Free | Free | Linear | L | Peg 3 = Peg 3 | 34 | NA | 50 % Hemolysis at 1.92 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 6})YGRKKRRQRR | 36d | Free | Free | Linear | L | Peg 6 = Peg 6 | 34 | NA | 50 % Hemolysis at 1.22 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg11})YGRKKRRQRR | 36e | Free | Free | Linear | L | Peg11 = Peg11 | 34 | NA | 50 % Hemolysis at 2.4 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 27})YGRKKRRQRR | 36f | Free | Free | Linear | L | Peg 27 = Peg 27 | 34 | NA | 50 % Hemolysis at 28 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGKKKKKQKK | 37a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.78 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHH | 37b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.90 ± 0.19 (n at 8) µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRR | 37c | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 1.77 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQR | 37d | Free | Free | Linear | L | None | 33 | NA | 50 % Hemolysis at 0.75 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQ | 37e | Free | Free | Linear | L | None | 32 | NA | 50 % Hemolysis at 0.96 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRR | 37f | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at 1.61 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKR | 37g | Free | Free | Linear | L | None | 30 | NA | 50 % Hemolysis at 7.8 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHR | 37h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.58 ± 0.17 (n at 10) µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC | 38a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.96 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | YGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYGC | 38b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.91 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CYGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYG | 38c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.17 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d}C{d} | 38d | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 5 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d} | 38e | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 0.1 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}G{d}L{d}F{d}E{d}A{d}I{d}E{d}G{d}F{d}I{d}E{d}N{d}G{d}W{d}E{d}G{d}M{d}I{d}D{d}G{d}W{d}Y{d}G{d}Y{d}G{d}R{d}K{d}K{d}R{d}R{d}Q{d}R{d}R{d} | 38f | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 2.3 µM (pH 5.5) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRK{ct:stearoyl} | 39d | stearoyl | Free | Linear | L | stearoyl = stearoyl | 35 | NA | 50 % Hemolysis at 0.58 ± 0.2 (n at6) µM (pH 5.5) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC{nt:stearoyl} | 39e | Free | stearoyl | Linear | L | stearoyl = stearoyl | 34 | NA | 50 % Hemolysis at 0.7 µM (pH 5.5) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 40 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.12 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 41 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.41 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDWWYGYGRKKRRQRR | 42 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.66 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDAWYGYGRKKRRQRR | 43 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.62 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 44 | Free | Free | Linear | L | None | 37 | NA | ~50 % Hemolysis at 1 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 45 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 2.98 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CRLFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 46 | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 0.35 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 47 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 1.55 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGLIDWWYGYGRKKRRQRR | 48 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.72 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIWGFIENGWEGLIDGWYGYGRKKRRQRR | 49 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 50 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 2 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 51 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.14 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 52 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.1 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 53 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.18 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 54 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.14 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 55 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.71 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGIFGAIEGFIENGWWGLIDAWYGYGRKKRRQRR | 56 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.07 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 57 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.17 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGLKGLIDWWYGYGRKKRRQRR | 58 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.06 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | 59 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.79 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}GFEFIEEFIENGLKNLIDWWYGYGRKKRRQRR | 60 | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at 1.14 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGRKKRRQRR | 61 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.97 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 62 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.28 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGRKKRRQRR | 63 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.6 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGHKKHHQHR | 64 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.91 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGLENLIDWWYGYGRKKRRQRR | 65 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.15 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGWENFIDWWYGYGRKKRRQRR | 66 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.08 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGWEGLIDWWYGYGRKKRRQRR | 67 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.4 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGRKKRRQRR | 68 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.11 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGHKKHHQHR | 69 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 8.73 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 70 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.28 µM (pH 5.5) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 27 | Antimicrobial | 50 % Hemolysis at 2.6 ± 0.6 (n at 25) µM (pH 7.4) | Human | Cell-Penetrating Peptide | NA | NA | ||
| 31159194 | 2019 | CYGRKKRRQRR | Tat | Free | Free | Linear | L | None | 11 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Cell Penetrating Cargo Delivery Peptides | NA | NA | ||
| 31159194 | 2019 | CRQIKIWFQNRRMKWKK | Penetratin | Free | Free | Linear | L | None | 17 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Cell Penetrating Cargo Delivery Peptides | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAGFIENGWEGMIDGWYG | HA2 | Free | Free | Linear | L | None | 24 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Parent Influenza Hemagglutinin Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG | INF7 | Free | Free | Linear | L | None | 24 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Ha2 Analog | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAGFIENGWEGMIDGWYGYGRKKRRQRR | HA2-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 5.7 ± 1.1 (n at 10) µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | INF7-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 4.6 ± 1.2 (n at 10) µM (pH 7.4) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | pH 7.4 = Random coil | NA | ||
| 31159194 | 2019 | CGLFHAIAHFIHGGWHGLIHGWYGYGRKKRRQRR | H5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 0.3 µM (pH 7.4) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFKAIAKFIKGGWKGLIKGWYGYGRKKRRQRR | K5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 0.9 µM (pH 7.4) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | E5WYG-Tat | Free | Free | Linear | L | None | 34 | Antimicrobial | 50 % Hemolysis at 2.2 µM (pH 7.4) | Human | Lead Chimeric Peptide By Combining Several Known Ha2 Analogs With Tat | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAGFIENGWEGMIDGWYGRQIKIWFQNRRMKWKKGG | HA2-Penetratin | Free | Free | Linear | L | None | 42 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Chimeric Fusion Peptides Of Ha2 And Inf7 With Penetratin | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGRQIKIWFQNRRMKWKKGG | INF7-Penetratin | Free | Free | Linear | L | None | 42 | Antimicrobial | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Chimeric Fusion Peptides Of Ha2 And Inf7 With Penetratin | NA | NA | ||
| 31159194 | 2019 | CRLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.5 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12c | Free | Free | Linear | L | None | 36 | NA | 50 % Hemolysis at 0.9 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C({nnr:Nle})LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12d | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 2.4 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CVLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}LFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12f | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at >20 (n at 5) µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CSLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 12g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.16 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGKFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGEFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGGFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGNFEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 13e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLNEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLGEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLKEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLEEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLLEAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 14f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.67 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFAAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.75 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFNAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.78 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFLAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFKAIEGFIENGWEGMIDGWYGYGRKKRRQRR | 15e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.27 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFENIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFELIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.93 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEKIEGFIENGWEGMIDGWYGYGRKKRRQRR | 16d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.11 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAKEGFIENGWEGMIDGWYGYGRKKRRQRR | 17a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAEEGFIENGWEGMIDGWYGYGRKKRRQRR | 17b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEALEGFIENGWEGMIDGWYGYGRKKRRQRR | 17c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 5 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIWGFIENGWEGMIDGWYGYGRKKRRQRR | 18a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.2 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIKGFIENGWEGMIDGWYGYGRKKRRQRR | 18b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.5 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIHGFIENGWEGMIDGWYGYGRKKRRQRR | 18c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >80 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIRGFIENGWEGMIDGWYGYGRKKRRQRR | 18d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.8 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIDGFIENGWEGMIDGWYGYGRKKRRQRR | 18e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIGGFIENGWEGMIDGWYGYGRKKRRQRR | 18f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIENFIENGWEGMIDGWYGYGRKKRRQRR | 19a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.09 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEKFIENGWEGMIDGWYGYGRKKRRQRR | 19b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEEFIENGWEGMIDGWYGYGRKKRRQRR | 19c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 19d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.71 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.97 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGGIENGWEGMIDGWYGYGRKKRRQRR | 20c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGAIENGWEGMIDGWYGYGRKKRRQRR | 20d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.71 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGLIENGWEGMIDGWYGYGRKKRRQRR | 20e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.97 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFGENGWEGMIDGWYGYGRKKRRQRR | 21a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFAENGWEGMIDGWYGYGRKKRRQRR | 21b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFLENGWEGMIDGWYGYGRKKRRQRR | 21c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.8 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFWENGWEGMIDGWYGYGRKKRRQRR | 21d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFKENGWEGMIDGWYGYGRKKRRQRR | 21e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFNENGWEGMIDGWYGYGRKKRRQRR | 21f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFILNGWEGMIDGWYGYGRKKRRQRR | 22a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIWNGWEGMIDGWYGYGRKKRRQRR | 22b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.95 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIKNGWEGMIDGWYGYGRKKRRQRR | 22c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIGNGWEGMIDGWYGYGRKKRRQRR | 22d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEPGWEGMIDGWYGYGRKKRRQRR | 23b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEGGWEGMIDGWYGYGRKKRRQRR | 23c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 6.55 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIELGWEGMIDGWYGYGRKKRRQRR | 23d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.31 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEWGWEGMIDGWYGYGRKKRRQRR | 23e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 5.18 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIEKGWEGMIDGWYGYGRKKRRQRR | 23f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENEWEGMIDGWYGYGRKKRRQRR | 24a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENKWEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENNWEGMIDGWYGYGRKKRRQRR | 24c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENHWEGMIDGWYGYGRKKRRQRR | 24d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.9 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENPWEGMIDGWYGYGRKKRRQRR | 24e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.72 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENAWEGMIDGWYGYGRKKRRQRR | 24f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.28 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENWWEGMIDGWYGYGRKKRRQRR | 24g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGEEGMIDGWYGYGRKKRRQRR | 25a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.31 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGKEGMIDGWYGYGRKKRRQRR | 24b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLEGMIDGWYGYGRKKRRQRR | 25c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 4.43 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWDGMIDGWYGYGRKKRRQRR | 26a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.3 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWRGMIDGWYGYGRKKRRQRR | 26b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.3 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDGWYGYGRKKRRQRR | 26c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWHGMIDGWYGYGRKKRRQRR | 26d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWNGMIDGWYGYGRKKRRQRR | 26e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWLGMIDGWYGYGRKKRRQRR | 26f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.03 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWAGMIDGWYGYGRKKRRQRR | 26g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWGGMIDGWYGYGRKKRRQRR | 26h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEAMIDGWYGYGRKKRRQRR | 27a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.95 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWENMIDGWYGYGRKKRRQRR | 27b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEKMIDGWYGYGRKKRRQRR | 27c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 8.99 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEEMIDGWYGYGRKKRRQRR | 27d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:M sulfoxide})IDGWYGYGRKKRRQRR | 28a | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG(M sulfone)IDGWYGYGRKKRRQRR | 28b | Free | Free | Linear | L | M sulfoxide = M sulfoxide | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGNIDGWYGYGRKKRRQRR | 28c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGQIDGWYGYGRKKRRQRR | 28d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGTIDGWYGYGRKKRRQRR | 28e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGSIDGWYGYGRKKRRQRR | 28f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 28g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.9 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEG({nnr:Nle})IDGWYGYGRKKRRQRR | 28h | Free | Free | Linear | L | Nle = Nle | 34 | NA | 50 % Hemolysis at 3.94 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGYIDGWYGYGRKKRRQRR | 28i | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGFIDGWYGYGRKKRRQRR | 28j | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 9.65 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGIDGWYGYGRKKRRQRR | 28k | Free | Free | Linear | L | delete | 33 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMLDGWYGYGRKKRRQRR | 29a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMADGWYGYGRKKRRQRR | 29b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMGDGWYGYGRKKRRQRR | 29c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMNDGWYGYGRKKRRQRR | 29d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMKDGWYGYGRKKRRQRR | 29e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 9.1 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMEDGWYGYGRKKRRQRR | 29f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIEGWYGYGRKKRRQRR | 30a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIAGWYGYGRKKRRQRR | 30b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.83 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIWGWYGYGRKKRRQRR | 30c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMILGWYGYGRKKRRQRR | 30d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDAWYGYGRKKRRQRR | 31a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDLWYGYGRKKRRQRR | 31b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.96 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDIWYGYGRKKRRQRR | 31c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDWWYGYGRKKRRQRR | 31d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.14 ± 0.73 (n at 8) µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDNWYGYGRKKRRQRR | 31e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 7.26 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDKWYGYGRKKRRQRR | 31f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDEWYGYGRKKRRQRR | 31g | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGYGRKKRRQRR | 32a | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGGGYGRKKRRQRR | 32b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGLYGYGRKKRRQRR | 33a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.75 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGAYGYGRKKRRQRR | 33b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGGYGYGRKKRRQRR | 33c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGNYGYGRKKRRQRR | 33d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGKYGYGRKKRRQRR | 33e | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGEYGYGRKKRRQRR | 33f | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWAGYGRKKRRQRR | 34a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWHGYGRKKRRQRR | 34b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWNGYGRKKRRQRR | 34c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 1.72 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWEGYGRKKRRQRR | 34d | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYAYGRKKRRQRR | 35a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYWYGRKKRRQRR | 35b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.05 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYEYGRKKRRQRR | 35c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Modifications To The Inf7 Portion Of The Chimeric Peptide. | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGCYGRKKRRQRR | 36a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.1 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 36b | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 7.9 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 3})YGRKKRRQRR | 36c | Free | Free | Linear | L | Peg 3 = Peg 3 | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 6})YGRKKRRQRR | 36d | Free | Free | Linear | L | Peg 6 = Peg 6 | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg11})YGRKKRRQRR | 36e | Free | Free | Linear | L | Peg11 = Peg11 | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYG({nnr:Peg 27})YGRKKRRQRR | 36f | Free | Free | Linear | L | Peg 27 = Peg 27 | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGKKKKKQKK | 37a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHH | 37b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 (n at 8) µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRR | 37c | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 6.82 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQR | 37d | Free | Free | Linear | L | None | 33 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQ | 37e | Free | Free | Linear | L | None | 32 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRR | 37f | Free | Free | Linear | L | None | 31 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKR | 37g | Free | Free | Linear | L | None | 30 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGHKKHHQHR | 37h | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 (n at 10) µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC | 38a | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | YGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYGC | 38b | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CYGRKKRRQRRGLFEAIEGFIENGWEGMIDGWYG | 38c | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d}C{d} | 38d | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at >100 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}R{d}R{d}Q{d}R{d}R{d}K{d}K{d}R{d}G{d}Y{d}G{d}Y{d}W{d}G{d}D{d}I{d}M{d}G{d}E{d}W{d}G{d}N{d}E{d}I{d}F{d}G{d}E{d}I{d}A{d}E{d}F{d}L{d}G{d} | 38e | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at 1.51 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | C{d}G{d}L{d}F{d}E{d}A{d}I{d}E{d}G{d}F{d}I{d}E{d}N{d}G{d}W{d}E{d}G{d}M{d}I{d}D{d}G{d}W{d}Y{d}G{d}Y{d}G{d}R{d}K{d}K{d}R{d}R{d}Q{d}R{d}R{d} | 38f | Free | Free | Linear | D | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Chimeric Peptide | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRK(Stearoyl){ct:stearoyl} | 39d | stearoyl | Free | Linear | L | stearoyl = stearoyl | 35 | NA | 50 % Hemolysis at 0.94 ± 0.4 (n at 6) µM (pH 7.4) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | GLFEAIEGFIENGWEGMIDGWYGYGRKKRRQRRC{nt:stearoyl} | 39e | Free | stearoyl | Linear | L | stearoyl = stearoyl | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Lipidated Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 40 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRR | 41 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.9 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWKGMIDWWYGYGRKKRRQRR | 42 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 0.29 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGWEGLIDAWYGYGRKKRRQRR | 43 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 44 | Free | Free | Linear | L | None | 37 | NA | ~60 % Hemolysis at 5 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFEAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 45 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 4.32 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CRLFEAIWGFIENGWEGMIDGWYGGGGYGRKKRRQRR | 46 | Free | Free | Linear | L | None | 37 | NA | 50 % Hemolysis at 0.12 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 47 | Free | Free | Linear | L | None | 35 | NA | 50 % Hemolysis at 3.97 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEGFIENGWEGLIDWWYGYGRKKRRQRR | 48 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIWGFIENGWEGLIDGWYGYGRKKRRQRR | 49 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWEGLIDGWYGYGRKKRRQRRR | 50 | Free | Free | Linear | L | None | 35 | NA | ~35 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 51 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.29 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 52 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.41 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 53 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDWWYGYGRKKRRQRR | 54 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.29 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CELFGAIEGFIENGWKGLIDAWYGYGRKKRRQRR | 55 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.19 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGIFGAIEGFIENGWWGLIDAWYGYGRKKRRQRR | 56 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2.35 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGFFEAIEGFIENGLKGLIDAWYGYGRKKRRQRR | 57 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 3.99 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLAEAIEGFIENGLKGLIDWWYGYGRKKRRQRR | 58 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 2 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEAIAEFIEGGWEGLIEGWYGYGRKKRRQRR | 59 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >10 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | C{nnr:Bala}GFEFIEEFIENGLKNLIDWWYGYGRKKRRQRR | 60 | Free | Free | Linear | L | Aβ = β-Ala{nnr:Bala} – β-Alanine , {nnr:Bala} – β-Alanine | 34 | NA | 50 % Hemolysis at 12.8 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGRKKRRQRR | 61 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at 8.07 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 62 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGRKKRRQRR | 63 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGLENLIDWWYGYGHKKHHQHR | 64 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGLENLIDWWYGYGRKKRRQRR | 65 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEEFIEEGWENFIDWWYGYGRKKRRQRR | 66 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFGEIEELIEEGWEGLIDWWYGYGRKKRRQRR | 67 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGRKKRRQRR | 68 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLENLIDWWYGYGHKKHHQHR | 69 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 31159194 | 2019 | CGLFEEIEELIEEGLKNLIDWWYGYGHKKHHQHR | 70 | Free | Free | Linear | L | None | 34 | NA | 50 % Hemolysis at >20 µM (pH 7.4) | Human | Combination Peptide Analogs | NA | NA | ||
| 30951211 | 2019 | {nnr:Nlys}-{nnr:Ntrp}-{nnr:Nlys}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Nile}{nt:H}{ct:Amid} | GN-2 | Amidation | H | Linear | L | Nlys = Nlys, Ntrp = Ntrp, Nile = Nile | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Peptoids Of Gn-2 | NA | Low hemolytic | ||
| 30951211 | 2019 | {nnr:Nlys}-{nnr:Nlys}-{nnr:Nlys}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Nile}{nt:H}{ct:Amid} | GN-2-Nlys1-4Ntrp5-8 | Amidation | H | Linear | L | Nlys = Nlys, Ntrp = Ntrp, Nile = Nile | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Peptoids Of Gn-2 | NA | Low hemolytic | ||
| 30951211 | 2019 | {nnr:Nlys}-{nnr:Ntrp}-{nnr:Nlys}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Ntrp}-{nnr:Nlys}-{nnr:Ntrp}-{nnr:Npm}{nt:H}{ct:Amid} | GN-2-Npm9 | Amidation | H | Linear | L | Nlys = Nlys, Ntrp = Ntrp, Npm = Npm | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Peptoids Of Gn-2 | NA | NA | ||
| 30951211 | 2019 | RWKRWWRWI{ct:Amid} | GN-2 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Peptide | water = α-Helix, TFE = α-Helix | NA | ||
| 30951211 | 2019 | RWRRWWRWI{ct:Amid} | GN-2-Arg1,3,4,7 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Analogue Peptide | water = Random coil, TFE = Random coil | Low hemolytic | ||
| 30951211 | 2019 | KWKKWWKWI{ct:Amid} | GN-2-Lys1,3,4,7 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Analogue Peptide | water = Random coil, TFE = Random coil | Low hemolytic | ||
| 30951211 | 2019 | KKKKWWWWI{ct:Amid} | GN-2-Lys1-4Trp5-8 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Analogue Peptide | NA | Low hemolytic | ||
| 30951211 | 2019 | KWKKWWKWF{ct:Amid} | GN-2-Lys1,3,4,7Phe9 | Amidation | Free | Linear | L | None | 9 | Antibiofilm, Antibacterial | <10 % Hemolysis at 128 μg/mL | Human | Synthetic Analogue Peptide | water = Random coil, TFE = Random coil | NA | ||
| 31303986 | 2019 | IWLTALKFLGKHAAKHLAKQQLSKL{ct:Amid} | M-lycotoxin | Amidation | Free | Linear | L | None | 25 | Antimicrobial | 50 % Hemolysis at 0.78 μM | Human | Wolf Spider Lycosa Carolinensis | α-Helix | NA | ||
| 31303986 | 2019 | GIGKFLHSAKKFGKAFVGEIMNS{nt:Acet}{ct:Amid} | Magainin 2 derivative | Amidation | Acetylation | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at >100 μM | Human | Xenopus Laevis (The African Clawed Frog | α-Helix | Non-hemolytic | ||
| 31303986 | 2019 | KKKKKKKKKGGGLLALLALLA{nt:H}{ct:Amid} | Block | Amidation | H | Linear | L | None | 21 | Antibacterial | 50 % Hemolysis at 25 μM | Human | Synthetic Peptide | 20 mM phosphate buffer solution with 1% SDS solution = α-Helix | NA | ||
| 31303986 | 2019 | KLLKKAGKLLKKAGKLLKKAG{nt:H}{ct:Amid} | Stripe | Amidation | H | Linear | L | None | 21 | Antibacterial | 50 % Hemolysis at >100 μM | Human | Synthetic Peptide | 20 mM phosphate buffer solution with 1% SDS solution = α-Helix | Non-hemolytic | ||
| 31303986 | 2019 | KKKLAKLKLGAKLKLKGKLGA{nt:H}{ct:Amid} | Random | Amidation | H | Linear | L | None | 21 | Antibacterial | 50 % Hemolysis at 100 μM | Human | Synthetic Peptide | 20 mM phosphate buffer solution with 1% SDS solution = α-Helix | Low hemolytic | ||
| 30790604 | 2019 | WFGKLYRGKTKVVKKVKGLLKG{nt:Amid} | Cnd-m3a | Free | Amidation | Linear | L | None | 22 | Antibacterial | 5 % Hemolysis at 3 μM | Human | Mutant Of Cnd(Icefish Chionodraco Hamatus) | α-Helix | NA | ||
| 30790604 | 2019 | WFGKLYRGKTKVVKKVKGLLKG{nt:Amid} | Cnd-m3a | Free | Amidation | Linear | L | None | 22 | Antibacterial | 30 % Hemolysis at 50 μM | Human | Mutant Of Cnd(Icefish Chionodraco Hamatus) | α-Helix | NA | ||
| 32641937 | 2019 | CGAGHVPC-YY{d}({nnr:GABA})F{d}YG{cyc:1-8} | MccJ25-derived peptide | Free | Free | Cyclic | Mix | GABA = gamma amino butyric acid | 14 | Antibacterial | 0.26 ± 0.01 % Hemolysis at 200 μM | Human | Bacteria Enterobacteriacea Mccj25- Derived Peptide | β-Sheet | Non-hemolytic | ||
| 31016969 | 2019 | KKLRLKIAFK | PaDBS1R6F10 | Free | Free | Linear | L | None | 10 | Antibiofilm, Antibacterial, Anti-infective | 50 % Hemolysis at >100 μM | Human | Derived From A Pyrobaculum Aerophilum Ribosomal Protein | NA | Low hemolytic | ||
| 31409990 | 2019 | ILPWKWPWWPWRR{ct:Amid} | indolicidin | Amidation | Free | Linear | L | None | 13 | Antimicrobial, Antifungal | 20 % Hemolysis at 50 µg/mL | Human | Host Defense Peptides (Hdps) | NA | NA | ||
| 31409990 | 2019 | ILPWKWPWWPWRR{ct:Amid} | indolicidin | Amidation | Free | Linear | L | None | 13 | Antimicrobial, Antifungal | 1 % Hemolysis at 0.78 µg/mL | Human | Host Defense Peptides (Hdps) | NA | NA | ||
| 31059203 | 2019 | KWLRRVWRWWR{ct:Amid} | MAP-0403 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 70.7 % Hemolysis at 100 μM | Human | Synthetic Amp | α-Helix | NA | ||
| 31059203 | 2019 | KWLRWVRRRWW{ct:Amid} | J-1 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 46.2 % Hemolysis at 100 μM | Human | Map-0403 Peptide Analogs | SDS = β-Sheet | NA | ||
| 31059203 | 2019 | KWLRRPWRRWR{ct:Amid} | J-2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 3.4 % Hemolysis at 100 μM | Human | Map-0403 Peptide Analogs | SDS = Random coil | Low hemolytic | ||
| 31059203 | 2019 | KWLRRPWRWWR{ct:Amid} | J-3 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 55.6 % Hemolysis at 100 μM | Human | Map-0403 Peptide Analogs | SDS = Random coil | NA | ||
| 31128493 | 2019 | GRTSKQELCTWERGSVRQADKTIAG | Skh-AMP1 | Free | Free | Linear | L | None | 25 | Antifungal | 0.19 % Hemolysis at 3.6 μM | Human | Plant Leaves Satureja Khuzistanica | α-Helix | Low hemolytic | ||
| 31128493 | 2019 | GRTSKQELCTWERGSVRQADKTIAG | Skh-AMP1 | Free | Free | Linear | L | None | 25 | Antifungal | 2.1 % Hemolysis at 72 μM | Human | Plant Leaves Satureja Khuzistanica | α-Helix | Low hemolytic | ||
| 31128493 | 2019 | GRTSKQELCTWERGSVRQADKTIAG | Skh-AMP1 | Free | Free | Linear | L | None | 25 | Antifungal | 0.67 % Hemolysis at 25.2 μM | Human | Plant Leaves Satureja Khuzistanica | α-Helix | Low hemolytic | ||
| 31128493 | 2019 | GRTSKQELCTWERGSVRQADKTIAG | Skh-AMP1 | Free | Free | Linear | L | None | 25 | Antifungal | 0.98 % Hemolysis at 32 μM | Human | Plant Leaves Satureja Khuzistanica | α-Helix | Low hemolytic | ||
| 31128493 | 2019 | GRTSKQELCTWERGSVRQADKTIAG | Skh-AMP1 | Free | Free | Linear | L | None | 25 | Antifungal | 1.45 % Hemolysis at 54 μM | Human | Plant Leaves Satureja Khuzistanica | α-Helix | Low hemolytic | ||
| 31321199 | 2019 | KDRPKKPGLCPLIWWLIIKVG{nt:Amid}{ct:Amid} | omw1 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 4.30 ± 0.15 % Hemolysis at 31.25 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | Low hemolytic | ||
| 31321199 | 2019 | KDRPKKPGLCPLIWWLIIKVG{nt:Amid}{ct:Amid} | omw1 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 4.82 ± 0.33 % Hemolysis at 62.5 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | Low hemolytic | ||
| 31321199 | 2019 | KDRPKKPGLCPLIWWLIIKVG{nt:Amid}{ct:Amid} | omw1 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 6.58 ± 0.25 % Hemolysis at 125 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | NA | ||
| 31321199 | 2019 | KDRPKKPGLCPLIWWLIIKVG{nt:Amid}{ct:Amid} | omw1 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 10.01 ± 0.52 % Hemolysis at 250 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | NA | ||
| 31321199 | 2019 | KDRPKKPGLCPLIWWLIIKVG{nt:Amid}{ct:Amid} | omw1 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 14.46 ± 1.82 % Hemolysis at 500 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | NA | ||
| 31321199 | 2019 | KDRPKKPGLCPAAKKAAAAKA{nt:Amid}{ct:Amid} | omw2 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 1.26 ± 0.38 % Hemolysis at 31.25 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | Low hemolytic | ||
| 31321199 | 2019 | KDRPKKPGLCPAAKKAAAAKA{nt:Amid}{ct:Amid} | omw2 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 3.12 ± 0.38 % Hemolysis at 62.5 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | Low hemolytic | ||
| 31321199 | 2019 | KDRPKKPGLCPAAKKAAAAKA{nt:Amid}{ct:Amid} | omw2 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 2.32 ± 0.43 % Hemolysis at 125 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | Low hemolytic | ||
| 31321199 | 2019 | KDRPKKPGLCPAAKKAAAAKA{nt:Amid}{ct:Amid} | omw2 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 4.82 ± 0.74 % Hemolysis at 250 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | Low hemolytic | ||
| 31321199 | 2019 | KDRPKKPGLCPAAKKAAAAKA{nt:Amid}{ct:Amid} | omw2 | Amidation | Amidation | Linear | L | None | 21 | Antibiofilm, Antibacterial | 9.27 ± 0.27 % Hemolysis at 500 µg/ml | Human | Derived From Snake Venom Peptide, Omwaprin(Oxyuranus Microlepidotus) | NA | NA | ||
| 31375699 | 2019 | KIFKKFKTIIKKVWRIFGRF | AmphiArc2 | Free | Free | Linear | L | None | 20 | Anticancer | 50 % Hemolysis at >15 μM | Human | Synthetic Peptide | water = unstructured, hydrophobic environment (in 50% v/v water:2,2-trifuoroethanol, TFE) = α-Helix | NA | ||
| 30569430 | 2019 | ALFDIIKKIAESF{ct:Amid} | G1A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 4.2 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GAFDIIKKIAESF{ct:Amid} | L2A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLADIIKKIAESF{ct:Amid} | F3A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFAIIKKIAESF{ct:Amid} | D4A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 61 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDAIKKIAESF{ct:Amid} | I5A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1.1 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIAKKIAESF{ct:Amid} | I6A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIAKIAESF{ct:Amid} | K7A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 4.6 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKAIAESF{ct:Amid} | K8A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 89.6 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKAAESF{ct:Amid} | I9A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAASF{ct:Amid} | E11A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 40.2 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKIAEAF{ct:Amid} | S12A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 23.5 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKIAESA{ct:Amid} | F13A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 256 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 58.8 % Hemolysis at 256 µg/ml | Human | Australian Bell Frogs Ranoidea Aurea And Ranoidea Raniformis | phosphate buffer = Random coil, SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | ALFDIIKKIAESF{ct:Amid} | G1A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GAFDIIKKIAESF{ct:Amid} | L2A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLADIIKKIAESF{ct:Amid} | F3A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFAIIKKIAESF{ct:Amid} | D4A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 23.2 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDAIKKIAESF{ct:Amid} | I5A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIAKKIAESF{ct:Amid} | I6A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIAKIAESF{ct:Amid} | K7A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKAIAESF{ct:Amid} | K8A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 49.3 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKAAESF{ct:Amid} | I9A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAASF{ct:Amid} | E11A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 11.9 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKIAEAF{ct:Amid} | S12A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 15.4 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKIAESA{ct:Amid} | F13A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 128 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 19.2 % Hemolysis at 128 µg/ml | Human | Australian Bell Frogs Ranoidea Aurea And Ranoidea Raniformis | phosphate buffer = Random coil, SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | ALFDIIKKIAESF{ct:Amid} | G1A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GAFDIIKKIAESF{ct:Amid} | L2A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLADIIKKIAESF{ct:Amid} | F3A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFAIIKKIAESF{ct:Amid} | D4A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 6.6 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDAIKKIAESF{ct:Amid} | I5A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIAKKIAESF{ct:Amid} | I6A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIAKIAESF{ct:Amid} | K7A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.7 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKAIAESF{ct:Amid} | K8A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 16.1 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKAAESF{ct:Amid} | I9A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAASF{ct:Amid} | E11A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 2.9 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAEAF{ct:Amid} | S12A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 12 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKIAESA{ct:Amid} | F13A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 64 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 4.5 % Hemolysis at 64 µg/ml | Human | Australian Bell Frogs Ranoidea Aurea And Ranoidea Raniformis | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | ALFDIIKKIAESF{ct:Amid} | G1A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GAFDIIKKIAESF{ct:Amid} | L2A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLADIIKKIAESF{ct:Amid} | F3A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFAIIKKIAESF{ct:Amid} | D4A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1.5 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDAIKKIAESF{ct:Amid} | I5A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIAKKIAESF{ct:Amid} | I6A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIAKIAESF{ct:Amid} | K7A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 3.4 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKAIAESF{ct:Amid} | K8A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 5.5 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKAAESF{ct:Amid} | I9A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAASF{ct:Amid} | E11A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.4 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAEAF{ct:Amid} | S12A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 6.5 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKIAESA{ct:Amid} | F13A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 32 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.5 % Hemolysis at 32 µg/ml | Human | Australian Bell Frogs Ranoidea Aurea And Ranoidea Raniformis | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | ALFDIIKKIAESF{ct:Amid} | G1A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GAFDIIKKIAESF{ct:Amid} | L2A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLADIIKKIAESF{ct:Amid} | F3A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFAIIKKIAESF{ct:Amid} | D4A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDAIKKIAESF{ct:Amid} | I5A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIAKKIAESF{ct:Amid} | I6A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIAKIAESF{ct:Amid} | K7A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKAIAESF{ct:Amid} | K8A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKAAESF{ct:Amid} | I9A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAASF{ct:Amid} | E11A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAEAF{ct:Amid} | S12A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 1.2 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKIAESA{ct:Amid} | F13A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 16 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.4 % Hemolysis at 16 µg/ml | Human | Australian Bell Frogs Ranoidea Aurea And Ranoidea Raniformis | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | ALFDIIKKIAESF{ct:Amid} | G1A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GAFDIIKKIAESF{ct:Amid} | L2A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.2 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLADIIKKIAESF{ct:Amid} | F3A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFAIIKKIAESF{ct:Amid} | D4A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDAIKKIAESF{ct:Amid} | I5A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIAKKIAESF{ct:Amid} | I6A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIAKIAESF{ct:Amid} | K7A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKAIAESF{ct:Amid} | K8A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKAAESF{ct:Amid} | I9A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAASF{ct:Amid} | E11A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAEAF{ct:Amid} | S12A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESA{ct:Amid} | F13A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.4 % Hemolysis at 8 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µg/ml | Human | Australian Bell Frogs Ranoidea Aurea And Ranoidea Raniformis | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | ALFDIIKKIAESF{ct:Amid} | G1A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GAFDIIKKIAESF{ct:Amid} | L2A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.4 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLADIIKKIAESF{ct:Amid} | F3A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFAIIKKIAESF{ct:Amid} | D4A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDAIKKIAESF{ct:Amid} | I5A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.2 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIAKKIAESF{ct:Amid} | I6A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.5 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIAKIAESF{ct:Amid} | K7A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKAIAESF{ct:Amid} | K8A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKAAESF{ct:Amid} | I9A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAASF{ct:Amid} | E11A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.2 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAEAF{ct:Amid} | S12A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESA{ct:Amid} | F13A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.5 % Hemolysis at 4 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 4 µg/ml | Human | Australian Bell Frogs Ranoidea Aurea And Ranoidea Raniformis | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | ALFDIIKKIAESF{ct:Amid} | G1A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GAFDIIKKIAESF{ct:Amid} | L2A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.6 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLADIIKKIAESF{ct:Amid} | F3A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFAIIKKIAESF{ct:Amid} | D4A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDAIKKIAESF{ct:Amid} | I5A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIAKKIAESF{ct:Amid} | I6A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.6 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIAKIAESF{ct:Amid} | K7A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKAIAESF{ct:Amid} | K8A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKAAESF{ct:Amid} | I9A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.6 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAASF{ct:Amid} | E11A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 17.4 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | NA | ||
| 30569430 | 2019 | GLFDIIKKIAEAF{ct:Amid} | S12A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESA{ct:Amid} | F13A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.6 % Hemolysis at 2 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 2 µg/ml | Human | Australian Bell Frogs Ranoidea Aurea And Ranoidea Raniformis | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | ALFDIIKKIAESF{ct:Amid} | G1A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GAFDIIKKIAESF{ct:Amid} | L2A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLADIIKKIAESF{ct:Amid} | F3A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFAIIKKIAESF{ct:Amid} | D4A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.2 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDAIKKIAESF{ct:Amid} | I5A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.2 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIAKKIAESF{ct:Amid} | I6A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.4 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIAKIAESF{ct:Amid} | K7A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.2 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKAIAESF{ct:Amid} | K8A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKAAESF{ct:Amid} | I9A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.6 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAASF{ct:Amid} | E11A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.1 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAEAF{ct:Amid} | S12A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | SDS or DPC = α-Helix | Non-hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESA{ct:Amid} | F13A | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0.3 % Hemolysis at 1 µg/ml | Human | Synthetic Analogs Of Aurein 1.2 | phosphate buffer = Random coil, SDS or DPC = α-Helix | Low hemolytic | ||
| 30569430 | 2019 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 1 µg/ml | Human | Australian Bell Frogs Ranoidea Aurea And Ranoidea Raniformis | phosphate buffer = Random coil, SDS or DPC = α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 18 % Hemolysis at 400 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Low hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 5 % Hemolysis at 200 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Low hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 100 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 50 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 25 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 12.5 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 6.25 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31252047 | 2019 | SRSSRAGLQFPVGRIHRLLRK{nt:Acet}{ct:Amid} | Fi-His1-21 | Amidation | Acetylation | Linear | L | None | 21 | Antimicrobial, Anticancer | 0 % Hemolysis at 3.125 μM | Human | Indian White Shrimp Histone, H2A Derived Amp From Fenneropenaeus Indicus | α-Helix | Non-hemolytic | ||
| 31319057 | 2019 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 170 μM | Human | Human Innate Immune Peptide Ll-37 | α-Helix | NA | ||
| 31319057 | 2019 | GFKRIVQRIKDFLRNLV{ct:Amid} | GF-17 | Amidation | Free | Linear | L | None | 17 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 180 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17tF-W | Amidation | Free | Linear | Mix | X1 = 4-t-butylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 12.1 % Hemolysis at 220 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17mF-W | Amidation | Free | Linear | Mix | X1 = 4-methylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 7.1 % Hemolysis at 220 μM | Human | Synthetic Ll-37 Derived Peptides | NA | Low hemolytic | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17W2 | Amidation | Free | Linear | Mix | X1 = 4-methylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 8 % Hemolysis at 220 μM | Human | Synthetic Ll-37 Derived Peptides | NA | Low hemolytic | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17tF2 | Amidation | Free | Linear | Mix | X1 = 4-t-butylphenylalanine, X2 = 4-t-butylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 32.5 % Hemolysis at 220 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17B-tF | Amidation | Free | Linear | Mix | X1 = biphenylalanine, X2 = 4-t-butylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 30.2 % Hemolysis at 220 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KD {nnr:X2}L{d}RKLV{ct:Amid} | 17BIPHE2 | Amidation | Free | Linear | Mix | X1 = biphenylalanine, X2 = biphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 61.5 % Hemolysis at 220 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17tF-W | Amidation | Free | Linear | Mix | X1 = 4-t-butylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 50 % Hemolysis at > 440 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17mF-W | Amidation | Free | Linear | Mix | X1 = 4-methylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 50 % Hemolysis at > 440 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17W2 | Amidation | Free | Linear | Mix | X1 = 4-methylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 50 % Hemolysis at > 440 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17tF2 | Amidation | Free | Linear | Mix | X1 = 4-t-butylphenylalanine, X2 = 4-t-butylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 50 % Hemolysis at > 440 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KDWL{d}RKLV{ct:Amid} | 17B-tF | Amidation | Free | Linear | Mix | X1 = biphenylalanine, X2 = 4-t-butylphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 50 % Hemolysis at > 440 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31319057 | 2019 | G{nnr:X1}KRL{d}VQRL{d}KD {nnr:X2}L{d}RKLV{ct:Amid} | 17BIPHE2 | Amidation | Free | Linear | Mix | X1 = biphenylalanine, X2 = biphenylalanine, l = D amino acid | 17 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 180 μM | Human | Synthetic Ll-37 Derived Peptides | NA | NA | ||
| 31880884 | 2019 | MLSTKQLVILGLLGCLSTLQAGVVLNVNPGKSLEEPAVKHLKVSPVNANEVPVLKELKSVQKTKSGDTLYGFVCTVGQIKTDSLGCVGSDSVAWPSEQNVELTVSCDKSNVGRIITYVEVHFVVSTQNVGCNVSAGSIGTSSIEVKVYAAGTNYLEYSSLFYIQ | AMP17 | Free | Free | Linear | L | None | 164 | Antimicrobial, Antifungal | 1.47 % Hemolysis at 300 μM | Human | Housefly Musca Domestica | Random coil, Extended Strand and ɑ-Helix | Non-hemolytic | ||
| 31489876 | 2019 | GFGGGRGGFGGGRGGFGGGGIGGGGFGGGYGGGKIKG{ct:Amid} | Serrulin | Amidation | Free | Linear | L | None | 37 | Antimicrobial | 0 % Hemolysis at 60 µg/mL | Human | Tityus Serrulatus (Brazilian Scorpion) | NA | Non-hemolytic | ||
| 31541146 | 2019 | VAEARQGSFSY | Pinipesin | Free | Free | Linear | L | None | 11 | Antimicrobial | 29.12 % Hemolysis at 1 M | Human | Centipede Scolopendra Subspinipes Subspinipes | water = Helix, 50% TFE/water = type II β-Turn | NA | ||
| 31541146 | 2019 | VAEARQGSFSY | Pinipesin | Free | Free | Linear | L | None | 11 | Antimicrobial | 25.14 % Hemolysis at 500 μM | Human | Centipede Scolopendra Subspinipes Subspinipes | water = Helix, 50% TFE/water = type II β-Turn | NA | ||
| 31541146 | 2019 | VAEARQGSFSY | Pinipesin | Free | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 250 μM | Human | Centipede Scolopendra Subspinipes Subspinipes | water = Helix, 50% TFE/water = type II β-Turn | Non-hemolytic | ||
| 31541146 | 2019 | VAEARQGSFSY | Pinipesin | Free | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 125 μM | Human | Centipede Scolopendra Subspinipes Subspinipes | water = Helix, 50% TFE/water = type II β-Turn | Non-hemolytic | ||
| 31541146 | 2019 | VAEARQGSFSY | Pinipesin | Free | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 32 μM | Human | Centipede Scolopendra Subspinipes Subspinipes | water = Helix, 50% TFE/water = type II β-Turn | Non-hemolytic | ||
| 31541146 | 2019 | VAEARQGSFSY | Pinipesin | Free | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 16 μM | Human | Centipede Scolopendra Subspinipes Subspinipes | water = Helix, 50% TFE/water = type II β-Turn | Non-hemolytic | ||
| 31541146 | 2019 | VAEARQGSFSY | Pinipesin | Free | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 8 μM | Human | Centipede Scolopendra Subspinipes Subspinipes | water = Helix, 50% TFE/water = type II β-Turn | Non-hemolytic | ||
| 31541146 | 2019 | VAEARQGSFSY | Pinipesin | Free | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 4 μM | Human | Centipede Scolopendra Subspinipes Subspinipes | water = Helix, 50% TFE/water = type II β-Turn | Non-hemolytic | ||
| 31448889 | 2019 | KIKKIIKKIIKI{ct:Amid} | A1 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 5 % Hemolysis at 4000 μM | Human | Synthetic Surfactant-Like Cationic Amps | α-Helical | Low hemolytic | ||
| 31448889 | 2019 | GIVKOIVKOIVKOI{ct:Amid} | A2 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 4000 μM | Human | Synthetic Surfactant-Like Cationic Amps | α-Helical | Low hemolytic | ||
| 31448889 | 2019 | GIVKKIVKKIVKKI{ct:Amid} | A3 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 1500 μM | Human | Synthetic Surfactant-Like Cationic Amps | α-Helical | Low hemolytic | ||
| 31448889 | 2019 | GIIKKIIKKIIKKI | A4 | Free | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 2000 μM | Human | Synthetic Surfactant-Like Cationic Amps | α-Helical | Low hemolytic | ||
| 31448889 | 2019 | GIIKKIIKKIIKKI{ct:Amid} | A5 (G3) | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 900 μM | Human | Synthetic Surfactant-Like Cationic Amps | α-Helical | Low hemolytic | ||
| 31448889 | 2019 | GILKKILKKILKKL{ct:Amid} | A6 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 80 μM | Human | Synthetic Surfactant-Like Cationic Amps | α-Helical | NA | ||
| 31513374 | 2019 | CFQWKRAMRKVR{ct:Amid} | HLopt2-NH2 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 200 µg/ml | Human | Antimicrobial Analogue | NA | Non-hemolytic | ||
| 31513374 | 2019 | {conj:CIP-CH2CO}CFQWKRAMRKVR{ct:Amid} | CIP-CH2CO-HLopt2-NH2 | Amidation | CIP-CH2CO | Linear | L | Cip = ciprofloxacin | 12 | Antibacterial | 0 % Hemolysis at 200 µg/ml | Human | Hlopt2 With Conjugate | NA | Non-hemolytic | ||
| 31513374 | 2019 | {conj:CIP-Cys-S-S}CFQWKRAMRKVR{ct:Amid} | CIP-Cys-S-S-HLopt2-NH2 | Amidation | CIP-Cys-S-S | Linear | L | Cip = ciprofloxacin | 13 | Antibacterial | 0 % Hemolysis at 200 µg/ml | Human | Hlopt2 With Conjugate | NA | Non-hemolytic | ||
| 31513374 | 2019 | {conj:LVX}CFQWKRAMRKVR{ct:Amid} | LVX-HLopt2-NH2 | Amidation | LVX | Linear | L | Lvx = levofloxacin | 12 | Antibacterial | 0 % Hemolysis at 200 µg/ml | Human | Hlopt2 With Conjugate | NA | Non-hemolytic | ||
| 31671555 | 2019 | FLSLIPHVISAIPHVVNALSNL{ct:Amid} | Phylloseptin-SP1 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | >40 % Hemolysis at 64 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | NA | ||
| 31671555 | 2019 | ASWKVFLKNIGKAAGKAVLNSVTDMVNQ{ct:Amid} | Dermaseptin-SP2 | Amidation | Free | Linear | L | None | 31 | Antimicrobial | <4 % Hemolysis at 64 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | Non-hemolytic | ||
| 31671555 | 2019 | SLWSSIKDMAAAAGRAALNAVNGIVNP{ct:Amid} | Dermaseptin-SP3 | Amidation | Free | Linear | L | None | 30 | Antimicrobial | <4 % Hemolysis at 64 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | Non-hemolytic | ||
| 31671555 | 2019 | SLWSSIKDMAAAAGRAALNAVNGILNP{ct:Amid} | Dermaseptin-SP4 | Amidation | Free | Linear | L | None | 30 | Antimicrobial | <4 % Hemolysis at 64 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | Non-hemolytic | ||
| 31671555 | 2019 | SLRSSIKDMAAAAGRAALNAVNGIVNP{ct:Amid} | Dermaseptin-SP5 | Amidation | Free | Linear | L | None | 30 | Antimicrobial | <2 % Hemolysis at 64 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | Non-hemolytic | ||
| 31671555 | 2019 | FLSLIPHVISAIPHVVNALSNL{ct:Amid} | Phylloseptin-SP1 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | >85 % Hemolysis at 256 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | NA | ||
| 31671555 | 2019 | ASWKVFLKNIGKAAGKAVLNSVTDMVNQ{ct:Amid} | Dermaseptin-SP2 | Amidation | Free | Linear | L | None | 31 | Antimicrobial | >10 % Hemolysis at 256 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | NA | ||
| 31671555 | 2019 | SLWSSIKDMAAAAGRAALNAVNGIVNP{ct:Amid} | Dermaseptin-SP3 | Amidation | Free | Linear | L | None | 30 | Antimicrobial | >10 % Hemolysis at 256 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | NA | ||
| 31671555 | 2019 | SLWSSIKDMAAAAGRAALNAVNGILNP{ct:Amid} | Dermaseptin-SP4 | Amidation | Free | Linear | L | None | 30 | Antimicrobial | >10 % Hemolysis at 256 μM | Human | Agalychnis Spurrelli (Gliding Leaf Frog) | α-Helix | NA | ||
| 31749789 | 2019 | RLCRIVVIRVCR{ct:Amid} | L2C3V10C11 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at 64 μM | Human | Derivatives Of Bactenecin | microbial membrane mimetic environments α-Helix | Low hemolytic | ||
| 31749789 | 2019 | RRFRIVVIRWLR{ct:Amid} | R2F3W10L11 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at 128 μM | Human | Derivatives Of Bactenecin | microbial membrane mimetic environments α-Helix | Low hemolytic | ||
| 31749789 | 2019 | RRWRIVVIRWRR{ct:Amid} | R2W3W10R11 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at 128 μM | Human | Derivatives Of Bactenecin | microbial membrane mimetic environments α-Helix | Low hemolytic | ||
| 31749789 | 2019 | RKWRIVVIRVRR{ct:Amid} | K2W3V10R11 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at >256 μM | Human | Derivatives Of Bactenecin | microbial membrane mimetic environments α-Helix | Non-hemolytic | ||
| 31749789 | 2019 | RWRRIVVIRVRR{ct:Amid} | W2R3V10R11 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at >256 μM | Human | Derivatives Of Bactenecin | microbial membrane mimetic environments α-Helix | Non-hemolytic | ||
| 31749789 | 2019 | RWKRIVVIRKRR{ct:Amid} | W2K3K10R11 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at >256 μM | Human | Derivatives Of Bactenecin | microbial membrane mimetic environments α-Helix | Non-hemolytic | ||
| 31749789 | 2019 | RKRRIVVIRRKR{ct:Amid} | K2R3R10K11 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at >256 μM | Human | Derivatives Of Bactenecin | microbial membrane mimetic environments α-Helix | Non-hemolytic | ||
| 31710627 | 2019 | FPFLLSLIPSAISAIKRL{ct:Amid} | Uy234 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 26.18 % Hemolysis at 380 μM | Human | Scorpion Urodacus Yaschenkoi | α-Helix | Low hemolytic | ||
| 31710627 | 2019 | ILSAIWSGIKGLL{ct:Amid} | Uy17 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 25 % Hemolysis at >380 μM | Human | Scorpion Urodacus Yaschenkoi | α-Helix | Low hemolytic | ||
| 31710627 | 2019 | FLSTIWNGIKGLL{ct:Amid} | Uy192 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 25 % Hemolysis at >380 μM | Human | Scorpion Urodacus Yaschenkoi | α-Helix | Low hemolytic | ||
| 31710627 | 2019 | FFSLIPSLISGLI{ct:Amid} | QnCs-BUAP | Amidation | Free | Linear | L | None | 13 | Antibacterial | 25 % Hemolysis at >380 μM | Human | Synthetic Peptide From Conserved Region | α-Helix | Low hemolytic | ||
| 31752079 | 2019 | FLQHIIGALGHLF | GHa | Free | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 10 % Hemolysis at 20 µM | Human | Frog Hylarana Guentheri | α-Helix | NA | ||
| 31752079 | 2019 | FLQKIIGALGKLF | GHaK | Free | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 10 % Hemolysis at 16 µM | Human | Gha Analogues | α-Helix | NA | ||
| 31752079 | 2019 | FLQKIIGALGHLF | GHa4K | Free | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 10 % Hemolysis at 26 µM | Human | Gha Analogues | α-Helix | NA | ||
| 31752079 | 2019 | FLQHIIGALGKLF | GHa11K | Free | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 10 % Hemolysis at 15 µM | Human | Gha Analogues | α-Helix | NA | ||
| 31752079 | 2019 | FLQHIIGALGHLF | GHa | Free | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 115 µM | Human | Frog Hylarana Guentheri | α-Helix | NA | ||
| 31752079 | 2019 | FLQKIIGALGKLF | GHaK | Free | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 66 µM | Human | Gha Analogues | α-Helix | NA | ||
| 31752079 | 2019 | FLQKIIGALGHLF | GHa4K | Free | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 69 µM | Human | Gha Analogues | α-Helix | NA | ||
| 31752079 | 2019 | FLQHIIGALGKLF | GHa11K | Free | Free | Linear | L | None | 13 | Antimicrobial, Antibiofilm | 50 % Hemolysis at 40 µM | Human | Gha Analogues | α-Helix | NA | ||
| 31667994 | 2019 | GIGKFLHSAKKFGKAFVGEIMNS{nt:H}{ct:Amid} | Mag 2 | Amidation | H | Linear | L | None | 23 | Antibacterial | Hemolysis at >100 µM | Human | Frogs | 1%SDS = α-Helix | NA | ||
| 31667994 | 2019 | GIGKFLHSAKKFGKAFV{nt:H}{ct:Amid} | peptide-7 | Amidation | H | Linear | L | None | 17 | Antibacterial | Hemolysis at >100 µM | Human | Truncated Peptide | 1%SDS = Random coil | NA | ||
| 31667994 | 2019 | GIKKFLKSAKKFVKAFK{nt:H}{ct:Amid} | peptide-8 | Amidation | H | Linear | L | None | 17 | Antibacterial | Hemolysis at 50 µM | Human | Truncated Peptide | 1%SDS = α-Helix | NA | ||
| 31667994 | 2019 | GIGKFLHS{nnr:U}KKFGK{nnr:U}FV{nt:H}{ct:Amid} | peptide-9 | Amidation | H | Linear | L | U = Aib(2-aminoisobutyric acid) | 17 | Antibacterial | Hemolysis at >100 µM | Human | Truncated Peptide | 1%SDS = α-Helix | NA | ||
| 31667994 | 2019 | GIGKFLHS{nnr:Z}KKFGK{nnr:Z}FV{nt:H}{ct:Amid} | peptide-10 | Amidation | H | Linear | L | Z = Ac6c(1-aminocyclohexylcarboxylic acid) | 17 | Antibacterial | Hemolysis at 3 µM | Human | Truncated Peptide | NA | NA | ||
| 31667994 | 2019 | GIKKFLKS{nnr:U}KKFVK{nnr:U}FK{nt:H}{ct:Amid} | peptide-11 | Amidation | H | Linear | L | U = Aib(2-aminoisobutyric acid) | 17 | Antibacterial | Hemolysis at 50 µM | Human | Truncated Peptide | 1%SDS = Helical | NA | ||
| 31667994 | 2019 | GIKKFLKS{nnr:Z}KKFVK{nnr:Z}FK{nt:H}{ct:Amid} | peptide-12 | Amidation | H | Linear | L | Z = Ac6c(1-aminocyclohexylcarboxylic acid) | 17 | Antibacterial | Hemolysis at 3 µM | Human | Truncated Peptide | 1%SDS = Helical | NA | ||
| 31775224 | 2019 | IRPIRP{cyc:N-C} | OIR1 | Free | Free | Cyclic | L | None | 6 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic Cyclic Amps | aqueous = unordered, β-Hairpin | Low hemolytic | ||
| 31775224 | 2019 | IRIRPIRIRP{cyc:N-C} | OIR2 | Free | Free | Cyclic | L | None | 10 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic Cyclic Amps | aqueous = unordered, β-Hairpin | Low hemolytic | ||
| 31775224 | 2019 | IRIRIRPIRIRIRP{cyc:N-C} | OIR3 | Free | Free | Cyclic | L | None | 14 | Antibacterial, Anti-Inflammatory | ≥5 % Hemolysis at >128 µM | Human | Synthetic Cyclic Amps | aqueous = unordered, β-Hairpin | Low hemolytic | ||
| 31775224 | 2019 | IRPIRP | IR1 | Free | Free | Linear | L | None | 6 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic Linear Amps | aqueous = unordered, 30 mM anionic = unordered | Low hemolytic | ||
| 31775224 | 2019 | IRIRPIRIRP | IR2 | Free | Free | Linear | L | None | 10 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic Linear Amps | aqueous = unordered, 30 mM anionic = unordered | Low hemolytic | ||
| 31775224 | 2019 | IRIRIRPIRIRIRP | IR3 | Free | Free | Linear | L | None | 14 | Antibacterial, Anti-Inflammatory | ≥5 % Hemolysis at >128 µM | Human | Synthetic Linear Amps | aqueous = unordered, 30 mM anionic = unordered | Low hemolytic | ||
| 31775224 | 2019 | IRP{d}IRP{d} | DIR1 | Free | Free | Linear | Mix | p = D-Proline | 6 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic D-Proline Amps | 50% TFE = β-Sheet | Low hemolytic | ||
| 31775224 | 2019 | IRIRP{d}IRIRP{d} | DIR2 | Free | Free | Linear | Mix | p = D-Proline | 10 | Antibacterial | ≥5 % Hemolysis at >128 µM | Human | Synthetic D-Proline Amps | aqueous = unordered, 50% TFE = β-Sheet | Low hemolytic | ||
| 31775224 | 2019 | IRIRIRP{d}IRIRIRP{d} | DIR3 | Free | Free | Linear | Mix | p = D-Proline | 14 | Antibacterial, Anti-Inflammatory | ≥5 % Hemolysis at >128 µM | Human | Synthetic D-Proline Amps | aqueous = unordered, 50% TFE = β-Hairpin | Low hemolytic | ||
| 31442359 | 2019 | WLKAAAKAAAKLW{ct:Amid} | WL | Amidation | Free | Linear | L | None | 13 | Antibacterial | 5 % Hemolysis at 256 µM | Human | Synthetic Peptide | 30 mM SDS or 50% TFE = α‐Helix | Low hemolytic | ||
| 31442359 | 2019 | LWKAAAKAAAKWL{ct:Amid} | LW | Amidation | Free | Linear | L | None | 13 | Antibacterial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | 30 mM SDS or 50% TFE = α‐Helix | Low hemolytic | ||
| 31442359 | 2019 | LWKAAAKAAAKLL{ct:Amid} | LW-1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 5 % Hemolysis at 256 µM | Human | Synthetic Peptide | 30 mM SDS or 50% TFE = α‐Helix | Low hemolytic | ||
| 31442359 | 2019 | LWKAAAKAAAKLW{ct:Amid} | LW-2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 5 % Hemolysis at 256 µM | Human | Synthetic Peptide | 30 mM SDS or 50% TFE = α‐Helix | Low hemolytic | ||
| 31442359 | 2019 | AAKAWLKLWAKAA{ct:Amid} | LW-3 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 5 % Hemolysis at >256 µM | Human | Synthetic Peptide | 30 mM SDS or 50% TFE = α‐Helix | Low hemolytic | ||
| 31642159 | 2019 | ILGKIWEGIKSLF{ct:Amid} | IsCT1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 6.25 mmol/L | Human | Scorpion Venom Opisthacanthus Madagascariensis | α-Helical | NA | ||
| 31642159 | 2019 | ILLKIWEGIKSLF{ct:Amid} | [L]3-IsCT1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 3.3 mmol/L | Human | Isct1 Analogs | α-Helical | NA | ||
| 31642159 | 2019 | ALGKFWEKIKSLF{ct:Amid} | [A]1[F]5[K]8-IsCT1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 25 μmol/L | Human | Isct1 Analogs | α-Helical | NA | ||
| 31642159 | 2019 | ILKKIWEGIKSLF{ct:Amid} | [K]3-IsCT1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 6.25 μmol/L | Human | Isct1 Analogs | α-Helical | NA | ||
| 31642159 | 2019 | ILGKFWEGIKSLF{ct:Amid} | [F]5-IsCT1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 6.25 mmol/L | Human | Isct1 Analogs | α-Helical | NA | ||
| 31642159 | 2019 | ILGKIWEPIKSLF{ct:Amid} | [P]8-IsCT1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 100 μmol/L | Human | Isct1 Analogs | α-Helical | Non-hemolytic | ||
| 31642159 | 2019 | WLGKIWEGIKSLF{ct:Amid} | [W]1-IsCT1 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 0 % Hemolysis at 1.56 mmol/L | Human | Isct1 Analogs | α-Helical | NA | ||
| 31668583 | 2019 | {nnr:Dap}-KKK{nt:(C12)2}{ct:Amid} | 1 | Amidation | (C12)2 | Linear | L | Dap = 2,3-diaminopropionic, C12 = lauric acid | 4 | Antimicrobial | 50 % Hemolysis at 128 µg/mL | Human | Lipopeptides With Surfactant | NA | NA | ||
| 31668583 | 2019 | {nnr:Dab}-KKK{nt:(C12)2}{ct:Amid} | 2 | Amidation | (C12)2 | Linear | L | Dab = 2,4-diaminobutyric, C12 = lauric acid | 4 | Antimicrobial | 13 % Hemolysis at 128 µg/mL | Human | Lipopeptides With Surfactant | NA | Low hemolytic | ||
| 31713951 | 2019 | KGIRGYKGGYCKGAFKQTCKCY | Os | Free | Free | Linear | L | None | 22 | Antibacterial | 0 % Hemolysis at 25 µM | Human | Soft Tick Ornithodoros Savignyi | NA | Non-hemolytic | ||
| 31713951 | 2019 | IRGYKGGYCK{ct:Amid} | Os(3‐12)NH2 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 0 % Hemolysis at 25 µM | Human | Synthetic Peptide Analogues Of Os | water = unstructured, SDS = unstructured | Non-hemolytic | ||
| 31713951 | 2019 | CKGAFKQTCKCY{ct:Amid} | Os(11‐22)NH2 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 µM | Human | Synthetic Peptide Analogues Of Os | water = Random coil, SDS = Random coil | Non-hemolytic | ||
| 31713951 | 2019 | KGIRGYKGGYCKGAFKQTCKCY | Os | Free | Free | Linear | L | None | 22 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Soft Tick Ornithodoros Savignyi | NA | Non-hemolytic | ||
| 31713951 | 2019 | IRGYKGGYCK{ct:Amid} | Os(3‐12)NH2 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide Analogues Of Os | water = unstructured, SDS = unstructured | Non-hemolytic | ||
| 31713951 | 2019 | CKGAFKQTCKCY{ct:Amid} | Os(11‐22)NH2 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Synthetic Peptide Analogues Of Os | water = Random coil, SDS = Random coil | Non-hemolytic | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 23 % Hemolysis at 150 µM | Human | Synthetic All D-Peptide Analogue Peptide | TFE = α-Helical | NA | ||
| 31847173 | 2019 | A{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-1 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 41 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}A{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-2 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 59 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}A{d}F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-3 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 2 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | Low hemolytic | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})A{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-4 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 22 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}A{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-5 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 47 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}A{d}K{d}({nnr:nle}){ct:Amid} | D2D analog-6 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 10 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})A{d}({nnr:nle}){ct:Amid} | D2D analog-7 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 67 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}A{d}{ct:Amid} | D2D analog-8 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 5 % Hemolysis at 150 µM | Human | D2D Analogues | α-Helical | Low hemolytic | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}({nnr:1-nal})({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-9 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 20 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}({nnr:dap})({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-10 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, dap = Diaminopropionic acid, D-amino acid | 8 | Antimicrobial | 28 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}({nnr:nle})({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-11 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 33 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}F{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-12 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 74 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}S{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-13 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 29 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}T{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-14 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 28 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}Y{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-15 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 40 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}V{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-16 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 54 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})({nnr:1-nal})({nnr:nle}){ct:Amid} | D2D analog-17 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 89 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})({nnr:dap})({nnr:nle}){ct:Amid} | D2D analog-18 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, dap = Diaminopropionic acid, D-amino acid | 8 | Antimicrobial | 21 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})({nnr:nle})({nnr:nle}){ct:Amid} | D2D analog-19 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 56 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})F{d}({nnr:nle}){ct:Amid} | D2D analog-20 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 91 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})S{d}({nnr:nle}){ct:Amid} | D2D analog-21 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 85 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})T{d}({nnr:nle}){ct:Amid} | D2D analog-22 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 66 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})Y{d}({nnr:nle}){ct:Amid} | D2D analog-23 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 74 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})V{d}({nnr:nle}){ct:Amid} | D2D analog-24 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}K{d}({nnr:1-nal})({nnr:nle}){ct:Amid} | D2D analog-25 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 50 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})({nnr:nle})K{d}{ct:Amid} | D2D analog-26 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 18 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-27 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 7 | Antimicrobial | 49 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | ({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-28 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 6 | Antimicrobial | 62 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-29 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 5 | Antimicrobial | 12 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}{ct:Amid} | D2D analog-30 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, D-amino acid | 7 | Antimicrobial | 11 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal}){ct:Amid} | D2D analog-31 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, D-amino acid | 6 | Antimicrobial | 20 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}{ct:Amid} | D2D analog-32 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, D-amino acid | 5 | Antimicrobial | 5 % Hemolysis at 150 µM | Human | D2D Analogues | NA | Low hemolytic | ||
| 31847173 | 2019 | R{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-33 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 60 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}R{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-34 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 35 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}R{d}({nnr:1-nal})K{d}({nnr:nle}){ct:Amid} | D2D analog-35 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 49 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31847173 | 2019 | K{d}K{d}({nnr:1-nal})F{d}K{d}({nnr:1-nal})R{d}({nnr:nle}){ct:Amid} | D2D analog-36 | Amidation | Free | Linear | D | 1-nal = D-1-naphthylalanine, nle = D-Norleucine, D-amino acid | 8 | Antimicrobial | 51 % Hemolysis at 150 µM | Human | D2D Analogues | NA | NA | ||
| 31549575 | 2019 | GVTF{d}NALK{d}GVAK{d}TVAAQLLK{d}TAR{cT{d}:Amid} | Brevinin-GR23 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antibiofilm | 0.13 % Hemolysis at 25 µM | Human | Frog Hylarana Guentheri | aqueous = Random coil, 30 mM SDS and 50% TFE solution(MME) = α-Helical | Non-hemolytic | ||
| 31549575 | 2019 | GVTF{d}NALK{d}GVAK{d}TVAAQLLK{d}TAR{cT{d}:Amid} | Brevinin-GR23 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antibiofilm | 0.23 % Hemolysis at 50 µM | Human | Frog Hylarana Guentheri | aqueous = Random coil, 30 mM SDS and 50% TFE solution(MME) = α-Helical | Non-hemolytic | ||
| 31549575 | 2019 | GVTF{d}NALK{d}GVAK{d}TVAAQLLK{d}TAR{cT{d}:Amid} | Brevinin-GR23 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antibiofilm | 0.38 % Hemolysis at 75 µM | Human | Frog Hylarana Guentheri | aqueous = Random coil, 30 mM SDS and 50% TFE solution(MME) = α-Helical | Non-hemolytic | ||
| 31549575 | 2019 | GVTF{d}NALK{d}GVAK{d}TVAAQLLK{d}TAR{cT{d}:Amid} | Brevinin-GR23 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antibiofilm | 0.75 % Hemolysis at 100 µM | Human | Frog Hylarana Guentheri | aqueous = Random coil, 30 mM SDS and 50% TFE solution(MME) = α-Helical | Non-hemolytic | ||
| 31549575 | 2019 | GVTF{d}NALK{d}GVAK{d}TVAAQLLK{d}TAR{cT{d}:Amid} | Brevinin-GR23 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antibiofilm | 0.83 % Hemolysis at 150 µM | Human | Frog Hylarana Guentheri | aqueous = Random coil, 30 mM SDS and 50% TFE solution(MME) = α-Helical | Non-hemolytic | ||
| 31549575 | 2019 | GVTF{d}NALK{d}GVAK{d}TVAAQLLK{d}TAR{cT{d}:Amid} | Brevinin-GR23 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antibiofilm | 1.6 % Hemolysis at 200 µM | Human | Frog Hylarana Guentheri | aqueous = Random coil, 30 mM SDS and 50% TFE solution(MME) = α-Helical | Low hemolytic | ||
| 30678611 | 2019 | FFTTSCRSGC | OA-FF10 | Free | Free | Linear | L | None | 10 | Promoted Wound healing and proliferation of human keratinocytes (HaCaT) | 0 % Hemolysis at 100 µM | Human | Frog Species, Odorrana Andersonii | NA | Non-hemolytic | ||
| 32435168 | 2020 | GWINEKKMQQKIDEKIGKNIIGGMAKAVIHKMAKNEFQCVANVDTLGNCKKHCAKTTGEKGYCHGTKCKCGIELSY | Smp76 | Free | Free | Linear | L | None | 76 | Antiviral | 50 % Hemolysis at >10 μg/ml | Human | Scorpion Scorpio Maurus Palmatus | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}RR{ct:Amid} | 3 | Amidation | C12 = Dodecanoic acid | Linear | L | None | 2 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}RR{ct:Amid} | 4 | Amidation | C14 = tetradecanoic acid | Linear | L | None | 2 | Antimicrobial | 50 % Hemolysis at 68.43(±1.41) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C16 = hexadecanoic acid}RR{ct:Amid} | 5 | Amidation | C16 = hexadecanoic acid | Linear | L | None | 2 | Antimicrobial | 50 % Hemolysis at 22.91(±1.18) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C18 = octadecanoic acid}RR{ct:Amid} | 6 | Amidation | C18 = octadecanoic acid | Linear | L | None | 2 | Antimicrobial | 50 % Hemolysis at 25.19(±0.67) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:A}RR{ct:Amid} | 10 | Amidation | C14 = tetradecanoic acid | Linear | L | A = non-proteinogenic amino acid A | 3 | Antimicrobial | 50 % Hemolysis at 41.08(±0.62) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:C(Acm)}RR{ct:Amid} | 14 | Amidation | C14 = tetradecanoic acid | Linear | L | C(Acm) = Acm = S-acetamidomethyl group(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 39.72(±1.25) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:D}RR{ct:Amid} | 18 | Amidation | C14 = tetradecanoic acid | Linear | L | D = non-proteinogenic amino acid D | 3 | Antimicrobial | 50 % Hemolysis at 49.95(±1.00) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:E}RR{ct:Amid} | 22 | Amidation | C14 = tetradecanoic acid | Linear | L | E = non-proteinogenic amino acid E | 3 | Antimicrobial | 50 % Hemolysis at 59.51(±4.00) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C10 = decanoic}{nnr:F}RR{ct:Amid} | 24 | Amidation | C10 = decanoic | Linear | L | F = non-proteinogenic amino acid F | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:F}RR{ct:Amid} | 25 | Amidation | C12 = Dodecanoic acid | Linear | L | F = non-proteinogenic amino acid F | 3 | Antimicrobial | 50 % Hemolysis at 91.21(±16.38) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:F}RR{ct:Amid} | 26 | Amidation | C14 = tetradecanoic acid | Linear | L | F = non-proteinogenic amino acid F | 3 | Antimicrobial | 50 % Hemolysis at 39.09(±1.18) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:G}RR{ct:Amid} | 29 | Amidation | C12 = Dodecanoic acid | Linear | L | G = non-proteinogenic amino acid G | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:G}RR{ct:Amid} | 30 | Amidation | C14 = tetradecanoic acid | Linear | L | G = non-proteinogenic amino acid G | 3 | Antimicrobial | 50 % Hemolysis at 31.94(±1.99) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:H}RR{ct:Amid} | 34 | Amidation | C14 = tetradecanoic acid | Linear | L | H = non-proteinogenic amino acid H | 3 | Antimicrobial | 50 % Hemolysis at 50.31(±0.52) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:I}RR{ct:Amid} | 37 | Amidation | C12 = Dodecanoic acid | Linear | L | I = non-proteinogenic amino acid I | 3 | Antimicrobial | 50 % Hemolysis at 120.40(±1.55) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:I}RR{ct:Amid} | 38 | Amidation | C14 = tetradecanoic acid | Linear | L | I = non-proteinogenic amino acid I | 3 | Antimicrobial | 50 % Hemolysis at 78.92(±4.38) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:K}RR{ct:Amid} | 42 | Amidation | C14 = tetradecanoic acid | Linear | L | K = non-proteinogenic amino acid K | 3 | Antimicrobial | 50 % Hemolysis at 212.08(±6.12) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:L}RR{ct:Amid} | 45 | Amidation | C12 = Dodecanoic acid | Linear | L | L = non-proteinogenic amino acid L | 3 | Antimicrobial | 50 % Hemolysis at 112.81(±1.39) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:L}RR{ct:Amid} | 46 | Amidation | C14 = tetradecanoic acid | Linear | L | L = non-proteinogenic amino acid L | 3 | Antimicrobial | 50 % Hemolysis at 29.50(±1.05) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:M}RR{ct:Amid} | 49 | Amidation | C12 = Dodecanoic acid | Linear | L | M = non-proteinogenic amino acid M | 3 | Antimicrobial | 50 % Hemolysis at 206.50(±9.14) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:M}RR{ct:Amid} | 50 | Amidation | C14 = tetradecanoic acid | Linear | L | M = non-proteinogenic amino acid M | 3 | Antimicrobial | 50 % Hemolysis at 35.11(±0.90) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:M(O)}RR{ct:Amid} | 54 | Amidation | C14 = tetradecanoic acid | Linear | L | Met(O)/M(O) = methionine sulfoxide(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 116.28(±1.77) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:M(O2)}RR{ct:Amid} | 58 | Amidation | C14 = tetradecanoic acid | Linear | L | Met(O2)/M(O2) = methionine sulfone(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 70.11(±2.93) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:N}RR{ct:Amid} | 62 | Amidation | C14 = tetradecanoic acid | Linear | L | N = non-proteinogenic amino acid N | 3 | Antimicrobial | 50 % Hemolysis at 64.37(±2.23) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C10 = decanoic}{nnr:Nle}RR{ct:Amid} | 64 | Amidation | C10 = decanoic | Linear | L | Nle = Norleucine(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:Nle}RR{ct:Amid} | 65 | Amidation | C12 = Dodecanoic acid | Linear | L | Nle = Norleucine(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:Nle}RR{ct:Amid} | 66 | Amidation | C14 = tetradecanoic acid | Linear | L | Nle = Norleucine(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 37.54(±1.39) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:Nva}RR{ct:Amid} | 69 | Amidation | C12 = Dodecanoic acid | Linear | L | Nva = Norvaline(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 207.62(±5.27) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:Nva}RR{ct:Amid} | 70 | Amidation | C14 = tetradecanoic acid | Linear | L | Nva = Norvaline(non-proteinogenic Amino acid) | 3 | Antimicrobial | 50 % Hemolysis at 42.04(±1.38) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:P}RR{ct:Amid} | 73 | Amidation | C12 = Dodecanoic acid | Linear | L | P = non-proteinogenic amino acid P | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:P}RR{ct:Amid} | 74 | Amidation | C14 = tetradecanoic acid | Linear | L | P = non-proteinogenic amino acid P | 3 | Antimicrobial | 50 % Hemolysis at 53.41(±1.84) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:Q}RR{ct:Amid} | 78 | Amidation | C14 = tetradecanoic acid | Linear | L | Q = non-proteinogenic amino acid Q | 3 | Antimicrobial | 50 % Hemolysis at 72.31(±3.00) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:R}{nnr:R}{nnr:R}{ct:Amid} | 81 | Amidation | C12 = Dodecanoic acid | Linear | L | R = non-proteinogenic amino acid R | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:R}{nnr:R}{nnr:R}{ct:Amid} | 82 | Amidation | C14 = tetradecanoic acid | Linear | L | R = non-proteinogenic amino acid R | 3 | Antimicrobial | 50 % Hemolysis at 211.32(±9.57) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:S}RR{ct:Amid} | 86 | Amidation | C14 = tetradecanoic acid | Linear | L | S = non-proteinogenic amino acid S | 3 | Antimicrobial | 50 % Hemolysis at 41.54(±1.29) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:T}RR{ct:Amid} | 89 | Amidation | C12 = Dodecanoic acid | Linear | L | T = non-proteinogenic amino acid T | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:T}RR{ct:Amid} | 90 | Amidation | C14 = tetradecanoic acid | Linear | L | T = non-proteinogenic amino acid T | 3 | Antimicrobial | 50 % Hemolysis at 43.43(±0.90) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:V}RR{ct:Amid} | 93 | Amidation | C12 = Dodecanoic acid | Linear | L | V = non-proteinogenic amino acid V | 3 | Antimicrobial | 50 % Hemolysis at 246.30(±14.12) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:V}RR{ct:Amid} | 94 | Amidation | C14 = tetradecanoic acid | Linear | L | V = non-proteinogenic amino acid V | 3 | Antimicrobial | 50 % Hemolysis at 30.73(±0.41) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C10 = decanoic}{nnr:W}RR{ct:Amid} | 96 | Amidation | C10 = decanoic | Linear | L | W = non-proteinogenic amino acid W | 3 | Antimicrobial | 50 % Hemolysis at >256 μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:W}RR{ct:Amid} | 97 | Amidation | C12 = Dodecanoic acid | Linear | L | W = non-proteinogenic amino acid W | 3 | Antimicrobial | 50 % Hemolysis at 42.42(±0.57) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:W}RR{ct:Amid} | 98 | Amidation | C14 = tetradecanoic acid | Linear | L | W = non-proteinogenic amino acid W | 3 | Antimicrobial | 50 % Hemolysis at 36.91 (±0.89) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C12 = Dodecanoic acid}{nnr:Y}RR{ct:Amid} | 101 | Amidation | C12 = Dodecanoic acid | Linear | L | Y = non-proteinogenic amino acid Y | 3 | Antimicrobial | 50 % Hemolysis at 123.08 (±1.12) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C14 = tetradecanoic acid}{nnr:Y}RR{ct:Amid} | 102 | Amidation | C14 = tetradecanoic acid | Linear | L | Y = non-proteinogenic amino acid Y | 3 | Antimicrobial | 50 % Hemolysis at 46.52 (±5.24) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | NA | ||
| 31936341 | 2020 | {conj:C10(6) = 2‐hexyldecanoic}RR{ct:Amid} | 105 | Amidation | C10(6) = 2‐hexyldecanoic | Linear | L | C10(6) = 2‐hexyldecanoic | 2 | Antimicrobial | 50 % Hemolysis at 200.25 (±16.07) μg/ml | Human | Synthetic Ultrashort Cationic Lipopeptides | NA | Low hemolytic | ||
| 31887002 | 2020 | LKKLCARLKKLCAR{ct:Amid} | CAR2 | Amidation | Free | Linear | L | None | 14 | Antifungal, Antibacterial | 10 % Hemolysis at >128 µM | Human | Heptad Repeat Sequence Antifungal Peptide | PBS = Random coil, PBS(208-222nm) = α-Helical, SDS/TFE = α-Helical | Low hemolytic | ||
| 31887002 | 2020 | LKKLCARLKKLCARLKKLCAR{ct:Amid} | CAR3 | Amidation | Free | Linear | L | None | 21 | Antifungal, Antibacterial | 10 % Hemolysis at >128 µM | Human | Heptad Repeat Sequence Antifungal Peptide | PBS = Random coil, PBS(208-222nm) = α-Helical, SDS/TFE = α-Helical | Low hemolytic | ||
| 31887002 | 2020 | LKKLCARLKKLCARLKKLCARLKKLCAR{ct:Amid} | CAR4 | Amidation | Free | Linear | L | None | 28 | Antifungal, Antibacterial | 10 % Hemolysis at 8 µM | Human | Heptad Repeat Sequence Antifungal Peptide | PBS = Random coil, SDS/TFE = α-Helical | NA | ||
| 31887002 | 2020 | LKKLACRLKKLACR{ct:Amid} | ACR2 | Amidation | Free | Linear | L | None | 14 | Antifungal, Antibacterial | 10 % Hemolysis at >128 µM | Human | Heptad Repeat Sequence Antifungal Peptide | PBS = Random coil, PBS(208-222nm) = α-Helical, SDS/TFE = α-Helical | Low hemolytic | ||
| 31887002 | 2020 | LKKLACRLKKLACRLKKLACR{ct:Amid} | ACR3 | Amidation | Free | Linear | L | None | 21 | Antibiofilm, Antifungal, Antibacterial | 10 % Hemolysis at >128 µM | Human | Heptad Repeat Sequence Antifungal Peptide | PBS = Random coil, PBS(208-222nm) = α-Helical, SDS/TFE = α-Helical | Low hemolytic | ||
| 31887002 | 2020 | LKKLACRLKKLACRLKKLACRLKKLACR{ct:Amid} | ACR4 | Amidation | Free | Linear | L | None | 28 | Antifungal, Antibacterial | 10 % Hemolysis at 32 µM | Human | Heptad Repeat Sequence Antifungal Peptide | PBS = Random coil, PBS(208-222nm) = α-Helical, SDS/TFE = α-Helical | NA | ||
| 31887002 | 2020 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin (MLT) | Amidation | Free | Linear | L | None | 26 | Antifungal, Antibacterial | 10 % Hemolysis at 1 µM | Human | Heptad Repeat Sequence Antifungal Peptide | PBS = Random coil, PBS(208-222nm) = α-Helical, SDS/TFE = α-Helical | NA | ||
| 31802582 | 2020 | GWWRRTVDKVRNAGRKVAGFASKACGALGH{ct:-OH} | P1-HC1 (EeCentrocin 1) | -OH | Free | Linear | L | None | 30 | Antimicrobial | 74.6 % Hemolysis at 200 μM | Human | Sea Urchin Echinus Esculentus | α‐Helix | NA | ||
| 31802582 | 2020 | GWWRRTVDKVRNAGRK{ct:-OH} | P2-HC(1‐16) | -OH | Free | Linear | L | None | 16 | Antibacterial | 0 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKVRNAGRK{ct:Amid} | P3-HC(1‐16)A8 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Low hemolytic | ||
| 31802582 | 2020 | AWWRRTVAKVRK{ct:Amid} | P8-G1A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 1.6 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Low hemolytic | ||
| 31802582 | 2020 | GAWRRTVAKVRK{ct:Amid} | P9-W2A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWARRTVAKVRK{ct:Amid} | P10-W3A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWARTVAKVRK{ct:Amid} | P11-R4A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 3.6 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Low hemolytic | ||
| 31802582 | 2020 | GWWRATVAKVRK{ct:Amid} | P12-R5A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRAVAKVRK{ct:Amid} | P13-T6A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 4.1 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Low hemolytic | ||
| 31802582 | 2020 | GWWRRTAAKVRK{ct:Amid} | P14-V7A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKVRK{ct:Amid} | P6-HC(1‐12)A8K12 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 25.1 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | α‐‐Helical | NA | ||
| 31802582 | 2020 | GWWRRTVAAVRK{ct:Amid} | P15-K9A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5.1 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Low hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKARK{ct:Amid} | P16-V10A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 1 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKVAK{ct:Amid} | P17-R11A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKVRA{ct:Amid} | P18-K12A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 200 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVDKVRNAGRKVAGFASKACGALGH{ct:-OH} | P1-HC1 (EeCentrocin 1) | -OH | Free | Linear | L | None | 30 | Antimicrobial | 13.5 % Hemolysis at 25 μM | Human | Sea Urchin Echinus Esculentus | α‐Helix | NA | ||
| 31802582 | 2020 | GWWRRTVDKVRNAGRK{ct:-OH} | P2-HC(1‐16) | -OH | Free | Linear | L | None | 16 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKVRNAGRK{ct:Amid} | P3-HC(1‐16)A8 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | AWWRRTVAKVRK{ct:Amid} | P8-G1A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GAWRRTVAKVRK{ct:Amid} | P9-W2A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWARRTVAKVRK{ct:Amid} | P10-W3A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWARTVAKVRK{ct:Amid} | P11-R4A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRATVAKVRK{ct:Amid} | P12-R5A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRAVAKVRK{ct:Amid} | P13-T6A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0.9 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Low hemolytic | ||
| 31802582 | 2020 | GWWRRTAAKVRK{ct:Amid} | P14-V7A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKVRK{ct:Amid} | P6-HC(1‐12)A8K12 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 2.4 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | α‐‐Helical | NA | ||
| 31802582 | 2020 | GWWRRTVAAVRK{ct:Amid} | P15-K9A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKARK{ct:Amid} | P16-V10A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKVAK{ct:Amid} | P17-R11A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31802582 | 2020 | GWWRRTVAKVRA{ct:Amid} | P18-K12A | Amidation | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolysis at 25 μM | Human | Truncated P1 Pepetide | NA | Non-hemolytic | ||
| 31862270 | 2020 | PFKISIHL | Jellein | Free | Free | Linear | L | None | 8 | Antibacterial, Anti-leishmanial activity, inhibition of Leishmania major promastigotes | 8 % Hemolysis at 500 μg/ml | Human | Royal Jelly Of Honeybee | NA | Low hemolytic | ||
| 31862270 | 2020 | {conj:Lauric acid}PFKISIHL | Lauric acid – Jellein (L-Jellein) | Free | Lauric acid | Linear | L | None | 8 | Anti-leishmanial | 0 % Hemolysis at 500 μg/ml | Human | Lauric Acid Conjugated Jellein | NA | Non-hemolytic | ||
| 31862270 | 2020 | LPKPPKPVSKMRMATPLLMQALPM | CLIP | Free | Free | Linear | L | None | 24 | Anti-leishmanial | 0 % Hemolysis at 500 μg/ml | Human | Mhc Class Ii Associated Invariant Chain Peptide | NA | Non-hemolytic | ||
| 31862270 | 2020 | {conj:Lauric acid}LPKPPKPVSKMRMATPLLMQALPM | Lauric acid-LIP (L-CLIP) | Free | Lauric acid | Linear | L | None | 24 | Antibacterial | 58 % Hemolysis at 319 μg/ml | Human | Lauric Acid Conjugated Clip | NA | NA | ||
| 32024261 | 2020 | KARKKKLNKKGRKMAGRKRGRPKK | Dot1l | Free | Free | Linear | L | None | 24 | CPPs (Cell-penetrating peptides) | <0.5 % Hemolysis at 10 μM | Human | Human Gene Dot1L | α-Helical | Non-hemolytic | ||
| 32024261 | 2020 | KARKKKLNKKGRKMAGRKRGRPKK | Dot1l | Free | Free | Linear | L | None | 24 | CPPs (Cell-penetrating peptides) | <0.5 % Hemolysis at 7.5 μM | Human | Human Gene Dot1L | α-Helical | Non-hemolytic | ||
| 31927997 | 2020 | KLLKLLKKLLKLLK | KL1 | Free | Free | Linear | L | None | 14 | Anticancer | 10 % Hemolysis at 0.52 μM | Human | Synthetic Peptide | PBS buffer = α-Helical, deionized water and 0.9% NaCl = Random coil | NA | ||
| 31927997 | 2020 | KELKLLKKLLKLLK | L2E | Free | Free | Linear | L | None | 14 | Anticancer | 10 % Hemolysis at 61.7 μM | Human | Kl1 Analogues. | Random coil, 10%TFE = single Helix | NA | ||
| 31927997 | 2020 | KQLKLLKKLLKLLK | L2Q | Free | Free | Linear | L | None | 14 | Anticancer | 10 % Hemolysis at 35.5 μM | Human | Kl1 Analogues. | NA | NA | ||
| 31927997 | 2020 | KKLKLLKKLLKLLK | L2K | Free | Free | Linear | L | None | 14 | Anticancer | 10 % Hemolysis at 19.5 μM | Human | Kl1 Analogues. | NA | NA | ||
| 32153522 | 2020 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at >80 μM | Human | Human Host Defense Peptide | SDS = α-Helical, Tris-buffer = Random coil | NA | ||
| 32153522 | 2020 | KRIVQRIKDFLR | KR-12 | Free | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at >80 μM | Human | Fragment Of Ll-37 | SDS = α-Helical, Tris-buffer = Random coil | NA | ||
| 32153522 | 2020 | AGGKRIVQRIKDFLRGAGGKRIVQRIKDFLRG{cyc:N-C} | cd4 | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 50 % Hemolysis at >40 μM | Human | Cyclized Kr-12 Dimer | SDS = α-Helical, Tris-buffer = Random coil | NA | ||
| 32153522 | 2020 | AGGKRIVKRIKKFLRGAGGKRIVKRIKKFLRG{cyc:N-C} | cd4(Q5K,D9K) | Free | Free | Cyclic | L | None | 32 | Antimicrobial | 50 % Hemolysis at 10 μM | Human | Cyclized Kr-12 Dimer | SDS = α-Helical, Tris-buffer = Random coil | NA | ||
| 32153547 | 2020 | RNGCIVDPRCPYQQCRRPLYCRRR | NCR247 | Free | Free | Linear | L | None | 24 | Antibacterial | 1.75 % Hemolysis at 100 μM | Human | Plant Medicago Truncatula Nodule-Specific Cysteine-Rich (Ncr) Peptides | NA | Low hemolytic | ||
| 32153547 | 2020 | QQCRRPLYCRRR | NCR247C | Free | Free | Linear | L | None | 12 | Antibacterial | 0.88 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | QQCRRPLYCRRRWSHPQFEK | NCR247C-StrepII | Free | Free | Linear | L | None | 20 | Antibacterial | 1.75 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | RPLNFKMLRFWGQQQCRRPLYCRRR | X1-NCR247C | Free | Free | Linear | L | None | 25 | Antibacterial | 3.51 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | RPLNFKMLRFWGQQQCRRPLYCRRRWSHPQFEK | X1-NCR247C-StrepII | Free | Free | Linear | L | None | 33 | Antibacterial | 3.51 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | QQCRRPLYCRRRKALAALAKKIL | NCR247C-X2 | Free | Free | Linear | L | None | 23 | Antibacterial | 7.02 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | NA | ||
| 32153547 | 2020 | QQCRRPLYCRRRKALAALAKKILWSHPQFEK | NCR247C-X2-StrepII | Free | Free | Linear | L | None | 31 | Antibacterial | 11.4 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | NA | ||
| 32153547 | 2020 | KALAALAKKILQQCRRPLYCRRR | X2-NCR247C | Free | Free | Linear | L | None | 23 | Antibacterial | 6.14 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | NA | ||
| 32153547 | 2020 | KALAALAKKIL | X2 | Free | Free | Linear | L | None | 11 | Antibacterial | 1.75 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | GWTLNSAGYLLGKINLKALAALAKKIL | Transportan | Free | Free | Linear | L | None | 27 | Antibacterial | 95.61 % Hemolysis at 100 μM | Human | Derivatives Of Ncr247 | NA | NA | ||
| 32153547 | 2020 | RNGCIVDPRCPYQQCRRPLYCRRR | NCR247 | Free | Free | Linear | L | None | 24 | Antibacterial | 0.88 % Hemolysis at 25 μM | Human | Plant Medicago Truncatula Nodule-Specific Cysteine-Rich (Ncr) Peptides | NA | Low hemolytic | ||
| 32153547 | 2020 | QQCRRPLYCRRR | NCR247C | Free | Free | Linear | L | None | 12 | Antibacterial | 0.88 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | QQCRRPLYCRRRWSHPQFEK | NCR247C-StrepII | Free | Free | Linear | L | None | 20 | Antibacterial | 1.75 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | RPLNFKMLRFWGQQQCRRPLYCRRR | X1-NCR247C | Free | Free | Linear | L | None | 25 | Antibacterial | 1.75 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | RPLNFKMLRFWGQQQCRRPLYCRRRWSHPQFEK | X1-NCR247C-StrepII | Free | Free | Linear | L | None | 33 | Antibacterial | 1.75 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | QQCRRPLYCRRRKALAALAKKIL | NCR247C-X2 | Free | Free | Linear | L | None | 23 | Antibacterial | 1.75 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | QQCRRPLYCRRRKALAALAKKILWSHPQFEK | NCR247C-X2-StrepII | Free | Free | Linear | L | None | 31 | Antibacterial | 6.14 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | NA | ||
| 32153547 | 2020 | KALAALAKKILQQCRRPLYCRRR | X2-NCR247C | Free | Free | Linear | L | None | 23 | Antibacterial | 1.75 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | KALAALAKKIL | X2 | Free | Free | Linear | L | None | 11 | Antibacterial | 0.88 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | Low hemolytic | ||
| 32153547 | 2020 | GWTLNSAGYLLGKINLKALAALAKKIL | Transportan | Free | Free | Linear | L | None | 27 | Antibacterial | 38.6 % Hemolysis at 25 μM | Human | Derivatives Of Ncr247 | NA | NA | ||
| 30962256 | 2019 | LRHKVYGYCVLGP{ct:Amid} | Periplanetasin-4 | Amidation | Free | Linear | L | None | 13 | Antifungal | 0 % Hemolysis at 1.3 μM | Human | American Cockroach (Periplaneta Americana) | NA | Low hemolytic | ||
| 30962256 | 2019 | LRHKVYGYCVLGP{ct:Amid} | Periplanetasin-4 | Amidation | Free | Linear | L | None | 13 | Antifungal | 0 % Hemolysis at 2.5 μM | Human | American Cockroach (Periplaneta Americana) | NA | Low hemolytic | ||
| 30962256 | 2019 | LRHKVYGYCVLGP{ct:Amid} | Periplanetasin-4 | Amidation | Free | Linear | L | None | 13 | Antifungal | 0 % Hemolysis at 5 μM | Human | American Cockroach (Periplaneta Americana) | NA | Low hemolytic | ||
| 30962256 | 2019 | LRHKVYGYCVLGP{ct:Amid} | Periplanetasin-4 | Amidation | Free | Linear | L | None | 13 | Antifungal | 0 % Hemolysis at 10 μM | Human | American Cockroach (Periplaneta Americana) | NA | Low hemolytic | ||
| 30962256 | 2019 | LRHKVYGYCVLGP{ct:Amid} | Periplanetasin-4 | Amidation | Free | Linear | L | None | 13 | Antifungal | 0 % Hemolysis at 20 μM | Human | American Cockroach (Periplaneta Americana) | NA | Low hemolytic | ||
| 30962256 | 2019 | LRHKVYGYCVLGP{ct:Amid} | Periplanetasin-4 | Amidation | Free | Linear | L | None | 13 | Antifungal | 0 % Hemolysis at 40 μM | Human | American Cockroach (Periplaneta Americana) | NA | Low hemolytic | ||
| 30962256 | 2019 | LRHKVYGYCVLGP{ct:Amid} | Periplanetasin-4 | Amidation | Free | Linear | L | None | 13 | Antifungal | 0 % Hemolysis at 80 μM | Human | American Cockroach (Periplaneta Americana) | NA | Low hemolytic | ||
| 31954105 | 2020 | LRKVRRLLRRL{nt:Amid}{ct:Amid} | AMP 21 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 25 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical, SDS = α-Helical | Non-hemolytic | ||
| 31954105 | 2020 | LRKVWRWLRRL{nt:Amid}{ct:Amid} | AMP 22 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 25 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical | Non-hemolytic | ||
| 31954105 | 2020 | LRKFRRLLRRL{nt:Amid}{ct:Amid} | AMP 23 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 25 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical | Non-hemolytic | ||
| 31954105 | 2020 | LRRLRRLLRRL{nt:Amid}{ct:Amid} | AMP 24 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 25 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical | Non-hemolytic | ||
| 31954105 | 2020 | LRKVRRLLRRL{nt:Amid}{ct:Amid} | AMP 21 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 50 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical, SDS = α-Helical | Non-hemolytic | ||
| 31954105 | 2020 | LRKVWRWLRRL{nt:Amid}{ct:Amid} | AMP 22 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | >10 % Hemolysis at 50 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical | NA | ||
| 31954105 | 2020 | LRKFRRLLRRL{nt:Amid}{ct:Amid} | AMP 23 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | >5 % Hemolysis at 50 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical | Low hemolytic | ||
| 31954105 | 2020 | LRRLRRLLRRL{nt:Amid}{ct:Amid} | AMP 24 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | >5 % Hemolysis at 50 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical | Low hemolytic | ||
| 31954105 | 2020 | LRKVRRLLRRL{nt:Amid}{ct:Amid} | AMP 21 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 100 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical, SDS = α-Helical | Non-hemolytic | ||
| 31954105 | 2020 | LRKVWRWLRRL{nt:Amid}{ct:Amid} | AMP 22 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | >10 % Hemolysis at 100 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical | NA | ||
| 31954105 | 2020 | LRKFRRLLRRL{nt:Amid}{ct:Amid} | AMP 23 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | >5 % Hemolysis at 100 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical | Low hemolytic | ||
| 31954105 | 2020 | LRRLRRLLRRL{nt:Amid}{ct:Amid} | AMP 24 | Amidation | Amidation | Linear | L | None | 11 | Antimicrobial | >5 % Hemolysis at 100 μM | Human | Synthetic Salt Tolerant Undecapeptides | water = Random coil, TFE = Helical, DPC = Random coil, D8PG = α-Helical | Low hemolytic | ||
| 32206496 | 2020 | RKGSRMGKKCECP | Tn CRT2 | Free | Free | Linear | L | None | 13 | Antimicrobial | 50.38 % Hemolysis at 40 μM | Human | Toadfish Thalassophryne Nattereri | α-Helix, aqueous bufer = Random coil | NA | ||
| 32206496 | 2020 | RKGSQMGKKCECP | Tn CRT3 | Free | Free | Linear | L | None | 13 | Antimicrobial | 34.49 % Hemolysis at 40 μM | Human | Toadfish Thalassophryne Nattereri | β-Sheet, aqueous bufer = Random coil | NA | ||
| 32003561 | 2020 | KWCFRVCYRGICYRRCRX | TPI (Tachyplesin I) | Free | Free | Linear | L | None | 18 | Antimicrobial | ≤10 % Hemolysis at 0.25 μg/mL | Human | Asian Horseshoe Crabs Tachypleus Tridentatus | β-Hairpin | NA | ||
| 32003561 | 2020 | K{d}W{d}C{d}F{d}R{d}V{d}C{d}Y{d}R{d}G{d}L{d}C{d}Y{d}R{d}R{d}C{d}R{d}X{d} | TPAD | Free | Free | Linear | D | None | 18 | Antibacterial | 10 % Hemolysis at 16 μg/mL | Human | D-Amino Acid Analogue Of Tpi | β-Hairpin | NA | ||
| 32134261 | 2020 | FIIWPLRYRK{ct:Amid} | somuncurin-1 | Amidation | Free | Linear | L | None | 10 | Antibacterial | <5 % Hemolysis at 180 μM | Human | Frog Pleurodema Somuncurence | water = Random coil, TFE = α-Helical | Low hemolytic | ||
| 32134261 | 2020 | FILKRSYPQYY{ct:Amid} | somuncurin-2 | Amidation | Free | Linear | L | None | 11 | Antibacterial | <5 % Hemolysis at 180 μM | Human | Frog Pleurodema Somuncurence | water = Random coil, TFE = Random coil | Low hemolytic | ||
| 32134261 | 2020 | NLVGSLLGGILKK{ct:Amid} | thaulin-3 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <5 % Hemolysis at 180 μM | Human | Frog Pleurodema Somuncurence | water = Random coil, TFE = α-Helix | Low hemolytic | ||
| 32342079 | 2020 | RLKKIGKVLKWI{ct:Amid} | RI12 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Dodecapeptide From Pig (Porcine Myeloid Antimicrobial Peptide-36 (Pmap-36) | 10 mM PBS = Random coil + <30% α-Helical, TFE = α-Helical | Low hemolytic | ||
| 32342079 | 2020 | RWKKIGKVWKWI{ct:Amid} | RI12[L2W,L9W] | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Dodecapeptide From Pig (Porcine Myeloid Antimicrobial Peptide-36 (Pmap-36) | 10 mM PBS & TFE = TrpZip Hairpin | Low hemolytic | ||
| 32342079 | 2020 | RWKKIGWVWKWI{ct:Amid} | RI12[L2W,K7W,L9W] | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at 128 μM | Human | Dodecapeptide From Pig (Porcine Myeloid Antimicrobial Peptide-36 (Pmap-36) | 10 mM PBS & TFE = TrpZip Hairpin | Low hemolytic | ||
| 32342079 | 2020 | RLKKIGWVLKWI{ct:Amid} | RI12[K7W] | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at 128 μM | Human | Dodecapeptide From Pig (Porcine Myeloid Antimicrobial Peptide-36 (Pmap-36) | 10 mM PBS = Random coil + <30% α-Helical, TFE = α-Helical | Low hemolytic | ||
| 32342079 | 2020 | RLWKIGKVLKWI{ct:Amid} | RI12[K3W] | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Dodecapeptide From Pig (Porcine Myeloid Antimicrobial Peptide-36 (Pmap-36) | 10 mM PBS = Random coil + <30% α-Helical, TFE = α-Helical | Low hemolytic | ||
| 32342079 | 2020 | RLWKIGWVLKWI{ct:Amid} | RI12[K3W,K7W] | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at 32 μM | Human | Dodecapeptide From Pig (Porcine Myeloid Antimicrobial Peptide-36 (Pmap-36) | 10 mM PBS = Random coil + <30% α-Helical, TFE = α-Helical | NA | ||
| 32342079 | 2020 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antimicobial | 5 % Hemolysis at 0.25 μM | Human | Honey Bee | α-Helical | NA | ||
| 32367434 | 2020 | PFKISIHL{ct:Amid} | JI (Jelleine-I) | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal | 50 % Hemolysis at 500 µmol /L | Human | Buffer = Random Coil, Anionic Environments = Β-Strands | octapeptide royal jelly honey bee | Low hemolytic | ||
| 32367434 | 2020 | PWKISIHL{ct:Amid} | JIF2W | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal | 50 % Hemolysis at 500 µmol /L | Human | Buffer = Random Coil, Anionic Environments = Β-Strands | analogs of Jelleine-I | Low hemolytic | ||
| 32367434 | 2020 | PWRISIRL{ct:Amid} | JIF2WR | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal | 50 % Hemolysis at 91 µmol /L | Human | Buffer = Random Coil, Anionic Environments = Β-Strands | analogs of Jelleine-I | NA | ||
| 32619153 | 2020 | ITRYLDKILRILRKYLKA | Pep-IA18 | Free | Free | Linear | L | None | 18 | Antifungal, Antibiofilm | 1 % Hemolysis at 450 μM | Human | Designed From Profilin, A Protein From Insect (Fall Armyworm)Spodoptera Frugiperda | water = Random coil, 50% TFE/water (v/v) and SDS micelle = α-Helix | Non-hemolytic | ||
| 32619153 | 2020 | ITRYLDKILRILRKYLKA | Pep-IA18 | Free | Free | Linear | L | None | 18 | Antifungal, Antibiofilm | | Human | Designed From Profilin, A Protein From Insect (Fall Armyworm)Spodoptera Frugiperda | water = Random coil, 50% TFE/water (v/v) and SDS micelle = α-Helix | Non-hemolytic | | ||
| 33937618 | 2020 | LLKELWTKMKGAGKAVLGKIKGLL | L1 | Free | Free | Linear | L | None | 24 | Antibacterial | 1 % Hemolysis at 15 μM | Human | Ponerine Ant Neoponera Goeldii | water = Random/dosordered structure, lipid vesicles = α-Helix | Low hemolytic | ||
| 33937618 | 2020 | LLKQLWTKMKGAGKAVLGKIKGLL | L1-Q | Free | Free | Linear | L | None | 24 | Antibacterial | 1 % Hemolysis at 15 μM | Human | L1 Variants | water = Random/dosordered structure, lipid vesicles = α-Helix | Low hemolytic | ||
| 33937618 | 2020 | LLKKLWTKMKGAGKAVLGKIKGLL | L1-K | Free | Free | Linear | L | None | 24 | Antibacterial | 1 % Hemolysis at 15 μM | Human | L1 Variants | water = Random/dosordered structure, lipid vesicles = α-Helix | Low hemolytic | ||
| 33937618 | 2020 | LLRELWTRMRGAGRAVLGRIRGLL | L1-R | Free | Free | Linear | L | None | 24 | Antibacterial | <5 % Hemolysis at 15 μM | Human | L1 Variants | water = Random/dosordered structure, lipid vesicles = α-Helix | Low hemolytic | ||
| 33937618 | 2020 | LL{nnr:O}ELWT{nnr:O}M{nnr:O}GAG{nnr:O}AVLG{nnr:O}I{nnr:O}GLL | L1-O | Free | Free | Linear | L | O = L-Ornithine | 24 | Antibacterial | 1 % Hemolysis at 15 μM | Human | L1 Variants | water = Helical, lipid vesicles = α-Helix | Low hemolytic | ||
| 33937618 | 2020 | LL{nnr:X}ELWT{nnr:X}M{nnr:X}GAG{nnr:X}AVLG{nnr:X}I{nnr:X}GLL | L1-X | Free | Free | Linear | L | X = L-di-amino-propionic acid | 24 | Antibacterial | 1 % Hemolysis at 15 μM | Human | L1 Variants | water = Random/dosordered structure, lipid vesicles = α-Helix | Low hemolytic | ||
| 32169940 | 2020 | MEKLMVLNEEKLSYVIGGGNPKVAHCASQIGRSTAWGAVSGAATGTAVGQAVGALGGALFGGSMGVIKGSAACVSYLTRHRHH | acidocin 4356 ACD | Free | Free | Linear | L | None | 83 | Antivirulence, Antimicrobial | 50 % Hemolysis at >400 μg/mL | Human | Lactobacillus Acidophilus | Helical | Low hemolytic | ||
| 32443921 | 2020 | FLGAILKIGHALAKTVLPMVTNAFKPKQ | Figainin 2 | Free | Free | Linear | L | None | 28 | Antibacterial, Anticancer, Anti-Epimastigote, Antiviral, Antitrypanosomal, exhibits immunomodulatory effects in human neutrophils | 50 % Hemolysis at 48.9 μM | Human | Skin Chaco Tree Frog, Boana Raniceps | α-Helix, Milli-Q water and 10% (v/v) TFE = Random coil, 30% and 50% (v/v) TFE = α-Helix | NA | ||
| 32443921 | 2020 | FLGAILKIGHALAKTVLPMVTNAFKPKQ | Figainin 2 | Free | Free | Linear | L | None | 28 | Antibacterial, Anticancer, Anti-Epimastigote, Antiviral, Antitrypanosomal, exhibits immunomodulatory effects in human neutrophils | 23 % Hemolysis at 32 μM | Human | Skin Chaco Tree Frog, Boana Raniceps | α-Helix, Milli-Q water and 10% (v/v) TFE = Random coil, 30% and 50% (v/v) TFE = α-Helix | NA | ||
| 32443921 | 2020 | FLGAILKIGHALAKTVLPMVTNAFKPKQ | Figainin 2 | Free | Free | Linear | L | None | 28 | Antibacterial, Anticancer, Anti-Epimastigote, Antiviral, Antitrypanosomal, exhibits immunomodulatory effects in human neutrophils | 9 % Hemolysis at 16 μM | Human | Skin Chaco Tree Frog, Boana Raniceps | α-Helix, Milli-Q water and 10% (v/v) TFE = Random coil, 30% and 50% (v/v) TFE = α-Helix | NA | ||
| 32670215 | 2020 | KRFWQLVPLAIKIYRAWKRR{ct:Amid} | dCATH | Amidation | Free | Linear | L | None | 20 | Antibacterial | 10 % Hemolysis at 4 μM | Human | Cath Amp From Duck | α-Helix | NA | ||
| 32670215 | 2020 | KRFAQLVPLAIKIYRAAKRR{ct:Amid} | dCATH-AA | Amidation | Free | Linear | L | None | 20 | Antibacterial | 10 % Hemolysis at 256 μM | Human | Modified Verison Of Dcath | α-Helix | Low hemolytic | ||
| 32670215 | 2020 | KRFWQLVPLAIKIYRA{ct:Amid} | dCATH(1–16) | Amidation | Free | Linear | L | None | 16 | Antibacterial | 10 % Hemolysis at 256 μM | Human | Modified Verison Of Dcath | α-Helix | Low hemolytic | ||
| 32670215 | 2020 | KRFWQLVPLAIKIYRAW{ct:Amid} | dCATH(1–17) | Amidation | Free | Linear | L | None | 17 | Antibacterial | 10 % Hemolysis at 8 μM | Human | Modified Verison Of Dcath | α-Helix | NA | ||
| 32670215 | 2020 | KRFWQLVPLAIKIYRAWK{ct:Amid} | dCATH(1–18) | Amidation | Free | Linear | L | None | 18 | Antibacterial | 10 % Hemolysis at 8 μM | Human | Modified Verison Of Dcath | α-Helix | NA | ||
| 32670215 | 2020 | QLVPLAIKIYRAWKRR{ct:Amid} | dCATH(5–20) | Amidation | Free | Linear | L | None | 16 | Antibacterial | 10 % Hemolysis at 128 μM | Human | Modified Verison Of Dcath | α-Helix | Low hemolytic | ||
| 32670215 | 2020 | WQLVPLAIKIYRAWKRR{ct:Amid} | dCATH(4–20) | Amidation | Free | Linear | L | None | 17 | Antibacterial | 10 % Hemolysis at 16 μM | Human | Modified Verison Of Dcath | α-Helix | NA | ||
| 32670215 | 2020 | FWQLVPLAIKIYRAWKRR{ct:Amid} | dCATH(3–20) | Amidation | Free | Linear | L | None | 18 | Antibacterial | 10 % Hemolysis at 4 μM | Human | Modified Verison Of Dcath | α-Helix | NA | ||
| 32670215 | 2020 | QLVPLAIKIYRA{ct:Amid} | dCATH(5–16) | Amidation | Free | Linear | L | None | 12 | Antibacterial | 10 % Hemolysis at 256 μM | Human | Modified Verison Of Dcath | unordered conformation | Low hemolytic | ||
| 32670215 | 2020 | KRFAQLVPLAIKIYRA{ct:Amid} | dCATH(1–16)-4A | Amidation | Free | Linear | L | None | 16 | Antibacterial | 10 % Hemolysis at 256 μM | Human | Modified Verison Of Dcath | α-Helix | Low hemolytic | ||
| 32670215 | 2020 | QLVPLAIKIYRAAKRR{ct:Amid} | dCATH(5–20)-17A | Amidation | Free | Linear | L | None | 16 | Antibacterial | 10 % Hemolysis at 256 μM | Human | Modified Verison Of Dcath | α-Helix | Low hemolytic | ||
| 32499514 | 2020 | RKEKIKKRIGKIDRL{ct:Amid} | P0 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at >250 µg/ml | Human | Designed From The Conserved Sequences Of Cathelicidin | α-Helical | Low hemolytic | ||
| 32499514 | 2020 | KIAKRIWKILRR{ct:Amid} | P7 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 10 % Hemolysis at 250 µg/ml | Human | Modification By Truncation Of P0 | NA | Low hemolytic | ||
| 32499514 | 2020 | GLFDIVKKVAG{ct:Amid} | A0 | Amidation | Free | Linear | L | None | 11 | Antibacterial | 10 % Hemolysis at >250 µg/ml | Human | Designed From The Conserved Sequences Of Aurein | α-Helical | Low hemolytic | ||
| 32499514 | 2020 | RLFRRVKKVAG{ct:Amid} | A3 | Amidation | Free | Linear | L | None | 11 | Antibacterial | 10 % Hemolysis at >250 µg/ml | Human | Modification By Truncation Of A0 | NA | Low hemolytic | ||
| 32499514 | 2020 | KIAKRIWKILRRRLFRRVKKVAG{ct:Amid} | P7A3 | Amidation | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at 3.91 µg/ml | Human | Hybrid Peptide Derivatives Of P7 & A3 | NA | NA | ||
| 32499514 | 2020 | KIAKRIWKILRRRLFRRV{ct:Amid} | PA-18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 10 % Hemolysis at 3.91 µg/ml | Human | Truncated Derivatives Of The Hybrid Analogue (P7A3) | α-Helical | NA | ||
| 32499514 | 2020 | KIAKRIWKILRRRLFRR{ct:Amid} | PA-17 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 10 % Hemolysis at 3.91 µg/ml | Human | Truncated Derivatives Of The Hybrid Analogue (P7A3) | NA | NA | ||
| 32499514 | 2020 | KIAKRIWKILRRRLFR{ct:Amid} | PA-16 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 10 % Hemolysis at 3.91 µg/ml | Human | Truncated Derivatives Of The Hybrid Analogue (P7A3) | NA | NA | ||
| 32499514 | 2020 | KIAKRIWKILRRRLF{ct:Amid} | PA-15 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at 3.91 µg/ml | Human | Truncated Derivatives Of The Hybrid Analogue (P7A3) | NA | NA | ||
| 32499514 | 2020 | KIAKRIWKILRRRL{ct:Amid} | PA-14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 15.63 µg/ml | Human | Truncated Derivatives Of The Hybrid Analogue (P7A3) | NA | NA | ||
| 32499514 | 2020 | KIAKRIWKILRRR{ct:Amid} | PA-13 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 10 % Hemolysis at 125 µg/ml | Human | Truncated Derivatives Of The Hybrid Analogue (P7A3) | aqueous = Random coil, 30mM SDS, 50% TFE, and 0.05% LPS (MME) = α-Helical | NA | ||
| 32521823 | 2020 | RYRRKKKMKKALQYIKLLKE{ct:Amid} | 35409 | Amidation | Free | Linear | L | None | 20 | Antibacterial | 10 % Hemolysis at 1.56 μM | Human | Parasite Plasmodium Falciparum Rifin Protein-Derived Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | NA | ||
| 32521823 | 2020 | RKKKMKKALQYIKLLKE{ct:Amid} | 35409-1 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiotic Synergy | 10 % Hemolysis at >200 μM | Human | 35409 Seven Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = α-Helix (200 to 260nm) | Non-hemolytic | ||
| 32521823 | 2020 | KKKMKKALQYIKLLKE{ct:Amid} | 35409-2 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antibiotic Synergy | 10 % Hemolysis at >200 μM | Human | 35409 Seven Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = α-Helix (200 to 260nm) | Non-hemolytic | ||
| 32521823 | 2020 | KKMKKALQYIKLLKE{ct:Amid} | 35409-3 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Seven Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = Helical | Non-hemolytic | ||
| 32521823 | 2020 | KMKKALQYIKLLKE{ct:Amid} | 35409-4 | Amidation | Free | Linear | L | None | 14 | Antibacterial, Antibiotic Synergy | 10 % Hemolysis at >200 μM | Human | 35409 Seven Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = α-Helix (200 to 260nm) | Non-hemolytic | ||
| 32521823 | 2020 | MKKALQYIKLLKE{ct:Amid} | 35409-5 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Seven Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = Helical | Non-hemolytic | ||
| 32521823 | 2020 | ALQYIKLLKE{ct:Amid} | 35409-6 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Seven Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | YIKLLKE{ct:Amid} | 35409-7 | Amidation | Free | Linear | L | None | 7 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Seven Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | RYRRKKKMKKALQYIKL{ct:Amid} | 35409-8 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Five Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | RYRRKKKMKKALQY{ct:Amid} | 35409-9 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Five Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | RYRRKKKMKKA{ct:Amid} | 35409-10 | Amidation | Free | Linear | L | None | 11 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Five Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | RYRRKKKMKK{ct:Amid} | 35409-11 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Five Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | RYRRKKK{ct:Amid} | 35409-12 | Amidation | Free | Linear | L | None | 7 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Five Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | KKMKKALQYIKLLK{ct:Amid} | 35409-13 | Amidation | Free | Linear | L | None | 14 | Antibacterial, Antibiotic Synergy | 10 % Hemolysis at >200 μM | Human | 35409 Four Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = α-Helix (200 to 260nm) | Non-hemolytic | ||
| 32521823 | 2020 | KKMKKALQYIKL{ct:Amid} | 35409-14 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 10 % Hemolysis at 100 μM | Human | 35409 Four Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | NA | ||
| 32521823 | 2020 | RKKKMKKALQY{ct:Amid} | 35409-15 | Amidation | Free | Linear | L | None | 11 | Antibacterial | 10 % Hemolysis at 200 μM | Human | 35409 Four Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32521823 | 2020 | KMKKALQY{ct:Amid} | 35409-16 | Amidation | Free | Linear | L | None | 8 | Antibacterial | 10 % Hemolysis at >200 μM | Human | 35409 Four Truncated Modification Sequence Peptide | 1X PBS = Disordered, PBS with 10 mM SDS = distorted trend (195 and 210nm) | Non-hemolytic | ||
| 32576824 | 2020 | GFCWYVCVYRNGVRVCYRRCN | Arenicin-3 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 204 µg/ml | Human | Marine Lugworm Arenicola Marina | (twisted β-Hairpin) anti-parallel β-Sheet and two stabilizing disulfide bonds | NA | ||
| 32576824 | 2020 | GFCWYVCARRNGARVCYRRCN | AA139 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at >300 µg/ml | Human | Arenicin-3 Analogs | NA | Non-hemolytic | ||
| 32576824 | 2020 | GFCWRVCASRNGLRVCYRRCN | NZ17125 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 181 µg/ml | Human | Arenicin-3 Analogs | NA | NA | ||
| 32576824 | 2020 | GFCWYACAKRNGLRVCYRRCN | NZ17126 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 232 µg/ml | Human | Arenicin-3 Analogs | NA | NA | ||
| 32576824 | 2020 | GFCWNVCVRRNGVRVCHRRCN | NZ17143 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at >300 µg/ml | Human | Arenicin-3 Analogs | NA | Non-hemolytic | ||
| 32576824 | 2020 | GFCWYVCVKRNGVRSCYRRCN | NZ17160 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at >300 µg/ml | Human | Arenicin-3 Analogs | NA | Non-hemolytic | ||
| 32576824 | 2020 | GFCWNVCVYRNGVRICHRRCN | NZ17211 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at >300 µg/ml | Human | Arenicin-3 Analogs | NA | Non-hemolytic | ||
| 32576824 | 2020 | GFCWHVCARRNGVRVCYRRCN | NZ17224 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at >300 µg/ml | Human | Arenicin-3 Analogs | NA | Non-hemolytic | ||
| 32576824 | 2020 | GFCWRACVYRNGVRACYRRCN | NZ17228 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at >300 µg/ml | Human | Arenicin-3 Analogs | NA | Non-hemolytic | ||
| 32576824 | 2020 | GFCWRACVYRNGVRVCYRRCN | NZ17230 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at >300 µg/ml | Human | Arenicin-3 Analogs | NA | Non-hemolytic | ||
| 32437150 | 2020 | GIP-CGESCVYIPCITAALGCSCKSKVCYRN{cyc:N-C} | viar 1 | Free | Free | Cyclic | L | None | 30 | Anticancer | 50 % Hemolysis at 11.1 ± 0.02 μM | Human | Plant Viola Arcuata | α-Helical | Low hemolytic | ||
| 32437150 | 2020 | GIP-CGESCVWIPCISAAIGCSCKSKVCYRN{cyc:N-C} | cO13 | Free | Free | Cyclic | L | None | 30 | Anticancer | 50 % Hemolysis at 14.9 ± 0.01 μM | Human | Plant Viola Arcuata | α-Helical | Low hemolytic | ||
| 32437150 | 2020 | GLPVCGETCVGGTCNTPG--CSCSWPVCTRN{cyc:N-C} | kalata S | Free | Free | Cyclic | L | None | 29 | Anticancer | 50 % Hemolysis at ≥50 μM | Human | Plant Viola Arcuata | NA | NA | ||
| 32636607 | 2020 | RNFFKRIRRAGKRIRKAI{nt:Amid} | CAMP-CecD | Free | Amidation | Linear | L | None | 18 | Antibacterial | 0 % Hemolysis at 256 µg/mL | Human | Derived Δm2 Greater Wax Moth Galleria Mellonella | Helical | Non-hemolytic | ||
| 32629881 | 2020 | K{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KN{cyc:N-C} | BSI-9 | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 33 % Hemolysis at 150 μM | Human | Synthetic Cyclic Amp | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}NK{cyc:N-C} | BSI-9 stage-1 (1) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}KN{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KK{cyc:N-C} | BSI-9 stage-1 (2) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | K{nnr:Nal}NK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KK{cyc:N-C} | BSI-9 stage-1 (3) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | N{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KK{cyc:N-C} | BSI-9 stage-1 (4) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | KFKK{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}KN{cyc:N-C} | BSI-9 stage-2 (5) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 4 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | K{nnr:Nal}KKF-{nnr:O2Oc}-{nnr:Nal}KN{cyc:N-C} | BSI-9 stage-2 (6) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 6 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | K{nnr:Nal}KK{nnr:Bip}-{nnr:O2Oc}-FKN{cyc:N-C} | BSI-9 stage-2 (7) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 7 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | KFKKF-{nnr:O2Oc}-FKN{cyc:N-C} | BSI-9 stage-2 (8) | Free | Free | Cyclic | L | O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 3 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}{nnr:Dab}{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-2 (9) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 76 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}{nnr:Dab}{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-3 (10) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 66 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}R{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-3 (11) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 36 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}{nnr:Dab}R{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-3 (12) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 98 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}{nnr:Dab}{nnr:Dab}{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}RN{cyc:N-C} | BSI-9 stage-3 (13) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 80 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}RR{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}RN{cyc:N-C} | BSI-9 stage-3 (14) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid | 9 | Antibacterial | 68 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}RDap{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (15) | Free | Free | Cyclic | L | Bip = L‐biphenylalanine, Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}R{nnr:Dab}F-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (16) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 16 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32629881 | 2020 | R{nnr:Nal}{nnr:Dab}{nnr:Dab}F-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (17) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 3 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | Non-hemolytic | ||
| 32629881 | 2020 | {nnr:Dab}{nnr:Nal}R{nnr:Dab}F-{nnr:O2Oc}-{nnr:Nal}{nnr:Dab}N{cyc:N-C} | BSI-9 stage-4 (18) | Free | Free | Cyclic | L | Nal = 3‐(2‐Naphthyl)‐L‐alanine, O2Oc = 8‐amino‐3,6‐dioxaoctanoic acid, Dab = L‐2,4‐diaminobutyric acid | 9 | Antibacterial | 30 % Hemolysis at 150 μM | Human | Analogues Of Bsi-9 | NA | NA | ||
| 32333997 | 2020 | MSLLERKLLMHFLRV | La-AMP1 | Free | Free | Linear | L | None | 15 | Antibacterial | 52 % Hemolysis at 128 µg/mL | Human | Plant Lippia Alba | α-Helix | NA | ||
| 32333997 | 2020 | GLMKLLRELLHMFSRVG | La-AMP1a | Free | Free | Linear | L | None | 17 | Antibacterial | 0.5 % Hemolysis at 128 µg/mL | Human | Derived From La-Amp1 Plant Lippia Alba | α-Helix | Non-hemolytic | ||
| 32333997 | 2020 | MRIGLRFVLM | Lr-AMP1 | Free | Free | Linear | L | None | 10 | Antibacterial | 71.5 % Hemolysis at 128 µg/mL | Human | Plant Lippia Rotundifolia | Random coil | NA | ||
| 32333997 | 2020 | SVAGRAMRIGLRFVLM | Lr-AMP1d | Free | Free | Linear | L | None | 16 | Antibacterial | 0 % Hemolysis at 128 µg/mL | Human | Derived From Lr-Amp1 Plant Lippia Rotundifolia | α-Helix | Non-hemolytic | ||
| 32333997 | 2020 | GIAGLLRSFVRMLAKIMGG | Lr-AMP1e | Free | Free | Linear | L | None | 19 | Antibacterial | 50 % Hemolysis at 128 µg/mL | Human | Derived From Lr-Amp1 Plant Lippia Rotundifolia | α-Helix | NA | ||
| 32333997 | 2020 | GSVLRAIMRMFAKLMG | Lr-AMP1f | Free | Free | Linear | L | None | 16 | Antibacterial | 0 % Hemolysis at 128 µg/mL | Human | Derived From Lr-Amp1 Plant Lippia Rotundifolia | α-Helix | Non-hemolytic | ||
| 32333997 | 2020 | GIHGVVRSFMRMLGHLG | Lr-AMP1g | Free | Free | Linear | L | None | 17 | Antibacterial | 0 % Hemolysis at 128 µg/mL | Human | Derived From Lr-Amp1 Plant Lippia Rotundifolia | α-Helix | Non-hemolytic | ||
| 32333997 | 2020 | GSVIRALMRMFARLVG | Lr-AMP1h | Free | Free | Linear | L | None | 16 | Antibacterial | 2.3 % Hemolysis at 128 µg/mL | Human | Derived From Lr-Amp1 Plant Lippia Rotundifolia | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQRIKDFLR{nt:NA}{ct:Amid} | 1 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | LKRIVQRIKDFLR{nt:NA}{ct:Amid} | 2 | Amidation | NA | Linear | L | None | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | AKRIVQRIKDFLR{nt:NA}{ct:Amid} | 3 | Amidation | NA | Linear | L | None | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | F{nnr:κ}RIVQRILDFLR{nt:Acet}{ct:Amid} | 4 | Amidation | Acetylation | Linear | L | κ = κ | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 450 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FK({nnr:SA})RIVQRILDFLR{nt:Acet}{ct:Amid} | 5 | Amidation | Acetylation | Linear | L | SA = SA | 14 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQRIRDFLR{nt:NA}{ct:Amid} | 6 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQRIRDFLR{nt:Acet}{ct:Amid} | 7 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQ{nnr:κ}IKDFLR{nt:NA}{ct:Amid} | 8 | Amidation | NA | Linear | L | κ = κ | 13 | Antibacterial, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQLIKDFLR{nt:NA}{ct:Amid} | 9 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 114 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQLIKDFLR{nt:Acet}{ct:Amid} | 10 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 227 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQRIKDLLR{nt:NA}{ct:Amid} | 11 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQRIKDLLR{nt:Acet}{ct:Amid} | 12 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRIVQIIKKFLR{nt:NA}{ct:Amid} | 13 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 361 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQIIKKFLR{nt:Acet}{ct:Amid} | 14 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 292 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQLLKKLLR{nt:NA}{ct:Amid} | 15 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 411 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRIVQLLKKLLR{nt:Acet}{ct:Amid} | 16 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 185 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | NA | ||
| 32567085 | 2020 | FKRILQRIKDFLR{nt:NA}{ct:Amid} | 17 | Amidation | NA | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32567085 | 2020 | FKRILQRIKDFLR{nt:Acet}{ct:Amid} | 18 | Amidation | Acetylation | Linear | L | None | 13 | Antibacterial,Antifungal, Anticancer | 50 % Hemolysis at 0 µg/mL | Human | Derivedm From Cathelicidin Ll-37 | α-Helix | Non-hemolytic | ||
| 32543191 | 2020 | AAAAMAGPK{ct:Amid} | Rice-derived-peptide-3 (RDP3) | Amidation | Free | Linear | L | None | 9 | Anti-gout, Anti-inflammation | 4.5±0.13 % Hemolysis at 100 µg/mL | Human | Shelled Oryza Sativa Fruits | NA | Non-hemolytic | ||
| 32543191 | 2020 | AAAAMAGPK{ct:Amid} | Rice-derived-peptide-3 (RDP3) | Amidation | Free | Linear | L | None | 9 | Anti-gout, Anti-inflammation | 5.0±0.07 % Hemolysis at 500 µg/mL | Human | Shelled Oryza Sativa Fruits | NA | Non-hemolytic | ||
| 32543191 | 2020 | AAAAMAGPK{ct:Amid} | Rice-derived-peptide-3 (RDP3) | Amidation | Free | Linear | L | None | 9 | Anti-gout, Anti-inflammation | 4.5±0.15 % Hemolysis at 1 mg/mL | Human | Shelled Oryza Sativa Fruits | NA | Non-hemolytic | ||
| 32569466 | 2020 | WFQVKTRVRTKVQFW | WF-1 | Free | Free | Linear | L | None | 15 | Antibacterial | 5 % Hemolysis at 64 μM | Human | Mutagenesis Modification Peptide Of Wi-6 | SDS = β-Sheet | NA | ||
| 32569466 | 2020 | FWRRYKKVKKYRRWF | FW-2 | Free | Free | Linear | L | None | 15 | Antibacterial | 5 % Hemolysis at >256 μM | Human | Mutagenesis Modification Peptide Of Wi-6 | PBS (aqueous)= Disordered, TFE = α-Helical | Low hemolytic | ||
| 32569466 | 2020 | FWQVIKKVKKIVQWF | FW-3 | Free | Free | Linear | L | None | 15 | Antibacterial | 5 % Hemolysis at 64 μM | Human | Mutagenesis Modification Peptide Of Wi-6 | PBS (aqueous)= Disordered, TFE = α-Helical | NA | ||
| 32569466 | 2020 | FKQFYRRVRRYFQKF | FK-4 | Free | Free | Linear | L | None | 15 | Antibacterial | 5 % Hemolysis at 128 μM | Human | Mutagenesis Modification Peptide Of Wi-6 | PBS (aqueous)= Disordered, TFE = α-Helical | NA | ||
| 32569466 | 2020 | FRQWYRRVRRYWQRF | FR-5 | Free | Free | Linear | L | None | 15 | Antibacterial | 5 % Hemolysis at 64 μM | Human | Mutagenesis Modification Peptide Of Wi-6 | PBS (aqueous)= Disordered, TFE = α-Helical | NA | ||
| 32569466 | 2020 | WIQPKTKVIPYVRYL | WI-6 | Free | Free | Linear | L | None | 15 | Antibacterial | 5 % Hemolysis at 256 μM | Human | Bovine Αs2-Casein F21 (193-207) | PBS (aqueous)= Disordered | Low hemolytic | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 0 % Hemolysis at 1 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | Non-hemolytic | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 1 % Hemolysis at 2 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 1 % Hemolysis at 4 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 3 % Hemolysis at 8 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 2 % Hemolysis at 16 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 2 % Hemolysis at 32 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 4 % Hemolysis at 64 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 6 % Hemolysis at 128 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antibacterial | 7 % Hemolysis at 256 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC (pH ≈ 6) = Random coil, DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = Mixture (Random coil + β-Sheet) | NA | ||
| 32704013 | 2020 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 11 % Hemolysis at 1 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10) = 54% β-Sheet (34% antiparallel, 20% parallel), rest Helical + others, 10 mM Phosphate Buffer (pH = 7.0) = β-Sheet (100%: 83% antiparallel, 17% parallel), DMPC/DMPG (4/1) (pH ≈ 6) = Mixture (Ran | NA | ||
| 32704013 | 2020 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 12 % Hemolysis at 2 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10) = 54% β-Sheet (34% antiparallel, 20% parallel), rest Helical + others, 10 mM Phosphate Buffer (pH = 7.0) = β-Sheet (100%: 83% antiparallel, 17% parallel), DMPC/DMPG (4/1) (pH ≈ 6) = Mixture (Ran | NA | ||
| 32704013 | 2020 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 16 % Hemolysis at 4 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10) = 54% β-Sheet (34% antiparallel, 20% parallel), rest Helical + others, 10 mM Phosphate Buffer (pH = 7.0) = β-Sheet (100%: 83% antiparallel, 17% parallel), DMPC/DMPG (4/1) (pH ≈ 6) = Mixture (Ran | NA | ||
| 32704013 | 2020 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 20 % Hemolysis at 8 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10) = 54% β-Sheet (34% antiparallel, 20% parallel), rest Helical + others, 10 mM Phosphate Buffer (pH = 7.0) = β-Sheet (100%: 83% antiparallel, 17% parallel), DMPC/DMPG (4/1) (pH ≈ 6) = Mixture (Ran | NA | ||
| 32704013 | 2020 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 28 % Hemolysis at 16 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10) = 54% β-Sheet (34% antiparallel, 20% parallel), rest Helical + others, 10 mM Phosphate Buffer (pH = 7.0) = β-Sheet (100%: 83% antiparallel, 17% parallel), DMPC/DMPG (4/1) (pH ≈ 6) = Mixture (Ran | NA | ||
| 32704013 | 2020 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 40 % Hemolysis at 32 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10) = 54% β-Sheet (34% antiparallel, 20% parallel), rest Helical + others, 10 mM Phosphate Buffer (pH = 7.0) = β-Sheet (100%: 83% antiparallel, 17% parallel), DMPC/DMPG (4/1) (pH ≈ 6) = Mixture (Ran | NA | ||
| 32704013 | 2020 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 59 % Hemolysis at 64 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10) = 54% β-Sheet (34% antiparallel, 20% parallel), rest Helical + others, 10 mM Phosphate Buffer (pH = 7.0) = β-Sheet (100%: 83% antiparallel, 17% parallel), DMPC/DMPG (4/1) (pH ≈ 6) = Mixture (Ran | NA | ||
| 32704013 | 2020 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 81 % Hemolysis at 128 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10) = 54% β-Sheet (34% antiparallel, 20% parallel), rest Helical + others, 10 mM Phosphate Buffer (pH = 7.0) = β-Sheet (100%: 83% antiparallel, 17% parallel), DMPC/DMPG (4/1) (pH ≈ 6) = Mixture (Ran | NA | ||
| 32704013 | 2020 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 94 % Hemolysis at 256 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10) = 54% β-Sheet (34% antiparallel, 20% parallel), rest Helical + others, 10 mM Phosphate Buffer (pH = 7.0) = β-Sheet (100%: 83% antiparallel, 17% parallel), DMPC/DMPG (4/1) (pH ≈ 6) = Mixture (Ran | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 47 % Hemolysis at 1 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 86 % Hemolysis at 2 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 96 % Hemolysis at 4 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 96 % Hemolysis at 8 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 95 % Hemolysis at 16 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 94 % Hemolysis at 32 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 94 % Hemolysis at 64 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 91 % Hemolysis at 128 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 89 % Hemolysis at 256 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 33 % Hemolysis at 1 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 80 % Hemolysis at 2 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 95 % Hemolysis at 4 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 95 % Hemolysis at 8 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 90 % Hemolysis at 16 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 82 % Hemolysis at 32 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 79 % Hemolysis at 64 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 78 % Hemolysis at 128 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32704013 | 2020 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antibacterial | 78 % Hemolysis at 256 µg/mL | Human | Kl Peptides | Water (pH ≈ 6), DMPC (pH ≈ 6) = Random coil, Water (pH ≈ 10), 10 mM Phosphate Buffer (pH = 7.0), DMPC/DMPG (4/1) (pH ≈ 6), POPC/POPG (1/1) (pH ≈ 6) = β-Sheet | NA | ||
| 32126228 | 2020 | VRRFPWWWPFLRR | Tritrpticin | Free | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Trp-Rich Porcine Cathelicidin Peptide | NA | NA | ||
| 32126228 | 2020 | VRRFPWWWPFLRR{ct:Amid} | Tritrp-Arg | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at 62.2 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V({nnr:Agb})({nnr:Agb})FPWWWPFL({nnr:Agb})({nnr:Agb}){ct:Amid} | Tritrp-Agb | Amidation | Free | Linear | L | Agb = (S)-2-amino-4 guanidinobutyric acid | 13 | Anticancer | 50 % Hemolysis at 34.6 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V({nnr:hArg})({nnr:hArg})FPWWWPFL({nnr:hArg})({nnr:hArg}){ct:Amid} | Tritrp-hArg | Amidation | Free | Linear | L | hArg = homo-arginine Arg Derivative | 13 | Anticancer | 50 % Hemolysis at 41.3 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VKKFPWWWPFLKK{ct:Amid} | Tritrp-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V({nnr:Dap})({nnr:Dap})FPWWWPFL({nnr:Dap})({nnr:Dap}){ct:Amid} | Tritrp-Dap | Amidation | Free | Linear | L | Dap = 2,3-diaminopropionic acid Lys Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V({nnr:Dab})({nnr:Dab})FPWWWPFL({nnr:Dab})({nnr:Dab}){ct:Amid} | Tritrp-Dab | Amidation | Free | Linear | L | Dab = 2,4-diaminobutyric acid Lys Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | V{nnr:O}{nnr:O}FPWWWPFL{nnr:O}{nnr:O}{ct:Amid} | Tritrp-Orn | Amidation | Free | Linear | L | O = L-Ornithine | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFAWWWAFLRR{ct:Amid} | Tritrp-P59A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at 52.5 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VKKFAWWWAFLKK{ct:Amid} | Tritrp-P59A-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFAWWWPFLRR{ct:Amid} | Tritrp-P5A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VKKFAWWWPFLKK{ct:Amid} | Tritrp-P5A-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWWWAFLRR{ct:Amid} | Tritrp-P9A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at 29.3 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VKKFPWWWAFLKK{ct:Amid} | Tritrp-P9A-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPFFFPFLRR{ct:Amid} | Tritrp-W678F | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFP({nnr:bTA})({nnr:bTA})({nnr:bTA})PFLRR{ct:Amid} | Tritrp-W678bTA | Amidation | Free | Linear | L | bTA = β-3-benzothienyl-1-AlaTrpDerivative | 13 | Anticancer | 50 % Hemolysis at 12.2 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFP({nnr:hW})WWPFLRR{ct:Amid} | Tritrp-W6hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPW({nnr:hW})WPFLRR{ct:Amid} | Tritrp-W7hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWW({nnr:hW})PFLRR{ct:Amid} | Tritrp-W8hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFP({nnr:hW})({nnr:hW})({nnr:hW})PFLRR{ct:Amid} | Tritrp-W678hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPAWWPFLRR{ct:Amid} | Tritrp-W6A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWAWPFLRR{ct:Amid} | Tritrp-W7A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWWAPFLRR{ct:Amid} | Tritrp-W8A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPAAWPFLRR{ct:Amid} | Tritrp-W67A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPAWAPFLRR{ct:Amid} | Tritrp-W68A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWAAPFLRR{ct:Amid} | Tritrp-W78A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPAAAPFLRR{ct:Amid} | Tritrp-W678A | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPYWWPFLRR{ct:Amid} | Tritrp-W6Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWYWPFLRR{ct:Amid} | Tritrp-W7Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWWYPFLRR{ct:Amid} | Tritrp-W8Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPYYWPFLRR{ct:Amid} | Tritrp-W67Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPYWYPFLRR{ct:Amid} | Tritrp-W68Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPWYYPFLRR{ct:Amid} | Tritrp-W78Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | VRRFPYYYPFLRR{ct:Amid} | Tritrp-W678Y | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | CVRRFPWWYPFLRRC{cyc:N-C}{ct:Amid} | Tritrp-DiSu* | Amidation | Free | Cyclic | L | None | 15 | Anticancer | 50 % Hemolysis at 20.9 μM | Human | Modification Tritrpticin | NA | NA | ||
| 32126228 | 2020 | GIGKWLHSAKKFGKAFVGEIMNS | MagaininF5W-Lys | Free | Free | Linear | L | None | 23 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | GIGRWLHSARRFGRAFVGEIMNS | MagaininF5W-Arg | Free | Free | Linear | L | None | 23 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FPVTWRWWRWWRG{ct:Amid} | PuroA-Arg | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FPVTWKWWKWWKG{ct:Amid} | PuroA-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | ILPWKWPWWPWRR{ct:Amid} | Indolicidin-Arg | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | ILPWKWPWWPWKK{ct:Amid} | Indolicidin-Lys | Amidation | Free | Linear | L | None | 13 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FRVTWRTKWWKG{ct:Amid} | PuroB3 | Amidation | Free | Linear | L | None | 12 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FRVT({nnr:hW})RTK({nnr:hW})({nnr:hW})KG{ct:Amid} | PuroB3-hW | Amidation | Free | Linear | L | hW = 5-hydroxytryptophan Trp Derivative | 12 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | GALFLGFLGAAGSTMGAWSQPKKKRKV{nt:Acet}{ct:CM = CysteAmidation} | MPG | CM = CysteAmidation | Acetylation | Linear | L | CM = CysteAmidation | 27 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | KETWWETWWTEWSQPKKKRKV{nt:Acet}{ct:CM = CysteAmidation} | Pep-1 | CM = CysteAmidation | Acetylation | Linear | L | CM = CysteAmidation | 21 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | RRWWRF{nt:Acet}{ct:Amid} | Combi-1 | Amidation | Acetylation | Linear | L | None | 6 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | FRWWHR{nt:Acet}{ct:Amid} | Combi-2 | Amidation | Acetylation | Linear | L | None | 6 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | RAWVAWR{ct:Amid} | LysH | Amidation | Free | Linear | L | None | 7 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | TRSSRAGLQFPVGRVHRLLRK | Buforin-2 | Free | Free | Linear | L | None | 21 | Anticancer | 50 % Hemolysis at ≥65 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32126228 | 2020 | GIGAVLKVLTTGLPAALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 21 | Anticancer | 50 % Hemolysis at ≤6.5 μM | Human | Antimicrobial Peptides | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Amid}{ct:Amid} | A1 | Amidation | Amidation | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Synthetic Amp | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:(β-Ala)(β-Ala)(Lys)}{ct:Amid} | A2 | Amidation | (β-Ala)(β-Ala)(Lys) | Linear | L | Ala spacers and Lys | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Ala Spacers And Lys | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Caprylic acid (C8)}{ct:Amid} | A3 | Amidation | Caprylic acid (C8) | Linear | L | C8 = Caprylic acid | 9 | Antibacterial | 50 % Hemolysis at 132 µg/mL | Human | Modification Of A1 With Caprylic Acid (C8) | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Capric acid (C10)}{ct:Amid} | A4 | Amidation | Capric acid (C10) | Linear | L | C10 = Capric acid | 9 | Antibacterial | 50 % Hemolysis at 73 µg/mL | Human | Modification Of A1 With Capric Acid (C10) | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Lauric acid (C12)}{ct:Amid} | A5 | Amidation | Lauric acid (C12) | Linear | L | C12 = Lauric acid | 9 | Antibacterial | 50 % Hemolysis at 35 µg/mL | Human | Modification Of A1 With Lauric Acid (C12) | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Myristic acid (C14)}{ct:Amid} | A6 | Amidation | Myristic acid (C14) | Linear | L | C14 = Myristic acid | 9 | Antibacterial | 50 % Hemolysis at 28 µg/mL | Human | Modification Of A1 With Myristic Acid (C14) | NA | NA | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-Glucose}{ct:Amid} | A7 | Amidation | Ser-Glucose | Linear | L | Glucose = Glucose | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Glucose | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-N-Acetylglucosamine (GlcNac)}{ct:Amid} | A8 | Amidation | Ser-N-Acetylglucosamine (GlcNac) | Linear | L | GlcNAc = GlcNAc | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Glcnac | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-Galactose}{ct:Amid} | A9 | Amidation | Ser-Galactose | Linear | L | Galactose = Galactose | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Galactose | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-Mannose}{ct:Amid} | A10 | Amidation | Ser-Mannose | Linear | L | Mannose = Mannose | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Mannose | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Ser-Lactose}{ct:Amid} | A11 | Amidation | Ser-Lactose | Linear | L | Lactose = Lactose | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Lactose | NA | Low hemolytic | ||
| 32130974 | 2020 | RIRIRWIIR{nt:Meo-PEG}{ct:Amid} | A12 | Amidation | Meo-PEG | Linear | L | PEG = PEG | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of A1 With Peg | NA | Low hemolytic | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Amid}{ct:Amid} | B1 | Amidation | Amidation | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Synthetic Amp | NA | Low hemolytic | ||
| 32130974 | 2020 | KRRVRWIIW{nt:(β-Ala)(β-Ala)(Lys)}{ct:Amid} | B2 | Amidation | (β-Ala)(β-Ala)(Lys) | Linear | L | Ala spacers and Lys | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of B1 With Ala Spacers And Lys | NA | Low hemolytic | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Caprylic acid (C8)}{ct:Amid} | B3 | Amidation | Caprylic acid (C8) | Linear | L | C8 = Caprylic acid | 9 | Antibacterial | 50 % Hemolysis at >250 µg/mL | Human | Modification Of B1 With Caprylic Acid (C8) | NA | Low hemolytic | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Capric acid (C10)}{ct:Amid} | B4 | Amidation | Capric acid (C10) | Linear | L | C10 = Capric acid | 9 | Antibacterial | 50 % Hemolysis at 50 µg/mL | Human | Modification Of B1 With Capric Acid (C10) | NA | NA | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Lauric acid (C12)}{ct:Amid} | B5 | Amidation | Lauric acid (C12) | Linear | L | C12 = Lauric acid | 9 | Antibacterial | 50 % Hemolysis at 38 µg/mL | Human | Modification Of B1 With Lauric Acid (C12) | NA | NA | ||
| 32130974 | 2020 | KRRVRWIIW{nt:Myristic acid (C14)}{ct:Amid} | B6 | Amidation | Myristic acid (C14) | Linear | L | C14 = Myristic acid | 9 | Antibacterial | 50 % Hemolysis at 25 µg/mL | Human | Modification Of B1 With Myristic Acid (C14) | NA | NA | ||
| 32171739 | 2020 | GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK | hBD-3 | Free | Free | Linear | L | None | 45 | Antibacterial | >15 % Hemolysis at 250 µg/mL | Human | Human Beta Defensin-3 | LPS aggregates = α-Helical | Low hemolytic | ||
| 32171739 | 2020 | GIINTLQKYYCRVRGGRSAVLSSLPKEEQIGKSSTRGRKCSRRKK{cyc:N-C} | hBD-3-c | Free | Free | Cyclic | L | None | 45 | Antibacterial | >15 % Hemolysis at 250 µg/mL | Human | Hbd-3 Cyclic Variant With One Disulfide Bond | LPS aggregates = α-Helical | Low hemolytic | ||
| 32171739 | 2020 | GIINTLQKYYSRVRGGRSAVLSSLPKEEQIGKSSTRGRKSSRRKK | hBD-3-l | Free | Free | Linear | L | None | 45 | Antibacterial | >15 % Hemolysis at 250 µg/mL | Human | Hbd-3 Linear Variant Without Disulfide Bond | LPS aggregates = α-Helical | Low hemolytic | ||
| 32406577 | 2020 | ALWKTLLKKVLKAAAKAALNAVLVGANA | K4S4 | Free | Free | Linear | L | None | 28 | Antibacterial | 50 % Hemolysis at 27.92 ± 8.1 μM | Human | Dermaseptin S4 Peptide Derivatives | α-Helix | NA | ||
| 32406577 | 2020 | TLLKKVLKAAAKAALNAVLVGANA | S4(5–28) | Free | Free | Linear | L | None | 24 | Antibacterial | 50 % Hemolysis at >100 ± 0.0 μM | Human | Dermaseptin S4 Peptide Derivatives | α-Helix | NA | ||
| 32406577 | 2020 | TLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | S4(5–28)a | Amidation | Free | Linear | L | None | 24 | Antibacterial | 50 % Hemolysis at >100 ± 0.0 μM | Human | Dermaseptin S4 Peptide Derivatives | α-Helix | NA | ||
| 32406577 | 2020 | TLLKKVLKAAAKAALKAVLVGANA | K20S4(5–28) | Free | Free | Linear | L | None | 24 | Antibacterial | 50 % Hemolysis at >100 ± 0.0 μM | Human | Dermaseptin S4 Peptide Derivatives | α-Helix | NA | ||
| 32406577 | 2020 | ALWKTLLKKVLKAAAK{ct:Amid} | K4S4(1–16)a | Amidation | Free | Linear | L | None | 16 | Antibacterial | 50 % Hemolysis at 88.21 ± 5.1 μM | Human | Dermaseptin S4 Peptide Derivatives | α-Helix | NA | ||
| 32406577 | 2020 | ALWKTLLKKVLKAAA{ct:Amid} | K4S4(1–15)a | Amidation | Free | Linear | L | None | 15 | Antibacterial | 50 % Hemolysis at 83.25 ± 7.0 μM | Human | Dermaseptin S4 Peptide Derivatives | α-Helix | NA | ||
| 32406577 | 2020 | ALWKTLLKKVLKAAAK | K4S4(1–15) | Free | Free | Linear | L | None | 16 | Antibacterial | 50 % Hemolysis at >100 ± 0.0 μM | Human | Dermaseptin S4 Peptide Derivatives | α-Helix | NA | ||
| 32752241 | 2020 | HHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2 [T2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 10 % Hemolysis at 1.4 μM | Human | Phylum Placozo Trichoplax Adhaerens | Helical | NA | ||
| 32752241 | 2020 | RHHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2A [T2R1] | Amidation | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | 10 % Hemolysis at 3 μM | Human | Analog Of Trichoplaxin-2 | Helical | NA | ||
| 32752241 | 2020 | GIKKAVGKALKGLKGLLKALGES{ct:Amid} | Adepantin-1A [A1A] | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Anticancer | 10 % Hemolysis at 25 μM | Human | Adepantin-1 Analog | Helical | NA | ||
| 32752241 | 2020 | GIGKFLKKAKKFGKAFVLILKK{ct:Amid} | Pexiganan-L18 [PEXA] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 10 % Hemolysis at 1.6 μM | Human | Pexiganan Analog | Helical | NA | ||
| 32752241 | 2020 | GIKKWVKGVAKGVAKDLAKKIL{ct:Amid} | Flexampin [FLEX] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 10 % Hemolysis at 6 μM | Human | Template From Ranatuerin-2Csa | Helical | NA | ||
| 32752241 | 2020 | GIGREIIKKIIKKIGKKIGRII{ct:Amid} | Zyk-1 [ZYK1] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 10 % Hemolysis at 3 μM | Human | Zyk Strain Of Bacillus Oryziterrae Peptide | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKVALKAL{ct:Amid} | DiPGLa-H [PG2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 10 % Hemolysis at 3 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKGALKAL{ct:Amid} | Kiadin-1 [KIA1] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 10 % Hemolysis at 3 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIGKKILKALKGALKELA{ct:Amid} | Mapegin [MAPA] | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Anticancer | 10 % Hemolysis at 1.7 μM | Human | Syntheitc Cell-Penetrating Peptide | Helical | NA | ||
| 32752241 | 2020 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MP1 [MP1] | Amidation | Free | Linear | L | None | 14 | Antimicrobial, Anticancer | 10 % Hemolysis at 20 μM | Human | Synthetic Amps | Helical | NA | ||
| 32752241 | 2020 | HHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2 [T2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 20 % Hemolysis at 3 μM | Human | Phylum Placozo Trichoplax Adhaerens | Helical | NA | ||
| 32752241 | 2020 | RHHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2A [T2R1] | Amidation | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | 20 % Hemolysis at 25 μM | Human | Analog Of Trichoplaxin-2 | Helical | NA | ||
| 32752241 | 2020 | GIKKAVGKALKGLKGLLKALGES{ct:Amid} | Adepantin-1A [A1A] | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Anticancer | 20 % Hemolysis at 80 μM | Human | Adepantin-1 Analog | Helical | NA | ||
| 32752241 | 2020 | GIGKFLKKAKKFGKAFVLILKK{ct:Amid} | Pexiganan-L18 [PEXA] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 20 % Hemolysis at 7 μM | Human | Pexiganan Analog | Helical | NA | ||
| 32752241 | 2020 | GIKKWVKGVAKGVAKDLAKKIL{ct:Amid} | Flexampin [FLEX] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 20 % Hemolysis at 25 μM | Human | Template From Ranatuerin-2Csa | Helical | NA | ||
| 32752241 | 2020 | GIGREIIKKIIKKIGKKIGRII{ct:Amid} | Zyk-1 [ZYK1] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 20 % Hemolysis at 8 μM | Human | Zyk Strain Of Bacillus Oryziterrae Peptide | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKVALKAL{ct:Amid} | DiPGLa-H [PG2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 20 % Hemolysis at 14 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKGALKAL{ct:Amid} | Kiadin-1 [KIA1] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 20 % Hemolysis at 6 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIGKKILKALKGALKELA{ct:Amid} | Mapegin [MAPA] | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Anticancer | 20 % Hemolysis at 3 μM | Human | Syntheitc Cell-Penetrating Peptide | Helical | NA | ||
| 32752241 | 2020 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MP1 [MP1] | Amidation | Free | Linear | L | None | 14 | Antimicrobial, Anticancer | 20 % Hemolysis at 37 μM | Human | Synthetic Amps | Helical | NA | ||
| 32752241 | 2020 | HHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2 [T2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 50 % Hemolysis at 28 μM | Human | Phylum Placozo Trichoplax Adhaerens | Helical | NA | ||
| 32752241 | 2020 | RHHWRRYARIGFRAVRTVIGK{ct:Amid} | Trichoplaxin-2A [T2R1] | Amidation | Free | Linear | L | None | 21 | Antimicrobial, Anticancer | 50 % Hemolysis at 7000 μM | Human | Analog Of Trichoplaxin-2 | Helical | Low hemolytic | ||
| 32752241 | 2020 | GIKKAVGKALKGLKGLLKALGES{ct:Amid} | Adepantin-1A [A1A] | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Anticancer | 50 % Hemolysis at 125 μM | Human | Adepantin-1 Analog | Helical | NA | ||
| 32752241 | 2020 | GIGKFLKKAKKFGKAFVLILKK{ct:Amid} | Pexiganan-L18 [PEXA] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 50 % Hemolysis at 520 μM | Human | Pexiganan Analog | Helical | NA | ||
| 32752241 | 2020 | GIKKWVKGVAKGVAKDLAKKIL{ct:Amid} | Flexampin [FLEX] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 50 % Hemolysis at 1600 μM | Human | Template From Ranatuerin-2Csa | Helical | Low hemolytic | ||
| 32752241 | 2020 | GIGREIIKKIIKKIGKKIGRII{ct:Amid} | Zyk-1 [ZYK1] | Amidation | Free | Linear | L | None | 22 | Antimicrobial, Anticancer | 50 % Hemolysis at 29 μM | Human | Zyk Strain Of Bacillus Oryziterrae Peptide | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKVALKAL{ct:Amid} | DiPGLa-H [PG2] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 50 % Hemolysis at 18 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIAKVALKALKIAKGALKAL{ct:Amid} | Kiadin-1 [KIA1] | Amidation | Free | Linear | L | None | 20 | Antimicrobial, Anticancer | 50 % Hemolysis at 20 μM | Human | Template From Pgla-H Xenopus Laevis | Helical | NA | ||
| 32752241 | 2020 | KIGKKILKALKGALKELA{ct:Amid} | Mapegin [MAPA] | Amidation | Free | Linear | L | None | 18 | Antimicrobial, Anticancer | 50 % Hemolysis at 20 μM | Human | Syntheitc Cell-Penetrating Peptide | Helical | NA | ||
| 32752241 | 2020 | IDWKKLLDAAKQIL{ct:Amid} | Polybia-MP1 [MP1] | Amidation | Free | Linear | L | None | 14 | Antimicrobial, Anticancer | 50 % Hemolysis at 170 μM | Human | Synthetic Amps | Helical | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal-)Ala} | 1 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Bu)Gly}-K-K-K | 2 | Free | Free | Linear | L | (N-Phe)Gly = N-benzylglycine, (N1-Nal)Gly = N-1-naphthylmethylglycine, (N-Bu)Gly = N-butylglycine | 7 | Antibacterial, Anticancer | 78.1 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-K-L{d}-K-K | 3 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala}-L{d}-K-K-K | 4 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-L-K-K-K | 5 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial, Anticancer | 36 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L-K-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 6 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 42.7 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(1-Nal)Ala}-F{nnr:(1-Nal)Ala} | 7 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 83.8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-K-L{d}-K-K | 8 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 34.3 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala}-L{d}-K-K-K | 9 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 30.8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-L{d}-K-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 10 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(1-nal)ala}-F{d}-{nnr:(1-nal)ala} | 11 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial, Anticancer | 33.3 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-F{d}-{nnr:(2-nal)ala} | 12 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanin, f = D-phenylalanine, l = D-Leu | 7 | Antibacterial | 43.5 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala}-K-L-K-K | 13 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 55.3 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-{nnr:(N-Bu)Gly}-K-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 14 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial | 66.4 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:(N-Bu)Gly}-{nnr:(N1-Nal)Gly}-{nnr:(N-Phe)Gly}-{nnr:(N1-Nal)Gly} | 15 | Free | Free | Linear | L | (N-Bu)Gly = N-butylglycine, (N1-Nal)Gly = N-1-napthylmethylglycine, (N-Phe)Gly = N-benyzylglycine | 7 | Antibacterial, Anticancer | 94.2 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala}-K-L-K-K | 16 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 55.5 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 17 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 78.1 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 18 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | 58.8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-Leu{nnr:(1-Nal)Ala}-Y-{nnr:(1-Nal)Ala} | 19 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine | 7 | Antibacterial | 82.7 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(1-Nal)Ala}-F-{nnr:(1-Nal)Ala} | 20 | Free | Free | Linear | L | (1-Nal)Ala = 1-napthylalanine, Nle= norleucine | 7 | Antibacterial | 27.5 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-l--{nnr:(1-nal)ala}-Y{d}-{nnr:(1-nal)ala} | 21 | Free | Free | Linear | Mix | (1-nal)ala = D-1-napthylalanine, y = D-Tyr | 7 | Antibacterial | <8 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | Low hemolytic | ||
| 32764602 | 2020 | K-K-K-{nnr:Nle}-{nnr:(2-Nal)Ala}-Y-{nnr:(2-Nal)Ala} | 22 | Free | Free | Linear | L | (2-Nal)Ala = 2-napthylalanine, Nle= norleucine | 7 | Antibacterial | 23.7 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | {nnr:N-Lys}-{nnr:N-Lys}-{nnr:N-Lys}-L-{nnr:(2-Nal)Ala}-F-{nnr:(2-Nal)Ala} | 23 | Free | Free | Linear | L | N-Lys = N-(4-aminobutyl)glycine, (2-Nal)Ala = 2-napthylalanine | 7 | Antibacterial | 35.9 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32764602 | 2020 | K-K-K-L{d}-{nnr:(2-nal)ala}-Y{d}-{nnr:(2-nal)ala} | 24 | Free | Free | Linear | Mix | (2-nal)ala = D-2-napthylalanine, y = D-Tyr, l = D-Leu | 7 | Antibacterial | 23.4 % Hemolysis at 150 µM | Human | Synthetic Amps | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | S3(B) | Free | Free | Cyclic | L | Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 77 % Hemolysis at 150 μM | Human | Cyclic Antimicrobial Peptide S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab(C10)}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)1 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Dab(C10)}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)2 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Dab(C12)}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C12)2 | Free | Free | Cyclic | L | Dab(C12) = Dab(C12), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Dab(C14)}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C14)2 | Free | Free | Cyclic | L | Dab(C14) = Dab(C14), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab(C10)}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)4 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C4)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C4)5 | Free | Free | Cyclic | L | Dab(C4) = Dab(C4), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 5 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | Low hemolytic | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C6)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C6)5 | Free | Free | Cyclic | L | Dab(C6) = Dab(C6), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 13 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C8)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C8)5 | Free | Free | Cyclic | L | Dab(C8) = Dab(C8), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 42 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C10)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C10)5 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C12)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C12)5 | Free | Free | Cyclic | L | Dab(C12) = Dab(C12), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Dab(C14)}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab}-N{cyc:N-C} | (C14)5 | Free | Free | Cyclic | L | Dab(C14) = Dab(C14), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C4)}-{nnr:Dab}-N{cyc:N-C} | (C4)7 | Free | Free | Cyclic | L | Dab(C4) = Dab(C4), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 4 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | Low hemolytic | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C6)}-{nnr:Dab}-N{cyc:N-C} | (C6)7 | Free | Free | Cyclic | L | Dab(C6) = Dab(C6), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 8 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C8)}-{nnr:Dab}-N{cyc:N-C} | (C8)7 | Free | Free | Cyclic | L | Dab(C8) = Dab(C8), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 56 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C10)}-{nnr:Dab}-N{cyc:N-C} | (C10)7 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C12)}-{nnr:Dab}-N{cyc:N-C} | (C12)7 | Free | Free | Cyclic | L | Dab(C12) = Dab(C12), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 96 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Dab(C14)}-{nnr:Dab}-N{cyc:N-C} | (C14)7 | Free | Free | Cyclic | L | Dab(C14) = Dab(C14), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 98 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32823798 | 2020 | {nnr:Dab}-{nnr:Nal}-R-{nnr:Dab}-{nnr:Bip}-{nnr:O2Oc}-{nnr:Nal}-{nnr:Dab(C10)}-N{cyc:N-C} | (C10)8 | Free | Free | Cyclic | L | Dab(C10) = Dab(C10), Dab = l-2,4-diaminobutyric acid, Nal = 3-(2-Naphthyl)-l-alanine, Bip = l-biphenylalanine, O2Oc = 8-amino-3,6-dioxaoctanoic acid | 9 | Antibacterial | 100 % Hemolysis at 150 μM | Human | Lipidated Analogues Of S3(B) | NA | NA | ||
| 32847054 | 2020 | ASSFLTPRLSSLGKRSWAV | AV19 | Free | Free | Linear | L | None | 19 | Antibacterial | 0 % Hemolysis at 5 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | GFCNFMHLKPISRELRRELYGRTRRRRK | GK28 | Free | Free | Linear | L | None | 28 | Antibacterial | 0 % Hemolysis at 5 μM | Human | Cuttlefish (Sepia Officinalis) | NA | Non-hemolytic | ||
| 32847054 | 2020 | NYWLLVLRRLLITKKVMWF | NF19 | Free | Free | Linear | L | None | 19 | Antibacterial | 0 % Hemolysis at 5 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | IYFHLFRKINFNLRIYYFI | II19 | Free | Free | Linear | L | None | 19 | NA | 0 % Hemolysis at 5 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | LKALKLPKGSTSTEVRRILVLEIRV | LV25 | Free | Free | Linear | L | None | 25 | NA | 0 % Hemolysis at 5 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | ASSFLTPRLSSLGKRSWAV | AV19 | Free | Free | Linear | L | None | 19 | Antibacterial | 33 % Hemolysis at 100 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | NA | ||
| 32847054 | 2020 | GFCNFMHLKPISRELRRELYGRTRRRRK | GK28 | Free | Free | Linear | L | None | 28 | Antibacterial | 0 % Hemolysis at 100 μM | Human | Cuttlefish (Sepia Officinalis) | NA | Non-hemolytic | ||
| 32847054 | 2020 | NYWLLVLRRLLITKKVMWF | NF19 | Free | Free | Linear | L | None | 19 | Antibacterial | 50 % Hemolysis at 100 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | IYFHLFRKINFNLRIYYFI | II19 | Free | Free | Linear | L | None | 19 | NA | 19 % Hemolysis at 100 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | LKALKLPKGSTSTEVRRILVLEIRV | LV25 | Free | Free | Linear | L | None | 25 | NA | 0 % Hemolysis at 100 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | GFCNFMHLKPISRELRRELYGRTRRRRK | GK28 | Free | Free | Linear | L | None | 28 | Antibacterial | 0 % Hemolysis at 20 μM | Human | Cuttlefish (Sepia Officinalis) | NA | Non-hemolytic | ||
| 32847054 | 2020 | IYFHLFRKINFNLRIYYFI | II19 | Free | Free | Linear | L | None | 19 | NA | 11 % Hemolysis at 20 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | LKALKLPKGSTSTEVRRILVLEIRV | LV25 | Free | Free | Linear | L | None | 25 | NA | 0 % Hemolysis at 20 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | GFCNFMHLKPISRELRRELYGRTRRRRK | GK28 | Free | Free | Linear | L | None | 28 | Antibacterial | 0 % Hemolysis at 50 μM | Human | Cuttlefish (Sepia Officinalis) | NA | Non-hemolytic | ||
| 32847054 | 2020 | NYWLLVLRRLLITKKVMWF | NF19 | Free | Free | Linear | L | None | 19 | Antibacterial | 35 % Hemolysis at 50 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | IYFHLFRKINFNLRIYYFI | II19 | Free | Free | Linear | L | None | 19 | NA | 17 % Hemolysis at 50 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32847054 | 2020 | LKALKLPKGSTSTEVRRILVLEIRV | LV25 | Free | Free | Linear | L | None | 25 | NA | 0 % Hemolysis at 50 μM | Human | Cuttlefish (Sepia Officinalis) | α-Helix | Non-hemolytic | ||
| 32350599 | 2020 | RFRRLRWKTRWRLKKIRFGRFLRKIRRFRPK{ct:Amid} | PR-FO | Amidation | Free | Linear | L | None | 31 | Antibacterial | 10 % Hemolysis at 128 μM | Human | Hybrid Peptide Of Prw4 And Fowlicidin-2 | α-Helix | Low hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR | rR8 | Free | Free | Linear | Mix | None | 8 | Antimalarial | 0 % Hemolysis at 5 μM | Human | Derived From A Cell-Penetrating Peptide | Random coil | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR | rR8 | Free | Free | Linear | Mix | None | 8 | Antimalarial | 0 % Hemolysis at 10 μM | Human | Derived From A Cell-Penetrating Peptide | Random coil | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR | rR8 | Free | Free | Linear | Mix | None | 8 | Antimalarial | 0.8 % Hemolysis at 20 μM | Human | Derived From A Cell-Penetrating Peptide | Random coil | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR | rR8 | Free | Free | Linear | Mix | None | 8 | Antimalarial | 1.3 % Hemolysis at 40 μM | Human | Derived From A Cell-Penetrating Peptide | Random coil | Non-hemolytic | ||
| 32673701 | 2020 | KKKKKKKKKYYKYKKKEKEKK | JR21 | Free | Free | Linear | L | None | 21 | Antimalarial | 0 % Hemolysis at 5 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | KKKKKKKKKYYKYKKKEKEKK | JR21 | Free | Free | Linear | L | None | 21 | Antimalarial | 0 % Hemolysis at 10 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | KKKKKKKKKYYKYKKKEKEKK | JR21 | Free | Free | Linear | L | None | 21 | Antimalarial | 0.8 % Hemolysis at 20 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | KKKKKKKKKYYKYKKKEKEKK | JR21 | Free | Free | Linear | L | None | 21 | Antimalarial | 1 % Hemolysis at 40 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR-KKKKKKKKKYYKYKKKEKEKK | rR8-JR21 | Free | Free | Linear | Mix | None | 29 | Antimalarial | 0 % Hemolysis at 5 μM | Human | Combination Of Rr8 And Jr21 Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR-KKKKKKKKKYYKYKKKEKEKK | rR8-JR21 | Free | Free | Linear | Mix | None | 29 | Antimalarial | 0 % Hemolysis at 10 μM | Human | Combination Of Rr8 And Jr21 Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR-KKKKKKKKKYYKYKKKEKEKK | rR8-JR21 | Free | Free | Linear | Mix | None | 29 | Antimalarial | 0.8 % Hemolysis at 20 μM | Human | Combination Of Rr8 And Jr21 Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR-KKKKKKKKKYYKYKKKEKEKK | rR8-JR21 | Free | Free | Linear | Mix | None | 29 | Antimalarial | 1.3 % Hemolysis at 40 μM | Human | Combination Of Rr8 And Jr21 Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | DDDDEEEDDFVYFNFNKEKEE | JR helix | Free | Free | Linear | L | None | 21 | NA | 0 % Hemolysis at 5 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | DDDDEEEDDFVYFNFNKEKEE | JR helix | Free | Free | Linear | L | None | 21 | NA | 0 % Hemolysis at 10 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | DDDDEEEDDFVYFNFNKEKEE | JR helix | Free | Free | Linear | L | None | 21 | NA | 0.6 % Hemolysis at 20 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | DDDDEEEDDFVYFNFNKEKEE | JR helix | Free | Free | Linear | L | None | 21 | NA | 1 % Hemolysis at 40 μM | Human | Designed Based On The Junctional Region Of Pfdhfr-Ts | Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR- DDDDEEEDDFVYFNFNKEKEE | rR8-JR helix | Free | Free | Linear | Mix | None | 29 | NA | 0 % Hemolysis at 5 μM | Human | Combination Of Rr8 And Jr Helix Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR- DDDDEEEDDFVYFNFNKEKEE | rR8-JR helix | Free | Free | Linear | Mix | None | 29 | NA | 0 % Hemolysis at 10 μM | Human | Combination Of Rr8 And Jr Helix Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR- DDDDEEEDDFVYFNFNKEKEE | rR8-JR helix | Free | Free | Linear | Mix | None | 29 | NA | 0.8 % Hemolysis at 20 μM | Human | Combination Of Rr8 And Jr Helix Sequences | Random coil and Helical | Non-hemolytic | ||
| 32673701 | 2020 | R{d}RR{d}RR{d}RRR- DDDDEEEDDFVYFNFNKEKEE | rR8-JR helix | Free | Free | Linear | Mix | None | 29 | NA | 1.1 % Hemolysis at 40 μM | Human | Combination Of Rr8 And Jr Helix Sequences | Random coil and Helical | Non-hemolytic | ||
| 32786271 | 2020 | KFFKRLLKSVRRAVKKFRK{ct:Amid} | HC1 | Amidation | Free | Linear | L | None | 19 | Antimicrobial, Anti-inflammatory, Antibiofilm | 13 % Hemolysis at 50 μM | Human | Snake Hydrophis Cyanocinctus | water = Random coil, 60 mM SDS solution = α-helica | NA | ||
| 32786271 | 2020 | K{d}FFK{d}R{d}LLK{d}SVR{d}R{d}AVK{d}K{d}FR{d}K{d}{ct:Amid} | HC1-D1 | Amidation | Free | Linear | Mix | None | 19 | Antimicrobial, Anti-inflammatory, Antibiofilm | 9 % Hemolysis at 50 μM | Human | Hc-Cath Derivatives | water = Random coil, 60 mM SDS solution = Random coil | NA | ||
| 32786271 | 2020 | K{d}ffK{d}R{d}L{d}L{d}K{d}S{d}V{d}R{d}R{d}A{d}V{d}K{d}K{d}F{d}R{d}K{d}{ct:Amid} | HC1-D2 | Amidation | Free | Linear | D | None | 19 | Antimicrobial, Anti-inflammatory, Antibiofilm | 12 % Hemolysis at 50 μM | Human | Hc-Cath Derivatives | water = Random coil, 60 mM SDS solution = α-Helix | NA | ||
| 32786271 | 2020 | KFFKRLLKSVRRAVKKFRKKPRLIGLSTLL | Hc-CATH | Free | Free | Linear | Mix | None | 30 | Antimicrobial, Anti-inflammatory, Antibiofilm | 16 % Hemolysis at 50 μM | Human | Hc-Cath Derivatives | amphipathic α-Helical | NA | ||
| 32841003 | 2020 | GITDLRGMLKRLKKMK | Sm-A1 | Free | Free | Linear | L | None | 16 | Antibacterial, Antibiofilm | 10 % Hemolysis at 80 μM | Human | Derived From Turbot Viscera Hydrolysate | α-Helix | Low hemolytic | ||
| 32841003 | 2020 | ATLTAKDLTFLQDYKKTKKRVK | Sm-A2 | Free | Free | Linear | L | None | 22 | Antibacterial | 10 % Hemolysis at 20 μM | Human | Derived From Turbot Viscera Hydrolysate | α-Helix | NA | ||
| 32841003 | 2020 | HTMWRCVRLSACLFSVRRR | Sm-A3 | Free | Free | Linear | L | None | 19 | Antibacterial | 10 % Hemolysis at 10 μM | Human | Derived From Turbot Viscera Hydrolysate | α-Helix | NA | ||
| 32967114 | 2020 | FIGTLIPLALGALTKLFK{ct:Amid} | Figainin 1 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Anticancer, Anti-infective, Antitrypanosomal | 50 % Hemolysis at 10 μM | Human | Frog Boana Raniceps | water and 10% (v/v) TFE = Disordered, 30% (v/v) and 50% (v/v) TFE = α-Helical | NA | ||
| 32959824 | 2020 | LKLLKKLLKLLKKL | LK Free | Free | Free | Linear | L | None | 14 | Antibacterial | ~100 % Hemolysis at 50 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 32710881 | 2020 | FQRYFHRYARFLAKIWKG | Adepamycin | Free | Free | Linear | L | None | 18 | Antibacterial, Antifungal | < 10 % Hemolysis at 1.3 μM | Human | Synthetic Peptide | aqueous = Disordered, TFE = α-Helix | NA | ||
| 32710881 | 2020 | FQRYFHRYARFLAKIWKG | Adepamycin | Free | Free | Linear | L | None | 18 | Antibacterial, Antifungal | < 10 % Hemolysis at 10.4 μM | Human | Synthetic Peptide | aqueous = Disordered, TFE = α-Helix | NA | ||
| 32710881 | 2020 | FQRYFHRYARFLAKIWKG | Adepamycin | Free | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 60 % Hemolysis at 335 μM | Human | Synthetic Peptide | aqueous = Disordered, TFE = α-Helix | NA | ||
| 33101226 | 2020 | KIGKVLLVKGIKKIGKVL{ct:Amid} | KV3 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at >64 μM | Human | Derivatives Of The Template Peptide Kv(Porcine Myeloid Amp) | aqueous solution (10-mM PBS) = unordered, 30-mM SDS(MME) = α-Helical | Low hemolytic | ||
| 33101226 | 2020 | RIGRVLLVRGIRRIGRVL{ct:Amid} | RV3 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at >64 μM | Human | Derivatives Of The Template Peptide Kv(Porcine Myeloid Amp) | aqueous solution (10-mM PBS) = unordered, 30-mM SDS(MME) = α-Helical | Low hemolytic | ||
| 33101226 | 2020 | KIGKFLLFKGIKKIGKFL{ct:Amid} | KF3 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at >64 μM | Human | Derivatives Of The Template Peptide Kv(Porcine Myeloid Amp) | aqueous solution (10-mM PBS) = unordered, 30-mM SDS(MME) = α-Helical | Low hemolytic | ||
| 33101226 | 2020 | KIGKWLLWKGIKKIGKWL{ct:Amid} | KW3 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at 2.69 μM | Human | Derivatives Of The Template Peptide Kv(Porcine Myeloid Amp) | aqueous solution (10-mM PBS) = unordered, 30-mM SDS(MME) = α-Helical | NA | ||
| 33101226 | 2020 | RIGRFLLFRGIRRIGRFL{ct:Amid} | RF3 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at >64 μM | Human | Derivatives Of The Template Peptide Kv(Porcine Myeloid Amp) | aqueous solution (10-mM PBS) = unordered, 30-mM SDS(MME) = α-Helical | Low hemolytic | ||
| 33101226 | 2020 | RIGRWLLWRGIRRIGRWL{ct:Amid} | RW3 | Amidation | Free | Linear | L | None | 18 | Antifungal | 10 % Hemolysis at 3.81 μM | Human | Derivatives Of The Template Peptide Kv(Porcine Myeloid Amp) | aqueous solution (10-mM PBS) = unordered, 30-mM SDS(MME) = α-Helical | NA | ||
| 32591801 | 2020 | AFRPIPTHSC | P1 | Free | Free | Linear | L | None | 10 | Antibacterial | <20 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 32591801 | 2020 | YNYSYIITRS | P2 | Free | Free | Linear | L | None | 10 | Antibacterial | <20 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 32591801 | 2020 | PTTVHIIYRI | P3 | Free | Free | Linear | L | None | 10 | Antibacterial | <20 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | NA | ||
| 32591801 | 2020 | ASVTWLLYAM | P4 | Free | Free | Linear | L | None | 10 | Antibacterial | <20 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 32591801 | 2020 | LRCLMLKFPI | P5 | Free | Free | Linear | L | None | 10 | Antibacterial | <20 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | NA | ||
| 32591801 | 2020 | CLRPSIISRA | P6 | Free | Free | Linear | L | None | 10 | Antibacterial | <20 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 32591801 | 2020 | WRYQWTILFI | P7 | Free | Free | Linear | L | None | 10 | Antibacterial | <20 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 32591801 | 2020 | FCIRLATYVI | P8 | Free | Free | Linear | L | None | 10 | Antibacterial | <20 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 32591801 | 2020 | PGHRVSCWLS | P9 | Free | Free | Linear | L | None | 10 | Antibacterial | <20 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | NA | ||
| 33063186 | 2020 | FTILKKLKSFIK | Coco1 | Free | Free | Linear | L | None | 12 | Antibacterial | 10 % Hemolysis at 100 μM | Human | Derived From The Green Algae Coccomyxa Subellipsoidea | NA | NA | ||
| 33063186 | 2020 | KLVKKLLKKYITF | Coco2 | Free | Free | Linear | L | None | 13 | Antibacterial | 10 % Hemolysis at 100 μM | Human | Derived From The Green Algae Coccomyxa Subellipsoidea | NA | NA | ||
| 33063186 | 2020 | LARFVLRILKYGFK | Coco3 | Free | Free | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 9.38 μM | Human | Derived From The Green Algae Coccomyxa Subellipsoidea. | α‐Helix | NA | ||
| 33063186 | 2020 | IPLLRKGKKIIWW | Opero1 | Free | Free | Linear | L | None | 13 | Antibacterial | 10 % Hemolysis at 100 μM | Human | Derived From The Invertebrate Operophtera Brumata | NA | NA | ||
| 33063186 | 2020 | GLKKVIKLLRPLL | Opero2 | Free | Free | Linear | L | None | 13 | Antibacterial | 10 % Hemolysis at 100 μM | Human | Derived From The Invertebrate Operophtera Brumata | NA | NA | ||
| 33063186 | 2020 | IVIKSLGKFLKNVGGFAG | Pyro1 | Free | Free | Linear | L | None | 18 | Antibacterial | 10 % Hemolysis at 100 μM | Human | Derived From The Thermophilic Bacteria Pyrococcus | NA | NA | ||
| 33063186 | 2020 | FKLVWKLLKKLALKL | Aper1 | Free | Free | Linear | L | None | 15 | Anticancer, Antimicrobial | 10 % Hemolysis at 5.96 μM | Human | Derived From The Thermophilic Bacteria Aeropyrum Pernix. | NA | NA | ||
| 33063186 | 2020 | ITKWLLNAIKKGFKL | Thermo1 | Free | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at 21.9 μM | Human | Derived From The Thermophilic Bacteria Thermococcus Onnurineus. | NA | NA | ||
| 33063186 | 2020 | IHKLVKLWLNLGKKF | Thermo2 | Free | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at 39.3 μM | Human | Derived From The Thermophilic Bacteria Thermococcus Onnurineus. | NA | NA | ||
| 33063186 | 2020 | LFSIIWKLNRKLIKA | Thermo3 | Free | Free | Linear | L | None | 15 | Antibacterial | 10 % Hemolysis at 37.3 μM | Human | Derived From The Thermophilic Bacteria Thermococcus Onnurineus. | NA | NA | ||
| 32909733 | 2020 | KIKKIIKKIIKI{ct:Amid} | KI | Amidation | Free | Linear | L | None | 12 | Antibacterial | 10 % Hemolysis at 4000 μM | Human | Synthetic Peptide | Random coil | Non-hemolytic | ||
| 32909733 | 2020 | GIIKKIIKKIIKKI{ct:Amid} | G3 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 50 % Hemolysis at 800 μM | Human | Synthetic Peptide | Random coil | Low hemolytic | ||
| 32909733 | 2020 | GILKKILKKILKKL{ct:Amid} | G7 | Amidation | Free | Linear | L | None | 14 | Antibacterial | 50 % Hemolysis at 80 μM | Human | Synthetic Peptide | aqueous = α-Helical | NA | ||
| 33194795 | 2020 | RFRLPFRRPPIRIHPPPFYPPFRRFL{ct:Amid} | ChBac3.4-NH2(caprine proline-rich bactenecin) | Amidation | Free | Linear | L | None | 26 | Antitumor, Antimicrobial, Antibiofilm | 25 ± 2 % Hemolysis at 64 μM | Human | Domestic Goat Capra Hircus | NA | NA | ||
| 33194795 | 2020 | RFRLPFRRPPIRIHPPPFYPPFRRFL | ChBac3.4-COOH | Free | Free | Linear | L | None | 26 | Antibacterial | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Full-Lenght Variants | NA | Low hemolytic | ||
| 33194795 | 2020 | RFRLPFRRIHPPPFVRIHPPPFYRRFL{ct:Amid} | ChBac3.4-1-NH2 | Amidation | Free | Linear | L | None | 27 | Antibacterial | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Full-Lenght Variants | NA | Low hemolytic | ||
| 33194795 | 2020 | RFRLPFRRIHPPPFVRIHPPPFYRRFL | ChBac3.4-1-COOH | Free | Free | Linear | L | None | 27 | Antitumor, Antibacterial | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Full-Lenght Variants | NA | Low hemolytic | ||
| 33194795 | 2020 | RFRRFRLPFRRIHPPPFVRIHPPPFYRRFL{ct:Amid} | RFR-ChBac3.4-1-NH2 | Amidation | Free | Linear | L | None | 30 | Antibacterial, Antibiofilm | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Full-Lenght Variants | NA | Low hemolytic | ||
| 33194795 | 2020 | RFRLPFRRPWPIRIHPPPFYPWPFRRFL | ChBac3.4-2-COOH | Free | Free | Linear | L | None | 28 | Antibacterial | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Full-Lenght Variants | NA | Low hemolytic | ||
| 33194795 | 2020 | RFRLPFRRPPIRIPPPFYPPFRRFL{ct:Amid} | ChBac3.4(Н-) | Amidation | Free | Linear | L | None | 25 | Antibacterial | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Full-Lenght Variants | NA | Low hemolytic | ||
| 33194795 | 2020 | RIHPPPFYPPFRRFL{ct:Amid} | ChBac3.4 (12-26) | Amidation | Free | Linear | L | None | 15 | Antibacterial | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Truncated Variants | NA | Low hemolytic | ||
| 33194795 | 2020 | RFRLPFRRPPIRIHPPPFY{ct:Amid} | ChBac3.4(1-19)-NH2 | Amidation | Free | Linear | L | None | 19 | Antibacterial | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Truncated Variants | NA | Low hemolytic | ||
| 33194795 | 2020 | RFRLPFRRPPIRIH{ct:Amid} | ChBac3.4(1-14)-NH2 | Amidation | Free | Linear | L | None | 14 | Antibacterial | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Truncated Variants | NA | Low hemolytic | ||
| 33194795 | 2020 | RFRRFRLPFRRPPIRIH{ct:Amid} | RFR-ChBac3.4(1-14)-NH2 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | <5 % Hemolysis at 64 μM | Human | Chbac3.4 Truncated Variants | NA | Low hemolytic | ||
| 32776410 | 2020 | AIGSILGALAKGLPTLISWIKNR{ct:Amid} | AR‐23 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 101.3 % Hemolysis at 10 μM (pH 7.4) | Human | Frog Skin‐Derived Amp From Rana Tagoi | 50% TFE = α-Helix | NA | ||
| 32776410 | 2020 | AIGSILGALAEGLPTLISWIKNR{ct:Amid} | aAR1 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 79.9 % Hemolysis at 10 μM (pH 7.4) | Human | Ar-23 Analogs | 50% TFE = α-Helix | NA | ||
| 32776410 | 2020 | AIGSILGALAEGLPTLISWIENR{ct:Amid} | aAR2 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 14.6 % Hemolysis at 10 μM (pH 7.4) | Human | Ar-23 Analogs | 50% TFE = α-Helix | NA | ||
| 32776410 | 2020 | AIGSILGALAEGLPTLISWIENE{ct:Amid} | aAR3 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 0.1 % Hemolysis at 10 μM (pH 7.4) | Human | Ar-23 Analogs | 50% TFE = α-Helix | Non-hemolytic | ||
| 32776410 | 2020 | AIGSILGALAEGLPTLISWIENE{ct:Amid} | aAR3 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 3.8 % Hemolysis at 40 μM (pH 7.4) | Human | Ar-23 Analogs | 50% TFE = α-Helix | Non-hemolytic | ||
| 32776410 | 2020 | AIGSILGALAKGLPTLISWIKNR{ct:Amid} | AR‐23 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 42.7 % Hemolysis at 20 μM (pH 5.2) | Human | Frog Skin‐Derived Amp From Rana Tagoi | 50% TFE = α-Helix | NA | ||
| 32776410 | 2020 | AIGSILGALAEGLPTLISWIKNR{ct:Amid} | aAR1 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 79.7 % Hemolysis at 20 μM (pH 5.2) | Human | Ar-23 Analogs | 50% TFE = α-Helix | NA | ||
| 32776410 | 2020 | AIGSILGALAEGLPTLISWIENR{ct:Amid} | aAR2 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 61.4 % Hemolysis at 20 μM (pH 5.2) | Human | Ar-23 Analogs | 50% TFE = α-Helix | NA | ||
| 32776410 | 2020 | AIGSILGALAEGLPTLISWIENE{ct:Amid} | aAR3 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 56 % Hemolysis at 20 μM (pH 5.2) | Human | Ar-23 Analogs | 50% TFE = α-Helix | NA | ||
| 32776410 | 2020 | AIGSILGALAEGLPTLISWIENE{ct:Amid} | aAR3 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 80.3 % Hemolysis at 40 μM (pH 7.4) | Human | Ar-23 Analogs | 50% TFE = α-Helix | NA | ||
| 32891601 | 2020 | GKWMTLLKHILK{ct:Amid} | P5T | Amidation | Free | Linear | L | None | 12 | Anti-leishmanial | 6.5 ± 0.9 % Hemolysis at 64 μM | Human | Analogues Of The Halictine-2 (Honeybee, Halictus Sexcinctus) | 10 mM PB = Disordered, 10 mM SDS or 50% TFE = α-Helix | Non-hemolytic | ||
| 32445120 | 2020 | DFFRKSKEKIGKEFKRIVQRIKDFLR | Human CAP18 | Free | Free | Linear | L | None | 26 | Antibacterial | ≥20 % Hemolysis at 1000 μg/mL | Human | Human Cap18 Peptide | NA | Low hemolytic | ||
| 32445120 | 2020 | RKRLRKFRNKKKIGQKIQ | Rabbit CAP18 | Free | Free | Linear | L | None | 18 | Antibacterial | ≥50 % Hemolysis at 1000 μg/mL | Human | Rabbit Cap18 Peptides | NA | Low hemolytic | ||
| 32445120 | 2020 | WKFFRKLLKKIRKKFKR | hCap18 | Free | Free | Linear | L | None | 17 | Antibacterial | 95 % Hemolysis at 1000 μg/mL | Human | Truncated Human Cap18 Peptides | Random coil | Low hemolytic | ||
| 32445120 | 2020 | WRKRLRKFRLKKKILQ | rCap18 | Free | Free | Linear | L | None | 16 | Antibacterial | ≥5 % Hemolysis at 1000 μg/mL | Human | Truncated Rabbit Cap18 Peptides | Random coil | Non-hemolytic | ||
| 32569448 | 2020 | GGLRRLGRKILRAVKKYG | CP | Free | Free | Linear | L | None | 18 | Antibacterial | 0.2 ± 0.2 % Hemolysis at 100 μM | Human | Modified Bmap28(1-18) Synthetic Peptide | NA | Non-hemolytic | ||
| 32569448 | 2020 | GGLRSLGLKILLAWKKYG | DP | Free | Free | Linear | L | None | 18 | Antibacterial | 14.9 ± 2.5 % Hemolysis at 100 μM | Human | Modified Bmap28(1-18) Synthetic Peptide | NA | NA | ||
| 32569448 | 2020 | RGLRRLGRKIKKGLKKYG | Mapcon | Free | Free | Linear | L | None | 18 | Antibacterial | 0 ± 0.02 % Hemolysis at 100 μM | Human | Map Family Consensus Peptide | NA | Non-hemolytic | ||
| 32569448 | 2020 | GGLRSLGRKILRAWKKYG | BMAP28(1-18) | Free | Free | Linear | L | None | 18 | Antibacterial | 4.6 ± 1.2 % Hemolysis at 100 μM | Human | Map Family Peptide | NA | NA | ||
| 32569448 | 2020 | GGLRSLGLKILLAWKKYG | DP | Free | Free | Linear | L | None | 18 | Antibacterial | 0.27 ± 0.44 % Hemolysis at 6.25 μM | Human | Modified Bmap28(1-18) Synthetic Peptide | NA | NA | ||
| 32569448 | 2020 | GGLRSLGRKILRAWKKYG | BMAP28(1-18) | Free | Free | Linear | L | None | 18 | Antibacterial | 1.11 ± 1.24 % Hemolysis at 25 μM | Human | Map Family Peptide | NA | NA | ||
| 33369262 | 2020 | KLLKKAGKLLKKAGKLLKKAG | Stripe | Free | Free | Linear | L | None | 21 | Antibacterial | No Hemolysis at >100 μM | Human | Synthetic Rationally Designed Amphipathic Amp | 20mM PBS (PH7.5) with 1%SDS at 202-222nm = α-Helical | Non-hemolytic | ||
| 33369262 | 2020 | KLLKKGGKLLKKGGKLLKKGG | 1 | Free | Free | Linear | L | None | 21 | Antibacterial | No Hemolysis at >100 μM | Human | Stripe Side-Chain Stapling Analogue Peptide | 20mM PBS (PH7.5) with 1%SDS at 202-222nm = Helical | Non-hemolytic | ||
| 33369262 | 2020 | KLLKK{nnr:X}GKLLKK{nnr:X}GKLLKK{nnr:X}G | 2 | Free | Free | Linear | L | X = Aib (2-aminoisobutyric acid) | 21 | Antibacterial | No Hemolysis at >100 μM | Human | Stripe Side-Chain Stapling Analogue Peptide | 20mM PBS (PH7.5) with 1%SDS at 202-222nm = α-Helical | Non-hemolytic | ||
| 33369262 | 2020 | KLLKK{nnr:Z}GKLLKK{nnr:Z}GKLLKK{nnr:Z}G | 3 | Free | Free | Linear | L | Z = Ac6c(1-aminocyclohexanecarboxylic acid) | 21 | Antibacterial | Hemolysis at 1.56 μM | Human | Stripe Side-Chain Stapling Analogue Peptide | 20mM PBS (PH7.5) with 1%SDS at 202-222nm = α-Helical | NA | ||
| 33369262 | 2020 | KLLKKAGKLLKK{nnr:R}GKLLKK{nnr:S}G | 4 | Free | Free | Linear | L | R8 = (R)-(7-octenyl)alanine, S5 = (S)-(4-pentenyl)alanine, R8 and S5 in peptides 4 and 5 denote side-stapling produced by (R)-(7-octenyl)alanine and (S)-(4-pentenyl)alanine. | 21 | Antibacterial | Hemolysis at 0.78 μM | Human | Stripe Side-Chain Stapling Analogue Peptide | 20mM PBS (PH7.5) with 1%SDS at 202-222nm = α-Helical | NA | ||
| 33369262 | 2020 | KLLKK{nnr:R}GKLLKK{nnr:S}GKLLKKAG | 5 | Free | Free | Linear | L | R8 = (R)-(7-octenyl)alanine, S5 = (S)-(4-pentenyl)alanine, R8 and S5 in peptides 4 and 5 denote side-stapling produced by (R)-(7-octenyl)alanine and (S)-(4-pentenyl)alanine. | 21 | Antibacterial | Hemolysis at 1.56 μM | Human | Stripe Side-Chain Stapling Analogue Peptide | 20mM PBS (PH7.5) with 1%SDS at 202-222nm = α-Helical | NA | ||
| 33291521 | 2020 | FLQRIIGALGRLF | GHaR | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 10 % Hemolysis at 13.6 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | NA | ||
| 33291521 | 2020 | FLQRIRGALGRLF | GHaR6R | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Antibiofilm | 10 % Hemolysis at 156 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | NA | ||
| 33291521 | 2020 | FLQRIIRALGRLF | GHaR7R | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Antibiofilm | 10 % Hemolysis at 11.6 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | NA | ||
| 33291521 | 2020 | FLQRIIGRLGRLF | GHaR8R | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Antibiofilm | 10 % Hemolysis at 22.3 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | NA | ||
| 33291521 | 2020 | FLQRIIGARGRLF | GHaR9R | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 10 % Hemolysis at >200 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | NA | Low hemolytic | ||
| 33291521 | 2020 | FLQRIIGAWGRLF | GHaR9W | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Antibiofilm | 10 % Hemolysis at 32.8 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | NA | ||
| 33291521 | 2020 | FLQRIIGALGRLF | GHaR | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at 46.4 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | NA | ||
| 33291521 | 2020 | FLQRIRGALGRLF | GHaR6R | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Antibiofilm | 50 % Hemolysis at >200 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | Low hemolytic | ||
| 33291521 | 2020 | FLQRIIRALGRLF | GHaR7R | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Antibiofilm | 50 % Hemolysis at 10.9 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | NA | ||
| 33291521 | 2020 | FLQRIIGRLGRLF | GHaR8R | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Antibiofilm | 50 % Hemolysis at 167.6 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | NA | ||
| 33291521 | 2020 | FLQRIIGARGRLF | GHaR9R | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at >200 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | NA | Low hemolytic | ||
| 33291521 | 2020 | FLQRIIGAWGRLF | GHaR9W | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal, Antibiofilm | 50 % Hemolysis at 86.3 μM | Human | Synthetic Temporin-Gha (Gha) Analogue | α-Helical | NA | ||
| 33291782 | 2020 | SPRVCIRVCRNGVCYRRCWG | Capitellacin | Free | Free | Linear | L | None | 20 | Antibacterial, Anti-infective | 0 % Hemolysis at 64 μM | Human | Marine Polychaeta Capitella Teleta | membrane mimicking media = β-Hairpin | Non-hemolytic | ||
| 33291782 | 2020 | SPRVCIRVCRNGVCYRRCWG | Capitellacin | Free | Free | Linear | L | None | 20 | Antibacterial, Anti-infective | ≥2 % Hemolysis at 128 μM | Human | Marine Polychaeta Capitella Teleta | membrane mimicking media = β-Hairpin | Non-hemolytic | ||
| 33291782 | 2020 | KWCFRVCYRGICYRRCR | Tachyplesin-1 | Free | Free | Linear | L | None | 17 | Antibacterial, Anti-infective | 50 % Hemolysis at 128 μM | Human | Horseshoe Crab Tachypleus Tridentatus | membrane mimicking media = β-Hairpin right-handed twist | NA | ||
| 33205989 | 2020 | LKKLLKLLKKLLKL{nt:Acet}{ct:Amid} | LK | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 5 μM | Human | Proline Hinged Amphipathic Α‑Helical Peptide | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | LKKLLPLLKKLLKL{nt:Acet}{ct:Amid} | LK-K6P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 1.25 μM | Human | Lk Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | LKKLLKLLPKLLKL{nt:Acet}{ct:Amid} | LK-K9P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 5 μM | Human | Lk Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | LKKLLKLLKPLLKL{nt:Acet}{ct:Amid} | LK-K10P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 5 μM | Human | Lk Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | LKKPLKLGKKLLKL{nt:Acet}{ct:Amid} | LK-L4P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 160 μM | Human | Lk Pro-Scanning Peptides | PPB + TFE = α-Helical | Low hemolytic | ||
| 33205989 | 2020 | LKKLPKLSKKLLKL{nt:Acet}{ct:Amid} | LK-L5P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 80 μM | Human | Lk Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | LKKLLKPLKKLLKL{nt:Acet}{ct:Amid} | LK-L7P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 160 μM | Human | Lk Pro-Scanning Peptides | PPB + TFE = α-Helical | Low hemolytic | ||
| 33205989 | 2020 | LKKLLKLLKKLPKL{nt:Acet}{ct:Amid} | LK-L12P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 40 μM | Human | Lk Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | LKKLLKLPKKLLKL{nt:Acet}{ct:Amid} | LK-L8P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 640 μM | Human | Lk Pro-Scanning Peptides | PPB + TFE = α-Helical | Non-hemolytic | ||
| 33205989 | 2020 | LKKLLKLLKKPLKL{nt:Acet}{ct:Amid} | LK-L11P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 320 μM | Human | Lk Pro-Scanning Peptides | PPB + TFE = α-Helical | Non-hemolytic | ||
| 33205989 | 2020 | KLLKLLKKLLKLLK{nt:Acet}{ct:Amid} | KL | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 0.625 μM | Human | Proline Hinged Amphipathic Α‑Helical Peptide | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | KPLKLLKKLLKLLK{nt:Acet}{ct:Amid} | KL-L2P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 5 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | KLPKLLKKLLKLLK{nt:Acet}{ct:Amid} | KL-L3P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 10 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | KLLKLLPKLLKLLK{nt:Acet}{ct:Amid} | KL-K7P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 5 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | KLLKLLKPLLKLLK{nt:Acet}{ct:Amid} | KL-K8P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 2.5 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | KLLKPLKKLLKLLK{nt:Acet}{ct:Amid} | KL-L5P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 80 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | KLLKLLKKLPKLLK{nt:Acet}{ct:Amid} | KL-L10P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 80 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | KLLKLLKKLLKPLK{nt:Acet}{ct:Amid} | KL-L12P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 40 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | KLLKLLKKLLKLPK{nt:Acet}{ct:Amid} | KL-L13P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 40 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | NA | ||
| 33205989 | 2020 | KLLKLPKKLLKLLK{nt:Acet}{ct:Amid} | KL-L6P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at 640 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | Non-hemolytic | ||
| 33205989 | 2020 | KLLKLLKKPLKLLK{nt:Acet}{ct:Amid} | KL-L9P | Amidation | Acetylation | Linear | L | None | 14 | Antibacterial | 10 % Hemolysis at >1280 μM | Human | Kl Pro-Scanning Peptides | PPB + TFE = α-Helical | Non-hemolytic | ||
| 33321960 | 2020 | RWCVYAYVRVRGVLVRYRRCW | Ar-1 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 2.9 ± 1.2 μM | Human | Sea Polychaete Arenicola Marina | Aqueous = right-twisted and kinked β-Hairpin, SDS = β-Sheet | NA | ||
| 33321960 | 2020 | RWCVYAYVRIRGVLVRYRRCW | Ar-2 | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 1.8 ± 0.9 μM | Human | Sea Polychaete Arenicola Marina | Aqueous = right-twisted and kinked β-Hairpin, SDS = β-Sheet | NA | ||
| 33321960 | 2020 | RWAVYAYVRVRGVLVRYRRAW | Ar-1-(C/A) | Free | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 11.1 ± 2.3 μM | Human | Synthetic Derivative Of Ar-1 | Aqueous = right-twisted antiparallel β-Sheet, SDS = relaxed antiparallel and parallel β-Sheets | NA | ||
| 33374458 | 2020 | GSKKPVPIIYCNRRSGKCQRM | TS | Free | Free | Linear | L | None | 21 | Antibacterial | <10 % Hemolysis at 160 μM | Human | Modified From Thanatin (Hemipteran Insect Podisus Maculiventris) | β-Helix | Non-hemolytic | ||
| 32798369 | 2021 | AIPWIWIWRLLRKG | WWW | Free | Free | Linear | L | None | 14 | Antibacterial | 100 % Hemolysis at 15 μM | Human | Short Length Bucathl4B Peptide (Water Buffalo (Bubalus Bubalis)) | NA | NA | ||
| 32798369 | 2021 | AIPYIWIYRLLRKG | YWY | Free | Free | Linear | L | None | 14 | Antibacterial | ~2 % Hemolysis at 15 μM | Human | Short Length Bucathl4B Peptide (Water Buffalo (Bubalus Bubalis)) | NA | Low hemolytic | ||
| 32798369 | 2021 | AIPFIWIFRLLRKG | FWF | Free | Free | Linear | L | None | 14 | Antibacterial | ~80 % Hemolysis at 15 μM | Human | Short Length Bucathl4B Peptide (Water Buffalo (Bubalus Bubalis)) | NA | NA | ||
| 32798369 | 2021 | AIPYIYIYRLLRKG | YYY | Free | Free | Linear | L | None | 14 | Antibacterial | ~2 % Hemolysis at 15 μM | Human | Short Length Bucathl4B Peptide (Water Buffalo (Bubalus Bubalis)) | NA | Low hemolytic | ||
| 32798369 | 2021 | AIPFIFIFRLLRKG | FFF | Free | Free | Linear | L | None | 14 | Antibacterial | ~2 % Hemolysis at 15 μM | Human | Short Length Bucathl4B Peptide (Water Buffalo (Bubalus Bubalis)) | NA | Low hemolytic | ||
| 32798369 | 2021 | AIPYIYIWRLLRKG | YYW | Free | Free | Linear | L | None | 14 | Antibacterial | ~5 % Hemolysis at 15 μM | Human | Short Length Bucathl4B Peptide (Water Buffalo (Bubalus Bubalis)) | NA | NA | ||
| 32798369 | 2021 | AIPFIFIWRLLRKG | FFW | Free | Free | Linear | L | None | 14 | Antibacterial | ~40 % Hemolysis at 15 μM | Human | Short Length Bucathl4B Peptide (Water Buffalo (Bubalus Bubalis)) | NA | NA | ||
| 32798369 | 2021 | AIPWIYIYRLLRKG | WYY | Free | Free | Linear | L | None | 14 | Antibacterial | ~40 % Hemolysis at 15 μM | Human | Short Length Bucathl4B Peptide (Water Buffalo (Bubalus Bubalis)) | NA | NA | ||
| 32798369 | 2021 | AIPWIFIFRLLRKG | WFF | Free | Free | Linear | L | None | 14 | Antibacterial | ~60 % Hemolysis at 15 μM | Human | Short Length Bucathl4B Peptide (Water Buffalo (Bubalus Bubalis)) | NA | NA | ||
| 33398076 | 2021 | R{d}I{d}V{d}Q{d}R{d}I{d}K{d}K{d}W{d}L{d}R{d}{ct:Amid} | D-11 | Amidation | Free | Linear | D | None | 11 | Antibacterial | 10 % Hemolysis at 1200 μM | Human | Subsitituted With D Amino Acid In L-11 (Synthetic Peptides ) | NA | Non-hemolytic | ||
| 33398076 | 2021 | R{d}I{d}V{d}Q{d}R{d}I{d}K{d}K{d}W{d}L{d}R{d}{ct:Amid} | D-11 | Amidation | Free | Linear | D | None | 11 | Antibacterial | 0 % Hemolysis at 500 μM | Human | Subsitituted With D Amino Acid In L-11 (Synthetic Peptides ) | NA | Non-hemolytic | ||
| 33398076 | 2021 | R{d}I{d}V{d}Q{d}R{d}I{d}K{d}K{d}W{d}L{d}R{d}{ct:Amid} | D-11 | Amidation | Free | Linear | D | None | 11 | Antibacterial | 0 % Hemolysis at 600 μM | Human | Subsitituted With D Amino Acid In L-11 (Synthetic Peptides ) | NA | Non-hemolytic | ||
| 33469079 | 2021 | RK{d}RW{d}WV{d}VK{d}RK{d}WW{d}V{ct:Amid} | AS01 | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 7.24 % Hemolysis at 8 µM | Human | Synthetic Syndiotactic Polypeptides | Helical | NA | ||
| 33469079 | 2021 | RK{d}RW{d}LW{d}LK{d}RK{d}WL{d}W{ct:Amid} | AS02 | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µM | Human | Synthetic Syndiotactic Polypeptides | Helical | Non-hemolytic | ||
| 33469079 | 2021 | KK{d}KW{d}WV{d}KK{d}KW{d}WV{d}V{ct:Amid} | AS03 | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µM | Human | Synthetic Syndiotactic Polypeptides | Helical | Non-hemolytic | ||
| 33469079 | 2021 | WW{d}KK{d}KV{d}WV{d}KK{d}KW{d}W{ct:Amid} | AS04 | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 0.25 % Hemolysis at 8 µM | Human | Synthetic Syndiotactic Polypeptides | Helical | Non-hemolytic | ||
| 33469079 | 2021 | KK{d}KV{d}VV{d}KK{d}KV{d}VW{d}K{ct:Amid} | AS06 | Amidation | Free | Linear | Mix | None | 13 | Antimicrobial | 0 % Hemolysis at 8 µM | Human | Synthetic Syndiotactic Polypeptides | Helical | Non-hemolytic | ||
| 33469079 | 2021 | WL{d}WL{d}WL{d}WV{d}KK{d}AK{d}AK{d}K{ct:Amid} | AS08 | Amidation | Free | Linear | Mix | None | 15 | Antimicrobial | 1.46 % Hemolysis at 8 µM | Human | Synthetic Syndiotactic Polypeptides | Helical | NA | ||
| 33532575 | 2021 | KYKKALKKLAKLL | L-SB1 | Free | Free | Linear | L | None | 13 | Antibacterial. Antibiofilm | MHC at >2000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | K{d}Y{d}K{d}K{d}A{d}L{d}K{d}K{d}L{d}A{d}K{d}L{d}L{d} | D-SB1 | Free | Free | Linear | D | None | 13 | Antibacterial. Antibiofilm | MHC at >2000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | VQWRAIRVRVIR | L-DJK5 | Free | Free | Linear | L | None | 12 | Antibacterial. Antibiofilm | MHC at >2000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | V{d}Q{d}W{d}R{d}A{d}I{d}R{d}V{d}R{d}V{d}I{d}R{d} | D-DJK5 | Free | Free | Linear | D | None | 12 | Antibacterial. Antibiofilm | MHC at 1000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | ILPWKWPWWPWRR | L-Indo | Free | Free | Linear | L | None | 13 | Antibacterial. Antibiofilm | MHC at 125 μg/mL | Human | Derived From Bovin | PB and 20%TFE = α-Helical | NA | ||
| 33532575 | 2021 | I{d}L{d}P{d}W{d}K{d}W{d}P{d}W{d}W{d}P{d}W{d}R{d}R{d} | D-Indo | Free | Free | Linear | D | None | 13 | Antibacterial. Antibiofilm | MHC at 125 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | NA | ||
| 33532575 | 2021 | KLKLKLKLKLKLKLKLKKLKKLKKLKKLKKLKKLKKL | L-G3KL | Free | Free | Branched | L | None | 37 | Antibacterial. Antibiofilm | MHC at 1000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d} | D-G3KL | Free | Free | Branched | D | None | 37 | Antibacterial. Antibiofilm | MHC at 1000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | OFOFOFOFKBLKBLKKLK{ct:C10} | L-TNS18 | Free | Free | Branched | L | None | 18 | Antibacterial. Antibiofilm | MHC at 1000 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Non-hemolytic | ||
| 33532575 | 2021 | O{d}F{d}O{d}F{d}O{d}F{d}O{d}F{d}K{d}B{d}L{d}K{d}B{d}L{d}K{d}K{d}L{d}K{d}{ct:C10} | D-TNS18 | Free | Free | Branched | D | None | 18 | Antibacterial. Antibiofilm | MHC at 500 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | Low hemolytic | ||
| 33532575 | 2021 | KLKLKLKLKLKLKLKLKKLKKLKKLKKLKLLKLLKKLL | L-T25 | Free | Free | Branched | L | None | 38 | Antibacterial. Antibiofilm | MHC at 62.5 μg/mL | Human | Synthetic Peptide | PB and 20%TFE = α-Helical | NA | ||
| 33532575 | 2021 | K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}K{d}L{d}K{d}L{d}L{d}K{d}L{d}L{d}K{d}K{d}L{d}L{d} | D-T25 | Free | Free | Branched | D | None | 38 | Antibacterial. Antibiofilm | MHC at 125 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 33271197 | 2021 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <5 % Hemolysis at 50 μg/mL | Human | Southern Bell Frog Litoria Aurea And Litoria Raniformis | 20 mM phosphate buffer with 10mM SDS = α-Helix | NA | ||
| 33271197 | 2021 | GLFDIIKKIWESF{ct:Amid} | Aurein M1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <5 % Hemolysis at 25 μg/mL | Human | Aurein 1.2 Analogs | 20 mM phosphate buffer with 10mM SDS = α-Helix | NA | ||
| 33271197 | 2021 | GLFKIIKKIAKSF{ct:Amid} | Aurein M2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <5 % Hemolysis at 100 μg/mL | Human | Aurein 1.2 Analogs | 20 mM phosphate buffer with 10mM SDS = α-Helix | NA | ||
| 33271197 | 2021 | GLFKIIKKIWKSF{ct:Amid} | Aurein M3 | Amidation | Free | Linear | L | None | 13 | Antibacterial | <5 % Hemolysis at 25 μg/mL | Human | Aurein 1.2 Analogs | 20 mM phosphate buffer with 10mM SDS = α-Helix | NA | ||
| 33271197 | 2021 | GLFDIIKKIAESF{ct:Amid} | Aurein 1.2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 39.96 % Hemolysis at 200 μg/mL | Human | Southern Bell Frog Litoria Aurea And Litoria Raniformis | 20 mM phosphate buffer with 10mM SDS = α-Helix | NA | ||
| 33271197 | 2021 | GLFDIIKKIWESF{ct:Amid} | Aurein M1 | Amidation | Free | Linear | L | None | 13 | Antibacterial | ~50 % Hemolysis at 200 μg/mL | Human | Aurein 1.2 Analogs | 20 mM phosphate buffer with 10mM SDS = α-Helix | NA | ||
| 33271197 | 2021 | GLFKIIKKIAKSF{ct:Amid} | Aurein M2 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 15.48 % Hemolysis at 200 μg/mL | Human | Aurein 1.2 Analogs | 20 mM phosphate buffer with 10mM SDS = α-Helix | NA | ||
| 33271197 | 2021 | GLFKIIKKIWKSF{ct:Amid} | Aurein M3 | Amidation | Free | Linear | L | None | 13 | Antibacterial | 43.86 % Hemolysis at 200 μg/mL | Human | Aurein 1.2 Analogs | 20 mM phosphate buffer with 10mM SDS = α-Helix | NA | ||
| 33669976 | 2021 | {nnr:Methyldecanoyl}-{nnr:MePro}-{nnr:AHMOD}-A-{nnr:Aib}-I-{nnr:Iva}-{nnr:βAla}-Alaol-{nnr:Glyol}{nt:amino group}{ct:hydroxyl} | EmiA | hydroxyl | amino group | Linear | L | MePro = Methylproline, AHMOD = 2-Amino-3-hydroxy-4-methyl-2-pentenoic acid, Aib = α-Amino isobutyric acid, Iva = Isovaline, βAla = β-Alanine{nnr:Bala} – β-Alanine , Glyol = Glycine with a hydroxyl modification, Methyldecanoyl = Methyldecanoyl | 9 | Antifungal, Anticancer | 12.6 % Hemolysis at 20 µM | Human | Derived From The Alkalophilic Fungus Emericellopsis Alkalina | NA | NA | ||
| 32889698 | 2021 | A({nnr:Nle})WKK({nnr:Nle})({nnr:Nle})KK({nnr:Nle})({nnr:Nle})KSAKK({nnr:Nle})G | C18G-Nle | Free | Free | Linear | L | Nle = Norleucine | 18 | Antibacterial | 24 % Hemolysis at 10 µM | Human | Variants Of C18G (Human Platelet Factor Iv Protein) | PBS = Disordered, TFE = α-Helix | NA | ||
| 32889698 | 2021 | A({nnr:Nva})WKK({nnr:Nva})({nnr:Nva})KK({nnr:Nva})({nnr:Nva})KSAKK({nnr:Nva})G | C18G-Nva | Free | Free | Linear | L | Nva = Norvaline | 18 | Antibacterial | <5 % Hemolysis at 10 µM | Human | Variants Of C18G (Human Platelet Factor Iv Protein) | PBS = Disordered, TFE = α-Helix | NA | ||
| 32889698 | 2021 | A({nnr:Cha})WKK({nnr:Cha})({nnr:Cha})KK({nnr:Cha})({nnr:Cha})KSAKK({nnr:Cha})G | C18G-Cha | Free | Free | Linear | L | Cha = Cyclohexylalanine | 18 | Antibacterial | 65 % Hemolysis at 10 µM | Human | Variants Of C18G (Human Platelet Factor Iv Protein) | PBS = Disordered, TFE = α-Helix | NA | ||
| 32889698 | 2021 | A({nnr:Abu})WKK({nnr:Abu})({nnr:Abu})KK({nnr:Abu})({nnr:Abu})KSAKK({nnr:Abu})G | C18G-Abu | Free | Free | Linear | L | Abu = Aminobutyric | 18 | Antibacterial | <5 % Hemolysis at 10 µM | Human | Variants Of C18G (Human Platelet Factor Iv Protein) | PBS = Disordered, TFE = α-Helix | NA | ||
| 32889698 | 2021 | AAWKKAAKKAAKSAKKAG | C18G-Ala | Free | Free | Linear | L | None | 18 | Antibacterial | <5 % Hemolysis at 10 µM | Human | Variants Of C18G (Human Platelet Factor Iv Protein) | PBS = Disordered, TFE = α-Helix | NA | ||
| 33206284 | 2021 | MASKRDCNLMKATCAGQAVTYAIHSLLNRLGGDSSDPAGC NDIVRKYCK | C13T | Free | Free | Linear | L | None | 49 | Antibacterial | 15-20 % Hemolysis at 600 µM | Human | Variant Of Ent96 | NA | Low hemolytic | ||
| 33206284 | 2021 | MASKYYGNGVKRDCNLMKACCAGQAVTYAIHSLLNRLGGDSSDPAGCNDIVRKYCK | Ent96-K4_K5insYYGNGV# | Free | Free | Linear | L | diglycosylated | 56 | Antibacterial | 15-20 % Hemolysis at 600 µM | Human | Variant Of Ent96 | NA | Low hemolytic | ||
| 33206284 | 2021 | MASKRDCNLMKACCAGQAVTYAIHSLLNRLGGDCSDPAGCNDIVRKYCK | S34C | Free | Free | Linear | L | None | 49 | Antibacterial | 15-20 % Hemolysis at 600 µM | Human | Variant Of Ent96 | NA | Low hemolytic | ||
| 33206284 | 2021 | MASKACCAGQAVTYAIHSLLNRLGGDSSDPAGCNDIVRKYCK | Ent96-R5_K11del# | Free | Free | Linear | L | diglycosylated | 42 | Antibacterial | 15-20 % Hemolysis at 600 µM | Human | Variant Of Ent96 | NA | Low hemolytic | ||
| 33206284 | 2021 | MASKRDCNLMKACCAGQAVTYAIHSLLNRLGGDSSGPAGC NDIVRKYCK | D36G | Free | Free | Linear | L | None | 49 | Antibacterial | 15-20 % Hemolysis at 600 µM | Human | Variant Of Ent96 | NA | Low hemolytic | ||
| 33206284 | 2021 | MASKRDCNLMKACCAEQAVTYAIQSLLNRLGGDSSDPAGCNDIVRKYCK | G16E-H24Q | Free | Free | Linear | L | None | 49 | Antibacterial | 15-20 % Hemolysis at 600 µM | Human | Variant Of Ent96 | NA | Low hemolytic | ||
| 33506605 | 2021 | GLLKRIKTLL{ct:Amid} | Anoplin | Amidation | Free | Linear | L | None | 10 | Antibacterial, Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Solitary Wasp Anoplius Samariensis | PBS = Random Coil, SDS = α-Helix | Low hemolytic | ||
| 33506605 | 2021 | GLLKIIKKLL{ct:Amid} | Ano 1-F | Amidation | Free | Linear | L | None | 10 | Antibacterial, Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Anoplin Analogs | PBS = Random Coil, SDS = α-Helix | Low hemolytic | ||
| 33506605 | 2021 | GLLKIIKKLL{nt:C8 = octanoic acid}{ct:Amid} | Ano 1-C8 | Amidation | C8 = octanoic acid | Linear | L | C8 = Octanoic Acid | 10 | Antibacterial, Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Anoplin Analogs | PBS = Helical, SDS = α-Helix | Low hemolytic | ||
| 33506605 | 2021 | GLLKIIKKLL{nt:C10 = decanoic acid}{ct:Amid} | Ano 1-C10 | Amidation | C10 = decanoic acid | Linear | L | C10 = decanoic acid | 10 | Antibacterial, Antifungal | 50 % Hemolysis at 44.6 μg/ml | Human | Anoplin Analogs | PBS = Helical, SDS = α-Helix | NA | ||
| 33506605 | 2021 | #ERROR! | Ano 2-F | Amidation | Free | Linear | L | None | 10 | Antibacterial, Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Anoplin Analogs | PBS = Random Coil, SDS = α-Helix | Low hemolytic | ||
| 33506605 | 2021 | GLKKIIKKLL{nt:C8 = octanoic acid}{ct:Amid} | Ano 2-C8 | Amidation | C8 = octanoic acid | Linear | L | C8 = Octanoic Acid | 10 | Antibacterial, Antifungal | 50 % Hemolysis at 80.8 μg/ml | Human | Anoplin Analogs | PBS = Random Coil, SDS = α-Helix | NA | ||
| 33506605 | 2021 | GLKKIIKKLL{nt:C10 = decanoic acid}{ct:Amid} | Ano 2-C10 | Amidation | C10 = decanoic acid | Linear | L | C10 = decanoic acid | 10 | Antibacterial, Antifungal | 50 % Hemolysis at 75.5 μg/ml | Human | Anoplin Analogs | PBS = Random Coil, SDS = α-Helix | NA | ||
| 33506605 | 2021 | GLLKFIKRLL{ct:Amid} | Ano 3-F | Amidation | Free | Linear | L | None | 10 | Antibacterial, Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Anoplin Analogs | PBS = Random Coil, SDS = α-Helix | Low hemolytic | ||
| 33506605 | 2021 | GLLKFIKRLL{nt:C10 = decanoic acid}{ct:Amid} | Ano 3-C10 | Amidation | C10 = decanoic acid | Linear | L | C10 = decanoic acid | 10 | Antibacterial, Antifungal | 50 % Hemolysis at 175.2 μg/ml | Human | Anoplin Analogs | PBS = Helical, SDS = α-Helix | NA | ||
| 33506605 | 2021 | GLLKKIKRLL{ct:Amid} | Ano 4-F | Amidation | Free | Linear | L | None | 10 | Antibacterial, Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Anoplin Analogs | PBS = Random Coil, SDS = α-Helix | Low hemolytic | ||
| 33506605 | 2021 | GLLKKIKRLL{nt:C10 = decanoic acid}{ct:Amid} | Ano 4-C10 | Amidation | C10 = decanoic acid | Linear | L | C10 = decanoic acid | 10 | Antibacterial, Antifungal | 50 % Hemolysis at 44.2 μg/ml | Human | Anoplin Analogs | PBS = Random Coil, SDS = α-Helix | NA | ||
| 33506605 | 2021 | GLLKIIKRLL{ct:Amid} | Ano 5-F | Amidation | Free | Linear | L | None | 10 | Antibacterial, Antifungal | 50 % Hemolysis at >200 μg/ml | Human | Anoplin Analogs | PBS = Helical, SDS = α-Helix | Low hemolytic | ||
| 33506605 | 2021 | GLLKIIKRLL{nt:C10 = decanoic acid}{ct:Amid} | Ano 5-C10 | Amidation | C10 = decanoic acid | Linear | L | C10 = decanoic acid | 10 | Antibacterial, Antifungal | 50 % Hemolysis at 68.1 μg/ml | Human | Anoplin Analogs | PBS = Random Coil, SDS = α-Helix | NA | ||
| 33917850 | 2021 | KKLFKKILKYL{ct:Amid} | BP100 | Amidation | Free | Linear | L | None | 11 | Antibacterial | 50 % Hemolysis at 163 µM | Human | Combines The Sequence Of Melittin And Cecropin A | α-Helical | NA | ||
| 33917850 | 2021 | {conj:Naphthalimide}AAKKLFKKILKYL{ct:Amid} | NAPHT-BP100 | Amidation | Naphthalimide | Linear | L | None | 13 | Antibacterial | 50 % Hemolysis at 23 µM | Human | Naphthalimide-Conjugated Bp10 Peptide | aqueous = Random/flexible structure, POPG = α-Helix | NA | ||
| 33244888 | 2021 | INWLKLGKAIIDAL{ct:Amid} | agelaia-MPI | Amidation | Free | Linear | L | None | 14 | Antimicrobial, Antinociceptive | 50 % Hemolysis at 11.5 ± 1.1 µM | Human | Wasp Parachartergus Fraternus | α-Helical | NA | ||
| 33244888 | 2021 | IFWLFRGKADVAL{ct:Amid} | neuroVAL | Amidation | Free | Linear | L | None | 13 | Anticancer, Antimicrobial | 50 % Hemolysis at >64 µM | Human | Agelaia-Mpi Analogues | 30% TFE = α-Helical | Low hemolytic | ||
| 33244888 | 2021 | ILGTILGLLKGL{ct:Amid} | protonectin | Amidation | Free | Linear | L | None | 12 | Anticancer, Antimicrobial | 50 % Hemolysis at >64 µM | Human | Wasp Parachartergus Fraternus | 30% TFE = α-Helical | Low hemolytic | ||
| 33244888 | 2021 | IFGTILGFLKGL{ct:Amid} | protonectin-F | Amidation | Free | Linear | L | None | 12 | Anticancer, Antimicrobial | 50 % Hemolysis at >64 µM | Human | Protonectin Analogues | 30% TFE = α-Helical | Low hemolytic | ||
| 33676184 | 2021 | KWKLFKKIKF | CMt1 | Free | Free | Linear | L | None | 10 | Antifungal | 10 % Hemolysis at 500 μg/ml | Human | C-Terminal Truncated Derivatives | α-Helix | Low hemolytic | ||
| 33676184 | 2021 | KWKLFKKI | CMt2 | Free | Free | Linear | L | None | 8 | Antifungal | 5 % Hemolysis at 500 μg/ml | Human | C-Terminal Truncated Derivatives | α-Helix Random coil | Low hemolytic | ||
| 33676184 | 2021 | KWKLFK | CMt3 | Free | Free | Linear | L | None | 6 | Antifungal | 5 % Hemolysis at 500 μg/ml | Human | C-Terminal Truncated Derivatives | Random coil | Low hemolytic | ||
| 33676184 | 2021 | KWKLFKKIKFLHSAKKF | CE-MA | Free | Free | Linear | L | None | 17 | Antibacterial, Antiviral, Antiparasitic, Antifungal, Anticancer | >20 % Hemolysis at 500 μg/ml | Human | Synthetic Peptide Consisting Of Cecropin A And Magenin B | α-Helix | NA | ||
| 33830736 | 2021 | LRKSEEEVAARRARVVW | LP-1 | Free | Free | Linear | L | None | 17 | NA | 0 % Hemolysis at 100 µM | Human | Human Lactoferrin | α-Helical and β-Sheet | Non-hemolytic | ||
| 33830736 | 2021 | RKVRGPPVSCIKRDSPIQ | LP-2 | Free | Free | Linear | L | None | 18 | Anti-osteoclastogenic | 0 % Hemolysis at 100 µM | Human | Fragment From The N-Terminus Of The N-Lobe Of Human Lactoferrin | aqueous environmen = nano-globular assembly Helical and β-Sheet | Non-hemolytic | ||
| 33689880 | 2021 | LVGKLLKGAVGDVCGLLPIC | Peptide 2 | Free | Free | Linear | L | None | 20 | Anti-inflammatory | 0.22 % Hemolysis at 21.875 µM | Human | Frog Skin Secretions Of Bombina Maxima | NA | Non-hemolytic | ||
| 33689880 | 2021 | LVGKLLKGAVGDVCGLLPIC | Peptide 2 | Free | Free | Linear | L | None | 20 | Anti-inflammatory | 0.26 % Hemolysis at 43.75 µM | Human | Frog Skin Secretions Of Bombina Maxima | NA | Non-hemolytic | ||
| 33689880 | 2021 | LVGKLLKGAVGDVCGLLPIC | Peptide 2 | Free | Free | Linear | L | None | 20 | Anti-inflammatory | 0.31 % Hemolysis at 87.5 µM | Human | Frog Skin Secretions Of Bombina Maxima | NA | Non-hemolytic | ||
| 33689880 | 2021 | LVGKLLKGAVGDVCGLLPIC | Peptide 2 | Free | Free | Linear | L | None | 20 | Anti-inflammatory | 0.32 % Hemolysis at 175 µM | Human | Frog Skin Secretions Of Bombina Maxima | NA | Non-hemolytic | ||
| 33689880 | 2021 | LVGKLLKGAVGDVCGLLPIC | Peptide 2 | Free | Free | Linear | L | None | 20 | Anti-inflammatory | 0.33 % Hemolysis at 350 µM | Human | Frog Skin Secretions Of Bombina Maxima | NA | Non-hemolytic | ||
| 33689880 | 2021 | LVGKLLKGAVGDVCGLLPIC | Peptide 2 | Free | Free | Linear | L | None | 20 | Anti-inflammatory | 0.33 % Hemolysis at 700 µM | Human | Frog Skin Secretions Of Bombina Maxima | NA | Non-hemolytic | ||
| 33689880 | 2021 | LVGKLLKGAVGDVCGLLPIC | Peptide 2 | Free | Free | Linear | L | None | 20 | Anti-inflammatory | 0.4 % Hemolysis at 1.4 mM | Human | Frog Skin Secretions Of Bombina Maxima | NA | Non-hemolytic | ||
| 33689880 | 2021 | LVGKLLKGAVGDVCGLLPIC | Peptide 2 | Free | Free | Linear | L | None | 20 | Anti-inflammatory | 0.56 % Hemolysis at 2.8 mM | Human | Frog Skin Secretions Of Bombina Maxima | NA | Non-hemolytic | ||
| 33981626 | 2021 | KKLFKKILKYL{ct:Amid} | BP100 | Amidation | Free | Linear | L | None | 11 | Antibacterial | 10 % Hemolysis at 45 μM | Human | Synthetic Peptide | micelles and lipid bilayers = α-Helix | NA | ||
| 33981626 | 2021 | GIGKFLHSAKKFGKAFVGEIMNS | MAG2 | Free | Free | Linear | L | None | 23 | Antibacterial | 10 % Hemolysis at >100 μM | Human | Frog Xenopus Laevis | NA | Low hemolytic | ||
| 33981626 | 2021 | GMASKAGAIAGKIAKVALKAL{ct:Amid} | PGLa | Amidation | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 16 μM | Human | Frog Xenopus Laevis | NA | NA | ||
| 33981626 | 2021 | KIAGKIAKIAGKIAKIAGKIA{ct:Amid} | MSI-103 | Amidation | Free | Linear | L | None | 21 | Antibacterial | 10 % Hemolysis at 9 μM | Human | Pgla Analog | α-Helix | NA | ||
| 33981626 | 2021 | KLALKLALKALKAALKLA{ct:Amid} | MAP | Amidation | Free | Linear | L | None | 18 | Antibacterial | 10 % Hemolysis at 2 μM | Human | Synthetic Peptide | Helical | NA | ||
| 33981626 | 2021 | GRKKRRQRRRPPQ | TAT | Free | Free | Linear | L | None | 13 | Antibacterial | 10 % Hemolysis at >>100 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33798688 | 2021 | CLELLEELLELLEELLELLEEL | LZEP | Free | Free | Linear | L | None | 22 | NA | ~2.5 % Hemolysis at ~20 μM at pH 7.4 | Human | Synthetic Peptide | α-Helical | Low hemolytic | ||
| 33798688 | 2021 | CLELLEELLELLEELLELLEEL | LZEP | Free | Free | Linear | L | None | 22 | NA | 40 % Hemolysis at ~20 μM at pH 5 | Human | Synthetic Peptide | α-Helical | NA | ||
| 34070683 | 2021 | {nnr:hArg}-{nnr:βNPhe}-{nnr:hArg}-{nnr:βNPhe}-{nnr:hArg}-{nnr:βNPhe}-{nnr:hArg}-{nnr:βNPhe}{nnr:hArg}-{nnr:βNPhe}-{nnr:hArg}-{nnr:βNPhe}-{nnr:hArg}-{nnr:βNPhe}-{nnr:hArg}-{nnr:βNPhe}{nt:Acet}{ct:Amid} | Subclass I-1 | Amidation | Acetylation | Linear | NA | hArg = homoarginine, βNPhe = N-benzyl-β-alanine | 16 | Antibacterial | 6.1 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | Low hemolytic | ||
| 34070683 | 2021 | {nnr:hArg}-{nnr:βNsce}-{nnr:hArg}-{nnr:βNsce}-{nnr:hArg}-{nnr:βNsce}-{nnr:hArg}-{nnr:βNsce}-{nnr:hArg}-{nnr:βNsce}-{nnr:hArg}-{nnr:βNsce}{nt:Acet}{ct:Amid} | Subclass I-2 | Amidation | Acetylation | Linear | NA | hArg = homoarginine, βNsce = N-(S)-1-cyclohexylethyl-β-alanine | 12 | Antibacterial | 98.4 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | NA | ||
| 34070683 | 2021 | {nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}-{nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}-{nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}{nt:SpermineAc = H2N(CH2)3NH(CH2)4NH(CH2)3NHCH2(C=O)-}{ct:Amid} | Subclass II-3 | Amidation | SpermineAc = H2N(CH2)3NH(CH2)4NH(CH2)3NHCH2(C=O)- | Linear | L | hArg = homoarginine, βNspe = N-(S)-1-phenylethyl-β-alanine | 13 | Antibacterial | 0.6 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | Non-hemolytic | ||
| 34070683 | 2021 | {nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}-{nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}-{nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}-{nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}{nt:H}{ct:Amid} | Subclass II-4 | Amidation | H | Linear | L | hArg = homoarginine, βNspe = N-(S)-1-phenylethyl-β-alanine | 16 | Antibacterial | 2.6 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | Non-hemolytic | ||
| 34070683 | 2021 | {nnr:hArg}-{nnr:βNsce}-K-{nnr:βNspe}-{nnr:hArg}-{nnr:βNsce}-K-{nnr:βNspe}-{nnr:hArg}-{nnr:βNsce}-K-{nnr:βNspe}{nt:Acet}{ct:Amid} | Subclass II-5 | Amidation | Acetylation | Linear | L | hArg = homoarginine, βNspe = N-(S)-1-phenylethyl-β-alanine, βNsce = N-(S)-1-cyclohexylethyl-β-alanine | 12 | Antibacterial | 9.4 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | Low hemolytic | ||
| 34070683 | 2021 | {nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}-{nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}-{nnr:hArg}-{nnr:βNspe}-K-{nnr:βNspe}{nt:Cinn = cinnamoyl}{ct:Amid} | Subclass II-6 | Amidation | Cinn = cinnamoyl | Linear | L | hArg = homoarginine, βNspe = N-(S)-1-phenylethyl-β-alanine | 13 | Antibacterial | 15.7 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | Low hemolytic | ||
| 34070683 | 2021 | K-{nnr:βNPhe(F)}-K-{nnr:βNPhe(F)}-K-{nnr:βNPhe(F)}-K-{nnr:βNPhe(F)}-K-{nnr:βNPhe(F)}-K-{nnr:βNPhe(F)}-K-{nnr:βNPhe(F)}-K-{nnr:βNPhe(F)}{nt:H}{ct:Amid} | Subclass III-7 | Amidation | H | Linear | L | βNPhe(F) = N-(4-fluorobenzyl)-β-alanine | 16 | Antibacterial | 1.5 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | Non-hemolytic | ||
| 34070683 | 2021 | K-{nnr:βNPhe(F3)}-K-{nnr:βNPhe(F3)}-K-{nnr:βNPhe(F3)}-K-{nnr:βNPhe(F3)}-K-{nnr:βNPhe(F3)}-K-{nnr:βNPhe(F3)}{nt:H}{ct:Amid} | Subclass III-8 | Amidation | H | Linear | L | βNPhe(F3) = N-(3,4,5-trifluorobenzyl)-β-alanine | 12 | Antibacterial | 28.8 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | Low hemolytic | ||
| 34070683 | 2021 | K-{nnr:βNCha}-K-{nnr:βNCha}-K-{nnr:βNCha}-K-{nnr:βNCha}-K-{nnr:βNCha}-K-{nnr:βNCha}-K-{nnr:βNCha}-K-{nnr:βNCha}{nt:H}{ct:Amid} | Subclass III-9 | Amidation | H | Linear | L | βNCha = N-cyclohexylmethyl-β-alanine | 16 | Antibacterial | 23 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | Low hemolytic | ||
| 34070683 | 2021 | K-{nnr:βNspe}-K-{nnr:βNspe}-K-{nnr:βNspe}-K-{nnr:βNspe}-K-{nnr:βNspe}-K-{nnr:βNspe}{nt:Oct = octanoyl}{ct:Amid} | Subclass III-10 | Amidation | Oct = octanoyl | Linear | L | βNspe = N-(S)-1-phenylethyl-β-alanine | 13 | Antibacterial | 6.9 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | Low hemolytic | ||
| 34070683 | 2021 | K-{nnr:βNPhe}-K-{nnr:βNPhe}-K-{nnr:βNPhe}-K-{nnr:βNPhe}-K-{nnr:βNPhe}-K-{nnr:βNPhe}{nt:Lau = lauroyl}{ct:Amid} | Subclass III-11 | Amidation | Lau = lauroyl | Linear | L | βNPhe = N-benzyl-β-alanine | 13 | Antibacterial | 95.6 % Hemolysis at 400 µg/mL | Human | Synthetic Peptide/Β-Peptoid Hybrids | NA | NA | ||
| 33942149 | 2021 | GFLDVLKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-16 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 0.1 % Hemolysis at 1.7 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | NA | ||
| 33942149 | 2021 | GFLDVLKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-16 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 1.1 % Hemolysis at 3.4 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | NA | ||
| 33942149 | 2021 | GFLDVLKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-16 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 1.2 % Hemolysis at 6.9 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | NA | ||
| 33942149 | 2021 | GFLDVLKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-16 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 2.8 % Hemolysis at 13.7 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | NA | ||
| 33942149 | 2021 | GFLDVLKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-16 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 6.3 % Hemolysis at 27.5 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | NA | ||
| 33942149 | 2021 | GFLDVLKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-16 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 9.7 % Hemolysis at 55.1 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | NA | ||
| 33942149 | 2021 | GFLDVLKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-16 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 21.8 % Hemolysis at 110.3 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | NA | ||
| 33942149 | 2021 | GFLDVLKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-16 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 55.2 % Hemolysis at 220.6 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | NA | ||
| 33942149 | 2021 | GFLDVVKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-17 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 0 % Hemolysis at 0.8 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | Non-hemolytic | ||
| 33942149 | 2021 | GFLDVVKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-17 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 0 % Hemolysis at 1.7 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | Non-hemolytic | ||
| 33942149 | 2021 | GFLDVVKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-17 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 0 % Hemolysis at 3.4 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | Non-hemolytic | ||
| 33942149 | 2021 | GFLDVVKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-17 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 0 % Hemolysis at 6.9 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | Non-hemolytic | ||
| 33942149 | 2021 | GFLDVVKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-17 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 0 % Hemolysis at 13.8 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | Non-hemolytic | ||
| 33942149 | 2021 | GFLDVVKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-17 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 0.1 % Hemolysis at 27.7 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | Non-hemolytic | ||
| 33942149 | 2021 | GFLDVVKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-17 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 0.7 % Hemolysis at 55.5 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | Non-hemolytic | ||
| 33942149 | 2021 | GFLDVVKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-17 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 4.3 % Hemolysis at 111 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | Low hemolytic | ||
| 33942149 | 2021 | GFLDVVKGVGKAALGAVTHLINQ{ct:Amid} | cruzioseptin-17 | Amidation | Free | Linear | L | None | 23 | Antimicrobial, Antifungal | 11.6 % Hemolysis at 222 µM | Human | Leaf Frog Cruziohyla Calcarifer | α-Helical | Low hemolytic | ||
| 34158805 | 2021 | PSAWQITKCAGSIAWALGSGIF | CBP22 | Free | Free | Linear | L | None | 22 | Antibacterial | <10 % Hemolysis at 256 μg/ml | Human | Bacteriocin Clostridium Butyricum Zju-F1 | NA | Low hemolytic | ||
| 33890759 | 2021 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES{ct:Amid} | LL-37 | Amidation | Free | Linear | L | None | 37 | Antibacterial | 50 % Hemolysis at 170 μM | Human | Human Cathelicidin Ll-37 | Helical | NA | ||
| 33890759 | 2021 | KRIWQRIKDFLR{ct:Amid} | KR12 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 50 % Hemolysis at >340 μM | Human | Fragement Of Ll-37 | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQRIKDF{nt:C14}{ct:Amid} | C14-KR10 | Amidation | C14 | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIK{nt:C14}{ct:Amid} | C14-KR8 | Amidation | C14 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQR{nt:C14}{ct:Amid} | C14-KR6 | Amidation | C14 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIW{nt:C14}{ct:Amid} | C14-KR4 | Amidation | C14 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIKDFLR{nt:C12}{ct:Amid} | C12-KR12 | Amidation | C12 | Linear | L | None | 12 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIKDF{nt:C12}{ct:Amid} | C12-KR10 | Amidation | C12 | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIK{nt:C12}{ct:Amid} | C12-KR8 | Amidation | C12 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 35 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQR{nt:C12}{ct:Amid} | C12-KR6 | Amidation | C12 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at 75 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIW{nt:C12}{ct:Amid} | C12-KR4 | Amidation | C12 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at 30 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIKDFLR{nt:C10}{ct:Amid} | C10-KR12 | Amidation | C10 | Linear | L | None | 12 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIKDF{nt:C10}{ct:Amid} | C10-KR10 | Amidation | C10 | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIK{nt:C10}{ct:Amid} | C10-KR8 | Amidation | C10 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at 300 μM | Human | Synthetic Peptide | Helical | Low hemolytic | ||
| 33890759 | 2021 | K{d}R{d}I{d}W{d}Q{d}R{d}I{d}K{d}{nt:C10}{ct:Amid} | C10-KR8d | Amidation | C10 | Linear | D | None | 8 | Antibacterial | 50 % Hemolysis at 300 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQR{nt:C10}{ct:Amid} | C10-KR6 | Amidation | C10 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at >340 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIW{nt:C10}{ct:Amid} | C10-KR4 | Amidation | C10 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at 150 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIKDFLR{nt:C8}{ct:Amid} | C8-KR12 | Amidation | C8 | Linear | L | None | 12 | Antibacterial | 50 % Hemolysis at <25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIKDF{nt:C8}{ct:Amid} | C8-KR10 | Amidation | C8 | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at 250 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | K{d}R{d}I{d}W{d}Q{d}R{d}I{d}K{d}D{d}F{d}{nt:C8}{ct:Amid} | C8-KR10d | Amidation | C8 | Linear | D | None | 10 | Antibacterial | 50 % Hemolysis at 150 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIK{nt:C8}{ct:Amid} | C8-KR8 | Amidation | C8 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQR{nt:C8}{ct:Amid} | C8-KR6 | Amidation | C8 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIW{nt:C8}{ct:Amid} | C8-KR4 | Amidation | C8 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQRIKDFLR{nt:C6}{ct:Amid} | C6-KR12 | Amidation | C6 | Linear | L | None | 12 | Antibacterial | 50 % Hemolysis at 25 μM | Human | Synthetic Peptide | NA | NA | ||
| 33890759 | 2021 | KRIWQRIKDF{nt:C6}{ct:Amid} | C6-KR10 | Amidation | C6 | Linear | L | None | 10 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQRIK{nt:C6}{ct:Amid} | C6-KR8 | Amidation | C6 | Linear | L | None | 8 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIWQR{nt:C6}{ct:Amid} | C6-KR6 | Amidation | C6 | Linear | L | None | 6 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33890759 | 2021 | KRIW{nt:C6}{ct:Amid} | C6-KR4 | Amidation | C6 | Linear | L | None | 4 | Antibacterial | 50 % Hemolysis at >200 μM | Human | Synthetic Peptide | NA | Low hemolytic | ||
| 33862164 | 2021 | FWSTLLSIGKSLL{ct:Amid} | VpCT1 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at 10.5±0.4 μM | Human | Scorpion Mesomexovis Variegatu | 60 % aqueous TFE = α-Helix | NA | ||
| 33862164 | 2021 | FWSTIWNAAKSLI{ct:Amid} | VpCT2 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at 10.8±0.4 μM | Human | Scorpion Mesomexovis Variegatu | 60 % aqueous TFE = α-Helix | NA | ||
| 33862164 | 2021 | FLQGIIDTVGKWL{ct:Amid} | VpCT3 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at 83.7±1.8 μM | Human | Scorpion Mesomexovis Variegatu | 60 % aqueous TFE = α-Helix | NA | ||
| 33862164 | 2021 | FLQGIWDTVGKWL{ct:Amid} | VpCT3W | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at 37.9±0.4 μM | Human | Scorpion Mesomexovis Variegatu | 60 % aqueous TFE = α-Helix | NA | ||
| 33862164 | 2021 | FLSKIWDGVKSLL{ct:Amid} | VpCTConsensus | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 50 % Hemolysis at 4.8±0.7 μM | Human | Scorpion Mesomexovis Variegatu | 60 % aqueous TFE = α-Helix | NA | ||
| 33862164 | 2021 | LWGALLGLGSTLLSKL{ct:Amid} | VpCT4 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 39.9±0.4 μM | Human | Scorpion Mesomexovis Variegatu | 60 % aqueous TFE = α-Helix | NA | ||
| 33972716 | 2021 | IWLTALKFLGKNLGKHLAKQQLAKL{nt:H}{ct:Amid} | LyeTx I | Amidation | H | Linear | L | None | 25 | Antibacterial, Antifungal | 50 % Hemolysis at 32.35 μM | Human | Lycosa Erythrognatha Spider Venom | NA | NA | ||
| 33972716 | 2021 | IWLTKALKFLGKNLGK{nt:H}{ct:Amid} | LyeTx I mnΔK | Amidation | H | Linear | L | None | 16 | Antibacterial, Antifungal | 50 % Hemolysis at 55.31 ± 5 μM | Human | Lycosa Erythrognatha Spider Venom | NA | NA | ||
| 33878564 | 2021 | PFKLSLHL | jelleine-1 | Free | Free | Linear | L | None | 8 | Antimicrobial | 1 % Hemolysis at 256 μM | Human | Royal Jelly Of Honeybees | NA | Non-hemolytic | ||
| 33878564 | 2021 | PFRLRLRL | 7 | Free | Free | Linear | L | None | 8 | Antimicrobial | 1 % Hemolysis at 256 μM | Human | Jelleine-1Analog | NA | Non-hemolytic | ||
| 33878564 | 2021 | PWRLRLRL | 15 | Free | Free | Linear | L | None | 8 | Antimicrobial | 1 % Hemolysis at 256 μM | Human | Jelleine-1Analog | NA | Non-hemolytic | ||
| 34335511 | 2021 | FIGAIARLLSKIF | BmKn2 | Free | Free | Linear | L | None | 13 | Antibacterial | 91.8 % Hemolysis at 25 μg/mL | Human | Scorpion Mesobuthus Martensii Karsch | α-Helical | NA | ||
| 34335511 | 2021 | FIKAIARLLSKIF | Kn2(G3K) | Free | Free | Linear | L | None | 13 | Antibacterial | 69 % Hemolysis at 25 μg/mL | Human | Mutant Of Bmkn2-7 | NA | NA | ||
| 34335511 | 2021 | FIGRIARLLSKIF | Kn2(A4R) | Free | Free | Linear | L | None | 13 | Antibacterial | 100 % Hemolysis at 25 μg/mL | Human | Mutant Of Bmkn2-7 | NA | NA | ||
| 34335511 | 2021 | FIGAIARLLRKIF | Kn2(S10R) | Free | Free | Linear | L | None | 13 | Antibacterial | 50.9 % Hemolysis at 25 μg/mL | Human | Mutant Of Bmkn2-7 | NA | NA | ||
| 34335511 | 2021 | FIKRIARLLSKIF | Kn2(G3K_A4R) | Free | Free | Linear | L | None | 13 | Antibacterial | 8.3 % Hemolysis at 25 μg/mL | Human | Mutant Of Bmkn2-7 | NA | NA | ||
| 34335511 | 2021 | FIKAIARLLRKIF | Kn2(G3K_S10R) | Free | Free | Linear | L | None | 13 | Antibacterial | 77.5 % Hemolysis at 25 μg/mL | Human | Mutant Of Bmkn2-7 | NA | NA | ||
| 34335511 | 2021 | FIGRIARLLRKIF | Kn2(A4R_S10R) | Free | Free | Linear | L | None | 13 | Antibacterial | 18 % Hemolysis at 25 μg/mL | Human | Mutant Of Bmkn2-7 | NA | NA | ||
| 34335511 | 2021 | FIKRIARLLRKIF | BmKn2-7 | Free | Free | Linear | L | None | 13 | Antibacterial | 6.9 % Hemolysis at 25 μg/mL | Human | Mutant Of Bmkn2-7 | aqueous = Random coil, 30% or 70% TFE solutions = α-Helical | NA | ||
| 34301247 | 2021 | FKRIVQRIKRFLRFKRIVQRIKRFLR | (FR)2 | Free | Free | Linear | L | None | 26 | Antibacterial | 20 % Hemolysis at 16 μM | Human | Synthetic Peptide | NA | NA | ||
| 34301247 | 2021 | FKRIVQRIKRFLRGGGGSFKRIVQRIKRFLR | LG | Free | Free | Linear | L | None | 31 | Antibacterial | 20 % Hemolysis at 64 μM | Human | Synthetic Peptide | NA | NA | ||
| 34301247 | 2021 | FKRIVQRIKRFLRAEAAAKAFKRIVQRIKRFLR | LA | Free | Free | Linear | L | None | 33 | Antibacterial | 20 % Hemolysis at 32 μM | Human | Synthetic Peptide | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA | DS4 (1–28) dermaseptin S4 (DS4) | Free | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 54.2±5.43 % Hemolysis at 8 μg/mL | Human | Frog Skin Of Phyllomedusa Sauvagii | lipid bilayers = amphipathic α-Helical | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA | DS4 (1–28) dermaseptin S4 (DS4) | Free | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 60±3.94 % Hemolysis at 16 μg/mL | Human | Frog Skin Of Phyllomedusa Sauvagii | lipid bilayers = amphipathic α-Helical | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA | DS4 (1–28) dermaseptin S4 (DS4) | Free | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 65.7±4.57 % Hemolysis at 32 μg/mL | Human | Frog Skin Of Phyllomedusa Sauvagii | lipid bilayers = amphipathic α-Helical | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA | DS4 (1–28) dermaseptin S4 (DS4) | Free | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 85.7±7.6 % Hemolysis at 64 μg/mL | Human | Frog Skin Of Phyllomedusa Sauvagii | lipid bilayers = amphipathic α-Helical | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA | DS4 (1–28) dermaseptin S4 (DS4) | Free | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 85.7±9.28 % Hemolysis at 128 μg/mL | Human | Frog Skin Of Phyllomedusa Sauvagii | lipid bilayers = amphipathic α-Helical | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA | DS4 (1–28) dermaseptin S4 (DS4) | Free | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 80±3.32 % Hemolysis at 256 μg/mL | Human | Frog Skin Of Phyllomedusa Sauvagii | lipid bilayers = amphipathic α-Helical | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (1–28)a | Amidation | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 0 % Hemolysis at 8 μg/mL | Human | Analogs Of Ds4 | NA | Non-hemolytic | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (1–28)a | Amidation | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 2.8±0.86 % Hemolysis at 16 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (1–28)a | Amidation | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 22.8±4.88 % Hemolysis at 32 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (1–28)a | Amidation | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 31.4±4.28 % Hemolysis at 64 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (1–28)a | Amidation | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 51.4±6.05 % Hemolysis at 128 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (1–28)a | Amidation | Free | Linear | L | None | 28 | Antibacterial, Anti-proliferative on SW620 colon cancer | 68.5±10.83 % Hemolysis at 256 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGA{ct:Amid} | DS4 (1–26)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 28.5±5.01 % Hemolysis at 8 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGA{ct:Amid} | DS4 (1–26)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 31.4±5.98 % Hemolysis at 16 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGA{ct:Amid} | DS4 (1–26)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 54.2±6.91 % Hemolysis at 32 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGA{ct:Amid} | DS4 (1–26)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 65.7±7.01 % Hemolysis at 64 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGA{ct:Amid} | DS4 (1–26)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 68.5±5.1 % Hemolysis at 128 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLVGA{ct:Amid} | DS4 (1–26)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 74.2±5.82 % Hemolysis at 256 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLV{ct:Amid} | DS4 (1–24)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 2.8±1.03 % Hemolysis at 8 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLV{ct:Amid} | DS4 (1–24)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 11.4±2.8 % Hemolysis at 16 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLV{ct:Amid} | DS4 (1–24)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 31.4±3.83 % Hemolysis at 32 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLV{ct:Amid} | DS4 (1–24)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 40±3.5 % Hemolysis at 64 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLV{ct:Amid} | DS4 (1–24)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 51.4±8.1 % Hemolysis at 128 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAVLV{ct:Amid} | DS4 (1–24)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 57.1±6.34 % Hemolysis at 256 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAV{ct:Amid} | DS4 (1–22)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 5.7±1.21 % Hemolysis at 8 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAV{ct:Amid} | DS4 (1–22)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 31.4±3.8 % Hemolysis at 16 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAV{ct:Amid} | DS4 (1–22)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 40±5.06 % Hemolysis at 32 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAV{ct:Amid} | DS4 (1–22)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 54.2±4.41 % Hemolysis at 64 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAV{ct:Amid} | DS4 (1–22)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 68.5±7.85 % Hemolysis at 128 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | ALWMTLLKKVLKAAAKAALNAV{ct:Amid} | DS4 (1–22)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 80±1.12 % Hemolysis at 256 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | WMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (3–28)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 0 % Hemolysis at 8 μg/mL | Human | Analogs Of Ds4 | NA | Non-hemolytic | ||
| 33774792 | 2021 | WMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (3–28)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 25.7±5.81 % Hemolysis at 16 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | WMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (3–28)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 40±5.25 % Hemolysis at 32 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | WMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (3–28)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 48.5±9.3 % Hemolysis at 64 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | WMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (3–28)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 57.1±7.45 % Hemolysis at 128 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | WMTLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (3–28)a | Amidation | Free | Linear | L | None | 26 | Antibacterial, Anti-proliferative on SW620 colon cancer | 68.5±7.58 % Hemolysis at 256 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | TLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (5–28)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 0 % Hemolysis at 8 μg/mL | Human | Analogs Of Ds4 | NA | Non-hemolytic | ||
| 33774792 | 2021 | TLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (5–28)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 5.7±3.14 % Hemolysis at 16 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | TLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (5–28)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 8.5±2.79 % Hemolysis at 32 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | TLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (5–28)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 34.2±4.43 % Hemolysis at 64 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | TLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (5–28)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 54.2±6.9 % Hemolysis at 128 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | TLLKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (5–28)a | Amidation | Free | Linear | L | None | 24 | Antibacterial, Anti-proliferative on SW620 colon cancer | 57.1±7.64 % Hemolysis at 256 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | LKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (7–28)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 0 % Hemolysis at 8 μg/mL | Human | Analogs Of Ds4 | NA | Non-hemolytic | ||
| 33774792 | 2021 | LKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (7–28)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 0 % Hemolysis at 16 μg/mL | Human | Analogs Of Ds4 | NA | Non-hemolytic | ||
| 33774792 | 2021 | LKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (7–28)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 3.2±0.62 % Hemolysis at 32 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | LKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (7–28)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 6.4±1.74 % Hemolysis at 64 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | LKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (7–28)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 6.4±2.88 % Hemolysis at 128 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 33774792 | 2021 | LKKVLKAAAKAALNAVLVGANA{ct:Amid} | DS4 (7–28)a | Amidation | Free | Linear | L | None | 22 | Antibacterial, Anti-proliferative on SW620 colon cancer | 35.4±6.28 % Hemolysis at 256 μg/mL | Human | Analogs Of Ds4 | NA | NA | ||
| 34022355 | 2021 | GILGKLWEGVKSIF | Hp1404 | Free | Free | Linear | L | None | 14 | Anti-Acinetobacter baumannii, Anti-Carbapenem-resistant Acinetobacter baumannii (CRAB | 10 % Hemolysis at 32.3 μM | Human | Scorpion Heterometrus Petersii | α-Helical | NA | ||
| 34022355 | 2021 | FLWGLIPGAISAVTSLIKK | ctriporin | Free | Free | Linear | L | None | 19 | Anti-Acinetobacter baumannii | 10 % Hemolysis at 14.9 μM | Human | Scorpion Chaerilus Tricostatus | NA | NA | ||
| 34022355 | 2021 | FLGSLFSIGSKLLPGVIKLFQRKKQ | Im5 | Free | Free | Linear | L | None | 25 | Anti-Acinetobacter baumannii | 10 % Hemolysis at 2.7 μM | Human | Scorpion Isometrus Maculatus | NA | NA | ||
| 34058259 | 2021 | EEVQRDVSIMPYKIIGADNGDAWLDVKGQKMAPPQISAEVLKK | DP1 | Free | Free | Linear | L | None | 43 | Anti-Salmonella | 1 % Hemolysis at 100 µg/ml | Human | Synthetic Multi-Epitope Dnak Peptides | NA | Non-hemolytic | ||
| 34058259 | 2021 | LPYITADATGPKHMNIKVTRAKLESLVE | DP2 | Free | Free | Linear | L | None | 28 | Anti-Salmonella | 1 % Hemolysis at 100 µg/ml | Human | Synthetic Multi-Epitope Dnak Peptides | NA | Non-hemolytic | ||
| 34058259 | 2021 | AEDNQSAVTIHVLQGERKRASDNKSLG | DP3 | Free | Free | Linear | L | None | 27 | Anti-Salmonella | 1 % Hemolysis at 100 µg/ml | Human | Synthetic Multi-Epitope Dnak Peptides | NA | Non-hemolytic | ||
| 34058259 | 2021 | HVSAKDKNSGKEQKITIK | DP4 | Free | Free | Linear | L | None | 18 | Anti-Salmonella | 1 % Hemolysis at 100 µg/ml | Human | Synthetic Multi-Epitope Dnak Peptides | NA | Non-hemolytic | ||
| 34058259 | 2021 | TRNQGDHLLHSTRKQVEEAGDKLPADDKTAIESALSALETALKG | DP5 | Free | Free | Linear | L | None | 44 | Anti-Salmonella | 1 % Hemolysis at 100 µg/ml | Human | Synthetic Multi-Epitope Dnak Peptides | NA | Non-hemolytic | ||
| 34058259 | 2021 | ETALKGEDKAAIEAKMQELAQVSQKLMEIA | DP6 | Free | Free | Linear | L | None | 30 | Anti-Salmonella | 1 % Hemolysis at 100 µg/ml | Human | Synthetic Multi-Epitope Dnak Peptides | NA | Non-hemolytic | ||
| 34058259 | 2021 | HAQQQAGSADASANNAKDDDVVDAEFEEVKDKK | DP7 | Free | Free | Linear | L | None | 33 | Anti-Salmonella | 1 % Hemolysis at 100 µg/ml | Human | Synthetic Multi-Epitope Dnak Peptides | NA | Non-hemolytic | ||
| 34282000 | 2021 | RLELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS | K9CATH | Free | Free | Linear | L | None | 37 | Antibacterial, Anti-inflammatory | >40 % Hemolysis at 80 μM | Human | Cathelicidin In Canines (Dogs) | 0.1% SDS or 50 μM LPS = α-Helical | NA | ||
| 34282000 | 2021 | ({nnr:Cit})LKELITTGGQKIGEKI({nnr:Cit})({nnr:Cit})IGQ({nnr:Cit})IKDFFKNLQP({nnr:Cit})EEKS | K9CATHCit5 | Free | Free | Linear | L | Cit = citrulline | 38 | Antibacterial | 0 % Hemolysis at 80 μM | Human | Cathelicidins Modified K9Cath | 0.1% SDS or 50 μM LPS = α-Helical | Non-hemolytic | ||
| 34282000 | 2021 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antibacterial | >25 % Hemolysis at 80 μM | Human | Human Cathelicidin Hcap18 | α-Helical | NA | ||
| 34282000 | 2021 | LLGDFF({nnr:Cit})KSKEKIGKEFK({nnr:Cit})IVQ({nnr:Cit})IKDFL({nnr:Cit})NLVP({nnr:Cit})TES | LL-37 Cit5 | Free | Free | Linear | L | Cit = citrulline | 37 | NA | 0 % Hemolysis at 80 μM | Human | Cathelicidins Modified Ll-37 | Helical | Non-hemolytic | ||
| 34436290 | 2021 | CAGSLRLTC{ct:OH} | A0 | OH | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34436290 | 2021 | CAGWRRLRC{nt:Acet}{ct:Amid} | A1 | Amidation | Acetylation | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34436290 | 2021 | CRWRLRLRC{ct:OH} | A2 | OH | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34436290 | 2021 | CRRWRRRRC{ct:OH} | A3 | OH | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34436290 | 2021 | CRRWGWRRC{ct:Amid} | A4 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 1 % Hemolysis at 100 µg/ml | Human | American Oyster Defensin (Aod) Analog | Extended Strand Random coil | Non-hemolytic | ||
| 34180670 | 2021 | GLLKRIKTLL | anoplin | Free | Free | Linear | L | None | 10 | Antibacterial, Antibiofilm | 10 % Hemolysis at ≥512 μM | Human | Venom Of Wasps (Anoplius Samariensis) | α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GAAKRAKTAA | A-1 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GAAKRAKTAL | A-2 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GALKRAKTAL | A-3 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GLAKRAKTLL | A-4 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GLLKRLKTLA | A-5 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GLLKRFKTLL | A-6 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GWFKRIKTFW | A-7 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at 384 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Low hemolytic | ||
| 34180670 | 2021 | GWWKRWKTWW | A-8 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at 40.79 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | NA | ||
| 34180670 | 2021 | GFLKRFKTLF | A-9 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at 384 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Low hemolytic | ||
| 34180670 | 2021 | GLLKRWKTLL | A-10 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GFFKRWKTFF | A-11 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GWLKRWKTLW | A-12 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at 320 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Low hemolytic | ||
| 34180670 | 2021 | GWWKRIKTWW | A-13 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at 102.54 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | NA | ||
| 34180670 | 2021 | GIRWKFWKFT | A-14 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | KWFKRIKTFW | A-15 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GLWKRWKKFW | A-16 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at 83.63 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | NA | ||
| 34180670 | 2021 | KWWKRWKKWW | A-17 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at 77.65 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | NA | ||
| 34180670 | 2021 | GFFRRIKTFF | A-18 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GFFKRIRTFF | A-19 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | GFFRRIRTFF | A-20 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at ≥512 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | Non-hemolytic | ||
| 34180670 | 2021 | KWWKKWKKWW | A-21 | Free | Free | Linear | L | None | 10 | Antibacterial, Antibiofilm | 10 % Hemolysis at 134.38 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | NA | ||
| 34180670 | 2021 | RWWRRWRRWW | A-22 | Free | Free | Linear | L | None | 10 | Antibacterial | 10 % Hemolysis at 43.67 μM | Human | Anoplin Analogues | water = Random coil, 50% trifluoroethanol = α-Helical | NA | ||
| 34227804 | 2021 | {nnr:NLys}-F-{nnr:NLys}-F-{nnr:NLys}-F-{nnr:NLys}-F-{nnr:NLys}-F-{nnr:NLys}-F{nt:H}{ct:Amid} | CEP-124 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine | 12 | Antibacterial | 2.7 % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | Low hemolytic | ||
| 34227804 | 2021 | {nnr:NLys}-L-{nnr:NLys}-L-{nnr:NLys}-L-{nnr:NLys}-L-{nnr:NLys}-L-{nnr:NLys}-L{nt:H}{ct:Amid} | CEP-126 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine | 12 | Antibacterial | 1.5 % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | Low hemolytic | ||
| 34227804 | 2021 | {nnr:NLys}-Y-{nnr:NLys}-Y-{nnr:NLys}-Y-{nnr:NLys}-Y-{nnr:NLys}-Y-{nnr:NLys}-Y{nt:H}{ct:Amid} | CEP-129 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine | 12 | Antibacterial | 1.6 % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | Low hemolytic | ||
| 34227804 | 2021 | {nnr:NLys}-{nnr:Tyr(Me)}-{nnr:NLys}-{nnr:Tyr(Me)}-{nnr:NLys}-{nnr:Tyr(Me)}-{nnr:NLys}-{nnr:Tyr(Me)}-{nnr:NLys}-{nnr:Tyr(Me)}-{nnr:NLys}-{nnr:Tyr(Me)}{nt:H}{ct:Amid} | CEP-130 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine, Tyr(Me) = Tyr(Me) | 12 | Antibacterial | 3 % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | Low hemolytic | ||
| 34227804 | 2021 | {nnr:NLys}-{nnr:tBuAla}-{nnr:NLys}-{nnr:tBuAla}-{nnr:NLys}-{nnr:tBuAla}-{nnr:NLys}-{nnr:tBuAla}-{nnr:NLys}-{nnr:tBuAla}-{nnr:NLys}-{nnr:tBuAla}{nt:H}{ct:Amid} | CEP-136 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine, tBuAla = tBuAla | 12 | Antibacterial | 3.9 (±2.0) % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | Low hemolytic | ||
| 34227804 | 2021 | {nnr:NLys}-{nnr:Phe(4)}-{nnr:NLys}-{nnr:Phe(4)}-{nnr:NLys}-{nnr:Phe(4)}-{nnr:NLys}-{nnr:Phe(4)}-{nnr:NLys}-{nnr:Phe(4)}-{nnr:NLys}-{nnr:Phe(4)}{nt:H}{ct:Amid} | CEP-140 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine, Phe(4-NH2) = Phe(4-NH2) | 12 | Antibacterial | 0.1 % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | Non-hemolytic | ||
| 34227804 | 2021 | {nnr:NOrn}-F-{nnr:NOrn}-F-{nnr:NOrn}-F-{nnr:NOrn}-F-{nnr:NOrn}-F-{nnr:NOrn}-F{nt:H}{ct:Amid} | CEP-144 | Amidation | H | Linear | L | NOrn = NOrn | 12 | Antibacterial | 5.5 (±2.5) % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | Low hemolytic | ||
| 34227804 | 2021 | {nnr:NLys}-W-{nnr:NLys}-W-{nnr:NLys}-W-{nnr:NLys}-W{nt:H}{ct:Amid} | CEP-246 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine | 8 | Antibacterial | 4.6 (±3) % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | Low hemolytic | ||
| 34227804 | 2021 | {nnr:NLys}-{nnr:Cha}-{nnr:NLys}-{nnr:Cha}-{nnr:NLys}-{nnr:Cha}{nt:H}{ct:Amid} | CEP-391 | Amidation | H | Linear | L | NLys = N-(4-aminobutyl)glycine, Cha = Cha | 6 | Antibacterial | 22.6 (±2) % Hemolysis at 400 μg/mL | Human | Synthetic Peptidomimetics | NA | NA | ||
| 34282895 | 2021 | KYEITTIHNLFRKLTHRLFRRNFGYTLR | KYE28 | Free | Free | Linear | L | None | 28 | Anti-inflammatory, Antimicrobial | ~20 % Hemolysis at 25 μM | Human | Heparin Cofactor Ii (Hcii)-Derived Peptide | α-Helical | NA | ||
| 34564152 | 2021 | FFKRLKNAFKSARQAWRDYK | β-Pte20 | Free | Free | Linear | L | None | 20 | Antibacterial | <5 % Hemolysis at 50 µM | Human | Lionfish (Pterois Volitans) | 75% trifluoroethanol (TFE) = α-Helix | Low hemolytic | ||
| 34564152 | 2021 | FFKRLKNAFKSARQAWR | β-Pte17 | Free | Free | Linear | L | None | 17 | Antibacterial | <5 % Hemolysis at 50 µM | Human | Lionfish (Pterois Volitans) | 75% trifluoroethanol (TFE) = α-Helix | Low hemolytic | ||
| 34564152 | 2021 | FFKRLKNAFKSAR | β-Pte13 | Free | Free | Linear | L | None | 13 | Antibacterial | <5 % Hemolysis at 50 µM | Human | Lionfish (Pterois Volitans) | 75% trifluoroethanol (TFE) = α-Helix | Low hemolytic | ||
| 34564152 | 2021 | FFKRLKNAFK | β-Pte10 | Free | Free | Linear | L | None | 10 | Antibacterial | <5 % Hemolysis at 50 µM | Human | Lionfish (Pterois Volitans) | NA | Low hemolytic | ||
| 34564152 | 2021 | FFRHLKSLWKGAKAAFRGAR | γ-Pte20 | Free | Free | Linear | L | None | 20 | Antibacterial | <10 % Hemolysis at 50 µM | Human | Lionfish (Pterois Volitans) | 75% trifluoroethanol (TFE) = α-Helix | Low hemolytic | ||
| 34564152 | 2021 | FFRHLKSLWKGAKAAFR | γ-Pte17 | Free | Free | Linear | L | None | 17 | Antibacterial | <10 % Hemolysis at 50 µM | Human | Lionfish (Pterois Volitans) | 75% trifluoroethanol (TFE) = α-Helix | Low hemolytic | ||
| 34564152 | 2021 | FFRHLKSLWKGAK | γ-Pte13 | Free | Free | Linear | L | None | 13 | Antibacterial | <10 % Hemolysis at 50 µM | Human | Lionfish (Pterois Volitans) | 75% trifluoroethanol (TFE) = α-Helix | Low hemolytic | ||
| 34564152 | 2021 | FFRHLKSLWK | γ-Pte10 | Free | Free | Linear | L | None | 10 | Antibacterial | <10 % Hemolysis at 50 µM | Human | Lionfish (Pterois Volitans) | NA | Low hemolytic | ||
| 34564152 | 2021 | FFRHLKSLWKGAKAAFRGAR | γ-Pte20 | Free | Free | Linear | L | None | 20 | Antibacterial | 19 % Hemolysis at 200 µM | Human | Lionfish (Pterois Volitans) | 75% trifluoroethanol (TFE) = α-Helix | NA | ||
| 34564152 | 2021 | FFRHLKSLWKGAKAAFR | γ-Pte17 | Free | Free | Linear | L | None | 17 | Antibacterial | 43 % Hemolysis at 200 µM | Human | Lionfish (Pterois Volitans) | 75% trifluoroethanol (TFE) = α-Helix | NA | ||
| 34423969 | 2021 | WLGSALKIGAKLLPSVVGLFKKKKQ{nt:NH3}{ct:Amid} | Ponericin W1 | Amidation | NH3 | Linear | L | None | 25 | Antibacterial | 80 % Hemolysis at 50 µM | Human | Ants Pachycondyla Goeldii | negatively charged liposomes = α-Helix | NA | ||
| 34423969 | 2021 | WLKKALKIGAKLLPSVVKLFKGSGQ{nt:NH3}{ct:Amid} | PonAmp | Amidation | NH3 | Linear | L | None | 25 | Antibacterial | 70 % Hemolysis at 100 µM | Human | Ponericin W1 Analogues | NA | NA | ||
| 34423969 | 2021 | KKKKKKWLGSALIGALLPSVVGLFQ{nt:NH3}{ct:Amid} | PonN | Amidation | NH3 | Linear | L | None | 25 | Antibacterial | 20 % Hemolysis at 100 µM | Human | Ponericin W1 Analogues | NA | NA | ||
| 34423969 | 2021 | WLGSALIGALLPSVVGLFQKKKKKK{nt:NH3}{ct:Amid} | PonC | Amidation | NH3 | Linear | L | None | 25 | Antibacterial | 90 % Hemolysis at 100 µM | Human | Ponericin W1 Analogues | Helical and unstructured | NA | ||
| 34423969 | 2021 | WAKKAAKIGAKLLPSVVKLFKGSGQ{nt:NH3}{ct:Amid} | PonAmp 2A | Amidation | NH3 | Linear | L | None | 25 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Ponericin W1 Analogues | NA | Non-hemolytic | ||
| 34423969 | 2021 | KKKKKKWAGSAAIGALLPSVVGLFQ{nt:NH3}{ct:Amid} | PonN 2A | Amidation | NH3 | Linear | L | None | 25 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Ponericin W1 Analogues | NA | Non-hemolytic | ||
| 34423969 | 2021 | WAGSAAIGALLPSVVGLFQKKKKKK{nt:NH3}{ct:Amid} | PonC 2A | Amidation | NH3 | Linear | L | None | 25 | Antibacterial | 0 % Hemolysis at 100 µM | Human | Ponericin W1 Analogues | NA | Non-hemolytic | ||
| 34159664 | 2021 | RGGRLCYCRRRFCVCVGR{nt:H}{ct:Amid} | PG-1 | Amidation | H | Linear | L | None | 18 | Antibacterial | 50 % Hemolysis at 6.3±1.6 µM | Human | Wild Boar Porcine Leukocytes (Sus Scrofa) | antiparallel β-Sheet | NA | ||
| 34159664 | 2021 | GGVCPKILQRCRRDSDCPGACICRGNGYCGSGSGGRLCYCRRRFCVCVGRR{cyc:N-C} | MCo-PG2 | Free | Free | Cyclic | L | None | 51 | Antibacterial | 50 % Hemolysis at 88± 5 µM | Human | Cyclotide Mcoti-I Modified From Pg-1 | NA | NA | ||
| 34526600 | 2021 | KRIVQRIKDWLRKLCKKW | CaD23 | Free | Free | Linear | L | None | 18 | Antibacterial | 7.1 % Hemolysis at 200 μg/ml | Human | 2Nd Generation Hyhdps (Human-Derived Hybrid Host Defense Peptides) | NA | Low hemolytic | ||
| 34576320 | 2021 | SMWSGMWRRKLKKLRNALKKKLKGE | Ltc1 | Free | Free | Linear | L | None | 25 | Antibacterial | 100 % Hemolysis at 256 μg/ml | Human | Spider Lachesana Tarabaevi | vesicles composed of DMPC/DMPG (7/3) = α-Helix | NA | ||
| 34576320 | 2021 | GLFGKLIKKFGRKAISYAVKKARGKH | Ltc2a | Free | Free | Linear | L | None | 26 | Antibacterial | 36 % Hemolysis at 256 μg/ml | Human | Spider Lachesana Tarabaevi | vesicles composed of DMPC/DMPG (7/3) = α-Helix | NA | ||
| 34576320 | 2021 | SWKSMAKKLKEYMEKLKQRA{ct:Amid} | Ltc3a | Amidation | Free | Linear | L | None | 20 | Antibacterial | 16 % Hemolysis at 256 μg/ml | Human | Spider Lachesana Tarabaevi | vesicles composed of DMPC/DMPG (7/3) = α-Helix | Low hemolytic | ||
| 34576320 | 2021 | GLKDKFKSMGEKLKQYIQTWKAKF{ct:Amid} | Ltc4a | Amidation | Free | Linear | L | None | 24 | Antibacterial | 12 % Hemolysis at 256 μg/ml | Human | Spider Lachesana Tarabaevi | vesicles composed of DMPC/DMPG (7/3) = α-Helix | Low hemolytic | ||
| 34576320 | 2021 | GFFGKMKEYFKKFGASFKRRFANLKKRL{ct:Amid} | Ltc5 | Amidation | Free | Linear | L | None | 28 | Antibacterial | 27 % Hemolysis at 256 μg/ml | Human | Spider Lachesana Tarabaevi | vesicles composed of DMPC/DMPG (7/3) = α-Helix | Low hemolytic | ||
| 34576320 | 2021 | QAFQTFKPDWNKIRYDAMKMQTSLGQMKKRFNL | Ltc6a | Free | Free | Linear | L | None | 33 | Antibacterial | 3 % Hemolysis at 256 μg/ml | Human | Spider Lachesana Tarabaevi | vesicles composed of DMPC/DMPG (7/3) = α-Helix | Low hemolytic | ||
| 34576320 | 2021 | GETFDKLKEKLKTFYQKLVEKAEDLKGDLKAKLS | Ltc7 | Free | Free | Linear | L | None | 34 | Antibacterial | 2 % Hemolysis at 256 μg/ml | Human | Spider Lachesana Tarabaevi | vesicles composed of DMPC/DMPG (7/3) = α-Helix | Low hemolytic | ||
| 34708005 | 2021 | RVCFRPVAPYLGVGVSGAVRDQIGVKLGSVYKGPRG | Cc-AFP1 | Free | Free | Linear | L | None | 36 | Antifungal | 12.56 % Hemolysis at 128 μg/ml | Human | Carum Carvi (Caraway) | α-Helix and Random coil | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:H}{ct:Amid} | SAMP-A4 | Amidation | H | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 69.26 μg/ml | Human | Synthesized Antimicrobial Peptide A4 | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:Acet}{ct:Amid} | SAMP-A4-C2 | Amidation | Acetylation | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 34.56 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:Butyryl}{ct:Amid} | SAMP-A4-C4 | Amidation | Butyryl | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 73.84 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:Hexanoyl}{ct:Amid} | SAMP-A4-C6 | Amidation | Hexanoyl | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 84.98 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:PEG}{ct:Amid} | SAMP-A4-PEG3 | Amidation | PEG | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 19.95 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34028137 | 2021 | VRLLRRRI{nt:Gluconyl}{ct:Amid} | SAMP-A4-GlcA | Amidation | Gluconyl | Linear | L | None | 8 | Antibacterial, Antifungal, Antibiofilm | 5 % Hemolysis at 22.16 μg/ml | Human | Samp-A4 Analogue | NA | Low hemolytic | ||
| 34302796 | 2021 | FLGALLKIGAKLLPSVVGLFKKKQQ | M-PONTX–Na1b | Free | Free | Linear | L | None | 25 | Antimicrobial, anthelmintic, Insecticidal | 50 % Hemolysis at 39.9–61.5 μM | Human | Ant Neoponera Apicalis | aqueous = Disordered, 20% TFE or 20 mM SOS = α-Helical | NA | ||
| 34302796 | 2021 | FWGAAAKMLGKALPGLISMFQKN | M-PONTX–Nc1a | Free | Free | Linear | L | None | 23 | Antimicrobial, anthelmintic, Insecticidal | 50 % Hemolysis at 28.6–48.2 μM | Human | Ant Neoponera Commutata | aqueous = Disordered, 20% TFE or 20 mM SOS = α-Helical | NA | ||
| 34302796 | 2021 | FVKELWDKVKKMGSAAWSAAKGAFA | M-PONTX–Nc2a | Free | Free | Linear | L | None | 25 | Antimicrobial, anthelmintic, Insecticidal | 50 % Hemolysis at >250 μM | Human | Ant Neoponera Commutata | aqueous = Disordered, 20% TFE or 20 mM SOS = α-Helical | Low hemolytic | ||
| 34302796 | 2021 | GWKDWLNKAKDFIKEKGPEILRAAANAAIN | M-PONTX–Nc3a | Free | Free | Linear | L | None | 30 | Antimicrobial, anthelmintic, Insecticidal | 50 % Hemolysis at >100 μM | Human | Ant Neoponera Commutata | aqueous = Disordered, 20% TFE or 20 mM SOS = α-Helical | NA | ||
| 34302796 | 2021 | AGTKEWLNKAKDFIKEKGLGMLSAAANAALN | M-PONTX–Nc3b | Free | Free | Linear | L | None | 31 | Antimicrobial, anthelmintic, Insecticidal | 50 % Hemolysis at >300 μM | Human | Ant Neoponera Commutata | aqueous = Disordered, 20% TFE or 20 mM SOS = α-Helical | Low hemolytic | ||
| 34461456 | 2021 | G{d}I{d}G{d}A{d}V{d}L{d}K{d}V{d}L{d}T{d}T{d}G{d}L{d}P{d}A{d}L{d}I{d}S{d}W{d}I{d}K{d}R{d}K{d}R{d}Q{d}Q{d}C{d} | D-melittin | Free | Free | Linear | L | None | 27 | Antitumor | 50 % Hemolysis at 14.8 μM (pH 5.4) | Human | Honeybee Venom | NA | NA | ||
| 34461456 | 2021 | G{d}I{d}G{d}A{d}V{d}L{d}K{d}V{d}L{d}T{d}T{d}G{d}L{d}P{d}A{d}L{d}I{d}S{d}W{d}I{d}K{d}R{d}K{d}R{d}Q{d}Q{d}C{d} | D-melittin | Free | Free | Linear | L | None | 27 | Antitumor | 50 % Hemolysis at 8.5 μM (pH 6.4) | Human | Honeybee Venom | NA | NA | ||
| 34461456 | 2021 | G{d}I{d}G{d}A{d}V{d}L{d}K{d}V{d}L{d}T{d}T{d}G{d}L{d}P{d}A{d}L{d}I{d}S{d}W{d}I{d}K{d}R{d}K{d}R{d}Q{d}Q{d}C{d} | D-melittin | Free | Free | Linear | L | None | 27 | Antitumor | 50 % Hemolysis at 3.3 μM (pH 7.4) | Human | Honeybee Venom | NA | NA | ||
| 34482475 | 2021 | {nnr:Z}QPVSSPK | Pep-Bax8 | Free | Free | Linear | L | Z = pyroglutamic acid | 8 | Antibacterial | 1.6 % Hemolysis at 250 μg/mL | Human | Snake Venom Of Bothrops Atrox | NA | Non-hemolytic | ||
| 34482475 | 2021 | {nnr:Z}KW | SVMPi-Bax/Bj | Free | Free | Linear | L | Z = pyroglutamic acid | 3 | Antibacterial | 1.7 % Hemolysis at 250 μg/mL | Human | Snake Venoms Of Bothrops Atrox And Bothrops Jararacussu | NA | Non-hemolytic | ||
| 34482475 | 2021 | GRVPDNPKAPP | BPP-Bax11 | Free | Free | Linear | L | None | 11 | Antibacterial | 1.8 % Hemolysis at 250 μg/mL | Human | Snake Venom Of Bothrops Atrox | NA | Non-hemolytic | ||
| 34680789 | 2021 | INLLKIAKGIIKSL{ct:Amid} | EMP-AF-OR | Amidation | Free | Linear | L | None | 14 | Antibacterial, Antifungal | 100 % Hemolysis at 100 μg/mL | Human | Wasp Eumenine Anterhynchium Flavomarginatum Micado | water = 17.73% Helical, 50% TFE = Helical | NA | ||
| 34680789 | 2021 | INKLVIKVGKIVSL{ct:Amid} | EMP-AF-KV | Amidation | Free | Linear | L | None | 14 | Antifungal | >50 % Hemolysis at 100 μg/mL | Human | Emp-Af Analog | 50% TFE = Helical | NA | ||
| 34680789 | 2021 | FDI{nnr:M*}GLIKKVAGAL{ct:Amid} | EMP-ER-OR | Amidation | Free | Linear | L | M* = Methionine in sulfoxide form | 14 | Antifungal | 0 % Hemolysis at 100 μg/mL | Human | Wasp Eumenes Rubrofemoratus | 50% TFE = Helical | Non-hemolytic | ||
| 34680789 | 2021 | FDI{nnr:M*}GLIEEVAGAL{ct:Amid} | EMP-ER-KE | Amidation | Free | Linear | L | M* = Methionine in sulfoxide form | 14 | Antifungal | >30 % Hemolysis at 100 μg/mL | Human | Emp-Er Analog | water = Random, 50% TFE = Helical | NA | ||
| 34680789 | 2021 | FKI{nnr:M*}GLIKKVAGAL{ct:Amid} | EMP-ER-D2K2 | Amidation | Free | Linear | L | M* = Methionine in sulfoxide form | 14 | Antibacterial, Antifungal | ~50 % Hemolysis at 100 μg/mL | Human | Emp-Er Analog | 50% TFE = Helical | NA | ||
| 34680789 | 2021 | FDI{nnr:M*}GLIKKVA{ct:Amid} | EMP-ER-C3 | Amidation | Free | Linear | L | M* = Methionine in sulfoxide form | 11 | Antifungal | ~50 % Hemolysis at 100 μg/mL | Human | Emp-Er Analog | 50% TFE = Helical | NA | ||
| 34721331 | 2021 | VKKLVKKAVKKLVKKA{ct:Amid} | VL1 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | NA | Low hemolytic | ||
| 34721331 | 2021 | VKKLVKKLVKKAVKKA{ct:Amid} | VL2 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | NA | Low hemolytic | ||
| 34721331 | 2021 | VKKLVKKLVKKLVKKA{ct:Amid} | VL3 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | NA | Low hemolytic | ||
| 34721331 | 2021 | VKKLVKKLVKKAVKKL{ct:Amid} | VL4 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | NA | Low hemolytic | ||
| 34721331 | 2021 | VKKLVKKLVKKLVKKL{ct:Amid} | VL5 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | NA | Low hemolytic | ||
| 34721331 | 2021 | VKKWVKKAVKKWVKKA{ct:Amid} | VW1 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | NA | Low hemolytic | ||
| 34721331 | 2021 | VKKWVKKWVKKAVKKA{ct:Amid} | VW2 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | NA | Low hemolytic | ||
| 34721331 | 2021 | VKKWVKKWVKKAVKKW{ct:Amid} | VW3 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | NA | Low hemolytic | ||
| 34721331 | 2021 | VKKWVKKWVKKWVKKA{ct:Amid} | VW4 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | NA | Low hemolytic | ||
| 34721331 | 2021 | VKKWVKKWVKKWVKKW{ct:Amid} | VW5 | Amidation | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at >128 μM | Human | Synthetic Trp-Rich Peptides | sodium phosphate buffer = unordered, 50% TFE = α-Helical | Low hemolytic | ||
| 34721331 | 2021 | GIGAVLKVLTTGLPALISWIKRKRQQ{ct:Amid} | Melittin | Amidation | Free | Linear | L | None | 26 | Antibacterial | 5 % Hemolysis at 1 μM | Human | Honeybee Venom | α-Helical | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKKY | S61 | Free | Free | Linear | L | None | 17 | Antibacterial | 13.03±0.00 % Hemolysis at 400 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKKY | S61 | Free | Free | Linear | L | None | 17 | Antibacterial | 11.44±0.25 % Hemolysis at 200 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKKY | S61 | Free | Free | Linear | L | None | 17 | Antibacterial | 10.74±0.75 % Hemolysis at 100 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKKY | S61 | Free | Free | Linear | L | None | 17 | Antibacterial | 9.15±1.99 % Hemolysis at 50 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKKY | S61 | Free | Free | Linear | L | None | 17 | Antibacterial | 6.34±4.98 % Hemolysis at 25 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKKY | S61 | Free | Free | Linear | L | None | 17 | Antibacterial | 4.58±4.48 % Hemolysis at 12.5 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKKY | S61 | Free | Free | Linear | L | None | 17 | Antibacterial | -0.18±0.75 % Hemolysis at 6.25 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKK | S62 | Free | Free | Linear | L | None | 16 | Antibacterial | 11.44±1.24 % Hemolysis at 400 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKK | S62 | Free | Free | Linear | L | None | 16 | Antibacterial | 9.33±1.74 % Hemolysis at 200 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKK | S62 | Free | Free | Linear | L | None | 16 | Antibacterial | 8.63±3.24 % Hemolysis at 100 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKK | S62 | Free | Free | Linear | L | None | 16 | Antibacterial | 7.22±3.73 % Hemolysis at 50 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKK | S62 | Free | Free | Linear | L | None | 16 | Antibacterial | 5.99±3.98 % Hemolysis at 25 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKK | S62 | Free | Free | Linear | L | None | 16 | Antibacterial | 4.05±3.24 % Hemolysis at 12.5 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWKK | S62 | Free | Free | Linear | L | None | 16 | Antibacterial | 0.35±0.50 % Hemolysis at 6.25 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWK | S63 | Free | Free | Linear | L | None | 15 | Antibacterial | 10.56±1.99 % Hemolysis at 400 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWK | S63 | Free | Free | Linear | L | None | 15 | Antibacterial | 9.68±2.74 % Hemolysis at 200 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWK | S63 | Free | Free | Linear | L | None | 15 | Antibacterial | 8.27±3.73 % Hemolysis at 100 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWK | S63 | Free | Free | Linear | L | None | 15 | Antibacterial | 7.04±3.98 % Hemolysis at 50 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWK | S63 | Free | Free | Linear | L | None | 15 | Antibacterial | 5.81±3.73 % Hemolysis at 25 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWK | S63 | Free | Free | Linear | L | None | 15 | Antibacterial | 3.52±4.98 % Hemolysis at 12.5 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | GGLRSLGRKILRAWK | S63 | Free | Free | Linear | L | None | 15 | Antibacterial | -0.53±0.75 % Hemolysis at 6.25 µg/ml | Human | Bovine Myeloid Cells | NA | Low hemolytic | ||
| 34780520 | 2021 | KLKLLLLLKL | KLK1 | Free | Free | Linear | L | None | 10 | Antibacterial | 22.18±1.99 % Hemolysis at 400 µg/ml | Human | Sarcophaga Peregrina (Flesh Fly) | NA | NA | ||
| 34780520 | 2021 | KLKLLLLLKL | KLK1 | Free | Free | Linear | L | None | 10 | Antibacterial | 18.13±0.25 % Hemolysis at 200 µg/ml | Human | Sarcophaga Peregrina (Flesh Fly) | NA | NA | ||
| 34780520 | 2021 | KLKLLLLLKL | KLK1 | Free | Free | Linear | L | None | 10 | Antibacterial | 15.85±1.49 % Hemolysis at 100 µg/ml | Human | Sarcophaga Peregrina (Flesh Fly) | NA | NA | ||
| 34780520 | 2021 | KLKLLLLLKL | KLK1 | Free | Free | Linear | L | None | 10 | Antibacterial | 12.15±0.25 % Hemolysis at 50 µg/ml | Human | Sarcophaga Peregrina (Flesh Fly) | NA | NA | ||
| 34780520 | 2021 | KLKLLLLLKL | KLK1 | Free | Free | Linear | L | None | 10 | Antibacterial | 8.27±1.74 % Hemolysis at 25 µg/ml | Human | Sarcophaga Peregrina (Flesh Fly) | NA | NA | ||
| 34780520 | 2021 | KLKLLLLLKL | KLK1 | Free | Free | Linear | L | None | 10 | Antibacterial | 4.93±2.49 % Hemolysis at 12.5 µg/ml | Human | Sarcophaga Peregrina (Flesh Fly) | NA | NA | ||
| 34780520 | 2021 | KLKLLLLLKL | KLK1 | Free | Free | Linear | L | None | 10 | Antibacterial | 0.7±0.50 % Hemolysis at 6.25 µg/ml | Human | Sarcophaga Peregrina (Flesh Fly) | NA | NA | ||
| 34867843 | 2021 | FLLKIVALLKKKLL | PHNX-1 | Free | Free | Linear | L | None | 14 | Antibacterial | ~40 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | Helical | NA | ||
| 34867843 | 2021 | FLLKLGLGKKKLL | PHNX-4 | Free | Free | Linear | L | None | 13 | Antibacterial | ~10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | Random coil | NA | ||
| 34867843 | 2021 | FLIKILKGGKGGK | PHNX-5 | Free | Free | Linear | L | None | 13 | Antibacterial | ~10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | Random coil | NA | ||
| 34867843 | 2021 | FIGAIASYLKKFR | PHNX-6 | Free | Free | Linear | L | None | 13 | Antibacterial | <10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | Random coil Helical | Low hemolytic | ||
| 34867843 | 2021 | GVVDIIKGAGKKFAKGLAGKIANKK | PHNX-7 | Free | Free | Linear | L | None | 25 | Antibacterial | ~10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | Helical | NA | ||
| 34867843 | 2021 | GLMDTVKNAAKNLAGQLLDKIKCKITG | PHNX-8 | Free | Free | Linear | L | None | 27 | Antibacterial | ~10 % Hemolysis at 100 μg/ml | Human | Synthetic Peptide | Helical | NA | ||
| 34867962 | 2021 | FLPLLISALTSLFPKLGK | SSTP1 | Free | Free | Linear | L | None | 18 | Anticancer | 0.25 % Hemolysis at 5 μM | Human | Frog Indosylvirana Aurantiaca Host Defense Peptide | NA | Low hemolytic | ||
| 34959645 | 2021 | LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | LL-37 | Free | Free | Linear | L | None | 37 | Antibacterial | 70 % Hemolysis at 200 μM | Human | Host Defense Peptide | PBS, 60mMSDS = Helical | NA | ||
| 34959645 | 2021 | SKEKIGKEFKRIVQRIKDFLRNLV{ct:Amid} | SK-24 | Amidation | Free | Linear | L | None | 24 | Antibacterial, Antibiofilm | <25 % Hemolysis at 200 μM | Human | Ll-37 Derived Peptide | PBS, 60mMSDS = Helical | Low hemolytic | ||
| 34959645 | 2021 | GIKEFKRIVQRIKDFLRNLV{ct:Amid} | GI-20 | Amidation | Free | Linear | L | None | 20 | Antibacterial, Antibiofilm | 50 % Hemolysis at ~160 μM | Human | Ll-37 Derived Peptide | PBS, 60mMSDS = Helical | NA | ||
| 34959645 | 2021 | GFKRIVQRIKDFLRNLV{ct:Amid} | GF-17 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 50 % Hemolysis at 175 μM | Human | Ll-37 Derived Peptide | PBS, 60mMSDS = Helical | NA | ||
| 34959645 | 2021 | G{nnr:X}KRlVQRlKD{nnr:X}LRNLV{ct:Amid} | 17BIPHE2 | Amidation | Free | Linear | Mix | X = biphenylalanines | 17 | Antibacterial, Antibiofilm | 50 % Hemolysis at ~200 μM | Human | Ll-37 Derived Peptide | PBS = distorted, 60mMSDS = Helical | NA | ||
| 34959645 | 2021 | RIVQRIKDFL{ct:Amid} | RI-10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | <25 % Hemolysis at 200 μM | Human | Ll-37 Derived Peptide | PBS = distorted, 60mMSDS = Helical | Low hemolytic | ||
| 34164880 | 2021 | KLLKKAGKLLKKAGKLLKKAG{nt:H}{ct:Amid} | Stripe | Amidation | H | Linear | L | None | 21 | Antibacterial | 0 % Hemolysis at 100 μM | Human | Synthetic Amp | phosphate buffer solution (pH 7.4) contain 1%SDS = right-handed Helical | Non-hemolytic | ||
| 34164880 | 2021 | KLLKKA{nnr:X}KLLKKA{nnr:X}KLLKKA{nnr:X}{nt:H}{ct:Amid} | Stripe1 | Amidation | H | Linear | L | X = sarcosine | 21 | Antibacterial | 0 % Hemolysis at 100 μM | Human | Stripe Modification With Sarcosine | phosphate buffer solution (pH 7.4) contain 1%SDS = Random coil | Non-hemolytic | ||
| 34164880 | 2021 | KLLKK{nnr:X}GKLLKK{nnr:X}GKLLKK{nnr:X}G{nt:H}{ct:Amid} | Stripe2 | Amidation | H | Linear | L | X = sarcosine | 21 | Antibacterial | 0 % Hemolysis at 100 μM | Human | Stripe Modification With Sarcosine | phosphate buffer solution (pH 7.4) contain 1%SDS = Random coil | Non-hemolytic | ||
| 34164880 | 2021 | KLLKK{nnr:X}{nnr:X}KLLKK{nnr:X}{nnr:X}KLLKK{nnr:X}{nnr:X}{nt:H}{ct:Amid} | Stripe3 | Amidation | H | Linear | L | X = sarcosine | 21 | Antibacterial | 0 % Hemolysis at 100 μM | Human | Stripe Modification With Sarcosine | phosphate buffer solution (pH 7.4) contain 1%SDS = Random coil | Non-hemolytic | ||
| 34164880 | 2021 | KL{nnr:X}KK{nnr:X}{nnr:X}KL{nnr:X}KK{nnr:X}{nnr:X}KL{nnr:X}KK{nnr:X}{nnr:X}{nt:H}{ct:Amid} | Stripe4 | Amidation | H | Linear | L | X = sarcosine | 21 | NA | 0 % Hemolysis at 100 μM | Human | Stripe Modification With Sarcosine | phosphate buffer solution (pH 7.4) contain 1%SDS = Random coil | Non-hemolytic | ||
| 34164880 | 2021 | K{nnr:X}{nnr:X}KK{nnr:X}{nnr:X}K{nnr:X}{nnr:X}KK{nnr:X}{nnr:X}K{nnr:X}{nnr:X}KK{nnr:X}{nnr:X}{nt:H}{ct:Amid} | Stripe5 | Amidation | H | Linear | L | X = sarcosine | 21 | NA | 0 % Hemolysis at 100 μM | Human | Stripe Modification With Sarcosine | phosphate buffer solution (pH 7.4) contain 1%SDS = Random coil | Non-hemolytic | ||
| 34977576 | 2021 | {nnr:B}KKLLKCLKCL{cyc:7-10} | bp3 | Free | Free | Bicyclic | L | B = 3,5-bis(methylene)toluoyl | 11 | Antibacterial | MHC at 500 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | Low hemolytic | ||
| 34977576 | 2021 | {nnr:B}KKLLKCLKCLL{cyc:7-10} | bp65 | Free | Free | Bicyclic | L | B = 3,5-bis(methylene)toluoyl | 12 | Antibacterial | MHC at 16.6 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | NA | ||
| 34977576 | 2021 | {nnr:B}K{d}KL{d}LK{d}CL{d}KC{d}LL{d}{cyc:7-10} | bp67 | Free | Free | Bicyclic | Mix | B = 3,5-bis(methylene)toluoyl | 12 | Antibacterial | MHC at >2000 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | Low hemolytic | ||
| 34977576 | 2021 | {nnr:B}KKLLKC{d}LKC{d}LL{cyc:7-10} | bp68 | Free | Free | Bicyclic | Mix | B = 3,5-bis(methylene)toluoyl | 12 | Antibacterial | MHC at 16.6 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | NA | ||
| 34977576 | 2021 | {nnr:B}K{d}K{d}LLK{d}CLK{d}CLL{cyc:7-10} | bp69 | Free | Free | Bicyclic | Mix | B = 3,5-bis(methylene)toluoyl | 12 | Antibacterial | MHC at 16.6 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | NA | ||
| 34977576 | 2021 | KKLLKLLKLLL | ln65 | Free | Free | Linear | L | None | 12 | Antibacterial | MHC at 125 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | NA | ||
| 34977576 | 2021 | {nnr:Tol}-KKLLK-{nnr:Cm}-LK-{nnr:Cm}-LL | ln65b | Free | Free | Linear | L | Tol = toluoyl group, Cm = S-methyl cysteine | 12 | Antibacterial | MHC at 16.6 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | NA | ||
| 34977576 | 2021 | K{d}K{d}LLK{d}LLK{d}LLL | ln69 | Free | Free | Linear | Mix | None | 12 | Antibacterial | MHC at 1000 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | Low hemolytic | ||
| 34977576 | 2021 | {nnr:Tol}-K{d}K{d}LLK{d}-{nnr:Cm}-LK{d}-{nnr:Cm}-LL | ln69b | Free | Free | Linear | Mix | Tol = toluoyl group, Cm = S-methyl cysteine | 12 | Antibacterial | MHC at 1000 μg/ml | Human | Synthetic Peptide | 5 mM DPC = α-Helical | Low hemolytic | ||
| 34966279 | 2021 | KIILRIRWR{ct:Amid} | optP1 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at 205 μM | Human | Optimized 9Mer | NA | Low hemolytic | ||
| 34966279 | 2021 | KRRVRWIIW{ct:Amid} | optP7 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 50 % Hemolysis at >195 μM | Human | Optimized 9Mer | NA | Low hemolytic | ||
| 34966279 | 2021 | VRKPPYLPRPRPRPL{ct:Amid} | consP1 | Amidation | Free | Linear | L | None | 15 | Antibacterial | 50 % Hemolysis at >139 μM | Human | Consensus Sequence Derived From Multiple Alignment | NA | Low hemolytic | ||
| 34966279 | 2021 | KIILRIRWRGGGVRKPPYLPRPRPRPL{ct:Amid} | hyP1CoG1 | Amidation | Free | Linear | L | None | 27 | Antibacterial | 50 % Hemolysis at >157 μM | Human | Hybrid Peptide With Gly Linker, Optp1 C-Terminal | NA | Low hemolytic | ||
| 34966279 | 2021 | VRKPPYLPRPRPRPLGGGKIILRIRWR{ct:Amid} | hyP1CoG2 | Amidation | Free | Linear | L | None | 27 | Antibacterial | 50 % Hemolysis at >157 μM | Human | Hybrid Peptide With Gly Linker, Optp1 C-Terminal | NA | Low hemolytic | ||
| 34966279 | 2021 | VRKPPYLPRPRPRPLGGGKRRVRWIIW{ct:Amid} | hyP7CoG1 | Amidation | Free | Linear | L | None | 27 | Antibacterial | 50 % Hemolysis at >154 μM | Human | Hybrid Peptide With Gly Linker, Optp7 C-Terminal | NA | Low hemolytic | ||
| 34966279 | 2021 | KRRVRWIIWGGGVRKPPYLPRPRPRPL{ct:Amid} | hyP7CoG2 | Amidation | Free | Linear | L | None | 27 | Antibacterial | 50 % Hemolysis at >154 μM | Human | Hybrid Peptide With Gly Linker, Optp7 N-Terminal | NA | Low hemolytic | ||
| 34966279 | 2021 | RWRRPIRRRPIRPPFWR{ct:Amid} | Bac5-v291 | Amidation | Free | Linear | L | None | 17 | Antibacterial | 50 % Hemolysis at >278 μM | Human | Optimized Bac5(1–17) Variant 291 | NA | Low hemolytic | ||
| 34966279 | 2021 | RWRRPIRRRPIRPPFWRGGGKRRVRWIIW{ct:Amid} | hyP7B5G | Amidation | Free | Linear | L | None | 29 | Antibacterial | 50 % Hemolysis at 102 μM | Human | Hybrid Peptide With Gly Linker, Optp7 C-Terminal | NA | NA | ||
| 34966279 | 2021 | RWRRPIRRRPIRPPFWRKKKKRRVRWIIW{ct:Amid} | hyP7B5K | Amidation | Free | Linear | L | None | 29 | Antibacterial | 50 % Hemolysis at 82 μM | Human | Hybrid Peptide With Lys Linker, Optp7 C-Terminal | NA | NA | ||
| 34966279 | 2021 | RWRRPIRRRPIRPPFWRKGKGKGKRRVRWIIW{ct:Amid} | hyP7B5GK | Amidation | Free | Linear | L | None | 32 | Antibacterial | 50 % Hemolysis at >120 μM | Human | Hybrid Peptide With Gly-Lys Linker, Optp7 C-Terminal | NA | Low hemolytic | ||
| 34966279 | 2021 | RWRRPIRRRPIRPPFWRKGKC-S-S-CKGKRRVRWIIW{ct:Amid} | hyP7B5Cys | Amidation | Free | Linear | L | None | 35 | Antibacterial | 50 % Hemolysis at 102 μM | Human | Hybrid Peptide With Disulfide Bridge, Designed To Be Cleaved In The Cytosol, Optp7 C-Terminal | NA | NA | ||
| 34941705 | 2021 | ASIGALIQKAIALIKAKAA{nt:Amid}{ct:Amid} | LVTX-9 | Amidation | Amidation | Linear | L | None | 19 | Anticancer | 0 % Hemolysis at 200 μM | Human | Venom Gland Of The Spider Lycosa Vittata | ultrapure water = Random coil, SDS = α-Helical | Non-hemolytic | ||
| 34941705 | 2021 | ASIGALIQKAIALIKAKAA{nt:CH3-(CH2)16CONH}{ct:Amid} | LVTX-9-C18 | Amidation | CH3-(CH2)16CONH | Linear | L | CH3-(CH2)16 = N-Terminal Fatty acid | 23 | Anticancer | 10 % Hemolysis at 25 μM | Human | Lvtx-9, Fatty Acid Modification | ultrapure water = α-Helical, SDS = α-Helical | NA | ||
| 35013238 | 2022 | KK WRK WLK WLA KK | W3_p1 | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 5 % Hemolysis at 120 μg/ml | Human | Synthetic Peptide | Helical | NA | ||
| 35013238 | 2022 | KK WLK WLK WLK KK | W3_p2 | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 5 % Hemolysis at 90 μg/ml | Human | Synthetic Peptide | Helical | NA | ||
| 35013238 | 2022 | KK WKC WAR WRL KK | W3_db5 | Free | Free | Linear | L | None | 13 | Antibacterial, Antifungal | 5 % Hemolysis at >>240 μg/ml | Human | Synthetic Peptide | Helical | Non-hemolytic | ||
| 35056876 | 2022 | INLKAIAAFAKKLI | MpVT | Free | Free | Linear | L | None | 14 | Antibacterial | <10 % Hemolysis at 50 μg/ml | Human | Vespa Tropica, The Greater Banded Horne | Water = unordered, 40% TFE, = α-Helix | Low hemolytic | ||
| 35056876 | 2022 | INLKAIAAFAKKFI | MpVT1 | Free | Free | Linear | L | None | 14 | Antibacterial | <10 % Hemolysis at 50 μg/ml | Human | Mpvt Analog | Water = unordered, 40% TFE, = α-Helix | Low hemolytic | ||
| 35056876 | 2022 | INLKAIAAFAKALI | MpVT3 | Free | Free | Linear | L | None | 14 | Antibacterial | 50 % Hemolysis at 100 μg/ml | Human | Mpvt Analog | Water = unordered, 40% TFE, = α-Helix | NA | ||
| 35056876 | 2022 | KAIAAFAKKFI | MpVT4 | Free | Free | Linear | L | None | 11 | Antibacterial | <10 % Hemolysis at 50 μg/ml | Human | Mpvt Analog | Water = unordered, 40% TFE, = Random coil | Low hemolytic | ||
| 35056876 | 2022 | KAIAAFAKKFFI | MpVT5 | Free | Free | Linear | L | None | 12 | Antibacterial | <10 % Hemolysis at 50 μg/ml | Human | Mpvt Analog | Water = unordered, 40% TFE, = Random coil | Low hemolytic | ||
| 35056876 | 2022 | KAIAAFAKALFI | MpVT6 | Free | Free | Linear | L | None | 12 | Antibacterial | <10 % Hemolysis at 50 μg/ml | Human | Mpvt Analog | Water = unordered, 40% TFE, = Random coil | Low hemolytic | ||
| 35056876 | 2022 | KAIAAFAAKLFI | MpVT7 | Free | Free | Linear | L | None | 12 | Antibacterial | <10 % Hemolysis at 50 μg/ml | Human | Mpvt Analog | Water = unordered, 40% TFE, = Random coil | Low hemolytic | ||
| 35111812 | 2022 | YPASFDDDFDALDDLDDLDLDDLLDLEPADLVLLDMWANMMDSQDFEDFE | TanP | Free | Free | Linear | L | None | 50 | Chelating, Antioxidant, Anti-inflammatory | 3 % Hemolysis at 50 μM | Human | Tityus Stigmurus Scorpion Venom | NA | Low hemolytic | ||
| 33749557 | 2022 | {conj:RhoB}-KRFKKFFKK{ct:Amid} | RhoB-Ctn[1-9] | Amidation | RhoB | Linear | L | RhoB = rhodamine B (N termianl conjugate) Crotalicidin fragment, residues 1 to 9, with a N-terminal conjugated rhodamine B | 9 | Antibacterial, Antifungal | 0.6 % Hemolysis at 12.5 μM | Human | Crotalicidin (Rattlesnake (Crotalus Durissus Terrificus))-Derived Peptides | Helical | Low hemolytic | ||
| 33749557 | 2022 | {conj:RhoB}-KRFKKFFKK{ct:Amid} | RhoB-Ctn[1-9] | Amidation | RhoB | Linear | L | RhoB = rhodamine B (N termianl conjugate) Crotalicidin fragment, residues 1 to 9, with a N-terminal conjugated rhodamine B | 9 | Antibacterial, Antifungal | 1.6 % Hemolysis at 25 μM | Human | Crotalicidin (Rattlesnake (Crotalus Durissus Terrificus))-Derived Peptides | Helical | Low hemolytic | ||
| 35792128 | 2022 | GLKSLGRKILRAWRKAVRIVQRI | MAA-41 | Free | Free | Linear | L | None | 23 | Antibacterial, Antibiofilm | 0.6 % Hemolysis at 5 μM | Human | Hybrid Of (Bamp-28/Ll37) | α-Helical | NA | ||
| 35792128 | 2022 | GLKSLGRKILRAWRKAVRIVQRI | MAA-41 | Free | Free | Linear | L | None | 23 | Antibacterial, Antibiofilm | 0.8 % Hemolysis at 10 μM | Human | Hybrid Of (Bamp-28/Ll37) | α-Helical | NA | ||
| 35792128 | 2022 | GLKSLGRKILRAWRKAVRIVQRI | MAA-41 | Free | Free | Linear | L | None | 23 | Antibacterial, Antibiofilm | 2.5 % Hemolysis at 20 μM | Human | Hybrid Of (Bamp-28/Ll37) | α-Helical | NA | ||
| 35792128 | 2022 | GLKSLGRKILRAWRKAVRIVQRI | MAA-41 | Free | Free | Linear | L | None | 23 | Antibacterial, Antibiofilm | 8.7 % Hemolysis at 40 μM | Human | Hybrid Of (Bamp-28/Ll37) | α-Helical | NA | ||
| 35792128 | 2022 | GLKSLGRKILRAWRKAVRIVQRI | MAA-41 | Free | Free | Linear | L | None | 23 | Antibacterial, Antibiofilm | 10.1 % Hemolysis at 60 μM | Human | Hybrid Of (Bamp-28/Ll37) | α-Helical | NA | ||
| 35792128 | 2022 | GLKSLGRKILRAWRKAVRIVQRI | MAA-41 | Free | Free | Linear | L | None | 23 | Antibacterial, Antibiofilm | 14.8 % Hemolysis at 80 μM | Human | Hybrid Of (Bamp-28/Ll37) | α-Helical | NA | ||
| 35792128 | 2022 | GLKSLGRKILRAWRKAVRIVQRI | MAA-41 | Free | Free | Linear | L | None | 23 | Antibacterial, Antibiofilm | 37.2 % Hemolysis at 100 μM | Human | Hybrid Of (Bamp-28/Ll37) | α-Helical | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{nt:Amid}{ct:OH} | 1L | OH | Amidation | Linear | L | Bip = 4,4′-biphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 2L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 120 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 3L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 105 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{nt:Amid}{ct:OH} | 4L | OH | Amidation | Linear | L | Bip = 4,4′-biphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 5L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 75 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 6L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 70 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{nt:Amid}{ct:OH} | 7L | OH | Amidation | Linear | L | Bip = 4,4′-biphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 8L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 145 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 9L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 130 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 10L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 185 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 11L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 180 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 12L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 165 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{nt:Amid}{ct:OH} | 13L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 190 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 14L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 255 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{nt:Amid}{ct:OH} | 15L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 280 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Dip}-R-R-{nnr:Dip}-{nnr:Dip}-R{nt:Amid}{ct:OH} | 16L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 220 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Dip}-{nnr:Dip}-R-R-{nnr:Dip}{nt:Amid}{ct:OH} | 17L | OH | Amidation | Linear | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 240 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Nal}-R-R-{nnr:Nal}-{nnr:Nal}-R{nt:Amid}{ct:OH} | 18L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 205 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Nal}-{nnr:Nal}-R-R-{nnr:Nal}{nt:Amid}{ct:OH} | 19L | OH | Amidation | Linear | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 195 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{cyc:N-C} | 1C | Free | Free | Cyclic | L | Bip = 4,4′-biphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 2C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 45 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 3C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 50 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{cyc:N-C} | 4C | Free | Free | Cyclic | L | Bip = 4,4′-biphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 5C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 40 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 6C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 30 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Bip}-{nnr:Bip}-{nnr:Bip}{cyc:N-C} | 7C | Free | Free | Cyclic | L | Bip = 4,4′-biphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 8C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 70 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 9C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 80 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 10C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 110 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 11C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 6 | Antibacterial | 50 % Hemolysis at 125 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 12C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 100 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-R-R-R-{nnr:Nal}-{nnr:Nal}-{nnr:Nal}{cyc:N-C} | 13C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 90 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 14C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 165 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | K-K-K-K-K-{nnr:Dip}-{nnr:Dip}-{nnr:Dip}{cyc:N-C} | 15C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 8 | Antibacterial | 50 % Hemolysis at 180 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Dip}-R-R-{nnr:Dip}-{nnr:Dip}-R{cyc:N-C} | 16C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 130 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Dip}-{nnr:Dip}-R-R-{nnr:Dip}{cyc:N-C} | 17C | Free | Free | Cyclic | L | Dip = 3,3-diphenyl-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 145 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-{nnr:Nal}-R-R-{nnr:Nal}-{nnr:Nal}-R{cyc:N-C} | 18C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 105 μM | Human | Synthetic Peptide | NA | NA | ||
| 34978443 | 2022 | R-R-{nnr:Nal}-{nnr:Nal}-R-R-{nnr:Nal}{cyc:N-C} | 19C | Free | Free | Cyclic | L | Nal = 3-(2-naphthyl)-L-alanine | 7 | Antibacterial | 50 % Hemolysis at 110 μM | Human | Synthetic Peptide | NA | NA | ||
| 36465844 | 2022 | GVKFAKRFWRFAKKAFKRFEK{nt:Amid} | HAZ | Free | Amidation | Linear | L | None | 21 | Antibacterial, Antibiofilm, Anticancer | 20 % Hemolysis at 120 μM | Human | Synthetic Hybride (Palustrin-1D And Hp(2–20)) Peptide | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDFLR{ct:Amid} | LL37-1 | Amidation | Free | Linear | L | None | 23 | Antibiofilm | ≤5 % Hemolysis at 1.5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | RKSKEKIGKEFKRIVQRIKDFLR{nt:Acet}{ct:Amid} | ACLL37-1 | Amidation | Acetylation | Linear | L | None | 23 | Antibacterial | ≤5 % Hemolysis at 1.5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDFLR{nt:Acet}{ct:Amid} | ACLL37-2 | Amidation | Acetylation | Linear | L | None | 23 | Antibacterial | ≤5 % Hemolysis at 1.5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDF{d}LR{nt:Acet}{ct:Amid} | DLL37-1 | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acid | 23 | Antibacterial, Antibiofilm | ≤5 % Hemolysis at 1.5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDFLR{ct:Amid} | LL37-1 | Amidation | Free | Linear | L | None | 23 | Antibiofilm | ≤5 % Hemolysis at 2.5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | RKSKEKIGKEFKRIVQRIKDFLR{nt:Acet}{ct:Amid} | ACLL37-1 | Amidation | Acetylation | Linear | L | None | 23 | Antibacterial | ≤5 % Hemolysis at 2.5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDFLR{nt:Acet}{ct:Amid} | ACLL37-2 | Amidation | Acetylation | Linear | L | None | 23 | Antibacterial | ≤5 % Hemolysis at 2.5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDF{d}LR{nt:Acet}{ct:Amid} | DLL37-1 | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acid | 23 | Antibacterial, Antibiofilm | ≤5 % Hemolysis at 2.5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDFLR{ct:Amid} | LL37-1 | Amidation | Free | Linear | L | None | 23 | Antibiofilm | ≤5 % Hemolysis at 5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | RKSKEKIGKEFKRIVQRIKDFLR{nt:Acet}{ct:Amid} | ACLL37-1 | Amidation | Acetylation | Linear | L | None | 23 | Antibacterial | ≤5 % Hemolysis at 5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDFLR{nt:Acet}{ct:Amid} | ACLL37-2 | Amidation | Acetylation | Linear | L | None | 23 | Antibacterial | ≤5 % Hemolysis at 5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDF{d}LR{nt:Acet}{ct:Amid} | DLL37-1 | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acid | 23 | Antibacterial, Antibiofilm | ≤5 % Hemolysis at 5 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDFLR{ct:Amid} | LL37-1 | Amidation | Free | Linear | L | None | 23 | Antibiofilm | ≤20 % Hemolysis at 10 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | RKSKEKIGKEFKRIVQRIKDFLR{nt:Acet}{ct:Amid} | ACLL37-1 | Amidation | Acetylation | Linear | L | None | 23 | Antibacterial | ≤20 % Hemolysis at 10 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDFLR{nt:Acet}{ct:Amid} | ACLL37-2 | Amidation | Acetylation | Linear | L | None | 23 | Antibacterial | ≤20 % Hemolysis at 10 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36350889 | 2022 | GRKSAKIGKRAKRIVQRIKDF{d}LR{nt:Acet}{ct:Amid} | DLL37-1 | Amidation | Acetylation | Linear | Mix | lowercase letters correspond to D-amino acid | 23 | Antibacterial, Antibiofilm | ≤20 % Hemolysis at 10 μM | Human | Ll37 Analogous | α-Helical | NA | ||
| 36358242 | 2022 | WLKKWLKKLL{ct:Amid} | WALK244.01 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 16 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | KWLLKWLKKL{ct:Amid} | WALK244.02 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | LKWLLKWLKK{ct:Amid} | WALK244.03 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36358242 | 2022 | LLKWLKKWLK{ct:Amid} | WALK244.04 | Amidation | Free | Linear | L | None | 10 | Antibacterial, Anti-inflammatory | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36358242 | 2022 | KLLKWLKKWL{ct:Amid} | WALK244.05 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | KKLLKWLLKW{ct:Amid} | WALK244.06 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | LKKWLKWLLK{ct:Amid} | WALK244.07 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | WLKKLLKWLK{ct:Amid} | WALK244.08 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 8 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | KWLKKLLKWL{ct:Amid} | WALK244.09 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 8 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | LKWLKKLLKW{ct:Amid} | WALK244.10 | Amidation | Free | Linear | L | None | 10 | Antibacterial | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | WLLKWLKKL{ct:Amid} | WALK243.01 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | KWLLKWLLK{ct:Amid} | WALK243.02 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36358242 | 2022 | LKWLLKWLK{ct:Amid} | WALK243.03 | Amidation | Free | Linear | L | None | 9 | Antibacterial, Anti-inflammatory | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | LLKWLKKWL{ct:Amid} | WALK243.04 | Amidation | Free | Linear | L | None | 9 | Antibacterial, Anti-inflammatory | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36358242 | 2022 | KLLKWLLKW{ct:Amid} | WALK243.05 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36358242 | 2022 | LKWLKWLLK{ct:Amid} | WALK243.06 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 32 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | LKKWLKWLL{ct:Amid} | WALK243.07 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 16 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | WLKKLLKWL{ct:Amid} | WALK243.08 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 8 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | NA | ||
| 36358242 | 2022 | KWLLKLLKW{ct:Amid} | WALK243.09 | Amidation | Free | Linear | L | None | 9 | Antibacterial | 5 % Hemolysis at 64 μg/mL | Human | Synthetic Walk Peptides | 10 mM sodium phosphate buffer = Disordered, 50% TFE or 10 mM SDS micelles = α-Helix | Low hemolytic | ||
| 36430320 | 2022 | (CGKKWWGWKC)KL{cyc:N-C}{ct:Amid} | cTurg-2 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >1045 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKWGWWKC)KL{cyc:N-C}{ct:Amid} | cTurg-3 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 849 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKPWWWKC)KL{cyc:N-C}{ct:Amid} | cTurg-4 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >1065 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGRRWWGWRC)RL{cyc:N-C}{ct:Amid} | cTurg-5 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >1101 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGRRWGWWRC)RL{cyc:N-C}{ct:Amid} | cTurg-6 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 1101 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGRRPWWWRC)RL{cyc:N-C}{ct:Amid} | cTurg-7 | Amidation | Free | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 197 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | CGKKPGGWKCKL{nt:C8}{ct:Amid} | C8-Turg-1 | Amidation | C8 | Linear | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >943 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | CGKKPGGWKCKL{nt:C10}{ct:Amid} | C10-Turg-1 | Amidation | C10 | Linear | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >957 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | CGKKPGGWKCKL{nt:C12}{ct:Amid} | C12-Turg-1 | Amidation | C12 | Linear | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >971 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | CGKKWWGWKCKL{nt:C8}{ct:Amid} | C8-Turg-2 | Amidation | C8 | Linear | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 198 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | CGKKWWGWKCKL{nt:C10}{ct:Amid} | C10-Turg-2 | Amidation | C10 | Linear | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 64 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | CGKKWWGWKCKL{nt:C12}{ct:Amid} | C12-Turg-2 | Amidation | C12 | Linear | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 55 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | CGRRWGWWRCRL{nt:C8}{ct:Amid} | C8-Turg-6 | Amidation | C8 | Linear | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 54 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | CGRRWGWWRCRL{nt:C10}{ct:Amid} | C10-Turg-6 | Amidation | C10 | Linear | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 21 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | CGRRWGWWRCRL{nt:C12}{ct:Amid} | C12-Turg-6 | Amidation | C12 | Linear | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 39 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGKKPGGWKC)KL{cyc:N-C}{nt:C8}{ct:Amid} | C8-cTurg-1 | Amidation | C8 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >942 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKPGGWKC)KL{cyc:N-C}{nt:C10}{ct:Amid} | C10-cTurg-1 | Amidation | C10 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at >956 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKPGGWKC)KL{cyc:N-C}{nt:C12}{ct:Amid} | C12-cTurg-1 | Amidation | C12 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 219 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGKKWWGWKC)KL{cyc:N-C}{nt:C8}{ct:Amid} | C8-cTurg-2 | Amidation | C8 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 439 μg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36430320 | 2022 | (CGKKWWGWKC)KL{cyc:N-C}{nt:C10}{ct:Amid} | C10-cTurg-2 | Amidation | C10 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 106 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGKKWWGWKC)KL{cyc:N-C}{nt:C12}{ct:Amid} | C12-cTurg-2 | Amidation | C12 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 32 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGRRWGWWRC)RL{cyc:N-C}{nt:C8}{ct:Amid} | C8-cTurg-6 | Amidation | C8 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 30 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGRRWGWWRC)RL{cyc:N-C}{nt:C10}{ct:Amid} | C10-cTurg-6 | Amidation | C10 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 16 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36430320 | 2022 | (CGRRWGWWRC)RL{cyc:N-C}{nt:C12}{ct:Amid} | C12-cTurg-6 | Amidation | C12 | Cyclic | L | None | 12 | Antibacterial, Antifungal | 50 % Hemolysis at 9 μg/mL | Human | Synthetic Peptide | NA | NA | ||
| 36559073 | 2022 | GWFSLVRKVVGGVGSL{ct:Amid} | Ramosin | Amidation | Free | Linear | L | None | 16 | Antibacterial | 0 % Hemolysis at 128 μM | Human | Colombian Salamander Bolitoglossa Ramosi | TFE 30% = α-Helical, water = Random coil | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 5 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 10 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 20 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 40 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 60 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 0 % Hemolysis at 80 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36704429 | 2022 | {conj:2-(6-Methoxy-2-naphthyl)propionic acid}RBRBR{ct:Amid} | naprolyginine | Amidation | 2-(6-Methoxy-2-naphthyl)propionic acid | Linear | L | 2-(6-Methoxy-2-naphthyl)propionic acid | 5 | Antibacterial | 1 % Hemolysis at 100 μM | Human | Synthetic Conjugated Ultrashort Antimicrobial Peptide | NA | Non-hemolytic | ||
| 36500545 | 2022 | VVVNVLVKVLPPPVV{nt:Amid} | P1 | Free | Amidation | Linear | L | None | 15 | Anti-MRSA, Antibacterial | 3.40 ± 0.29 % Hemolysis at 2 μg/mL | Human | Soil Bacterium Brevibacillus Sp. Spr-20 | H2O = β-Strand and Random coil, 50 mM SDS = β-Strand, Random coil and α-Helical | NA | ||
| 36500545 | 2022 | VVVNVLVKVLPPPVV{nt:Amid} | P1 | Free | Amidation | Linear | L | None | 15 | Anti-MRSA, Antibacterial | 62.23 ± 0.69 % Hemolysis at 64 μg/mL | Human | Soil Bacterium Brevibacillus Sp. Spr-20 | H2O = β-Strand and Random coil, 50 mM SDS = β-Strand, Random coil and α-Helical | NA | ||
| 36500545 | 2022 | VVVNVLVKVLPPPVV{nt:Amid} | P1 | Free | Amidation | Linear | L | None | 15 | Anti-MRSA, Antibacterial | 1.64 ± 0.17 % Hemolysis at 0.25 μg/mL | Human | Soil Bacterium Brevibacillus Sp. Spr-20 | H2O = β-Strand and Random coil, 50 mM SDS = β-Strand, Random coil and α-Helical | NA | ||
| 36500545 | 2022 | VVVNVLVKVLPPPVV{nt:Amid} | P1 | Free | Amidation | Linear | L | None | 15 | Anti-MRSA, Antibacterial | 5.52 ± 0.92 % Hemolysis at 32 μg/mL | Human | Soil Bacterium Brevibacillus Sp. Spr-20 | H2O = β-Strand and Random coil, 50 mM SDS = β-Strand, Random coil and α-Helical | NA | ||
| 36442155 | 2022 | RRRRWWWW{cyc:N-C} | 1 | Free | Free | Cyclic | L | None | 8 | Antibacterial | 50 % Hemolysis at 175 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRWWW{cyc:N-C} | 2a | Free | Free | Cyclic | L | None | 5 | Antibacterial | 50 % Hemolysis at 120 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRWWWW{cyc:N-C} | 2b | Free | Free | Cyclic | L | None | 6 | Antibacterial | 50 % Hemolysis at 85 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWW{cyc:N-C} | 3a | Free | Free | Cyclic | L | None | 6 | Antibacterial | 50 % Hemolysis at 155 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWW{cyc:N-C} | 3b | Free | Free | Cyclic | L | None | 7 | Antibacterial | 50 % Hemolysis at 105 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWWW{cyc:N-C} | 3c | Free | Free | Cyclic | L | None | 8 | Antibacterial | 50 % Hemolysis at 80 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWWWW{cyc:N-C} | 3d | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 65 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRWWWWWWW{cyc:N-C} | 3e | Free | Free | Cyclic | L | None | 10 | Antibacterial | 50 % Hemolysis at 60 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | R{d}R{d}R{d}R{d}WWWW{cyc:N-C} | 4a | Free | Free | Cyclic | Mix | r = D-Arginine | 8 | Antibacterial | 50 % Hemolysis at 110 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRWWWWW{cyc:N-C} | 4b | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 100 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRWWWWWW{cyc:N-C} | 4c | Free | Free | Cyclic | L | None | 10 | Antibacterial | 50 % Hemolysis at 75 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRWWWWWWW{cyc:N-C} | 4d | Free | Free | Cyclic | L | None | 11 | Antibacterial | 50 % Hemolysis at 60 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRWWWW{cyc:N-C} | 5a | Free | Free | Cyclic | L | None | 9 | Antibacterial | 50 % Hemolysis at 340 μg/mL | Human | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 36442155 | 2022 | RRRRRWWWWW{cyc:N-C} | 5b | Free | Free | Cyclic | L | None | 10 | Antibacterial | 50 % Hemolysis at 230 μg/mL | Human | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 36442155 | 2022 | RRRRRWWWWWW{cyc:N-C} | 5c | Free | Free | Cyclic | L | None | 11 | Antibacterial | 50 % Hemolysis at 140 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRWWWWWWW{cyc:N-C} | 5d | Free | Free | Cyclic | L | None | 12 | Antibacterial | 50 % Hemolysis at 115 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRWWWW{cyc:N-C} | 6a | Free | Free | Cyclic | L | None | 10 | Antibacterial | 50 % Hemolysis at 265 μg/mL | Human | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 36442155 | 2022 | RRRRRRWWWWW{cyc:N-C} | 6b | Free | Free | Cyclic | L | None | 11 | Antibacterial | 50 % Hemolysis at 255 μg/mL | Human | Synthetic Cyclic Peptide | NA | Low hemolytic | ||
| 36442155 | 2022 | RRRRRRWWWWWW{cyc:N-C} | 6c | Free | Free | Cyclic | L | None | 12 | Antibacterial | 50 % Hemolysis at 170 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRWWWWWWW{cyc:N-C} | 6d | Free | Free | Cyclic | L | None | 13 | Antibacterial | 50 % Hemolysis at 85 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRRWWWW{cyc:N-C} | 7a | Free | Free | Cyclic | L | None | 11 | Antibacterial | 50 % Hemolysis at 190 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRRWWWWW{cyc:N-C} | 7b | Free | Free | Cyclic | L | None | 12 | Antibacterial | 50 % Hemolysis at 175 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRRWWWWWW{cyc:N-C} | 7c | Free | Free | Cyclic | L | None | 13 | Antibacterial | 50 % Hemolysis at 170 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36442155 | 2022 | RRRRRRRWWWWWWW{cyc:N-C} | 7d | Free | Free | Cyclic | L | None | 14 | Antibacterial | 50 % Hemolysis at 140 μg/mL | Human | Synthetic Cyclic Peptide | NA | NA | ||
| 36551443 | 2022 | RGGRLCYCRRRFCVCVGR | PG-1 | Free | Free | Linear | L | None | 18 | Antimycobacterial | 100 % Hemolysis at 1000 µg/mL | Human | Sus Domesticus | NA | NA | ||
| 36551443 | 2022 | AVKKLLRWWSRWWKK | AK 15-6 | Free | Free | Linear | L | None | 15 | Antimycobacterial | 33.57 % Hemolysis at 1000 µg/mL | Human | Mycobac Teriophage | NA | NA | ||
| 36551443 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | AM-mel | Free | Free | Linear | L | None | 26 | Antimycobacterial | 100 % Hemolysis at 1000 µg/mL | Human | Apis Mellifera | NA | NA | ||
| 36551443 | 2022 | GRRRRSVQWCA | hLF 1-11(L-form) | Free | Free | Linear | L | None | 11 | Antimycobacterial | <1 % Hemolysis at 4000 µg/mL | Human | Homo Sapiens | NA | Non-hemolytic | ||
| 36551443 | 2022 | G{d}R{d}R{d}R{d}R{d}S{d}V{d}Q{d}W{d}C{d}A{d} | hLF 1-11(D-form) | Free | Free | Linear | D | None | 11 | Antimycobacterial | <1 % Hemolysis at 4000 µg/mL | Human | Homo Sapiens | NA | Non-hemolytic | ||
| 36508333 | 2022 | FPWIIS{ct:Amid} | BmT-2 | Amidation | Free | Linear | L | None | 6 | Antioxidant | 0 % Hemolysis at 400 µg/mL | Human | Crude Venom Of Bothrops Moojeni | NA | Non-hemolytic | ||
| 36279986 | 2022 | {nnr:β2,2-Ac6c}-{nnr:Gpn}-{nnr:β2,2-Ac6c}-{nnr:Gpn}-{nnr:β2,2-Ac6c}-{nnr:Gpn}{nt:H}{ct:OMe} | BG6 | OMe | H | Linear | NA | β2,2-Ac6c = 1-aminomethylcyclohexane carboxylic acid, Gpn = 2-(1-(aminomethyl)cyclohexyl)acetic acid | 6 | Anticancer, Anti-migratory and Anti-invasive | 8.05 % Hemolysis at 30 µM/ml | Human | Short Hybrid Synthetic Peptide | NA | Low hemolytic | ||
| 36336133 | 2022 | GLFWIIKKTIGKLR | Aurein N2 | Free | Free | Linear | L | None | 14 | Antifungal | <15 % Hemolysis at 500 μg/mL | Human | Modified Peptide Based On Aurein 1.2 | Random coil | Low hemolytic | ||
| 36336133 | 2022 | ILFWIKKLTIGKKR | Aurein N3 | Free | Free | Linear | L | None | 14 | Antifungal | <15 % Hemolysis at 500 μg/mL | Human | Modified Peptide Based On Aurein N2 | Random coil | Low hemolytic | ||
| 36336133 | 2022 | GLFDIIKKIAESF | Aurein 1.2 | Free | Free | Linear | L | None | 13 | Antimicrobial, Anticancer | >20 % Hemolysis at 500 μg/mL | Human | Skin Of Australian Bell Frogs, Ranoidea Aurea (Formerly Litoria Aurea) And R. Raniformis (Formerly L. Raniformis) | α-Helix | NA | ||
| 36336133 | 2022 | GLFWIIKKTIGKLR | Aurein N2 | Free | Free | Linear | L | None | 14 | Antifungal | <30 % Hemolysis at 1000 μg/mL | Human | Modified Peptide Based On Aurein 1.2 | Random coil | Low hemolytic | ||
| 36336133 | 2022 | ILFWIKKLTIGKKR | Aurein N3 | Free | Free | Linear | L | None | 14 | Antifungal | <20 % Hemolysis at 1000 μg/mL | Human | Modified Peptide Based On Aurein N2 | Random coil | Low hemolytic | ||
| 36336133 | 2022 | GLFDIIKKIAESF | Aurein 1.2 | Free | Free | Linear | L | None | 13 | Antimicrobial, Anticancer | <35 % Hemolysis at 1000 μg/mL | Human | Skin Of Australian Bell Frogs, Ranoidea Aurea (Formerly Litoria Aurea) And R. Raniformis (Formerly L. Raniformis) | α-Helix | NA | ||
| 36327032 | 2023 | RNCKWLFKTWLKLPK{nt:Amid} | RN15m4 | Free | Amidation | Linear | L | None | 15 | Antibacterial | <12 % Hemolysis at 200 μg/mL | Human | Analog Of Rn15 (Cathelin Domain Of Crocodylus Siamensis) | 73.33% α-Helix | Low hemolytic | ||
| 36769243 | 2023 | MNLVDRAILIRKRRRAALQLRDKVLRYLK | AMP 1 | Free | Free | Linear | L | None | 29 | Antibacterial | 22.3 ± 4 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | NA | ||
| 36769243 | 2023 | MKRKKKILIKKVLKLKSSAY | AMP 2 | Free | Free | Linear | L | None | 20 | Antibacterial | 8.5 ± 1.4 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | NA | ||
| 36769243 | 2023 | MTDGRYLIKRVKKKKKAVLQLILKFL | AMP 3 | Free | Free | Linear | L | None | 26 | Antibacterial | 37 ± 5.1 % Hemolysis at 100 µM | Human | Synthetic Peptide | NA | NA | ||
| 36903328 | 2023 | KRFKKFFKKLRKSVKKRVKKFFKKPKVIGVSIPF | Hydrostatin-AMP2 | Free | Free | Linear | L | None | 34 | Antibacterial, Antibiofilm | 4.6 % Hemolysis at 250 μg/mL | Human | Sea Snake Hydrophis Cyanocinctus | Water = Random coil, SDS = α-Helical | Low hemolytic | ||
| 36910465 | 2023 | RFFVPLFLVGILFPAILAKQFTK | ALA‐A1 | Free | Free | Linear | L | None | 23 | NA | 5.6 ± 0.6 % Hemolysis at 200 µM | Human | Synthetic Peptide Sequence Of Alphalactalbumin | coil–Helix–coil–Helix | Low hemolytic | ||
| 36910465 | 2023 | KLWCKSSQVPQSR | ALA‐A2 | Free | Free | Linear | L | None | 13 | Anticancer | 7.8 ± 10.2 % Hemolysis at 200 µM | Human | Synthetic Peptide Sequence Of Alphalactalbumin | Helix–coil | Low hemolytic | ||
| 36910465 | 2023 | RFFVPLFLVGILFPAILAKQFTKC | ALA‐A3 | Free | Free | Linear | L | None | 24 | NA | 1.3± 1.2 % Hemolysis at 200 µM | Human | Synthetic Peptide Sequence Of Alphalactalbumin | Helix–coil–Helix | Low hemolytic | ||
| 36910465 | 2023 | LFQISNKLWCKSSQVPQSRN | ALA‐A4 | Free | Free | Linear | L | None | 20 | NA | 0.7 ± 0.6 % Hemolysis at 200 µM | Human | Synthetic Peptide Sequence Of Alphalactalbumin | coil | Low hemolytic | ||
| 36910465 | 2023 | FKCRRWQWRMKKLGAPSITCVR | BMP‐S6 (positive control)[ 5 , 10 ] | Free | Free | Linear | L | None | 22 | Anticancer | 6.0± 9.2 % Hemolysis at 200 µM | Human | Bovine-Derived Acp | coil–Helix | Low hemolytic | ||
| 36979401 | 2023 | KWKWRPLKRKLVLRM | PAM-5 | Free | Free | Linear | L | None | 15 | Antibacterial | <1 % Hemolysis at 256 µg/mL | Human | Synthetic Peptide | NA | Non-hemolytic | ||
| 36914718 | 2023 | LGIKILWSAYKHRKTI{ct:CH3-(CH2)3-CONH} | L-6-C5 | CH3-(CH2)3-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at > 100 µM | Human | Synthetic Lippopeptide | NA | Low hemolytic | ||
| 36914718 | 2023 | LGIKILWSAYKHRKTI{ct:CH3-(CH2)3-CONH} | D-6-C5 | CH3-(CH2)3-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at > 100 µM | Human | Synthetic Lippopeptide | NA | Low hemolytic | ||
| 36914718 | 2023 | LGLKLLWSAYKHRKTL{ct:CH3-(CH2)3-CONH} | L-6-C5-Leu | CH3-(CH2)3-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at > 100 µM | Human | Synthetic Lippopeptide | NA | Low hemolytic | ||
| 36914718 | 2023 | LGLKLLWSAYKHRKTL{ct:CH3-(CH2)3-CONH} | D-6-C5-Leu | CH3-(CH2)3-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at > 100 µM | Human | Synthetic Lippopeptide | NA | Low hemolytic | ||
| 36914718 | 2023 | LGIKILWSAYKHRKTI{ct:CH3-(CH2)4-CONH} | L-6-C6 | CH3-(CH2)4-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at > 100 µM | Human | Synthetic Lippopeptide | NA | Low hemolytic | ||
| 36914718 | 2023 | LGIKILWSAYKHRKTI{ct:CH3-(CH2)4-CONH} | D-6-C6 | CH3-(CH2)4-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at > 100 µM | Human | Synthetic Lippopeptide | NA | Low hemolytic | ||
| 36914718 | 2023 | LGLKLLWSAYKHRKTL{ct:CH3-(CH2)4-CONH} | L-6-C6-Leu | CH3-(CH2)4-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at 60 µM | Human | Synthetic Lippopeptide | NA | NA | ||
| 36914718 | 2023 | LGLKLLWSAYKHRKTL{ct:CH3-(CH2)4-CONH} | D-6-C6-Leu | CH3-(CH2)4-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at 65 µM | Human | Synthetic Lippopeptide | NA | NA | ||
| 36914718 | 2023 | LGIKILWSAYKHRKTI{ct:CH3-(CH2)5-CONH} | L-6-C7 | CH3-(CH2)5-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at 80 µM | Human | Synthetic Lippopeptide | NA | NA | ||
| 36914718 | 2023 | LGIKILWSAYKHRKTI{ct:CH3-(CH2)5-CONH} | D-6-C7 | CH3-(CH2)5-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at 65 µM | Human | Synthetic Lippopeptide | NA | NA | ||
| 36914718 | 2023 | LGLKLLWSAYKHRKTL{ct:CH3-(CH2)5-CONH} | L-6-C7-Leu | CH3-(CH2)5-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at 30 µM | Human | Synthetic Lippopeptide | NA | NA | ||
| 36914718 | 2023 | LGLKLLWSAYKHRKTL{ct:CH3-(CH2)5-CONH} | D-6-C7-Leu | CH3-(CH2)5-CONH | Free | Linear | L | None | 16 | Antibacterial | 5 % Hemolysis at 35 µM | Human | Synthetic Lippopeptide | NA | NA | ||
| 36982579 | 2023 | KRIVQRIKDFLR{ct:Amid} | KR12-NH2 | Amidation | Free | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at ≥512 µg/mL | Human | Ll-37-Derived Peptide Fragment | POPG and POPC = α-Helical | Non-hemolytic | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:C8}{ct:Amid} | C8α-KR12-NH2 | Amidation | C8 | Linear | L | None | 12 | Antibacterial | 5 % Hemolysis at 64 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | NA | ||
| 36982579 | 2023 | K({nnr:C8})RIVQRIKDFLR{ct:Amid} | C8ε-KR12-NH2 | Amidation | Free | Linear | L | C8 = C8 | 12 | Antibacterial | 5 % Hemolysis at ≥512 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Non-hemolytic | ||
| 36982579 | 2023 | KKRIVQRIKDFLR{nt:C8}{ct:Amid} | C8α-Lys-KR12-NH2 | Amidation | C8 | Linear | L | C8 = C8 | 13 | Antibacterial | 5 % Hemolysis at 256 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Low hemolytic | ||
| 36982579 | 2023 | K({nnr:C8})KRIVQRIKDFLR{ct:Amid} | C8ε-Lys-KR12-NH2 | Amidation | Free | Linear | L | C8 = C8 | 13 | Antibacterial | 5 % Hemolysis at 256 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Low hemolytic | ||
| 36982579 | 2023 | KRIVQRIKDFLRK({nnr:C8}){ct:Amid} | KR12-Lysε(C8)-NH2 | Amidation | Free | Linear | L | C8 = C8 | 13 | Antibacterial | 5 % Hemolysis at ≥512 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Non-hemolytic | ||
| 36982579 | 2023 | KRIVQRIKDFLK({nnr:C8}){ct:Amid} | [Lysε(C8)]12KR12-NH2 | Amidation | Free | Linear | L | C8 = C8 | 12 | Antibacterial | 5 % Hemolysis at ≥512 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Non-hemolytic | ||
| 36982579 | 2023 | KRIVQRIK({nnr:C8})DFLR{ct:Amid} | [Lysε(C8)]8KR12-NH2 | Amidation | Free | Linear | L | C8 = C8 | 12 | Antibacterial | 5 % Hemolysis at 64 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | NA | ||
| 36982579 | 2023 | K({nnr:C8})RIVQRIKDFLR{nt:C8}{ct:Amid} | C8α,C8ε-KR12-NH2 | Amidation | C8 | Linear | L | C8 = C8 | 12 | Antibacterial | 5 % Hemolysis at 8 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | NA | ||
| 36982579 | 2023 | K({nnr:C4})RIVQRIKDFLR{nt:C4}{ct:Amid} | C4α, C4ε-KR12-NH2 | Amidation | C4 | Linear | L | C4 = C4 | 12 | Antibacterial | 5 % Hemolysis at ≥512 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Non-hemolytic | ||
| 36982579 | 2023 | RLFDKIRQVIRK({nnr:C8}){ct:Amid} | retro-KR12-C8ε-NH2 | Amidation | Free | Linear | L | C8 = C8 | 12 | Antibacterial | 5 % Hemolysis at 256 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Low hemolytic | ||
| 36982579 | 2023 | RLFDKIRQVIRK{nt:C8}{ct:Amid} | C8α-retro-KR12-NH2 | Amidation | C8 | Linear | L | C8 = C8 | 12 | Antibacterial | 5 % Hemolysis at ≥512 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Non-hemolytic | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:CH3-(CH2)5-CH(C4H9)-CO}{ct:Amid} | 2-Buthyloctanoic acid-KR12-NH2 | Amidation | CH3-(CH2)5-CH(C4H9)-CO | Linear | L | CH3-(CH2)5-CH(C4H9)-CO | 12 | Antibacterial | 5 % Hemolysis at 16 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | NA | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:CH3-(CH2)3-CH(C2H5)-CO}{ct:Amid} | 2-Ethylhexanoic acid-KR12-NH2 | Amidation | CH3-(CH2)3-CH(C2H5)-CO | Linear | L | CH3-(CH2)3-CH(C2H5)-CO | 12 | Antibacterial | 5 % Hemolysis at 256 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Low hemolytic | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:C6H5-CO}{ct:Amid} | Benzoic acid-KR12-NH2 | Amidation | C6H5-CO | Linear | L | C6H5-CO | 12 | Antibacterial | 5 % Hemolysis at ≥512 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Non-hemolytic | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:C6H5-CH2-CO}{ct:Amid} | Phenylacetic acid-KR12-NH2 | Amidation | C6H5-CH2-CO | Linear | L | C6H5-CH2-CO | 12 | Antibacterial | 5 % Hemolysis at 256 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Low hemolytic | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:C6H5-CH2-CH2-CO}{ct:Amid} | 3-Phenylpropionic acid- KR12-NH2 | Amidation | C6H5-CH2-CH2-CO | Linear | L | C6H5-CH2-CH2-CO | 12 | Antibacterial | 5 % Hemolysis at 256 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Low hemolytic | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:C6H5-(CH2)3-CO}{ct:Amid} | 4-Phenylbutanoic acid-KR12-NH2 | Amidation | C6H5-(CH2)3-CO | Linear | L | C6H5-(CH2)3-CO | 12 | Antibacterial | 5 % Hemolysis at 128 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | NA | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:C6H5-CH=CH-CO}{ct:Amid} | trans-cinnamic acid-KR12-NH2 | Amidation | C6H5-CH=CH-CO | Linear | L | C6H5-CH=CH-CO | 12 | Antibacterial | 5 % Hemolysis at 128 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | NA | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:C6H5-C≡C-CO}{ct:Amid} | Phenylpropiolic acid-KR12-NH2 | Amidation | C6H5-C≡C-CO | Linear | L | C6H5-C≡C-CO | 12 | Antibacterial | 5 % Hemolysis at 256 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | Low hemolytic | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:C6H5-C6H4-CO}{ct:Amid} | 4-Phenylbenzoic acid- KR12-NH2 | Amidation | C6H5-C6H4-CO | Linear | L | C6H5-C6H4-CO | 12 | Antibacterial | 5 % Hemolysis at 32 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | NA | ||
| 36982579 | 2023 | KRIVQRIKDFLR{nt:C24H39O3}{ct:Amid} | Deoxycholic acid- KR12-NH2 | Amidation | C24H39O3 | Linear | L | C24H39O3 | 12 | Antibacterial | 5 % Hemolysis at 8 µg/mL | Human | Kr12-Nh2 Lipidated Analogs | POPG and POPC = α-Helical | NA | ||
| 36979510 | 2023 | AWLDKLKSIGKVVGKVAIGVAKNLLNPQ | Raniseptins-3 | Free | Free | Linear | L | None | 28 | Antibacterial, Antifungal | ≤20 % Hemolysis at 128 µM | Human | Frog Boana Raniceps Skin Secretion | SDS = α-Helix | NA | ||
| 36979510 | 2023 | ALLDKLKSLGKVVGKVALGVVQNYLNPRQ | Raniseptins-6 | Free | Free | Linear | L | None | 29 | Antibacterial, Antifungal | ≤20 % Hemolysis at 128 µM | Human | Frog Boana Raniceps Skin Secretion | SDS = α-Helix | NA | ||
| 37242633 | 2023 | VRLIVAVRIWRR{ct:Amid} | IDR1018 | Amidation | Free | Linear | L | None | 12 | Wound healing, Antibiofilm, Antibacterial | 20 % Hemolysis at 128 μg/mL | Human | Cationic Host Defense Peptides | NA | NA | ||
| 37242633 | 2023 | VRLIVAVRIWRR{nt:PEG6}{ct:Amid} | PEG6-IDR1018 | Amidation | PEG6 | Linear | L | None | 12 | Wound healing, Antibiofilm, Antibacterial | 0 % Hemolysis at 128 μg/mL | Human | Cationic Host Defense Peptides | NA | Non-hemolytic | ||
| 37242633 | 2023 | T({nnr:GlcNAc})VRLIVAVRIWRR{ct:Amid} | Glc-IDR1018 | Amidation | Free | Linear | L | GlcNAc = N-acetyl glucosamine | 13 | Wound healing, Antibiofilm, Antibacterial | 0 % Hemolysis at 128 μg/mL | Human | Cationic Host Defense Peptides | NA | Non-hemolytic | ||
| 37093361 | 2023 | WRLFRRILRVL{nt:Amid}{ct:Amid} | mCM11 | Amidation | Amidation | Linear | L | None | 11 | Antibacterial, Antibioflm | 2.78 % Hemolysis at 4 μg/mL | Human | Modifed Cecropin–Melittin | SDS = α-Helix | Low hemolytic | ||
| 37093361 | 2023 | WRLFRRILRVL{nt:Amid}{ct:Amid} | mCM11 | Amidation | Amidation | Linear | L | None | 11 | Antibacterial, Antibioflm | 2.98 % Hemolysis at 8 μg/mL | Human | Modifed Cecropin–Melittin | SDS = α-Helix | Low hemolytic | ||
| 37093361 | 2023 | WRLFRRILRVL{nt:Amid}{ct:Amid} | mCM11 | Amidation | Amidation | Linear | L | None | 11 | Antibacterial, Antibioflm | 3.15 % Hemolysis at 16 μg/mL | Human | Modifed Cecropin–Melittin | SDS = α-Helix | Low hemolytic | ||
| 37093361 | 2023 | WRLFRRILRVL{nt:Amid}{ct:Amid} | mCM11 | Amidation | Amidation | Linear | L | None | 11 | Antibacterial, Antibioflm | 3.83 % Hemolysis at 32 μg/mL | Human | Modifed Cecropin–Melittin | SDS = α-Helix | Low hemolytic | ||
| 37093361 | 2023 | WRLFRRILRVL{nt:Amid}{ct:Amid} | mCM11 | Amidation | Amidation | Linear | L | None | 11 | Antibacterial, Antibioflm | 5.79 % Hemolysis at 64 μg/mL | Human | Modifed Cecropin–Melittin | SDS = α-Helix | Low hemolytic | ||
| 37093361 | 2023 | WRLFRRILRVL{nt:Amid}{ct:Amid} | mCM11 | Amidation | Amidation | Linear | L | None | 11 | Antibacterial, Antibioflm | 6.64 % Hemolysis at 128 μg/mL | Human | Modifed Cecropin–Melittin | SDS = α-Helix | Low hemolytic | ||
| 37093361 | 2023 | WRLFRRILRVL{nt:Amid}{ct:Amid} | mCM11 | Amidation | Amidation | Linear | L | None | 11 | Antibacterial, Antibioflm | 15.5 % Hemolysis at 256 μg/mL | Human | Modifed Cecropin–Melittin | SDS = α-Helix | Low hemolytic | ||
| 37093361 | 2023 | WRLFRRILRVL{nt:Amid}{ct:Amid} | mCM11 | Amidation | Amidation | Linear | L | None | 11 | Antibacterial, Antibioflm | 24.53 % Hemolysis at 512 μg/mL | Human | Modifed Cecropin–Melittin | SDS = α-Helix | Low hemolytic | ||
| 37140456 | 2023 | VRVGPCDQVCSRTNPEKDECCRAHGHSGHSSCYGGRMNCYG | blapstin | Free | Free | Linear | L | None | 41 | Antibiofilm, Antifungal | 50 % Hemolysis at >112.5 µM | Human | Beetle Blaps Rhynchopetera | Random curl (34.80%), β-Turns (22.54%), β-Sheet (20.66%), α-Helix (5.22%) | NA | ||
| 37446618 | 2023 | YA{d}FGYPSGHFM | LENART01 | Free | Free | Linear | Mix | a = D-alanine | 11 | Antibacterial | 4.8 % Hemolysis at 200 µM (1 hour) | Human | Opioid–Ranatensin Hybrid Peptide | NA | Low hemolytic | ||
| 37446618 | 2023 | YA{d}FGYPSGHFM | LENART01 | Free | Free | Linear | Mix | a = D-alanine | 11 | Antibacterial | 8.3 % Hemolysis at 200 µM (2 hour) | Human | Opioid–Ranatensin Hybrid Peptide | NA | Low hemolytic | ||
| 37446618 | 2023 | YA{d}FGYPSGHFM | LENART01 | Free | Free | Linear | Mix | a = D-alanine | 11 | Antibacterial | 16.4 % Hemolysis at 200 µM (4 hour) | Human | Opioid–Ranatensin Hybrid Peptide | NA | Low hemolytic | ||
| 37300579 | 2023 | HIDWKKLLDAAKQIL{ct:Amid} | MP1 | Amidation | Free | Linear | L | None | 15 | Antibacterial, Antibiofilm, Antifungal | 50 % Hemolysis at 221.4 µM | Human | Mastoparan Family | α-Helix | Low hemolytic | ||
| 37300579 | 2023 | HIDWKKLLDAAKKIL{ct:Amid} | MP1-Q12K | Amidation | Free | Linear | L | None | 15 | Antibacterial, Antibiofilm, Antifungal | 50 % Hemolysis at 187.4 µM | Human | Mp1 Analog | α-Helix | Low hemolytic | ||
| 37513276 | 2023 | GPKTKAACKMACKLATCGKKPGGWKCKLCELGCDAV | Turgencin A | Free | Free | Linear | L | None | 36 | Antibacterial | 0 % Hemolysis at 10 μg/mL | Human | Fungi Pichia Pastoris | α-Helix and Random coil | Non-hemolytic | ||
| 37631261 | 2023 | RGGRLCYCRRRFCVCVGR | Protegrin-1 (PG-1) | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 0.7 µM | Human | Porcine (Sus Scrofa) Leukocytes | β-Hairpin | NA | ||
| 37631261 | 2023 | RGG-LCYCRGRFCVCVGR | Iseganan | Free | Free | Linear | L | None | 17 | Antibacterial | 2 % Hemolysis at 1 µM | Human | Protegrin-1 Analogs | NA | NA | ||
| 37631261 | 2023 | RGGRRCYCRRRFCVCVGR | [L5R] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 4.1 µM | Human | Protegrin-1 Analogs | NA | NA | ||
| 37631261 | 2023 | RGGRACYCRRRFCVCVGR | [L5A] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 4.1 µM | Human | Protegrin-1 Analogs | NA | NA | ||
| 37631261 | 2023 | RGGRLCYCRRRFCVCRGR | [V16R] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 49.2 µM | Human | Protegrin-1 Analogs | β-Hairpin | Low hemolytic | ||
| 37631261 | 2023 | RGGRLCYCRRRFCVCAGR | [V16A] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 4.3 µM | Human | Protegrin-1 Analogs | NA | NA | ||
| 37631261 | 2023 | RGGRLCYCRRRFCRCVGR | [V14R] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at >64 µM | Human | Protegrin-1 Analogs | NA | Low hemolytic | ||
| 37631261 | 2023 | RGGRLCYCRRRFCACVGR | [V14A] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 5.5 µM | Human | Protegrin-1 Analogs | NA | NA | ||
| 37631261 | 2023 | RGGRLCRCRRRFCVCVGR | [Y7R] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 61.4 µM | Human | Protegrin-1 Analogs | NA | Low hemolytic | ||
| 37631261 | 2023 | RGGRLCTCRRRFCVCVGR | [Y7T] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 33.5 µM | Human | Protegrin-1 Analogs | NA | Low hemolytic | ||
| 37631261 | 2023 | RGGRLCTCRRRFCVCRGR | [Y7T,V16R] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at >64 µM | Human | Protegrin-1 Analogs | NA | Low hemolytic | ||
| 37631261 | 2023 | RGGRLCYCRRRFCACRGR | [V14A,V16R] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at >64 µM | Human | Protegrin-1 Analogs | NA | Low hemolytic | ||
| 37631261 | 2023 | RGGRACYCRRRFCVCRGR | [L5A, V16R] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at >64 µM | Human | Protegrin-1 Analogs | NA | Low hemolytic | ||
| 37631261 | 2023 | RGGRACYCRRRFCACVGR | [L5A, V14A] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 18.8 µM | Human | Protegrin-1 Analogs | NA | NA | ||
| 37631261 | 2023 | RGGRACYCRRRFCVCAGR | [L5A,V16A] | Free | Free | Linear | L | None | 18 | Antibacterial | 2 % Hemolysis at 11.9 µM | Human | Protegrin-1 Analogs | NA | NA | ||
| 37310533 | 2023 | RIIDLLWRVRRPQKPKFVTVWVR | PMAP-23 | Free | Free | Linear | L | None | 23 | Antibacterial | <10 % Hemolysis at 100 µM | Human | Cathelicidin-Derived Amp | aqueous bufer = unordered structure, membrane-mimetic environments = Helix–hinge–Helix | Low hemolytic | ||
| 37310533 | 2023 | RIIDRLWLVRRPQKPKFVLVWVL | PMAP-NC | Free | Free | Linear | L | None | 23 | Antibacterial, Anticancer | 20 % Hemolysis at 64 µM | Human | Pmap-23 Analogs | Helix–hinge–Helix | NA | ||
| 37635252 | 2023 | GLLSRLRDFLSDRGRRLGEKIERIGQKIKDLSERFQS | PMAP-37(F34-R) | Free | Free | Linear | L | None | 37 | Antibacterial | ≤1.5 % Hemolysis at 0.36 μg/mL | Human | Pamp-37 (Pig Bone Marrow) Analogue | α-Helix | Low hemolytic | ||
| 36857655 | 2023 | KLLPSVVGLFKKKKQ{ct:Amid} | At1 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 32 µM | Human | Derived Amp Ponericin-W1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = α-Helical | NA | ||
| 36857655 | 2023 | KLLKKVVKLFKKKKK{ct:Amid} | At2 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 4 µM | Human | Modified Sequence Of At1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = α-Helical | NA | ||
| 36857655 | 2023 | KLLKKVVKLFKKLLK{ct:Amid} | At3 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 31.3 µM | Human | Modified Sequence Of At1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = α-Helical | NA | ||
| 36857655 | 2023 | KLLKKLLKLLKKLLK{ct:Amid} | At4 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 0.2 µM | Human | Modified Sequence Of At1 | water = Random coil, α-Helical, DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = α-Helical | NA | ||
| 36857655 | 2023 | KIIKKIIKIIKKIIK{ct:Amid} | At5 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 31.3 µM | Human | Modified Sequence Of At1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = α-Helical | NA | ||
| 36857655 | 2023 | KVVKKVVKVVKKVVK{ct:Amid} | At6 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 16 µM | Human | Modified Sequence Of At1 | water = Random coil, α-Helical, DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = α-Helical | NA | ||
| 36857655 | 2023 | KIIKKIKKKIKKIIK{ct:Amid} | At7 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 16 µM | Human | Modified Sequence Of At1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = α-Helical | NA | ||
| 36857655 | 2023 | KLLKKLKKKLKKLLK{ct:Amid} | At8 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 16 µM | Human | Modified Sequence Of At1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = Helical | NA | ||
| 36857655 | 2023 | KVVKKVKKKVKKVVK{ct:Amid} | At9 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 8 µM | Human | Modified Sequence Of At1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = Helical | NA | ||
| 36857655 | 2023 | IKKIIKIIKKIIKKI{ct:Amid} | At10 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 16.1 µM | Human | Modified Sequence Of At1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = α-Helical | NA | ||
| 36857655 | 2023 | IIIKKIKKKIKKIII{ct:Amid} | At11 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 16 µM | Human | Modified Sequence Of At1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = α-Helical | NA | ||
| 36857655 | 2023 | KIIIKIKKKIKIIIK{ct:Amid} | At12 | Amidation | Free | Linear | L | None | 15 | Antifungal | 10 % Hemolysis at 1 µM | Human | Modified Sequence Of At1 | water and DPPC SUVs = Random coil, SDS = α-Helical, DPPG SUVs = β-Sheet | NA | ||
| 36870201 | 2023 | FVQWFSKFLGRIL{ct:Amid} | Temporin L | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 50 % Hemolysis at 15 µM | Human | European Frog Rana Temporaria | PC/PG (3:1 w/w) = 70.1% Helical, PC/Chol (8:1 w/w) vesicles = 61.7% Helical | NA | ||
| 36870201 | 2023 | FVQWFSKF(βL)RIL{ct:Amid} | L9βl-TL | Amidation | Free | Linear | L | None | 12 | Antibacterial, Antibiofilm | 50 % Hemolysis at 33.3 µM | Human | Tl-Analogue | PC/PG (3:1 w/w) = 13.8% Helical, PC/Chol (8:1 w/w) vesicles = 7.2% Helical | NA | ||
| 36907048 | 2023 | IWLTALKFLGKNLGKHLAKQQLSKL{nt:H}{ct:Amid} | LVTX-8 | Amidation | H | Linear | L | None | 25 | Anticancer | 66.7 % Hemolysis at >5 µM | Human | Spider Lycosa Vittata | PBS buffer = α-Helical | NA | ||
| 36907048 | 2023 | IWLTALKFLGKNLGKHLAKQQLSKL{nt:hydrazide = NHNH2}{ct:Acet} | 825 | Acetylation | hydrazide = NHNH2 | Linear | L | None | 25 | Anticancer | 16.7 % Hemolysis at >5 µM | Human | Lvtx-8-Analogs | PBS buffer = α-Helical | Low hemolytic | ||
| 36907048 | 2023 | GFLG-IWLTALKFLGKNLGKHLAKQQLSKL{nt:MTX}{ct:Amid} | 827 | Amidation | MTX | Linear | L | MTX = methotrexate | 29 | Anticancer | 35.8 % Hemolysis at >5 µM | Human | Lvtx-8-Analogs | PBS buffer = α-Helical | NA | ||
| 37336295 | 2023 | FVDLKKIANIINSIFGK{ct:Amid} | Temporin-1CEa | Amidation | Free | Linear | L | None | 17 | Antimycobacterial | 50 % Hemolysis at 95.74 µM | Human | Chinese Brown Frog Rana Chensinensis | NA | NA | ||
| 37336295 | 2023 | FVDLKKIANIINSIFKK{ct:Amid} | LK1 | Amidation | Free | Linear | L | None | 17 | Antimycobacterial | 50 % Hemolysis at 1467 µM | Human | Analog Of Temporin-1Cea | NA | NA | ||
| 37336295 | 2023 | FVKLKKILNIILSIFKK{ct:Amid} | LK2(6)AN(2L) | Amidation | Free | Linear | L | None | 17 | Antimycobacterial | 50 % Hemolysis at 28.34 µM | Human | Analog Of Temporin-1Cea | NA | NA | ||
| 37336295 | 2023 | IKKILSKIKKLLK{ct:Amid} | LK6 | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Temporin-1Ceb | NA | Low hemolytic | ||
| 37336295 | 2023 | IWLSKIKKLLK{ct:Amid} | I4W | Amidation | Free | Linear | L | None | 11 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Lk6 | NA | Low hemolytic | ||
| 37336295 | 2023 | IKKWWSKIKKLLK{ct:Amid} | I4WL5W | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Lk6 | NA | Low hemolytic | ||
| 37336295 | 2023 | IKKIWSKIKKLLK{ct:Amid} | L5W | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Lk6 | NA | Low hemolytic | ||
| 37336295 | 2023 | IKKILSKIKKWLK{ct:Amid} | L11W | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Lk6 | NA | Low hemolytic | ||
| 37336295 | 2023 | IKKILSKIKKLWK{ct:Amid} | L12W | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Lk6 | NA | Low hemolytic | ||
| 37336295 | 2023 | WKKIWSKIKKLLK{ct:Amid} | I1WL5W | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Lk6 | NA | Low hemolytic | ||
| 37336295 | 2023 | WKKILSKIKKLLK{ct:Amid} | I1W | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Lk6 | NA | Low hemolytic | ||
| 37336295 | 2023 | SAVGRHGRRFGLRKHRKH{ct:Amid} | Chensinin-1 | Amidation | Free | Linear | L | None | 18 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Frog Rana Chensinensis | NA | Low hemolytic | ||
| 37336295 | 2023 | SKVWRHWRRFWHRAHRKL{ct:Amid} | Chensinin-1b | Amidation | Free | Linear | L | None | 18 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Chensinin-1 | NA | Low hemolytic | ||
| 37336295 | 2023 | SKVWRHWRRFWHRAHRK({nnr:C8})L | OA-C1b | Free | Free | Linear | L | C8 = C8 | 19 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Lipidated Analog Of Chensinin-1B | NA | Low hemolytic | ||
| 37336295 | 2023 | SKVWRHWRRFWHRAHRK({nnr:C12})L | LA-C1b | Free | Free | Linear | L | C12 = C12 | 19 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Lipidated Analog Of Chensinin-1B | NA | Low hemolytic | ||
| 37336295 | 2023 | SKVWRHWRRFWHRAHRK({nnr:C16})L | PA-C1b | Free | Free | Linear | L | C16 = C16 | 19 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Lipidated Analog Of Chensinin-1B | NA | Low hemolytic | ||
| 37336295 | 2023 | V{d}W{d}R{d}R{d}W{d}R{d}R{d}F{d}W{d}R{d}R{d}{ct:Amid} | D-W3R6 | Amidation | Free | Linear | D | None | 11 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of W3R6 | NA | Low hemolytic | ||
| 37336295 | 2023 | VWRRWRRFWRR{ct:Amid} | W3R6 | Amidation | Free | Linear | L | None | 11 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Chensinin-1 | 40% H2O/TFE-d3 = Random coil, 50%H2O/TFE-d3 = α-Helical | Low hemolytic | ||
| 37336295 | 2023 | V{d}W{d}R{d}R{d}W{d}R{d}R{d}F{d}W{d}R{d}R{d}{ct:Amid} | D-Arg-W3R6 | Amidation | Free | Linear | D | None | 11 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Diastereomer Of W3R6 | NA | Low hemolytic | ||
| 37336295 | 2023 | V{d}W{d}R{d}R{d}W{d}R{d}R{d}F{d}W{d}R{d}R{d}{nt:Acetylation(CH3COOH)}{ct:Amid} | AC-D-W3R6 | Amidation | Acetylation(CH3COOH) | Linear | D | None | 11 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Lipidated Analog Of D-W3R6 (Acetyl) | NA | Low hemolytic | ||
| 37336295 | 2023 | V{d}W{d}R{d}R{d}W{d}R{d}R{d}F{d}W{d}R{d}R{d}{nt:butanoyl = CH3(CH2)2COOH}{ct:Amid} | BA-D-W3R6 | Amidation | butanoyl = CH3(CH2)2COOH | Linear | D | None | 11 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Lipidated Analog Of D-W3R6 (Butanoyl) | NA | Low hemolytic | ||
| 37336295 | 2023 | V{d}W{d}R{d}R{d}W{d}R{d}R{d}F{d}W{d}R{d}R{d}{nt:octanoyl = C8H16O2}{ct:Amid} | OA-D-W3R6 | Amidation | octanoyl = C8H16O2 | Linear | D | None | 11 | Antimycobacterial | 50 % Hemolysis at 100 µM | Human | Lipidated Analog Of D-W3R6 (Octanoyl) | NA | NA | ||
| 37336295 | 2023 | V{d}W{d}R{d}R{d}W{d}R{d}R{d}F{d}W{d}R{d}R{d}{nt:lauric acyl = C12H24O2}{ct:Amid} | LA-D-W3R6 | Amidation | lauric acyl = C12H24O2 | Linear | D | None | 11 | Antimycobacterial | 50 % Hemolysis at 25 µM | Human | Lipidated Analog Of D-W3R6 (Lauric Acid) | NA | NA | ||
| 37336295 | 2023 | V{d}W{d}R{d}R{d}W{d}R{d}R{d}F{d}W{d}R{d}R{d}{nt:palmitic acyl = C16H32O2}{ct:Amid} | PA-D-W3R6 | Amidation | palmitic acyl = C16H32O2 | Linear | D | None | 11 | Antimycobacterial | 50 % Hemolysis at 25 µM | Human | Lipidated Analog Of D-W3R6 (Palmitic Acid) | NA | NA | ||
| 37336295 | 2023 | ILPILSLIGGLL{ct:Amid} | Temporin-1CEb | Amidation | Free | Linear | L | None | 12 | Antimycobacterial | 50 % Hemolysis at 122 µM | Human | Rana Chensinensis | NA | NA | ||
| 37336295 | 2023 | IIPLPLGYFAKKT{ct:Amid} | Temporin-1CEc | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Rana Chensinensis | NA | Low hemolytic | ||
| 37336295 | 2023 | IIPLPLKKFAKKT{ct:Amid} | 2 K | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Temporin-1Cec | NA | Low hemolytic | ||
| 37336295 | 2023 | KIPKPLKKFAKKT{ct:Amid} | 4 K | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Temporin-1Cec | NA | Low hemolytic | ||
| 37336295 | 2023 | IIPLPLKKFLKKL{ct:Amid} | 2 K2L | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Temporin-1Cec | NA | Low hemolytic | ||
| 37336295 | 2023 | KIPKPLKKFLKKL{ct:Amid} | 4 K2L | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Temporin-1Cec | NA | Low hemolytic | ||
| 37336295 | 2023 | IILLLLKKFLKKL{ct:Amid} | 2 K4L | Amidation | Free | Linear | L | None | 14 | Antimycobacterial | 50 % Hemolysis at 62.5 µM | Human | Analog Of Temporin-1Cec | NA | NA | ||
| 37336295 | 2023 | KILKLLKKFLKKL{ct:Amid} | 4 K4L | Amidation | Free | Linear | L | None | 13 | Antimycobacterial | 50 % Hemolysis at >500 µM | Human | Analog Of Temporin-1Cec | NA | Low hemolytic | ||
| 31608030 | 2019 | FKRIVQRIKDFLRNLV | FK16 | Free | Free | Linear | L | None | 16 | Antibacterial | <10% (1 hr) % Hemolysis at 256 μg/mL | Human | Cathelicidin-Derived Peptides | NA | Low hemolytic | ||
| 19451300 | 2009 | FFSLLPSLIGGLVSAIK | imcroporin | Free | Free | Linear | L | None | 17 | Antibacterial | <50 % Hemolysis at 50 μg/ml | Human | Scorpion Isometrus Maculates | α-Helix | NA | ||
| 25633390 | 2015 | ARDGYIVDEKGCKFACFIN | Cm38 | Free | Free | Linear | L | None | 19 | Antibacterial | 0 % Hemolysis at 64 µM | Human | Scorpion Centruroides Margaritatus | NA | Non-hemolytic | ||
| 35216177 | 2022 | FVQWFSKFLGRIL | Temporin L | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | ∼70 % Hemolysis at 100 µM | Human | Rana Temporaria (Red Frog) | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}GRIL{ct:Amid} | [Pro3 , DLeu9 ] TL | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial, Antibiofilm | ∼50 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVQWFSKFLGRIL | Temporin L | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | ∼43 % Hemolysis at 50 µM | Human | Rana Temporaria (Red Frog) | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}GRIL{ct:Amid} | [Pro3 , DLeu9 ] TL | Amidation | Free | Linear | Mix | l = D-Leucine | 13 | Antibacterial, Antibiofilm | ∼25 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}GRIL{ct:Amid} | [Pro3,DLeu9] TL (TL1) | Amidation | Free | Linear | Mix | l=D-Leu | 13 | Antibacterial, Antibiofilm | 60 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}PRIL{ct:Amid} | [Pro3,DLeu9,Pro10] TL (TL2) | Amidation | Free | Linear | Mix | l=D-Leu | 14 | Antibacterial, Antibiofilm | 60 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}P{d}RIL{ct:Amid} | [Pro3,DLeu9,DPro10] TL (TL3) | Amidation | Free | Linear | Mix | l=D-Leu, p = D-Pro | 14 | Antibacterial, Antibiofilm | 20 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}{nnr:O}RIL{ct:Amid} | [Pro3,DLeu9,Hyp10] TL (TL4) | Amidation | Free | Linear | Mix | l=D-Leu, O = Hyp = hydroxyproline | 14 | Antibacterial, Antibiofilm | 80 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}{nnr:o}RIL{ct:Amid} | [Pro3,DLeu9,DHyp10] TL (TL5) | Amidation | Free | Linear | Mix | l=D-Leu, o = D-Hyp = hydroxyproline | 14 | Antibacterial, Antibiofilm | 20 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}{nnr:N=Nle}RIL{ct:Amid} | [Pro3,DLeu9,Nle10] TL (TL6) | Amidation | Free | Linear | Mix | l=D-Leu, N = Nle | 14 | Antibacterial, Antibiofilm | 60 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}{nnr:n=D-Nle}RIL{ct:Amid} | [Pro3,DLeu9,DNle10] TL (TL7) | Amidation | Free | Linear | Mix | l=D-Leu, n = D-Nle | 14 | Antibacterial, Antibiofilm | 40 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}KRIL{ct:Amid} | [Pro3,DLeu9,Lys10] TL (TL8) | Amidation | Free | Linear | Mix | l=D-Leu | 14 | Antibacterial, Antibiofilm | 80 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}K{d}RIL{ct:Amid} | [Pro3,DLeu9,DLys10] TL (TL9) | Amidation | Free | Linear | Mix | l=D-Leu, k = D-Lys | 14 | Antibacterial, Antibiofilm | 40 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}WRIL{ct:Amid} | [Pro3,DLeu9,Trp10] TL (TL10) | Amidation | Free | Linear | Mix | l=D-Leu | 14 | Antibacterial, Antibiofilm | 60 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFL{d}W{d}RIL{ct:Amid} | [Pro3,DLeu9,DTrp10] TL (TL11) | Amidation | Free | Linear | Mix | l=D-Leu, w = D-Trp | 14 | Antibacterial, Antibiofilm | 80 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35216177 | 2022 | FVPWFSKFl{nnr:Aic}RIL{ct:Amid} | [Pro3,DLeu9,Aic10] TL (TL12) | Amidation | Free | Linear | Mix | Aic = 2-aminoindane-2-carboxylic acid | 14 | Antibacterial, Antibiofilm | 100 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35323465 | 2022 | SPRVCIRVCRNGVCYRRCWG | Capitellacin | Free | Free | Linear | L | None | 20 | Antibacterial | 50 % Hemolysis at 128 µM | Human | Capitella Teleta | NA | Low hemolytic | ||
| 35323465 | 2022 | RSPRVCIRVCRNGVCYRRCWG | CT2 | Free | Free | Linear | L | None | 21 | Antibacterial | >5 % Hemolysis at 128 µM | Human | Synthetic | NA | Non-hemolytic | ||
| 35323465 | 2022 | SPRVCIRVCRNGVCYRRCW | CT3 | Free | Free | Linear | L | None | 19 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic | NA | Non-hemolytic | ||
| 35323465 | 2022 | RVCIRVCRNGVCYRRCW | CT4 | Free | Free | Linear | L | None | 17 | Antibacterial | <5 % Hemolysis at 128 µM | Human | Synthetic | NA | Non-hemolytic | ||
| 35323465 | 2022 | KWCI RVCRNGVCYRRCR | CT5 | Free | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | <2.5 % Hemolysis at 128 µM | Human | Synthetic | NA | Non-hemolytic | ||
| 35323465 | 2022 | RVC FRVCRNGVCYRRCW | CT6 | Free | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | <2.5 % Hemolysis at 128 µM | Human | Synthetic | NA | Non-hemolytic | ||
| 35323465 | 2022 | RVCIRVCYRGVCYRRCW | CT7 | Free | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 50 % Hemolysis at 128 µM | Human | Synthetic | NA | Low hemolytic | ||
| 35323465 | 2022 | KWCFRVCYRGICYRRCR | Tachyplesin-1 | Free | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | <5 % Hemolysis at 128 µM | Human | Synthetic | NA | Non-hemolytic | ||
| 35123230 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antibacterial, Antibiofilm | 96 ± 2.1 % Hemolysis at 5 µg/mL | Human | Synthetic | NA | NA | ||
| 35123230 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antibacterial, Antibiofilm | 80.5 ± 2.3 % Hemolysis at 2.5 µg/mL | Human | Synthetic | NA | NA | ||
| 35123230 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antibacterial, Antibiofilm | 74.2 ± 2.2 % Hemolysis at 1.25 µg/mL | Human | Synthetic | NA | NA | ||
| 35123230 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antibacterial, Antibiofilm | 59.5 ± 1.8 % Hemolysis at 0.625 µg/mL | Human | Synthetic | NA | NA | ||
| 35123230 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antibacterial, Antibiofilm | 25 ± 1.2 % Hemolysis at 0.312 µg/mL | Human | Synthetic | NA | NA | ||
| 35123230 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antibacterial, Antibiofilm | 6 ± 0.8 % Hemolysis at 0.156 µg/mL | Human | Synthetic | NA | NA | ||
| 35123230 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antibacterial, Antibiofilm | 0 % Hemolysis at 0.078 µg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 35123230 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antibacterial, Antibiofilm | 0 % Hemolysis at 0.039 µg/mL | Human | Synthetic | NA | Non-hemolytic | ||
| 35326879 | 2022 | RRRRWWWW{cyc:N-C} | [R4W4] | Free | Free | Cyclic | L | None | 8 | Antibacterial, Cytotoxic | 80 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | RRRRWWWW | (R4W4) | Free | Free | Linear | L | None | 8 | Antibacterial, Cytotoxic | 38 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | ({conj:Levo}-{conj:C10}-KRRRWWWW) | (Levo-C10-KR3W4) | Free | Free | Linear | L | Levo = Levofloxacin covalent conjugates, C10 = 10-hydroxy decanoic acid(linker) | 8 | Antibacterial, Cytotoxic | ∼9 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | [{conj:Levo}-{conj:C10}-KRRRWWWW]{cyc:N-C} | [Levo-C10-KR3W4] | Free | Free | Cyclic | L | Levo = Levofloxacin covalent conjugates, C10 = 10-hydroxy decanoic acid(linker) | 8 | Antibacterial, Cytotoxic | ∼30 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | {conj:Levo}+ (RRRRWWWW) | Levo + (R4W4) | Free | Free | Linear | L | Levo = Levofloxacin, physical mixture of Levofloxacin and peptides (500 µg/mL (1:1; w/w)) | 8 | Antibacterial, Cytotoxic | ∼10 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35326879 | 2022 | {conj:Levo}+ [RRRRWWWW]{cyc:N-C} | Levo + [R4W4] | Free | Free | Cyclic | L | Levo = Levofloxacin, physical mixture of Levofloxacin and peptides (500 µg/mL (1:1; w/w)) | 8 | Antibacterial, Cytotoxic | ∼22 % Hemolysis at 500 µg/mL | Human | Synthetic | NA | NA | ||
| 35290038 | 2022 | LKLLKKLLKKLLKLL{ct:Amid} | Amp1L | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | ∼55 % Hemolysis at 10 µM | Human | Synthetic | α-Helix | NA | ||
| 35290038 | 2022 | L{nnr:k}LLKKLLKKLLKLL{ct:Amid} | Amp1EP2 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | ∼35 % Hemolysis at 10 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35290038 | 2022 | LKLL{nnr:k}KLLKKLLKLL{ct:Amid} | Amp1EP5 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | <10 % Hemolysis at 10 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35290038 | 2022 | LKLLK{nnr:k}LLKKLLKLL{ct:Amid} | Amp1EP6 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | <5 % Hemolysis at 10 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35290038 | 2022 | LKLLKKLL{nnr:k}KLLKLL{ct:Amid} | Amp1EP9 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | <5 % Hemolysis at 10 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35290038 | 2022 | LKLLKKLLK{nnr:k}LLKLL{ct:Amid} | Amp1EP10 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | <5 % Hemolysis at 10 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35290038 | 2022 | LKLLKKLLKKLL{nnr:k}LL{ct:Amid} | Amp1EP13 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | < 10 % Hemolysis at 10 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35290038 | 2022 | LKLLKKLLKKLLKLL{ct:Amid} | Amp1L | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | 100 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | NA | ||
| 35290038 | 2022 | L{nnr:k}LLKKLLKKLLKLL{ct:Amid} | Amp1EP2 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | 100 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35290038 | 2022 | LKLL{nnr:k}KLLKKLLKLL{ct:Amid} | Amp1EP5 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | ∼85 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35290038 | 2022 | LKLLK{nnr:k}LLKKLLKLL{ct:Amid} | Amp1EP6 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | ∼60 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35290038 | 2022 | LKLLKKLL{nnr:k}KLLKLL{ct:Amid} | Amp1EP9 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | >35 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35290038 | 2022 | LKLLKKLLK{nnr:k}LLKLL{ct:Amid} | Amp1EP10 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | <10 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35290038 | 2022 | LKLLKKLLKKLL{nnr:k}LL{ct:Amid} | Amp1EP13 | Amidation | Free | Linear | L | k = involved in isopeptide bond formation | 15 | Antibacterial | < 10 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35538042 | 2022 | FLQRIRGALGRLF | GHaR6R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 0 % Hemolysis at 3.1 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35538042 | 2022 | FLQRIRGALGRLF | GHaR6R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 0 % Hemolysis at 6.2 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35538042 | 2022 | FLQRIRGALGRLF | GHaR6R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 0 % Hemolysis at 12.5 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35538042 | 2022 | FLQRIRGALGRLF | GHaR6R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 0 % Hemolysis at 25 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35538042 | 2022 | FLQRIRGALGRLF | GHaR6R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 0 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35538042 | 2022 | FLQRIRGALGRLF | GHaR6R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 0 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35538042 | 2022 | FLQRIRGALGRLF | GHaR6R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 0 % Hemolysis at 200 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35538042 | 2022 | FLQRIIRALGRLF | GHaR7R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | >85 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | NA | ||
| 35538042 | 2022 | FLQRIIRALGRLF | GHaR7R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 50 % Hemolysis at 25 µM | Human | Synthetic | α-Helix | NA | ||
| 35538042 | 2022 | FLQRIIRALGRLF | GHaR7R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | >100 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35538042 | 2022 | FLQRIIGRLGRLF | GHaR8R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | ∼1 % Hemolysis at 25 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35538042 | 2022 | FLQRIIGRLGRLF | GHaR8R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | <10 % Hemolysis at 50 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35538042 | 2022 | FLQRIIGRLGRLF | GHaR8R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | <25 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35538042 | 2022 | FLQRIIGRLGRLF | GHaR8R | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | <50 % Hemolysis at 200 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35538042 | 2022 | FLQRIIGAWGRLF | GHaR9W | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 0 % Hemolysis at 12.5 µM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35538042 | 2022 | FLQRIIGAWGRLF | GHaR9W | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | ∼10 % Hemolysis at 37.5 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35538042 | 2022 | FLQRIIGAWGRLF | GHaR9W | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 62.5 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | NA | ||
| 35538042 | 2022 | FLQRIIGAWGRLF | GHaR9W | Free | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | >100 % Hemolysis at 200 µM | Human | Synthetic | α-Helix | NA | ||
| 35050481 | 2022 | TTLRLNTLAYKVAWLVNVKAFWAAGRALKKVGR | dendrocin-ZM1 | Free | Free | Linear | L | None | 34 | Antibacterial | >5 % Hemolysis at 16 μg/mL | Human | Zataria Multifora | α-Helix | Low hemolytic | ||
| 35050481 | 2022 | TTLRLNTLAYKVAWLVNVKAFWAAGRALKKVGR | dendrocin-ZM1 | Free | Free | Linear | L | None | 34 | Antibacterial | 17 % Hemolysis at 128 μg/mL | Human | Zataria Multifora | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVGMLGKLF{ct:Amid} | SHa | Amidation | Free | Linear | L | None | 13 | Antibacterial, Antibiofilm | 50 % Hemolysis at 25 µM | Human | Synthetic | α-Helix | NA | ||
| 35092568 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | <1 % Hemolysis at 2.812 µM | Human | Synthetic | α-Helix | NA | ||
| 35092568 | 2022 | FLSA{d}IVGMLGKLF{ct:Amid} | [G4a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | <1 % Hemolysis at 2.812 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVA{d}MLGKLF{ct:Amid} | [G7a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | <1 % Hemolysis at 2.812 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 1±0.62 % Hemolysis at 5.625 µM | Human | Synthetic | α-Helix | NA | ||
| 35092568 | 2022 | FLSA{d}IVGMLGKLF{ct:Amid} | [G4a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | <1 % Hemolysis at 5.625 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVA{d}MLGKLF{ct:Amid} | [G7a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | <1 % Hemolysis at 5.625 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 7±0.55 % Hemolysis at 11.25 µM | Human | Synthetic | α-Helix | NA | ||
| 35092568 | 2022 | FLSA{d}IVGMLGKLF{ct:Amid} | [G4a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | <1 % Hemolysis at 11.25 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVA{d}MLGKLF{ct:Amid} | [G7a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 1.8±0.9 % Hemolysis at 11.25 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 52.74 ± 5.94 % Hemolysis at 22.5 µM | Human | Synthetic | α-Helix | NA | ||
| 35092568 | 2022 | FLSA{d}IVGMLGKLF{ct:Amid} | [G4a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 2.88 ± 1.24 % Hemolysis at 22.5 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVA{d}MLGKLF{ct:Amid} | [G7a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 2 ± 0.94 % Hemolysis at 22.5 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 55.07 ± 5.23 % Hemolysis at 45 µM | Human | Synthetic | α-Helix | NA | ||
| 35092568 | 2022 | FLSA{d}IVGMLGKLF{ct:Amid} | [G4a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 18.18 ± 7.65 % Hemolysis at 45 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVA{d}MLGKLF{ct:Amid} | [G7a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 7.49 ± 1.20 % Hemolysis at 45 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 58.93 ± 6.02 % Hemolysis at 90 µM | Human | Synthetic | α-Helix | NA | ||
| 35092568 | 2022 | FLSA{d}IVGMLGKLF{ct:Amid} | [G4a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 42.93 ± 4.75 % Hemolysis at 90 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVA{d}MLGKLF{ct:Amid} | [G7a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 44.69 ± 3.73 % Hemolysis at 90 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 61.64 ± 13.83 % Hemolysis at 180 µM | Human | Synthetic | α-Helix | NA | ||
| 35092568 | 2022 | FLSA{d}IVGMLGKLF{ct:Amid} | [G4a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 47.60 ± 7.88 % Hemolysis at 180 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVA{d}MLGKLF{ct:Amid} | [G7a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 57.01 ± 8.50 % Hemolysis at 180 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 64.71 ± 11.34 % Hemolysis at 360 µM | Human | Synthetic | α-Helix | NA | ||
| 35092568 | 2022 | FLSA{d}IVGMLGKLF{ct:Amid} | [G4a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 51.15 ± 10.41 % Hemolysis at 360 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35092568 | 2022 | FLSGIVA{d}MLGKLF{ct:Amid} | [G7a]-SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antibacterial, Antibiofilm | 58.97 ± 5.51 % Hemolysis at 360 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKVARRTVAKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | WT | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 0.12 ± 0.07 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}RRT{nnr:X}AKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 2 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 6.6 ± 0.3 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKVARR{nnr:X}VAK{nnr:X}RE{nnr:NIe}L{nt:Acet}{ct:Amid} | 10 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 10.7 ± 0.3 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}RRT{nnr:X}AKYRE{nnr:NIe}|{nt:Acet}{ct:Amid} | 14 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 35.0 ± 0.5 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}KRT{nnr:X}AKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 17 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 3.3 ± 0.7 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}RKT{nnr:X}AKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 18 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 3.3 ± 0.05 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FKV{nnr:X}RRT{nnr:X}GKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 31 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 0.53 ± 0.05 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35647551 | 2022 | {nnr:B}FRV{nnr:X}RRT{nnr:X}AKYRE{nnr:NIe}L{nt:Acet}{ct:Amid} | 33 | Amidation | Acetylation | Stapled | L | B = β-alanine {nnr:Bala} – β-Alanine , X = (S)-2-4-(pentenyl)alanine, Z = (R)-2-(7- octenyl)alanine, Nle = Norleucine, O = Ornithine, stapled b/w X and X | 16 | Antivirulente | 1.5 ± 0.03 % Hemolysis at 100 µM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35740895 | 2022 | FLSGIVGMLGKLF | Temporin SHa | Free | Free | Linear | L | None | 13 | Antimicrobial, Antiproliferative | 50 % Hemolysis at 266.20 ± 41.27 µM | Human | Pelophylax Saharicus | α-Helix | Low hemolytic | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a] SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antimicrobial, Antiproliferative | 50 % Hemolysis at 43.66 ± 1.01 µM | Human | Analog Of Temporin-Sha | α-Helix | NA | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLFK-FLSGIVGMLDAKLF{ct:Amid} | [G10a]2 SHa | Amidation | Free | Linear | Mix | a = D-alanine, Linked b/w Phe26 and Lys40 and Lys41 and Phe39 | 27 | Antimicrobial, Antiproliferative | 50 % Hemolysis at 11.55 ± 0.38 µM | Human | Dendrimeric Analog Of Temporin-Sha | α-Helix | NA | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLFKK-FLSGIVGMLDAKLF-FLSGIVGMLDAKLF{ct:Amid} | [G10a]3 SHa | Amidation | Free | Branched | Mix | a = D-alanine, Linked b/w Lys27 and Phe27 | 41 | Antimicrobial, Antiproliferative | 50 % Hemolysis at 10.46 ± 0.36 µM | Human | Dendrimeric Analog Of Temporin-Sha | α-Helix | NA | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLF-FLSGIVGMLDAKLF{ct:Amid} | Jeff-[G10a2 SHa conjugate | Amidation | Free | Linear | Mix | Jeffamine linker b/w Phe13 and Phe26 | 26 | Antimicrobial, Antiproliferative | 50 % Hemolysis at 1926 ± 242 µM | Human | Dendrimeric Analog Of Temporin-Sha | Triple Helical | Non-hemolytic | ||
| 35740895 | 2022 | FLSGIVGMLGKLF | Temporin SHa | Free | Free | Linear | L | None | 13 | Antimicrobial, Antiproliferative | 24.54 ± 1.88 % Hemolysis at 100 µM | Human | Pelophylax Saharicus | α-Helix | Low hemolytic | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLF{ct:Amid} | [G10a] SHa | Amidation | Free | Linear | Mix | a = D-alanine | 13 | Antimicrobial, Antiproliferative | 102.03 ± 6.18 % Hemolysis at 100 µM | Human | Analog Of Temporin-Sha | α-Helix | NA | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLFK-FLSGIVGMLDAKLF{ct:Amid} | [G10a]2 SHa | Amidation | Free | Linear | Mix | a = D-alanine, Linked b/w Phe26 and Lys40 and Lys41 and Phe39 | 27 | Antimicrobial, Antiproliferative | 100 % Hemolysis at 100 µM | Human | Dendrimeric Analog Of Temporin-Sha | α-Helix | NA | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLFKK-FLSGIVGMLDAKLF-FLSGIVGMLDAKLF{ct:Amid} | [G10a]3 SHa | Amidation | Free | Branched | Mix | a = D-alanine, Linked b/w Lys27 and Phe27 | 41 | Antimicrobial, Antiproliferative | 100 % Hemolysis at 100 µM | Human | Dendrimeric Analog Of Temporin-Sha | α-Helix | NA | ||
| 35740895 | 2022 | FLSGIVGMLA{d}KLF-FLSGIVGMLDAKLF{ct:Amid} | Jeff-[G10a2 SHa conjugate | Amidation | Free | Linear | Mix | a = D-alanine, Jeffamine linker b/w Phe13 and Phe26 | 26 | Antimicrobial, Antiproliferative | 24.01 ± 5.06 % Hemolysis at 100 µM | Human | Dendrimeric Analog Of Temporin-Sha | Triple Helical | Non-hemolytic | ||
| 35814659 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial, Cytotoxic | 6 % Hemolysis at 0.156 µg/mL | Human | Apis Mellifera | α-Helix | NA | ||
| 35814659 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial, Cytotoxic | 0 % Hemolysis at 0.039 µg/mL | Human | Apis Mellifera | α-Helix | NA | ||
| 35814659 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial, Cytotoxic | 0 % Hemolysis at 0.019 µg/mL | Human | Apis Mellifera | α-Helix | NA | ||
| 35814659 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial, Cytotoxic | 0 % Hemolysis at 0.009 µg/mL | Human | Apis Mellifera | α-Helix | NA | ||
| 35814659 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial, Cytotoxic | 0 % Hemolysis at 0.004 µg/mL | Human | Apis Mellifera | α-Helix | NA | ||
| 35814659 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial, Cytotoxic | 50 % Hemolysis at 1.48 µg/mL | Human | Apis Mellifera | α-Helix | NA | ||
| 35814659 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial, Cytotoxic | 91.6 % Hemolysis at 5 µg/mL | Human | Apis Mellifera | α-Helix | NA | ||
| 35814659 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ | Melittin | Free | Free | Linear | L | None | 26 | Antimicrobial, Cytotoxic | 80.5 % Hemolysis at 45327 µg/mL | Human | Apis Mellifera | α-Helix | NA | ||
| 35616397 | 2022 | GAIPKCCVGTSRNIPLSILMRVERYDVOHNHGACEIDAWLHANGRKYCADPRVKKVLGVAMQIRKAQLMREKLNSIMRR | omCK11 | Free | Free | Linear | L | None | 79 | Antibacterial, Antibiofilm | <1 % Hemolysis at 250 µg/mL | Human | Oncorhynchus Mykiss | α-Helix | NA | ||
| 35616397 | 2022 | AHPKVKRKLKRMQRKKDGKQKRH | omCCL28-like-23 | Free | Free | Linear | L | None | 23 | Antibacterial, Antibiofilm | <1 % Hemolysis at 250 µg/mL | Human | Synthetic; Omck11 Analogues | α-Helix | NA | ||
| 35616397 | 2022 | ATPKMEQFLQKLMKRMARLKASAV | drCCL27b-24 | Free | Free | Linear | L | None | 24 | Antibacterial, Antibiofilm | <1 % Hemolysis at 250 µg/mL | Human | Synthetic; Omck11 Analogues | α-Helix | NA | ||
| 35616397 | 2022 | AHPKWMEVRSRQRKKKHNKRRATY | IcCCL28-25 | Free | Free | Linear | L | None | 24 | Antibacterial, Antibiofilm | <1 % Hemolysis at 250 µg/mL | Human | Synthetic; Omck11 Analogues | α-Helix | NA | ||
| 35616397 | 2022 | APLKMKAILEIVHRRMKQNKMKAAF | smCCL27b-25 | Free | Free | Linear | L | None | 25 | Antibacterial, Antibiofilm | <1 % Hemolysis at 250 µg/mL | Human | Synthetic; Omck11 Analogues | α-Helix | NA | ||
| 35616397 | 2022 | VDQTVFKDIWWRMKQWKQRVKKRAAKYNV | trCCL28-29 | Free | Free | Linear | L | None | 29 | Antibacterial, Antibiofilm | <1 % Hemolysis at 250 µg/mL | Human | Synthetic; Omck11 Analogues | α-Helix | NA | ||
| 35616397 | 2022 | AHPRIKKHLDLLMKKKRHLAMKIAAP | chCCL27a-26 | Free | Free | Linear | L | None | 26 | Antibacterial, Antibiofilm | <1 % Hemolysis at 250 µg/mL | Human | Synthetic; Omck11 Analogues | α-Helix | NA | ||
| 35378215 | 2022 | MDKLQLKGMSYSMCTGKF | PD1 CD44 | Free | Free | Linear | L | None | 18 | Antiviral | 8 % Hemolysis at 196.3 µM | Human | Human | α-Helix | NA | ||
| 35526666 | 2022 | FFSLIPSLVGGLISAFK{ct:Amid} | Stig (stigmurin) | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 0 % Hemolysis at 150–1.17 µM | Human | Tityus Stigmurus | α-Helix | Non-hemolytic | ||
| 35526666 | 2022 | FFSLIPKLVGKLISAFK{ct:Amid} | StigA8 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 11.5 % Hemolysis at 9.17 µM | Human | Synthetic; Analog Of Stigmurin | α-Helix | Non-hemolytic | ||
| 35526666 | 2022 | FFSLIPKLVGKLIKAFK{ct:Amid} | StigA18 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 14 % Hemolysis at 9.17 µM | Human | Synthetic; Analog Of Stigmurin | α-Helix | Non-hemolytic | ||
| 35526666 | 2022 | FFSLIPKLVGKLISAFK{ct:Amid} | StigA8 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 15 % Hemolysis at 150 µM | Human | Synthetic; Analog Of Stigmurin | α-Helix | Non-hemolytic | ||
| 35526666 | 2022 | FFSLIPKLVGKLIKAFK{ct:Amid} | StigA18 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 22 % Hemolysis at 150 µM | Human | Synthetic; Analog Of Stigmurin | α-Helix | Non-hemolytic | ||
| 35526666 | 2022 | FFSLIPSLVKKLIKAFK{ct:Amid} | StigA25 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 100 % Hemolysis at 150 µM | Human | Synthetic; Analog Of Stigmurin | NA | NA | ||
| 35526666 | 2022 | FFKLIPKLVKKLIKAFK{ct:Amid} | StigA31 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 80 % Hemolysis at 150 µM | Human | Synthetic; Analog Of Stigmurin | NA | NA | ||
| 35526666 | 2022 | FLSLIPSLVGGSISAFK{ct:Amid} | TsAP-1 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 5 % Hemolysis at 160 µM | Human | T. Serrulatus Scorpion | NA | NA | ||
| 35526666 | 2022 | FLGMIPGLIGGLISAFK{ct:Amid} | TsAP-2 | Amidation | Free | Linear | L | None | 17 | Antibacterial, Antibiofilm | 86 % Hemolysis at 40 µM | Human | T. Serrulatus Scorpion | NA | NA | ||
| 35891269 | 2022 | KLFGKVGNLLQKGWQKIKNIGRRIKDFFRNIRPMQEA{ct:Amid} | To-KL37 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Antifungal | 16 % Hemolysis at 50 µM | Human | Cathelicidin-Derived | NA | Low hemolytic | ||
| 35847280 | 2022 | QR{d}W{d}GL{d}SL{d}APYK{d}NFR{d}R{d}L{d}S | ASU2056 | Free | Free | Linear | Mix | Lower-case letters signify D-amino acids | 17 | Antimicrobial | <1 % Hemolysis at 32 µM | Human | Synthetic | NA | Low hemolytic | ||
| 35847280 | 2022 | QR{d}W{d}GL{d}SL{d}APYK{d}NFR{d}R{d}L{d}S | ASU2056 | Free | Free | Linear | Mix | Lower-case letters signify D-amino acids | 17 | Antimicrobial | <1 % Hemolysis at 64 µM | Human | Synthetic | NA | Low hemolytic | ||
| 35847280 | 2022 | QR{d}W{d}GL{d}SL{d}APYK{d}NFR{d}R{d}L{d}S | ASU2056 | Free | Free | Linear | Mix | Lower-case letters signify D-amino acids | 17 | Antimicrobial | <1 % Hemolysis at 128 µM | Human | Synthetic | NA | Low hemolytic | ||
| 35847280 | 2022 | VGR{d}W{d}SAR{d}YNFR{d}W{d}R{d}K{d}SGL{d} | ASU2060 | Free | Free | Linear | Mix | Lower-case letters signify D-amino acids | 17 | Antimicrobial | <0.1 % Hemolysis at 8 µM | Human | Synthetic | NA | Low hemolytic | ||
| 35847280 | 2022 | VGR{d}W{d}SAR{d}YNFR{d}W{d}R{d}K{d}SGL{d} | ASU2060 | Free | Free | Linear | Mix | Lower-case letters signify D-amino acids | 17 | Antimicrobial | <0.1 % Hemolysis at 16 µM | Human | Synthetic | NA | Low hemolytic | ||
| 35847280 | 2022 | VGR{d}W{d}SAR{d}YNFR{d}W{d}R{d}K{d}SGL{d} | ASU2060 | Free | Free | Linear | Mix | Lower-case letters signify D-amino acids | 17 | Antimicrobial | <0.1 % Hemolysis at 32 µM | Human | Synthetic | NA | Low hemolytic | ||
| 35834028 | 2022 | GLLSVFKGVLKTAGKNVAKNVAGSLLDQLKCKISGGC | B2CE | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at 56.92 µM | Human | Chinese Forest Frog Rana Chensinensis | α-Helix | Low hemolytic | ||
| 35834028 | 2022 | GLLSVFKGVLKTAGKNVAKNVAGSLLDQLKCKISGGC | B2CE-nonDS | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at 130.27 µM | Human | B2Ce Analogs | α-Helix | Low hemolytic | ||
| 35834028 | 2022 | GLLSVFKGVLKTAGKNVAKNVAGSLLDQLKSKISGGS | B2CE-C31,37 S | Free | Free | Linear | L | None | 37 | Antimicrobial | 50 % Hemolysis at 25 µM | Human | B2Ce Analogs | α-Helix | NA | ||
| 35834028 | 2022 | GLLSVFKGVLKTAGKNVAKNVAGSLL | B2CE-N26 | Free | Free | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | B2Ce Analogs | α-Helix | Low hemolytic | ||
| 35834028 | 2022 | GLLSKFKGVLKTAGKNVAKNVAGSLL | B2CE-N26-V5K | Free | Free | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | B2Ce Analogs | α-Helix | Low hemolytic | ||
| 35834028 | 2022 | GLLSVFKGVLKTAGKWVKKNVAKSLL | B2CE-N26- N16WA18KG23K | Free | Free | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at 30.68 µM | Human | B2Ce Analogs | α-Helix | NA | ||
| 35834028 | 2022 | GLLSVFKGVLKTAGK | B2-N15 | Free | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | B2Ce Analogs | α-Helix | Low hemolytic | ||
| 35834028 | 2022 | GLLSVFKKVLKTAGK | B2-N15-G8K | Free | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at >150 µM | Human | B2Ce Analogs | α-Helix | Low hemolytic | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}L{d}{ct:Amid} | BP214 | Amidation | Free | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 41 % Hemolysis at 150 μM | Human | Synthetic | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}L{d}{nt:lipidated (C4)}{ct:Amid} | 1 | Amidation | lipidated (C4) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 100 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp214 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}L{d}{nt:lipidated (C6)}{ct:Amid} | 2 | Amidation | lipidated (C6) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 100 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp215 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}L{d}{nt:lipidated (C8)}{ct:Amid} | 3 | Amidation | lipidated (C8) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 100 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp216 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}L{d}{nt:lipidated (C10)}{ct:Amid} | 4 | Amidation | lipidated (C10) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 100 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp217 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}L{d}{nt:lipidated (C12)}{ct:Amid} | 5 | Amidation | lipidated (C12) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 100 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp218 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}L{d}{nt:lipidated (C14)}{ct:Amid} | 6 | Amidation | lipidated (C14) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 100 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp219 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{ct:Amid} | 7 | Amidation | Free | Linear | D | Lower-case letters signify D-amino acids | 11 | Antimicrobial | 3 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp220 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{ct:Amid} | 8 | Amidation | Free | Linear | D | Lower-case letters signify D-amino acids | 11 | Antimicrobial | 3 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp221 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{ct:Amid} | 9 | Amidation | Free | Linear | D | Lower-case letters signify D-amino acids | 11 | Antimicrobial | 3 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp222 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{nt:lipidated (C10)}{ct:Amid} | 10 | Amidation | lipidated (C10) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 81 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp223 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{nt:lipidated (C12)}{ct:Amid} | 11 | Amidation | lipidated (C12) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 96 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp224 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{nt:lipidated (C14)}{ct:Amid} | 12 | Amidation | lipidated (C14) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 95 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp225 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{nt:lipidated (C10)}{ct:Amid} | 13 | Amidation | lipidated (C10) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 36 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp226 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{nt:lipidated (C12)}{ct:Amid} | 14 | Amidation | lipidated (C12) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 98 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp227 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{nt:lipidated (C14)}{ct:Amid} | 15 | Amidation | lipidated (C14) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 83 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp228 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{nt:lipidated (C10)}{ct:Amid} | 16 | Amidation | lipidated (C10) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 59 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp229 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{nt:lipidated (C12)}{ct:Amid} | 17 | Amidation | lipidated (C12) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 100 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp230 | NA | NA | ||
| 36009951 | 2022 | K{d}K{d}L{d}F{d}K{d}K{d}I{d}L{d}R{d}Y{d}K{d}{nt:lipidated (C14)}{ct:Amid} | 18 | Amidation | lipidated (C14) | Linear | D | C= lipidated; Lower-case letters signify D-amino acids | 11 | Antimicrobial | 94 % Hemolysis at 150 μM | Human | Synthetic; C-Locked Analog Of Bp231 | NA | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 50 % Hemolysis at >256 μg/mL | Human | Synthetic | β-Sheets | Low hemolytic | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 50 % Hemolysis at >256 μg/mL | Human | Synthetic | β-Sheets | Low hemolytic | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 50 % Hemolysis at >256 μg/mL | Human | Synthetic | β-Sheets | Low hemolytic | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 50 % Hemolysis at 145 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 50 % Hemolysis at 47 μg/mL | Human | Synthetic | β-Sheets | Non-hemolytic | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 50 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | Non-hemolytic | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 50 % Hemolysis at >256 μg/mL | Human | Synthetic | β-Sheets | Non-hemolytic | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 50 % Hemolysis at 3 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 50 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at 9 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 50 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 50 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 50 % Hemolysis at <1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 50 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 50 % Hemolysis at <1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 50 % Hemolysis at <1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 50 % Hemolysis at <1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at <1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 0 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 2 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 11 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 5 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 9 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 9 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 47 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 29 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 37 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 33 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 56 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 58 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 57 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 52 % Hemolysis at 1 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 1 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 5 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 6 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 12 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 8 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 19 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 22 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 86 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 55 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 59 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 80 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 77 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 87 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 94 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 71 % Hemolysis at 2 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 1 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 7 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 8 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 16 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 10 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 31 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 33 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 96 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 74 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 59 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 95 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 80 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 87 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 94 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 72 % Hemolysis at 4 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 3 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 9 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 9 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 20 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 9 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 48 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 46 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 96 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 86 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 69 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 95 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 76 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 77 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 92 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 72 % Hemolysis at 8 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 2 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 9 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 9 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 28 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 12 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 72 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 64 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 95 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 93 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 68 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 90 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 59 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 53 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 81 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at 16 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 2 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 10 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 11 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 40 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 15 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 86 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 81 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 94 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 94 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 51 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 82 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 37 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 49 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 81 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 47 % Hemolysis at 32 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 4 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 12 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 14 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 59 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 20 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 94 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 90 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 94 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 97 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 41 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 79 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 30 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 49 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 82 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 47 % Hemolysis at 64 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 6 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 16 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 18 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 81 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 29 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 98 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 93 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 91 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 97 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 35 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 78 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 29 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 50 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 84 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 42 % Hemolysis at 128 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKL{ct:Amid} | KL6 | Amidation | Free | Linear | L | None | 6 | Antimicrobial | 7 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKL{ct:Amid} | KL8 | Amidation | Free | Linear | L | None | 8 | Antimicrobial | 0 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLK{ct:Amid} | KL9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 21 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKL{ct:Amid} | LK9 | Amidation | Free | Linear | L | None | 9 | Antimicrobial | 20 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKL{ct:Amid} | KL10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 94 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLK{ct:Amid} | LK10 | Amidation | Free | Linear | L | None | 10 | Antimicrobial | 43 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLK{ct:Amid} | KL11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 100 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKL{ct:Amid} | LK11 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 100 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKL{ct:Amid} | KL12 | Amidation | Free | Linear | L | None | 12 | Antimicrobial | 89 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLK{ct:Amid} | KL13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 99 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKL{ct:Amid} | LK13 | Amidation | Free | Linear | L | None | 13 | Antimicrobial | 32 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKL{ct:Amid} | KL14 | Amidation | Free | Linear | L | None | 14 | Antimicrobial | 78 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLK{ct:Amid} | KL15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 0 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | LKLKLKLKLKLKLKL{ct:Amid} | LK15 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 31 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKL{ct:Amid} | KL16 | Amidation | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKL{ct:Amid} | KL18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | 48 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL20 | Amidation | Free | Linear | L | None | 20 | Antimicrobial | 0 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL22 | Amidation | Free | Linear | L | None | 22 | Antimicrobial | 87 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL24 | Amidation | Free | Linear | L | None | 24 | Antimicrobial | 0 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 36140173 | 2022 | KLKLKLKLKLKLKLKLKLKLKLKLKL{ct:Amid} | KL26 | Amidation | Free | Linear | L | None | 26 | Antimicrobial | 39 % Hemolysis at 256 μg/mL | Human | Synthetic | β-Sheets | NA | ||
| 35779173 | 2022 | GIGAVLKVLTTGLPALIKRKRQQ{ct:Amid} | MDP1 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at 30 µg/mL | Human | Synthetic | α-Helix | NA | ||
| 35779173 | 2022 | GIGAVLKVLTTGLPALIKRKRQQ{ct:Amid} | MDP2 | Amidation | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolysis at 24 µg/mL | Human | Synthetic | α-Helix | NA | ||
| 35779173 | 2022 | GIGAVLKVLTTGLPALISWIKRKRQQ{nt:H}{ct:Amid} | melittin | Amidation | H | Linear | L | None | 26 | Antimicrobial | 50 % Hemolysis at 0.47 µg/mL | Human | Snake | α-Helix | NA | ||
| 35812346 | 2022 | RRRRRRRRRRRRRRRRRR{nt:H}{ct:OH} | R18 (acetate) | OH | H | Linear | L | None | 18 | Mast cell degranulation inducer | low Hemolysis at 16 μM | Human | Synthetic | NA | Low hemolytic | ||
| 35812346 | 2022 | RRRRRRRRRRRRRRRRRR{nt:H}{ct:OH} | R18 (HCl) | OH | H | Linear | L | None | 18 | Mast cell degranulation inducer | No Hemolysis at 16 μM | Human | Synthetic | NA | Non-hemolytic | ||
| 35812346 | 2022 | R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}R{d}{nt:H}{ct:OH} | R18D (acetate) | OH | H | Linear | D | Lower case r = d-arginine | 18 | Mast cell degranulation inducer | No Hemolysis at 16 μM | Human | Synthetic | NA | Non-hemolytic | ||
| 35812346 | 2022 | GRKKRRQRRRKLSSIESDV{nt:H}{ct:OH} | Tat-NR2B9c (TFA) | OH | H | Linear | L | TFA = Trifluoroacetic acid | 19 | Mast cell degranulation inducer | No Hemolysis at 16 μM | Human | Synthetic | NA | Non-hemolytic | ||
| 35812346 | 2022 | PRRRRSSSRPIRRRRPRRASRRRRRGGRRRR{nt:H}{ct:OH} | Protamine (sulfate) | OH | H | Linear | L | None | 31 | Mast cell degranulation inducer | No Hemolysis at 16 μM | Human | Synthetic | NA | Non-hemolytic | ||
| 35852614 | 2022 | FLGAVLKVAGKLVPAAICKISKKC | BR-1GHa | Free | Free | Linear | L | None | 24 | Antimicrobial | 16 % Hemolysis at 1 μM | Human | Hylarana Guentheri | α-Helix | NA | ||
| 35852614 | 2022 | FLGAVLKVAGKLVPAAICKISKKC | BR-1GHa | Free | Free | Linear | L | None | 24 | Antimicrobial | 100 % Hemolysis at 8 μM | Human | Synthetic; Br-1Gha Analogue | α-Helix | NA | ||
| 35852614 | 2022 | FLGAVLKVAGKLV | BR-1GHa-1 | Free | Free | Linear | L | None | 11 | Antimicrobial | 12 % Hemolysis at 128 μM | Human | Synthetic; Br-1Gha Analogue | α-Helix | Non-hemolytic | ||
| 35852614 | 2022 | FLGAVLKVLGKLV{ct:Amid} | BR-1GHa-2 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 20.7 % Hemolysis at 16 μM | Human | Synthetic; Br-1Gha Analogue | α-Helix | NA | ||
| 35852614 | 2022 | FLGLVLKVLGKLV{ct:Amid} | BR-1GHa-3 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 48.2 % Hemolysis at 16 μM | Human | Synthetic; Br-1Gha Analogue | α-Helix | NA | ||
| 35852614 | 2022 | FLPLVLKVLGKLV{ct:Amid} | BR-1GHa-4 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 13.4 % Hemolysis at 64 μM | Human | Synthetic; Br-1Gha Analogue | α-Helix | NA | ||
| 35852614 | 2022 | FLPLVLKVLGKLV{ct:Amid} | BR-1GHa-4 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 69.4 % Hemolysis at 128 μM | Human | Synthetic; Br-1Gha Analogue | α-Helix | NA | ||
| 35852614 | 2022 | FLPLVLKVLGKLL{ct:Amid} | BR-1GHa-5 | Amidation | Free | Linear | L | None | 11 | Antimicrobial | 0 % Hemolysis at 32 μM | Human | Synthetic; Br-1Gha Analogue | α-Helix | NA | ||
| 35861280 | 2022 | KLLPSVVGLFKKKKQ{ct:Amid} | At1 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 4 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | KLLKKVVKLFKKKKK{ct:Amid} | At2 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 4 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | KLLKKVVKLFKKLLK{ct:Amid} | At3 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 32 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | KLLKKLLKLLKKLLK{ct:Amid} | At4 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 0.4 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | KIIKKIIKIIKKIIK{ct:Amid} | At5 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 32.3 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | KVVKKVVKVVKKVVK{ct:Amid} | At6 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 4 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | KIIKKIKKKIKKIIK{ct:Amid} | At7 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 32 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | KLLKKLKKKLKKLLK{ct:Amid} | At8 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 129 μM | Human | Synthetic | α-Helix | Non-hemolytic | ||
| 35861280 | 2022 | KVVKKVKKKVKKVVK{ct:Amid} | At9 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 4 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | IKKIIKIIKKIIKKI{ct:Amid} | At10 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | ~30 % Hemolysis at 200 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | IKKIIKIIKKIIKKI{ct:Amid} | At10 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 32.3 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | IIIKKIKKKIKKIII{ct:Amid} | At11 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 32.3 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35861280 | 2022 | KIIIKIKKKIKIIIK{ct:Amid} | At12 | Amidation | Free | Linear | L | None | 15 | Antimicrobial | 10 % Hemolysis at 32 μM | Human | Synthetic | α-Helix | Low hemolytic | ||
| 35640793 | 2022 | GVFKDALKQLGAALLDKAANALKPK{nt:H}{ct:OH} | Picturin-1 | OH | H | Linear | L | None | 25 | Antimicrobial | 8.8 % Hemolysis at 198.37 (512) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GVFKDALKQFGAALLDKAANALKPK{nt:H}{ct:OH} | Picturin-2 | OH | H | Linear | L | None | 25 | Antimicrobial | 4.5 % Hemolysis at 195.79 (512) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GVFKDALKQFGAALLDQAANALKPK{nt:H}{ct:OH} | Picturin-3 | OH | H | Linear | L | None | 25 | Antimicrobial | 88.1 % Hemolysis at 195.91 (512) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGRIALNVLT{nt:H}{ct:Amid} | Pictuseptin-1 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 61.6 % Hemolysis at 218.54 (512) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGGIALNVLT{nt:H}{ct:Amid} | Pictuseptin-2 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 33 % Hemolysis at 228.20 (512) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGKVALDVAKNVLT{nt:H}{ct:Amid} | Pictuseptin-3 | Amidation | H | Linear | L | None | 26 | Antimicrobial | 22.3 % Hemolysis at 188.64 (512) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GVFKDALKQLGAALLDKAANALKPK{nt:H}{ct:OH} | Picturin-1 | OH | H | Linear | L | None | 25 | Antimicrobial | 3.88 % Hemolysis at 99.19 (256) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GVFKDALKQFGAALLDKAANALKPK{nt:H}{ct:OH} | Picturin-2 | OH | H | Linear | L | None | 25 | Antimicrobial | 2.8 % Hemolysis at 97.89 (256) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GVFKDALKQFGAALLDQAANALKPK{nt:H}{ct:OH} | Picturin-3 | OH | H | Linear | L | None | 25 | Antimicrobial | 28.3 % Hemolysis at 97.85 (256) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGRIALNVLT{nt:H}{ct:Amid} | Pictuseptin-1 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 54.9 % Hemolysis at 209.27 (256) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGGIALNVLT{nt:H}{ct:Amid} | Pictuseptin-2 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 15 % Hemolysis at 114.1 (256) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGKVALDVAKNVLT{nt:H}{ct:Amid} | Pictuseptin-3 | Amidation | H | Linear | L | None | 26 | Antimicrobial | 8.3 % Hemolysis at 94.32 (256) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GVFKDALKQLGAALLDKAANALKPK{nt:H}{ct:OH} | Picturin-1 | OH | H | Linear | L | None | 25 | Antimicrobial | 0.67 % Hemolysis at 49.59 (128) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GVFKDALKQFGAALLDKAANALKPK{nt:H}{ct:OH} | Picturin-2 | OH | H | Linear | L | None | 25 | Antimicrobial | 1.4 % Hemolysis at 48.95 (128) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GVFKDALKQFGAALLDQAANALKPK{nt:H}{ct:OH} | Picturin-3 | OH | H | Linear | L | None | 25 | Antimicrobial | 0 % Hemolysis at 48.98 (128) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGRIALNVLT{nt:H}{ct:Amid} | Pictuseptin-1 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 29.2 % Hemolysis at 54.64 (128) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGGIALNVLT{nt:H}{ct:Amid} | Pictuseptin-2 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 8 % Hemolysis at 57.05 (128) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGKVALDVAKNVLT{nt:H}{ct:Amid} | Pictuseptin-3 | Amidation | H | Linear | L | None | 26 | Antimicrobial | 4.1 % Hemolysis at 47.16 (128) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGRIALNVLT{nt:H}{ct:Amid} | Pictuseptin-1 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 12 % Hemolysis at 27.32 (64) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGGIALNVLT{nt:H}{ct:Amid} | Pictuseptin-2 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 3 % Hemolysis at 28.52 (64) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGKVALDVAKNVLT{nt:H}{ct:Amid} | Pictuseptin-3 | Amidation | H | Linear | L | None | 26 | Antimicrobial | 1.2 % Hemolysis at 23.58 (64) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGRIALNVLT{nt:H}{ct:Amid} | Pictuseptin-1 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 5.3 % Hemolysis at 13.66 (32) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGGIALNVLT{nt:H}{ct:Amid} | Pictuseptin-2 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 1 % Hemolysis at 14.26 (32) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGKVALDVAKNVLT{nt:H}{ct:Amid} | Pictuseptin-3 | Amidation | H | Linear | L | None | 26 | Antimicrobial | 0.1 % Hemolysis at 11.79 (32) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 35640793 | 2022 | GFLDTLKNIGKTVGRIALNVLT{nt:H}{ct:Amid} | Pictuseptin-1 | Amidation | H | Linear | L | None | 22 | Antimicrobial | 1.7 % Hemolysis at 6.83 (16) μM (mg/L) | Human | Boana Picturata | α-Helix | NA | ||
| 36144584 | 2022 | FRIMRILRVLKL | pept_1 | Free | Free | Linear | L | None | 12 | Antimicrobial | 30 % Hemolysis at 50 μM | Human | Synthetic | NA | NA | ||
| 36144584 | 2022 | FRIMRILRVLK | pept_2 | Free | Free | Linear | L | None | 11 | Antimicrobial | <10 % Hemolysis at 50 μM | Human | Synthetic | NA | Low hemolytic | ||
| 36144584 | 2022 | RWRLVCFLCRRKKV | pept_3 | Free | Free | Linear | L | None | 14 | Antimicrobial | 22 % Hemolysis at 50 μM | Human | Synthetic | NA | Low hemolytic | ||
| 36144584 | 2022 | KFKKVIWKSFL | pept_4 | Free | Free | Linear | L | None | 11 | Antimicrobial | ∼5 % Hemolysis at 50 μM | Human | Synthetic | NA | Low hemolytic | ||
| 36144584 | 2022 | RPILIRVRRIRVI | pept_5 | Free | Free | Linear | L | None | 13 | Antimicrobial | ∼15 % Hemolysis at 50 μM | Human | Synthetic | NA | Low hemolytic | ||
| 36144584 | 2022 | FRIMRILRVLKL | pept_1 | Free | Free | Linear | L | None | 12 | Antimicrobial | 80 % Hemolysis at 100 μM | Human | Synthetic | NA | NA | ||
| 36144584 | 2022 | FRIMRILRVLK | pept_2 | Free | Free | Linear | L | None | 11 | Antimicrobial | ∼15 % Hemolysis at 100 μM | Human | Synthetic | NA | Low hemolytic | ||
| 36144584 | 2022 | RWRLVCFLCRRKKV | pept_3 | Free | Free | Linear | L | None | 14 | Antimicrobial | ∼30 % Hemolysis at 100 μM | Human | Synthetic | NA | Low hemolytic | ||
| 36144584 | 2022 | KFKKVIWKSFL | pept_4 | Free | Free | Linear | L | None | 11 | Antimicrobial | ∼15 % Hemolysis at 100 μM | Human | Synthetic | NA | Low hemolytic | ||
| 36144584 | 2022 | RPILIRVRRIRVI | pept_5 | Free | Free | Linear | L | None | 13 | Antimicrobial | ∼35 % Hemolysis at 100 μM | Human | Synthetic | NA | Low hemolytic | ||
| 36297519 | 2022 | K{d}K{d}I{d}R{d}V{d}R{d}L{d}S{d}A{d} | M33D | Free | Free | Linear | D | None | 9 | Antimicrobial | NA | Human | Synthetic | NA | Non-hemolytic | ||
| 36297519 | 2022 | K{d}K{d}L{d}R{d}V{d}R{d}L{d}S{d}A{d} | M33i/l | Free | Free | Linear | D | None | 9 | Antimicrobial | NA | Human | Synthetic | NA | Non-hemolytic | ||
| 36299717 | 2022 | GWGAKRWGKRGWKWKRHW{ct:Amid} | GW18 | Amidation | Free | Linear | L | None | 18 | Antimicrobial | No Hemolysis at 1.32–169.01 μM | Human | Synthetic | NA | Non-hemolytic | ||
| 36287965 | 2022 | IKGIMSIVKAFLGNLR | Ca-MAP1 | Free | Free | Linear | L | None | 16 | Antimicrobial | 91.09 % Hemolysis at 72.7 μM | Human | Synthetic | NA | NA | ||
| 36287965 | 2022 | IKGIMSIVKAFLGNLR | Ca-MAP1 | Free | Free | Linear | L | None | 16 | Antimicrobial | 71.95 % Hemolysis at 36.3 μM | Human | Synthetic | NA | NA | ||
| 36287965 | 2022 | IKGIMSIVKAFLGNLR | Ca-MAP1 | Free | Free | Linear | L | None | 16 | Antimicrobial | 32.25 % Hemolysis at 18.1 μM | Human | Synthetic | NA | NA | ||
| 36287965 | 2022 | IKGIMSIVKAFLGNLR | Ca-MAP1 | Free | Free | Linear | L | None | 16 | Antimicrobial | 5 % Hemolysis at 9.1 μM | Human | Synthetic | NA | NA | ||
| 36287965 | 2022 | IKGIMSIVKAFLGNLR | Ca-MAP1 | Free | Free | Linear | L | None | 16 | Antimicrobial | 0 % Hemolysis at 4.5 μM | Human | Synthetic | NA | NA | ||
| 35972429 | 2022 | RRRLCFVRP{d}KFVVCVRRP{d} | PLP-3 | Free | Free | Linear | Mix | None | 18 | Antimicrobial | 50 % Hemolysis at 48.5 mg/L | Human | Protegrin-1 (Pg-1) Analog | β-Hairpin | Non-hemolytic | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 25.45 ± 1 % Hemolysis at 5 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 39.21 ± 1.5 % Hemolysis at 10 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 49.10 ± 1.89 % Hemolysis at 15 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 69 ± 1.3 % Hemolysis at 20 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 36364155 | 2022 | PTECQVGTTCVESS{nt:Amid} | PS14 | Free | Amidation | Linear | L | None | 14 | Anticancer, Anti-inflammatory | 77 ± 2.8 % Hemolysis at 25 μM | Human | Aphanomyces Invadans | NA | NA | ||
| 36044031 | 2022 | GSVPCGESCVWIPCIS-GILGCSCSNKVCYYN{cyc:N-C} | anpy A | Free | Free | Cyclic | L | None | 32 | Cytotoxic | 50 % Hemolysis at 22 μM | Human | Anchietea Pyrifolia | NA | NA | ||
| 36044031 | 2022 | SIPCGESCVWIPCTVTALAGCSCKNKVCYKN{cyc:N-C} | anpy B | Free | Free | Cyclic | L | None | 31 | Cytotoxic | 50 % Hemolysis at 78 μM | Human | Anchietea Pyrifolia | NA | Low hemolytic | ||
| 36044031 | 2022 | GIPCGESCVWIPCIS-SAIGCSCKNKVCYRN{cyc:N-C} | cy04 | Free | Free | Cyclic | L | None | 31 | Cytotoxic | 50 % Hemolysis at >156 μM | Human | Anchietea Pyrifolia | NA | Non-hemolytic | ||
| 36044031 | 2022 | GIPCGESCVWIPCIS-AAIGCSCKNKVCYRN{cyc:N-C} | cy017 | Free | Free | Cyclic | L | None | 31 | Cytotoxic | 50 % Hemolysis at >156 μM | Human | Anchietea Pyrifolia | NA | Non-hemolytic | ||
| 2317508 | 1990 | FLPLIAGLLGKLF{ct:Amid} | Hemolytic protein B9 | Amidation | Free | Linear | L | None | 13 | Hemolytic | 4 % Hemolysis at 1nmol/ml | Human | Rana Esculenta (Edible Frog) (Pelophylax Esculentus) | α-Helix | NA | ||
| 2317508 | 1990 | FLPLIAGLLGKLF{ct:Amid} | Hemolytic protein B9 | Amidation | Free | Linear | L | None | 13 | Hemolytic | 5 % Hemolysis at 1.5nmol/ml | Human | Rana Esculenta (Edible Frog) (Pelophylax Esculentus) | α-Helix | NA | ||
| 2317508 | 1990 | FLPLIAGLLGKLF{ct:Amid} | Hemolytic protein B9 | Amidation | Free | Linear | L | None | 13 | Hemolytic | 17 % Hemolysis at 2nmol/ml | Human | Rana Esculenta (Edible Frog) (Pelophylax Esculentus) | α-Helix | NA | ||
| 2317508 | 1990 | FLPLIAGLLGKLF{ct:Amid} | Hemolytic protein B9 | Amidation | Free | Linear | L | None | 13 | Hemolytic | 20 % Hemolysis at 2.5nmol/ml | Human | Rana Esculenta (Edible Frog) (Pelophylax Esculentus) | α-Helix | NA | ||
| 2317508 | 1990 | FLPLIAGLLGKLF{ct:Amid} | Hemolytic protein B9 | Amidation | Free | Linear | L | None | 13 | Hemolytic | 35 % Hemolysis at 3nmol/ml | Human | Rana Esculenta (Edible Frog) (Pelophylax Esculentus) | α-Helix | NA | ||
| 2317508 | 1990 | FLPLIAGLLGKLF{ct:Amid} | Hemolytic protein B9 | Amidation | Free | Linear | L | None | 13 | Hemolytic | 90 % Hemolysis at 3.5nmol/ml | Human | Rana Esculenta (Edible Frog) (Pelophylax Esculentus) | α-Helix | NA | ||
| 25561178 | 2015 | {nnr:x}ISQ{d}I{d}IST{d}A{nnr:X}I | Teixobactin | Free | Free | Linear | Mix | x = NmPhe(N-methylated phenylalanine), X = End (Enduracididine) | 11 | Anticancer, Antibacterial | No Hemolysis | Human | Eleftheria Terrae | NA | Non-hemolytic | ||
| 25329706 | 2014 | RFPGLMMKLLV | LBP/BPI (324334), ofLBP1N | Free | Free | Linear | L | None | 11 | Antibacterial, Antifungal | 45 % Hemolysis at 100μg/mL | Human | Synthetic Construct | NA | NA | ||
| 25329706 | 2014 | RFPKLMMKLLV | LBP/BPI (324334)[G4K], ofLBP2A | Free | Free | Linear | L | None | 11 | Antibacterial, Antifungal | 30 % Hemolysis at 100μg/mL | Human | Synthetic Construct | NA | NA | ||
| 25329706 | 2014 | KLVKTQLKVLK | LBP/BPI (450460), ofLBP4N | Free | Free | Linear | L | None | 11 | Antibacterial, Antifungal | 0 % Hemolysis at 100μg/mL | Human | Synthetic Construct | NA | Non-hemolytic | ||
| 25329706 | 2014 | KLVKTWLKVLK | LBP/BPI (450460)[Q6W], ofLBP5A | Free | Free | Linear | L | None | 11 | Antibacterial, Antifungal | 0 % Hemolysis at 100μg/mL | Human | Synthetic Construct | NA | Non-hemolytic | ||
| 25329706 | 2014 | MKLVKTWLKVLK | LBP/BPI (449460)[Q7W], ofLBP6A | Free | Free | Linear | L | None | 12 | Antibacterial, Antifungal | 28 % Hemolysis at 100μg/mL | Human | Synthetic Construct | NA | NA | ||
| 28002968 | 2016 | WGEAFSAGVHRLANGGNG{ct:Amid} | Leucocin A (18-35)/ WG18 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 10 % Hemolysis at >71.15μM | Human | Synthetic Construct | TFE = α-Helix | NA | ||
| 28002968 | 2016 | WGRAFSAGVHRLANGGNG{ct:Amid} | WR1 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 10 % Hemolysis at >70.09μM | Human | Synthetic Construct | TFE = Random coil | NA | ||
| 28002968 | 2016 | WGRAFSAGVHRLARGGRG{ct:Amid} | WR3 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 10 % Hemolysis at >67.01μM | Human | Synthetic Construct | TFE = α-Helix | NA | ||
| 28002968 | 2016 | WGRAFSRGVRRLARGGRG{ct:Amid} | WR5 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 10 % Hemolysis at >63.54μM | Human | Synthetic Construct | TFE = Random coil | NA | ||
| 28002968 | 2016 | WGRAFRRGVRRLARGGRR{ct:Amid} | WR7 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 10 % Hemolysis at >58.64μM | Human | Synthetic Construct | TFE = Random coil | NA | ||
| 28002968 | 2016 | WGRAFRRLVRRLARGLRR{ct:Amid} | WRL2 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 10 % Hemolysis at >55.78μM | Human | Synthetic Construct | TFE = α-Helix | NA | ||
| 28002968 | 2016 | WLRAFRRLVRRLARGLRR{ct:Amid} | WRL3 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 10 % Hemolysis at 27.22μM | Human | Synthetic Construct | TFE = α-Helix | NA | ||
| 28002968 | 2016 | WLRAFRRLVRRLARLLRR{ct:Amid} | WRL4 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal | 10 % Hemolysis at 53.18μM | Human | Synthetic Construct | TFE = α-Helix | NA | ||
| 11600395 | 2001 | KNIRRIIRKIIHIIKKYG | OV-5 | Free | Free | Linear | L | None | 18 | Antibacterial | 76 % Hemolysis at 100μM | Human | Synthetic Construct | NA | NA | ||
| 28741926 | 2017 | {nnr:Z}CRRLCYKQRCVTYCRGR{ct:Amid} | Gomesin | Amidation | Free | Linear | L | Z = pyroglutamic acid | 18 | Antibacterial, Antifungal | 47.2±6 % Hemolysis at 64μM | Human | Acanthoscurria Gomesiana [Tarantula Spider] | NA | NA | ||
| 24269514 | 2014 | GLLKKWLKKWKEFKRIVGY{ct:Amid} | peptide2 | Amidation | Free | Linear | L | None | 19 | Antibacterial | 20 % Hemolysis at 160μg/mL | Human | Synthetic Construct | α-Helix | NA | ||
| 15019209 | 2003 | GIFSKLAGKKLKNLLISGL{ct:Amid} | Esculentin-1B (1-18) | Amidation | Free | Linear | L | None | 19 | Antibacterial, Antifungal | 7 % Hemolysis at 15μM | Human | Synthetic Construct | NA | NA | ||
| 32828795 | 2020 | WPKWWKWKRRWGRKKAKKRRG | Peptide 1 | Free | Free | Linear | L | None | 21 | Antibacterial | 3.4 % Hemolysis at 100μM | Human | Synthetic Construct | NA | Low hemolytic | ||
| 24495783 | 2014 | TQQAFQKFLAAVTSALGKQYH{ct:Amid} | SHbetaAP-NH2 | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antifungal | 0 % Hemolysis at 100μg/mL | Human | C-Terminus Of Katsuwonus Pelamis Hemoglobin Beta Synthetic Construct | α-Helix Random coil | Non-hemolytic | ||
| 24495783 | 2014 | TQQAFQKFLAAVTSALGKQYH{ct:OH} | SHbetaAP-OH | OH | Free | Linear | L | None | 21 | Antibacterial, Antifungal | 0 % Hemolysis at 100μg/mL | Human | Synthetic Construct | α-Helix Random coil | Non-hemolytic | ||
| 24412436 | 2014 | VKVGINGFGRIGRLVTRAAFHGKKVEIVAIND | SJGAP (Skipjack tuna GAPDH-related AMP) | Free | Free | Linear | L | None | 32 | Antibacterial, Antifungal | 0 % Hemolysis at <100μg/mL | Human | Fish Skipjack Tuna Katsuwonus Pelamis | one Alphα-Helix Strand, two parallel Betα-Strands, and 2 Loop regions | Non-hemolytic | ||
| 33179211 | 2021 | QGWEAVAAAVASKIVGLWRNETTELLGHECKFTVKPYIKRFQLNYKGGRLWC | Cf-ALF2 | Free | Free | Linear | L | None | 52 | Antibacterial | 0 % Hemolysis at 20μM | Human | Charybdis Feriatus [Crucifix Crab] | NA | Non-hemolytic | ||
| 23711469 | 2013 | AATAKKGAKKADAPAKPKKATKPKSPKKAAKKAGAKKGVKRAGKKGAKKTTKAKK | Molluscidin-1, cgMolluscidin | Free | Free | Linear | L | None | 55 | Antibacterial, Antifungal | 0 % Hemolysis at 100μg/mL | Human | Pacific Oyster Crassostrea Gigas | α-Helix and Random coil | Non-hemolytic | ||
| 8223491 | 1993 | IIGPVLGMVGSALGGLLKKI{ct:Amid} | Peptide B Bombinin H1 | Amidation | Free | Linear | L | None | 21 | Antibacterial, hemolytic | Hemolysis at 17μM | Human | Yellow-Bellied Toad, Bombina Variegata L, Europe | NA | NA | ||
| 8223491 | 1993 | I{nnr:l}GPVLGLVGSALGGLLKKI | Bombinin H4 | Free | Free | Linear | Mix | l = D-aILe(D-alloisoleucine) | 20 | Antibacterial, hemolytic, Antifungal, candidacidal, Antiparasitic | Hemolysis at 14.6μM | Human | Yellow-Bellied Toad, Bombina Variegata L, Europe | Helix | NA | ||
| 8163497 | 1994 | GIFSKLAGKKLKNLLISGLKNVGKEVGMDVVRTGIDIAGCKIKGEC | Esculentin-1B | Free | Free | Linear | L | None | 46 | Antibacterial, Anti-diabetes, Hemolytic | Hemolytic | Human | Edible Frog, Rana Esculenta , Europe | Helix | NA | ||
| 10931184 | 2000 | GILDTIKSIASKVWNSKTVQDLKRKGINWVANKLGVSPQAA | Hadrurin | Free | Free | Linear | L | None | 41 | Antibacterial, hemolytic | 80 % Hemolysis at 20μM | Human | Venom, Hadrurus Aztecus, Mexico, North America | NA | NA | ||
| 10931184 | 2000 | GILDTIKSIASKVWNSKTVQDLKRKGINWVANKLGVSPQAA | Hadrurin | Free | Free | Linear | L | None | 41 | Antibacterial, hemolytic | 50 % Hemolysis at <10μM | Human | Venom, Hadrurus Aztecus, Mexico, North America | NA | NA | ||
| 10931184 | 2000 | G{d}I{d}L{d}D{d}T{d}I{d}K{d}S{d}I{d}A{d}S{d}K{d}V{d}W{d}N{d}S{d}K{d}T{d}V{d}Q{d}D{d}L{d}K{d}R{d}K{d}G{d}I{d}N{d}W{d}V{d}A{d}N{d}K{d}L{d}G{d}V{d}S{d}P{d}Q{d}A{d}A{d} | D-isomer Hadrurin | Free | Free | Linear | D | None | 41 | Antibacterial, hemolytic | 100 % Hemolysis at 5μM | Human | Venom, Hadrurus Aztecus, Mexico, North America | NA | NA | ||
| 9257708 | 1997 | GWLRKAAKSVGKFYYKHKYYIKAAWQIGKHAL | Styelin D | Free | Free | Linear | L | None | 32 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolysis at <10μg/mL | Human | Sea Squirt, Styela Clava | Helix | NA | ||
| 8353519 | 1993 | SIGSAFKKALPVAKKIGKAALPIAKAALP | Ceratotoxin B | Free | Free | Linear | L | None | 29 | Antibacterial Gram-, Hemolytic | Hemolytic | Human | Female Reproductive Accessory Glands, Medfly, Ceratitis Capitata | Helix | NA | ||
| 15648972 | 2004 | GVVDILKGAGKDLLAHLVGKISEKV{ct:Amid} | Ocellatin-1 | Amidation | Free | Linear | L | None | 25 | Antibacterial Gram-, Hemolytic | Hemolytic | Human | Frog Skin South American Leptodactylus Ocellatus | NA | NA | ||
| 15648972 | 2004 | GVLDIFKDAAKQILAHAAEKQI{ct:Amid} | Ocellatin-2 | Amidation | Free | Linear | L | None | 22 | Antibacterial Gram-, Hemolytic | Hemolytic | Human | Frog Skin South American Leptodactylus Ocellatus | NA | NA | ||
| 15648972 | 2004 | GVLDILKNAAKNILAHAAEQI{ct:Amid} | Ocellatin-3 | Amidation | Free | Linear | L | None | 21 | Antibacterial Gram-, Hemolytic | Hemolytic | Human | South American Frog Leptodactylus Ocellatus | NA | NA | ||
| 17698251 | 2004 | VWPLGLVICKALKIC | Dybowskin-4 | Free | Free | Linear | L | None | 15 | Antibacterial, Antifungal, candidacidal, Hemolytic | 47.58 % Hemolysis | Human | Frog Rana Dybowskii , Asia | NA | NA | ||
| 17698251 | 2004 | FLPLLLAGLPLKLCFLFKKC | Dybowskin-6 | Free | Free | Linear | L | None | 20 | Antibacterial Gram+, Antifungal, candidacidal, Hemolytic | 59.39 % Hemolysis | Human | Frog Rana Dybowskii , Asia | NA | NA | ||
| 14978112 | 2004 | RKSKEKIGKEFKRIVQRIKDFLRNLVPRTES | human RK-31 | Free | Free | Linear | L | None | 31 | Antibacterial, Antifungal, candidacidal, Hemolytic | 6 % Hemolysis at 100µM | Human | Human Protease Truncation; Human Sweat, Homo Sapiens | NA | Low hemolytic | ||
| 2317508 | 1990 | FLPLIAGLIGKLF{ct:Amid} | Peptide B9 | Amidation | Free | Linear | L | None | 13 | Hemolytic | Hemolytic | Human | Frog Rana Esculenta, Europe | NA | NA | ||
| 16207177 | 2006 | GSVLNCGETCLLGTCYTTGCTCNKYRVCTKD{cyc:N-C} | Kalata B8 | Free | Free | Cyclic | L | None | 31 | Antiviral, Anti-HIV, Hemolytic | 0 % Hemolysis at 370µM | Human | Plant African Herb, Oldenlandia Affinis | Beta | Non-hemolytic | ||
| 9022710 | 1993 | I{nnr:l}GPVLGMVGSALGGLLKKI | Bombinin H3 | Free | Free | Linear | Mix | l = D-alloisoleucine | 20 | Antibacterial, Hemolytic | Hemolytic at 15.7µM | Human | Toad, Bombina Variegata, Europe | NA | NA | ||
| 10477123 | 1999 | ALWKTMLKKLGTMALHAGKAAFGAAADTISQ | Dermaseptin-DI3 (DD M) | Free | Free | Linear | L | None | 31 | Antibacterial, Hemolytic | Hemolytic at >33µM | Human | Brazilian Frog, Phyllomedusa Distincta, South America | NA | NA | ||
| 10477123 | 1999 | ALWKTLLKNVGKAAGKAALNAVTDMVNQ | Dermaseptin-DI2 (Dermaseptin DI2, DRS-DI2, DD L) | Free | Free | Linear | L | None | 28 | Antibacterial, Antiparasitic, Hemolytic | Hemolytic at 12.5µM | Human | Brazilian Frog, Phyllomedusa Distincta, South America | NA | NA | ||
| 16872274 | 2006 | GLPTCGETCFGGTCNTPGCTCDPWPVCTHN{cyc:N-C} | Cycloviolacin O24 | Free | Free | Cyclic | L | None | 30 | Antiviral, Anti-HIV, Hemolytic | 75 % Hemolytic at 25µg/ml | Human | Plant Viola Odorata | Bridge | NA | ||
| 19254736 | 2009 | FLPAIVGAAAKFLPKIFCAISKKC | Brevinin-1BLa | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer | 50 % Hemolytic at 14µM | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 19254736 | 2009 | FLPIIAGVAAKVLPKIFCAISKKC | Brevinin-1BLb | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, Hemolytic, Anticancer | Hemolytic | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 19254736 | 2009 | FLPIIAGIAAKFLPKIFCTISKKC | Brevinin-1BLc | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer | 50 % Hemolytic at 9µM | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 19254736 | 2009 | FLPVIAGVAANFLPKLFCAISKKC | Brevinin-1Ya | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer | 50 % Hemolytic at 18µM | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 19254736 | 2009 | FLPIIAGAAAKVVEKIFCAISKKC | Brevinin-1Yc | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic, Anticancer | 50 % Hemolytic at 13µM | Human | Leopard Frog, Lithobates Yavapaiensis, North America | NA | NA | ||
| 15556063 | 2004 | FFPIIAGMAAKLIPSLFCKITKKC | Brevinin-1SPa | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 7µM | Human | Frog Rana Septentrionalis , North America | NA | NA | ||
| 15556063 | 2004 | FLPIIAGMAAKVICAITKKC | Brevinin-1SPb | Free | Free | Linear | L | None | 20 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 25µM | Human | Frog Rana Septentrionalis , North America | NA | NA | ||
| 15556063 | 2004 | FFPIIAGMAAKVICAITKKC | Brevinin-1SPd | Free | Free | Linear | L | None | 20 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 8µM | Human | Frog Rana Septentrionalis , North America | NA | NA | ||
| 21295070 | 2011 | GIFSALAAGVKLLGNTLFKMAGKAGAEHLACKATNQC | Esculentin-2PRb | Free | Free | Linear | L | None | 37 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 35µM | Human | Frog North America, The Oregon Spotted Rana Pretiosa | NA | NA | ||
| 21295070 | 2011 | FLPVLTGLTPSIVPKLVCLLTKKC | Brevinin-1PRa | Free | Free | Linear | L | None | 24 | Antibacterial Gram+, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 7µM | Human | Frog North America, The Oregon Spotted Rana Pretiosa | NA | NA | ||
| 21295070 | 2011 | FLPIITNLLGKLL{ct:Amid} | Temporin-PRb | Amidation | Free | Linear | L | None | 13 | Antibacterial Gram+, Hemolytic | 50 % Hemolytic at 35µM | Human | Frog North America, The Oregon Spotted Rana Pretiosa | NA | NA | ||
| 21338048 | 2011 | ILGPVLGLVGNALGGLIKKL{ct:Amid} | Maximin H39 | Amidation | Free | Linear | L | None | 20 | Antibacterial Gram+, Hemolytic | 50 % Hemolytic at 100µg/ml | Human | Toad Brain, Bombina Maxima, China, Asia | NA | NA | ||
| 21596752 | 2011 | GIPCGESCVFIPCITGAIGCSCKSKVCYRN{cyc:N-C} | Cliotide T1 | Free | Free | Cyclic | L | None | 30 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 7.1µM | Human | Plant Clitoria Ternatea | NA | NA | ||
| 21596752 | 2011 | GLPTCGETCTLGTCYVPDCSCSWPICMKN{cyc:N-C} | Cliotide T3 | Free | Free | Cyclic | L | None | 29 | Hemolytic, Anticancer | 50 % Hemolytic at 13.1µM | Human | Plant Clitoria Ternatea | NA | NA | ||
| 21596752 | 2011 | GIPCGESCVFIPCITAAIGCSCKSKVCYRN{cyc:N-C} | Cliotide T4 | Free | Free | Cyclic | L | None | 30 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 8.4µM | Human | Plant Clitoria Ternatea | NA | NA | ||
| 22074926 | 2012 | GGSVPCGESCVFIPCITSLAGCSCKNKVCYYD{cyc:N-C} | Parigidin-br1 | Free | Free | Cyclic | L | None | 32 | Insecticidal, Hemolytic | 28 % Hemolytic at 20µM | Human | Plant Palicourea Rigida (Rubiaceae) | Bridge | NA | ||
| 22074926 | 2012 | GGSVPCGESCVFIPCITSLAGCSCKNKVCYYD{cyc:N-C} | Parigidin-br1 | Free | Free | Cyclic | L | None | 32 | Insecticidal, Hemolytic | 41 % Hemolytic at 40µM | Human | Plant Palicourea Rigida (Rubiaceae) | Bridge | NA | ||
| 21303203 | 2011 | GLWDSIKNFGKTIALNVMDKIKCKIGGGCPP | Palustrin-2CE | Free | Free | Linear | L | None | 31 | Antibacterial, hemolytic | 50 % Hemolytic at 64µM | Human | The Chinese Brown Frog, Rana Chensinensis, China, Asia | NA | NA | ||
| 22306820 | 2012 | FALGAVTKLLPSLLCMITRKC | Hainanenin 1 | Free | Free | Linear | L | None | 21 | Antibacterial, Antifungal, hemolytic, candidacidal | 20.72 % Hemolytic at 25µg/ml | Human | Skin Secretions, Hainan Cascade-Frog, Amolops Hainanensis; China, Asia | NA | NA | ||
| 22306820 | 2012 | FALGAVTKLLPSLLCMITRKC | Hainanenin 1 | Free | Free | Linear | L | None | 21 | Antibacterial, Antifungal, hemolytic, candidacidal | 42.34 % Hemolytic at 50µg/ml | Human | Skin Secretions, Hainan Cascade-Frog, Amolops Hainanensis; China, Asia | NA | NA | ||
| 22306820 | 2012 | FALGAVTKRLPSLFCLITRKC | Hainanenin 5 | Free | Free | Linear | L | None | 21 | Antibacterial, Antifungal, hemolytic, candidacidal | 23.31 % Hemolytic at 25µg/ml | Human | Skin Secretions, Hainan Cascade-Frog, Amolops Hainanensis; China, Asia | NA | NA | ||
| 22306820 | 2012 | FALGAVTKRLPSLFCLITRKC | Hainanenin 5 | Free | Free | Linear | L | None | 21 | Antibacterial, Antifungal, hemolytic, candidacidal | 49.14 % Hemolytic at 50µg/ml | Human | Skin Secretions, Hainan Cascade-Frog, Amolops Hainanensis; China, Asia | NA | NA | ||
| 22467870 | 2012 | GDACGETCFTGICFTAGCSCNPWPTCTRN{cyc:N-C} | ChaC1 (chassatide C1) | Free | Free | Cyclic | L | None | 29 | Hemolytic, Anticancer | Hemolytic | Human | Hybrid Peptide | Bridge | NA | ||
| 22467870 | 2012 | GASCGETCFTGICFTAGCSCNPWPTCTRN{cyc:N-C} | ChaC4 (chassatide C4) | Free | Free | Cyclic | L | None | 29 | Hemolytic, Anticancer | Hemolytic | Human | Plant Chassalia Chartacea (Or Chassalia Curviflora) | Bridge | NA | ||
| 22467870 | 2012 | IPCGESCVWIPCITAIAGCSCKNKVCYT | ChaC7 (chassatide C7) | Free | Free | Linear | L | None | 28 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 11.6µM | Human | Plant Chassalia Chartacea (Or Chassalia Curviflora) | Bridge | NA | ||
| 22467870 | 2012 | AIPCGESCVWIPCISTVIGCSCSNKVCYR | ChaC8 (chassatide C8) | Free | Free | Linear | L | None | 29 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 25.5µM | Human | Plant Chassalia Chartacea (Or Chassalia Curviflora) | Bridge | NA | ||
| 22467870 | 2012 | IPCGESCVWIPCISGMFGCSCKDKVCYS | ChaC11 (chassatide C11) | Free | Free | Linear | L | None | 28 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 13.3µM | Human | Plant Chassalia Chartacea (Or Chassalia Curviflora) | Bridge | NA | ||
| 22951323 | 2012 | SLFSIFKTAAKFVGKNLLKQAGKAGLETLACKAKNEC | Esculentin-2CG1 | Free | Free | Linear | L | None | 37 | Antibacterial, Antifungal, hemolytic | 50 % Hemolytic at 75µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 22951323 | 2012 | GLWNTIKEAGKKFAINVLDKIRCGIAGGCKT | Palustrin-2CG1 | Free | Free | Linear | L | None | 31 | Antibacterial, Antifungal, hemolytic | 50 % Hemolytic at 75µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 22951323 | 2012 | FLPIVAGLAANFLPKIVCKITKKC | Brevinin-1CG2 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, hemolytic | 50 % Hemolytic at 19µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 22951323 | 2012 | FLSTLLNVASNVVPTLICKITKKC | Brevinin-1CG3 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, hemolytic | 50 % Hemolytic at 19µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 22951323 | 2012 | FLSTLLNVASKVVPTLFCKITKKC | Brevinin-1CG4 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, hemolytic | 50 % Hemolytic at 37.5µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 22951323 | 2012 | FLPMLAGLAANFLPKIVCKITKKC | Brevinin-1CG5 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, hemolytic, candidacidal | 50 % Hemolytic at 19µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 22951323 | 2012 | GILDKLKEFGISAARGVAQSLLNTTASCKLAKTC | Brevinin-2CG1 | Free | Free | Linear | L | None | 34 | Antibacterial, Antifungal, hemolytic | 50 % Hemolytic at 75µM | Human | Frog Skin Secretions, Amolops Chunganensis, China, Asia | NA | NA | ||
| 23000095 | 2012 | SGTSEKERESGRLLGVVKRLIVCFRSPFP{ct:Amid} | HsAp1 | Amidation | Free | Linear | L | None | 29 | Antibacterial, Antifungal, hemolytic | 95 % Hemolytic at 3.2µM | Human | Scorpions Venom, Heterometrus Spinifer, Asia | NA | NA | ||
| 23000095 | 2012 | SGTSEKERESGRLLGVVKRLIVCFRSPFP{ct:Amid} | HsAp1 | Amidation | Free | Linear | L | None | 29 | Antibacterial, Antifungal, hemolytic | 100 % Hemolytic at 6.4µM | Human | Scorpions Venom, Heterometrus Spinifer, Asia | NA | NA | ||
| 23000095 | 2012 | SGTSEKERESGRLLGVVKRLIVCFRSPFP{ct:Amid} | HsAp1 | Amidation | Free | Linear | L | None | 29 | Antibacterial, Antifungal, hemolytic | 35 % Hemolytic at 1.6µM | Human | Scorpions Venom, Heterometrus Spinifer, Asia | NA | NA | ||
| 18339450 | 2008 | MAADIISTIGDLVKLIINTVKKFQK | delta-lysin I | Free | Free | Linear | L | None | 25 | Antibacterial, hemolytic | 50 % Hemolytic at ~12.5µM | Human | Bacteria Staphylococcus Warneri Rk | NA | NA | ||
| 21262304 | 2011 | FLPIIAGVAAKVLPKLFCAITKKC | Brevinin-1CHa | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 5µM | Human | Skin Secretions, Chiricahua Leopard Frog, Lithobates Chiricahuensis, Arizona, Usa, North America | NA | NA | ||
| 21262304 | 2011 | FLPVIAGLAAKVLPKLFCAITKKC | Brevinin-1CHb | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 5µM | Human | Skin Secretions, Chiricahua Leopard Frog, Lithobates Chiricahuensis, Arizona, Usa, North America | NA | NA | ||
| 20308076 | 2010 | FLPAALAGIGGILGKLF | Temporin-SHd (Temp-SHd) | Free | Free | Linear | L | None | 17 | Antibacterial, Antiparasitic, Anti-MRSA, Hemolytic | 50 % Hemolytic at 44µM | Human | Skin, Pelophylax Saharica, Africa | Helix | NA | ||
| 22342498 | 2012 | FLSTLWNAAKSIF{ct:Amid} | VmCT2 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Hemolytic | 50 % Hemolytic at 35µM | Human | Scorpions Vaejovis Mexicanus Smithi | Helix | NA | ||
| 22426384 | 2012 | FLAGLIGGLAKML | Temporin-LTe | Free | Free | Linear | L | None | 13 | Antibacterial Gram+, Hemolytic | 50 % Hemolytic at 40µM | Human | Broad-Folded Frog, Hylarana Latouchii, China, Asia | NA | NA | ||
| 25066917 | 2014 | FLPLLVGAISSILPKIF{ct:Amid} | Temporin-TP2 | Amidation | Free | Linear | L | None | 17 | Antibacterial Gram+, Hemolytic | 50 % Hemolytic at 59.4µM | Human | Frog Skin Secretions, Hylarana Taipehensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | FLPLLFGALSTLLPKIF{ct:Amid} | Temporin-TP3 | Amidation | Free | Linear | L | None | 17 | Antibacterial Gram+, Hemolytic | 50 % Hemolytic at 94.6µM | Human | Frog Skin Secretions, Hylarana Taipehensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | FLPGLIKAAVGVGSTILCKITKKC | Brevinin-1TP1 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, Antioxidant, Hemolytic | 50 % Hemolytic at 44.4µM | Human | Frog Skin Secretions, Hylarana Taipehensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | FLPGLIKAAVGIGSTIFCKISKKC | Brevinin-1TP2 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Antioxidant, Hemolytic | 50 % Hemolytic at 43.1µM | Human | Frog Skin Secretions, Hylarana Taipehensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | FLPGLIKVAVGVGSTILCKITKKC | Brevinin-1TP3 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, Antioxidant, Hemolytic | 50 % Hemolytic at 65.4µM | Human | Frog Skin Secretions, Hylarana Taipehensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | FLPGLIKAAVGIGSTIFCKISRKC | Brevinin-1TP4 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 82µM | Human | Frog Skin Secretions, Hylarana Taipehensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | SILSTLKDVGISAIKSAGSGVLSTLLCKLNKNC | Brevinin-2TP1 | Free | Free | Linear | L | None | 33 | Antibacterial, Hemolytic | 50 % Hemolytic at 18.2µM | Human | Frog Skin Secretions, Hylarana Taipehensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | FLPFVGKLLSGLL{ct:Amid} | Temporin-LF1 | Amidation | Free | Linear | L | None | 13 | Antibacterial Gram+, Antifungal, Hemolytic | 50 % Hemolytic at 34.2µM | Human | Frog Skin Secretions, Amolops Lifanensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | FLPMLAGLAANFLPKIICKITKKC | Brevinin-1LF1 | Free | Free | Linear | L | None | 24 | Antibacterial Gram+, Antifungal, Antioxidant, Hemolytic | 50 % Hemolytic at 100µM | Human | Frog Skin Secretions, Amolops Lifanensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | FLPIVASLAANFLPKIICKITKKC | Brevinin-1LF2 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 68µM | Human | Frog Skin Secretions, Amolops Lifanensis, China, Asia | NA | NA | ||
| 25066917 | 2014 | GLWNTIKEAGKKFALNLLDKIRCGIAGGCKG | Palustrin-2GN1 | Free | Free | Linear | L | None | 31 | Antibacterial, Antioxidant, Hemolytic | 50 % Hemolytic at 46.4µM | Human | Frog Skin Secretions, Amolops Granulosus, China, Asia | NA | NA | ||
| 25066917 | 2014 | GILDTLKQLGKAAAQSLLSKAACKLAKTC | Palustrin-2GN3 | Free | Free | Linear | L | None | 29 | Antibacterial, Antifungal, Hemolytic | 50 % Hemolytic at 52.2µM | Human | Frog Skin Secretions, Amolops Granulosus, China, Asia | NA | NA | ||
| 32933215 | 2020 | FLPALAGIAGLLGKIF{ct:Amid} | Temporin-SHe | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal, Antiparasitic, Hemolytic | 84 % Hemolytic at 25µM | Human | Sahara Frog, Pelophylax Saharicus, Africa | Helix | NA | ||
| 31328553 | 2021 | SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC{ct:Amid} | Esculentin-2 HYba1 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 15µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 31328553 | 2021 | SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC{ct:Amid} | Esculentin-2 HYba2 | Amidation | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 12µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 31328553 | 2021 | SIFSLFKMGAKALGKTLLKQAGKAGAEYAACKATNQC | Esculentin-2 HYba1 | Free | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 10µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 31328553 | 2021 | SILSLFKMGAKALGKTLIKQAGKAGAEYVACKATNQC | Esculentin-2 HYba2 | Free | Free | Linear | L | None | 37 | Antibacterial, Anti-MRSA, Hemolytic, Anticancer | 50 % Hemolytic at 10µM | Human | Frog Skin Secretion, Hydrophylax Bahuvistara, India, Asia | NA | NA | ||
| 33508505 | 2021 | RIRIRIWRIRIRICTKSIPPIC | RI3 | Free | Free | Linear | L | None | 22 | Antibacterial, Anti-MRSA, Hemolytic | 10 % Hemolytic at 8µM | Human | Synthetic Peptide | NA | NA | ||
| 37516110 | 2023 | GSKPWWWSYFTSLSTHRPRWLLKY | CBPZ-GSK24 | Free | Free | Linear | L | None | 24 | Antibacterial Gram-, Hemolytic | 50 % Hemolytic at 19.42µM | Human | Synthetic Peptide | NA | NA | ||
| 31386688 | 2019 | LKMLGMLFHNIRNILKTV{ct:Amid} | Hs01 | Amidation | Free | Linear | L | None | 18 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at >128µM | Human | Human Prame Family Member 20 | Helix | NA | ||
| 31386688 | 2019 | KWAVRIIRKFIKGFIS{ct:Amid} | Hs02 | Amidation | Free | Linear | L | None | 16 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at >128µM | Human | Human Unconventional Myosin-Ih | Helix | NA | ||
| 31386688 | 2019 | FLREFHKWIERVVGWLGKVF{ct:Amid} | Hs03 | Amidation | Free | Linear | L | None | 20 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at >128µM | Human | Human Anaphase-Promoting Complex Subunit 2 | Helix | NA | ||
| 31386688 | 2019 | LFNNYITAALKLLEKLYKV{ct:Amid} | Hs04 | Amidation | Free | Linear | L | None | 19 | Antibacterial, Antifungal, candidacidal, Hemolytic | 50 % Hemolytic at 64µM | Human | Human Unconventional Myosin 1H Protein, Intragenic Antimicrobial Peptide, Homo Sapiens (Probable E3 Ubiquitin-Protein Ligase Herc3 Isoform 1) | Helix | NA | ||
| 37938588 | 2023 | MRRKTPVKWKTFFKALKHKKKIFKKTFEKFKFLAKGPAFLKGFDQKLKS | CFPS_AMP_5 | Free | Free | Linear | L | None | 49 | Antibacterial, Hemolytic | 50 % Hemolytic at 82.9µM | Human | Synthetic Peptide | NA | NA | ||
| 37938588 | 2023 | MYLKKFLALKNSLKKLSPFKCAVKSWLKKCAEVTFYSKLLGRRGKKDGN | CFPS_AMP_6 | Free | Free | Linear | L | None | 49 | Antibacterial, Hemolytic | 50 % Hemolytic at 73.8µM | Human | Synthetic Peptide | NA | NA | ||
| 37938588 | 2023 | MWFDRKKFFWPGVCLFLLFFPKRFYKKGPEKVFSFRKKYKFARKCKCKL | CFPS_AMP_12 | Free | Free | Linear | L | None | 49 | Antibacterial, Hemolytic | 50 % Hemolytic at 17.1µM | Human | Synthetic Peptide | NA | NA | ||
| 37938588 | 2023 | MEAFKKKPRLPLFKVKLTRFLERARGLGSYRIFEFFKKFGVKKFVSSLR | CFPS_AMP_15 | Free | Free | Linear | L | None | 49 | Antibacterial, Hemolytic | 50 % Hemolytic at 24.8µM | Human | Synthetic Peptide | NA | NA | ||
| 37938588 | 2023 | MCFFPRRKSKVKVKGGLCRLLFIFFKTTFCFKAKTKKEIKKGTGKKIVR | CFPS_AMP_18 | Free | Free | Linear | L | None | 49 | Antibacterial, Hemolytic | 50 % Hemolytic at 4.7µM | Human | Synthetic Peptide | NA | NA | ||
| 37938588 | 2023 | MSTRSSSIRRLVEAVRTRFRAALRTVLFFALRTTKRRPRR | CFPS_AMP_23 | Free | Free | Linear | L | None | 40 | Antibacterial, Hemolytic | 50 % Hemolytic at 11.5µM | Human | Synthetic Peptide | NA | NA | ||
| 37938588 | 2023 | MKKKKKGILKQNNKKKKYTLFNRMVVFLFLGFIMIIFVQKYKKVIYHK | CFPS_AMP_29 | Free | Free | Linear | L | None | 48 | Antibacterial, Hemolytic | 50 % Hemolytic at 50.6µM | Human | Synthetic Peptide | NA | NA | ||
| 28161291 | 2017 | FWRIVRWIKRWLR{ct:Amid} | FK13-a2 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-inflammatory, Hemolytic | 50 % Hemolytic at 14µM | Human | Human Cathelicidin Analog | Helix | NA | ||
| 28161291 | 2017 | FWRIVRRIWRWLR{ct:Amid} | FK13-a3 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-inflammatory, Hemolytic | 50 % Hemolytic at 12.5µM | Human | Human Cathelicidin Analog | Helix | NA | ||
| 37812567 | 2023 | RRWWRWWL | W544 | Free | Free | Linear | L | None | 8 | Antibacterial, Hemolytic | 50 % Hemolytic at 80µM | Human | Human Cathelicidin Analog | NA | NA | ||
| 27915018 | 2017 | WWWLKRIW{ct:Amid} | TetraF2W-KR | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 30µM | Human | Synthetic Peptide | Rich | NA | ||
| 27915018 | 2017 | WWWLRKIW{ct:Amid} | TetraF2W-RK | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 30µM | Human | Synthetic Peptide | Helix | NA | ||
| 27915018 | 2017 | WWWLKKIW{ct:Amid} | TetraF2W-KK | Amidation | Free | Linear | L | None | 8 | Antibacterial, Antifungal, candidacidal, Anti-MRSA, Hemolytic | 50 % Hemolytic at 40µM | Human | Synthetic Peptide | Rich | NA | ||
| 32723829 | 2020 | RRRWWWWL | WW306 (Horine-L) | Free | Free | Linear | L | None | 8 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 60µM | Human | Synthetic Peptide | Rich | NA | ||
| 9010936 | 1996 | GFFALIAKTISSPLFKTL{ct:Amid} | 18A | Amidation | Free | Linear | L | None | 18 | Antibacterial Gram+, Hemolytic | 100 % Hemolytic at 33µg/ml | Human | Synthetic Peptide | NA | NA | ||
| 38074470 | 2023 | FLGTVLKVAAKVLPAALCQIFKKC | Brevinin-1LTe | Free | Free | Linear | L | None | 24 | Antibacterial, Anti-MRSA, Hemolytic, Antibiofilm | 50 % Hemolytic at 6.4µM | Human | Skin Secretion, The Broad-Folded Frog, Hylarana Latouchii | NA | NA | ||
| 38360076 | 2024 | KWIRRIIRDYKKFFIKFII | KWI-19 | Free | Free | Linear | L | None | 19 | Antifungal, Hemolytic, Antibiofilm | 50 % Hemolytic at 10µM | Human | Synthetic Peptide | Helix | NA | ||
| 36249542 | 2022 | FLSKILSTLRILL | YZ106 | Free | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 50µM | Human | Synthetic Peptide | NA | NA | ||
| 36249542 | 2022 | FLSKILSTLRILF | YZ107 | Free | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 25µM | Human | Synthetic Peptide | NA | NA | ||
| 39141008 | 2024 | GLLKKLLKKLLKKLLKKI | LK4 | Free | Free | Linear | L | None | 18 | Antibacterial, Hemolytic | 50 % Hemolytic at 64µM | Human | Synthetic Peptide | Helix | NA | ||
| 39141008 | 2024 | GLLKKLLKKLLKKLLKKI | LK4 | Free | Free | Linear | L | None | 18 | Antibacterial, Hemolytic | 10 % Hemolytic at 5.42µM | Human | Synthetic Peptide | Helix | NA | ||
| 39141008 | 2024 | GFFKKFFKKFFKKFFKKI | FK4 | Free | Free | Linear | L | None | 18 | Antibacterial, Hemolytic | 50 % Hemolytic at 32-64µM | Human | Synthetic Peptide | Helix | NA | ||
| 39141008 | 2024 | GFFKKFFKKFFKKFFKKI | FK4 | Free | Free | Linear | L | None | 18 | Antibacterial, Hemolytic | 10 % Hemolytic at 4.02µM | Human | Synthetic Peptide | Helix | NA | ||
| 39141008 | 2024 | GWWKKWWKKWWKKI | WK3 | Free | Free | Linear | L | None | 14 | Antibacterial, Hemolytic | 50 % Hemolytic at 32-64µM | Human | Synthetic Peptide | Helix | NA | ||
| 39141008 | 2024 | GWWKKWWKKWWKKI | WK3 | Free | Free | Linear | L | None | 14 | Antibacterial, Hemolytic | 10 % Hemolytic at 55.52µM | Human | Synthetic Peptide | Helix | NA | ||
| 39141008 | 2024 | GWWKKWWKKWWKKWWKKI | WK4 | Free | Free | Linear | L | None | 18 | Antibacterial, Hemolytic | 10 % Hemolytic at 4.38µM | Human | Synthetic Peptide | Helix | NA | ||
| 39427973 | 2025 | FLPFLGKLFSGIF{ct:Amid} | Temporin-PMb | Amidation | Free | Linear | L | None | 13 | Antibacterial, Hemolytic, Anticancer | 50 % Hemolytic at 32-64µM | Human | Skin Secretion, The Amazon River Frog, Lithobates Palmipes (Ranidae), Brazil, South America | NA | NA | ||
| 39357847 | 2025 | FLKLIGKVLSGIL{ct:Amid} | Temporin F P3K analog | Amidation | Free | Linear | L | None | 13 | Antibacterial, Hemolytic | 50 % Hemolytic at 70µM | Human | Synthetic Peptide | Helix | NA | ||
| 39357847 | 2025 | FLKLIGKVLSKIL{ct:Amid} | Temporin F P3K,G11K analog | Amidation | Free | Linear | L | None | 13 | Antibacterial, Hemolytic | 50 % Hemolytic at 30µM | Human | Synthetic Peptide | Helix | NA | ||
| 34953322 | 2022 | IILLLLKKFLKKL{ct:Amid} | 2K4L | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 62.5µM | Human | Synthetic Peptide | Helix | NA | ||
| 34953322 | 2022 | WILLLLKKFLKKL{ct:Amid} | 2K4L_W1 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 12.5µM | Human | Synthetic Peptide | Helix | NA | ||
| 34953322 | 2022 | IWLLLLKKFLKKL{ct:Amid} | 2K4L_W2 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 50µM | Human | Synthetic Peptide | Helix | NA | ||
| 34953322 | 2022 | IILLLLKKFWKKL{ct:Amid} | 2K4L_W10 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 12.5µM | Human | Synthetic Peptide | Helix | NA | ||
| 34953322 | 2022 | IILLLLKKFLKKW{ct:Amid} | 2K4L_W13 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 12.5µM | Human | Synthetic Peptide | Helix | NA | ||
| 34953322 | 2022 | IILLLLKKFWKKW{ct:Amid} | 2K4L_2W | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 25µM | Human | Synthetic Peptide | Helix | NA | ||
| 34953322 | 2022 | IWLLLLKKFWKKW{ct:Amid} | 2K4L_3W (Temporin-1CEc analog) | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | 50 % Hemolytic at 6.25µM | Human | Synthetic Peptide | Helix | NA | ||
| 32414842 | 2020 | GFPCGESCVYIPCFTAAIGCSCKSKVCYKN | Hyen D | Free | Free | Linear | L | None | 30 | Anticancer, Hemolytic | 50 % Hemolytic at 24.56µM | Human | Hybanthus Enneaspermus | NA | NA | ||
| 23326415 | 2013 | MERRTLLVVLLVCSCVVAAAAEASPSRWPSPGRPRPFPGRPKPIFRPRPCNCYAPPCPCDRWRH | Arasin 1 (Ara-1) (Proline-rich antimicrobial peptide) (PR-AMP) (Pro-rich AMP) | Free | Free | Linear | L | None | 64 | Antibiotic;Antimicrobial | Hemolytic at 100µM | Human | Hyas Araneus (Atlantic Lyre Crab) (Great Spider Crab) | NA | Non-hemolytic | ||
| 21692149 | 2011 | MYVHLALILGCWTVVLQGAETDVGERADNRRPIWNLAHMVNAVKQIPTFLDLGANALEADVTFKGSVPTYTYHGTPCDFGRDCIRWEYFNVFLKTLREYTTPGNAKYRDGFILFVLDLKTGSLSNDQVRPAGENVAKELLQNYWNNGNNGGRAYVVLSLPDIGHYEFVRGFKEVLKKEGHEDLLEKVGYDFSGPYLPSLPTLDATHEAYKKAGVDGHIWLSDGLTNFSPLGDMARLKEAIKSRDSANGFINKIYYWSVDKYSTTRTALDVGVDGIMTNYPNVLIDVLNEDGYKDNYRLATYDDNPWETYKK | Dermonecrotic toxin (EC 4.6.1.-) (Phospholipase D isoform 1) (LlPLD1) (PLD1) (Sphingomyelin phosphodiesterase D) (SMD) (SMase D) (Sphingomyelinase D) | Free | Free | Linear | L | None | 311 | Antimicrobial | Hemolytic | Human | Loxosceles Laeta (South American Recluse Spider) (Scytodes Laeta) | NA | NA | ||
| 21933345 | 2011 | MKISQVFIFVFLLMISVAWANEAYEEESNYLSERFDADVEEITPEFRGIRCPKSWKCKAFKQRVLKRLLAMLRQHAF | Oxyopinin-4a (Oxt-4a) | Free | Free | Linear | L | None | 77 | Antimicrobial | EC50 % Hemolytic at 7µM | Human | Oxyopes Takobius (Lynx Spider) (Oxyopes Foliiformis) | NA | NA | ||
| 23967105 | 2013 | FLSLIPHIVSGVASIAKHF{ct:Amid} | Phylloseptin-S1 (PLS-S1) (Phylloseptin-1) (PSN-1) | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LC50 % Hemolytic at 39µM | Human | Phyllomedusa Sauvagei (Sauvage'S Leaf Frog) | NA | NA | ||
| 23967105 | 2013 | FLSLIPHIVSGVASLAKHF{ct:Amid} | Phylloseptin-S2 (PLS-S2) | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LC50 % Hemolytic at 25µM | Human | Phyllomedusa Sauvagei (Sauvage'S Leaf Frog) | NA | NA | ||
| 23967105 | 2013 | FLSMIPHIVSGVAALAKHL{ct:Amid} | Phylloseptin-S4 (PLS-S4) | Amidation | Free | Linear | L | None | 19 | Antimicrobial | LC50 % Hemolytic at 33µM | Human | Phyllomedusa Sauvagei (Sauvage'S Leaf Frog) | NA | NA | ||
| 21816202 | 2012 | DSMGAVKLAKLLIDKMKCEVTKAC | Jindongenin-1a (Jindongenin-1) | Free | Free | Linear | L | None | 24 | Antimicrobial | IC50 % Hemolytic at 150µM | Human | Amolops Jingdongensis (Chinese Torrent Frog) | NA | Low hemolytic | ||
| 21816202 | 2012 | GFMDTAKNVAKNVAVTLIDKLRCKVTGGC | Palustrin-2AJ1 | Free | Free | Linear | L | None | 29 | Antimicrobial | IC50 % Hemolytic at 135µM | Human | Amolops Jingdongensis (Chinese Torrent Frog) | NA | Low hemolytic | ||
| 30214940 | 2018 | GLGRLIGKIAKKGAKIAAEAAANAAAEKAAEAL{ct:Amid} | U-myrmeciitoxin(01)-Mg1a (MIITX(01)-Mg1a) (U-MIITX(01)-Mg1a) | Amidation | Free | Linear | L | None | 33 | Antimicrobial | HC(50) % Hemolytic at >10.2µM | Human | Myrmecia Gulosa (Red Bulldog Ant) | NA | Non-hemolytic | ||
| 32092412 | 2021 | MRSLGALLLLLSACLAVSAGPVPTPPDNIQVQENFNISRIYGKWYNLAIGSTCPWLKKIMDRMTVSTLVLGEGATEAEISMTSTRWRKGVCEETSGAYEKTDTDGKFLYHKSKWNITMESYVVHTNYDEYAIFLTKKFSRHHGPTITAKLYGRAPQLRETLLQDFRVVAQGVGIPEDSIFTMADRGECVPGEQEPEPILIPRVRRAVLPQEEEGSGGGQLVTEVTKKEDSCQLGYSAGPCMGMTSRYFYNGTSMACETFQYGGCMGNGNNFVTEKECLQTCRTVAACNLPIVRGPCRAFIQLWAFDAVKGKCVLFPYGGCQGNGNKFYSEKECREYCGVPGDGDEELLRFSN | Protein AMBP (Protein HC) [Cleaved into: Alpha-1-microglobulin (EC 1.6.2.-) (Alpha-1 microglycoprotein) (Complex-forming glycoprotein heterogeneous in charge); Inter-alpha-trypsin inhibitor light chain (ITI-LC) (Bikunin) (EDC1) (HI-30) (Uronic-acid-rich protein); Trypstatin] | Free | Free | Linear | L | None | 352 | Antioxidant | Hemolytic | Human | Homo Sapiens (Human) | NA | NA | ||
| 10978735 | 2001 | ALAGTIIAGASLTFQVLDKVLEELGKVSRKIAVGIDNESGGTWTALNAYFRSGTTDVILPEFVPNTKALLYSGRKDTGPVATGAVAAFAYYMSSGNTLGVMFSVPFDYNWYSNWWDVKIYSGKRRADQGMYEDLYYGNPYRGDNGWHEKNLGYGLRMKGIMTSAGEAKMQIKISR | DELTA-stichotoxin-She4b (DELTA-SHTX-She4b) (Cytolysin III) (Sticholysin II) (St II) (St-II) (StII) (StnII) (Sticholysin-2) (STCH2) | Free | Free | Linear | L | None | 175 | Cytolytic | 50 % Hemolytic at 30-45ng/ml | Human | Stichodactyla Helianthus (Sun Anemone) (Stoichactis Helianthus) | NA | NA | ||
| 20624979 | 2010 | MKTRIVSSVTTTLLLGSILMNPVAGAADSDINIKTGTTDIGSNTTVKTGDLVTYDKENGMHKKVFYSFIDDKNHNKKLLVIRTKGTIAGQYRVYSEEGANKSGLAWPSAFKVQLQLPDNEVAQISDYYPRNSIDTKEYMSTLTYGFNGNVTGDDTGKIGGLIGANVSIGHTLKYVQPDFKTILESPTDKKVGWKVIFNNMVNQNWGPYDRDSWNPVYGNQLFMKTRNGSMKAADNFLDPNKASSLLSSGFSPDFATVITMDRKASKQQTNIDVIYERVRDDYQLHWTSTNWKGTNTKDKWTDRSSERYKIDWEKEEMTN | Alpha-hemolysin (Alpha-HL) (Alpha-toxin) | Free | Free | Linear | L | None | 319 | Cytolytic | Hemolytic | Human | Staphylococcus Aureus | β-barrel | NA | ||
| 28513074 | 2017 | LIGLVSKGTCVLVKTVCKKVLKQ | M-myrmeciitoxin-Mp2b (M-MIITX-Mp2b) (DELTA-myrtoxin-Mp1a B chain) (Mp1a B chain) (Pilosin-3 subunit b) (Pilosulin-3b) | Free | Free | Linear | L | None | 23 | Antimicrobial | 50 % Hemolytic at 2.18µM | Human | Myrmecia Pilosula (Jack Jumper Ant) (Australian Jumper Ant) | β-Turn | NA | ||
| 29885399 | 2018 | NLYQFKNMVQCVGTQLCVAYVKYGCYCGPG | Non-toxic phospholipase A2 (WaPLA2) (svPLA2) (Phosphatidylcholine 2-acylhydrolase) (EC 3.1.1.4) | Free | Free | Linear | L | None | 30 | Antimicrobial | 100 % Hemolytic at 3ug | Human | Walterinnesia Aegyptia (Desert Black Snake) | NA | NA | ||
| 11085990 | 2001 | MRIHYLLFALLFLFLVPVPGHGGIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK | Beta-defensin 103 (Beta-defensin 3) (BD-3) (DEFB-3) (HBD3) (hBD-3) (Defensin, beta 103) (Defensin-like protein) | Free | Free | Linear | L | None | 67 | Antimicrobial | <0.5 % Hemolytic at 500ug/ml | Human | Homo Sapiens (Human) | NA | Non-hemolytic | ||
| 18215128 | 2008 | MKYFVVALALVAAFACIAESKPAESEHELAEVEEENELADLEDAVWLEHLADLSDLEEARGFFGNTWKKIKGKADKIMLKKAVKIMVKKEGISKEEAQAKVDAMSKKQIRLYLLKYYGKKALQKASEKL{ct:Amid} | M-zodatoxin-Lt8a (M-ZDTX-Lt8a) (Cytoinsectotoxin-1a) (CIT-1a) | Amidation | Free | Linear | L | None | 129 | Antimicrobial | EC50 % Hemolytic at 6µM | Human | Lachesana Tarabaevi (Spider) | NA | NA | ||
| 21593408 | 2011 | MAYVRLTSLAVLFFLAASVMKTEGGLPTCGETCTLGTCYVPDCSCSWPICMKNHIIAANAKTVNEHRLLCTSHEDCFKKGTGNYCASFPDSNIHFGWCFHAESEGYLLKDFMNMSKDDLKMPLESTN | Cyclotide cter-M | Free | Free | Linear | L | None | 127 | Anti-HIV | 50 % Hemolytic at >100µM | Human | Clitoria Ternatea (Butterfly Pea) | NA | Low hemolytic | ||
| 20736081 | 2010 | MGSEHPVDGMTRRQFFAKAAAATTAGAFMSLAGPIIEKAYGAGPCPGHLTDIEHIVLLMQENRSFDHYFGTLSDTRGFDDTTPPVVFAQSGWNPMTQAVDPAGVTLPYRFDTTRGPLVAGECVNDPDHSWIGMHNSWNGGANDNWLPAQVPFSPLQGNVPVTMGFYTRRDLPIHYLLADTFTVCDGYFCSLLGGTTPNRLYWMSAWIDPDGTDGGPVLIEPNIQPLQHYSWRIMPENLEDAGVSWKVYQNKLLGALNNTVVGYNGLVNDFKQAADPRSNLARFGISPTYPLDFAADVRNNRLPKVSWVLPGFLLSEHPAFPVNVGAVAIVDALRILLSNPAVWEKTALIVNYDENGGFFDHVVPPTPPPGTPGEFVTVPDIDSVPGSGGIRGPIGLGFRVPCLVISPYSRGPLMVHDTFDHTSTLKLIRARFGVPVPNLTAWRDATVGDMTSTFNFAAPPNPSKPNLDHPRLNALPKLPQCVPNAVLGTVTKTAIPYRVPFPQSMPTQETAPTRGIPSGLC | Phospholipase C B (PLC-B) (EC 3.1.4.3) (Mycobacterial phospholipase C B) | Free | Free | Linear | L | None | 521 | Cytotoxic | Hemolytic | Human | Mycobacterium Tuberculosis (Strain Atcc 25618 / H37Rv) | NA | Non-hemolytic | ||
| 20736081 | 2010 | MSASPLLGMSRREFLTKLTGAGAAAFLMDWAAPVIEKAYGAGPCPGHLTDIEHIVLLMQENRSFDHYFGTLSSTNGFNAASPAFQQMGWNPMTQALDPAGVTIPFRLDTTRGPFLDGECVNDPEHQWVGMHLAWNGGANDNWLPAQATTRAGPYVPLTMGYYTRQDIPIHYLLADTFTICDGYHCSLLTGTLPNRLYWLSANIDPAGTDGGPQLVEPGFLPLQQFSWRIMPENLEDAGVSWKVYQNKGLGRFINTPISNNGLVQAFRQAADPRSNLARYGIAPTYPGDFAADVRANRLPKVSWLVPNILQSEHPALPVALGAVSMVTALRILLSNPAVWEKTALIVSYDENGGFFDHVTPPTAPPGTPGEFVTVPNIDAVPGSGGIRGPLGLGFRVPCIVISPYSRGPLMVSDTFDHTSQLKLIRARFGVPVPNMTAWRDGVVGDMTSAFNFATPPNSTRPNLSHPLLGALPKLPQCIPNVVLGTTDGALPSIPYRVPYPQVMPTQETTPVRGTPSGLCS | Phospholipase C A (PLC-A) (EC 3.1.4.3) (MTP40 antigen) (Mycobacterial phospholipase C A) | Free | Free | Linear | L | None | 520 | Cytotoxic | Hemolytic | Human | Mycobacterium Tuberculosis (Strain Atcc 25618 / H37Rv) | NA | Non-hemolytic | ||
| 15639237 | 2005 | MKLSCLLLTLTIIFVLTIVHAPNVEAKDLADPESEAVGFADAFGEADAVGEADPNAGLGSVFGRLARILGRVIPKVAKKLGPKVAKVLPKVMKEAIPMAVEMAKSQEEQQPQ | M-myrmeciitoxin-Mp1 (M-MIITX-Mp1) (Allergen Myr p I) (Major allergen Myr p 1) (Pilosulin-1) (allergen Myr p 1) [Cleaved into: M-myrmeciitoxin-Mp1a (M-MIITX-Mp1a) (M-myrmeciitoxin-Mp1b) (M-MIITX-Mp1b) (Pilosulin-1 57->112) (Myr p 1 57->112) (Myr p 1 57->112 (Ile5)) ([Ile-5]pilosulin-1); M-myrmeciitoxin-Mp1c (M-MIITX-Mp1c) (Pilosulin-1 65->112) (Myr p 1 65->112); M-myrmeciitoxin-Mp1d (M-MIITX-Mp1d) (Pilosulin-1 68->112) (Myr p 1 68->112); M-myrmeciitoxin-Mp1e (M-MIITX-Mp1e) (Pilosulin-1 71->112) (Myr p 1 71->112); U1-myrmeciitoxin-Mp1f (U1-MIITX-Mp1f) (Pilosulin-1 86->112) (Myr p 1 86->112)] | Free | Free | Linear | L | None | 112 | Antimicrobial | 50 % Hemolytic at 0.1µM | Human | Myrmecia Pilosula (Jack Jumper Ant) (Australian Jumper Ant) | NA | NA | ||
| 21980286 | 2011 | MTIKEELGQPQSHSIELDEVSKEAASTRAALTSNLSGRFDQYPTKKGDFAIDGYLLDYSSPKQGCWVDGITVYGDIYIGKQNWGTYTRPVFAYLQYVETISIPQNVTTTLSYQLTKGHTRSFETSVNAKYSVGANIDIVNVGSEISTGFTRSESWSTTQSFTDTTEMKGPGTFVIYQVVLVYAHNATSAGRQNANAFAYSKTQAVGSRVDLYYLSAITQRKRVIVPSSNAVTPLDWDTVQRNVLMENYNPGSNSGHFSFDWSAYNDPHRRY | Monalysin (beta-barrel pore-forming toxin) (beta-PFT) | Free | Free | Linear | L | None | 271 | Antimicrobial | Hemolytic | Human | Pseudomonas Entomophila (Strain L48) | NA | NA | ||
| 21590705 | 2011 | MQLFIILCLAGSAVQLEGTELDGVERADNRRPIWNIAHMVNDKGLIDEYLDDGANSVESDVSFDSNGKPEKMLHGSPCDCGRSCKRQMSFADYLDYMRQLTTPGDPKFRENLILVMLDLKLKKLSSEQAYSAGQEVASQMLDKYWKRGESGARAYIVLSIPTITRVTFVNGFYDKLHSEGFDQYREKVGVDFSGNEDLEDTGKILKSRDILDHIWQSDGITNCLFRIMKRLKAAIRKRDSNGYMVKVYTWSVDKYTTMRKALRAGADGMITNFPKRLVSVLNEREFSGKFRLATYNDNPWERYTG | Dermonecrotic toxin LiSicTox-betaID1 (EC 4.6.1.-) (Dermonecrotic toxin 5) (DT5) (LiRecDT5) (Phospholipase D) (PLD) (Sphingomyelin phosphodiesterase D 5) (SMD 5) (SMase D 5) (Sphingomyelinase D 5) | Free | Free | Linear | L | None | 305 | Antimicrobial | <25 % Hemolytic at 25µM | Human | Loxosceles Intermedia (Brown Spider) | NA | Non-hemolytic | ||
| 21590705 | 2011 | MLLHIALILGCWSVFSEGAETDVAERADGRRPIWNMGHMVNGIWQIDQFVDLGVNSIEFDINFDKNGKPVYTYHGVPCDCFRSCLNWEYFGEFLTALRHRTTPGDKLYKEKLILFVFDMKTNSLYDNQAYQAGVNMATDIFKYYWNNGQNGGRAYFILSIPNLNHYDLIKGFRETITKKGHPELMEKVGYDFSANDNIPDVEKAYGKVGVTDHVWQSDGITNCIARGLSRVKEAVKERDSGGVINKVYIWTIDKFSSTRDALDAGVDGIMTNYPYVLNDVLKEGAYKNKFRMATYEDNPWVTFKA | Dermonecrotic toxin LiSicTox-alphaII1 (EC 4.6.1.-) (Dermonecrotic toxin 4) (DT4) (LiRecDT4) (Phospholipase D) (Sphingomyelin phosphodiesterase D 4) (SMD 4) (SMase D 4) (Sphingomyelinase D 4) | Free | Free | Linear | L | None | 305 | Antimicrobial | <75 % Hemolytic at 25µM | Human | Loxosceles Intermedia (Brown Spider) | NA | Non-hemolytic | ||
| 30036605 | 2018 | MKNRLVIIVFMVVTMLCASLALPLEEKEDEKDEKRSLEVAGAVMEGANLGMSVLQTILQAIGDVSRKIAVGVDNESGRSWTAQNAYFRSGTSDVILPHTVPSGKALLYDGQKNRGPVATGVVGVITYTMGDGNTLAVMFSVPYDYNWYSNWWNVKIYHGKVRASQKMYEDLYYYRSPFKGDNGWHERNLGYGLKSKGFMNSSGAALLQIKVMKA | Nigrelysin (Ng) (Actinoporin) (DELTA-actitoxin-Ani1a) (DELTA-AITX-Ani1a) (Pore-forming toxine) (PFT) | Free | Free | Linear | L | None | 214 | Antimicrobial | 50 % Hemolytic at 0.09nM | Human | Anthopleura Nigrescens (Sea Anemone) (Tealiopsis Nigrescens) | NA | NA | ||
| 31671555 | 2019 | ASWKVFLKNIGKAAGKAVLNSVTDMVNQ{ct:Amid} | Dermaseptin-SP2 (DRS-SP2) | Amidation | Free | Linear | L | None | 28 | Antimicrobial | >20 % Hemolytic at 512mg/L | Human | Agalychnis Spurrelli (Gliding Leaf Frog) (Agalychnis Litodryas) | α-Helix | Non-hemolytic | ||
| 17046111 | 2006 | MSAEALADPKADPLAGPNPDADPEAINLKAIAALAKKLLG{ct:Amid} | Mastoparan-like peptide 12c | Amidation | Free | Linear | L | None | 40 | Antimicrobial | Low hemolytic | Human | Vespa Magnifica (Hornet) | NA | Low hemolytic | ||
| 22542795 | 2012 | MAKLIAFALVASLCLSMVLCNPLPEEVQEEGLVRQKRVTCDVLSFEAKGIAVNHSACALHCIALRKKGGSCQNGVCVCRN | Defensin coprisin | Free | Free | Linear | L | None | 80 | Antimicrobial | 0 % Hemolytic at 100µM | Human | Copris Tripartitus (Dung Beetle) | NA | Non-hemolytic | ||
| 18584916 | 2008 | FLSGIVGMLGKLF{ct:Amid} | Temporin-SHa (Temporin-1Sa) (Temp-1Sa) | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LC50 % Hemolytic at 25µM | Human | Pelophylax Saharicus (Sahara Frog) (Rana Saharica) | NA | NA | ||
| 18584916 | 2008 | FLSHIAGFLSNLF{ct:Amid} | Temporin-SHc (Temporin-1Sc) (Temp-1Sc) | Amidation | Free | Linear | L | None | 13 | Antimicrobial | LC50 % Hemolytic at >80µM | Human | Pelophylax Saharicus (Sahara Frog) (Rana Saharica) | NA | Non-hemolytic | ||
| 18620012 | 2008 | MEGFFWKTLLVVGALAIGGTSSLPHKPLTYEEAVDLAVSIYNSKSGEDSLYRLLEAVPPPEWDPLSESNQELNFTIKETVCLVAEERSLEECDFQEDGAIMGCTGYYFFGESPPVLVLTCKPVGEEEEQKQEEGNEEEKEVEKEEKEEDEKDQPRRVKRFKKFFKKLKNSVKKRAKKFFKKPRVIGVSIPF | Cathelicidin-related peptide Oh-Cath (Cathelicidin-related antimicrobial peptide) (Oh_CRAMP) (Vipericidin) | Free | Free | Linear | L | None | 191 | Antimicrobial | 0 % Hemolytic at 200µg/ml | Human | Ophiophagus Hannah (King Cobra) (Naja Hannah) | NA | Non-hemolytic | ||
| 24523715 | 2014 | VRDICKKEAERQDLSSCENYITQRRGY | Trypsin inhibitor 1 (JcTI-I) | Free | Free | Linear | L | None | 27 | Antimicrobial | 0 % Hemolytic at 25µM | Human | Jatropha Curcas (Barbados Nut) | NA | Non-hemolytic | ||
| 23093408 | 2012 | GFGCPGDAYQCSEHCRALGGGRTGGYCAGPWYLGHPTCTCSF | Fungal defensin eurocin | Free | Free | Linear | L | None | 42 | Antimicrobial | 0.5– 4 % Hemolytic at 1024ug/ml | Human | Aspergillus Amstelodami | Alpha Beta fold | Non-hemolytic | ||
| 23182832 | 2013 | MKNQFVLLLLAIVFLQMIFQSDAILSAIWSGIKSLFGKRGLENMDKFDELFDGDLSEADLDFLKELMR{ct:Amid} | Antimicrobial peptide UyCT3 (CT3) (Non-disulfide-bridged peptide 4.17) (NDBP-4.17) (Non-disulfide-bridged peptide 5.15) (NDBP-5.15) | Amidation | Free | Linear | L | None | 68 | Antimicrobial | 95 % Hemolytic at 50µM | Human | Urodacus Yaschenkoi (Inland Robust Scorpion) | NA | NA | ||
| 22091349 | 2011 | NLFQFARMINGKLGAFSV | Acidic phospholipase A2 Drs-PLA2 (svPLA2) (EC 3.1.1.4) (Phosphatidylcholine 2-acylhydrolase) | Free | Free | Linear | L | None | 18 | Antimicrobial | Hemolytic | Human | Daboia Siamensis (Eastern Russel'S Viper) (Daboia Russelii Siamensis) | NA | NA | ||
| 23733617 | 2013 | MLFPTALIFGCWALVIEGADNRRPIWNMGHMVNEVYQIDEFVDLGANSIETDITFDDDAMAEYSYHGVPCDCRRWCHKWEYVNVFLDGLRRATTPGDSKYRPELTLVVFDLKTGDLSSSTAYKGGKLFAQKLLDRYWNGGNNGGRAYIIISIPDIDHYAFITGFREALKNANHEELLDKVGYDFSGNDDLSSTRTALNKAGVKDREHVWQSDGITNCILRGLDRVREAVRNRDSSNGYINKVYYWTIEKYVSVRDALDAGVDGIMTNEPDVIVNVLNEGNYRGRFRLANYDDNPWVTFK | Dermonecrotic toxin LiSicTox-alphaIVA1 (EC 4.6.1.-) (Dermonecrotic toxin 7) (DT7) (LiRecDT7) (Phospholipase D) (PLD) (Sphingomyelin phosphodiesterase D 7) (SMD 7) (SMase D 7) (Sphingomyelinase D 7) | Free | Free | Linear | L | None | 299 | Hemolytic | 100 % Hemolytic at 25ug/ml | Human | Loxosceles Intermedia (Brown Spider) | NA | NA | ||
| 27128943 | 2016 | MKTIVLLFVLALVFCTLEMGIVEAGFGCPFNQGQCHKHCQSIRRRGGYCDGFLKQRCVCYRK{ct:Amid} | Defensin BmKDfsin4 (4 kDa defensin) | Amidation | Free | Linear | L | None | 62 | Antimicrobial | 50 % Hemolytic at 66.85µM | Human | Mesobuthus Martensii (Manchurian Scorpion) (Buthus Martensii) | NA | Non-hemolytic | ||
| 14572904 | 2003 | GITPDCTFNEKDIELHVYSRDKRNGIILKKEILKNYDLFKES | Phospholipase A1 (PLA1) (EC 3.1.1.32) (allergen Pol g 1) | Free | Free | Linear | L | None | 42 | Antimicrobial | Hemolytic | Human | Polistes Gallicus (Paper Wasp) | Loop | Low hemolytic | ||
| 19253295 | 2008 | YDLSKNCRLRGGICYIGKCPRRFFRSGSCSRGNVCCLRFG | Beta-defensin 1 (TBD-1) | Free | Free | Linear | L | None | 40 | Antimicrobial | 0 % Hemolytic at 25µmol/L | Human | Emys Orbicularis (European Pond Turtle) | NA | Non-hemolytic | ||
| 20736081 | 2010 | MSASPLLGMSRREFLTKLTGAGAAAFLMDWAAPVIEKAYGAGPCPGHLTDIEHIVLLMQENRSFDHYFGTLSSTNGFNAASPAFQQMGWNPMTQALDPAGVTIPFRLDTTRGPFLDGECVNDPEHQWVGMHLAWNGGANDNWLPAQATTRAGPYVPLTMGYYTRQDIPIHYLLADTFTICDGYHCSLLTGTLPNRLYWLSANIDPAGTDGGPQLVEPGFLPLQQFSWRIMPENLEDAGVSWKVYQNKGLGRFINTPISNNGLVQAFRQAADPRSNLARYGIAPTYPGDFAADVRANRLPKVSWLVPNILQSEHPALPVALGAVSMVTALRILLSNPAVWEKTALIVSYDENGGFFDHVTPPTAPPGTPGEFVTVPNIDAVPGSGGIRGPLGLGFRVPCIVISPYSRGPLMVSDTFDHTSQLKLIRARFGVPVPNMTAWRDGVVGDMTSAFNFATPPNSTRPNLSHPLLGALPKLPQCIPNVVLGTTDGALPSIPYRVPYPQVMPTQETTPVRGTPSGLCS | Phospholipase C A (PLC-A) (EC 3.1.4.3) (MTP40 antigen) (Mycobacterial phospholipase C A) | Free | Free | Linear | L | None | 520 | Cytotoxic | 0 % Hemolytic at 45µg | Human | Mycobacterium Tuberculosis (Strain Atcc 25618 / H37Rv) | NA | Non-hemolytic | ||
| 20736081 | 2010 | MGSEHPVDGMTRRQFFAKAAAATTAGAFMSLAGPIIEKAYGAGPCPGHLTDIEHIVLLMQENRSFDHYFGTLSDTRGFDDTTPPVVFAQSGWNPMTQAVDPAGVTLPYRFDTTRGPLVAGECVNDPDHSWIGMHNSWNGGANDNWLPAQVPFSPLQGNVPVTMGFYTRRDLPIHYLLADTFTVCDGYFCSLLGGTTPNRLYWMSAWIDPDGTDGGPVLIEPNIQPLQHYSWRIMPENLEDAGVSWKVYQNKLLGALNNTVVGYNGLVNDFKQAADPRSNLARFGISPTYPLDFAADVRNNRLPKVSWVLPGFLLSEHPAFPVNVGAVAIVDALRILLSNPAVWEKTALIVNYDENGGFFDHVVPPTPPPGTPGEFVTVPDIDSVPGSGGIRGPIGLGFRVPCLVISPYSRGPLMVHDTFDHTSTLKLIRARFGVPVPNLTAWRDATVGDMTSTFNFAAPPNPSKPNLDHPRLNALPKLPQCVPNAVLGTVTKTAIPYRVPFPQSMPTQETAPTRGIPSGLC | Phospholipase C B (PLC-B) (EC 3.1.4.3) (Mycobacterial phospholipase C B) | Free | Free | Linear | L | None | 521 | Cytotoxic | 0 % Hemolytic at 45µg | Human | Mycobacterium Tuberculosis (Strain Atcc 25618 / H37Rv) | NA | Non-hemolytic | ||
| 20736081 | 2010 | MVSQGAFAGMSRRAFLAKAAGAGAAAVLTDWAAPVIEKAYGAGPCSGHLTDIEHIVLCLQENRSFDHYFGTLSAVDGFDTPTPLFQQKGWNPETQALDPTGITLPYRINTTGGPNGVGECVNDPDHQWIAAHLSWNGGANDGWLPAQARTRSVANTPVVMGYYARPDIPIHYLLADTFTICDQYFSSLLGGTMPNRLYWISATVNPDGDQGGPQIVEPAIQPKLTFTWRIMPQNLSDAGISWKVYNSKLLGGLNDTSLSRNGYVGSFKQAADPRSDLARYGIAPAYPWDFIRDVINNTLPQVSWVVPLTVESEHPSFPVAVGAVTIVNLIRVLLRNPAVWEKTALIIAYDEHGGFFDHVTPLTAPEGTPGEWIPNSVDIDKVDGSGGIRGPIGLGFRVPCFVISPYSRGGLMVHDRFDHTSQLQLIGKRFGVPVPNLTPWRASVTGDMTSAFNFAAPPDPSPPNLDHPVRQLPKVAKCVPNVVLGFLNEGLPYRVPYPQTTPVQESGPARPIPSGIC | Phospholipase C C (PLC-C) (EC 3.1.4.3) | Free | Free | Linear | L | None | 517 | Cytotoxic | 0 % Hemolytic at 45µg | Human | Mycobacterium Tuberculosis (Strain Atcc 25618 / H37Rv) | NA | Non-hemolytic | ||
| 20736081 | 2010 | DAGVSWKVYRNKTLGPISSVLTYGSLVTSFKQSADPRSDLVRFGVAPSYPASFAADVLANRLPRVSWVIPNVLESEHPAVPAAAGAFAIVNILRILLANPAVWEKTALIVSYDENGGFFDHVVPATAPAGTPGEYVTVPDIDQVPGSGGIRGPIGLGFRVPCFVISPYSRGPQMVHDTFDHTSQLRLLETRFGVPVPNLTAWRRSVTGDMTSTFNFAVPPNSSWPNLDYPGLHALSTVPQCVPNAALGTINRGIPYRVPDPQIMPTQETTPTRGIPSGPC | Phospholipase C D (PLC-D) (EC 3.1.4.3) | Free | Free | Linear | L | None | 280 | Cytotoxic | 0 % Hemolytic at 45µg | Human | Mycobacterium Tuberculosis (Strain Atcc 25618 / H37Rv) | NA | Non-hemolytic | ||
| 33387653 | 2021 | MNQVMTIFLVLGVIVYSVESSSTPDGTWVKCRHDCFTKYKSCQMSDSCHDEQSCHQCHVKHTDCVNTGCP | U-actitoxin-Aeq5a (U-AITX-Aeq5a) (Acrorhagin I) (Acrorhagin-1) | Free | Free | Linear | L | None | 70 | Antimicrobial | 0 % Hemolytic | Human | Actinia Equina (Beadlet Anemone) | two antiparallel α‑helices | NA | ||
| 16872274 | 2006 | GIPCGESCVWIPCISSAIGCSCKSKVCYRN{cyc:N-C} | Cycloviolacin-O2 | Free | Free | Cyclic | L | None | 30 | Antimicrobial | HD50 % Hemolytic at 36µM | Human | Viola Odorata (Sweet Violet) | NA | NA | ||
| 16872274 | 2006 | GIPCGESCVWIPCISAAIGCSCKSKVCYRN{cyc:N-C} | Cycloviolacin-O13 (Cyclotide c3) | Free | Free | Cyclic | L | None | 30 | Antimicrobial | HD50 % Hemolytic at 11µM | Human | Viola Odorata (Sweet Violet) | NA | NA | ||
| 15197474 | 2004 | ACQFWSCNSSCISRGYRQGYCWGIQYKYCQCQ | Defensin-1 (Cll-dlp) | Free | Free | Linear | L | None | 32 | Antimicrobial | Hemolytic | Human | Centruroides Limpidus (Mexican Scorpion) | NA | NA | ||
| 11751887 | 2001 | MSKFWLLLLLVAAFQFAHSYPAAEYELDETTNDEVRQFIGDGYFEDEGDDGDEERFKIKPGKVLDKFGKIVGKVLKQLKKVSAVAKVAMKKGAALLKKMGVKISPLKCEEKTCKSCVIFKIPTENSFCLTIRFMKTNIATYLVVAGEINRKSKFEEKLKLGNMPRCVNVEGFIGKVCMKGIEGHAKSSSGQANVNFCLGLVAEKFGVGAKLCGIYANKKVRVKISPQLFPGATSLDGDIVKLDDNGEDATTLDVDEVEID | Trialysin (Triatoma infestans cytolysin) | Free | Free | Linear | L | None | 260 | Antimicrobial | Hemolytic | Human | Triatoma Infestans (Assassin Bug) | NA | NA | ||
| 29467168 | 2018 | MQFTKLATVLIVSLMGSAAIAAPSVDNAPAVAAEEVAAAPAENLEKRGFGCPLNERECHSHCQSIGRKFGYCGGTLRLTCICGKE | Fungal defensin triintsin | Free | Free | Linear | L | None | 85 | Antimicrobial | HC(50) % Hemolytic at 325µmol/L | Human | Trichophyton Interdigitale (Strain Mr816) | NA | Low hemolytic | ||
| 26456928 | 2015 | VVTIVCLDLGYTLKCNKLVPLFYKTCPAGKNLCYKMYMVATPKVPVKRGCIDVCPKSSLLVKYVCCNTDRCN | Cytotoxin 9 (CTX9) | Free | Free | Linear | L | None | 72 | cytotoxicity | 50 % Hemolytic at 0.171µM | Human | Naja Naja (Indian Cobra) | NA | NA | ||
| 31671555 | 2019 | MAFLKKSLFLVLFLGLVSLSMCEEEKRENEVEEEQEDDEQSELRRSLRSSIKDMAAAAGRAALNAVNGIVNPGEQ{ct:Amid} | Dermaseptin-SP5 (DRS-SP5) | Amidation | Free | Linear | L | None | 75 | Antibacterial, Antifungal | <20 % Hemolytic at 256mg/L | Human | Agalychnis Spurrelli (Gliding Leaf Frog) (Agalychnis Litodryas) | Alpha Helix | Non-hemolytic | ||
| 31671555 | 2019 | MAFLKKSLFLVLFLGLVSLSMCEEEKRENEVEEEQEDDEQSELRRSLWSSIKDMAAAAGRAALNAVNGILNPGEQ{ct:Amid} | Dermaseptin-SP4 (DRS-SP4) | Amidation | Free | Linear | L | None | 75 | Antibacterial, Antifungal | <20 % Hemolytic at 256mg/L | Human | Agalychnis Spurrelli (Gliding Leaf Frog) (Agalychnis Litodryas) | Alpha Helix | Low hemolytic | ||
| 31671555 | 2019 | MAFLKKSLFLVLFLGLVSLSMCEEEKRENEVEEEQEDDEQSELRRSLWSSIKDMAAAAGRAALNAVNGIVNPGEQ{ct:Amid} | Dermaseptin-SP3 (DRS-SP3) | Amidation | Free | Linear | L | None | 75 | Antibacterial, Antifungal | <20 % Hemolytic at 256mg/L | Human | Agalychnis Spurrelli (Gliding Leaf Frog) (Agalychnis Litodryas) | Alpha Helix | Low hemolytic | ||
| 22438972 | 2012 | IKFEPPLPPKKAHKKFWEDDGIYYPPNHNFP | L-amino-acid oxidase (Bm-LAO) (LAAO) (EC 1.4.3.2) | Free | Free | Linear | L | None | 31 | Antibacterial Antiparasitic | 12.5+-5.3 % Hemolytic at 512μg/mL | Human | Bothrops Mattogrossensis (Pitviper) (Bothrops Neuwiedi Mattogrossensis) | NA | NA | ||
| 24371568 | 2012 | IIIQYEGHKH | Rondonin | Free | Free | Linear | L | None | 10 | Antifungal | 0 % Hemolytic at 67µM | Human | Acanthoscurria Rondoniae (Spider) | NA | Non-hemolytic | ||
| 18584916 | 2008 | FLGTINLSLCEQERDADEEERRDEPDESDVEVEKRFLPIVTNLLSGLLGK{ct:Amid} | Temporin-SHb (Temporin-1Sb) (Temp-1Sb) | Amidation | Free | Linear | L | None | 50 | NA | 50 % Hemolytic at >116µM | Human | Pelophylax Saharicus (Sahara Frog) (Rana Saharica) | Alpha Helix | NA | ||
| 26322745 | 2015 | GKYTCGETCFKGKCYTPGCTCSYPICKKD{cyc:N-C} | Cyclotide mela-1 | Free | Free | Cyclic | L | None | 29 | Antibacterial | 50 % Hemolytic at >64µM | Human | Melicytus Latifolius (Norfolk Island Mahoe) (Hymenanthera Latifolia) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GKPTCGETCFKGKCYTPGCTCSYPLCKKD{cyc:N-C} | Cyclotide mela-2 | Free | Free | Cyclic | L | None | 29 | Antibacterial | 50 % Hemolytic at >64µM | Human | Melicytus Latifolius (Norfolk Island Mahoe) (Hymenanthera Latifolia) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GLPTCGETCFKGKCYTPGCSCSYPICKKD{cyc:N-C} | Cyclotide mela-6 | Free | Free | Cyclic | L | None | 29 | Antibacterial | 50 % Hemolytic at >64µM | Human | Melicytus Latifolius (Norfolk Island Mahoe) (Hymenanthera Latifolia) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GLPTCGETCFKGKCYTPGCSCSYPICKKN{cyc:N-C} | Cyclotide mela-7 | Free | Free | Cyclic | L | None | 29 | Antibacterial | 50 % Hemolytic at >64µM | Human | Melicytus Latifolius (Norfolk Island Mahoe) (Hymenanthera Latifolia) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GLPTCGETCTLGKCNTPKCTCNWPICYKD{cyc:N-C} | Cyclotide mech-2 | Free | Free | Cyclic | L | None | 29 | cytotoxicity | 50 % Hemolytic at >64µM | Human | Melicytus Chathamicus (Chatham Island Mahoe) (Hymenanthera Latifolia Var. Chathamica) | NA | Non-hemolytic | ||
| 26322745 | 2015 | GLPTCGETCTLGKCNTPKCTCNWPICYKN{cyc:N-C} | Cyclotide mech-3 | Free | Free | Cyclic | L | None | 29 | cytotoxicity | 50 % Hemolytic at >64µM | Human | Melicytus Chathamicus (Chatham Island Mahoe) (Hymenanthera Latifolia Var. Chathamica) | NA | Non-hemolytic | ||
| 25220871 | 2014 | FWGAVWKILSKVLPHIPGTVKWLQEKV | M-ectatotoxin-Eb2a (M-ECTX-Eb2a) (Ponericin-Q42) | Free | Free | Linear | L | None | 27 | Antibacterial | 50 % Hemolytic at 2.5+-0.1µM | Human | Ectatomma Brunneum (Ant) (Ectatomma Quadridens) | NA | NA | ||
| 22467870 | 2012 | GEYCGESCYLIPCFTPGCYCVSRQCVNKN{cyc:N-C} | Chassatide C10 (Cyclotide chaC10) | Free | Free | Cyclic | L | None | 29 | NA | 50 % Hemolytic at >25µM | Human | Chassalia Chartacea | NA | Non-hemolytic | ||
| 32414842 | 2020 | GVPCGESCVYIPCFTGIINCSCRDKVCYNN{cyc:N-C} | Cyclotide hyen-E | Free | Free | Cyclic | L | None | 30 | cytotoxicity | 50 % Hemolytic at >50µM | Human | Pigea Enneasperma (Spade Flower) (Hybanthus Enneaspermus) | NA | NA | ||
| 32414842 | 2020 | GIPCAESCVYIPCTVTALLGCSCSDKVCYN{cyc:N-C} | Cyclotide hyen-L | Free | Free | Cyclic | L | None | 30 | cytotoxicity | 50 % Hemolytic at >50µM | Human | Pigea Enneasperma (Spade Flower) (Hybanthus Enneaspermus) | NA | NA | ||
| 22450466 | 2012 | FLPLIASVAANLVPKIFCKITKKC | Brevinin-1V | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal | 50 % Hemolytic at 75µM | Human | Odorrana Hainanensis (Odor Frog) (Rana Hainanensis) | Helical | NA | ||
| 22450466 | 2012 | FLPLIASLAANFVPKIFCKITKKC | Brevinin-1HN1 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal | 50 % Hemolytic at 75µM | Human | Odorrana Hainanensis (Odor Frog) (Rana Hainanensis) | Helical | NA | ||
| 22450466 | 2012 | SLLGTVKDLLIGAGKSAAQSVLKGLSCKLSKDC | Brevinin-2HS2 | Free | Free | Linear | L | None | 33 | Antibacterial, Antifungal | 50 % Hemolytic at 300µM | Human | Odorrana Hainanensis (Odor Frog) (Rana Hainanensis) | Helical | Low hemolytic | ||
| 22450466 | 2012 | AILTTLANWARKFL{ct:Amid} | temporin-HN1 | Amidation | Free | Linear | L | None | 14 | Antibacterial, Antifungal | 50 % Hemolytic at 75µM | Human | Odorrana Hainanensis (Odor Frog) (Rana Hainanensis) | Helical | NA | ||
| 22450466 | 2012 | NILNTIINLAKKIL{ct:Amid} | temporin-HN2: | Amidation | Free | Linear | L | None | 14 | Antibacterial, Antifungal | 50 % Hemolytic at 300µM | Human | Odorrana Hainanensis (Odor Frog) (Rana Hainanensis) | Helical | Low hemolytic | ||
| 22342498 | 2012 | FLKGIIDTVSNWL{ct:Amid} | Amphipathic peptide CT1 (VsCT1) (Non-disulfide-bridged peptide 5.11) (NDBP-5.11) | Amidation | Free | Linear | L | None | 13 | hemolytic | 6 % Hemolytic at 50µM | Human | Mesomexovis Subcristatus (Scorpion) (Vaejovis Subcristatus) | Alpha Helix | Low hemolytic | ||
| 22342498 | 2012 | FLKGIIDTVSKLF{ct:Amid} | Amphipathic peptide CT2 (VsCT2) (Non-disulfide-bridged peptide 5.12) (NDBP-5.12) | Amidation | Free | Linear | L | None | 13 | hemolytic | 2 % Hemolytic at 50µM | Human | Mesomexovis Subcristatus (Scorpion) (Vaejovis Subcristatus) | Alpha Helix | Low hemolytic | ||
| 15893660 | 2005 | SLETKDVITRAAYENLVNSGAIQGITMTKTIISNPILEEALVSHFNRKLG{cyc:N-C} | Tricyclon-A | Free | Free | Cyclic | L | None | 50 | Plant defense | 2 % Hemolytic at 500µM | Human | Viola Arvensis (European Field Pansy) (Field Violet) | Helix and Extended | NA | ||
| 19716842 | 2010 | FLPKMSTKLRVPYRRGTKDYH | Antimicrobial peptide scolopin-1 | Free | Free | Linear | L | None | 21 | Antibacterial, Antiyeast | 25±2 % Hemolytic at 50μg/mL | Human | Scolopendra Mutilans (Chinese Red-Headed Centipede) (Scolopendra Subspinipes Mutilans) | NA | NA | ||
| 19716842 | 2010 | GILKKFMLHRGTKVYKMRTLSKRSH | Antimicrobial peptide scolopin-2 | Free | Free | Linear | L | None | 25 | Antibacterial, Antiyeast | 32±7 % Hemolytic at 50μg/mL | Human | Scolopendra Mutilans (Chinese Red-Headed Centipede) (Scolopendra Subspinipes Mutilans) | NA | NA | ||
| 15207717 | 2004 | GFRDVLKGAAKAFVKTVAGHIAN{ct:Amid} | Ascaphin-1 | Amidation | Free | Linear | L | None | 23 | Antibacterial | 50 % Hemolytic at >200µM | Human | Ascaphus Truei (Coastal Tailed Frog) | NA | NA | ||
| 15207717 | 2004 | GFRDVLKGAAKAFVKTVAGHIANI | Ascaphin-3 | Free | Free | Linear | L | None | 24 | Antibacterial | 50 % Hemolytic at >200µM | Human | Ascaphus Truei (Coastal Tailed Frog) | NA | NA | ||
| 15207717 | 2004 | GIKDWIKGAAKKLIKTVASHIANQ | Ascaphin-5 | Free | Free | Linear | L | None | 24 | Antibacterial, Antifungal | 50 % Hemolytic at >200µM | Human | Ascaphus Truei (Coastal Tailed Frog) | NA | NA | ||
| 15207717 | 2004 | GFKDWIKGAAKKLIKTVASAIANQ | Ascaphin-7 | Free | Free | Linear | L | None | 24 | Antibacterial | 50 % Hemolytic at >200µM | Human | Ascaphus Truei (Coastal Tailed Frog) | NA | NA | ||
| 15556063 | 2004 | FLSAITSLLGKLL{ct:Amid} | Temporin-1SPb | Amidation | Free | Linear | L | None | 13 | Antibacterial | 50 % Hemolytic at 60µM | Human | Lithobates Septentrionalis (Mink Frog) (Rana Septentrionalis) | NA | NA | ||
| 15556063 | 2004 | GIWDTIKSMGKVFAGKILQNL{ct:Amid} | Brevinin-2-related peptide | Amidation | Free | Linear | L | None | 21 | Antibacterial, Antifungal, Anti-HIV | 50 % Hemolytic at 70µM | Human | Lithobates Septentrionalis (Mink Frog) (Rana Septentrionalis) | NA | NA | ||
| 19463738 | 2009 | GLKDIFKAGLGSLVKGIAAHVAN{ct:Amid} | Alyteserin-1a | Amidation | Free | Linear | L | None | 23 | Antibacterial Gram- | 50 % Hemolytic at >100µM | Human | Alytes Obstetricans (Common Midwife Toad) (Bufo Obstetricans) | Alphα-Helical | NA | ||
| 19463738 | 2009 | GLKEIFKAGLGSLVKGIAAHVAN{ct:Amid} | Alyteserin-1b | Amidation | Free | Linear | L | None | 23 | Antibacterial Gram- | 50 % Hemolytic at 210µM | Human | Alytes Obstetricans (Common Midwife Toad) (Bufo Obstetricans) | Alphα-Helical | NA | ||
| 19463738 | 2009 | ILGKLLSTAAGLLSNL{ct:Amid} | Alyteserin-2a | Amidation | Free | Linear | L | None | 16 | Antibacterial | 50 % Hemolytic at 135µM | Human | Alytes Obstetricans (Common Midwife Toad) (Bufo Obstetricans) | NA | NA | ||
| 38110035 | 2024 | GIFSALKTLGKILLPVILPTVAEKIKEKV{ct:Amid} | Myrmicitoxin(1)-Pm6a (MYRTX(1)-Pm6a) | Amidation | Free | Linear | L | None | 29 | NA | 50 % Hemolytic at 614±148nm | Human | Pogonomyrmex Maricopa (Maricopa Harvester Ant) | NA | NA | ||
| 19428765 | 2009 | GLVNGLLSSVLGGGQGGGGLLGGIL | Plasticin-L1 (PTC-L1) | Free | Free | Linear | L | None | 25 | NA | Hemolytic at 500µM | Human | Leptodactylus Laticeps (Santa Fe Frog) | NA | Non-hemolytic | ||
| 34941722 | 2021 | ISEALKSIIVG{ct:Amid} | Annulatin (Linear alpha-helical peptide) | Amidation | Free | Linear | L | None | 11 | Histamine releasing activity from mast cells | 15.4 % Hemolytic at 12.5µmol/l | Human | Campsomeriella Annulata (Wasp) (Campsomeris Annulata) | Alpha Helix | Low hemolytic | ||
| 10691983 | 2000 | LLPIVGNLLNSLL{ct:Amid} | Temporin-1Td (TD) (Temporin-D) | Amidation | Free | Linear | L | None | 13 | NA | 80 % Hemolytic at 20µM | Human | Rana Temporaria (European Common Frog) | α-Helical | NA | ||
| 15638808 | 2005 | FIGAILPAIAGLVHGLINR{ct:Amid} | Hylin-b1 (Hy-b1) | Amidation | Free | Linear | L | None | 19 | Antimicrobial | Hemolytic | Human | Boana Lundii (Brazilian Tree Frog) (Hypsiboas Lundii) | NA | NA | ||
| 15638808 | 2005 | FIGAILPAIAGLVGGLINR{ct:Amid} | Hylin-b2 (Hy-b2) | Amidation | Free | Linear | L | None | 19 | Antimicrobial | Hemolytic | Human | Boana Lundii (Brazilian Tree Frog) (Hypsiboas Lundii) | NA | NA | ||
| 16076139 | 2005 | LPSDATLVLDQTGKELDARL{nt:Amid} | Antifungal protein J (AFP-J) | Free | Amidation | Linear | L | None | 20 | Antifungal | 0 % Hemolytic at 25µg | Human | Solanum Tuberosum (Potato) | NA | Non-hemolytic | ||
| 15809084 | 2005 | DICTNCCAGTKGCNTTSANGAFICEGQSDPKKPKACPLNCDPHIAYA{nt:Amid} | Potamin-1 (PT-1) | Free | Amidation | Linear | L | None | 47 | Antibacterial, Antifungal | 0 % Hemolytic at 40µM | Human | Solanum Tuberosum (Potato) | NA | Non-hemolytic | ||
| 18976634 | 2008 | MAFLKKSLFLVLFLGIVSLSICEEEKREGEEEEKQEEENEELSEEELRERRAWLDKLKSLGKVVGKVALGVAQNYLNPQQ | Raniseptin-1 (Rsp-1) | Free | Free | Linear | L | None | 80 | Antibacterial | 20 % Hemolytic at 80µM | Human | Boana Raniceps (Chaco Tree Frog) (Hyla Roeschmanni) | NA | NA | ||
| 26456928 | 2016 | LKCNKLIPLAYKTCPAGKDLCYKMYMVSNKTVPVKRGCIDVCPKNSLLVKYECCNTDRCN | Cytotoxin 7 (CTX7) | Free | Free | Linear | L | None | 60 | Cytolytic | 50 % Hemolytic at 0.096µM | Human | Naja Naja (Indian Cobra) | NA | NA | ||
| 26456928 | 2016 | LQCNKLVPIASKTCPPGKNLCYKMFMVSDLTIPVKRGCIDVCPKNSLLVKYECCNTDRCN | Cytotoxin 2a (CTX2a) (Cytotoxin 2) (CTX2) | Free | Free | Linear | L | None | 60 | Cytolytic | 50 % Hemolytic at 1.024µM | Human | Naja Naja (Indian Cobra) | NA | NA | ||
| 26456928 | 2016 | LKCNKLIPLAYKTCPAGKDLCYKMYMVSDKTVPVKRGCIDVCPKNSLLVKYECCNTDRCN | Cytotoxin 8 (CTX8) | Free | Free | Linear | L | None | 60 | Cytolytic | 50 % Hemolytic at 0.074µM | Human | Naja Naja (Indian Cobra) | NA | NA | ||
| 26456928 | 2016 | LKCNKLVPLFYKTCPAGKDLCYKMYMVATPKVPVKRGCIDVCPKSSLLVKYVCCNTDRCN | Cytotoxin 10 (CTX10) | Free | Free | Linear | L | None | 60 | Cytolytic | 50 % Hemolytic at 0.162µM | Human | Naja Naja (Indian Cobra) | NA | NA | ||
| 21539875 | 2011 | MLLTISDFLFLSLTFSRYARMRDSRPWSDRKNNYSGPQFTYPPEKAPPEKLIKWNNEGSPIFEMPAEGGHIEP | Antimicrobial peptide lumbricin-PG (Lumbricin-PG) | Free | Free | Linear | L | None | 73 | Antibacterial, Antifungal | 1.5 % Hemolytic at 200μg/mL | Human | Metaphire Guillelmi (Earthworm) (Pheretima Guillelmi) | NA | Low hemolytic | ||
| 11682065 | 2001 | GLLDSIKGMAISAGKGALQNLLKVASCKLDKTC | Nigrocin-1 | Free | Free | Linear | L | None | 33 | Antibacterial, Antifungal | 1.1 % Hemolytic at 100μg/mL | Human | Pelophylax Nigromaculatus (Black-Spotted Frog) (Rana Nigromaculata) | α-Helical | Non-hemolytic | ||
| 11682065 | 2001 | GLLSKVLGVGKKVLCGVSGLC | Nigrocin-2 | Free | Free | Linear | L | None | 21 | Antibacterial, Antifungal | 0.9 % Hemolytic at 100μg/mL | Human | Pelophylax Nigromaculatus (Black-Spotted Frog) (Rana Nigromaculata) | α-Helical | Non-hemolytic | ||
| 26930596 | 2016 | AVAGEKLWLLPHLLKMLLTPTP | Polydim-I | Free | Free | Linear | L | None | 22 | Antibacterial | <2.6 % Hemolytic at 121.6μg/mL | Human | Polybia Dimorpha (Neotropical Wasp) | NA | Non-hemolytic | ||
| 9784389 | 1998 | SMLSVLKNLGKVGLGFVACKINKQC | Ranatuerin-1 | Free | Free | Linear | L | None | 25 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 9784389 | 1998 | GLFLDTLKGAAKDVAGKLEGLKCKITGCKLP | Ranatuerin-2 | Free | Free | Linear | L | None | 31 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 9784389 | 1998 | GFLDIINKLGKTFAGHMLDKIKCTIGTCPPSP | Ranatuerin-3 | Free | Free | Linear | L | None | 32 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 9784389 | 1998 | FLPFIARLAAKVFPSIICSVTKKC | Ranatuerin-4 | Free | Free | Linear | L | None | 24 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 9784389 | 1998 | FLPIASLLGKYL | Ranatuerin-5 (Temporin) | Free | Free | Linear | L | None | 12 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 9784389 | 1998 | FISAIASMLGKFL | Ranatuerin-6 (Temporin) | Free | Free | Linear | L | None | 13 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 9784389 | 1998 | FLSAIASMLGKFL | Ranatuerin-7 (Temporin) | Free | Free | Linear | L | None | 13 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 9784389 | 1998 | FISAIASFLGKFL | Ranatuerin-8 (Temporin) | Free | Free | Linear | L | None | 13 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 9784389 | 1998 | FLFPLITSFLSKVL | Ranatuerin-9 (Temporin) | Free | Free | Linear | L | None | 14 | Antibacterial | 0 % Hemolytic at 20μg/mL | Human | Aquarana Catesbeiana (American Bullfrog) (Rana Catesbeiana) | NA | Non-hemolytic | ||
| 19298834 | 2009 | GLLGGLLGPLLGGGGGGGGGLL | Leptoglycin | Free | Free | Linear | L | None | 22 | Antibacterial | 0 % Hemolytic at 2-200µM | Human | Leptodactylus Pentadactylus (Smokey Jungle Frog) (Rana Pentadactyla) | NA | Non-hemolytic | ||
| 19807165 | 2009 | QGIGVGDNDGKRGKR | Antifungal protein Pr-2 | Free | Free | Linear | L | None | 15 | Antifungal | Hemolytic at 160µM | Human | Cucurbita Maxima (Pumpkin) (Winter Squash) | NA | Low hemolytic | ||
| 21520894 | 2011 | PVVDTTGNNPLQQQEEYYV | Kunitz-type serine protease inhibitor 1 (Xb-KTI) | Free | Free | Linear | L | None | 19 | Antibacterial, trypsin inhibitor | 0 % Hemolytic at 250μg/mL | Human | Xanthosoma Sagittifolium (Arrowleaf Elephant'S Ear) (Arum Sagittifolium) | NA | Non-hemolytic | ||
| 15246874 | 2004 | MKLSCLLLTLAIIFVLTIVHAPNVKAKALADPESDAVGFADAVGEADPFDITKLNIKKLTKATCKVISKGASMCKVLFDKKKQE | M-myrmeciitoxin-Mb2a (M-MIITX-Mb2a) (M-myrmeciitoxin-Mp3a) (M-MIITX-Mp3a) (Pilosulin-4) | Free | Free | Linear | L | None | 84 | Antibacterial | 0 % Hemolysis at 50µM | Human | Myrmecia Banksi (Jack Jumper Ant) (Australian Jumper Ant) | NA | Non-hemolytic | ||
| 31209048 | 2019 | GLLSLLSLLGKLL{ct:Amid} | DFTamP1 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at <3.1µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GALSLLSLLGKLL{ct:Amid} | DFT506 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 4µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLASLLSLLGKLL{ct:Amid} | DFT507 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at <3.1µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSALSLLGKLL{ct:Amid} | DFT508 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 6µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSLASLLGKLL{ct:Amid} | DFT509 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 4µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSLLSALGKLL{ct:Amid} | DFT510 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 19µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSLLSLAGKLL{ct:Amid} | DFT511 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 14µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSLLSLLGKAL{ct:Amid} | DFT512 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 4µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSLLSLLGKLA{ct:Amid} | DFT513 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at <3.1µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSALKALGKLL{ct:Amid} | DFT514 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 36µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSAL{nnr:O}ALGKLL{ct:Amid} | DFT515 | Amidation | Free | Linear | L | O = L-Ornithine | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 36µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSAL{nnr:O}ALG{nnr:O}LL{ct:Amid} | DFT516 | Amidation | Free | Linear | L | O = L-Ornithine | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 36µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSALKAAGKLL{ct:Amid} | DFT521 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at > 50µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GALSALKALGKLL{ct:Amid} | DFT528 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at > 50µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSALKALGKAL{ct:Amid} | DFT529 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at > 50µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSAAKAAGKLL{ct:Amid} | DFT522 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 50µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GALSALKALGKAL{ct:Amid} | DFT530 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at >100µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSLSLLGKLL{ct:Amid} | DFT523 | Amidation | Free | Linear | L | None | 12 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at >50µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSLSLGKLL{ct:Amid} | DFT524 | Amidation | Free | Linear | L | None | 11 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at >300µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSLGKLL{ct:Amid} | DFT525 | Amidation | Free | Linear | L | None | 9 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at >300µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLSSLGKLL{ct:Amid} | DFT526 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at >300µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLSLLLSLLGKLL{ct:Amid} | DFT502 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 3.1µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLSLLLSLGLKLL{ct:Amid} | DFT503 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at >300µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLSLLLSLLLGKL{ct:Amid} | DFT504 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 8µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSSLLLLGKLL{ct:Amid} | DFT505 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 20µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GKLLSLLSLLGLL{ct:Amid} | DFT527 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 20µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | GLLSLLSLGLKLL{ct:Amid} | DFT531 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 7µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | LLGSLLSLGLKLL{ct:Amid} | DFT532 | Amidation | Free | Linear | L | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at 13µM | Human | Synthetic Peptide | NA | NA | ||
| 31209048 | 2019 | G{d}L{d}S{d}L{d}L{d}L{d}S{d}L{d}G{d}L{d}K{d}L{d}L{d}{ct:Amid} | DFT503d | Amidation | Free | Linear | D | None | 13 | Antibacterial, Anti-MRSA, Hemolytic | HL50 % Hemolysis at >300µM | Human | Synthetic Peptide | NA | NA |